<SEC-DOCUMENT>0001171843-19-004174.txt : 20190626
<SEC-HEADER>0001171843-19-004174.hdr.sgml : 20190626
<ACCEPTANCE-DATETIME>20190626081206
ACCESSION NUMBER:		0001171843-19-004174
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		148
CONFORMED PERIOD OF REPORT:	20190331
FILED AS OF DATE:		20190626
DATE AS OF CHANGE:		20190626

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Acasti Pharma Inc.
		CENTRAL INDEX KEY:			0001444192
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A8
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35776
		FILM NUMBER:		19919987

	BUSINESS ADDRESS:	
		STREET 1:		545 PROMENADE DU CENTROPOLIS, SUITE 100
		CITY:			LAVAL
		STATE:			A8
		ZIP:			H7T 0A3
		BUSINESS PHONE:		450-686-4555

	MAIL ADDRESS:	
		STREET 1:		545 PROMENADE DU CENTROPOLIS, SUITE 100
		CITY:			LAVAL
		STATE:			A8
		ZIP:			H7T 0A3
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>f20f_062519p.htm
<DESCRIPTION>FORM 20-F
<TEXT>
<HTML><HEAD>
     <TITLE></TITLE>
</HEAD><BODY STYLE="font: 10pt Times New Roman, Times, Serif">





<p style="margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.6pt; border-bottom: Black 2.5pt double">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.1pt; text-align: center"><font style="font-size: 12pt">UNITED
STATES</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.25pt; text-align: center"><font style="font-size: 12pt"><b>
SECURITIES AND EXCHANGE COMMISSION</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.25pt; text-align: center"><font style="font-size: 12pt"><b>WASHINGTON,
D.C. 20549</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.25pt; text-align: center">_____________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center"><font style="font-size: 12pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center"><font style="font-size: 12pt"><b>FORM
20-F</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.25pt; text-align: center">_____________________________</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 227.6pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">&#9744; </td><td style="width: 5pt"></td><td style="text-align: justify">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES
EXCHANGE ACT OF 1934</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center">OR</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">&#9746; </td><td style="width: 5pt"></td><td style="text-align: justify">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934</td>
</tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.2pt; text-align: center">For the fiscal year
ended March 31, 2019</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center">OR</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">&#9744;</td><td style="width: 5pt"></td><td style="text-align: justify"> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center">OR</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">&#9744;</td><td style="width: 5pt"></td><td style="text-align: justify"> SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.1pt; text-align: center"><b>
Commission file number: 001-35776</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.25pt; text-align: center">_____________________________</p>
<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center; text-indent: 0in">Acasti
Pharma Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134pt; text-align: center">(Exact name of Registrant
as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.25pt; text-align: center">_____________________________</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center"><font style="font-size: 8pt"><b>N/A</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center"><font style="font-size: 8pt">(Translation
of Registrant&#8217;s name into English)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center"><font style="font-size: 8pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center"><font style="font-size: 8pt"><b>Qu&#233;bec,
Canada</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center"><font style="font-size: 8pt">(Jurisdiction
of incorporation or organization)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center"><font style="font-size: 8pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.2pt; text-align: center"><font style="font-size: 8pt">545,
Promenade du Centropolis, Suite 100, Laval, Qu&#233;bec H7T 0A3</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center"><font style="font-size: 8pt">(Address
of principal executive office)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center"><font style="font-size: 8pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 210.95pt 0pt 216.95pt; text-align: center"><font style="font-size: 8pt">Jean-Fran&#231;ois
Boily, Vice President, Finance, Acasti Pharma Inc.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 210.95pt 0pt 217.05pt; text-align: center"><font style="font-size: 8pt">545,
Promenade du Centropolis, Suite 100 Laval, Qu&#233;bec H7T 0A3</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center"><font style="font-size: 8pt">Tel:
450-687-2262</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.25pt; text-align: center"><font style="font-size: 8pt">Fax:
450-687-2272</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center"><font style="font-size: 8pt">(Name,
Telephone, Email and/or Facsimile number and Address of Company Contact Person)</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.15pt; text-align: center"><font style="font-size: 8pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.1pt; text-align: center"><font style="font-size: 8pt">Securities
registered or to be registered pursuant to Section 12(b) of the Act.</font></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><font style="font-size: 8pt"><b>Title
        of each class</b></font></p></td>
    <td style="width: 2%"><font style="font-size: 8pt">&nbsp;</font></td>
    <td style="width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><font style="font-size: 8pt"><b>Trading
        symbol(s)</b></font></p></td>
    <td style="width: 2%"><font style="font-size: 8pt">&nbsp;</font></td>
    <td style="width: 32%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; border-bottom: Black 0.5pt solid"><font style="font-size: 8pt"><b>Name
        of each exchange on which registered</b></font></p></td></tr>
<tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center"><font style="font-size: 8pt"><b>Common Shares, no par value</b></font></td>
    <td><font style="font-size: 8pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: center"><font style="font-size: 8pt"><b>ACST</b></font></td>
    <td><font style="font-size: 8pt">&nbsp;</font></td>
    <td style="font-size: 10pt; text-align: center"><font style="font-size: 8pt"><b>The NASDAQ Capital Market</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.1pt; text-align: center"><font style="font-size: 8pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.1pt; text-align: center"><font style="font-size: 8pt">Securities
registered or to be registered pursuant to Section 12(g) of the Act.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.2pt; text-align: center"><font style="font-size: 8pt"><b>Not
applicable</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.2pt; text-align: center"><font style="font-size: 8pt"><b>&nbsp;</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.05pt; text-align: center"><font style="font-size: 8pt">Securities
for which there is a reporting obligation pursuant to Section 15(d) of the Act.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.1pt; text-align: center"><font style="font-size: 8pt"><b>
None</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.25pt; text-align: center"><font style="font-size: 8pt">_____________________________</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.9pt; text-align: justify"><font style="font-size: 8pt">Indicate
the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period
covered by the annual report.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 128.25pt 0pt 134.25pt; text-align: center"><font style="font-size: 8pt"><b>78,132,734
Common Shares issued and outstanding as of March 31, 2019.</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.9pt; text-align: justify"><font style="font-size: 8pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.9pt; text-align: justify"><font style="font-size: 8pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <font style="font-family: Times New Roman, Times, Serif">&#9744;
</font>No <font style="font-family: Times New Roman, Times, Serif">&#9746;</font></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 18.25pt 0pt 11.9pt"><font style="font-size: 8pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 18.25pt 0pt 11.9pt"><font style="font-size: 8pt">If this report
is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934. Yes <font style="font-family: Times New Roman, Times, Serif">&#9744; </font>No
<font style="font-family: Times New Roman, Times, Serif">&#9746;</font></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.9pt; text-align: justify"><font style="font-size: 8pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.9pt; text-align: justify"><font style="font-size: 8pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes <font style="font-family: Times New Roman, Times, Serif">&#9746;
</font>No <font style="font-family: Times New Roman, Times, Serif">&#9744;</font></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 11.9pt; text-align: justify"><font style="font-size: 8pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 11.9pt; text-align: justify"><font style="font-size: 8pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive
Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes <font style="font-family: Times New Roman, Times, Serif">&#9746;
</font>No <font style="font-family: Times New Roman, Times, Serif">&#9744;</font></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.9pt"><font style="font-size: 8pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.9pt"><font style="font-size: 8pt">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of &#8220;accelerated
filer and large accelerated filer&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="width: 25%; text-align: left; padding-left: 11.9pt"><font style="font-size: 8pt">Large accelerated filer &#9744;</font></td><td style="width: 1%"><font style="font-size: 8pt">&nbsp;</font></td>
    <td style="width: 24%; text-align: left"><font style="font-size: 8pt">Accelerated filer &#9744;</font></td><td style="width: 1%"><font style="font-size: 8pt">&nbsp;</font></td>
    <td style="width: 24%; text-align: left"><font style="font-size: 8pt">Non-accelerated filer &#9746;</font></td><td style="width: 1%"><font style="font-size: 8pt">&nbsp;</font></td>
    <td style="width: 24%; text-align: left"><font style="font-size: 8pt">Emerging growth company &#9744;</font></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.9pt"><font style="font-size: 8pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.9pt"><font style="font-size: 8pt">If an emerging growth
company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act <font style="font-family: Times New Roman, Times, Serif">&#9744;</font>.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.9pt; text-align: justify"><font style="font-size: 8pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.9pt; text-align: justify"><font style="font-size: 8pt">Indicate
by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 11.9pt; text-align: justify"><font style="font-size: 8pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="width: 33%; text-align: left; padding-left: 76.3pt"><font style="font-size: 8pt">U.S. GAAP &#9744;</font></td><td style="width: 1%"><font style="font-size: 8pt">&nbsp;</font></td>
    <td style="width: 33%; text-align: left"><font style="font-size: 8pt">International Financial Reporting Standards as</font></td><td style="width: 1%"><font style="font-size: 8pt">&nbsp;</font></td>
    <td style="width: 32%; text-align: left"><font style="font-size: 8pt">Other &#9744;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 175.8pt"><font style="font-size: 8pt">&nbsp;</font></td><td><font style="font-size: 8pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">issued by the International Accounting Standards Board &#9746;</font></td><td><font style="font-size: 8pt">&nbsp;</font></td>
    <td><font style="font-size: 8pt">&nbsp;</font></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 175.8pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 83.65pt 0pt 76.35pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 51.35pt 0pt 11.9pt"><font style="font-size: 8pt">If &#8220;Other&#8221;
has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has
elected to follow. Item 17 <font style="font-family: Times New Roman, Times, Serif">&#9744;	</font>Item 18 <font style="font-family: Times New Roman, Times, Serif">&#9744;</font></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 11.9pt"><font style="font-size: 8pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 11.9pt"><font style="font-size: 8pt">If this is an annual
report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <font style="font-family: Times New Roman, Times, Serif">&#9744;
</font>No <font style="font-family: Times New Roman, Times, Serif">&#9746;</font></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-bottom: Black 2.5pt double; margin-bottom: 0pt"><font style="font-size: 8pt"><font style="font-family: Times New Roman, Times, Serif">&nbsp;</font></font></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 210.35pt 0pt 213.25pt; text-align: center"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&nbsp;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 210.35pt 0pt 213.25pt; text-align: center">TABLE OF CONTENTS</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 210.35pt 0pt 213.25pt; text-align: center">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 210.35pt 0pt 213.25pt; text-align: center"></p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td colspan="3"><a href="#a_006">INTRODUCTION AND USE OF CERTAIN TERMS</a></td>
    <td style="text-align: right"><a href="#a_006">1</a></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3"><a href="#a_007">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></td>
    <td style="text-align: right"><a href="#a_007">1</a></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3">&nbsp;</td>
    <td style="text-align: right">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 10%; white-space: nowrap"><a href="#a_008">PART I</a></td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 78%">&nbsp;</td>
    <td style="text-align: right; width: 10%"><a href="#a_008">5</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_009">Item 1.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_009">Identity of Directors, Senior Management and Advisers</a></td>
    <td style="text-align: right"><a href="#a_009">5</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_010">Item 2.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_010">Offer Statistics and Expected Timetable</a></td>
    <td style="text-align: right"><a href="#a_010">5</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_011">Item 3.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_011">Key Information</a></td>
    <td style="text-align: right"><a href="#a_011">5</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_012">Item 4.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_012">Information on the Company</a></td>
    <td style="text-align: right"><a href="#a_012">23</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_013">Item 4A.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_013">Unresolved Staff Comments</a></td>
    <td style="text-align: right"><a href="#a_013">46</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_014">Item 5.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_014">Operating and Financial Review and Prospects</a></td>
    <td style="text-align: right"><a href="#a_014">46</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_015">Item 6.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_015">Directors, Senior Management and Employees</a></td>
    <td style="text-align: right"><a href="#a_015">60</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_016">Item 7.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_016">Major Shareholders and Related Party Transactions</a></td>
    <td style="text-align: right"><a href="#a_016">72</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_017">Item 8.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_017">Financial Statements</a></td>
    <td style="text-align: right"><a href="#a_017">73</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_018">Item 9.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_018">The Offer and Listing</a></td>
    <td style="text-align: right"><a href="#a_018">73</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_019">Item 10.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_019">Additional Information</a></td>
    <td style="text-align: right"><a href="#a_019">73</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_020">Item 11.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_020">Quantitative and Qualitative Disclosure about Market Risk</a></td>
    <td style="text-align: right"><a href="#a_020">84</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_021">Item 12.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_021">Description of Securities other than Equity Securities</a></td>
    <td style="text-align: right"><a href="#a_021">84</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><a href="#a_022">PART II</a></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><a href="#a_022">86</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_023">Item 13.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_023">Defaults, Dividend Arrearages and Delinquencies</a></td>
    <td style="text-align: right"><a href="#a_023">86</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_024">Item 14.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_024">Material Modification to the Rights of Security Holdings and Use of Proceeds</a></td>
    <td style="text-align: right"><a href="#a_024">86</a></td></tr>
<tr style="vertical-align: middle">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_025">Item 15.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_025">Controls and Procedures</a></td>
    <td style="text-align: right"><a href="#a_025">86</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_026">Item 16.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_026">Reserved</a></td>
    <td style="text-align: right"><a href="#a_026">86</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_027">Item 16A.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_027">Audit Committee Financial Expert</a></td>
    <td style="text-align: right"><a href="#a_027">86</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_028">Item 16B.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_028">Code of Ethics</a></td>
    <td style="text-align: right"><a href="#a_028">86</a></td></tr>
<tr style="vertical-align: middle">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_029">Item 16C.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_029">Principal Accountant Fees and Services</a></td>
    <td style="text-align: right"><a href="#a_029">87</a></td></tr>
<tr style="vertical-align: middle">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_030">Item 16D.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_030">Exemptions from the Listing Standards for Audit Committees</a></td>
    <td style="text-align: right"><a href="#a_030">87</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_031">Item 16E.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_031">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a></td>
    <td style="text-align: right"><a href="#a_031">87</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_032">Item 16F.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_032">Change in Registrant&#8217;s Certifying Accountant</a></td>
    <td style="text-align: right"><a href="#a_032">87</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_033">Item 16G.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_033">Corporation Governance</a></td>
    <td style="text-align: right"><a href="#a_033">88</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_034">Item 16H.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_034">Mining Safety Disclosure</a></td>
    <td style="text-align: right"><a href="#a_034">88</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><a href="#a_035">PART III</a></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><a href="#a_035">88</a></td></tr>
<tr style="vertical-align: middle">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_036">Item 17.</a></td>
    <td>&nbsp;</td>
        <td style="text-align: left"><a href="#a_036">Financial Statements</a></td>
    <td style="text-align: right"><a href="#a_036">88</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_037">Item 18.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_037">Financial Statements</a></td>
    <td style="text-align: right"><a href="#a_037">88</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 20pt; white-space: nowrap"><a href="#a_038">Item 19.</a></td>
    <td>&nbsp;</td>
    <td><a href="#a_038">Exhibits</a></td>
    <td style="text-align: right"><a href="#a_038">88</a></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="white-space: nowrap"><a href="#a_039">EXHIBITS INDEX</a></td>
    <td style="text-align: right"><a href="#a_039">89</a></td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="white-space: nowrap"><a href="#a_040">SIGNATURES</a></td>
    <td style="text-align: right"><a href="#a_040">91</a></td></tr>
</table>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 210.35pt 0pt 213.25pt; text-align: center"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 210.35pt 0pt 213.25pt; text-align: center">&nbsp;</p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt; text-align: center"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><p style="margin: 0pt">&nbsp;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt; text-align: center"><a name="a_006"></a>INTRODUCTION AND USE OF CERTAIN
TERMS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">As
used in this annual report on Form 20-F, or this annual report, unless the context otherwise requires, references to &#8220;we&#8221;,
&#8220;our&#8221;, &#8220;us&#8221;, &#8220;Acasti&#8221;, &#8220;Acasti Pharma&#8221;, &#8220;Corporation&#8221;, &#8220;it&#8221;,
&#8220;its&#8221; or similar terms refer to Acasti Pharma Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Market
data and certain industry data and forecasts included in this annual report were obtained from internal company surveys,
market research, and publicly available information, reports of governmental agencies and industry publications and surveys.
We have relied upon industry publications as our primary sources for third-party industry data and forecasts. Industry
surveys, publications and forecasts generally state that the information they contain has been obtained from sources believed
to be reliable, but that the accuracy and completeness of that information is not guaranteed. We have not independently
verified any of the data from third-party sources or the underlying economic assumptions they made. Similarly, internal
surveys, industry forecasts and market research, which we believe to be reliable based upon our management&#8217;s knowledge
of our industry, have not been independently verified. Our estimates involve risks and uncertainties, including assumptions
that may prove not to be accurate, and these estimates and certain industry data are subject to change based on various
factors, including those discussed under &#8220;Risk Factors&#8221; in this annual report. While we believe our internal
business research is reliable and the market definitions we use in this annual report are appropriate, neither our business
research nor the definitions we use have been verified by any independent source.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
own or have rights to trademarks, service marks or trade names that we use in connection with the operation of our business. In
addition, our name, logo and website names and addresses are our service marks or trademarks. CaPre&#174; is our registered trademark.
The other trademarks, trade names and service marks appearing in this annual report are the property of their respective owners.
Solely for convenience, the trademarks, service marks, tradenames and copyrights referred to in this annual report are listed without
the &#169;, &#174; and <font style="font-size: 10pt">TM </font>symbols, but we will assert, to the fullest extent under applicable
law, our rights or the rights of the applicable licensors to these trademarks, service marks and tradenames.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Financial Information</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">All
financial information in this annual report is presented in accordance with International Financial Reporting Standards, or IFRS,
as issued by the International Accounting Standards Board, or IASB, unless otherwise specified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
use multiple financial measures for the review of our operating performance. These measures are generally IFRS financial
measures, but one adjusted financial measure, &#8220;Non-IFRS operating loss&#8221; (adding to net loss, finance expenses,
depreciation and amortization and impairment loss, litigation settlement expected to be paid via common shares, change in
fair value of derivative warrant liabilities, stock-based compensation and by subtracting finance income and deferred income
tax recovery), is also used to assess our operating performance. This non-IFRS financial measure is derived from our
financial statements and is presented in a consistent manner. We use this measure, in addition to the IFRS financial
measures, for the purposes of evaluating our historical and prospective financial performance, as well as our
performance relative to competitors. All of these measures also help us to plan and forecast future periods as well as to
make operational and strategic decisions. We believe that providing this Non-IFRS information to investors, in addition to
IFRS measures, allows them to see our results through the eyes of our management, and to better understand our historical and
future financial performance. See &#8220;Item 5. Operating and Financial Review and Prospects&#8221; for a reconciliation to
net loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
this annual report, all references to &#8220;CA$&#8221; or &#8220;$&#8221; are to Canadian dollars, unless expressly otherwise
stated. All amounts related to our financial results are presented in thousands of Canadian dollars, except where noted and per
share amounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.45pt; margin-bottom: 0pt; text-align: center"><a name="a_007"></a>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">This
annual report contains information that may be forward-looking information within the meaning of Canadian securities laws and forward-looking
statements within the meaning of U.S. federal securities laws, both of which we refer to in this annual report as forward-looking
information. Forward-looking information can be identified by the use of terms such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;,
&#8220;expect&#8221;, &#8220;plan&#8221;, &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;,
&#8220;predict&#8221;, &#8220;potential&#8221;, &#8220;continue&#8221; or other similar expressions concerning matters that are
not statements about the present or historical facts. Forward-looking information in this annual report includes, among other things,
information or statements about:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our ability to conduct all required clinical and nonclinical trials for CaPre, including the timing
and results of those trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our strategy, future operations, prospects and the plans of our management;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the design, regulatory plan, timeline, costs and results of our clinical and nonclinical trials
for CaPre;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the timing and outcome of our meetings and discussions with the U.S. Food and Drug Administration,
or FDA;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our planned regulatory filings for CaPre, and their timing;</td></tr></table>
<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our expectation that our Bridging Study (as defined below) results will support our plan to get
authorization from the FDA to use the 505(b)(2) pathway with new chemical entity, or NCE, status towards a New Drug Application,
or NDA, approval in the United States;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the timing and results from the STRENGTH study (conducted by Astra Zeneca with their omega-3 (OM3)
drug EPANOVA) in patients with high triglycerides, or TGs (blood levels between 200-499 mg/dL) and concomitantly taking a statin;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the potential benefits and risks of CaPre as compared to other products in the pharmaceutical,
medical food and natural health products markets;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our estimates of the size of the potential market for CaPre, unmet medical needs in that market,
the potential for market expansion, and the rate and degree of market acceptance of CaPre if it reaches commercialization, and
our ability to serve that market;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our anticipated marketing advantages and product differentiation of CaPre and its potential to
become a best-in-class OM3 compound for the treatment of HTG;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the potential to expand CaPre&#8217;s indication for the treatment of high TGs (200-499 mg/dL);</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the degree to which physicians would switch their patients to a product with CaPre&#8217;s target
product profile;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our strategy and ability to develop, commercialize and distribute CaPre in the United States and
elsewhere;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the manufacturing scale-up of CaPre beyond 20 tons per year and the related timing;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our ability to strengthen our patent portfolio and other means of protecting our intellectual property
rights, including our ability to obtain additional patent protection for CaPre;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our expectation that following expiration of the license agreement with Neptune Technologies &amp;
Bioressources Inc. (&#8220;<b>Neptune</b>&#8221;) we will not require any license from third parties to support the commercialization
of CaPre;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the availability, consistency and sources of our raw materials, including krill oil;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our expectation to be able to rely on third parties to manufacture CaPre whose manufacturing processes
and facilities are in compliance with current good manufacturing practices, or cGMP;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the potential for Omega-3 therapeutics, or OM3s in other cardiometabolic medicine indications;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our intention and ability to build a U.S. commercial organization and to successfully launch CaPre
and compete in the U.S. market;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our intention and ability to complete development and/or distribution partnerships to support the
commercialization of CaPre outside of the United States, and to pursue strategic opportunities to provide capital and market access;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our need for additional financing and our estimates regarding our future financing and capital
requirements;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our expectation regarding our financial performance, including our revenues, profitability, research
and development, costs and expenses, gross margins, liquidity, capital resources, and capital expenditures; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our projected capital requirements to fund our anticipated expenses, including our research and
development and general and administrative expenses, and capital expenditures.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Although the
forward-looking information in this annual report is based upon what we believe are reasonable assumptions, you should not place
undue reliance on that forward-looking information since actual results may vary materially from it. Important assumptions made
by us when making forward-looking statements include, among other things, assumptions by us that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we are able to obtain the additional capital and financing we require;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we successfully and timely complete all required clinical and nonclinical trials necessary for
regulatory approval of CaPre;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the timeline and costs for our clinical and nonclinical programs are not materially underestimated
or affected by unforeseen circumstances;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">CaPre is safe and effective;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">outcome study data from the STRENGTH study is positive;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we obtain and maintain regulatory approval for CaPre on a timely basis;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we are able to attract, hire and retain key management and skilled scientific and commercial personnel;</td></tr></table>
<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">third parties provide their services to us on a timely and effective basis;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we are able to maintain our required supply of raw materials, including krill oil;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we are able to find and retain a third-party to manufacture CaPre in compliance with cGMP;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we are able to successfully build a commercial organization, launch CaPre in the United States,
and compete in the U.S. market;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we are able to secure distribution arrangements for CaPre outside of the United States, if it reaches
commercialization;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we are able to manage our future growth effectively;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we are able to gain acceptance of CaPre in its markets and we are able to serve those markets;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our patent portfolio is sufficient and valid;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we are able to secure and defend our intellectual property rights and to avoid infringing upon
the intellectual property rights of third parties;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we are able to take advantage of business opportunities in the pharmaceutical industry and receive
strategic partner support;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we are able to continue as a going concern;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
    <td style="width: 0.25in">&nbsp;</td>
    <td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td>
    <td style="text-align: justify">there is no
significant increase in competition for CaPre from other companies in the pharmaceutical, medical food and natural health product
industries;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">CaPre would be viewed favorably by payers at launch and receive appropriate healthcare reimbursement;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">market data and reports reviewed by us are accurate;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">there are no adverse changes in relevant laws or regulations; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we face no product liability lawsuits and other proceedings or any such matters, if they arise,
are satisfactorily resolved.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
addition, the forward-looking information in this annual report is subject to a number of known and unknown risks, uncertainties
and other factors, including those described in this annual report under the heading &#8220;Item 3.D. Risk Factors&#8221;, many
of which are beyond our control, that could cause our actual results and developments to differ materially from those that are
disclosed in or implied by the forward-looking information, including, among others:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">risks related to timing and possible difficulties, delays or failures in our ongoing TRILOGY Phase
3 program for CaPre;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">nonclinical and clinical trials may be more costly or take longer to complete than anticipated,
and may never be initiated or completed, or may not generate results that warrant future development of CaPre;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">CaPre may not prove to be as safe and effective or as potent as we currently believe;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our planned TRILOGY Phase 3 program may not produce positive results;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our anticipated studies and submissions to the FDA may not occur as currently anticipated, or at
all;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the FDA could reject our 505(b)(2) regulatory pathway;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">while the REDUCE-IT results (a Cardiovascular outcome study conducted by Amarin with their OM3
drug VASCEPA) were positive, the cardiovascular outcome study data from the STRENGTH study could be negative, which could also
negatively affect the market perception of CaPre;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we may encounter difficulties, delays or failures in obtaining regulatory approvals for the initiation
of clinical trials or to market CaPre, or the FDA may refuse to approve CaPre, or place restrictions on our ability to commercialize
CaPre;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we may need to conduct additional future clinical trials for CaPre, the occurrence and success
of which cannot be assured;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">CaPre may have unknown side effects;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">CaPre could be subject to extensive post-market obligations and continued regulatory review, which
may result in significant additional expense and affect sales, marketing and profitability;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we may fail to achieve our publicly announced milestones on time;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we may encounter difficulties in completing the development and commercialization of CaPre;</td></tr></table>
<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">third parties we will rely upon to conduct our TRILOGY Phase 3 program for CaPre may not effectively
fulfill their obligations to us, including complying with FDA requirements;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">there may be difficulties, delays, or failures in obtaining health care reimbursements for CaPre;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">recently enacted and future laws may increase the difficulty and cost for us to obtain marketing
approval of and commercialize CaPre and affect the prices we can charge;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">new laws, regulatory requirements, and the continuing efforts of governmental and third-party payors
to contain or reduce the costs of healthcare through various means could adversely affect our business;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the market opportunity for, and demand and market acceptance of, CaPre may not be as strong as
we anticipate;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">third parties that we will rely upon to manufacture, supply and distribute CaPre may not effectively
fulfill their obligations to us, including complying with FDA requirements;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">there may not be an adequate supply of raw materials, including krill oil, in sufficient quantities
and quality and to produce CaPre under cGMP standards;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we may not be able to meet applicable regulatory standards for the manufacture of CaPre or scale-up
our manufacturing successfully;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">as a development stage company, we have limited sales, marketing and distribution personnel and
resources;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our patent applications may not result in issued patents, our issued patents may be circumvented
or challenged and ultimately struck down, and we may not be able to successfully protect our trade secrets or other confidential
proprietary information;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we may face claims of infringement of third party intellectual property and other proprietary rights;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we may face product liability claims and product recalls;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we may face intense competition from other companies in the pharmaceutical, medical food and natural
health product industries;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we have a history of negative operating cash flow and may never become profitable or be able to
sustain profitability;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we have significant additional future capital needs and may not be able to raise additional financing
required to fund further research and development, clinical studies, obtain regulatory approvals, build a commercial organization
in the United States, and meet ongoing capital requirements to continue our current operations on commercially acceptable terms
or at all;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we may not be able to successfully compete in the U.S. market with competitors who are larger and
have more resources than we do;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we may acquire businesses or products or form strategic partnerships in the future that may not
be successful;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we may be unable to secure development and/or distribution partnerships to support the development
and commercialization of CaPre outside the United States, provide development capital, or market access;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we rely on the retention of key management and skilled scientific, manufacturing, regulatory and
commercial personnel; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">general changes in economic and capital market conditions could adversely affect us.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">All
of the forward-looking information in this annual report is qualified by this cautionary statement. There can be no guarantee that
the results or developments that we anticipate will be realized or, even if substantially realized, that they will have the consequences
or effects on our business, financial condition or results of operations that we anticipate. As a result, you should not place
undue reliance on the forward-looking information. Except as required by applicable law, we do not undertake to update or amend
any forward-looking information, whether as a result of new information, future events or otherwise. All forward-looking information
is made as of the date of this annual report.<br style="clear: both">
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt; text-align: center"></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt; text-align: center"><a name="a_008"></a>PART I</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.45pt; text-align: center">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 50pt"><a name="a_009"></a>Item 1.</td><td>Identity of Directors, Senior Management and Advisers</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 50pt"><a name="a_010"></a>Item 2.</td><td>Offer Statistics and Expected Timetable</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 50pt"><a name="a_011"></a>Item 3.</td><td>Key Information</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">A.</td><td>Selected Financial Data</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
following information should be read in conjunction with &#8220;Item 5. Operating and Financial Review and Prospects&#8221; and
our audited financial statements and the related notes for our fiscal years ended March 31, 2019 and 2018 and the thirteen-month
period ended March 31, 2017 which are prepared in accordance with IFRS as issued by the IASB and are included in this annual report.
The selected financial information below includes financial information derived from our audited financial statements. Our historical
results from any prior period are not necessarily indicative of results to be expected for any future period. The following table
is a summary of our selected financial information in accordance with IFRS as issued by the IASB for each of our five most recently
completed fiscal years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 5.9pt; text-align: justify; text-indent: 32.75pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="18" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">For the fiscal year ended</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center"><b>&nbsp;</b></td><td style="text-align: center"><b>&nbsp;</b></td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b><u>March 31, 2019</u></b></td><td style="text-align: center"><b>&nbsp;</b></td><td style="text-align: center"><b>&nbsp;</b></td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b><u>March 31, 2018</u></b></td><td style="text-align: center"><b>&nbsp;</b></td><td style="font-weight: bold; text-align: center"><b>&nbsp;</b></td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><b><u>March 31, 2017</u><font style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></font></b></td><td style="font-weight: bold; text-align: center"><b>&nbsp;</b></td><td style="text-align: center"><b>&nbsp;</b></td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b><u>February 29, 2016</u></b></td><td style="text-align: center"><b>&nbsp;</b></td><td style="text-align: center"><b>&nbsp;</b></td>
    <td colspan="2" style="white-space: nowrap; text-align: center"><b><u>February 28, 2015</u></b></td><td style="text-align: center"><b>&nbsp;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Revenue from sales</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">nil</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">nil</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">nil</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">nil</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">nil</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operating activities</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(45,015</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(19,696</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(11,210</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(9,612</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(12,395</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss and total comprehensive loss</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(51,566</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(21,504</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(11,247</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,317</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,655</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -9pt; padding-left: 9pt">Basic and diluted loss per share</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.95</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.23</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.01</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.59</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(0.16</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total assets</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48,471</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">22,959</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">25,456</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">28,517</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">37,208</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">34,509</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">14,735</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,753</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,297</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,980</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share capital</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">129,318</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">73,338</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">66,576</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">61,973</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">61,628</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equity - Classified Warrants and rights</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">998</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">715</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">453</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted average number of shares outstanding</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">54,290,295</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">17,486,515</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">11, 094,512</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">10,659,936</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">10,617,704</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Dividends declared per share</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.65pt 0pt 0"><font style="font-size: 8pt">Note:</font></p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 16.85pt"></td><td style="width: 16.35pt"><font style="font-size: 8pt">(1)</font></td><td><font style="font-size: 8pt">For the thirteen-month period
                                         ended March 31, 2017.</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">B.</td><td>Capitalization and Indebtedness</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">C.</td><td>Reasons for the Offer and Use of Proceeds</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 5.9pt"></td><td style="width: 21.85pt">D.</td><td>Risk Factors</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"><i>Investing in our securities
involves a high degree of risk due to, among other things, the nature of our business and the present stage of our development.
Prospective and current investors should carefully consider the following risks and uncertainties, together with all other information
in this annual report, as well as our financial statements included in this annual report and &#8220;Item 5. Operating and Financial
Review and Prospects.&#8221; If any of these risks actually occur, our business, financial condition, prospects, results of operations
or cash flow could be materially and adversely affected and you could lose all or a part of the value of your investment. Additional
risks or uncertainties not currently known to us, or that we deem immaterial, may also negatively affect our business operations.&#8221;
</i></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">General Risks Related to the Corporation</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We may not be able to maintain our operations
and advance our research and development of CaPre without additional funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
have incurred operating losses and negative cash flows from operations since our inception. To date, we have financed our operations
through public offerings and private placements of securities, proceeds from exercises of warrants, rights and options, and receipt
of research tax credits and research grant programs. Our cash and cash equivalents (including restricted investments) were $ 34.4
million as of March 31, 2019 and $8.2 million as of March 31, 2018. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our current assets,
as of March 31, 2019, are projected to support our current liabilities as at that date when combined with the projected level of
our expenses for the next twelve months, including fully funding the completion of our Phase 3 program for CaPre. We expect that
additional time and capital will be required by us to file an NDA to obtain FDA approval for CaPre in the United States, to further
scale up our manufacturing capabilities, and to complete marketing and other pre-commercialization activities. Consequently, we
expect to require additional capital to fund our daily operating needs beyond the next twelve months. Based on a conservative estimate,
we believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements
beyond the completion of our Phase 3 trials. To fully execute our business plan, we plan to raise the necessary capital primarily
through additional securities offerings and multiple sources of non-dilutive capital such as grants or loans and strategic alliances.
If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay
the commercial launch of CaPre. Unexpected negative results in our TRILOGY Phase 3 program for CaPre may affect our ability to
raise additional capital and/or complete strategic development and/or distribution partnerships to support the commercial launch
of CaPre. Additional funding from third parties may not be available on acceptable terms or at all to enable us to continue with
the commercialization of CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">If we do not raise
additional funds, we may not be able to realize our assets and discharge our liabilities in the normal course of business. As a
result, there exists a material uncertainty that casts substantial doubt about our ability to continue as a going concern and,
therefore, realize our assets and discharge our liabilities in the normal course of business. Our financial statements have been
prepared on a going-concern basis, which assumes we will continue our operations in the foreseeable future and will be able to
realize our assets and discharge our liabilities and commitments in the ordinary course of business. If we are unable to continue
as a going concern, material write-downs to the carrying value of our assets, including intangible assets, could be required. If
we fail to obtain additional financing, we may not be able to continue as a going concern.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We may never become profitable or be able
to sustain profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
are a clinical-stage biopharmaceutical company with a limited operating history. The likelihood of the success of our business
plan must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered when
developing and expanding early-stage businesses and the regulatory and competitive environment in which we operate. Biopharmaceutical
product development is a highly speculative undertaking, involves a substantial degree of risk and is a capital- intensive business.
We expect to incur expenses without any meaningful corresponding revenues unless and until we are able to obtain regulatory approval
for and begin selling CaPre in significant quantities. We filed our investigational new drug application, or IND, for CaPre in
late 2013, which allowed us to initiate clinical development in the United States towards FDA approval for CaPre. To date, we
have not generated any revenue from CaPre, and we may never be able to obtain regulatory approval for marketing CaPre in any indication.
Even if we are able to commercialize CaPre, we may still not generate significant revenues or achieve profitability. Additionally,
we may not be able to attain our targeted cost of goods sold, and levels of insurance reimbursement for CaPre may not be commercially
viable in all global markets. We incurred net losses for the fiscal year ended March 31, 2019 of $ 51.6 million, $21.5
million for the year ended March 31, 2018 and $11.2 million for the thirteen-month period ended March 31, 2017, respectively.
As of March 31, 2019, we had an accumulated deficit of $ 123.9 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We expect that our
expenses will increase in the future as we prepare to seek FDA approval for the commercial launch of CaPre. However, our research
and development expenses could increase in the future if we decide to develop CaPre for other indications. As a result, we expect
to continue to incur substantial losses for the foreseeable future, and these losses may be increasing. We are uncertain about
when or if we will be able to achieve or sustain profitability. If we fail to become and remain profitable, our ability to sustain
our operations and to raise capital could be impaired and the price of our common shares could decline.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">If outcome
studies being conducted by our competitors testing the impact of OM3 on treating patients with high TGs are negative, there could
also be an adverse impact for CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Top-line
results from the cardiovascular outcome trial (CVOT) sponsored by Amarin (the REDUCE-IT trial) were recently released. A second
CVOT sponsored by AstraZeneca (the STRENGTH trial) is expected to be reported in 2020. While the REDUCE-IT trial provided positive
top line results, there can be no assurance that further detailed or subsequent results will be positive. If those studies show
or continue to show that OM3 therapeutic drugs effectively treat patients with high TGs and improve cardiovascular, morbidity
and mortality outcomes, we believe that the potential to expand CaPre&#8217;s indication in the future to include the treatment
of high TGs would be significantly advanced. Conversely, if outcome study data from Astra Zeneca&#8217;s STRENGTH trial is negative,
or if it fails to be completed, our potential target market for CaPre could be limited to patients with severe HTG (for which
the total U.S. market was estimated based on audited prescription data by Symphony Health Analytics to be approximately $1.4 billion
in 2018) and our ability to realize greater market potential of CaPre could be harmed.</p>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We rely on
third parties to conduct our TRILOGY Phase 3 program for CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We rely on contract
research organizations, or CROs, to monitor and manage data for our TRILOGY Phase 3 program for CaPre. While we will only control
certain aspects of the CRO&#8217;s activities, we nevertheless are responsible for ensuring that our clinical trials are conducted
in accordance with applicable protocols, and legal, regulatory and scientific standards, and our reliance on the CRO does not relieve
us from those responsibilities. We and the CRO are required to comply with current good clinical practices, or cGCPs, which are
regulations and guidelines enforced by the FDA, Health Canada and comparable foreign regulatory authorities for any products in
clinical development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The FDA enforces these
cGCP regulations through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CRO fail
to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, Health
Canada or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing
applications for CaPre. Upon inspection, the FDA could determine that our clinical trials do not comply with cGCPs. In addition,
our clinical trials must be conducted with products produced under current good manufacturing practice, or cGMP, regulations and
require a large number of test subjects. If we or the CRO fail to comply with these regulations, we may have to repeat preclinical
studies or clinical trials for CaPre, which would delay the regulatory approval process and could also subject us to enforcement
action up to and including civil and criminal penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">If our relationship
with a CRO terminates, we may not be able to enter into arrangements with alternative CROs. If the CRO does not successfully carry
out its duties or obligations or meet expected deadlines, if it needs to be replaced or if the quality or accuracy of the clinical
data it obtains is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons,
we may have to extend, delay or terminate our preclinical studies or clinical trials, and we may not be able to obtain regulatory
approval for or successfully commercialize CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The third parties that
are conducting our TRILOGY Phase 3 program for CaPre will not be our employees and, except for remedies available to us under our
agreements with the CROs, we cannot control whether or not they devote sufficient time and resources to our preclinical, clinical
and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors,
for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance
on our behalf.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We rely on
third parties to manufacture, produce and supply CaPre and we may be adversely affected if those third parties are unable or unwilling
to fulfill their obligations, including complying with FDA requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Producing pharmaceutical
products requires significant expertise and capital investment, including the development of advanced manufacturing techniques
and process controls. Currently, while we do own our manufacturing and encapsulation equipment, we outsource the production of
CaPre, and do not own or operate the manufacturing facilities. Accordingly, we need to rely on one or more third party contract
manufacturers to produce and supply our required drug product for our nonclinical research and clinical trials for CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Although we are currently
working with CordenPharma at its Chen&#244;ve facility in Dijon, France to scale up our manufacturing processes for CaPre, doing
so is a difficult and uncertain task, and there are risks associated with scaling to the level required for full commercialization,
including, among others, pricing, cost overruns, potential problems with process scale up, process reproducibility, stability issues,
lot consistency and timely availability of reagents or raw materials. Consequently, we may not be able to attain our targeted cost
of goods sold for CaPre. Any of these challenges could delay the commercial launch of CaPre, require bridging or repetition of
studies or trials, increase development costs, delay approval of CaPre, impair our commercialization efforts, and increase our
costs. We may have to delay or suspend the production of CaPre if a third-party manufacturer:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">becomes unavailable for any reason, including as a result of the failure to comply with cGMP regulations;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">experiences manufacturing problems or other operational failures, such as equipment failures or
unplanned facility shutdowns required to comply with cGMP or damage from any event, including fire, flood, earthquake, business
restructuring or insolvency; or</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">fails or refuses to perform its contractual obligations under its agreement with us, such as failing
or refusing to deliver the quantities of CaPre requested by us on a timely basis.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">If our third-party
contract manufacturers fail to achieve and maintain high manufacturing standards in compliance with cGMP regulations, we may be
subject to sanctions, including fines, product recalls or seizures, injunctions, delays or suspensions of our clinical trials for
CaPre, total or partial suspension of production of CaPre, civil penalties, withdrawals of previously granted regulatory approvals,
and criminal prosecution. We do not currently have arrangements in place for redundant supply. If any one of our current contract
manufacturers cannot perform as agreed, we may be required to replace that manufacturer. Although we believe that there are several
potential alternative contract manufacturers who could manufacture CaPre, we may incur added costs and delays in identifying and
qualifying any such replacement.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">We have historically had
no marketing and sales organization and, as a company, have no experience in marketing products. If we are unable to properly establish
marketing and sales capabilities or enter into agreements with a strategic partner to market and sell CaPre, we may not be able
to generate revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
have historically had no sales, marketing or distribution capabilities and, as a company, we have also historically had no experience
in marketing products. If CaPre or another of our future product candidates is approved for commercialization, unless we find a
strategic partner to assist us with sales, marketing and distribution, we will be required to develop in-house marketing and sales
force capability, which would require significant capital expenditures, management resources and time. Also, we would have to compete
with other biotechnology and pharmaceutical companies to recruit, hire, train and retain marketing and sales personnel. We face
competition in our search for strategic partners to assist us with sales, marketing and distribution, and we may not be able to
establish or maintain any such arrangements. If we do find a strategic partner, any revenue we receive from CaPre would partly
depend upon the efforts of that strategic partner, which may not be successful. We may have little or no control over the marketing
and sales efforts by any strategic partner we find for CaPre and our revenue may be lower than if we had commercialized CaPre independently.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">If we are not successful
in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
ability to compete in the highly competitive pharmaceuticals industry largely depends upon our ability to attract and retain highly
qualified managerial, scientific, medical, and commercial personnel. Competition for skilled personnel in our market is intense
and competition may limit our ability to hire and retain highly qualified personnel on acceptable terms. We are highly dependent
on our management, financial, commercial, and scientific personnel. Despite our efforts to retain valuable employees, members of
our management, financial, commercial, scientific and medical teams may terminate their employment with us on short notice or,
potentially, without any notice at all. The loss of the services of any of our executive officers or other key employees could
potentially harm our business, operating results or financial condition. Our success may also depend on our ability to attract,
retain and motivate highly skilled junior, mid-level, and senior managers and scientific personnel. In addition, we do not maintain
&#8220;key person&#8221; insurance policies on the lives of our executives or those of any of our other employees. Other pharmaceutical
companies with which we compete for qualified personnel have greater financial and other resources, different risk profiles, and
a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement.
Some of these characteristics may be more appealing to high-quality candidates than what we can offer. If we are unable to continue
to attract and retain high-quality personnel, the rate and success at which we can develop and commercialize CaPre and any other
future product candidates would be limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Business disruptions could seriously harm
our future revenue and financial condition and increase our costs and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
operations, and those of our suppliers, third party manufacturers and other contractors and consultants could be subject to earthquakes,
power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions,
medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self- insured.
The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our
costs and expenses. We rely on third-party manufacturers to manufacture CaPre. Our ability to obtain supplies of CaPre could be
disrupted if the operations of our manufacturers and suppliers are affected by a man-made or natural disaster or other business
interruption.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our prospects currently depend entirely
on the success of CaPre, which is still in clinical development, and we may not be able to generate revenues from CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
have no prescription drug products that have been reviewed or approved by the FDA, Health Canada or any similar regulatory authority.
Our only prescription drug candidate is CaPre, for which we have not yet filed an NDA, and for which we must complete the TRILOGY
Phase 3 program and seek and receive regulatory approval prior to commercial launch, which we do not anticipate will occur until
2021 at the earliest. We have invested significant effort and financial resources in researching and developing CaPre. Further
development of CaPre will require substantial investment, access to sufficient commercial manufacturing capacity and significant
marketing efforts before we can generate any revenue from sales of CaPre, if it is ever approved for commercialization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
do not have any other prescription drug candidates in development and so our business prospects currently depend entirely on the
successful development, regulatory approval and commercialization of CaPre, which may never occur. Most prescription drug candidates
never reach the clinical development stage and even those that do reach clinical development have only a small chance of successfully
completing clinical development and gaining regulatory approval. If we are unable to successfully commercialize CaPre, we may never
generate meaningful revenues. In addition, if CaPre reaches commercialization and there is low market demand for CaPre or the market
for CaPre develops less rapidly than we anticipate, we may not have the ability to shift our resources to the development of alternative
products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We may not be able
to obtain required regulatory approvals for CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
have limited experience in obtaining regulatory approvals, including approval by the FDA and, as a company, we have no experience
in obtaining approval of any product candidates. The research, testing, manufacturing, labeling, packaging, storage, sale, marketing,
pricing, export, import and distribution of prescription drug products are subject to extensive regulation by the FDA and other
regulatory authorities in the United States and other countries and those regulations differ from country to country. We are not
permitted to market CaPre in the United States until we receive approval of an NDA from the FDA and similar restrictions apply
in other countries. In the United States, the FDA generally requires the completion of preclinical testing and clinical trials
of each drug to establish its safety and efficacy and extensive pharmaceutical development to ensure its quality before an NDA
is approved. Regulatory authorities in other jurisdictions impose similar requirements. Of the large number of drugs in development,
only a small percentage result in the submission of an NDA to the FDA and even fewer are approved for commercialization. To date,
we have not submitted an NDA for CaPre to the FDA or comparable applications to other regulatory authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our receipt of required regulatory approvals for
CaPre is uncertain and subject to a number of risks, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the FDA or comparable foreign regulatory authorities or independent institutional review boards,
or IRBs, may disagree with the design or implementation of our clinical trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we may not be able to provide acceptable evidence of the safety and efficacy of CaPre;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the results of our clinical trials may not meet the level of statistical or clinical significance
required by the FDA or other regulatory agencies for marketing approval;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the dosing of CaPre in a particular clinical trial may not be at an optimal level;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">patients in our clinical trials may suffer adverse effects for reasons that may or may not be related
to CaPre;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we may be unable to demonstrate that CaPre&#8217;s clinical and other benefits outweigh its safety
risks;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the data collected from our clinical trials may not be sufficient to support the submission of
an NDA for CaPre or to obtain regulatory approval for CaPre in the United States or elsewhere;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the FDA or comparable foreign regulatory authorities may not approve the manufacturing processes
or facilities of third party manufacturers with which we contract for clinical and commercial supplies of CaPre; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may
significantly change in a manner rendering our clinical data insufficient for approval.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
FDA and other similar regulators have substantial discretion in the approval process and may refuse to accept our application or
may decide that our data is insufficient for approval and require additional clinical trials, or preclinical or other studies for
CaPre. If regulatory approval for CaPre is obtained in one jurisdiction that does not necessarily mean that CaPre will receive
regulatory approval in all jurisdictions in which we seek approval. If we fail to obtain approval for CaPre in one or more jurisdictions,
our ability to obtain approval in a different jurisdiction may be negatively affected.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Even if we receive
regulatory approval for CaPre, it may just be for a limited indication.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">If
we obtain regulatory approval for CaPre, we will only be permitted to market it for the indication(s) approved by the FDA, and
any such approval may put limits on the indicated uses or promotional claims we may make for it, or otherwise not permit labeling
that sufficiently differentiates CaPre from competitive products with comparable therapeutic profiles. For example, while our initial
objective is to seek regulatory approval for the treatment of severe HTG, afterwards obtaining approval for CaPre to address mild
to moderate HTG could greatly expand our potential market for CaPre. However, even if CaPre is approved for severe HTG, it may
never be approved for the treatment of mild to moderate HTG. In addition, any approval we receive for CaPre could contain significant
use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval
study or risk management requirements. If any regulatory approval for CaPre contains significant limits, we may not be able to
obtain sufficient funding or generate meaningful revenue from CaPre or be able to continue developing, marketing or commercializing
CaPre.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We may be unable
to find successful strategic partnerships to develop and commercialize CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
are currently engaged in strategic partnership discussions with several pharmaceutical companies for the development and commercialization
of CaPre. We intend to seek co-development, licensing and/or marketing partnership opportunities with third parties that we believe
will complement or augment our development and commercialization efforts for CaPre. Entering into partnership relationships may
require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute
our existing shareholders or disrupt our management and business. Entering into partnership relationships could also delay the
development of CaPre and our other future product candidates if we become dependent upon a strategic partner and that strategic
partner does not prioritize the development of CaPre relative to its other development activities. In addition, we face significant
competition in seeking strategic partners and the negotiation process is time-consuming and complex. We may not be successful in
our efforts to establish a strategic partnership or other alternative arrangements for CaPre on our anticipated timeline, or at
all, because CaPre may be deemed to be at too early of a stage for collaborative effort and third parties may not view CaPre as
having the requisite potential to demonstrate safety and efficacy. Even if we do enter into strategic partnerships, those partnerships
may not achieve our objectives.</p>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We may be unable
to develop alternative product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">To
date, we have not commercialized any prescription drug candidates and, other than CaPre, we do not have any compounds in clinical
trials, nonclinical testing, lead optimization or lead identification stages. If we fail to obtain regulatory approval for and
successfully commercialize CaPre as a treatment for severe HTG or any other indication, whether as a stand-alone therapy or in
combination with other treatments, we would have to develop, acquire or license alternative product candidates or drug compounds
to expand our product candidate pipeline beyond CaPre. In such a scenario, we may not be able to identify and develop or acquire
product candidates that prove to be successful products, or to develop or acquire them on terms that are acceptable to us.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We may not be able
to compete effectively against our competitors&#8217; pharmaceutical products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
biotechnology and pharmaceutical industries are highly competitive. There are many pharmaceutical companies, biotechnology companies,
public and private universities and research organizations actively engaged in the research and development of products that may
be similar to CaPre. It is probable that the number of companies seeking to develop products and therapies similar to CaPre will
increase. Many of these and other existing or potential competitors have substantially greater financial, technical and human resources
than we do and may be better equipped to develop, manufacture and market products. These companies may develop and introduce products
and processes competitive with or superior to CaPre. In addition, other technologies or products may be developed that have an
entirely different approach or means of accomplishing the intended purposes of CaPre, which might render our technology and CaPre
non-competitive or obsolete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
competitors in the United States and globally include large, well-established pharmaceutical companies, specialty pharmaceutical
sales and marketing companies, and specialized cardiovascular treatment companies. GlaxoSmithKline plc, which currently sells LOVAZA,
a prescription-only OM3 fatty acid indicated for patients with severe HTG, was approved by the FDA in 2004 and has been on the
market in the United States since 2005. Multiple generic versions of LOVAZA are now available in the United States. Amarin launched
its prescription-only OM3 drug VASCEPA in 2013, and reached a market share of approximately 20% by the end of 2015. In addition,
EPANOVA (OM3-carboxylic acids) capsules, a free fatty acid form of OM3 (comprised of 55% EPA and 20% DHA), is FDA-approved for
patients with severe HTG. <font style="text-transform: uppercase">Omtryg</font>, another OM3 fatty acid composition developed by
Trygg Pharma AS, received FDA approval for severe HTG. Neither EPANOVA nor <font style="text-transform: uppercase">Omtryg</font>
have yet been commercially launched, but could launch at any time. Other large companies with products competing indirectly with
CaPre include AbbVie, Inc., which currently sells TRICOR and TRILIPIX for the treatment of severe HTG, and NIASPAN, which is primarily
used to raise HDL-C but is also used to lower TGs. Generic versions of TRICOR, TRILIPIX and NIASPAN are also now available in the
United States. In addition, we are aware of a number of other pharmaceutical companies in earlier stages of developing products
that, if approved and marketed, could compete with CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Even
if it receives regulatory approval, CaPre may need to demonstrate compelling comparative advantages in efficacy, convenience, tolerability
and safety to be commercially successful. Other competitive factors, including generic drug competition, could force us to lower
prices or could result in reduced sales of CaPre. In addition, new products developed by others could emerge as competitors to
CaPre. If we are not able to compete effectively against our current and future competitors, our business will not grow and our
financial condition and operations will suffer.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">CaPre could face competition from products
for which no prescription is required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">If
it receives regulatory approval, CaPre will be a prescription-only OM3. Mixtures of OM3 fatty acids are naturally occurring substances
in various foods, including fatty fish. Lower potency and lower purity forms of OM3 fatty acids are also marketed by other companies
as dietary supplements or natural health products. Dietary supplements may generally be marketed without a lengthy FDA premarket
review and approval process and do not require a prescription. However, unlike drug products, manufacturers of dietary supplements
may not make therapeutic claims for their products; dietary supplements may be marketed with claims describing how the product
affects the structure or function of the body without premarket approval, but may not expressly or implicitly represent that the
dietary supplement will diagnose, cure, mitigate, treat, or prevent disease. We cannot be certain that physicians or consumers
will view CaPre as superior to these alternatives or that physicians will be more likely to prescribe CaPre. If CaPre is not broadly
covered by insurance, or the patient co-pay is significantly higher than the prices of commercially available OM3 fatty acids marketed
by other companies as dietary supplements or natural health products, physicians may recommend these commercial alternatives instead
of CaPre or patients may elect on their own to take commercially available non-prescription OM3 fatty acids. Either of these outcomes
could limit how we price CaPre and negatively affect our revenues.</p>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Recent and future legal developments could
make it more difficult and costly for us to obtain regulatory approvals for CaPre and negatively affect the prices we may charge.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
the United States and elsewhere, recent and proposed legal and regulatory changes to healthcare systems could prevent or delay
our receipt of regulatory approval for CaPre, restrict or regulate our post-approval marketing activities, and adversely affect
our ability to profitably sell CaPre. Proposals have also been made to expand post-approval requirements and to restrict sales
and promotional activities for pharmaceutical products. We do not know whether additional legislative changes will be enacted,
or whether the FDA&#8217;s regulations, guidance or interpretations will be changed, or what impact any such changes will have,
if any, on our ability to obtain regulatory approvals for CaPre. Further, the Centers for Medicare and Medicaid Services, or CMS,
frequently changes product descriptors, coverage policies, product and service codes, payment methodologies and reimbursement values.
Also, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process could significantly delay or prevent our receipt
of regulatory approval for CaPre and subject us to more stringent product labeling and post-marketing testing and other requirements.
Furthermore, for market approval in EU countries, a CVOT outcome trial is currently required. These types of trials are large and
follow patients for at least 5 years. There can be no guarantee that we will ever conduct an outcome trial to meet these requirements
to market in the EU.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
the United States, the Medicare Modernization Act, or the MMA, changed the way Medicare covers and pays for pharmaceutical products.
The MMA expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average
sales prices for drugs. In addition, the MMA authorized Medicare Part D prescription drug plans to use formularies where they can
limit the number of drugs that will be covered in any therapeutic class. As a result of the MMA and the expansion of federal coverage
of drug products, we expect there will be additional pressure to contain and reduce healthcare costs. These healthcare cost reduction
initiatives and other provisions of the MMA could decrease the coverage and price that we would receive for CaPre. While the MMA
applies only to drug benefits for Medicare beneficiaries, private health insurance companies often follow Medicare coverage policy
and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement that results from the MMA
may result in a similar reduction in payments from private health insurance companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (the Health
Care Reform Law), has broadened access to health insurance, reduced or constrained the growth of healthcare spending, enhanced
remedies against fraud and abuse, added new transparency requirements for the healthcare and health insurance industries, imposed
new taxes and fees on the health industry and imposed additional health policy reforms. Provisions of the Health Care Reform Law
affecting pharmaceutical companies include requirements to offer discounts on brand-name drugs to patients who fall within the
Medicare Part D coverage gap, commonly referred to as the &#8220;donut hole&#8221;, and to pay an annual non-tax deductible fee
to the federal government based on each company&#8217;s market share of prior year total sales of branded products to certain federal
healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs and Department of Defense. The Healthcare Reform
Law also includes significant provisions that encourage state and federal law enforcement agencies to increase activities related
to preventing, detecting and prosecuting those who commit fraud, waste and abuse in federal healthcare programs, including Medicare,
Medicaid and Tricare.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Despite
initiatives to invalidate the Health Care Reform Law, the U.S. Supreme Court has upheld key aspects of it. There is still uncertainty
with respect to the impact the current U.S. presidential administration and the U.S. Congress may have, if any, and the effects
of any changes will likely take time to unfold. As judicial challenges and legislative initiatives to modify, limit, or repeal
the Healthcare Reform Law continue to evolve, the Health Care Reform Law may be significantly changed and we do not know whether
any such changes could have significant negative financial impact on the development or potential profitability of CaPre. At this
time, it remains unclear whether there will be any changes made to the Health Care Reform Law, whether to certain provisions or
its entirety. The Health Care Reform Law or any replacement of it could continue to apply downward pressure on pharmaceutical pricing,
especially under the Medicare program, and may also increase our regulatory burdens and operating costs. Additional federal healthcare
reform measures could be adopted in the future limiting the amounts that federal and state governments will pay for healthcare
products and services, which could negatively affect the value of CaPre and our ability to achieve profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
Canada, most new patented drug prices are limited so that the cost of therapy is in the range of the cost of therapy for existing
drugs sold in Canada used to treat the same disease. As a result:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">prices of moderate and substantial improvement drugs and breakthrough drugs are also restricted
by a variety of tests;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">existing patented drug prices cannot increase by more than the Canadian Consumer Price Index; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the Canadian prices of patented medicines can never be the highest in the world.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">If
CaPre receives regulatory approval in Canada, restrictions on the price we can charge there for CaPre could reduce the value of
CaPre and our ability to generate revenue and achieve profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
many jurisdictions outside the United States, a product candidate must be approved for health care reimbursement before it can
be approved for sale. In some cases, the price that we intend to charge for CaPre will also be subject to approval. If we fail
to comply with the regulatory requirements in our target international markets or to receive required marketing approvals, our
potential market for CaPre will be reduced and our ability to realize the full market potential for CaPre will be harmed.</p>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.5pt; margin-bottom: 0pt">Reimbursement decisions by third-party
payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for CaPre, it is less
likely that it will be widely used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Even
if CaPre is approved for sale by the appropriate regulatory authorities, market acceptance and sales of CaPre will depend on reimbursement
policies and may be affected by future healthcare reform measures. Government authorities and third-party payors, such as private
health insurers and health maintenance organizations, decide which drugs they will reimburse and establish payment levels. We cannot
be certain that reimbursement will be available for CaPre. If reimbursement is not available or is available on a limited basis,
we may not be able to successfully commercialize CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">There
may be significant delays in obtaining coverage and reimbursement for newly-approved drugs, and coverage may be more limited than
the purposes for which the drug is approved by the FDA or other regulatory authorities. Moreover, eligibility for coverage and
reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research,
development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also be
insufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of a drug and
the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated
into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government
healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries
where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable payment
rates from both government-funded and private payors for CaPre could have a material adverse effect on our operating results and
our overall financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">Even if we obtain
FDA approval of CaPre, we may never obtain approval or commercialize it outside of the United States, which would limit our ability
to realize CaPre&#8217;s full market potential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
order to market CaPre outside of the United States, we must establish and comply with numerous and varying regulatory requirements
of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities
in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other
country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative
review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may
require additional preclinical studies or clinical trials, which would be costly and time consuming. Regulatory requirements can
vary widely from country to country and could delay or prevent the introduction of CaPre in those countries. In addition, our failure
to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other
countries. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals,
our target market will be reduced and our ability to realize the full market potential of CaPre will be harmed.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">If we or our
third-party service providers fail to comply with healthcare laws and regulations or government price reporting laws, we could
be subject to civil or criminal penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
addition to the FDA&#8217;s restrictions on marketing pharmaceutical products, several other types of federal and state
healthcare fraud and abuse laws restrict marketing practices in the pharmaceutical industry. These laws include the U.S.
Anti-Kickback Statute, U.S. False Claims Act and similar state laws. The U.S. Anti-Kickback Statute prohibits, among other
things, offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, or ordering
any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. A
person or entity does not need to have actual knowledge of the U.S.<font style="font-family: Times New Roman, Times, Serif">&nbsp; </font>Anti-Kickback
Statute or special intent to violate the law in order to have committed a violation. This statute has been interpreted
broadly to apply to arrangements between pharmaceutical manufacturers and prescribers, dispensers, purchasers and formulary
managers. The exemptions and safe harbors from prosecution are drawn narrowly and we may fail to meet all of the criteria for
safe harbor protection from anti-kickback liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.75pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
addition, the Health Care Reform Law provides that the government may assert that a claim including items or services resulting
from a violation of the U.S. Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the U.S. False Claims
Act. Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment
to the federal government or knowingly making, or causing to be made, a false statement to get a false claim paid. The &#8220;qui
tam&#8221; provisions of the False Claims Act allow a private individual to bring civil actions on behalf of the federal government
alleging that the defendant has submitted a false claim to the federal government. These individuals, sometimes known as &#8220;relators&#8221;
or, more commonly, as &#8220;whistleblowers&#8221;, may share in any amounts paid by the entity to the government in fines or settlement.
The number of filings of qui tam actions has increased significantly in recent years, causing more healthcare companies to have
to defend a case brought under the federal False Claim Act. If an entity is determined to have violated the federal False Claims
Act, it may be required to pay up to three times the actual damages sustained by the government, plus attorneys&#8217; fees and
costs, and civil penalties of up to US$21,563 for each separate false claim. Certain administrative sanctions, up to and including
exclusion of an entity from participation in the federal healthcare programs, may also ensue.</p>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.75pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Additional laws and regulations include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 31.5pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the federal Anti-Inducement Law (also known as the Civil Monetary Penalties Law), which prohibits
a person from offering or transferring remuneration to a Medicare or State healthcare program beneficiary that the person knows
or should know is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner or supplier of any
item or service for which payment may be made, in whole or in part, by Medicare or a State healthcare program;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 31.5pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the Ethics in Patient Referrals Act of 1989, commonly referred to as the Stark Law, which prohibits
physicians from referring Medicare or Medicaid patients for certain designated health services where that physician or family member
has a financial relationship with the entity providing the designated health service, unless an exception applies;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 31.5pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the U.S. federal Health Insurance Portability and Accountability Act (HIPAA), as amended by the
Health Information Technology for Economic and Clinical Health Act (HITECH), which created additional federal criminal statutes
that prohibit, among other things, schemes to defraud healthcare programs and imposes requirements on certain types of people and
entities relating to the privacy, security, and transmission of individually identifiable health information, and requires notification
to affected individuals and regulatory authorities of breaches of security of individually identifiable health information;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 31.5pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices,
biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance
Program, to report annually to the CMS information related to payments and other transfers of value to physicians, other healthcare
providers and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and
their immediate family members, which is published in a searchable form on an annual basis;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 31.5pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program
or making false statements relating to healthcare matters;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 31.5pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply
to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party
payors, including private insurers, and some state laws require pharmaceutical companies report or disclose pricing or other financial
information and to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance
guidance promulgated by the federal government; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 31.5pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws, which generally
prohibit companies and their intermediaries from making improper payments to government officials for the purpose of obtaining
or retaining business. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution
and have a negative impact on our business, results of operations and reputation.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Over
the past few years, a number of pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety
of alleged prohibited promotional and marketing activities, such as providing free trips, free goods, sham consulting fees and
grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then
used by federal programs to set reimbursement rates; engaging in off-label promotion that caused claims to be submitted to Medicaid
for non-covered, off-label uses; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability
for Medicaid rebates. Most states also have statutes or regulations similar to the U.S. Anti-Kickback Statute and the U.S. False
Claims Act, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply
regardless of the payor. Sanctions under these federal and state laws may include civil monetary penalties, exclusion of a manufacturer&#8217;s
products from reimbursement under government programs, criminal fines and imprisonment. Settlements of U.S. government litigation
may include Corporate Integrity Agreements with commitments for monitoring, training, and reporting designed to prevent future
violations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Any
action against us for an alleged or suspected violation of these laws could cause us to incur significant legal expenses and could
divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving
and sustaining compliance with these laws and regulations may be costly to us in terms of money, time and resources. If we or any
strategic partners, manufacturers or service providers fail to comply with these laws, we could be subject to enforcement actions,
including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">adverse regulatory inspection findings;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">warning letters;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">voluntary or mandatory product recalls or public notification or medical product safety alerts
to healthcare professionals;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">restrictions on, or prohibitions against, marketing our products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">restrictions on, or prohibitions against, importation or exportation of our products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">suspension of review or refusal to approve pending applications or supplements to approved applications;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">exclusion from participation in government-funded healthcare programs;</td></tr></table>
<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">exclusion from eligibility for the award of government contracts for our products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">suspension or withdrawal of product approvals;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">product seizures;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">injunctions; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">civil and criminal penalties and fines.</td></tr></table>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We rely on third parties to conduct our
clinical trials for CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
rely heavily on contract research organizations, or CROs, to monitor and manage data for our preclinical studies and clinical trials
for CaPre. While we only control certain aspects of the CRO&#8217;s activities, we nevertheless are responsible for ensuring that
our clinical trials are conducted in accordance with applicable protocols, legal, regulatory and scientific standards, and our
reliance on the CRO does not relieve us from those responsibilities. We and the CRO are required to comply with cGCPs, which are
regulations and guidelines enforced by the FDA, Health Canada and comparable foreign regulatory authorities for any products in
clinical development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
FDA enforces these cGCP regulations through periodic inspections of trial sponsors, principal investigators and trial sites. If
we or the CRO fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable
and the FDA, Health Canada or comparable foreign regulatory authorities may require us to perform additional clinical trials before
approving our marketing applications for CaPre. Upon inspection, the FDA could determine that our clinical trials do not comply
with cGCPs. In addition, our clinical trials must be conducted with products produced under cGMP regulations and require a large
number of test subjects. If we or the CRO fail to comply with these regulations, we may have to repeat preclinical studies or clinical
trials for CaPre, which would delay the regulatory approval process and could also subject us to enforcement action up to and including
civil and criminal penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">If
our relationship with a CRO terminates, we may not be able to enter into arrangements with alternative CROs. If the CRO does not
successfully carry out its duties or obligations or meet expected deadlines, if it needs to be replaced or if the quality or accuracy
of the clinical data it obtains is compromised due to the failure to adhere to our clinical protocols, regulatory requirements
or for other reasons, we may have to extend, delay or terminate our preclinical studies or clinical trials, and we may not be able
to obtain regulatory approval for or successfully commercialize CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
third parties conducting our preclinical studies and clinical trials at CROs will not be our employees and, except for remedies
available to us under our agreements with the CROs, we cannot control whether or not they devote sufficient time and resources
to our preclinical, clinical and nonclinical programs. These third parties may also have relationships with other commercial entities,
including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could
affect their performance on our behalf.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The research, development and manufacture
of CaPre involves using potentially hazardous materials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
research and development activities relating to CaPre involve the controlled use of potentially hazardous substances, including
chemical materials such as acetone. Our manufacturers for CaPre will be subject to federal, provincial, state and local laws and
regulations in Canada, the United States and in other jurisdictions governing laboratory procedures and the use, manufacture, storage,
handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#8217; procedures for using,
handling, storing and disposing of these materials comply with legally prescribed standards, we cannot completely eliminate the
risk of contamination or injury resulting from medical or hazardous materials. If any such contamination or injury were to occur,
we may incur liability or local, city, provincial, state or federal authorities may curtail the use of these materials and interrupt
our business operations and the production of CaPre. In the event of an accident, we could be held liable for damages or penalized
with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or
hazardous materials. Complying with environmental, health and safety laws and regulations is expensive, and current or future environmental
regulations may impair our research, development and production efforts relating to CaPre, which could harm our business, prospects,
financial condition or results of operations. Although we maintain workers&#8217; compensation insurance to cover us for costs
and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not
provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort
claims that may be asserted against us in connection with our storage or disposal of potentially hazardous materials. In addition,
we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.
These laws and regulations may make it more difficult for us to conduct our research, development or production activities relating
to CaPre and if we fail to comply with them, we could have substantial fines, penalties or other sanctions imposed against us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">If product liability lawsuits are brought
against us, we may incur substantial liabilities and may be required to cease the sale, marketing and distribution of CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
face a potential risk of product liability associated with any future commercialization of CaPre or any other future product candidate
we develop. For example, we may be sued if CaPre allegedly causes injury. Any such product liability claims may include allegations
of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability
and a breach of warranties. Claims could also be asserted under U.S. state or Canadian provincial or other foreign consumer protection
legislation. If we cannot successfully defend against product liability claims, we may incur substantial liabilities or may be
required to cease the sale, marketing and distribution of CaPre. Even successful defense against product liability claims would
require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result
in:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">decreased demand for CaPre or any future products that we may develop;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">injury to our reputation;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">costs to defend the related litigation;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">a diversion of management&#8217;s time and our resources;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">substantial monetary awards to consumers, trial participants or patients;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">product recalls, withdrawals or labeling, marketing or promotional restrictions;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">loss of revenue;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">an inability to commercialize CaPre; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">a decline in the price of our common shares.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">If
we are unable to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product
liability claims, the commercialization of CaPre or any other product candidates we develop could be hindered or prevented. We
currently carry product liability insurance, in the amount of $10.0 million in the aggregate. Any claim that may be brought against
us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that
is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject
to a product liability claim for which we have no coverage. In the event of a successful product liability claim against us, we
may have to pay from our own resources any amounts awarded by a court or negotiated in a settlement that exceed coverage limitations
or that is not covered by our insurance, and we may not have, or be able to obtain, sufficient funds to pay such amounts.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We may not
achieve our publicly announced milestones on time, or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">From
time to time, we may publicly announce the timing of certain events we expect to occur, such as the anticipated timing of results
from our clinical trials. These statements are forward-looking and are based on the best estimate of management at the time relating
to the occurrence of the events. However, the actual timing of these events may differ from what has been publicly disclosed. The
timing of events such as completion of a clinical trial, discovery of a new product candidate, filing of an application to obtain
regulatory approval, beginning of commercialization of products, or announcement of additional clinical trials for a product candidate
may ultimately vary from what is publicly disclosed. For example, we cannot provide assurances that we will complete our ongoing
Phase 3 clinical trial for CaPre, that we will make regulatory submissions or receive regulatory approvals as planned, or that
we will be able to adhere to plans for the scale-up of manufacturing and launch of CaPre. These variations in timing may occur
as a result of different events, including the nature of the results obtained during a clinical trial or during a research phase,
problems with a supplier or a distribution partner or any other event having the effect of delaying the publicly announced timeline.
We undertake no obligation to update or revise any forward-looking information, whether as a result of new information, future
events or otherwise, except as otherwise required by law. Any variation in the timing of previously-announced milestones could
have a material adverse effect on our business, financial condition or operating results and the trading price of our common shares.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We may be
subject to foreign exchange rate fluctuations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
reporting currency is the Canadian dollar. However, many of our expenses, such as CaPre&#8217;s chief manufacturing organization&#8217;s
production activities and certain CRO arrangements for our ongoing TRILOGY Phase 3 program, currently are and/or are expected to
be, denominated in foreign currencies, including European euros and U.S. dollars. As we currently complete financings in both Canadian
and U.S. dollars, both currencies are maintained and used to make required payments in the applicable currency. Though we plan
to implement measures designed to reduce our foreign exchange rate exposure, the U.S. dollar/Canadian dollar and European euro/Canadian
dollar exchange rates have fluctuated significantly in the recent past and may continue to do so, which could have a material adverse
effect on our business, financial position and results of operations.</p>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">In the past,
Neptune supplied us with the krill oil needed to produce CaPre for our clinical programs, including the krill oil needed for our
TRILOGY Phase 3 program, and we are now evaluating alternative suppliers for commercial supply.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We sourced all of our
krill oil from Neptune in the past to produce CaPre. We have sufficient krill oil inventories that we anticipate will be required
to complete our TRILOGY Phase 3 program. However, in light of Neptune&#8217;s sale of its krill oil business and inventory to Aker
in August 2017, we have been validating several alternative suppliers of krill oil. While we believe that these alternative supplies
of krill oil can meet our specifications and will be readily available, we do not have enough experience with any one of them to
guarantee that these alternative supplies of krill oil will be of comparable quality as compared to the krill oil provided by Neptune,
which could negatively affect the cost of CaPre. Our reliance on third-party suppliers for krill oil exposes us to risks such as
potential fluctuations in supply and reduced control over our production costs and delivery schedules for CaPre.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">CaPre may
cause or be perceived to cause undesirable side effects or have other properties that could delay or prevent its regulatory approval,
limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval,
if any.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Many of the patients
that we expect to enroll in our ongoing Phase 3 clinical trial may have pre-existing disorders. While such disorders may lead to
serious adverse events during the clinical trial that may be found to be unrelated to CaPre, such events may create a negative
safety perception and adversely impact market acceptance of CaPre following any approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">If unacceptable side
effects arise during the clinical trials for CaPre, we, the FDA or comparable foreign regulatory authorities, the Institutional
Review Boards, or IRBs, or independent ethics committees at the institutions in which our studies are conducted, could suspend
or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials
or deny approval of our product candidates for any or all targeted indications. Side effects, whether treatment-related or not,
could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product
liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff.
Inadequate training in recognizing or managing the potential side effects of CaPre could result in patient injury. Any of these
occurrences may harm our business, financial condition and prospects significantly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Moreover, clinical
trials of CaPre are conducted in carefully defined sets of patients who have agreed to enter into clinical trials. Consequently,
it is possible that our clinical trials, or those of any future collaborator or third party researcher, may indicate an apparent
positive effect of CaPre that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable
side effects. If, following approval of a product candidate, we, or others, discover that the product is less effective than previously
believed or causes undesirable side effects that were not previously identified during the clinical trial phase, any of the following
adverse events could occur:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">regulatory authorities may withdraw their approval of the product or seize the product;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we, or any future collaborators or third party researcher, may need to recall the product, or be
required to change the way the product is administered or conduct additional clinical trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">restrictions may be imposed on the marketing of, or the manufacturing processes for CaPre;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">regulatory authorities may require the addition of labeling statements;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we, or any future collaborators, may be required to issue a communication outlining the risks of
the previously unidentified side effects for distribution to patients;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we, or any future collaborators, could be sued and held liable for harm caused to patients;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">CaPre may become less competitive; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our reputation may suffer.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Any
of these events could harm our business and operations and could negatively impact our share price.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Risks Related to Intellectual Property</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b><i>In addition to our own patents, CaPre
is covered by patents that are sublicensed to us by Neptune and Aker.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In addition to our
proprietary patent applications, pursuant to a license agreement we entered into with Neptune in August 2008, which was later amended
on February 9, 2009 and March 7, 2013 (the &#8220;License Agreement&#8221;), we have a license to use certain intellectual property
developed by Neptune and now owned by Aker to develop and commercialize CaPre, and our novel and active pharmaceutical ingredients,
or APIs, for use in pharmaceutical and medical food applications in the cardiovascular field.</p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Moreover, the intellectual
property which was licensed to us has recently been acquired by Aker. Aker has granted to Neptune the right to sublicense to us
certain intellectual property as necessary to allow us to maintain its license grant under the License Agreement. Accordingly,
the license granted to us under the License Agreement remains in full force.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Disputes may arise
between us and Neptune or Aker regarding the intellectual property that is subject to the License Agreement, including with respect
to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the scope of rights granted under the License Agreement and other interpretation-related issues;
and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our right to sublicense patent and other rights to third parties under collaborative development
relationships.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">If our sublicense with
Neptune is terminated due to a breach by us of its terms (or should the License Agreement otherwise terminate) and we are unable
to enter into a direct license agreement with Aker, we may not be able to manufacture and market CaPre prior to the expiration
of the licensed patents in 2022. Any such occurrence could delay our launch by 6 to 12 months, which would have a material adverse
effect on our business and financial condition.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">It is difficult and costly to protect
our intellectual property rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The success of our business will largely depend on
our ability to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">obtain and maintain patents, trade secret protection and operate without infringing the intellectual
proprietary rights of third parties;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">successfully defend our patents, including enforcing licensed patents through the licensor Neptune/Aker,
against third-party challenges; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">successfully enforce our patents against third party competitors.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
patents and/or proprietary technologies could be circumvented through the adoption of competitive, though non-infringing, processes
or products. The patent positions of pharmaceutical companies can be highly uncertain and involve complex legal, scientific and
factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in interpretations
of patent laws may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowable
or enforceable in our patents, including the patents licensed to us by Neptune.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We face risks that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our rights under our Canadian, U.S. or foreign patents or other patents that Neptune or other third
parties license to us could be curtailed;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we may not be the first inventor of inventions covered by our issued patents or pending applications
or be the first to file patent applications for those inventions;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our pending or future patent applications may not be issued with the breadth of claim coverage
sought by us, or be issued at all;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our competitors could independently develop or patent technologies that are substantially equivalent
or superior to our technologies;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">our trade secrets could be learned independently by our competitors;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the steps we take to protect our intellectual property may not be adequate; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">effective patent, trademark, copyright and trade secret protection may be unavailable, limited
or not sought by us in some foreign countries.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Further,
patents have a limited lifespan. In the United States, a patent generally expires 20 years after it is filed (or 20 years after
the filing date of the first non-provisional U.S. patent application to which it claims priority). While extensions may be available,
the life of a patent, and the protection it affords, is limited. Without patent protection for CaPre or any other of our future
product candidates, we may be open to competition from generic versions of CaPre or our other future product candidates. Further,
the extensive period of time between patent filing and regulatory approval for a product candidate limits the time during which
we can market that product candidate under patent protection. Patents owned by third parties could have priority over patent applications
filed or in-licensed by us, or we or our licensors could become involved in interference, opposition or invalidity proceedings
before U.S., Canadian or foreign patent offices. The cost of defending and enforcing our patent rights against infringement charges
by other patent holders may be significant and could limit our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.5pt; margin-bottom: 0pt">CaPre may infringe the intellectual
property rights of others, which could increase our costs and delay or prevent our development and commercialization efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
success depends in part on avoiding infringement of the proprietary technologies of others. The pharmaceutical industry has been
characterized by frequent litigation regarding patent and other intellectual property rights. Identification of third party patent
rights that may be relevant to our proprietary or licensed technology is difficult because patent searching is imperfect due to
differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Additionally,
because patent applications are maintained in secrecy until the application is published, we may be unaware of third-party patents
that may be infringed by our development and commercialization of CaPre or any other future product candidate. There may be certain
issued patents and patent applications claiming subject matter that we may be required to license in order to research, develop
or commercialize CaPre, and any such patents and patent applications may not be available to license on commercially reasonable
terms, or at all. If claims of patent infringement are asserted by third parties against us, they could be time-consuming and may:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">result in costly litigation;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">divert the time and attention of our technical personnel and management;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">delay our clinical trials for CaPre;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">prevent us from commercializing CaPre until the asserted patent expires or is held finally invalid
or not infringed in court;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">require us to cease or to modify our use of the technology and/or develop non-infringing technology;
or</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">require us to enter into royalty or licensing agreements.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Others may hold
proprietary rights that could prevent CaPre from being marketed. Any patent-related legal action against us claiming damages and
seeking to enjoin commercial activities relating to CaPre or our processes could subject us to potential liability for damages
and require us to obtain a license to continue to manufacture or market CaPre or any other future prescription drug candidates.
We might not prevail in any such actions or if any license is required under any of these patents it may not be available on commercially
acceptable terms, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Even
if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the
same technology or intellectual property rights licensed to us. We could be forced to redesign CaPre or any other future product
candidates or processes to avoid infringement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual
property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary
rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Some
of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have
substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings
could delay our research and development efforts and limit our ability to continue our operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">A number
of companies, including several major pharmaceutical companies, have conducted research on pharmaceutical uses of OM3 fatty acids,
which has resulted in the filing of many patent applications related to this research. We are aware of third-party U.S., Canadian
or other foreign patents that contain broad claims related to methods of using these general types of compounds, which may be construed
to include potential uses of CaPre. If we were to challenge the validity of these or any other issued U.S., Canadian or other foreign
patents in court, we would need to overcome a statutory presumption of validity that attaches to every U.S. and Canadian patent.
This means that, in order to prevail, we would have to present clear and convincing evidence as to the invalidity of the other
party&#8217;s patent&#8217;s claims. If we were to challenge the validity of any issued U.S. patent in an administrative trial
before the Patent Trial and Appeal Board in the United States Patent and Trademark Office, or USPTO, we would have to prove that
the claims are unpatentable by a preponderance of the evidence. If there are disputes over our intellectual property rights, a
jury and/or court may not find in our favor on questions of infringement, validity or enforceability.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">If we do not protect
our trademark for CaPre, we may not be able to build name recognition in our markets of interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
have registered CaPre as a trademark in several jurisdictions. Our trademark may be challenged, infringed, circumvented or declared
generic or determined to be infringing on other marks. We may not be able to protect our rights to this trademark or may be forced
to stop using this name, which we need for name recognition by potential strategic partners and customers. If we are unable to
establish name recognition based on our trademark, we may not be able to compete effectively, and our business may be adversely
affected.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">We may be involved in lawsuits
to protect or enforce our patents or the patents of our licensors, which could be expensive, time- consuming and unsuccessful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Competitors
may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file
infringement claims, which can be expensive and time-consuming. If we or our licensors were to initiate legal proceedings against
a third party to enforce a patent covering CaPre or our technology, the defendant could counterclaim that our or our licensor&#8217;s
patent is invalid or unenforceable. In patent litigation, defendant counterclaims alleging invalidity or unenforceability are commonplace.
Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements; for example, lack of
novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected
with prosecution of the patent withheld relevant information from the patent office, such as the USPTO, or made a misleading statement,
during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable.
With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or
our licensors and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity
or unenforceability, we would lose at least part, and perhaps all, of the patent protection on CaPre or certain aspects of our
platform technology. Such a loss of patent protection could have a material adverse impact on our business. Patents and other intellectual
property rights also will not protect our technology if competitors design around our protected technology without legally infringing
our patents or other intellectual property rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
addition, in an infringement proceeding, a court may refuse to stop the other party from using the technology at issue on the grounds
that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put
one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications
at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would
be a substantial diversion of employee resources from our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Interference
proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect
to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent
rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party.
Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, or at all. Litigation
or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial
costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation
of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully
as in Canada and the United States. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type
of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings
or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse
effect on the price of our common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other
requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance
with these requirements.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Changes in patent law could diminish the
value of patents in general, thereby impairing our ability to protect CaPre and any of our other future product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Numerous
recent changes to the patent laws and proposed changes to the rules of the various patent offices around the world may have a significant
impact on our ability to protect our technology and enforce our intellectual property rights. These changes may lead to increasing
uncertainty with regard to the scope and value of our issued patents and to our ability to obtain patents in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Once
granted, patents may remain open to opposition, interference, re-examination, post-grant review, <i>inter partes</i> review, nullification
derivation and opposition proceedings in court or before patent offices or similar proceedings for a given period after allowance
or grant, during which time third parties can raise objections against the initial grant. In the course of any such proceedings,
which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted
claims attacked, or may lose the allowed or granted claims altogether. Depending on decisions by authorities in various jurisdictions,
the laws and regulations governing patents could change in unpredictable ways that may weaken our and our licensors&#8217; ability
to obtain new patents or to enforce existing patents we and our licensors or partners may obtain in the future.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We may not
be able to protect our intellectual property rights throughout the world.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Many companies have
encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems
of some countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other
intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of
competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions
could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents
at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third
parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded,
if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world
may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Risks Relating to
Our Common Shares</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The price
of our common shares may be volatile.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Market prices for securities
in general, and specifically that of pharmaceutical companies in particular, tend to fluctuate. Factors such as the announcement
to the public or in various scientific or industry forums of technological innovations; new commercial products; patents or exclusive
rights obtained by us or others; disputes or other developments relating to proprietary rights, including patents, litigation matters
and our ability to obtain patent protection for our technologies; the commencement, enrollment or results of future clinical trials
we may conduct, or changes in the development status of our product candidates; results or delays of pre-clinical and clinical
studies by us or others; any delay in our regulatory filings for our product candidates and any adverse development or perceived
adverse development with respect to the applicable regulatory authority&#8217;s review of such filings; a change of regulations;
additions or departures of key scientific or management personnel; overall performance of the equity markets; general political
and economic conditions; publications; failure to meet the estimates and projections of the investment community or that we may
otherwise provide to the public; research reports or positive or negative recommendations or withdrawal of research coverage by
securities analysts; actual or anticipated variations in quarterly operating results; announcements of significant acquisitions,
strategic partnerships, joint ventures or capital commitments by us or our competitors; public concerns over the risks of pharmaceutical
products and dietary supplements; unanticipated serious safety concerns related to the use of CaPre; the ability to finance, future
sales of securities by us or our shareholders; and many other factors, many of which are beyond our control, could have considerable
effects on the price of our securities. There can be no assurance that the market price of our common shares will not experience
significant fluctuations in the future. As a result of any of these factors, the market price of our securities at any given point
in time may not accurately reflect our value or the value of our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In addition, the stock
market in general, and pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have
often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may
negatively affect the market price of our common shares, regardless of our actual operating performance. In the past, securities
class action litigation has often been instituted against companies following periods of volatility in the market price of these
securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention
and resources, which would harm our business, operating results or financial condition.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 10.2pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 10.2pt; margin-bottom: 0pt">Raising additional capital may cause
dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our technologies or product
candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We may seek additional
capital through a combination of public and private equity offerings, debt financings, strategic partnerships and alliances and
licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
the ownership interests of our shareholders will be diluted, and the terms may include liquidation or other preferences that adversely
affect the rights of our shareholders. The incurrence of indebtedness by us would result in increased fixed payment obligations
and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our
ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability
to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with
third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms
unfavorable to us.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The market
price of our common shares could decline as a result of operating results falling below the expectations of investors or fluctuations
in operating results each quarter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our net losses and
expenses may fluctuate significantly and any failure to meet financial expectations may disappoint securities analysts or investors
and result in a decline in the price of our common shares. Our net losses and expenses have fluctuated in the past and are likely
to do so in the future. These fluctuations could cause the market price of our common shares to decline. Some of the factors that
could cause the Corporation&#8217;s net losses and expenses to fluctuate include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">results of preclinical studies and clinical trials, or the addition or termination of preclinical
studies, clinical trials or funding support;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the fluctuations in valuation of our derivative warrant liabilities;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the timing of the release of results from any preclinical studies and clinical trials;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the inability to complete product development in a timely manner that results in a failure or delay
in receiving the required regulatory approvals or allowances to commercialize product candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the timing of regulatory submissions and approvals;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the timing and willingness of any current or future collaborators to invest the resources necessary
to commercialize our products;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the outcome of any litigation;</td></tr></table>
<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">changes in foreign currency fluctuations;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">competition;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the timing of achievement and the receipt of milestone payments from current or future third parties;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">failure to enter into new or the expiration or termination of current agreements with third parties;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">failure to introduce our products to the market in a manner that generates anticipated revenues;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">execution of any new collaboration, licensing or similar arrangement, and the timing of payments
we may make or receive under such existing or future arrangements or the termination or modification of any such existing or future
arrangements;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding
in which we may become involved;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">additions and departures of key personnel;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint
ventures, strategic investments or changes in business strategy;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">if any of our product candidates receives regulatory approval, market acceptance and demand for
such product candidates;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">regulatory developments affecting our product candidates or those of our competitors; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">changes in general market and economic conditions.</td></tr></table>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><font style="font-style: normal; font-weight: normal">If
our quarterly operating results fall below the expectations of investors or securities analysts, the market price of our common
shares could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the market
price of the common shares to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily
meaningful and should not be relied upon as an indication of our future performance.</font></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">There can
be no assurance that an active market for our common shares will be sustained.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">There can be no assurance
that an active market for our common shares will be sustained. Holders of common shares may be unable to sell their investments
on satisfactory terms. As a result of any risk factor discussed herein, the market price of our common shares at any given point
in time may not accurately reflect our long-term value. Furthermore, responding to these risk factors could result in substantial
costs and divert management&#8217;s attention and resources. Substantial and potentially permanent declines in the value of our
common shares may result and adversely affect the liquidity of the market for our common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Other factors unrelated
to our performance that may have an effect on the price and liquidity of our common shares include: extent of analyst coverage;
lessening in trading volume and general market interest in our common shares; the size of our public float; and any event resulting
in a delisting of our common shares.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">A large number
of common shares may be issued and subsequently sold upon the exercise of existing warrants. The sale or availability for sale
of existing warrants or other securities convertible into common shares may depress the price of our common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">To the extent that
existing holders of warrants sell common shares issued upon the exercise of warrants, the market price of our common shares may
decrease due to the additional selling pressure in the market. The risk of dilution from issuances of common shares underlying
existing warrants may cause shareholders to sell their common shares, which could further contribute to any decline in our common
share market price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Any downward pressure
on the price of our common shares caused by the sale of common shares issued upon the exercise of existing warrants could encourage
short sales by third parties. In a short sale, a prospective seller borrows common shares from a shareholder or broker and sells
the borrowed common shares. The prospective seller anticipates that the common share price will decline, at which time the seller
can purchase common shares at a lower price for delivery back to the lender. The seller profits when the common share price declines
because it is purchasing common shares at a price lower than the sale price of the borrowed common shares. Such short sales of
common shares could place downward pressure on the price of our common shares by increasing the number of common shares being sold,
which could lead to a decline in the market price of our common shares.</p>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We do not
currently intend to pay any cash dividends on our common shares in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We have never paid
any cash dividends on our common shares and we do not anticipate paying any cash dividends on our common shares in the foreseeable
future because, among other reasons, we currently intend to retain any future earnings to finance our business. The future payment
of cash dividends will be dependent on factors such as cash on hand and achieving profitability, the financial requirements to
fund growth, our general financial condition and other factors our board of directors may consider appropriate in the circumstances.
Until we pay cash dividends, which we may never do, our shareholders will not be able to receive a return on their common shares
unless they sell them. See &#8220;Dividend Policy&#8221;.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">If we fail to meet applicable
listing requirements, the NASDAQ Stock Market or the TSXV may delist our common shares from trading, in which case the liquidity
and market price of our common shares could decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
common shares are currently listed on the NASDAQ Stock Market and the TSXV, but we cannot assure you that our securities will continue
to be listed on the NASDAQ Stock Market and the TSXV in the future. In the past, we have received notices from the NASDAQ Stock
Market that we have not been in compliance with its continued listing standards, and we have taken responsive actions and regained
compliance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">On
May 16, 2019, we received written notification from the NASDAQ Listing Qualifications Department for failing to maintain a minimum
bid price of U.S.$1.00 per share for the last 30 consecutive business days, as required by NASDAQ Listing Rule 5550(a)(2) &#8211;
bid price (the &#8220;<b>Minimum Bid Price Rule</b>&#8221;). The NASDAQ notification has no immediate effect on the listing of
our common shares. Under NASDAQ Listing Rule 5810(c)(3)(A) &#8211; compliance period, we have 180 calendar days, or until November
12, 2019, to regain compliance. If at any time over this period the bid price of our common shares closes at U.S.$1.00 per share
or more for a minimum of ten (10) consecutive business days, NASDAQ will provide written confirmation of compliance and the matter
will be closed. If we do not regain compliance within the initial 180-day period, but otherwise meet the continued listing requirements
for market value of publicly-held shares and all other initial listing standards for the NASDAQ Listing Rule 5505 &#8211; Capital
Market criteria, except for the Minimum Bid Price Rule, we may be eligible for an additional 180 calendar days to regain compliance.
If we are not granted additional time, then our common shares will be subject to delisting, at which time we may appeal the delisting
determination to a NASDAQ Hearings Panel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">If
we fail to comply with listing standards and the NASDAQ Stock Market or TSXV delists our common shares, we and our shareholders
could face significant material adverse consequences, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">a limited availability of market quotations for our common shares;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">reduced liquidity for our common shares;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">a determination that our common shares are &#8220;penny stock&#8221;, which would require brokers
trading in our common shares to adhere to more stringent rules and possibly result in a reduced level of trading activity in the
secondary trading market for our common shares;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">a limited amount of news about us and analyst coverage of us; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">a decreased ability for us to issue additional equity securities or obtain additional equity or
debt financing in the future.</td></tr></table>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We may pursue opportunities
or transactions that adversely affect our business and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our management, in
the ordinary course of our business, regularly explores potential strategic opportunities and transactions. These opportunities
and transactions may include strategic joint venture relationships, significant debt or equity investments in us by third parties,
the acquisition or disposition of material assets, the licensing, acquisition or disposition of material intellectual property,
the development of new product lines or new applications for our existing products, significant distribution arrangements, the
sale of our common shares and other similar opportunities and transactions. The public announcement of any of these or similar
strategic opportunities or transactions might have a significant effect on the price of our common shares. Our policy is to not
publicly disclose the pursuit of a potential strategic opportunity or transaction unless we are required to do so by applicable
law, including applicable securities laws relating to continuous disclosure obligations. There can be no assurance that investors
who buy or sell securities are doing so at a time when we are not pursuing a particular strategic opportunity or transaction that,
when announced, would have a significant effect on the price of our common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In addition, any such
future corporate development may be accompanied by certain risks, including exposure to unknown liabilities of the strategic opportunities
and transactions, higher than anticipated transaction costs and expenses, the difficulty and expense of integrating operations
and personnel of any acquired companies, disruption of our ongoing business, diversion of management&#8217;s time and attention,
and possible dilution to shareholders. We may not be able to successfully overcome these risks and other problems associated with
any future acquisitions and this may adversely affect our business and financial condition.</p>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">As a foreign private issuer, we are subject
to different U.S. securities laws and regulations than a domestic U.S. issuer, which may limit the information publicly available
to our U.S. shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
are a foreign private issuer under applicable U.S. federal securities laws, and therefore, we are not required to comply with all
the periodic disclosure and current reporting requirements of the U.S. Securities and Exchange Act of 1934, as amended (the &#8220;<b>Exchange
Act</b>&#8221;). As a result, we do not file the same reports that a U.S. domestic issuer would file with the SEC, although we
are required to file with or furnish to the SEC the continuous disclosure documents that we are required to file in Canada under
Canadian securities laws. In addition, our officers, directors and principal shareholders are exempt from the reporting and short-swing
profit recovery provisions of Section 16 of the Exchange Act. Therefore, our shareholders may not know on as timely a basis when
our officers, directors and principal shareholders purchase or sell common shares as the reporting periods under the corresponding
Canadian insider reporting requirements are longer. In addition, as a foreign private issuer, we are exempt from the proxy rules
under the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We cannot be certain
that we will qualify as a foreign private issuer for our next fiscal year. If we no longer qualify as a foreign private issuer,
we will no longer be exempt from the more stringent disclosure requirements applicable to U.S. companies.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">As a non-accelerated filer, we are not
required to comply with the auditor attestation requirements of the Sarbanes-Oxley Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
are a non-accelerated filer under the Exchange Act and not required to comply with the auditor attestation requirements of Section
404(b) of the Sarbanes-Oxley Act of 2002. Therefore, our internal controls over financial reporting will not receive the level
of review provided by the process relating to the auditor attestation included in annual reports of issuers that are subject to
the auditor attestation requirements. In addition, we cannot predict if investors will find our common shares less attractive because
we are not required to comply with the auditor attestation requirements. If some investors find our common shares less attractive
as a result, there may be a less active trading market for our common shares and trading price for our common shares may be negatively
affected.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">U.S. investors may be unable to enforce
certain judgments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
are a company existing under the <i>Business Corporations Act </i>(Qu&#233;bec). Some of our directors and officers are residents
of Canada, and substantially all of our assets are located outside the United States. As a result, it may be difficult to effect
service within the United States upon us or upon some of our directors and officers. Execution by U.S. courts of any judgment obtained
against us or any of our directors or officers in U.S. courts may be limited to assets located in the United States. It may also
be difficult for holders of securities who reside in the United States to realize in the United States upon judgments of U.S. courts
predicated upon civil liability of us and our directors and executive officers under the U.S. federal securities laws. There may
be doubt as to the enforceability in Canada against non-U.S. entities or their controlling persons, directors and officers who
are not residents of the United States, in original actions or in actions for enforcement of judgments of U.S. courts, of liabilities
predicated solely upon U.S. federal or state securities laws.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">There is a significant risk that we may
be classified as a PFIC for U.S. federal income tax purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Current
or potential investors in our common shares who are U.S. holders should be aware that, based on our most recent financial statements
and projections and given uncertainty regarding the composition of our future income and assets, there is a significant risk that
we may have been classified as a &#8220;passive foreign investment company&#8221; or &#8220;PFIC&#8221; for the 2019 taxable year
and may be classified as a PFIC for our current taxable year and possibly subsequent years. If we are a PFIC for any year during
a U.S. holder&#8217;s holding period of our common shares, then such U.S. taxpayer generally will be required to treat any gain
realized upon a disposition of such common shares or any so-called &#8220;excess distribution&#8221; received on such common shares,
as ordinary income (with a portion subject to tax at the highest rate in effect), and to pay an interest charge on a portion of
such gain or excess distribution. In certain circumstances, the sum of the tax and the interest charge may exceed the total amount
of proceeds realized on the disposition, or the amount of excess distribution received, by the U.S. holder. Subject to certain
limitations, a timely and effective QEF Election under Section 1295 of the U.S. Internal Revenue Code of 1986, as amended, or the
Code, or a Mark-to-Market election under Section 1296 of the Code may be made with respect to the common shares. A U.S. holder
who makes a timely and effective QEF Election generally must report on a current basis its share of our net capital gain and ordinary
earnings for any year in which we are a PFIC, whether or not we distribute any amounts to our shareholders. A U.S. holder who makes
the Mark-to-Market Election generally must include as ordinary income each year the excess of the fair market value of their common
shares over the holder&#8217;s basis therein. This paragraph is qualified in its entirety by the discussion under the heading &#8220;Item
10.E. Taxation&#8212;U.S. Federal Income Tax Considerations of the Acquisition, Ownership, and Disposition of Common Shares&#8212;Passive
Foreign Investment Company Rules&#8221;. Each current or potential investor who is a U.S. holder should consult its own tax advisor
regarding the U.S. federal, U.S. state and local, and non-U.S. tax consequences of the acquisition, ownership, and disposition
of our common shares, the U.S. federal tax consequences of the PFIC rules, and the availability of any election that may be available
to the holder to mitigate adverse U.S. federal income tax consequences of holding shares in a PFIC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 50pt"><a name="a_012"></a>Item 4.</td><td>Information on the Company</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">A.</td><td>History and Development of the Company</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Acasti was incorporated
on February&nbsp;1, 2002 under Part 1A of the <i>Companies Act </i>(Qu&#233;bec) under the name &#8220;9113-0310 Qu&#233;bec
Inc.&#8221;. On February&nbsp;14, 2011, the <i>Business Corporations Act </i>(Qu&#233;bec) (&#8220;<b>QBCA</b>&#8221;) came into
effect and replaced the <i>Companies Act </i>(Qu&#233;bec). We are now governed by the QBCA. On August&nbsp;7, 2008, pursuant
to a Certificate of Amendment, we changed our name to &#8220;Acasti Pharma Inc.&#8221;, our share capital description, the provisions
regarding the restriction on securities transfers and our borrowing powers. On November&nbsp;7, 2008, pursuant to a Certificate
of Amendment, we changed the provisions regarding our borrowing powers. We became a reporting issuer in the Province of Qu&#233;bec
on November&nbsp;17, 2008.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Acasti&#8217;s head
and registered office is located at 545 Promenade du Centropolis, Suite 100, Laval, Qu&#233;bec H7T 0A3. We currently employ
28 full-time employees with the majority working out of our headquarters in Laval and our laboratory in Sherbrooke. Our website
address is http://www.acastipharma.com. We do not incorporate the information on or accessible
through our website into this annual report, and you should not consider any information on, or that can be accessed through, our
website as part of this annual report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Intercorporate Relationships</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We have no subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">B.</td><td>Our Business</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We are a biopharmaceutical
innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids, or OM3, delivered
both as free fatty acids and bound-to-phospholipid esters, or PLs, derived from krill oil. OM3 fatty acids have extensive clinical
evidence of safety and efficacy in lowering triglycerides, or TGs, in patients with hypertriglyceridemia, or HTG. Our lead product
candidate is CaPre, an OM3 phospholipid therapeutic, which we are developing initially for the treatment of severe HTG, a condition
characterized by very high or severe levels of TGs in the bloodstream (&#8805; 500 mg/dL). In accordance with a study published in
2009 in the Archives of Internal Medicine by Ford et al., it is estimated that three to four million people in the United States
have severe HTG. In primary qualitative market research studies commissioned by Acasti in August 2016 and November of 2017 by DP
Analytics, a division of Destum Partners, Key Opinion Leaders (KOLs), High Volume Prescribers (HVPs) and Pharmacy Benefit Managers
who were interviewed indicated a significant unmet medical need exists for an effective, safe and well-absorbing OM3 therapeutic
that can also demonstrate a positive impact on the major blood lipids associated with cardiovascular disease, or CVD, risk. We
believe that CaPre will address this unmet medical need, if our Phase 3 results reproduce what we observed in our Phase 2 data.
We initiated TRILOGY, our Phase 3 clinical program in North America, during the second half of 2017 and started clinical site activation
as planned at the end of 2017. As of the date of this annual report, patient enrollment and randomization have been completed,
and the two TRILOGY Phase 3 studies continue on schedule to report topline results by December 2019 for TRILOGY 1, and January
2020 for TRILOGY 2. We also believe the potential exists to expand CaPre&#8217;s initial indication to the roughly 36 million patients
with high TGs in the mild to moderate range (e.g., blood levels between 200 - 499 mg/dL), although at least one additional clinical
trial would likely be required to support FDA approval of a Supplemental New Drug Application (SNDA) to expand CaPre&#8217;s indication
to this segment. Data from our Phase 2 studies indicated that CaPre may have a positive effect in diabetes and other inflammatory
diseases; consequently, we may also seek to identify new potential indications for CaPre that may be appropriate for future studies
and pipeline expansion. In addition, we may also seek to in-license other cardiometabolic drug candidates for drug development
and commercialization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
four clinical trials conducted to date, we saw the following consistent results with CaPre, and we are seeking to demonstrate similar
safety and efficacy in our TRILOGY Phase 3 program:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">significant reduction of TGs and non-high density lipoprotein cholesterol (non-HDL-C) levels in
the blood of patients with mild to severe HTG;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">no deleterious effect on low-density lipoprotein cholesterol (LDL-C), or &#8220;bad&#8221; cholesterol,
with the potential to reduce LDL-C;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">potential to increase high-density lipoprotein cholesterol (HDL-C), or &#8220;good&#8221; cholesterol;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">potential to benefit diabetes patients by decreasing hemoglobin A1c (HbA1c), a marker of glucose
control;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">good bioavailability (absorption by the body), even under fasting conditions;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">no significant food effect when taken with either low-fat or high-fat meals; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">an overall safety profile similar to that demonstrated by currently marketed OM3s.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We believe that if we are able to reproduce these results in
our TRILOGY Phase 3 program, we potentially could set CaPre apart from current FDA-approved fish oil-derived OM3 treatment options,
and it could give us a significant clinical and marketing advantage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>About Hypertriglyceridemia (HTG)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">According
to the American Heart Association Scientific Statement on Triglycerides and Cardiovascular Disease from 2011, TG levels provide
important information as a marker associated with the risk for heart disease and stroke, especially when an individual also has
low levels of HDL-C and elevated levels of LDL-C. HTG can be caused by both genetic and environmental factors, including obesity,
sedentary lifestyle and high-fat diets. HTG is also associated with comorbid conditions such as chronic renal failure, pancreatitis,
nephrotic syndrome, and diabetes. Multiple epidemiological, clinical, genetic studies suggest that patients with elevated TG levels
(&#8805; 200 mg/dL) are at a greater risk of coronary artery disease, or CAD, and pancreatitis, a life-threatening condition,
as compared to those with normal TG levels. The genes regulating TGs and LDL-C are equally strong predictors of CAD. Other studies
suggest that lowering and managing TG levels may reduce these risks. In addition, the Japan EPA Lipid Intervention Study, or JELIS,
demonstrated the long-term benefit of an OM3 eicosapentaenoic acid, or EPA, in preventing major coronary events in hypercholesterolemic
patients receiving statin treatment. JELIS found a 19% relative risk reduction in major coronary events in patients with relatively
normal TGs but a more pronounced 53% reduction in the subgroup of patients with TGs &gt; 150mg/dL and HDL-C &lt; 40mg/dL. Recently
published meta-analyses by Alexander et al. (Mayo Clinic Proceedings, 2017) and Maki et al. (Journal of Clinical Lipidology, 2016)
suggest that EPA and docosahexaenoic acid, or DHA, may be associated with reducing coronary heart disease risk to a greater extent
in populations with elevated TG levels, and that drugs lowering TG and TG-rich lipoproteins may reduce cardiovascular event risk
in patients with elevated TG levels, particularly if associated with low HDL-C. More recently in November of 2018, Amarin published
the results of their REDUCE-IT cardiovascular outcome trial (CVOT), which showed that a therapeutic dose of VASCEPA at 4 grams
per day, taken on top of a statin, reduced residual cardiovascular risk by 25%. Astra Zeneca is currently investigating the potential
for EPANOVA, their therapeutic OM3 containing both EPA and DHA, taken with a statin to reduce cardiovascular risk in patients
with elevated levels of TGs and low HDL-C in their ongoing STRENGTH CVOT, the results of which are expected to be published in
2020. A table summarizing the various outcome studies conducted over approximately the last decade is set forth below. The data
from these trials support the conclusion that lowering TGs in an &#8220;at risk&#8221; patient population with the right dose
of a therapeutic drug &#8211; independent of the drug class &#8211; significantly reduces CVD risk.</p>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><img src="p25.jpg" alt=""></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">About CaPre</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">CaPre is a highly purified,
proprietary krill oil-derived mixture containing polyunsaturated fatty acids, or PUFAs, primarily composed of OM3 fatty acids,
principally eicosapentaenoic acid, or EPA, and docosahexaenoic acid, or DHA, present as a combination of phospholipid esters and
free fatty acids. EPA and DHA are well known to be complementary and beneficial for human health, and according to numerous recent
clinical studies, may promote healthy heart, brain and visual function (Kwantes and Grundmann, Journal of Dietary Supplements,
2014), and may also contribute to reducing inflammation and blood levels of TGs (Ulven and Holven, Vascular health and risk management,
2015). Krill is a rich natural source of phospholipids and OM3 fatty acids. The EPA and DHA contained in CaPre are delivered as
a combination of OM3s as free fatty acids and OM3s bound to phospholipid esters. Both forms allow these PUFAs to reach the small
intestine where they undergo rapid absorption and transformation into complex fat molecules that are required for lipid transport
in the bloodstream. We believe that EPA and DHA are more efficiently transported by phospholipids sourced from krill oil than the
EPA and DHA contained in fish oil, which are transported either by TGs (as in dietary supplements) or as ethyl esters as in other
prescription OM3 drugs (such as LOVAZA and VASCEPA). These OM3 ethyl ester prescription products must undergo additional digestion
before they are ready for transport into the bloodstream. The digestion and absorption of OM3 ethyl ester drugs requires a particular
enzymatic process that is highly dependent on the fat content of a meal &#8211; the higher the fat content, the better the OM3
ethyl ester absorption. High fat content meals are not recommended in patients with HTG. We believe that CaPre&#8217;s superior
absorption profile could represent a significant clinical advantage, since taking it with a low-fat meal represents a healthier
and more realistic regimen for patients with HTG who must follow a restricted low-fat diet. CaPre is intended to be used as a therapy
combined with positive lifestyle changes, such as a healthy diet and exercise, and can be administered either alone or with other
drug treatment regimens such as statins (a class of drug used to reduce LDL-C). CaPre is intended to be taken orally once or twice
per day in capsule form.</p>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Potential Market for CaPre</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We believe a significant opportunity exists for OM3
market expansion because, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 31.5pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">Cardiovascular diseases, or CVD, and stroke are the leading causes of morbidity and mortality in
the United States. The burden of CVD and stroke in terms of life-years lost, diminished quality of life, and direct and indirect
medical costs also remains enormous. According to the American Heart Association, in 2016, CVD cost the American healthcare system
$555 billion. By 2035, the cost is estimated to increase to $1.1 trillion;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 31.5pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">Evidence suggests potential for OM3s in other cardiometabolic indications, such as diabetes and
high blood pressure;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 31.5pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">Subgroup analyses from outcome studies conducted since 2007 such as JELIS, ACCORD-Lipid and AIM-HIGH,
have all shown that patients who entered these studies with high TGs (above 150 mg/dl) and low HDL (below 40 mg/dl) and received
a TG-lowering medication (either an OM3, fibrate or niacin) saw a relative cardiovascular risk reduction of 31 &#8211; 53% by the
end of the study when compared to placebo or standard of care;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 31.5pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">Based on the assumption that the REDUCE-IT trial sponsored by Amarin and the STRENGTH trial sponsored
by Astra Zeneca, would be positive, key opinion leaders interviewed by DP Analytics in the market research study conducted in 2018
before the results of REDUCE-IT were announced and described further below, estimated that they would increase their own prescribing
of OM3s by 43% in patients with high TGs (blood levels between 200 &#8211; 499 mg/dL) and by 35% in patients with severe HTG (based
on qualitative market research with Key Opinion Leaders (KOLs) and High Volume Prescribers (HVPs) conducted for Acasti in November,
2017 by Destum Partners, an independent market research firm);</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 31.5pt"></td><td style="width: 18pt"><FONT STYLE="font-family: Symbol">&#183;</FONT></td><td style="text-align: justify">In
                                         February 2019, following the release of the REDUCE-IT results in September 2018, Cantor
                                         Fitzgerald projected that based on their market research, prescriptions for OM3s are
                                         expected to grow in 2019 by 100%. The most recent (March 2019) audited prescription data
                                         from Symphony Health Analytics indicates that VASCEPA sales in March 2019 had increased
                                         by 77% over March 2018; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 31.5pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">Some analysts who cover the HTG segment of the market are now projecting that this market could
reach $10 billion or more in the US alone over the next few years.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">According to the American
Heart Association, the prevalence of HTG in the United States and globally correlates to the aging of the population and the increasing
incidence of obesity and diabetes. Market participants, including the American Heart Association, have estimated that one-third
of adults (approximately 70 million people) in the United States have elevated levels of TGs ((TGs &gt;150 mg/dL) (Ford, Archives
of Internal Medicine, 2009; 169(6):572-578), including approximately 3 to 4 million people diagnosed with severe HTG (Miller et
al. Circulation, 2011 and Maki et al. J. Clin. Lipid, 2012). Moreover, according to Ford, Archives of Internal Medicine in a study
conducted between 1999 and 2004, 18% of adults in the United States, corresponding to approximately 40 million people, had elevated
TG levels equal to or greater than 200 mg/dl, of which only 3.6% were treated specifically with TG-lowering medication (Ford, Archives
of Internal Medicine, 2009; 169(6):572-578; Kapoor and Miller, ACC, 2016, Christian et al. Am. J. Cardiology, 2011). We believe
this data indicates there is a large underserved market opportunity for CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">CaPre&#8217;s
target market in the United States for treatment of HTG was estimated by Symphony Health Analytics Audit data to be approximately
US$1.4 billion in 2018, with approximately 4.5 million prescriptions written annually. The total global market for treatment of
HTG was estimated by GOED Proprietary Research in 2015 to be approximately US$2.3 billion annually. Currently, all marketed OM3
products are approved by the FDA only for patients with severe HTG. We believe there is the potential to greatly expand the treatable
market in the United States to the approximately 70 million people with TGs above 150 mg/dl, assuming the FDA approves expanded
labeling for VASCEPA based on the recent positive REDUCE-IT outcome study results, and favorable results are reported from the
STRENGTH outcome trial, which is currently ongoing and expected to report sometime in 2020. These CV studies were designed to
evaluate the long-term benefit of lowering TGs on CVD risk with prescription drugs containing OM3 fatty acids in patients with
mild to moderately elevated TGs, low HDL-C, and concurrently taking a statin. Additional clinical trials would likely be required
for CaPre to also expand its label claims to this segment. Given the large portion of the adult population in the United States
that have elevated levels of TGs above 150 mg/dL but who go largely untreated, we believe there is the potential for a very significant
increase in the total number of patients eligible for treatment based on the positive REDUCE-IT results and provided the outcome
of the STRENGTH trial is also positive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">CaPre currently has two FDA-approved and marketed branded competitors
(LOVAZA and VASCEPA). In addition, Astra Zeneca has an FDA-approved product, EPANOVA, which has not yet been launched. Generic
LOVAZA became available on the U.S. market in 2013. In spite of generic options, 2017 audited prescription data from IMS NSP indicates
that approximately 70% of OM3 prescriptions are written for branded products (predominantly VASCEPA). According to the most recently
available Symphony Health Analytics Audit data from April 2019, the U.S. OM3 market for HTG was valued at approximately $1.4 billion
in 2018. However, the number of prescriptions written for OM3s is now increasing significantly since Amarin announced its REDUCE-IT
results in late 2018. Some analysts are predicting that this trend will continue, driving substantial market growth. For example,
in February 2019, Cantor Fitzgerald projected that based on their market research based on interviews with 50 physicians, they
expect prescriptions for OM3s to grow in 2019 by 100%.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">We conduct market research at
least annually with physicians and payers to monitor market developments and clinical practice. Except as otherwise indicated,
all of the information that follows under this section has been derived from secondary sources, including audited U.S. prescribing
data, and from qualitative U.S. primary market research with physicians and payers conducted for us by DP Analytics, a division
of Destum Partners, Inc., or Destum, and other well-respected third party survey providers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">Destum utilized secondary market
data and reports to develop market projections for us, and they also conducted primary qualitative market research with physicians
and third-party payers, such as PBMs. One-on-one in-depth phone interviews conducted in November 2017 lasting on average 30-60
minutes were conducted with 22 physicians and 5 PBMs. Key insights and data were collected by Destum on current clinical practice
for treating patients with HTG, and physician and payer perceptions of the current unmet medical and key economic needs in this
space. All interviews were conducted by the same individual at Destum to ensure consistency in the collection of key information.
Destum utilized OM3 prescription data from 2009 to 2017 to estimate the size of CaPre&#8217;s potential market. Based on its discussions
with the PBMs, Destum also assumed CaPre would be viewed favorably by payers at launch (e.g., Tier 2 or 3, depending on payer plan,
which is comparable to LOVAZA and VASCEPA). Upon completing the screening questionnaire and being approved for inclusion in Destum&#8217;s
study, key opinion leaders (KOLs) and high volume prescribers (HVPs), were provided with a study questionnaire and were asked to
comment on a target profile for a potential new OM3 &#8220;Product X&#8221; delivering a &#8220;trifecta&#8221; of cardio-metabolic
benefits similar to the potential efficacy and safety benefits demonstrated by CaPre in our two Phase 1 pharmacokinetic studies
and two Phase 2 clinical trials, which we refer to as the Target Product Profile. Respondents were told that the unidentified product
was being prepared for a Phase 3 program designed to confirm with statistical significance the product&#8217;s safety and efficacy
in patients with severe HTG. The Target Product Profile was used by Destum strictly for market research analysis purposes and should
not be construed as an indication of future performance of CaPre and should not be read as an expectation or guarantee of future
performance or results of CaPre, and will not necessarily be an accurate indication of whether or not such results will be achieved
by CaPre in our Phase 3 program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">In the market research for us,
KOLs and HVPs interviewed by Destum were asked to assess the level of unmet medical need associated with treating patients with
severe HTG based on currently available treatment options. 91% of physicians interviewed by Destum in 2016 indicated that they
believe that the current unmet medical need for treating HTG was moderate to high. That number increased to 100% in the subsequent
December 2017 research. The reasons identified by these physicians for their dissatisfaction with the currently available OM3s
included insufficient lowering of TGs (a complaint principally related to VASCEPA), negative LDL-C effects (a complaint principally
related to LOVAZA), the &#8220;food effect&#8221; or reduced absorption of both LOVAZA and VASCEPA when taken with a low-fat meal
(or the corollary to this concern which is that their patients had to take either drug with a fatty meal to get full efficacy benefit),
gastrointestinal side effects, and the fishy taste from these fish oil-derived OM3s. Physicians reported that their patients have
difficulty swallowing the large 1 gram softgel capsules of VASCEPA and LOVAZA, and they worried about these issues contributing
to patient non-compliance. Despite the availability of other drug classes to treat severe HTG, interviewed physicians indicated
that they would welcome the introduction of new and improved OM3 products, particularly if they can address these perceived deficiencies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">Interviewed physicians responded
favorably to the blinded Target Product Profile of CaPre in the Destum Market Research studies. In the most recent study conducted
in December 2017, they indicated that they would prescribe a new OM3 drug with the Target Product Profile to approximately 82%
of their patients in the severe HTG patient population and 68% of their patients in the high HTG segment within two years of the
new OM3 drug&#8217;s approval. Approximately 60% of the interviewed physicians indicated that they would switch to a drug with
the Target Product Profile primarily due to the &#8220;trifecta effect&#8221; of reducing TGs and LDL-C while elevating HDL-C,
and the remaining 40% indicated they would switch primarily due to a drug with the Target Product Profile due to the effective
reduction of TGs alone. In connection with their responses, the interviewed physicians were instructed to assume the drug with
the Target Product Profile and all currently available OM3 products were not subject to any reimbursement or coverage hurdles (e.g.,
all products were on an equal health care coverage playing field). This assumption was subsequently supported by our interviews
with leading PBMs in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.85pt 0pt 0">This market research was updated in March 2019 to reflect
the current views of physicians and third party payers following the publication of the REDUCE-IT study results. This updated
primary qualitative market research project was conducted by a well-respected third party survey provider, and the design
of the study was similar to the Destum project, with one-on-one interviews lasting approximately 60 minutes in duration. These
interviews were conducted with 10 physicians and 20 pharmacy directors, covering 179,913,005 commercial lives across the United
States, consistent with the current payer mix for the OM3 market. CaPre was evaluated positively by physicians with particular
value placed on its potential to lower TGs, LDL-C, and HbA1c (this was seen as unique, and especially valued), and to increase
HDL-C, as well as its potentially superior tolerability features (e.g. easier to swallow when compared to the ethyl ester fish
oils, and no fishy taste or &quot;burpiness&quot;). Importantly, since this research was conducted after the REDUCE-IT trial outcome
results, the lack of clinical outcomes data for CaPre at launch was generally not seen as problematic for the majority of the
physicians interviewed. On average, physicians indicated that they would begin prescribing CaPre 3 months after launch and would
evaluate its performance in their initial patients after 3 to 6 months of use. Depending on favorable experience in initial use,
some physicians indicated peak use could begin as quickly as 12 to 18 months after launch. Physicians expect CaPre to be priced
similar to VASCEPA, and to have an out-of-pocket cost of approximately $10-$50. Payers also viewed CaPre favorably and did not
anticipate any major reimbursement restrictions, with likely coverage at Tier 2 or 3 depending on payer plan.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">Based
on both primary market research with pharmacy benefit managers, or PBMs, and audited prescription reports, the pricing for branded
products currently averages between US$299 and US$355 per month. Amarin has raised prices for VASCEPA annually since its launch
in late 2013. PBMs offer &#8220;Preferred Brand&#8221; status (Tier 2 or Tier 3), without significant restrictions (i.e., no prior
authorization, step edits, or high co-payments) for these branded OM3s. By the end of 2018, VASCEPA had reached about 45% market
share in the United States, in spite of generic competition from LOVAZA. Amarin continues to gain market share in the United States
and, as of the date of this report has reached approximately 50% of the market share based on dollar. This growth is principally
coming from market expansion rather than necessarily from an erosion of generic sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">We plan to regularly conduct
additional market research with KOLs, HVPs, primary care physicians and payers to further develop and refine our understanding
of the potential market for CaPre ahead of commercial launch in the United States.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Our Clinical Data</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">CaPre
is being developed by us for the treatment of patients with severe HTG. In two Phase 2 clinical trials conducted by us in Canada
(our COLT and TRIFECTA trials), CaPre was well-tolerated at all doses tested, with no serious adverse events that were considered
treatment-related. Among the reported adverse events with an occurrence of greater than 2% of subjects and greater than placebo,
only diarrhea had an incidence of 2.2%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
both Phase 2 clinical trials, CaPre significantly lowered TGs in patients with mild to severe HTG. Importantly, in these studies,
CaPre also demonstrated no deleterious effect on LDL-C (unlike LOVAZA and EPANOVA, which have been shown to significantly increase
LDL-C in patients with severe HTG). Further, our Phase 2 data indicated that unlike LOVAZA, CaPre may actually reduce LDL-C with
a 4 gram per day dose (a dose equivalent to VASCEPA and LOVAZA). LDL-C is undesirable because it accumulates in the walls of blood
vessels, where it can cause blockages (atherosclerosis). In the Phase 2 trials, CaPre also significantly reduced non-HDL-C (all
cholesterol contained in the bloodstream except HDL-C), which is also considered to be a marker of cardiovascular disease. The
COLT trial data showed a mean increase of 7.7% in HDL-C with CaPre at 4 grams per day (p=0.07). Further analysis of the data from
our on-going TRILOGY Phase 3 program will be required to demonstrate CaPre&#8217;s statistical significance with respect to lowering
LDL-C and increasing HDL-C. Finally, we saw a statistically significant reduction of HbA1c in the CaPre 4g treatment group in the
COLT study after only 8 weeks on drug. This interesting and potentially differentiating effect will be investigated more thoroughly
in our TRILOGY Phase 3 program, where a larger proportion of the patients are diabetic, and they will be followed for 6 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
believe that these multiple potential cardiometabolic benefits, if confirmed in our on-going TRILOGY Phase 3 program, could be
significant differentiators for CaPre in the marketplace, as no currently approved OM3 drug has shown an ability to positively
modulate all four of these important blood lipids (TGs, non-HDL-C, LDL-C and HDL-C) in the treatment of severe HTG. We also believe
that if supported by additional clinical trials, CaPre has the potential to become the best-in-class OM3 compound for the treatment
of mild to moderate HTG.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">On
September 14, 2016, we announced positive data from our completed comparative bioavailability study, or the &#8220;Bridging Study&#8221;.
The Bridging Study was an open-label, randomized, four-way, cross-over, bioavailability study comparing CaPre, given as a single
dose of 4 grams in fasting and fed (high-fat) states, as compared to the FDA-approved HTG drug LOVAZA (OM3-acid ethyl esters) in
56 healthy volunteers. The protocol was reviewed and approved by the FDA. The primary objective of the Bridging Study was to compare
the bioavailability of CaPre to LOVAZA, each administered as a single 4-gram dose with a high-fat meal, which is the condition
under which administration of OM3 drugs will yield the highest levels of EPA and DHA in the blood, and therefore has the highest
potential for toxicity. For us to rely on the long-term safety data of LOVAZA to support a 505(b)(2) NDA for CaPre, our results
had to show that the blood levels of EPA and DHA resulting from a single 4-gram dose of CaPre, are not significantly higher than
that those from a single 4-gram dose of LOVAZA under fed (high-fat meal) conditions. The Bridging Study met all of its objectives
and demonstrated that the levels of EPA and DHA following administration of CaPre did not exceed corresponding levels following
administration of LOVAZA in subjects who were fed a high-fat meal. We expect that these results will support a claim by us that
CaPre and LOVAZA have a comparable safety profile. Also, among subjects in a fasting state, CaPre demonstrated better bioavailability
than LOVAZA, as measured by significantly higher blood levels of EPA and DHA. Since most HTG patients must follow a restricted
low-fat diet, we believe that CaPre&#8217;s strong bioavailability profile could provide a more effective clinical solution for
these patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
summarized and submitted data from our Bridging Study to the FDA for review and discussed it with the FDA at an End of Phase 2
meeting during the first quarter of 2017. We also presented our Bridging Study data at the National Lipid Association Conference
in May 2017 and this data was subsequently published in the peer-reviewed Journal of Clinical Therapeutics.</p>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The graph below illustrates that the Bridging Study
achieved all of its objectives:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="p29.jpg" ALT=""></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Absorption
of EPA and DHA as ethyl ester formulations in the currently available prescription OM3 drugs derived from fish oil (such as LOVAZA
and VASCEPA) require the breakdown of the ethyl esters by pancreatic enzymes (lipases) to be released into the blood. These particular
enzymes are produced in response to the consumption of high-fat content meals, leading to optimal absorption of DHA and/or EPA.
As a result, these OM3 ethyl ester formulations have demonstrated lower absorption and bioavailability when taken with a low-fat
meal or on an empty stomach. As shown in our CAP13-101 study described further below, absorption of CaPre, which is formulated
as a combination of OM3 phospholipids and free fatty acids, is not meaningfully affected by the fat content of a meal consumed
prior to drug administration. Since a low-fat diet is typically a critical component for treatment of patients with severe HTG,
we believe that being able to effectively combine CaPre with a low-fat diet could give CaPre a significant clinical and marketing
advantage over the ethyl ester-based OM3s, such as LOVAZA and VASCEPA, that must be taken with a high-fat meal to achieve optimal
absorption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
CAP13-101 study was an open-label, randomized, multiple-dose, single-center, parallel-design study in healthy volunteers. 42 subjects
were enrolled into 3 groups of 14 subjects who took 1 gram, 2 grams or 4 grams of CaPre, administered once a day 30 minutes after
breakfast. The objectives of the study were to determine the pharmacokinetic, or PK, profile and safety on Day 1 following a single
oral dose and Day 14 following multiple oral doses of CaPre in individuals pursuing a low-fat diet (therapeutic lifestyle changes
diet). The effect of a high-fat meal on the bioavailability of CaPre was also evaluated at Day 15. Blood samples were collected
for assessment of EPA and DHA total lipids in plasma to derive the PK parameters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
PK profile of CaPre following multiple 4-gram doses obtained in the CAP13-101 study at Day 14 was compared to the results obtained
in a similar PK study (Offman 2013 - ECLIPSE 2) where LOVAZA was also administered at 4 grams a day for 14 days with a low-fat
diet. Although CaPre contains approximately 2.5 times less EPA and DHA compared to LOVAZA (approximately 310 mg/1g capsule for
CaPre versus 770 mg/1g capsule for LOVAZA), when administered with a low-fat meal, CaPre plasma levels of EPA and DHA are very
similar to those of LOVAZA. This is indicated by the area under the plasma drug concentration against time curve, or AUC, and the
maximal plasma drug concentration. This study gives us confidence in the dosing and design of our ongoing TRILOGY Phase 3 program,
as we believe blood levels of EPA and DHA should translate into efficacy of TG reduction. This study gives us confidence that 4
grams/day of CaPre could be as effective in lowering TGs as LOVAZA. Our Phase 3 TRILOGY clinical program will confirm if this hypothesis
is correct.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 6pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 6pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">As illustrated
by the two graphs below, CaPre reached similar blood and therapeutic levels to LOVAZA after 14 daily doses of CaPre at 4 grams/day,
despite CaPre containing 2.5 times less EPA and DHA compared to LOVAZA:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 6pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="p30a.jpg" ALT=""></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
graph below illustrates that the bioavailability of CaPre (total EPA+DHA levels in the blood) does not appear to be meaningfully
affected by the fat content of a meal after multiple daily doses of CaPre at 4 grams/day (&lt; 20% difference in AUC). We believe
that CaPre&#8217;s strong bioavailability could represent a significant clinical advantage for CaPre since taking it with a low-fat
meal represents a more realistic and attractive regimen for patients with HTG who must follow a restricted low-fat diet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Our CAP13-101 Study for
CaPre Pharmacokinetics Shows No Significant Food Effect</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="p30b.jpg" ALT=""></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The graph below
presents a summary of the effects of CaPre on patients&#8217; lipid profiles as obtained in our completed TRIFECTA and COLT Phase
2 clinical trials. 90% of the patients in these clinical trials had mild to moderate HTG (levels between 200 - 499 mg/dL) and only
10% of patients had severe HTG (levels between 500 and 877 mg/dL), which was the maximum level of TGs permitted by Health Canada&#8217;s
study protocol. Only 30% of the participating patients were taking statins, which we believe is important because statins appear
to enhance the TG-lowering effect of OM3s. In contrast, in our competitors&#8217; summary data that follows, 100% of the patients
in those studies with mild to moderate HTG were taking statins with their OM3s.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
summary data from our COLT and TRIFECTA clinical trials shows that CaPre significantly reduces TGs, but unlike some other prescription
EPA/DHA-based OM3s, it has no deleterious effect on LDL-C and may potentially increase HDL-C (p=0.07), which we refer to as the
&#8220;trifecta effect&#8221;. Also, a dose response was seen for all of the major lipid markers; the greater the dose of CaPre,
the greater the beneficial effect of CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Our Phase 2 Study Results
Show CaPre Dose Response and Potential for &#8220;Trifecta&#8221; Lipid Effect</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="p31.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">* Indicates results reached
statistical significance</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>TRIFECTA for 1g (N=130)
&amp; 2g (N=128) and COLT for 4g (N=62). HDL-C results at 4g from COLT approached statistical significance at P=0.07.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 7.3pt; margin-bottom: 0pt; text-align: center"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 7.3pt; margin-bottom: 0pt; text-align: center"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We conducted
a subgroup analysis including only patients with severe HTG, consisting of approximately 10% of the patients from our TRIFECTA
study, to compare the effects of CaPre versus other OM3 drugs in the initial target population of patients with severe HTG. Despite
being given at a lower dose (only 1 gram and 2 grams), CaPre&#8217;s results compared very well with data from independent studies
for the other prescription OM3 drugs that are FDA-approved for the treatment of severe HTG at higher doses of 2 grams and 4 grams.
While the results of this subgroup analysis were not statistically significant for CaPre (potentially due to the small sample size),
numerically, the results compared well with the other OM3 drugs, even though CaPre was given at a much lower dose. The results
for LDL-C, HDL-C and non-HDL-C levels in the subgroup shown in the table below are based on descriptive statistics only and are
solely directional, meaning that no statistical testing was conducted and so no &#8220;p&#8221; values were generated. Note also
that VASCEPA&#8217;s TG lowering results from the MARINE study were inflated due to a significant placebo effect. This resulted
in VASCEPA&#8217;s placebo-corrected TG reduction being overstated by about 10%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><IMG SRC="p32.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">Since statins appear to
enhance the TG-lowering property of OM3 drugs, we conducted a subgroup analysis that only included patients who were taking a statin
at baseline in the COLT and TRIFECTA studies (approximately 30% of the population of both trials, combined). The graph below compares
the TG-lowering effects of CaPre to other OM3s, all on a background of a statin drug, and shows that CaPre&#8217;s TG-lowering
effects compare well with other FDA-approved OM3 drugs. We believe it is noteworthy that only 39 patients on 2 grams of CaPre in
our TRIFECTA study (out of a total of 128) and only 22 patients on 4 grams of CaPre in our COLT study (out of 62) were taking statins.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The CaPre 2-gram
bar graph in the table below shows the results from patients in our TRIFECTA trial who were taking statins. A statistically significant
reduction in TGs (-25.7% placebo-corrected) was seen in that statin subgroup. The CaPre 4-gram bar graph in the table below shows
patient results only from our COLT trial (as there was no 4-gram component for our TRIFECTA trial). None of the results were statistically
significant at 4 grams of CaPre, potentially due to the small number of patients (22) in the statins subgroup.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">As seen in the
larger full study analyses in the tables above, CaPre does not show any deleterious effect on LDL, and shows the potential to decrease
LDL and increase HDL (p=0.07). These observations will need to be confirmed in our ongoing TRILOGY Phase 3 program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">VASCEPA&#8217;s
TG lowering results from the ANCHOR study were also inflated due to a placebo effect from their use of mineral oil. This resulted
in VASCEPA&#8217;s placebo-corrected TG reduction being overstated by about 6% in this study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: Red"><img src="p33.jpg" alt=""></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.5pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In summary, in addition
to effectively reducing TG levels in patients with mild to severe HTG, clinical data collected by us to date indicates that CaPre
may also have:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.5pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 21.9pt"><font style="font-family: Symbol">&#183;</font></td><td>beneficial clinical effects on other blood lipids, such as HDL-C (good cholesterol) and non-HDL-C;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 21.9pt"><font style="font-family: Symbol">&#183;</font></td><td>no deleterious effect on, and may potentially reduce, LDL-C (bad cholesterol) levels;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 21.9pt"><font style="font-family: Symbol">&#183;</font></td><td>potential to benefit diabetes patients by reducing HbA1c, an important marker of diabetes; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 21.9pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">absorption capability that, unlike VASCEPA and LOVAZA, is not meaningfully
affected by the fat content of a meal consumed prior to drug administration, providing patients with the reassurance that following
their physician-recommended low-fat diet will still result in high absorption.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We believe that these features
could set CaPre apart from currently available FDA-approved OM3 treatment options in the marketplace and could give us a significant
clinical and marketing advantage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">CaPre&#8217;s potential clinical
benefits as compared to currently available FDA-approved OM3 treatment options are summarized in the table below and indicate that
CaPre may deliver a more complete lipid management solution for patients with severe HTG:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: Red"></p>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: Red"><img src="p34.jpg" alt=""></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our Nonclinical Research</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
addition to our Phase 2 clinical trials, we carried out an extensive nonclinical program to demonstrate the safety of CaPre in
a defined set of studies required by the FDA. These studies were carried out by contract research organizations in compliance with
Good Laboratory Practices (GLPs) and conducted on various species of animals recommended by the FDA to investigate the long-term
effects of CaPre at doses of up to 65 grams of human equivalent dose over 39 weeks. In these studies, hematological, biochemical,
coagulation and overall health parameters of CaPre were evaluated and no toxic effects were observed in any of the segments of
the studies. Other studies focused on the potential toxic effects of CaPre on vital systems, such as the cardiovascular, respiratory
and central nervous system as evaluated by behavioral studies of the various species. These studies showed that CaPre did not have
any adverse or toxic effects on any of the vital systems investigated, again up to doses well above the recommended clinical dose
of CaPre. To rule out short term toxic effects of CaPre on genes, genomic toxicity studies were undertaken on accepted cellular
and animal models. These studies showed no toxic effects of CaPre on any of the genetic markers indicative of potential gene altering
toxic effects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
believe the studies conducted to date indicate that CaPre is well-tolerated and shows no toxic effects on any of the physiological
and vital systems of the tested animals or their genes at doses well above CaPre&#8217;s anticipated clinical therapeutic dose
of 4 grams daily.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
parallel to our TRILOGY Phase 3 program, we are currently completing additional nonclinical studies, including a pre- and postnatal
development study in rodents and a 26-week oral carcinogenicity study in transgenic homozygous rasH2 mice. Both study protocols
were pre-approved by the FDA by means of Special Protocol Assessment (SPA) through the FDA&#8217;s Executive Carcinogenicity Assessment
Committee. These nonclinical studies are required to support an NDA filing for CaPre.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our TRILOGY Phase 3 Program</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In March 2017, we announced
our plans to proceed with our TRILOGY Phase 3 program following our End-of-Phase 2 meeting with the FDA in February 2017. Based
on the guidance we received from the FDA, we are now actively conducting two pivotal, randomized, placebo-controlled, double-blinded
Phase 3 studies to evaluate the safety and efficacy of CaPre in patients with severe HTG. These studies of 26-week duration will
evaluate CaPre&#8217;s ability to lower TGs from baseline in approximately 500 patients (approximately 250 per study) randomized
to either 4 grams daily or placebo. The FDA&#8217;s feedback supported our plan to conduct two studies in parallel, potentially
reducing the cost and shortening the time to an NDA submission. These studies are being conducted in approximately 150 sites across
North America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The primary endpoint
of these studies is to determine the efficacy of CaPre at 4 grams/day compared to placebo in lowering TGs after 12 weeks in severe
HTG patients, and to confirm safety by continuing to follow these patients for the full 26 weeks. The study was designed to provide
at least 90% statistical power to detect a difference of at least a 20% decrease from baseline in TGs between CaPre and placebo.
In addition, the Phase 3 studies will include numerous secondary and exploratory endpoints, which are designed to assess the effect
of CaPre on the broader lipid profile and certain metabolic, inflammatory and CVD risk markers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In November 2017, we
announced that Dariush Mozaffarian, M.D., Dr.P.H., agreed to serve as the principal investigator of our Phase 3 clinical program.
Dr. Mozaffarian is a cardiologist and epidemiologist serving as the Jean Mayer Professor of Nutrition &amp; Medicine, and the Dean
of the Friedman School of Nutrition Science &amp; Policy at Tuft&#8217;s University. His widely published research focuses on how
diets, such as those rich in OM3s, and lifestyle influence cardiometabolic health and how effective policies can improve health
and wellness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Late in 2017, based
on feedback from the FDA, we finalized our Chemistry, Manufacturing, and Controls plans and the clinical trial design that supports
our TRILOGY Phase 3 program. In parallel with our Phase 3 clinical trial planning, additional current Good Manufacturing Practices
(cGMP) production lots of API (known as NKPL66) and CaPre were manufactured, enabling us to build the CaPre and placebo inventory
required to support the activated clinical trial sites and complete patient randomization. In the first calendar quarter of 2018,
additional raw krill oil was purchased and additional lots of CaPre have been manufactured with this material for use in our Phase
3 program. With manufacturing of clinical trial material complete, we are now allocating additional technical resources to other
activities related to the scale-up of manufacturing for the planned commercial launch of CaPre in 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
initiated our TRILOGY Phase 3 program and began site activation and patient enrollment on schedule at the end of 2017. We are
working with a major clinical research organization to manage our TRILOGY Phase 3 program. The TRILOGY studies continued to progress
on schedule throughout 2018, and as of the date of this annual report, they remain on schedule for delivery of topline results
for TRILOGY 1 in December 2019, and TRILOGY 2 in January 2020. As of June 2019, our two on-going Phase 3 TRILOGY trials had reached
100% patient randomization at more than 150 clinical sites across the United States, Canada, and Mexico, and more than 60% of
the patients in both trials had completed their 6-month treatment plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our first study, designated
as TRILOGY 1, is being conducted exclusively in the United States and is fully randomized with a total of 245 patients. The TRILOGY
2 study, which is also fully randomized as of the date of this annual report, also has a total of 245 patients, and is being conducted
in the United States, Canada and Mexico. We expect to report topline results independently for each study as we receive the results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The following chart
illustrates the design and dosing of our TRILOGY Phase 3 program for CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center; color: #17365D"><b>TRILOGY Phase 3 Clinical
Program</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center; color: Red">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center; color: Red"><img src="p35.jpg" alt=""></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><font style="font-style: normal">Clinical
Trial Process and Timeline </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">During the second half
of 2017, our clinical research organization, or CRO, began the process of identifying a sufficient number of clinical sites with
experienced investigators to conduct the two Phase 3 clinical trials. Site activation involves negotiating a contract, gaining
approval from the site&#8217;s Institutional Review Board, or IRB, and delivery of clinical supplies. It was determined that approximately
150 sites across North America would be used to randomize the total of about 500 patients with severe HTG required to complete
the two Phase 3 studies. Site activation was initiated in the fourth quarter of 2017, and was completed in the first half of 2018.
Site activation runs concurrently with patient screening and enrollment in order to secure an adequate number of sites to achieve
the patient enrollment goals of the program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Initiating a clinical
trial involves numerous steps to engage investigators to screen and qualify patients as participants, prior to randomizing them
to test the investigational drug. This entire screening and randomization process takes an average of six to nine weeks. Patient
recruitment is conducted by each clinical trial site, supported by resources provided by the CRO. After a patient is identified
by the investigator as a possible candidate for the clinical trial, they are screened to determine their eligibility for trial
enrollment. The screening period takes four to six weeks. Patients must meet the inclusion criteria of the study, as described
in the trial plan, also known as a protocol. We expect each patient will require two screening visits with the investigator&#8217;s
clinical staff, whereby medical history and patient consent are obtained. This further qualification process takes two to three
weeks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">When patient qualification
is confirmed, the process of randomization begins. Approximately 245 patients were randomized in each Phase 3 study. This sample
size per study would provide 90% statistical power to detect at least a 20% decrease in TG levels from baseline to week 12 between
CaPre and placebo with a two-sided &#945; at 0.05 (primary endpoint), a difference that is believed to be clinically relevant.
A randomized controlled trial is designed to reduce bias when testing an investigational treatment. The process of assigning patients
to these groups by chance, rather than choice, is completely blinded, and is called randomization. The groups are referred to as
the experimental group or the control group. In the TRILOGY Phase 3 clinical trials, patients were assigned to either receive CaPre
(experimental) or placebo (control). Each patient stays on CaPre or placebo for a period of 26 weeks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The two TRILOGY Phase
3 clinical trials proceed to dosing both the experimental and control groups, according to the protocol, to assess CaPre&#8217;s
efficacy and safety compared to placebo. In these double-blind studies, neither we, the patients or the investigators know which
treatment (experimental drug or placebo) a patient receives. Only after all data has been recorded and analyzed will we, the investigators
and the participants learn which were which. The trial conduct and patient safety are rigorously monitored to ensure regulatory
compliance and to maintain the integrity of the study in order to assess outcomes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our Regulatory Strategy for CaPre</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
strategy is to develop and initially commercialize CaPre for the treatment of severe HTG. The TRILOGY Phase 3 program was initiated
during the second half of 2017 and has been designed to evaluate the clinical effect of CaPre on TGs, non-HDL-C, LDL-C, and HDL-C
levels together with a variety of other cardiometabolic biomarkers in patients with severe HTG.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
intend to pursue a 505(b)(2) regulatory pathway towards an NDA approval in the United States. A 505(b)(2) regulatory pathway is
defined in the U.S. Federal Food Drug and Cosmetic Act (FDCA) as an NDA containing investigations of safety and effectiveness that
are being relied upon for approval and were not, in whole, conducted by or for the applicant, and for which the applicant has not
obtained a right of reference. 505(b)(2) regulatory pathways differ from a typical NDA because they allow a sponsor to rely, at
least in part, on the FDA&#8217;s findings of safety and/or effectiveness for a previously- approved drug. We intend to pursue
the 505(b)(2) regulatory pathway as a strategy to leverage the large body of safety data for LOVAZA, which could accelerate and
streamline the development of CaPre and reduce associated costs and risks. This pathway still allows CaPre to retain its New Chemical
Entity (NCE) status due to its novel, patented OM3 free fatty acid/phospholipid ester formulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
connection with our intended use of the 505(b)(2) pathway, the FDA supported our proposal to conduct our Bridging Study that compared
CaPre (which has an OM3 free fatty acid/phospholipid composition) with LOVAZA (which has an OM3-acid ethyl esters composition)
in healthy volunteers. In February 2017, we met with the FDA at an End-of-Phase 2 meeting where our Bridging Study data was discussed.
We confirmed with the FDA the 505(b)(2) regulatory approach to use the safety data for LOVAZA and finalized the study design for
our Phase 3 program that would be required for NDA approval.</p>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our planned remaining key development and regulatory milestones
and timeline are presented below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt; color: Red"><img src="p37.jpg" alt=""></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>Our Intellectual Property Strategy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Under a license agreement
we entered into with Neptune in August 2008, which was later amended on February 9, 2009 and March 7, 2013 (the &#8220;License
Agreement&#8221;), we received an exclusive license to use certain intellectual property of Neptune (which includes several patents)
to develop and commercialize CaPre and our novel and active pharmaceutical ingredients, or APIs, for use in pharmaceutical and
medical food applications in the cardiometabolic field. The term of the License Agreement expires on the date of the last-to-expire
licensed patents in 2022. As the result of a royalty prepayment transaction we entered into with Neptune on December 4, 2012, we
are no longer required to pay any royalties to Neptune under the License Agreement during its term for the use of the licensed
intellectual property.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">On August 8, 2017,
Neptune announced that it sold its krill oil inventory and intellectual property to Aker BioMarine Antarctic AS, or Aker. The sold
intellectual property included the intellectual property to which rights were granted us under the License Agreement. As part of
that transaction, Aker entered into a patent license agreement with Neptune pursuant to which it granted to Neptune the right to
sublicense to us certain intellectual property as necessary to allow us to maintain our license grant under the original License
Agreement. Accordingly, the license granted to us under the License Agreement remains in force.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Upon the expiry of
the License Agreement, we believe that CaPre will be covered under our own issued and pending patents, and we do not believe that
we will afterwards require any licenses to support the commercialization of CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We currently have patents
granted and allowed in the following countries: United States, Canada, Russia, Belgium, Switzerland, Germany, Denmark, Spain, Finland,
France, United Kingdom, Italy, Netherlands, Norway, Portugal, Sweden, Japan, Israel, Australia, China, Mexico, Panama, Saudi Arabia,
Taiwan, South Africa, Chile and South Korea. We continue to expand our own intellectual property, or IP, patent portfolio. We have
filed patent applications in more than 20 jurisdictions, including with the European Patent Office (but excluding the individual
countries where we have subsequently registered), and in countries in North America, Asia and Australia for our &#8220;Concentrated
Therapeutic Phospholipid Composition&#8221;, or Proprietary Composition, to treat HTG. We currently have more than 20 issued or
allowed patents (including registered European countries) and numerous patent applications pending. A patent is generally valid
for 20 years from the date of first filing. However, patent terms can be subject to extensions in some jurisdictions in order to
compensate, for example, for delays caused by the patent office during prosecution of the patent application or for regulatory
delays during the pre-market approval process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Two U.S. patents, U.S.
Patent Nos. 8,586,567 and 9,475,830, have issued which relate to the use of concentrated therapeutic phospholipid compositions
for treating or preventing diseases associated with cardiovascular disease, comprising administering an effective amount of a concentrated
therapeutic phospholipid composition. More specifically, U.S. Patent No. 8,586,567 covers a method of reducing serum TG levels
comprising administering to a subject an effective amount of a concentrated phospholipid (PL) composition having, among other things,
a concentration of total phospholipids in the composition of approximately 66% (w/w). U.S. Patent No. 9,475,830 covers a method
of treating HTG comprising administering to a subject a therapeutically effective amount of a concentrated therapeutic phospholipid
composition, having, among other things, a concentration of total phospholipids in the composition of approximately 60% (w/w).
U.S. Patent No. 10,130,644 (U.S. Patent Application Serial No. 15/258,044) was granted and covers claims directed towards a composition
encompassing an extract comprising a PL content between approximately 60% to approximately 99%. We also filed a U.S. continuation
patent application (U.S. Patent Application Serial No. 16/135212) to pursue claims directed towards a composition encompassing
an extract comprising a PL content between approximately 50% (w/w) to approximately 70% (w/w).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In 2017, additional
patents were granted to us by the Taiwanese, South Korean, and Australian patent offices to protect our Proprietary Composition
using compositions of matter claims and medical use claims. In 2018, we were also granted patents by the Canadian Intellectual
Property Office, the European Patent Office (EPO), the Russian Patent Office, and the Japanese Patent Office for the Proprietary
Composition, all of which contain compositions of matter claims and medical use claims. On January 9, 2019, we announced a Certificate
for a European Patent had been issued by the European Patent Office. The granted patent is valid until 2030 and relates to a concentrated
phospholipid composition and method of using the same for modulating blood lipids. This patent was validated in Belgium, Switzerland,
Germany, Denmark, Spain, Finland, France, United Kingdom, Italy, Netherlands, Norway, Portugal and Sweden. We also received notices
of allowances for patents in Chile, Mexico and Israel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We believe these patents
and patent applications increase potential commercial opportunities for CaPre, including through possible licensing and partnership
opportunities. We are committed to building a global portfolio of patents to ensure long-lasting and comprehensive intellectual
property protection and to safeguard potentially valuable market expansion opportunities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our patent No. 600167
in New Zealand, which is in force until 2030 and relates to a concentrated phospholipid composition comprising 60% PL and method
of using the same for treating cardiovascular diseases, has been opposed by BIO-MER Ltd. The evidentiary stage in the New Zealand
patent opposition has been completed. The next step is the hearing. In our view, no new prior art has been presented that was not
already considered in other jurisdictions, such as in the United States, where our patents are in force.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We have received a
notice issued from the Japan Patent Office (JPO) indicating that a third party filed an opposition against our Japanese Patent
No. 6346121. We are in the process of replying by amendment of our claims to the Japanese Patent Office, which we believe would
allow us to overcome the prior art cited in the opposition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The trademark CaPre&#174;
is registered in the United States, Canada, Australia, China, Japan and Europe. We are currently in the process of developing a
new brand name and logo for CaPre for launch into the U.S. market. That name, once it is developed, will be trademarked in all
of the major jurisdictions around the world. In addition, two PCT applications that cover our encapsulation apparatus and manufacturing
process while maintaining industrial trade secrets and know-how. We also filed a provisional application directed to our RKO manufacturing
process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Manufacturing of CaPre</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We are developing CaPre
as a new chemical entity (which means a novel chemical product protected by patents), and we are conducting our TRILOGY Phase 3
program using good manufacturing practices, or cGMP, good clinical practices, or cGCP, and good laboratory practices, or cGLP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The contract manufacturing
organizations, or CMOs, selected by us for manufacturing and packaging are all cGMP compliant. In preparation for our TRILOGY Phase
3 program, working together with our pharmaceutical CMOs, we advanced the installation and qualification of the proprietary extraction
and purification equipment used to manufacture CaPre. We ran our first scaled cGMP production lots of CaPre at CordenPharma&#8217;s
Chen&#244;ve facility in Dijon, France during the first half of 2017. We scaled up to 100 kg/day in late 2017 to fulfill the clinical
product requirements for our TRILOGY Phase 3 program. We are currently operating at a scale of 20 tons per year, and plan to scale
further to 40 tons to support our initial commercial launch. As of the date of this annual report, we have completed all clinical
lots of NKPL66 and CaPre for our TRILOGY Phase 3 program, and we have made additional safety batches to mitigate any potential
loss in shipping.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our Business and Commercialization Strategy</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Key elements of our
business and commercialization strategy include initially obtaining regulatory approval for CaPre in the United States for severe
HTG. We plan to launch CaPre ourselves in the U.S. market. Our preferred strategy outside the United States is to commercialize
CaPre through regional or country-specific strategic partnerships, and to potentially seek support and funding from each partner
for in-country clinical development, registration and commercialization activities. We believe that a late development-stage and
differentiated drug candidate like CaPre could be attractive to various global, regional or specialty pharmaceutical companies,
and we are taking a targeted approach to partnering and licensing in various geographies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Our key commercialization
goals include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">complete our TRILOGY Phase 3 program and, assuming the results are positive, file an NDA by mid
2020 to obtain regulatory approval for CaPre in the United States, initially for the treatment of severe HTG, with the potential
to afterwards expand CaPre&#8217;s indication to the treatment of high TGs (although at least one additional clinical trial would
likely be required to expand CaPre&#8217;s indication to this segment);</td></tr></table>
<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">continue to strengthen our patent portfolio and other intellectual property rights;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">continue planning for the potential launch of CaPre in the United States by the second half of
2021; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">continue to pursue strategic opportunities outside of the United States, such as licensing or similar
transactions, joint ventures, partnerships, strategic alliances or alternative financing transactions, to provide development capital,
market access and other strategic sources of capital.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In addition to completing
our TRILOGY Phase 3 program, we expect that additional time and capital will be required to complete the filing of an NDA to obtain
FDA approval for CaPre in the United States, and to complete business development collaborations, marketing and other pre-commercialization
activities before reaching the commercial launch of CaPre in the United States.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Competition</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
biotechnology and pharmaceutical industries are highly competitive. There are many pharmaceutical companies, biotechnology companies,
public and private universities and research organizations actively engaged in the research and development of products that may
be similar to CaPre. We believe that the number of companies seeking to develop products and therapies similar to CaPre will likely
increase, particularly based on the positive REDUCE-IT CVOT by Amarin, and if Astra Zeneca&#8217;s STRENGTH CVOT is successful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 20pt; margin: 0pt 5.85pt 0pt 0">Our competitors in the United States
and globally include large, well-established pharmaceutical companies, specialty pharmaceutical sales and marketing companies,
and specialized cardiovascular treatment companies. GlaxoSmithKline plc, which currently sells LOVAZA, a prescription-only OM3
fatty acid indicated for patients with severe HTG, was approved by the FDA in 2004 and has been available in the U.S. market since
2005. Multiple generic versions of LOVAZA are now available in the United States. Amarin launched its prescription-only OM3 drug
VASCEPA in 2013, and reached a market share of approximately 45% by the end of 2018. In addition, EPANOVA (OM3-carboxylic acids)
capsules, a free fatty acid form of OM3 (comprised of 55% EPA and 20% DHA), is FDA-approved for patients with severe HTG. <FONT STYLE="text-transform: uppercase">Omtryg</FONT>,
another OM3-acid fatty acid composition developed by Trygg Pharma AS, received FDA approval for severe HTG. Neither EPANOVA nor
<FONT STYLE="text-transform: uppercase">Omtryg</FONT> have yet been commercially launched, but could launch at any time. <FONT STYLE="color: Black">Matinas
recently decided to restart their development program for MAT9001, an omega-3 free fatty acid that consists primarily of EPA and
docosapentaenoic acid (DPA). Other large</FONT> companies with products that would compete indirectly with CaPre include AbbVie,
Inc., which currently sells TRICOR and TRILIPIX for the treatment of severe HTG, and NIASPAN, which is primarily used to raise
HDL-C but is also used to lower TGs. Generic versions of TRICOR, TRILIPIX, and NIASPAN are also now available in the United States.
In addition, we are aware of a number of other pharmaceutical companies that are developing products that, if approved and marketed,
could compete with CaPre.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Raw Materials</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We use semi-refined
raw krill oil as our primary raw material to produce CaPre. Krill are generally harvested in Antarctic waters. The krill biomass
is the world&#8217;s most abundant biomass and it is monitored to help ensure sustainable cultivation. Historically, we sourced
all of our krill oil from Neptune. On August&nbsp;8, 2017, Neptune announced it was discontinuing krill oil production, and selling
its krill oil inventory and intellectual property to Aker. In the three-month period ending December 31, 2017, we purchased a reserve
of krill oil from Neptune and Aker that was used in the production of CaPre capsules for our Phase 3 clinical trials. In addition,
krill oil was purchased from Aker, which was also used in our Phase 3 trials. There are several alternative suppliers of krill
oil that we have confirmed can meet our specifications for CaPre. Combined, they have more than adequate production capacity to
meet our future needs.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Employees, Specialized Skills and Knowledge</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
management consists of professionals from business development, sales and marketing, clinical development, pharmaceutical manufacturing,
finance and science backgrounds. Our research team includes scientists with expertise in pharmaceutical development, chemistry,
manufacturing and controls, nonclinical and clinical studies, pharmacology, regulatory affairs, quality assurance/quality control,
intellectual property and strategic alliances. We currently employ 28 full-time employees with the majority working out of our
headquarters in Laval and at our laboratory in Sherbrooke. We generally require all of our employees to enter into invention assignment,
non-disclosure and non-compete agreements. We rely on third-party consultants and contractors from time to time. Our employees
are not covered by any collective bargaining agreement or represented by a trade union.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Additional Information About Our Phase 2 Clinical
Trials</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our COLT Trial</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
COLT clinical trial, which was completed in 2014, was a randomized, open-label, dose-ranging, multi-center trial in Canada designed
to assess the safety and efficacy of CaPre in the treatment of patients with TG levels between 200-877 mg/dL. The primary objectives
of the COLT study were to evaluate the safety and efficacy of 0.5 gram, 1 gram, 2 grams and 4 grams of CaPre per day in reducing
fasting plasma TGs over 4 and 8 weeks, as compared to the standard of care alone.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The secondary objectives of the COLT study were to
evaluate:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the effect of CaPre on fasting plasma TGs in patients with TGs between 200-499 mg/dL (mild to moderate
HTG);</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the dose dependent effect on fasting plasma TGs in patients with TGs between 500-877 mg/dL (severe
HTG); and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the effect of CaPre on fasting plasma levels of LDL-C (direct measurement), HDL-C, non-HDL-C, hs-CRP
and OM3 index.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
final results of the COLT trial indicated that CaPre was safe and effective in reducing TGs in patients with mild to severe HTG
with significant mean (average) TG reductions above 20% after 8 weeks of treatment with daily doses of 4 grams and 2 grams. Demographics
and baseline characteristics of the patient population were balanced in terms of age, race and gender. A total of 288 patients
were enrolled and randomized and 270 patients completed the study, which exceeded our targeted number of evaluable patients. From
this patient population, approximately 90% had mild to moderate HTG.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
proportion of patients treated with CaPre that experienced one or more adverse events in the COLT trial was similar to that of
the standard of care group (30.0% versus 34.5%, respectively). A substantial majority of adverse events were mild (82.3%) and no
severe treatment-related adverse effects were reported. Only one patient was discontinued from the study due to an adverse event
of moderate intensity. While the rate of gastrointestinal side effects was higher in the CaPre groups compared to standard of care
alone and appeared to increase in a dose-related manner, none of the subjects participating in the study suffered from a serious
adverse event. The COLT study results showed that even at higher doses, CaPre is safe and well tolerated with only transient and
predominantly mild adverse events occurring at low rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
COLT trial met its primary objective of showing CaPre to be safe and effective in reducing TGs in patients with mild to severe
HTG. After only a 4-week treatment, CaPre achieved a statistically significant TG reduction as compared to standard of care alone.
Standard of care could be any treatment physicians considered appropriate in a real-life clinical setting and included lifestyle
modifications as well as statins and/or ezetimibe. Patients treated with 4 grams of CaPre per day over 4 weeks reached a mean TG
decrease of 15.4% from baseline and a mean improvement of 18.0% over the standard of care. Results also showed increased benefits
after 8 weeks of treatment, with patients on a daily dose of 4 grams of CaPre registering a mean TG decrease of 21.6% from baseline
and a mean improvement of 14.4% over the standard of care.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">After
8 weeks of treatment, patients treated with 1 gram of CaPre for the first 4 weeks of treatment and 2 grams for the following 4
weeks, showed a statistically significant TG mean improvement of 16.2% over the standard of care, corresponding to a 23.3% reduction
for the 1-2 grams patient population as compared to a 7.1% reduction for the standard of care. After 8 weeks of treatment, patients
treated with 2 grams of CaPre for the entire 8 weeks showed statistically significant TG mean improvements of 14.8% over the standard
of care, corresponding to a 22.0% reduction for the 2 grams group as compared to a 7.1% reduction for the standard of care. Also,
after 8 weeks of treatment, patients treated with 4 grams for the entire 8 weeks showed statistically significant TG, non-HDL-C
and HbA1<font style="font-size: 10pt">C </font>mean improvements of 14.4% and 9.8% and 15.0%, respectively, as compared to standard
of care. The 4-gram group showed mean improvements in:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">TGs of 14.4%, corresponding to a reduction of 21.6% as compared to a reduction of a 7.1% for the
standard of care group;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">non-HDL-C of 9.8%, corresponding to a reduction of 12.0% as compared to a reduction of 2.3% for
the standard of care group; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">HbA1C of 15.0%, corresponding to a reduction of 3.5% as compared to an increase of 11.5% for the
standard of care group.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
addition, all combined doses of CaPre showed a statistically significant treatment effect on HDL-C levels, with an increase of
7.4% as compared to standard of care. Trends (p-value &lt; 0.1) were also noted on patients treated with 4 grams of CaPre for the
entire 8-week treatment period with mean reduction of total cholesterol of 7.0% and increase of HDL-C levels of 7.7%, as compared
to the standard of care. The results of the COLT trial indicated that CaPre has no significant deleterious effect on LDL-C levels.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our TRIFECTA Trial</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
TRIFECTA clinical trial, which was completed in 2015, was a 12-week, randomized, placebo-controlled, double-blind, dose-ranging
trial in Canada, designed to assess the safety and efficacy of CaPre at a dose of 1 gram or 2 grams on fasting plasma TGs as compared
to a placebo in patients with TG levels between 200-877 mg/dL. A total of 387 patients were randomized and 365 patients completed
the 12-week study, consistent with our targeted number of evaluable patients. From this patient population, approximately 90% had
mild to moderate HTG with baseline TGs between 200 and 499 mg/dL. The remainder had severe HTG with baseline TGs between 500 and
877 mg/dL. Approximately 30% of patients were on lipid-lowering medications, such as statins, and approximately 10% were diabetic.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Similar
to our COLT study, the primary objective of the TRIFECTA study was to evaluate the effect of CaPre on fasting plasma TGs in patients
with TGs between 200-877 mg/dL and to assess the tolerability and safety of CaPre. The secondary objectives of the TRIFECTA study
were to evaluate:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the effect of CaPre on fasting plasma TGs in patients with TGs between 200-499 mg/dL;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the dose dependent effect on fasting plasma TGs in patients with TGs between 500-877 mg/dL; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the effect of CaPre in patients with mild to moderate HTG and severe HTG on fasting plasma levels
of LDL-C (direct measurement), and on fasting plasma levels of HDL-C, non-HDL-C, hs-CRP and OM3 index.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">CaPre
successfully met the TRIFECTA study&#8217;s primary objective. The placebo-corrected percentage change in TGs were decreases of
9.1% (p=0.049) and 9.7% (p=0.044) for 1 gram and 2 grams of CaPre, respectively. Key secondary objectives were also met:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">there was a statistically significant decrease in non-HDL-C versus placebo (p=0.038), with the
2-gram group decreasing by 5.3% from baseline versus placebo over the 12-week period;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">HDL-C slightly increased at both the 1-gram and 2-gram levels; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">LDL-C and slightly decreased at the 2-gram level.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Finally,
a statistically significant dose response increase in the OM3 index for patients on 1 gram and 2 grams versus placebo was noted.
The OM3 index reflects the percentage of EPA and DHA in red blood cell fatty acids and the risk of cardiovascular disease is considered
to be lower as the OM3 index increases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">CaPre
was found to be safe and well tolerated at all doses tested, with no serious adverse events that were considered treatment- related.
Out of 387 randomized patients, a total of 7 (1.8%) were discontinued as a result of adverse events, three were on placebo, two
were on 1 gram and two were on 2 grams of CaPre. The predominant incidence was gastrointestinal-related, with no difference between
CaPre and placebo. The safety profiles of patients on CaPre and placebo were similar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Government Regulation</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">United States Drug Development</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Government
authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other
things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record- keeping,
promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug products
such as CaPre. Generally, before a new drug can be marketed, considerable data demonstrating its quality, safety and efficacy must
be obtained, organized into a format specific to each regulatory authority, submitted for review and approved by the regulatory
authority.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">FDA Regulatory Process</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In the United
States, the FDA regulates drugs under the FDCA and its implementing regulations. Drugs are also subject to other federal, state
and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate
federal, state and local statutes and regulations require the expenditure of substantial time and financial resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
order to be marketed in the United States, CaPre must be approved by the FDA through the NDA review process. The process required
before a drug may be marketed in the United States generally involves the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">completion of extensive nonclinical (animal) and formulation studies in accordance with applicable
regulations, including the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">submission of an investigational new drug application, or IND, which must become effective before
human clinical trials may begin in the United States;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">performance of adequate and well-controlled clinical trials in accordance with the applicable IND
and other clinical study- related regulations, such as current Good Clinical Practices, or cGMP, to establish the safety and efficacy
of the proposed drug for its proposed indication;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">submission of an NDA for a new drug;</td></tr></table>
<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities
where the drug is produced to assess compliance with cGMP to assure that the facilities, methods and controls are adequate to preserve
the drug&#8217;s identity, strength, quality and purity;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">satisfactory completion of potential FDA audit of the nonclinical and/or clinical trial sites that
generated the data in support of the NDA; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">FDA review and approval of the NDA prior to any commercial marketing or sale of the drug in the
United States.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
data required to support an NDA is generated in two distinct development stages: nonclinical and clinical. The nonclinical development
stage generally involves synthesizing or otherwise producing the active component, developing the formulation and determining the
manufacturing process, as well as carrying out non-human toxicology, pharmacology and drug metabolism studies in the laboratory,
which support subsequent clinical testing. The sponsor must submit the results of the nonclinical tests, together with manufacturing
information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of
the IND, which is a request for authorization from the FDA to administer an investigational drug product to humans. The IND automatically
becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical
trials. The FDA may also place the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the
FDA must resolve any outstanding concerns before the clinical trial can begin. A clinical hold may be imposed at any time before
or during a clinical trial due to safety concerns or non-compliance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
clinical stage of development first involves the administration of the investigational drug to healthy volunteers and then to patients
with the disease being targeted with the drug, all done under the supervision of qualified investigators, generally physicians
not employed by or under the trial sponsor&#8217;s control, in accordance with cGCP. All research subjects must provide their informed
consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things,
the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, data collection, and the parameters
to be used to monitor subject safety and assess the investigational drug&#8217;s efficacy. Each protocol, and any subsequent amendments
to the protocol or new investigator&#8217;s information, must be submitted to the FDA as part of the IND. Further, each clinical
trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which
the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers
such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation
to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or
its legal representative. There are also requirements governing the reporting of ongoing clinical trials and completed clinical
trial results to public registries, as well as reporting of safety information under the IND.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Clinical
studies are generally conducted in three sequential phases that may overlap, known as Phase 1, Phase 2 and Phase 3 clinical trials.
Phase 1 generally involves a small number of healthy volunteers who are initially exposed to a single dose and then multiple doses
of the investigational drug. The primary purpose of these studies is to assess the metabolism, pharmacologic action, side effect
tolerability and safety of the drug. Phase 2 trials typically involve studies in disease-affected patients to determine the dose
required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information
is collected, as well as identification of possible adverse effects and safety risks and preliminary evaluation of efficacy. Phase
3 clinical trials generally involve large numbers of patients at multiple sites, often in multiple countries (from several hundred
to several thousand subjects) and are designed to provide the data necessary to demonstrate the effectiveness of the product for
its intended use, its safety in use, and to establish the overall benefit/risk relationship of the product and provide an adequate
basis for product approval. Phase 3 clinical trials should, if possible, include comparisons with placebo and may include a comparison
to approved therapies. The duration of treatment is often extended to mimic the actual use of a product during marketing. Generally,
two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA (Pivotal Studies).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA. In addition, written IND safety
reports must be submitted to the FDA and the investigators for serious and unexpected adverse events or any finding from tests
in laboratory animals that suggests a significant risk for human subjects. The FDA, the IRB, or the sponsor may suspend or terminate
a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to
an unacceptable health risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Additionally, some clinical
trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety
monitoring board or committee. This group provides oversight and will determine whether or not a trial may move forward at designated
check points based on review of interim data from the study. A clinical trial may be terminated or suspended based on evolving
business objectives and/or competitive climate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
manufacturing process must be capable of consistently producing quality batches of the investigational drug and, among other things,
must develop methods for testing the identity, strength, quality and purity of the final drug product. The sponsor must develop
appropriate labeling that sets forth the conditions of intended use. Additionally, appropriate packaging must be selected and tested
and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over
its shelf life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Post-approval
studies, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are
used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances,
the FDA may mandate the performance of Phase 4 studies as part of a post-approval commitment, such as pediatric studies.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">NDA and FDA Review
Process</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Nonclinical
and clinical information is filed with the FDA in an NDA along with proposed labeling. The NDA is a request for approval to market
the drug and must contain proof of safety, purity, potency and efficacy, which is demonstrated by extensive nonclinical and clinical
testing. Data may come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product,
or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data
submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational drug product
to the satisfaction of the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: right">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited
circumstances. FDA approval of an NDA must be obtained before marketing a drug in the United States. In addition, under the Pediatric
Research Equity Act, an NDA or supplement to an NDA must contain data to assess the safety and effectiveness of the drug for the
claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation
for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
FDA reviews all NDAs submitted before it accepts them for filing and may request additional information. The FDA must make a decision
on accepting an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an in-depth
review of the NDA. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA
has ten months from the filing date in which to complete its initial review of a standard NDA and respond to the applicant. This
review typically takes 12 months from the date the NDA is submitted to the FDA including the screening which takes a period of
60 days. The FDA does not always meet its PDUFA goal dates for standard NDAs, and the review process may be significantly extended
by FDA requests for additional information or clarification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">After
the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product
is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and
preserve the product&#8217;s identity, strength, quality and purity. The FDA will likely re-analyze the clinical trial data, which
could result in extensive discussions with the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Before
approving an NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine
whether they comply with cGMP. The FDA will not approve the product unless it determines that the manufacturing processes and facilities
are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.
In addition, before approving an NDA, the FDA may also audit data from clinical trials to ensure compliance with cGCP requirements.
After the FDA evaluates the application, manufacturing process and manufacturing facilities, it will issue a Complete Response
Letter, or CRL. A CRL indicates that the review cycle of the application is complete and whether the application is approved and,
when applicable, the CRL describes the specific deficiencies in the NDA and may require additional clinical data and/or an additional
Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, nonclinical studies
or manufacturing. The applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw
the application. Even if such data and information is submitted, the FDA may ultimately decide that the NDA does not satisfy the
criteria for approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">If
a product receives marketing approval, the approval may be significantly limited to specific diseases and dosages or the indications
for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain
contraindications, warnings or precautions be included in the product labeling, may condition the approval of the NDA on other
changes to the proposed labeling, or may require a Risk Evaluation and Mitigation Strategy (REMS), which could limit the ability
to market the drug once approved. The FDA may also require the development of adequate controls and specifications, or a commitment
to conduct post-market testing or clinical trials and surveillance to monitor the effects of approved products.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">U.S. Post-Marketing Requirements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Following
approval of a new product, a pharmaceutical company and the approved product are subject to continuing regulation by the FDA, including,
among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences
with the product and reporting Field Alert information relating to bacteriological contamination, significant deterioration of
the product or failure of distributed product to meet specifications, providing the regulatory authorities with updated safety
and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising requirements,
which include, among others, standards for direct-to-consumer advertising, restrictions on promoting drugs for uses or in patient
populations that are not described in the drug&#8217;s approved labeling, or &#8220;off-label use&#8221;, limitations on industry-sponsored
scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians
may prescribe legally available drugs for off-label uses, manufacturers and distributors may not market or promote such off-label
uses. Modifications or enhancements to the product or its labeling or changes of the site of manufacture are often subject to the
approval of the FDA and other regulators, which may or may not be received or may result in a lengthy review process. In some cases,
these changes will require the submission of clinical data and the payment of a user fee.</p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">U.S. Patent Term Restoration and Marketing
Exclusivity</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Depending
upon the timing, duration and specifics of the FDA approval of our prescription drug candidates, some of our U.S. patents may be
eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred
to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation
for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot
extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration
period is generally one-half the time between the effective date of an IND and the submission date of an NDA plus the time between
the submission date of an NDA and the approval of that application. Only one patent applicable to an approved drug is eligible
for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO in consultation
with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply
for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond its current expiration
date, depending on the expected length of the clinical trials and other factors involved in the filing and review of the relevant
NDA.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Non-U.S. Drug Regulation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.75pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
Canada, biopharmaceutical product candidates are regulated by the Food and Drugs Act and the related rules and regulations, which
are enforced by the Therapeutic Products Directorate of Health Canada. In order to obtain approval for commercializing new drugs
in Canada, the sponsor must satisfy many regulatory conditions. The sponsor must first complete preclinical studies in order to
file a clinical trial application, or CTA, in Canada. The sponsor will then receive different clearance authorizations to proceed
with Phase I clinical trials, which can then lead to Phase 2 and Phase 3 clinical trials. Once all three phases of trials are completed,
the sponsor must file a registration file named a New Drug Submission, or NDS, in Canada. If the NDS demonstrates that the product
was developed in accordance with the regulatory authorities&#8217; rules, regulations and guidelines and demonstrates favorable
safety and efficacy and receives a favorable risk/benefit analysis, then the regulatory authorities issue a notice of compliance,
which allows the sponsor to market the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
addition to regulations in the United States and Canada, we are subject to a variety of regulations governing clinical studies
and commercial sales and distribution of our products in other jurisdictions around the world. These laws and regulations typically
require the licensing of manufacturing and contract research facilities, carefully controlled research and testing of product candidates
and governmental review and approval of results prior to marketing therapeutic product candidates. Additionally, they require adherence
to good laboratory practices, good clinical practices and good manufacturing practices during production. The process of new drug
approvals by regulators in the United States, Canada and the European Union are generally considered to be among the most rigorous
in the world.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Whether
or not the FDA or Health Canada approval is obtained for a product, we must obtain approval from the comparable regulatory authorities
of other countries before we can commence clinical studies or marketing of the product in those countries. The approval process
varies from country to country and the time may be longer or shorter than that required for the FDA or Health Canada approval.
The requirements governing the conduct of clinical studies, product licensing, pricing and reimbursement vary greatly from country
to country. In some international markets, additional clinical trials may be required prior to the filing or approval of marketing
applications within the country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Active Pharmaceutical Ingredient Regulation</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The FDA will
regulate finished products containing APIs developed or under development by us. Depending on its intended uses, a finished product
containing the API may be regulated as a drug under the procedures described above. It may be possible to market a finished product
containing an API developed or under development by us as a dietary supplement. Dietary supplements do not require FDA premarket
approval. However, it may be necessary to submit a notification to the FDA that a company intends to market a dietary supplement
containing a &#8220;new dietary ingredient.&#8221; In general, the regulatory requirements in other countries also depend on the
nature of the finished product and do not focus on the API itself.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Fiscal Year 2019 Developments</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 18pt"><font style="font-family: Symbol; font-weight: normal">&#183;</font></td><td style="text-align: justify"><font style="font-weight: normal">On April 20-21, 2018, we hosted a well-attended investigators
meeting for the TRILOGY Phase 3 studies in Fairfax, Virginia. The aim of the investigators meeting was to ensure that the clinical
studies are conducted in compliance with the clinical study protocol, guidelines and applicable regulations. Approximately 200
attendees participated in this meeting, which was composed of physicians, study nurses and study coordinators representing 90 of
the TRILOGY clinical sites together with the clinical team of Acasti, our CRO, and the lead Principal Investigator for the TRILOGY
studies, Dariush Mozaffarian, M.D., Dr.P.H., who also presented at the meeting. Dr. Mozaffarian is a highly regarded cardiologist
at Tufts University, and his research focuses on the influence of OM3s, diet and lifestyle on cardiometabolic health.</font></td></tr></table>
<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 18pt"><font style="font-family: Symbol; font-weight: normal">&#183;</font></td><td style="text-align: justify"><font style="font-weight: normal">On May 9, 2018, we announced the closing of a public offering
of 9,530,000 units at a price of $1.05 per unit for aggregate gross proceeds to us of $10,006,500, with each unit consisting of
one common share and one common share purchase warrant. The common share purchase warrants comprising the units are exercisable
at any time prior to May 9, 2023 at an exercise price of $1.31 per common share. On May 14, 2018, we announced that the underwriter
had exercised the over-allotment option in full pursuant to which we issued, on the same date, 1,429,500 additional units upon
the same terms as set forth above for additional aggregate gross proceeds to us of $1,500,975.</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">On April 27, 2018, we announced the appointment of Donald Olds to our board
of directors and audit committee. See &#8220;Item 6. Directors, Senior Management and Employees &#8211; Directors and Senior Management.&#8221;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">On June 4, 2018, we announced the appointment of Mr. Brian Groch as our Chief
Commercial Officer. Mr. Groch brings over 25 years of senior experience in the healthcare and life science industries, including
product commercialization, developing and executing global sales strategies, business development, and operations. Mr. Groch will
drive our global commercialization strategy, including U.S. launch planning and execution, and commercial partnering activities
in the rest of the world. See &#8220;Item 6. Directors, Senior Management and Employees &#8211; Directors and Senior Management.&#8221;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">As of June 26, 2018, we had activated 110 clinical sites, 463 patients had
been enrolled and 41 patients had been randomized for the CaPre TRILOGY Phase 3 program. Additional cGMP production lots of API
and CaPre were manufactured during the fourth quarter, enabling us to continue to accumulate the CaPre and placebo inventory required
to support the TRILOGY Phase 3 trials.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">On September 24, 2018, we announced that Mr. Jean-Fran&#231;ois Boily was
appointed as the Vice President of Finance and Mrs. Linda O&#8217;Keefe, our former Chief Financial Officer, announced her retirement.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">On October 11, 2018, we announced the closing of its underwritten public
offering in the United States of 19,090,000 Common Shares on October 9, 2018 (which included the exercise in full by the underwriters
of their over-allotment option to purchase 2,490,000 additional common shares), at an offering price of US$1.00 per common share
generating net proceeds to us of approximately $22.6 million (US$17.4 million).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">On October 23, 2018, we announced the closing of an underwritten public offering
in Canada of 21,562,000 common shares (which included the exercise in full by the underwriters of their over-allotment option to
purchase 2,812,500 additional common shares), at an offering price of $1.28 per common share generating net proceeds to us of approximately
$25.4 million.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">On January 9, 2019, we announced a Certificate for a European Patent had
been issued to us by the European Patent Office. The granted patent is valid until 2030 and relates to a concentrated phospholipid
composition and method of using the same for modulating blood lipids. This patent was validated in Belgium, Switzerland, Germany,
Denmark, Spain, Finland, France, United Kingdom, Italy, Netherlands, Norway, Portugal and Sweden.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">On February 21, 2019, we announced announces we had been recognized by the
TSX Venture Exchange in its &#8220;2019 Venture 50,&#8221; a ranking of the strongest companies on TSX Venture Exchange by share
price, trading volume and market capitalization.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">On April 1, 2019, we announced publication of CaPre&#8217;s bioavailability
study in a leading peer-reviewed journal. This study further validated our prior study results demonstrating that the bioavailability
of CaPre is significantly better than LOVAZA when taken with a low-fat meal.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 38.7pt"></td><td style="width: 18pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">As of June 3, 2019, 100% of the required total patients for our two TRILOGY
Phase 3 studies had been randomized, and more than 60% of patients who had previously been randomized in our TRILOGY program had
already completed their 6-month treatment plans. This progress supports management&#8217;s expectation for announcing topline results
of TRILOGY&nbsp;1 before the end of calendar 2019 and topline results of TRILOGY&nbsp;2 in January&nbsp;2020.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">C.</td><td>Organizational Structure</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
have no subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">D.</td><td>Property, Plants and Equipment</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
head office and operations are located at 545, Promenade Centropolis, suite 100, Laval, Qu&#233;bec, Canada, H7T 0A3 and our
R&amp;D and quality control laboratory is located at Espace Lab, 2650 Maximilien-Chagnon, Sherbrooke, Qu&#233;bec, Canada, J1E0M8.
We do not own our own manufacturing facility for the production of CaPre; however, we do own the proprietary equipment for producing
the API and drug product. We currently do not have plans to develop our own manufacturing facility. However, this could change
in the foreseeable future, as we consider the most cost-effective approaches to producing CaPre while ensuring the highest level
of quality. We currently depend on third party suppliers and manufacturers to produce our required raw krill oil and drug substance
and products. If CaPre is approved for distribution by the FDA, we initially expect to rely on cGMP-compliant third parties to
manufacture NKPL66, which is API in CaPre, encapsulate, bottle and package clinical supplies of CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
have entered into an agreement CordenPharma Chen&#244;ve, a third party CMO, for the manufacturing of CaPre clinical material
for the purposes of our ongoing TRILOGY Phase 3 program in accordance with cGMP regulations imposed by the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0; text-align: right"></td><td style="width: 50pt"><a name="a_013"></a>Item 4A. </td><td style="text-align: justify">Unresolved Staff Comments</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 50pt"><a name="a_014"></a>Item 5.</td><td>Operating and Financial Review and Prospects</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">This
annual report contains forward-looking statements, principally in, but not limited to, &#8220;Item 4 - Information on the Company&#8221;
and &#8220;Item 5 - Operating and Financial Review and Prospects&#8221;. These statements may be identified by the use of words
like &#8220;plan&#8221;, &#8220;expect&#8221;, &#8220;aim&#8221;, believe&#8221;, &#8220;project&#8221;, &#8220;anticipate&#8221;,
&#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;could&#8221; and similar expressions
in connection with any discussion, expectation, or projection of future operating or financial performance, events or trends. In
particular, these include statements about our strategy for growth, future performance or results of current sales and production,
interest rates, foreign exchange rates, and the outcome of contingencies, such as acquisitions and/or legal proceedings and intellectual
property issues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Forward-looking
statements are based on certain assumptions and expectations of future events that are subject to risks and uncertainties. Actual
future results and trends may differ materially from historical results or those projected in any forward-looking statements depending
on a variety of factors, including, among other things, the factors discussed in this annual report under &#8220;Item 3.D - Risk
Factors&#8221; and factors described in documents that we may furnish from time to time to the SEC. Although the forward-looking
information is based upon what we believe to be reasonable assumptions, no person should place undue reliance on forward-looking
information since actual results may vary materially from the forward-looking information. Except as required by law, we undertake
no obligation to update publicly or revise any forward- looking statements because of new information. Please refer to &#8220;Special
Note Regarding Forward-Looking Statements&#8221; at the beginning of this annual report for additional details.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><b>Management&#8217;s Discussion and Analysis
of Financial Situation and Operating Results Fiscal Years Ended March 31, 2018 and 2019</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>Introduction</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">This management&#8217;s
discussion and analysis (&#8220;<b>MD&amp;A</b>&#8221;) is presented in order to provide the reader with an overview of the financial
results and changes to our financial position as at March 31, 2019 and for the year then ended. This MD&amp;A explains our material
variations in the financial statements of operations, financial position and cash flows for the year ended March 31, 2019 and 2018,
thirteen-month and one-month periods ended March 31, 2017 and the twelve-month period ended February 28, 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">This MD&amp;A
must be read in conjunction with our audited financial statements for the year ended March 31, 2019 and 2018, and the thirteen-month
period ended March 31, 2017. Our audited financial statements were prepared in accordance with International Financial Reporting
Standards (&#8220;<b>IFRS</b>&#8221;), as issued by the International Accounting Standards Board. Our financial results are published
in Canadian dollars. All amounts appearing in this MD&amp;A are in thousands of Canadian dollars, except share and per share amounts
or unless otherwise indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Caution Regarding Non-IFRS
Financial Measures </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We use multiple financial
measures for the review of our operating performance. These measures are generally IFRS financial measures, but one adjusted financial
measure, non-IFRS operating loss, is also used to assess our operating performance. This non-IFRS financial measure is directly
derived from our financial statements and is presented in a consistent manner. We use this measure, in addition to the IFRS financial
measures, for the purposes of evaluating our historical and prospective financial performance, as well as our performance relative
to competitors, and to plan and forecast future periods as well as to make operational and strategic decisions. We believe that
providing this non-IFRS information to investors, in addition to IFRS measures, allows them to see our results through the eyes
of management, and to better understand its historical and future financial performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Earnings and other
measures adjusted to a basis other than IFRS do not have standardized meanings and are unlikely to be comparable to similar measures
used by other companies. Accordingly, they should not be considered in isolation. We use non-IFRS operating loss to measure our
performance from one period to the next without the variation caused by certain adjustments that could potentially distort the
analysis of trends in its operating performance, and because we believe it provides meaningful information on our financial condition
and operating results. Our method for calculating non-IFRS operating loss may differ from that used by other corporations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We calculate our non-IFRS
operating loss measurement by adding to net loss finance expenses that includes change in fair value of derivative warrant liabilities
and foreign exchange gain (loss), depreciation and amortization, impairment loss, litigation settlement expected to be paid via
common shares, and stock-based compensation and by subtracting finance income and deferred tax recovery. Items that do not impact
our core operating performance are excluded from the calculation as they may vary significantly from one period to another. We
also exclude the effects of certain non-monetary transactions recorded, such as stock-based compensation and litigation settlement
expected to be paid via common shares, from our non-IFRS operating loss calculation. Excluding this item does not imply it is necessarily
non-recurring.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">A reconciliation of
net loss to non-IFRS operating loss is presented later in this MD&amp;A.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Basis of Presentation of the
Financial Statements </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We are subject to a
number of risks associated with our ongoing priorities, including the conduct of our clinical program and its results, the establishment
of strategic alliances and the development of new pharmaceutical products and their marketing. Our current product in development
requires approval from the FDA and equivalent regulatory organizations in other countries before its sale can be authorized. Certain
risks have been reduced for the longer term with the outcome of our actions, including our intellectual property strategy execution
with filed patent applications in more than 20 jurisdictions, with more than 20 issued patents and with numerous additional patent
applications pending. We have incurred significant operating losses and negative cash flows from operations since our inception.
To date, we have financed our operations through the public offering and private placement of common shares (with or without warrants)
and convertible debt, the proceeds from research grants and research tax credits, and the exercises of warrants, rights and options.
To achieve the objectives of our business plan, we plan to raise the necessary funds through additional securities offerings and
the establishment of strategic alliances as well as additional research grants and research tax credits. Our ability to complete
the needed financing and ultimately achieve profitable operations is dependent on a number of factors outside of our control. See
Item 3 &#8220;Risk Factors&#8221; in this MD&amp;A.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
have incurred operating losses and negative cash flows from operations since inception. Our current assets of $37.3 million as
at March 31, 2019 include cash and cash equivalents totaling $22.5 million, and marketable securities of $11.9 million mainly
generated by the net proceeds from our recent securities offerings. Our current liabilities of $18.2 million at March 31, 2019
are comprised primarily of amounts due to or accrued for creditors. Management projects that additional funds will be needed in
the future, after TRILOGY phase 3 clinical trials for activities necessary to prepare for CaPre&#8217;s commercial launch, including
the scale up of our manufacturing operations, the completion of the potential regulatory (NDA) submission package (assuming positive
Phase 3 clinical results), and the expansion of business development and U.S. commercial launch activities. We are working towards
the development of strategic partner relationships, as well as actively seeking additional non-dilutive funds in the future, but
there can be no assurance as to when or whether we will complete any strategic collaborations or succeed in identifying non-dilutive
funding sources. Consequently, we may need to raise additional equity capital in the future to fund these activities. In particular,
raising additional capital is subject to market conditions and is not within our control. If we do not raise additional
funds or find one or more strategic partners, we may not be able to realize our assets and discharge our liabilities in the normal
course of business. As a result, there exists a material uncertainty that casts substantial doubt about our ability to continue
as a going concern and, therefore, realize our assets and discharge our liabilities in the normal course of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The financial statements
have been prepared on a going concern basis, which assumes we will continue our operations in the foreseeable future and will be
able to realize our assets and discharge our liabilities and commitments in the ordinary course of business. These financial statements
do not include any adjustments to the carrying values and classification of assets and liabilities and reported expenses that may
be necessary if the going concern basis was not appropriate for these financial statements. If we are unable to continue as a going
concern, material write-downs to the carrying values of our assets, including our intangible asset, could be required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>Selected Financial Information </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Three-month periods ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid; text-align: right">Year ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">One-month ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-month <br>
period <br>ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>
2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>
2018</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>
2018</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>
2017</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>
2017</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left">Net loss</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">(16,806</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">(8,140</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">(51,566</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">(21,504</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">(769</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">(11,247</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Basic and diluted loss per share</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(0.22</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(0.32</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(0.95</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(1.23</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(0.05</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(1.01</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><font style="font-size: 10pt">Non-IFRS operating loss<font style="font-family: Times New Roman, Times, Serif"><sup>1</sup></font></font></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(12,095</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(6,427</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(40,157</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(16,095</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(406</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(7,798</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">48,471</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">22,959</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">48,471</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">22,959</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">25,456</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">25,456</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><font style="font-size: 10pt">Working capital<font style="font-family: Times New Roman, Times, Serif"><sup>2</sup></font></font></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">19,085</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,795</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">19,085</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,795</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8,143</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8,143</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -15.9pt; padding-left: 15.9pt">Total non-current financial liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">16,263</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8,038</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">16,263</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8,038</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,615</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,615</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Total equity</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,962</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,224</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,962</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,224</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,703</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,703</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table>

<p style="margin-top: 0; margin-right: 0; margin-bottom: 0">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>Comments on the Significant Variations of Results from
Operations for the Three-Month Periods, Years Ended March 31, 2019 and 2018 and the Thirteen-Month Period Ended March 31, 2017</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The net loss totaling
$16,806 or ($0.22) per share for the three months ended March 31, 2019 increased by $8,666 or $0.10 per share from the net loss
totaling $8,140 or ($0.32) per share for the three months ended March 31, 2018. The increase in net loss was resulted primarily
from the $5,668 increased non-IFRS operating loss generated by planned research and development expenses to execute the TRILOGY
Phase 3 clinical program as well as from a $2,084 (see &#8220;Reconciliation of Net Loss to Non-IFRS Operating Loss&#8221;) increase
in financial expenses due mostly to a loss related to the increase in value of the warrant derivative liability of $2,055. These
losses were also affected by the legal settlement expected to be paid via common shares of $990 in addition
to the increased depreciation and amortization expense of $64, offset by decreased stock-based compensation of $140.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
net loss totaling $51,566 or ($0.95) per share for the year ended March 31, 2019 increased by $30,062 from the net loss for
the year ended March 31, 2018 while the loss per share decreased by ($0.28) per share from the loss of ($1.23) per share for
the year ended March 31, 2018. The per share loss decreased due to the issuance of 52,494,519 common shares primarily in
connection with the public financings that occurred in May and October 2018. The increased net loss resulted primarily from
the $24,062 increased non-IFRS operating loss generated by planned research and development expenses to execute the TRILOGY
Phase 3 clinical program, as well as increases in stock-based compensation of $112 and depreciation and amortization of $155.
The increase in loss is also affected by the loss related to the legal settlement with our former CEO expected to be paid via
common shares of $990 and the reimbursement of related legal fees of $64. These increased losses were further increased by a net increase of $4,743 in financial expenses, due
mostly to a loss related to increased value of the warrant derivative liability of $5,943 (see &#8220;Reconciliation of Net
Loss to Non-IFRS Operating Loss&#8221;), offset by a decrease of $481 in derivative warrant liability-related transaction
costs and by the remaining gains of $311 due to a foreign exchange gain as well as an increase in interest income of $403.
The foreign exchange gain is mostly due to the U.S. cash flows generated by the U.S. public financing of US$17.4 million that
took place on October 9, 2018 and the U.S. denominated accounts payable, as well as the strengthening of the U.S. dollar in
relation to the Canadian dollar functional currency. At the time of the U.S. public financing, a major portion of the net
offering was invested in U.S. dollar investments as per our treasury policy (see &#8220;<i>Treasury Operations&#8221;</i>).
The increase in interest income is a result of the increase in marketable securities and cash equivalents investments as per
our treasury policy. As at March 31, 2019 cash equivalents and marketable securities amounted to $34,413 versus $8,249 as at
March 31, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The net loss totaling
$21,504 or ($1.23) per share for the year ended March 31, 2018 increased by $10,257 or ($0.22) per share from the net loss totaling
$11,247 or ($1.01) per share for the thirteen-month period ended March 31, 2017. This resulted primarily from the $8,297 increased
non-IFRS operating loss, a $1,642 increase in financial expense, a $255 increase in stock-based compensation, and a decrease of $129 in deferred tax recovery offset by a
$66 decrease in depreciation and amortization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">______________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><font style="font-size: 8pt"><sup>1
</sup>The non-IFRS operating loss (adding to net loss financial expenses (income), depreciation and amortization, change in fair
value of derivative warrant liabilities and stock-based compensation) is not a standard measure endorsed by IFRS requirements.
A reconciliation to net loss is presented below. On May 10, 2019 we announced the settlement regarding legal claims made by our
former chief executive (&#8220;CEO&#8221;) officer with respect to the termination of his employment. Pursuant to the settlement
agreement, we have agreed to issue 900,000 common shares at $1.10 per share to the former CEO.&nbsp; In addition, we have agreed
to reimburse the former CEO for legal fees of $64. Furthermore, pursuant to the settlement agreement, we have received a full
and final release from the former CEO on all procedures in connection with the termination of his employment. This settlement
has been accrued as at March 31, 2019 and the expense of $990 is included as part of general and administrative expenses.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><font style="font-size: 8pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><sup>2
</sup></font><font style="font-size: 8pt">Working capital is presented for information purposes only and represents a measurement
of our short-term financial health. Working capital is calculated by subtracting current liabilities from current assets. Because
there is no standard method endorsed by IFRS requirements, the results may not be comparable to similar measurements presented
by other public companies.</font></p>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>Breakdown of Major Components of the Statement of Earnings
and Comprehensive Loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">Research and Development Expenses</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="10" style="white-space: nowrap; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Three-month periods ended</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">Year ended</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2018</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2018</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: left; padding-left: 10pt; text-indent: -10pt">Salaries and benefits</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">676</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">615</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">1,805</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">1,705</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Research contracts</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">9,358</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,719</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">32,850</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">9,381</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Professional fees</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">81</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">248</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">719</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,790</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">Other</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">183</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">38</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">506</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">222</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Government grants and tax credits</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(298</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(325</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(588</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(409</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Total before stock-based compensation and depreciation and amortization</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">10,000</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,295</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">35,292</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">12,689</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Stock-based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">64</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">91</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">247</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">308</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Depreciation and amortization</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">731</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">667</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,827</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,672</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">Total</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,795</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,053</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,366</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">15,669</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">General and Administrative Expenses</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="10" style="white-space: nowrap; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Three-month periods ended</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">Year ended</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2018</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2018</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: left; padding-left: 10pt; text-indent: -10pt">Salaries and benefits</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">934</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">584</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">2,305</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">1,576</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Administrative fees</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">14</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">34</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">121</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Professional fees</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">775</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">428</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,732</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,347</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Other</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">378</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">106</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">794</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">362</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Total before stock-based compensation and legal settlement expected to be paid via common shares</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,095</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,132</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,865</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,406</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Stock-based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">64</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">177</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">794</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">621</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Legal settlement expected to be paid via common shares</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">990</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">990</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">Total</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,149</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,309</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,649</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,027</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>Three-Month Period Ended March 31, 2019 Compared to the
Three-Month Period Ended March 31, 2018</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">During the three months
ended March 31, 2019 we continued our planned advancement of the two-study TRILOGY Phase 3 clinical study program for our drug
candidate, CaPre, in partnership with one of the world&#8217;s largest providers of biopharmaceutical development and clinical
outsourcing services (&#8220;<b>CRO</b>&#8221;). The $10,795 in total research and development expenses for the three-months ended
March 31, 2019 totaled $10,000 before depreciation, amortization and stock-based compensation expense, compared to $6,053 in total
research and development expenses for the three-months ended March 31, 2018 or $5,295 before depreciation, amortization and stock-based
compensation expense. There is a $4,705 increase in research and development expenses before depreciation, amortization and stock-based
compensation which was mainly attributable to a $4,639 increase in research contracts, a $61 increase to salaries, a $27 increase
to government grants and tax credits and a $145 increase to other research and development expenses, offset by $167 decrease in
professional fees. Higher research contract expenses resulted primarily from a $3,988 increase in the CRO&#8217;s Phase 3 clinical
trial program contract expense with continued site activation and patient enrollment, randomization and treatment. The decrease
in professional fees is made up mostly of a $159 decrease in legal fees relating to services for contracting and due diligence
activities performed during the three-months ended March 31, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">General
and administrative expenses totaling $2,095 before stock-based compensation expense for the three months ended March 31, 2019
increased by $963 from $1,132 for the three months ended March 31, 2018. This $963 increase was mainly attributable to a $350
increase in salaries and benefits, an increase of $347 related to professional fees, an increase of $272 related to other
fees. The $350 increase in salaries and benefits primarily resulted from the hiring of a Chief Commercial Officer to support
expanded business and market development activities. The professional fee increase of $347 was due in part to additional
legal fees resulting from independence from Neptune, including no continued internal counsel services. Finally, the $272
increase in other expenses is associated with risk management programs now also independent of Neptune.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Stock-based compensation
and depreciation and amortization included in both research and development and general and administrative expenses are explained
in the following discussion of reconciliation of Net Loss to Non-IFRS Operating Loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>Year ended March 31, 2019 Compared to the Year Ended March
31, 2018</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">As we continue advancing
our planned TRILOGY Phase 3 clinical program and production scale-up of CaPre within its research and development program, $38,366
was incurred in total research and development expenses for the year ended March 31, 2019 and $35,292 was incurred before depreciation,
amortization and stock-based compensation expense. This compares to $15,669 in total research and development expenses for the
year ended March 31, 2018 or $12,689 before depreciation, amortization and stock-based compensation expense. The $22,603 increase
in research and development expenses before depreciation, amortization and stock-based compensation was mainly attributable to
the $23,469 increase in contracts with a $22,272 increase in Phase 3 CRO contract expenses and $1,196 of increased research contracts
resulting from the planned scale-up of CaPre production activities in the year ended March 31, 2019. An increase of $100 in salaries
and benefits relates to the increased headcount. These increases are offset by a $1,071 decrease in legal fees for contracting
and due diligence activities, as well as the $179 increase in tax credits which relates to higher research and development expenditures
combined with a higher investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">General and administrative
expenses totaling $4,865 before stock-based compensation expense for the year ended March 31, 2019 increased by $1,459 from $3,406
for the year ended March 31, 2018. This increase was mainly attributable to a $729 increase in salaries and benefits primarily
resulting from the expansion of the team to become independent of Neptune, and the expansion of our commercialization
team and business development activities. Professional fees increased by $385 due in part to additional legal fees resulting
from independence from Neptune. Additionally, professional fees increased due to implementation of a new ERP system. An increase
of $432 of other general and administrative expenses associated with risk management programs as we became independent of Neptune.
These increases were partially offset by an $87 reduction in Neptune&#8217;s administrative fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Stock-based compensation
and depreciation and amortization included in both research and development and general and administrative expenses are explained
in the following discussion of reconciliation of Net Loss to Non-IFRS Operating Loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>Reconciliation of Net Loss to Non-IFRS Operating Loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Three-month periods ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Year ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>
2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>
2018</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>
2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>
2018</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: left">Net loss</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(16,806</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(8,140</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(51,566</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(21,504</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Add (deduct):</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 5.65pt">Stock-based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">128</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">268</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,041</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">929</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10.25pt; padding-left: 15.9pt">Depreciation and amortization</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">731</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">667</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,827</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,672</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10.25pt; padding-left: 15.9pt">Legal settlement &#8211; expected to be settled in
    common shares</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">990</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">990</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 5.65pt">Financial expenses</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,862</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">778</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,551</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,808</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1.5pt solid; padding-left: 5.65pt">Non-IFRS operating loss</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(12,095</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,427</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(40,157</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,095</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td></tr>
</table>

<p style="margin-top: 0; margin-right: 0; margin-bottom: 0">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">For the three-month
period and year ended March 31, 2019 we recognized stock-based compensation under our compensation plans in the amount of $128
and $1,041, respectively, compared to the three-month and year ended March 31, 2018 totalling $268 and $929 respectively. The weighted
average grant date fair value of the options granted to employees and directors during the year ended March 31, 2019 was $0.51
compared to the grant date value of options granted in the year ended March 31, 2018 of $1.22, whereas an increase of 1,052,023
of number of options granted occurred, with total granted stock options of 2,173,523 for the year ended March 31, 2019 compared
to 1,121,500 stock options granted for the year ended March 31, 2018. No stock options were granted during the three-month periods
March 31, 2019 and 2018. No options were granted to consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The depreciation and
amortization expense increased by $64 to $731 for the three months ended March 31, 2019 from $667 for the three months ended March
31, 2018. The depreciation and amortization expense increased by $155 to $2,827 for the year ended March 31, 2019 from $2,672 for
the year ended March 31, 2018. The depreciation increased due to encapsulation production equipment being put into use during the
three months ended March 31, 2019 and therefore related depreciation commencing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Legal settlement expected
to be paid via common shares relates to the settlement regarding legal claims made by our former CEO with respect to the termination
of his employment. Pursuant to the settlement agreement, we have agreed to issue 900,000 common shares at $1.10 per share to the
former CEO.&nbsp; Furthermore, pursuant to the settlement agreement, we receive a full and final release from the former CEO on
all procedures in connection with the termination of his employment. This settlement amount of $990 has been accrued as at March
31, 2019, included as part of general and administrative expenses thus increasing the loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Financial expenses
increased by $2,084 from a loss of $778 for the three months ended March 31, 2019 to a loss of $2,862 for the three months ended
March 31, 2018. The main component of this increase resulted from the measurement of the fair value of the derivative warrant liabilities
as at March 31, 2019, which resulted due to an increase to the derivative warrant liabilities included in the statement of financial
position of $2,055 and a corresponding loss to change in fair value of warrant liabilities, included in financial income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Financial
expenses increased by $4,743 to $6,551 for the year ended March 31, 2019 from financial expenses of $1,808 for the year ended
March 31, 2018. The main component of this increase relates to the measurement of the fair value of the derivative warrant
liabilities as at March 31, 2019. This increase was offset by a decrease of $481 in derivative warrant liability-related
transaction costs, by foreign exchange gain of $311 as well as an increase in interest income of $403.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Two separate derivative
warrant liabilities are included in the statement of financial position as at March 31, 2019, compared to one derivative warrant
liability as at March 31, 2018. These derivative warrant liabilities stem from the financing transactions that took place in May
2018 and December 2017. The derivative warrant liabilities are re-measured at each reporting date using the Black-Scholes option
pricing model. The valuations are driven by the fluctuation in our common stock price resulting in an increased or decreased loss
or gain related to the change in fair value of the warrant liabilities and increasing or decreasing the corresponding liability
in the statement of financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>Selected Quarterly Financial Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify; border-top: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">March 31,</td><td style="border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">December 31,</td><td style="border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">September 30,</td><td style="border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">June 30,</td><td style="border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">2018</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">2018</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">2018</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Net loss</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(16,806</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(4,610</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(22,729</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(7,421</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Add (deduct):</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Depreciation and amortization</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">731</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">723</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">689</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">684</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Stock based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">128</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">336</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">326</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">251</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Legal settlement expected to be paid via common shares</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">990</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Financial (income) expense</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,862</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,100</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,291</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,502</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Non-IFRS operating loss</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,095</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,651</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(9,423</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,988</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; border-bottom: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">Basic and diluted net loss per share</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.22</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.07</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.62</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.23</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>


<p style="margin-top: 0; margin-right: 0; margin-bottom: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify; border-top: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">March 31,</td><td style="border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">December 31,</td><td style="border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">September 30,</td><td style="border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">June 30,</td><td style="border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">2018</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">2017</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">2017</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">2017</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: justify; padding-left: 10pt; text-indent: -10pt">Net loss</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(8,140</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(6,079</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(4,507</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(2,778</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Add (deduct):</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Depreciation and amortization</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">667</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">671</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">667</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">667</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">Stock based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">268</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">330</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">295</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">36</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Financial (income) expense</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">778</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">929</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">122</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(21</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Non-IFRS operating loss</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,427</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,149</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,423</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,096</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; border-bottom: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">Basic and diluted net loss per share</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.32</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.40</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.31</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.19</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td></tr>
</table>

<p style="margin-top: 0; margin-right: 0; margin-bottom: 0">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The quarterly year-to-year
non-IFRS operating loss variances are mainly attributable to fluctuations in research and development expenses from quarter-to-quarter
as well as an increase in general and administrative expenses over the last four quarters as we established an administrative and
finance team independent from Neptune and expanded our business development and pre-commercialization activities. The increase
in net loss, net loss per share in the fourth quarter of fiscal 2019 compared to the fourth quarter of fiscal 2018 can primarily
be explained by the costs incurred in CRO&#8217;s expenses associated with its TRILOGY Phase 3 clinical trial program. The increases
in net loss from quarter to quarter, in addition to the increased non-IFRS operating losses, are mainly due to the changes in fair
value of the derivative warrant liabilities as well as variations in foreign exchange gains or losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>Share Capital Structure</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our authorized share capital consists of
an unlimited number of Class A, Class B, Class C, Class D and Class E shares, without par value. Issued and outstanding fully paid
shares, stock options, restricted shares units and warrants, were as follows for the periods ended:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-top: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">March 31, <br>2019</td><td style="border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">March 31, <br>2018</td><td style="border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Number <br>
outstanding</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Number <br>
outstanding</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left; padding-left: 10pt; text-indent: -10pt">Class A shares, voting, participating and without par value</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">78,132,734</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">25,638,215</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Stock options granted and outstanding</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,046,677</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,284,388</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">May 2018 public offering of warrants exercisable at $1.31, until May 9, 2023</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">10,188,100</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Public offering broker warrants May 2018 exercisable at $1.05 until May 9, 2023</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">547,975</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">December 2017 U.S. public offering of warrants exercisable at US$1.26, until December 27, 2022</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">9,801,861</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">9,802,935</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">December 2017 U.S. broker warrants exercisable at US$1.2625, until December 27, 2022</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">495,050</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">495,050</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">February 2017 public offering of warrants exercisable at $2.15, until February 21, 2022</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,904,034</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,904,034</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">2017 unsecured convertible debentures conversion option contingent
warrants exercisable at $1.90, until February 21, 2020<font style="font-family: Times New Roman, Times, Serif"><sup>1</sup></font></font></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,052,630</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,052,630</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Series 8 warrants exercisable at US$15.00, until December&nbsp;3, 2018<font style="font-family: Times New Roman, Times, Serif"><sup>2</sup></font></font></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,840,000</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Series 9 warrants exercisable at $13.30 until December 3, 2018</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">161,654</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">Total fully diluted shares</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">106,169,061</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">43,178,906</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>Comparison of Cash Flows and Financial Condition Between
the Three Month and Year End Periods March 31, 2019 and 2018 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>Summary</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">As at March 31, 2019,
cash and cash equivalents totaled $22,521 with a net decrease in cash and cash equivalents totaling $6,372 for the three-month
period ended March 31, 2019 and sources of cash totaling $14,298 for the year ended March 31, 2019. This compares to $8,223 in
total cash and cash equivalents as at March 31, 2018 with a net decrease in cash and cash equivalents totaling $4,252 for the three-month
period ended March 31, 2018 and a net decrease in cash and cash equivalents totaling $1,549 for the year ended March 31, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>Operating Activities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">During the three months
ended March 31, 2019 and March 31, 2018, our operating activities used cash of $10,330 and $4,362, respectively, and during the
years ended March 31, 2019 and March 31, 2018, our operating activities used cash of $32,476 and $12,519, respectively (see &#8220;Reconciliation
of Net Loss to Non-IFRS Operating Loss&#8221;), further modified by changes in working capital, excluding cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>Investing Activities </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">During the three months
ended March 31, 2019, our investing activities generated cash of $5,148 compared to a use of cash of $123 for the three months
ended March 31, 2018. The significant increase in cash generated by investing activities during the three months ended March 31,
2019 resulted from our disposal of marketable securities due to cash on hand following the financings in October 2018. Cash used
by investing activities during the three-month period ended March 31, 2018 was due to the acquisition of equipment of $128, acquisition
of marketable securities of $26, offset by interest received of $31.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">______________________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><font style="font-size: 8pt"><sup>1</sup>
The debentures are convertible into common shares at a fixed price of $1.90 per common share except if we pay before the maturity,
if we pay all or any portion of the convertible debentures before maturity, then warrants become exercisable at $1.90 per common
share for the equivalent convertible debenture amount prepaid.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><font style="font-size: 8pt"><sup>2</sup>
Total of 18,400,000 warrants. In order to obtain one common share, 10 warrants must be exercised for a total amount of US$15.00.</font></p>
<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">During the year ended
March 31, 2019, our investing activities used cash of $12,136 compared to a use of cash of $411 for the year ended March 31, 2018.
The significant increase in cash used by investing activities resulted from our investment in marketable securities. Additionally,
cash used by investing activities during the year ended March 31, 2019 was due to the acquisition of equipment of $700, partially
offset by interest received of $384. Cash used by investing activities during the year ended March 31, 2018 was due to the acquisition
of equipment totaling $455, acquisition of marketable securities of $26, partially offset by interest received of $70.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>Financing Activities </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">During the three months
ended March 31, 2019, our financing activities used cash of $483 due primarily to the payment of transaction costs related to the
public offerings. For March 31, 2018 we used cash of $36.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">During the year ended
March 31, 2019, our financing activities generated cash of $58,862 mainly from the net proceeds of the public offerings of $57,892
and proceeds from warrants exercised related to the May 2018 public offering (see &#8220;<i>Derivative warrant liabilities</i>&#8221;)
of $1,011. During the year ended March 31, 2018, our financing activities generated cash of $11,406 primarily to the net proceeds
from a public offering of $11,065 and proceeds from warrants exercised of $384.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">See basis of presentation
for additional discussion of our financial condition, including the need for additional funds and the material uncertainty that
casts substantial doubt about our ability to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b><i>ATM Program</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">On February 14, 2019,
we entered into an &#8220;at-the-market&#8221; (&#8220;<b>ATM</b>&#8221;) sales agreement with B. Riley FBR, Inc., pursuant to
which our common shares may be sold from time to time for aggregate gross proceeds of up to US $30 million, with sales only being
made on the NASDAQ Stock Market. The common shares will be distributed at market prices prevailing at the time of the sale and,
as a result, prices may vary between purchasers and during the period of distribution. As at March 31, 2019, no securities have
been issued in relation to the ATM, and it remains our intent to use this facility to prepare for commercial launch. Costs incurred
in connection to the ATM of $179 have been included as deferred financing costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b><i>October 2018 Public Offering</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">On October 9, 2018,
we closed a U.S. public offering of 16,600,000 common shares at a price of US$1.00 per share. In addition, the underwriters fully
exercised their over-allotment option to purchase 2,490,000 additional common shares at the same public offering price. This offering
generated gross proceeds of $24.7 million (US$19.1 million), which resulted in net proceeds to us of $22.6 million (US$17.4 million)
and a total of 19,090,000 common shares issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">On October 23, 2018,
we closed a Canadian public offering of 18,750,000 common shares at a price of $1.28 per share. In addition, the underwriters fully
exercised their over-allotment option to purchase 2,812,500 additional common shares at the same public offering price. This offering
generated gross proceeds of $27.6 million, which resulted in net proceeds to us of approximately $25.4 million and a total of 21,562,500
common shares issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b><i>May 2018 Public Offering</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">On May 9, 2018 we closed
a Canadian public offering issuing 9,530,000 units of Acasti (&#8220;<b>Units</b>&#8221;) at a price of $1.05 per Unit for gross
proceeds of $10 million. The Units issued consist of 9,530,000 common shares and 9,530,000 Warrants. Each Warrant entitles the
holder thereof to acquire one of our common shares at an exercise price of $1.31 at any time until May 9, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">On May 14, 2018, the
underwriters exercised their over-allotment option by purchasing an additional 1,429,500 units at a price of $1.05 per Unit, for
additional gross proceeds of $1.5 million. The units issued consist of 1,429,500 common shares and 1,429,500 warrants. Each Warrant
entitles the holder thereof to acquire one of our common shares at an exercise price of $1.31 at any time until May 9, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The warrant component
of these Units are Derivative Warrant Liabilities for accounting purposes due to the warrant agreement, which contains certain
contingent provisions that allow for cash settlement. The proceeds of the offering are required to be split between the Derivative
Warrant Liabilities and the equity-classified common shares at the time of issuance of the Units. The fair value of the Derivative
Warrant Liabilities at the time of issuance was determined to be $4.3 million and the residual of the proceeds of $6.2 million
was allocated to the Common Shares. Issuance costs related to this transaction totaled approximately $1.8 million and have been
allocated between the Derivative Warrant Liabilities and Common shares based on relative value. Resulting from this allocation,
$0.7 million has been allocated to the Derivative Warrant Liability and is recognized in finance costs in the Statements of Earnings
and Comprehensive Loss, whereas the remaining portion of $1.1 million in issuance costs was allocated to the common shares and
recognized as a reduction to share capital, in the Statements of Financial Position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The weighted average
fair value of the 2018 Warrants issued in May 2018 was determined to be $0.39 per warrant. Changes in the fair value of the 2018
Warrants are recognized in finance expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">As part of the May
financing, we also issued broker warrants to purchase up to 547,975 Common Shares. Each broker warrant entitles the holder thereof
to acquire one of our common shares at an exercise price of $1.05, at any time until May 9, 2023. The broker warrants are considered
for compensation to non-employees under IFRS 2, stock-based compensation, and are accounted for at fair value at issuance date
and not subsequently revalued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>Financial Position</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The following table
details the significant changes to the statements of financial position as at March 31, 2019 compared to the prior fiscal period
end at March 31, 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Accounts</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Increase <br>(Decrease)</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Comments</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 42%; text-align: justify; white-space: nowrap">Cash and cash equivalents</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">14,298</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 42%; text-align: right; white-space: nowrap">See cash flow statement</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -15.9pt; padding-left: 15.9pt; white-space: nowrap">Marketable securities &#8211; current and long term</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">11,866</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right; white-space: nowrap">See cash flow statement</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; white-space: nowrap">Receivable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">857</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right; white-space: nowrap">Timing of receipts</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; white-space: nowrap">Prepaid expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">709</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right; white-space: nowrap">Advancement of contracts</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; white-space: nowrap">Other Asset &#8211; current and long term</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(37</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: right; white-space: nowrap">Usage of Krill Oil supply</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; white-space: nowrap">Deferred financing costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">179</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right; white-space: nowrap">Equity transactions</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; white-space: nowrap">Equipment</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(8</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: right; white-space: nowrap">Acquisition of equipment and depreciation</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; white-space: nowrap">Intangible asset</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(2,322</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: right; white-space: nowrap">Amortization</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; white-space: nowrap">Trade and other payables</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">11,549</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right; white-space: nowrap">Increased expenses and accruals</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; white-space: nowrap">Derivative warrant liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">9,837</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right; white-space: nowrap">&nbsp;&nbsp;Issuance of derivative warrants and change in fair value</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; border-bottom: Black 1.5pt solid; white-space: nowrap">Unsecured convertible debentures</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">205</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: right; border-bottom: Black 1.5pt solid; white-space: nowrap">Accretion of interest</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">See the statement of
changes in equity in our financial statements for details of changes to the equity accounts since March 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Treasury Operations </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our treasury policy is to invest cash that
is not required immediately into instruments with an investment strategy based on capital preservation. Cash equivalents and marketable
securities are primarily made in guaranteed investment certificates (&#8220;<b>GICs</b>&#8221;), term deposits and high-interest
savings accounts, which are issued and held with Canadian chartered banks; high rated promissory notes issued by government bodies
and commercial paper. We hold cash denominated in both US and CAD dollars. Funds received in US dollars from the equity private
placement are invested as per our treasury policy in US dollar investments and converted to CAD dollars as appropriate to fulfill
operational requirements and funding.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Derivative warrant liabilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The 2018 Warrants issued
as part of our May 2018 public offering were recognized as Derivative Warrant Liabilities with a fair value of $4,272. As of March
31, 2019, the Derivative Warrant Liabilities for the 2018 Warrants totaled $8,246, which represents the fair value of these warrants.
The weighted average fair value of the 2018 Warrants issued was determined to be $0.39 per warrant at inception and approximately
$0.81 per 2018 Warrant as at March 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">On December 27, 2017,
warrants were issued as part of our U.S. public offering and recognized as Derivative Warrant Liabilities with a fair value of
$5,873 (&#8220;<b>2017 Warrants</b>&#8221;). The 2017 Warrants are Derivative Warrant Liabilities for accounting purposes due to
the currency of the exercise price (US$) being different from our Canadian dollar functional currency. The fair value of the 2017
Warrants as of March 31, 2019, totaled $8,017 which represents the fair value of these warrants. The fair value of the 2017 Warrants
was determined to be $0.60 per warrant upon issuance and approximately $0.82 per warrant as of March 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">As
of March 31, 2019, the fair value of the Derivative Warrant Liabilities issued as part of our Series 8 December 2013
securities offering was  nil as the warrants expired December 3, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The increase in the
fair value of both existing derivative warrant liabilities as at March 31, 2019 is due to the increase in our share price and the
dilution factor, and the impact within the valuation model.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Warrant liabilities <br>
issued May 2018</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Warrant liabilities issued <br>
December 27, 2017</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Warrant liabilities issued <br>
December 3, 2013</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="10" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">Fair value per shares issuable</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%">March 31, 2019</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.81</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">0.82</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>December 31, 2018</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.68</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.66</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>September 30, 2018</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.96</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.95</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>June 30, 2018</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.36</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.36</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid">March 31, 2018</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.65</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">During October 2018,
771,400 - 2018 Warrants were exercised for one of our common shares at an exercise price of $1.31 for aggregate gross proceeds
of approximately $1.0 million. In addition, 4,455 2017 Warrants were exercised in a cashless manner to acquire 1,074 of our common
shares. A total of 772,474 common shares were issued as a result of 775,855 warrants exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Contractual Obligations, Off-Balance-Sheet
Arrangements and Commitments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">As at March 31, 2019,
our liabilities total $34,509, of which $18,426 is due within twelve months, $16,263 relates to Derivative Warrant Liabilities
that will likely be settled by issuing common shares in exchange for proceeds equal to the strike price of the instrument, and
$1,817 of outstanding unsecured convertible debentures. The unsecured convertible debentures may be prepaid. The debentures are
convertible into common shares at a fixed price of $1.90 per common share except if we pay before the maturity, all or any portion
of the convertible debentures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We also entered into
a contract to purchase production equipment to be used in the manufacturing of the clinical and future commercial supply of CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">A summary of the contractual
obligations at March 31, 2019, is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Carrying value</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Total contractual <br>
cash flows</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">1 year or less</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">1 to 3 years</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: left">Trade, other payables and due to related party</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">16,429</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">16,429</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">16,429</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Lease</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">79</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">79</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">79</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid">Unsecured convertible debentures</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,817</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,817</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,817</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid">Total</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,325</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,325</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,325</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Research and development contracts and
contract research organizations agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We utilize CMOs for
the development and production of clinical materials and research organizations to perform services related to our clinical trials.
Pursuant to the agreements with these contract manufacturing and contract research organizations, we have either the right to terminate
the agreements without penalties or under certain penalty conditions. For agreements which contain penalty conditions, we would
be required to pay penalties of approximately $109.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Lease</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">During
fiscal year 2018, we entered into a lease agreement for our  research and development and quality control laboratory facility
located in Sherbrooke, Qu&#233;bec, resulting in a commitment of $79 over the remaining lease term, which is committed in the
next year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We evaluate contingencies
on an ongoing basis and establishes loss provisions for matters in which losses are probable and the amount of the loss can be
reasonably estimated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">On May 10, 2019 we
announced the settlement regarding legal claims made by our former CEO with respect to the termination of his employment. Pursuant
to the settlement agreement, we have agreed to issue 900,000 common shares at $1.10 per share to the former CEO.&nbsp; In addition,
we have agreed to reimburse the former CEO for legal fees of $64. Furthermore, pursuant to the settlement agreement, we received
a full and final release from the former CEO on all procedures in connection with the termination of his employment. This settlement
has been accrued as at March 31, 2019 and the expense of $1,054 is included as part of general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Related Party Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We were charged by
Neptune, our former parent company, for the purchase of research supplies and for certain costs incurred by Neptune for our benefit
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br>
months ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month <br>
ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br>
ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>
2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>
2018</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2017</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>
2017</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">February 28, <br>
2017</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -8.25pt; padding-left: 8.25pt">Research and development expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%; text-align: left; padding-left: 13.65pt">Supplies and incremental costs</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">7</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 13.65pt">Shared service agreement</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">20</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">60</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">59</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; padding-left: 15.3pt">Total</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">27</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">60</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">59</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -8.25pt; padding-left: 8.25pt">General and administrative expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 13.65pt">Supplies and incremental costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">211</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">239</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">293</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">16</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">277</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 13.65pt">Shared service agreement</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">34</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">121</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">325</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">25</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">300</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; padding-left: 15.3pt">Total</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">245</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">360</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">618</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">41</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">577</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Total related parties expenses</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">245</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">387</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">678</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">636</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Where Neptune incurs
specific incremental costs for our benefit, it charges those amounts directly. Neptune provides us with the services of personnel
for certain administrative work as part of a shared service agreement. The employees&#8217; salaries and benefits are charged proportionally
to the time allocation agreed upon within the shared service agreement. Effective September 30, 2017, the laboratory support, the
corporate affairs and the public company reporting services previously provided by Neptune as part of the shared service agreement
were discontinued. We are now incurring incremental costs and expects to do so in the future, partially offset by reduced shared
service fees. The account payable to Neptune amounted to $2 at March 31, 2019, $44 at March 31, 2018 and $12 at March 31, 2017,
is non-interest bearing and has no specified maturity date. These charges do not represent all charges incurred by Neptune that
may have benefited us. Also, these charges do not necessarily represent the cost that we would otherwise need to incur, should
it not receive these services or benefits through the shared resources of Neptune.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">During the three-months
and year ended March 31, 2019, we recognized expenses of $47 and $245, respectively in general and administrative expenses in relation
to supplies and incremental costs, compared to $80 and $387, respectively, for the three-month and year ended March 31, 2018. As
the research and development and quality control laboratory facility is now completely independent of the Neptune facility, there
were no related party charges for research and development as at March 31, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Historically, Neptune
has provided us with the raw krill oil needed to produce CaPre for our clinical programs, including all of the raw krill oil projected
as needed for our Phase 3 clinical study program. However, Neptune discontinued its krill oil production and sold its krill oil
inventory to Aker on August 7, 2017. We are continually evaluating alternative suppliers of raw krill oil. At March 31, 2019, a
reserve of raw krill oil was still stored at Neptune&#8217;s facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our key management
personnel are our officers and the members of our Board of Directors. They control in the aggregate less than 1% of our total voting
shares (1% at March 31, 2018). See note 7 to the financial statements for disclosures of key management personnel compensation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Use of estimates and measurement of
uncertainty</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The preparation of
the financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the
application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ
from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Estimates are based
on management&#8217;s best knowledge of current events and actions that we may undertake in the future. Estimates and underlying
assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates
are revised and in any future periods affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Critical judgments
in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements include
the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 14.2pt"></td><td style="width: 17pt; text-align: left; vertical-align: top"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.95pt"><font style="font-size: 10pt">The use of the going concern basis of preparation
of the financial statements. At the end of each reporting period, management assesses the basis of preparation of the financial
statements. The financial statements have been prepared on a going concern basis in accordance with IFRS. The going concern basis
of presentation assumes that we will continue our operations for the foreseeable future and can realize its assets and discharge
its liabilities and commitments in the normal course of business.</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Assumptions and estimation
uncertainties that have a significant risk of resulting in a material adjustment within the next financial year include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 14.2pt"></td><td style="width: 17pt; text-align: left; vertical-align: top"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.65pt"><font style="font-size: 10pt">Measurement of derivative warrant liabilities
and stock-based compensation.</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Also, management uses
judgment to determine which research and development expenses qualify for research and development tax credits and in what amounts.
We recognize the tax credits once it we have had reasonable assurance that they will be realized. Recorded tax credits are subject
to review and approval by tax authorities and therefore, could be different from the amounts recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>CRITICAL ACCOUNTING POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Derivative warrant liabilities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The warrants forming
part of the Units issued from the May 2018 public offering are derivative liabilities for accounting purposes given to the fact
that the warrant indenture contains certain contingent provisions that allow for cash settlement. The warrants forming part of
the Units issued from the December 2017 and December 2013 public offering are derivative liabilities for accounting purposes due
to the currency of the exercise price being different from our functional currency. The derivative warrant liabilities are required
to be measured at fair value at each reporting date with changes in fair value recognized in earnings. We use Black-Scholes pricing
model to determine the fair value. The model requires the assumption of future stock price volatility, which is estimated based
on weighted average historic volatility. Changes to the expected volatility could cause significant variations in the estimated
fair value of the derivative warrant liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Stock-based compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We have a stock-based
compensation plan, which is described in note 17 of the financial statements. We account for stock options granted to employees
based on the fair value method, with fair value determined using the Black-Scholes model. The Black Scholes model requires certain
assumptions such as future stock price volatility and expected life of the instrument. Expected volatility is estimated based on
weighted average historic volatility. The expected life of the instrument is estimated based on historical experience and general
holder behavior. Under the fair value method, compensation cost is measured at fair value at date of grant and is expensed over
the award&#8217;s vesting period with a corresponding increase in contributed surplus. For stock options granted to non-employees,
we measure based on the fair value of services received, unless those are not reliably estimable, in which case we measure the
fair value of the equity instruments granted. Compensation cost is measured when we obtain the goods or the counterparty renders
the service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Tax credits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Refundable tax credits
related to eligible expenses are accounted for as a reduction of related costs in the year during which the expenses are incurred
as long as there is reasonable assurance of their realization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>FINANCIAL INSTRUMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Credit Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Credit risk is the
risk of a loss if a customer or counterparty to a financial asset fails to meet its contractual obligations. We have credit risks
relating to cash, cash equivalents and marketable securities, which it manages by dealing only with highly-rated Canadian institutions.
The carrying amount of financial assets, as disclosed in the statements of financial position, represents our credit exposure at
the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Currency risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We are exposed to the
financial risk related to the fluctuation of foreign exchange rates and the degrees of volatility of those rates. Foreign currency
risk is limited to the portion of our business transactions denominated in currencies other than the Canadian dollar. Fluctuations
related to foreign exchange rates could cause unforeseen fluctuations in our operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">A portion of the expenses,
mainly related to research contracts and purchase of production equipment, is incurred in US dollars and in Euros, for which no
financial hedging is required. There is a financial risk related to the fluctuation in the value of the US&nbsp;dollar and the
Euro in relation to the Canadian dollar. In order to minimize the financial risk related to the fluctuation in the value of the
US dollar in relation to the Canadian dollar, funds which were part of US dollar financings continue to be invested as short-term
investments in the US dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Furthermore, a portion
of our cash and cash equivalents and marketable securities are denominated in US dollars, further exposing us to fluctuations in
the value of the US dollar in relation to the Canadian dollar presented in <i>Note&nbsp;21</i> of the financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Interest rate risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Interest rate risk
is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our exposure to interest
rate risk as at March 31, 2019 and March 31, 2018 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>



<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: left; border-top: Black 1.5pt solid">Cash and cash equivalents</td><td style="width: 1%; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="width: 49%; text-align: left; border-top: Black 1.5pt solid">Short-term fixed interest rate</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Marketable Securities</td><td>&nbsp;</td>
    <td style="text-align: left">Short-term fixed interest rate</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Unsecured convertible debentures</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Short-term fixed interest rate</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our capacity to reinvest
the short-term amounts with equivalent return will be impacted by variations in short-term fixed interest rates available on the
market. Management believes the risk we will realize a loss as a result of the decline in the fair value of its short-term investments
is limited because these investments have short-term maturities and are generally held to maturity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Liquidity risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Liquidity risk is the
risk that we will not be able to meet our financial obligations as they fall due. We manage liquidity risk through the management
of our capital structure and financial leverage, as outlined in <i>Note 21</i> to the financial statements. We also manage liquidity
risk by continuously monitoring actual and projected cash flows. The Board of Directors reviews and approves our operating budgets,
and reviews material transactions outside the normal course of business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our contractual obligations
related to financial instruments and other obligations and liquidity resources are presented in the liquidity and capital resources
of this MD&amp;A.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Future accounting changes:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The following new standards,
and amendments to standards and interpretations, are not yet effective for the period ended March&nbsp;31,&nbsp;2019, and have
not been applied in preparing these financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">New standards and interpretations
not yet adopted:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Leases &#8211; IFRS 16</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">IFRS 16, Leases (&#8220;IFRS
16&#8221;) In January 2016, the IASB issued IFRS 16, a new standard that replaces IAS 17, Leases. IFRS 16 is a major revision of
the way in which companies account for leases and will no longer permit off balance sheet leases. Adoption of IFRS 16 is mandatory
and will be effective in our fiscal year beginning on April 1, 2019. We are assessing the impact of adoption of IFRS 16, and currently
there is only one lease that will be impacted by this new standard and the impact is expected to be minimal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>&nbsp;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b></b></p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 50pt"><a name="a_015"></a>Item 6.</td><td>Directors, Senior Management and Employees</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">A.</td><td>Directors and Senior Management</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
following table sets out the name and the province or state and country of residence of each of our directors and all offices with
us held by them, their principal occupation, the year in which they became a director, and the number of common shares they have
declared to beneficially own, directly or indirectly, or over which control or direction is exercised by them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="3" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; background-color: #BFBFBF">
    <td style="width: 35%; border: Black 1pt solid; text-align: center"><b>Name, Province or State, as the case <br>
may be, and Country or Residence of <br>
each Director</b></td>
    <td style="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><b>Principal Occupation</b></td>
    <td style="width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><b>First <br>
Year as <br>
Director </b></td>
    <td style="width: 23%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><b>Number of Common <br>
Shares Beneficially <br>
Owned or Controlled or <br>
Directed by Each Director <font style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></font></b></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><b>Roderick Carter</b><br>
California, United States<br>
Chairman of the Board</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">Principal Aquila Life Sciences LLC</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">2015</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">-</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><b>Jean-Marie (John) Canan<br>
</b>Florida, United States</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">Corporate Director</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">2016</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">107,500</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><b>Jan D&#8217;Alvise</b> <br>
California, United States</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">President and CEO of Acasti</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">2016</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">52,500</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><b>Donald Olds</b><br>
Quebec, Canada</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">President and CEO of NEOMED Institute</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">2018</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">38,000</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify">______________________________</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.85pt 0pt 20pt; text-align: justify"><font style="font-size: 8pt">Notes:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt"><font style="font-size: 8pt">(1)	Based on information
publicly available on SEDI.	</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The following is a brief biography of our current
directors and senior management:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><u>Dr. Roderick N. Carter</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Dr.
Carter has a strong history of contributions to healthcare through clinical, research, business and people leadership. He has significant
experience developing and commercializing nutraceutical and pharmaceutical products and has successfully led clinical research
and business development strategies for cardiovascular and inflammation related diseases. Dr. Carter is currently Principal at
Aquila Life Sciences LLC, a consulting firm he founded in April 2008 focusing on pharmaceutical development and commercialization.
Prior to this, he was Vice President of Clinical Development at Reliant Pharmaceuticals, which developed the OM3 cardiovascular
drug LOVAZA, and today is a wholly-owned subsidiary of GlaxoSmithKline. He also served as Executive Director at Merck and Co.,
USA, President and Chief Executive Officer of WellGen and Senior Medical Director at Pfizer Inc., USA. Dr. Carter received his
Medical Degree from the University of Witwatersrand, Johannesburg, along with a Master of Science degree in Sports Medicine from
Trinity College, Dublin.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><u>Jan D&#8217;Alvise
(also our President and CEO)</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Ms.
D&#8217;Alvise has extensive experience in diagnostics, medical devices, pharmaceuticals and drug discovery research tools. Until
2016, Ms. D&#8217;Alvise was the President and Chairman of Pediatric Bioscience. Before that, she was the CEO of Gish Biomedical,
a cardiopulmonary medical device company. Prior to Gish, Ms. D&#8217;Alvise was the CEO of the Sidney Kimmel Cancer Center (SKCC),
a drug discovery research institute. From 1995 until 1998, she was also the Co-Founder and Executive VP/COO of Metrika Inc., and
in 1999 was the Co- Founder/President/CEO/Chairman of NuGEN, Inc. Ms. D&#8217;Alvise built both companies from technology concept
through to successful regulatory approvals, product introduction and sustainable revenue growth. Prior to 1995, Ms. D&#8217;Alvise
was a VP of Drug Development at Syntex/Roche and Business Unit Director of their Pain and Inflammation business, and also VP of
Commercial Operations at SYVA, (Syntex&#8217;s clinical diagnostics division), and began her career with Diagnostic Products Corporation.
Ms. D&#8217;Alvise has a B.S. in Biochemistry from Michigan Technological University. She has completed post- graduate work at
the University of Michigan, Stanford University, and the Wharton Business Schools. Ms. D&#8217;Alvise has served on the board of
numerous private companies and non-profits, and is an Entrepreneur-in-Residence for the von Liebig Institute for Entrepreneurship
at the University of California, San Diego.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><u>Jean-Marie (John)
Canan</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Mr.
Canan is an accomplished business executive with over 34 years of strategic, business development and financial leadership experience.
Mr. Canan recently retired from Merck &amp; Co., Inc. where his last senior position was as Senior Vice-President, Global Controller,
and Chief Accounting Officer for Merck from November 2009 to March 2014. He has managed all interactions with the audit committee
of the Merck board of directors, while participating extensively with the main board and the compensation &amp; benefits committee.
Mr. Canan serves as a director of REV Group, a public company, where he chairs the audit committee. He also serves on the board
of trustees of Angkor Hospital for Children, where he also chairs the audit &amp; risk committee. Mr. Canan is a graduate of McGill
University, Montreal, Canada, and is a Canadian Chartered Accountant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><u>Donald Olds</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 20pt; margin: 0pt 5.85pt 0pt 0">Mr. Olds <FONT STYLE="color: Black">was
until recently  President and Chief Executive Officer of the NEOMED Institute, an R&amp;D organization dedicated to advancing
Canadian research discoveries to commercial success. Prior to NEOMED, he was the Chief Operating Officer of Telesta Therapeutics
Inc., a TSX-listed biotechnology company, where he was responsible for finance and investor relations, manufacturing operations,
business development, human resources and strategy. In 2016, he led the successful sale of Telesta to a larger public biotechnology
company. Prior to Telesta, he was President and Chief Executive Officer of Presagia Corp., and Chief Financial Officer and Chief
Operating Officer of Aegera Therapeutics, where he was responsible for clinical operations, business development, finance, and
mergers and acquisitions. At both Telesta and Aegera, Mr. Olds was responsible for raising more than $100 million in equity financing
and leading regional and global licensing transactions with life sciences companies. Mr. Olds is currently Director of Goodfood
Market Corp, Oxfam Quebec and Director of Presagia Corp. He has extensive past corporate governance experience serving on the
boards of private and public for-profit and not-for-profit organizations. He holds an MBA (Finance &amp; Strategy) and M.Sc. (Renewable
Resources) from McGill University.</FONT></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
following are brief biographies of our senior managers, other than our President and Chief Financial Officer, Jan D&#8217; Alvise,
whose biography appears further above:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><u>Dr. Pierre Lemieux &#8211; Chief Operating
Officer and Chief Scientific Officer (COO and CSO)</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Dr.
Lemieux has been our Chief Operating Officer since April 12, 2010 and our Chief Scientific Officer since June 2018<i>.</i> Previously,
Mr. Lemieux was CEO, Co-Founder and Chairman of BiolActis Inc. which he sold in 2009 to interests affiliated with the Nestl&#233;
multinational group. Mr. Lemieux joined Suprateck Pharma in 1999 as Director and Vice-President involved in the development of
formulations for gene therapy on behalf of Rhone-Poulenc Rorer and Genzyme, which today are under the Sanofi banner. Prior to this,
Mr. Lemieux was involved in the development of cardiovascular products at Angiotech Pharmaceuticals. Mr. Lemieux has a Ph.D. in
biochemistry from Universit&#233; Laval (Qu&#233;bec). He holds more than 16 patents and has authored over 50 publications.
Mr. Lemieux&#8217;s research was conducted at Universit&#233; Laval as well as at the anti-cancer center Paul Papin D&#8217;Angers
(France) and the University of Nottingham (England). His research focused on ovarian cancer and its treatment with monoclonal antibodies
used to target cancer drugs. After completing his graduate studies, Mr. Lemieux joined the Oncology division of the Center for
Health Research, University of Texas (U.S.). He obtained a postdoctoral fellowship from the Susan G. Komen Foundation (Breast Cancer).
Mr. Lemieux has served on the boards of BioQu&#233;bec, Montreal in vivo and PharmaBio Development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><u>Mr. Brian Groch &#8211; Chief Commercial
Officer (CCO)</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Mr.
Groch has been our Chief Commercial Officer since June 4, 2018. Mr. Groch brings over 25 years of senior experience in the healthcare
and life science industries, including product commercialization, developing and executing global sales strategies, business development,
and operations. Most recently, Mr. Groch served as Executive Vice President and Chief Commercial Officer at Veru Inc., a urology,
oncology and female health products company, where he was responsible for leading the development and execution of the company&#8217;s
long-term commercial strategy. Under his leadership, Veru experienced rapid growth in sales of the company&#8217;s women&#8217;s
health product. Mr. Groch also served as Chief Commercial Officer for Telesta Therapeutics, where he led the development and implementation
of the global commercial strategy. Previously, Mr. Groch served as Vice President of Commercial Operations and Market Access for
Horizon Therapeutics, where he oversaw global operations including the integration of two acquisitions valued over $1.5 billion.
Mr. Groch has also served as CEO and President of Exsto Therapeutics, Head of Market Access for Dendreon, and Director of Health
Policy for Phadia. He has held senior management roles with Novartis and Merck &amp; Co. He holds an M.S. in Healthcare Administration
and Marketing from Central Michigan University, as well as a B.S. in Physiology from Central Michigan University.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><u>Jean-Fran&#231;ois Boily &#8211;
Vice-President, Finance</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Mr.
Boily has been our Vice-President of Finance since September 24, 2018. Prior to joining Acasti, Mr. Boily served as a Director
of Finance &amp; Information Technology (IT) at Innovaderm Research Inc., a large North American contract research organization
(CRO) specialized in dermatology. At Innovaderm Mr. Boily worked closely with the President and Chief Medical Officer and founder,
where Mr. Boily was responsible for all aspects of Finance and IT. Mr. Boily undertook a major financial, IT and growth mandate
where Mr. Boily increased revenues and profits over 25%. Prior to that, Mr. Boily was a Director of Finance at Teva Canada, a generic
drug products manufacturer, where he oversaw manufacturing of generics, managing branded product launches and clinical R&amp;D
activities. At Teva, Mr.&nbsp;Boily worked closely with the CFO, where he had oversight of four production sites that generated
more than four billion doses. Most recently, Mr. Boily worked as a consultant and Vice President of Finance and IT for a pharmaceutical
start-up led by a US-based investor, where he helped raise seed capital in advance of a planned initial public offering in Canada
and the US. Mr. Boily holds a BS in Accounting from HEC Montreal and is a Chartered Public Accountant (CPA).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">B.</td><td>Compensation</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>Summary of our Compensation Programs</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
executive compensation program is intended to attract, motivate and retain high-performing senior executives, encourage and reward
superior performance and align the executives&#8217; interests with ours by providing compensation which is competitive with the
compensation received by executives employed by comparable companies and ensuring that the achievement of annual objectives is
rewarded through the payment of bonuses and providing executives with long-term incentive through the grant of stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our governance &amp; human resources,
or GHR, committee has authority to retain the services of independent compensation consultants to advise its members on executive
compensation and related matters, and to determine the fees and the terms and conditions of the engagement of those consultants.
During our fiscal year ended March 31, 2019, the GHR committee retained compensation consulting services, including those led by
The Sarkaria Group, to review our executive compensation programs, including base salary, short-term and long-term incentives,
total cash compensation levels and total direct compensation of certain senior positions, against those of peer groups of similar
and larger size, as measured by market capitalization, biotechnology and pharmaceutical companies listed or headquartered in North
America. All of the services provided by the consultants were provided to the GHR committee. The GHR committee assessed the independence
of the consultants and concluded that its engagement of the consultants did not raise any conflict of interest with us or any of
our directors or executive officers. As influenced by the consultants&#8217; fiscal period 2019 executive compensation review,
the board and GHR committee set the following executive compensation program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Use of Fixed and
Variable Pay Components</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Compensation
of our named executive officers (&#8220;<b>NEOs</b>&#8221;) is revised each year and has been structured to encourage and reward
executive officers on the basis of short-term and long-term corporate performance. In the context of its analysis of compensation
for our fiscal year ended March 31, 2019, the following components were examined by the GHR committee:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">base salary;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">short term incentive plan, consisting of a cash bonus;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">long term incentive plan, consisting of stock options and equity incentive grants based on performance
and/or time vesting conditions; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">other elements of compensation, consisting of group benefits and perquisites.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><u>Base Salary</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We
intend to be competitive with comparator companies and to attract and retain top talent. The GHR committee will review compensation
periodically to be sure it meets this strategic imperative. Base salary is set to reflect an individual&#8217;s skills, experience
and contributions within a salary structure consistent with our gender pay equity policy. Base salary structure is revised annually
by the GHR committee as our financial and market conditions evolve.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><u>Short Term Incentive
Plan (STIP)</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
Short-Term Incentive Plan, or STIP, provides for potential rewards when a threshold of corporate performance is met. Personal objectives
that support corporate goals are established annually with each employee and are assessed at the end of each financial year. Personal
objectives are assessed through a performance grid, with pre-specified, objective performance criteria. STIP awards are paid out
in proportion to individual performance, determined in end-of-year performance reviews. For the most senior participants in the
STIP, greater weight is assigned to corporate objectives. Target payout is expressed as a percentage of base salary and is determined
by employment contracts and board discretion. Annual salary for STIP purposes is the annual salary in effect at the end of the
plan year (i.e., prior to annual salary increases).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
actual amount awarded ranges from zero for performance well below expectation and is capped at two times target for exceptional
performance. The STIP is a discretionary variable compensation plan and all STIP payments are subject to board approval. Participants
must be employed by us at the end of the financial year to qualify. We reserve the right to modify or discontinue the STIP at any
time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Ms.
D&#8217;Alvise, our CEO, is eligible for up to a 50% bonus of her annual base salary. Dr. Lemieux, our COO, and Mr. Groch, our
CCO, are each eligible for up to a 40% bonus of their annual base salary. Mr. Boily, our Vice-President, Finance, is eligible for
up to a 30% bonus of his annual base salary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">These
performance goals will take into account the achievement of R&amp;D milestones within timelines and budget and individual objectives
determined annually by the board according to short-term priorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><u>Long Term Incentive
Plan (LITP)</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
LTIP has been adopted as a reward and retention mechanism. Participation is determined annually at the discretion of the board.
Employees approved by our board of directors may participate in our stock option plan, which is designed to align the long-term
interests of participants with those of shareholders, in order to promote shareholder value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
GHR committee determines the number of stock options to be granted to a participant based on peer group data and taking into account
corporate performance and level in the organization. The LTIP calculation is based on a guideline percentage of base salary and
the number of options is determined based on an approved dollar value (rather than a specific number of shares). The guideline
ranges from 15% to 200% and is subject to adjustment by the board in reviewing annual achievement of corporate performance and
availability of shares. The GHR committee may also determine, in its sole discretion, <i>ad hoc </i>stock option awards to be granted
to participants in order to address extraordinary situations. Awards at any level may be adjusted as necessary to maintain an equity
burn rate and overhang similar to comparator companies. In addition to our stock option plan, the board is also empowered to grant
<i>ad hoc </i>awards, from time to time, under our equity incentive plan to provide for a share-related mechanism to attract, retain
and motivate qualified directors, senior employees and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our directors
and executive officers are not permitted to purchase financial instruments, such as prepaid variable forward contracts, equity
swaps, collars or units of exchange funds that are designed to hedge or offset a decrease in market value of equity securities
granted as compensation or held, directly or indirectly, by the director or officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><u>Share Ownership Guidelines</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">To
further align the interests of our executives with those of our other shareholders, the board has adopted share ownership guidelines.
Under these guidelines, the CEO and other executives (i.e., CFO, COO, VPs) are required to retain and hold 50% of the shares acquired
by them under any equity incentive award granted on or after June 7, 2017 (after subtracting shares sold to pay for option exercise
costs, and relevant federal, state, and local taxes which are assumed to be at the highest marginal tax rates). In addition, the
share retention rule applies unless the executive beneficially owns shares with a value at or in excess of the following share
ownership guidelines:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">CEO &#8212; 2x then-current annual base salary</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">Other executives &#8212; 1x then-current annual base salary.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
value of an individual&#8217;s shares for purposes of the share ownership guidelines is deemed to be the greater of the then- current
fair market value of the shares, or the individual&#8217;s cost basis in the shares. Shares counted in calculating the share ownership
guidelines include shares beneficially owned outright, whether from open market purchases, shares retained after option exercises,
and shares of restricted stock or deferred stock units that have fully vested. In addition, in the case of vested, unexercised,
in-the-money stock options, the in-the-money value of the stock options will be included in the share ownership calculation. Executives
have five years from their date of hire or promotion to satisfy the share ownership guidelines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><u>Stock Option Plan</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
stock option plan was adopted by our board of directors on October 8, 2008 and has been amended from time to time, including most
recently on April 15, 2019. The grant of options is part of the long-term incentive component of executive and director compensation
and an essential part of compensation. Qualified directors, employees and consultants may participate in our stock option plan,
which is designed to encourage option holders to link their interests with those of our shareholders, in order to promote an increase
in shareholder value. Awards and the determination of any exercise price are made by our board of directors, after recommendation
by the GHR committee. Awards are established, among other things, according to the role and responsibilities associated with the
participant&#8217;s position and his or her influence over appreciation in shareholder value. Any award grants a participant the
right to purchase a certain number of common shares during a specified term in the future, after a vesting period and/or specific
performance conditions, at an exercise price equal to at least 100% of the market price (as defined below) of our common shares
on the grant date. The &#8220;market price&#8221; of common shares as of a particular date generally means the closing price per
common share on the TSXV, or any other exchange on which the common shares are listed from time to time, for the last preceding
date on which there was a sale of common shares on that exchange (subject to certain exceptions set forth in the stock option plan
in the event that we are no longer traded on any stock exchange). Previous awards may sometimes be taken into account when new
awards are considered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
accordance with the stock option plan, all of an option holder&#8217;s options will immediately vest on the date of a Change of
Control event (as defined in the stock option plan), subject to the terms of any employment agreement or other contractual arrangement
between the option holder and us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">However, in no
case will the grant of options under the plan, together with any proposed or previously existing security based compensation arrangement,
result in (in each case, as determined on the grant date): the grant to any one consultant within any 12-month period, of options
reserving for issuance a number of common shares exceeding in the aggregate 2% of our issued and outstanding common shares (on
a non-diluted basis); or the grant to any one employee, director and/or consultant, which provides investor relations services,
within any 12-month period, of options reserving for issuance a number of common shares exceeding in the aggregate 2% of our issued
and outstanding common shares (on a non-diluted basis).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Options
granted under the stock option plan are non-transferable and are subject to a minimum vesting period of 18 months, with gradual
and equal vesting on no less than a quarterly basis. They are exercisable, subject to vesting and/or performance conditions, at
a price equal to the closing price of the common shares on the TSXV on the day prior to the grant of such options. In addition,
and unless otherwise provided for in the agreement between us and the holder, options will also lapse upon termination of employment
or the end of the business relationship with us except that they may be exercised for 60 days after termination or the end of the
business relationship (30 days for investor relations services employees), to the extent that they will have vested on such date
of termination of employment, except in the case of death, disability or retirement where this period is extended to 12 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Subject
to the approval of relevant regulatory authorities, including the TSXV, if applicable, and compliance with any conditions attached
to that approval (including, in certain circumstances, approval by disinterested shareholders) if applicable, the board of directors
has the right to amend or terminate the stock option plan. However, unless option holders consent to the amendment or termination
of the stock option plan in writing, any such amendment or termination of the stock option plan cannot affect the conditions of
options that have already been granted and that have not been exercised under the stock option plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Options
for common shares representing a fixed rate of 15% of our outstanding issued common shares as of April 9, 2019 may be granted
by the board under the stock option plan. As at April 9, 2019, there were 11,719,910 common shares reserved for issuance under
the stock option plan. As of the date of this annual report, there were 600,081 options outstanding under the stock option plan.
</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><u>Equity Incentive Plan</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">On
May 22, 2013, our equity incentive plan was adopted by the board in order to, among other things, provide us with a share- related
mechanism to attract, retain and motivate qualified directors, employees and consultants. The adoption of the equity incentive
plan was initially approved by shareholders at our 2013 Shareholders&#8217; meeting held on June 27, 2013 and has been amended
from time to time, including most recently on April 15, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Eligible
persons may participate in the equity incentive plan. &#8220;eligible persons&#8221; under the equity incentive plan consist of
any director, officer, employee or consultant (as defined in the equity incentive plan) of us or a subsidiary may participate in
the equity incentive plan. A participant is an eligible person to whom an award has been granted under the equity incentive plan.
The equity incentive plan provides us with the option to grant to eligible persons bonus shares, restricted shares, restricted
share units, performance share units, deferred share units and other share-based awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">If,
and for so long as our common shares are listed on the TSXV, no more than 2% of the issued and outstanding common shares may be
granted to any one consultant or employee conducting investor relations activities in any 12-month period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
board has the right to determine that any unvested or unearned restricted share units, deferred share units, performance share
units or other share-based awards or restricted shares subject to a restricted period outstanding immediately prior to the occurrence
of a change in control will become fully vested or earned or free of restriction upon the occurrence of a change in control. The
board may also determine that any vested or earned restricted share units, deferred share units, performance share units or other
share-based awards will be cashed out at the market price as of the date a change in control is deemed to have occurred, or as
of such other date as the board may determine prior to the change in control. Further, the board has the right to provide for the
conversion or exchange of any restricted share unit, deferred share unit, performance share unit or other share-based award into
or for rights or other securities in any entity participating in or resulting from the change in control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
equity incentive plan is administered by the board and the board has sole and complete authority, in its discretion, to determine
the type of awards under the equity incentive plan relating to the issuance of common shares (including any combination of bonus
shares, restricted share units, performance share units, deferred share units, restricted shares or other share-based awards) in
such amounts, to such persons and under such terms and conditions as the board may determine, in accordance with the provisions
of the equity incentive plan and the recommendations made by the GHR committee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Subject to the
adjustment provisions provided for in the equity incentive plan and the applicable rules and regulations of all regulatory authorities
to which we are subject (including any stock exchange), the total number of common shares reserved for issuance pursuant to awards
granted under the equity incentive plan will be equal to a number that (A) if, and for so long as the common shares are listed
on the TSXV, will not exceed the lower of (i) 1,953,318 common shares, and (ii) 15% of the issued and outstanding common shares
as of April 9, 2019, representing 11,719,910 common shares, which includes common shares issuable pursuant to options issued under
our stock option plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><u>Other Forms of Compensation</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>RRSP
Matching Program. </i>Effective June 1, 2016, we sponsor a voluntary Registered Retirement Savings Plan, or RRSP, matching program,
which is open to all eligible employees, including NEOs. The RRSP matching program matches employees&#8217; contributions up to
a maximum of $1,500 per fiscal year for eligible employees who participate in the program. Other than matching contributions under
the RRSP matching program (which amounts are disclosed in the column entitled &#8220;All Other Compensation&#8221; in the summary
compensation table below), we do not provide pension or retirement benefits to our executive officers or directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Other
Benefits and Perquisites. </i>Our executive employee benefit program also includes life, medical, dental and disability insurance.
These benefits and perquisites are designed to be competitive overall with equivalent positions in comparable organizations. We
do not have a pension plan for employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Compensation Paid to Named Executive Officers</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 10.2pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The following table sets
forth the compensation information for the NEOs during the fiscal year ended March 31, 2019, the fiscal year ended March 31, 2018
and the fiscal year ended March 31, 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 10.2pt; margin-bottom: 0pt">&nbsp;</p>

<table cellspacing="0" cellpadding="3" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; background-color: #BFBFBF">
    <td style="width: 23%; border: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Name and <br>
Principal <br>
Position</b></font></td>
    <td style="width: 11%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Period
    <br>
ended</b></font></td>
    <td style="width: 11%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Salary<br>
    ($)</b></font></td>
    <td style="width: 11%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Share-<br>
Based
    <br>
Awards<br>
    ($)</b></font></td>
    <td style="width: 11%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Option-Based
    <br>
Awards<br>
    ($)<font style="font-family: Times New Roman, Times, Serif"><sup>(1) (2)</sup></font></b></font></td>
    <td style="width: 11%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Annual
    <br>
Incentive <br>
Plans<br>
    ($)</b></font></td>
    <td style="width: 11%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>All
    Other <br>
Compensation<br>
    ($)</b></font></td>
    <td style="width: 11%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Total
    <br>
Compensation <br>
($)</b></font></td></tr>
<tr style="vertical-align: top">
    <td rowspan="3" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Jan
    D&#8217;Alvise<font style="font-family: Times New Roman, Times, Serif"><sup>(4)</sup></font></b></font><font style="font-size: 10pt"><br>
    President and CEO</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">March
    31, 2019</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">498,332</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">497,196</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">241,291<sup>(10)</sup></font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">1,236,819</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">March
    31, 2018</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">431,902</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">528,279</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">183,500<sup>(6)</sup></font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><i>-</i></font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">1,143,681</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">March
    31, 2017</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">365,072</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">502,163</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">136,049<sup>(7)</sup></font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">1,003,284</font></td></tr>
<tr style="vertical-align: top">
    <td rowspan="3" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Pierre
    Lemieux</b><br>
    COO</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">March
    31, 2019</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">261,018</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">200,533</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">99,298</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">560,849</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">March
    31, 2018</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">253,680</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">190,426</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">71,155</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">1,500<sup>(3)</sup></font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">516,761</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">March
    31, 2017</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">275,819</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">96,522</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">49,000</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">421,341</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Brian
    Groch</b><sup>(8)</sup><br>
 CCO</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">March
    31, 2019</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">295,681</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">164,589</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">88,864<sup>(11)</sup></font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">549,134</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Jean-Fran&#231;ois
    Boily</b><sup>(9)</sup><b><br>
    </b>VP Finance</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">March
    31, 2019</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">103,821</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">111,693</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">30,638</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">246,152</font></td></tr>
<tr style="vertical-align: top">
    <td rowspan="3" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Linda
    O&#8217;Keefe</b><br>
    Former CFO<sup>(12)</sup></font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">March
    31, 2019</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">269,762</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">269,762</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">March
    31, 2018</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">327,199</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">159,712</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">64,475<sup>(13)</sup></font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">551,386</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">March
    31, 2017</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">114,183</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">-</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">237,340</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">39,897<sup>(14)</sup></font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">109,414</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">500,834</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 10.2pt; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 10.2pt; margin-bottom: 0pt"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">______________________________</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 10.2pt; margin-bottom: 0pt"><font style="font-size: 8pt">Notes:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><font style="font-size: 8pt">&nbsp;</font></p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 11.35pt"></td><td style="width: 21.85pt"><font style="font-size: 8pt">(1)</font></td><td style="text-align: justify; padding-right: 5.95pt"><font style="font-size: 8pt">The
                                         fair value of stock options is estimated at the grant date using the Black-Scholes option
                                         pricing model. This model requires the input of a number of parameters, including share
                                         price, share exercise price, expected share price volatility, expected time until exercise
                                         and risk-free interest rates. Although the assumptions used reflect management&#8217;s
                                         best estimates, they involve inherent uncertainties based on market conditions generally
                                         outside of our control.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 11.25pt"></td><td style="width: 21.85pt"><font style="font-size: 8pt">(2)</font></td><td style="text-align: justify; padding-right: 5.85pt"><font style="font-size: 8pt">The
                                         fair value of the option-based awards granted on July 2, 2018 in the fiscal year ended
                                         March 31, 2019 is $0.5486.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 11.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(3)</font></td><td style="text-align: justify; padding-right: 5.85pt"><font style="font-size: 8pt">The
                                         value of perquisites and other personal benefits received by these executives did not
                                         total an aggregate value of $50,000 or more, and does not represent 10% or more of their
                                         total salary during the fiscal years ended March 31, 2019, March 31, 2018 and March 31,
                                         2017.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 11.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(4)</font></td><td style="text-align: justify; padding-right: 5.9pt"><font style="font-size: 8pt">Ms.
                                         D&#8217;Alvise was appointed our President and CEO on May 11, 2016 and began her functions
                                         on June 1, 2016. Her employment agreement provides for payments in U.S. dollars with
                                         an annual base salary of US$380,000. In fiscal 2019, Ms. D&#8217;Alvise earned an annual
                                         base salary of US$394,398.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 11.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(5)</font></td><td><font style="font-size: 8pt">US$142,303
                                         <i>converted as at March 31, 2018, based on a closing exchange rate of US$1.00 = $1.2895.</i></font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 11.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(6)</font></td><td><font style="font-size: 8pt">US$102,300,
                                         converted as at March 31, 2017, based on a closing exchange rate of US1.00= $1.3299.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 11.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(7)</font></td><td><font style="font-size: 8pt">US$50,000
                                         <i>converted as at March 31, 2018, based on a closing exchange rate of US$1.00 = $1.2895.</i></font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 11.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(8)</font></td><td><font style="font-size: 8pt">Mr.
                                         Groch was appointed our CCO on June 1, 2018. His employment agreement provides for payments
                                         in U.S. dollars with an annual base salary of US$280,000. In fiscal 2019, Mr. Groch earned
                                         an annual base salary of US$225,346.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 11.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(9)</font></td><td><font style="font-size: 8pt">Mr.
                                         Boily was appointed our VP Finance on September 24, 2018. His employment agreement provides
                                         for an annual base salary of $215,000.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 11.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(10)</font></td><td><font style="font-size: 8pt">US$180,566
                                         converted as <i>at March 31, 2019, based on a closing exchange rate of US$1.00 = $1.3363.</i></font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 11.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(11)</font></td><td><font style="font-size: 8pt">US$66,500
                                         converted as <i>at March 31, 2019, based on a closing exchange rate of US$1.00 = $1.3363.</i></font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 11.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(12)</font></td><td><font style="font-size: 8pt">Ms.
                                         O&#8217;Keefe resigned as CFO effective October 26, 2018<i>.</i></font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 11.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(13)</font></td><td><font style="font-size: 8pt"><i>US$50,000
                                         </i>converted as at March 31, 2018, based on a closing exchange rate of US$1.00 = $1.2895.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 11.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(14)</font></td><td><font style="font-size: 8pt">US$30,000
                                         converted as at March 31, 2017, based on a closing exchange rate of US$1.00 = $1.3299.</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><font style="font-size: 8pt">&nbsp;</font></p>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Outstanding Share-Based and Option-Based
Awards</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.65pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The following tables provide
information about the number and value of the outstanding option-based awards held by the NEOs as of March 31, 2019. There are
no share-based awards outstanding as of the date of this annual report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.65pt; margin-bottom: 0pt">&nbsp;</p>

<table cellspacing="0" cellpadding="3" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; background-color: #BFBFBF">
    <td style="width: 20%; border: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Name/Grant Date</b></font></td>
    <td style="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Number of Securities <br>
Underlying Unexercised <br>
Options <br>
(#)</b></font></td>
    <td style="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Option Exercise Price<br>
($)<font style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></font></b></font></td>
    <td style="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Option Expiration Date</b></font></td>
    <td style="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Value of Unexercised <br>
In-The-Money Options<br>
($)<sup>(2)</sup></b></font></td></tr>
<tr style="vertical-align: top; background-color: #BFBFBF">
    <td colspan="5" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt"><b>Jan D&#8217;Alvise</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">July 2, 2018</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">906,248</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">0.77</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">July 2, 2028</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">525,624</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">June 14, 2017</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">430,000</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">1.77</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">June 14, 2027</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">May 12, 2016</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">525,000</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">1.56</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">May 12, 2023</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="5" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt"><b>Pierre Lemieux</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">July 2, 2018</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">365,515</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">0.77</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">July 2, 2028</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">211,999</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">June 14, 2017</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">155,000</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">1.77</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">June 14, 2027</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">February 24, 2017</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">50,000</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">1.65</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">February 24, 2027</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">May 30, 2016</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">31,400</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">1.99</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">May 29, 2023</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">June 1, 2015</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">16,900</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">4.50</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">June 1, 2022</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">October 20, 2014</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">7,500</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">6.50</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">October 19, 2019</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="5" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt"><b>Brian Groch</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">July 2, 2018</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">300,000</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">0.77</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">July 2, 2028</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">174,000</td></tr>
<tr style="vertical-align: top">
    <td colspan="5" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt"><b>Jean-Fran&#231;ois Boily</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">September 21, 2018</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">200,000</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">0.78</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">September 21, 2028</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">114,000</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">______________________________</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.65pt; margin-bottom: 0pt"><font style="font-size: 8pt">Notes:</font></p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 16.85pt"></td><td style="width: 16.35pt"><font style="font-size: 8pt">(1)</font></td><td><font style="font-size: 8pt">Option-based awards were consolidated
                                         following our share consolidation. The exercise price was increased proportionally to
                                         reflect the consolidation.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 16.85pt"></td><td style="width: 16.35pt"><font style="font-size: 8pt">(2)</font></td><td><font style="font-size: 8pt">Calculation is based on a
                                         trading price of $1.35 of our common shares on the TSXV, as at closing on March 29, 2019.</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The following table sets out
the value of share-based, option-based, and warrant-based awards held by the NEOs that vested during the fiscal year ended March
31, 2019:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellspacing="0" cellpadding="3" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; background-color: #BFBFBF">
    <td style="width: 34%; border: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Name</b></font></td>
    <td style="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Share-Based Awards<br>
($)</b></font></td>
    <td style="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Option-Based Awards<br>
($)</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt"><b>Jan D&#8217;Alvise</b></font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">439,821</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt"><b>Jean-Fran&#231;ois Boily</b></font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">18,250</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt"><b>Pierre Lemieux</b></font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">150,624</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt"><b>Brian Groch</b></font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">40,635</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Compensation of Directors</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
directors&#8217; compensation consists of an annual fixed compensation of US$60,000 for the chairman of the board and US$30,000
for the other non-executive board members. In addition, the chairperson of the audit committee and the chairperson of the governance
and human resources committee receive additional compensation of US$15,000 and US$10,000, respectively, while members of the audit
committee and the governance and human resources committee receive additional compensation of US$7,500 and US$5,000, respectively.
The directors are also entitled to be reimbursed for travelling and other reasonable expenses properly incurred by them in attending
meetings of the board or any committee or in otherwise serving us, in accordance with our policy on travel and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Following
their first election to our board of directors, non-executive directors are eligible to receive an initial equity grant of up to
150% of their annual cash retainer worth of stock options vesting annually in equal installments over an 18-month period, subject
to the other terms and conditions set forth under the heading &#8220;Stock Option Plan&#8221;. In addition to their initial grant,
non-executive directors are eligible to receive an annual equity-based award equal to 100% of their total annual cash retainer
vesting quarterly in equal installments over an 18-month period. These awards will be granted at the same time that we are performing
our annual performance review for our employees, subject to availability of common shares and subject to the terms and conditions
described under the headings &#8220;Stock Purchase Plan&#8221; and &#8220;Equity Incentive Plan&#8221;. The level of these awards
will be consistent with equivalent awards in comparable companies obtained from the benchmark exercise and in accordance with the
recommendations obtained from our independent compensation consultant. The total compensation for our non-executive directors during
fiscal year ended March 31, 2019 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="3" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; background-color: #BFBFBF">
    <td style="width: 20%; border: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Name</b></font></td>
    <td style="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Fiscal Year Ended <br>
March 31</b></font></td>
    <td style="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Fees Earned<br>
($)</b></font></td>
    <td style="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Option-Based <br>
Awards<br>
($)<font style="font-family: Times New Roman, Times, Serif"><sup>(1)(2)</sup></font></b></font></td>
    <td style="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>All Other <br>
Compensation<br>
($)<font style="font-family: Times New Roman, Times, Serif"><sup>(3)</sup></font></b></font></td>
    <td style="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Total<br>
($)</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><font style="font-size: 10pt">Roderick N. Carter</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">2019</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">85,291 (4)</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">80,377</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">165,668</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><font style="font-size: 10pt">Jean-Marie (John) Canan</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">2019</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">58,778 (5)</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">60,283</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">119,061</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify"><font style="font-size: 10pt">Donald Olds</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">2019</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">36,657 (6)</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">50,000</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">86,657</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">______________________________</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"><font style="font-size: 8pt">Notes:</font></p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.3pt"></td><td style="width: 21.85pt"><font style="font-size: 8pt">(1)</font></td><td style="text-align: justify; padding-right: 7.85pt"><font style="font-size: 8pt">The
                                         fair value of the awards is estimated at the grant date using the Black-Scholes option
                                         pricing model. This model requires the input of a number of parameters, including share
                                         price, share exercise price, expected share price volatility, expected time until exercise
                                         and risk-free interest rates. Although the assumptions used reflect management&#8217;s
                                         best estimates, they involve inherent uncertainties based on market conditions generally
                                         outside of our control.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.3pt"></td><td style="width: 21.85pt"><font style="font-size: 8pt">(2)</font></td><td style="text-align: justify; padding-right: 7.85pt"><font style="font-size: 8pt">For
                                         the fiscal year ended on March 31, 2019, the fair market value of the July 2, 2018 option-based
                                         awards is based on a fair value of $ 0.51 per option granted.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(3)</font></td><td><font style="font-size: 8pt">The directors do not receive
                                         pension benefits or other non-equity based annual compensation.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(4)</font></td><td><font style="font-size: 8pt">Dr. Carter earned a director
                                         compensation of US$65,000.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(5)</font></td><td><font style="font-size: 8pt">Mr. Canan earned a director
                                         compensation of US$45,000.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 23.3pt"></td><td style="width: 21.8pt"><font style="font-size: 8pt">(6)</font></td><td><font style="font-size: 8pt">Mr. Olds was appointed as a
                                         director on April 27, 2018 and earned a director compensation of US$27,885.</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The following table provides
information about the number and value of the outstanding share-based and option-based awards held by non-executive directors.
There were no share-based awards outstanding as of the date of this annual report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellspacing="0" cellpadding="3" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; background-color: #BFBFBF">
    <td style="width: 20%; border: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Name/Grant Date</b></font></td>
    <td style="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Number of Securities <br>
Underlying Unexercised <br>
Options <br>
(#)</b></font></td>
    <td style="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Option Exercise Price<br>
($)<font style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></font></b></font></td>
    <td style="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Option Expiration Date</b></font></td>
    <td style="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Value of Unexercised <br>
In-The-Money Options<br>
($)<sup>(2)</sup></b></font></td></tr>
<tr style="vertical-align: top">
    <td colspan="5" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt"><b>Roderick N. Carter</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">July 2, 2018</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">80,377</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">0.77</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">July 2, 2028</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">46,619</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">June 14, 2017</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">51,000</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">1.77</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">June 14, 2027</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">May 30, 2016</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">200,000</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">1.99</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">May 29, 2023</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">August 19, 2015</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">10,000</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">4.80</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">August 19, 2022</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="5" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt"><b>Jean-Marie (John) Canan</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">July 2, 2018</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">60,283</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">0.77</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">July 2, 2028</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">34,964</td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">June 14, 2017</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">29,000</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">1.77</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">June 14, 2027</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">February 24, 2017</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">50,000</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">1.65</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">February 24, 2027</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">--</font></td></tr>
<tr style="vertical-align: top">
    <td colspan="5" style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt"><b>Donald Olds</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><font style="font-size: 10pt">July 2, 2018</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">50,000</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">0.77</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt">July 2, 2028</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">29,000</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">______________________________</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><font style="font-size: 8pt">Notes:</font></p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 15pt"></td><td style="width: 17.25pt"><font style="font-size: 8pt">(1)</font></td><td><font style="font-size: 8pt">Option-based awards were consolidated
                                         following our share consolidation. The exercise price was increased proportionally to
                                         reflect the consolidation.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 15pt"></td><td style="width: 17.25pt"><font style="font-size: 8pt">(2)</font></td><td><font style="font-size: 8pt">Calculation is based on a trading
                                         price of $1.35 for our common shares on the TSXV, as at closing on March 29, 2019.</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">C.</td><td>Board Practices</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>Board of Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>Director Independence</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
board of directors believes that, in order to maximize its effectiveness, the board must be able to operate independently. A majority
of directors must satisfy the applicable tests of independence, such that the board of directors complies with all independence
requirements under applicable corporate and securities laws and stock exchange requirements applicable to us. No director will
be independent unless the board of directors has affirmatively determined that the director has no material relationship with us
or any of our affiliates, either directly or indirectly or as a partner, shareholder or officer of an organization that has a relationship
with us or our affiliates. Such determinations will be made on an annual basis and, if a director joins the board of directors
between annual meetings, at such time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><u>Independent Directors</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
board of directors determined that Mr. Canan, Dr. Carter and Mr. Olds are independent within the meaning of NI 52-110 and NASDAQ
Stock Market rules.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><u>Directors Who are Not Independent</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
board of directors determined that Ms. D&#8217;Alvise is not independent within the meaning of NI 52-110 and NASDAQ given that
she is our President and CEO.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">During
the fiscal year ended March 31, 2019, the board of directors held 14 meetings. All directors were in attendance for each regularly
scheduled quarterly and annual meeting of the Board.</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Chairman of the Board</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Dr.
Carter acts as Chairman of the board. His duties and responsibilities consist of the oversight of the quality and integrity of
the board of directors&#8217; practices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Board Mandate</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">There is no specific
mandate for the board of directors, since the board has plenary power. Any responsibility that is not delegated to senior management
or a committee of the board remains with the full board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Position Descriptions</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">No
written position description has been approved for the chair of the board of directors and for the chairs of each committee. The
primary role and responsibility of the chair of each committee of the board of directors is to: (i) in general, ensure that the
committee fulfills its mandate, as determined by the board of directors; (ii) chair meetings of the committee; (iii) report to
the board of directors; and (iv) act as liaison between the committee and the board of directors and, if necessary, our management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Orientation and Continuing Education</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We provide orientation
for new appointees to the board of directors and committees in the form of informal meetings with members of the board and senior
management, complemented by presentations on the main areas of our business. The board does not formally provide continuing education
to its directors, as directors are experienced members. The board of directors relies on professional assistance, when judged necessary,
in order to be educated/updated on a particular topic.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Code of Business Conduct and Ethics</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
board of directors adopted a Code of Business Conduct and Ethics, or Code of Conduct, for our directors, officers and employees
on May 31, 2007, as amended from time to time. Our Code of Conduct can be found on SEDAR at www.sedar.com and on our web site on
www.acastipharma.com. A copy of the Code of Conduct can also be obtained by contacting our Corporate Secretary. Since its adoption
by the board of directors, any breach of the Code of Conduct must be brought to the attention of the board of directors by our
CEO or other senior executives. No report has ever been filed which pertains to any conduct of a director or executive officer
that constitutes a breach to our Code of Conduct.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Since
the adoption of the Code of Conduct and the following policies, the board of directors actively monitors compliance with the Code
Conduct and promotes a business environment where employees are encouraged to report malfeasance, irregularities and other concerns.
The Code of Conduct provides for specific procedures for reporting non-compliant practices in a manner which, in the opinion of
the board of directors, encourages and promotes a culture of ethical business conduct.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
board of directors also adopted a disclosure policy, insider trading policy, majority voting policy, management and board compensation
policies, and a whistleblower policy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
addition, under the <i>Civil Code of Qu&#233;bec, </i>to which we are subject as a legal person incorporated under the <i>Business
Corporations Act </i>(Qu&#233;bec) (L.R.Q., c. S-31), a director must immediately disclose to the board any situation that may
place him or her in a conflict of interest. Any such declaration of interest is recorded in the minutes of proceeding of the board
of directors. The director abstains, except if required, from the discussion and voting on the question. In addition, it is our
policy that an interested director recuse himself or herself from the decision-making process pertaining to a contract or transaction
in which he or she has an interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Nomination of Directors</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
board of directors receives recommendations from the GHR committee, but retains responsibility for managing its own affairs by,
among other things, giving its approval for the composition and size of the board of directors, and the selection of candidates
nominated for election to the board of directors. The GHR committee initially evaluates candidates for nomination for election
as directors, having regard to the background, employment and qualifications of possible candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
selection of the nominees for the board of directors is made by the other members of the board, based on our needs and the qualities
required for the board of directors, including ethical character, integrity and maturity of judgment of the candidates; the level
of experience of the candidates, their ideas regarding the material aspects of our business, the expertise of the candidates in
fields relevant to us while complementing the training and experience of the other members of the board of directors; the will
and ability of the candidates to devote the necessary time to their duties to the board of directors and its committees, the will
of the candidates to serve on the board of directors for numerous consecutive financial periods and finally, the will of the candidates
to refrain from engaging in activities which conflict with the responsibilities and duties of a director. The board researches
the training and qualifications of potential new directors which seem to correspond to the selection criteria of the board of directors
and, depending on the results of said research, organizes meetings with the potential candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
the case of incumbent directors whose terms of office are set to expire, the board will review such directors&#8217; overall service
to us during their term of office, including the number of meetings attended, level of participation, quality of performance and
any transactions of such directors with us during their term of office.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We may
use various sources in order to identify the candidates for the board of directors, including our own contacts and the references
of other directors, officers, advisors and executive placement agencies. We will consider director candidates recommended by shareholders
and will evaluate those director candidates in the same manner in which we evaluate candidates recommended by other sources. In
making recommendations for director nominees for the annual meeting of shareholders, we will consider any written recommendations
of director candidates by shareholders received by our Corporate Secretary not later than 120 days before the anniversary of the
previous year&#8217;s annual meeting of shareholders. Recommendations must include the candidate&#8217;s name, contact information
and a statement of the candidate&#8217;s background and qualifications, and must be mailed to us. Following the selection of the
candidates by the board of directors, we will propose a list of candidates to the shareholders, for our annual meeting of shareholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
board of directors does not have a nominating committee and has not adopted any formal written director term limit policy. Proposed
nominations of director candidates are evaluated by our GHR committee.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">GHR Committee</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
mandate of the GHR committee consists of the evaluation of the proposed nominations of senior executives and director candidates
to our board of directors, recommending for board approval, if appropriate, revisions of our corporate governance practices and
procedures, developing new charters for any new committees established by the board of directors, monitoring relationships and
communication between management and the board of directors, monitoring emerging best practices in corporate governance and oversight
of governance matters and assessing the board of directors and its committees. The GHR committee is also in charge of establishing
the procedure which must be followed by us to comply with applicable guidelines of the TSXV and NASDAQ Stock Market regarding corporate
governance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The GHR committee
has the responsibility of evaluating the compensation, performance incentives as well as the benefits granted to our upper management
in accordance with their responsibilities and performance as well as to recommend the necessary adjustments to our board of directors.
The GHR committee also reviews the amount and method of compensation granted to the directors. The GHR committee may retain an
external firm in order to assist it during the execution of its mandate. The GHR committee considers time commitment, comparative
fees and responsibilities in determining compensation.</p>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The GHR committee
is composed of independent members within the meaning of NI 52-110 and NASDAQ Stock Exchange rules, namely Dr. Carter, Mr. Canan
and Mr. Olds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Periodic Assessments</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
board of directors, its committees and each director are subject to periodic evaluations of their efficacy and contribution. The
evaluation procedure consists in identifying any shortcomings and implementing adjustments proposed by directors at the beginning
and during meetings of the board of directors and of each of its committees. Among other things, these adjustments deal with the
level of preparation of directors, management and consultants employed by us, the relevance and sufficiency of the documentation
provided to directors and the time allowed to directors for discussion and debate of items on the agenda.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Director Term Limits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
board actively considers the issue of term limits from time to time. At this time, the board does not believe that it is in our
best interests to establish a limit on the number of times a director may stand for election. While such a limit could help create
an environment where fresh ideas and viewpoints are available to the board, a director term limit could also disadvantage us through
the loss of the beneficial contribution of directors who have developed increasing knowledge of, and insight into, us and our operations
over a period of time. As we operate in a unique industry, it is difficult to find qualified directors with the appropriate background
and experience and the introduction of a director term limit would impose further difficulty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Policies Regarding the Representation
of Women on the Board and Among Executive Officers</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">We have not adopted
a formal written policy regarding diversity amongst executive officers and members of the board of directors, including mechanisms
for board renewal, in connection with, among other things, the identification and nomination of women directors. Nevertheless,
we recognize that gender diversity is a significant aspect of diversity and acknowledges the important role that women with appropriate
and relevant skills and experience can play in contributing to the diversity of perspective on the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Rather
than considering the level of representation of women for directorship and executive officer positions when making board or executive
officer appointments, we consider all candidates based on their merit and qualifications relevant to the specific role. While we
recognize the benefits of diversity at all levels within its organization, we do not currently have any targets, rules or formal
policies that specifically require the identification, consideration, nomination or appointment of candidates for directorship
or executive management positions or that would otherwise force the composition of our board of directors and executive management
team. Currently, we have one women director who is also our CEO.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Audit Committee</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our audit committee is responsible
for assisting the board of directors in fulfilling its oversight responsibilities with respect to financial reporting, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">reviewing our procedures for internal control management performing financial functions;</td></tr></table>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">reviewing and approving the engagement of the auditor;</td></tr></table>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">reviewing annual and quarterly financial statements and all other material continuous disclosure
documents, including our annual information form and management&#8217;s discussion and analysis;</td></tr></table>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">assessing our financial and accounting personnel;</td></tr></table>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">assessing our accounting policies;</td></tr></table>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">reviewing our risk management procedures; and</td></tr></table>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">reviewing any significant transactions outside our ordinary course of business and any pending
litigation involving us.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The audit committee
has direct communication channels with our management performing financial functions and our external auditor to discuss and review
such issues as the audit committee may deem appropriate. As of March 31, 2019, the audit committee was composed of Mr. Canan, as
chairperson, Dr. Carter and Mr. Olds. Each of Mr. Canan, Dr. Carter and Mr. Olds is &#8220;financially literate&#8221; and &#8220;independent&#8221;
within the meaning of NI 52-110 and the Exchange Act. As of the date of this annual report, the composition of the audit committee
remains the same as at March 31, 2019.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Compensation Governance</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Compensation
of our executive officers and directors is recommended to the board of directors by the GHR committee. In its review process, the
GHR committee relies on input from management on the assessment of executives and corporate performance. During the fiscal year
ended March 31, 2019, the GHR committee was composed of the following members, each of whom is independent: Dr. Carter, Mr. Canan
and Mr. Olds. The GHR committee establishes management compensation policies and oversees their general implementation. All members
of the GHR committee have direct experience which is relevant to their responsibilities as GHR committee members. All members are
or have held senior executive or director roles within significant businesses, several also having public companies experience,
and have a good financial understanding which allows them to assess the costs versus benefits of compensation plans. The members
combined experience in our sector provides them with the understanding of our success factors and risks, which is very important
when determining metrics for measuring success.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Risk
management is a primary consideration of the GHR committee when implementing its compensation program. We do not believe that our
compensation program results in unnecessary or inappropriate risk taking, including risks that are likely to have a material adverse
effect on us. Payments of bonuses, if any, are not made unless performance goals are met.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.75pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">For
executives, more than half of target direct compensation (base salary + target STIP awards + target LTIP awards) is considered
&#8220;at risk&#8221;. We believe this mix results in a strong pay-for-performance relationship and an alignment with shareholders
and is competitive with other firms of comparable size in similar fields. The CEO (or any person acting in that capacity) makes
recommendations to the GHR committee as to the compensation of our executive officers, other than himself or herself, for approval
by the board. The GHR committee makes recommendations to the board of directors as to the compensation of the CEO, for approval.
The CEO&#8217;s salary is based on comparable market consideration and the GHR committee&#8217;s assessment of his or her performance,
with regard to our financial performance and progress in achieving strategic goals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Qualitative factors
beyond the quantitative financial metrics are also a key consideration in determination of individual executive compensation payments.
How executives achieve their financial results and demonstrate leadership consistent with our values are key to individual compensation
decisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">D.</td><td>Employees</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.75pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
management consists of professionals experienced in business development, finance and science. Our research team includes scientists
with expertise in pharmaceutical development, chemistry, manufacturing and controls, nonclinical and clinical studies, pharmacology,
regulatory affairs, quality assurance/quality control, intellectual property and strategic alliances. As of March 31, 2019, we
had 28 full-time employees. We generally require all of our employees to enter into an invention assignment, non-disclosure and
non-compete agreement. We rely, in part on the administrative and other staff of Neptune and also rely on consultants from time
to time. Our employees are not covered by any collective bargaining agreement or represented by a trade union. We consider our
relations with our employees to be good and our operations have never been interrupted as the result of a labor dispute.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">E.</td><td>Share Ownership</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.5pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The following table shows
the total number of common shares beneficially owned by each of our directors and executive officers and the percentage of the
total issued and outstanding common shares that such holdings represent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Common shares beneficially owned</td><td style="font-weight: bold">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Percentage of total issued and</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>outstanding common shares</b></p></td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; text-align: left; border-bottom: Black 1pt solid">Name</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">as of March 31, 2019</td><td style="border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">as of March
    31, 2019<sup>(1)</sup></td><td style="border-bottom: Black 1pt solid; font-weight: bold">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Roderick N. Carter</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; text-align: left">Jean-Marie (John) Canan</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">107,500</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right"><font style="font-size: 10pt">*</font></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Donald Olds</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">38,000</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-size: 10pt">*</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Jan D&#8217;Alvise</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">52,500</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-size: 10pt">*</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Pierre Lemieux</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7,000</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-size: 10pt">*</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Brian Groch</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jean-Fran&#231;ois Boily</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; margin: 0pt 0 0pt 87.8pt; width: 70%; font: 8pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="width: 5%; text-align: left"><font style="font-size: 8pt">(1)</font></td><td style="width: 1%"><font style="font-size: 8pt">&nbsp;</font></td>
    <td style="width: 94%; text-align: left"><font style="font-size: 8pt">Based on 78,132,734 common shares outstanding as of
    the date of this annual report.</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left"><font style="font-size: 8pt">*</font></td><td><font style="font-size: 8pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 8pt">Less than 1%.</font></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">See &#8220;Item
6.B. Compensation&#8221; above for information regarding the share-based, option-based, call-option-based, and warrant- based awards
held by our directors and executive officers and for a description of our stock option plan and equity incentive plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 60.55pt"><a name="a_016"></a>Item 7.</td><td>Major Shareholders and Related Party Transactions</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">A.</td><td>Major Shareholders</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">To the best of
our knowledge, there are no beneficial owners of 5% or more of any class of our voting securities other than Mr. George W. Haywood,
who, according to a beneficial ownership report on Schedule 13G/A filed by Mr. Haywood with the U.S. Securities and Exchange Commission
(the &#8220;Commission&#8221;) on February 13, 2019, beneficially owns 7,396,906 of our common shares, representing approximately
9.2% of our issued and outstanding common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">All
common shares are common shares with the same voting rights. Based on the most recent information received from our registrar
and transfer agent, Computershare Investor Services Inc., as of the date of this annual report, there are approximately 9 registered
holders (including The Depository Trust Company) of our common shares resident in the United States (approximately 37.5% of all
registered holders).</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt; text-align: justify"></td><td style="width: 30pt; text-align: justify">B.</td><td style="text-align: justify">Related Party Transactions</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">Please see the section entitled &#8220;&#8212;Related
Party Transactions&#8221; in &#8220;Item 5. Operating and Financial Review and Prospects&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt; text-align: justify"></td><td style="width: 30pt; text-align: justify">C.</td><td style="text-align: justify">Interests of Experts and Counsel</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0; text-align: justify"></td><td style="width: 60.5pt; text-align: justify"><a name="a_017"></a>Item 8.</td><td style="text-align: justify">Financial Statements</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0pt; text-align: justify">A.</td><td style="width: 30pt; text-align: justify"></td><td style="text-align: justify">Financial Statements and Other Financial Information</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">See &#8220;Item 17. Financial Statements&#8221;
for our audited financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Legal Proceedings</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">Due
to the fact that a portion of our intellectual property rights are licensed to us by Neptune/Aker, we rely on Neptune/Aker to protect
a certain of the intellectual property rights that we use under our license agreement with Neptune/Aker. Neptune/Aker are engaged
in a number of legal actions related to their intellectual property.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.75pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">On
May 10, 2019 the we announced the settlement regarding legal claims made by our former chief executive officer (&#8220;CEO&#8221;)
with respect to the termination of his employment. Pursuant to the settlement agreement, Acasti agreed to issue 900,000 common
shares to the former CEO and also agreed to reimburse the former CEO for nominal legal fees. Furthermore, pursuant to the settlement
agreement, the Acasti received a full and final release from the former CEO on all proceedings in connection with the termination
of his employment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Dividend Policy</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">We
do not anticipate paying any cash dividend on the common shares in the foreseeable future. We presently intend to retain future
earnings to finance the expansion and growth of our business. Any future determination to pay dividends will be at the discretion
of our board of directors and will depend on our financial condition, results of operations, capital requirements and other factors
the board of directors deems relevant. In addition, the terms of any future debt or credit facility may preclude us from paying
dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0; text-align: justify"></td><td style="width: 60.5pt; text-align: justify"><a name="a_018"></a>Item 9.</td><td style="text-align: justify">The Offer and Listing</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">Not applicable except for
Item 9.A.4 and Item 9.C.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">Since March 31, 2011, the
common shares have been listed on the TSX-V under the ticker symbol ACST. Since January 7, 2013, the common shares have been listed
on the NASDAQ Stock Market under the ticker symbol ACST.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><a name="a_019"></a>Item 10. Additional Information</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt; text-align: justify"></td><td style="width: 30pt; text-align: justify">A.</td><td style="text-align: justify">Share Capital</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt; text-align: justify"></td><td style="width: 30pt; text-align: justify">B.</td><td style="text-align: justify">Memorandum and Articles of Association</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">We were
incorporated on February 1, 2002 under Part 1A of the <i>Companies Act </i>(Qu&#233;bec) under the name &#8220;9113-0310 Qu&#233;bec
Inc&#8221;. On August 7, 2008, pursuant to a Certificate of Amendment, we changed our name to &#8220;Acasti Pharma Inc.&#8221;,
our share capital, the provisions regarding the restrictions on securities transfers and our borrowing powers. On November 7, 2008,
pursuant to a Certificate of Amendment, we further revised our provisions regarding our borrowing powers. We became a reporting
issuer in Qu&#233;bec on November 17, 2008. On February 14, 2011, the <i>Business Corporations Act </i>(Qu&#233;bec) came into
effect and replaced the <i>Companies Act </i>(Qu&#233;bec). We are now governed by the <i>Business Corporations Act</i> (Qu&#233;bec),
or the BCA.</p>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Register, Entry Number and
Purposes</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
articles of incorporation, as amended, or Articles, and general by-laws, do not define any of our objects and purposes. In that
respect, we have no limit on the type of business we can carry out.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Directors&#8217; Powers</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
Articles and by-laws do not contain any provision regarding: (a) a director&#8217;s power in the absence of an independent quorum,
to vote compensation to itself or any members of the committees of the board; (b) retirement or non-retirement of directors under
an age limit requirement; and (c) number of shares, if any, required for a director&#8217;s qualification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
by-laws provide that a director may not vote on a resolution to approve, amend or terminate a contract or transaction in
which the director has any financial stake that may reasonably be considered to influence decision-making or be present
during deliberations concerning the approval, amendment or termination of such a contract or transaction, unless the contract
or transaction: (a) relates primarily to the remuneration of the director or an associate of the director as a director of us
or an affiliate of us, (b) relates primarily to the remuneration of the director or an associate of the director as an
officer, employee or mandatary of us or an affiliate of us, if we are not a reporting issuer, (c) is for indemnity or
liability insurance, or (d) is with an affiliate of us, and the sole interest of the director is as a director or officer of
the affiliate. In addition, our by-laws provide that a director must avoid placing himself or herself in any situation where
his or her personal interests would be in conflict with his obligations as a director of ours, and that a director must
disclose to us any interest he or she has in a business or association that may place him or her in a situation of conflict
of interest and of any right he or she may set up against us, indicating their nature and value, where applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our Articles provide that the board may, on
behalf us, (a) borrow money, (b) issue, reissue, sell or pledge debt instruments, (c)<font style="font-family: Times New Roman, Times, Serif">&nbsp; </font>guarantee
the obligations of a third party, and (d) hypothecate all or any of its assets, both present and future, to guarantee the
performance of any of our obligations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.75pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
quorum at every meeting of the board has been set to the minimum number of directors required under our Articles. In the absence
of a quorum, a director has no power to make any decision regarding, among other things, compensation to himself or herself or
to any member of the committees of the board.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our by-laws do
not contain any requirements with respect to a mandatory retirement age for our directors and the number of shares required for
directors&#8217; qualifications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Rights, Preferences and Restrictions Attaching
to Each Class of Shares</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
authorized capital consists of an unlimited number of no par value common shares and an unlimited number of no par value Class
B, Class C, Class D and Class E preferred shares (collectively, the preferred shares), issuable in one or more series. As of March
31, 2019, there were:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify; padding-right: 5.85pt">a total of 78,132,734 common shares issued and outstanding and no preferred
shares issued and outstanding,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify; padding-right: 5.85pt">4,046,677 options to purchase common shares issued and outstanding, at a weighted average exercise price
of $1.25 per common share,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 36pt">(iii)</TD><TD STYLE="text-align: justify; padding-right: 5.85pt">$2,000,000 aggregate principal amount of unsecured convertible debentures,
maturing on February 21, 2020, issued in our February 2017 private placement and contingent warrants to acquire 1,052,630 common
shares (the debentures are convertible into up to 1,052,630 common shares at any time by the holders at a fixed price of $1.90
per common share, except if we pay before the maturity all or any portion of the convertible debentures, in which case the applicable
pro rata share of the contingent warrants will be exercisable for the remaining term of the convertible debentures at a fixed price
of $1.90 per common share),</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 36pt">(iv)</TD><TD STYLE="text-align: justify; padding-right: 5.85pt">warrants issued in connection with our February 2017 public offering
to purchase up to 1,904,034 common shares at an exercise price of $2.15 per common share,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 36pt">(v)</TD><TD STYLE="text-align: justify; padding-right: 5.85pt">broker warrants issued in connection with our December 2017 public offering
to purchase up to 495,050 common shares at an exercise price of US$1.26 per common share,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 36pt">(vi)</TD><TD STYLE="text-align: justify; padding-right: 5.85pt">warrants issued in connection with our December 2017 public offering to
purchase up to 9,801,861 common shares at an exercise price of US$1.26 per common share.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20pt"></TD><TD STYLE="width: 36pt">(vii)</TD><TD STYLE="text-align: justify; padding-right: 5.85pt">warrants issued in connection with our May 2018 public offering to purchase
up to 10,188,100 common shares at an exercise price of $1.31 per common share.</TD></TR>                                                                                        <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>(viii)</TD><TD STYLE="text-align: justify; padding-right: 5.85pt">broker warrants issued in connection with our May 2018 public offering to purchase up to 547,975 common
shares at an exercise price of $1.05 per common share</TD></TR>
</TABLE>

<P STYLE="margin: 0pt 0"></P>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">The
following is a brief description of the rights, privileges, conditions and restrictions attaching to the common shares and preferred
shares.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Common Shares</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i><u>Voting Rights</u></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Each
common share entitles its holder to receive notice of, and to attend and vote at, all annual or special meetings of our shareholders.
Each common share entitles its holder to one vote at any meeting of our shareholders, other than meetings at which only the holders
of a particular class or series of shares are entitled to vote due to statutory provisions or the specific attributes of this class
or series.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><u>Dividends</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Subject to the
prior rights of the holders of preferred shares ranking before the common shares as to dividends, the holders of common shares
are entitled to receive dividends as declared by the board our funds that are available for the payment of dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><u>Winding-up and Dissolution</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
the event of our voluntary or involuntary winding-up or dissolution, or any other distribution of our assets among our shareholders
for the purposes of winding up its affairs, the holders of common shares shall be entitled to receive, after payment by us to the
holders of preferred shares ranking prior to common shares regarding the distribution of our assets in the case of winding-up or
dissolution, share for share, the remainder of our property, with neither preference nor distinction. The order of priority, applicable
to all classes of our shares with respect to the redemption, liquidation, dissolution or distribution of property (the order of
priority) is as follows: First, the</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Class E non-voting shares;
Second, the Class D non-voting shares; Third, the Class B multiple voting shares and Class C non-voting shares, <i>pari passu</i>;
and Fourth, the common shares. Notwithstanding the order of priority, shareholders of a class of shares may renounce the order
of priority by unanimous approval by all shareholders of that class of shares.</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Preferred Shares</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b><i><u>Class B Multiple Voting
Shares</u></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Each Class B multiple voting share entitles the
holder thereof to 10 votes per share in all of our shareholder meetings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Dividends.
</i>Holders of Class B multiple voting shares are entitled to receive, as and when such dividends are declared, an annual non-cumulative
dividend of 5% on the amount paid for the said shares, payable at the time and in the manner which the directors may determine
and subject to the order of priority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Participation.
</i>Subject to the provisions of subsection 5.2.2 of our Articles, holders of Class B multiple voting shares do not have the right
to participate in our profits or surplus assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Conversion</i>.
Holders of Class B multiple voting shares have the right, at their entire discretion, to convert, part or all of the Class B multiple
voting shares they hold into common shares on the basis of 1 common share for each Class B multiple voting share converted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Redemption</i>.
Subject to the provisions of the BCA and the order of priority, holders of Class B multiple voting shares have the right to demand
from us, upon 30 days&#8217; written notice, that we redeem the Class B multiple voting shares at a price equivalent to the amount
paid for such shares plus the redemption premium, as defined in subsection 5.2.4.1 of the Articles, and any and all declared but
yet unpaid dividends on same.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Liquidation.
</i>In the event of our dissolution or liquidation or any other distribution of our property, the Class B voting shareholders have
the right to be reimbursed for the amount paid for their Class B multiple voting shares plus the redemption premium, as defined
in subsection 5.2.4.1 of our Articles as well as the amount of any and all declared but yet unpaid dividends on their shares, subject
to the order of priority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><u>Class C Non-Voting
Shares</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 6pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Subject
to the provisions of the BCA, holders of Class C non-voting shares are neither entitled to vote at any meeting of our shareholders,
receive a notice of any such meeting, nor attend any such meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.75pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Dividends</i>.
Holders of Class C non-voting shares are entitled to receive, as and when such dividends are declared, an annual non-cumulative
dividend of 5% on the amount paid for the said shares, plus a redemption premium as defined in subsection 5.3.6.1 of our Articles,
payable at the time and in the manner which the directors may determine and subject to the order of priority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Participation.
</i>Subject to the provisions of subsection 5.3.2 of our Articles, holders of Class C non-voting shares do not have the right to
participate in our profits or surplus assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Conversion.
</i>Holders of Class C non-voting shares have the right, at their entire discretion, to convert, part or all of the Class C non-voting
shares they hold into common shares on the basis of 1 common share for each Class C non-voting share converted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Forced
Conversion</i>. All of our Class C non-voting shares shall automatically be converted in common shares upon the request of an unrelated
third-party investor in us investing more than $500,000, or any other amount to be determined by the board of directors in us and
requesting as a condition to the investment that the Class C non-voting shares be converted into common shares on the basis of
1 common share for each Class C non-voting share converted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Redemption.
</i>Subject to the provisions of the BCA and the order of priority, holders of Class C non-voting shares have the right to demand,
upon 30 days&#8217; written notice, that we redeem their Class C non-voting shares at a price equivalent to the amount paid for
the shares plus the redemption premium, as defined in subsection 5.3.6.1 of our Articles, and any and all declared but yet unpaid
dividends on the shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Liquidation.
</i>In the event of our dissolution or liquidation or any other distribution of our property, Class C non-voting shareholders have
the right to be reimbursed for the amount paid for their Class C non-voting shares plus the redemption premium, as defined in subsection
5.3.6.1 of our Articles, as well as the amount of any and all declared but yet unpaid dividends on their shares, subject to the
order of priority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><u>Class D Non-Voting Shares</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Subject to the
provisions of the BCA, holders of Class D non-voting shares are neither entitled to vote at any meeting of the shareholders, receive
a notice of any such meeting, nor attend any such meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Dividends.
</i>Holders of Class D non-voting shares are entitled to receive, as and when such dividends are declared, a monthly non-cumulative
dividend of 0.5% to 2% on the amount paid for the shares, plus a redemption premium as defined in subsection 5.4.6.1 of our Articles,
payable at the time and in the manner which the directors may determine and subject to the order of priority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Participation.
</i>Subject to the provisions of subsection 5.4.2 of our Articles, holders of Class D non-voting shares do not have the right to
participate in our profits or surplus assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Conversion.
</i>Holders of Class D non-voting shares have the right, at their discretion, to convert, part or all of their Class D non-voting
shares into common shares on the basis of a number of common shares equal to the number of Class D non-voting shares converted
multiplied by a conversion ratio, calculated as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 60pt; text-align: justify">The product obtained by
multiplying a factor to be agreed at the time of the issuance of the Class D non-voting shares by the average amount paid per share
for the Class D non-voting shares plus the redemption premium per share, as defined in subsection 5.4.6.1 of our Articles as well
as the amount of any and all declared but yet paid</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"></p>




<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 1%; white-space: nowrap">Conversion Ratio</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 4%; text-align: center"> =</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%; border-bottom: Black 1pt solid">dividends on the shares</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>
Fair market value of the common shares at the date of any conversion of Class D non-voting shares into common shares</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Conversion
</i>All of our Class D non-voting shares automatically convert into common shares upon the request of an unrelated third party
investor in us, investing more than $500,000, or any other amount to be determined by the board of directors, in us and requesting
as a condition to the investment that the Class D non-voting shares be converted into common shares in all cases, on the basis
of a number of common shares equal to the number of Class D non-voting shares converted multiplied by the conversion ratio, calculated
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 1%; white-space: nowrap; text-align: left; vertical-align: bottom">Conversion Ratio</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 4%; text-align: center; vertical-align: bottom"> =</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%; border-bottom: Black 1pt solid">The product obtained
by multiplying a factor to be agreed at the time of the issuance of the Class D non-voting shares by the average amount paid per
share for the Class D non-voting shares plus the redemption premium per share, as defined in subsection 5.4.6.1 of our Articles
as well as the amount of any and all declared but yet paid dividends on the shares</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>
Fair market value of the common shares at the date of
any conversion of Class D non-voting shares into common shares</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Redemption.
</i>Subject to the provisions of the BCA and the order of priority, holders of Class D non-voting shares have the right to demand,
upon 30 days&#8217; written notice, that we redeem their Class D non-voting shares at a price equivalent to the amount paid for
the shares plus the redemption premium, as defined in subsection 5.4.6.1 of our Articles, and any and all declared but yet unpaid
dividends on the shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Liquidation.
</i>In the event of our dissolution or liquidation or any other distribution of our property, the Class D non-voting shareholders
shall have the right to be reimbursed for the amount paid for their Class D non-voting shares plus the redemption premium, as defined
in subsection 5.4.6.1 of our Articles as well as the amount of any and all declared but yet unpaid dividends on their shares, subject
to the order of priority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><u>Class E Non-Voting Shares</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Subject
to the provisions of the BCA, holders of Class E non-voting shares are neither entitled to vote at any meeting of the shareholders,
receive a notice of any such meeting, nor attend any such meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Dividends.
</i>Holders of Class E non-voting shares are entitled to receive, as and when such dividends are declared, a monthly non-cumulative
dividend of 0.5% to 2% on the amount paid for the shares, payable at the time and in the manner which the directors may determine
and subject to the order of priority.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Participation.
</i>Subject to the provisions of subsection 5.5.2 of our Articles, holders of Class E non-voting shares do not have the right to
participate in our profits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Conversion.
</i>Holders of Class E non-voting shares have the right, at their discretion, to convert, part or all of their Class E non-voting
shares into common shares on the basis of a number of common shares equal to the number of Class E non-voting shares converted
multiplied by the conversion ratio, calculated as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 1%; white-space: nowrap; text-align: left; vertical-align: bottom">Conversion Ratio</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 4%; text-align: center; vertical-align: bottom"> =</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 93%; border-bottom: Black 1pt solid">The product obtained by
multiplying a factor to be agreed at the time of the issuance of the Class E non-voting shares by the average amount paid per share
for the Class E non-voting shares plus the amount of any and all declared but yet paid dividends on the shares</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>Fair market value of the common shares at the date of
any conversion of Class E non-voting shares into common shares</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><i></i></p>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Redemption.
</i>Subject to the provisions of the BCA and the order of priority, we have the right, upon 30 days&#8217; written notice, to redeem
the Class E non-voting shares at a price equivalent to the amount paid for the shares and any and all declared but yet unpaid dividends
on the shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt"><i>Liquidation.
</i>In the event of our dissolution or liquidation or any other distribution of our property, the Class E non-voting shareholders
have the right to be reimbursed for the amount paid for their Class E non-voting shares as well as the amount of any and all declared
but yet unpaid dividends on the shares, subject to the order of priority.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Procedures to Change the Rights of Shareholders</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">In
order to change the rights attached to all classes of our shares, the vote of at least 66 2/3% of the holders of each class, must
be cast at a shareholders meeting called for amending the rights attached to our common shares or preferred shares, as the case
may be.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Ordinary and Extraordinary Shareholders&#8217;
Meetings</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our
by-laws provide that our annual meeting of shareholders must be held on a yearly basis on such date and on such time as may be
fixed by the board. Our by-laws provide that special meetings of shareholders may be called at any time as determined by the board.
Our shareholders are entitled to call special meetings of shareholders, provided that they hold at least 10% of the issued and
outstanding shares entitled to vote at the meeting so called. Our by-laws provide that notice of each annual and special meeting
of shareholders must be sent to the shareholders entitled to attend such meetings not less than 21 days and not more than 60 days
before the date fixed for such meeting. Our by-laws provide that during any meeting of shareholders, the attendance, in person
or by proxy, of at least two shareholders representing at least 10% of the issued and outstanding shares entitled to vote at the
meeting will constitute a quorum.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Limitations on Rights to Own Securities</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">There exists no limitation on the right to own our
securities.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Impediments to Change of Control</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.55pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Neither
our Articles nor by-laws contain any provision that would have an effect of delaying, deferring or preventing a change in control
of us.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Stockholder Ownership Disclosure Threshold in
Bylaws</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Our Articles and
By-laws do not contain any provision requiring a shareholder to disclose his ownership above a particular threshold.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">C.</td><td>Material Contracts</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">For
the two years preceding this annual report, we have not entered into any material contracts, other than contracts entered into
in the ordinary course of our business and other than the warrant agency agreement relating to the warrants that we issued in connection
with our public offering of units in December 2017 and the indenture relating to the warrants that we issued in connection with
our public offering of units in May 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">D.</td><td>Exchange Controls</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">Subject to the
following paragraph, there is no law or governmental decree or regulation in Canada that restricts the export or import of capital,
or affects the remittance of dividends, interest or other payments to non-resident holders of our subordinate voting shares, other
than withholding tax requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify; text-indent: 20pt">There
is no limitation imposed by Canadian law or by our Articles or our other charter documents on the right of a non-resident to hold
or vote voting shares, other than as provided by the <i>Investment Canada Act </i>(Canada), or Investment Canada Act, the <i>North
American Free Trade Agreement Implementation Act </i>(Canada), or North American Free Trade Agreement, and the <i>World Trade Organization
Agreement Implementation Act</i>. The Investment Canada Act requires notification and, in certain cases, advance review and approval
by the Government of Canada of an investment to establish a new Canadian business by a non-Canadian or of the acquisition by a
&#8220;non-Canadian&#8221; of &#8220;control&#8221; of a &#8220;Canadian business&#8221;, all as defined in the Investment Canada
Act. Generally, the threshold for review will be higher in monetary terms for a member of the World Trade Organization or North
American Free Trade Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">E.</td><td>Taxation</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The following is a summary of certain U.S.
federal income tax considerations arising from and relating to the acquisition, ownership, and disposition of our common shares
to a U.S. Holder (as defined below) as capital assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">This summary provides only general information
and does not purport to be a complete analysis or listing of all potential U.S. federal income tax consequences that may apply
to a U.S. Holder as a result of the acquisition, ownership, and disposition of our common shares. In addition, this summary does
not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income
tax consequences applicable to that U.S. Holder. Accordingly, this summary is not intended to be, and should not be construed as,
legal or U.S. federal income tax advice with respect to any U.S. Holder. Each U.S. Holder should consult its own tax advisor regarding
the U.S. federal, U.S. state and local, and non-U.S. tax consequences arising from or relating to the acquisition, ownership, and
disposition of our common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">No legal opinion from U.S. legal counsel
or ruling from the Internal Revenue Service, or IRS, has been requested, or will be obtained, regarding the U.S. federal income
tax consequences to U.S. Holders of the acquisition, ownership, and disposition of our common shares. This summary is not binding
on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in
this summary. In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS
and the U.S. courts could disagree with one or more of the positions taken in this summary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Scope of this Disclosure</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b><i>Authorities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">This summary is based on the Code, U.S.
Treasury Regulations promulgated thereunder (whether final, temporary or proposed), published IRS rulings, judicial decisions,
published administrative positions of the IRS, and the Convention between Canada and the United States of America with Respect
to Taxes on Income and on Capital, signed September 26, 1980, as amended (the Canada-U.S. Tax Treaty), in each case, as in effect
as of the date of this report. Any of the authorities on which this summary is based could be changed in a material and adverse
manner at any time, and any such change could be applied on a retroactive basis. Unless otherwise discussed, this summary does
not discuss the potential effects, whether adverse or beneficial, of any proposed legislation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b><i>U.S. Holders</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">For purposes of this summary, a &#8220;U.S.
Holder&#8221; is a beneficial owner of common shares that, for U.S. federal income tax purposes, is (a) an individual who is a
citizen or resident of the United States, (b) a corporation, or other entity classified as a corporation for U.S. federal income
tax purposes, that is created or organized in or under the laws of the U.S., any state in the United States or the District of
Columbia, (c) an estate if the income of such estate is subject to U.S. federal income tax regardless of the source of such income,
or (d) a trust if (i) such trust has validly elected to be treated as a U.S. person for U.S. federal income tax purposes or (ii)
a U.S. court is able to exercise primary supervision over the administration of such trust and one or more U.S. persons have the
authority to control all substantial decisions of such trust.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b><i>U.S. Holders Subject to Special U.S.
Federal Income Tax Rules Not Addressed</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">This summary does not address the U.S.
federal income tax consequences applicable to U.S. Holders that are subject to special provisions under the Code, including, but
not limited to, the following U.S. Holders: (a) U.S. Holders that are tax-exempt organizations, qualified retirement plans, individual
retirement accounts, or other tax deferred accounts; (b) U.S. Holders that are financial institutions, insurance companies, real
estate investment trusts, or regulated investment companies; (c) U.S. Holders that are dealers in securities or currencies or U.S.
Holders that are traders in securities that elect to apply a mark-to-market accounting method; (d) U.S. Holders that have a &#8220;functional
currency&#8221; other than the U.S. dollar; (e) U.S. Holders subject to the alternative minimum tax provisions of the Code; (f)
U.S. Holders that own common shares as part of a straddle, hedging transaction, conversion transaction, integrated transaction,
constructive sale, or other arrangement involving more than one position; (g) U.S. Holders that acquired common shares through
the exercise of employee stock options or otherwise as compensation for services; (h) U.S. Holders that hold common shares other
than as a capital asset within the meaning of Section 1221 of the Code; (i) U.S. Holders that beneficially own (directly, indirectly
or by attribution) 10% or more of our equity securities (by vote or value); and (j) U.S. expatriates. U.S. Holders that are subject
to special provisions under the Code, including U.S. Holders described above, should consult their own tax advisor regarding the
U.S. federal, U.S. federal alternative minimum, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences
arising from and relating to the acquisition, ownership, and disposition of the common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">If an entity or arrangement that is classified
as a partnership for U.S. federal income tax purposes holds common shares, the U.S. federal income tax consequences to that partnership
and the partners of that partnership generally will depend on the activities of the partnership and the status of the partners.
Partners of entities that are classified as partnerships for U.S. federal income tax purposes should consult their own tax advisors
regarding the U.S. federal income tax consequences arising from and relating to the acquisition, ownership and disposition of the
common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b><i>Tax Consequences Other than U.S.
Federal Income Tax Consequences Not Addressed</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">This summary does not address the U.S.
estate and gift, alternative minimum, state, local or non-U.S. tax consequences to U.S. Holders of the acquisition, ownership,
and disposition of our common shares. Each U.S. Holder should consult its own tax advisor regarding the U.S. estate and gift, alternative
minimum, state, local and non-U.S. tax consequences arising from and relating to the acquisition, ownership, and disposition of
our common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>U.S. Federal Income Tax Considerations
of the Acquisition, Ownership, and Disposition of Common Shares</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b><i>Distributions on Common Shares</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Subject to the discussion under &#8220;&#8212;Passive
Foreign Investment Company Rules&#8221; below, a U.S. Holder that receives a distribution, including a constructive distribution
or a taxable stock distribution, with respect to the common shares generally will be required to include the amount of that distribution
in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of
our current or accumulated &#8220;earnings and profits&#8221; (as computed for U.S. federal income tax purposes). To the extent
that a distribution exceeds our current and accumulated &#8220;earnings and profits&#8221;, the excess amount will be treated (a)
first, as a tax-free return of capital to the extent of a U.S. Holder&#8217;s adjusted tax basis in the common shares with respect
to which the distribution is made (resulting in a corresponding reduction in the tax basis of those common shares) and, (b) thereafter,
as gain from the sale or exchange of those common shares (see the more detailed discussion at &#8220;&#8212;Disposition of Common
Shares&#8221; below). We do not intend to calculate our current or accumulated earnings and profits for U.S. federal income tax
purposes and, therefore, will not be able to provide U.S. Holders with that information. U.S. Holders should therefore assume that
any distribution by us with respect to our common shares will constitute a dividend. However, U.S. Holders should consult their
own tax advisors regarding whether distributions from us should be treated as dividends for U.S. federal income tax purposes. Dividends
paid on our common shares generally will not be eligible for the &#8220;dividends received deduction&#8221; allowed to corporations
under the Code with respect to dividends received from U.S. corporations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">A dividend paid by us generally will be
taxed at the preferential tax rates applicable to long-term capital gains if, among other requirements, (a) we are a &#8220;qualified
foreign corporation&#8221; (as defined below), (b) the U.S. Holder receiving the dividend is an individual, estate, or trust, and
(c) the dividend is paid on common shares that have been held by the U.S. Holder for at least 61 days during the 121-day period
beginning 60 days before the &#8220;ex-dividend date&#8221; (i.e., the first date that a purchaser of the common shares will not
be entitled to receive the dividend).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">For purposes of the rules described in
the preceding paragraph, we generally will be a &#8220;qualified foreign corporation&#8221;, or a QFC, if (a) we are eligible for
the benefits of the Canada-U.S. Tax Treaty, or (b) our common shares are readily tradable on an established securities market in
the United States, within the meaning provided in the Code. However, even if we satisfy one or more of the requirements, we will
not be treated as a QFC if we are classified as a PFIC (as discussed below) for the taxable year during which we pay the applicable
dividend or for the preceding taxable year. The dividend rules are complex, and each U.S. Holder should consult its own tax advisor
regarding the application of those rules to them in their particular circumstances. Even if we satisfy one or more of the requirements,
as noted below, there can be no assurance that we will not be a PFIC in the current taxable year, or become a PFIC in the future.
Thus, there can be no assurance that we will qualify as a QFC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b><i>Disposition of Common Shares</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Subject to the discussion under &#8220;&#8212;Passive
Foreign Investment Company Rules&#8221; below, a U.S. Holder will recognize gain or loss on the sale or other taxable disposition
of common shares (that is treated as a sale or exchange for U.S. federal income tax purposes) equal to the difference, if any,
between (a) the U.S. dollar value of the amount realized on the date of the sale or disposition and (b) the U.S. Holder&#8217;s
adjusted tax basis (determined in U.S. dollars) in the common shares sold or otherwise disposed of. Any such gain or loss generally
will be capital gain or loss, which will be long-term capital gain or loss if the common shares are held for more than one year.
Each U.S. Holder should consult its own tax advisor as to the tax treatment of dispositions of common shares in exchange for Canadian
dollars.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Preferential tax rates apply to long-term
capital gains of a U.S. Holder that is an individual, estate, or trust. There are currently no preferential tax rates for long-term
capital gains of a U.S. Holder that is a corporation. Deductions for capital losses are subject to complex limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b><i>Passive Foreign Investment Company
Rules</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">If we are or become a PFIC, the preceding
sections of this summary may not describe the U.S. federal income tax consequences to U.S. Holders of the acquisition, ownership,
and disposition of our common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><i><u>Passive Foreign Investment Company
Status.</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Special, generally unfavorable, rules apply
to the ownership and disposition of the stock of a PFIC. For U.S. federal income tax purposes, a non-U.S. corporation is classified
as a PFIC for each taxable year in which either:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><font style="font-family: Symbol; font-size: 10pt">&#183;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">at least 75% of its gross income is &#8220;passive&#8221; income (referred to as the &#8220;income test&#8221;); or</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><font style="font-family: Symbol; font-size: 10pt">&#183;</font></td>
    <td><font style="font-size: 10pt">at least 50% of the average value of its assets is attributable to assets that produce passive income or are held for the production of passive income (referred to as the &#8220;asset test&#8221;).</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Passive income generally includes the following
types of income:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><font style="font-family: Symbol; font-size: 10pt">&#183;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">dividends, royalties, rents, annuities, interest, and income equivalent to interest; and</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&nbsp;</td>
    <td style="width: 24px"><font style="font-family: Symbol; font-size: 10pt">&#183;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">net gains from the sale or exchange of property that gives rise to dividends, interest, royalties, rents, or annuities and certain gains from the commodities transactions.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">In determining whether we are a PFIC, we
will be required to take into account a pro rata portion of the income and assets of each corporation in which we own, directly
or indirectly, at least 25% by value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As described above, PFIC status of a non-U.S.
corporation for a taxable year depends on the relative values of certain categories of assets and the relative amount of certain
kinds of income. Therefore, our status as a PFIC for any given taxable year depends upon the financial results for such year and
upon relative valuations, which are subject to change and beyond our ability to predict or control. Based on our most recent financial
statements and projections and given uncertainty regarding the composition of our future income and assets, there is a significant
risk that we may have been classified as a PFIC for the 2019 taxable year and may be classified as a PFIC for our current taxable
year and possibly subsequent years. However, PFIC status is fundamentally factual in nature, depends on the application of complex
U.S. federal income tax rules (which are subject to differing interpretations), generally cannot be determined until the close
of the taxable year in question and is determined annually. Accordingly, there can be no assurance that we will not be a PFIC in
our current taxable year or subsequent years. The PFIC rules are complex, and each U.S. Holder should consult its tax advisor regarding
the application of the PFIC rules to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><i><u>Default PFIC Rules Under Section
1291 of the Code.</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Generally, if we are or have been treated
as a PFIC for any taxable year during a U.S. Holder&#8217;s holding period of common shares, subject to the special rules described
below applicable to a U.S. Holder who makes a Mark-to-Market Election or a QEF Election (each as defined below), any &#8220;excess
distribution&#8221; with respect to the common shares would be allocated ratably over the U.S. Holder&#8217;s holding period. The
amounts allocated to the taxable year of the excess distribution and to any year before we became a PFIC would be taxed as ordinary
income. The amount allocated to each other taxable year would be subject to tax at the highest rate in effect for individuals or
corporations in that taxable year, as appropriate, and an interest charge would be imposed on the amount allocated to that taxable
year. Distributions made in respect of common shares during a taxable year will be excess distributions to the extent they exceed
125% of the average of the annual distributions on common shares received by the U.S. Holder during the preceding three taxable
years or the U.S. Holder&#8217;s holding period, whichever is shorter. In addition, dividends generally will not be qualified dividend
income if we are a PFIC in the taxable year of payment or the preceding year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Generally, if we are treated as a PFIC
for any taxable year during which a U.S. Holder owns common shares, any gain on the disposition of the common shares would be treated
as an excess distribution and would be allocated ratably over the U.S. Holder&#8217;s holding period and subject to taxation in
the same manner as described in the preceding paragraph, and would not be eligible for the preferential long-term capital gains
rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Certain elections (including the Mark-to-Market
Election and the QEF Election, as defined and discussed below) may sometimes be used to mitigate the adverse impact of the PFIC
rules on U.S. Holders, but these elections may accelerate the recognition of taxable income and have other adverse results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Each current or prospective U.S. Holder
should consult its own tax advisor regarding potential status of us as a PFIC, the possible effect of the PFIC rules to such holder
in their particular circumstances, information reporting required if we were treated as a PFIC and the availability of any election
that may be available to the holder to mitigate adverse U.S. federal income tax consequences of holding shares in a PFIC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><i><u>QEF Election.</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">A U.S. Holder of common shares in a PFIC
generally would not be subject to the PFIC rules discussed above if the U.S. Holder had made a timely and effective election (a
&#8220;QEF Election&#8221;) to treat us as a &#8220;qualified electing fund&#8221; (a &#8220;QEF&#8221;). Instead, such U.S. Holder
would be subject to U.S. federal income tax on its <i>pro rata</i> share of our (i) net capital gain, which would be taxed as long-term
capital gain to such U.S. Holder, and (ii) ordinary earnings, which would be taxed as ordinary income to such U.S. Holder, in each
case regardless of whether such amounts are actually distributed to such U.S. Holder. However, a U.S. Holder that makes a QEF Election
may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest
charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as &#8220;personal interest,&#8221; which
is not deductible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">A U.S. Holder that makes a timely and effective
QEF Election generally (a) may receive a tax-free distribution from us to the extent that such distribution represents our &#8220;earnings
and profits&#8221; that were previously included in income by such U.S. Holder because of such QEF Election and (b) will adjust
such U.S. Holder&#8217;s tax basis in the common shares to reflect the amount included in income or allowed as a tax-free distribution
because of such QEF Election. In addition, for U.S. federal income tax purposes, a U.S. Holder that makes a timely QEF Election
generally will recognize capital gain or loss on the sale or other taxable disposition of the common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">A QEF Election will be treated as &#8220;timely&#8221;
if such QEF Election is made for the first taxable year in the U.S. Holder&#8217;s holding period for the common shares in which
we are a PFIC. A U.S. Holder may make a timely QEF election by filing the appropriate QEF Election documents at the time such U.S.
Holder files a U.S. federal income tax return for such first year. If a U.S. Holder makes a QEF Election after the first taxable
year in the U.S. Holder&#8217;s holding period for the common shares in which we are a PFIC, then, in addition to filing the QEF
Election documents, a U.S. Holder may elect to recognize gain (which will be taxed under the rules discussed under &#8220;&#8212;<i>Default
PFIC Rules Under Section 1291 of the Code</i>&#8221;) as if the common shares were sold on the qualification date. The &#8220;qualification
date&#8221; is the first day of the first taxable year in which we are a QEF with respect to such U.S. Holder. The election to
recognize such gain can only be made if such U.S. Holder&#8217;s holding period for the common shares includes the qualification
date. By electing to recognize such gain, such U.S. Holder will be deemed to have made a timely QEF Election. In addition, under
very limited circumstances, it is possible that a U.S. Holder might make a retroactive QEF Election if such U.S. Holder failed
to file the QEF Election documents in a timely manner. If a U.S. Holder fails to make a QEF Election for the first taxable year
in the U.S. Holder&#8217;s holding period for the common shares in which we are a PFIC and does not elect to recognize gain as
if the common shares were sold on the qualification date, such holder will not be treated as having made a &#8220;timely&#8221;
QEF election and will continue to be subject to the special adverse taxation rules discussed above under &#8220;&#8212;<i>Default
PFIC Rules Under Section 1291 of the Code</i>&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">A QEF Election will apply to the taxable
year for which such QEF election is made and to all subsequent taxable years, unless such QEF Election is invalidated or terminated
or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent taxable year,
we cease to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those taxable years in
which we are not a PFIC. Accordingly, if we become a PFIC in another subsequent taxable year, the QEF Election will be effective
and the U.S. Holder will be subject to the rules described above during any such subsequent taxable year in which we qualify as
a PFIC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">A U.S. Holder cannot make and maintain
a valid QEF Election unless we provide certain U.S. tax information necessary to make such an election. On an annual basis, we
intend to use commercially reasonable efforts to make available to U.S. Holders, upon their written request (a) timely information
as to our status as a PFIC, and (b) for each year in which we are a PFIC, information and documentation that a U.S. Holder making
a QEF Election with respect to us is required to obtain for U.S. federal income tax purposes. Each U.S. Holder should consult its
own tax advisor regarding the availability of, and procedure for making, a QEF Election with respect to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><i><u>Mark-to-Market Election.</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">A U.S. Holder of common shares in a PFIC
would not be subject to the PFIC rules discussed above under &#8220;&#8212;<i>Default PFIC Rules Under Section 1291 of the Code</i>&#8221;
if the U.S. Holder had made a timely and effective election to mark the PFIC common shares to market (a &#8220;Mark-to-Market Election&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">A U.S. Holder may make a Mark-to-Market
Election with respect to the common shares only if such shares are marketable stock. Such shares generally will be &#8220;marketable
stock&#8221; if they are regularly traded on a &#8220;qualified exchange,&#8221; which is defined as (a) a national securities
exchange that is registered with the Securities and Exchange Commission, (b) the national market system established pursuant to
section 11A of the Exchange Act of 1934, or (c) a non-U.S. securities exchange that is regulated or supervised by a governmental
authority of the country in which the market is located, provided that (i) such non-U.S. exchange has trading volume, listing,
financial disclosure, surveillance, and other requirements, and the laws of the country in which such non-U.S. exchange is located,
together with the rules of such non-U.S. exchange, ensure that such requirements are actually enforced and (ii) the rules of such
non-U.S. exchange ensure active trading of listed stocks. Our common shares will generally be treated as &#8220;regularly traded&#8221;
in any calendar year in which more than a <i>de minimis</i> quantity of common shares is traded on a qualified exchange for at
least 15 days during each calendar quarter. Each U.S. Holder should consult its own tax advisor with respect to the availability
of a Mark-to-Market Election with respect to the common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">In general, a U.S. Holder that makes a
timely Mark-to-Market Election with respect to the common shares will include in ordinary income, for each taxable year in which
we are a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the common shares as of the close of such
taxable year over (b) such U.S. Holder&#8217;s tax basis in such shares. A U.S. Holder that makes a Mark-to-Market Election will
be allowed a deduction in an amount equal to the lesser of (a) the excess, if any, of (i) such U.S. Holder&#8217;s adjusted tax
basis in the common shares over (ii) the fair market value of such shares as of the close of such taxable year or (b) the excess,
if any, of (i) the amount included in ordinary income because of such Mark-to-Market Election for prior taxable years over (ii)
the amount allowed as a deduction because of such Mark-to-Market Election for prior taxable years. If a U.S. Holder makes a Mark-to-Market
Election after the first taxable year in which we are a PFIC and such U.S. Holder has not made a timely QEF Election with respect
to us, the PFIC rules described above under &#8220;&#8212;<i>Default PFIC Rules Under Section 1291 of the Code</i>&#8221; will
apply to certain dispositions of, and distributions on, the common shares, and the U.S. Holder&#8217;s mark-to-market income for
the year of the election. If we were to cease being a PFIC, a U.S. Holder that marked its common shares to market would not include
mark-to-market gain or loss with respect to its common shares for any taxable year that we were not a PFIC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">A U.S. Holder that makes a Mark-to-Market
Election generally will also adjust such U.S. Holder&#8217;s tax basis in his common shares to reflect the amount included in gross
income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition
of the common shares subject to a Mark-to-Market Election, any gain or loss on such disposition will be ordinary income or loss
(to the extent that such loss does not to exceed the excess, if any, of (a) the amount included in ordinary income because of such
Mark-to-Market Election for prior taxable years over (b) the amount allowed as a deduction because of such Mark-to-Market Election
for prior taxable years). A Mark-to-Market Election applies to the taxable year in which such Mark-to-Market Election is made and
to each subsequent taxable year, unless the common shares cease to be &#8220;marketable stock&#8221; or the IRS consents to revocation
of such election. Each U.S. Holder should consult its own tax advisor regarding the availability of, and procedure for making,
a Mark-to-Market Election with respect to the common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><i><u>Reporting</u></i>. If we were to
be treated as a PFIC in any taxable year, a U.S. Holder will generally be required to file an annual report with the IRS containing
such information as the U.S. Treasury Department may require.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Each U.S. Holder should consult its
own tax advisor regarding our potential status as a PFIC, the possible effect of the PFIC rules to such holder and information
reporting required if we were a PFIC, as well as the availability of any election that may be available to the holder to mitigate
adverse U.S. federal income tax consequences of holding shares in a PFIC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Receipt of Foreign Currency</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The amount of a distribution paid in Canadian
dollars or Canadian dollar proceeds received on the sale or other taxable disposition of common shares will generally be equal
to the U.S. dollar value of the currency on the date of receipt. If any Canadian dollars received with respect to the common shares
are later converted into U.S. dollars, U.S. Holders may realize gain or loss on the conversion. Any gain or loss generally will
be treated as ordinary income or loss and generally will be from sources within the United States for U.S. foreign tax credit purposes.
Each U.S. Holder should consult its own tax advisor concerning the possibility of foreign currency gain or loss if any such currency
is not converted into U.S. dollars on the date of receipt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Foreign Tax Credit</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Subject to certain limitations, a U.S.
Holder who pays (whether directly or through withholding) Canadian or other non-U.S. income tax with respect to the common shares
may be entitled, at the election of the U.S. Holder, to receive either a deduction or a credit for Canadian or other non-U.S. income
tax paid. Dividends paid on common shares generally will constitute income from sources outside the United States. The foreign
tax credit rules (including the limitations with respect thereto) are complex, and each U.S. Holder should consult its own tax
advisor regarding the foreign tax credit rules, having regard to such holder&#8217;s particular circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Information Reporting; Backup Withholding</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Generally, information reporting and backup
withholding will apply to distributions on, and the payment of proceeds from the sale or other taxable disposition of, the common
shares unless (i) the U.S. Holder is a corporation or other exempt entity, or (ii) in the case of backup withholding, the U.S.
Holder provides a correct taxpayer identification number and certifies that the U.S. Holder is not subject to backup withholding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Backup withholding is not an additional
tax. Any amount withheld generally will be creditable against a U.S. Holder&#8217;s U.S. federal income tax liability or refundable
to the extent that it exceeds such liability provided the required information is provided to the IRS in a timely manner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">In addition, certain categories of U.S.
Holders must file information returns with respect to their investment in a non-U.S. corporation. For example, certain U.S. Holders
must file IRS Form 8938 with respect to certain &#8220;specified foreign financial assets&#8221; (such as the common shares) with
an aggregate value in excess of US$50,000 (and, in some circumstances, a higher threshold). Failure to do so could result in substantial
penalties and in the extension of the statute of limitations with respect to such holder&#8217;s U.S. federal income tax returns.
Each U.S. Holder should consult its own tax advisor regarding application of the information reporting and backup withholding rules
to it in connection with an investment in our common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>Medicare Contribution Tax</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">U.S. Holders that are individuals, estates
or certain trusts generally will be subject to a 3.8% Medicare contribution tax on, among other things, dividends on, and capital
gains from the sale or other taxable disposition of, common shares, subject to certain limitations and exceptions. Each U.S. Holder
should consult its own tax advisor regarding possible application of this additional tax to income earned in connection with an
investment in our common shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">F.</td><td>Dividends and Paying Agents</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 413.85pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">G.</td><td>Statement by Experts</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 413.85pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">H.</td><td>Documents on Display</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">Any
statement in this annual report about any of our contracts or other documents is not necessarily complete. If the contract or document
is filed as an exhibit to this annual report, the contract or document is deemed to modify the description contained in this annual
report. You must review the exhibits themselves for a complete description of the contract or document.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">We
are subject to the informational requirements of the Exchange Act and are required to file reports and other information with the
SEC. Our SEC filings are available at the SEC&#8217;s website at www.sec.gov. In addition, we are required by Canadian securities
laws to file documents electronically with Canadian securities regulatory authorities and these filings are available on our SEDAR
profile at www.sedar.com. Requests for such documents should be directed to our Corporate Secretary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">I.</td><td>Subsidiary Information</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 413.85pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 50pt"><a name="a_020"></a>Item 11.</td><td>Quantitative and Qualitative Disclosure about Market Risk</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt">Information
relating to quantitative and qualitative disclosures about market risks is detailed in &#8220;Item 5. Operating and Financial Review
and Prospects&#8221;, as well as in Note 21 to our audited financial statements contained in &#8220;Item 17. Financial Statements&#8221;.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 50pt"><a name="a_021"></a>Item 12.</td><td>Description of Securities other than Equity Securities</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">A.</td><td>Debt Securities</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 413.85pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">B.</td><td>Warrants and Rights</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 413.85pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">C.</td><td>Other Securities</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 413.85pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0pt"></td><td style="width: 30pt">D.</td><td>American Depositary Shares</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 413.85pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.5pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.5pt; margin-bottom: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.5pt; margin-bottom: 0pt; text-align: center"><a name="a_022"></a>PART II</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 50pt"><a name="a_023"></a>Item 13.</td><td>Defaults, Dividend Arrearages and Delinquencies</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 450.8pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 50pt"><a name="a_024"></a>Item 14.</td><td>Material Modification to the Rights of Security Holdings and Use of Proceeds</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 450.8pt; margin-bottom: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 50pt"><a name="a_025"></a>Item 15.</td><td>Controls and Procedures Disclosure Controls and Procedures</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">As
of the end of the period covered by this annual report, our management, with the participation of our CEO and Vice President Finance,
has performed an evaluation of the effectiveness of our disclosure controls and procedures within the meaning of Rules 13a-15
(e) and 15d-15(e) of the Exchange Act. Based upon this evaluation, our management has concluded that, as of March 31, 2019, our
existing disclosure controls and procedures were effective. It should be noted that while the CEO and Vice President Finance believe that our disclosure
controls and procedures provide a reasonable level of assurance that they are effective, they do not expect the disclosure controls
and procedures to be capable of preventing all errors and fraud. A control system, no matter how well conceived or operated, can
provide only reasonable, not absolute, assurance that the objectives of the control system are met.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Management&#8217;s Report on Internal Controls
over Financial Reporting</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">Our
management, with the participation of our CEO and Vice President Finance, is responsible for establishing and maintaining adequate internal control
over financial reporting. Our internal control system was designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation and fair presentation of its published financial statements. All internal control systems,
no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective may not prevent
or detect misstatements and can provide only reasonable assurance with respect to financial statement preparation and presentation.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Our management
conducted an assessment of the design and operation effectiveness of our internal control over financial reporting as of March
31, 2019. In making this assessment, we used the criteria established within the Internal Control&#8212;Integrated Framework (2013)
issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, our management
has concluded that, as of March 31, 2019, our internal control over financial reporting was effective.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Changes in Internal Control over Financial Reporting</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">No
changes were made to our internal controls over financial reporting that occurred during the quarter and fiscal year ended March
31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">We
are a non-accelerated filer under the Exchange Act and not required to comply with the auditor attestation requirements of Section
404(b) of the Sarbanes-Oxley Act of 2002. Therefore, this annual report does not include an attestation report of our registered
public accounting firm regarding our management&#8217;s assessment of internal control over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 50pt"><a name="a_026"></a>Item 16.</td><td>Reserved</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 50pt"><a name="a_027"></a>Item 16A.</td><td>Audit Committee Financial Expert</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">Our
board of directors has determined that Mr. Canan is the &#8220;audit committee financial expert&#8221;, as defined by applicable
regulations of the Commission. The Commission has indicated that the designation of Mr. Canan as an audit committee financial expert
does not make him an &#8220;expert&#8221; for any purpose, impose any duties, obligations or liability on Mr. Canan that are greater
than those imposed on members of the audit committee and board of directors who do not carry this designation or affect the duties,
obligations or liability of any other member of the audit committee or board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>


<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 50pt"><a name="a_028"></a>Item 16B.</td><td>Code of Ethics</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">The
board of directors adopted a Code of Business Conduct and Ethics for our directors, officers and employees on May 31, 2007, which
can be found on SEDAR at www.sedar.com and on our web site on www.acastipharma.com. A copy of the Code of Ethics and Conduct can
also be obtained by contacting our Corporate Secretary. Any breach of the Code of Ethics must be brought to the attention of the
board of directors by our CEO or other senior executive officer. No report has ever been filed which pertains to any conduct of
a director or executive officer that constitutes a breach of the Code of Business Conduct and Ethics.</p>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">The board of directors
also adopted an insider trading program for its directors, officers and employees and adopted recently a majority voting policy
for the election of proposed director candidates at our annual general shareholders meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0; text-align: justify"></td><td style="width: 50pt; text-align: justify"><a name="a_029"></a>Item 16C.</td><td style="padding-right: 328.4pt; text-align: justify">Principal Accountant Fees and Services Audit Fees</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">&#8220;Audit
fees&#8221; consist of fees for professional services for the audit of our annual financial statements, interim reviews and limited
procedures on interim financial statements, securities filings and consultations on accounting or disclosure issues. KPMG LLP,
our external auditors, billed $403,500 for audit fees for the fiscal year ended March 31, 2019 and $349,100 for audit fees for
the fiscal year ended March 31, 2018.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Audit-Related Fees</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.85pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">&#8220;Audit-related
fees&#8221; consist of fees for professional services that are reasonably related to the performance of the audit or review of
our financial statements and which are not reported under &#8220;Audit Fees&#8221; above. KPMG LLP billed $53,000 for the fiscal
year ended March 31, 2019 and $8,440 for the fiscal year ended March 31, 2018. Audit-related fees include French translation services.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Tax Fees</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">&#8220;Tax fees&#8221; consist of fees for
professional services for tax compliance, tax advice and tax planning. KPMG LLP billed $28,100 for tax fees for fiscal year ended
March 31, 2019 and $57,100 for tax fees for fiscal year ended March 31, 2018. Tax fees include, but are not limited to, preparation
of tax returns.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">All Other Fees</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">&#8220;Other
fees&#8221; include all other fees billed for professional services other than those mentioned hereinabove. KPMG LLP billed no
fees under this category for the fiscal years ended March 31, 2019 and March 31, 2018.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Pre-Approval Policies and Procedures</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">The
audit committee approves all audit, audit-related services, tax services and other non-audit related services provided by the external
auditors in advance of any engagement. Under the Sarbanes-Oxley Act of 2002, audit committees are permitted to approve certain
fees for non-audit related services pursuant to a de minimus exception prior to the completion of an audit engagement. Non-audit
related services satisfy the de minimus exception if the following conditions are met:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.8pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify"></td><td style="width: 0.25in; text-align: justify"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the aggregate amount of all non-audit services that were not pre-approved is reasonably expected
to constitute no more than five per cent of the total amount of fees paid by us and our subsidiaries to our external auditors during
the fiscal year in which the services are provided;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify"></td><td style="width: 0.25in; text-align: justify"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">we or our subsidiaries, as the case may be, did not recognize the services as non-audit services
at the time of the engagement; and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in; text-align: justify"></td><td style="width: 0.25in; text-align: justify"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify">the services are promptly brought to the attention of the audit committee and approved, prior to
the completion of the audit, by the audit committee or by one or more of its members to whom authority to grant such approvals
had been delegated by the audit committee.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">None of the services
described above under &#8220;Principal Accountant Fees and Services&#8221; were approved by the audit committee pursuant to the
de minimus exception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0; text-align: justify"></td><td style="width: 50pt; text-align: justify"><a name="a_030"></a>Item 16D.</td><td style="text-align: justify">Exemptions from the Listing Standards for Audit Committees</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0; text-align: justify"></td><td style="width: 50pt; text-align: justify"><a name="a_031"></a>Item 16E.</td><td style="text-align: justify">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0; text-align: justify"></td><td style="width: 50pt; text-align: justify"><a name="a_032"></a>Item 16F.</td><td style="text-align: justify">Change in Registrant&#8217;s Certifying Accountant</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 50pt"><a name="a_033"></a>Item 16G.</td><td>Corporation Governance</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 4.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">NASDAQ
Marketplace Rule 5615(a)(3) permits a foreign private issuer to follow its home country practice in lieu of certain of the requirements
of the Rule 5600 Series. A foreign private issuer that follows a home country practice in lieu of one or more provisions of the
Rule 5600 Series is required to disclose in its annual report filed with the SEC, or on its website, each requirement of the Rule
5600 Series that it does not follow and describe the home country practice followed by the issuer in lieu of such NASDAQ corporate
governance requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 4.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">A description
of the significant ways in which our governance practices currently differ from those followed by domestic companies pursuant to
the Rule 5600 series is set out below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 4.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 9pt; text-align: justify"></td><td style="width: 18pt; text-align: justify"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 4.9pt">we do not follow NASDAQ Marketplace Rule 5620(c), but instead follow our
home country practice. The NASDAQ minimum quorum requirement under Rule 5620(c) for a meeting of shareholders is 33.33% of the
outstanding shares of common voting stock. Our quorum requirement, as set forth in our by-laws, is that a quorum for a meeting
of our holders of common shares is the attendance, in person or by proxy, of the shareholders representing 10% of our common shares.
The foregoing is consistent with the laws, customs and practices in Qu&#233;bec, Canada, and the rules and policies of the TSX-V;
and</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 4.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 9pt; text-align: justify"></td><td style="width: 18pt; text-align: justify"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 4.9pt">we do not follow NASDAQ Stock Market Rule 5635(d), but instead follow our
home country practice. NASDAQ Stock Market Rule 5635(d) requires each issuer to obtain shareholder approval for the issuance of
securities in connection with a transaction other than a public offering involving certain issuances of common shares in amounts
equaling 20% or more of such issuer&#8217;s common shares then outstanding. We do not follow this NASDAQ Stock Market Rule and
instead comply with the applicable requirements of the TSX-V. The TSX-V requires shareholder approval for any issuance of securities
if following such issuance, we would have a new &#8220;control person&#8221; (i.e. any individual or entity holding greater than
20% of our voting rights).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0; text-align: justify"></td><td style="width: 50pt; text-align: justify"><a name="a_034"></a>Item 16H.</td><td style="text-align: justify">Mining Safety Disclosure</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><a name="a_035"></a>PART III</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0; text-align: justify"></td><td style="width: 50pt; text-align: justify"><b><a name="a_036"></a>Item 17.</b></td><td style="text-align: justify"><b>Financial Statements</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 20pt; text-align: justify">The financial statements of Acasti Pharma Inc. are
located at the end of this annual report, beginning on page F-1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0; text-align: justify"></td><td style="width: 50pt; text-align: justify"><a name="a_037"></a>Item 18.</td><td style="text-align: justify">Financial Statements</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">See Item 17.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0; text-align: justify"></td><td style="width: 50pt; text-align: justify"><a name="a_038"></a>Item 19.</td><td style="text-align: justify">Exhibits</td></tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-align: center"></p>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-align: center"><a name="a_039"></a>EXHIBITS INDEX</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit <BR>
    Number</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Description of Document</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312513378663/d596972dex41.htm"><FONT STYLE="font-size: 10pt">1.1</FONT></A></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%"><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312513378663/d596972dex41.htm"><FONT STYLE="font-size: 10pt">Articles of Incorporation (incorporated by reference to Exhibit 4.1 from Form S-8 (File No. 333-191383) filed with the Commission on September 25, 2013)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312517050526/d347890dex991.htm"><FONT STYLE="font-size: 10pt">1.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312517050526/d347890dex991.htm"><FONT STYLE="font-size: 10pt">Amended and Restated General By-Law (incorporated by reference to Exhibit 99.1 from Form 6-K (File No. 001-35776) filed with the Commission on February 21, 2017)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312513378663/d596972dex43.htm"><FONT STYLE="font-size: 10pt">1.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312513378663/d596972dex43.htm"><FONT STYLE="font-size: 10pt">Advance Notice bylaw No. 2013-1 (incorporated by reference to Exhibit 4.3 from Form S-8 (File No. 333-191383) filed with the Commission on September 25, 2013)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312514228010/d732577dex21.htm"><FONT STYLE="font-size: 10pt">2.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312514228010/d732577dex21.htm"><FONT STYLE="font-size: 10pt">Specimen Certificate for Common Shares of Acasti Pharma Inc. (incorporated by reference to Exhibit 2.1 from Form 20-F (File No. 001-35776) filed with the Commission on June 6, 2014)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312513460382/d634512dex991.htm"><FONT STYLE="font-size: 10pt">2.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312513460382/d634512dex991.htm"><FONT STYLE="font-size: 10pt">Warrant Indenture dated December 3, 2013 between Acasti Pharma Inc. and Computershare Trust Company of Canada (incorporated by reference to Exhibit 99.1 from Form 6-K (File No. 001-35776) filed with the Commission on December 3, 2013)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312517215074/d416340dex23.htm"><FONT STYLE="font-size: 10pt">2.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312517215074/d416340dex23.htm"><FONT STYLE="font-size: 10pt">Warrant Indenture dated February 21, 2017 between Acasti Pharma Inc. and Computershare Trust Company of Canada (incorporated by reference to Exhibit 2.3 from Form 20-F (File No. 001-35776) filed with the Commission on June 27, 2017)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000117184318004911/exh_24.htm"><FONT STYLE="font-size: 10pt">2.4</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000117184318004911/exh_24.htm"><FONT STYLE="font-size: 10pt">Warrant
    Agency Agreement dated December 27, 2017 between Acasti Pharma Inc. and Computershare Inc. and its wholly-owned subsidiary,
    Computershare Trust Company N.A. (incorporated by reference to Exhibit 2.4 from Form 20-F (File No. 001-35776) filed with
    the Commission on June 29, 2018)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000117184318004911/exh_25.htm"><FONT STYLE="font-size: 10pt">2.5</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000117184318004911/exh_25.htm"><FONT STYLE="font-size: 10pt">Amended
    and Restated Warrant Indenture dated May 10, 2018 between Acasti Pharma Inc. and Computershare Trust Company of Canada (incorporated
    by reference to Exhibit 2.5 from Form 20-F (File No. 001-35776) filed with the Commission on June 29, 2018)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312513416220/d619105dex991.htm"><FONT STYLE="font-size: 10pt">4.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312513416220/d619105dex991.htm"><FONT STYLE="font-size: 10pt">Prepayment Agreement, dated December 4, 2012, between Neptune Technologies &amp; Bioressources Inc. and Acasti Pharma Inc. (incorporated by reference to Exhibit 99.1 from Form 6-K (File No. 001-35776) filed with the Commission on October 29, 2013)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312517215074/d416340dex42.htm"><FONT STYLE="font-size: 10pt">4.2</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312517215074/d416340dex42.htm"><FONT STYLE="font-size: 10pt">Equity Incentive Plan, as amended June 8, 2017 (incorporated by reference to Exhibit 4.2 from Form 20-F (File No. 001-35776) filed with the Commission on June 27, 2017)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312517215074/d416340dex43.htm"><FONT STYLE="font-size: 10pt">4.3</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312517215074/d416340dex43.htm"><FONT STYLE="font-size: 10pt">Stock Option Plan, as amended June 8, 2017 (incorporated by reference to Exhibit 4.3 from Form 20-F (File No. 001-35776) filed with the Commission on June 27, 2017)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312517299790/d464165dex105.htm"><FONT STYLE="font-size: 10pt">4.4</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312517299790/d464165dex105.htm"><FONT STYLE="font-size: 10pt">Employment Agreement with Jan D&rsquo;Alvise, dated May 11, 2016 (incorporated by reference to Exhibit 10.6 from Form F-1 (File No. 333-220755) filed with the SEC on September 29, 2017)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312517299790/d464165dex106.htm"><FONT STYLE="font-size: 10pt">4.5</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000119312517299790/d464165dex106.htm"><FONT STYLE="font-size: 10pt">Employment Agreement with Pierre Lemieux, dated September 26, 2017 (incorporated by reference to Exhibit 10.7 from Form F-1 (File No. 333-220755) filed with the SEC on September 29, 2017)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="exh_46.htm"><FONT STYLE="font-size: 10pt">4.6*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="exh_46.htm"><FONT STYLE="font-size: 10pt">Employment Agreement with Brian Groch, dated May 31, 2018</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="exh_47.htm"><FONT STYLE="font-size: 10pt">4.7*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="exh_47.htm"><FONT STYLE="font-size: 10pt">Employment Agreement with Jean-Fran&ccedil;ois Boily, dated September
    24, 2018</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000117184313002319/exh_994.htm"><FONT STYLE="font-size: 10pt">11.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1444192/000117184313002319/exh_994.htm"><FONT STYLE="font-size: 10pt">Code of Business Conduct and Ethics for Directors, Officers and Employees (incorporated by reference to Exhibit 99.4 from Form 40-F (File No. 001-35776) filed with the Commission on May 30, 2013)</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 93.95pt 0pt 10.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 93.95pt 0pt 10.95pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 93.95pt 0pt 10.95pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 93.95pt 0pt 10.95pt; text-align: justify"></p>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><A HREF="exh_121.htm"><FONT STYLE="font-size: 10pt">12.1*</FONT></A></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%"><A HREF="exh_121.htm"><FONT STYLE="font-size: 10pt">Principal Executive Officer Certification Pursuant to Section 302
    of the Sarbanes-Oxley Act of 2002</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="exh_122.htm"><FONT STYLE="font-size: 10pt">12.2*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="exh_122.htm"><FONT STYLE="font-size: 10pt">Principal Financial Officer Certification Pursuant to Section 302
    of the Sarbanes-Oxley Act of 2002 </FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="exh_131.htm"><FONT STYLE="font-size: 10pt">13.1*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="exh_131.htm"><FONT STYLE="font-size: 10pt">Principal Executive Officer Certification Pursuant to Section 906
    of the Sarbanes-Oxley Act of 2002</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="exh_132.htm"><FONT STYLE="font-size: 10pt">13.2*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="exh_132.htm"><FONT STYLE="font-size: 10pt">Principal Financial Officer Certification Pursuant to Section 906
    of the Sarbanes-Oxley Act of 2002</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="exh_151.htm"><FONT STYLE="font-size: 10pt">15.1*</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="exh_151.htm"><FONT STYLE="font-size: 10pt">Consent of KPMG LLP</FONT></A></TD></TR>
</TABLE>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 10%; text-align: left"><A HREF="exh_152.htm">15.2*</A></td><td style="width: 2%"></td><td style="text-align: justify; width: 88%"><A HREF="exh_152.htm">Consent of Destum Partners, Inc.</A></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">* Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-indent: 38.2pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-indent: 38.2pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-indent: 38.2pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-indent: 38.2pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-indent: 38.2pt"><B>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-align: center; text-indent: 38.2pt"><b></b></p>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-align: center; text-indent: 38.2pt"><b><a name="a_040"></a>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-indent: 38.2pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt; text-indent: 38.2pt">The registrant hereby certifies
that it meets all of the requirements for filing on this Annual Report and that it has duly caused and authorized the undersigned
to sign this Annual Report on its behalf.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td colspan="3" style="font-weight: bold; text-align: left">ACASTI PHARMA INC.</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td style="font-weight: bold">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 50%">&nbsp;</td>
    <td style="width: 10%">By:</td><td style="width: 1%; font-style: italic">&nbsp;</td>
    <td style="width: 39%; font-style: italic; border-bottom: Black 1pt solid">/s/ Jan D&#8217;Alvise</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>Name:</td><td>&nbsp;</td>
    <td>Jan D&#8217;Alvise</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td>Title:</td><td>&nbsp;</td>
    <td style="text-align: left">Principal Executive Officer</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.9pt">Date: June 26, 2019</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 93; Options: NewSection; Value: 91 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --> -</td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67pt; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67pt; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67pt; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67pt; text-align: left">Financial Statements of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67pt; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 104.95pt 0pt 67pt; text-align: left"><font style="font-size: 16pt; text-transform: uppercase"><b>Acasti
pharma inc.</b></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 67pt; text-indent: 0in">For the years ended March 31,
2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67pt; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: 0.1in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: 0.1in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: 0.1in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: 0.1in"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.8in; text-indent: 0.1in"><b>&nbsp;</b></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><img src="kpmg.jpg" alt=""><b></b></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: left">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: left">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: left"></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="width: 20%"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 30%; font-weight: bold; text-align: left"><font style="font-size: 10pt">KPMG LLP</font></td><td style="width: 1%"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 10%"><font style="font-size: 10pt">Telephone</font></td><td style="width: 1%"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 38%"><font style="font-size: 10pt">(514) 840-2100</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">600 de Maisonneuve Blvd. West</font></td><td><font style="font-size: 10pt">&nbsp;</font></td>
    <td><font style="font-size: 10pt">Fax</font></td><td><font style="font-size: 10pt">&nbsp;</font></td>
    <td><font style="font-size: 10pt">(514) 840-2187</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">Suite 1500, Tour KPMG</font></td><td><font style="font-size: 10pt">&nbsp;</font></td>
    <td><font style="font-size: 10pt">Internet</font></td><td><font style="font-size: 10pt">&nbsp;</font></td>
    <td><font style="font-size: 10pt">www.kpmg.ca</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 10pt">Montr&#233;al (Qu&#233;bec) H3A 0A3</font></td><td><font style="font-size: 10pt">&nbsp;</font></td>
    <td><font style="font-size: 10pt">&nbsp;</font></td><td><font style="font-size: 10pt">&nbsp;</font></td>
    <td><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 10pt">&nbsp;</font></td>
    <td><font style="font-size: 10pt">Canada</font></td><td><font style="font-size: 10pt">&nbsp;</font></td>
    <td><font style="font-size: 10pt">&nbsp;</font></td><td><font style="font-size: 10pt">&nbsp;</font></td>
    <td><font style="font-size: 10pt">&nbsp;</font></td></tr>
</table>




<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: left"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: left">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: left">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: left"><font style="font-size: 14pt">REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Shareholders and Board of Directors</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acasti Pharma Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Opinion on the Financial Statements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying statements of financial position
of Acasti Pharma, Inc. (the Company) as of March 31, 2019 and 2018, the related statements of earnings and comprehensive loss,
changes in equity, and cash flows for the years ended March 31, 2019 and 2018 and the thirteen-month period ended March 31, 2017,
and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all
material respects, the financial position of the Company as of March&nbsp;31, 2019 and 2018, and its financial performance and
its cash flows for the years ended March 31, 2019 and 2018 and the thirteen-month period ended March 31, 2017, in conformity with
International Financial Reporting Standards as issued by the International Accounting Standards Board.</P>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Material Uncertainty Related to Going
Concern</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Without qualifying our opinion on the financial
statements, we draw attention to Note 2 (c) to the financial statements, which indicates that the Company has incurred operating
losses and negative cash flows from operations since inception, and additional funds will be needed in the future for activities
necessary to prepare for commercial launch. These events or conditions, along with other matters as set forth in Note 2 (c), indicate
that a material uncertainty exists that casts substantial doubt on the Company&rsquo;s ability to continue as a going concern.</P>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Basis for Opinion</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required
to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="width: 30%"><font style="font-size: 7pt">&nbsp;</font></td>
    <td style="width: 70%"><font style="font-size: 7pt">KPMG LLP is a Canadian limited liability partnership and a member firm
    of the KPMG<br> network of independent member firms affiliated with KPMG International Cooperative<br> ("KPMG International"),
    a Swiss entity.<br> KPMG Canada provides services to KPMG LLP.</font></td></tr>
</table>


<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><img src="kpmg.jpg" alt="" style="height: 29; width: 75">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Page 2</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: left">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a
reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Matter</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements of Acasti Pharma
Inc. for the twelve-month and one-month periods ended February 28, 2017 and March 31, 2017 respectively are unaudited. Accordingly,
we do not express an opinion on them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="kpmg_sig.jpg" ALT=""></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as Company&#8217;s auditor
since 2009.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Montreal, Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 26, 2019</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-size: 7pt">*CPA auditor, CA, public accountancy
permit No. A122596</font></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase"><font style="font-size: 18pt">Acasti
pharma inc.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in">For the years ended March 31, 2019,
2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</p>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial Statements</p>

<table cellpadding="5" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="width: 50%; text-align: left; padding-left: 0.25in"><a href="#a_001">Statements of Financial Position</a></td><td style="width: 1%">&nbsp;</td>
    <td style="width: 49%; text-align: right"><a href="#a_001">F-5</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.25in"><a href="#a_002">Statements of Earnings and Comprehensive Loss</a></td><td>&nbsp;</td>
    <td style="text-align: right"><a href="#a_002">F-6</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.25in"><a href="#a_003">Statements of Changes in Equity</a></td><td>&nbsp;</td>
    <td style="text-align: right"><a href="#a_003">F-7</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.25in"><a href="#a_004">Statements of Cash Flows</a></td><td>&nbsp;</td>
    <td style="text-align: right"><a href="#a_004">F-9</a></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.25in"><a href="#a_005">Notes to Financial Statements</a></td><td>&nbsp;</td>
    <td style="text-align: right"><a href="#a_005">F-10</a></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 4 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><a name="a_001"></a>Acasti
Pharma inc.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Statements
of Financial Position</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">As
at March 31, 2019 and March 31, 2018</font></p>




<div data-td-taggable-table="" data-td-statement-type="balance-sheet"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="font-weight: bold; text-align: center; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="font-weight: normal; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; text-align: right; border-top: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">March 31, 2019</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="font-weight: normal; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; text-align: right; border-top: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">March 31, 2018</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left; border-bottom: Black 1pt solid; padding-left: 0pt">(thousands of Canadian dollars)</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">Notes</font></td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">$</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">$</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Assets </td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Current assets:</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; font-weight: normal; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%; font-weight: normal">&nbsp;</td>
    <td style="width: 8%; font-weight: normal; text-align: center">24</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">22,521</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 2%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">8,223</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; padding-left: 10pt">Marketable securities</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: center">5</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">11,865</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&#8211;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; padding-left: 10pt">Receivables</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: center">4</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">1,586</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">759</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; padding-left: 10pt">Other Assets</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: center">6</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">65</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">104</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; padding-left: 10pt">Deferred financing costs</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: center">14(b)</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">179</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&#8211;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; padding-left: 10pt">Prepaid expenses</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">1,115</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">406</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; padding-left: 0pt">Total current assets</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">37,331</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">9,492</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; padding-left: 0pt">Marketable securities</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: center">5</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">27</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">26</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; padding-left: 0pt">Other Asset</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: center">6</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">557</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">555</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; padding-left: 0pt">Equipment</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: center">9</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">2,813</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">2,821</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; padding-left: 0pt">Intangible assets</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: center">10</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">7,743</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">10,065</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; border-bottom: Black 1pt solid; padding-left: 0pt">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 0pt">Total assets</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">48,471</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">22,959</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Liabilities and Equity</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Current liabilities:</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; padding-left: 10pt">Trade and other payables</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: center">11</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">16,429</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">6,697</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; padding-left: 10pt">Unsecured convertible debentures</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: center">13</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">1,817</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; padding-left: 0pt">Total current liabilities</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">18,246</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">6,697</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-left: 0pt">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; padding-left: 0pt">Derivative warrant liabilities</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: center; white-space: nowrap"><font style="font-weight: normal">12, 14(d)( e)</font></td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">16,263</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">6,426</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; padding-left: 0pt">Unsecured convertible debentures</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: center">13</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">1,612</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; padding-left: 0pt">Total liabilities</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">34,509</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">14,735</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Equity:</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; padding-left: 10pt">Share capital</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: center">14</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">129,318</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">73,338</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; padding-left: 10pt">Other equity</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: center">14</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">309</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">309</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; padding-left: 10pt">Contributed surplus</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">8,280</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">6,956</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; border-bottom: Black 1pt solid; padding-left: 10pt">Deficit</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(123,945</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(72,379</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; padding-left: 10pt">Total equity</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">13,962</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">8,224</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: 0pt">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; padding-left: 0pt">Commitments and contingencies </td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: center">22</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; padding-left: 0pt">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 0pt">Total liabilities and equity</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">48,471</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">22,959</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt">See accompanying notes to financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">On behalf of the Board:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<tr style="vertical-align: middle">
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left; width: 28%">/s/ Dr. Roderick Carter</td>
    <TD STYLE="font-size: 10pt; font-style: italic; text-align: left; width: 72%">/s/ Jean-Marie Canan</td></tr>
<tr style="vertical-align: middle">
    <TD STYLE="font-size: 10pt; text-align: left">Roderick Carter</td>
    <TD STYLE="font-size: 10pt; text-align: left">Jean-Marie Canan</td></tr>
<tr style="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left">Chair of the Board</td>
    <TD STYLE="font-size: 10pt; text-align: left">Director</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 5 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><a name="a_002"></a>Acasti
Pharma inc.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Statements
of Earnings and Comprehensive Loss</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For
the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period
ended February 28, 2017</font></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">&nbsp;</p>
<div data-td-taggable-table="" data-td-statement-type="income"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right; border-top: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">Thirteen-<br>
months <br>
ended</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right; border-top: Black 1.5pt solid">&nbsp;Month ended</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right; border-top: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">Twelve-<br>
months <br>
ended</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">March 31, <br>
2019</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">March 31, <br>
2018</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">March 31, <br>
2017</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">March 31, <br>
2017</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">February 28, <br>
2017</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">(Unaudited)</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">(Unaudited)</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; border-bottom: Black 1pt solid">(thousands of Canadian dollars, except per share data)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif">Notes</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 31%; text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development expenses, net of government assistance</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 9%; text-align: center">8</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">(38,366</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">(15,669</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">(7,653</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">(426</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">(7,227</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid">General and administrative expenses</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,649</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,027</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,557</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(292</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3,265</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operating activities</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(45,015</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(19,696</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(11,210</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(718</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(10,492</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid">Financial expenses</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; white-space: nowrap"><font style="font-family: Times New Roman, Times, Serif">12, 14 (d)(e), 16</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,551</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,808</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(166</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(51</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(115</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>

<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center; white-space: nowrap">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss and comprehensive loss before income tax</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(51,566</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(21,504</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(11,376</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(769</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(10,607</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid">Deferred income tax recovery</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">129</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">129</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Net loss and total comprehensive loss</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,566</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(21,504</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,247</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(769</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,478</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Basic and diluted loss per share</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">18</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.95</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1.23</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1.01</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.05</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.97</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid">Weighted average number of shares outstanding</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">54,290,295</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">17,486,515</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,094,512</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,702,556</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,788,075</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.55pt 0pt 9pt; text-indent: -9pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.55pt 0pt 9pt; text-indent: -9pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.55pt 0pt 9pt; text-indent: -9pt">See accompanying notes to financial
statements</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">&nbsp;</p>

<!-- Field: Page; Sequence: 6 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><a name="a_003"></a>Acasti
Pharma inc.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Statements
of Changes in Equity</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For
the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period
ended February 28, 2017</font></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="stockholders-equity"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: center; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td colspan="5" style="text-align: center; border-top: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">Share capital</font></td><td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="text-align: right; border-top: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">Other</font></td><td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="text-align: right; border-top: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">Contributed</font></td><td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="text-align: right; border-top: Black 1.5pt solid">&nbsp;</td><td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="text-align: right; border-top: Black 1.5pt solid">&nbsp;</td><td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">Number</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">Dollar</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">equity</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">surplus</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">Deficit</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">(thousands of Canadian dollars)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif">Notes</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 26%; padding-left: 10pt; text-indent: -10pt">Balance, March 31, 2018</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 8%; text-align: center">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">25,638,215</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">73,338</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">309</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">6,956</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">(72,379</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">8,224</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Net loss and total comprehensive loss for the period</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(51,566</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(51,566</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">25,638,215</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">73,338</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">309</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">6,956</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(123,945</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(43,342</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Transactions with owners, recorded directly in equity</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; padding-left: 10pt; text-indent: -10pt">Contributions by and distributions to equity holders</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Public offering</td><td>&nbsp;</td>
    <td style="text-align: center">14(c)(d)</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">51,612,000</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">54,124</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">283</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">54,407</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Warrants exercised</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">772,474</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,733</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,733</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Share-based payment transactions</td><td>&nbsp;</td>
    <td style="text-align: center">17</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,167</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,041</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,044</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Issuance of shares for payment of interest on convertible debentures</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">14(g)</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">105,878</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">120</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">120</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Total contributions by and distributions to equity holders</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">52,494,519</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">55,980</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,324</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">57,304</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">Balance at March 31, 2019</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">78,132,734</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">129,318</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">309</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,280</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(123,945</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,962</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="stockholders-equity"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 10pt; text-indent: -10pt; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="text-align: center; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td colspan="6" style="text-align: center; border-top: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif"><u>Share capital</u></font></td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="text-align: right; border-top: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">Other</font></td><td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="text-align: right; border-top: Black 1.5pt solid"><font style="font-family: Times New Roman, Times, Serif">Contributed</font></td><td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="text-align: right; border-top: Black 1.5pt solid">&nbsp;</td><td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="text-align: right; border-top: Black 1.5pt solid">&nbsp;</td><td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">Number</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">Dollar</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">equity</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">surplus</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">Deficit</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">Total</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">(thousands of Canadian dollars)</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: center"><font style="font-family: Times New Roman, Times, Serif">Notes</font></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-family: Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 26%; padding-left: 10pt; text-indent: -10pt">Balance, March 31, 2017</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: center">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">14,702,556</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">66,576</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">309</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">5,693</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">(50,875</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">21,703</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Net loss and total comprehensive loss for the period</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(21,504</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(21,504</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-indent: -10pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">14,702,556</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">66,576</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">309</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,693</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(72,379</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">199</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Transactions with owners, recorded directly in equity</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; padding-left: 10pt; text-indent: -10pt">Contributions by and distributions to equity holders</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Public offering</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">14(e)</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">10,667,169</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">6,169</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">406</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">6,575</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Warrants exercised</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">178,721</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">456</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(72</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">384</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Share-based payment transactions</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">17</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">929</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">929</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Issuance of shares for payment of interest on convertible debentures</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: center">14(g)</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">89,769</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">137</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">137</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">Total contributions by and distributions to equity holders</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,935,659</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,762</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,263</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,025</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">Balance at March 31, 2018</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,638,215</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">73,338</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">309</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,956</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(72,379</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,224</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 0; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0; text-indent: 0in">See accompanying notes to financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-indent: -9pt">&nbsp;</p>
<!-- Field: Page; Sequence: 7 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 0; text-indent: 0in"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt">Acasti
pharma INC.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Statements
of Changes in Equity, Continued</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For
the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period
ended February 28, 2017</font></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 0; text-indent: 0in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.6pt 0pt 0; text-indent: 0in">&nbsp;</p>

<div data-td-taggable-table="" data-td-statement-type="stockholders-equity"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-indent: -10pt; padding-left: 10pt; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="text-align: center; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td colspan="5" style="text-align: center; border-top: Black 1.5pt solid"><u>Share capital</u></td><td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="text-align: right; border-top: Black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td><td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="text-align: right; border-top: Black 1.5pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Contributed</font></td><td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="text-align: right; border-top: Black 1.5pt solid">&nbsp;</td><td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="text-align: right; border-top: Black 1.5pt solid">&nbsp;</td><td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">Number</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">Dollar</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">equity</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">surplus</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">Deficit</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-style: italic; text-align: left; border-bottom: Black 1pt solid; text-indent: -10pt; padding-left: 10pt">(thousands of Canadian dollars)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">Notes</font></td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 38%; border-bottom: Black 1pt solid; text-indent: -10pt; padding-left: 10pt">Balance, February 29, 2016</td><td style="width: 1%; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="width: 6%; border-bottom: Black 1pt solid; text-align: center">&nbsp;</td><td style="width: 1%; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="width: 6%; border-bottom: Black 1pt solid; text-align: right">10,712,038</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="width: 1%; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="width: 6%; border-bottom: Black 1pt solid; text-align: right">61,973</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="width: 1%; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="width: 6%; border-bottom: Black 1pt solid; text-align: right">&#8211;</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="width: 1%; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="width: 6%; border-bottom: Black 1pt solid; text-align: right">4,875</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="width: 1%; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="width: 6%; border-bottom: Black 1pt solid; text-align: right">(39,628</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">)</td><td style="width: 1%; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="width: 6%; border-bottom: Black 1pt solid; text-align: right">27,220</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss and total comprehensive loss for the twelve-month period (unaudited)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(10,478</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(10,478</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; border-bottom: Black 1pt solid">Net loss and total comprehensive loss for the one-month period (unaudited)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: center; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">(769</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">(769</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; border-bottom: Black 1pt solid">Net loss and total comprehensive loss for the thirteen-month Period</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: center; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">(11,247</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">(11,247</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-indent: -10pt; padding-left: 10pt">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,712,038</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">61,973</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,875</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(50,875</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,973</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Transactions with owners, recorded directly in equity</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; text-indent: -10pt; padding-left: 10pt">Contributions by and distributions to equity holders</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Public offering</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">14(f)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,930,518</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,509</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8211;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">144</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,653</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Issue of unsecured convertible debentures, net of deferred income tax expense of $129</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;&nbsp;<font style="font: 10pt Times New Roman, Times, Serif">&nbsp;13, 20</font></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">309</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">309</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; text-indent: -10pt; padding-left: 10pt">Equity settled non-employee share-based payment</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">60,000</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">94</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">94</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Share-based payment transactions for the twelve-month period (unaudited)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">17</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">588</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">588</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; border-bottom: Black 1pt solid">Share-based payment transactions for the one-month period (unaudited)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: center; border-bottom: Black 1pt solid">17</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">86</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">86</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; border-bottom: Black 1pt solid">Share-based payment transactions for the thirteen-month period</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: center; border-bottom: Black 1pt solid">17</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">674</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">674</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Total contributions by and distributions to equity holders for the twelve-month period (unaudited)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,990,518</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,603</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">309</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">732</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&#8212;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,644</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt; border-bottom: Black 1pt solid">Total contributions by and distributions to equity holders for the one-month period (unaudited)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: center; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">86</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="text-align: right; border-bottom: Black 1pt solid">86</td><td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; text-indent: -10pt; padding-left: 10pt">Total contributions by and distributions to equity holders for the thirteen-month period</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,990,518</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,603</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">309</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">818</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,730</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-indent: -10pt; padding-left: 10pt">Balance at February 28, 2017 (unaudited)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,702,556</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">66,576</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">309</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,607</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(50,106</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">22,386</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid; text-indent: -10pt; padding-left: 10pt">Balance at March 31, 2017</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: center">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,702,556</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">66,576</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">309</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,693</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(50,875</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,703</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0; text-indent: 0in">See accompanying notes to financial
statements.</p>
<!-- Field: Page; Sequence: 8 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 16.55pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><a name="a_004"></a>acasti
pharma INC.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.55pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Statements
of Cash Flows</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.55pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For
the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period
ended February 28, 2017</font></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</p>
<div data-td-taggable-table="" data-td-statement-type="cash-flows"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br>
months <br>
ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-<br>
months <br>
ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">Notes</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, <br>
2019</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, <br>
2018</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, <br>
2017</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br>
2017 <br>
(Unaudited)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">February 28, <br>
2017 <br>
(Unaudited)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-style: italic; text-align: left; border-bottom: Black 1pt solid">(thousands of Canadian dollars)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash flows used in operating activities:</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 10%; text-align: center">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">(51,566</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">(21,504</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">(11,247</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">(769</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">(10,478</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Net loss for the period</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 10pt">Adjustments:</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 30pt">Amortization of intangible assets</td><td>&nbsp;</td>
    <td style="text-align: center">10</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,322</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,323</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,517</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">194</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,323</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 30pt">Depreciation of equipment</td><td>&nbsp;</td>
    <td style="text-align: center">9</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">505</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">349</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">221</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">32</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">189</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 30pt">Stock-based compensation</td><td>&nbsp;</td>
    <td style="text-align: center">17</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,041</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">929</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">674</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">86</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">588</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 30pt">Net financial expenses</td><td>&nbsp;</td>
    <td style="text-align: center">16</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">6,551</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,808</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">166</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">51</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">115</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 30pt">Realized foreign exchange gain (loss)</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">581</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(7</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">48</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(12</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">60</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; text-indent: 0pt; padding-left: 30pt">Deferred income tax recovery</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: center; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(129</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(129</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 30pt">Total adjustments</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(40,566</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(16,102</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(7,750</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(418</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(7,332</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; text-indent: 0pt; padding-left: 0pt">Changes in working capital items</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: center; border-bottom: Black 1pt solid">19</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,090</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,583</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">792</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(328</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,120</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid; text-indent: 0pt; padding-left: 0pt">Net cash used in operating activities</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: center; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(32,476</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,519</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,958</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(746</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(6,212</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Cash flows from (used in) investing activities:</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 20pt">Interest received</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">384</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">70</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">150</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">146</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 20pt">Acquisition of equipment</td><td>&nbsp;</td>
    <td style="text-align: center">9, 19</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(700</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(455</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(2,527</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(24</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(2,503</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 20pt">Acquisition of short-term investments</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(12,765</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(12,765</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 20pt">Acquisition of marketable securities</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(23,753</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(26</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 20pt">Maturity of short-term investments</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">22,030</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">22,030</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; text-indent: 0pt; padding-left: 20pt">Maturity of marketable securities</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: center; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,933</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid; text-indent: 0pt; padding-left: 20pt">Net cash (used in) investing activities</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: center; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,136</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(411</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,888</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(20</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,908</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Cash flows from (used in) financing activities:</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 20pt">Net proceeds from public offering</td><td>&nbsp;</td>
    <td style="text-align: center">14(c)(d)(e)(f)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">57,892</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">11,065</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,010</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(34</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,044</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 20pt">Net proceeds from private placement</td><td>&nbsp;</td>
    <td style="text-align: center">13, 14(f)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(40</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,872</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(10</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,882</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 20pt">Proceeds from exercise of warrants</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,011</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">384</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 20pt">Share based payment</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid; text-indent: 0pt; padding-left: 20pt">Interest paid</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: center; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(44</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(3</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(18</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(18</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; text-indent: 0pt; padding-left: 20pt">Net cash from (used in) financing activities</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: center; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">58,862</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">11,406</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,864</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(44</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,908</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; text-indent: 0pt; padding-left: 0pt">Foreign exchange (loss) gain on cash and cash equivalents held in foreign currencies</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: center; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">48</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(25</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(49</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">9</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(58</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid; text-indent: 0pt; padding-left: 0pt">Net increase (decrease) in cash and cash equivalents</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: center; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,298</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,549</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">6,745</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(801</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">7,546</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; text-indent: 0pt; padding-left: 0pt">Cash and cash equivalents, beginning of period</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="text-align: center; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,223</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,772</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,027</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,573</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,027</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1.5pt solid; text-indent: 0pt; padding-left: 0pt">Cash and cash equivalents, end of period</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,521</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,223</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,772</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,772</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,573</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash and cash equivalents is comprised of:</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Cash</td><td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,896</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,583</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">6,778</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">6,778</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7,584</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1.5pt solid; text-indent: 0pt; padding-left: 0pt">Cash equivalents</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,625</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,640</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,994</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,994</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,989</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.55pt 0pt 0; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.55pt 0pt 0; text-indent: 0in">See accompanying notes to financial
statements.</p>

<!-- Field: Page; Sequence: 9; Options: NewSection; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b><a name="a_005"></a>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 16.55pt 0pt 0"></p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">1.</td><td style="width: 5pt"></td><td style="text-align: justify">Reporting entity</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Acasti Pharma Inc. (<b>Acasti</b>
or the <b>Corporation</b>) is incorporated under the <i>Business Corporations Act</i> (Qu&#233;bec) (formerly Part 1A of the
<i>Companies Act </i>(Qu&#233;bec)). The Corporation is domiciled in Canada and its registered office is located at 545, Promenade
du Centropolis, Laval, Qu&#233;bec, H7T&nbsp;0A3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation is subject
to a number of risks associated with its ongoing priorities, including the conduct of its clinical program and its results, the
establishment of strategic alliances and the development of new pharmaceutical products and their marketing. The Corporation&#8217;s
current product in development requires approval from the U.S Food and Drug Administration and equivalent regulatory organizations
in other countries before their sale can be authorized. Certain risks have been reduced for the longer term with the outcome of
the Corporation&#8217;s actions, including its intellectual property strategy execution with filed patent applications in more
than 20 jurisdictions, with more than 20 issued patents and with numerous additional patent applications pending.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation has incurred
significant operating losses and negative cash flows from operations since inception. To date, the Corporation has financed its
operations through the public offering and private placement of Common Shares, units consisting of Common Shares and warrants and
convertible debt, the proceeds from research grants and research tax credits, and the exercises of warrants, rights and options.
To achieve the objectives of its business plan, Acasti plans to raise the necessary funds through additional securities offerings
and the establishment of strategic alliances as well as additional research grants and research tax credits. The ability of the
Corporation to complete the needed financing and ultimately achieve profitable operations is dependent on a number of factors outside
of the Corporation&#8217;s control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">2.</td><td style="width: 5pt"></td><td style="text-align: justify">Basis of preparation</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(a)</td><td style="width: 5pt"></td><td style="text-align: justify">Statement of compliance:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">These financial statements
have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as issued by the International
Accounting Standards Board (&#8220;IASB&#8221;). Beginning in fiscal 2017, the Corporation&#8217;s fiscal year end is on March
31. Fiscal 2017 is a transition year, and includes thirteen months of operations, beginning on March&nbsp;1, 2016 and ending on
March 31, 2017. As a result, for comparative purposes the above financial statements and corresponding notes to financial statements
include two unaudited periods: the one-month period ended March 31, 2017 and the twelve-month period ended February 28, 2017. The
Canadian Securities regulator permits, in the transition year, the presentation of a thirteen-month period for the financial year
ended March 31, 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The
financial statements were approved by the Board of Directors on June 26, 2019.</P>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(b)</td><td style="width: 5pt"></td><td style="text-align: justify">Basis of measurement:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The
financial statements have been prepared on the historical cost basis, except for:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 18pt"><font style="font-family: Symbol; font-size: 10pt">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">Stock-based compensation which is measured pursuant to IFRS 2, <i>Share-based
payments</i> (<i>Note 3(e) (ii</i>)); and,</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 18pt"><font style="font-family: Symbol; font-size: 10pt">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">Derivative warrant liabilities measured at fair value on a recurring basis
<i>(Note 12)</i>.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(c)</td><td style="width: 5pt"></td><td style="text-align: justify">Going concern uncertainty:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation has incurred operating losses and negative cash flows from operations since inception.
The Corporation&rsquo;s current assets of $37.3 million as at March 31, 2019 include cash and cash equivalents totaling $22.5 million,
and marketable securities of $11.9 million mainly generated by the net proceeds from the recent Public Offerings. The Corporation&rsquo;s
current liabilities total $18.2 million at March 31, 2019 and are comprised primarily of amounts due to or accrued for creditors<FONT STYLE="font-size: 10pt">.
Management projects that additional funds will be needed in the future, after TRILOGY phase 3 clinical trials, for activities necessary
to prepare for commercial launch, including the scale up of our manufacturing operations, the completion of the potential regulatory
(NDA) submission package (assuming positive Phase 3 clinical results), and the expansion of business development and US commercial
launch activities. The Corporation is working towards development of strategic partner relationships, as well as actively seeking
additional non-dilutive funds in the future, but there can be no assurance as to when or whether Acasti will complete any strategic
collaborations or succeed in identifying non-dilutive funding sources. Consequently, the Corporation may need to raise additional
equity capital in the future to fund these activities. In particular, raising additional capital is subject to market conditions
and is not within the Corporation&rsquo;s control. If the Corporation does not raise additional funds or find one or more strategic
partners, it may not be able to realize its assets and discharge its liabilities in the normal course of business. As a result,
there exists a material uncertainty that casts substantial doubt about the Corporation&rsquo;s ability to continue as a going concern
and, therefore, realize its assets and discharge its liabilities in the normal course of business. </FONT></P>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 10; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">2.</td><td style="width: 5pt"></td><td style="text-align: justify">Basis of preparation (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(c)</td><td style="width: 5pt"></td><td style="text-align: justify">Going concern uncertainty (continued):</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The financial statements
have been prepared on a going concern basis, which assumes the Corporation will continue its operations in the foreseeable future
and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business. These
financial statements do not include any adjustments to the carrying values and classification of assets and liabilities and reported
expenses that may be necessary if the going concern basis was not appropriate for these financial statements. If the Corporation
was unable to continue as a going concern, material write-downs to the carrying values of the Corporation&#8217;s assets, including
the intangible asset, could be required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(d)</td><td style="width: 5pt"></td><td style="text-align: justify">Functional and presentation currency:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">These
financial statements are presented in Canadian dollars, which is the Corporation&#8217;s functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(e)</td><td style="width: 5pt"></td><td style="text-align: justify">Use of estimates and judgments:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">The preparation
of the financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect
the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may
differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">Estimates are based on management&#8217;s
best knowledge of current events and actions that the Corporation may undertake in the future. Estimates and underlying assumptions
are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised
and in any future periods affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">Critical judgments in applying
accounting policies that have the most significant effect on the amounts recognized in the financial statements include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 35pt"><font style="font: 10pt Symbol">&#183;</font></td><td style="width: 5pt"></td><td style="text-align: justify; padding-right: 5.95pt">The use of the going concern basis of preparation of the financial statements.
At the end of each reporting period, management assesses the basis of preparation of the financial statements (Note 2(c)).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">Assumptions and estimation
uncertainties that have a significant risk of resulting in a material adjustment within the next financial year include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 35pt"><font style="font: 10pt Symbol">&#183;</font></td><td style="width: 5pt"></td><td style="text-align: justify; padding-right: 5.6pt">Measurement of derivative warrant liabilities (<i>note 12</i>) and stock-based
compensation (<i>note 17</i>).</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(f)</td><td style="width: 5pt"></td><td style="text-align: justify">Use of estimates and judgments (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">Also, management uses judgment
to determine which research and development (&#8220;R&amp;D&#8221;) expenses qualify for R&amp;D tax credits and in what amounts.
The Corporation recognizes the tax credits once it has reasonable assurance that they will be realized. Recorded tax credits are
subject to review and approval by tax authorities and therefore, could be different from the amounts recorded.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">3.</td><td style="width: 5pt"></td><td style="text-align: justify">Significant accounting policies:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The accounting policies
set out below have been applied consistently to all periods presented in these financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(a)</td><td style="width: 5pt"></td><td style="text-align: justify">Financial instruments:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">A financial instrument is any
contract that gives rise to a financial asset of one party and a financial liability or equity instrument of another party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 40pt; text-align: right"></td><td style="width: 35pt">(i)</td><td style="text-align: justify">Non-derivative financial assets:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation has the
following non-derivative financial assets: cash, cash equivalents, marketable securities and receivables. The Corporation determines
the classification of its financial assets at initial recognition. The subsequent measurement of financial assets depends on their
classification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Financial assets and liabilities
are offset and the net amount presented in the statements of financial position when, and only when, the Corporation has a legal
right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0pt">Cash, cash equivalents, marketable securities and
receivables with maturities of less than one year are classified at amortized cost as they meet both of the following conditions;
they are held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms
give rise on specified dates to cashflows that are solely payments of principal and interest on the principal amount outstanding.
Cash and cash equivalents comprise cash balances and highly liquid investments purchased three months or less from maturity.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0.25in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 11; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">3.</td><td style="width: 5pt"></td><td style="text-align: justify">Significant accounting policies (continued):</td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 40pt; text-align: right"></td><td style="width: 35pt">(ii)</td><td style="text-align: justify">Non-derivative financial liabilities:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation has the
following non-derivative financial liabilities: trade and other payables. Such financial liabilities are recognized initially at
fair value plus any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are
measured at amortized cost using the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation derecognizes
a financial liability when its contractual obligations are discharged, cancelled or expire.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 40pt; text-align: right"></td><td style="width: 35pt">(iii)</td><td style="text-align: justify">Compound financial instruments:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Compound financial instruments
are instruments that can be converted to share capital at the option of the holder, and the number of shares to be issued is fixed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">The unsecured convertible
debentures are compound instruments and have been separated into liability and equity components. The liability component is recognized
initially at the fair value of a similar liability that does not have an equity conversion option. The equity component is recognized
initially as the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability
component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their
initial carrying amounts. Subsequent to initial recognition, the liability component of a compound financial instrument is measured
at amortized cost using the effective interest method. The equity component of a compound financial instrument is not remeasured
subsequent to initial recognition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 40pt; text-align: right"></td><td style="width: 35pt">(iv)</td><td style="text-align: justify">Share capital:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><i>&nbsp;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><i>Common Shares</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Class A Common Shares
are classified as equity. Incremental costs directly attributable to the issue of Common Shares and share options are recognized
as a deduction from share capital, net of any tax effects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 40pt; text-align: right"></td><td style="width: 35pt">(v)</td><td style="text-align: justify">Derivative financial instruments:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation has issued
liability-classified derivatives over its own equity. Derivatives are recognized initially at fair value; attributable transaction
costs are recognized in profit and loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value,
and all changes in their fair value are recognized immediately in profit or loss as a component of finance expense (income).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 40pt; text-align: right"></td><td style="width: 35pt">(vi)</td><td style="text-align: justify">Other equity instruments:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Warrants, options and rights
over the Corporation&#8217;s equity issued outside of share-based payment transactions that do not meet the definition of a liability
instrument are recognized in equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(b)</td><td style="width: 5pt"></td><td style="text-align: justify">Equipment:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 40pt"></td><td style="width: 35pt">(i)</td><td style="text-align: justify; padding-right: 5.9pt">Recognition and measurement:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Equipment is measured at
cost less accumulated depreciation and accumulated impairment losses, if any.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Cost includes expenditures
that are directly attributable to the acquisition of the asset, including all costs incurred in bringing the asset to its present
location and condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Purchased software that
is integral to the functionality of the related equipment is capitalized as part of that equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Gains and losses on disposal
of equipment are determined by comparing the proceeds from disposal with the carrying amount of equipment, and are recognized net
within ''other income or expenses'' in profit or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 40pt"></td><td style="width: 35pt">(ii)</td><td style="text-align: justify; padding-right: 5.9pt">Subsequent costs:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The cost of replacing a
part of an equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied
within the part will flow to the Corporation, and its cost can be measured reliably. The carrying amount of the replaced part is
derecognized. The costs of the day-to-day servicing of equipment are recognized in profit or loss as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 12; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">3.</td><td style="width: 5pt"></td><td style="text-align: justify">Significant accounting policies (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 40pt"></td><td style="width: 35pt">(iii)</td><td style="text-align: justify; padding-right: 5.9pt">Depreciation:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Depreciation is recognized
in profit or loss on either a straight-line basis or a declining basis over the estimated useful lives of each part of an item
of equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in
the asset. Items of equipment are depreciated from the date that they are available for use or, in respect of assets not yet in
service, from the date they are ready for their intended use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The estimated useful lives
and rates for the current and comparative periods are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-indent: -9.05pt">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><font style="font-size: 10pt">Assets</font></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid; text-align: right"><font style="font-size: 10pt">Method</font></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><font style="font-size: 10pt">&nbsp;</font></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><font style="font-size: 10pt">Period/Rate</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">&nbsp;Furniture
    and office equipment</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">Declining balance</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">20%</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt"> to</font></td>
    <td style="text-align: center"><font style="font-size: 10pt"> 30%</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 28%; font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Computer
    equipment</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 30%; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">Declining
    balance</font></td><td style="width: 20%; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 7%; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">30%</font></td>
    <td style="width: 7%; text-align: center"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-size: 10pt">Laboratory
    equipment</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font-size: 10pt">Declining balance</font></td><td style="font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><font style="font-size: 10pt">30%</font></td>
    <td style="text-align: center"><font style="font-size: 10pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid"><font style="font-size: 10pt">Production
    equipment (in years)</font></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><font style="font-size: 10pt">Straight-line</font></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-size: 10pt">&nbsp;</font></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><font style="font-size: 10pt">10</font></td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid"><font style="font-size: 10pt">&nbsp;</font></td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Depreciation methods,
useful lives and residual values are reviewed at each financial year-end and adjusted prospectively if appropriate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(c)</td><td style="width: 5pt"></td><td style="text-align: justify">Intangible assets:</td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 40pt"></td><td style="width: 35pt">(i)</td><td style="text-align: justify; padding-right: 5.9pt">Research and development:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Expenditure on research
activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit
or loss as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Development activities involve
a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized
only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic
benefits are probable, and the Corporation intends to and has sufficient resources to complete development and to use or sell the
asset. The expenditure capitalized includes the cost of materials, direct labour, overhead costs that are directly attributable
to preparing the asset for its intended use, and borrowing costs on qualifying assets. Other development expenditures are recognized
in profit or loss as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Capitalized development
expenditure is measured at cost less accumulated amortization and accumulated impairment losses. As of the reporting periods presented,
the Corporation has not capitalized any development expenditure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 40pt"></td><td style="width: 35pt">(ii)</td><td style="text-align: justify; padding-right: 5.9pt">Other intangible assets:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><i>Patent costs</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Patents for technologies
that are no longer in the research phase are recorded at cost. Patent costs include legal fees to obtain patents and patent application
fees. When the technology is still in the research and development phase, those costs are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><i>Licenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Licenses that are acquired
by the Corporation and have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 40pt"></td><td style="width: 35pt">(iii)</td><td style="text-align: justify; padding-right: 5.9pt">Subsequent expenditure:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Subsequent expenditure is
capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditures,
including expenditure on internally generated goodwill and brands, are recognized in profit or loss as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 40pt; text-align: right"></td><td style="width: 35pt">(iv)</td><td style="text-align: justify">Amortization:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Amortization is calculated
over the cost of the intangible asset less its residual value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>


<!-- Field: Page; Sequence: 13; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">3.</td><td style="width: 5pt"></td><td style="text-align: justify">Significant accounting policies (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Amortization is recognized
in profit or loss on a straight-line basis over the estimated useful lives of intangible assets from the date that they are available
for use, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset.
The estimated useful lives for the current and comparative periods are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>


<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Assets</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Period (in years)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Patents</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 7%; text-align: center">&nbsp;</td>
    <td style="width: 7%; text-align: center">20</td>
    <td style="width: 7%; text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid">License</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid">8 </td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid">to</td>
    <td style="text-align: center; border-bottom: Black 1.5pt solid"> 14</td></tr>
</table></div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(d)</td><td style="width: 5pt"></td><td style="text-align: justify">Impairment:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 40pt"></td><td style="width: 35pt">(i)</td><td style="text-align: justify; padding-right: 5.9pt">Financial assets:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation assesses
at each reporting date the expected credit loss for calculating impairment of financial assets and recognizes expected credit losses
as loss allowances for assets measured at amortized cost.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 40pt"></td><td style="width: 35pt">(ii)</td><td style="text-align: justify; padding-right: 5.9pt">Non-financial assets:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The carrying amounts of
the Corporation&#8217;s non-financial assets are reviewed at each reporting date to determine whether there is any indication of
impairment. If any such indication exists, then the asset&#8217;s recoverable amount is estimated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The recoverable amount of
an asset or cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in
use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current
market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets
that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing
use that are largely independent of the cash inflows of other assets or groups of assets (the &#8220;cash-generating unit, or &#8220;CGU&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation&#8217;s
corporate assets do not generate separate cash inflows. If there is an indication that a corporate asset may be impaired, then
the recoverable amount is determined for the CGU to which the corporate asset belongs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">An impairment loss is recognized
if the carrying amount of an asset or its CGU exceeds its estimated recoverable amount. Impairment losses are recognized in profit
or loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Impairment losses recognized
in prior years are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment
loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed
only to the extent that the asset&#8217;s carrying amount does not exceed the carrying amount that would have been determined,
net of depreciation or amortization, if no impairment loss had been recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(e)</td><td style="width: 5pt"></td><td style="text-align: justify">Employee benefits:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 40pt"></td><td style="width: 35pt">(i)</td><td style="text-align: justify; padding-right: 5.9pt">Short-term employee benefits:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Short-term employee benefit
obligations are measured on an undiscounted basis and are expensed as the related service is provided.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">A liability is recognized
for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Corporation has a present legal or
constructive obligation to pay this amount as a result of past service provided by the employee, and the obligation can be estimated
reliably.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 14; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">3.</td><td style="width: 5pt"></td><td style="text-align: justify">Significant accounting policies (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<div data-td-statement-type="note"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 35pt">(ii)</TD><TD STYLE="text-align: justify; padding-right: 5.9pt">Share-based payment transactions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P></DIV>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The grant date fair value
of share-based payment awards granted to employees is recognized as an employee expense, with a corresponding increase in contributed
surplus, over the period that the employees unconditionally become entitled to the awards. The grant date fair value takes into
consideration market performance conditions when applicable. The amount recognized as an expense is adjusted to reflect the number
of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately
recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions
at the vesting date. Share-based payment arrangements
in which the Corporation receives goods or services as consideration for its own equity instruments are accounted for as equity-settled
share-based payment transactions, regardless of how the equity instruments are obtained by the Corporation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 40pt"></td><td style="width: 35pt">(iii)</td><td style="text-align: justify; padding-right: 5.9pt">Termination benefits:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Termination benefits are
recognized as an expense when the Corporation is committed demonstrably, without realistic possibility of withdrawal, to a formal
detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result
of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognized as an expense
if the Corporation has made an offer of voluntary redundancy, it is probable that the offer will be accepted, and the number of
acceptances can be estimated reliably. If benefits are payable more than 12 months after the reporting year, then they are discounted
to their present value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(f)</td><td style="width: 5pt"></td><td style="text-align: justify">Provisions:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0pt">A provision is recognized if, as a result of a past
event, the Corporation has a present legal or constructive obligation that can be estimated reliably, and it is probable that
an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected
future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific
to the liability. The unwinding of the discount is recognized as a component of finance expense (income).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 40pt"></td><td style="width: 35pt">(i)</td><td style="text-align: justify; padding-right: 5.9pt">Onerous contracts:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">A provision for onerous
contracts is recognized when the expected benefits to be derived by the Corporation from a contract are lower than the unavoidable
cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected
cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established,
the Corporation recognizes any impairment loss on the assets associated with that contract.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 40pt"></td><td style="width: 35pt">(ii)</td><td style="text-align: justify; padding-right: 5.9pt">Contingent liability:</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">A contingent liability is
a possible obligation that arises from past events and of which the existence will be confirmed only by the occurrence or non-occurrence
of one or more uncertain future events not within the control of the Corporation; or a present obligation that arises from past
events (and therefore exists), but is not recognized because it is not probable that a transfer or use of assets, provision of
services or any other transfer of economic benefits will be required to settle the obligation; or the amount of the obligation
cannot be estimated reliably.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(g)</td><td style="width: 5pt"></td><td style="text-align: justify">Government grants:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Government grants are recorded
as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable
assurance that the Corporation has met the requirements of the approved grant program and there is reasonable assurance that the
grant will be received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Grants that compensate the
Corporation for expenses incurred are recognized in profit or loss in reduction thereof on a systematic basis in the same years
in which the expenses are recognized. Grants that compensate the Corporation for the cost of an asset are recognized in profit
or loss on a systematic basis over the useful life of the asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(h)</td><td style="width: 5pt"></td><td style="text-align: justify">Lease payments:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Payments made under operating
leases are recognized in profit or loss on a straight-line basis over the term of the lease. Lease incentives received are recognized
as an integral part of the total lease expense, over the term of the lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(i)</td><td style="width: 5pt"></td><td style="text-align: justify">Foreign currency:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Transactions in foreign
currencies are translated into the functional currency at exchange rates at the dates of the transactions. Monetary assets and
liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate
at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency
at the beginning of the period, adjusted for effective interest and payments during the period, and the amortized cost in foreign
currency translated at the exchange rate at the end of the reporting period. Foreign currency differences arising on translation
are recognized in profit or loss.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 15; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">3.</td><td style="width: 5pt"></td><td style="text-align: justify">Significant accounting policies (continued):</td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(j)</td><td style="width: 5pt"></td><td style="text-align: justify">Finance income and finance expense:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Finance income comprises
interest income on funds invested. Interest income is recognized as it accrues in profit or loss, using the effective interest
method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Finance costs comprise
interest expense, accretion on borrowings, unwinding of the discount on provisions, impairment losses recognized on financial assets,
transaction costs for issuance of derivative warrant liabilities and changes of fair value of derivative warrant liabilities. Borrowing
costs that are not directly attributable to the acquisition, construction or production of a qualifying asset are recognized in
profit or loss using the effective interest method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Foreign currency gains and
losses are reported on a net basis. The Corporation recognizes interest income as a component of investing activities and interest
expense as a component of financing activities in the statements of cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(k)</td><td style="width: 5pt"></td><td style="text-align: justify">Income tax:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Income tax expense comprises
current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they relate to
items recognized directly in equity or in other comprehensive income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Current tax is the expected
tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment
to tax payable in respect of previous years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Deferred tax is recognized
in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and
the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences arising from the initial recognition
of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit
or loss. Deferred tax is measured at the tax rates, enacted or substantively enacted, that are expected to be applied to temporary
differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred
tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and
they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they
intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.
A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that
it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed
at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(l)</td><td style="width: 5pt"></td><td style="text-align: justify">Earnings per share:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation presents
basic and diluted earnings per share (&#8220;EPS&#8221;) data for its Class A shares (or &#8220;Common Shares&#8221;). Basic EPS
is calculated by dividing the profit or loss attributable to the holders of Class A shares (Common Shares) of the Corporation by
the weighted average number of Common Shares outstanding during the year, adjusted for own shares held. Diluted EPS is determined
by adjusting the profit or loss attributable to the holders of Class A shares (Common Shares) and the weighted average number of
Class A shares (Common Shares) outstanding adjusted for the effects of all dilutive potential Common Shares, which comprise warrants,
rights and share options granted to employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(m)</td><td style="width: 5pt"></td><td style="text-align: justify">Segment reporting:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">An operating segment is
a component of the Corporation that engages in business activities from which it may earn revenues and incur expenses. The Corporation
has one reportable operating segment: the development and commercialization of pharmaceutical applications of its licensed rights
for cardiovascular diseases. The majority of the Corporation&#8217;s assets are located in Canada, while one major production unit,
with a carrying value of $1,831 (March 31, 2018 - $2,077), is located in France.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 16; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">3.</td><td style="width: 5pt"></td><td style="text-align: justify">Significant accounting policies (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(n)</td><td style="width: 5pt"></td><td style="text-align: justify">Change in accounting policy:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Adoption
of new accounting standards</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The accounting policies
used in these annual financial statements are consistent with those applied by the Corporation in its March 31, 2018 annual financial
statements except for the amendments to certain accounting standards which are relevant to the Corporation and were adopted by
the Corporation as of April 1, 2018 as described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 40pt; text-align: right"></td><td style="width: 35pt">(i)</td><td style="text-align: justify">Financial instruments:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">IFRS 9, Financial Instruments,
replaces IAS 39, Financial Instruments: Recognition and Measurement. IFRS 9 introduces a revised approach for the classification
of financial assets based on how an entity manages financial assets and the characteristics of the contractual cash flows of the
financial assets replacing the multiple rules in IAS 39. Most of the requirements in IAS 39 for classification and measurement
of financial liabilities have been carried forward in IFRS 9. IFRS 9 also introduces a new hedge accounting model that is more
closely aligned with risk-management activities and a new expected credit loss model for calculating impairment on financial assets
replacing the incurred loss model in IAS 39. The Corporation adopted IFRS 9 as of April 1, 2018 and assessed the impact of the
adoption on its financial statements, and determined there was no material impact. The Corporation does not apply hedge accounting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 40pt; text-align: right"></td><td style="width: 35pt">(ii)</td><td style="text-align: justify">Amendments to IFRS 2 &#8211; Classification and Measurement of Share-Based Payment
Transactions:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">On June 20, 2016, the IASB
issued amendments to IFRS 2, Share-Based Payment, clarifying how to account for certain types of share-based payment transactions.
The amendments provide requirements on the accounting for: the effects of vesting and non-vesting conditions on the measurement
of cash-settled share-based payments; share-based payment transactions with a net settlement feature for withholding tax obligations;
and a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from
cash-settled to equity-settled. The Corporation adopted the amendments to IFRS 2 as of April 1, 2018 and assessed the impact of
the adoption of IFRS 2 on its financial statements, and determined that there was no material impact.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Future accounting change:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The following new standards,
and amendments to standards and interpretations, are not yet effective for the period ended March&nbsp;31,&nbsp;2019, and have
not been applied in preparing these financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">New standards and interpretations
not yet adopted:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 40pt"></td><td style="width: 35pt">(i)</td><td style="text-align: justify; padding-right: 5.9pt">Leases &#8211; IFRS 16</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">IFRS 16, Leases (&#8220;IFRS
16&#8221;) In January 2016, the IASB issued IFRS 16, a new standard that replaces IAS 17, Leases. IFRS 16 is a major revision of
the way in which companies account for leases and will no longer permit off balance sheet leases. Adoption of IFRS 16 is mandatory
and will be effective for the Corporation&#8217;s fiscal year beginning on April 1, 2019. The Corporation is assessing the impact
of adoption of IFRS 16, and currently there is only one lease that will be impacted by this new standard and the impact is expected
to be minimal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">4.</td><td style="width: 5pt"></td><td style="text-align: justify">Receivables:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify">&nbsp;</p>
<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid">Notes</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-weight: normal; text-align: left">Sales tax receivables</td><td style="width: 1%; font-weight: bold">&nbsp;</td>
    <td style="width: 14%; font-weight: bold; text-align: center">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">618</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">470</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">Government assistance and tax credits receivable</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: center">8</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">872</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">282</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">Interest receivable</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">80</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Other receivables</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">16</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">7</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Total receivables</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">1,586</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">759</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</p></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 17; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">5.</td><td style="width: 5pt"></td><td style="text-align: justify">Marketable Securities</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.65pt; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.65pt; margin-bottom: 0pt"><font style="font-weight: normal">The corporation
holds various marketable securities with maturities greater than 90 days at the time of purchase as follows: </font></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-weight: normal; text-align: left">Term deposit issued in US currency [US $20], earning interest at 2.23% and maturing on March 13, 2019</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">26</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">Term deposits issued in US currency [US $2,020], earning interest at 2.50% and maturing on various dates from April 8, 2019 to March 12, 2020</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,696</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Treasury bills issued in CAD currencyearning interest at rates ranging from 1.83% to 1.90% and maturing on various dates from April 2, 2019 to July 25, 2019</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,196</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Total Marketable securities</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">11,892</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">26</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; padding-left: 10pt">Current marketable securities</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">11,865</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 10pt">Marketable securities</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">27</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">26</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt">&nbsp;</p></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">6.</td><td style="width: 5pt"></td><td style="text-align: justify">Other Assets</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.65pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.65pt; margin-bottom: 0pt; text-align: justify"><font style="font-weight: normal">During
the year, the Corporation owned a reserve of krill oil in which amounts are expensed as it is being used. The following table summarizes
information regarding activities of amounts of the krill oil usage in the R&amp;D production processes and for NKPL66 manufacturing
for the year (see note 7 (a)):</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-weight: normal; text-align: left">Balance &#8211; beginning of year</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">659</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal">Purchased</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">68</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">970</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; border-bottom: Black 1pt solid">Used</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(105</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(311</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Balance &#8211; end of year</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">622</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">659</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"> <font style="font-weight: normal"></font> <font style="font-weight: normal">Current other
         asset</font></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">65</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">104</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Other asset</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">557</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">555</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b>&nbsp;</b></p></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><b></b></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">7.</td><td style="width: 5pt"></td><td style="text-align: justify">Related parties:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Neptune Technologies (Neptune)
Acasti&#8217;s former parent company, owned approximately 6.5% of the issued and outstanding Class A shares (Common Shares) of
the Corporation as at March 31, 2019. Neptune&#8217;s ownership reduced below a control position, following Acasti&#8217;s U.S.
public financing activities in December 2017 and January 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(a)</td><td style="width: 5pt"></td><td style="text-align: justify">Administrative and research and development expenses:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">The Corporation has significantly
reduced its reliance on the support of Neptune for a portion of its general and administrative needs; however, it will continue
to utilize their IT support for the near term. The Corporation was charged by Neptune for the purchase of research supplies and
for certain costs incurred by Neptune for the benefit of the Corporation, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 18; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">7.</td><td style="width: 5pt"></td><td style="text-align: justify">Related parties (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>
<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br>
months ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br>
ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>
2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>
2018</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2017</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>
2017</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">February 28, <br>
2017</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -8.25pt; padding-left: 8.25pt">Research and development expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%; text-align: left; padding-left: 13.65pt">Supplies and incremental costs</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">7</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 13.65pt">Shared service agreement</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">20</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">60</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">59</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; padding-left: 15.3pt">Total</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">27</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">60</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">59</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -8.25pt; padding-left: 8.25pt">General and administrative expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 13.65pt">Supplies and incremental costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">211</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">239</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">293</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">16</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">277</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 13.65pt">Shared service agreement</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">34</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">121</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">325</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">25</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">300</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid; padding-left: 15.3pt">Total</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">245</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">360</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">618</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">41</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">577</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Total related parties expenses</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">245</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">387</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">678</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">636</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 16.3pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Where Neptune incurs specific
incremental costs for the benefit of the Corporation, it charges those amounts directly. Neptune provides Acasti with the services
of personnel for certain administrative work as part of a shared service agreement. The employees&#8217; salaries and benefits
are charged proportionally to the time allocation agreed upon within the shared service agreement. Effective September 30, 2017,
the laboratory support, the corporate affairs and the public company reporting services previously provided by Neptune as part
of the shared service agreement were discontinued. The Corporation is now incurring incremental costs and expects to do so in the
future, partially offset by reduced shared service fees. The account payable to Neptune amounted to $2 at March 31, 2019 and $44
at March 31, 2018, is non-interest bearing and has no specified maturity date. These charges do not represent all charges incurred
by Neptune that may have benefited the Corporation. Also, these charges do not necessarily represent the cost that the Corporation
would otherwise need to incur, should it not receive these services or benefits through the shared resources of Neptune.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Historically, Neptune has
provided the Corporation with the krill oil needed to produce CaPre for Acasti&#8217;s clinical programs, including all of the
krill oil projected to be needed for its Phase 3 clinical study program. However, Neptune discontinued its krill oil production
and sold its krill oil inventory to Aker on August 7, 2017. In 2017 Acasti purchased a reserve of krill oil from Aker that will
be used in the production of CaPre capsules for its Phase 3 clinical trials (see also note 6). The Corporation is currently evaluating
alternative suppliers of krill oil. At March 31, 2019, a reserve of krill oil owned by the Corporation was physically stored at
Neptune&#8217;s facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(b)</td><td style="width: 5pt"></td><td style="text-align: justify">Interest revenue:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">On January 7, 2016 Neptune
announced the acquisition of Biodroga Nutraceuticals Inc. As part of this transaction, the Corporation pledged an amount of $2
million (&#8220;Committed Funds&#8221;) to partly guarantee the financing for the said transaction (&#8220;Pledge Agreement&#8221;).
Neptune had agreed to pay Acasti an annual fee on the Committed Funds outstanding at an annual rate of 9% during the first six
months and 11% for the remaining term of the Pledge Agreement. On September 20, 2016, Neptune fully released the pledged amount.
The Corporation recognized interest revenue of nil for the years ended March 31, 2019 and 2018, $89 for the thirteen-month period
ended March 31, 2017, nil (unaudited) for the month ended March 31, 2017, and $89 (unaudited) for the twelve-month period ended
February 28, 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 19; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">7.</td><td style="width: 5pt"></td><td style="text-align: justify">Related parties (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(c)</td><td style="width: 5pt"></td><td style="text-align: justify">Key management personnel compensation:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">The key management personnel
are the officers of the Corporation and the members of the Board of Directors of the Corporation. They control in the aggregate
less than 1% of the voting shares of the Corporation (less than 1% in 2018 and 2% in 2017).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Key management personnel
compensation includes the following for the years ended March 31, 2019 and 2018, the thirteen-month and one-month periods ended
March 31, 2017 and the twelve-month period ended February 28, 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br>
months ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br>ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2018</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2017</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2017</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">February 28, <br>
2017</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Compensation</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">1,641</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">1,754</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">1,510</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">146</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">1,364</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid">Share-based compensation costs</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">940</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">826</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">619</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">78</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">541</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Total key management personnel compensation</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,581</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,580</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,129</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">224</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,905</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">8.</td><td style="width: 5pt"></td><td style="text-align: justify">Government assistance:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br>
months ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br>ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2018</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2017</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2017</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">February 28, <br>
2017</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Investment tax credit</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">588</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">409</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">103</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">8</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">95</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid">Government grant</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">7</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">227</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">37</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">190</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Total government assistance</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">595</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">409</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">330</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">285</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Government assistance
is comprised of a government grant from the federal government and research and development investment tax credits receivable from
the provincial government which relate to qualifiable research and development expenditures under the applicable tax laws. The
amounts recorded as receivables are subject to a government tax audit and the final amounts received may differ from those recorded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Unrecognized federal tax
credits may be used to reduce future income tax and expire as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">$</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; text-align: left">2029</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">11</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2030</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">30</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2031</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">45</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2032</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">431</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2033</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">441</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2034</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">436</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2035</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">519</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2036</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">286</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2037</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">315</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2038</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">324</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid">2039</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">329</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,167</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 20; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">9.</td><td style="width: 5pt"></td><td style="text-align: justify">Equipment:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0.5in; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Furniture and <br>
office equipment</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Computer <br>
equipment</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Laboratory <br>
equipment</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Production <br>
equipment</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Total</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Cost:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 35%">Balance at February 29, 2016</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">59</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">3</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">336</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">398</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid">Additions for the twelve-month period (Unaudited)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">8</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">186</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,484</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,678</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at February 28, 2017 (Unaudited)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">59</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">11</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">522</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,484</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,076</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid">Additions for the one-month period (Unaudited)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">43</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">43</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid">Additions for the thirteen-month period</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">8</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">186</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,527</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,721</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at March 31, 2017</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">59</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">11</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">522</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,527</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,119</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid">Additions</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">4</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">6</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">192</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">181</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">383</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at March 31, 2018</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">63</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">17</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">714</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,708</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,502</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid">Additions</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">5</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">13</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">219</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">260</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">497</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid">Balance at March 31, 2019</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">68</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">933</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,968</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,999</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Accumulated depreciation:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at February 29, 2016</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">52</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">56</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">111</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid">Depreciation for the twelve-month period (Unaudited)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">7</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">129</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">52</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">189</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at February 28, 2017 (Unaudited)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">59</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">185</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">52</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">300</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid">Depreciation for the one-month period (Unaudited)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">11</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">21</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">32</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid">Depreciation for thirteen-month period</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">7</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">140</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">73</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">221</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at March 31, 2017</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">59</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">196</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">73</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">332</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid">Depreciation</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">107</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">239</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">349</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at March 31, 2018</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">59</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">303</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">312</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">681</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid">Depreciation</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">7</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">180</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">317</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">505</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid">Balance at March 31, 2019</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">483</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">629</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,186</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net carrying amounts:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.1in">March 31, 2018</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">10</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">411</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,396</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,821</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 0.1in">March 31, 2019</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">450</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,339</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,813</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 28.35pt; text-indent: -10.5pt"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Depreciation expense for
the periods end March 31, 2019 and 2018, the thirteen-month and one-month periods ended March 31, 2017 and twelve-month period
ended February&nbsp;28,&nbsp;2017 has been recorded in &#8220;research and development expenses&#8221; in the statements of earnings
and comprehensive loss.</p></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 21; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">10.</td><td style="width: 5pt"></td><td style="text-align: justify">Intangible assets :</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">In December 2012, the
Corporation entered into a prepayment agreement with Neptune pursuant to which the Corporation exercised its option under the License
Agreement to pay in advance all of the future royalties payable. The license allows the Corporation to exploit the intellectual
property rights in order to develop novel active pharmaceutical ingredients (&#8220;APIs&#8221;) into commercial products for the
prescription drugs market. The license Agreement, together with the Corporation own IP, allows the &#8220;freedom to operate&#8221;
for CaPre, which is currently the Corporation&#8217;s only prescription drug candidate in development. The Corporation believes
that upon the expiry of the last licensed Neptune patent in 2022, the Corporation&#8217;s expanding patent portfolio will cover
CaPre, and that it will not require any license from Neptune to support the commercialization of CaPre.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Patents</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">License</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Total</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">Cost:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 55%">Balance at February 29, 2016, February 28, 2017 (Unaudited) and March 31, 2017</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">362</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">24,330</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right">24,692</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid">Additions</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2018</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">362</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">24,330</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">24,692</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid">Additions</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid">Balance at March 31, 2019</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">362</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,330</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24,692</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Accumulated amortization:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at February 29, 2016</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">362</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">9,425</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">9,787</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid">Amortization for the twelve-month period (Unaudited)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,323</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,323</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at February 28, 2017 (Unaudited)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">362</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">11,748</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">12,110</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid">Amortization for the one-month period (Unaudited)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">194</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">194</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid">Amortization for the thirteen-month period</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,517</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,517</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2017</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">362</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">11,942</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">12,304</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid">Amortization for the year</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,323</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,323</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Balance at March 31, 2018</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">362</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">14,265</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">14,627</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid">Amortization for the year</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,322</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,322</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid">Balance at March 31, 2019</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">362</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,587</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,949</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net carrying amounts:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.1in">March 31, 2018</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">10,065</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">10,065</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 0.1in">March 31, 2019</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,743</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,743</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><font style="font-weight: normal">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><font style="font-weight: normal">Amortization
expense and impairment loss for the period ended March 31, 2019 and 2018, the thirteen-month and one-month periods ended March
31, 2017, and the twelve-month period ended February&nbsp;28,&nbsp;2017 have been recorded in &#8220;research and development expenses&#8221;
in the statements of earnings and comprehensive loss. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 22; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">11.</td><td style="width: 5pt"></td><td style="text-align: justify">Trade and other payables:</td>
</tr></table>



<p style="margin: 0">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">&nbsp;</td><td style="font-weight: normal">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">&nbsp;</td><td style="font-weight: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-weight: normal; text-align: left">Trade payables</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">4,064</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">3,420</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">Accrued liabilities and other payables</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">10,319</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">2,479</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">Employee salaries and benefits payable</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">1,054</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">754</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">Legal settlement expected to be paid via common shares (note 25)</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">990</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Payable to Neptune</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">2</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">44</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Total trade and other payables</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">16,429</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">6,697</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">The Corporation&#8217;s
exposure to currency and liquidity risks related to trade and other payables is presented in Note 21.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><i>&nbsp;</i></p></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><i></i></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">12.</td><td style="width: 5pt"></td><td style="text-align: justify">Derivative warrant liabilities:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The warrants issued as part
of the public offering of units composed of Common Share and Common Share purchase warrants on both May 9, 2018 and May 14, 2018
(<i>see note 14</i>) are derivative liabilities (&#8220;Derivative Warrant Liabilities&#8221;) given the warrant indenture contains
certain contingent provisions that allow for cash settlement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Warrants issued as part of
a public offering of units composed of class A share (Common Share) and Common Share purchase warrants on both December 27, 2017
and December 3, 2013 are derivative liabilities (&#8220;Derivative warrant liabilities&#8221;) given the currency of the exercise
price is different from the Corporation&#8217;s functional currency.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The derivative warrant liabilities
are measured at fair value at each reporting period and the reconciliation of changes in fair value is presented in the following
tables:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>


<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Warrant liabilities issued <br>
May 2018</td><td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Warrant liabilities issued <br>
December 27, 2017</td><td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><font style="font-weight: normal">Warrant liabilities issued <br>
December 3, 2013<sup>1</sup></font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">March 31, <br>
2019</td><td style="font-weight: normal">&nbsp;</td><td style="font-weight: normal; font-style: normal">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; font-style: normal; text-align: right">March 31, <br>
2018</td><td style="font-weight: normal; font-style: normal">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">March 31, <br>
2019</td><td style="font-weight: normal">&nbsp;</td><td style="font-weight: normal; font-style: normal">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; font-style: normal; text-align: right">March 31, <br>
2018</td><td style="font-weight: normal; font-style: normal">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">March 31, <br>
2019</td><td style="font-weight: normal">&nbsp;</td><td style="font-weight: normal; font-style: normal">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; font-style: normal; text-align: right">March 31, <br>
2018</td><td style="font-weight: normal; font-style: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-weight: normal">Balance &#8211; beginning of period</td><td style="width: 1%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 8%; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 8%; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 8%; font-weight: normal; text-align: right">6,405</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 8%; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 8%; font-weight: normal; text-align: right">21</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 8%; font-weight: normal; text-align: right">209</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal">Issued during period</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">4,272</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">5,873</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-indent: -4.95pt; padding-left: 4.95pt">Exercised during period</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">(722</td><td style="white-space: nowrap; font-weight: normal; text-align: left">)</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; text-indent: -4.95pt; padding-left: 4.95pt">Change in fair value of derivative warrant liabilities</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,696</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,612</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">532</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(21</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(188</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; border-bottom: Black 1pt solid">Balance &#8211; end of period</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">8,246</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">8,017</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">6,405</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">21</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; border-bottom: Black 1.5pt solid">Fair value per share issuable</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">0.81</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">0.82</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">0.65</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">0.01</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
</table></div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <font style="font-size: 8pt">(1)</font> <font style="font-size: 8pt">In order to obtain one Common Share, 10 warrants must be exercised. All unexercised warrants expired on December 3, 2018.</font></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0.75in; text-align: justify; text-indent: 0in">&nbsp;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0.75in; text-align: justify; text-indent: 0in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 23; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">12.</td><td style="width: 5pt"></td><td style="text-align: justify">Derivative warrant liabilities (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The fair value of the derivative
warrant liabilities was estimated using the Black-Scholes option pricing model and based on the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Warrant liabilities issued <br>May 2018</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Warrant liabilities issued <br>December 27, 2017</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Warrant liabilities issued</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">December 3, 2013 <sup>1</sup></p></td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br>2019</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br>
2018</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br>2019</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br>
2018</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br>2019</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br>
2018</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-weight: normal">Exercise price</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">$</td><td style="width: 8%; font-weight: normal; text-align: right">1.31</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 8%; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 8%; font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.26</font></td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 8%; font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.26</font></td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 8%; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 8%; font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.50</font></td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal">Share price</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">$</td><td style="font-weight: normal; text-align: right">1.35</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.02</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.02</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.02</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">Risk-free interest</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">1.52</td><td style="white-space: nowrap; font-weight: normal; text-align: left">%</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">2.23</td><td style="white-space: nowrap; font-weight: normal; text-align: left">%</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">2.56</td><td style="white-space: nowrap; font-weight: normal; text-align: left">%</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">2.19</td><td style="white-space: nowrap; font-weight: normal; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">Estimated life (in years)</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">4.11</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">3.75</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">4.75</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">0.68</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">94.58</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">107.57</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">95.15</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">133.86</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <font style="font-size: 8pt">(1)</font> <font style="font-size: 8pt">In order to obtain one Common Share, 10 warrants must be exercised. All unexercised warrants expired on December 3, 2018.</font></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">13.</td><td style="width: 5pt"></td><td style="text-align: justify">Unsecured convertible debentures</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Concurrent with the Public
Offering described in note 14, on February 21, 2017, the Corporation issued $2,000 aggregate principal amount of unsecured convertible
debentures maturing February 21, 2020 and contingent warrants to acquire up to 1,052,630 Common Shares (the &#8220;Private Placement&#8221;).
The principal may be prepaid, in whole or in part, at any time and from time to time, in cash, at the sole discretion of the Corporation<b>.
</b>The debentures are convertible into Common Shares at any time by the holder at a fixed price of $1.90 per Common Share except
if the Corporation pays before the maturity, all or any portion of the convertible debentures. Should the Corporation pay all or
any portion of the convertible debenture before maturity, then warrants become exercisable at $1.90 per Common Share for the equivalent
convertible debenture amount prepaid. The contingent warrants will be exercisable for the remaining term of the convertible debt
for the same price as the conversion options. The unsecured convertible debentures were issued at a discount of 3.5% to the principal
amount, for aggregate gross proceeds of $1,930.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><font style="font-weight: normal">The
convertible debentures provide the Corporation an accelerated conversion right whereby the Corporation may, at any time at least
four months after the date of issuance of the convertible debentures, accelerate the conversion of the debentures to Common Shares
in the event that the volume weighted average price of the Corporation&#8217;s Common Shares on the TSX Venture Exchange is equal
to or exceeds $2.65, subject to customary adjustment provisions, during 20 consecutive trading days. </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The interest to be paid on
the convertible debentures under the terms of the agreement is 8% per annum, payable on a quarterly basis in cash or Common Shares
of the Corporation or a combination thereof, commencing on March 31, 2017. The decision to pay the interest due in cash or shares
is at the discretion of the Corporation and the number of Common Shares to be issued will be calculated at the current market price
as at the close of business on the day before the interest payment is to be made. Payment in shares shall be at a floor price of
$0.10 per share, with the difference between the amount payable and the amount computed at floor price payable in cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The proceeds of the Private
Placement were split between the liability and the equity at the time of issuance of the Private Placement. Both the conversion
option and contingent warrants are considered the equity component of the Private Placement. The fair value of the liability component
was determined through a discounted cash flow analysis using a discount rate of 20% that was set based on a similar debt and maturity
considering the Corporation&#8217;s credit risk excluding the conversion option and contingent warrants. The amount allocated to
the equity component is the residual amount after deducting the fair value of the financial liability component from the fair value
of the entire compound instrument. Subsequent to initial recognition, the liability is measured at amortized cost calculated using
the effective interest rate method and will accrete up to the principal balance at maturity. The interest accretion is presented
as a financial expense. The equity component is not re-measured. Transaction costs were allocated to the components in proportion
to their initial carrying amounts. The portion allocated to the liability was recognized as a reduction of the debt whereas the
portion allocated to other equity was recognized as a reduction to other equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 24; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">13.</td><td style="width: 5pt"></td><td style="text-align: justify">Unsecured convertible debentures (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The split between the liability
and equity component portions of the Private Placement are summarized below:</p>


<p style="margin: 0">&nbsp;</p>


<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid; vertical-align: top">Liability component</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid; vertical-align: top">Equity component</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">Total Private <br>
Placement</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 55%; font-weight: normal; border-bottom: Black 1pt solid">Balance at March 31, 2017</td><td style="width: 1%; font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; border-bottom: Black 1pt solid; font-weight: normal; text-align: right">1,406</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; border-bottom: Black 1pt solid; font-weight: normal; text-align: right">309</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; border-bottom: Black 1pt solid; font-weight: normal; text-align: right">1,715</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">Effective interest for the twelve-month period</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">366</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">366</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Interest payable during the period</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(160</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(160</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal">Balance at March 31, 2018</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">1,612</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">309</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">1,921</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">Effective interest during the period</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">365</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">365</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Interest payable during the period</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(160</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(160</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; border-bottom: Black 1.5pt solid">Balance at March 31, 2019</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; text-align: right; border-bottom: Black 1.5pt solid">1,817</td><td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; text-align: right; border-bottom: Black 1.5pt solid">309</td><td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; text-align: right; border-bottom: Black 1.5pt solid">2,126</td><td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td></tr>
</table></div>



<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>


<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">14.</td><td style="width: 5pt"></td><td style="text-align: justify">Capital and other components of equity</td>
</tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(a)</td><td style="width: 5pt"></td><td style="text-align: justify">Share capital:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Authorized capital stock:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Unlimited number of shares:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 30pt"></td><td style="width: 20pt"><font style="font-family: Wingdings">&#216;</font></td><td style="text-align: justify; padding-right: 5.9pt">Class A shares (Common Shares), voting (one vote per share), participating
and without par value</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 30pt"></td><td style="width: 20pt"><font style="font-family: Wingdings">&#216;</font></td><td style="text-align: justify; padding-right: 5.9pt">Class B shares, voting (ten votes per share), non-participating, without
par value and maximum annual non-cumulative dividend of 5% on the amount paid for said shares. Class B shares are convertible,
at the holder&#8217;s discretion, into Class A shares (Common Shares), on a one-for-one basis, and Class B shares are redeemable
at the holder&#8217;s discretion for $0.80 per share, subject to certain conditions. There are non issued and outstanding.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 30pt"></td><td style="width: 20pt"><font style="font-family: Wingdings">&#216;</font></td><td style="text-align: justify; padding-right: 5.9pt">Class C shares, non-voting, non-participating, without par value and maximum
annual non-cumulative dividend of 5% on the amount paid for said shares. Class C shares are convertible, at the holder&#8217;s
discretion, into Class A shares (Common Shares), on a one-for-one basis, and Class C shares are redeemable at the holder&#8217;s
discretion for $0.20 per share, subject to certain conditions. There are non issued and outstanding.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 30pt"></td><td style="width: 20pt"><font style="font-family: Wingdings">&#216;</font></td><td style="text-align: justify; padding-right: 5.9pt">Class D and E shares, non-voting, non-participating, without par value and
maximum monthly non-cumulative dividend between 0.5% and 2% on the amount paid for said shares. Class D and E shares are convertible,
at the holder&#8217;s discretion, into Class A shares (Common Shares), on a one-for-one basis, and Class D and E shares are redeemable
at the holder&#8217;s discretion, subject to certain conditions. There are non issued and outstanding.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(b)</td><td style="width: 5pt"></td><td style="text-align: justify">&#8220;At-the-market&#8221; (&#8220;ATM&#8221;) sales agreement</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On February 14, 2019, the Corporation
entered into an &ldquo;at-the-market&rdquo; (&ldquo;ATM&rdquo;) sales agreement with an underwriter B. Riley FBR, Inc. (B. Riley),
pursuant to which the Corporation&rsquo;s common shares may be sold from time to time for aggregate gross proceeds of up to US
$30 million, with sales only being made on the NASDAQ Stock Market. The common shares would be issued at market prices prevailing
at the time of the sale and, as a result, prices may vary between purchasers and during the period of distribution. The ATM provides
the Company with a flexible alternative for raising additional capital. The ATM has a 3 year term, and requires the company to
pay a 3% fee to B. Riley when any sales are made. As at March 31, 2019, no securities have been issued in relation to the ATM.
Costs incurred in connection to the ATM of $179 have been recorded as deferred financing costs.</P>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(c)</td><td style="width: 5pt"></td><td style="text-align: justify">Public Offerings &#8211; October 2018:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On October 9, 2018, the Corporation
closed a U.S. public offering of 16,600,000 Common Shares at a price of US$1.00 per share. In addition, the underwriters fully
exercised their over-allotment option to purchase 2,490,000 additional Common Shares at the same public offering price. This offering
generated gross proceeds of $24.7 million (US$19.1 million), which resulted in net proceeds to the Corporation of $22.6 million
(US$17.4 million) and a total of 19,090,000 Common Shares issued.</p>
<!-- Field: Page; Sequence: 25; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">14.</td><td style="width: 5pt"></td><td style="text-align: justify">Capital and other components of equity (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On October 23, 2018, the Corporation
closed a Canadian public offering of 18,750,000 Common Shares at a price of $1.28 per share. In addition, the underwriters fully
exercised their over-allotment option to purchase 2,812,500 additional Common Shares at the same public offering price. This offering
generated gross proceeds of $27.6 million, which resulted in net proceeds to the Corporation of approximately $25.4 million and
a total of 21,562,500 Common Shares issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(d)</td><td style="width: 5pt"></td><td style="text-align: justify">Public Offering &#8211; May 2018:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On May 9, 2018 the Corporation
closed a Canadian public offering issuing 9,530,000 units of Acasti (&#8220;Units&#8221;) at a price of $1.05 per Unit for gross
proceeds of $10 million. The units issued consist of 9,530,000 Common Shares and 9,530,000 Warrants. Each Warrant entitles the
holder thereof to acquire one Common Share of the Corporation at an exercise price of $1.31 at any time until May 9, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On May 14, 2018, the underwriters
exercised their over-allotment option by purchasing an additional 1,429,500 units at a price of $1.05 per Unit, for additional
gross proceeds of $1.5 million. The units issued consist of 1,429,500 Common Shares and 1,429,500 warrants. Each Warrant entitles
the holder thereof to acquire one Common Share of the Corporation at an exercise price of $1.31 at any time until May 9, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The warrant component of these
Units are Derivative Warrant Liabilities for accounting purposes due to the warrant agreement, which contains certain contingent
provisions that allow for cash settlement (note 12). The proceeds of the offering are required to be split between the Derivative
Warrant Liabilities and the equity-classified Common shares at the time of issuance of the Units. The fair value of the Derivative
Warrant Liabilities at the time of issuance was determined to be $4.3 million and the residual of the proceeds of $6.2 million
were allocated to the Common Shares. Issuance costs related to this transaction totaled approximately $1.8 million and have been
allocated between the Derivative Warrant Liabilities and Common shares based on relative value. Resulting from this allocation,
$0.7 million has been allocated to the Derivative Warrant Liability and is recognized in finance costs in the Statements of Earnings
and Comprehensive Loss, whereas the remaining portion of $1.1 million in issuance costs was allocated to the Common Shares and
recognized as a reduction to share capital, in the Statements of Financial Position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The fair value of the public
offering warrants at issuance was estimated using to the Black-Scholes option pricing model and was based on the following weighted
average assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">May 2018</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-weight: normal">Exercise price</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">$</td><td style="width: 12%; font-weight: normal; text-align: right">1.31</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal">Share price</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">$</td><td style="font-weight: normal; text-align: right">0.82</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">Risk-free interest</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">2.21</td><td style="white-space: nowrap; font-weight: normal; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">Estimated life (in years)</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">5</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">87.40</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The weighted average fair value
of the public offering warrants issued in May 2018 was determined to be $0.39 per warrant. Changes in the subsequent measurement
of fair value of the Warrants are recognized in financial expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As part of the transaction,
the Corporation also issued broker warrants to purchase up to 547,975 Common Shares. Each broker warrant entitles the holder thereof
to acquire one Common Share of the Corporation at an exercise price of $1.05, at any time until May 9, 2023. The broker warrants
are considered to be compensation to non-employees under IFRS 2, as stock-based compensation, and are thus accounted for at fair
value at issuance date and not subsequently revalued. To determine the fair value of these broker warrants, a Black-Scholes options
pricing model was used based on the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">May 2018</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-weight: normal">Exercise price</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">$</td><td style="width: 12%; font-weight: normal; text-align: right">1.05</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal">Share price</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">$</td><td style="font-weight: normal; text-align: right">0.81</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">Risk-free interest</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">2.20</td><td style="white-space: nowrap; font-weight: normal; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">Estimated life (in years)</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">5</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">87.40</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The total value associated
with the broker warrants amounted to $283 and was recorded in contributed surplus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<!-- Field: Page; Sequence: 26; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">14.</td><td style="width: 5pt"></td><td style="text-align: justify">Capital and Other Components of Equity (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(e)</td><td style="width: 5pt"></td><td style="text-align: justify">Public offering &#8211; December 27, 2017</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On December 27, 2017, the Corporation
closed a U.S. public offering issuing 9,900,990 units of Acasti at a price of US$1.01 per Unit for gross proceeds of $12.6 million
(US$10 million). The units issued consist of 9,900,990 Common Shares and 8,910,891 warrants with the right to purchase one Common
Share of Acasti. As part of this closing, the underwriters&#8217; also partially exercised for nil consideration the over-allotment
option for warrants, which were issued for a right to purchase 892,044 Common Shares at an exercise price of US$1.26.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Warrants forming part of
the Units are Derivative Warrant Liabilities for accounting purposes due to the currency of the exercise price being different
from the Corporation&#8217;s functional currency. The proceeds of the offering are required to be split between the Derivative
Warrant Liabilities and the equity-classified Common Share at the time of issuance of the Units. The fair value of the Derivative
Warrant Liabilities at the time of issuance was determined to be $5.9 million and the residual of the proceeds was allocated to
the Common Shares. Total issuance costs related to this transaction totaled approximately $2.5 million. The issuance costs have
been allocated between the Warrants and Common Shares based on relative value. The portion allocated to the Warrants was recognized
in finance costs in the Statements of Earnings and Comprehensive Loss, whereas the portion allocated to Common Shares was recognized
as a reduction to share capital, in the Statements of Financial Position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The fair value of the public
offering Warrants at issuance was estimated according to the Black-Scholes option pricing model and based on the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">December 27, <br>2017</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal">Exercise price</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.26</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal">Share price</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">US $0.97</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-weight: normal; text-align: left">Risk-free interest</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">2.22</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">Estimated life (in years)</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">5</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">93.52</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The fair value of the public
offering Warrants issued was determined to be $0.60 per warrant as at December 27, 2017. Changes in the fair value of the Warrants
are recognized in finance income or expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As part of the transaction,
the Corporation also issued broker warrants to purchase up to 495,050 Common Shares. Each broker warrant entitles the holder thereof
to acquire one Common Share of the Corporation at an exercise price of US$1.2625, at any time until December 27, 2022. The broker
warrants are considered for compensation to non-employees under IFRS 2, stock-based compensation, and are accounted for at fair
value. To determine the fair value of the Broker Warrants, a Black-Scholes option pricing model was used based on the following
assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">December 27, <br>2017</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal">Exercise price</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.2625</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal">Share price</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">US $0.97</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-weight: normal; text-align: left">Risk-free interest</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">2.22</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">Estimated life (in years)</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">5</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">93.52</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The total cost associated with
the Broker Warrants amounted to $406 and was recorded in contributed surplus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 27; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">14.</td><td style="width: 5pt"></td><td style="text-align: justify">Capital and Other Components of Equity (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(f)</td><td style="width: 5pt"></td><td style="text-align: justify">Public offering - February 21, 2017:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Concurrent with the private
placement described in Note 12, on February 21, 2017, the Corporation closed a public offering (&#8220;Public Offering&#8221;)
issuing 3,930,518 units of Acasti (&#8220;Units&#8221;) at a price of $1.45 per Unit for gross proceeds of $5,699. Each Unit consists
of one class A share (Common Share) and one half of one class A or common share purchase warrant. Each whole warrant entitles the
holder thereof to purchase one common share at an exercise price of $2.15 per common share, at any time until February 21, 2022.
The Units issued as part of the public offering are considered equity instruments. The transaction costs associated with the Public
Offering amounted to $1,190. The proceeds and transaction costs were allocated to share capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As part of the transaction,
the Corporation also issued broker warrants (the &#8220;Broker Warrants&#8221;) to purchase up to 234,992 Common Shares. Each Broker
Warrant entitles the holder thereof to acquire one Common Share of the Corporation at an exercise price of $2.15 per common share,
at any time until February 21, 2018. The broker warrants are considered for compensation to non-employees under IFRS 2, stock-based
compensation, and are accounted for at fair value through contributed surplus. To determine the fair value of the Broker Warrants,
the Black-Scholes pricing model was used. The total costs associated with the Broker Warrants amounted to $144 and were allocated
to share capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The warrants issued as part
of the Units of the Public Offering and the broker warrants include an &#8220;Acceleration Right&#8221;, related to the Corporation&#8217;s
right to accelerate the expiry date of the warrants. The Acceleration Right clause means the right of the Corporation to accelerate
the expiry date to a date that is not less than 30 days following delivery of the acceleration notice if, at any time at least
four months after the effective date, the volume weighted average trading price of the common shares equals or exceeds $2.65 for
a period of 20 consecutive trading days on the TSXV.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Furthermore, as part of the
February 2017 Public Offering and convertible debt transactions, a total of 60,000 Common Shares were issued as equity settled
share-based payments for services received from an employee of the previous parent at a price of $1.57 per share for a total cost
of $94. The equity settled share-based payment costs have been allocated to share capital for a cost that amounted to $85 and to
debt for a cost that amounted to $9 based on relative value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The value of the broker warrants
was estimated using a Black-Scholes option pricing model and based on the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">February 21, 2017</td><td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 85%; font-weight: normal">Exercise price</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">$</td><td style="width: 12%; font-weight: normal; text-align: right">2.15</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal">Share price</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">$</td><td style="font-weight: normal; text-align: right">1.70</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal">Dividend</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">Risk-free interest</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">0.79</td><td style="white-space: nowrap; font-weight: normal; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">Estimated life (in years)</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">1.00</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">112.09</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The total cost associated with
the Broker Warrants amounted to $144 and was recorded as contributed surplus.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(g)</td><td style="width: 5pt"></td><td style="text-align: justify">Issuance of shares:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The following table summarizes
the shares issued to settle the payment of accrued interest on the unsecured convertible debentures with the corresponding amount
recorded to share capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; color: #00528C"><font style="font-style: normal">&nbsp;</font></p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"><font style="font-weight: normal">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"><font style="font-weight: normal">Accrued interest as at</font></p></td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"><font style="font-weight: normal">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"><font style="font-weight: normal">Share issuance date</font></p></td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-weight: normal">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-weight: normal">Number of shares</font></p></td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-weight: normal">Amount </font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-weight: normal">$</font></p></td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; font-weight: normal">March 31, 2017</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 35%; font-weight: normal">April 7, 2017</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">9,496</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">17</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal">June 30, 2017</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal">August 15, 2017</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">23,885</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">40</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal">September 30, 2017</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal">December 27, 2017</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">22,783</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">40</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal">December 31, 2017</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal">March 27, 2018</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">33,605</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">40</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal">March 31, 2018</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal">June 6, 2018</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">30,348</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">40</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal">June 30, 2018</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal">August 21, 2018</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">51,807</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">40</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; border-bottom: Black 1pt solid">September 30, 2018</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="font-weight: normal; border-bottom: Black 1pt solid">October 31, 2018</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">23,723</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">40</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">195,647</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">257</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
</table></div>
<!-- Field: Page; Sequence: 28; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">14.</td><td style="width: 5pt"></td><td style="text-align: justify">Capital and other components of equity (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(h)</td><td style="width: 5pt"></td><td style="text-align: justify">Warrants:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The warrants of the Corporation
are composed of the following as at March 31, 2019, March 31, 2018, March 31, 2017 and February 28, 2017:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1.5pt solid"><font style="font-size: 9pt">March
    31, 2019</font></td><td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1.5pt solid"><font style="font-size: 9pt">March
    31, 2018</font></td><td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1.5pt solid"><font style="font-size: 9pt">March
    31, 2017</font></td><td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-size: 9pt; font-weight: normal">February
                                         28, 2017</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-size: 9pt; font-weight: normal">(Unaudited)</font></p></td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">Number
    <br> outstanding</font></td><td style="border-bottom: Black 1pt solid; font-weight: normal"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-size: 9pt; font-weight: normal">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-size: 9pt; font-weight: normal">Amount</font></p></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">Number
    <br> outstanding</font></td><td style="border-bottom: Black 1pt solid; font-weight: normal"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-size: 9pt; font-weight: normal">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-size: 9pt; font-weight: normal">Amount</font></p></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">Number
    <br> outstanding</font></td><td style="border-bottom: Black 1pt solid; font-weight: normal"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-size: 9pt; font-weight: normal">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-size: 9pt; font-weight: normal">Amount</font></p></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">Number
    <br> outstanding</font></td><td style="border-bottom: Black 1pt solid; font-weight: normal"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-size: 9pt; font-weight: normal">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-size: 9pt; font-weight: normal">Amount</font></p></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">$</font></td><td style="border-bottom: Black 1pt solid; font-weight: normal"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">$</font></td><td style="border-bottom: Black 1pt solid; font-weight: normal"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">$</font></td><td style="border-bottom: Black 1pt solid; font-weight: normal"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">$</font></td><td style="border-bottom: Black 1pt solid; font-weight: normal"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"><font style="font-size: 9pt">Liability</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 28%; font-weight: normal; font-style: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-size: 9pt">May
    2018 Public offering Warrants 2018 (i)</font></td><td style="width: 1%; font-weight: normal; font-style: normal"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="width: 6%; font-weight: normal; font-style: normal; text-align: right"><font style="font-size: 9pt">10,188,100</font></td><td style="white-space: nowrap; width: 1%; font-weight: normal; font-style: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="width: 1%; font-weight: normal; font-style: normal"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="width: 6%; font-weight: normal; font-style: normal; text-align: right"><font style="font-size: 9pt">8,246</font></td><td style="white-space: nowrap; width: 1%; font-weight: normal; font-style: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="width: 1%; font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="width: 6%; font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="width: 1%; font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="width: 6%; font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="width: 1%; font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="width: 6%; font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="width: 1%; font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="width: 6%; font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="width: 1%; font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="width: 6%; font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="width: 1%; font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="width: 6%; font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-size: 9pt">Series
    December 2017 US Public offering Warrants 2017 (ii)</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">9,801,861</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">8,017</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">9,802,935</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">6,405</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; font-style: normal; text-align: left; text-indent: -10pt; padding-left: 10pt; border-bottom: Black 1pt solid"><font style="font-size: 9pt">Series
    8 Public offering Warrants December 2013 (iii)</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">18,400,000</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">21</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">18,400,000</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">209</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">18,400,000</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><font style="font-size: 9pt">187</font></td><td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-indent: -10pt; padding-left: 10pt"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">19,989,961</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">16,263</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">28,202,935</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">6,426</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">18,400,000</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">209</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">18,400,000</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">187</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"><font style="font-size: 9pt">Equity</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-size: 9pt">Public
    offering warrants</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-size: 9pt">Public
    offering broker warrants May 2018 (iv)</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">547,975</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">283</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-size: 9pt">Public
    offering U.S. broker warrants December 2017 (v)</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">495,050</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">406</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">495,050</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">406</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-size: 9pt">Public
    offering warrants February 2017 (vi)</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">1,904,034</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">1,904,034</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">1,965,259</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">1,965,259</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-size: 9pt">Private
    Placement- contingent warrants</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; text-align: right"><font style="font-size: 9pt">&nbsp;</font></td><td style="white-space: nowrap; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-size: 9pt">2017
    unsecured convertible debenture conversion option and contingent warrants (vii)</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">1,052,630</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">309</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">1,052,630</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">309</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">1,052,630</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">309</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">1,052,630</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">309</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><font style="font-size: 9pt">Series
    9 Private Placement warrants 2013 (viii)</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">161,654</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">161,654</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">161,654</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; text-indent: -10pt; padding-left: 10pt"><font style="font-size: 9pt">Series
    2017 BW Broker warrants (ix)</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: bold; border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><font style="font-size: 9pt">-</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 9pt">234,992</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 9pt">144</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 9pt">234,992</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1pt solid; text-align: right"><font style="font-size: 9pt">144</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-indent: -10pt; padding-left: 10pt"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">3,999,689</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">998</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">3,613,368</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">715</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">3,414,535</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">453</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">3,414,535</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="font-weight: normal; border-bottom: Black 1.5pt solid"><font style="font-size: 9pt">&nbsp;</font></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><font style="font-size: 9pt">453</font></td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><font style="font-size: 9pt">&nbsp;</font></td></tr>
</table></div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 25pt"><font style="font-size: 8pt">(i)</font></td><td style="text-align: justify"><font style="font-size: 8pt">Warrant
                                         to acquire one Common Share of the Corporation at an exercise price of $1.31, expiring
                                         on May 9, 2023.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 25pt"><font style="font-size: 8pt">(ii)</font></td><td style="text-align: justify"><font style="font-size: 8pt">Warrant
                                         to acquire one Common Share of the Corporation at an exercise price of US$1.26, expiring
                                         on December 27, 2022.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 25pt"><font style="font-size: 8pt">(iii)</font></td><td style="text-align: justify"><font style="font-size: 8pt">In
                                         order to obtain one Common Share of the Corporation at an exercise price of US$15.00,
                                         10 warrants must be exercised. Warrants expired on December&nbsp;3, 2018.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 25pt"><font style="font-size: 8pt">(iv)</font></td><td style="text-align: justify"><font style="font-size: 8pt">Warrant
                                         to acquire one Common Share of the Corporation at an exercise price of $1.05, expiring
                                         on May 9, 2023.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 25pt"><font style="font-size: 8pt">(v)</font></td><td style="text-align: justify"><font style="font-size: 8pt">Warrant
                                         to acquire one Common Share of the Corporation at an exercise price of US$1.2625, expiring
                                         on December 27, 2022.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 25pt"><font style="font-size: 8pt">(vi)</font></td><td style="text-align: justify"><font style="font-size: 8pt">Warrant
                                         to acquire one Common Share of the Corporation at an exercise price of $2.15, expiring
                                         on February 21, 2022.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 25pt"><font style="font-size: 8pt">(vii)</font></td><td style="text-align: justify"><font style="font-size: 8pt">Warrant
                                         to acquire one Common Share of the Corporation at an exercise price of $1.90 expiring
                                         on February 21, 2020, net of deferred tax expense of $129. Exercisable only for any portion
                                         of or all debentures paid by the Corporation prior to maturity.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 25pt"><font style="font-size: 8pt">(viii)</font></td><td style="text-align: justify"><font style="font-size: 8pt">Warrant
                                         to acquire one Common Share of the Corporation at an exercise price of $13.30, expired
                                         on December 3, 2018.</font></td></tr></table>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 25pt"><font style="font-size: 8pt">(ix)</font></td><td style="text-align: justify"><font style="font-size: 8pt">Warrant
                                         to acquire one Common Share of the Corporation at an exercise price of 2.15 expiring
                                         on February 21, 2018. 117,496 warrants amounted to $71 were exercised in November 2017
                                         and 117,496 warrants expired on February 21, 2018</font></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-align: justify">&nbsp;</p>

<!-- Field: Page; Sequence: 29; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">14.</td><td style="width: 5pt"></td><td style="text-align: justify">Capital and other components of equity (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(h)</td><td style="width: 5pt"></td><td style="text-align: justify">Warrants (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Warrants exercise:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">During the year 771,400 warrants
offered as part of the May 2018 public offering were exercised at an exercise price of $1.31 per Common Share of the Company, resulting
in $1.0 million of cash proceeds. In addition, 4,455 warrants offered as part of the December 2017 U.S. public offering were exercised
in a cashless manner to acquire 1,074 Common Shares of the Company.&nbsp; A total of 772,474 Common Shares were issued as a result
of 775,855 warrants being exercised. During the year ended December 31, 2017, 178,721 warrants offered as part of the February
2017 public offering were exercised at an exercise price of $2.15 per Common Share of the Company, resulting in $384 of cash proceeds.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">15.</td><td style="width: 5pt"></td><td style="text-align: justify">Personnel expenses:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>




<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br>
months ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-month <br>period ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">March 31, <br>2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">March 31, <br>2018</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">March 31, <br>2017</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2017 <br>(Unaudited)</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">February 28, <br>
2017 <br>(Unaudited)</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Salaries and other short-term employee benefits</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">4,144</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">3,281</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">2,491</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">214</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">2,277</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid">Share-based compensation costs</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,041</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">929</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">674</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">86</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">588</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Total personnel expenses</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,185</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,210</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,165</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">300</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,865</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0; text-align: justify">&nbsp;</p></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">16.</td><td style="width: 5pt"></td><td style="text-align: justify">Financial expenses:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0.5in; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br>
months ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-month <br>period ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">March 31, <br>2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">March 31, <br>2018</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">March 31, <br>2017</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2017 <br>(Unaudited)</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">February 28, <br>
2017 <br>(Unaudited)</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Interest income</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">475</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">72</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">125</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">6</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">119</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Foreign exchange gain (loss)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">279</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(32</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(180</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(3</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(177</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest payable on convertible debenture</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(160</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(160</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(17</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(14</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(3</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accretion of interest on convertible debenture</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(205</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(206</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(22</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(17</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(5</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Transaction costs related to derivative warrant liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(653</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(1,134</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of warrant liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(6,287</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(344</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(53</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(22</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(31</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid">Other charges</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(19</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(18</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Financial expenses</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,551</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,808</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(166</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(115</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td></tr>
</table></div>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase">&nbsp;</p></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="text-transform: uppercase"><b>&nbsp;</b></font></p>

<!-- Field: Page; Sequence: 30; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="text-transform: uppercase"><b></b></font></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">17.</td><td style="width: 5pt"></td><td style="text-align: justify">Share-based payments:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">At March 31, 2019, the Corporation
has the following share-based payment arrangement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(a)</td><td style="width: 5pt"></td><td style="text-align: justify">Corporation stock option plan:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Corporation has in place
a stock option plan for directors, officers, employees and consultants of the Corporation (&#8220;Stock Option Plan&#8221;). An
amendment of the Plan was approved by shareholders on August 28, 2018. The amendment provides for an increase to the existing limits
for Common Shares reserved for issuance under the Stock Option Plan as well as certain changes to the minimum vesting period applicable
to options granted to directors and employees under the Stock Option Plan. The plan continues to provide for the granting of options
to purchase Common Shares. The exercise price of the stock options granted under this amended plan is not lower than the closing
price of the shares listed on the TSXV at the close of markets the day preceding the grant. The maximum number of Common Shares
that may be issued upon exercise of options granted under the amended Stock Option Plan was increased from 2,940,511, representing
20% of the issued and outstanding Common Shares of the Company as of March 31, 2017, to 5,494,209 representing 15% of the issued
and outstanding Common Shares of the Company as of June 27, 2018. The terms and conditions for acquiring and exercising options
are set by the Corporation&#8217;s Board of Directors, subject among others, to the following limitations: the term of the options
cannot exceed ten years and (i) all options granted to a director will be vested evenly on a quarterly basis over a period of at
least eighteen (18) months, and (ii) all options granted to an employee will be vested evenly on a quarterly basis over a period
of at least thirty-six (36) months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The total number of shares issued
to any one consultant within any twelve-month period cannot exceed 2% of the Corporation&#8217;s total issued and outstanding shares
(on a non-diluted basis). The Corporation is not authorized to grant within any twelve-month period such number of options under
the stock option plan that could result in a number of Common Shares issuable pursuant to options granted to (a) related persons
exceeding 2% of the Corporation&#8217;s issued and outstanding Common Shares (on a non-diluted basis) on the date an option is
granted, or (b) any one eligible person in a twelve-month period exceeding 2% of the Corporation&#8217;s issued and outstanding
Common Shares (on a non-diluted basis) on the date an option is granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The following tables summarize
information about activities within the stock option plan:</p>





<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, 2019</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, 2018</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">Weighted average <br>
exercise price</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">Number of <br>
options</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">Weighted average <br>
exercise price</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">Number of <br>
options</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: left">Outstanding at beginning of year</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">1.81</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">2,284,388</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">2.58</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">1,424,788</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">0.77</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,173,523</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.75</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,121,500</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercised</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">0.77</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(4,167</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Forfeited</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.84</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(407,067</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.89</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(199,800</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid">Expired</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">18.06</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(62,100</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Outstanding at end of year</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.25</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,046,677</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.81</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,284,388</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Exercisable at end of year</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.56</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,613,200</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.92</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">591,113</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></p>




<p style="margin: 0">&nbsp;</p>





<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-month period <br>
ended <br>
<font style="font-family: Times New Roman, Times, Serif">March 31, 2017</font></td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended <br>
March 31, 2017</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-month period <br>
ended <br>
February 28, 2017</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Weighted <br>
average <br>
exercise price</td><td style="text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Number <br>
of options</td><td style="text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Weighted <br>
average <br>
exercise price</td><td style="text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Number <br>
of options</td><td style="text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Weighted <br>
average <br>
exercise price</td><td style="text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Number <br>
of options</td><td style="text-align: right; vertical-align: top">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%">Outstanding at beginning of period</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">13.52</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">454,151</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">2.59</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">1,427,288</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">13.52</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%; text-align: right">454,151</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.69</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,300,400</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.69</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,300,400</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Forfeited</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">13.27</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(190,138</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">11.50</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(2,500</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">13.29</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(187,638</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid">Expired</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">15.38</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(139,625</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">15.38</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(139,625</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid">Outstanding at end of period</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.58</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,424,788</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.58</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,424,788</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.59</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,427,288</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1.5pt solid">Exercisable at end of period</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.44</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">238,482</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.44</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">238,482</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6.49</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">240,982</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="margin: 0">&nbsp;</p><p style="margin: 0"></p>



<!-- Field: Page; Sequence: 31; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">17.</td><td style="width: 5pt"></td><td style="text-align: justify">Share-based payments (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(a)</td><td style="width: 5pt"></td><td style="text-align: justify">Corporation stock option plan (continued):</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>



<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-month <br>
period ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-month <br>Period ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br>
2019</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br>
2018</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br>
2017</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">February 28, 2017 <br>(Unaudited)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; text-align: left; border-bottom: Black 1.5pt solid; text-indent: -6.75pt; padding-left: 6.75pt">Weighted average fair value of the options granted to employees and directors of the Corporation</td><td style="width: 1%; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">0.51</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="width: 1%; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">1.22</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="width: 1%; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">1.40</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="width: 1%; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">1.40</td><td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">There were no options granted
during the month ended March 31, 2017 and no options granted to consultants during the thirteen-month period ended March&nbsp;31,&nbsp;2017.
4,167 options were exercised during the period ended March 31, 2019 (nil for period ended March 31, 2018 and nil for the thirteen-month
period ended March 31, 2017). Stock-based compensation recognized under this plan for the period ended March 31, 2019 was $1,041
(March 31, 2018 amounted to $929, thirteen-month and one-month periods ended March 31, 2017 amounted to $674 and $86 (unaudited),
respectively and amounted to $588 (unaudited) for the twelve-month period ended February 28, 2017).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The fair value of options granted
was estimated using the Black-Scholes option pricing model, resulting in the following weighted average assumptions for options
granted during the periods ended:</p>



<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-month <br>
period ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-month <br>Period ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, 2019</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, 2018</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, 2017</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">February 28, 2017 <br>(Unaudited)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%">Exercise price</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.77</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1.75</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1.69</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1.69</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>Share price</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.73</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.75</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.69</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.69</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Dividend</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2.10</td><td style="white-space: nowrap; text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.21</td><td style="white-space: nowrap; text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">0.87</td><td style="white-space: nowrap; text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">0.87</td><td style="white-space: nowrap; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Estimated life (in years)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">5.78</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">5.89</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">4.94</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif">4.94</font></td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid">Expected volatility</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">85.35</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">82.4</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">123.5</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">123.5</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The expected life of the stock
options is based on historical data and current expectation and is not necessarily indicative of exercise patterns that may occur.
The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the options
is indicative of future trends, which may also not necessarily be the actual outcome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: -17.85pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The following tables summarize
the status of the outstanding and exercisable options of the Corporation:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="14" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2019</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">Options outstanding</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">Exercisable options</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="white-space: nowrap; border-bottom: Black 1pt solid">Exercise price</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Weighted remaining <br>
contractual life <br>
outstanding</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Number of options <br>
outstanding</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Weighted average <br>
exercise price <br>$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Number of options <br>
exercisable</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 5%">$0.77</td>
    <td style="width: 2%">-</td>
    <td style="width: 41%">$0.77</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">9.26</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">1,898,523</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.77</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">348,197</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>$0.78</td>
    <td>-</td>
    <td>$1.58</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5.86</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">775,000</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.50</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">518,750</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>$1.59</td>
    <td>-</td>
    <td>$1.71</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7.90</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">273,333</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.65</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">233,333</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>$1.72</td>
    <td>-</td>
    <td>$1.88</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8.21</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">790,833</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.77</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">292,500</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 1pt solid">$1.89</td>
    <td style="border-bottom: Black 1pt solid">-</td>
    <td style="border-bottom: Black 1pt solid">$6.50</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">3.97</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">308,988</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">2.57</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">220,420</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7.91</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,046,677</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.56</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,613,200</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 10.65pt; text-align: justify; text-indent: 0.1in"><i>&nbsp;</i></p>


<!-- Field: Page; Sequence: 32; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 10.65pt; text-align: justify"><i></i></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">17.</td><td style="width: 5pt"></td><td style="text-align: justify">Share-based payments (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(a)</td><td style="width: 5pt"></td><td style="text-align: justify">Corporation stock option plan (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><i>Share-based
payment transactions and broker warrants:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The fair value of share-based
payment transaction is measured using the Black-Scholes option pricing model. Measurement inputs include share price on measurement
date, exercise price of the instrument, expected volatility (based on weighted average historic volatility), weighted average expected
life of the instruments (based on historical experience and general option holder behaviour unless no entity-specific information
exists in which case the average of the vesting and contractual periods is used), and the risk-free interest rate (based on government
bonds). Service and non-market performance conditions attached to the transactions, if any, are not taken into account in determining
fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(b)</td><td style="width: 5pt"></td><td style="text-align: justify">Corporation equity incentive plan:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation established
an equity incentive plan for employees, directors and consultants. The plan provides for the issuance of restricted share units
(&#8220;RSU&#8221;), performance share units, restricted shares, deferred share units and other share-based awards, subject to
restricted conditions as may be determined by the Board of Directors. There are no such awards outstanding as of March 31, 2019
and March 31, 2018, and no stock-based compensation was recognized for the period ended March 31, 2019 and March 31, 2018 (nil
for the one-month and thirteen-month periods ended March 31,&nbsp;2017).</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">18.</td><td style="width: 5pt"></td><td style="text-align: justify">Loss per share:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Diluted loss per share
was the same amount as basic loss per share, as the effect of options, RSUs and warrants would have been anti-dilutive, because
the Corporation incurred losses in each of the periods presented. All outstanding options, RSUs and warrants could potentially
be dilutive in the future.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">19.</td><td style="width: 5pt"></td><td style="text-align: justify">Supplemental cash flow disclosure:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(a)</td><td style="width: 5pt"></td><td style="text-align: justify">Changes in working capital items:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br>
months ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br>ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, <br>2019</td><td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, <br>2018</td><td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, <br>2017</td><td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, <br>2017 <br>(Unaudited)</td><td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">February 28, <br>
2017 <br>(Unaudited)</td><td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%">Receivables</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(738</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(553</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">193</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(40</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">233</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(709</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(103</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">247</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(33</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">280</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other Assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">37</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(659</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred financing costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(179</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid">Trade and other payables</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,679</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,898</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">352</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(255</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">607</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Total changes in working capital items</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,090</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,583</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">792</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(328</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,120</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>


<!-- Field: Page; Sequence: 33; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">19.</td><td style="width: 5pt"></td><td style="text-align: justify">Supplemental cash flow disclosure (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(b)</td><td style="width: 5pt"></td><td style="text-align: justify">Non-cash transactions:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-months <br>ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br>
ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2019</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2018</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2017</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">March 31, <br>2017 <br>(Unaudited)</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">February 28, 2017 <br>(Unaudited)</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left; padding-left: 10pt; text-indent: -10pt">Issuance of shares for interest on convertible debt</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">120</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">137</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">94</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">94</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Issuance of broker warrants included in net proceeds
    from public offering</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">283</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">406</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">144</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">144</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Public offering transaction costs included in trade and other payables</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">132</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">381</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">381</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">416</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Interest receivable included in receivables</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">96</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Reduction in share issue costs from reduction in trade and other payables</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">109</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">109</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Private Placement transaction costs included in trade and other payables</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">40</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">40</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">50</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Equipment included in trade and other payables</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">12</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">216</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">288</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">288</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">269</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">Interest payable
    included in trade and other payables</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="margin: 0">&nbsp;</p></div><p style="margin: 0"></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 35.85pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p>

<!-- Field: Page; Sequence: 34; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">20.</td><td style="width: 5pt"></td><td style="text-align: justify">Income taxes:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Deferred tax (recovery) expense:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0.4in; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-months <br>ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month <br>ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right; border-top: Black 1.5pt solid">Twelve-months <br>ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">March 31, <br>2019</td><td style="text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">March 31, <br>2018</td><td style="text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">March 31, <br>2017</td><td style="text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">March 31, <br>2017 <br>(Unaudited)</td><td style="text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">February 28, <br>
2017 <br>(Unaudited)</td><td style="text-align: right; vertical-align: top">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left; text-indent: -7.35pt; padding-left: 7.35pt">Origination and reversal of temporary differences</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">11,599</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">5,241</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">2,240</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">163</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">2,077</td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1pt solid; text-indent: -7.35pt; padding-left: 7.35pt">Change in unrecognized deductible temporary differences</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(11,599</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,241</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,369</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(163</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,206</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Deferred tax (recovery) expense</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(129</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(129</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td></tr>
</table></div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.65pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Reconciliation of effective
tax rate:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-months <br>ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month <br>ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right; border-top: Black 1.5pt solid">Twelve-months <br>ended</td><td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">March 31, <br>2019</td><td style="text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">March 31, <br>2018</td><td style="text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">March 31, <br>2017</td><td style="text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">March 31, <br>2017 <br>(Unaudited)</td><td style="text-align: right; vertical-align: top">&nbsp;</td><td style="text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">February 28, <br>
2017 <br>(Unaudited)</td><td style="text-align: right; vertical-align: top">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Loss before income taxes</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(51,566</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(21,504</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(11,376</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(769</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 10%; text-align: right">(10,607</td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic combined Canadian statutory income tax rate <sup>1</sup></p></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">26.68</td><td style="white-space: nowrap; text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">26.78</td><td style="white-space: nowrap; text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">26.87</td><td style="white-space: nowrap; text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">26.80</td><td style="white-space: nowrap; text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">26.88</td><td style="white-space: nowrap; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computed income tax recovery</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(13,758</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(5,759</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(3,057</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(206</td><td style="white-space: nowrap; text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(2,851</td><td style="white-space: nowrap; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Increase resulting from:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -7.15pt; padding-left: 21.55pt">Change in unrecognized deductible temporary differences</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">11,599</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,241</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,369</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">162</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,207</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.2in">Non-deductible stock-based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">279</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">248</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">178</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">23</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">155</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.2in">Non-deductible change in fair value</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,677</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">92</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">14</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">6</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.2in">Permanent differences and other</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">203</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">178</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">166</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">12</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">154</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 0.2in">Change in statutory income tax rate</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">201</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">198</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; border-bottom: Black 1.5pt solid">Total tax (recovery) expense</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(129</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(129</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.65pt; text-align: justify">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt"><sup>1</sup></font>
The Canadian combined statutory income tax rate has decreased due to a reduction in the provincial statutory income tax rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="text-transform: uppercase"><b>&nbsp;</b></font></p>

<!-- Field: Page; Sequence: 35; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="text-transform: uppercase"><b></b></font></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">20.</td><td style="width: 5pt"></td><td style="text-align: justify">Income taxes (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Unrecognized deferred tax assets:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">At March 31, 2019, 2018, and
2017, the net deferred tax assets, which have not been recognized in these financial statements because the criteria for recognition
of these assets were not met, were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-weight: normal">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-weight: normal">March 31, 2019</font></p></td><td style="border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-weight: normal">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-weight: normal">March 31, 2018</font></p></td><td style="border-top: Black 1.5pt solid">&nbsp;</td><td style="border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-weight: normal">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><font style="font-weight: normal">March 31, 2017</font></p></td><td style="border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Deferred tax assets</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 55%; font-weight: normal; text-align: left">Tax losses carried forward</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">23,695</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">12,670</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">8,293</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">Research and development expenses</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">5,362</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">4,927</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">4,220</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">Property, plan and equipment and intangible assets</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">766</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">567</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">435</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">Financing expenses</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">1,852</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">116</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">-</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Other deductible temporary differences</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">378</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">768</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">522</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Deferred tax assets</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">32,053</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">19,048</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">13,470</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&nbsp;Deferred tax liabilities</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Tax basis of unsecured convertible debentures in excess of carrying value</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">13</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">67</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">122</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Deferred tax liabilities</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">13</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">67</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">122</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Net deferred tax assets</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">32,040</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,981</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,348</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.55pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On initial recognition of the
unsecured convertible debenture equity component on February 21, 2017, a deferred tax liability of $129 was recognized with the
corresponding entry recognized directly in Other equity. Consequently, an equal amount of deferred tax asset related to unrecognized
tax losses was recognized with the offsetting entry in the Corporation statement of earnings and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As at March 31, 2019, the amounts
and expiry dates of tax attributes and temporary differences, which are available to reduce future years&#8217; taxable income,
were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2019</td><td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">Federal</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">Provincial</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; border-bottom: Black 1pt solid; padding-left: 0.2in; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">$</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">$</font></td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">Tax losses carried forward</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-weight: normal; text-align: left">2029</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">714</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">714</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">2030</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">1,627</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">1,620</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">2031</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">2,071</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">2,063</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">2032</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">2,262</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">2,241</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">2033</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">1,854</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">1,825</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">2034</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">3,598</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">3,598</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">2035</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">4,595</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">4,459</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">2036</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,494</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,494</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">2037</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8,584</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8,456</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">2038</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">17,340</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">17,270</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">2039</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">41,447</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">41,447</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">89,586</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">89,187</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Research and development expenses, without time limitation</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">19,617</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,036</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left">Other deductible temporary differences, without time limitation</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">30,875</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">32,294</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
</table></div>


<!-- Field: Page; Sequence: 36; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"></p>

</div><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">21.</td><td style="width: 5pt"></td><td style="text-align: justify">Financial instruments:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">This note provides disclosures
relating to the nature and extent of the Corporation&#8217;s exposure to risks arising from financial instruments, including credit
risk, foreign currency risk, interest rate risk and liquidity risk, and how the Corporation manages those risks.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(a)</td><td style="width: 5pt"></td><td style="text-align: justify">Credit risk:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Credit risk is the risk
of a loss if a customer or counterparty to a financial asset fails to meet its contractual obligations. The Corporation has credit
risk relating to cash and cash equivalents and marketable securities, which it manages by dealing only with highly-rated Canadian
institutions. The carrying amount of financial assets, as disclosed in the statements of financial position, represents the Corporation&#8217;s
credit exposure at the reporting date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(b)</td><td style="width: 5pt"></td><td style="text-align: justify">Currency risk:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation is exposed
to the financial risk related to the fluctuation of foreign exchange rates and the degrees of volatility of those rates. Foreign
currency risk is limited to the portion of the Corporation's business transactions denominated in currencies other than the Canadian
dollar. Fluctuations related to foreign exchange rates could cause unforeseen fluctuations in the Corporation's operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">A portion of the expenses,
mainly related to research contracts and purchase of production equipment, is incurred in US dollars and in Euros. There is a financial
risk related to the fluctuation in the value of the US&nbsp;dollar and the Euro in relation to the Canadian dollar. In order to
minimize the financial risk related to the fluctuation in the value of the US dollar in relation to the Canadian dollar, funds
continue to be invested as short-term investments in the US dollar.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The following table provides
an indication of the Corporation&#8217;s significant foreign exchange currency exposures as stated in Canadian dollars at the following
dates:</p>



<p style="margin: 0">&nbsp;</p>


<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2019</td><td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2018</td><td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: normal; border-bottom: Black 1pt solid; text-align: left; vertical-align: top">Denominated in</td><td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">US <br>
$</td><td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">Euro</td><td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">US <br>
$</td><td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">Euro</td><td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-weight: normal; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: normal; text-align: right">3,369</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: normal; text-align: right">7,024</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left">Marketable securities</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">2,696</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">26</td><td style="white-space: nowrap; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal">Receivables</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">16</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">6</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Trade and other payables</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(13,251</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(131</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(3,924</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">(627</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">(7,170</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">)</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">(131</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">)</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">3,132</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">(627</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">)</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 23.4pt; text-indent: -9pt">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The following exchange
rates are those applicable to the following periods and dates:</p>



<p style="margin: 0">&nbsp;</p>


<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">March 31, 2019</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">March 31, 2018</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Average</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Reporting</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Average</td><td style="border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Reporting</td><td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%; font-weight: normal">CA$ per US$</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: normal; text-align: right">1.3122</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: normal; text-align: right">1.3349</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: normal; text-align: right">1.2834</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: normal; text-align: right">1.2900</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; border-bottom: Black 1.5pt solid">CA$ per Euro</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">1.5192</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">1.4975</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">1.5008</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">1.5898</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt">&nbsp;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Based on the Corporation&#8217;s
foreign currency exposures noted above, varying the above foreign exchange rates to reflect a 5% strengthening of the US dollar
and Euro would have an increase (decrease) in net loss as follows, assuming that all other variables remain constant:</p>



<p style="margin: 0">&nbsp;</p>


<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="width: 70%; font-weight: bold">&nbsp;</td><td style="width: 1%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Increase (decrease) in net loss</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">364</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">(88</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">)</td></tr>
</table></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 20.5pt; text-indent: -9pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">An assumed 5% weakening
of the foreign currencies would have an equal but opposite effect on the basis that all other variables remained constant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p>

<!-- Field: Page; Sequence: 37; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">21.</td><td style="width: 5pt"></td><td style="text-align: justify">Financial instruments (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(c)</td><td style="width: 5pt"></td><td style="text-align: justify">Interest rate risk:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Interest rate risk is the
risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market rates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation&#8217;s
exposure to interest rate risk as at March 31, 2019 and March 31, 2018 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 60%; border-top: Black 2.25pt solid; font-weight: bold">&nbsp;</td>
    <td style="width: 40%; border-top: Black 2.25pt solid; text-align: right; font-weight: bold">&nbsp;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">Cash and cash equivalents</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">Short-term fixed interest rate</font></td></tr>
<tr style="vertical-align: top; background-color: White">
    <td style="font-weight: bold"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">Marketable Securities</font></td>
    <td style="text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">Short-term fixed interest rate</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.25pt solid; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">Unsecured convertible debentures </font></td>
    <td style="border-bottom: Black 2.25pt solid; text-align: right; font-weight: bold"><font style="font-family: Times New Roman, Times, Serif; font-weight: normal">Long-term fixed interest rate</font></td></tr>
</table></div>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The capacity of the Corporation
to reinvest the short-term amounts with equivalent return will be impacted by variations in short-term fixed interest rates available
on the market. Management believes that the risk the Corporation will realize a loss as a result of the decline in the fair value
of its cash equivalents is limited because these investments have short-term maturities and are generally held to maturity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">(d)</td><td style="width: 5pt"></td><td style="text-align: justify">Liquidity risk:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Liquidity risk is the risk
that the Corporation will not be able to meet its financial obligations as they fall due. The Corporation manages liquidity risk
through the management of its capital structure and financial leverage, as outlined in Note 24. It also manages liquidity risk
by continuously monitoring actual and projected cash flows. The Board of Directors reviews and approves the Corporation's operating
budgets, and reviews material transactions outside the normal course of business. Refer to Note 2(c).</P>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The following are the contractual
maturities of financial liabilities as at March 31, 2019 and March 31, 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2019</td><td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: normal">Required payments per year</td><td style="font-weight: bold">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">Total</td><td>&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">Carrying amount</td><td style="font-weight: normal">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">Less than 1 year</td><td style="font-weight: normal">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">1 to 3 years</td><td style="font-weight: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">Notes</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-weight: normal; text-align: left">Trade and other payables</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 12%; font-weight: normal; text-align: center">11</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: normal; text-align: right">16,429</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: normal; text-align: right">16,429</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: normal; text-align: right">16,429</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Unsecured convertible debentures</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">13</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">2,143</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">1,817</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">2,143</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">18,572</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">18,246</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">18,572</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td></tr>
</table></div>





<p style="margin: 0">&nbsp;</p>



<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2018</td><td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: normal">Required payments per year</td><td style="font-weight: bold">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; text-align: right">Total</td><td>&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">Carrying amount</td><td style="font-weight: normal">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">Less than 1 year</td><td style="font-weight: normal">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">1 to 3 years</td><td style="font-weight: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">Notes</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-weight: normal; text-align: left">Trade and other payables</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 12%; font-weight: normal; text-align: center">11</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: normal; text-align: right">6,697</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: normal; text-align: right">6,697</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: normal; text-align: right">6,697</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 10%; font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Unsecured convertible debentures</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="font-weight: normal; text-align: center; border-bottom: Black 1pt solid">13</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">2,303</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">1,612</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">160</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">2,143</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">9,000</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">8,309</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">6,857</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">2,143</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
</table></div>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The Derivative warrant liabilities
are excluded from the above tables as they expected to be settled in shares and not by the use of liquidities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">22.</td><td style="width: 5pt"></td><td style="text-align: justify">Commitments and contingencies:</td>
</tr></table>





<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><i>Research and development
contracts and contract research organizations agreements: </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Corporation utilizes contract
manufacturing organizations related to the development and production of clinical material and clinical research organizations
to perform services related to the Company&#8217;s clinical trials. Pursuant to these agreements with manufacturing and contract
research organizations, the Corporation has the right to terminate the agreements either without penalties or under certain penalty
conditions. For agreements which contain penalty conditions, the Company would be required to pay penalties of approximately $109.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">During Fiscal 2018, the Corporation
entered into a lease agreement, for its research and development and quality control laboratory facility located in Sherbrooke,
Qu&#233;bec, resulting in a commitment of $79 over the remaining lease term, which is committed in the next year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><i>Contingencies:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.1pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.1pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.1pt; margin-bottom: 0pt; text-align: justify">The Corporation evaluates
contingencies on an ongoing basis and establishes loss provisions for matters in which losses are probable and the amount of the
loss can be reasonably estimated. Refer to Note 25, Subsequent Events.</P>
</div>

<!-- Field: Page; Sequence: 38; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.1pt 0pt 17.85pt; text-align: justify"></p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">23.</td><td style="width: 5pt"></td><td style="text-align: justify">Determination of fair values:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.1pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.1pt; margin-bottom: 0pt; text-align: justify">Certain of the Corporation&#8217;s
accounting policies and disclosures require the determination of fair value, for both financial assets and liabilities. Fair values
have been determined for measurement and/or disclosure purposes based on the following methods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><i>Financial assets and
liabilities:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">In establishing fair value,
the Corporation uses a fair value hierarchy based on levels as defined below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"></td><td style="width: 20.7pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">Level 1: defined as observable inputs such as quoted prices in active markets.</td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"></td><td style="width: 20.7pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">Level 2: defined as inputs other than quoted prices in active markets that
are either directly or indirectly observable.</td></tr></table>

<table cellpadding="0" cellspacing="0" width="100%" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 36pt"></td><td style="width: 20.7pt"><font style="font-family: Symbol">&#183;</font></td><td style="text-align: justify; padding-right: 5.9pt">Level 3: defined as inputs that are based on little or no observable market
data, therefore requiring entities to develop their own assumptions.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">The Corporation has determined
that the carrying values of its short-term financial assets and liabilities (cash and cash equivalents, marketable securities and
trade and other payables) approximate their fair value given the short-term nature of these instruments. The fair value of the
liability component of the convertible debenture is determined by discounting future cash flows using a rate that the Corporation
could obtain for loans with similar terms, conditions and maturity dates. The fair value of this liability at March 31, 2019 approximates
the carrying amount and was measured using level 3 inputs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><i>Derivative warrant
liabilities:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Corporation measured its
derivative warrant liabilities at fair value on a recurring basis. These financial liabilities were measured using level 3 inputs
<i>(Note 12).</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As at March 31, 2019, the effect
of an increase or a decrease of 5% of the volatility used, which is the significant unobservable input in the fair value estimate,
would result in a loss of $569 or a gain of $598, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As at March 31, 2019, the effect
of a 5% strengthening of the US dollar, would result in a loss of $405. An assumed 5% weakening of the foreign currency would have
an equal but opposite effect on the basis that all other variables remained constant.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left"></td></tr></table><div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">24.</td><td style="width: 5pt"></td><td style="text-align: justify">Capital management:</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><font style="font-weight: normal">Since
inception, the Corporation&#8217;s objective in managing capital is to ensure sufficient liquidity to finance its research and
development activities, general and administrative expenses, expenses associated with intellectual property protection and its
overall capital expenditures. The Corporation is not exposed to external requirements by regulatory agencies or third parties regarding
its capital, except for certain covenants included within the convertible debentures <i>(Note 13</i>).</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Since the beginning of
its operations, the Corporation has primarily financed its liquidity needs from funding provided through public offerings, private
placements, from the exercise of warrants that were distributed to its related party&#8217;s shareholders, from a rights offering
and from the issuance of options to employees. The Corporation defines capital to include total shareholders&#8217; equity, derivative
warrant liabilities and unsecured convertible debentures. The Corporation&#8217;s policy is to maintain a minimal level of debt.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The following
table summarizes the cash and cash equivalents of the Corporation:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<div data-td-taggable-table=""><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-size: 12pt; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td><td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td><td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-weight: normal">Cash</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">1,896</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 1%; font-weight: normal">&nbsp;</td>
    <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td><td style="width: 12%; font-weight: normal; text-align: right">1,583</td><td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash equivalents</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Term deposits issued in CAD currency</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">12,100</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Term deposits issued in US currency [US - $3,250]</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">4,193</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Commercial papers issued in CAD currency</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">5,693</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Commercial papers issued in US currency [US - $1,099]</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">1,418</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Promissory notes issued in CAD currency</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">498</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Promissory notes issued in US currency [US - $798]</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">-</td><td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: normal">&nbsp;</td>
    <td style="font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; text-align: right">1,029</td><td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; padding-left: 8.75pt">Bankers acceptance</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">2,334</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Total Cash equivalents</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">20,625</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right">6,640</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&nbsp;</td><td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Total Cash and cash equivalents</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">22,521</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,223</td><td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td></tr>
</table></div>
<!-- Field: Page; Sequence: 39; Value: 9 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt"></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"><tr style="vertical-align: top; text-align: left"><td style="width: 100%"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-transform: uppercase"><font style="font-size: 16pt"><b>acasti pharma INC.</b></font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">Notes to Financial Statements</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"><font style="font-size: 10pt">&nbsp;</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt">For the years ended March 31, 2019, 2018 and the thirteen-month and one-month periods ended March 31, 2017, and the twelve-month period ended February 28, 2017</font></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-indent: 0in"><font style="font-size: 10pt"><i>(thousands of Canadian dollars, except where noted and for share and per share amounts)</i></font></p></td></tr></table><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">24.</td><td style="width: 5pt"></td><td style="text-align: justify">Capital management (continued):</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">As at March 31, 2019, the
term deposits, commercial paper, promissory note and bankers acceptance have maturity dates of ranging between April 1, 2019 and
June 25, 2019, bearing interest rates ranging from 1.76% and 2.40% per annum, cashable at any time at the discretion of the Corporation,
under certain conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">As at March 31, 2018, the
term deposits, commercial paper and promissory note have maturity dates of ranging between April 2, 2018 and May 11, 2018, bearing
interest rates ranging from 1.26% and 1.72% per annum, cashable at any time at the discretion of the Corporation, under certain
conditions.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<div data-td-statement-type="note"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 35pt; text-align: left">25.</td><td style="width: 5pt"></td><td style="text-align: justify">Subsequent events</td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">On April 15, 2019 the Corporation
announced the annual grant of stock options to its employees, executives and directors of its stock option plan (the &#8220;Stock
Option Plan&#8221;). The stock options were granted by the Board of Directors as part of the Corporation&#8217;s annual performance
review in accordance with the Corporation&#8217;s Long-Term Incentive Program (LTIP).&nbsp;An aggregate of 644,117 stock options
were granted to certain employees, executives and directors of the Corporation under the Corporation&#8217;s Stock Option Plan.
Subject to the terms and conditions of the Stock Option Plan, options granted to directors will vest in equal quarterly installments
over a period of 18 months and options granted to executives and employees will vest in equal quarterly installments over a period
of 36 months. Each option will entitle the holder to purchase one common share of the Corporation at a price of CDN$1.28, until
April 15, 2029.&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">On
May 10, 2019 the Corporation announced the settlement regarding legal claims made by its former chief executive (&ldquo;CEO&rdquo;)
officer with respect to the termination of his employment. Pursuant to the settlement agreement, the Corporation has agreed to
issue 900,000 common shares at $1.10 per share to the former CEO.&nbsp; In addition, the Corporation has agreed to reimburse the
former CEO for legal fees of $64. Furthermore, pursuant to the settlement agreement, the Corporation receives a full and final
release from the former CEO on all procedures in connection with the termination of his employment. This settlement has been accrued
as at March 31, 2019 and the expense of $1,054 is included as part of General and administrative expenses.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 21.3pt">&nbsp;</p></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 0in">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-40</p>



<p style="margin: 0"></p>

<hr noshade="" size="4" style="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<p style="margin: 0"></p>











<p style="margin: 0"></p>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.6
<SEQUENCE>2
<FILENAME>exh_46.htm
<DESCRIPTION>EXHIBIT 4.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.6</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh46_01.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh46_02.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh46_03.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh46_04.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh46_05.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh46_06.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh46_07.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh46_08.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh46_09.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh46_10.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.7
<SEQUENCE>3
<FILENAME>exh_47.htm
<DESCRIPTION>EXHIBIT 4.7
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.7</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh47_01.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh47_02.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh47_03.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh47_04.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh47_05.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh47_06.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh47_07.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh47_08.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="exh47_09.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>exh_121.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: right"><B>Exhibit 12.1</B></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECTION 302 CERTIFICATION</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">I, Janelle D&rsquo;Alvise, certify that:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 5.9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this annual report on Form 20-F of Acasti Pharma Inc.;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d&ndash;15(f)) for the company and have:</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: justify"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 96%; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted&nbsp;&nbsp;accounting principles;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">c)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">d)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; font-style: italic; border-bottom: Black 1pt solid">/s/ Jan D&rsquo;Alvise</TD>
    <TD STYLE="width: 70%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Name: Jan D&rsquo;Alvise</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 416.95pt; margin-bottom: 0pt">Title: Principal Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 416.95pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 416.95pt; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Date: June 26, 2019</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 416.95pt; margin-bottom: 0pt"></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>5
<FILENAME>exh_122.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: right"><B>Exhibit 12.2</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>SECTION 302 CERTIFICATION</B></P>



<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1pt">I, Jean-Fran&ccedil;ois Boily, certify that:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this annual report on Form 20-F of Acasti Pharma Inc.;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d&ndash;15(f)) for the company and have:</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: justify"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 96%; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted&nbsp;&nbsp;accounting principles;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">c)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">d)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Disclosed in this report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">a)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">b)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; font-style: italic; border-bottom: Black 1pt solid">/s/ Jean-Fran&ccedil;ois Boily</TD>
    <TD STYLE="width: 70%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Name: Jean-Fran&ccedil;ois Boily</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 419.75pt; margin-bottom: 0pt">Title: Principal
Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 419.75pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 419.75pt; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Date: June 26, 2019</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 419.75pt; margin-bottom: 0pt"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>exh_131.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: right"><B>Exhibit 13.1</B></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT
TO SECTION 906 OF THE SARBANES&ndash;OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.05pt; margin: 0pt 0.9pt 0pt 1pt">In connection with the Annual
Report on Form 20-F of Acasti Pharma Inc. (the &ldquo;Company&rdquo;) for the fiscal year ended March 31, 2019, as filed with the
Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Janelle D&rsquo;Alvise, Principal Executive
Officer of the Company certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 98%"><FONT STYLE="font-size: 10pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1pt">Date: June 26, 2019</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>



<P STYLE="margin-top: 0; margin-right: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-right: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-right: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; font-style: italic; border-bottom: Black 1pt solid">/s/ Jan D&rsquo;Alvise</TD>
    <TD STYLE="width: 70%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Name: Jan D&rsquo;Alvise</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Title: Principal Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>7
<FILENAME>exh_132.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt; text-align: right"><B>Exhibit 13.2</B></P>



<P STYLE="margin: 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT
TO SECTION 906 OF THE SARBANES&ndash;OXLEY ACT OF 2002</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.05pt; margin: 0pt 0.9pt 0pt 1pt">In connection with the Annual
Report on Form 20-F of Acasti Pharma Inc. (the &ldquo;Company&rdquo;) for the fiscal year ended March 31, 2019, as filed with the
Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Jean-Fran&ccedil;ois Boily, Principal Financial
Officer of the Company certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 98%"><FONT STYLE="font-size: 10pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 1pt">Date: June 26, 2019</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"></P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; font-style: italic; border-bottom: Black 1pt solid">/s/ Jean-Fran&ccedil;ois Boily</TD>
    <TD STYLE="width: 70%">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Name: Jean-Fran&ccedil;ois Boily</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Title: Principal Financial Officer</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>exh_151.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 15.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="kpmg.jpg" ALT=""></P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 37%; font-weight: bold; text-align: left; padding-left: 1.75in">&nbsp;</TD>
    <TD STYLE="width: 19%; font-weight: bold; text-align: left; padding-left: 0pt">KPMG LLP</TD><TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: left">Telephone</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 30%; text-align: left">(514) 840-2100</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 1.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">600 de Maisonneuve Blvd. West</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Fax</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">(514) 840-2187</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 1.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">Suite 1500, Tour KPMG</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Internet</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">www.kpmg.ca</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 1.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">Montr&eacute;al (Qu&eacute;bec) H3A 0A3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 1.75in">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">Canada</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: left">Consent of
Independent Registered Public Accounting Firm</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors of Acasti Pharma
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We consent to the incorporation by reference
in the registration statements on Form S-8 (No. 333-191383 and No. 333-227476), and Form F-3 (No. 333-223464) of Acasti Pharma
Inc. of our report dated June 26, 2019, with respect to the statements of financial position as at March 31, 2019 and 2018, the
related statements of earnings and comprehensive loss, changes in equity and cash flows for the years ended March 31, 2019 and
2018 and the thirteen month period ended March 31, 2017, and the related notes, which report appears in the annual report on Form
20-F of Acasti Pharma Inc. dated June 26, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our report dated June 26, 2019 contains
an explanatory paragraph that states that Acasti Pharma&nbsp;Inc. has incurred operating losses and negative cash flows from operations
since inception and additional funds will be needed in the future for activities necessary to prepare for commercial launch, which
indicate that a material uncertainty exists that casts substantial doubt about its ability to continue as a going concern. The
financial statements do not include any adjustments that may be necessary if the going concern basis was not appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our report dated June 26, 2019 also contains
an explanatory paragraph that states that the financial statements of Acasti Pharma Inc. for the twelve-month and one-month periods
ended February 28, 2017 and March 31, 2017 respectively are unaudited. Accordingly, we do not express an opinion on them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="exh991_01.jpg" ALT="" STYLE="height: 62px; width: 164px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">June 26, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Montr&eacute;al, Canada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>9
<FILENAME>exh_152.htm
<DESCRIPTION>EXHIBIT 15.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 15.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">June 26, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Acasti Pharma Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">545 Promenade du Centropolis, Suite
100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Laval, Qu&eacute;bec</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Canada H7T 0A3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Re: Consent of Destum Partners, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Board of Directors of Acasti Pharma
Inc.,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We hereby consent to the references
to our name and the inclusion of information, data and statements from our market research reports with respect to CaPre, dated
August&nbsp;19, 2016 and November 17, 2017 (the &ldquo;Reports&rdquo;), as well as any citation of the Reports, in (i)&nbsp;Acasti
Pharma Inc.&rsquo;s (the &ldquo;Company&rdquo;) annual report on Form 20-F (&ldquo;Annual Report&rdquo;) dated June 26, 2019 for
its fiscal year ended March 31, 2019 and (ii) the Company&rsquo;s registration statements on Form S-8 (No. 333-191383 and No. 333-227476),
on Form F-1 (No. 333-220755) and on Form F-3 (No. 333-223464).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">We further hereby consent to the filing
of this letter as an exhibit to the Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">In giving such consent, we do not thereby
admit that we come within the category of persons whose consent is required under Section&nbsp;7 of the U.S. Securities Act of
1933, as amended, or the rules and regulations of the U.S. Securities and Exchange Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Yours faithfully,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">For and on behalf of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD COLSPAN="2">Destum Partners, Inc.</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 28%">&nbsp;</TD>
    <TD STYLE="width: 65%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Thomas J. Filipczak</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name: Thomas J. Filipczak</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title: Managing Director &amp; Partner</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>acst-20190331.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:59AM UTC 2019-06-26--><xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.xbrl.org/2003/instance" xmlns:acst="http://www.acastipharma.com/20190331" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2017-03-09/ifrs-full" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="acst-20190331.xsd" xlink:type="simple"/>
  <acst:AccretionOfInterestOnConvertibleDebenture contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924069" unitRef="iso4217-cad">205000</acst:AccretionOfInterestOnConvertibleDebenture>
  <acst:AccretionOfInterestOnConvertibleDebenture contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924070" unitRef="iso4217-cad">206000</acst:AccretionOfInterestOnConvertibleDebenture>
  <acst:AccretionOfInterestOnConvertibleDebenture contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924071" unitRef="iso4217-cad">22000</acst:AccretionOfInterestOnConvertibleDebenture>
  <acst:AccretionOfInterestOnConvertibleDebenture contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924072" unitRef="iso4217-cad">17000</acst:AccretionOfInterestOnConvertibleDebenture>
  <acst:AccretionOfInterestOnConvertibleDebenture contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924073" unitRef="iso4217-cad">5000</acst:AccretionOfInterestOnConvertibleDebenture>
  <acst:AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924444" unitRef="iso4217-cad">-179000</acst:AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts>
  <acst:AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts contextRef="d_2017-04-01_2018-03-31" id="c47924445" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts contextRef="d_2016-03-01_2017-03-31" id="c47924446" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts contextRef="d_2017-03-01_2017-03-31" id="c47924447" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts contextRef="d_2016-03-01_2017-02-28" id="c47924448" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924434" unitRef="iso4217-cad">-709000</acst:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
  <acst:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924435" unitRef="iso4217-cad">-103000</acst:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
  <acst:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924436" unitRef="iso4217-cad">247000</acst:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
  <acst:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924437" unitRef="iso4217-cad">-33000</acst:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
  <acst:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924438" unitRef="iso4217-cad">280000</acst:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
  <acst:AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds contextRef="d_2019-02-14_2019-02-14" decimals="-5" id="c47923713" unitRef="iso4217-usd">30000000</acst:AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds>
  <acst:AtTheMarketSalesAgreementFeePercentage contextRef="d_2019-02-14_2019-02-14" decimals="INF" id="c47923716" unitRef="xbrli-pure">0.03</acst:AtTheMarketSalesAgreementFeePercentage>
  <acst:AtTheMarketSalesAgreementTerm contextRef="d_2019-02-14_2019-02-14" id="c47923715">P3Y</acst:AtTheMarketSalesAgreementTerm>
  <acst:BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate contextRef="d_2017-02-21_2017-02-21_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" id="c47923663">P120D</acst:BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate>
  <acst:BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum contextRef="i_2017-02-21_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="INF" id="c47923664" unitRef="iso4217-cad-per-xbrli-shares">2.65</acst:BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum>
  <acst:BorrowingsConvertibleConversionPrice contextRef="i_2017-02-21_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="INF" id="c47923659" unitRef="iso4217-cad-per-xbrli-shares">1.90</acst:BorrowingsConvertibleConversionPrice>
  <acst:BorrowingsConvertibleEquityIssuedFloorPrice contextRef="i_2017-02-21_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="INF" id="c47923667" unitRef="iso4217-cad-per-xbrli-shares">0.10</acst:BorrowingsConvertibleEquityIssuedFloorPrice>
  <acst:BorrowingsConvertibleThresholdConsecutiveTradingDays contextRef="d_2017-02-21_2017-02-21_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" id="c47923665">P20D</acst:BorrowingsConvertibleThresholdConsecutiveTradingDays>
  <acst:BorrowingsDiscountOfBorrowingPrincipalAmount contextRef="i_2017-02-21_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="3" id="c47923661" unitRef="xbrli-pure">0.035</acst:BorrowingsDiscountOfBorrowingPrincipalAmount>
  <acst:ChangesInDeferredTaxLiabilityAssetTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-42">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right; border-top: Black 1.5pt solid"&gt;Twelve-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2019&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2018&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, &lt;/div&gt;&lt;br /&gt; 2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; text-align: left; text-indent: -7.35pt; padding-left: 7.35pt"&gt;Origination and reversal of temporary differences&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,599&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,241&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,240&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;163&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,077&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid; text-indent: -7.35pt; padding-left: 7.35pt"&gt;Change in unrecognized deductible temporary differences&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11,599&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5,241&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,369&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(163&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,206&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Deferred tax (recovery) expense&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:ChangesInDeferredTaxLiabilityAssetTextBlock>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" decimals="INF" id="c47923936" unitRef="xbrli-shares">10188100</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" id="c47923938" unitRef="xbrli-shares" xs:nil="true"/>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" id="c47923940" unitRef="xbrli-shares" xs:nil="true"/>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" id="c47923942" unitRef="xbrli-shares" xs:nil="true"/>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsPublicOfferingWarrants2017Member" decimals="INF" id="c47923944" unitRef="xbrli-shares">9801861</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsPublicOfferingWarrants2017Member" decimals="INF" id="c47923946" unitRef="xbrli-shares">9802935</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsPublicOfferingWarrants2017Member" id="c47923948" unitRef="xbrli-shares" xs:nil="true"/>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsPublicOfferingWarrants2017Member" id="c47923950" unitRef="xbrli-shares" xs:nil="true"/>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" id="c47923952" unitRef="xbrli-shares" xs:nil="true"/>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" decimals="INF" id="c47923954" unitRef="xbrli-shares">18400000</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" decimals="INF" id="c47923956" unitRef="xbrli-shares">18400000</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" decimals="INF" id="c47923958" unitRef="xbrli-shares">18400000</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatingToLiabilitiesMember" decimals="INF" id="c47923960" unitRef="xbrli-shares">19989961</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatingToLiabilitiesMember" decimals="INF" id="c47923962" unitRef="xbrli-shares">28202935</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatingToLiabilitiesMember" decimals="INF" id="c47923964" unitRef="xbrli-shares">18400000</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-WarrantsRelatingToLiabilitiesMember" decimals="INF" id="c47923966" unitRef="xbrli-shares">18400000</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember" decimals="INF" id="c47923970" unitRef="xbrli-shares">547975</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember" id="c47923972" unitRef="xbrli-shares" xs:nil="true"/>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember" id="c47923974" unitRef="xbrli-shares" xs:nil="true"/>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember" id="c47923976" unitRef="xbrli-shares" xs:nil="true"/>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" decimals="INF" id="c47923978" unitRef="xbrli-shares">495050</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" decimals="INF" id="c47923980" unitRef="xbrli-shares">495050</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" id="c47923982" unitRef="xbrli-shares" xs:nil="true"/>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" id="c47923984" unitRef="xbrli-shares" xs:nil="true"/>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember" decimals="INF" id="c47923986" unitRef="xbrli-shares">1904034</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember" decimals="INF" id="c47923988" unitRef="xbrli-shares">1904034</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember" decimals="INF" id="c47923990" unitRef="xbrli-shares">1965259</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember" decimals="INF" id="c47923992" unitRef="xbrli-shares">1965259</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" decimals="INF" id="c47923995" unitRef="xbrli-shares">1052630</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" decimals="INF" id="c47923997" unitRef="xbrli-shares">1052630</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" decimals="INF" id="c47923999" unitRef="xbrli-shares">1052630</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" decimals="INF" id="c47924001" unitRef="xbrli-shares">1052630</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series9PrivatePlacementWarrants2013RelatedToEquityMember" id="c47924003" unitRef="xbrli-shares" xs:nil="true"/>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-Series9PrivatePlacementWarrants2013RelatedToEquityMember" decimals="INF" id="c47924005" unitRef="xbrli-shares">161654</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-Series9PrivatePlacementWarrants2013RelatedToEquityMember" decimals="INF" id="c47924007" unitRef="xbrli-shares">161654</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-Series9PrivatePlacementWarrants2013RelatedToEquityMember" decimals="INF" id="c47924009" unitRef="xbrli-shares">161654</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember" id="c47924011" unitRef="xbrli-shares" xs:nil="true"/>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember" id="c47924013" unitRef="xbrli-shares" xs:nil="true"/>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember" decimals="INF" id="c47924015" unitRef="xbrli-shares">234992</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember" decimals="INF" id="c47924017" unitRef="xbrli-shares">234992</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatedToEquityMember" decimals="INF" id="c47924019" unitRef="xbrli-shares">3999689</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatedToEquityMember" decimals="INF" id="c47924021" unitRef="xbrli-shares">3613368</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatedToEquityMember" decimals="INF" id="c47924023" unitRef="xbrli-shares">3414535</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-WarrantsRelatedToEquityMember" decimals="INF" id="c47924025" unitRef="xbrli-shares">3414535</acst:ClassOfWarrantOrRightOutstanding>
  <acst:ClassOfWarrantOrRightOutstandingTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-34">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;March 31, 2019&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;March 31, 2018&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;March 31, 2017&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;February 28, 2017&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;(Unaudited)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Number &lt;br /&gt; outstanding&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Number &lt;br /&gt; outstanding&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Number &lt;br /&gt; outstanding&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Number &lt;br /&gt; outstanding&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Liability&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 28%; font-weight: normal; font-style: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;May 2018 Public offering Warrants 2018 (i)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; font-style: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; font-style: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: normal; font-style: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;10,188,100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; font-style: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; font-style: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; font-style: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: normal; font-style: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;8,246&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; font-style: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Series December 2017 US Public offering Warrants 2017 (ii)&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;9,801,861&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;8,017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;9,802,935&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;6,405&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; font-style: normal; text-align: left; text-indent: -10pt; padding-left: 10pt; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Series 8 Public offering Warrants December 2013 (iii)&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;18,400,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;18,400,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;209&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;18,400,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;187&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;19,989,961&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;16,263&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;28,202,935&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;6,426&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;18,400,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;209&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;18,400,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;187&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Equity&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Public offering warrants&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Public offering broker warrants May 2018 (iv)&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;547,975&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;283&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Public offering U.S. broker warrants December 2017 (v)&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;495,050&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;406&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;495,050&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;406&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Public offering warrants February 2017 (vi)&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,904,034&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,904,034&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,965,259&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,965,259&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Private Placement- contingent warrants&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;2017 unsecured convertible debenture conversion option and contingent warrants (vii)&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,052,630&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;309&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,052,630&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;309&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,052,630&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;309&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,052,630&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;309&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Series 9 Private Placement warrants 2013 (viii)&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;161,654&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;161,654&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;161,654&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Series 2017 BW Broker warrants (ix)&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;234,992&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;144&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;234,992&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;144&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;3,999,689&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;998&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;3,613,368&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;715&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;3,414,535&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;453&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;3,414,535&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;453&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:ClassOfWarrantOrRightOutstandingTextBlock>
  <acst:ConversionOfConvertibleInstrumentsEquitySharesIssued contextRef="d_2017-04-07_2017-04-07" decimals="INF" id="c47923912" unitRef="xbrli-shares">9496</acst:ConversionOfConvertibleInstrumentsEquitySharesIssued>
  <acst:ConversionOfConvertibleInstrumentsEquitySharesIssued contextRef="d_2017-08-15_2017-08-15" decimals="INF" id="c47923915" unitRef="xbrli-shares">23885</acst:ConversionOfConvertibleInstrumentsEquitySharesIssued>
  <acst:ConversionOfConvertibleInstrumentsEquitySharesIssued contextRef="d_2017-12-27_2017-12-27" decimals="INF" id="c47923918" unitRef="xbrli-shares">22783</acst:ConversionOfConvertibleInstrumentsEquitySharesIssued>
  <acst:ConversionOfConvertibleInstrumentsEquitySharesIssued contextRef="d_2018-03-27_2018-03-27" decimals="INF" id="c47923921" unitRef="xbrli-shares">33605</acst:ConversionOfConvertibleInstrumentsEquitySharesIssued>
  <acst:ConversionOfConvertibleInstrumentsEquitySharesIssued contextRef="d_2018-06-06_2018-06-06" decimals="INF" id="c47923924" unitRef="xbrli-shares">30348</acst:ConversionOfConvertibleInstrumentsEquitySharesIssued>
  <acst:ConversionOfConvertibleInstrumentsEquitySharesIssued contextRef="d_2018-08-21_2018-08-21" decimals="INF" id="c47923927" unitRef="xbrli-shares">51807</acst:ConversionOfConvertibleInstrumentsEquitySharesIssued>
  <acst:ConversionOfConvertibleInstrumentsEquitySharesIssued contextRef="d_2018-10-31_2018-10-31" decimals="INF" id="c47923930" unitRef="xbrli-shares">23723</acst:ConversionOfConvertibleInstrumentsEquitySharesIssued>
  <acst:ConversionOfConvertibleInstrumentsEquitySharesIssued contextRef="d_2018-04-01_2018-09-30" decimals="INF" id="c47923933" unitRef="xbrli-shares">195647</acst:ConversionOfConvertibleInstrumentsEquitySharesIssued>
  <acst:ConversionOfConvertibleInstrumentsEquitySharesIssued contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922579" unitRef="xbrli-shares">105878</acst:ConversionOfConvertibleInstrumentsEquitySharesIssued>
  <acst:ConversionOfConvertibleInstrumentsEquitySharesIssued contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922644" unitRef="xbrli-shares">89769</acst:ConversionOfConvertibleInstrumentsEquitySharesIssued>
  <acst:ConversionRatio contextRef="d_2018-04-01_2019-03-31_ClassesOfShareCapitalAxis-ClassBSharesMember" decimals="INF" id="c47923702" unitRef="xbrli-pure">1</acst:ConversionRatio>
  <acst:ConversionRatio contextRef="d_2018-04-01_2019-03-31_ClassesOfShareCapitalAxis-ClassCSharesMember" decimals="INF" id="c47923705" unitRef="xbrli-pure">1</acst:ConversionRatio>
  <acst:ConversionRatio contextRef="d_2018-04-01_2019-03-31_ClassesOfShareCapitalAxis-ClassDAndESharesMember" decimals="INF" id="c47923710" unitRef="xbrli-pure">1</acst:ConversionRatio>
  <acst:DeferredFinancingCostsCurrent contextRef="i_2019-02-14" decimals="INF" id="c47923718" unitRef="iso4217-cad">179000</acst:DeferredFinancingCostsCurrent>
  <acst:DeferredFinancingCostsCurrent contextRef="i_2019-03-31" decimals="-3" id="c47922403" unitRef="iso4217-cad">179000</acst:DeferredFinancingCostsCurrent>
  <acst:DeferredFinancingCostsCurrent contextRef="i_2018-03-31" id="c47922404" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:DepreciationPercentage contextRef="d_2018-04-01_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember_RangeAxis-BottomOfRangeMember" decimals="1" id="c47923116" unitRef="xbrli-pure">0.2</acst:DepreciationPercentage>
  <acst:DepreciationPercentage contextRef="d_2018-04-01_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember_RangeAxis-TopOfRangeMember" decimals="1" id="c47923118" unitRef="xbrli-pure">0.3</acst:DepreciationPercentage>
  <acst:DepreciationPercentage contextRef="d_2018-04-01_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="1" id="c47923124" unitRef="xbrli-pure">0.3</acst:DepreciationPercentage>
  <acst:DepreciationPercentage contextRef="d_2018-04-01_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="1" id="c47923131" unitRef="xbrli-pure">0.3</acst:DepreciationPercentage>
  <acst:DerivativeFinancialLiabilitiesExercisedDuringPeriod contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" decimals="-3" id="c47923601" unitRef="iso4217-cad">722000</acst:DerivativeFinancialLiabilitiesExercisedDuringPeriod>
  <acst:DerivativeFinancialLiabilitiesExercisedDuringPeriod contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" id="c47923602" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:DerivativeFinancialLiabilitiesExercisedDuringPeriod contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" id="c47923603" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:DerivativeFinancialLiabilitiesExercisedDuringPeriod contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" id="c47923604" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:DerivativeFinancialLiabilitiesExercisedDuringPeriod contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" id="c47923605" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:DerivativeFinancialLiabilitiesExercisedDuringPeriod contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" id="c47923606" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:DerivativeFinancialLiabilitiesIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" decimals="-3" id="c47923595" unitRef="iso4217-cad">4272000</acst:DerivativeFinancialLiabilitiesIssued>
  <acst:DerivativeFinancialLiabilitiesIssued contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" id="c47923596" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:DerivativeFinancialLiabilitiesIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" id="c47923597" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:DerivativeFinancialLiabilitiesIssued contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="-3" id="c47923598" unitRef="iso4217-cad">5873000</acst:DerivativeFinancialLiabilitiesIssued>
  <acst:DerivativeFinancialLiabilitiesIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" id="c47923599" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:DerivativeFinancialLiabilitiesIssued contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" id="c47923600" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock contextRef="d_2018-04-01_2019-03-31" id="c47927255">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(n)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Change in accounting policy:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Adoption of new accounting standards&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The accounting policies used in these annual financial statements are consistent with those applied by the Corporation in its &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018 &lt;/div&gt;annual financial statements except for the amendments to certain accounting standards which are relevant to the Corporation and were adopted by the Corporation as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 1, 2018 &lt;/div&gt;as described below.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(i)&lt;/td&gt; &lt;td style="text-align: justify"&gt;Financial instruments:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,&lt;/div&gt; Financial Instruments, replaces IAS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39,&lt;/div&gt; Financial Instruments: Recognition and Measurement. IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9&lt;/div&gt; introduces a revised approach for the classification of financial assets based on how an entity manages financial assets and the characteristics of the contractual cash flows of the financial assets replacing the multiple rules in IAS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39.&lt;/div&gt; Most of the requirements in IAS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39&lt;/div&gt; for classification and measurement of financial liabilities have been carried forward in IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.&lt;/div&gt; IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9&lt;/div&gt; also introduces a new hedge accounting model that is more closely aligned with risk-management activities and a new expected credit loss model for calculating impairment on financial assets replacing the incurred loss model in IAS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39.&lt;/div&gt; The Corporation adopted IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 1, 2018 &lt;/div&gt;and assessed the impact of the adoption on its financial statements, and determined there was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; material impact. The Corporation does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; apply hedge accounting.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(ii)&lt;/td&gt; &lt;td style="text-align: justify"&gt;Amendments to IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; &amp;#x2013; Classification and Measurement of Share-Based Payment Transactions:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 20, 2016, &lt;/div&gt;the IASB issued amendments to IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,&lt;/div&gt; Share-Based Payment, clarifying how to account for certain types of share-based payment transactions. The amendments provide requirements on the accounting for: the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based payments; share-based payment transactions with a net settlement feature for withholding tax obligations; and a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from cash-settled to equity-settled. The Corporation adopted the amendments to IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 1, 2018 &lt;/div&gt;and assessed the impact of the adoption of IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; on its financial statements, and determined that there was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; material impact.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;Future accounting change:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The following new standards, and amendments to standards and interpretations, are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; yet effective for the period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019,&lt;/div&gt; and have &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; been applied in preparing these financial statements.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;New standards and interpretations &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; yet adopted:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(i)&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Leases &amp;#x2013; IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,&lt;/div&gt; Leases (&amp;#x201c;IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&amp;#x201d;&lt;/div&gt;) In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2016, &lt;/div&gt;the IASB issued IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,&lt;/div&gt; a new standard that replaces IAS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,&lt;/div&gt; Leases. IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt; is a major revision of the way in which companies account for leases and will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer permit off balance sheet leases. Adoption of IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt; is mandatory and will be effective for the Corporation&amp;#x2019;s fiscal year beginning on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 1, 2019. &lt;/div&gt;The Corporation is assessing the impact of adoption of IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,&lt;/div&gt; and currently there is only &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; lease that will be impacted by this new standard and the impact is expected to be minimal.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</acst:DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock>
  <acst:DescriptionOfVestingPeriodShareOptionGranted contextRef="d_2019-04-15_2019-04-15_CounterpartiesAxis-DirectorsMember_NonadjustingEventsAfterReportingPeriodAxis-MajorOrdinaryShareTransactionsMember_RangeAxis-BottomOfRangeMember_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" id="c47924862">P1Y180D</acst:DescriptionOfVestingPeriodShareOptionGranted>
  <acst:DescriptionOfVestingPeriodShareOptionGranted contextRef="d_2019-04-15_2019-04-15_CounterpartiesAxis-EmployeeMember_NonadjustingEventsAfterReportingPeriodAxis-MajorOrdinaryShareTransactionsMember_RangeAxis-BottomOfRangeMember_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" id="c47924863">P3Y</acst:DescriptionOfVestingPeriodShareOptionGranted>
  <acst:DisclosureForComponentsOfFinanceIncomeCostTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-36">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-&lt;br /&gt; months ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-month &lt;br /&gt;period ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2019&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, &lt;/div&gt;&lt;br /&gt; 2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; text-align: left"&gt;Interest income&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;475&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;72&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;119&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Foreign exchange gain (loss)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;279&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(32&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(180&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(177&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Interest payable on convertible debenture&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(160&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(160&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(17&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(14&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Accretion of interest on convertible debenture&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(205&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(206&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(22&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(17&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Transaction costs related to derivative warrant liabilities&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(653&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,134&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Change in fair value of warrant liabilities&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(6,287&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(344&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(53&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(22&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(31&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Other charges&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(19&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Financial expenses&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(6,551&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,808&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(166&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(51&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(115&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:DisclosureForComponentsOfFinanceIncomeCostTextBlock>
  <acst:DisclosureOfChangesInNoncashOperatingItemsTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-40">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-&lt;br /&gt; months ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;March 31, &lt;br /&gt;2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;March 31, &lt;br /&gt;2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;March 31, &lt;br /&gt;2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;March 31, &lt;br /&gt;2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;February 28, &lt;br /&gt; 2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%"&gt;Receivables&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(738&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(553&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;193&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;233&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(709&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(103&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;247&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(33&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;280&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Other Assets&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;37&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(659&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Deferred financing costs&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(179&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Trade and other payables&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,679&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,898&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;352&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(255&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;607&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Total changes in working capital items&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,090&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,583&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;792&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(328&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,120&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:DisclosureOfChangesInNoncashOperatingItemsTextBlock>
  <acst:DisclosureOfComponentsOfPersonnelExpensesTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-35">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-&lt;br /&gt; months ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-month &lt;br /&gt;period ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2019&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, &lt;/div&gt;&lt;br /&gt; 2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; text-align: left"&gt;Salaries and other short-term employee benefits&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,144&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,281&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,491&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;214&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,277&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Share-based compensation costs&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,041&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;929&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;674&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;86&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;588&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Total personnel expenses&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,185&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,210&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,165&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;300&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,865&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:DisclosureOfComponentsOfPersonnelExpensesTextBlock>
  <acst:DisclosureOfConvertibleDebenturesTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-33">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"&gt;&lt;div style="display: inline; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"&gt;&lt;div style="display: inline; font-weight: normal"&gt;Accrued interest as at&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"&gt;&lt;div style="display: inline; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"&gt;&lt;div style="display: inline; font-weight: normal"&gt;Share issuance date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;Number of shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;Amount &lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 34%; font-weight: normal"&gt;March 31, 2017&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 35%; font-weight: normal"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;April 7, 2017&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,496&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;June 30, 2017&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;August 15, 2017&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,885&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal"&gt;September 30, 2017&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;December 27, 2017&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22,783&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;December 31, 2017&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 27, 2018&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;33,605&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;June 6, 2018&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,348&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;June 30, 2018&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;August 21, 2018&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;51,807&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;September 30, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;October 31, 2018&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,723&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;195,647&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;257&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:DisclosureOfConvertibleDebenturesTextBlock>
  <acst:DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-24">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-&lt;br /&gt; months ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2019&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, &lt;/div&gt;&lt;br /&gt; 2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; text-align: left"&gt;Investment tax credit&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;588&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;409&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;103&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;95&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Government grant&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;227&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;37&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;190&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Total government assistance&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;595&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;409&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;330&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;45&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;285&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock>
  <acst:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-28">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 70%; font-weight: normal; text-align: left"&gt;Trade payables&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,064&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,420&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Accrued liabilities and other payables&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,319&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,479&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Employee salaries and benefits payable&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,054&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;754&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Legal settlement expected to be paid via common shares (note 25)&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;990&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Payable to Neptune&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;44&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Total trade and other payables&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,429&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,697&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock>
  <acst:DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-19">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: center; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid"&gt;Notes&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-weight: normal; text-align: left"&gt;Sales tax receivables&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 14%; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;618&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;470&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Government assistance and tax credits receivable&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;872&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;282&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Interest receivable&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;80&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Other receivables&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Total receivables&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,586&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;759&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock>
  <acst:DisclosureOfMarketableSecuritiesTextBlock contextRef="d_2018-04-01_2019-03-31" id="s1233015">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Marketable Securities&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.65pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.65pt; margin-bottom: 0pt"&gt;&lt;div style="display: inline; font-weight: normal"&gt;The corporation holds various marketable securities with maturities greater than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;90&lt;/div&gt; days at the time of purchase as follows: &lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 70%; font-weight: normal; text-align: left"&gt;Term deposit issued in US currency [US $20], earning interest at 2.23% and maturing on March 13, 2019&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Term deposits issued in US currency [US $2,020], earning interest at 2.50% and maturing on various dates from April 8, 2019 to March 12, 2020&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,696&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Treasury bills issued in CAD currencyearning interest at rates ranging from 1.83% to 1.90% and maturing on various dates from April 2, 2019 to July 25, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,196&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Total Marketable securities&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,892&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; padding-left: 10pt"&gt;Current marketable securities&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,865&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 10pt"&gt;Marketable securities&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</acst:DisclosureOfMarketableSecuritiesTextBlock>
  <acst:DisclosureOfNoncashTransactionsTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-41">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-months &lt;br /&gt; ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; padding-left: 10pt; text-indent: -10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2019&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, 2017 &lt;/div&gt;&lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Issuance of shares for interest on convertible debt&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;120&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;137&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;94&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;94&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Issuance of broker warrants included in net proceeds from public offering&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;283&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;406&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;144&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;144&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Public offering transaction costs included in trade and other payables&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;132&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;381&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;381&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;416&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Interest receivable included in receivables&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;96&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Reduction in share issue costs from reduction in trade and other payables&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;109&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;109&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Private Placement transaction costs included in trade and other payables&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Equipment included in trade and other payables&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;216&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;288&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;288&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;269&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt"&gt;Interest payable included in trade and other payables&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:DisclosureOfNoncashTransactionsTextBlock>
  <acst:DisclosureOfPersonnelExpensesTextBlock contextRef="d_2018-04-01_2019-03-31" id="s1233044">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Personnel expenses:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-&lt;br /&gt; months ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-month &lt;br /&gt;period ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2019&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, &lt;/div&gt;&lt;br /&gt; 2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; text-align: left"&gt;Salaries and other short-term employee benefits&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,144&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,281&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,491&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;214&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,277&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Share-based compensation costs&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,041&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;929&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;674&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;86&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;588&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Total personnel expenses&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,185&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,210&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,165&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;300&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,865&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</acst:DisclosureOfPersonnelExpensesTextBlock>
  <acst:DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-44">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;March 31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;March 31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;March 31, 2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Deferred tax assets&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 55%; font-weight: normal; text-align: left"&gt;Tax losses carried forward&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,695&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,670&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,293&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Research and development expenses&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,927&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,220&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Property, plan and equipment and intangible assets&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;766&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;567&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;435&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Financing expenses&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,852&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;116&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Other deductible temporary differences&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;378&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;768&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;522&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Deferred tax assets&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,053&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,048&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,470&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;Deferred tax liabilities&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Tax basis of unsecured convertible debentures in excess of carrying value&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;67&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;122&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Deferred tax liabilities&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;67&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;122&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Net deferred tax assets&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,040&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,981&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,348&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock>
  <acst:DisclosureOfUsefulLivesAndRatesTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-18">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="border-collapse: collapse; min-; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Method&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Period/Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;Furniture and office equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Declining balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; to&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; 30%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 28%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 30%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Declining balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 20%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Declining balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Production equipment (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Straight-line&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Assets&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Period (in years)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 78%"&gt;Patents&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 7%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;License&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8 &lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;to&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; 14&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:DisclosureOfUsefulLivesAndRatesTextBlock>
  <acst:EquipmentIncludedInTradeAndOtherPayables contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924494" unitRef="iso4217-cad">12000</acst:EquipmentIncludedInTradeAndOtherPayables>
  <acst:EquipmentIncludedInTradeAndOtherPayables contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924495" unitRef="iso4217-cad">216000</acst:EquipmentIncludedInTradeAndOtherPayables>
  <acst:EquipmentIncludedInTradeAndOtherPayables contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924496" unitRef="iso4217-cad">288000</acst:EquipmentIncludedInTradeAndOtherPayables>
  <acst:EquipmentIncludedInTradeAndOtherPayables contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924497" unitRef="iso4217-cad">288000</acst:EquipmentIncludedInTradeAndOtherPayables>
  <acst:EquipmentIncludedInTradeAndOtherPayables contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924498" unitRef="iso4217-cad">269000</acst:EquipmentIncludedInTradeAndOtherPayables>
  <acst:ExercisePriceFor10Warrants contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" decimals="INF" id="c47923834" unitRef="iso4217-usd-per-xbrli-shares">15</acst:ExercisePriceFor10Warrants>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-05-09_2018-05-09" decimals="INF" id="c47923746" unitRef="iso4217-cad-per-xbrli-shares">1.31</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-05-14_2018-05-14_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member_CounterpartiesAxis-UnderwriterMember" decimals="INF" id="c47923753" unitRef="iso4217-cad-per-xbrli-shares">1.31</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-05-01_2018-05-31_CounterpartiesAxis-BrokerMember" decimals="INF" id="c47923763" unitRef="iso4217-cad-per-xbrli-shares">1.05</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2017-12-27_2017-12-27_CounterpartiesAxis-UnderwriterMember" decimals="INF" id="c47923782" unitRef="iso4217-usd-per-xbrli-shares">1.26</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2017-12-27_2017-12-27" decimals="INF" id="c47923788" unitRef="iso4217-usd-per-xbrli-shares">1.2625</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2017-02-21_2017-02-21" decimals="INF" id="c47923805" unitRef="iso4217-cad-per-xbrli-shares">2.15</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" decimals="INF" id="c47923830" unitRef="iso4217-cad-per-xbrli-shares">1.31</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsPublicOfferingWarrants2017Member" decimals="INF" id="c47923832" unitRef="iso4217-usd-per-xbrli-shares">1.26</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingBrokerWarrantsMay2018Member" decimals="INF" id="c47923839" unitRef="iso4217-cad-per-xbrli-shares">1.05</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember" decimals="INF" id="c47923841" unitRef="iso4217-usd-per-xbrli-shares">1.2625</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsBrokerWarrantsEquityPortionMember" decimals="INF" id="c47923843" unitRef="iso4217-cad-per-xbrli-shares">2.15</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" decimals="INF" id="c47923845" unitRef="iso4217-cad-per-xbrli-shares">1.90</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series9PrivatePlacementWarrants2013RelatedToEquityMember" decimals="INF" id="c47923848" unitRef="iso4217-cad-per-xbrli-shares">13.30</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember" decimals="INF" id="c47923850" unitRef="iso4217-cad-per-xbrli-shares">2.15</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2017-01-01_2017-12-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember" decimals="INF" id="c47923868" unitRef="iso4217-cad-per-xbrli-shares">2.15</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-05-01_2018-05-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" decimals="INF" id="c47923885" unitRef="iso4217-cad-per-xbrli-shares">1.31</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-05-01_2018-05-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember" decimals="INF" id="c47923890" unitRef="iso4217-cad-per-xbrli-shares">1.05</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2017-12-27_2017-12-27_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsIn2017Member" decimals="INF" id="c47923895" unitRef="iso4217-usd-per-xbrli-shares">1.26</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2017-12-27_2017-12-27_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" decimals="INF" id="c47923900" unitRef="iso4217-usd-per-xbrli-shares">1.2625</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2017-02-21_2017-02-21_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" decimals="INF" id="c47923905" unitRef="iso4217-cad-per-xbrli-shares">2.15</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" decimals="INF" id="c47923625" unitRef="iso4217-cad-per-xbrli-shares">1.31</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" id="c47923626" unitRef="iso4217-usd-per-xbrli-shares" xs:nil="true"/>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="INF" id="c47923627" unitRef="iso4217-usd-per-xbrli-shares">1.26</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2016-03-01_2017-02-28_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="INF" id="c47923628" unitRef="iso4217-usd-per-xbrli-shares">1.26</acst:ExercisePriceWarrantsIssued>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" id="c47923629" unitRef="iso4217-usd-per-xbrli-shares" xs:nil="true"/>
  <acst:ExercisePriceWarrantsIssued contextRef="d_2016-03-01_2017-02-28_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" decimals="INF" id="c47923630" unitRef="iso4217-usd-per-xbrli-shares">1.50</acst:ExercisePriceWarrantsIssued>
  <acst:ExpectedDividendWarrantsGranted contextRef="d_2017-02-21_2017-02-21_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" id="c47923907" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:ExpectedVolatilityWarrantsIssued contextRef="d_2018-05-01_2018-05-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" decimals="4" id="c47923889" unitRef="xbrli-pure">0.874</acst:ExpectedVolatilityWarrantsIssued>
  <acst:ExpectedVolatilityWarrantsIssued contextRef="d_2018-05-01_2018-05-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember" decimals="4" id="c47923894" unitRef="xbrli-pure">0.874</acst:ExpectedVolatilityWarrantsIssued>
  <acst:ExpectedVolatilityWarrantsIssued contextRef="d_2017-12-27_2017-12-27_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsIn2017Member" decimals="4" id="c47923899" unitRef="xbrli-pure">0.9352</acst:ExpectedVolatilityWarrantsIssued>
  <acst:ExpectedVolatilityWarrantsIssued contextRef="d_2017-12-27_2017-12-27_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" decimals="4" id="c47923904" unitRef="xbrli-pure">0.9352</acst:ExpectedVolatilityWarrantsIssued>
  <acst:ExpectedVolatilityWarrantsIssued contextRef="d_2017-02-21_2017-02-21_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" decimals="4" id="c47923910" unitRef="xbrli-pure">1.1209</acst:ExpectedVolatilityWarrantsIssued>
  <acst:ExpectedVolatilityWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" decimals="4" id="c47923649" unitRef="xbrli-pure">0.9458</acst:ExpectedVolatilityWarrantsIssued>
  <acst:ExpectedVolatilityWarrantsIssued contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" id="c47923650" unitRef="xbrli-pure" xs:nil="true"/>
  <acst:ExpectedVolatilityWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="4" id="c47923651" unitRef="xbrli-pure">1.0757</acst:ExpectedVolatilityWarrantsIssued>
  <acst:ExpectedVolatilityWarrantsIssued contextRef="d_2016-03-01_2017-02-28_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="4" id="c47923652" unitRef="xbrli-pure">0.9515</acst:ExpectedVolatilityWarrantsIssued>
  <acst:ExpectedVolatilityWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" id="c47923653" unitRef="xbrli-pure" xs:nil="true"/>
  <acst:ExpectedVolatilityWarrantsIssued contextRef="d_2016-03-01_2017-02-28_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" decimals="4" id="c47923654" unitRef="xbrli-pure">1.3386</acst:ExpectedVolatilityWarrantsIssued>
  <acst:FairValuePerShareIssuable contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" decimals="INF" id="c47923619" unitRef="iso4217-cad-per-xbrli-shares">0.81</acst:FairValuePerShareIssuable>
  <acst:FairValuePerShareIssuable contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" id="c47923620" unitRef="iso4217-cad-per-xbrli-shares" xs:nil="true"/>
  <acst:FairValuePerShareIssuable contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="INF" id="c47923621" unitRef="iso4217-cad-per-xbrli-shares">0.82</acst:FairValuePerShareIssuable>
  <acst:FairValuePerShareIssuable contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="INF" id="c47923622" unitRef="iso4217-cad-per-xbrli-shares">0.65</acst:FairValuePerShareIssuable>
  <acst:FairValuePerShareIssuable contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" id="c47923623" unitRef="iso4217-cad-per-xbrli-shares" xs:nil="true"/>
  <acst:FairValuePerShareIssuable contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" decimals="INF" id="c47923624" unitRef="iso4217-cad-per-xbrli-shares">0.01</acst:FairValuePerShareIssuable>
  <acst:FairValuePerSharesIssuableWarrants contextRef="i_2018-05-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" decimals="INF" id="c47923760" unitRef="iso4217-cad-per-xbrli-shares">0.39</acst:FairValuePerSharesIssuableWarrants>
  <acst:FairValuePerSharesIssuableWarrants contextRef="i_2017-12-27_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="INF" id="c47923785" unitRef="iso4217-cad-per-xbrli-shares">0.60</acst:FairValuePerSharesIssuableWarrants>
  <acst:FinancialInstrumentInterestRate contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositOneMember_RangeAxis-BottomOfRangeMember" id="c47923184" unitRef="xbrli-pure" xs:nil="true"/>
  <acst:FinancialInstrumentInterestRate contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositOneMember_RangeAxis-BottomOfRangeMember" decimals="4" id="c47923185" unitRef="xbrli-pure">0.0223</acst:FinancialInstrumentInterestRate>
  <acst:FinancialInstrumentInterestRate contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember" decimals="4" id="c47923192" unitRef="xbrli-pure">0.025</acst:FinancialInstrumentInterestRate>
  <acst:FinancialInstrumentInterestRate contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember" id="c47923193" unitRef="xbrli-pure" xs:nil="true"/>
  <acst:FinancialInstrumentInterestRate contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember_RangeAxis-BottomOfRangeMember" decimals="4" id="c47923200" unitRef="xbrli-pure">0.0183</acst:FinancialInstrumentInterestRate>
  <acst:FinancialInstrumentInterestRate contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember_RangeAxis-BottomOfRangeMember" id="c47923201" unitRef="xbrli-pure" xs:nil="true"/>
  <acst:FinancialInstrumentInterestRate contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember_RangeAxis-TopOfRangeMember" decimals="4" id="c47923202" unitRef="xbrli-pure">0.019</acst:FinancialInstrumentInterestRate>
  <acst:FinancialInstrumentInterestRate contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember_RangeAxis-TopOfRangeMember" id="c47923203" unitRef="xbrli-pure" xs:nil="true"/>
  <acst:FinancialInstrumentMaturityDate contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositOneMember_RangeAxis-TopOfRangeMember" id="c47923186" xs:nil="true"/>
  <acst:FinancialInstrumentMaturityDate contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositOneMember_RangeAxis-TopOfRangeMember" id="c47923187">March 13, 2019</acst:FinancialInstrumentMaturityDate>
  <acst:FinancialInstrumentMaturityDate contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember_RangeAxis-BottomOfRangeMember" id="c47923194">April 8, 2019</acst:FinancialInstrumentMaturityDate>
  <acst:FinancialInstrumentMaturityDate contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember_RangeAxis-BottomOfRangeMember" id="c47923195" xs:nil="true"/>
  <acst:FinancialInstrumentMaturityDate contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember_RangeAxis-TopOfRangeMember" id="c47923196">March 12, 2020</acst:FinancialInstrumentMaturityDate>
  <acst:FinancialInstrumentMaturityDate contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember_RangeAxis-TopOfRangeMember" id="c47923197" xs:nil="true"/>
  <acst:FinancialInstrumentMaturityDate contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember_RangeAxis-BottomOfRangeMember" id="c47923204">April 2, 2019</acst:FinancialInstrumentMaturityDate>
  <acst:FinancialInstrumentMaturityDate contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember_RangeAxis-BottomOfRangeMember" id="c47923205" xs:nil="true"/>
  <acst:FinancialInstrumentMaturityDate contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember_RangeAxis-TopOfRangeMember" id="c47923206">July 25, 2019</acst:FinancialInstrumentMaturityDate>
  <acst:FinancialInstrumentMaturityDate contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember_RangeAxis-TopOfRangeMember" id="c47923207" xs:nil="true"/>
  <acst:ForeignCurrencyExposuresIncreaseDecreaseInNetLoss contextRef="d_2018-04-01_2019-03-31_TypesOfRisksAxis-CurrencyRiskMember" decimals="INF" id="c47924742" unitRef="iso4217-cad">364</acst:ForeignCurrencyExposuresIncreaseDecreaseInNetLoss>
  <acst:ForeignCurrencyExposuresIncreaseDecreaseInNetLoss contextRef="d_2017-04-01_2018-03-31_TypesOfRisksAxis-CurrencyRiskMember" decimals="INF" id="c47924743" unitRef="iso4217-cad">-88</acst:ForeignCurrencyExposuresIncreaseDecreaseInNetLoss>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2019-03-31_ClassesOfAssetsAxis-CashAndCashEquivalentsMember_TypesOfRisksAxis-CurrencyRiskForUSDMember" decimals="INF" id="c47924664" unitRef="iso4217-cad">3369000</acst:ForeignExchangeRiskCurrencyExposure>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2019-03-31_ClassesOfAssetsAxis-CashAndCashEquivalentsMember_TypesOfRisksAxis-CurrencyRiskForEuroMember" id="c47924665" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2018-03-31_ClassesOfAssetsAxis-CashAndCashEquivalentsMember_TypesOfRisksAxis-CurrencyRiskForUSDMember" decimals="INF" id="c47924666" unitRef="iso4217-cad">7024000</acst:ForeignExchangeRiskCurrencyExposure>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2018-03-31_ClassesOfAssetsAxis-CashAndCashEquivalentsMember_TypesOfRisksAxis-CurrencyRiskForEuroMember" id="c47924667" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2019-03-31_ClassesOfAssetsAxis-MarketableSecuritiesMember_TypesOfRisksAxis-CurrencyRiskForUSDMember" decimals="INF" id="c47924674" unitRef="iso4217-cad">2696000</acst:ForeignExchangeRiskCurrencyExposure>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2019-03-31_ClassesOfAssetsAxis-MarketableSecuritiesMember_TypesOfRisksAxis-CurrencyRiskForEuroMember" id="c47924675" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2018-03-31_ClassesOfAssetsAxis-MarketableSecuritiesMember_TypesOfRisksAxis-CurrencyRiskForUSDMember" decimals="INF" id="c47924676" unitRef="iso4217-cad">26000</acst:ForeignExchangeRiskCurrencyExposure>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2018-03-31_ClassesOfAssetsAxis-MarketableSecuritiesMember_TypesOfRisksAxis-CurrencyRiskForEuroMember" id="c47924677" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2019-03-31_ClassesOfAssetsAxis-ReceivablesMember_TypesOfRisksAxis-CurrencyRiskForUSDMember" decimals="INF" id="c47924684" unitRef="iso4217-cad">16000</acst:ForeignExchangeRiskCurrencyExposure>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2019-03-31_ClassesOfAssetsAxis-ReceivablesMember_TypesOfRisksAxis-CurrencyRiskForEuroMember" id="c47924685" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2018-03-31_ClassesOfAssetsAxis-ReceivablesMember_TypesOfRisksAxis-CurrencyRiskForUSDMember" decimals="INF" id="c47924686" unitRef="iso4217-cad">6000</acst:ForeignExchangeRiskCurrencyExposure>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2018-03-31_ClassesOfAssetsAxis-ReceivablesMember_TypesOfRisksAxis-CurrencyRiskForEuroMember" id="c47924687" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_TypesOfRisksAxis-CurrencyRiskForUSDMember" decimals="INF" id="c47924694" unitRef="iso4217-cad">-13251000</acst:ForeignExchangeRiskCurrencyExposure>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_TypesOfRisksAxis-CurrencyRiskForEuroMember" decimals="INF" id="c47924695" unitRef="iso4217-cad">-131000</acst:ForeignExchangeRiskCurrencyExposure>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_TypesOfRisksAxis-CurrencyRiskForUSDMember" decimals="INF" id="c47924696" unitRef="iso4217-cad">-3924000</acst:ForeignExchangeRiskCurrencyExposure>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_TypesOfRisksAxis-CurrencyRiskForEuroMember" decimals="INF" id="c47924697" unitRef="iso4217-cad">-627000</acst:ForeignExchangeRiskCurrencyExposure>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2019-03-31_TypesOfRisksAxis-CurrencyRiskForUSDMember" decimals="INF" id="c47924704" unitRef="iso4217-cad">-7170000</acst:ForeignExchangeRiskCurrencyExposure>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2019-03-31_TypesOfRisksAxis-CurrencyRiskForEuroMember" decimals="INF" id="c47924705" unitRef="iso4217-cad">-131000</acst:ForeignExchangeRiskCurrencyExposure>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2018-03-31_TypesOfRisksAxis-CurrencyRiskForUSDMember" decimals="INF" id="c47924706" unitRef="iso4217-cad">3132000</acst:ForeignExchangeRiskCurrencyExposure>
  <acst:ForeignExchangeRiskCurrencyExposure contextRef="i_2018-03-31_TypesOfRisksAxis-CurrencyRiskForEuroMember" decimals="INF" id="c47924707" unitRef="iso4217-cad">-627000</acst:ForeignExchangeRiskCurrencyExposure>
  <acst:GovernmentAssistanceAndTaxCreditsReceivable contextRef="i_2019-03-31" decimals="-3" id="c47923167" unitRef="iso4217-cad">872000</acst:GovernmentAssistanceAndTaxCreditsReceivable>
  <acst:GovernmentAssistanceAndTaxCreditsReceivable contextRef="i_2018-03-31" decimals="-3" id="c47923168" unitRef="iso4217-cad">282000</acst:GovernmentAssistanceAndTaxCreditsReceivable>
  <acst:GovernmentGrantsAndInvestmentTaxCredits contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47923355" unitRef="iso4217-cad">595000</acst:GovernmentGrantsAndInvestmentTaxCredits>
  <acst:GovernmentGrantsAndInvestmentTaxCredits contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47923356" unitRef="iso4217-cad">409000</acst:GovernmentGrantsAndInvestmentTaxCredits>
  <acst:GovernmentGrantsAndInvestmentTaxCredits contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47923357" unitRef="iso4217-cad">330000</acst:GovernmentGrantsAndInvestmentTaxCredits>
  <acst:GovernmentGrantsAndInvestmentTaxCredits contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47923358" unitRef="iso4217-cad">45000</acst:GovernmentGrantsAndInvestmentTaxCredits>
  <acst:GovernmentGrantsAndInvestmentTaxCredits contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47923359" unitRef="iso4217-cad">285000</acst:GovernmentGrantsAndInvestmentTaxCredits>
  <acst:GrossFinanceIncomeCost contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922499" unitRef="iso4217-cad">-6551000</acst:GrossFinanceIncomeCost>
  <acst:GrossFinanceIncomeCost contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922500" unitRef="iso4217-cad">-1808000</acst:GrossFinanceIncomeCost>
  <acst:GrossFinanceIncomeCost contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922501" unitRef="iso4217-cad">-166000</acst:GrossFinanceIncomeCost>
  <acst:GrossFinanceIncomeCost contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922502" unitRef="iso4217-cad">-51000</acst:GrossFinanceIncomeCost>
  <acst:GrossFinanceIncomeCost contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922503" unitRef="iso4217-cad">-115000</acst:GrossFinanceIncomeCost>
  <acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment contextRef="d_2017-02-21_2017-02-21" decimals="INF" id="c47923819" unitRef="iso4217-cad">94000</acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment>
  <acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922724" unitRef="iso4217-cad">94000</acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment>
  <acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922725" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" id="c47922726" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922727" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922728" unitRef="iso4217-cad">94000</acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment>
  <acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares contextRef="d_2017-02-21_2017-02-21" decimals="INF" id="c47923817" unitRef="xbrli-shares">60000</acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares>
  <acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922723" unitRef="xbrli-shares">60000</acst:IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares>
  <acst:IncreaseDecreaseThroughSharebasedPaymentTransactionsShares contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922572" unitRef="xbrli-shares">4167</acst:IncreaseDecreaseThroughSharebasedPaymentTransactionsShares>
  <acst:IntangibleAssetsUsefulLife contextRef="d_2018-04-01_2019-03-31_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" id="c47923148">P20Y</acst:IntangibleAssetsUsefulLife>
  <acst:IntangibleAssetsUsefulLife contextRef="d_2018-04-01_2019-03-31_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember_RangeAxis-BottomOfRangeMember" id="c47923154">P8Y</acst:IntangibleAssetsUsefulLife>
  <acst:IntangibleAssetsUsefulLife contextRef="d_2018-04-01_2019-03-31_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember_RangeAxis-TopOfRangeMember" id="c47923156">P14Y</acst:IntangibleAssetsUsefulLife>
  <acst:InterestPayableIncludedInTradeAndOtherPayables contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924499" unitRef="iso4217-cad">40000</acst:InterestPayableIncludedInTradeAndOtherPayables>
  <acst:InterestPayableIncludedInTradeAndOtherPayables contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924500" unitRef="iso4217-cad">40000</acst:InterestPayableIncludedInTradeAndOtherPayables>
  <acst:InterestPayableIncludedInTradeAndOtherPayables contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924501" unitRef="iso4217-cad">18000</acst:InterestPayableIncludedInTradeAndOtherPayables>
  <acst:InterestPayableIncludedInTradeAndOtherPayables contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924502" unitRef="iso4217-cad">18000</acst:InterestPayableIncludedInTradeAndOtherPayables>
  <acst:InterestPayableIncludedInTradeAndOtherPayables contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924503" unitRef="iso4217-cad">4000</acst:InterestPayableIncludedInTradeAndOtherPayables>
  <acst:InterestReceivableIncludedInReceivables contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924479" unitRef="iso4217-cad">96000</acst:InterestReceivableIncludedInReceivables>
  <acst:InterestReceivableIncludedInReceivables contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924480" unitRef="iso4217-cad">7000</acst:InterestReceivableIncludedInReceivables>
  <acst:InterestReceivableIncludedInReceivables contextRef="d_2016-03-01_2017-03-31" id="c47924481" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:InterestReceivableIncludedInReceivables contextRef="d_2017-03-01_2017-03-31" id="c47924482" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:InterestReceivableIncludedInReceivables contextRef="d_2016-03-01_2017-02-28" id="c47924483" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:InvestmentTaxCredit contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47923345" unitRef="iso4217-cad">588000</acst:InvestmentTaxCredit>
  <acst:InvestmentTaxCredit contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47923346" unitRef="iso4217-cad">409000</acst:InvestmentTaxCredit>
  <acst:InvestmentTaxCredit contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47923347" unitRef="iso4217-cad">103000</acst:InvestmentTaxCredit>
  <acst:InvestmentTaxCredit contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47923348" unitRef="iso4217-cad">8000</acst:InvestmentTaxCredit>
  <acst:InvestmentTaxCredit contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47923349" unitRef="iso4217-cad">95000</acst:InvestmentTaxCredit>
  <acst:IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924469" unitRef="iso4217-cad">283000</acst:IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering>
  <acst:IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924470" unitRef="iso4217-cad">406000</acst:IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering>
  <acst:IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924471" unitRef="iso4217-cad">144000</acst:IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering>
  <acst:IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering contextRef="d_2017-03-01_2017-03-31" id="c47924472" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924473" unitRef="iso4217-cad">144000</acst:IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering>
  <acst:IssuanceOfSharesForInterestOnConvertibleDebt contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924464" unitRef="iso4217-cad">120000</acst:IssuanceOfSharesForInterestOnConvertibleDebt>
  <acst:IssuanceOfSharesForInterestOnConvertibleDebt contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924465" unitRef="iso4217-cad">137000</acst:IssuanceOfSharesForInterestOnConvertibleDebt>
  <acst:IssuanceOfSharesForInterestOnConvertibleDebt contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924466" unitRef="iso4217-cad">94000</acst:IssuanceOfSharesForInterestOnConvertibleDebt>
  <acst:IssuanceOfSharesForInterestOnConvertibleDebt contextRef="d_2017-03-01_2017-03-31" id="c47924467" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:IssuanceOfSharesForInterestOnConvertibleDebt contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924468" unitRef="iso4217-cad">94000</acst:IssuanceOfSharesForInterestOnConvertibleDebt>
  <acst:IssueOfEquityNumberOfShares contextRef="d_2018-10-01_2018-10-31" decimals="INF" id="c47923726" unitRef="xbrli-shares">19090000</acst:IssueOfEquityNumberOfShares>
  <acst:IssueOfEquityNumberOfShares contextRef="d_2018-10-23_2018-10-23" decimals="INF" id="c47923739" unitRef="xbrli-shares">21562500</acst:IssueOfEquityNumberOfShares>
  <acst:IssueOfEquityNumberOfShares contextRef="d_2018-05-09_2018-05-09" decimals="INF" id="c47923743" unitRef="xbrli-shares">9530000</acst:IssueOfEquityNumberOfShares>
  <acst:IssueOfEquityNumberOfShares contextRef="d_2018-05-14_2018-05-14_CounterpartiesAxis-UnderwriterMember" decimals="INF" id="c47923750" unitRef="xbrli-shares">1429500</acst:IssueOfEquityNumberOfShares>
  <acst:IssueOfEquityNumberOfShares contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922558" unitRef="xbrli-shares">51612000</acst:IssueOfEquityNumberOfShares>
  <acst:IssueOfEquityNumberOfShares contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922623" unitRef="xbrli-shares">10667169</acst:IssueOfEquityNumberOfShares>
  <acst:IssueOfEquityNumberOfShares contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922702" unitRef="xbrli-shares">3930518</acst:IssueOfEquityNumberOfShares>
  <acst:LegalExpense contextRef="d_2018-04-01_2019-03-31_CounterpartiesAxis-FormerCEOMember" decimals="INF" id="c47924869" unitRef="iso4217-cad">1054000</acst:LegalExpense>
  <acst:LegalFeesReimburse contextRef="d_2019-05-10_2019-05-10_CounterpartiesAxis-FormerCEOMember_NonadjustingEventsAfterReportingPeriodAxis-MajorOrdinaryShareTransactionsMember" decimals="INF" id="c47924868" unitRef="iso4217-cad">64000</acst:LegalFeesReimburse>
  <acst:LegalSettlementPayableCurrent contextRef="i_2019-03-31" decimals="-3" id="c47923568" unitRef="iso4217-cad">990000</acst:LegalSettlementPayableCurrent>
  <acst:LegalSettlementPayableCurrent contextRef="i_2018-03-31" id="c47923569" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:MarketableSecuritiesCurrent contextRef="i_2019-03-31" decimals="-3" id="c47923210" unitRef="iso4217-cad">11865000</acst:MarketableSecuritiesCurrent>
  <acst:MarketableSecuritiesCurrent contextRef="i_2018-03-31" id="c47923211" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:MarketableSecuritiesNoncurrent contextRef="i_2019-03-31" decimals="-3" id="c47923212" unitRef="iso4217-cad">27000</acst:MarketableSecuritiesNoncurrent>
  <acst:MarketableSecuritiesNoncurrent contextRef="i_2018-03-31" decimals="-3" id="c47923213" unitRef="iso4217-cad">26000</acst:MarketableSecuritiesNoncurrent>
  <acst:MarketableSecurties contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositOneMember" id="c47923182" unitRef="iso4217-usd" xs:nil="true"/>
  <acst:MarketableSecurties contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositOneMember" decimals="-4" id="c47923183" unitRef="iso4217-usd">20000</acst:MarketableSecurties>
  <acst:MarketableSecurties contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember" decimals="-4" id="c47923190" unitRef="iso4217-usd">2020000</acst:MarketableSecurties>
  <acst:MarketableSecurties contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember" id="c47923191" unitRef="iso4217-usd" xs:nil="true"/>
  <acst:MarketableSecurties contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositOneMember" id="c47923180" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:MarketableSecurties contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositOneMember" decimals="-3" id="c47923181" unitRef="iso4217-cad">26000</acst:MarketableSecurties>
  <acst:MarketableSecurties contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember" decimals="-3" id="c47923188" unitRef="iso4217-cad">2696000</acst:MarketableSecurties>
  <acst:MarketableSecurties contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember" id="c47923189" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:MarketableSecurties contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember" decimals="-3" id="c47923198" unitRef="iso4217-cad">9196000</acst:MarketableSecurties>
  <acst:MarketableSecurties contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember" id="c47923199" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:MarketableSecurties contextRef="i_2019-03-31" decimals="-3" id="c47923208" unitRef="iso4217-cad">11892000</acst:MarketableSecurties>
  <acst:MarketableSecurties contextRef="i_2018-03-31" decimals="-3" id="c47923209" unitRef="iso4217-cad">26000</acst:MarketableSecurties>
  <acst:MaximumNumberOfCommonSharesIssuableFromContingentWarrants contextRef="i_2017-02-21_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="INF" id="c47923658" unitRef="xbrli-shares">1052630</acst:MaximumNumberOfCommonSharesIssuableFromContingentWarrants>
  <acst:MaximumNumberOfSharesAuthorized contextRef="i_2017-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924096" unitRef="xbrli-shares">2940511</acst:MaximumNumberOfSharesAuthorized>
  <acst:MaximumNumberOfSharesAuthorized contextRef="i_2018-06-27_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924098" unitRef="xbrli-shares">5494209</acst:MaximumNumberOfSharesAuthorized>
  <acst:MaximumNumberOfSharesAuthorizedAsPercentage contextRef="i_2017-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924097" unitRef="xbrli-pure">0.2</acst:MaximumNumberOfSharesAuthorizedAsPercentage>
  <acst:MaximumNumberOfSharesAuthorizedAsPercentage contextRef="i_2018-06-27_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924099" unitRef="xbrli-pure">0.15</acst:MaximumNumberOfSharesAuthorizedAsPercentage>
  <acst:MaximumNumberOfSharesAuthorizedAsPercentage contextRef="i_2019-03-31_CounterpartiesAxis-ConsultantsMember_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924107" unitRef="xbrli-pure">0.02</acst:MaximumNumberOfSharesAuthorizedAsPercentage>
  <acst:NetEquity contextRef="i_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922550" unitRef="iso4217-cad">73338000</acst:NetEquity>
  <acst:NetEquity contextRef="i_2019-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" decimals="-3" id="c47922551" unitRef="iso4217-cad">309000</acst:NetEquity>
  <acst:NetEquity contextRef="i_2019-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922552" unitRef="iso4217-cad">6956000</acst:NetEquity>
  <acst:NetEquity contextRef="i_2019-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" decimals="-3" id="c47922553" unitRef="iso4217-cad">-123945000</acst:NetEquity>
  <acst:NetEquity contextRef="i_2019-03-31" decimals="-3" id="c47922554" unitRef="iso4217-cad">-43342000</acst:NetEquity>
  <acst:NetEquity contextRef="i_2018-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922615" unitRef="iso4217-cad">66576000</acst:NetEquity>
  <acst:NetEquity contextRef="i_2018-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" decimals="-3" id="c47922616" unitRef="iso4217-cad">309000</acst:NetEquity>
  <acst:NetEquity contextRef="i_2018-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922617" unitRef="iso4217-cad">5693000</acst:NetEquity>
  <acst:NetEquity contextRef="i_2018-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" decimals="-3" id="c47922618" unitRef="iso4217-cad">-72379000</acst:NetEquity>
  <acst:NetEquity contextRef="i_2018-03-31" decimals="-3" id="c47922619" unitRef="iso4217-cad">199000</acst:NetEquity>
  <acst:NetEquity contextRef="i_2017-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922694" unitRef="iso4217-cad">61973000</acst:NetEquity>
  <acst:NetEquity contextRef="i_2017-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922695" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:NetEquity contextRef="i_2017-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922696" unitRef="iso4217-cad">4875000</acst:NetEquity>
  <acst:NetEquity contextRef="i_2017-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" decimals="-3" id="c47922697" unitRef="iso4217-cad">-50875000</acst:NetEquity>
  <acst:NetEquity contextRef="i_2017-03-31" decimals="-3" id="c47922698" unitRef="iso4217-cad">15973000</acst:NetEquity>
  <acst:NonCumulativeDividendRate contextRef="i_2019-03-31_ClassesOfShareCapitalAxis-ClassBSharesMember" decimals="INF" id="c47923700" unitRef="xbrli-pure">0.05</acst:NonCumulativeDividendRate>
  <acst:NonCumulativeDividendRate contextRef="i_2019-03-31_ClassesOfShareCapitalAxis-ClassCSharesMember" decimals="INF" id="c47923704" unitRef="xbrli-pure">0.05</acst:NonCumulativeDividendRate>
  <acst:NonCumulativeDividendRate contextRef="i_2019-03-31_ClassesOfShareCapitalAxis-ClassDAndESharesMember_RangeAxis-BottomOfRangeMember" decimals="INF" id="c47923708" unitRef="xbrli-pure">0.005</acst:NonCumulativeDividendRate>
  <acst:NonCumulativeDividendRate contextRef="i_2019-03-31_ClassesOfShareCapitalAxis-ClassDAndESharesMember_RangeAxis-TopOfRangeMember" decimals="INF" id="c47923709" unitRef="xbrli-pure">0.02</acst:NonCumulativeDividendRate>
  <acst:NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare contextRef="i_2018-12-03_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" decimals="INF" id="c47923578" unitRef="xbrli-shares">10</acst:NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare>
  <acst:NumberOfSharesCalledByEachWarrant contextRef="i_2017-02-21" decimals="INF" id="c47923804" unitRef="xbrli-shares">1</acst:NumberOfSharesCalledByEachWarrant>
  <acst:NumberOfSharesCalledByWarrants contextRef="i_2018-05-31_CounterpartiesAxis-BrokerMember" decimals="INF" id="c47923761" unitRef="xbrli-shares">547975</acst:NumberOfSharesCalledByWarrants>
  <acst:NumberOfSharesCalledByWarrants contextRef="i_2017-12-27_CategoriesOfRelatedPartiesAxis-UnderwriterMember" decimals="INF" id="c47923781" unitRef="xbrli-shares">892044</acst:NumberOfSharesCalledByWarrants>
  <acst:NumberOfSharesCalledByWarrants contextRef="i_2017-12-27" decimals="INF" id="c47923786" unitRef="xbrli-shares">495050</acst:NumberOfSharesCalledByWarrants>
  <acst:NumberOfSharesCalledByWarrants contextRef="i_2017-02-21" decimals="INF" id="c47923807" unitRef="xbrli-shares">234992</acst:NumberOfSharesCalledByWarrants>
  <acst:NumberOfSharesIssuedForLegalSettlement contextRef="d_2019-05-10_2019-05-10_CounterpartiesAxis-FormerCEOMember_NonadjustingEventsAfterReportingPeriodAxis-MajorOrdinaryShareTransactionsMember" decimals="INF" id="c47924866" unitRef="xbrli-shares">900000</acst:NumberOfSharesIssuedForLegalSettlement>
  <acst:NumberOfSharesIssuedForOptionExercised contextRef="d_2018-10-01_2018-10-31_CounterpartiesAxis-UnderwriterMember" decimals="INF" id="c47923721" unitRef="xbrli-shares">2490000</acst:NumberOfSharesIssuedForOptionExercised>
  <acst:NumberOfSharesIssuedForOptionExercised contextRef="d_2018-10-23_2018-10-23_CounterpartiesAxis-UnderwriterMember" decimals="INF" id="c47923736" unitRef="xbrli-shares">2812500</acst:NumberOfSharesIssuedForOptionExercised>
  <acst:NumberOfSharesIssuedInPublicOffering contextRef="d_2018-10-01_2018-10-31" decimals="INF" id="c47923719" unitRef="xbrli-shares">16600000</acst:NumberOfSharesIssuedInPublicOffering>
  <acst:NumberOfSharesIssuedInPublicOffering contextRef="d_2018-10-23_2018-10-23" decimals="INF" id="c47923734" unitRef="xbrli-shares">18750000</acst:NumberOfSharesIssuedInPublicOffering>
  <acst:NumberOfUnitsIssuedDuringPeriod contextRef="d_2018-05-09_2018-05-09" decimals="INF" id="c47923740" unitRef="xbrli-shares">9530000</acst:NumberOfUnitsIssuedDuringPeriod>
  <acst:NumberOfUnitsIssuedDuringPeriod contextRef="d_2018-05-14_2018-05-14_CounterpartiesAxis-UnderwriterMember" decimals="INF" id="c47923747" unitRef="xbrli-shares">1429500</acst:NumberOfUnitsIssuedDuringPeriod>
  <acst:NumberOfUnitsIssuedDuringPeriod contextRef="d_2017-12-27_2017-12-27" decimals="INF" id="c47923773" unitRef="xbrli-shares">9900990</acst:NumberOfUnitsIssuedDuringPeriod>
  <acst:NumberOfUnitsIssuedDuringPeriod contextRef="d_2017-12-27_2017-12-27_ClassesOfOrdinarySharesAxis-ClassASharesMember" decimals="INF" id="c47923777" unitRef="xbrli-shares">9900990</acst:NumberOfUnitsIssuedDuringPeriod>
  <acst:NumberOfUnitsIssuedDuringPeriod contextRef="d_2017-12-27_2017-12-27_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="INF" id="c47923778" unitRef="xbrli-shares">8910891</acst:NumberOfUnitsIssuedDuringPeriod>
  <acst:NumberOfUnitsIssuedDuringPeriod contextRef="d_2017-02-21_2017-02-21" decimals="INF" id="c47923798" unitRef="xbrli-shares">3930518</acst:NumberOfUnitsIssuedDuringPeriod>
  <acst:NumberOfWarrantsExercised contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" decimals="INF" id="c47923860" unitRef="xbrli-shares">771400</acst:NumberOfWarrantsExercised>
  <acst:NumberOfWarrantsExercised contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" decimals="INF" id="c47923863" unitRef="xbrli-shares">4455</acst:NumberOfWarrantsExercised>
  <acst:NumberOfWarrantsExercised contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47923866" unitRef="xbrli-shares">775855</acst:NumberOfWarrantsExercised>
  <acst:NumberOfWarrantsExercised contextRef="d_2017-01-01_2017-12-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember" decimals="INF" id="c47923867" unitRef="xbrli-shares">178721</acst:NumberOfWarrantsExercised>
  <acst:NumberOfWarrantsIssuedDuringPeriod contextRef="d_2018-05-09_2018-05-09" decimals="INF" id="c47923744" unitRef="xbrli-shares">9530000</acst:NumberOfWarrantsIssuedDuringPeriod>
  <acst:NumberOfWarrantsIssuedDuringPeriod contextRef="d_2018-05-14_2018-05-14_CounterpartiesAxis-UnderwriterMember" decimals="INF" id="c47923751" unitRef="xbrli-shares">1429500</acst:NumberOfWarrantsIssuedDuringPeriod>
  <acst:PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables contextRef="d_2018-04-01_2019-03-31" id="c47924489" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables contextRef="d_2017-04-01_2018-03-31" id="c47924490" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924491" unitRef="iso4217-cad">40000</acst:PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables>
  <acst:PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924492" unitRef="iso4217-cad">40000</acst:PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables>
  <acst:PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924493" unitRef="iso4217-cad">50000</acst:PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables>
  <acst:ProceedsFromExerciseOfWarrants contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" decimals="INF" id="c47923862" unitRef="iso4217-cad">1000000</acst:ProceedsFromExerciseOfWarrants>
  <acst:ProceedsFromExerciseOfWarrants contextRef="d_2017-01-01_2017-12-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember" decimals="INF" id="c47923869" unitRef="iso4217-cad">384000</acst:ProceedsFromExerciseOfWarrants>
  <acst:ProceedsFromExerciseOfWarrants contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922904" unitRef="iso4217-cad">1011000</acst:ProceedsFromExerciseOfWarrants>
  <acst:ProceedsFromExerciseOfWarrants contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922905" unitRef="iso4217-cad">384000</acst:ProceedsFromExerciseOfWarrants>
  <acst:ProceedsFromExerciseOfWarrants contextRef="d_2016-03-01_2017-03-31" id="c47922906" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:ProceedsFromExerciseOfWarrants contextRef="d_2017-03-01_2017-03-31" id="c47922907" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:ProceedsFromExerciseOfWarrants contextRef="d_2016-03-01_2017-02-28" id="c47922908" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:ProceedsFromIssuingSharesInPublicOfferingGross contextRef="d_2018-10-01_2018-10-31" decimals="INF" id="c47923722" unitRef="iso4217-cad">24700000</acst:ProceedsFromIssuingSharesInPublicOfferingGross>
  <acst:ProceedsFromIssuingSharesInPublicOfferingGross contextRef="d_2018-10-01_2018-10-31" decimals="-5" id="c47923723" unitRef="iso4217-usd">19100000</acst:ProceedsFromIssuingSharesInPublicOfferingGross>
  <acst:ProceedsFromIssuingSharesInPublicOfferingGross contextRef="d_2018-10-23_2018-10-23" decimals="INF" id="c47923737" unitRef="iso4217-cad">27600000</acst:ProceedsFromIssuingSharesInPublicOfferingGross>
  <acst:ProceedsFromIssuingSharesPrivatePlacement contextRef="d_2018-04-01_2019-03-31" id="c47922898" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:ProceedsFromIssuingSharesPrivatePlacement contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922899" unitRef="iso4217-cad">-40000</acst:ProceedsFromIssuingSharesPrivatePlacement>
  <acst:ProceedsFromIssuingSharesPrivatePlacement contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922900" unitRef="iso4217-cad">1872000</acst:ProceedsFromIssuingSharesPrivatePlacement>
  <acst:ProceedsFromIssuingSharesPrivatePlacement contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922901" unitRef="iso4217-cad">-10000</acst:ProceedsFromIssuingSharesPrivatePlacement>
  <acst:ProceedsFromIssuingSharesPrivatePlacement contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922902" unitRef="iso4217-cad">1882000</acst:ProceedsFromIssuingSharesPrivatePlacement>
  <acst:ProceedsFromIssuingUnits contextRef="d_2018-05-09_2018-05-09" decimals="INF" id="c47923742" unitRef="iso4217-cad">10000000</acst:ProceedsFromIssuingUnits>
  <acst:ProceedsFromIssuingUnits contextRef="d_2018-05-14_2018-05-14_CounterpartiesAxis-UnderwriterMember" decimals="INF" id="c47923749" unitRef="iso4217-cad">1500000</acst:ProceedsFromIssuingUnits>
  <acst:ProceedsFromIssuingUnits contextRef="d_2017-12-27_2017-12-27" decimals="INF" id="c47923775" unitRef="iso4217-cad">12600000</acst:ProceedsFromIssuingUnits>
  <acst:ProceedsFromIssuingUnits contextRef="d_2017-12-27_2017-12-27" decimals="-5" id="c47923776" unitRef="iso4217-usd">10000000</acst:ProceedsFromIssuingUnits>
  <acst:ProceedsFromIssuingUnits contextRef="d_2017-02-21_2017-02-21" decimals="INF" id="c47923800" unitRef="iso4217-cad">5699000</acst:ProceedsFromIssuingUnits>
  <acst:ProportionOfOwnershipInterestsHeldByRelatedParty contextRef="d_2018-04-01_2019-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="3" id="c47923230" unitRef="xbrli-pure">0.065</acst:ProportionOfOwnershipInterestsHeldByRelatedParty>
  <acst:ProportionOfVotingRightsHeldByAnAssociate contextRef="d_2018-04-01_2019-03-31_CategoriesOfRelatedPartiesAxis-KeyManagementPersonnelOfEntityOrParentMember_RangeAxis-TopOfRangeMember" decimals="3" id="c47923265" unitRef="xbrli-pure">0.01</acst:ProportionOfVotingRightsHeldByAnAssociate>
  <acst:ProportionOfVotingRightsHeldByAnAssociate contextRef="d_2017-04-01_2018-03-31_CategoriesOfRelatedPartiesAxis-KeyManagementPersonnelOfEntityOrParentMember_RangeAxis-TopOfRangeMember" decimals="3" id="c47923266" unitRef="xbrli-pure">0.01</acst:ProportionOfVotingRightsHeldByAnAssociate>
  <acst:ProportionOfVotingRightsHeldByAnAssociate contextRef="d_2016-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-KeyManagementPersonnelOfEntityOrParentMember_RangeAxis-TopOfRangeMember" decimals="3" id="c47923268" unitRef="xbrli-pure">0.02</acst:ProportionOfVotingRightsHeldByAnAssociate>
  <acst:PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables contextRef="d_2018-04-01_2019-03-31" id="c47924474" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924475" unitRef="iso4217-cad">132000</acst:PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables>
  <acst:PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924476" unitRef="iso4217-cad">381000</acst:PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables>
  <acst:PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924477" unitRef="iso4217-cad">381000</acst:PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables>
  <acst:PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924478" unitRef="iso4217-cad">416000</acst:PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables>
  <acst:PurchasesOtherAssets contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47923219" unitRef="iso4217-cad">68000</acst:PurchasesOtherAssets>
  <acst:PurchasesOtherAssets contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47923220" unitRef="iso4217-cad">970000</acst:PurchasesOtherAssets>
  <acst:ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-43">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right; border-top: Black 1.5pt solid"&gt;Twelve-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2019&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2018&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, &lt;/div&gt;&lt;br /&gt; 2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; text-align: left"&gt;Loss before income taxes&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(51,566&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(21,504&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11,376&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(769&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(10,607&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basic combined Canadian statutory income tax rate &lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26.68&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26.78&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26.87&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26.80&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26.88&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Computed income tax recovery&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(13,758&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5,759&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3,057&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(206&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,851&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Increase resulting from:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -7.15pt; padding-left: 21.55pt"&gt;Change in unrecognized deductible temporary differences&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,599&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,241&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,369&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;162&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,207&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 0.2in"&gt;Non-deductible stock-based compensation&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;279&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;248&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;178&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;155&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 0.2in"&gt;Non-deductible change in fair value&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,677&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;92&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 0.2in"&gt;Permanent differences and other&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;203&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;178&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;166&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;154&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 0.2in"&gt;Change in statutory income tax rate&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;201&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;198&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Total tax (recovery) expense&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock>
  <acst:RedeemablePricePerShare contextRef="i_2019-03-31_ClassesOfShareCapitalAxis-ClassBSharesMember" decimals="INF" id="c47923703" unitRef="iso4217-cad-per-xbrli-shares">0.80</acst:RedeemablePricePerShare>
  <acst:RedeemablePricePerShare contextRef="i_2019-03-31_ClassesOfShareCapitalAxis-ClassCSharesMember" decimals="INF" id="c47923707" unitRef="iso4217-cad-per-xbrli-shares">0.20</acst:RedeemablePricePerShare>
  <acst:ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables contextRef="d_2018-04-01_2019-03-31" id="c47924484" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables contextRef="d_2017-04-01_2018-03-31" id="c47924485" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924486" unitRef="iso4217-cad">109000</acst:ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables>
  <acst:ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables contextRef="d_2017-03-01_2017-03-31" id="c47924487" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924488" unitRef="iso4217-cad">109000</acst:ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables>
  <acst:ResearchDevelopmentGeneralAndAdministrationExpense contextRef="d_2018-04-01_2019-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923314" unitRef="iso4217-cad">245000</acst:ResearchDevelopmentGeneralAndAdministrationExpense>
  <acst:ResearchDevelopmentGeneralAndAdministrationExpense contextRef="d_2017-04-01_2018-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923315" unitRef="iso4217-cad">387000</acst:ResearchDevelopmentGeneralAndAdministrationExpense>
  <acst:ResearchDevelopmentGeneralAndAdministrationExpense contextRef="d_2016-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923316" unitRef="iso4217-cad">678000</acst:ResearchDevelopmentGeneralAndAdministrationExpense>
  <acst:ResearchDevelopmentGeneralAndAdministrationExpense contextRef="d_2017-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923317" unitRef="iso4217-cad">42000</acst:ResearchDevelopmentGeneralAndAdministrationExpense>
  <acst:ResearchDevelopmentGeneralAndAdministrationExpense contextRef="d_2016-03-01_2017-02-28_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923318" unitRef="iso4217-cad">636000</acst:ResearchDevelopmentGeneralAndAdministrationExpense>
  <acst:RiskFreeInterestRateWarrantsIssued contextRef="d_2018-05-01_2018-05-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" decimals="4" id="c47923887" unitRef="xbrli-pure">0.0221</acst:RiskFreeInterestRateWarrantsIssued>
  <acst:RiskFreeInterestRateWarrantsIssued contextRef="d_2018-05-01_2018-05-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember" decimals="4" id="c47923892" unitRef="xbrli-pure">0.022</acst:RiskFreeInterestRateWarrantsIssued>
  <acst:RiskFreeInterestRateWarrantsIssued contextRef="d_2017-12-27_2017-12-27_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsIn2017Member" decimals="4" id="c47923897" unitRef="xbrli-pure">0.0222</acst:RiskFreeInterestRateWarrantsIssued>
  <acst:RiskFreeInterestRateWarrantsIssued contextRef="d_2017-12-27_2017-12-27_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" decimals="4" id="c47923902" unitRef="xbrli-pure">0.0222</acst:RiskFreeInterestRateWarrantsIssued>
  <acst:RiskFreeInterestRateWarrantsIssued contextRef="d_2017-02-21_2017-02-21_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" decimals="4" id="c47923908" unitRef="xbrli-pure">0.0079</acst:RiskFreeInterestRateWarrantsIssued>
  <acst:RiskFreeInterestRateWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" decimals="4" id="c47923637" unitRef="xbrli-pure">0.0152</acst:RiskFreeInterestRateWarrantsIssued>
  <acst:RiskFreeInterestRateWarrantsIssued contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" id="c47923638" unitRef="xbrli-pure" xs:nil="true"/>
  <acst:RiskFreeInterestRateWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="4" id="c47923639" unitRef="xbrli-pure">0.0223</acst:RiskFreeInterestRateWarrantsIssued>
  <acst:RiskFreeInterestRateWarrantsIssued contextRef="d_2016-03-01_2017-02-28_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="4" id="c47923640" unitRef="xbrli-pure">0.0256</acst:RiskFreeInterestRateWarrantsIssued>
  <acst:RiskFreeInterestRateWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" id="c47923641" unitRef="xbrli-pure" xs:nil="true"/>
  <acst:RiskFreeInterestRateWarrantsIssued contextRef="d_2016-03-01_2017-02-28_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" decimals="4" id="c47923642" unitRef="xbrli-pure">0.0219</acst:RiskFreeInterestRateWarrantsIssued>
  <acst:ShareBasedPaymentCostsAllocatedToDebt contextRef="d_2017-02-21_2017-02-21" decimals="INF" id="c47923821" unitRef="iso4217-cad">9000</acst:ShareBasedPaymentCostsAllocatedToDebt>
  <acst:ShareBasedPaymentCostsAllocatedToShareCapital contextRef="d_2017-02-21_2017-02-21" decimals="INF" id="c47923820" unitRef="iso4217-cad">85000</acst:ShareBasedPaymentCostsAllocatedToShareCapital>
  <acst:ShareIssuedPricePerShare contextRef="i_2018-10-31" decimals="INF" id="c47923720" unitRef="iso4217-usd-per-xbrli-shares">1</acst:ShareIssuedPricePerShare>
  <acst:ShareIssuedPricePerShare contextRef="i_2018-10-23" decimals="INF" id="c47923735" unitRef="iso4217-cad-per-xbrli-shares">1.28</acst:ShareIssuedPricePerShare>
  <acst:ShareIssuedPricePerShare contextRef="i_2017-02-21" decimals="INF" id="c47923818" unitRef="iso4217-cad-per-xbrli-shares">1.57</acst:ShareIssuedPricePerShare>
  <acst:ShareIssuedPricePerShare contextRef="i_2019-05-10_CounterpartiesAxis-FormerCEOMember_NonadjustingEventsAfterReportingPeriodAxis-MajorOrdinaryShareTransactionsMember" decimals="INF" id="c47924867" unitRef="iso4217-cad-per-xbrli-shares">1.10</acst:ShareIssuedPricePerShare>
  <acst:SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924817" unitRef="iso4217-cad">405000</acst:SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss>
  <acst:SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924815" unitRef="iso4217-cad">598000</acst:SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain>
  <acst:SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924814" unitRef="iso4217-cad">569000</acst:SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss>
  <acst:SummaryOfMarketableSecuritiesTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-20">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 70%; font-weight: normal; text-align: left"&gt;Term deposit issued in US currency [US $20], earning interest at 2.23% and maturing on March 13, 2019&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Term deposits issued in US currency [US $2,020], earning interest at 2.50% and maturing on various dates from April 8, 2019 to March 12, 2020&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,696&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Treasury bills issued in CAD currencyearning interest at rates ranging from 1.83% to 1.90% and maturing on various dates from April 2, 2019 to July 25, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,196&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Total Marketable securities&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,892&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; padding-left: 10pt"&gt;Current marketable securities&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,865&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 10pt"&gt;Marketable securities&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:SummaryOfMarketableSecuritiesTextBlock>
  <acst:SummaryOfOtherAssetsTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-21">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 70%; font-weight: normal; text-align: left"&gt;Balance &amp;#x2013; beginning of year&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;659&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Purchased&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;68&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;970&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;Used&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(105&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(311&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Balance &amp;#x2013; end of year&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;622&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;659&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt; &lt;div style="display: inline; font-weight: normal"&gt;&lt;/div&gt; &lt;div style="display: inline; font-weight: normal"&gt;Current other asset&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;65&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;104&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Other asset&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;557&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;555&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:SummaryOfOtherAssetsTextBlock>
  <acst:TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock contextRef="d_2018-04-01_2019-03-31" id="c-45">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; text-align: left; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;Federal&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;Provincial&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; padding-left: 0.2in; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Tax losses carried forward&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 70%; font-weight: normal; text-align: left"&gt;2029&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;714&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;714&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2030&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,627&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,620&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2031&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,071&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,063&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2032&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,262&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,241&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2033&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,854&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,825&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2034&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,598&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,598&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2035&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,595&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,459&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2036&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,494&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,494&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2037&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,584&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,456&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2038&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,340&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,270&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;2039&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,447&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,447&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;89,586&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;89,187&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Research and development expenses, without time limitation&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,617&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,036&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Other deductible temporary differences, without time limitation&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,875&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,294&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</acst:TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock>
  <acst:TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924563" unitRef="iso4217-cad">11599000</acst:TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences>
  <acst:TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924564" unitRef="iso4217-cad">5241000</acst:TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences>
  <acst:TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924565" unitRef="iso4217-cad">2369000</acst:TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences>
  <acst:TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924566" unitRef="iso4217-cad">162000</acst:TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences>
  <acst:TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924567" unitRef="iso4217-cad">2207000</acst:TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences>
  <acst:TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924573" unitRef="iso4217-cad">1677000</acst:TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss>
  <acst:TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924574" unitRef="iso4217-cad">92000</acst:TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss>
  <acst:TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924575" unitRef="iso4217-cad">14000</acst:TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss>
  <acst:TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924576" unitRef="iso4217-cad">6000</acst:TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss>
  <acst:TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924577" unitRef="iso4217-cad">8000</acst:TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss>
  <acst:TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924568" unitRef="iso4217-cad">279000</acst:TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss>
  <acst:TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924569" unitRef="iso4217-cad">248000</acst:TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss>
  <acst:TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924570" unitRef="iso4217-cad">178000</acst:TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss>
  <acst:TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924571" unitRef="iso4217-cad">23000</acst:TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss>
  <acst:TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924572" unitRef="iso4217-cad">155000</acst:TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss>
  <acst:TaxEffectOfPermanentDifferencesAndOther contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924578" unitRef="iso4217-cad">203000</acst:TaxEffectOfPermanentDifferencesAndOther>
  <acst:TaxEffectOfPermanentDifferencesAndOther contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924579" unitRef="iso4217-cad">178000</acst:TaxEffectOfPermanentDifferencesAndOther>
  <acst:TaxEffectOfPermanentDifferencesAndOther contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924580" unitRef="iso4217-cad">166000</acst:TaxEffectOfPermanentDifferencesAndOther>
  <acst:TaxEffectOfPermanentDifferencesAndOther contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924581" unitRef="iso4217-cad">12000</acst:TaxEffectOfPermanentDifferencesAndOther>
  <acst:TaxEffectOfPermanentDifferencesAndOther contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924582" unitRef="iso4217-cad">154000</acst:TaxEffectOfPermanentDifferencesAndOther>
  <acst:UnitIssuanceCosts contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47923757" unitRef="iso4217-cad">1800000</acst:UnitIssuanceCosts>
  <acst:UnitIssuanceCosts contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-DerivativeWarrantLiabilitiesMember" decimals="INF" id="c47923758" unitRef="iso4217-cad">700000</acst:UnitIssuanceCosts>
  <acst:UnitIssuanceCosts contextRef="d_2018-04-01_2019-03-31_ClassesOfOrdinarySharesAxis-CommonSharesMember" decimals="INF" id="c47923759" unitRef="iso4217-cad">1100000</acst:UnitIssuanceCosts>
  <acst:UnitIssuanceCosts contextRef="d_2017-02-21_2017-02-21" decimals="INF" id="c47923806" unitRef="iso4217-cad">1190000</acst:UnitIssuanceCosts>
  <acst:UnitIssuedPricePerUnit contextRef="i_2018-05-09" decimals="INF" id="c47923741" unitRef="iso4217-cad-per-xbrli-shares">1.05</acst:UnitIssuedPricePerUnit>
  <acst:UnitIssuedPricePerUnit contextRef="i_2018-05-14_CounterpartiesAxis-UnderwriterMember" decimals="INF" id="c47923748" unitRef="iso4217-cad-per-xbrli-shares">1.05</acst:UnitIssuedPricePerUnit>
  <acst:UnitIssuedPricePerUnit contextRef="i_2017-12-27" decimals="INF" id="c47923774" unitRef="iso4217-usd-per-xbrli-shares">1.01</acst:UnitIssuedPricePerUnit>
  <acst:UnitIssuedPricePerUnit contextRef="i_2017-02-21" decimals="INF" id="c47923799" unitRef="iso4217-cad-per-xbrli-shares">1.45</acst:UnitIssuedPricePerUnit>
  <acst:UnitSharesOfClassAShare contextRef="i_2017-02-21" decimals="INF" id="c47923801" unitRef="xbrli-shares">1</acst:UnitSharesOfClassAShare>
  <acst:UnitSharesOfClassASharePurchaseWarrant contextRef="i_2017-02-21" decimals="INF" id="c47923802" unitRef="xbrli-shares">0.5</acst:UnitSharesOfClassASharePurchaseWarrant>
  <acst:UsedOtherAssets contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47923221" unitRef="iso4217-cad">105000</acst:UsedOtherAssets>
  <acst:UsedOtherAssets contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47923222" unitRef="iso4217-cad">311000</acst:UsedOtherAssets>
  <acst:UsefulLifeOfAssets contextRef="d_2018-04-01_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" id="c47923138">P10Y</acst:UsefulLifeOfAssets>
  <acst:WarrantCosts contextRef="d_2018-05-01_2018-05-31_CounterpartiesAxis-BrokerMember" decimals="INF" id="c47923766" unitRef="iso4217-cad">283000</acst:WarrantCosts>
  <acst:WarrantCosts contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-DerivativeWarrantLiabilitiesMember" decimals="INF" id="c47923784" unitRef="iso4217-cad">2500000</acst:WarrantCosts>
  <acst:WarrantCosts contextRef="d_2017-12-27_2017-12-27" decimals="INF" id="c47923790" unitRef="iso4217-cad">406000</acst:WarrantCosts>
  <acst:WarrantCosts contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="INF" id="c47923822" unitRef="iso4217-cad">144</acst:WarrantCosts>
  <acst:WarrantLifeWarrantsIssued contextRef="d_2018-05-01_2018-05-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" id="c47923888">P5Y</acst:WarrantLifeWarrantsIssued>
  <acst:WarrantLifeWarrantsIssued contextRef="d_2018-05-01_2018-05-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember" id="c47923893">P5Y</acst:WarrantLifeWarrantsIssued>
  <acst:WarrantLifeWarrantsIssued contextRef="d_2017-12-27_2017-12-27_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsIn2017Member" id="c47923898">P5Y</acst:WarrantLifeWarrantsIssued>
  <acst:WarrantLifeWarrantsIssued contextRef="d_2017-12-27_2017-12-27_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" id="c47923903">P5Y</acst:WarrantLifeWarrantsIssued>
  <acst:WarrantLifeWarrantsIssued contextRef="d_2017-02-21_2017-02-21_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" id="c47923909">P1Y</acst:WarrantLifeWarrantsIssued>
  <acst:WarrantLifeWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" id="c47923643">P4Y40D</acst:WarrantLifeWarrantsIssued>
  <acst:WarrantLifeWarrantsIssued contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" id="c47923644" xs:nil="true"/>
  <acst:WarrantLifeWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" id="c47923645">P3Y273D</acst:WarrantLifeWarrantsIssued>
  <acst:WarrantLifeWarrantsIssued contextRef="d_2016-03-01_2017-02-28_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" id="c47923646">P4Y273D</acst:WarrantLifeWarrantsIssued>
  <acst:WarrantLifeWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" id="c47923647" xs:nil="true"/>
  <acst:WarrantLifeWarrantsIssued contextRef="d_2016-03-01_2017-02-28_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" id="c47923648">P248D</acst:WarrantLifeWarrantsIssued>
  <acst:WarrantTransactionCosts contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924074" unitRef="iso4217-cad">653000</acst:WarrantTransactionCosts>
  <acst:WarrantTransactionCosts contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924075" unitRef="iso4217-cad">1134000</acst:WarrantTransactionCosts>
  <acst:WarrantTransactionCosts contextRef="d_2016-03-01_2017-03-31" id="c47924076" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantTransactionCosts contextRef="d_2017-03-01_2017-03-31" id="c47924077" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantTransactionCosts contextRef="d_2016-03-01_2017-02-28" id="c47924078" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-02-21" decimals="INF" id="c47923811" unitRef="iso4217-cad">144000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" decimals="-3" id="c47923937" unitRef="iso4217-cad">8246000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" id="c47923939" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" id="c47923941" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" id="c47923943" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsPublicOfferingWarrants2017Member" decimals="-3" id="c47923945" unitRef="iso4217-cad">8017000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsPublicOfferingWarrants2017Member" decimals="-3" id="c47923947" unitRef="iso4217-cad">6405000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsPublicOfferingWarrants2017Member" id="c47923949" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsPublicOfferingWarrants2017Member" id="c47923951" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" id="c47923953" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" decimals="-3" id="c47923955" unitRef="iso4217-cad">21000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" decimals="-3" id="c47923957" unitRef="iso4217-cad">209000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" decimals="-3" id="c47923959" unitRef="iso4217-cad">187000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatingToLiabilitiesMember" decimals="-3" id="c47923961" unitRef="iso4217-cad">16263000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatingToLiabilitiesMember" decimals="-3" id="c47923963" unitRef="iso4217-cad">6426000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatingToLiabilitiesMember" decimals="-3" id="c47923965" unitRef="iso4217-cad">209000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-WarrantsRelatingToLiabilitiesMember" decimals="-3" id="c47923967" unitRef="iso4217-cad">187000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember" decimals="-3" id="c47923971" unitRef="iso4217-cad">283000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember" id="c47923973" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember" id="c47923975" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember" id="c47923977" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" decimals="-3" id="c47923979" unitRef="iso4217-cad">406000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" decimals="-3" id="c47923981" unitRef="iso4217-cad">406000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" id="c47923983" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" id="c47923985" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember" id="c47923987" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember" id="c47923989" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember" id="c47923991" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember" id="c47923993" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" decimals="-3" id="c47923996" unitRef="iso4217-cad">309000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" decimals="-3" id="c47923998" unitRef="iso4217-cad">309000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" decimals="-3" id="c47924000" unitRef="iso4217-cad">309000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" decimals="-3" id="c47924002" unitRef="iso4217-cad">309000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series9PrivatePlacementWarrants2013RelatedToEquityMember" id="c47924004" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-Series9PrivatePlacementWarrants2013RelatedToEquityMember" id="c47924006" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-Series9PrivatePlacementWarrants2013RelatedToEquityMember" id="c47924008" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-Series9PrivatePlacementWarrants2013RelatedToEquityMember" id="c47924010" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember" id="c47924012" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember" id="c47924014" unitRef="iso4217-cad" xs:nil="true"/>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember" decimals="-3" id="c47924016" unitRef="iso4217-cad">144000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember" decimals="-3" id="c47924018" unitRef="iso4217-cad">144000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatedToEquityMember" decimals="-3" id="c47924020" unitRef="iso4217-cad">998000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatedToEquityMember" decimals="-3" id="c47924022" unitRef="iso4217-cad">715000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatedToEquityMember" decimals="-3" id="c47924024" unitRef="iso4217-cad">453000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsAndRightsOutstanding contextRef="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-WarrantsRelatedToEquityMember" decimals="-3" id="c47924026" unitRef="iso4217-cad">453000</acst:WarrantsAndRightsOutstanding>
  <acst:WarrantsExercisablePricePerShareAfterBorrowingsConversion contextRef="i_2017-02-21_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="INF" id="c47923660" unitRef="iso4217-cad-per-xbrli-shares">1.90</acst:WarrantsExercisablePricePerShareAfterBorrowingsConversion>
  <acst:WarrantsExercisedEquitySharesIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember" decimals="INF" id="c47923851" unitRef="xbrli-shares">117496</acst:WarrantsExercisedEquitySharesIssued>
  <acst:WarrantsExercisedEquitySharesIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" decimals="INF" id="c47923864" unitRef="xbrli-shares">1074</acst:WarrantsExercisedEquitySharesIssued>
  <acst:WarrantsExercisedEquitySharesIssued contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47923865" unitRef="xbrli-shares">772474</acst:WarrantsExercisedEquitySharesIssued>
  <acst:WarrantsExercisedEquitySharesIssued contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922565" unitRef="xbrli-shares">772474</acst:WarrantsExercisedEquitySharesIssued>
  <acst:WarrantsExercisedEquitySharesIssued contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922630" unitRef="xbrli-shares">178721</acst:WarrantsExercisedEquitySharesIssued>
  <acst:WarrantsExercisedEquitySharesIssuedAmount contextRef="d_2017-12-27_2017-12-27_CategoriesOfRelatedPartiesAxis-UnderwriterMember" decimals="INF" id="c47923780" unitRef="iso4217-cad">0</acst:WarrantsExercisedEquitySharesIssuedAmount>
  <acst:WarrantsExercisedEquitySharesIssuedAmount contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember" decimals="INF" id="c47923852" unitRef="iso4217-cad">71000</acst:WarrantsExercisedEquitySharesIssuedAmount>
  <acst:WarrantsExpired contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember" decimals="INF" id="c47923853" unitRef="xbrli-shares">117496</acst:WarrantsExpired>
  <acst:WeightedAverageSharePriceWarrantsIssued contextRef="d_2018-05-01_2018-05-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member" decimals="INF" id="c47923886" unitRef="iso4217-cad">0.82</acst:WeightedAverageSharePriceWarrantsIssued>
  <acst:WeightedAverageSharePriceWarrantsIssued contextRef="d_2018-05-01_2018-05-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember" decimals="INF" id="c47923891" unitRef="iso4217-cad">0.81</acst:WeightedAverageSharePriceWarrantsIssued>
  <acst:WeightedAverageSharePriceWarrantsIssued contextRef="d_2017-12-27_2017-12-27_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsIn2017Member" decimals="INF" id="c47923896" unitRef="iso4217-usd">0.97</acst:WeightedAverageSharePriceWarrantsIssued>
  <acst:WeightedAverageSharePriceWarrantsIssued contextRef="d_2017-12-27_2017-12-27_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" decimals="INF" id="c47923901" unitRef="iso4217-usd">0.97</acst:WeightedAverageSharePriceWarrantsIssued>
  <acst:WeightedAverageSharePriceWarrantsIssued contextRef="d_2017-02-21_2017-02-21_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" decimals="INF" id="c47923906" unitRef="iso4217-cad">1.70</acst:WeightedAverageSharePriceWarrantsIssued>
  <acst:WeightedAverageSharePriceWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" decimals="INF" id="c47923631" unitRef="iso4217-cad">1.35</acst:WeightedAverageSharePriceWarrantsIssued>
  <acst:WeightedAverageSharePriceWarrantsIssued contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" id="c47923632" unitRef="iso4217-usd" xs:nil="true"/>
  <acst:WeightedAverageSharePriceWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="INF" id="c47923633" unitRef="iso4217-usd">1.02</acst:WeightedAverageSharePriceWarrantsIssued>
  <acst:WeightedAverageSharePriceWarrantsIssued contextRef="d_2016-03-01_2017-02-28_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="INF" id="c47923634" unitRef="iso4217-usd">1.02</acst:WeightedAverageSharePriceWarrantsIssued>
  <acst:WeightedAverageSharePriceWarrantsIssued contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" id="c47923635" unitRef="iso4217-usd" xs:nil="true"/>
  <acst:WeightedAverageSharePriceWarrantsIssued contextRef="d_2016-03-01_2017-02-28_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" decimals="INF" id="c47923636" unitRef="iso4217-usd">1.02</acst:WeightedAverageSharePriceWarrantsIssued>
  <dei:AmendmentFlag contextRef="d_2018-04-01_2019-03-31" id="c-16">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2018-04-01_2019-03-31" id="c-4">--03-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2018-04-01_2019-03-31" id="c-15">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2018-04-01_2019-03-31" id="c-14">2019</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2018-04-01_2019-03-31" id="c-13">2019-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2018-04-01_2019-03-31" id="c-12">20-F</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2018-04-01_2019-03-31" id="c-2">0001444192</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2019-03-31" decimals="INF" id="c-11" unitRef="xbrli-shares">78132734</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2018-04-01_2019-03-31" id="c-6">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="d_2018-04-01_2019-03-31" id="c-9">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityFilerCategory contextRef="d_2018-04-01_2019-03-31" id="c-5">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="d_2018-04-01_2019-03-31" id="c-1">Acasti Pharma Inc.</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="d_2018-04-01_2019-03-31" id="c-7">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2018-04-01_2019-03-31" id="c-8">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="d_2018-04-01_2019-03-31" id="c-3">acst</dei:TradingSymbol>
   <dei:EntityShellCompany contextRef="d_2018-04-01_2019-03-31" id="c-102">false</dei:EntityShellCompany>
  <ifrs-full:AccountingProfit contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924547" unitRef="iso4217-cad">-51566000</ifrs-full:AccountingProfit>
  <ifrs-full:AccountingProfit contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924548" unitRef="iso4217-cad">-21504000</ifrs-full:AccountingProfit>
  <ifrs-full:AccountingProfit contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924549" unitRef="iso4217-cad">-11376000</ifrs-full:AccountingProfit>
  <ifrs-full:AccountingProfit contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924550" unitRef="iso4217-cad">-769000</ifrs-full:AccountingProfit>
  <ifrs-full:AccountingProfit contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924551" unitRef="iso4217-cad">-10607000</ifrs-full:AccountingProfit>
  <ifrs-full:AccrualsClassifiedAsCurrent contextRef="i_2019-03-31" decimals="-3" id="c47923564" unitRef="iso4217-cad">10319000</ifrs-full:AccrualsClassifiedAsCurrent>
  <ifrs-full:AccrualsClassifiedAsCurrent contextRef="i_2018-03-31" decimals="-3" id="c47923565" unitRef="iso4217-cad">2479000</ifrs-full:AccrualsClassifiedAsCurrent>
  <ifrs-full:AdditionalPaidinCapital contextRef="i_2019-03-31" decimals="-3" id="c47922454" unitRef="iso4217-cad">8280000</ifrs-full:AdditionalPaidinCapital>
  <ifrs-full:AdditionalPaidinCapital contextRef="i_2018-03-31" decimals="-3" id="c47922455" unitRef="iso4217-cad">6956000</ifrs-full:AdditionalPaidinCapital>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="d_2016-03-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" id="c47923510" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="d_2016-03-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" id="c47923511" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="d_2016-03-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" id="c47923512" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" id="c47923516" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" id="c47923517" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" id="c47923518" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" id="c47923390" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923391" unitRef="iso4217-cad">8000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923392" unitRef="iso4217-cad">186000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923393" unitRef="iso4217-cad">2484000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" decimals="-3" id="c47923394" unitRef="iso4217-cad">2678000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" id="c47923400" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" id="c47923401" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" id="c47923402" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923403" unitRef="iso4217-cad">43000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" decimals="-3" id="c47923404" unitRef="iso4217-cad">43000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" id="c47923405" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923406" unitRef="iso4217-cad">8000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923407" unitRef="iso4217-cad">186000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923408" unitRef="iso4217-cad">2527000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" decimals="-3" id="c47923409" unitRef="iso4217-cad">2721000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923415" unitRef="iso4217-cad">4000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923416" unitRef="iso4217-cad">6000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923417" unitRef="iso4217-cad">192000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923418" unitRef="iso4217-cad">181000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" decimals="-3" id="c47923419" unitRef="iso4217-cad">383000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923425" unitRef="iso4217-cad">5000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923426" unitRef="iso4217-cad">13000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923427" unitRef="iso4217-cad">219000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923428" unitRef="iso4217-cad">260000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" decimals="-3" id="c47923429" unitRef="iso4217-cad">497000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
  <ifrs-full:AdjustmentsForAmortisationExpense contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922794" unitRef="iso4217-cad">2322000</ifrs-full:AdjustmentsForAmortisationExpense>
  <ifrs-full:AdjustmentsForAmortisationExpense contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922795" unitRef="iso4217-cad">2323000</ifrs-full:AdjustmentsForAmortisationExpense>
  <ifrs-full:AdjustmentsForAmortisationExpense contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922796" unitRef="iso4217-cad">2517000</ifrs-full:AdjustmentsForAmortisationExpense>
  <ifrs-full:AdjustmentsForAmortisationExpense contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922797" unitRef="iso4217-cad">194000</ifrs-full:AdjustmentsForAmortisationExpense>
  <ifrs-full:AdjustmentsForAmortisationExpense contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922798" unitRef="iso4217-cad">2323000</ifrs-full:AdjustmentsForAmortisationExpense>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924439" unitRef="iso4217-cad">37000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924440" unitRef="iso4217-cad">-659000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="d_2016-03-01_2017-03-31" id="c47924441" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="d_2017-03-01_2017-03-31" id="c47924442" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="d_2016-03-01_2017-02-28" id="c47924443" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924429" unitRef="iso4217-cad">-738000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924430" unitRef="iso4217-cad">-553000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924431" unitRef="iso4217-cad">193000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924432" unitRef="iso4217-cad">-40000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924433" unitRef="iso4217-cad">233000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
  <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="d_2018-04-01_2019-03-31" id="c47922824" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="d_2017-04-01_2018-03-31" id="c47922825" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922826" unitRef="iso4217-cad">-129000</ifrs-full:AdjustmentsForDeferredTaxExpense>
  <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="d_2017-03-01_2017-03-31" id="c47922827" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AdjustmentsForDeferredTaxExpense contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922828" unitRef="iso4217-cad">-129000</ifrs-full:AdjustmentsForDeferredTaxExpense>
  <ifrs-full:AdjustmentsForDepreciationExpense contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922800" unitRef="iso4217-cad">505000</ifrs-full:AdjustmentsForDepreciationExpense>
  <ifrs-full:AdjustmentsForDepreciationExpense contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922801" unitRef="iso4217-cad">349000</ifrs-full:AdjustmentsForDepreciationExpense>
  <ifrs-full:AdjustmentsForDepreciationExpense contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922802" unitRef="iso4217-cad">221000</ifrs-full:AdjustmentsForDepreciationExpense>
  <ifrs-full:AdjustmentsForDepreciationExpense contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922803" unitRef="iso4217-cad">32000</ifrs-full:AdjustmentsForDepreciationExpense>
  <ifrs-full:AdjustmentsForDepreciationExpense contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922804" unitRef="iso4217-cad">189000</ifrs-full:AdjustmentsForDepreciationExpense>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922812" unitRef="iso4217-cad">-6551000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922813" unitRef="iso4217-cad">-1808000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922814" unitRef="iso4217-cad">-166000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922815" unitRef="iso4217-cad">-51000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922816" unitRef="iso4217-cad">-115000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924449" unitRef="iso4217-cad">9679000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924450" unitRef="iso4217-cad">4898000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924451" unitRef="iso4217-cad">352000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924452" unitRef="iso4217-cad">-255000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924453" unitRef="iso4217-cad">607000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
  <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922830" unitRef="iso4217-cad">-40566000</ifrs-full:AdjustmentsForReconcileProfitLoss>
  <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922831" unitRef="iso4217-cad">-16102000</ifrs-full:AdjustmentsForReconcileProfitLoss>
  <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922832" unitRef="iso4217-cad">-7750000</ifrs-full:AdjustmentsForReconcileProfitLoss>
  <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922833" unitRef="iso4217-cad">-418000</ifrs-full:AdjustmentsForReconcileProfitLoss>
  <ifrs-full:AdjustmentsForReconcileProfitLoss contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922834" unitRef="iso4217-cad">-7332000</ifrs-full:AdjustmentsForReconcileProfitLoss>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922806" unitRef="iso4217-cad">1041000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922807" unitRef="iso4217-cad">929000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922808" unitRef="iso4217-cad">674000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922809" unitRef="iso4217-cad">86000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922810" unitRef="iso4217-cad">588000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922818" unitRef="iso4217-cad">581000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
  <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922819" unitRef="iso4217-cad">-7000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
  <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922820" unitRef="iso4217-cad">48000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
  <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922821" unitRef="iso4217-cad">-12000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
  <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922822" unitRef="iso4217-cad">60000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" id="c47923526" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" decimals="-3" id="c47923527" unitRef="iso4217-cad">2323000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923528" unitRef="iso4217-cad">2323000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" id="c47923532" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" decimals="-3" id="c47923533" unitRef="iso4217-cad">194000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923534" unitRef="iso4217-cad">194000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" id="c47923535" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" decimals="-3" id="c47923536" unitRef="iso4217-cad">2517000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923537" unitRef="iso4217-cad">2517000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" id="c47923541" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" decimals="-3" id="c47923542" unitRef="iso4217-cad">2323000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923543" unitRef="iso4217-cad">2323000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" id="c47923547" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" decimals="-3" id="c47923548" unitRef="iso4217-cad">2322000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923549" unitRef="iso4217-cad">2322000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
  <ifrs-full:ApplicableTaxRate contextRef="d_2018-04-01_2019-03-31" decimals="4" id="c47924552" unitRef="xbrli-pure">0.2668</ifrs-full:ApplicableTaxRate>
  <ifrs-full:ApplicableTaxRate contextRef="d_2017-04-01_2018-03-31" decimals="4" id="c47924553" unitRef="xbrli-pure">0.2678</ifrs-full:ApplicableTaxRate>
  <ifrs-full:ApplicableTaxRate contextRef="d_2016-03-01_2017-03-31" decimals="4" id="c47924554" unitRef="xbrli-pure">0.2687</ifrs-full:ApplicableTaxRate>
  <ifrs-full:ApplicableTaxRate contextRef="d_2017-03-01_2017-03-31" decimals="4" id="c47924555" unitRef="xbrli-pure">0.268</ifrs-full:ApplicableTaxRate>
  <ifrs-full:ApplicableTaxRate contextRef="d_2016-03-01_2017-02-28" decimals="4" id="c47924556" unitRef="xbrli-pure">0.2688</ifrs-full:ApplicableTaxRate>
  <ifrs-full:Assets contextRef="i_2019-03-31_GeographicalAreasAxis-FR" decimals="-3" id="c47923076" unitRef="iso4217-cad">1831000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="i_2018-03-31_GeographicalAreasAxis-FR" decimals="-3" id="c47923077" unitRef="iso4217-cad">2077000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="i_2019-03-31" decimals="-3" id="c47922424" unitRef="iso4217-cad">48471000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="i_2018-03-31" decimals="-3" id="c47922425" unitRef="iso4217-cad">22959000</ifrs-full:Assets>
  <ifrs-full:AverageForeignExchangeRate contextRef="d_2018-04-01_2019-03-31_TypesOfRisksAxis-CurrencyRiskForUSDMember" decimals="INF" id="c47924718" unitRef="xbrli-pure">1.3122</ifrs-full:AverageForeignExchangeRate>
  <ifrs-full:AverageForeignExchangeRate contextRef="d_2017-04-01_2018-03-31_TypesOfRisksAxis-CurrencyRiskForUSDMember" decimals="INF" id="c47924720" unitRef="xbrli-pure">1.2834</ifrs-full:AverageForeignExchangeRate>
  <ifrs-full:AverageForeignExchangeRate contextRef="d_2018-04-01_2019-03-31_TypesOfRisksAxis-CurrencyRiskForEuroMember" decimals="INF" id="c47924728" unitRef="xbrli-pure">1.5192</ifrs-full:AverageForeignExchangeRate>
  <ifrs-full:AverageForeignExchangeRate contextRef="d_2017-04-01_2018-03-31_TypesOfRisksAxis-CurrencyRiskForEuroMember" decimals="INF" id="c47924730" unitRef="xbrli-pure">1.5008</ifrs-full:AverageForeignExchangeRate>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47922523" unitRef="iso4217-cad-per-xbrli-shares">-0.95</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="d_2017-04-01_2018-03-31" decimals="INF" id="c47922524" unitRef="iso4217-cad-per-xbrli-shares">-1.23</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="d_2016-03-01_2017-03-31" decimals="INF" id="c47922525" unitRef="iso4217-cad-per-xbrli-shares">-1.01</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="d_2017-03-01_2017-03-31" decimals="INF" id="c47922526" unitRef="iso4217-cad-per-xbrli-shares">-0.05</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="d_2016-03-01_2017-02-28" decimals="INF" id="c47922527" unitRef="iso4217-cad-per-xbrli-shares">-0.97</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:Borrowings contextRef="i_2017-03-31_BorrowingsByNameAxis-LiabilityPortionOfUnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923676" unitRef="iso4217-cad">1406000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="i_2017-03-31_BorrowingsByNameAxis-EquityComponentOfUnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923677" unitRef="iso4217-cad">309000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="i_2017-03-31_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923678" unitRef="iso4217-cad">1715000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="i_2018-03-31_BorrowingsByNameAxis-LiabilityPortionOfUnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923685" unitRef="iso4217-cad">1612000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="i_2018-03-31_BorrowingsByNameAxis-EquityComponentOfUnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923686" unitRef="iso4217-cad">309000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="i_2018-03-31_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923687" unitRef="iso4217-cad">1921000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="i_2019-03-31_BorrowingsByNameAxis-LiabilityPortionOfUnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923694" unitRef="iso4217-cad">1817000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="i_2019-03-31_BorrowingsByNameAxis-EquityComponentOfUnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923695" unitRef="iso4217-cad">309000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="i_2019-03-31_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923696" unitRef="iso4217-cad">2126000</ifrs-full:Borrowings>
  <ifrs-full:BorrowingsInterestRate contextRef="i_2016-01-07_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember_MaturityAxis-NotLaterThanSixMonthsMember" decimals="3" id="c47923248" unitRef="xbrli-pure">0.09</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:BorrowingsInterestRate contextRef="i_2016-01-07_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember_MaturityAxis-LaterThanSixMonthsMember" decimals="3" id="c47923251" unitRef="xbrli-pure">0.11</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:BorrowingsInterestRate contextRef="i_2017-02-21_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="3" id="c47923666" unitRef="xbrli-pure">0.08</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:BorrowingsInterestRate contextRef="i_2019-03-31_RangeAxis-BottomOfRangeMember" decimals="4" id="c47924829" unitRef="xbrli-pure">0.0176</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:BorrowingsInterestRate contextRef="i_2019-03-31_RangeAxis-TopOfRangeMember" decimals="4" id="c47924830" unitRef="xbrli-pure">0.024</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:BorrowingsInterestRate contextRef="i_2018-03-31_RangeAxis-BottomOfRangeMember" decimals="4" id="c47924831" unitRef="xbrli-pure">0.0126</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:BorrowingsInterestRate contextRef="i_2018-03-31_RangeAxis-TopOfRangeMember" decimals="4" id="c47924832" unitRef="xbrli-pure">0.0172</ifrs-full:BorrowingsInterestRate>
  <ifrs-full:CapitalCommitments contextRef="i_2019-03-31" id="c47922463" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CapitalCommitments contextRef="i_2018-03-31" id="c47922464" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:Cash contextRef="i_2019-03-31" decimals="-3" id="c47924833" unitRef="iso4217-cad">1896000</ifrs-full:Cash>
  <ifrs-full:Cash contextRef="i_2018-03-31" decimals="-3" id="c47924834" unitRef="iso4217-cad">1583000</ifrs-full:Cash>
  <ifrs-full:Cash contextRef="i_2017-03-31" decimals="-3" id="c47922955" unitRef="iso4217-cad">6778000</ifrs-full:Cash>
  <ifrs-full:Cash contextRef="i_2017-02-28" decimals="-3" id="c47922957" unitRef="iso4217-cad">7584000</ifrs-full:Cash>
  <ifrs-full:CashAndCashEquivalents contextRef="i_2019-03-31" decimals="-3" id="c47922985" unitRef="iso4217-cad">22521000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="i_2018-03-31" decimals="-3" id="c47922940" unitRef="iso4217-cad">8223000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="i_2017-03-31" decimals="-3" id="c47922941" unitRef="iso4217-cad">9772000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="i_2016-02-29" decimals="-3" id="c47922942" unitRef="iso4217-cad">3027000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="i_2017-02-28" decimals="-3" id="c47922943" unitRef="iso4217-cad">10573000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition contextRef="i_2019-03-31" decimals="-3" id="c47924858" unitRef="iso4217-cad">22521000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
  <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition contextRef="i_2018-03-31" decimals="-3" id="c47924859" unitRef="iso4217-cad">8223000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
  <ifrs-full:CashEquivalents contextRef="i_2019-03-31_CategoriesOfFinancialAssetsAxis-TermDepositsIssuedInUsCurrencyMember" id="c47924840" unitRef="iso4217-usd" xs:nil="true"/>
  <ifrs-full:CashEquivalents contextRef="i_2018-03-31_CategoriesOfFinancialAssetsAxis-TermDepositsIssuedInUsCurrencyMember" decimals="-3" id="c47924841" unitRef="iso4217-usd">3250000</ifrs-full:CashEquivalents>
  <ifrs-full:CashEquivalents contextRef="i_2019-03-31_CategoriesOfFinancialAssetsAxis-CommercialPapersIssuedInUsCurrencyMember" id="c47924846" unitRef="iso4217-usd" xs:nil="true"/>
  <ifrs-full:CashEquivalents contextRef="i_2018-03-31_CategoriesOfFinancialAssetsAxis-CommercialPapersIssuedInUsCurrencyMember" decimals="-3" id="c47924847" unitRef="iso4217-usd">1099000</ifrs-full:CashEquivalents>
  <ifrs-full:CashEquivalents contextRef="i_2019-03-31_CategoriesOfFinancialAssetsAxis-PromissoryNotesIssuedInUsCurrencyMember" id="c47924852" unitRef="iso4217-usd" xs:nil="true"/>
  <ifrs-full:CashEquivalents contextRef="i_2018-03-31_CategoriesOfFinancialAssetsAxis-PromissoryNotesIssuedInUsCurrencyMember" decimals="-3" id="c47924853" unitRef="iso4217-usd">798000</ifrs-full:CashEquivalents>
  <ifrs-full:CashEquivalents contextRef="i_2019-03-31_CategoriesOfFinancialAssetsAxis-TermDepositsIssuedInCadCurrencyMember" decimals="-3" id="c47924836" unitRef="iso4217-cad">12100000</ifrs-full:CashEquivalents>
  <ifrs-full:CashEquivalents contextRef="i_2018-03-31_CategoriesOfFinancialAssetsAxis-TermDepositsIssuedInCadCurrencyMember" id="c47924837" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CashEquivalents contextRef="i_2019-03-31_CategoriesOfFinancialAssetsAxis-TermDepositsIssuedInUsCurrencyMember" id="c47924838" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CashEquivalents contextRef="i_2018-03-31_CategoriesOfFinancialAssetsAxis-TermDepositsIssuedInUsCurrencyMember" decimals="-3" id="c47924839" unitRef="iso4217-cad">4193000</ifrs-full:CashEquivalents>
  <ifrs-full:CashEquivalents contextRef="i_2019-03-31_CategoriesOfFinancialAssetsAxis-CommercialPapersIssuedInCadCurrencyMember" decimals="-3" id="c47924842" unitRef="iso4217-cad">5693000</ifrs-full:CashEquivalents>
  <ifrs-full:CashEquivalents contextRef="i_2018-03-31_CategoriesOfFinancialAssetsAxis-CommercialPapersIssuedInCadCurrencyMember" id="c47924843" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CashEquivalents contextRef="i_2019-03-31_CategoriesOfFinancialAssetsAxis-CommercialPapersIssuedInUsCurrencyMember" id="c47924844" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CashEquivalents contextRef="i_2018-03-31_CategoriesOfFinancialAssetsAxis-CommercialPapersIssuedInUsCurrencyMember" decimals="-3" id="c47924845" unitRef="iso4217-cad">1418000</ifrs-full:CashEquivalents>
  <ifrs-full:CashEquivalents contextRef="i_2019-03-31_CategoriesOfFinancialAssetsAxis-PromissoryNotesIssuedInCadCurrencyMember" decimals="-3" id="c47924848" unitRef="iso4217-cad">498000</ifrs-full:CashEquivalents>
  <ifrs-full:CashEquivalents contextRef="i_2018-03-31_CategoriesOfFinancialAssetsAxis-PromissoryNotesIssuedInCadCurrencyMember" id="c47924849" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CashEquivalents contextRef="i_2019-03-31_CategoriesOfFinancialAssetsAxis-PromissoryNotesIssuedInUsCurrencyMember" id="c47924850" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CashEquivalents contextRef="i_2018-03-31_CategoriesOfFinancialAssetsAxis-PromissoryNotesIssuedInUsCurrencyMember" decimals="-3" id="c47924851" unitRef="iso4217-cad">1029000</ifrs-full:CashEquivalents>
  <ifrs-full:CashEquivalents contextRef="i_2019-03-31_CategoriesOfFinancialAssetsAxis-BankersAcceptanceMember" decimals="-3" id="c47924854" unitRef="iso4217-cad">2334000</ifrs-full:CashEquivalents>
  <ifrs-full:CashEquivalents contextRef="i_2018-03-31_CategoriesOfFinancialAssetsAxis-BankersAcceptanceMember" id="c47924855" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CashEquivalents contextRef="i_2019-03-31" decimals="-3" id="c47924856" unitRef="iso4217-cad">20625000</ifrs-full:CashEquivalents>
  <ifrs-full:CashEquivalents contextRef="i_2018-03-31" decimals="-3" id="c47924857" unitRef="iso4217-cad">6640000</ifrs-full:CashEquivalents>
  <ifrs-full:CashEquivalents contextRef="i_2017-03-31" decimals="-3" id="c47922961" unitRef="iso4217-cad">2994000</ifrs-full:CashEquivalents>
  <ifrs-full:CashEquivalents contextRef="i_2017-02-28" decimals="-3" id="c47922963" unitRef="iso4217-cad">2989000</ifrs-full:CashEquivalents>
  <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="d_2018-04-01_2019-03-31" id="c47922861" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="d_2017-04-01_2018-03-31" id="c47922862" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922863" unitRef="iso4217-cad">-12765000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
  <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="d_2017-03-01_2017-03-31" id="c47922864" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922865" unitRef="iso4217-cad">-12765000</ifrs-full:CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922922" unitRef="iso4217-cad">58862000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922923" unitRef="iso4217-cad">11406000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922924" unitRef="iso4217-cad">6864000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922925" unitRef="iso4217-cad">-44000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922926" unitRef="iso4217-cad">6908000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922885" unitRef="iso4217-cad">-12136000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922886" unitRef="iso4217-cad">-411000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922887" unitRef="iso4217-cad">6888000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922888" unitRef="iso4217-cad">-20000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922889" unitRef="iso4217-cad">6908000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922842" unitRef="iso4217-cad">-32476000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922843" unitRef="iso4217-cad">-12519000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922844" unitRef="iso4217-cad">-6958000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922845" unitRef="iso4217-cad">-746000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922846" unitRef="iso4217-cad">-6212000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" decimals="-3" id="c47923607" unitRef="iso4217-cad">4696000</ifrs-full:ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability>
  <ifrs-full:ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" id="c47923608" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="-3" id="c47923609" unitRef="iso4217-cad">1612000</ifrs-full:ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability>
  <ifrs-full:ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="-3" id="c47923610" unitRef="iso4217-cad">532000</ifrs-full:ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability>
  <ifrs-full:ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" decimals="-3" id="c47923611" unitRef="iso4217-cad">-21000</ifrs-full:ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability>
  <ifrs-full:ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability contextRef="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" decimals="-3" id="c47923612" unitRef="iso4217-cad">-188000</ifrs-full:ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability>
  <ifrs-full:ClosingForeignExchangeRate contextRef="i_2019-03-31_TypesOfRisksAxis-CurrencyRiskForUSDMember" decimals="INF" id="c47924719" unitRef="xbrli-pure">1.3349</ifrs-full:ClosingForeignExchangeRate>
  <ifrs-full:ClosingForeignExchangeRate contextRef="i_2018-03-31_TypesOfRisksAxis-CurrencyRiskForUSDMember" decimals="INF" id="c47924721" unitRef="xbrli-pure">1.29</ifrs-full:ClosingForeignExchangeRate>
  <ifrs-full:ClosingForeignExchangeRate contextRef="i_2019-03-31_TypesOfRisksAxis-CurrencyRiskForEuroMember" decimals="INF" id="c47924729" unitRef="xbrli-pure">1.4975</ifrs-full:ClosingForeignExchangeRate>
  <ifrs-full:ClosingForeignExchangeRate contextRef="i_2018-03-31_TypesOfRisksAxis-CurrencyRiskForEuroMember" decimals="INF" id="c47924731" unitRef="xbrli-pure">1.5898</ifrs-full:ClosingForeignExchangeRate>
  <ifrs-full:ComprehensiveIncome contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" id="c47922543" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ComprehensiveIncome contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922544" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ComprehensiveIncome contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" id="c47922545" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ComprehensiveIncome contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" decimals="-3" id="c47922546" unitRef="iso4217-cad">-51566000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922547" unitRef="iso4217-cad">-51566000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" id="c47922608" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ComprehensiveIncome contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922609" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ComprehensiveIncome contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" id="c47922610" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ComprehensiveIncome contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" decimals="-3" id="c47922611" unitRef="iso4217-cad">-21504000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922612" unitRef="iso4217-cad">-21504000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-IssuedCapitalMember" id="c47922673" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ComprehensiveIncome contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922674" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ComprehensiveIncome contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" id="c47922675" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ComprehensiveIncome contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-RetainedEarningsMember" decimals="-3" id="c47922676" unitRef="iso4217-cad">-10478000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922677" unitRef="iso4217-cad">-10478000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" id="c47922680" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ComprehensiveIncome contextRef="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922681" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ComprehensiveIncome contextRef="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" id="c47922682" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ComprehensiveIncome contextRef="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" decimals="-3" id="c47922683" unitRef="iso4217-cad">-769000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922684" unitRef="iso4217-cad">-769000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" id="c47922687" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ComprehensiveIncome contextRef="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922688" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ComprehensiveIncome contextRef="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" id="c47922689" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ComprehensiveIncome contextRef="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" decimals="-3" id="c47922690" unitRef="iso4217-cad">-11247000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922691" unitRef="iso4217-cad">-11247000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination contextRef="i_2016-01-07_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember" decimals="-3" id="c47923247" unitRef="iso4217-cad">2000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
  <ifrs-full:CurrentAssets contextRef="i_2019-03-31" decimals="-3" id="c47922984" unitRef="iso4217-cad">37331000</ifrs-full:CurrentAssets>
  <ifrs-full:CurrentAssets contextRef="i_2018-03-31" decimals="-3" id="c47922410" unitRef="iso4217-cad">9492000</ifrs-full:CurrentAssets>
  <ifrs-full:CurrentDebtInstrumentsIssued contextRef="i_2019-03-31" decimals="-3" id="c47922432" unitRef="iso4217-cad">1817000</ifrs-full:CurrentDebtInstrumentsIssued>
  <ifrs-full:CurrentDebtInstrumentsIssued contextRef="i_2018-03-31" id="c47922433" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" id="c47923589" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="i_2017-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" id="c47923590" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="-3" id="c47923591" unitRef="iso4217-cad">6405000</ifrs-full:CurrentDerivativeFinancialLiabilities>
  <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="i_2017-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" id="c47923592" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" decimals="-3" id="c47923593" unitRef="iso4217-cad">21000</ifrs-full:CurrentDerivativeFinancialLiabilities>
  <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="i_2017-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" decimals="-3" id="c47923594" unitRef="iso4217-cad">209000</ifrs-full:CurrentDerivativeFinancialLiabilities>
  <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member" decimals="-3" id="c47923613" unitRef="iso4217-cad">8246000</ifrs-full:CurrentDerivativeFinancialLiabilities>
  <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member" decimals="-3" id="c47923615" unitRef="iso4217-cad">8017000</ifrs-full:CurrentDerivativeFinancialLiabilities>
  <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member" id="c47923617" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="i_2019-03-31" decimals="-3" id="c47922438" unitRef="iso4217-cad">16263000</ifrs-full:CurrentDerivativeFinancialLiabilities>
  <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="i_2018-03-31" decimals="-3" id="c47922439" unitRef="iso4217-cad">6426000</ifrs-full:CurrentDerivativeFinancialLiabilities>
  <ifrs-full:CurrentLiabilities contextRef="i_2019-03-31" decimals="-3" id="c47922987" unitRef="iso4217-cad">18246000</ifrs-full:CurrentLiabilities>
  <ifrs-full:CurrentLiabilities contextRef="i_2018-03-31" decimals="-3" id="c47922436" unitRef="iso4217-cad">6697000</ifrs-full:CurrentLiabilities>
  <ifrs-full:CurrentPrepaidExpenses contextRef="i_2019-03-31" decimals="-3" id="c47922406" unitRef="iso4217-cad">1115000</ifrs-full:CurrentPrepaidExpenses>
  <ifrs-full:CurrentPrepaidExpenses contextRef="i_2018-03-31" decimals="-3" id="c47922407" unitRef="iso4217-cad">406000</ifrs-full:CurrentPrepaidExpenses>
  <ifrs-full:CurrentValueAddedTaxReceivables contextRef="i_2019-03-31" decimals="-3" id="c47923164" unitRef="iso4217-cad">618000</ifrs-full:CurrentValueAddedTaxReceivables>
  <ifrs-full:CurrentValueAddedTaxReceivables contextRef="i_2018-03-31" decimals="-3" id="c47923165" unitRef="iso4217-cad">470000</ifrs-full:CurrentValueAddedTaxReceivables>
  <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember" decimals="-3" id="c47924649" unitRef="iso4217-cad">30875000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
  <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-ProvincialMember" decimals="-3" id="c47924650" unitRef="iso4217-cad">32294000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
  <ifrs-full:DeferredTaxAssets contextRef="i_2019-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-UnusedTaxLossesMember" decimals="-3" id="c47924594" unitRef="iso4217-cad">23695000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2018-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-UnusedTaxLossesMember" decimals="-3" id="c47924595" unitRef="iso4217-cad">12670000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2017-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-UnusedTaxLossesMember" decimals="-3" id="c47924596" unitRef="iso4217-cad">8293000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2019-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-ResearchAndDevelopmentProjectsMember" decimals="-3" id="c47924597" unitRef="iso4217-cad">5362000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2018-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-ResearchAndDevelopmentProjectsMember" decimals="-3" id="c47924598" unitRef="iso4217-cad">4927000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2017-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-ResearchAndDevelopmentProjectsMember" decimals="-3" id="c47924599" unitRef="iso4217-cad">4220000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2019-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-PropertyPlanAndEquipmentAndIntangibleAssetsMember" decimals="-3" id="c47924600" unitRef="iso4217-cad">766000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2018-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-PropertyPlanAndEquipmentAndIntangibleAssetsMember" decimals="-3" id="c47924601" unitRef="iso4217-cad">567000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2017-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-PropertyPlanAndEquipmentAndIntangibleAssetsMember" decimals="-3" id="c47924602" unitRef="iso4217-cad">435000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2019-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-FinancingExpensesMember" decimals="-3" id="c47924603" unitRef="iso4217-cad">1852000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2018-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-FinancingExpensesMember" decimals="-3" id="c47924604" unitRef="iso4217-cad">116000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2017-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-FinancingExpensesMember" id="c47924605" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:DeferredTaxAssets contextRef="i_2019-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-OtherTemporaryDifferencesMember" decimals="-3" id="c47924606" unitRef="iso4217-cad">378000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2018-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-OtherTemporaryDifferencesMember" decimals="-3" id="c47924607" unitRef="iso4217-cad">768000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2017-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-OtherTemporaryDifferencesMember" decimals="-3" id="c47924608" unitRef="iso4217-cad">522000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2019-03-31" decimals="-3" id="c47924609" unitRef="iso4217-cad">32053000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2018-03-31" decimals="-3" id="c47924610" unitRef="iso4217-cad">19048000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="i_2017-03-31" decimals="-3" id="c47924611" unitRef="iso4217-cad">13470000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxExpenseIncome contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" decimals="INF" id="c47923846" unitRef="iso4217-cad">129000</ifrs-full:DeferredTaxExpenseIncome>
  <ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924527" unitRef="iso4217-cad">11599000</ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences>
  <ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924528" unitRef="iso4217-cad">5241000</ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences>
  <ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924529" unitRef="iso4217-cad">2240000</ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences>
  <ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924530" unitRef="iso4217-cad">163000</ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences>
  <ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924531" unitRef="iso4217-cad">2077000</ifrs-full:DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences>
  <ifrs-full:DeferredTaxLiabilities contextRef="i_2019-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember" decimals="-3" id="c47924613" unitRef="iso4217-cad">13000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilities contextRef="i_2018-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember" decimals="-3" id="c47924614" unitRef="iso4217-cad">67000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilities contextRef="i_2017-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember" decimals="-3" id="c47924615" unitRef="iso4217-cad">122000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilities contextRef="i_2019-03-31" decimals="-3" id="c47924616" unitRef="iso4217-cad">13000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilities contextRef="i_2018-03-31" decimals="-3" id="c47924617" unitRef="iso4217-cad">67000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilities contextRef="i_2017-03-31" decimals="-3" id="c47924618" unitRef="iso4217-cad">122000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="i_2019-03-31" decimals="-3" id="c47924619" unitRef="iso4217-cad">-32040000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="i_2018-03-31" decimals="-3" id="c47924620" unitRef="iso4217-cad">-18981000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxLiabilityAsset contextRef="i_2017-03-31" decimals="-3" id="c47924621" unitRef="iso4217-cad">-13348000</ifrs-full:DeferredTaxLiabilityAsset>
  <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity contextRef="d_2017-02-21_2017-02-21" decimals="-3" id="c47924516" unitRef="iso4217-cad">129000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923441" unitRef="iso4217-cad">7000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923442" unitRef="iso4217-cad">1000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923443" unitRef="iso4217-cad">129000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923444" unitRef="iso4217-cad">52000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923445" unitRef="iso4217-cad">189000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" id="c47923451" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" id="c47923452" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923453" unitRef="iso4217-cad">11000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923454" unitRef="iso4217-cad">21000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923455" unitRef="iso4217-cad">32000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923456" unitRef="iso4217-cad">7000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923457" unitRef="iso4217-cad">1000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923458" unitRef="iso4217-cad">140000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923459" unitRef="iso4217-cad">73000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923460" unitRef="iso4217-cad">221000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" id="c47923466" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923467" unitRef="iso4217-cad">3000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923468" unitRef="iso4217-cad">107000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923469" unitRef="iso4217-cad">239000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923470" unitRef="iso4217-cad">349000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923476" unitRef="iso4217-cad">1000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923477" unitRef="iso4217-cad">7000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923478" unitRef="iso4217-cad">180000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923479" unitRef="iso4217-cad">317000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923480" unitRef="iso4217-cad">505000</ifrs-full:DepreciationPropertyPlantAndEquipment>
  <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="d_2018-04-01_2019-03-31" id="c47927253">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(l)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Earnings per share:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation presents basic and diluted earnings per share (&amp;#x201c;EPS&amp;#x201d;) data for its Class A shares (or &amp;#x201c;Common Shares&amp;#x201d;). Basic EPS is calculated by dividing the profit or loss attributable to the holders of Class A shares (Common Shares) of the Corporation by the weighted average number of Common Shares outstanding during the year, adjusted for own shares held. Diluted EPS is determined by adjusting the profit or loss attributable to the holders of Class A shares (Common Shares) and the weighted average number of Class A shares (Common Shares) outstanding adjusted for the effects of all dilutive potential Common Shares, which comprise warrants, rights and share options granted to employees.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="d_2018-04-01_2019-03-31" id="c47927246">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 35pt; text-align: left"&gt;(e)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Employee benefits:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(i)&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Short-term employee benefits:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;A liability is recognized for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Corporation has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the obligation can be estimated reliably.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 14; Value: 9 --&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(ii)&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Share-based payment transactions:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The grant date fair value of share-based payment awards granted to employees is recognized as an employee expense, with a corresponding increase in contributed surplus, over the period that the employees unconditionally become entitled to the awards. The grant date fair value takes into consideration market performance conditions when applicable. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. Share-based payment arrangements in which the Corporation receives goods or services as consideration for its own equity instruments are accounted for as equity-settled share-based payment transactions, regardless of how the equity instruments are obtained by the Corporation.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(iii)&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Termination benefits:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Termination benefits are recognized as an expense when the Corporation is committed demonstrably, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognized as an expense if the Corporation has made an offer of voluntary redundancy, it is probable that the offer will be accepted, and the number of acceptances can be estimated reliably. If benefits are payable more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt; months after the reporting year, then they are discounted to their present value.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory contextRef="d_2018-04-01_2019-03-31" id="c47927251">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 35pt; text-align: left"&gt;(j)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Finance income and finance expense:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;Finance income comprises interest income on funds invested. Interest income is recognized as it accrues in profit or loss, using the effective interest method.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;Finance costs comprise interest expense, accretion on borrowings, unwinding of the discount on provisions, impairment losses recognized on financial assets, transaction costs for issuance of derivative warrant liabilities and changes of fair value of derivative warrant liabilities. Borrowing costs that are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; directly attributable to the acquisition, construction or production of a qualifying asset are recognized in profit or loss using the effective interest method.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Foreign currency gains and losses are reported on a net basis. The Corporation recognizes interest income as a component of investing activities and interest expense as a component of financing activities in the statements of cash flows.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="d_2018-04-01_2019-03-31" id="c47927242">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 35pt; text-align: left"&gt;(a)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Financial instruments:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;A financial instrument is any contract that gives rise to a financial asset of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; party and a financial liability or equity instrument of another party.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(i)&lt;/td&gt; &lt;td style="text-align: justify"&gt;Non-derivative financial assets:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation has the following non-derivative financial assets: cash, cash equivalents, marketable securities and receivables. The Corporation determines the classification of its financial assets at initial recognition. The subsequent measurement of financial assets depends on their classification.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Financial assets and liabilities are offset and the net amount presented in the statements of financial position when, and only when, the Corporation has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0pt"&gt;Cash, cash equivalents, marketable securities and receivables with maturities of less than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; year are classified at amortized cost as they meet both of the following conditions; they are held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms give rise on specified dates to cashflows that are solely payments of principal and interest on the principal amount outstanding. Cash and cash equivalents comprise cash balances and highly liquid investments purchased &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months or less from maturity.&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0.25in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 11; Value: 9 --&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(ii)&lt;/td&gt; &lt;td style="text-align: justify"&gt;Non-derivative financial liabilities:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation has the following non-derivative financial liabilities: trade and other payables. Such financial liabilities are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are measured at amortized cost using the effective interest method.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(iii)&lt;/td&gt; &lt;td style="text-align: justify"&gt;Compound financial instruments:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;Compound financial instruments are instruments that can be converted to share capital at the option of the holder, and the number of shares to be issued is fixed.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;The unsecured convertible debentures are compound instruments and have been separated into liability and equity components. The liability component is recognized initially at the fair value of a similar liability that does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; remeasured subsequent to initial recognition.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(iv)&lt;/td&gt; &lt;td style="text-align: justify"&gt;Share capital:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Common Shares&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;Class A Common Shares are classified as equity. Incremental costs directly attributable to the issue of Common Shares and share options are recognized as a deduction from share capital, net of any tax effects.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(v)&lt;/td&gt; &lt;td style="text-align: justify"&gt;Derivative financial instruments:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation has issued liability-classified derivatives over its own equity. Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit and loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and all changes in their fair value are recognized immediately in profit or loss as a component of finance expense (income).&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(vi)&lt;/td&gt; &lt;td style="text-align: justify"&gt;Other equity instruments:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;Warrants, options and rights over the Corporation&amp;#x2019;s equity issued outside of share-based payment transactions that do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; meet the definition of a liability instrument are recognized in equity.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="d_2018-04-01_2019-03-31" id="c47927250">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 35pt; text-align: left"&gt;(i)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Foreign currency:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Transactions in foreign currencies are translated into the functional currency at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the period, adjusted for effective interest and payments during the period, and the amortized cost in foreign currency translated at the exchange rate at the end of the reporting period. Foreign currency differences arising on translation are recognized in profit or loss.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants contextRef="d_2018-04-01_2019-03-31" id="c47927248">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 35pt; text-align: left"&gt;(g)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Government grants:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Government grants are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Corporation has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Grants that compensate the Corporation for expenses incurred are recognized in profit or loss in reduction thereof on a systematic basis in the same years in which the expenses are recognized. Grants that compensate the Corporation for the cost of an asset are recognized in profit or loss on a systematic basis over the useful life of the asset.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
  <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory contextRef="d_2018-04-01_2019-03-31" id="c47927245">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 35pt; text-align: left"&gt;(d)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Impairment:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(i)&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Financial assets:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation assesses at each reporting date the expected credit loss for calculating impairment of financial assets and recognizes expected credit losses as loss allowances for assets measured at amortized cost.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(ii)&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Non-financial assets:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The carrying amounts of the Corporation&amp;#x2019;s non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset&amp;#x2019;s recoverable amount is estimated.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the &amp;#x201c;cash-generating unit, or &amp;#x201c;CGU&amp;#x201d;).&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation&amp;#x2019;s corporate assets do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; generate separate cash inflows. If there is an indication that a corporate asset &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be impaired, then the recoverable amount is determined for the CGU to which the corporate asset belongs.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;An impairment loss is recognized if the carrying amount of an asset or its CGU exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Impairment losses recognized in prior years are assessed at each reporting date for any indications that the loss has decreased or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset&amp;#x2019;s carrying amount does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; exceed the carrying amount that would have been determined, net of depreciation or amortization, if &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; impairment loss had been recognized.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="d_2018-04-01_2019-03-31" id="c47927252">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 35pt; text-align: left"&gt;(k)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Income tax:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Income tax expense comprises current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they relate to items recognized directly in equity or in other comprehensive income.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; recognized for temporary differences arising from the initial recognition of assets or liabilities in a transaction that is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; a business combination and that affects neither accounting nor taxable profit or loss. Deferred tax is measured at the tax rates, enacted or substantively enacted, that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously. A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer probable that the related tax benefit will be realized.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory contextRef="d_2018-04-01_2019-03-31" id="c47927244">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 35pt; text-align: left"&gt;(c)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Intangible assets:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(i)&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Research and development:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss as incurred.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Corporation intends to and has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized includes the cost of materials, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use, and borrowing costs on qualifying assets. Other development expenditures are recognized in profit or loss as incurred.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Capitalized development expenditure is measured at cost less accumulated amortization and accumulated impairment losses. As of the reporting periods presented, the Corporation has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; capitalized any development expenditure.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(ii)&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Other intangible assets:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patent costs&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Patents for technologies that are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer in the research phase are recorded at cost. Patent costs include legal fees to obtain patents and patent application fees. When the technology is still in the research and development phase, those costs are expensed as incurred.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Licenses&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Licenses that are acquired by the Corporation and have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(iii)&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Subsequent expenditure:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditures, including expenditure on internally generated goodwill and brands, are recognized in profit or loss as incurred.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(iv)&lt;/td&gt; &lt;td style="text-align: justify"&gt;Amortization:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Amortization is calculated over the cost of the intangible asset less its residual value.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 13; Value: 9 --&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets from the date that they are available for use, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are as follows:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Assets&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Period (in years)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 78%"&gt;Patents&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 7%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;License&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8 &lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;to&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; 14&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="d_2018-04-01_2019-03-31" id="c47927249">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 35pt; text-align: left"&gt;(h)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Lease payments:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease. Lease incentives received are recognized as an integral part of the total lease expense, over the term of the lease.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="d_2018-04-01_2019-03-31" id="c47927243">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 35pt; text-align: left"&gt;(b)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Equipment:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(i)&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Recognition and measurement:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Equipment is measured at cost less accumulated depreciation and accumulated impairment losses, if any.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Cost includes expenditures that are directly attributable to the acquisition of the asset, including all costs incurred in bringing the asset to its present location and condition.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Gains and losses on disposal of equipment are determined by comparing the proceeds from disposal with the carrying amount of equipment, and are recognized net within ''other income or expenses'' in profit or loss.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(ii)&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Subsequent costs:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The cost of replacing a part of an equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Corporation, and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the day-to-day servicing of equipment are recognized in profit or loss as incurred.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 12; Value: 9 --&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(iii)&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Depreciation:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Depreciation is recognized in profit or loss on either a straight-line basis or a declining basis over the estimated useful lives of each part of an item of equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Items of equipment are depreciated from the date that they are available for use or, in respect of assets &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; yet in service, from the date they are ready for their intended use.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The estimated useful lives and rates for the current and comparative periods are as follows:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-indent: -9.05pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Assets&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Method&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Period/Rate&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;Furniture and office equipment&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Declining balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;20%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt; to&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt; 30%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 28%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Computer equipment&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 30%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Declining balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 20%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;30%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Laboratory equipment&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Declining balance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;30%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Production equipment (in years)&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;Straight-line&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;Depreciation methods, useful lives and residual values are reviewed at each financial year-end and adjusted prospectively if appropriate.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="d_2018-04-01_2019-03-31" id="c47927247">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 35pt; text-align: left"&gt;(f)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Provisions:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0pt"&gt;A provision is recognized if, as a result of a past event, the Corporation has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as a component of finance expense (income).&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(i)&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Onerous contracts:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;A provision for onerous contracts is recognized when the expected benefits to be derived by the Corporation from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Corporation recognizes any impairment loss on the assets associated with that contract.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;(ii)&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Contingent liability:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;A contingent liability is a possible obligation that arises from past events and of which the existence will be confirmed only by the occurrence or non-occurrence of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; or more uncertain future events &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; within the control of the Corporation; or a present obligation that arises from past events (and therefore exists), but is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; recognized because it is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; probable that a transfer or use of assets, provision of services or any other transfer of economic benefits will be required to settle the obligation; or the amount of the obligation cannot be estimated reliably.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory contextRef="d_2018-04-01_2019-03-31" id="c47927254">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="width: 35pt; text-align: left"&gt;(m)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Segment reporting:&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;An operating segment is a component of the Corporation that engages in business activities from which it &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;earn revenues and incur expenses. The Corporation has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; reportable operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The majority of the Corporation&amp;#x2019;s assets are located in Canada, while &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; major production unit, with a carrying value of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,831&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018 - &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,077&lt;/div&gt;), is located in France.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
  <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections contextRef="i_2017-02-21_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="3" id="c47923668" unitRef="xbrli-pure">0.2</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47924381" unitRef="xbrli-pure">0.8535</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="d_2017-03-01_2018-03-31" decimals="INF" id="c47924382" unitRef="xbrli-pure">0.824</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="d_2016-03-01_2017-03-31" decimals="INF" id="c47924383" unitRef="xbrli-pure">1.235</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="d_2016-03-01_2017-02-28" decimals="INF" id="c47924384" unitRef="xbrli-pure">1.235</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="d_2016-03-01_2019-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924100" unitRef="xbrli-pure">10</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47924377" unitRef="xbrli-pure">5.78</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="d_2017-03-01_2018-03-31" decimals="INF" id="c47924378" unitRef="xbrli-pure">5.89</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="d_2016-03-01_2017-03-31" decimals="INF" id="c47924379" unitRef="xbrli-pure">4.94</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="d_2016-03-01_2017-02-28" decimals="INF" id="c47924380" unitRef="xbrli-pure">4.94</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47924373" unitRef="xbrli-pure">0.021</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="d_2017-03-01_2018-03-31" decimals="INF" id="c47924374" unitRef="xbrli-pure">0.0121</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="d_2016-03-01_2017-03-31" decimals="INF" id="c47924375" unitRef="xbrli-pure">0.0087</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="d_2016-03-01_2017-02-28" decimals="INF" id="c47924376" unitRef="xbrli-pure">0.0087</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233055">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Supplemental cash flow disclosure:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(a)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Changes in working capital items:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-&lt;br /&gt; months ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;March 31, &lt;br /&gt;2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;March 31, &lt;br /&gt;2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;March 31, &lt;br /&gt;2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;March 31, &lt;br /&gt;2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;February 28, &lt;br /&gt; 2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%"&gt;Receivables&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(738&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(553&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;193&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;233&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(709&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(103&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;247&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(33&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;280&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Other Assets&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;37&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(659&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Deferred financing costs&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(179&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Trade and other payables&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,679&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,898&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;352&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(255&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;607&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Total changes in working capital items&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,090&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,583&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;792&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(328&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,120&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 33; Value: 9 --&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(b)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Non-cash transactions:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-months &lt;br /&gt; ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; padding-left: 10pt; text-indent: -10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2019&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, 2017 &lt;/div&gt;&lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Issuance of shares for interest on convertible debt&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;120&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;137&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;94&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;94&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Issuance of broker warrants included in net proceeds from public offering&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;283&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;406&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;144&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;144&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Public offering transaction costs included in trade and other payables&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;132&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;381&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;381&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;416&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Interest receivable included in receivables&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;96&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Reduction in share issue costs from reduction in trade and other payables&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;109&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;109&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Private Placement transaction costs included in trade and other payables&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 10pt; text-indent: -10pt"&gt;Equipment included in trade and other payables&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;216&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;288&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;288&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;269&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt"&gt;Interest payable included in trade and other payables&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory>
  <ifrs-full:DisclosureOfBasisOfConsolidationExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233008">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Reporting entity&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Acasti Pharma Inc. (&lt;div style="display: inline; font-weight: bold;"&gt;Acasti&lt;/div&gt; or the &lt;div style="display: inline; font-weight: bold;"&gt;Corporation&lt;/div&gt;) is incorporated under the &lt;div style="display: inline; font-style: italic;"&gt;Business Corporations Act&lt;/div&gt; (Qu&amp;eacute;bec) (formerly Part &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1A&lt;/div&gt; of the &lt;div style="display: inline; font-style: italic;"&gt;Companies Act &lt;/div&gt;(Qu&amp;eacute;bec)). The Corporation is domiciled in Canada and its registered office is located at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;545,&lt;/div&gt; Promenade du Centropolis, Laval, Qu&amp;eacute;bec, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;H7T&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0A3.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation is subject to a number of risks associated with its ongoing priorities, including the conduct of its clinical program and its results, the establishment of strategic alliances and the development of new pharmaceutical products and their marketing. The Corporation&amp;#x2019;s current product in development requires approval from the U.S Food and Drug Administration and equivalent regulatory organizations in other countries before their sale can be authorized. Certain risks have been reduced for the longer term with the outcome of the Corporation&amp;#x2019;s actions, including its intellectual property strategy execution with filed patent applications in more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20&lt;/div&gt; jurisdictions, with more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20&lt;/div&gt; issued patents and with numerous additional patent applications pending.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation has incurred significant operating losses and negative cash flows from operations since inception. To date, the Corporation has financed its operations through the public offering and private placement of Common Shares, units consisting of Common Shares and warrants and convertible debt, the proceeds from research grants and research tax credits, and the exercises of warrants, rights and options. To achieve the objectives of its business plan, Acasti plans to raise the necessary funds through additional securities offerings and the establishment of strategic alliances as well as additional research grants and research tax credits. The ability of the Corporation to complete the needed financing and ultimately achieve profitable operations is dependent on a number of factors outside of the Corporation&amp;#x2019;s control.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfConsolidationExplanatory>
  <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233009">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Basis of preparation&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(a)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Statement of compliance:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;These financial statements have been prepared in accordance with International Financial Reporting Standards (&amp;#x201c;IFRS&amp;#x201d;) as issued by the International Accounting Standards Board (&amp;#x201c;IASB&amp;#x201d;). Beginning in fiscal &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; the Corporation&amp;#x2019;s fiscal year end is on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31. &lt;/div&gt;Fiscal &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; is a transition year, and includes &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;thirteen&lt;/div&gt; months of operations, beginning on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; and ending on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2017. &lt;/div&gt;As a result, for comparative purposes the above financial statements and corresponding notes to financial statements include &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; unaudited periods: the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2017 &lt;/div&gt;and the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 28, 2017. &lt;/div&gt;The Canadian Securities regulator permits, in the transition year, the presentation of a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;thirteen&lt;/div&gt;-month period for the financial year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2017.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The financial statements were approved by the Board of Directors on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 26, 2019.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(b)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Basis of measurement:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;The financial statements have been prepared on the historical cost basis, except for:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 18pt"&gt;&lt;div style="display: inline; font-family: Symbol; font-size: 10pt"&gt;&amp;middot;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Stock-based compensation which is measured pursuant to IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Share-based payments&lt;/div&gt; (&lt;div style="display: inline; font-style: italic;"&gt;Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;(e) (ii&lt;/div&gt;)); and,&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 18pt"&gt;&lt;div style="display: inline; font-family: Symbol; font-size: 10pt"&gt;&amp;middot;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Derivative warrant liabilities measured at fair value on a recurring basis &lt;div style="display: inline; font-style: italic;"&gt;(Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt;)&lt;/div&gt;.&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(c)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Going concern uncertainty:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation has incurred operating losses and negative cash flows from operations since inception. The Corporation&amp;#x2019;s current assets of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$37.3&lt;/div&gt; million as at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;include cash and cash equivalents totaling &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$22.5&lt;/div&gt; million, and marketable securities of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$11.9&lt;/div&gt; million mainly generated by the net proceeds from the recent Public Offerings. The Corporation&amp;#x2019;s current liabilities total &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$18.2&lt;/div&gt; million at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and are comprised primarily of amounts due to or accrued for creditors&lt;div style="display: inline; font-size: 10pt"&gt;. Management projects that additional funds will be needed in the future, after TRILOGY phase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; clinical trials, for activities necessary to prepare for commercial launch, including the scale up of our manufacturing operations, the completion of the potential regulatory (NDA) submission package (assuming positive Phase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; clinical results), and the expansion of business development and US commercial launch activities. The Corporation is working towards development of strategic partner relationships, as well as actively seeking additional non-dilutive funds in the future, but there can be &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; assurance as to when or whether Acasti will complete any strategic collaborations or succeed in identifying non-dilutive funding sources. Consequently, the Corporation &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;need to raise additional equity capital in the future to fund these activities. In particular, raising additional capital is subject to market conditions and is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; within the Corporation&amp;#x2019;s control. If the Corporation does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; raise additional funds or find &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; or more strategic partners, it &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be able to realize its assets and discharge its liabilities in the normal course of business. As a result, there exists a material uncertainty that casts substantial doubt about the Corporation&amp;#x2019;s ability to continue as a going concern and, therefore, realize its assets and discharge its liabilities in the normal course of business. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 10; Value: 9 --&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The financial statements have been prepared on a going concern basis, which assumes the Corporation will continue its operations in the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business. These financial statements do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; include any adjustments to the carrying values and classification of assets and liabilities and reported expenses that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be necessary if the going concern basis was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; appropriate for these financial statements. If the Corporation was unable to continue as a going concern, material write-downs to the carrying values of the Corporation&amp;#x2019;s assets, including the intangible asset, could be required.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(d)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Functional and presentation currency:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"&gt;These financial statements are presented in Canadian dollars, which is the Corporation&amp;#x2019;s functional currency.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(e)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Use of estimates and judgments:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"&gt;The preparation of the financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;differ from these estimates.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify"&gt;Estimates are based on management&amp;#x2019;s best knowledge of current events and actions that the Corporation &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify"&gt;Critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements include the following:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font: 10pt Symbol"&gt;&amp;middot;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.95pt"&gt;The use of the going concern basis of preparation of the financial statements. At the end of each reporting period, management assesses the basis of preparation of the financial statements (Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;(c)).&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify"&gt;Assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the next financial year include the following:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font: 10pt Symbol"&gt;&amp;middot;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.6pt"&gt;Measurement of derivative warrant liabilities (&lt;div style="display: inline; font-style: italic;"&gt;note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt;&lt;/div&gt;) and stock-based compensation (&lt;div style="display: inline; font-style: italic;"&gt;note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17&lt;/div&gt;&lt;/div&gt;).&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(f)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Use of estimates and judgments (continued):&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify"&gt;Also, management uses judgment to determine which research and development (&amp;#x201c;R&amp;amp;D&amp;#x201d;) expenses qualify for R&amp;amp;D tax credits and in what amounts. The Corporation recognizes the tax credits once it has reasonable assurance that they will be realized. Recorded tax credits are subject to review and approval by tax authorities and therefore, could be different from the amounts recorded.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
  <ifrs-full:DisclosureOfBorrowingsExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233034">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Unsecured convertible debentures&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;Concurrent with the Public Offering described in note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,&lt;/div&gt; on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 21, 2017, &lt;/div&gt;the Corporation issued &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,000&lt;/div&gt; aggregate principal amount of unsecured convertible debentures maturing &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 21, 2020 &lt;/div&gt;and contingent warrants to acquire up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,052,630&lt;/div&gt; Common Shares (the &amp;#x201c;Private Placement&amp;#x201d;). The principal &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be prepaid, in whole or in part, at any time and from time to time, in cash, at the sole discretion of the Corporation&lt;div style="display: inline; font-weight: bold;"&gt;. &lt;/div&gt;The debentures are convertible into Common Shares at any time by the holder at a fixed price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.90&lt;/div&gt; per Common Share except if the Corporation pays before the maturity, all or any portion of the convertible debentures. Should the Corporation pay all or any portion of the convertible debenture before maturity, then warrants become exercisable at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.90&lt;/div&gt; per Common Share for the equivalent convertible debenture amount prepaid. The contingent warrants will be exercisable for the remaining term of the convertible debt for the same price as the conversion options. The unsecured convertible debentures were issued at a discount of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.5%&lt;/div&gt; to the principal amount, for aggregate gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,930.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-weight: normal"&gt;The convertible debentures provide the Corporation an accelerated conversion right whereby the Corporation &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may, &lt;/div&gt;at any time at least &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;four&lt;/div&gt; months after the date of issuance of the convertible debentures, accelerate the conversion of the debentures to Common Shares in the event that the volume weighted average price of the Corporation&amp;#x2019;s Common Shares on the TSX Venture Exchange is equal to or exceeds &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.65,&lt;/div&gt; subject to customary adjustment provisions, during &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20&lt;/div&gt; consecutive trading days. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The interest to be paid on the convertible debentures under the terms of the agreement is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8%&lt;/div&gt; per annum, payable on a quarterly basis in cash or Common Shares of the Corporation or a combination thereof, commencing on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2017. &lt;/div&gt;The decision to pay the interest due in cash or shares is at the discretion of the Corporation and the number of Common Shares to be issued will be calculated at the current market price as at the close of business on the day before the interest payment is to be made. Payment in shares shall be at a floor price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.10&lt;/div&gt; per share, with the difference between the amount payable and the amount computed at floor price payable in cash.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The proceeds of the Private Placement were split between the liability and the equity at the time of issuance of the Private Placement. Both the conversion option and contingent warrants are considered the equity component of the Private Placement. The fair value of the liability component was determined through a discounted cash flow analysis using a discount rate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20%&lt;/div&gt; that was set based on a similar debt and maturity considering the Corporation&amp;#x2019;s credit risk excluding the conversion option and contingent warrants. The amount allocated to the equity component is the residual amount after deducting the fair value of the financial liability component from the fair value of the entire compound instrument. Subsequent to initial recognition, the liability is measured at amortized cost calculated using the effective interest rate method and will accrete up to the principal balance at maturity. The interest accretion is presented as a financial expense. The equity component is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; re-measured. Transaction costs were allocated to the components in proportion to their initial carrying amounts. The portion allocated to the liability was recognized as a reduction of the debt whereas the portion allocated to other equity was recognized as a reduction to other equity.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 24; Value: 9 --&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The split between the liability and equity component portions of the Private Placement are summarized below:&lt;/div&gt; &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid; vertical-align: top"&gt;Liability component&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid; vertical-align: top"&gt;Equity component&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;Total Private &lt;br /&gt; Placement&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-weight: normal; border-bottom: Black 1pt solid"&gt;Balance at March 31, 2017&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,406&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;309&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,715&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Effective interest for the twelve-month period&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;366&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;366&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Interest payable during the period&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(160&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(160&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Balance at March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,612&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;309&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,921&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Effective interest during the period&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;365&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;365&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Interest payable during the period&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(160&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(160&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;Balance at March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,817&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;309&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,126&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfBorrowingsExplanatory>
  <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="d_2018-04-01_2019-03-31" id="c-48">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-size: 12pt; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 70%; font-weight: normal"&gt;Cash&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,896&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,583&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Cash equivalents&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; padding-left: 8.75pt"&gt;Term deposits issued in CAD currency&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,100&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; padding-left: 8.75pt"&gt;Term deposits issued in US currency [US - $3,250]&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,193&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; padding-left: 8.75pt"&gt;Commercial papers issued in CAD currency&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,693&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; padding-left: 8.75pt"&gt;Commercial papers issued in US currency [US - $1,099]&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,418&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; padding-left: 8.75pt"&gt;Promissory notes issued in CAD currency&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;498&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; padding-left: 8.75pt"&gt;Promissory notes issued in US currency [US - $798]&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,029&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; padding-left: 8.75pt"&gt;Bankers acceptance&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,334&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Total Cash equivalents&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,625&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,640&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid"&gt;Total Cash and cash equivalents&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22,521&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,223&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
  <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233069">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Commitments and contingencies:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and development contracts and contract research organizations agreements: &lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The Corporation utilizes contract manufacturing organizations related to the development and production of clinical material and clinical research organizations to perform services related to the Company&amp;#x2019;s clinical trials. Pursuant to these agreements with manufacturing and contract research organizations, the Corporation has the right to terminate the agreements either without penalties or under certain penalty conditions. For agreements which contain penalty conditions, the Company would be required to pay penalties of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$109.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;During Fiscal &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; the Corporation entered into a lease agreement, for its research and development and quality control laboratory facility located in Sherbrooke, Qu&amp;eacute;bec, resulting in a commitment of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$79&lt;/div&gt; over the remaining lease term, which is committed in the next year.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Contingencies:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.1pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.1pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.1pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation evaluates contingencies on an ongoing basis and establishes loss provisions for matters in which losses are probable and the amount of the loss can be reasonably estimated. Refer to Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25,&lt;/div&gt; Subsequent Events.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
  <ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233031">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Derivative warrant liabilities:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The warrants issued as part of the public offering of units composed of Common Share and Common Share purchase warrants on both &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 9, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 14, 2018 (&lt;/div&gt;&lt;div style="display: inline; font-style: italic;"&gt;see note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14&lt;/div&gt;&lt;/div&gt;) are derivative liabilities (&amp;#x201c;Derivative Warrant Liabilities&amp;#x201d;) given the warrant indenture contains certain contingent provisions that allow for cash settlement.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;Warrants issued as part of a public offering of units composed of class A share (Common Share) and Common Share purchase warrants on both &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 27, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 3, 2013 &lt;/div&gt;are derivative liabilities (&amp;#x201c;Derivative warrant liabilities&amp;#x201d;) given the currency of the exercise price is different from the Corporation&amp;#x2019;s functional currency.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value is presented in the following tables:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Warrant liabilities issued &lt;br /&gt; May 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Warrant liabilities issued &lt;br /&gt; December 27, 2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-weight: normal"&gt;Warrant liabilities issued &lt;br /&gt; December 3, 2013&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;March 31, &lt;br /&gt; 2019&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; font-style: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; font-style: normal; text-align: right"&gt;March 31, &lt;br /&gt; 2018&lt;/td&gt; &lt;td style="font-weight: normal; font-style: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;March 31, &lt;br /&gt; 2019&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; font-style: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; font-style: normal; text-align: right"&gt;March 31, &lt;br /&gt; 2018&lt;/td&gt; &lt;td style="font-weight: normal; font-style: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;March 31, &lt;br /&gt; 2019&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; font-style: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; font-style: normal; text-align: right"&gt;March 31, &lt;br /&gt; 2018&lt;/td&gt; &lt;td style="font-weight: normal; font-style: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 34%; font-weight: normal"&gt;Balance &amp;#x2013; beginning of period&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,405&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;209&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Issued during period&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,272&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,873&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-indent: -4.95pt; padding-left: 4.95pt"&gt;Exercised during period&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(722&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; text-indent: -4.95pt; padding-left: 4.95pt"&gt;Change in fair value of derivative warrant liabilities&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,696&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,612&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;532&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(21&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(188&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;Balance &amp;#x2013; end of period&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,246&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,017&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,405&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;Fair value per share issuable&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.81&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.82&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.65&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.01&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;div style="display: inline; font-size: 8pt"&gt;(&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;)&lt;/div&gt; &lt;div style="display: inline; font-size: 8pt"&gt;In order to obtain &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt; warrants must be exercised. All unexercised warrants expired on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 3, 2018.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0.75in; text-align: justify; text-indent: 0in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The fair value of the derivative warrant liabilities was estimated using the Black-Scholes option pricing model and based on the following assumptions:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Warrant liabilities issued &lt;br /&gt;May 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Warrant liabilities issued &lt;br /&gt;December 27, 2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Warrant liabilities issued&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;December 3, 2013 &lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt;2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt; 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt;2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt; 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt;2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt; 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 34%; font-weight: normal"&gt;Exercise price&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.31&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.26&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.26&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Share price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.35&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Risk-free interest&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.23&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.56&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.19&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Estimated life (in years)&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;4.11&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;3.75&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;4.75&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;0.68&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;94.58&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;107.57&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;95.15&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;133.86&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt; &lt;div style="display: inline; font-size: 8pt"&gt;(&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;)&lt;/div&gt; &lt;div style="display: inline; font-size: 8pt"&gt;In order to obtain &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt; warrants must be exercised. All unexercised warrants expired on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 3, 2018.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDerivativeFinancialInstrumentsExplanatory>
  <ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory contextRef="d_2018-04-01_2019-03-31" id="c-31">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid; vertical-align: top"&gt;Liability component&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid; vertical-align: top"&gt;Equity component&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;Total Private &lt;br /&gt; Placement&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-weight: normal; border-bottom: Black 1pt solid"&gt;Balance at March 31, 2017&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,406&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;309&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,715&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Effective interest for the twelve-month period&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;366&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;366&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Interest payable during the period&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(160&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(160&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Balance at March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,612&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;309&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,921&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Effective interest during the period&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;365&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;365&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Interest payable during the period&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(160&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(160&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;Balance at March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,817&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;309&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,126&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory>
  <ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory contextRef="d_2018-04-01_2019-03-31" id="c-27">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Patents&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;License&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Total&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold"&gt;Cost:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 55%"&gt;Balance at February 29, 2016, February 28, 2017 (Unaudited) and March 31, 2017&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,330&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,692&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Additions&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Balance at March 31, 2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,330&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,692&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Additions&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;Balance at March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,330&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,692&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated amortization:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance at February 29, 2016&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,425&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,787&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Amortization for the twelve-month period (Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,323&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,323&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance at February 28, 2017 (Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,748&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,110&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Amortization for the one-month period (Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;194&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;194&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Amortization for the thirteen-month period&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,517&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,517&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Balance at March 31, 2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,942&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,304&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Amortization for the year&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,323&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,323&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Balance at March 31, 2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,265&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,627&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Amortization for the year&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,322&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,322&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;Balance at March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,587&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,949&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Net carrying amounts:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.1in"&gt;March 31, 2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,065&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,065&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.5pt solid; padding-left: 0.1in"&gt;March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,743&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,743&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory>
  <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="d_2018-04-01_2019-03-31" id="c-26">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Furniture and &lt;br /&gt; office equipment&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Computer &lt;br /&gt; equipment&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Laboratory &lt;br /&gt; equipment&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Production &lt;br /&gt; equipment&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Total&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold"&gt;Cost:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 35%"&gt;Balance at February 29, 2016&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;336&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;398&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Additions for the twelve-month period (Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;186&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,484&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,678&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Balance at February 28, 2017 (Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;522&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,484&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,076&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Additions for the one-month period (Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;43&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;43&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Additions for the thirteen-month period&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;186&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,527&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,721&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance at March 31, 2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;522&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,527&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,119&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Additions&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;192&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;181&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;383&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance at March 31, 2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;63&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;714&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,708&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,502&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Additions&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;219&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;260&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;497&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;Balance at March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;68&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;933&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,968&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,999&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Balance at February 29, 2016&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;56&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;111&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Depreciation for the twelve-month period (Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;189&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Balance at February 28, 2017 (Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;185&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;300&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Depreciation for the one-month period (Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Depreciation for thirteen-month period&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;140&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;73&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;221&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance at March 31, 2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;196&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;73&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;332&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Depreciation&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;107&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;239&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;349&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance at March 31, 2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;303&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;312&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;681&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Depreciation&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;180&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;317&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;505&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;Balance at March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;60&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;483&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;629&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,186&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Net carrying amounts:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-left: 0.1in"&gt;March 31, 2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;411&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,396&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,821&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1.5pt solid; padding-left: 0.1in"&gt;March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;450&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,339&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,813&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
  <ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory contextRef="d_2018-04-01_2019-03-31" id="c-46">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: normal; border-bottom: Black 1pt solid; text-align: left; vertical-align: top"&gt;Denominated in&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;US &lt;br /&gt; $&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;Euro&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;US &lt;br /&gt; $&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;Euro&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; font-weight: normal; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,369&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,024&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Marketable securities&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,696&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal"&gt;Receivables&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Trade and other payables&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(13,251&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(131&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3,924&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(627&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(7,170&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(131&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,132&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(627&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Average&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Reporting&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Average&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Reporting&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; font-weight: normal"&gt;CA$ per US$&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.3122&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.3349&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.2834&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.2900&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;CA$ per Euro&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.5192&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.4975&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.5008&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.5898&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 70%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Increase (decrease) in net loss&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;364&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(88&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory>
  <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233073">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Subsequent events&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 15, 2019 &lt;/div&gt;the Corporation announced the annual grant of stock options to its employees, executives and directors of its stock option plan (the &amp;#x201c;Stock Option Plan&amp;#x201d;). The stock options were granted by the Board of Directors as part of the Corporation&amp;#x2019;s annual performance review in accordance with the Corporation&amp;#x2019;s Long-Term Incentive Program (LTIP).&amp;nbsp;An aggregate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;644,117&lt;/div&gt; stock options were granted to certain employees, executives and directors of the Corporation under the Corporation&amp;#x2019;s Stock Option Plan. Subject to the terms and conditions of the Stock Option Plan, options granted to directors will vest in equal quarterly installments over a period of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt; months and options granted to executives and employees will vest in equal quarterly installments over a period of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;36&lt;/div&gt; months. Each option will entitle the holder to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share of the Corporation at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;CDN$1.28,&lt;/div&gt; until &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 15, 2029.&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 10, 2019 &lt;/div&gt;the Corporation announced the settlement regarding legal claims made by its former chief executive (&amp;#x201c;CEO&amp;#x201d;) officer with respect to the termination of his employment. Pursuant to the settlement agreement, the Corporation has agreed to issue &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;900,000&lt;/div&gt; common shares at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.10&lt;/div&gt; per share to the former CEO.&amp;nbsp; In addition, the Corporation has agreed to reimburse the former CEO for legal fees of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$64.&lt;/div&gt; Furthermore, pursuant to the settlement agreement, the Corporation receives a full and final release from the former CEO on all procedures in connection with the termination of his employment. This settlement has been accrued as at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and the expense of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,054&lt;/div&gt; is included as part of General and administrative expenses.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
  <ifrs-full:DisclosureOfFairValueMeasurementExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233070">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Determination of fair values:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.1pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.1pt; margin-bottom: 0pt; text-align: justify"&gt;Certain of the Corporation&amp;#x2019;s accounting policies and disclosures require the determination of fair value, for both financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Financial assets and liabilities:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;In establishing fair value, the Corporation uses a fair value hierarchy based on levels as defined below:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 36pt"&gt;&lt;/td&gt; &lt;td style="width: 20.7pt"&gt;&lt;div style="display: inline; font-family: Symbol"&gt;&amp;middot;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1:&lt;/div&gt; defined as observable inputs such as quoted prices in active markets.&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 36pt"&gt;&lt;/td&gt; &lt;td style="width: 20.7pt"&gt;&lt;div style="display: inline; font-family: Symbol"&gt;&amp;middot;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2:&lt;/div&gt; defined as inputs other than quoted prices in active markets that are either directly or indirectly observable.&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 36pt"&gt;&lt;/td&gt; &lt;td style="width: 20.7pt"&gt;&lt;div style="display: inline; font-family: Symbol"&gt;&amp;middot;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3:&lt;/div&gt; defined as inputs that are based on little or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; observable market data, therefore requiring entities to develop their own assumptions.&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation has determined that the carrying values of its short-term financial assets and liabilities (cash and cash equivalents, marketable securities and trade and other payables) approximate their fair value given the short-term nature of these instruments. The fair value of the liability component of the convertible debenture is determined by discounting future cash flows using a rate that the Corporation could obtain for loans with similar terms, conditions and maturity dates. The fair value of this liability at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;approximates the carrying amount and was measured using level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; inputs.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Derivative warrant liabilities:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The Corporation measured its derivative warrant liabilities at fair value on a recurring basis. These financial liabilities were measured using level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; inputs &lt;div style="display: inline; font-style: italic;"&gt;(Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt;).&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;As at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019, &lt;/div&gt;the effect of an increase or a decrease of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5%&lt;/div&gt; of the volatility used, which is the significant unobservable input in the fair value estimate, would result in a loss of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$569&lt;/div&gt; or a gain of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$598,&lt;/div&gt; respectively.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;As at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019, &lt;/div&gt;the effect of a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5%&lt;/div&gt; strengthening of the US dollar, would result in a loss of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$405.&lt;/div&gt; An assumed &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5%&lt;/div&gt; weakening of the foreign currency would have an equal but opposite effect on the basis that all other variables remained constant.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
  <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233046">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Financial expenses:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0.5in; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-&lt;br /&gt; months ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-month &lt;br /&gt;period ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2019&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, &lt;/div&gt;&lt;br /&gt; 2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; text-align: left"&gt;Interest income&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;475&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;72&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;119&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Foreign exchange gain (loss)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;279&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(32&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(180&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(177&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Interest payable on convertible debenture&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(160&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(160&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(17&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(14&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Accretion of interest on convertible debenture&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(205&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(206&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(22&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(17&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Transaction costs related to derivative warrant liabilities&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(653&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,134&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Change in fair value of warrant liabilities&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(6,287&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(344&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(53&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(22&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(31&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Other charges&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(19&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Financial expenses&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(6,551&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,808&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(166&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(51&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(115&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
  <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233063">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Financial instruments:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;This note provides disclosures relating to the nature and extent of the Corporation&amp;#x2019;s exposure to risks arising from financial instruments, including credit risk, foreign currency risk, interest rate risk and liquidity risk, and how the Corporation manages those risks.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(a)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Credit risk:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Credit risk is the risk of a loss if a customer or counterparty to a financial asset fails to meet its contractual obligations. The Corporation has credit risk relating to cash and cash equivalents and marketable securities, which it manages by dealing only with highly-rated Canadian institutions. The carrying amount of financial assets, as disclosed in the statements of financial position, represents the Corporation&amp;#x2019;s credit exposure at the reporting date.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(b)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Currency risk:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation is exposed to the financial risk related to the fluctuation of foreign exchange rates and the degrees of volatility of those rates. Foreign currency risk is limited to the portion of the Corporation's business transactions denominated in currencies other than the Canadian dollar. Fluctuations related to foreign exchange rates could cause unforeseen fluctuations in the Corporation's operating results.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;A portion of the expenses, mainly related to research contracts and purchase of production equipment, is incurred in US dollars and in Euros. There is a financial risk related to the fluctuation in the value of the US&amp;nbsp;dollar and the Euro in relation to the Canadian dollar. In order to minimize the financial risk related to the fluctuation in the value of the US dollar in relation to the Canadian dollar, funds continue to be invested as short-term investments in the US dollar.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The following table provides an indication of the Corporation&amp;#x2019;s significant foreign exchange currency exposures as stated in Canadian dollars at the following dates:&lt;/div&gt; &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: normal; border-bottom: Black 1pt solid; text-align: left; vertical-align: top"&gt;Denominated in&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;US &lt;br /&gt; $&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;Euro&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;US &lt;br /&gt; $&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;Euro&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; font-weight: normal; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,369&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,024&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Marketable securities&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,696&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal"&gt;Receivables&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Trade and other payables&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(13,251&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(131&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3,924&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(627&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(7,170&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(131&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,132&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(627&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 23.4pt; text-indent: -9pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The following exchange rates are those applicable to the following periods and dates:&lt;/div&gt; &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Average&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Reporting&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Average&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Reporting&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; font-weight: normal"&gt;CA$ per US$&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.3122&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.3349&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.2834&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.2900&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;CA$ per Euro&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.5192&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.4975&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.5008&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.5898&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Based on the Corporation&amp;#x2019;s foreign currency exposures noted above, varying the above foreign exchange rates to reflect a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5%&lt;/div&gt; strengthening of the US dollar and Euro would have an increase (decrease) in net loss as follows, assuming that all other variables remain constant:&lt;/div&gt; &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 70%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Increase (decrease) in net loss&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;364&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(88&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 20.5pt; text-indent: -9pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;An assumed &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5%&lt;/div&gt; weakening of the foreign currencies would have an equal but opposite effect on the basis that all other variables remained constant.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 37; Value: 9 --&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(c)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Interest rate risk:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market rates.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation&amp;#x2019;s exposure to interest rate risk as at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018 &lt;/div&gt;is as follows:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 60%; border-top: Black 2.25pt solid; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 40%; border-top: Black 2.25pt solid; text-align: right; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;Short-term fixed interest rate&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: White"&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;Marketable Securities&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right; font-weight: bold"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;Short-term fixed interest rate&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 2.25pt solid; font-weight: bold"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;Unsecured convertible debentures &lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 2.25pt solid; text-align: right; font-weight: bold"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;Long-term fixed interest rate&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The capacity of the Corporation to reinvest the short-term amounts with equivalent return will be impacted by variations in short-term fixed interest rates available on the market. Management believes that the risk the Corporation will realize a loss as a result of the decline in the fair value of its cash equivalents is limited because these investments have short-term maturities and are generally held to maturity.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(d)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Liquidity risk:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Liquidity risk is the risk that the Corporation will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be able to meet its financial obligations as they fall due. The Corporation manages liquidity risk through the management of its capital structure and financial leverage, as outlined in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24.&lt;/div&gt; It also manages liquidity risk by continuously monitoring actual and projected cash flows. The Board of Directors reviews and approves the Corporation's operating budgets, and reviews material transactions outside the normal course of business. Refer to Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;(c).&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The following are the contractual maturities of financial liabilities as at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: normal"&gt;Required payments per year&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Carrying amount&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Less than 1 year&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1 to 3 years&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Notes&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-weight: normal; text-align: left"&gt;Trade and other payables&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,429&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,429&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,429&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Unsecured convertible debentures&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,143&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,817&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,143&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,572&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,246&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,572&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: normal"&gt;Required payments per year&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Carrying amount&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Less than 1 year&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1 to 3 years&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Notes&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-weight: normal; text-align: left"&gt;Trade and other payables&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,697&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,697&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,697&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Unsecured convertible debentures&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,303&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,612&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;160&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,143&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,000&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,309&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,857&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,143&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;The Derivative warrant liabilities are excluded from the above tables as they expected to be settled in shares and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; by the use of liquidities.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
  <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="d_2018-04-01_2019-03-31" id="c-47">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: normal"&gt;Required payments per year&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Carrying amount&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Less than 1 year&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1 to 3 years&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Notes&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-weight: normal; text-align: left"&gt;Trade and other payables&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,429&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,429&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,429&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Unsecured convertible debentures&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,143&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,817&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,143&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,572&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,246&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,572&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: normal"&gt;Required payments per year&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Carrying amount&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Less than 1 year&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1 to 3 years&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Notes&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; font-weight: normal; text-align: left"&gt;Trade and other payables&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,697&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,697&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,697&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Unsecured convertible debentures&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,303&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,612&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;160&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,143&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,000&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,309&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,857&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,143&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
  <ifrs-full:DisclosureOfGovernmentGrantsExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233022">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Government assistance:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-&lt;br /&gt; months ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2019&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, &lt;/div&gt;&lt;br /&gt; 2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; text-align: left"&gt;Investment tax credit&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;588&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;409&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;103&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;95&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Government grant&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;227&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;37&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;190&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Total government assistance&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;595&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;409&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;330&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;45&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;285&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;Government assistance is comprised of a government grant from the federal government and research and development investment tax credits receivable from the provincial government which relate to qualifiable research and development expenditures under the applicable tax laws. The amounts recorded as receivables are subject to a government tax audit and the final amounts received &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;differ from those recorded.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;Unrecognized federal tax credits &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be used to reduce future income tax and expire as follows:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 85%; text-align: left"&gt;2029&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;2030&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;2031&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;45&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;2032&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;431&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;2033&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;441&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;2034&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;436&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;2035&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;519&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;2036&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;286&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;2037&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;315&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;2038&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;324&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;2039&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;329&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,167&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGovernmentGrantsExplanatory>
  <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233058">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Income taxes:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;Deferred tax (recovery) expense:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0.4in; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right; border-top: Black 1.5pt solid"&gt;Twelve-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2019&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2018&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, &lt;/div&gt;&lt;br /&gt; 2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; text-align: left; text-indent: -7.35pt; padding-left: 7.35pt"&gt;Origination and reversal of temporary differences&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,599&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,241&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,240&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;163&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,077&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid; text-indent: -7.35pt; padding-left: 7.35pt"&gt;Change in unrecognized deductible temporary differences&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11,599&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5,241&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,369&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(163&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,206&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Deferred tax (recovery) expense&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.65pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;Reconciliation of effective tax rate:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right; border-top: Black 1.5pt solid"&gt;Twelve-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2019&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2018&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, &lt;/div&gt;&lt;br /&gt; 2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%; text-align: left"&gt;Loss before income taxes&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(51,566&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(21,504&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(11,376&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(769&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(10,607&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Basic combined Canadian statutory income tax rate &lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26.68&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26.78&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26.87&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26.80&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;26.88&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Computed income tax recovery&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(13,758&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(5,759&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3,057&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(206&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,851&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Increase resulting from:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; text-indent: -7.15pt; padding-left: 21.55pt"&gt;Change in unrecognized deductible temporary differences&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,599&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,241&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,369&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;162&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,207&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 0.2in"&gt;Non-deductible stock-based compensation&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;279&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;248&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;178&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;155&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 0.2in"&gt;Non-deductible change in fair value&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,677&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;92&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; padding-left: 0.2in"&gt;Permanent differences and other&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;203&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;178&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;166&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;154&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 0.2in"&gt;Change in statutory income tax rate&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;201&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;198&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Total tax (recovery) expense&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.65pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; The Canadian combined statutory income tax rate has decreased due to a reduction in the provincial statutory income tax rate.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;div style="display: inline; text-transform: uppercase"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 35; Value: 9 --&gt;   &lt;!-- Field: /Page --&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;div style="display: inline; text-transform: uppercase"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Income taxes (continued):&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;Unrecognized deferred tax assets:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; the net deferred tax assets, which have &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; been recognized in these financial statements because the criteria for recognition of these assets were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; met, were as follows:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;March 31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;March 31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;March 31, 2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Deferred tax assets&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 55%; font-weight: normal; text-align: left"&gt;Tax losses carried forward&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,695&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,670&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,293&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Research and development expenses&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,927&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,220&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Property, plan and equipment and intangible assets&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;766&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;567&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;435&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Financing expenses&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,852&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;116&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Other deductible temporary differences&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;378&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;768&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;522&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Deferred tax assets&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,053&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,048&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,470&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;Deferred tax liabilities&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Tax basis of unsecured convertible debentures in excess of carrying value&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;67&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;122&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Deferred tax liabilities&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;67&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;122&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Net deferred tax assets&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,040&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,981&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,348&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.55pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;On initial recognition of the unsecured convertible debenture equity component on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 21, 2017, &lt;/div&gt;a deferred tax liability of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$129&lt;/div&gt; was recognized with the corresponding entry recognized directly in Other equity. Consequently, an equal amount of deferred tax asset related to unrecognized tax losses was recognized with the offsetting entry in the Corporation statement of earnings and comprehensive loss.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;As at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019, &lt;/div&gt;the amounts and expiry dates of tax attributes and temporary differences, which are available to reduce future years&amp;#x2019; taxable income, were as follows:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; text-align: left; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;Federal&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;Provincial&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid; padding-left: 0.2in; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Tax losses carried forward&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 70%; font-weight: normal; text-align: left"&gt;2029&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;714&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;714&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2030&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,627&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,620&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2031&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,071&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,063&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2032&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,262&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,241&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2033&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,854&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,825&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2034&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,598&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,598&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2035&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,595&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,459&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2036&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,494&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,494&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2037&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,584&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,456&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;2038&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,340&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,270&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;2039&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,447&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41,447&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;89,586&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;89,187&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Research and development expenses, without time limitation&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,617&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,036&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Other deductible temporary differences, without time limitation&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,875&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32,294&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;!-- Field: Page; Sequence: 36; Value: 9 --&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
  <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="d_2018-04-01_2019-03-31" id="c-38">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-month &lt;br /&gt; period ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-month &lt;br /&gt;Period ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;March 31, 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;March 31, 2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;February 28, 2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%"&gt;Exercise price&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.77&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.75&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.69&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.69&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Share price&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.73&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.75&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.69&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.69&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Dividend&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Risk-free interest&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.10&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.21&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.87&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.87&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Estimated life (in years)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif"&gt;5.78&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif"&gt;5.89&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif"&gt;4.94&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif"&gt;4.94&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Expected volatility&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;85.35&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;82.4&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;%&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;123.5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;%&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;123.5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
  <ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory contextRef="d_2018-04-01_2019-03-31" id="c-23">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-&lt;br /&gt; months ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2019&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, &lt;/div&gt;&lt;br /&gt; 2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%"&gt;Compensation&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,641&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,754&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,510&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;146&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,364&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Share-based compensation costs&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;940&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;826&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;619&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;78&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;541&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Total key management personnel compensation&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,581&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,580&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;224&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,905&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory>
  <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233027">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Intangible assets :&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2012, &lt;/div&gt;the Corporation entered into a prepayment agreement with Neptune pursuant to which the Corporation exercised its option under the License Agreement to pay in advance all of the future royalties payable. The license allows the Corporation to exploit the intellectual property rights in order to develop novel active pharmaceutical ingredients (&amp;#x201c;APIs&amp;#x201d;) into commercial products for the prescription drugs market. The license Agreement, together with the Corporation own IP, allows the &amp;#x201c;freedom to operate&amp;#x201d; for CaPre, which is currently the Corporation&amp;#x2019;s only prescription drug candidate in development. The Corporation believes that upon the expiry of the last licensed Neptune patent in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2022,&lt;/div&gt; the Corporation&amp;#x2019;s expanding patent portfolio will cover CaPre, and that it will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; require any license from Neptune to support the commercialization of CaPre.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Patents&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;License&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Total&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold"&gt;Cost:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 55%"&gt;Balance at February 29, 2016, February 28, 2017 (Unaudited) and March 31, 2017&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,330&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,692&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Additions&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Balance at March 31, 2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,330&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,692&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Additions&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;Balance at March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,330&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24,692&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated amortization:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance at February 29, 2016&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,425&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,787&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Amortization for the twelve-month period (Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,323&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,323&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance at February 28, 2017 (Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,748&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,110&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Amortization for the one-month period (Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;194&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;194&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Amortization for the thirteen-month period&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,517&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,517&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Balance at March 31, 2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,942&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,304&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Amortization for the year&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,323&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,323&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Balance at March 31, 2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,265&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,627&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Amortization for the year&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,322&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,322&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;Balance at March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;362&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,587&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,949&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Net carrying amounts:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-left: 0.1in"&gt;March 31, 2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,065&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,065&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.5pt solid; padding-left: 0.1in"&gt;March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,743&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,743&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-weight: normal"&gt;Amortization expense and impairment loss for the period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;thirteen&lt;/div&gt;-month and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-month periods ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2017, &lt;/div&gt;and the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;28,&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; have been recorded in &amp;#x201c;research and development expenses&amp;#x201d; in the statements of earnings and comprehensive loss. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
  <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="d_2018-04-01_2019-03-31" id="c-37">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;Weighted average &lt;br /&gt; exercise price&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;Number of &lt;br /&gt; options&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;Weighted average &lt;br /&gt; exercise price&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;Number of &lt;br /&gt; options&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.81&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,284,388&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.58&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,424,788&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.77&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,173,523&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.75&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,121,500&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercised&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.77&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,167&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Forfeited&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.84&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(407,067&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.89&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(199,800&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Expired&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18.06&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(62,100&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Outstanding at end of year&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.25&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,046,677&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.81&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,284,388&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Exercisable at end of year&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.56&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,613,200&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.92&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;591,113&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-month period &lt;br /&gt; ended &lt;br /&gt; &lt;div style="display: inline; font-family: Times New Roman, Times, Serif"&gt;March 31, 2017&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended &lt;br /&gt; March 31, 2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-month period &lt;br /&gt; ended &lt;br /&gt; February 28, 2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; exercise price&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;Number &lt;br /&gt; of options&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; exercise price&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;Number &lt;br /&gt; of options&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; exercise price&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;Number &lt;br /&gt; of options&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 34%"&gt;Outstanding at beginning of period&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;454,151&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,427,288&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;454,151&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.69&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,300,400&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.69&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,300,400&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Forfeited&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.27&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(190,138&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11.50&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,500&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.29&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(187,638&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Expired&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15.38&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(139,625&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15.38&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(139,625&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;Outstanding at end of period&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.58&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,424,788&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.58&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,424,788&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,427,288&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;Exercisable at end of period&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.44&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;238,482&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.44&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;238,482&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.49&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;240,982&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-month &lt;br /&gt; period ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-month &lt;br /&gt;Period ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt; 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt; 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt; 2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;February 28, 2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; text-align: left; border-bottom: Black 1.5pt solid; text-indent: -6.75pt; padding-left: 6.75pt"&gt;Weighted average fair value of the options granted to employees and directors of the Corporation&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.51&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.22&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
  <ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233071">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Capital management:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-weight: normal"&gt;Since inception, the Corporation&amp;#x2019;s objective in managing capital is to ensure sufficient liquidity to finance its research and development activities, general and administrative expenses, expenses associated with intellectual property protection and its overall capital expenditures. The Corporation is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; exposed to external requirements by regulatory agencies or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties regarding its capital, except for certain covenants included within the convertible debentures &lt;div style="display: inline; font-style: italic;"&gt;(Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13&lt;/div&gt;&lt;/div&gt;).&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Since the beginning of its operations, the Corporation has primarily financed its liquidity needs from funding provided through public offerings, private placements, from the exercise of warrants that were distributed to its related party&amp;#x2019;s shareholders, from a rights offering and from the issuance of options to employees. The Corporation defines capital to include total shareholders&amp;#x2019; equity, derivative warrant liabilities and unsecured convertible debentures. The Corporation&amp;#x2019;s policy is to maintain a minimal level of debt.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The following table summarizes the cash and cash equivalents of the Corporation:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-size: 12pt; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 70%; font-weight: normal"&gt;Cash&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,896&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,583&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Cash equivalents&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; padding-left: 8.75pt"&gt;Term deposits issued in CAD currency&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,100&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; padding-left: 8.75pt"&gt;Term deposits issued in US currency [US - $3,250]&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,193&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; padding-left: 8.75pt"&gt;Commercial papers issued in CAD currency&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,693&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; padding-left: 8.75pt"&gt;Commercial papers issued in US currency [US - $1,099]&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,418&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; padding-left: 8.75pt"&gt;Promissory notes issued in CAD currency&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;498&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; padding-left: 8.75pt"&gt;Promissory notes issued in US currency [US - $798]&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,029&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; padding-left: 8.75pt"&gt;Bankers acceptance&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,334&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Total Cash equivalents&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,625&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,640&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid"&gt;Total Cash and cash equivalents&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22,521&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,223&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;!-- Field: Page; Sequence: 39; Value: 9 --&gt;   &lt;!-- Field: /Page --&gt; &lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;24.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Capital management (continued):&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;As at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019, &lt;/div&gt;the term deposits, commercial paper, promissory note and bankers acceptance have maturity dates of ranging between &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 1, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 25, 2019, &lt;/div&gt;bearing interest rates ranging from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.76%&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.40%&lt;/div&gt; per annum, cashable at any time at the discretion of the Corporation, under certain conditions.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;As at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018, &lt;/div&gt;the term deposits, commercial paper and promissory note have maturity dates of ranging between &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 2, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 11, 2018, &lt;/div&gt;bearing interest rates ranging from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.26%&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.72%&lt;/div&gt; per annum, cashable at any time at the discretion of the Corporation, under certain conditions.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory>
  <ifrs-full:DisclosureOfOtherAssetsExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233017">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Other Assets&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.65pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.65pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-weight: normal"&gt;During the year, the Corporation owned a reserve of krill oil in which amounts are expensed as it is being used. The following table summarizes information regarding activities of amounts of the krill oil usage in the R&amp;amp;D production processes and for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;NKPL66&lt;/div&gt; manufacturing for the year (see note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt; (a)):&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 70%; font-weight: normal; text-align: left"&gt;Balance &amp;#x2013; beginning of year&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;659&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Purchased&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;68&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;970&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;Used&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(105&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(311&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Balance &amp;#x2013; end of year&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;622&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;659&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt; &lt;div style="display: inline; font-weight: normal"&gt;&lt;/div&gt; &lt;div style="display: inline; font-weight: normal"&gt;Current other asset&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;65&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;104&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Other asset&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;557&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;555&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfOtherAssetsExplanatory>
  <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233025">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Equipment:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0.5in; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Furniture and &lt;br /&gt; office equipment&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Computer &lt;br /&gt; equipment&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Laboratory &lt;br /&gt; equipment&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Production &lt;br /&gt; equipment&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Total&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold"&gt;Cost:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 35%"&gt;Balance at February 29, 2016&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;336&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;398&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Additions for the twelve-month period (Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;186&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,484&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,678&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Balance at February 28, 2017 (Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;522&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,484&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,076&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Additions for the one-month period (Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;43&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;43&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Additions for the thirteen-month period&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;186&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,527&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,721&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance at March 31, 2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;522&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,527&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,119&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Additions&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;192&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;181&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;383&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance at March 31, 2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;63&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;714&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,708&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,502&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Additions&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;219&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;260&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;497&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;Balance at March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;68&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;933&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,968&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,999&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Accumulated depreciation:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Balance at February 29, 2016&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;56&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;111&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Depreciation for the twelve-month period (Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;189&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Balance at February 28, 2017 (Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;185&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;300&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Depreciation for the one-month period (Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;32&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Depreciation for thirteen-month period&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;140&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;73&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;221&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance at March 31, 2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;196&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;73&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;332&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Depreciation&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;107&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;239&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;349&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Balance at March 31, 2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;303&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;312&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;681&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Depreciation&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;180&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;317&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;505&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;Balance at March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;60&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;483&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;629&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,186&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left"&gt;Net carrying amounts:&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-left: 0.1in"&gt;March 31, 2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;411&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,396&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,821&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1.5pt solid; padding-left: 0.1in"&gt;March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;450&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,339&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,813&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 28.35pt; text-indent: -10.5pt"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;Depreciation expense for the periods end &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;thirteen&lt;/div&gt;-month and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-month periods ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;28,&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; has been recorded in &amp;#x201c;research and development expenses&amp;#x201d; in the statements of earnings and comprehensive loss.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
  <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="d_2018-04-01_2019-03-31" id="c-39">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="14" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"&gt;Options outstanding&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"&gt;Exercisable options&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="3" style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;Exercise price&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Weighted remaining &lt;br /&gt; contractual life &lt;br /&gt; outstanding&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Number of options &lt;br /&gt; outstanding&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Weighted average &lt;br /&gt; exercise price &lt;br /&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Number of options &lt;br /&gt; exercisable&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 5%"&gt;$0.77&lt;/td&gt; &lt;td style="width: 2%"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 41%"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.77&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.26&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,898,523&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.77&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;348,197&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;$0.78&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.58&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.86&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;775,000&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.50&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;518,750&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;$1.59&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.71&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.90&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;273,333&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.65&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;233,333&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;$1.72&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.88&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.21&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;790,833&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.77&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;292,500&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;$1.89&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6.50&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.97&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;308,988&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.57&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;220,420&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.91&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,046,677&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.56&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,613,200&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
  <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233019">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Related parties:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;Neptune Technologies (Neptune) Acasti&amp;#x2019;s former parent company, owned approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.5%&lt;/div&gt; of the issued and outstanding Class A shares (Common Shares) of the Corporation as at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019. &lt;/div&gt;Neptune&amp;#x2019;s ownership reduced below a control position, following Acasti&amp;#x2019;s U.S. public financing activities in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2018.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(a)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Administrative and research and development expenses:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation has significantly reduced its reliance on the support of Neptune for a portion of its general and administrative needs; however, it will continue to utilize their IT support for the near term. The Corporation was charged by Neptune for the purchase of research supplies and for certain costs incurred by Neptune for the benefit of the Corporation, as follows:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="text-align: justify"&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-&lt;br /&gt; months ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-months &lt;br /&gt; ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt; 2019&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt; 2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt; 2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, &lt;/div&gt;&lt;br /&gt; 2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left; text-indent: -8.25pt; padding-left: 8.25pt"&gt;Research and development expenses&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 35%; text-align: left; padding-left: 13.65pt"&gt;Supplies and incremental costs&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 13.65pt"&gt;Shared service agreement&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;60&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1pt solid; padding-left: 15.3pt"&gt;Total&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;60&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: left; text-indent: -8.25pt; padding-left: 8.25pt"&gt;General and administrative expenses&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 13.65pt"&gt;Supplies and incremental costs&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;211&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;239&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;293&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;277&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 13.65pt"&gt;Shared service agreement&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;121&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;325&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;300&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid; padding-left: 15.3pt"&gt;Total&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;245&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;360&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;618&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;577&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Total related parties expenses&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;245&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;387&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;678&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;42&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;636&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 16.3pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;Where Neptune incurs specific incremental costs for the benefit of the Corporation, it charges those amounts directly. Neptune provides Acasti with the services of personnel for certain administrative work as part of a shared service agreement. The employees&amp;#x2019; salaries and benefits are charged proportionally to the time allocation agreed upon within the shared service agreement. Effective &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 30, 2017, &lt;/div&gt;the laboratory support, the corporate affairs and the public company reporting services previously provided by Neptune as part of the shared service agreement were discontinued. The Corporation is now incurring incremental costs and expects to do so in the future, partially offset by reduced shared service fees. The account payable to Neptune amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$44&lt;/div&gt; at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018, &lt;/div&gt;is non-interest bearing and has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; specified maturity date. These charges do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; represent all charges incurred by Neptune that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;have benefited the Corporation. Also, these charges do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; necessarily represent the cost that the Corporation would otherwise need to incur, should it &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; receive these services or benefits through the shared resources of Neptune.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;Historically, Neptune has provided the Corporation with the krill oil needed to produce CaPre for Acasti&amp;#x2019;s clinical programs, including all of the krill oil projected to be needed for its Phase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; clinical study program. However, Neptune discontinued its krill oil production and sold its krill oil inventory to Aker on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 7, 2017. &lt;/div&gt;In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; Acasti purchased a reserve of krill oil from Aker that will be used in the production of CaPre capsules for its Phase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; clinical trials (see also note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt;). The Corporation is currently evaluating alternative suppliers of krill oil. At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019, &lt;/div&gt;a reserve of krill oil owned by the Corporation was physically stored at Neptune&amp;#x2019;s facility.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(b)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Interest revenue:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 7, 2016 &lt;/div&gt;Neptune announced the acquisition of Biodroga Nutraceuticals Inc. As part of this transaction, the Corporation pledged an amount of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2&lt;/div&gt; million (&amp;#x201c;Committed Funds&amp;#x201d;) to partly guarantee the financing for the said transaction (&amp;#x201c;Pledge Agreement&amp;#x201d;). Neptune had agreed to pay Acasti an annual fee on the Committed Funds outstanding at an annual rate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9%&lt;/div&gt; during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;six&lt;/div&gt; months and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11%&lt;/div&gt; for the remaining term of the Pledge Agreement. On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; September 20, 2016, &lt;/div&gt;Neptune fully released the pledged amount. The Corporation recognized interest revenue of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nil&lt;/div&gt; &lt;/div&gt;for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$89&lt;/div&gt; for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;thirteen&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2017, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nil&lt;/div&gt; (unaudited) for the month ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2017, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$89&lt;/div&gt; (unaudited) for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 28, 2017.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 19; Value: 9 --&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(c)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Key management personnel compensation:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;The key management personnel are the officers of the Corporation and the members of the Board of Directors of the Corporation. They control in the aggregate less than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1%&lt;/div&gt; of the voting shares of the Corporation (less than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1%&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2%&lt;/div&gt; in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt;).&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;Key management personnel compensation includes the following for the years ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;thirteen&lt;/div&gt;-month and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-month periods ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2017 &lt;/div&gt;and the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 28, 2017.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-&lt;br /&gt; months ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-months &lt;br /&gt;ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2019&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, &lt;/div&gt;&lt;br /&gt; 2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 35%"&gt;Compensation&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,641&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,754&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,510&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;146&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,364&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Share-based compensation costs&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;940&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;826&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;619&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;78&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;541&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Total key management personnel compensation&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,581&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,580&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,129&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;224&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,905&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
  <ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory contextRef="d_2018-04-01_2019-03-31" id="c-22">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-&lt;br /&gt; months ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-months &lt;br /&gt; ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt; 2019&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt; 2018&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt;2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 31, &lt;/div&gt;&lt;br /&gt; 2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;February 28, &lt;/div&gt;&lt;br /&gt; 2017&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;(Unaudited)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-align: left; text-indent: -8.25pt; padding-left: 8.25pt"&gt;Research and development expenses&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 35%; text-align: left; padding-left: 13.65pt"&gt;Supplies and incremental costs&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 13.65pt"&gt;Shared service agreement&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;60&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1pt solid; padding-left: 15.3pt"&gt;Total&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;60&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: left; text-indent: -8.25pt; padding-left: 8.25pt"&gt;General and administrative expenses&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; padding-left: 13.65pt"&gt;Supplies and incremental costs&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;211&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;239&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;293&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;277&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 13.65pt"&gt;Shared service agreement&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;34&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;121&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;325&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;300&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid; padding-left: 15.3pt"&gt;Total&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;245&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;360&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;618&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;41&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;577&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Total related parties expenses&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;245&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;387&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;678&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;42&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;636&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory>
  <ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-DerivativeWarrantLiabilitiesMember" id="c-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Warrant liabilities issued &lt;br /&gt;May 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Warrant liabilities issued &lt;br /&gt;December 27, 2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;Warrant liabilities issued&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;December 3, 2013 &lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt;2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt; 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt;2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt; 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt;2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt; 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 34%; font-weight: normal"&gt;Exercise price&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 8%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.31&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.26&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.26&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.50&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Share price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.35&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.02&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Risk-free interest&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.23&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.56&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.19&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Estimated life (in years)&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;4.11&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;3.75&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;4.75&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;0.68&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;94.58&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;107.57&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;95.15&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;133.86&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory>
  <ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory contextRef="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsMember" id="c-32">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;May 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 85%; font-weight: normal"&gt;Exercise price&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.31&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Share price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.82&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Risk-free interest&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.21&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Estimated life (in years)&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;87.40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;May 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 85%; font-weight: normal"&gt;Exercise price&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.05&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Share price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.81&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Risk-free interest&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.20&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Estimated life (in years)&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;87.40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;December 27, &lt;br /&gt;2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal"&gt;Exercise price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.26&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Share price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $0.97&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 85%; font-weight: normal; text-align: left"&gt;Risk-free interest&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.22&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Estimated life (in years)&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;93.52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;December 27, &lt;br /&gt;2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal"&gt;Exercise price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.2625&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Share price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $0.97&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 85%; font-weight: normal; text-align: left"&gt;Risk-free interest&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.22&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Estimated life (in years)&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;93.52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;February 21, 2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 85%; font-weight: normal"&gt;Exercise price&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.15&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Share price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.70&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal"&gt;Dividend&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Risk-free interest&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.79&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Estimated life (in years)&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;112.09&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory>
  <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233036">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Capital and other components of equity&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(a)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Share capital:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;Authorized capital stock:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;Unlimited number of shares:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 30pt"&gt;&lt;/td&gt; &lt;td style="width: 20pt"&gt;&lt;div style="display: inline; font-family: Wingdings"&gt;&amp;Oslash;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Class A shares (Common Shares), voting (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; vote per share), participating and without par value&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 30pt"&gt;&lt;/td&gt; &lt;td style="width: 20pt"&gt;&lt;div style="display: inline; font-family: Wingdings"&gt;&amp;Oslash;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Class B shares, voting (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt; votes per share), non-participating, without par value and maximum annual non-cumulative dividend of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5%&lt;/div&gt; on the amount paid for said shares. Class B shares are convertible, at the holder&amp;#x2019;s discretion, into Class A shares (Common Shares), on a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-for-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; basis, and Class B shares are redeemable at the holder&amp;#x2019;s discretion for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.80&lt;/div&gt; per share, subject to certain conditions. There are non issued and outstanding.&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 30pt"&gt;&lt;/td&gt; &lt;td style="width: 20pt"&gt;&lt;div style="display: inline; font-family: Wingdings"&gt;&amp;Oslash;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Class C shares, non-voting, non-participating, without par value and maximum annual non-cumulative dividend of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5%&lt;/div&gt; on the amount paid for said shares. Class C shares are convertible, at the holder&amp;#x2019;s discretion, into Class A shares (Common Shares), on a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-for-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; basis, and Class C shares are redeemable at the holder&amp;#x2019;s discretion for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.20&lt;/div&gt; per share, subject to certain conditions. There are non issued and outstanding.&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 30pt"&gt;&lt;/td&gt; &lt;td style="width: 20pt"&gt;&lt;div style="display: inline; font-family: Wingdings"&gt;&amp;Oslash;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;Class D and E shares, non-voting, non-participating, without par value and maximum monthly non-cumulative dividend between &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.5%&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2%&lt;/div&gt; on the amount paid for said shares. Class D and E shares are convertible, at the holder&amp;#x2019;s discretion, into Class A shares (Common Shares), on a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-for-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; basis, and Class D and E shares are redeemable at the holder&amp;#x2019;s discretion, subject to certain conditions. There are non issued and outstanding.&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(b)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&amp;#x201c;At-the-market&amp;#x201d; (&amp;#x201c;ATM&amp;#x201d;) sales agreement&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 14, 2019, &lt;/div&gt;the Corporation entered into an &amp;#x201c;at-the-market&amp;#x201d; (&amp;#x201c;ATM&amp;#x201d;) sales agreement with an underwriter B. Riley FBR, Inc. (B. Riley), pursuant to which the Corporation&amp;#x2019;s common shares &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be sold from time to time for aggregate gross proceeds of up to US &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$30&lt;/div&gt; million, with sales only being made on the NASDAQ Stock Market. The common shares would be issued at market prices prevailing at the time of the sale and, as a result, prices &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;vary between purchasers and during the period of distribution. The ATM provides the Company with a flexible alternative for raising additional capital. The ATM has a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; year term, and requires the company to pay a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3%&lt;/div&gt; fee to B. Riley when any sales are made. As at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; securities have been issued in relation to the ATM. Costs incurred in connection to the ATM of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$179&lt;/div&gt; have been recorded as deferred financing costs.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(c)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Public Offerings &amp;#x2013; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 2018:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 9, 2018, &lt;/div&gt;the Corporation closed a U.S. public offering of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,600,000&lt;/div&gt; Common Shares at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;US$1.00&lt;/div&gt; per share. In addition, the underwriters fully exercised their over-allotment option to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,490,000&lt;/div&gt; additional Common Shares at the same public offering price. This offering generated gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$24.7&lt;/div&gt; million (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;US$19.1&lt;/div&gt; million), which resulted in net proceeds to the Corporation of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$22.6&lt;/div&gt; million (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;US$17.4&lt;/div&gt; million) and a total of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,090,000&lt;/div&gt; Common Shares issued.&lt;/div&gt; &lt;!-- Field: Page; Sequence: 25; Value: 9 --&gt;  &lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="text-align: justify"&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; October 23, 2018, &lt;/div&gt;the Corporation closed a Canadian public offering of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18,750,000&lt;/div&gt; Common Shares at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.28&lt;/div&gt; per share. In addition, the underwriters fully exercised their over-allotment option to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,812,500&lt;/div&gt; additional Common Shares at the same public offering price. This offering generated gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$27.6&lt;/div&gt; million, which resulted in net proceeds to the Corporation of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$25.4&lt;/div&gt; million and a total of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,562,500&lt;/div&gt; Common Shares issued.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(d)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Public Offering &amp;#x2013; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2018:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 9, 2018 &lt;/div&gt;the Corporation closed a Canadian public offering issuing &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,530,000&lt;/div&gt; units of Acasti (&amp;#x201c;Units&amp;#x201d;) at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.05&lt;/div&gt; per Unit for gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10&lt;/div&gt; million. The units issued consist of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,530,000&lt;/div&gt; Common Shares and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,530,000&lt;/div&gt; Warrants. Each Warrant entitles the holder thereof to acquire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share of the Corporation at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.31&lt;/div&gt; at any time until &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 9, 2023.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 14, 2018, &lt;/div&gt;the underwriters exercised their over-allotment option by purchasing an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,429,500&lt;/div&gt; units at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.05&lt;/div&gt; per Unit, for additional gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.5&lt;/div&gt; million. The units issued consist of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,429,500&lt;/div&gt; Common Shares and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,429,500&lt;/div&gt; warrants. Each Warrant entitles the holder thereof to acquire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share of the Corporation at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.31&lt;/div&gt; at any time until &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 9, 2023.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The warrant component of these Units are Derivative Warrant Liabilities for accounting purposes due to the warrant agreement, which contains certain contingent provisions that allow for cash settlement (note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt;). The proceeds of the offering are required to be split between the Derivative Warrant Liabilities and the equity-classified Common shares at the time of issuance of the Units. The fair value of the Derivative Warrant Liabilities at the time of issuance was determined to be &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$4.3&lt;/div&gt; million and the residual of the proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6.2&lt;/div&gt; million were allocated to the Common Shares. Issuance costs related to this transaction totaled approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.8&lt;/div&gt; million and have been allocated between the Derivative Warrant Liabilities and Common shares based on relative value. Resulting from this allocation, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.7&lt;/div&gt; million has been allocated to the Derivative Warrant Liability and is recognized in finance costs in the Statements of Earnings and Comprehensive Loss, whereas the remaining portion of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.1&lt;/div&gt; million in issuance costs was allocated to the Common Shares and recognized as a reduction to share capital, in the Statements of Financial Position.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The fair value of the public offering warrants at issuance was estimated using to the Black-Scholes option pricing model and was based on the following weighted average assumptions:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;May 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 85%; font-weight: normal"&gt;Exercise price&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.31&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Share price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.82&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Risk-free interest&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.21&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Estimated life (in years)&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;87.40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The weighted average fair value of the public offering warrants issued in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2018 &lt;/div&gt;was determined to be &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.39&lt;/div&gt; per warrant. Changes in the subsequent measurement of fair value of the Warrants are recognized in financial expenses.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;As part of the transaction, the Corporation also issued broker warrants to purchase up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;547,975&lt;/div&gt; Common Shares. Each broker warrant entitles the holder thereof to acquire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share of the Corporation at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.05,&lt;/div&gt; at any time until &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 9, 2023. &lt;/div&gt;The broker warrants are considered to be compensation to non-employees under IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,&lt;/div&gt; as stock-based compensation, and are thus accounted for at fair value at issuance date and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; subsequently revalued. To determine the fair value of these broker warrants, a Black-Scholes options pricing model was used based on the following assumptions:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;May 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 85%; font-weight: normal"&gt;Exercise price&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.05&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Share price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.81&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Risk-free interest&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.20&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Estimated life (in years)&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;87.40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The total value associated with the broker warrants amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$283&lt;/div&gt; and was recorded in contributed surplus.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 26; Value: 9 --&gt;  &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(e)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Public offering &amp;#x2013; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 27, 2017&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;On &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 27, 2017, &lt;/div&gt;the Corporation closed a U.S. public offering issuing &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,900,990&lt;/div&gt; units of Acasti at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;US$1.01&lt;/div&gt; per Unit for gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$12.6&lt;/div&gt; million (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;US$10&lt;/div&gt; million). The units issued consist of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,900,990&lt;/div&gt; Common Shares and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,910,891&lt;/div&gt; warrants with the right to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share of Acasti. As part of this closing, the underwriters&amp;#x2019; also partially exercised for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nil&lt;/div&gt; consideration the over-allotment option for warrants, which were issued for a right to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;892,044&lt;/div&gt; Common Shares at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;US$1.26.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The Warrants forming part of the Units are Derivative Warrant Liabilities for accounting purposes due to the currency of the exercise price being different from the Corporation&amp;#x2019;s functional currency. The proceeds of the offering are required to be split between the Derivative Warrant Liabilities and the equity-classified Common Share at the time of issuance of the Units. The fair value of the Derivative Warrant Liabilities at the time of issuance was determined to be &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.9&lt;/div&gt; million and the residual of the proceeds was allocated to the Common Shares. Total issuance costs related to this transaction totaled approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.5&lt;/div&gt; million. The issuance costs have been allocated between the Warrants and Common Shares based on relative value. The portion allocated to the Warrants was recognized in finance costs in the Statements of Earnings and Comprehensive Loss, whereas the portion allocated to Common Shares was recognized as a reduction to share capital, in the Statements of Financial Position.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The fair value of the public offering Warrants at issuance was estimated according to the Black-Scholes option pricing model and based on the following assumptions:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;December 27, &lt;br /&gt;2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal"&gt;Exercise price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.26&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Share price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $0.97&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 85%; font-weight: normal; text-align: left"&gt;Risk-free interest&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.22&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Estimated life (in years)&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;5&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;93.52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The fair value of the public offering Warrants issued was determined to be &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.60&lt;/div&gt; per warrant as at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 27, 2017. &lt;/div&gt;Changes in the fair value of the Warrants are recognized in finance income or expenses.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;As part of the transaction, the Corporation also issued broker warrants to purchase up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;495,050&lt;/div&gt; Common Shares. Each broker warrant entitles the holder thereof to acquire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share of the Corporation at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;US$1.2625,&lt;/div&gt; at any time until &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 27, 2022. &lt;/div&gt;The broker warrants are considered for compensation to non-employees under IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,&lt;/div&gt; stock-based compensation, and are accounted for at fair value. To determine the fair value of the Broker Warrants, a Black-Scholes option pricing model was used based on the following assumptions:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;December 27, &lt;br /&gt;2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal"&gt;Exercise price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $1.2625&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Share price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;US $0.97&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 85%; font-weight: normal; text-align: left"&gt;Risk-free interest&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.22&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Estimated life (in years)&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;93.52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The total cost associated with the Broker Warrants amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$406&lt;/div&gt; and was recorded in contributed surplus.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 27; Value: 9 --&gt;  &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(f)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Public offering - &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 21, 2017:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;Concurrent with the private placement described in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,&lt;/div&gt; on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 21, 2017, &lt;/div&gt;the Corporation closed a public offering (&amp;#x201c;Public Offering&amp;#x201d;) issuing &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,930,518&lt;/div&gt; units of Acasti (&amp;#x201c;Units&amp;#x201d;) at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.45&lt;/div&gt; per Unit for gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5,699.&lt;/div&gt; Each Unit consists of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; class A share (Common Share) and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; half of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; class A or common share purchase warrant. Each whole warrant entitles the holder thereof to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; common share at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.15&lt;/div&gt; per common share, at any time until &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 21, 2022. &lt;/div&gt;The Units issued as part of the public offering are considered equity instruments. The transaction costs associated with the Public Offering amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,190.&lt;/div&gt; The proceeds and transaction costs were allocated to share capital.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;As part of the transaction, the Corporation also issued broker warrants (the &amp;#x201c;Broker Warrants&amp;#x201d;) to purchase up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;234,992&lt;/div&gt; Common Shares. Each Broker Warrant entitles the holder thereof to acquire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share of the Corporation at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.15&lt;/div&gt; per common share, at any time until &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 21, 2018. &lt;/div&gt;The broker warrants are considered for compensation to non-employees under IFRS &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,&lt;/div&gt; stock-based compensation, and are accounted for at fair value through contributed surplus. To determine the fair value of the Broker Warrants, the Black-Scholes pricing model was used. The total costs associated with the Broker Warrants amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$144&lt;/div&gt; and were allocated to share capital.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The warrants issued as part of the Units of the Public Offering and the broker warrants include an &amp;#x201c;Acceleration Right&amp;#x201d;, related to the Corporation&amp;#x2019;s right to accelerate the expiry date of the warrants. The Acceleration Right clause means the right of the Corporation to accelerate the expiry date to a date that is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; less than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30&lt;/div&gt; days following delivery of the acceleration notice if, at any time at least &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;four&lt;/div&gt; months after the effective date, the volume weighted average trading price of the common shares equals or exceeds &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.65&lt;/div&gt; for a period of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20&lt;/div&gt; consecutive trading days on the TSXV.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;Furthermore, as part of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2017 &lt;/div&gt;Public Offering and convertible debt transactions, a total of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;60,000&lt;/div&gt; Common Shares were issued as equity settled share-based payments for services received from an employee of the previous parent at a price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.57&lt;/div&gt; per share for a total cost of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$94.&lt;/div&gt; The equity settled share-based payment costs have been allocated to share capital for a cost that amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$85&lt;/div&gt; and to debt for a cost that amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$9&lt;/div&gt; based on relative value.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The value of the broker warrants was estimated using a Black-Scholes option pricing model and based on the following assumptions:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;February 21, 2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 85%; font-weight: normal"&gt;Exercise price&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.15&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Share price&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;$&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.70&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal"&gt;Dividend&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Risk-free interest&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.79&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Estimated life (in years)&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal"&gt;1.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Expected volatility&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;112.09&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The total cost associated with the Broker Warrants amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$144&lt;/div&gt; and was recorded as contributed surplus.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(g)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Issuance of shares:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The following table summarizes the shares issued to settle the payment of accrued interest on the unsecured convertible debentures with the corresponding amount recorded to share capital.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; color: #00528C"&gt;&lt;div style="display: inline; font-style: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"&gt;&lt;div style="display: inline; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"&gt;&lt;div style="display: inline; font-weight: normal"&gt;Accrued interest as at&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"&gt;&lt;div style="display: inline; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"&gt;&lt;div style="display: inline; font-weight: normal"&gt;Share issuance date&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;Number of shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;Amount &lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-weight: normal"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 34%; font-weight: normal"&gt;March 31, 2017&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 35%; font-weight: normal"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;April 7, 2017&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,496&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;June 30, 2017&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;August 15, 2017&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,885&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal"&gt;September 30, 2017&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;December 27, 2017&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;22,783&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;December 31, 2017&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;March 27, 2018&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;33,605&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;June 6, 2018&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,348&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;June 30, 2018&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;August 21, 2018&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;51,807&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;September 30, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;October 31, 2018&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;23,723&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;195,647&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;257&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;!-- Field: Page; Sequence: 28; Value: 9 --&gt; &lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="text-align: justify"&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(h)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Warrants:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The warrants of the Corporation are composed of the following as at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 28, 2017:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;March 31, 2019&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;March 31, 2018&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;March 31, 2017&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;February 28, 2017&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;(Unaudited)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Number &lt;br /&gt; outstanding&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Number &lt;br /&gt; outstanding&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Number &lt;br /&gt; outstanding&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Number &lt;br /&gt; outstanding&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt; font-weight: normal"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;$&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Liability&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 28%; font-weight: normal; font-style: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;May 2018 Public offering Warrants 2018 (i)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; font-style: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; font-style: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: normal; font-style: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;10,188,100&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; font-style: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; font-style: normal"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; font-style: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: normal; font-style: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;8,246&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; font-style: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Series December 2017 US Public offering Warrants 2017 (ii)&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;9,801,861&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;8,017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;9,802,935&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;6,405&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; font-style: normal; text-align: left; text-indent: -10pt; padding-left: 10pt; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Series 8 Public offering Warrants December 2013 (iii)&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;18,400,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;21&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;18,400,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;209&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;18,400,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;187&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;19,989,961&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;16,263&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;28,202,935&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;6,426&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;18,400,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;209&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;18,400,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;187&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Equity&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Public offering warrants&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Public offering broker warrants May 2018 (iv)&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;547,975&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;283&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Public offering U.S. broker warrants December 2017 (v)&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;495,050&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;406&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;495,050&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;406&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Public offering warrants February 2017 (vi)&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,904,034&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,904,034&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,965,259&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,965,259&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Private Placement- contingent warrants&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;2017 unsecured convertible debenture conversion option and contingent warrants (vii)&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,052,630&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;309&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,052,630&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;309&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,052,630&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;309&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;1,052,630&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;309&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Series 9 Private Placement warrants 2013 (viii)&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;161,654&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;161,654&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;161,654&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;Series 2017 BW Broker warrants (ix)&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;234,992&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;144&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;234,992&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;144&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-indent: -10pt; padding-left: 10pt"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;3,999,689&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;998&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;3,613,368&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;715&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;3,414,535&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;453&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;3,414,535&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;453&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&lt;div style="display: inline; font-size: 9pt"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 25pt"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;(i)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;Warrant to acquire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share of the Corporation at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.31,&lt;/div&gt; expiring on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 9, 2023.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 25pt"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;(ii)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;Warrant to acquire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share of the Corporation at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;US$1.26,&lt;/div&gt; expiring on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 27, 2022.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 25pt"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;(iii)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;In order to obtain &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share of the Corporation at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;US$15.00,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt; warrants must be exercised. Warrants expired on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 25pt"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;(iv)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;Warrant to acquire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share of the Corporation at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.05,&lt;/div&gt; expiring on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 9, 2023.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 25pt"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;(v)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;Warrant to acquire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share of the Corporation at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;US$1.2625,&lt;/div&gt; expiring on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 27, 2022.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 25pt"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;(vi)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;Warrant to acquire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share of the Corporation at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.15,&lt;/div&gt; expiring on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 21, 2022.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 25pt"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;(vii)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;Warrant to acquire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share of the Corporation at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.90&lt;/div&gt; expiring on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 21, 2020, &lt;/div&gt;net of deferred tax expense of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$129.&lt;/div&gt; Exercisable only for any portion of or all debentures paid by the Corporation prior to maturity.&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 25pt"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;(viii)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;Warrant to acquire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share of the Corporation at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$13.30,&lt;/div&gt; expired on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 3, 2018.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 25pt"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;(ix)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-size: 8pt"&gt;Warrant to acquire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; Common Share of the Corporation at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.15&lt;/div&gt; expiring on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 21, 2018. &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;117,496&lt;/div&gt; warrants amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$71&lt;/div&gt; were exercised in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; November 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;117,496&lt;/div&gt; warrants expired on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 21, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;Warrants exercise:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;During the year &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;771,400&lt;/div&gt; warrants offered as part of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; May 2018 &lt;/div&gt;public offering were exercised at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.31&lt;/div&gt; per Common Share of the Company, resulting in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.0&lt;/div&gt; million of cash proceeds. In addition, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,455&lt;/div&gt; warrants offered as part of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 2017 &lt;/div&gt;U.S. public offering were exercised in a cashless manner to acquire &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,074&lt;/div&gt; Common Shares of the Company.&amp;nbsp; A total of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;772,474&lt;/div&gt; Common Shares were issued as a result of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;775,855&lt;/div&gt; warrants being exercised. During the year ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December 31, 2017, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;178,721&lt;/div&gt; warrants offered as part of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 2017 &lt;/div&gt;public offering were exercised at an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.15&lt;/div&gt; per Common Share of the Company, resulting in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$384&lt;/div&gt; of cash proceeds.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
  <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233048">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Share-based payments:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;At &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019, &lt;/div&gt;the Corporation has the following share-based payment arrangement:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(a)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Corporation stock option plan:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The Corporation has in place a stock option plan for directors, officers, employees and consultants of the Corporation (&amp;#x201c;Stock Option Plan&amp;#x201d;). An amendment of the Plan was approved by shareholders on &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; August 28, 2018. &lt;/div&gt;The amendment provides for an increase to the existing limits for Common Shares reserved for issuance under the Stock Option Plan as well as certain changes to the minimum vesting period applicable to options granted to directors and employees under the Stock Option Plan. The plan continues to provide for the granting of options to purchase Common Shares. The exercise price of the stock options granted under this amended plan is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; lower than the closing price of the shares listed on the TSXV at the close of markets the day preceding the grant. The maximum number of Common Shares that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be issued upon exercise of options granted under the amended Stock Option Plan was increased from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,940,511,&lt;/div&gt; representing &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20%&lt;/div&gt; of the issued and outstanding Common Shares of the Company as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2017, &lt;/div&gt;to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,494,209&lt;/div&gt; representing &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15%&lt;/div&gt; of the issued and outstanding Common Shares of the Company as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 27, 2018. &lt;/div&gt;The terms and conditions for acquiring and exercising options are set by the Corporation&amp;#x2019;s Board of Directors, subject among others, to the following limitations: the term of the options cannot exceed &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt; years and (i) all options granted to a director will be vested evenly on a quarterly basis over a period of at least &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;eighteen&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18&lt;/div&gt;) months, and (ii) all options granted to an employee will be vested evenly on a quarterly basis over a period of at least &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;thirty-six&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;36&lt;/div&gt;) months.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The total number of shares issued to any &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; consultant within any &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt;-month period cannot exceed &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2%&lt;/div&gt; of the Corporation&amp;#x2019;s total issued and outstanding shares (on a non-diluted basis). The Corporation is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; authorized to grant within any &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt;-month period such number of options under the stock option plan that could result in a number of Common Shares issuable pursuant to options granted to (a) related persons exceeding &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2%&lt;/div&gt; of the Corporation&amp;#x2019;s issued and outstanding Common Shares (on a non-diluted basis) on the date an option is granted, or (b) any &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; eligible person in a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt;-month period exceeding &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2%&lt;/div&gt; of the Corporation&amp;#x2019;s issued and outstanding Common Shares (on a non-diluted basis) on the date an option is granted.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The following tables summarize information about activities within the stock option plan:&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;Weighted average &lt;br /&gt; exercise price&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;Number of &lt;br /&gt; options&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;Weighted average &lt;br /&gt; exercise price&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;Number of &lt;br /&gt; options&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; text-align: left"&gt;Outstanding at beginning of year&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.81&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,284,388&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.58&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,424,788&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.77&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,173,523&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.75&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,121,500&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercised&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.77&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4,167&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Forfeited&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.84&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(407,067&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.89&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(199,800&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Expired&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18.06&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(62,100&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Outstanding at end of year&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.25&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,046,677&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.81&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,284,388&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;Exercisable at end of year&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.56&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,613,200&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.92&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;591,113&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-month period &lt;br /&gt; ended &lt;br /&gt; &lt;div style="display: inline; font-family: Times New Roman, Times, Serif"&gt;March 31, 2017&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Month ended &lt;br /&gt; March 31, 2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-month period &lt;br /&gt; ended &lt;br /&gt; February 28, 2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; exercise price&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;Number &lt;br /&gt; of options&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; exercise price&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;Number &lt;br /&gt; of options&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;Weighted &lt;br /&gt; average &lt;br /&gt; exercise price&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"&gt;Number &lt;br /&gt; of options&lt;/td&gt; &lt;td style="text-align: right; vertical-align: top"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 34%"&gt;Outstanding at beginning of period&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;454,151&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,427,288&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.52&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;454,151&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.69&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,300,400&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.69&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,300,400&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Forfeited&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.27&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(190,138&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11.50&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,500&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.29&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(187,638&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;Expired&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15.38&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(139,625&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15.38&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(139,625&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;Outstanding at end of period&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.58&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,424,788&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.58&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,424,788&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.59&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,427,288&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;Exercisable at end of period&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.44&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;238,482&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.44&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;238,482&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.49&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;240,982&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0"&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 31; Value: 9 --&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;&lt;td style="text-align: justify"&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-month &lt;br /&gt; period ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-month &lt;br /&gt;Period ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt; 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt; 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;March 31, &lt;br /&gt; 2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;February 28, 2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%; text-align: left; border-bottom: Black 1.5pt solid; text-indent: -6.75pt; padding-left: 6.75pt"&gt;Weighted average fair value of the options granted to employees and directors of the Corporation&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.51&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.22&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.40&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;There were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; options granted during the month ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; options granted to consultants during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;thirteen&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,167&lt;/div&gt; options were exercised during the period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 (&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nil&lt;/div&gt; for period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nil&lt;/div&gt; for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;thirteen&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2017). &lt;/div&gt;Stock-based compensation recognized under this plan for the period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,041&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018 &lt;/div&gt;amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$929,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;thirteen&lt;/div&gt;-month and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-month periods ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2017 &lt;/div&gt;amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$674&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$86&lt;/div&gt; (unaudited), respectively and amounted to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$588&lt;/div&gt; (unaudited) for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;twelve&lt;/div&gt;-month period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; February 28, 2017).&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The fair value of options granted was estimated using the Black-Scholes option pricing model, resulting in the following weighted average assumptions for options granted during the periods ended:&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Thirteen-month &lt;br /&gt; period ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Twelve-month &lt;br /&gt;Period ended&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;March 31, 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top"&gt;March 31, 2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;February 28, 2017 &lt;br /&gt;(Unaudited)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 48%"&gt;Exercise price&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.77&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.75&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.69&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.69&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Share price&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.73&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.75&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.69&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.69&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Dividend&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;Risk-free interest&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.10&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.21&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.87&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.87&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;Estimated life (in years)&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif"&gt;5.78&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif"&gt;5.89&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif"&gt;4.94&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-family: Times New Roman, Times, Serif"&gt;4.94&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;Expected volatility&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;85.35&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;82.4&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;%&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;123.5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;%&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;123.5&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;%&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The expected life of the stock options is based on historical data and current expectation and is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; necessarily indicative of exercise patterns that &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the options is indicative of future trends, which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;also &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; necessarily be the actual outcome.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: -17.85pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The following tables summarize the status of the outstanding and exercisable options of the Corporation:&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="14" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"&gt;Options outstanding&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"&gt;Exercisable options&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td colspan="3" style="white-space: nowrap; border-bottom: Black 1pt solid"&gt;Exercise price&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Weighted remaining &lt;br /&gt; contractual life &lt;br /&gt; outstanding&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Number of options &lt;br /&gt; outstanding&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Weighted average &lt;br /&gt; exercise price &lt;br /&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;Number of options &lt;br /&gt; exercisable&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: center"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 5%"&gt;$0.77&lt;/td&gt; &lt;td style="width: 2%"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 41%"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.77&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.26&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,898,523&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.77&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 10%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;348,197&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;$0.78&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.58&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.86&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;775,000&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.50&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;518,750&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;$1.59&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.71&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.90&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;273,333&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.65&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;233,333&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;$1.72&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.88&lt;/div&gt;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.21&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;790,833&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;$&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.77&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;292,500&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;$1.89&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6.50&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.97&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;308,988&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.57&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;220,420&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.91&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,046,677&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.56&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,613,200&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 10.65pt; text-align: justify; text-indent: 0.1in"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 32; Value: 9 --&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Share-based payment transactions and broker warrants:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;The fair value of share-based payment transaction is measured using the Black-Scholes option pricing model. Measurement inputs include share price on measurement date, exercise price of the instrument, expected volatility (based on weighted average historic volatility), weighted average expected life of the instruments (based on historical experience and general option holder behaviour unless &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; entity-specific information exists in which case the average of the vesting and contractual periods is used), and the risk-free interest rate (based on government bonds). Service and non-market performance conditions attached to the transactions, if any, are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; taken into account in determining fair value.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;(b)&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Corporation equity incentive plan:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation established an equity incentive plan for employees, directors and consultants. The plan provides for the issuance of restricted share units (&amp;#x201c;RSU&amp;#x201d;), performance share units, restricted shares, deferred share units and other share-based awards, subject to restricted conditions as &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;be determined by the Board of Directors. There are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; &lt;/div&gt;such awards outstanding as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018, &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; &lt;/div&gt;stock-based compensation was recognized for the period ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2019 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018 (&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;nil&lt;/div&gt; for the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-month and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;thirteen&lt;/div&gt;-month periods ended &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31,&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt;).&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
  <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233010">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Significant accounting policies:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;The accounting policies set out below have been applied consistently to all periods presented in these financial statements.&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&amp;nbsp;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(a)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Financial instruments:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;A financial instrument is any contract that gives rise to a financial asset of &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; party and a financial liability or equity instrument of another party.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(i)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Non-derivative financial assets:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The Corporation has the following non-derivative financial assets: cash, cash equivalents, marketable securities and receivables. The Corporation determines the classification of its financial assets at initial recognition. The subsequent measurement of financial assets depends on their classification.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Financial assets and liabilities are offset and the net amount presented in the statements of financial position when, and only when, the Corporation has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Cash, cash equivalents, marketable securities and receivables with maturities of less than &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; year are classified at amortized cost as they meet both of the following conditions; they are held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms give rise on specified dates to cashflows that are solely payments of principal and interest on the principal amount outstanding. Cash and cash equivalents comprise cash balances and highly liquid investments purchased &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; months or less from maturity.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0.25in"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 11; Value: 9 --&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(ii)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Non-derivative financial liabilities:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The Corporation has the following non-derivative financial liabilities: trade and other payables. Such financial liabilities are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are measured at amortized cost using the effective interest method.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The Corporation derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(iii)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Compound financial instruments:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Compound financial instruments are instruments that can be converted to share capital at the option of the holder, and the number of shares to be issued is fixed.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The unsecured convertible debentures are compound instruments and have been separated into liability and equity components. The liability component is recognized initially at the fair value of a similar liability that does &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; remeasured subsequent to initial recognition.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(iv)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Share capital:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Common Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Class A Common Shares are classified as equity. Incremental costs directly attributable to the issue of Common Shares and share options are recognized as a deduction from share capital, net of any tax effects.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(v)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Derivative financial instruments:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The Corporation has issued liability-classified derivatives over its own equity. Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit and loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and all changes in their fair value are recognized immediately in profit or loss as a component of finance expense (income).&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(vi)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Other equity instruments:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Warrants, options and rights over the Corporation&amp;#x2019;s equity issued outside of share-based payment transactions that do &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; meet the definition of a liability instrument are recognized in equity.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(b)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Equipment:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(i)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Recognition and measurement:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Equipment is measured at cost less accumulated depreciation and accumulated impairment losses, if any.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Cost includes expenditures that are directly attributable to the acquisition of the asset, including all costs incurred in bringing the asset to its present location and condition.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Gains and losses on disposal of equipment are determined by comparing the proceeds from disposal with the carrying amount of equipment, and are recognized net within ''other income or expenses'' in profit or loss.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(ii)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Subsequent costs:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The cost of replacing a part of an equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Corporation, and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the day-to-day servicing of equipment are recognized in profit or loss as incurred.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 12; Value: 9 --&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(iii)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Depreciation:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Depreciation is recognized in profit or loss on either a straight-line basis or a declining basis over the estimated useful lives of each part of an item of equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Items of equipment are depreciated from the date that they are available for use or, in respect of assets &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; yet in service, from the date they are ready for their intended use.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The estimated useful lives and rates for the current and comparative periods are as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-indent: -9.05pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Method&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Period/Rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;Furniture and office equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Declining balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; to&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; 30%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="width: 28%; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Computer equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 30%; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Declining balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 20%; font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Laboratory equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Declining balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Production equipment (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Straight-line&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-size: 10pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Depreciation methods, useful lives and residual values are reviewed at each financial year-end and adjusted prospectively if appropriate.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(c)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Intangible assets:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(i)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Research and development:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss as incurred.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Corporation intends to and has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized includes the cost of materials, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use, and borrowing costs on qualifying assets. Other development expenditures are recognized in profit or loss as incurred.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Capitalized development expenditure is measured at cost less accumulated amortization and accumulated impairment losses. As of the reporting periods presented, the Corporation has &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; capitalized any development expenditure.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(ii)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Other intangible assets:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Patent costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Patents for technologies that are &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; longer in the research phase are recorded at cost. Patent costs include legal fees to obtain patents and patent application fees. When the technology is still in the research and development phase, those costs are expensed as incurred.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Licenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Licenses that are acquired by the Corporation and have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(iii)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Subsequent expenditure:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditures, including expenditure on internally generated goodwill and brands, are recognized in profit or loss as incurred.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(iv)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Amortization:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Amortization is calculated over the cost of the intangible asset less its residual value.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 13; Value: 9 --&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets from the date that they are available for use, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div&gt; &lt;table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Assets&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Period (in years)&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 78%"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Patents&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 7%; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;License&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8 &lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;to&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; 14&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(d)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Impairment:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(i)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Financial assets:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The Corporation assesses at each reporting date the expected credit loss for calculating impairment of financial assets and recognizes expected credit losses as loss allowances for assets measured at amortized cost.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(ii)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Non-financial assets:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The carrying amounts of the Corporation&amp;#x2019;s non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset&amp;#x2019;s recoverable amount is estimated.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the &amp;#x201c;cash-generating unit, or &amp;#x201c;CGU&amp;#x201d;).&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The Corporation&amp;#x2019;s corporate assets do &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; generate separate cash inflows. If there is an indication that a corporate asset &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;be impaired, then the recoverable amount is determined for the CGU to which the corporate asset belongs.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;An impairment loss is recognized if the carrying amount of an asset or its CGU exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Impairment losses recognized in prior years are assessed at each reporting date for any indications that the loss has decreased or &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset&amp;#x2019;s carrying amount does &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; exceed the carrying amount that would have been determined, net of depreciation or amortization, if &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; impairment loss had been recognized.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(e)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Employee benefits:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(i)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Short-term employee benefits:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;A liability is recognized for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Corporation has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the obligation can be estimated reliably.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 14; Value: 9 --&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(ii)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Share-based payment transactions:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The grant date fair value of share-based payment awards granted to employees is recognized as an employee expense, with a corresponding increase in contributed surplus, over the period that the employees unconditionally become entitled to the awards. The grant date fair value takes into consideration market performance conditions when applicable. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. Share-based payment arrangements in which the Corporation receives goods or services as consideration for its own equity instruments are accounted for as equity-settled share-based payment transactions, regardless of how the equity instruments are obtained by the Corporation.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(iii)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Termination benefits:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Termination benefits are recognized as an expense when the Corporation is committed demonstrably, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognized as an expense if the Corporation has made an offer of voluntary redundancy, it is probable that the offer will be accepted, and the number of acceptances can be estimated reliably. If benefits are payable more than &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; months after the reporting year, then they are discounted to their present value.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(f)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Provisions:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;A provision is recognized if, as a result of a past event, the Corporation has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as a component of finance expense (income).&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(i)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Onerous contracts:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;A provision for onerous contracts is recognized when the expected benefits to be derived by the Corporation from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Corporation recognizes any impairment loss on the assets associated with that contract.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(ii)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Contingent liability:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;A contingent liability is a possible obligation that arises from past events and of which the existence will be confirmed only by the occurrence or non-occurrence of &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; or more uncertain future events &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; within the control of the Corporation; or a present obligation that arises from past events (and therefore exists), but is &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; recognized because it is &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; probable that a transfer or use of assets, provision of services or any other transfer of economic benefits will be required to settle the obligation; or the amount of the obligation cannot be estimated reliably.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(g)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Government grants:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Government grants are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Corporation has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Grants that compensate the Corporation for expenses incurred are recognized in profit or loss in reduction thereof on a systematic basis in the same years in which the expenses are recognized. Grants that compensate the Corporation for the cost of an asset are recognized in profit or loss on a systematic basis over the useful life of the asset.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(h)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Lease payments:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease. Lease incentives received are recognized as an integral part of the total lease expense, over the term of the lease.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(i)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Foreign currency:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Transactions in foreign currencies are translated into the functional currency at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the period, adjusted for effective interest and payments during the period, and the amortized cost in foreign currency translated at the exchange rate at the end of the reporting period. Foreign currency differences arising on translation are recognized in profit or loss.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 15; Value: 9 --&gt;   &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(j)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Finance income and finance expense:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Finance income comprises interest income on funds invested. Interest income is recognized as it accrues in profit or loss, using the effective interest method.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Finance costs comprise interest expense, accretion on borrowings, unwinding of the discount on provisions, impairment losses recognized on financial assets, transaction costs for issuance of derivative warrant liabilities and changes of fair value of derivative warrant liabilities. Borrowing costs that are &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; directly attributable to the acquisition, construction or production of a qualifying asset are recognized in profit or loss using the effective interest method.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Foreign currency gains and losses are reported on a net basis. The Corporation recognizes interest income as a component of investing activities and interest expense as a component of financing activities in the statements of cash flows.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(k)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Income tax:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Income tax expense comprises current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they relate to items recognized directly in equity or in other comprehensive income.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; recognized for temporary differences arising from the initial recognition of assets or liabilities in a transaction that is &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; a business combination and that affects neither accounting nor taxable profit or loss. Deferred tax is measured at the tax rates, enacted or substantively enacted, that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously. A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; longer probable that the related tax benefit will be realized.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(l)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Earnings per share:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The Corporation presents basic and diluted earnings per share (&amp;#x201c;EPS&amp;#x201d;) data for its Class A shares (or &amp;#x201c;Common Shares&amp;#x201d;). Basic EPS is calculated by dividing the profit or loss attributable to the holders of Class A shares (Common Shares) of the Corporation by the weighted average number of Common Shares outstanding during the year, adjusted for own shares held. Diluted EPS is determined by adjusting the profit or loss attributable to the holders of Class A shares (Common Shares) and the weighted average number of Class A shares (Common Shares) outstanding adjusted for the effects of all dilutive potential Common Shares, which comprise warrants, rights and share options granted to employees.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(m)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Segment reporting:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;An operating segment is a component of the Corporation that engages in business activities from which it &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;earn revenues and incur expenses. The Corporation has &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; reportable operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The majority of the Corporation&amp;#x2019;s assets are located in Canada, while &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; major production unit, with a carrying value of &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,831&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; (&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018 - &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2,077&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;), is located in France.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;!-- Field: Page; Sequence: 16; Value: 9 --&gt;   &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(n)&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Change in accounting policy:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Adoption of new accounting standards&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The accounting policies used in these annual financial statements are consistent with those applied by the Corporation in its &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March 31, 2018 &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;annual financial statements except for the amendments to certain accounting standards which are relevant to the Corporation and were adopted by the Corporation as of &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 1, 2018 &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;as described below.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(i)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Financial instruments:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; Financial Instruments, replaces IAS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39,&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; Financial Instruments: Recognition and Measurement. IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; introduces a revised approach for the classification of financial assets based on how an entity manages financial assets and the characteristics of the contractual cash flows of the financial assets replacing the multiple rules in IAS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39.&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; Most of the requirements in IAS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; for classification and measurement of financial liabilities have been carried forward in IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; also introduces a new hedge accounting model that is more closely aligned with risk-management activities and a new expected credit loss model for calculating impairment on financial assets replacing the incurred loss model in IAS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39.&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; The Corporation adopted IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; as of &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 1, 2018 &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;and assessed the impact of the adoption on its financial statements, and determined there was &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; material impact. The Corporation does &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; apply hedge accounting.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 40pt; text-align: right"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(ii)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Amendments to IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &amp;#x2013; Classification and Measurement of Share-Based Payment Transactions:&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;On &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June 20, 2016, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;the IASB issued amendments to IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; Share-Based Payment, clarifying how to account for certain types of share-based payment transactions. The amendments provide requirements on the accounting for: the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based payments; share-based payment transactions with a net settlement feature for withholding tax obligations; and a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from cash-settled to equity-settled. The Corporation adopted the amendments to IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; as of &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 1, 2018 &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;and assessed the impact of the adoption of IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; on its financial statements, and determined that there was &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; material impact.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Future accounting change:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The following new standards, and amendments to standards and interpretations, are &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; yet effective for the period ended &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; March&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019,&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; and have &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; been applied in preparing these financial statements.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;New standards and interpretations &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; yet adopted:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"&gt;  &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 40pt"&gt;&lt;/td&gt; &lt;td style="width: 35pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(i)&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: justify; padding-right: 5.9pt"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;Leases &amp;#x2013; IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; Leases (&amp;#x201c;IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&amp;#x201d;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;) In &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2016, &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;the IASB issued IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; a new standard that replaces IAS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; Leases. IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; is a major revision of the way in which companies account for leases and will &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; longer permit off balance sheet leases. Adoption of IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; is mandatory and will be effective for the Corporation&amp;#x2019;s fiscal year beginning on &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; April 1, 2019. &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;The Corporation is assessing the impact of adoption of IFRS &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; and currently there is only &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; lease that will be impacted by this new standard and the impact is expected to be minimal.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
  <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory contextRef="d_2018-04-01_2019-03-31" id="c-25">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 85%; text-align: left"&gt;2029&lt;/td&gt; &lt;td style="width: 1%"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;2030&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;2031&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;45&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;2032&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;431&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;2033&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;441&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;2034&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;436&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;2035&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;519&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;2036&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;286&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left"&gt;2037&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;315&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left"&gt;2038&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;324&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;2039&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;329&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: left; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,167&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
  <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233029">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Trade and other payables:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" margin: 0"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 70%; font-weight: normal; text-align: left"&gt;Trade payables&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,064&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,420&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Accrued liabilities and other payables&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,319&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,479&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Employee salaries and benefits payable&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,054&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;754&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Legal settlement expected to be paid via common shares (note 25)&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;990&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Payable to Neptune&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;44&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Total trade and other payables&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16,429&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,697&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;The Corporation&amp;#x2019;s exposure to currency and liquidity risks related to trade and other payables is presented in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
  <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233013">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Receivables:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: center; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2019&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid"&gt;March 31, 2018&lt;/td&gt; &lt;td style="font-weight: normal; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid"&gt;Notes&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 55%; font-weight: normal; text-align: left"&gt;Sales tax receivables&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 14%; font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;618&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;470&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Government assistance and tax credits receivable&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;872&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;282&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left"&gt;Interest receivable&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;80&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"&gt;Other receivables&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid"&gt;Total receivables&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,586&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;759&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
  <ifrs-full:EarningsPerShareExplanatory contextRef="d_2018-04-01_2019-03-31" id="s1233054">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 35pt; text-align: left"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;18.&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5pt"&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;Loss per share:&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"&gt;Diluted loss per share was the same amount as basic loss per share, as the effect of options, RSUs and warrants would have been anti-dilutive, because the Corporation incurred losses in each of the periods presented. All outstanding options, RSUs and warrants could potentially be dilutive in the future.&lt;/div&gt;&lt;/div&gt;</ifrs-full:EarningsPerShareExplanatory>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922928" unitRef="iso4217-cad">48000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922929" unitRef="iso4217-cad">-25000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922930" unitRef="iso4217-cad">-49000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922931" unitRef="iso4217-cad">9000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922932" unitRef="iso4217-cad">-58000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EmployeeBenefitsExpense contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924043" unitRef="iso4217-cad">5185000</ifrs-full:EmployeeBenefitsExpense>
  <ifrs-full:EmployeeBenefitsExpense contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924044" unitRef="iso4217-cad">4210000</ifrs-full:EmployeeBenefitsExpense>
  <ifrs-full:EmployeeBenefitsExpense contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924045" unitRef="iso4217-cad">3165000</ifrs-full:EmployeeBenefitsExpense>
  <ifrs-full:EmployeeBenefitsExpense contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924046" unitRef="iso4217-cad">300000</ifrs-full:EmployeeBenefitsExpense>
  <ifrs-full:EmployeeBenefitsExpense contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924047" unitRef="iso4217-cad">2865000</ifrs-full:EmployeeBenefitsExpense>
  <ifrs-full:Equity contextRef="i_2018-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922536" unitRef="iso4217-cad">73338000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2018-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" decimals="-3" id="c47922537" unitRef="iso4217-cad">309000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2018-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922538" unitRef="iso4217-cad">6956000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2018-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" decimals="-3" id="c47922539" unitRef="iso4217-cad">-72379000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2018-03-31" decimals="-3" id="c47922540" unitRef="iso4217-cad">8224000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922594" unitRef="iso4217-cad">129318000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2019-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" decimals="-3" id="c47922595" unitRef="iso4217-cad">309000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2019-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922596" unitRef="iso4217-cad">8280000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2019-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" decimals="-3" id="c47922597" unitRef="iso4217-cad">-123945000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2019-03-31" decimals="-3" id="c47922598" unitRef="iso4217-cad">13962000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2017-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922601" unitRef="iso4217-cad">66576000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2017-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" decimals="-3" id="c47922602" unitRef="iso4217-cad">309000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2017-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922603" unitRef="iso4217-cad">5693000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2017-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" decimals="-3" id="c47922604" unitRef="iso4217-cad">-50875000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2017-03-31" decimals="-3" id="c47922605" unitRef="iso4217-cad">21703000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2016-02-29_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922666" unitRef="iso4217-cad">61973000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2016-02-29_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922667" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:Equity contextRef="i_2016-02-29_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922668" unitRef="iso4217-cad">4875000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2016-02-29_ComponentsOfEquityAxis-RetainedEarningsMember" decimals="-3" id="c47922669" unitRef="iso4217-cad">-39628000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2016-02-29" decimals="-3" id="c47922670" unitRef="iso4217-cad">27220000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2017-02-28_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922773" unitRef="iso4217-cad">66576000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2017-02-28_ComponentsOfEquityAxis-OtherEquityInterestMember" decimals="-3" id="c47922774" unitRef="iso4217-cad">309000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2017-02-28_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922775" unitRef="iso4217-cad">5607000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2017-02-28_ComponentsOfEquityAxis-RetainedEarningsMember" decimals="-3" id="c47922776" unitRef="iso4217-cad">-50106000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="i_2017-02-28" decimals="-3" id="c47922777" unitRef="iso4217-cad">22386000</ifrs-full:Equity>
  <ifrs-full:EquityAndLiabilities contextRef="i_2019-03-31" decimals="-3" id="c47922466" unitRef="iso4217-cad">48471000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:EquityAndLiabilities contextRef="i_2018-03-31" decimals="-3" id="c47922467" unitRef="iso4217-cad">22959000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:EstimatedFinancialEffectOfContingentLiabilities contextRef="i_2019-03-31_ClassesOfContingentLiabilitiesAxis-ResearchAndDevelopmentProjectsMember" decimals="-3" id="c47924795" unitRef="iso4217-cad">109000</ifrs-full:EstimatedFinancialEffectOfContingentLiabilities>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="i_2019-03-31_RangeAxis-BottomOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeOneOfExercisesPricesMember" decimals="INF" id="c47924385" unitRef="iso4217-cad">0.77</ifrs-full:ExercisePriceOfOutstandingShareOptions>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="i_2019-03-31_RangeAxis-TopOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeOneOfExercisesPricesMember" decimals="INF" id="c47924386" unitRef="iso4217-cad">0.77</ifrs-full:ExercisePriceOfOutstandingShareOptions>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="i_2019-03-31_RangeAxis-BottomOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeTwoOfExercisesPricesMember" decimals="INF" id="c47924391" unitRef="iso4217-cad">0.78</ifrs-full:ExercisePriceOfOutstandingShareOptions>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="i_2019-03-31_RangeAxis-TopOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeTwoOfExercisesPricesMember" decimals="INF" id="c47924392" unitRef="iso4217-cad">1.58</ifrs-full:ExercisePriceOfOutstandingShareOptions>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="i_2019-03-31_RangeAxis-BottomOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeThreeOfExercisesPricesMember" decimals="INF" id="c47924397" unitRef="iso4217-cad">1.59</ifrs-full:ExercisePriceOfOutstandingShareOptions>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="i_2019-03-31_RangeAxis-TopOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeThreeOfExercisesPricesMember" decimals="INF" id="c47924398" unitRef="iso4217-cad">1.71</ifrs-full:ExercisePriceOfOutstandingShareOptions>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="i_2019-03-31_RangeAxis-BottomOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFourOfExercisesPricesMember" decimals="INF" id="c47924403" unitRef="iso4217-cad">1.72</ifrs-full:ExercisePriceOfOutstandingShareOptions>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="i_2019-03-31_RangeAxis-TopOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFourOfExercisesPricesMember" decimals="INF" id="c47924404" unitRef="iso4217-cad">1.88</ifrs-full:ExercisePriceOfOutstandingShareOptions>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="i_2019-03-31_RangeAxis-BottomOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFiveOfExercisesPricesMember" decimals="INF" id="c47924409" unitRef="iso4217-cad">1.89</ifrs-full:ExercisePriceOfOutstandingShareOptions>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="i_2019-03-31_RangeAxis-TopOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFiveOfExercisesPricesMember" decimals="INF" id="c47924410" unitRef="iso4217-cad">6.50</ifrs-full:ExercisePriceOfOutstandingShareOptions>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="i_2019-03-31_RangeAxis-BottomOfRangeMember" id="c47924415" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions contextRef="i_2019-03-31_RangeAxis-TopOfRangeMember" id="c47924416" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ExercisePriceShareOptionsGranted contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47924361" unitRef="iso4217-cad">0.77</ifrs-full:ExercisePriceShareOptionsGranted>
  <ifrs-full:ExercisePriceShareOptionsGranted contextRef="d_2017-03-01_2018-03-31" decimals="INF" id="c47924362" unitRef="iso4217-cad">1.75</ifrs-full:ExercisePriceShareOptionsGranted>
  <ifrs-full:ExercisePriceShareOptionsGranted contextRef="d_2016-03-01_2017-03-31" decimals="INF" id="c47924363" unitRef="iso4217-cad">1.69</ifrs-full:ExercisePriceShareOptionsGranted>
  <ifrs-full:ExercisePriceShareOptionsGranted contextRef="d_2016-03-01_2017-02-28" decimals="INF" id="c47924364" unitRef="iso4217-cad">1.69</ifrs-full:ExercisePriceShareOptionsGranted>
  <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="d_2018-04-01_2019-03-31" id="c47924369" unitRef="xbrli-pure" xs:nil="true"/>
  <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="d_2017-03-01_2018-03-31" id="c47924370" unitRef="xbrli-pure" xs:nil="true"/>
  <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="d_2016-03-01_2017-03-31" id="c47924371" unitRef="xbrli-pure" xs:nil="true"/>
  <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="d_2016-03-01_2017-02-28" id="c47924372" unitRef="xbrli-pure" xs:nil="true"/>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="d_2018-04-01_2019-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="-3" id="c47924129" unitRef="iso4217-cad">1041000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="d_2017-04-01_2018-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="-3" id="c47924130" unitRef="iso4217-cad">929000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="d_2016-03-01_2017-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="-3" id="c47924133" unitRef="iso4217-cad">674000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="d_2017-03-01_2017-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="-3" id="c47924134" unitRef="iso4217-cad">86000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="d_2016-03-01_2017-02-28_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="-3" id="c47924135" unitRef="iso4217-cad">588000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="d_2018-04-01_2019-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationEquityIncentivePlanMember" decimals="-3" id="c47924148" unitRef="iso4217-cad">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="d_2016-03-01_2017-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationEquityIncentivePlanMember" decimals="-3" id="c47924149" unitRef="iso4217-cad">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="d_2017-04-01_2018-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationEquityIncentivePlanMember" decimals="-3" id="c47924154" unitRef="iso4217-cad">0</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924038" unitRef="iso4217-cad">1041000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924039" unitRef="iso4217-cad">929000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924040" unitRef="iso4217-cad">674000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924041" unitRef="iso4217-cad">86000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924042" unitRef="iso4217-cad">588000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:FinanceCosts contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924089" unitRef="iso4217-cad">6551000</ifrs-full:FinanceCosts>
  <ifrs-full:FinanceCosts contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924090" unitRef="iso4217-cad">1808000</ifrs-full:FinanceCosts>
  <ifrs-full:FinanceCosts contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924091" unitRef="iso4217-cad">166000</ifrs-full:FinanceCosts>
  <ifrs-full:FinanceCosts contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924092" unitRef="iso4217-cad">51000</ifrs-full:FinanceCosts>
  <ifrs-full:FinanceCosts contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924093" unitRef="iso4217-cad">115000</ifrs-full:FinanceCosts>
  <ifrs-full:FinancialAssets contextRef="i_2019-03-31" decimals="-5" id="c47922986" unitRef="iso4217-cad">11900000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialLiabilities contextRef="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember" decimals="-3" id="c47924755" unitRef="iso4217-cad">16429000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember" decimals="-3" id="c47924756" unitRef="iso4217-cad">16429000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_MaturityAxis-NotLaterThanOneYearMember" decimals="-3" id="c47924757" unitRef="iso4217-cad">16429000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_MaturityAxis-LaterThanOneYearAndNotLaterThanThreeYearsMember" id="c47924758" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:FinancialLiabilities contextRef="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember" decimals="-3" id="c47924760" unitRef="iso4217-cad">2143000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember" decimals="-3" id="c47924761" unitRef="iso4217-cad">1817000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember_MaturityAxis-NotLaterThanOneYearMember" decimals="-3" id="c47924762" unitRef="iso4217-cad">2143000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember_MaturityAxis-LaterThanOneYearAndNotLaterThanThreeYearsMember" id="c47924763" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:FinancialLiabilities contextRef="i_2019-03-31" decimals="-3" id="c47924765" unitRef="iso4217-cad">18572000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" decimals="-3" id="c47924766" unitRef="iso4217-cad">18246000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2019-03-31_MaturityAxis-NotLaterThanOneYearMember" decimals="-3" id="c47924767" unitRef="iso4217-cad">18572000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2019-03-31_MaturityAxis-LaterThanOneYearAndNotLaterThanThreeYearsMember" id="c47924768" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:FinancialLiabilities contextRef="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember" decimals="-3" id="c47924780" unitRef="iso4217-cad">6697000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember" decimals="-3" id="c47924781" unitRef="iso4217-cad">6697000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_MaturityAxis-NotLaterThanOneYearMember" decimals="-3" id="c47924782" unitRef="iso4217-cad">6697000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_MaturityAxis-LaterThanOneYearAndNotLaterThanThreeYearsMember" id="c47924783" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:FinancialLiabilities contextRef="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember" decimals="-3" id="c47924785" unitRef="iso4217-cad">2303000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember" decimals="-3" id="c47924786" unitRef="iso4217-cad">1612000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember_MaturityAxis-NotLaterThanOneYearMember" decimals="-3" id="c47924787" unitRef="iso4217-cad">160000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember_MaturityAxis-LaterThanOneYearAndNotLaterThanThreeYearsMember" decimals="-3" id="c47924788" unitRef="iso4217-cad">2143000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2018-03-31" decimals="-3" id="c47924790" unitRef="iso4217-cad">9000000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" decimals="-3" id="c47924791" unitRef="iso4217-cad">8309000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2018-03-31_MaturityAxis-NotLaterThanOneYearMember" decimals="-3" id="c47924792" unitRef="iso4217-cad">6857000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilities contextRef="i_2018-03-31_MaturityAxis-LaterThanOneYearAndNotLaterThanThreeYearsMember" decimals="-3" id="c47924793" unitRef="iso4217-cad">2143000</ifrs-full:FinancialLiabilities>
  <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss contextRef="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-DerivativeWarrantLiabilitiesMember" decimals="INF" id="c47923755" unitRef="iso4217-cad">4300000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
  <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss contextRef="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-DerivativeWarrantLiabilitiesMember" decimals="INF" id="c47923783" unitRef="iso4217-cad">5900000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
  <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924079" unitRef="iso4217-cad">-6287000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
  <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924080" unitRef="iso4217-cad">-344000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
  <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924081" unitRef="iso4217-cad">-53000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
  <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924082" unitRef="iso4217-cad">-22000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
  <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924083" unitRef="iso4217-cad">-31000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922487" unitRef="iso4217-cad">6649000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922488" unitRef="iso4217-cad">4027000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922489" unitRef="iso4217-cad">3557000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922490" unitRef="iso4217-cad">292000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922491" unitRef="iso4217-cad">3265000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2018-04-01_2019-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SuppliesAndIncrementalCostsMember" decimals="-3" id="c47923299" unitRef="iso4217-cad">211000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2017-04-01_2018-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SuppliesAndIncrementalCostsMember" decimals="-3" id="c47923300" unitRef="iso4217-cad">239000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2016-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SuppliesAndIncrementalCostsMember" decimals="-3" id="c47923301" unitRef="iso4217-cad">293000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2017-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SuppliesAndIncrementalCostsMember" decimals="-3" id="c47923302" unitRef="iso4217-cad">16000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2016-03-01_2017-02-28_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SuppliesAndIncrementalCostsMember" decimals="-3" id="c47923303" unitRef="iso4217-cad">277000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2018-04-01_2019-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SharedServiceAgreementMember" decimals="-3" id="c47923304" unitRef="iso4217-cad">34000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2017-04-01_2018-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SharedServiceAgreementMember" decimals="-3" id="c47923305" unitRef="iso4217-cad">121000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2016-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SharedServiceAgreementMember" decimals="-3" id="c47923306" unitRef="iso4217-cad">325000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2017-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SharedServiceAgreementMember" decimals="-3" id="c47923307" unitRef="iso4217-cad">25000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2016-03-01_2017-02-28_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SharedServiceAgreementMember" decimals="-3" id="c47923308" unitRef="iso4217-cad">300000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2018-04-01_2019-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923309" unitRef="iso4217-cad">245000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2017-04-01_2018-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923310" unitRef="iso4217-cad">360000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2016-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923311" unitRef="iso4217-cad">618000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2017-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923312" unitRef="iso4217-cad">41000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="d_2016-03-01_2017-02-28_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923313" unitRef="iso4217-cad">577000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="d_2018-04-01_2019-03-31" id="c47924588" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="d_2017-04-01_2018-03-31" id="c47924589" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924590" unitRef="iso4217-cad">-129000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="d_2017-03-01_2017-03-31" id="c47924591" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924592" unitRef="iso4217-cad">-129000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922721" unitRef="iso4217-cad">129000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="d_2018-04-01_2019-03-31" id="c47922511" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="d_2017-04-01_2018-03-31" id="c47922512" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922513" unitRef="iso4217-cad">129000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome>
  <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome contextRef="d_2017-03-01_2017-03-31" id="c47922514" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922934" unitRef="iso4217-cad">14298000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922935" unitRef="iso4217-cad">-1549000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922936" unitRef="iso4217-cad">6745000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922937" unitRef="iso4217-cad">-801000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922938" unitRef="iso4217-cad">7546000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
  <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922586" unitRef="xbrli-shares">52494519</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
  <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922651" unitRef="xbrli-shares">10935659</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
  <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922751" unitRef="xbrli-shares">3990518</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
  <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding contextRef="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922765" unitRef="xbrli-shares">3990518</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2017-04-07_2017-04-07" decimals="-3" id="c47923913" unitRef="iso4217-cad">17000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2017-08-15_2017-08-15" decimals="-3" id="c47923916" unitRef="iso4217-cad">40000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2017-12-27_2017-12-27" decimals="-3" id="c47923919" unitRef="iso4217-cad">40000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2018-03-27_2018-03-27" decimals="-3" id="c47923922" unitRef="iso4217-cad">40000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2018-06-06_2018-06-06" decimals="-3" id="c47923925" unitRef="iso4217-cad">40000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2018-08-21_2018-08-21" decimals="-3" id="c47923928" unitRef="iso4217-cad">40000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2018-10-31_2018-10-31" decimals="-3" id="c47923931" unitRef="iso4217-cad">40000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2018-04-01_2018-09-30" decimals="-3" id="c47923934" unitRef="iso4217-cad">257000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922580" unitRef="iso4217-cad">120000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922581" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" id="c47922582" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922583" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922584" unitRef="iso4217-cad">120000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922645" unitRef="iso4217-cad">137000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922646" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" id="c47922647" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922648" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922649" unitRef="iso4217-cad">137000</ifrs-full:IncreaseDecreaseThroughConversionOfConvertibleInstruments>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922566" unitRef="iso4217-cad">1733000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922567" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" id="c47922568" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922569" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922570" unitRef="iso4217-cad">1733000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922631" unitRef="iso4217-cad">456000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922632" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922633" unitRef="iso4217-cad">-72000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922634" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922635" unitRef="iso4217-cad">384000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922573" unitRef="iso4217-cad">3000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922574" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922575" unitRef="iso4217-cad">1041000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922576" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922577" unitRef="iso4217-cad">1044000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" id="c47922638" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922639" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922640" unitRef="iso4217-cad">929000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922641" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922642" unitRef="iso4217-cad">929000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-IssuedCapitalMember" id="c47922731" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922732" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922733" unitRef="iso4217-cad">588000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922734" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922735" unitRef="iso4217-cad">588000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" id="c47922738" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922739" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922740" unitRef="iso4217-cad">86000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922741" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922742" unitRef="iso4217-cad">86000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" id="c47922745" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922746" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922747" unitRef="iso4217-cad">674000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922748" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922749" unitRef="iso4217-cad">674000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922587" unitRef="iso4217-cad">55980000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922588" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922589" unitRef="iso4217-cad">1324000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922590" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922591" unitRef="iso4217-cad">57304000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922652" unitRef="iso4217-cad">6762000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922653" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922654" unitRef="iso4217-cad">1263000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922655" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922656" unitRef="iso4217-cad">8025000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922752" unitRef="iso4217-cad">4603000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-OtherEquityInterestMember" decimals="-3" id="c47922753" unitRef="iso4217-cad">309000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922754" unitRef="iso4217-cad">732000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922755" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922756" unitRef="iso4217-cad">5644000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" id="c47922759" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922760" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922761" unitRef="iso4217-cad">86000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922762" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922763" unitRef="iso4217-cad">86000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922766" unitRef="iso4217-cad">4603000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" decimals="-3" id="c47922767" unitRef="iso4217-cad">309000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922768" unitRef="iso4217-cad">818000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922769" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922770" unitRef="iso4217-cad">5730000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" decimals="-3" id="c47923507" unitRef="iso4217-cad">362000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" decimals="-3" id="c47923508" unitRef="iso4217-cad">24330000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" decimals="-3" id="c47923509" unitRef="iso4217-cad">24692000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" decimals="-3" id="c47923513" unitRef="iso4217-cad">362000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" decimals="-3" id="c47923514" unitRef="iso4217-cad">24330000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" decimals="-3" id="c47923515" unitRef="iso4217-cad">24692000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" decimals="-3" id="c47923519" unitRef="iso4217-cad">362000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" decimals="-3" id="c47923520" unitRef="iso4217-cad">24330000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" decimals="-3" id="c47923521" unitRef="iso4217-cad">24692000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" decimals="-3" id="c47923523" unitRef="iso4217-cad">362000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" decimals="-3" id="c47923524" unitRef="iso4217-cad">9425000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923525" unitRef="iso4217-cad">9787000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" decimals="-3" id="c47923529" unitRef="iso4217-cad">362000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" decimals="-3" id="c47923530" unitRef="iso4217-cad">11748000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923531" unitRef="iso4217-cad">12110000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" decimals="-3" id="c47923538" unitRef="iso4217-cad">362000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" decimals="-3" id="c47923539" unitRef="iso4217-cad">11942000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923540" unitRef="iso4217-cad">12304000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" decimals="-3" id="c47923544" unitRef="iso4217-cad">362000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" decimals="-3" id="c47923545" unitRef="iso4217-cad">14265000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923546" unitRef="iso4217-cad">14627000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" decimals="-3" id="c47923550" unitRef="iso4217-cad">362000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" decimals="-3" id="c47923551" unitRef="iso4217-cad">16587000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923552" unitRef="iso4217-cad">16949000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2018-03-31_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" id="c47923554" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2018-03-31_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" decimals="-3" id="c47923555" unitRef="iso4217-cad">10065000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2018-03-31" decimals="-3" id="c47923556" unitRef="iso4217-cad">10065000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2019-03-31_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember" id="c47923557" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2019-03-31_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember" decimals="-3" id="c47923558" unitRef="iso4217-cad">7743000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:IntangibleAssetsAndGoodwill contextRef="i_2019-03-31" decimals="-3" id="c47923559" unitRef="iso4217-cad">7743000</ifrs-full:IntangibleAssetsAndGoodwill>
  <ifrs-full:InterestCostsIncurred contextRef="d_2017-04-01_2018-03-31_BorrowingsByNameAxis-LiabilityPortionOfUnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923682" unitRef="iso4217-cad">160000</ifrs-full:InterestCostsIncurred>
  <ifrs-full:InterestCostsIncurred contextRef="d_2017-04-01_2018-03-31_BorrowingsByNameAxis-EquityComponentOfUnsecuredConvertibleDebenturesMember" id="c47923683" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:InterestCostsIncurred contextRef="d_2017-04-01_2018-03-31_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923684" unitRef="iso4217-cad">160000</ifrs-full:InterestCostsIncurred>
  <ifrs-full:InterestCostsIncurred contextRef="d_2018-04-01_2019-03-31_BorrowingsByNameAxis-LiabilityPortionOfUnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923691" unitRef="iso4217-cad">160000</ifrs-full:InterestCostsIncurred>
  <ifrs-full:InterestCostsIncurred contextRef="d_2018-04-01_2019-03-31_BorrowingsByNameAxis-EquityComponentOfUnsecuredConvertibleDebenturesMember" id="c47923692" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:InterestCostsIncurred contextRef="d_2018-04-01_2019-03-31_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923693" unitRef="iso4217-cad">160000</ifrs-full:InterestCostsIncurred>
  <ifrs-full:InterestExpenseOnBorrowings contextRef="d_2017-04-01_2018-03-31_BorrowingsByNameAxis-LiabilityPortionOfUnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923679" unitRef="iso4217-cad">366000</ifrs-full:InterestExpenseOnBorrowings>
  <ifrs-full:InterestExpenseOnBorrowings contextRef="d_2017-04-01_2018-03-31_BorrowingsByNameAxis-EquityComponentOfUnsecuredConvertibleDebenturesMember" id="c47923680" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:InterestExpenseOnBorrowings contextRef="d_2017-04-01_2018-03-31_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923681" unitRef="iso4217-cad">366000</ifrs-full:InterestExpenseOnBorrowings>
  <ifrs-full:InterestExpenseOnBorrowings contextRef="d_2018-04-01_2019-03-31_BorrowingsByNameAxis-LiabilityPortionOfUnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923688" unitRef="iso4217-cad">365000</ifrs-full:InterestExpenseOnBorrowings>
  <ifrs-full:InterestExpenseOnBorrowings contextRef="d_2018-04-01_2019-03-31_BorrowingsByNameAxis-EquityComponentOfUnsecuredConvertibleDebenturesMember" id="c47923689" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:InterestExpenseOnBorrowings contextRef="d_2018-04-01_2019-03-31_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="-3" id="c47923690" unitRef="iso4217-cad">365000</ifrs-full:InterestExpenseOnBorrowings>
  <ifrs-full:InterestExpenseOnBorrowings contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924064" unitRef="iso4217-cad">160000</ifrs-full:InterestExpenseOnBorrowings>
  <ifrs-full:InterestExpenseOnBorrowings contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924065" unitRef="iso4217-cad">160000</ifrs-full:InterestExpenseOnBorrowings>
  <ifrs-full:InterestExpenseOnBorrowings contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924066" unitRef="iso4217-cad">17000</ifrs-full:InterestExpenseOnBorrowings>
  <ifrs-full:InterestExpenseOnBorrowings contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924067" unitRef="iso4217-cad">14000</ifrs-full:InterestExpenseOnBorrowings>
  <ifrs-full:InterestExpenseOnBorrowings contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924068" unitRef="iso4217-cad">3000</ifrs-full:InterestExpenseOnBorrowings>
  <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922916" unitRef="iso4217-cad">44000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
  <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922917" unitRef="iso4217-cad">3000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
  <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922918" unitRef="iso4217-cad">18000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
  <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="d_2017-03-01_2017-03-31" id="c47922919" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922920" unitRef="iso4217-cad">18000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
  <ifrs-full:InterestReceivable contextRef="i_2019-03-31" decimals="-3" id="c47923170" unitRef="iso4217-cad">80000</ifrs-full:InterestReceivable>
  <ifrs-full:InterestReceivable contextRef="i_2018-03-31" id="c47923171" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922849" unitRef="iso4217-cad">384000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
  <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922850" unitRef="iso4217-cad">70000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
  <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922851" unitRef="iso4217-cad">150000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
  <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922852" unitRef="iso4217-cad">4000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
  <ifrs-full:InterestReceivedClassifiedAsInvestingActivities contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922853" unitRef="iso4217-cad">146000</ifrs-full:InterestReceivedClassifiedAsInvestingActivities>
  <ifrs-full:InterestRevenueExpense contextRef="d_2018-04-01_2019-03-31_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember" decimals="-3" id="c47923252" unitRef="iso4217-cad">0</ifrs-full:InterestRevenueExpense>
  <ifrs-full:InterestRevenueExpense contextRef="d_2016-03-01_2017-03-31_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember" decimals="-3" id="c47923254" unitRef="iso4217-cad">89000</ifrs-full:InterestRevenueExpense>
  <ifrs-full:InterestRevenueExpense contextRef="d_2017-03-01_2017-03-31_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember" decimals="-3" id="c47923256" unitRef="iso4217-cad">0</ifrs-full:InterestRevenueExpense>
  <ifrs-full:InterestRevenueExpense contextRef="d_2016-03-01_2017-02-28_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember" decimals="-3" id="c47923257" unitRef="iso4217-cad">89000</ifrs-full:InterestRevenueExpense>
  <ifrs-full:InterestRevenueExpense contextRef="d_2017-04-01_2018-03-31_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember" decimals="-3" id="c47923274" unitRef="iso4217-cad">0</ifrs-full:InterestRevenueExpense>
  <ifrs-full:IssueOfConvertibleInstruments contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-IssuedCapitalMember" id="c47922710" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IssueOfConvertibleInstruments contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-OtherEquityInterestMember" decimals="-3" id="c47922711" unitRef="iso4217-cad">309000</ifrs-full:IssueOfConvertibleInstruments>
  <ifrs-full:IssueOfConvertibleInstruments contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" id="c47922712" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IssueOfConvertibleInstruments contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922713" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IssueOfConvertibleInstruments contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922714" unitRef="iso4217-cad">309000</ifrs-full:IssueOfConvertibleInstruments>
  <ifrs-full:IssueOfEquity contextRef="d_2018-04-01_2019-03-31_ClassesOfOrdinarySharesAxis-CommonSharesMember" decimals="INF" id="c47923756" unitRef="iso4217-cad">6200000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922559" unitRef="iso4217-cad">54124000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922560" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IssueOfEquity contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922561" unitRef="iso4217-cad">283000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922562" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IssueOfEquity contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922563" unitRef="iso4217-cad">54407000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922624" unitRef="iso4217-cad">6169000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922625" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IssueOfEquity contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922626" unitRef="iso4217-cad">406000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922627" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IssueOfEquity contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922628" unitRef="iso4217-cad">6575000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="-3" id="c47922703" unitRef="iso4217-cad">4509000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-OtherEquityInterestMember" id="c47922704" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IssueOfEquity contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember" decimals="-3" id="c47922705" unitRef="iso4217-cad">144000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-RetainedEarningsMember" id="c47922706" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:IssueOfEquity contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922707" unitRef="iso4217-cad">4653000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssuedCapital contextRef="i_2019-03-31" decimals="-3" id="c47922448" unitRef="iso4217-cad">129318000</ifrs-full:IssuedCapital>
  <ifrs-full:IssuedCapital contextRef="i_2018-03-31" decimals="-3" id="c47922449" unitRef="iso4217-cad">73338000</ifrs-full:IssuedCapital>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47923334" unitRef="iso4217-cad">2581000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47923335" unitRef="iso4217-cad">2580000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47923336" unitRef="iso4217-cad">2129000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47923337" unitRef="iso4217-cad">224000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47923338" unitRef="iso4217-cad">1905000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47923329" unitRef="iso4217-cad">940000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47923330" unitRef="iso4217-cad">826000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47923331" unitRef="iso4217-cad">619000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47923332" unitRef="iso4217-cad">78000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47923333" unitRef="iso4217-cad">541000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47923324" unitRef="iso4217-cad">1641000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47923325" unitRef="iso4217-cad">1754000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47923326" unitRef="iso4217-cad">1510000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47923327" unitRef="iso4217-cad">146000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47923328" unitRef="iso4217-cad">1364000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:Liabilities contextRef="i_2019-03-31" decimals="-3" id="c47922444" unitRef="iso4217-cad">34509000</ifrs-full:Liabilities>
  <ifrs-full:Liabilities contextRef="i_2018-03-31" decimals="-3" id="c47922445" unitRef="iso4217-cad">14735000</ifrs-full:Liabilities>
  <ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities contextRef="d_2018-04-01_2019-03-31" id="c-29">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Warrant liabilities issued &lt;br /&gt; May 2018&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;Warrant liabilities issued &lt;br /&gt; December 27, 2017&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"&gt;&lt;div style="display: inline; font-weight: normal"&gt;Warrant liabilities issued &lt;br /&gt; December 3, 2013&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;March 31, &lt;br /&gt; 2019&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; font-style: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; font-style: normal; text-align: right"&gt;March 31, &lt;br /&gt; 2018&lt;/td&gt; &lt;td style="font-weight: normal; font-style: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;March 31, &lt;br /&gt; 2019&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; font-style: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; font-style: normal; text-align: right"&gt;March 31, &lt;br /&gt; 2018&lt;/td&gt; &lt;td style="font-weight: normal; font-style: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"&gt;March 31, &lt;br /&gt; 2019&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; font-style: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; font-style: normal; text-align: right"&gt;March 31, &lt;br /&gt; 2018&lt;/td&gt; &lt;td style="font-weight: normal; font-style: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 34%; font-weight: normal"&gt;Balance &amp;#x2013; beginning of period&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,405&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 8%; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;209&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal"&gt;Issued during period&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,272&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,873&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; text-indent: -4.95pt; padding-left: 4.95pt"&gt;Exercised during period&lt;/td&gt; &lt;td style="font-weight: normal"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(722&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: normal; text-align: left"&gt;)&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; text-indent: -4.95pt; padding-left: 4.95pt"&gt;Change in fair value of derivative warrant liabilities&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,696&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,612&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;532&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(21&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(188&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;Balance &amp;#x2013; end of period&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,246&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,017&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,405&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: right"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="white-space: nowrap; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;Fair value per share issuable&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.81&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.82&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.65&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-weight: normal; border-bottom: Black 1.5pt solid"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.01&lt;/div&gt;&lt;/td&gt; &lt;td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities>
  <ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease contextRef="i_2018-03-31_ArrangementsInvolvingLegalFormOfLeaseAxis-LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember_MaturityAxis-LaterThanOneYearAndNotLaterThanTwoYearsMember" decimals="-3" id="c47924797" unitRef="iso4217-cad">79000</ifrs-full:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease>
  <ifrs-full:NetForeignExchangeGain contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924059" unitRef="iso4217-cad">279000</ifrs-full:NetForeignExchangeGain>
  <ifrs-full:NetForeignExchangeGain contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924060" unitRef="iso4217-cad">-32000</ifrs-full:NetForeignExchangeGain>
  <ifrs-full:NetForeignExchangeGain contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924061" unitRef="iso4217-cad">-180000</ifrs-full:NetForeignExchangeGain>
  <ifrs-full:NetForeignExchangeGain contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924062" unitRef="iso4217-cad">-3000</ifrs-full:NetForeignExchangeGain>
  <ifrs-full:NetForeignExchangeGain contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924063" unitRef="iso4217-cad">-177000</ifrs-full:NetForeignExchangeGain>
  <ifrs-full:NoncurrentDebtInstrumentsIssued contextRef="i_2019-03-31" id="c47922441" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:NoncurrentDebtInstrumentsIssued contextRef="i_2018-03-31" decimals="-3" id="c47922442" unitRef="iso4217-cad">1612000</ifrs-full:NoncurrentDebtInstrumentsIssued>
  <ifrs-full:NotionalAmount contextRef="i_2017-02-21_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="-4" id="c47923657" unitRef="iso4217-cad">2000000</ifrs-full:NotionalAmount>
  <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement contextRef="d_2019-04-15_2019-04-15_NonadjustingEventsAfterReportingPeriodAxis-MajorOrdinaryShareTransactionsMember_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924861" unitRef="xbrli-pure">644117</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="i_2019-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationEquityIncentivePlanMember" decimals="INF" id="c47924147" unitRef="xbrli-pure">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="i_2018-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationEquityIncentivePlanMember" decimals="INF" id="c47924153" unitRef="xbrli-pure">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeOneOfExercisesPricesMember" decimals="INF" id="c47924388" unitRef="xbrli-pure">1898523</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeTwoOfExercisesPricesMember" decimals="INF" id="c47924394" unitRef="xbrli-pure">775000</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeThreeOfExercisesPricesMember" decimals="INF" id="c47924400" unitRef="xbrli-pure">273333</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFourOfExercisesPricesMember" decimals="INF" id="c47924406" unitRef="xbrli-pure">790833</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFiveOfExercisesPricesMember" decimals="INF" id="c47924412" unitRef="xbrli-pure">308988</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="i_2019-03-31" decimals="INF" id="c47924418" unitRef="xbrli-pure">4046677</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="i_2018-03-31" decimals="INF" id="c47924166" unitRef="xbrli-pure">2284388</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="i_2017-03-31" decimals="INF" id="c47924168" unitRef="xbrli-pure">1424788</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="i_2016-02-29" decimals="INF" id="c47924268" unitRef="xbrli-pure">454151</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfOutstandingShareOptions contextRef="i_2017-02-28" decimals="INF" id="c47924270" unitRef="xbrli-pure">1427288</ifrs-full:NumberOfOutstandingShareOptions>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeOneOfExercisesPricesMember" decimals="INF" id="c47924390" unitRef="xbrli-pure">348197</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeTwoOfExercisesPricesMember" decimals="INF" id="c47924396" unitRef="xbrli-pure">518750</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeThreeOfExercisesPricesMember" decimals="INF" id="c47924402" unitRef="xbrli-pure">233333</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFourOfExercisesPricesMember" decimals="INF" id="c47924408" unitRef="xbrli-pure">292500</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFiveOfExercisesPricesMember" decimals="INF" id="c47924414" unitRef="xbrli-pure">220420</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2019-03-31" decimals="INF" id="c47924420" unitRef="xbrli-pure">1613200</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2018-03-31" decimals="INF" id="c47924252" unitRef="xbrli-pure">591113</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2017-03-31" decimals="INF" id="c47924338" unitRef="xbrli-pure">238482</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2017-02-28" decimals="INF" id="c47924342" unitRef="xbrli-pure">240982</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="d_2018-04-01_2019-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924125" unitRef="xbrli-pure">4167</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="d_2017-04-01_2018-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924126" unitRef="xbrli-pure">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="d_2016-03-01_2017-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924127" unitRef="xbrli-pure">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47924194" unitRef="xbrli-pure">4167</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="d_2017-04-01_2018-03-31" id="c47924196" unitRef="xbrli-pure" xs:nil="true"/>
  <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="d_2018-04-01_2019-03-31" id="c47924222" unitRef="xbrli-pure" xs:nil="true"/>
  <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="d_2017-04-01_2018-03-31" decimals="INF" id="c47924224" unitRef="xbrli-pure">62100</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="d_2016-03-01_2017-03-31" decimals="INF" id="c47924310" unitRef="xbrli-pure">139625</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="d_2017-03-01_2017-03-31" id="c47924312" unitRef="xbrli-pure" xs:nil="true"/>
  <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="d_2016-03-01_2017-02-28" decimals="INF" id="c47924314" unitRef="xbrli-pure">139625</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47924208" unitRef="xbrli-pure">407067</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="d_2017-04-01_2018-03-31" decimals="INF" id="c47924210" unitRef="xbrli-pure">199800</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="d_2016-03-01_2017-03-31" decimals="INF" id="c47924296" unitRef="xbrli-pure">190138</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="d_2017-03-01_2017-03-31" decimals="INF" id="c47924298" unitRef="xbrli-pure">2500</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="d_2016-03-01_2017-02-28" decimals="INF" id="c47924300" unitRef="xbrli-pure">187638</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="d_2017-03-01_2017-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924120" unitRef="xbrli-pure">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="d_2016-03-01_2017-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924121" unitRef="xbrli-pure">0</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47924180" unitRef="xbrli-pure">2173523</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="d_2017-04-01_2018-03-31" decimals="INF" id="c47924182" unitRef="xbrli-pure">1121500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="d_2016-03-01_2017-03-31" decimals="INF" id="c47924282" unitRef="xbrli-pure">1300400</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="d_2017-03-01_2017-03-31" id="c47924284" unitRef="xbrli-pure" xs:nil="true"/>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="d_2016-03-01_2017-02-28" decimals="INF" id="c47924286" unitRef="xbrli-pure">1300400</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfSharesIssued contextRef="i_2019-03-31_ClassesOfShareCapitalAxis-ClassCSharesMember" decimals="INF" id="c47923870" unitRef="xbrli-shares">0</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesIssued contextRef="i_2019-03-31_ClassesOfShareCapitalAxis-ClassBSharesMember" decimals="INF" id="c47923871" unitRef="xbrli-shares">0</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesIssued contextRef="i_2019-03-31_ClassesOfShareCapitalAxis-ClassASharesMember" decimals="INF" id="c47923872" unitRef="xbrli-shares">0</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesIssued contextRef="i_2019-03-31_ClassesOfShareCapitalAxis-ClassDAndESharesMember" decimals="INF" id="c47923873" unitRef="xbrli-shares">0</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesOutstanding contextRef="i_2019-03-31_ClassesOfShareCapitalAxis-ClassCSharesMember" decimals="INF" id="c47923874" unitRef="xbrli-shares">0</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="i_2019-03-31_ClassesOfShareCapitalAxis-ClassASharesMember" decimals="INF" id="c47923875" unitRef="xbrli-shares">0</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="i_2019-03-31_ClassesOfShareCapitalAxis-ClassBSharesMember" decimals="INF" id="c47923876" unitRef="xbrli-shares">0</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="i_2018-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922535" unitRef="xbrli-shares">25638215</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="i_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922593" unitRef="xbrli-shares">78132734</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="i_2017-03-31_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922600" unitRef="xbrli-shares">14702556</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="i_2016-02-29_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922665" unitRef="xbrli-shares">10712038</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="i_2017-02-28_ComponentsOfEquityAxis-IssuedCapitalMember" decimals="INF" id="c47922772" unitRef="xbrli-shares">14702556</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922836" unitRef="iso4217-cad">8090000</ifrs-full:OtherAdjustmentsForNoncashItems>
  <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922837" unitRef="iso4217-cad">3583000</ifrs-full:OtherAdjustmentsForNoncashItems>
  <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922838" unitRef="iso4217-cad">792000</ifrs-full:OtherAdjustmentsForNoncashItems>
  <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922839" unitRef="iso4217-cad">-328000</ifrs-full:OtherAdjustmentsForNoncashItems>
  <ifrs-full:OtherAdjustmentsForNoncashItems contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922840" unitRef="iso4217-cad">1120000</ifrs-full:OtherAdjustmentsForNoncashItems>
  <ifrs-full:OtherAssets contextRef="i_2018-03-31" decimals="-3" id="c47923217" unitRef="iso4217-cad">659000</ifrs-full:OtherAssets>
  <ifrs-full:OtherAssets contextRef="i_2017-03-31" id="c47923218" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:OtherAssets contextRef="i_2019-03-31" decimals="-3" id="c47923223" unitRef="iso4217-cad">622000</ifrs-full:OtherAssets>
  <ifrs-full:OtherComprehensiveIncomeBeforeTax contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922505" unitRef="iso4217-cad">-51566000</ifrs-full:OtherComprehensiveIncomeBeforeTax>
  <ifrs-full:OtherComprehensiveIncomeBeforeTax contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922506" unitRef="iso4217-cad">-21504000</ifrs-full:OtherComprehensiveIncomeBeforeTax>
  <ifrs-full:OtherComprehensiveIncomeBeforeTax contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922507" unitRef="iso4217-cad">-11376000</ifrs-full:OtherComprehensiveIncomeBeforeTax>
  <ifrs-full:OtherComprehensiveIncomeBeforeTax contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922508" unitRef="iso4217-cad">-769000</ifrs-full:OtherComprehensiveIncomeBeforeTax>
  <ifrs-full:OtherComprehensiveIncomeBeforeTax contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922509" unitRef="iso4217-cad">-10607000</ifrs-full:OtherComprehensiveIncomeBeforeTax>
  <ifrs-full:OtherCurrentAssets contextRef="i_2019-03-31" decimals="-3" id="c47923225" unitRef="iso4217-cad">65000</ifrs-full:OtherCurrentAssets>
  <ifrs-full:OtherCurrentAssets contextRef="i_2018-03-31" decimals="-3" id="c47923226" unitRef="iso4217-cad">104000</ifrs-full:OtherCurrentAssets>
  <ifrs-full:OtherCurrentReceivables contextRef="i_2019-03-31" decimals="-3" id="c47923173" unitRef="iso4217-cad">16000</ifrs-full:OtherCurrentReceivables>
  <ifrs-full:OtherCurrentReceivables contextRef="i_2018-03-31" decimals="-3" id="c47923174" unitRef="iso4217-cad">7000</ifrs-full:OtherCurrentReceivables>
  <ifrs-full:OtherEquityInterest contextRef="i_2019-03-31" decimals="-3" id="c47922451" unitRef="iso4217-cad">309000</ifrs-full:OtherEquityInterest>
  <ifrs-full:OtherEquityInterest contextRef="i_2018-03-31" decimals="-3" id="c47922452" unitRef="iso4217-cad">309000</ifrs-full:OtherEquityInterest>
  <ifrs-full:OtherExpenseByNature contextRef="d_2018-04-01_2019-03-31" id="c47924084" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:OtherExpenseByNature contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924085" unitRef="iso4217-cad">4000</ifrs-full:OtherExpenseByNature>
  <ifrs-full:OtherExpenseByNature contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924086" unitRef="iso4217-cad">19000</ifrs-full:OtherExpenseByNature>
  <ifrs-full:OtherExpenseByNature contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924087" unitRef="iso4217-cad">1000</ifrs-full:OtherExpenseByNature>
  <ifrs-full:OtherExpenseByNature contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924088" unitRef="iso4217-cad">18000</ifrs-full:OtherExpenseByNature>
  <ifrs-full:OtherNoncurrentAssets contextRef="i_2019-03-31" decimals="-3" id="c47923227" unitRef="iso4217-cad">557000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:OtherNoncurrentAssets contextRef="i_2018-03-31" decimals="-3" id="c47923228" unitRef="iso4217-cad">555000</ifrs-full:OtherNoncurrentAssets>
  <ifrs-full:PaymentsForShareIssueCosts contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922910" unitRef="iso4217-cad">-3000</ifrs-full:PaymentsForShareIssueCosts>
  <ifrs-full:PaymentsForShareIssueCosts contextRef="d_2017-04-01_2018-03-31" id="c47922911" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:PaymentsForShareIssueCosts contextRef="d_2016-03-01_2017-03-31" id="c47922912" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:PaymentsForShareIssueCosts contextRef="d_2017-03-01_2017-03-31" id="c47922913" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:PaymentsForShareIssueCosts contextRef="d_2016-03-01_2017-02-28" id="c47922914" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="d_2017-02-21_2017-02-21_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember" decimals="-4" id="c47923662" unitRef="iso4217-cad">1930000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:ProceedsFromIssuingShares contextRef="d_2019-02-14_2019-03-31" decimals="INF" id="c47923717" unitRef="iso4217-cad">0</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares contextRef="d_2018-10-01_2018-10-31" decimals="INF" id="c47923724" unitRef="iso4217-cad">22600000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares contextRef="d_2018-10-01_2018-10-31" decimals="-5" id="c47923725" unitRef="iso4217-usd">17400000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares contextRef="d_2018-10-23_2018-10-23" decimals="INF" id="c47923738" unitRef="iso4217-cad">25400000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922892" unitRef="iso4217-cad">57892000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922893" unitRef="iso4217-cad">11065000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922894" unitRef="iso4217-cad">5010000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922895" unitRef="iso4217-cad">-34000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromIssuingShares contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922896" unitRef="iso4217-cad">5044000</ifrs-full:ProceedsFromIssuingShares>
  <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="d_2018-04-01_2019-03-31" id="c47922873" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="d_2017-04-01_2018-03-31" id="c47922874" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922875" unitRef="iso4217-cad">22030000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="d_2017-03-01_2017-03-31" id="c47922876" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922877" unitRef="iso4217-cad">22030000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
  <ifrs-full:ProfitLoss contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922786" unitRef="iso4217-cad">-51566000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922787" unitRef="iso4217-cad">-21504000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922788" unitRef="iso4217-cad">-11247000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922789" unitRef="iso4217-cad">-769000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922790" unitRef="iso4217-cad">-10478000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922493" unitRef="iso4217-cad">-45015000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922494" unitRef="iso4217-cad">-19696000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922495" unitRef="iso4217-cad">-11210000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922496" unitRef="iso4217-cad">-718000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922497" unitRef="iso4217-cad">-10492000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923385" unitRef="iso4217-cad">59000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923386" unitRef="iso4217-cad">3000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923387" unitRef="iso4217-cad">336000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" id="c47923388" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" decimals="-3" id="c47923389" unitRef="iso4217-cad">398000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923395" unitRef="iso4217-cad">59000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923396" unitRef="iso4217-cad">11000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923397" unitRef="iso4217-cad">522000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923398" unitRef="iso4217-cad">2484000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" decimals="-3" id="c47923399" unitRef="iso4217-cad">3076000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923410" unitRef="iso4217-cad">59000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923411" unitRef="iso4217-cad">11000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923412" unitRef="iso4217-cad">522000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923413" unitRef="iso4217-cad">2527000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" decimals="-3" id="c47923414" unitRef="iso4217-cad">3119000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923420" unitRef="iso4217-cad">63000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923421" unitRef="iso4217-cad">17000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923422" unitRef="iso4217-cad">714000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923423" unitRef="iso4217-cad">2708000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" decimals="-3" id="c47923424" unitRef="iso4217-cad">3502000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923430" unitRef="iso4217-cad">68000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923431" unitRef="iso4217-cad">30000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923432" unitRef="iso4217-cad">933000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923433" unitRef="iso4217-cad">2968000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember" decimals="-3" id="c47923434" unitRef="iso4217-cad">3999000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923436" unitRef="iso4217-cad">52000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923437" unitRef="iso4217-cad">3000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923438" unitRef="iso4217-cad">56000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" id="c47923439" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923440" unitRef="iso4217-cad">111000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923446" unitRef="iso4217-cad">59000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923447" unitRef="iso4217-cad">4000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923448" unitRef="iso4217-cad">185000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923449" unitRef="iso4217-cad">52000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923450" unitRef="iso4217-cad">300000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923461" unitRef="iso4217-cad">59000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923462" unitRef="iso4217-cad">4000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923463" unitRef="iso4217-cad">196000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923464" unitRef="iso4217-cad">73000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923465" unitRef="iso4217-cad">332000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923471" unitRef="iso4217-cad">59000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923472" unitRef="iso4217-cad">7000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923473" unitRef="iso4217-cad">303000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923474" unitRef="iso4217-cad">312000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923475" unitRef="iso4217-cad">681000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923481" unitRef="iso4217-cad">60000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923482" unitRef="iso4217-cad">14000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923483" unitRef="iso4217-cad">483000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923484" unitRef="iso4217-cad">629000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember" decimals="-3" id="c47923485" unitRef="iso4217-cad">1186000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2018-03-31_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923487" unitRef="iso4217-cad">4000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2018-03-31_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923488" unitRef="iso4217-cad">10000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2018-03-31_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923489" unitRef="iso4217-cad">411000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2018-03-31_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923490" unitRef="iso4217-cad">2396000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2018-03-31" decimals="-3" id="c47923491" unitRef="iso4217-cad">2821000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember" decimals="-3" id="c47923492" unitRef="iso4217-cad">8000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember" decimals="-3" id="c47923493" unitRef="iso4217-cad">16000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember" decimals="-3" id="c47923494" unitRef="iso4217-cad">450000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember" decimals="-3" id="c47923495" unitRef="iso4217-cad">2339000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="i_2019-03-31" decimals="-3" id="c47923496" unitRef="iso4217-cad">2813000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922867" unitRef="iso4217-cad">23753000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922868" unitRef="iso4217-cad">26000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="d_2016-03-01_2017-03-31" id="c47922869" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="d_2017-03-01_2017-03-31" id="c47922870" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="d_2016-03-01_2017-02-28" id="c47922871" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922879" unitRef="iso4217-cad">-11933000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="d_2017-04-01_2018-03-31" id="c47922880" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="d_2016-03-01_2017-03-31" id="c47922881" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="d_2017-03-01_2017-03-31" id="c47922882" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="d_2016-03-01_2017-02-28" id="c47922883" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922855" unitRef="iso4217-cad">700000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922856" unitRef="iso4217-cad">455000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922857" unitRef="iso4217-cad">2527000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922858" unitRef="iso4217-cad">24000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922859" unitRef="iso4217-cad">2503000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47922481" unitRef="iso4217-cad">38366000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47922482" unitRef="iso4217-cad">15669000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47922483" unitRef="iso4217-cad">7653000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47922484" unitRef="iso4217-cad">426000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47922485" unitRef="iso4217-cad">7227000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2018-04-01_2019-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SuppliesAndIncrementalCostsMember" id="c47923283" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2017-04-01_2018-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SuppliesAndIncrementalCostsMember" decimals="-3" id="c47923284" unitRef="iso4217-cad">7000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2016-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SuppliesAndIncrementalCostsMember" id="c47923285" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2017-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SuppliesAndIncrementalCostsMember" id="c47923286" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2016-03-01_2017-02-28_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SuppliesAndIncrementalCostsMember" id="c47923287" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2018-04-01_2019-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SharedServiceAgreementMember" id="c47923288" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2017-04-01_2018-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SharedServiceAgreementMember" decimals="-3" id="c47923289" unitRef="iso4217-cad">20000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2016-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SharedServiceAgreementMember" decimals="-3" id="c47923290" unitRef="iso4217-cad">60000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2017-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SharedServiceAgreementMember" decimals="-3" id="c47923291" unitRef="iso4217-cad">1000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2016-03-01_2017-02-28_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SharedServiceAgreementMember" decimals="-3" id="c47923292" unitRef="iso4217-cad">59000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2018-04-01_2019-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember" id="c47923293" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2017-04-01_2018-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923294" unitRef="iso4217-cad">27000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2016-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923295" unitRef="iso4217-cad">60000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2017-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923296" unitRef="iso4217-cad">1000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="d_2016-03-01_2017-02-28_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923297" unitRef="iso4217-cad">59000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:RetainedEarnings contextRef="i_2019-03-31" decimals="-3" id="c47922457" unitRef="iso4217-cad">-123945000</ifrs-full:RetainedEarnings>
  <ifrs-full:RetainedEarnings contextRef="i_2018-03-31" decimals="-3" id="c47922458" unitRef="iso4217-cad">-72379000</ifrs-full:RetainedEarnings>
  <ifrs-full:RevenueFromGovernmentGrants contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47923350" unitRef="iso4217-cad">7000</ifrs-full:RevenueFromGovernmentGrants>
  <ifrs-full:RevenueFromGovernmentGrants contextRef="d_2017-04-01_2018-03-31" id="c47923351" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:RevenueFromGovernmentGrants contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47923352" unitRef="iso4217-cad">227000</ifrs-full:RevenueFromGovernmentGrants>
  <ifrs-full:RevenueFromGovernmentGrants contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47923353" unitRef="iso4217-cad">37000</ifrs-full:RevenueFromGovernmentGrants>
  <ifrs-full:RevenueFromGovernmentGrants contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47923354" unitRef="iso4217-cad">190000</ifrs-full:RevenueFromGovernmentGrants>
  <ifrs-full:RevenueFromInterest contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924054" unitRef="iso4217-cad">475000</ifrs-full:RevenueFromInterest>
  <ifrs-full:RevenueFromInterest contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924055" unitRef="iso4217-cad">72000</ifrs-full:RevenueFromInterest>
  <ifrs-full:RevenueFromInterest contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924056" unitRef="iso4217-cad">125000</ifrs-full:RevenueFromInterest>
  <ifrs-full:RevenueFromInterest contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924057" unitRef="iso4217-cad">6000</ifrs-full:RevenueFromInterest>
  <ifrs-full:RevenueFromInterest contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924058" unitRef="iso4217-cad">119000</ifrs-full:RevenueFromInterest>
  <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="i_2019-03-31" decimals="-3" id="c47923566" unitRef="iso4217-cad">1054000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
  <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="i_2018-03-31" decimals="-3" id="c47923567" unitRef="iso4217-cad">754000</ifrs-full:ShorttermEmployeeBenefitsAccruals>
  <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924033" unitRef="iso4217-cad">4144000</ifrs-full:ShorttermEmployeeBenefitsExpense>
  <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924034" unitRef="iso4217-cad">3281000</ifrs-full:ShorttermEmployeeBenefitsExpense>
  <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924035" unitRef="iso4217-cad">2491000</ifrs-full:ShorttermEmployeeBenefitsExpense>
  <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924036" unitRef="iso4217-cad">214000</ifrs-full:ShorttermEmployeeBenefitsExpense>
  <ifrs-full:ShorttermEmployeeBenefitsExpense contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924037" unitRef="iso4217-cad">2277000</ifrs-full:ShorttermEmployeeBenefitsExpense>
  <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924532" unitRef="iso4217-cad">11599000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense>
  <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924533" unitRef="iso4217-cad">5241000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense>
  <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924534" unitRef="iso4217-cad">2369000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense>
  <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924535" unitRef="iso4217-cad">163000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense>
  <ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924536" unitRef="iso4217-cad">2206000</ifrs-full:TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense>
  <ifrs-full:TaxEffectFromChangeInTaxRate contextRef="d_2018-04-01_2019-03-31" id="c47924583" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:TaxEffectFromChangeInTaxRate contextRef="d_2017-04-01_2018-03-31" id="c47924584" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:TaxEffectFromChangeInTaxRate contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924585" unitRef="iso4217-cad">201000</ifrs-full:TaxEffectFromChangeInTaxRate>
  <ifrs-full:TaxEffectFromChangeInTaxRate contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924586" unitRef="iso4217-cad">3000</ifrs-full:TaxEffectFromChangeInTaxRate>
  <ifrs-full:TaxEffectFromChangeInTaxRate contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924587" unitRef="iso4217-cad">198000</ifrs-full:TaxEffectFromChangeInTaxRate>
  <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="d_2018-04-01_2019-03-31" decimals="-3" id="c47924557" unitRef="iso4217-cad">-13758000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
  <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="d_2017-04-01_2018-03-31" decimals="-3" id="c47924558" unitRef="iso4217-cad">-5759000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
  <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="d_2016-03-01_2017-03-31" decimals="-3" id="c47924559" unitRef="iso4217-cad">-3057000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
  <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="d_2017-03-01_2017-03-31" decimals="-3" id="c47924560" unitRef="iso4217-cad">-206000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
  <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="d_2016-03-01_2017-02-28" decimals="-3" id="c47924561" unitRef="iso4217-cad">-2851000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
  <ifrs-full:TradeAndOtherCurrentPayables contextRef="i_2019-03-31" decimals="-3" id="c47923572" unitRef="iso4217-cad">16429000</ifrs-full:TradeAndOtherCurrentPayables>
  <ifrs-full:TradeAndOtherCurrentPayables contextRef="i_2018-03-31" decimals="-3" id="c47923573" unitRef="iso4217-cad">6697000</ifrs-full:TradeAndOtherCurrentPayables>
  <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties contextRef="i_2019-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923237" unitRef="iso4217-cad">2000</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
  <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties contextRef="i_2018-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember" decimals="-3" id="c47923238" unitRef="iso4217-cad">44000</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
  <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties contextRef="i_2019-03-31" decimals="-3" id="c47923570" unitRef="iso4217-cad">2000</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
  <ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties contextRef="i_2018-03-31" decimals="-3" id="c47923571" unitRef="iso4217-cad">44000</ifrs-full:TradeAndOtherCurrentPayablesToRelatedParties>
  <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="i_2019-03-31" decimals="-3" id="c47923562" unitRef="iso4217-cad">4064000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
  <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="i_2018-03-31" decimals="-3" id="c47923563" unitRef="iso4217-cad">3420000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
  <ifrs-full:TradeAndOtherCurrentReceivables contextRef="i_2019-03-31" decimals="-3" id="c47923176" unitRef="iso4217-cad">1586000</ifrs-full:TradeAndOtherCurrentReceivables>
  <ifrs-full:TradeAndOtherCurrentReceivables contextRef="i_2018-03-31" decimals="-3" id="c47923177" unitRef="iso4217-cad">759000</ifrs-full:TradeAndOtherCurrentReceivables>
  <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_MaturityAxis-LaterThanElevenYearsAndNotLaterThanTwelveYearsMember" decimals="-3" id="c47923360" unitRef="iso4217-cad">11000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_MaturityAxis-LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember" decimals="-3" id="c47923361" unitRef="iso4217-cad">30000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_MaturityAxis-LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember" decimals="-3" id="c47923362" unitRef="iso4217-cad">45000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_MaturityAxis-LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember" decimals="-3" id="c47923363" unitRef="iso4217-cad">431000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_MaturityAxis-LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember" decimals="-3" id="c47923364" unitRef="iso4217-cad">441000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_MaturityAxis-LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember" decimals="-3" id="c47923365" unitRef="iso4217-cad">436000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_MaturityAxis-LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember" decimals="-3" id="c47923366" unitRef="iso4217-cad">519000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_MaturityAxis-LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember" decimals="-3" id="c47923367" unitRef="iso4217-cad">286000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_MaturityAxis-LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember" decimals="-3" id="c47923368" unitRef="iso4217-cad">315000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_MaturityAxis-LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember" decimals="-3" id="c47923369" unitRef="iso4217-cad">324000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_MaturityAxis-LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember" decimals="-3" id="c47923370" unitRef="iso4217-cad">329000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31" decimals="-3" id="c47923371" unitRef="iso4217-cad">3167000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember" decimals="-3" id="c47924647" unitRef="iso4217-cad">19617000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-ProvincialMember" decimals="-3" id="c47924648" unitRef="iso4217-cad">21036000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandTwentyNineMember" decimals="-3" id="c47924623" unitRef="iso4217-cad">714000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandTwentyNineMember" decimals="-3" id="c47924624" unitRef="iso4217-cad">714000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtyMember" decimals="-3" id="c47924625" unitRef="iso4217-cad">1627000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtyMember" decimals="-3" id="c47924626" unitRef="iso4217-cad">1620000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtyOneMember" decimals="-3" id="c47924627" unitRef="iso4217-cad">2071000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtyOneMember" decimals="-3" id="c47924628" unitRef="iso4217-cad">2063000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtyTwoMember" decimals="-3" id="c47924629" unitRef="iso4217-cad">2262000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtyTwoMember" decimals="-3" id="c47924630" unitRef="iso4217-cad">2241000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtyThreeMember" decimals="-3" id="c47924631" unitRef="iso4217-cad">1854000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtyThreeMember" decimals="-3" id="c47924632" unitRef="iso4217-cad">1825000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtyFourMember" decimals="-3" id="c47924633" unitRef="iso4217-cad">3598000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtyFourMember" decimals="-3" id="c47924634" unitRef="iso4217-cad">3598000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtyFiveMember" decimals="-3" id="c47924635" unitRef="iso4217-cad">4595000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtyFiveMember" decimals="-3" id="c47924636" unitRef="iso4217-cad">4459000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtySixMember" decimals="-3" id="c47924637" unitRef="iso4217-cad">5494000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtySixMember" decimals="-3" id="c47924638" unitRef="iso4217-cad">5494000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThouandThirtySevenMember" decimals="-3" id="c47924639" unitRef="iso4217-cad">8584000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThouandThirtySevenMember" decimals="-3" id="c47924640" unitRef="iso4217-cad">8456000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThouandThirtyEightMember" decimals="-3" id="c47924641" unitRef="iso4217-cad">17340000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThouandThirtyEightMember" decimals="-3" id="c47924642" unitRef="iso4217-cad">17270000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtyNineMember" decimals="-3" id="c47924643" unitRef="iso4217-cad">41447000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtyNineMember" decimals="-3" id="c47924644" unitRef="iso4217-cad">41447000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember" decimals="-3" id="c47924645" unitRef="iso4217-cad">89586000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="i_2019-03-31_GeographicalAreasAxis-ProvincialMember" decimals="-3" id="c47924646" unitRef="iso4217-cad">89187000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeOneOfExercisesPricesMember" decimals="INF" id="c47924389" unitRef="iso4217-cad">0.77</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeTwoOfExercisesPricesMember" decimals="INF" id="c47924395" unitRef="iso4217-cad">1.50</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeThreeOfExercisesPricesMember" decimals="INF" id="c47924401" unitRef="iso4217-cad">1.65</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFourOfExercisesPricesMember" decimals="INF" id="c47924407" unitRef="iso4217-cad">1.77</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFiveOfExercisesPricesMember" decimals="INF" id="c47924413" unitRef="iso4217-cad">2.57</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2019-03-31" decimals="INF" id="c47924419" unitRef="iso4217-cad">1.56</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2018-03-31" decimals="INF" id="c47924251" unitRef="iso4217-cad">1.92</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2017-03-31" decimals="INF" id="c47924337" unitRef="iso4217-cad">6.44</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="i_2017-02-28" decimals="INF" id="c47924341" unitRef="iso4217-cad">6.49</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47924193" unitRef="iso4217-cad">0.77</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="d_2017-04-01_2018-03-31" id="c47924195" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="d_2018-04-01_2019-03-31" id="c47924221" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="d_2017-04-01_2018-03-31" decimals="INF" id="c47924223" unitRef="iso4217-cad">18.06</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="d_2016-03-01_2017-03-31" decimals="INF" id="c47924309" unitRef="iso4217-cad">15.38</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="d_2017-03-01_2017-03-31" id="c47924311" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="d_2016-03-01_2017-02-28" decimals="INF" id="c47924313" unitRef="iso4217-cad">15.38</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47924207" unitRef="iso4217-cad">1.84</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="d_2017-04-01_2018-03-31" decimals="INF" id="c47924209" unitRef="iso4217-cad">1.89</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="d_2016-03-01_2017-03-31" decimals="INF" id="c47924295" unitRef="iso4217-cad">13.27</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="d_2017-03-01_2017-03-31" decimals="INF" id="c47924297" unitRef="iso4217-cad">11.50</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="d_2016-03-01_2017-02-28" decimals="INF" id="c47924299" unitRef="iso4217-cad">13.29</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="d_2019-04-15_2019-04-15_NonadjustingEventsAfterReportingPeriodAxis-MajorOrdinaryShareTransactionsMember_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924865" unitRef="iso4217-cad">1.28</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47924179" unitRef="iso4217-cad">0.77</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="d_2017-04-01_2018-03-31" decimals="INF" id="c47924181" unitRef="iso4217-cad">1.75</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="d_2016-03-01_2017-03-31" decimals="INF" id="c47924281" unitRef="iso4217-cad">1.69</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="d_2017-03-01_2017-03-31" id="c47924283" unitRef="iso4217-cad" xs:nil="true"/>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="d_2016-03-01_2017-02-28" decimals="INF" id="c47924285" unitRef="iso4217-cad">1.69</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="i_2018-03-31" decimals="INF" id="c47924165" unitRef="iso4217-cad">1.81</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="i_2017-03-31" decimals="INF" id="c47924167" unitRef="iso4217-cad">2.58</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="i_2019-03-31" decimals="INF" id="c47924235" unitRef="iso4217-cad">1.25</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="i_2016-02-29" decimals="INF" id="c47924267" unitRef="iso4217-cad">13.52</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="i_2017-02-08" decimals="INF" id="c47924269" unitRef="iso4217-cad">2.59</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement contextRef="i_2017-02-28" decimals="INF" id="c47924327" unitRef="iso4217-cad">2.59</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="i_2019-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924357" unitRef="iso4217-cad">0.51</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
  <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="i_2018-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924358" unitRef="iso4217-cad">1.22</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
  <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="i_2017-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924359" unitRef="iso4217-cad">1.40</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
  <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="i_2017-02-28_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember" decimals="INF" id="c47924360" unitRef="iso4217-cad">1.40</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeOneOfExercisesPricesMember" decimals="INF" id="c47924387" unitRef="xbrli-pure">9.26</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeTwoOfExercisesPricesMember" decimals="INF" id="c47924393" unitRef="xbrli-pure">5.86</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeThreeOfExercisesPricesMember" decimals="INF" id="c47924399" unitRef="xbrli-pure">7.9</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFourOfExercisesPricesMember" decimals="INF" id="c47924405" unitRef="xbrli-pure">8.21</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFiveOfExercisesPricesMember" decimals="INF" id="c47924411" unitRef="xbrli-pure">3.97</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions contextRef="i_2019-03-31" decimals="INF" id="c47924417" unitRef="xbrli-pure">7.91</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions>
  <ifrs-full:WeightedAverageSharePrice contextRef="d_2017-02-21_2017-02-21" decimals="INF" id="c47923815" unitRef="iso4217-cad">2.65</ifrs-full:WeightedAverageSharePrice>
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47924365" unitRef="iso4217-cad">0.73</ifrs-full:WeightedAverageSharePriceShareOptionsGranted>
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted contextRef="d_2017-03-01_2018-03-31" decimals="INF" id="c47924366" unitRef="iso4217-cad">1.75</ifrs-full:WeightedAverageSharePriceShareOptionsGranted>
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted contextRef="d_2016-03-01_2017-03-31" decimals="INF" id="c47924367" unitRef="iso4217-cad">1.69</ifrs-full:WeightedAverageSharePriceShareOptionsGranted>
  <ifrs-full:WeightedAverageSharePriceShareOptionsGranted contextRef="d_2016-03-01_2017-02-28" decimals="INF" id="c47924368" unitRef="iso4217-cad">1.69</ifrs-full:WeightedAverageSharePriceShareOptionsGranted>
  <ifrs-full:WeightedAverageShares contextRef="d_2018-04-01_2019-03-31" decimals="INF" id="c47922529" unitRef="xbrli-shares">54290295</ifrs-full:WeightedAverageShares>
  <ifrs-full:WeightedAverageShares contextRef="d_2017-04-01_2018-03-31" decimals="INF" id="c47922530" unitRef="xbrli-shares">17486515</ifrs-full:WeightedAverageShares>
  <ifrs-full:WeightedAverageShares contextRef="d_2016-03-01_2017-03-31" decimals="INF" id="c47922531" unitRef="xbrli-shares">11094512</ifrs-full:WeightedAverageShares>
  <ifrs-full:WeightedAverageShares contextRef="d_2017-03-01_2017-03-31" decimals="INF" id="c47922532" unitRef="xbrli-shares">14702556</ifrs-full:WeightedAverageShares>
  <ifrs-full:WeightedAverageShares contextRef="d_2016-03-01_2017-02-28" decimals="INF" id="c47922533" unitRef="xbrli-shares">10788075</ifrs-full:WeightedAverageShares>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="#c47924552" xlink:label="c47924552" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924552" xlink:to="f-82-1" xlink:type="arc"/>
    <link:loc xlink:href="#c47924553" xlink:label="c47924553" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924553" xlink:to="f-82-1" xlink:type="arc"/>
    <link:loc xlink:href="#c47924554" xlink:label="c47924554" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924554" xlink:to="f-82-1" xlink:type="arc"/>
    <link:loc xlink:href="#c47924555" xlink:label="c47924555" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924555" xlink:to="f-82-1" xlink:type="arc"/>
    <link:loc xlink:href="#c47924556" xlink:label="c47924556" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924556" xlink:to="f-82-1" xlink:type="arc"/>
    <link:footnote xlink:label="f-82-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Canadian combined statutory income tax rate has decreased due to a reduction in the provincial statutory income tax rate.</link:footnote>
    <link:loc xlink:href="#c47923957" xlink:label="c47923957" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923957" xlink:to="f-62-3" xlink:type="arc"/>
    <link:loc xlink:href="#c47923956" xlink:label="c47923956" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923956" xlink:to="f-62-3" xlink:type="arc"/>
    <link:loc xlink:href="#c47923955" xlink:label="c47923955" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923955" xlink:to="f-62-3" xlink:type="arc"/>
    <link:loc xlink:href="#c47923999" xlink:label="c47923999" xlink:type="locator"/>
    <link:footnoteArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923999" xlink:to="f-62-7" xlink:type="arc"/>
    <link:loc xlink:href="#c47923954" xlink:label="c47923954" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923954" xlink:to="f-62-3" xlink:type="arc"/>
    <link:loc xlink:href="#c47923998" xlink:label="c47923998" xlink:type="locator"/>
    <link:footnoteArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923998" xlink:to="f-62-7" xlink:type="arc"/>
    <link:loc xlink:href="#c47924009" xlink:label="c47924009" xlink:type="locator"/>
    <link:footnoteArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924009" xlink:to="f-62-8" xlink:type="arc"/>
    <link:loc xlink:href="#c47923953" xlink:label="c47923953" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923953" xlink:to="f-62-3" xlink:type="arc"/>
    <link:loc xlink:href="#c47923997" xlink:label="c47923997" xlink:type="locator"/>
    <link:footnoteArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923997" xlink:to="f-62-7" xlink:type="arc"/>
    <link:loc xlink:href="#c47924008" xlink:label="c47924008" xlink:type="locator"/>
    <link:footnoteArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924008" xlink:to="f-62-8" xlink:type="arc"/>
    <link:loc xlink:href="#c47923952" xlink:label="c47923952" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923952" xlink:to="f-62-3" xlink:type="arc"/>
    <link:loc xlink:href="#c47923996" xlink:label="c47923996" xlink:type="locator"/>
    <link:footnoteArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923996" xlink:to="f-62-7" xlink:type="arc"/>
    <link:loc xlink:href="#c47924007" xlink:label="c47924007" xlink:type="locator"/>
    <link:footnoteArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924007" xlink:to="f-62-8" xlink:type="arc"/>
    <link:loc xlink:href="#c47923951" xlink:label="c47923951" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923951" xlink:to="f-62-2" xlink:type="arc"/>
    <link:loc xlink:href="#c47923995" xlink:label="c47923995" xlink:type="locator"/>
    <link:footnoteArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923995" xlink:to="f-62-7" xlink:type="arc"/>
    <link:loc xlink:href="#c47924006" xlink:label="c47924006" xlink:type="locator"/>
    <link:footnoteArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924006" xlink:to="f-62-8" xlink:type="arc"/>
    <link:loc xlink:href="#c47923950" xlink:label="c47923950" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923950" xlink:to="f-62-2" xlink:type="arc"/>
    <link:loc xlink:href="#c47924005" xlink:label="c47924005" xlink:type="locator"/>
    <link:footnoteArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924005" xlink:to="f-62-8" xlink:type="arc"/>
    <link:loc xlink:href="#c47923959" xlink:label="c47923959" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923959" xlink:to="f-62-3" xlink:type="arc"/>
    <link:loc xlink:href="#c47923958" xlink:label="c47923958" xlink:type="locator"/>
    <link:footnoteArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923958" xlink:to="f-62-3" xlink:type="arc"/>
    <link:loc xlink:href="#c47924015" xlink:label="c47924015" xlink:type="locator"/>
    <link:footnoteArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924015" xlink:to="f-62-9" xlink:type="arc"/>
    <link:loc xlink:href="#c47924014" xlink:label="c47924014" xlink:type="locator"/>
    <link:footnoteArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924014" xlink:to="f-62-9" xlink:type="arc"/>
    <link:loc xlink:href="#c47924013" xlink:label="c47924013" xlink:type="locator"/>
    <link:footnoteArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924013" xlink:to="f-62-9" xlink:type="arc"/>
    <link:loc xlink:href="#c47924012" xlink:label="c47924012" xlink:type="locator"/>
    <link:footnoteArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924012" xlink:to="f-62-9" xlink:type="arc"/>
    <link:loc xlink:href="#c47924011" xlink:label="c47924011" xlink:type="locator"/>
    <link:footnoteArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924011" xlink:to="f-62-9" xlink:type="arc"/>
    <link:loc xlink:href="#c47924010" xlink:label="c47924010" xlink:type="locator"/>
    <link:footnoteArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924010" xlink:to="f-62-8" xlink:type="arc"/>
    <link:loc xlink:href="#c47924018" xlink:label="c47924018" xlink:type="locator"/>
    <link:footnoteArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924018" xlink:to="f-62-9" xlink:type="arc"/>
    <link:loc xlink:href="#c47924017" xlink:label="c47924017" xlink:type="locator"/>
    <link:footnoteArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924017" xlink:to="f-62-9" xlink:type="arc"/>
    <link:loc xlink:href="#c47924016" xlink:label="c47924016" xlink:type="locator"/>
    <link:footnoteArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924016" xlink:to="f-62-9" xlink:type="arc"/>
    <link:loc xlink:href="#c47923971" xlink:label="c47923971" xlink:type="locator"/>
    <link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923971" xlink:to="f-62-4" xlink:type="arc"/>
    <link:loc xlink:href="#c47923970" xlink:label="c47923970" xlink:type="locator"/>
    <link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923970" xlink:to="f-62-4" xlink:type="arc"/>
    <link:loc xlink:href="#c47923979" xlink:label="c47923979" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923979" xlink:to="f-62-5" xlink:type="arc"/>
    <link:loc xlink:href="#c47923978" xlink:label="c47923978" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923978" xlink:to="f-62-5" xlink:type="arc"/>
    <link:loc xlink:href="#c47923977" xlink:label="c47923977" xlink:type="locator"/>
    <link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923977" xlink:to="f-62-4" xlink:type="arc"/>
    <link:loc xlink:href="#c47923976" xlink:label="c47923976" xlink:type="locator"/>
    <link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923976" xlink:to="f-62-4" xlink:type="arc"/>
    <link:loc xlink:href="#c47923975" xlink:label="c47923975" xlink:type="locator"/>
    <link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923975" xlink:to="f-62-4" xlink:type="arc"/>
    <link:loc xlink:href="#c47923974" xlink:label="c47923974" xlink:type="locator"/>
    <link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923974" xlink:to="f-62-4" xlink:type="arc"/>
    <link:loc xlink:href="#c47923973" xlink:label="c47923973" xlink:type="locator"/>
    <link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923973" xlink:to="f-62-4" xlink:type="arc"/>
    <link:loc xlink:href="#c47923972" xlink:label="c47923972" xlink:type="locator"/>
    <link:footnoteArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923972" xlink:to="f-62-4" xlink:type="arc"/>
    <link:loc xlink:href="#c47923939" xlink:label="c47923939" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923939" xlink:to="f-62-1" xlink:type="arc"/>
    <link:loc xlink:href="#c47923938" xlink:label="c47923938" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923938" xlink:to="f-62-1" xlink:type="arc"/>
    <link:loc xlink:href="#c47923937" xlink:label="c47923937" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923937" xlink:to="f-62-1" xlink:type="arc"/>
    <link:loc xlink:href="#c47923936" xlink:label="c47923936" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923936" xlink:to="f-62-1" xlink:type="arc"/>
    <link:loc xlink:href="#c47923982" xlink:label="c47923982" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923982" xlink:to="f-62-5" xlink:type="arc"/>
    <link:loc xlink:href="#c47923981" xlink:label="c47923981" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923981" xlink:to="f-62-5" xlink:type="arc"/>
    <link:loc xlink:href="#c47923980" xlink:label="c47923980" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923980" xlink:to="f-62-5" xlink:type="arc"/>
    <link:loc xlink:href="#c47923946" xlink:label="c47923946" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923946" xlink:to="f-62-2" xlink:type="arc"/>
    <link:loc xlink:href="#c47923945" xlink:label="c47923945" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923945" xlink:to="f-62-2" xlink:type="arc"/>
    <link:loc xlink:href="#c47923989" xlink:label="c47923989" xlink:type="locator"/>
    <link:footnoteArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923989" xlink:to="f-62-6" xlink:type="arc"/>
    <link:loc xlink:href="#c47923944" xlink:label="c47923944" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923944" xlink:to="f-62-2" xlink:type="arc"/>
    <link:loc xlink:href="#c47923988" xlink:label="c47923988" xlink:type="locator"/>
    <link:footnoteArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923988" xlink:to="f-62-6" xlink:type="arc"/>
    <link:loc xlink:href="#c47923943" xlink:label="c47923943" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923943" xlink:to="f-62-1" xlink:type="arc"/>
    <link:loc xlink:href="#c47923987" xlink:label="c47923987" xlink:type="locator"/>
    <link:footnoteArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923987" xlink:to="f-62-6" xlink:type="arc"/>
    <link:loc xlink:href="#c47923942" xlink:label="c47923942" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923942" xlink:to="f-62-1" xlink:type="arc"/>
    <link:loc xlink:href="#c47923986" xlink:label="c47923986" xlink:type="locator"/>
    <link:footnoteArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923986" xlink:to="f-62-6" xlink:type="arc"/>
    <link:loc xlink:href="#c47923941" xlink:label="c47923941" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923941" xlink:to="f-62-1" xlink:type="arc"/>
    <link:loc xlink:href="#c47923985" xlink:label="c47923985" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923985" xlink:to="f-62-5" xlink:type="arc"/>
    <link:loc xlink:href="#c47923940" xlink:label="c47923940" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923940" xlink:to="f-62-1" xlink:type="arc"/>
    <link:loc xlink:href="#c47923984" xlink:label="c47923984" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923984" xlink:to="f-62-5" xlink:type="arc"/>
    <link:loc xlink:href="#c47923983" xlink:label="c47923983" xlink:type="locator"/>
    <link:footnoteArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923983" xlink:to="f-62-5" xlink:type="arc"/>
    <link:loc xlink:href="#c47923949" xlink:label="c47923949" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923949" xlink:to="f-62-2" xlink:type="arc"/>
    <link:loc xlink:href="#c47923948" xlink:label="c47923948" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923948" xlink:to="f-62-2" xlink:type="arc"/>
    <link:loc xlink:href="#c47923947" xlink:label="c47923947" xlink:type="locator"/>
    <link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923947" xlink:to="f-62-2" xlink:type="arc"/>
    <link:loc xlink:href="#c47923993" xlink:label="c47923993" xlink:type="locator"/>
    <link:footnoteArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923993" xlink:to="f-62-6" xlink:type="arc"/>
    <link:loc xlink:href="#c47924004" xlink:label="c47924004" xlink:type="locator"/>
    <link:footnoteArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924004" xlink:to="f-62-8" xlink:type="arc"/>
    <link:loc xlink:href="#c47923992" xlink:label="c47923992" xlink:type="locator"/>
    <link:footnoteArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923992" xlink:to="f-62-6" xlink:type="arc"/>
    <link:loc xlink:href="#c47924003" xlink:label="c47924003" xlink:type="locator"/>
    <link:footnoteArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924003" xlink:to="f-62-8" xlink:type="arc"/>
    <link:loc xlink:href="#c47923991" xlink:label="c47923991" xlink:type="locator"/>
    <link:footnoteArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923991" xlink:to="f-62-6" xlink:type="arc"/>
    <link:loc xlink:href="#c47924002" xlink:label="c47924002" xlink:type="locator"/>
    <link:footnoteArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924002" xlink:to="f-62-7" xlink:type="arc"/>
    <link:loc xlink:href="#c47923990" xlink:label="c47923990" xlink:type="locator"/>
    <link:footnoteArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47923990" xlink:to="f-62-6" xlink:type="arc"/>
    <link:loc xlink:href="#c47924001" xlink:label="c47924001" xlink:type="locator"/>
    <link:footnoteArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924001" xlink:to="f-62-7" xlink:type="arc"/>
    <link:loc xlink:href="#c47924000" xlink:label="c47924000" xlink:type="locator"/>
    <link:footnoteArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c47924000" xlink:to="f-62-7" xlink:type="arc"/>
    <link:footnote xlink:label="f-62-1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Warrant to acquire one Common Share of the Corporation at an exercise price of $1.31, expiring on May 9, 2023.</link:footnote>
    <link:footnote xlink:label="f-62-2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Warrant to acquire one Common Share of the Corporation at an exercise price of US$1.26, expiring on December 27, 2022.</link:footnote>
    <link:footnote xlink:label="f-62-3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In order to obtain one Common Share of the Corporation at an exercise price of US$15.00, 10 warrants must be exercised. Warrants expired on December 3, 2018.</link:footnote>
    <link:footnote xlink:label="f-62-4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Warrant to acquire one Common Share of the Corporation at an exercise price of $1.05, expiring on May 9, 2023.</link:footnote>
    <link:footnote xlink:label="f-62-5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Warrant to acquire one Common Share of the Corporation at an exercise price of US$1.2625, expiring on December 27, 2022.</link:footnote>
    <link:footnote xlink:label="f-62-6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Warrant to acquire one Common Share of the Corporation at an exercise price of $2.15, expiring on February 21, 2022.</link:footnote>
    <link:footnote xlink:label="f-62-7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Warrant to acquire one Common Share of the Corporation at an exercise price of $1.90 expiring on February 21, 2020, net of deferred tax expense of $129. Exercisable only for any portion of or all debentures paid by the Corporation prior to maturity.</link:footnote>
    <link:footnote xlink:label="f-62-8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Warrant to acquire one Common Share of the Corporation at an exercise price of $13.30, expired on December 3, 2018.</link:footnote>
    <link:footnote xlink:label="f-62-9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Warrant to acquire one Common Share of the Corporation at an exercise price of 2.15 expiring on February 21, 2018. 117,496 warrants amounted to $71 were exercised in November 2017 and 117,496 warrants expired on February 21, 2018</link:footnote>
  </link:footnoteLink>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-cad-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:CAD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="iso4217-cad">
    <xbrli:measure>iso4217:CAD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="d_2016-03-01_2017-02-28">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">acst:BiodrogaNutraceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_CategoriesOfRelatedPartiesAxis-NeptuneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SharedServiceAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">acst:SharedServiceAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SuppliesAndIncrementalCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">acst:SuppliesAndIncrementalCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedDecember272017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedDecember32013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-OtherEquityInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_ComponentsOfEquityAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-02-28_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-02-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">acst:BiodrogaNutraceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-KeyManagementPersonnelOfEntityOrParentMember_RangeAxis-TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SharedServiceAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">acst:SharedServiceAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SuppliesAndIncrementalCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">acst:SuppliesAndIncrementalCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_ComponentsOfEquityAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationEquityIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2017-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-03-01_2019-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-03-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:PublicOfferingWarrantsFebruary2017EquityPortionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-02-21_2017-02-21">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-02-21</xbrli:startDate>
      <xbrli:endDate>2017-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-02-21_2017-02-21_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:UnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-02-21</xbrli:startDate>
      <xbrli:endDate>2017-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-02-21_2017-02-21_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-02-21</xbrli:startDate>
      <xbrli:endDate>2017-02-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">acst:BiodrogaNutraceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SharedServiceAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">acst:SharedServiceAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SuppliesAndIncrementalCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">acst:SuppliesAndIncrementalCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_ComponentsOfEquityAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2018-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_BorrowingsByNameAxis-EquityComponentOfUnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:EquityComponentOfUnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_BorrowingsByNameAxis-LiabilityPortionOfUnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:LiabilityPortionOfUnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:UnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">acst:BiodrogaNutraceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CategoriesOfRelatedPartiesAxis-KeyManagementPersonnelOfEntityOrParentMember_RangeAxis-TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SharedServiceAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">acst:SharedServiceAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SuppliesAndIncrementalCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">acst:SuppliesAndIncrementalCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositOneMember_RangeAxis-BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TermDepositOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositOneMember_RangeAxis-TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TermDepositOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TermDepositTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember_RangeAxis-BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TermDepositTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember_RangeAxis-TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TermDepositTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember_RangeAxis-BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TreasuryBillsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember_RangeAxis-TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TreasuryBillsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-DerivativeWarrantLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:DerivativeWarrantLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedDecember272017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedDecember32013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedMay2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_ComponentsOfEquityAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_TypesOfRisksAxis-CurrencyRiskForEuroMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForEuroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_TypesOfRisksAxis-CurrencyRiskForUSDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForUSDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_TypesOfRisksAxis-CurrencyRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationEquityIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-01_2018-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-01</xbrli:startDate>
      <xbrli:endDate>2018-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-04-07_2017-04-07">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-04-07</xbrli:startDate>
      <xbrli:endDate>2017-04-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-08-15_2017-08-15">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-08-15</xbrli:startDate>
      <xbrli:endDate>2017-08-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-12-27_2017-12-27">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-12-27</xbrli:startDate>
      <xbrli:endDate>2017-12-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-12-27_2017-12-27_CategoriesOfRelatedPartiesAxis-UnderwriterMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:UnderwriterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-12-27</xbrli:startDate>
      <xbrli:endDate>2017-12-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-12-27_2017-12-27_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsIn2017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:PublicOfferingWarrantsIn2017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-12-27</xbrli:startDate>
      <xbrli:endDate>2017-12-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-12-27_2017-12-27_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsIssuedToBrokerInDecember2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-12-27</xbrli:startDate>
      <xbrli:endDate>2017-12-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-12-27_2017-12-27_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedDecember272017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-12-27</xbrli:startDate>
      <xbrli:endDate>2017-12-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-12-27_2017-12-27_ClassesOfOrdinarySharesAxis-ClassASharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">acst:ClassASharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-12-27</xbrli:startDate>
      <xbrli:endDate>2017-12-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-12-27_2017-12-27_CounterpartiesAxis-UnderwriterMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">acst:UnderwriterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-12-27</xbrli:startDate>
      <xbrli:endDate>2017-12-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-03-27_2018-03-27">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-03-27</xbrli:startDate>
      <xbrli:endDate>2018-03-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2018-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2018-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_BorrowingsByNameAxis-EquityComponentOfUnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:EquityComponentOfUnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_BorrowingsByNameAxis-LiabilityPortionOfUnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:LiabilityPortionOfUnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:UnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">acst:BiodrogaNutraceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CategoriesOfRelatedPartiesAxis-KeyManagementPersonnelOfEntityOrParentMember_RangeAxis-TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SharedServiceAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">acst:SharedServiceAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember_ProductsAndServicesAxis-SuppliesAndIncrementalCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">acst:SuppliesAndIncrementalCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:May2018PublicOfferingWarrants2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingBrokerWarrantsMay2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:PublicOfferingBrokerWarrantsMay2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:PublicOfferingWarrantsFebruary2017EquityPortionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:Series2017BWBrokerWarrantsRelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series9PrivatePlacementWarrants2013RelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:Series9PrivatePlacementWarrants2013RelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsBrokerWarrantsEquityPortionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:SeriesDecember2017UsBrokerWarrantsEquityPortionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsPublicOfferingWarrants2017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:SeriesDecember2017UsPublicOfferingWarrants2017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositOneMember_RangeAxis-BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TermDepositOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositOneMember_RangeAxis-TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TermDepositOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TermDepositTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember_RangeAxis-BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TermDepositTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember_RangeAxis-TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TermDepositTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember_RangeAxis-BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TreasuryBillsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember_RangeAxis-TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TreasuryBillsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-DerivativeWarrantLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:DerivativeWarrantLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedDecember272017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedDecember32013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedMay2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember_RangeAxis-BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember_RangeAxis-TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfOrdinarySharesAxis-CommonSharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">acst:CommonSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember_RangeAxis-BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember_RangeAxis-TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfShareCapitalAxis-ClassBSharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">acst:ClassBSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfShareCapitalAxis-ClassCSharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">acst:ClassCSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ClassesOfShareCapitalAxis-ClassDAndESharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">acst:ClassDAndESharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_ComponentsOfEquityAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_CounterpartiesAxis-FormerCEOMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">acst:FormerCEOMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_TypesOfRisksAxis-CurrencyRiskForEuroMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForEuroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_TypesOfRisksAxis-CurrencyRiskForUSDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForUSDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_TypesOfRisksAxis-CurrencyRiskMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationEquityIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-04-01_2019-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-04-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-05-01_2018-05-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:May2018PublicOfferingWarrants2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-05-01_2018-05-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsIssuedToBrokerInMay2018PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-05-01_2018-05-31_CounterpartiesAxis-BrokerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">acst:BrokerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-01</xbrli:startDate>
      <xbrli:endDate>2018-05-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-05-09_2018-05-09">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-09</xbrli:startDate>
      <xbrli:endDate>2018-05-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-05-14_2018-05-14_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member_CounterpartiesAxis-UnderwriterMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedMay2018Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">acst:UnderwriterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-14</xbrli:startDate>
      <xbrli:endDate>2018-05-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-05-14_2018-05-14_CounterpartiesAxis-UnderwriterMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">acst:UnderwriterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-05-14</xbrli:startDate>
      <xbrli:endDate>2018-05-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-06-06_2018-06-06">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-06-06</xbrli:startDate>
      <xbrli:endDate>2018-06-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-08-21_2018-08-21">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-08-21</xbrli:startDate>
      <xbrli:endDate>2018-08-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-10-01_2018-10-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-01</xbrli:startDate>
      <xbrli:endDate>2018-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-10-01_2018-10-31_CounterpartiesAxis-UnderwriterMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">acst:UnderwriterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-01</xbrli:startDate>
      <xbrli:endDate>2018-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-10-23_2018-10-23">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-23</xbrli:startDate>
      <xbrli:endDate>2018-10-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-10-23_2018-10-23_CounterpartiesAxis-UnderwriterMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">acst:UnderwriterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-23</xbrli:startDate>
      <xbrli:endDate>2018-10-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-10-31_2018-10-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-10-31</xbrli:startDate>
      <xbrli:endDate>2018-10-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-02-14_2019-02-14">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-14</xbrli:startDate>
      <xbrli:endDate>2019-02-14</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-02-14_2019-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-02-14</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-04-15_2019-04-15_CounterpartiesAxis-DirectorsMember_NonadjustingEventsAfterReportingPeriodAxis-MajorOrdinaryShareTransactionsMember_RangeAxis-BottomOfRangeMember_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">acst:DirectorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-15</xbrli:startDate>
      <xbrli:endDate>2019-04-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-04-15_2019-04-15_CounterpartiesAxis-EmployeeMember_NonadjustingEventsAfterReportingPeriodAxis-MajorOrdinaryShareTransactionsMember_RangeAxis-BottomOfRangeMember_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">acst:EmployeeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-15</xbrli:startDate>
      <xbrli:endDate>2019-04-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-04-15_2019-04-15_NonadjustingEventsAfterReportingPeriodAxis-MajorOrdinaryShareTransactionsMember_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-15</xbrli:startDate>
      <xbrli:endDate>2019-04-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2019-05-10_2019-05-10_CounterpartiesAxis-FormerCEOMember_NonadjustingEventsAfterReportingPeriodAxis-MajorOrdinaryShareTransactionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">acst:FormerCEOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-05-10</xbrli:startDate>
      <xbrli:endDate>2019-05-10</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-01-07_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">acst:BiodrogaNutraceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-01-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-01-07_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember_MaturityAxis-LaterThanSixMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">acst:BiodrogaNutraceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-01-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-01-07_BusinessCombinationsAxis-BiodrogaNutraceuticalsIncMember_CategoriesOfRelatedPartiesAxis-ParentMember_MaturityAxis-NotLaterThanSixMonthsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">acst:BiodrogaNutraceuticalsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:ParentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:NotLaterThanSixMonthsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-01-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ComponentsOfEquityAxis-IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ComponentsOfEquityAxis-OtherEquityInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-02-29_ComponentsOfEquityAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-08">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-21">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-21_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:UnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:May2018PublicOfferingWarrants2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:PublicOfferingWarrantsFebruary2017EquityPortionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:Series2017BWBrokerWarrantsRelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-Series9PrivatePlacementWarrants2013RelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:Series9PrivatePlacementWarrants2013RelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsPublicOfferingWarrants2017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:SeriesDecember2017UsPublicOfferingWarrants2017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsIssuedToBrokerInDecember2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsIssuedToBrokerInMay2018PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-WarrantsRelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsRelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_ClassesOfFinancialInstrumentsAxis-WarrantsRelatingToLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsRelatingToLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_ComponentsOfEquityAxis-IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_ComponentsOfEquityAxis-OtherEquityInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_ComponentsOfEquityAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-02-28_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-02-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_BorrowingsByNameAxis-EquityComponentOfUnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:EquityComponentOfUnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_BorrowingsByNameAxis-LiabilityPortionOfUnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:LiabilityPortionOfUnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:UnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:May2018PublicOfferingWarrants2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:PublicOfferingWarrantsFebruary2017EquityPortionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:Series2017BWBrokerWarrantsRelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-Series9PrivatePlacementWarrants2013RelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:Series9PrivatePlacementWarrants2013RelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsPublicOfferingWarrants2017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:SeriesDecember2017UsPublicOfferingWarrants2017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsIssuedToBrokerInDecember2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsIssuedToBrokerInMay2018PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsRelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatingToLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsRelatingToLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedDecember272017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedDecember32013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedMay2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ComponentsOfEquityAxis-IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_ComponentsOfEquityAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-FinancingExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">acst:FinancingExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-OtherTemporaryDifferencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-PropertyPlanAndEquipmentAndIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">acst:PropertyPlanAndEquipmentAndIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-ResearchAndDevelopmentProjectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">acst:ResearchAndDevelopmentProjectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">acst:TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-UnusedTaxLossesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-27">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-27_CategoriesOfRelatedPartiesAxis-UnderwriterMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:UnderwriterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-27_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedDecember272017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ArrangementsInvolvingLegalFormOfLeaseAxis-LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember_MaturityAxis-LaterThanOneYearAndNotLaterThanTwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ArrangementsInvolvingLegalFormOfLeaseAxis">acst:LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_BorrowingsByNameAxis-EquityComponentOfUnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:EquityComponentOfUnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_BorrowingsByNameAxis-LiabilityPortionOfUnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:LiabilityPortionOfUnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:UnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:UnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CategoriesOfFinancialAssetsAxis-BankersAcceptanceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">acst:BankersAcceptanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CategoriesOfFinancialAssetsAxis-CommercialPapersIssuedInCadCurrencyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">acst:CommercialPapersIssuedInCadCurrencyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CategoriesOfFinancialAssetsAxis-CommercialPapersIssuedInUsCurrencyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">acst:CommercialPapersIssuedInUsCurrencyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CategoriesOfFinancialAssetsAxis-PromissoryNotesIssuedInCadCurrencyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">acst:PromissoryNotesIssuedInCadCurrencyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CategoriesOfFinancialAssetsAxis-PromissoryNotesIssuedInUsCurrencyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">acst:PromissoryNotesIssuedInUsCurrencyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CategoriesOfFinancialAssetsAxis-TermDepositsIssuedInCadCurrencyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">acst:TermDepositsIssuedInCadCurrencyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CategoriesOfFinancialAssetsAxis-TermDepositsIssuedInUsCurrencyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">acst:TermDepositsIssuedInUsCurrencyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfAssetsAxis-CashAndCashEquivalentsMember_TypesOfRisksAxis-CurrencyRiskForEuroMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">acst:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForEuroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfAssetsAxis-CashAndCashEquivalentsMember_TypesOfRisksAxis-CurrencyRiskForUSDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">acst:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForUSDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfAssetsAxis-MarketableSecuritiesMember_TypesOfRisksAxis-CurrencyRiskForEuroMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">acst:MarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForEuroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfAssetsAxis-MarketableSecuritiesMember_TypesOfRisksAxis-CurrencyRiskForUSDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">acst:MarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForUSDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfAssetsAxis-ReceivablesMember_TypesOfRisksAxis-CurrencyRiskForEuroMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">acst:ReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForEuroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfAssetsAxis-ReceivablesMember_TypesOfRisksAxis-CurrencyRiskForUSDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">acst:ReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForUSDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:May2018PublicOfferingWarrants2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:PublicOfferingWarrantsFebruary2017EquityPortionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:Series2017BWBrokerWarrantsRelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-Series9PrivatePlacementWarrants2013RelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:Series9PrivatePlacementWarrants2013RelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsPublicOfferingWarrants2017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:SeriesDecember2017UsPublicOfferingWarrants2017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TermDepositOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TermDepositTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TreasuryBillsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsIssuedToBrokerInDecember2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsIssuedToBrokerInMay2018PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsRelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatingToLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsRelatingToLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-DerivativeWarrantLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:DerivativeWarrantLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_MaturityAxis-LaterThanOneYearAndNotLaterThanThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:TradeAndOtherPayablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_MaturityAxis-NotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:TradeAndOtherPayablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_TypesOfRisksAxis-CurrencyRiskForEuroMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:TradeAndOtherPayablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForEuroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_TypesOfRisksAxis-CurrencyRiskForUSDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:TradeAndOtherPayablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForUSDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:UnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember_MaturityAxis-LaterThanOneYearAndNotLaterThanThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:UnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember_MaturityAxis-NotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:UnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedDecember272017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedDecember32013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedMay2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ComponentsOfEquityAxis-IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_ComponentsOfEquityAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_GeographicalAreasAxis-FR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_MaturityAxis-LaterThanOneYearAndNotLaterThanThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_MaturityAxis-NotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_RangeAxis-BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_RangeAxis-TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-FinancingExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">acst:FinancingExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-OtherTemporaryDifferencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-PropertyPlanAndEquipmentAndIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">acst:PropertyPlanAndEquipmentAndIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-ResearchAndDevelopmentProjectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">acst:ResearchAndDevelopmentProjectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">acst:TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-UnusedTaxLossesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_TypesOfRisksAxis-CurrencyRiskForEuroMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForEuroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_TypesOfRisksAxis-CurrencyRiskForUSDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForUSDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationEquityIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-05-09">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-05-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-05-14_CounterpartiesAxis-UnderwriterMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">acst:UnderwriterMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-05-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-05-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedMay2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-05-31_CounterpartiesAxis-BrokerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">acst:BrokerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-06-27_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-06-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-10-23">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-10-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-10-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-12-03_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedDecember32013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-02-14">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-02-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_BorrowingsByNameAxis-EquityComponentOfUnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:EquityComponentOfUnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_BorrowingsByNameAxis-LiabilityPortionOfUnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:LiabilityPortionOfUnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_BorrowingsByNameAxis-UnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">acst:UnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-AccumulatedDepreciationAmortisationAndImpairmentMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:UnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-GrossCarryingAmountMember_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CategoriesOfFinancialAssetsAxis-BankersAcceptanceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">acst:BankersAcceptanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CategoriesOfFinancialAssetsAxis-CommercialPapersIssuedInCadCurrencyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">acst:CommercialPapersIssuedInCadCurrencyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CategoriesOfFinancialAssetsAxis-CommercialPapersIssuedInUsCurrencyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">acst:CommercialPapersIssuedInUsCurrencyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CategoriesOfFinancialAssetsAxis-PromissoryNotesIssuedInCadCurrencyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">acst:PromissoryNotesIssuedInCadCurrencyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CategoriesOfFinancialAssetsAxis-PromissoryNotesIssuedInUsCurrencyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">acst:PromissoryNotesIssuedInUsCurrencyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CategoriesOfFinancialAssetsAxis-TermDepositsIssuedInCadCurrencyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">acst:TermDepositsIssuedInCadCurrencyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CategoriesOfFinancialAssetsAxis-TermDepositsIssuedInUsCurrencyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialAssetsAxis">acst:TermDepositsIssuedInUsCurrencyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CategoriesOfRelatedPartiesAxis-NeptuneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">acst:NeptuneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfAssetsAxis-CashAndCashEquivalentsMember_TypesOfRisksAxis-CurrencyRiskForEuroMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">acst:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForEuroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfAssetsAxis-CashAndCashEquivalentsMember_TypesOfRisksAxis-CurrencyRiskForUSDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">acst:CashAndCashEquivalentsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForUSDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfAssetsAxis-MarketableSecuritiesMember_TypesOfRisksAxis-CurrencyRiskForEuroMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">acst:MarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForEuroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfAssetsAxis-MarketableSecuritiesMember_TypesOfRisksAxis-CurrencyRiskForUSDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">acst:MarketableSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForUSDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfAssetsAxis-ReceivablesMember_TypesOfRisksAxis-CurrencyRiskForEuroMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">acst:ReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForEuroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfAssetsAxis-ReceivablesMember_TypesOfRisksAxis-CurrencyRiskForUSDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">acst:ReceivablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForUSDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfContingentLiabilitiesAxis-ResearchAndDevelopmentProjectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfContingentLiabilitiesAxis">acst:ResearchAndDevelopmentProjectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-May2018PublicOfferingWarrants2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:May2018PublicOfferingWarrants2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-PublicOfferingWarrantsFebruary2017EquityPortionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:PublicOfferingWarrantsFebruary2017EquityPortionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series2017BWBrokerWarrantsRelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:Series2017BWBrokerWarrantsRelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-Series9PrivatePlacementWarrants2013RelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:Series9PrivatePlacementWarrants2013RelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-SeriesDecember2017UsPublicOfferingWarrants2017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:SeriesDecember2017UsPublicOfferingWarrants2017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TermDepositOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-TermDepositTwomember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TermDepositTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-TreasuryBillsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:TreasuryBillsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInDecember2017PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsIssuedToBrokerInDecember2017PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsIssuedToBrokerInMay2018PublicOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsIssuedToBrokerInMay2018PublicOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatedToEquityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsRelatedToEquityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialInstrumentsAxis-WarrantsRelatingToLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">acst:WarrantsRelatingToLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-DerivativeWarrantLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:DerivativeWarrantLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_MaturityAxis-LaterThanOneYearAndNotLaterThanThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:TradeAndOtherPayablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_MaturityAxis-NotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:TradeAndOtherPayablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_TypesOfRisksAxis-CurrencyRiskForEuroMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:TradeAndOtherPayablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForEuroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-TradeAndOtherPayablesMember_TypesOfRisksAxis-CurrencyRiskForUSDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:TradeAndOtherPayablesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForUSDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:UnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember_MaturityAxis-LaterThanOneYearAndNotLaterThanThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:UnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-UnsecuredConvertibleDebenturesMember_MaturityAxis-NotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:UnsecuredConvertibleDebenturesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember272017Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedDecember272017Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedDecember32013Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedDecember32013Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfFinancialLiabilitiesAxis-WarrantLiabilitiesIssuedMay2018Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">acst:WarrantLiabilitiesIssuedMay2018Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfIntangibleAssetsAndGoodwillAxis-LicencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">ifrs-full:LicencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfIntangibleAssetsAndGoodwillAxis-PatentsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">acst:PatentsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-ComputerEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-FurnitureAndOfficeEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfPropertyPlantAndEquipmentAxis-ProductionEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">acst:ProductionEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfShareCapitalAxis-ClassASharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">acst:ClassASharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfShareCapitalAxis-ClassBSharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">acst:ClassBSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfShareCapitalAxis-ClassCSharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">acst:ClassCSharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfShareCapitalAxis-ClassDAndESharesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">acst:ClassDAndESharesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfShareCapitalAxis-ClassDAndESharesMember_RangeAxis-BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">acst:ClassDAndESharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ClassesOfShareCapitalAxis-ClassDAndESharesMember_RangeAxis-TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">acst:ClassDAndESharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ComponentsOfEquityAxis-AdditionalPaidinCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AdditionalPaidinCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ComponentsOfEquityAxis-IssuedCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ComponentsOfEquityAxis-OtherEquityInterestMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherEquityInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_ComponentsOfEquityAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_CounterpartiesAxis-ConsultantsMember_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">acst:ConsultantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThouandThirtyEightMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThouandThirtyEightMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThouandThirtySevenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThouandThirtySevenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtyFiveMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtyFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtyFourMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtyFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtyNineMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtyNineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtyOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtyOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtySixMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtySixMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtyThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtyThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandThirtyTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtyTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-CountryOfDomicileMember_MaturityAxis-TwoThousandTwentyNineMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandTwentyNineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-FR">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:FR</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-ProvincialMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">acst:ProvincialMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThouandThirtyEightMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">acst:ProvincialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThouandThirtyEightMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThouandThirtySevenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">acst:ProvincialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThouandThirtySevenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtyFiveMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">acst:ProvincialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtyFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtyFourMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">acst:ProvincialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtyFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">acst:ProvincialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtyNineMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">acst:ProvincialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtyNineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtyOneMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">acst:ProvincialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtyOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtySixMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">acst:ProvincialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtySixMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtyThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">acst:ProvincialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtyThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandThirtyTwoMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">acst:ProvincialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandThirtyTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_GeographicalAreasAxis-ProvincialMember_MaturityAxis-TwoThousandTwentyNineMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">acst:ProvincialMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:TwoThousandTwentyNineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_MaturityAxis-LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_MaturityAxis-LaterThanElevenYearsAndNotLaterThanTwelveYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:LaterThanElevenYearsAndNotLaterThanTwelveYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_MaturityAxis-LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_MaturityAxis-LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_MaturityAxis-LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_MaturityAxis-LaterThanOneYearAndNotLaterThanThreeYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_MaturityAxis-LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_MaturityAxis-LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_MaturityAxis-LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_MaturityAxis-LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_MaturityAxis-LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_MaturityAxis-LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">acst:LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_MaturityAxis-NotLaterThanOneYearMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangeAxis-BottomOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangeAxis-BottomOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFiveOfExercisesPricesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">acst:RangeFiveOfExercisesPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangeAxis-BottomOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFourOfExercisesPricesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">acst:RangeFourOfExercisesPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangeAxis-BottomOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeOneOfExercisesPricesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">acst:RangeOneOfExercisesPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangeAxis-BottomOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeThreeOfExercisesPricesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">acst:RangeThreeOfExercisesPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangeAxis-BottomOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeTwoOfExercisesPricesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">acst:RangeTwoOfExercisesPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangeAxis-TopOfRangeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangeAxis-TopOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFiveOfExercisesPricesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">acst:RangeFiveOfExercisesPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangeAxis-TopOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFourOfExercisesPricesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">acst:RangeFourOfExercisesPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangeAxis-TopOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeOneOfExercisesPricesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">acst:RangeOneOfExercisesPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangeAxis-TopOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeThreeOfExercisesPricesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">acst:RangeThreeOfExercisesPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangeAxis-TopOfRangeMember_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeTwoOfExercisesPricesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">acst:RangeTwoOfExercisesPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFiveOfExercisesPricesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">acst:RangeFiveOfExercisesPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeFourOfExercisesPricesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">acst:RangeFourOfExercisesPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeOneOfExercisesPricesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">acst:RangeOneOfExercisesPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeThreeOfExercisesPricesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">acst:RangeThreeOfExercisesPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_RangesOfExercisePricesForOutstandingShareOptionsAxis-RangeTwoOfExercisesPricesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">acst:RangeTwoOfExercisesPricesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-FinancingExpensesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">acst:FinancingExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-OtherTemporaryDifferencesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-PropertyPlanAndEquipmentAndIntangibleAssetsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">acst:PropertyPlanAndEquipmentAndIntangibleAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-ResearchAndDevelopmentProjectsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">acst:ResearchAndDevelopmentProjectsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">acst:TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-UnusedTaxLossesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_TypesOfRisksAxis-CurrencyRiskForEuroMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForEuroMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_TypesOfRisksAxis-CurrencyRiskForUSDMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">acst:CurrencyRiskForUSDMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationEquityIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-03-31_TypesOfSharebasedPaymentArrangementsAxis-CorporationStockOptionPlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">acst:CorporationStockOptionPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2019-05-10_CounterpartiesAxis-FormerCEOMember_NonadjustingEventsAfterReportingPeriodAxis-MajorOrdinaryShareTransactionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001444192</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">acst:FormerCEOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-05-10</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>acst-20190331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:59AM UTC 2019-06-26--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:acst="http://www.acastipharma.com/20190331" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2017-03-09/ifrs-full" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.acastipharma.com/20190331">
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.ifrs.org/taxonomy/2017-03-09/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acst-20190331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acst-20190331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acst-20190331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acst-20190331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.acastipharma.com/20190331/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-statements-of-financial-position" roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-financial-position">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Statements of Financial Position</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-statements-of-earnings-and-comprehensive-loss-twelve-month-and-month-ended-2017-unaudited" roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-earnings-and-comprehensive-loss-twelve-month-and-month-ended-2017-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Statements of Earnings and Comprehensive Loss (Twelve Month and Month Ended 2017 Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited" roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Statements of Changes In Equity (Twelve Month and Month Ended 2017 Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited-parentheticals" roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Statements of Changes In Equity (Twelve Month and Month Ended 2017 Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-statements-of-cash-flows-twelve-month-and-month-ended-2017-unaudited" roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-cash-flows-twelve-month-and-month-ended-2017-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Statements of Cash Flows (Twelve Month and Month Ended 2017 Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-reporting-entity" roleURI="http://www.acastipharma.com/20190331/role/statement-note-1-reporting-entity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - Reporting Entity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-basis-of-preparation-" roleURI="http://www.acastipharma.com/20190331/role/statement-note-2-basis-of-preparation-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Basis of Preparation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-significant-accounting-policies" roleURI="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-receivables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-4-receivables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Receivables</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-marketable-securities" roleURI="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-other-assets" roleURI="http://www.acastipharma.com/20190331/role/statement-note-6-other-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Other Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-related-parties" roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Related Parties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-government-assistance" roleURI="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Government Assistance</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-equipment-" roleURI="http://www.acastipharma.com/20190331/role/statement-note-9-equipment-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-intangible-assets" roleURI="http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 10 - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-trade-and-other-payables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 11 - Trade and Other Payables</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-derivative-warrant-liabilities-" roleURI="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 12 - Derivative Warrant Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-unsecured-convertible-debentures" roleURI="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 13 - Unsecured Convertible Debentures</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-capital-and-other-components-of-equity" roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 14 - Capital and Other Components of Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-personnel-expenses" roleURI="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 15 - Personnel Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-financial-expenses" roleURI="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 16 - Financial Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-17-sharebased-payments" roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 17 - Share-based Payments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-18-loss-per-share" roleURI="http://www.acastipharma.com/20190331/role/statement-note-18-loss-per-share">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 18 - Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-19-supplemental-cash-flow-disclosure" roleURI="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 19 - Supplemental Cash Flow Disclosure</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-20-income-taxes" roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 20 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-21-financial-instruments" roleURI="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 21 - Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-22-commitments-and-contingencies" roleURI="http://www.acastipharma.com/20190331/role/statement-note-22-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 22 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-23-determination-of-fair-values" roleURI="http://www.acastipharma.com/20190331/role/statement-note-23-determination-of-fair-values">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 23 - Determination of Fair Values</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-24-capital-management" roleURI="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 24 - Capital Management</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-25-subsequent-events" roleURI="http://www.acastipharma.com/20190331/role/statement-note-25-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 25 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.acastipharma.com/20190331/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-significant-accounting-policies-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 3 - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-receivables-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-4-receivables-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 4 - Receivables (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-marketable-securities-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 5 - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-other-assets-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-6-other-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 6 - Other Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-related-parties-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 7 - Related Parties (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-government-assistance-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 8 - Government Assistance (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-equipment-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-9-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 9 - Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-intangible-assets-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 10 - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-trade-and-other-payables-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 11 - Trade and Other Payables (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-derivative-warrant-liabilities-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 12 - Derivative Warrant Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-unsecured-convertible-debentures-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 13 - Unsecured Convertible Debentures (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-capital-and-other-components-of-equity-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 14 - Capital and Other Components of Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-personnel-expenses-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 15 - Personnel Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-financial-expenses-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note 16 - Financial Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-17-sharebased-payments-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Disclosure - Note 17 - Share-based Payments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-19-supplemental-cash-flow-disclosure-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Disclosure - Note 19 - Supplemental Cash Flow Disclosure (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-20-income-taxes-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Disclosure - Note 20 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-21-financial-instruments-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note 21 - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-24-capital-management-tables" roleURI="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note 24 - Capital Management (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-basis-of-preparation-details-textual" roleURI="http://www.acastipharma.com/20190331/role/statement-note-2-basis-of-preparation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">051 - Disclosure - Note 2 - Basis of Preparation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-significant-accounting-policies-details-textual" roleURI="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">052 - Disclosure - Note 3 - Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">053 - Disclosure - Note 3 - Significant Accounting Policies - Estimated Useful Lives and Rates (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-receivables-schedule-of-receivables-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-4-receivables-schedule-of-receivables-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">054 - Disclosure - Note 4 - Receivables - Schedule of Receivables (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-marketable-securities-marketable-securities-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-marketable-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">055 - Disclosure - Note 5 - Marketable Securities - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-marketable-securities-marketable-securities-details-parentheticals" roleURI="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-marketable-securities-details-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">056 - Disclosure - Note 5 - Marketable Securities - Marketable Securities (Details) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-other-assets-other-assets-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-6-other-assets-other-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">057 - Disclosure - Note 6 - Other Assets - Other Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-related-parties-details-textual" roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">058 - Disclosure - Note 7 - Related Parties (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-administrative-and-research-and-development-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">059 - Disclosure - Note 7 - Related Parties - Administrative and Research and Development Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-related-parties-key-management-personnel-compensation-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-key-management-personnel-compensation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">060 - Disclosure - Note 7 - Related Parties - Key Management Personnel Compensation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">061 - Disclosure - Note 8 - Government Assistance - Government Grants and Investment Tax Credits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-government-assistance-unrecognized-federal-tax-credits-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-unrecognized-federal-tax-credits-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">062 - Disclosure - Note 8 - Government Assistance - Unrecognized Federal Tax Credits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-equipment-components-of-equipment-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-9-equipment-components-of-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">063 - Disclosure - Note 9 - Equipment - Components of Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-intangible-assets-components-of-intangible-assets-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets-components-of-intangible-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">064 - Disclosure - Note 10 - Intangible Assets - Components of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">065 - Disclosure - Note 11 - Trade and Other Payables - Components of Trade and Other Payables (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-derivative-warrant-liabilities-details-textual" roleURI="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">066 - Disclosure - Note 12 - Derivative Warrant Liabilities (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-derivative-warrant-liabilities-reconciliation-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-reconciliation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">067 - Disclosure - Note 12 - Derivative Warrant Liabilities - Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-derivative-warrant-liabilities-assumptions-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">068 - Disclosure - Note 12 - Derivative Warrant Liabilities - Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-unsecured-convertible-debentures-details-textual" roleURI="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">069 - Disclosure - Note 13 - Unsecured Convertible Debentures (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">070 - Disclosure - Note 13 - Unsecured Convertible Debentures - Liability and Equity Component Portions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-capital-and-other-components-of-equity-details-textual" roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">071 - Disclosure - Note 14 - Capital and Other Components of Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-capital-and-other-components-of-equity-assumptions-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">072 - Disclosure - Note 14 - Capital and Other Components of Equity - Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">073 - Disclosure - Note 14 - Capital and Other Components of Equity - Unsecured Convertible Debentures (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">074 - Disclosure - Note 14 - Capital and Other Components of Equity - Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-personnel-expenses-components-of-personnel-expenses-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses-components-of-personnel-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">075 - Disclosure - Note 15 - Personnel Expenses - Components of Personnel Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-financial-expenses-components-of-finance-income-expenses-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses-components-of-finance-income-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">076 - Disclosure - Note 16 - Financial Expenses - Components of Finance Income (Expenses) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-17-sharebased-payments-details-textual" roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">077 - Disclosure - Note 17 - Share-based Payments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-17-sharebased-payments-option-activity-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">078 - Disclosure - Note 17 - Share-based Payments - Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-17-sharebased-payments-weighted-average-assumptions-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-weighted-average-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">079 - Disclosure - Note 17 - Share-based Payments - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">080 - Disclosure - Note 17 - Share-based Payments - Outstanding and Exercisable Options (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">081 - Disclosure - Note 19 - Supplemental Cash Flow Disclosure - Changes in Non-cash Operating Items (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">082 - Disclosure - Note 19 - Supplemental Cash Flow Disclosure - Non-cash Transactions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-20-income-taxes-details-textual" roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">083 - Disclosure - Note 20 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-20-income-taxes-deferred-tax-recovery-expense-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-deferred-tax-recovery-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">084 - Disclosure - Note 20 - Income Taxes - Deferred Tax (Recovery) Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">085 - Disclosure - Note 20 - Income Taxes - Reconciliation of Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">086 - Disclosure - Note 20 - Income Taxes - Unrecognized Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">087 - Disclosure - Note 20 - Income Taxes - Tax attributes and Temporary Differences Available to Reduce Future Years' Taxable Income (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-21-financial-instruments-currency-risk-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-currency-risk-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">088 - Disclosure - Note 21 - Financial Instruments - Currency Risk (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-21-financial-instruments-financial-liabilities-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-financial-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">089 - Disclosure - Note 21 - Financial Instruments - Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-22-commitments-and-contingencies-details-textual" roleURI="http://www.acastipharma.com/20190331/role/statement-note-22-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">090 - Disclosure - Note 22 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-23-determination-of-fair-values-details-textual" roleURI="http://www.acastipharma.com/20190331/role/statement-note-23-determination-of-fair-values-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">091 - Disclosure - Note 23 - Determination of Fair Values (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-24-capital-management-details-textual" roleURI="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">092 - Disclosure - Note 24 - Capital Management (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-24-capital-management-cash-and-cash-equivalents-details" roleURI="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-cash-and-cash-equivalents-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">093 - Disclosure - Note 24 - Capital Management - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals" roleURI="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">094 - Disclosure - Note 24 - Capital Management - Cash and Cash Equivalents (Details) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-25-subsequent-events-details-textual" roleURI="http://www.acastipharma.com/20190331/role/statement-note-25-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">095 - Disclosure - Note 25 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="acst_AccretionOfInterestOnConvertibleDebenture" name="AccretionOfInterestOnConvertibleDebenture" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts" name="AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" name="AdjustmentsForDecreaseIncreaseInPrepaidExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds" name="AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_AtTheMarketSalesAgreementFeePercentage" name="AtTheMarketSalesAgreementFeePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_AtTheMarketSalesAgreementTerm" name="AtTheMarketSalesAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_BankersAcceptanceMember" name="BankersAcceptanceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_BiodrogaNutraceuticalsIncMember" name="BiodrogaNutraceuticalsIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate" name="BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum" name="BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="acst_BorrowingsConvertibleConversionPrice" name="BorrowingsConvertibleConversionPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="acst_BorrowingsConvertibleEquityIssuedFloorPrice" name="BorrowingsConvertibleEquityIssuedFloorPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="acst_BorrowingsConvertibleThresholdConsecutiveTradingDays" name="BorrowingsConvertibleThresholdConsecutiveTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_BorrowingsDiscountOfBorrowingPrincipalAmount" name="BorrowingsDiscountOfBorrowingPrincipalAmount" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acst_BrokerMember" name="BrokerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_CashAndCashEquivalentsMember" name="CashAndCashEquivalentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_ChangesInDeferredTaxLiabilityAssetTextBlock" name="ChangesInDeferredTaxLiabilityAssetTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_ClassASharesMember" name="ClassASharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_ClassBSharesMember" name="ClassBSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_ClassCSharesMember" name="ClassCSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_ClassDAndESharesMember" name="ClassDAndESharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_ClassOfWarrantOrRightOutstanding" name="ClassOfWarrantOrRightOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="acst_ClassOfWarrantOrRightOutstandingTextBlock" name="ClassOfWarrantOrRightOutstandingTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_CommercialPapersIssuedInCadCurrencyMember" name="CommercialPapersIssuedInCadCurrencyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_CommercialPapersIssuedInUsCurrencyMember" name="CommercialPapersIssuedInUsCurrencyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_CommonSharesMember" name="CommonSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_ConsultantsMember" name="ConsultantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_ConversionOfConvertibleInstrumentsEquitySharesIssued" name="ConversionOfConvertibleInstrumentsEquitySharesIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_ConversionRatio" name="ConversionRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_CorporationEquityIncentivePlanMember" name="CorporationEquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_CorporationStockOptionPlanMember" name="CorporationStockOptionPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_CurrencyRiskForEuroMember" name="CurrencyRiskForEuroMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_CurrencyRiskForUSDMember" name="CurrencyRiskForUSDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DeferredFinancingCostsCurrent" name="DeferredFinancingCostsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="acst_DepreciationPercentage" name="DepreciationPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod" name="DerivativeFinancialLiabilitiesExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_DerivativeFinancialLiabilitiesIssued" name="DerivativeFinancialLiabilitiesIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_DerivativeWarrantLiabilitiesMember" name="DerivativeWarrantLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock" name="DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DescriptionOfVestingPeriodShareOptionGranted" name="DescriptionOfVestingPeriodShareOptionGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_DirectorsMember" name="DirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock" name="DisclosureForComponentsOfFinanceIncomeCostTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock" name="DisclosureOfChangesInNoncashOperatingItemsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock" name="DisclosureOfComponentsOfPersonnelExpensesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DisclosureOfConvertibleDebenturesTextBlock" name="DisclosureOfConvertibleDebenturesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock" name="DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock" name="DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock" name="DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DisclosureOfMarketableSecuritiesTextBlock" name="DisclosureOfMarketableSecuritiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DisclosureOfNoncashTransactionsTextBlock" name="DisclosureOfNoncashTransactionsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DisclosureOfPersonnelExpensesTextBlock" name="DisclosureOfPersonnelExpensesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_DisclosureOfSignificantAccountingPoliciesAbstract" name="DisclosureOfSignificantAccountingPoliciesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock" name="DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_DisclosureOfUsefulLivesAndRatesTextBlock" name="DisclosureOfUsefulLivesAndRatesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_EmployeeMember" name="EmployeeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_EquipmentIncludedInTradeAndOtherPayables" name="EquipmentIncludedInTradeAndOtherPayables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_EquityComponentOfUnsecuredConvertibleDebenturesMember" name="EquityComponentOfUnsecuredConvertibleDebenturesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_ExercisePriceFor10Warrants" name="ExercisePriceFor10Warrants" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="acst_ExercisePriceWarrantsIssued" name="ExercisePriceWarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_ExpectedDividendWarrantsGranted" name="ExpectedDividendWarrantsGranted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_ExpectedVolatilityWarrantsIssued" name="ExpectedVolatilityWarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_FairValuePerShareIssuable" name="FairValuePerShareIssuable" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_FairValuePerSharesIssuableWarrants" name="FairValuePerSharesIssuableWarrants" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="acst_FinancialInstrumentInterestRate" name="FinancialInstrumentInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_FinancialInstrumentMaturityDate" name="FinancialInstrumentMaturityDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_FinancingExpensesMember" name="FinancingExpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss" name="ForeignCurrencyExposuresIncreaseDecreaseInNetLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acst_ForeignExchangeRiskCurrencyExposure" name="ForeignExchangeRiskCurrencyExposure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acst_FormerCEOMember" name="FormerCEOMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_GovernmentAssistanceAndTaxCreditsReceivable" name="GovernmentAssistanceAndTaxCreditsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="acst_GovernmentGrantsAndInvestmentTaxCredits" name="GovernmentGrantsAndInvestmentTaxCredits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acst_GrossFinanceIncomeCost" name="GrossFinanceIncomeCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment" name="IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares" name="IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares" name="IncreaseDecreaseThroughSharebasedPaymentTransactionsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_IntangibleAssetsUsefulLife" name="IntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_InterestPayableIncludedInTradeAndOtherPayables" name="InterestPayableIncludedInTradeAndOtherPayables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acst_InterestReceivableIncludedInReceivables" name="InterestReceivableIncludedInReceivables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acst_InvestmentTaxCredit" name="InvestmentTaxCredit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering" name="IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acst_IssuanceOfSharesForInterestOnConvertibleDebt" name="IssuanceOfSharesForInterestOnConvertibleDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acst_IssueOfEquityNumberOfShares" name="IssueOfEquityNumberOfShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember" name="LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember" name="LaterThanElevenYearsAndNotLaterThanTwelveYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember" name="LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember" name="LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember" name="LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember" name="LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember" name="LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember" name="LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember" name="LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember" name="LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember" name="LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" name="LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_LegalExpense" name="LegalExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_LegalFeesReimburse" name="LegalFeesReimburse" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_LegalSettlementPayableCurrent" name="LegalSettlementPayableCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember" name="LiabilityPortionOfUnsecuredConvertibleDebenturesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_MarketableSecuritiesCurrent" name="MarketableSecuritiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acst_MarketableSecuritiesMember" name="MarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_MarketableSecuritiesNoncurrent" name="MarketableSecuritiesNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="acst_MarketableSecurties" name="MarketableSecurties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants" name="MaximumNumberOfCommonSharesIssuableFromContingentWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="acst_MaximumNumberOfSharesAuthorized" name="MaximumNumberOfSharesAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="acst_MaximumNumberOfSharesAuthorizedAsPercentage" name="MaximumNumberOfSharesAuthorizedAsPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acst_May2018PublicOfferingWarrants2018Member" name="May2018PublicOfferingWarrants2018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_NeptuneMember" name="NeptuneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_NetEquity" name="NetEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="acst_NonCumulativeDividendRate" name="NonCumulativeDividendRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acst_NotLaterThanSixMonthsMember" name="NotLaterThanSixMonthsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare" name="NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="acst_NumberOfSharesCalledByEachWarrant" name="NumberOfSharesCalledByEachWarrant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="acst_NumberOfSharesCalledByWarrants" name="NumberOfSharesCalledByWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="acst_NumberOfSharesIssuedForLegalSettlement" name="NumberOfSharesIssuedForLegalSettlement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_NumberOfSharesIssuedForOptionExercised" name="NumberOfSharesIssuedForOptionExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_NumberOfSharesIssuedInPublicOffering" name="NumberOfSharesIssuedInPublicOffering" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_NumberOfUnitsIssuedDuringPeriod" name="NumberOfUnitsIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_NumberOfWarrantsExercised" name="NumberOfWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_NumberOfWarrantsIssuedDuringPeriod" name="NumberOfWarrantsIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_PatentsMember" name="PatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables" name="PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acst_ProceedsFromExerciseOfWarrants" name="ProceedsFromExerciseOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_ProceedsFromIssuingSharesInPublicOfferingGross" name="ProceedsFromIssuingSharesInPublicOfferingGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_ProceedsFromIssuingSharesPrivatePlacement" name="ProceedsFromIssuingSharesPrivatePlacement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_ProceedsFromIssuingUnits" name="ProceedsFromIssuingUnits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_ProductionEquipmentMember" name="ProductionEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_PromissoryNotesIssuedInCadCurrencyMember" name="PromissoryNotesIssuedInCadCurrencyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_PromissoryNotesIssuedInUsCurrencyMember" name="PromissoryNotesIssuedInUsCurrencyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember" name="PropertyPlanAndEquipmentAndIntangibleAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_ProportionOfOwnershipInterestsHeldByRelatedParty" name="ProportionOfOwnershipInterestsHeldByRelatedParty" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_ProportionOfVotingRightsHeldByAnAssociate" name="ProportionOfVotingRightsHeldByAnAssociate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_ProvincialMember" name="ProvincialMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_PublicOfferingBrokerWarrantsMay2018Member" name="PublicOfferingBrokerWarrantsMay2018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables" name="PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" name="PublicOfferingWarrantsFebruary2017EquityPortionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_PublicOfferingWarrantsIn2017Member" name="PublicOfferingWarrantsIn2017Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_PurchasesOtherAssets" name="PurchasesOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_RangeFiveOfExercisesPricesMember" name="RangeFiveOfExercisesPricesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_RangeFourOfExercisesPricesMember" name="RangeFourOfExercisesPricesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_RangeOneOfExercisesPricesMember" name="RangeOneOfExercisesPricesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_RangeThreeOfExercisesPricesMember" name="RangeThreeOfExercisesPricesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_RangeTwoOfExercisesPricesMember" name="RangeTwoOfExercisesPricesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_ReceivablesMember" name="ReceivablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock" name="ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_RedeemablePricePerShare" name="RedeemablePricePerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables" name="ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_ResearchAndDevelopmentProjectsMember" name="ResearchAndDevelopmentProjectsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_ResearchDevelopmentGeneralAndAdministrationExpense" name="ResearchDevelopmentGeneralAndAdministrationExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_RiskFreeInterestRateWarrantsIssued" name="RiskFreeInterestRateWarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_ScenarioUnspecifiedDomain" name="ScenarioUnspecifiedDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_Series2017BWBrokerWarrantsRelatedToEquityMember" name="Series2017BWBrokerWarrantsRelatedToEquityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" name="Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" name="Series9PrivatePlacementWarrants2013RelatedToEquityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" name="SeriesDecember2017UsBrokerWarrantsEquityPortionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" name="SeriesDecember2017UsPublicOfferingWarrants2017Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_ShareBasedPaymentCostsAllocatedToDebt" name="ShareBasedPaymentCostsAllocatedToDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acst_ShareBasedPaymentCostsAllocatedToShareCapital" name="ShareBasedPaymentCostsAllocatedToShareCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acst_ShareIssuedPricePerShare" name="ShareIssuedPricePerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acst_SharedServiceAgreementMember" name="SharedServiceAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss" name="SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain" name="SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss" name="SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_StatementLineItems" name="StatementLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_StatementScenarioAxis" name="StatementScenarioAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_StatementTable" name="StatementTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_SummaryOfMarketableSecuritiesTextBlock" name="SummaryOfMarketableSecuritiesTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_SummaryOfOtherAssetsTextBlock" name="SummaryOfOtherAssetsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_SuppliesAndIncrementalCostsMember" name="SuppliesAndIncrementalCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock" name="TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember" name="TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences" name="TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss" name="TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss" name="TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_TaxEffectOfPermanentDifferencesAndOther" name="TaxEffectOfPermanentDifferencesAndOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TermDepositOneMember" name="TermDepositOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TermDepositTwoMember" name="TermDepositTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TermDepositsIssuedInCadCurrencyMember" name="TermDepositsIssuedInCadCurrencyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TermDepositsIssuedInUsCurrencyMember" name="TermDepositsIssuedInUsCurrencyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" name="The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TradeAndOtherPayablesMember" name="TradeAndOtherPayablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TreasuryBillsMember" name="TreasuryBillsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TwoThouandThirtyEightMember" name="TwoThouandThirtyEightMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TwoThouandThirtySevenMember" name="TwoThouandThirtySevenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TwoThousandThirtyFiveMember" name="TwoThousandThirtyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TwoThousandThirtyFourMember" name="TwoThousandThirtyFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TwoThousandThirtyMember" name="TwoThousandThirtyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TwoThousandThirtyNineMember" name="TwoThousandThirtyNineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TwoThousandThirtyOneMember" name="TwoThousandThirtyOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TwoThousandThirtySixMember" name="TwoThousandThirtySixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TwoThousandThirtyThreeMember" name="TwoThousandThirtyThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TwoThousandThirtyTwoMember" name="TwoThousandThirtyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_TwoThousandTwentyNineMember" name="TwoThousandTwentyNineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_UnderwriterMember" name="UnderwriterMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_UnitIssuanceCosts" name="UnitIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_UnitIssuedPricePerUnit" name="UnitIssuedPricePerUnit" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="acst_UnitSharesOfClassAShare" name="UnitSharesOfClassAShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="acst_UnitSharesOfClassASharePurchaseWarrant" name="UnitSharesOfClassASharePurchaseWarrant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acst_UnsecuredConvertibleDebenturesMember" name="UnsecuredConvertibleDebenturesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_UsedOtherAssets" name="UsedOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acst_UsefulLifeOfAssets" name="UsefulLifeOfAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_WarrantCosts" name="WarrantCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_WarrantLiabilitiesIssuedDecember272017Member" name="WarrantLiabilitiesIssuedDecember272017Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_WarrantLiabilitiesIssuedDecember32013Member" name="WarrantLiabilitiesIssuedDecember32013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_WarrantLiabilitiesIssuedMay2018Member" name="WarrantLiabilitiesIssuedMay2018Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_WarrantLifeWarrantsIssued" name="WarrantLifeWarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_WarrantTransactionCosts" name="WarrantTransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acst_WarrantsAndRightsOutstanding" name="WarrantsAndRightsOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion" name="WarrantsExercisablePricePerShareAfterBorrowingsConversion" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="acst_WarrantsExercisedEquitySharesIssued" name="WarrantsExercisedEquitySharesIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_WarrantsExercisedEquitySharesIssuedAmount" name="WarrantsExercisedEquitySharesIssuedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acst_WarrantsExpired" name="WarrantsExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" name="WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" name="WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" name="WarrantsIssuedToBrokerInMay2018PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_WarrantsMember" name="WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_WarrantsRelatedToEquityMember" name="WarrantsRelatedToEquityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_WarrantsRelatingToLiabilitiesMember" name="WarrantsRelatingToLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acst_WeightedAverageSharePriceWarrantsIssued" name="WeightedAverageSharePriceWarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-10-intangible-assets-components-of-intangible-assets-details" name="statement-statement-note-10-intangible-assets-components-of-intangible-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-10-intangible-assets-tables" name="statement-statement-note-10-intangible-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" name="statement-statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-11-trade-and-other-payables-tables" name="statement-statement-note-11-trade-and-other-payables-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-12-derivative-warrant-liabilities-assumptions-details" name="statement-statement-note-12-derivative-warrant-liabilities-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-12-derivative-warrant-liabilities-reconciliation-details" name="statement-statement-note-12-derivative-warrant-liabilities-reconciliation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-12-derivative-warrant-liabilities-tables" name="statement-statement-note-12-derivative-warrant-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details" name="statement-statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-13-unsecured-convertible-debentures-tables" name="statement-statement-note-13-unsecured-convertible-debentures-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-14-capital-and-other-components-of-equity-assumptions-details" name="statement-statement-note-14-capital-and-other-components-of-equity-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-14-capital-and-other-components-of-equity-tables" name="statement-statement-note-14-capital-and-other-components-of-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details" name="statement-statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details" name="statement-statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-15-personnel-expenses-components-of-personnel-expenses-details" name="statement-statement-note-15-personnel-expenses-components-of-personnel-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-15-personnel-expenses-tables" name="statement-statement-note-15-personnel-expenses-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-16-financial-expenses-components-of-finance-income-expenses-details" name="statement-statement-note-16-financial-expenses-components-of-finance-income-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-16-financial-expenses-tables" name="statement-statement-note-16-financial-expenses-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-17-sharebased-payments-option-activity-details" name="statement-statement-note-17-sharebased-payments-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details" name="statement-statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-17-sharebased-payments-tables" name="statement-statement-note-17-sharebased-payments-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-17-sharebased-payments-weighted-average-assumptions-details" name="statement-statement-note-17-sharebased-payments-weighted-average-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" name="statement-statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details" name="statement-statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-tables" name="statement-statement-note-19-supplemental-cash-flow-disclosure-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-20-income-taxes-deferred-tax-recovery-expense-details" name="statement-statement-note-20-income-taxes-deferred-tax-recovery-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" name="statement-statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-20-income-taxes-tables" name="statement-statement-note-20-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" name="statement-statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" name="statement-statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-21-financial-instruments-currency-risk-details" name="statement-statement-note-21-financial-instruments-currency-risk-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-21-financial-instruments-financial-liabilities-details" name="statement-statement-note-21-financial-instruments-financial-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-21-financial-instruments-tables" name="statement-statement-note-21-financial-instruments-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details" name="statement-statement-note-24-capital-management-cash-and-cash-equivalents-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals" name="statement-statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-24-capital-management-tables" name="statement-statement-note-24-capital-management-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details" name="statement-statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-3-significant-accounting-policies-tables" name="statement-statement-note-3-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-4-receivables-schedule-of-receivables-details" name="statement-statement-note-4-receivables-schedule-of-receivables-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-4-receivables-tables" name="statement-statement-note-4-receivables-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-5-marketable-securities-marketable-securities-details" name="statement-statement-note-5-marketable-securities-marketable-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-5-marketable-securities-marketable-securities-details-parentheticals" name="statement-statement-note-5-marketable-securities-marketable-securities-details-parentheticals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-5-marketable-securities-tables" name="statement-statement-note-5-marketable-securities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-6-other-assets-other-assets-details" name="statement-statement-note-6-other-assets-other-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-6-other-assets-tables" name="statement-statement-note-6-other-assets-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" name="statement-statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-7-related-parties-key-management-personnel-compensation-details" name="statement-statement-note-7-related-parties-key-management-personnel-compensation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-7-related-parties-tables" name="statement-statement-note-7-related-parties-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" name="statement-statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-8-government-assistance-tables" name="statement-statement-note-8-government-assistance-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-8-government-assistance-unrecognized-federal-tax-credits-details" name="statement-statement-note-8-government-assistance-unrecognized-federal-tax-credits-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-9-equipment-components-of-equipment-details" name="statement-statement-note-9-equipment-components-of-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-note-9-equipment-tables" name="statement-statement-note-9-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acst_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>acst-20190331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:00AM UTC 2019-06-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-4-receivables-schedule-of-receivables-details" xlink:href="acst-20190331.xsd#statement-note-4-receivables-schedule-of-receivables-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-4-receivables-schedule-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_GovernmentAssistanceAndTaxCreditsReceivable" xlink:label="acst_GovernmentAssistanceAndTaxCreditsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestReceivable" xlink:label="ifrs-full_InterestReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="acst_GovernmentAssistanceAndTaxCreditsReceivable" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_InterestReceivable" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-marketable-securities-details" xlink:href="acst-20190331.xsd#statement-note-5-marketable-securities-marketable-securities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-marketable-securities-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesCurrent" xlink:label="acst_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesNoncurrent" xlink:label="acst_MarketableSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecurties" xlink:label="acst_MarketableSecurties" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acst_MarketableSecurties" xlink:to="acst_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acst_MarketableSecurties" xlink:to="acst_MarketableSecuritiesNoncurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses-components-of-personnel-expenses-details" xlink:href="acst-20190331.xsd#statement-note-15-personnel-expenses-components-of-personnel-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses-components-of-personnel-expenses-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences" xlink:label="acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss" xlink:label="acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss" xlink:label="acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfPermanentDifferencesAndOther" xlink:label="acst_TaxEffectOfPermanentDifferencesAndOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="ifrs-full_TaxEffectFromChangeInTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="acst_TaxEffectOfPermanentDifferencesAndOther" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_TaxEffectFromChangeInTaxRate" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="ifrs-full_DeferredTaxLiabilityAsset" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_DeferredTaxLiabilityAsset" xlink:to="ifrs-full_DeferredTaxLiabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_DeferredTaxLiabilityAsset" xlink:to="ifrs-full_DeferredTaxAssets" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-cash-flows-twelve-month-and-month-ended-2017-unaudited" xlink:href="acst-20190331.xsd#statement-statements-of-cash-flows-twelve-month-and-month-ended-2017-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-statements-of-cash-flows-twelve-month-and-month-ended-2017-unaudited" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromExerciseOfWarrants" xlink:label="acst_ProceedsFromExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromIssuingSharesPrivatePlacement" xlink:label="acst_ProceedsFromIssuingSharesPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="acst_ProceedsFromExerciseOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsForShareIssueCosts" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromIssuingShares" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="acst_ProceedsFromIssuingSharesPrivatePlacement" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" xlink:href="acst-20190331.xsd#statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_GovernmentGrantsAndInvestmentTaxCredits" xlink:label="acst_GovernmentGrantsAndInvestmentTaxCredits" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_InvestmentTaxCredit" xlink:label="acst_InvestmentTaxCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acst_GovernmentGrantsAndInvestmentTaxCredits" xlink:to="acst_InvestmentTaxCredit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acst_GovernmentGrantsAndInvestmentTaxCredits" xlink:to="ifrs-full_RevenueFromGovernmentGrants" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" xlink:href="acst-20190331.xsd#statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_LegalSettlementPayableCurrent" xlink:label="acst_LegalSettlementPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="acst_LegalSettlementPayableCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses-components-of-finance-income-expenses-details" xlink:href="acst-20190331.xsd#statement-note-16-financial-expenses-components-of-finance-income-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses-components-of-finance-income-expenses-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_AccretionOfInterestOnConvertibleDebenture" xlink:label="acst_AccretionOfInterestOnConvertibleDebenture" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantTransactionCosts" xlink:label="acst_WarrantTransactionCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="ifrs-full_InterestExpenseOnBorrowings" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherExpenseByNature" xlink:label="ifrs-full_OtherExpenseByNature" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RevenueFromInterest" xlink:label="ifrs-full_RevenueFromInterest" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_NetForeignExchangeGain" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="acst_WarrantTransactionCosts" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_InterestExpenseOnBorrowings" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_RevenueFromInterest" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="acst_AccretionOfInterestOnConvertibleDebenture" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_OtherExpenseByNature" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" xlink:href="acst-20190331.xsd#statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts" xlink:label="acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-deferred-tax-recovery-expense-details" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes-deferred-tax-recovery-expense-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-deferred-tax-recovery-expense-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-financial-position" xlink:href="acst-20190331.xsd#statement-statements-of-financial-position" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-statements-of-financial-position" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DeferredFinancingCostsCurrent" xlink:label="acst_DeferredFinancingCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesCurrent" xlink:label="acst_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesNoncurrent" xlink:label="acst_MarketableSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionalPaidinCapital" xlink:label="ifrs-full_AdditionalPaidinCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CapitalCommitments" xlink:label="ifrs-full_CapitalCommitments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentDebtInstrumentsIssued" xlink:label="ifrs-full_CurrentDebtInstrumentsIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentDebtInstrumentsIssued" xlink:label="ifrs-full_NoncurrentDebtInstrumentsIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherEquityInterest" xlink:label="ifrs-full_OtherEquityInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="acst_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="acst_DeferredFinancingCostsCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentPrepaidExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_OtherNoncurrentAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="acst_MarketableSecuritiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_PropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentDebtInstrumentsIssued" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_NoncurrentDebtInstrumentsIssued" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_CurrentLiabilities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_RetainedEarnings" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_OtherEquityInterest" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_IssuedCapital" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_AdditionalPaidinCapital" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_CapitalCommitments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Liabilities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-key-management-personnel-compensation-details" xlink:href="acst-20190331.xsd#statement-note-7-related-parties-key-management-personnel-compensation-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-key-management-personnel-compensation-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-earnings-and-comprehensive-loss-twelve-month-and-month-ended-2017-unaudited" xlink:href="acst-20190331.xsd#statement-statements-of-earnings-and-comprehensive-loss-twelve-month-and-month-ended-2017-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-statements-of-earnings-and-comprehensive-loss-twelve-month-and-month-ended-2017-unaudited" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_GrossFinanceIncomeCost" xlink:label="acst_GrossFinanceIncomeCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:to="acst_GrossFinanceIncomeCost" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" xlink:href="acst-20190331.xsd#statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ResearchDevelopmentGeneralAndAdministrationExpense" xlink:label="acst_ResearchDevelopmentGeneralAndAdministrationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acst_ResearchDevelopmentGeneralAndAdministrationExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acst_ResearchDevelopmentGeneralAndAdministrationExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>acst-20190331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:59AM UTC 2019-06-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments" xlink:href="acst-20190331.xsd#statement-note-21-financial-instruments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure" xlink:href="acst-20190331.xsd#statement-note-19-supplemental-cash-flow-disclosure" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" xlink:label="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-18-loss-per-share" xlink:href="acst-20190331.xsd#statement-note-18-loss-per-share" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-18-loss-per-share" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_EarningsPerShareExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses" xlink:href="acst-20190331.xsd#statement-note-16-financial-expenses" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses" xlink:href="acst-20190331.xsd#statement-note-15-personnel-expenses" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfPersonnelExpensesTextBlock" xlink:label="acst_DisclosureOfPersonnelExpensesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfPersonnelExpensesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables" xlink:href="acst-20190331.xsd#statement-note-11-trade-and-other-payables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets" xlink:href="acst-20190331.xsd#statement-note-10-intangible-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-9-equipment-" xlink:href="acst-20190331.xsd#statement-note-9-equipment-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-9-equipment-" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance" xlink:href="acst-20190331.xsd#statement-note-8-government-assistance" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfGovernmentGrantsExplanatory" xlink:label="ifrs-full_DisclosureOfGovernmentGrantsExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfGovernmentGrantsExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-6-other-assets" xlink:href="acst-20190331.xsd#statement-note-6-other-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-6-other-assets" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities" xlink:href="acst-20190331.xsd#statement-note-5-marketable-securities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfMarketableSecuritiesTextBlock" xlink:label="acst_DisclosureOfMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfMarketableSecuritiesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-4-receivables" xlink:href="acst-20190331.xsd#statement-note-4-receivables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-4-receivables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-1-reporting-entity" xlink:href="acst-20190331.xsd#statement-note-1-reporting-entity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-1-reporting-entity" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-document-and-entity-information" xlink:href="acst-20190331.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
	<link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>

  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited-parentheticals" xlink:href="acst-20190331.xsd#statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-2-basis-of-preparation-" xlink:href="acst-20190331.xsd#statement-note-2-basis-of-preparation-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-2-basis-of-preparation-" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies" xlink:href="acst-20190331.xsd#statement-note-3-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_FR" xlink:label="country_FR" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_GeographicalAreasAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_FR" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties" xlink:href="acst-20190331.xsd#statement-note-7-related-parties" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_BiodrogaNutraceuticalsIncMember" xlink:label="acst_BiodrogaNutraceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NeptuneMember" xlink:label="acst_NeptuneMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NotLaterThanSixMonthsMember" xlink:label="acst_NotLaterThanSixMonthsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanSixMonthsMember" xlink:label="ifrs-full_LaterThanSixMonthsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="acst_NeptuneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_ParentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_BusinessCombinationsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="acst_BiodrogaNutraceuticalsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_MaturityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_NotLaterThanSixMonthsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanSixMonthsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-" xlink:href="acst-20190331.xsd#statement-note-12-derivative-warrant-liabilities-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures" xlink:href="acst-20190331.xsd#statement-note-13-unsecured-convertible-debentures" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnsecuredConvertibleDebenturesMember" xlink:label="acst_UnsecuredConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_BorrowingsByNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="acst_UnsecuredConvertibleDebenturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity" xlink:href="acst-20190331.xsd#statement-note-14-capital-and-other-components-of-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_BrokerMember" xlink:label="acst_BrokerMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassASharesMember" xlink:label="acst_ClassASharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassBSharesMember" xlink:label="acst_ClassBSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassCSharesMember" xlink:label="acst_ClassCSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassDAndESharesMember" xlink:label="acst_ClassDAndESharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CommonSharesMember" xlink:label="acst_CommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DerivativeWarrantLiabilitiesMember" xlink:label="acst_DerivativeWarrantLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_May2018PublicOfferingWarrants2018Member" xlink:label="acst_May2018PublicOfferingWarrants2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingBrokerWarrantsMay2018Member" xlink:label="acst_PublicOfferingBrokerWarrantsMay2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:label="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:label="acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:label="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:label="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" xlink:label="acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:label="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:label="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnderwriterMember" xlink:label="acst_UnderwriterMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedMay2018Member" xlink:label="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionalPaidinCapitalMember" xlink:label="ifrs-full_AdditionalPaidinCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="acst_ClassBSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="acst_ClassCSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="acst_ClassDAndESharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CounterpartiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="acst_UnderwriterMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_DerivativeWarrantLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="acst_CommonSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="acst_BrokerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="acst_ClassASharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="acst_UnderwriterMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_AdditionalPaidinCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_May2018PublicOfferingWarrants2018Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_PublicOfferingBrokerWarrantsMay2018Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="acst_ClassASharesMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments" xlink:href="acst-20190331.xsd#statement-note-17-sharebased-payments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ConsultantsMember" xlink:label="acst_ConsultantsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationEquityIncentivePlanMember" xlink:label="acst_CorporationEquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationStockOptionPlanMember" xlink:label="acst_CorporationStockOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="acst_CorporationStockOptionPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CounterpartiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="acst_ConsultantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="acst_CorporationEquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-22-commitments-and-contingencies" xlink:href="acst-20190331.xsd#statement-note-22-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-22-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" xlink:label="acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ResearchAndDevelopmentProjectsMember" xlink:label="acst_ResearchAndDevelopmentProjectsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:label="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:label="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:label="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:to="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ContingentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ContingentLiabilitiesMember" xlink:to="acst_ResearchAndDevelopmentProjectsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ContingentLiabilitiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:to="acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:to="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_MaturityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-23-determination-of-fair-values" xlink:href="acst-20190331.xsd#statement-note-23-determination-of-fair-values" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-23-determination-of-fair-values" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management" xlink:href="acst-20190331.xsd#statement-note-24-capital-management" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-25-subsequent-events" xlink:href="acst-20190331.xsd#statement-note-25-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-25-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationStockOptionPlanMember" xlink:label="acst_CorporationStockOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DirectorsMember" xlink:label="acst_DirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_EmployeeMember" xlink:label="acst_EmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FormerCEOMember" xlink:label="acst_FormerCEOMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="acst_CorporationStockOptionPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CounterpartiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="acst_DirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="acst_EmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="acst_FormerCEOMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-significant-accounting-policies-policies" xlink:href="acst-20190331.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock" xlink:label="acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:label="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-tables" xlink:href="acst-20190331.xsd#statement-note-3-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfUsefulLivesAndRatesTextBlock" xlink:label="acst_DisclosureOfUsefulLivesAndRatesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfUsefulLivesAndRatesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-4-receivables-tables" xlink:href="acst-20190331.xsd#statement-note-4-receivables-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-4-receivables-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock" xlink:label="acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-tables" xlink:href="acst-20190331.xsd#statement-note-5-marketable-securities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SummaryOfMarketableSecuritiesTextBlock" xlink:label="acst_SummaryOfMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_SummaryOfMarketableSecuritiesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-6-other-assets-tables" xlink:href="acst-20190331.xsd#statement-note-6-other-assets-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-6-other-assets-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SummaryOfOtherAssetsTextBlock" xlink:label="acst_SummaryOfOtherAssetsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_SummaryOfOtherAssetsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-tables" xlink:href="acst-20190331.xsd#statement-note-7-related-parties-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-tables" xlink:href="acst-20190331.xsd#statement-note-8-government-assistance-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock" xlink:label="acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-9-equipment-tables" xlink:href="acst-20190331.xsd#statement-note-9-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-9-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets-tables" xlink:href="acst-20190331.xsd#statement-note-10-intangible-assets-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables-tables" xlink:href="acst-20190331.xsd#statement-note-11-trade-and-other-payables-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock" xlink:label="acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-tables" xlink:href="acst-20190331.xsd#statement-note-12-derivative-warrant-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DerivativeWarrantLiabilitiesMember" xlink:label="acst_DerivativeWarrantLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:label="ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_DerivativeWarrantLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-tables" xlink:href="acst-20190331.xsd#statement-note-13-unsecured-convertible-debentures-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-tables" xlink:href="acst-20190331.xsd#statement-note-14-capital-and-other-components-of-equity-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassOfWarrantOrRightOutstandingTextBlock" xlink:label="acst_ClassOfWarrantOrRightOutstandingTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfConvertibleDebenturesTextBlock" xlink:label="acst_DisclosureOfConvertibleDebenturesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsMember" xlink:label="acst_WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfConvertibleDebenturesTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ClassOfWarrantOrRightOutstandingTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses-tables" xlink:href="acst-20190331.xsd#statement-note-15-personnel-expenses-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock" xlink:label="acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses-tables" xlink:href="acst-20190331.xsd#statement-note-16-financial-expenses-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock" xlink:label="acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-tables" xlink:href="acst-20190331.xsd#statement-note-17-sharebased-payments-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-tables" xlink:href="acst-20190331.xsd#statement-note-19-supplemental-cash-flow-disclosure-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock" xlink:label="acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfNoncashTransactionsTextBlock" xlink:label="acst_DisclosureOfNoncashTransactionsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfNoncashTransactionsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-tables" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ChangesInDeferredTaxLiabilityAssetTextBlock" xlink:label="acst_ChangesInDeferredTaxLiabilityAssetTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock" xlink:label="acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock" xlink:label="acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock" xlink:label="acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ChangesInDeferredTaxLiabilityAssetTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-tables" xlink:href="acst-20190331.xsd#statement-note-21-financial-instruments-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-tables" xlink:href="acst-20190331.xsd#statement-note-24-capital-management-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-2-basis-of-preparation-details-textual" xlink:href="acst-20190331.xsd#statement-note-2-basis-of-preparation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-2-basis-of-preparation-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CurrentAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_FinancialAssets" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CurrentLiabilities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-details-textual" xlink:href="acst-20190331.xsd#statement-note-3-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_FR" xlink:label="country_FR" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_GeographicalAreasAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_FR" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_Assets" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-marketable-securities-details-parentheticals" xlink:href="acst-20190331.xsd#statement-note-5-marketable-securities-marketable-securities-details-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-marketable-securities-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_FinancialInstrumentInterestRate" xlink:label="acst_FinancialInstrumentInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FinancialInstrumentMaturityDate" xlink:label="acst_FinancialInstrumentMaturityDate" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecurties" xlink:label="acst_MarketableSecurties" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositOneMember" xlink:label="acst_TermDepositOneMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositTwoMember" xlink:label="acst_TermDepositTwomember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TreasuryBillsMember" xlink:label="acst_TreasuryBillsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_TermDepositOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_TermDepositTwomember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_TreasuryBillsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_MarketableSecurties" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_FinancialInstrumentInterestRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_FinancialInstrumentMaturityDate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-details-textual" xlink:href="acst-20190331.xsd#statement-note-7-related-parties-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_BiodrogaNutraceuticalsIncMember" xlink:label="acst_BiodrogaNutraceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NeptuneMember" xlink:label="acst_NeptuneMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NotLaterThanSixMonthsMember" xlink:label="acst_NotLaterThanSixMonthsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProportionOfOwnershipInterestsHeldByRelatedParty" xlink:label="acst_ProportionOfOwnershipInterestsHeldByRelatedParty" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProportionOfVotingRightsHeldByAnAssociate" xlink:label="acst_ProportionOfVotingRightsHeldByAnAssociate" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestRevenueExpense" xlink:label="ifrs-full_InterestRevenueExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanSixMonthsMember" xlink:label="ifrs-full_LaterThanSixMonthsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="acst_NeptuneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_ParentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_BusinessCombinationsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="acst_BiodrogaNutraceuticalsIncMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_MaturityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_NotLaterThanSixMonthsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanSixMonthsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ProportionOfOwnershipInterestsHeldByRelatedParty" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_InterestRevenueExpense" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ProportionOfVotingRightsHeldByAnAssociate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-details-textual" xlink:href="acst-20190331.xsd#statement-note-12-derivative-warrant-liabilities-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare" xlink:label="acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-details-textual" xlink:href="acst-20190331.xsd#statement-note-13-unsecured-convertible-debentures-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate" xlink:label="acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum" xlink:label="acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsConvertibleConversionPrice" xlink:label="acst_BorrowingsConvertibleConversionPrice" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsConvertibleEquityIssuedFloorPrice" xlink:label="acst_BorrowingsConvertibleEquityIssuedFloorPrice" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsConvertibleThresholdConsecutiveTradingDays" xlink:label="acst_BorrowingsConvertibleThresholdConsecutiveTradingDays" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsDiscountOfBorrowingPrincipalAmount" xlink:label="acst_BorrowingsDiscountOfBorrowingPrincipalAmount" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants" xlink:label="acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnsecuredConvertibleDebenturesMember" xlink:label="acst_UnsecuredConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion" xlink:label="acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:label="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_BorrowingsByNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="acst_UnsecuredConvertibleDebenturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NotionalAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_BorrowingsConvertibleConversionPrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_BorrowingsDiscountOfBorrowingPrincipalAmount" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_BorrowingsConvertibleThresholdConsecutiveTradingDays" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_BorrowingsConvertibleEquityIssuedFloorPrice" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-details-textual" xlink:href="acst-20190331.xsd#statement-note-14-capital-and-other-components-of-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds" xlink:label="acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_AtTheMarketSalesAgreementFeePercentage" xlink:label="acst_AtTheMarketSalesAgreementFeePercentage" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_AtTheMarketSalesAgreementTerm" xlink:label="acst_AtTheMarketSalesAgreementTerm" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BrokerMember" xlink:label="acst_BrokerMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassASharesMember" xlink:label="acst_ClassASharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassBSharesMember" xlink:label="acst_ClassBSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassCSharesMember" xlink:label="acst_ClassCSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassDAndESharesMember" xlink:label="acst_ClassDAndESharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CommonSharesMember" xlink:label="acst_CommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ConversionRatio" xlink:label="acst_ConversionRatio" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DeferredFinancingCostsCurrent" xlink:label="acst_DeferredFinancingCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DerivativeWarrantLiabilitiesMember" xlink:label="acst_DerivativeWarrantLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ExercisePriceFor10Warrants" xlink:label="acst_ExercisePriceFor10Warrants" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ExercisePriceWarrantsIssued" xlink:label="acst_ExercisePriceWarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FairValuePerSharesIssuableWarrants" xlink:label="acst_FairValuePerSharesIssuableWarrants" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment" xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares" xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IssueOfEquityNumberOfShares" xlink:label="acst_IssueOfEquityNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_May2018PublicOfferingWarrants2018Member" xlink:label="acst_May2018PublicOfferingWarrants2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NonCumulativeDividendRate" xlink:label="acst_NonCumulativeDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfSharesCalledByEachWarrant" xlink:label="acst_NumberOfSharesCalledByEachWarrant" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfSharesCalledByWarrants" xlink:label="acst_NumberOfSharesCalledByWarrants" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfSharesIssuedForOptionExercised" xlink:label="acst_NumberOfSharesIssuedForOptionExercised" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfSharesIssuedInPublicOffering" xlink:label="acst_NumberOfSharesIssuedInPublicOffering" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfUnitsIssuedDuringPeriod" xlink:label="acst_NumberOfUnitsIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfWarrantsExercised" xlink:label="acst_NumberOfWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfWarrantsIssuedDuringPeriod" xlink:label="acst_NumberOfWarrantsIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromExerciseOfWarrants" xlink:label="acst_ProceedsFromExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromIssuingSharesInPublicOfferingGross" xlink:label="acst_ProceedsFromIssuingSharesInPublicOfferingGross" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromIssuingUnits" xlink:label="acst_ProceedsFromIssuingUnits" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingBrokerWarrantsMay2018Member" xlink:label="acst_PublicOfferingBrokerWarrantsMay2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:label="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RedeemablePricePerShare" xlink:label="acst_RedeemablePricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:label="acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:label="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:label="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" xlink:label="acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:label="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ShareBasedPaymentCostsAllocatedToDebt" xlink:label="acst_ShareBasedPaymentCostsAllocatedToDebt" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ShareBasedPaymentCostsAllocatedToShareCapital" xlink:label="acst_ShareBasedPaymentCostsAllocatedToShareCapital" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ShareIssuedPricePerShare" xlink:label="acst_ShareIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:label="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnderwriterMember" xlink:label="acst_UnderwriterMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnitIssuanceCosts" xlink:label="acst_UnitIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnitIssuedPricePerUnit" xlink:label="acst_UnitIssuedPricePerUnit" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnitSharesOfClassAShare" xlink:label="acst_UnitSharesOfClassAShare" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnitSharesOfClassASharePurchaseWarrant" xlink:label="acst_UnitSharesOfClassASharePurchaseWarrant" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantCosts" xlink:label="acst_WarrantCosts" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedMay2018Member" xlink:label="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsAndRightsOutstanding" xlink:label="acst_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsExercisedEquitySharesIssued" xlink:label="acst_WarrantsExercisedEquitySharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsExercisedEquitySharesIssuedAmount" xlink:label="acst_WarrantsExercisedEquitySharesIssuedAmount" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsExpired" xlink:label="acst_WarrantsExpired" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionalPaidinCapitalMember" xlink:label="ifrs-full_AdditionalPaidinCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="ifrs-full_DeferredTaxExpenseIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageSharePrice" xlink:label="ifrs-full_WeightedAverageSharePrice" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="acst_ClassBSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="acst_ClassCSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="acst_ClassDAndESharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CounterpartiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="acst_UnderwriterMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_DerivativeWarrantLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="acst_CommonSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="acst_BrokerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="acst_ClassASharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="acst_UnderwriterMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_AdditionalPaidinCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_May2018PublicOfferingWarrants2018Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_PublicOfferingBrokerWarrantsMay2018Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="acst_ClassASharesMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_NonCumulativeDividendRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ConversionRatio" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_RedeemablePricePerShare" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_AtTheMarketSalesAgreementTerm" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_AtTheMarketSalesAgreementFeePercentage" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DeferredFinancingCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfSharesIssuedInPublicOffering" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ShareIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfSharesIssuedForOptionExercised" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ProceedsFromIssuingSharesInPublicOfferingGross" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_IssueOfEquityNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfUnitsIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_UnitIssuedPricePerUnit" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ProceedsFromIssuingUnits" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfWarrantsIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ExercisePriceWarrantsIssued" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IssueOfEquity" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_UnitIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_FairValuePerSharesIssuableWarrants" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfSharesCalledByWarrants" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantCosts" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantsExercisedEquitySharesIssuedAmount" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_UnitSharesOfClassAShare" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_UnitSharesOfClassASharePurchaseWarrant" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfSharesCalledByEachWarrant" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ShareBasedPaymentCostsAllocatedToShareCapital" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ShareBasedPaymentCostsAllocatedToDebt" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ExercisePriceFor10Warrants" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DeferredTaxExpenseIncome" xlink:type="arc"/>
    <link:definitionArc order="37" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantsExercisedEquitySharesIssued" xlink:type="arc"/>
    <link:definitionArc order="38" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantsExpired" xlink:type="arc"/>
    <link:definitionArc order="39" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="40" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ProceedsFromExerciseOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="41" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="42" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-details-textual" xlink:href="acst-20190331.xsd#statement-note-17-sharebased-payments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ConsultantsMember" xlink:label="acst_ConsultantsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationEquityIncentivePlanMember" xlink:label="acst_CorporationEquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationStockOptionPlanMember" xlink:label="acst_CorporationStockOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MaximumNumberOfSharesAuthorized" xlink:label="acst_MaximumNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MaximumNumberOfSharesAuthorizedAsPercentage" xlink:label="acst_MaximumNumberOfSharesAuthorizedAsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="acst_CorporationStockOptionPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CounterpartiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="acst_ConsultantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="acst_CorporationEquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_MaximumNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_MaximumNumberOfSharesAuthorizedAsPercentage" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-details-textual" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-22-commitments-and-contingencies-details-textual" xlink:href="acst-20190331.xsd#statement-note-22-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-22-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" xlink:label="acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ResearchAndDevelopmentProjectsMember" xlink:label="acst_ResearchAndDevelopmentProjectsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:label="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:label="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:label="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" xlink:label="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:to="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ContingentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ContingentLiabilitiesMember" xlink:to="acst_ResearchAndDevelopmentProjectsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ContingentLiabilitiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:to="acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:to="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_MaturityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-23-determination-of-fair-values-details-textual" xlink:href="acst-20190331.xsd#statement-note-23-determination-of-fair-values-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-23-determination-of-fair-values-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss" xlink:label="acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain" xlink:label="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss" xlink:label="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-details-textual" xlink:href="acst-20190331.xsd#statement-note-24-capital-management-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals" xlink:href="acst-20190331.xsd#statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_CommercialPapersIssuedInUsCurrencyMember" xlink:label="acst_CommercialPapersIssuedInUsCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PromissoryNotesIssuedInUsCurrencyMember" xlink:label="acst_PromissoryNotesIssuedInUsCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositsIssuedInUsCurrencyMember" xlink:label="acst_TermDepositsIssuedInUsCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashEquivalents" xlink:label="ifrs-full_CashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsCategoryMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="acst_TermDepositsIssuedInUsCurrencyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsCategoryMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="acst_CommercialPapersIssuedInUsCurrencyMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="acst_PromissoryNotesIssuedInUsCurrencyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CashEquivalents" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-25-subsequent-events-details-textual" xlink:href="acst-20190331.xsd#statement-note-25-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-25-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationStockOptionPlanMember" xlink:label="acst_CorporationStockOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DescriptionOfVestingPeriodShareOptionGranted" xlink:label="acst_DescriptionOfVestingPeriodShareOptionGranted" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DirectorsMember" xlink:label="acst_DirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_EmployeeMember" xlink:label="acst_EmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FormerCEOMember" xlink:label="acst_FormerCEOMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LegalExpense" xlink:label="acst_LegalExpense" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LegalFeesReimburse" xlink:label="acst_LegalFeesReimburse" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfSharesIssuedForLegalSettlement" xlink:label="acst_NumberOfSharesIssuedForLegalSettlement" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ShareIssuedPricePerShare" xlink:label="acst_ShareIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="acst_CorporationStockOptionPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CounterpartiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="acst_DirectorsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="acst_EmployeeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="acst_FormerCEOMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DescriptionOfVestingPeriodShareOptionGranted" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfSharesIssuedForLegalSettlement" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ShareIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_LegalFeesReimburse" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_LegalExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-unrecognized-federal-tax-credits-details" xlink:href="acst-20190331.xsd#statement-note-8-government-assistance-unrecognized-federal-tax-credits-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-unrecognized-federal-tax-credits-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember" xlink:label="acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember" xlink:label="acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember" xlink:label="acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember" xlink:label="acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember" xlink:label="acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember" xlink:label="acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember" xlink:label="acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember" xlink:label="acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember" xlink:label="acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember" xlink:label="acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember" xlink:label="acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:label="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_MaturityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-assumptions-details" xlink:href="acst-20190331.xsd#statement-note-14-capital-and-other-components-of-equity-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ExercisePriceWarrantsIssued" xlink:label="acst_ExercisePriceWarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ExpectedDividendWarrantsGranted" xlink:label="acst_ExpectedDividendWarrantsGranted" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ExpectedVolatilityWarrantsIssued" xlink:label="acst_ExpectedVolatilityWarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_May2018PublicOfferingWarrants2018Member" xlink:label="acst_May2018PublicOfferingWarrants2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingWarrantsIn2017Member" xlink:label="acst_PublicOfferingWarrantsIn2017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RiskFreeInterestRateWarrantsIssued" xlink:label="acst_RiskFreeInterestRateWarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLifeWarrantsIssued" xlink:label="acst_WarrantLifeWarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" xlink:label="acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" xlink:label="acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" xlink:label="acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WeightedAverageSharePriceWarrantsIssued" xlink:label="acst_WeightedAverageSharePriceWarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_May2018PublicOfferingWarrants2018Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_PublicOfferingWarrantsIn2017Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ExercisePriceWarrantsIssued" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_WeightedAverageSharePriceWarrantsIssued" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_RiskFreeInterestRateWarrantsIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantLifeWarrantsIssued" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ExpectedVolatilityWarrantsIssued" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ExpectedDividendWarrantsGranted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details" xlink:href="acst-20190331.xsd#statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DepreciationPercentage" xlink:label="acst_DepreciationPercentage" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FurnitureAndOfficeEquipmentMember" xlink:label="acst_FurnitureAndOfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IntangibleAssetsUsefulLife" xlink:label="acst_IntangibleAssetsUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaboratoryEquipmentMember" xlink:label="acst_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PatentsMember" xlink:label="acst_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProductionEquipmentMember" xlink:label="acst_ProductionEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UsefulLifeOfAssets" xlink:label="acst_UsefulLifeOfAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="acst_FurnitureAndOfficeEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="acst_PatentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="ifrs-full_LicencesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="acst_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="acst_ProductionEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DepreciationPercentage" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_UsefulLifeOfAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_IntangibleAssetsUsefulLife" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-6-other-assets-other-assets-details" xlink:href="acst-20190331.xsd#statement-note-6-other-assets-other-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-6-other-assets-other-assets-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_PurchasesOtherAssets" xlink:label="acst_PurchasesOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UsedOtherAssets" xlink:label="acst_UsedOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherAssets" xlink:label="ifrs-full_OtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_PurchasesOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_UsedOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherCurrentAssets" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherNoncurrentAssets" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-assumptions-details" xlink:href="acst-20190331.xsd#statement-note-12-derivative-warrant-liabilities-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ExercisePriceWarrantsIssued" xlink:label="acst_ExercisePriceWarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ExpectedVolatilityWarrantsIssued" xlink:label="acst_ExpectedVolatilityWarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RiskFreeInterestRateWarrantsIssued" xlink:label="acst_RiskFreeInterestRateWarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedMay2018Member" xlink:label="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLifeWarrantsIssued" xlink:label="acst_WarrantLifeWarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WeightedAverageSharePriceWarrantsIssued" xlink:label="acst_WeightedAverageSharePriceWarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ExercisePriceWarrantsIssued" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_WeightedAverageSharePriceWarrantsIssued" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_RiskFreeInterestRateWarrantsIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantLifeWarrantsIssued" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ExpectedVolatilityWarrantsIssued" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details" xlink:href="acst-20190331.xsd#statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_EquityComponentOfUnsecuredConvertibleDebenturesMember" xlink:label="acst_EquityComponentOfUnsecuredConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember" xlink:label="acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnsecuredConvertibleDebenturesMember" xlink:label="acst_UnsecuredConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestCostsIncurred" xlink:label="ifrs-full_InterestCostsIncurred" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="ifrs-full_InterestExpenseOnBorrowings" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_BorrowingsByNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="acst_EquityComponentOfUnsecuredConvertibleDebenturesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="acst_UnsecuredConvertibleDebenturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_Borrowings" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_InterestExpenseOnBorrowings" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_InterestCostsIncurred" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-cash-and-cash-equivalents-details" xlink:href="acst-20190331.xsd#statement-note-24-capital-management-cash-and-cash-equivalents-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-cash-and-cash-equivalents-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_BankersAcceptanceMember" xlink:label="acst_BankersAcceptanceMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CommercialPapersIssuedInCadCurrencyMember" xlink:label="acst_CommercialPapersIssuedInCadCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CommercialPapersIssuedInUsCurrencyMember" xlink:label="acst_CommercialPapersIssuedInUsCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PromissoryNotesIssuedInCadCurrencyMember" xlink:label="acst_PromissoryNotesIssuedInCadCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PromissoryNotesIssuedInUsCurrencyMember" xlink:label="acst_PromissoryNotesIssuedInUsCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositsIssuedInCadCurrencyMember" xlink:label="acst_TermDepositsIssuedInCadCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositsIssuedInUsCurrencyMember" xlink:label="acst_TermDepositsIssuedInUsCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashEquivalents" xlink:label="ifrs-full_CashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsCategoryMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="acst_TermDepositsIssuedInCadCurrencyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsCategoryMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="acst_TermDepositsIssuedInUsCurrencyMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="acst_CommercialPapersIssuedInCadCurrencyMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="acst_CommercialPapersIssuedInUsCurrencyMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="acst_PromissoryNotesIssuedInCadCurrencyMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="acst_PromissoryNotesIssuedInUsCurrencyMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="acst_BankersAcceptanceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_Cash" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-4-receivables-schedule-of-receivables-details" xlink:href="acst-20190331.xsd#statement-note-4-receivables-schedule-of-receivables-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-4-receivables-schedule-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_GovernmentAssistanceAndTaxCreditsReceivable" xlink:label="acst_GovernmentAssistanceAndTaxCreditsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestReceivable" xlink:label="ifrs-full_InterestReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_GovernmentAssistanceAndTaxCreditsReceivable" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_InterestReceivable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherCurrentReceivables" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details" xlink:href="acst-20190331.xsd#statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ConversionOfConvertibleInstrumentsEquitySharesIssued" xlink:label="acst_ConversionOfConvertibleInstrumentsEquitySharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ConversionOfConvertibleInstrumentsEquitySharesIssued" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-marketable-securities-details" xlink:href="acst-20190331.xsd#statement-note-5-marketable-securities-marketable-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-marketable-securities-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesCurrent" xlink:label="acst_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesNoncurrent" xlink:label="acst_MarketableSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecurties" xlink:label="acst_MarketableSecurties" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositOneMember" xlink:label="acst_TermDepositOneMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositTwoMember" xlink:label="acst_TermDepositTwomember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TreasuryBillsMember" xlink:label="acst_TreasuryBillsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_TermDepositOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_TermDepositTwomember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_TreasuryBillsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_MarketableSecurties" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_MarketableSecuritiesNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-reconciliation-details" xlink:href="acst-20190331.xsd#statement-note-12-derivative-warrant-liabilities-reconciliation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod" xlink:label="acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DerivativeFinancialLiabilitiesIssued" xlink:label="acst_DerivativeFinancialLiabilitiesIssued" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FairValuePerShareIssuable" xlink:label="acst_FairValuePerShareIssuable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedMay2018Member" xlink:label="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:label="ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DerivativeFinancialLiabilitiesIssued" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_FairValuePerShareIssuable" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses-components-of-personnel-expenses-details" xlink:href="acst-20190331.xsd#statement-note-15-personnel-expenses-components-of-personnel-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses-components-of-personnel-expenses-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_EmployeeBenefitsExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-weighted-average-assumptions-details" xlink:href="acst-20190331.xsd#statement-note-17-sharebased-payments-weighted-average-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-weighted-average-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExercisePriceShareOptionsGranted" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details" xlink:href="acst-20190331.xsd#statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_EquipmentIncludedInTradeAndOtherPayables" xlink:label="acst_EquipmentIncludedInTradeAndOtherPayables" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_InterestPayableIncludedInTradeAndOtherPayables" xlink:label="acst_InterestPayableIncludedInTradeAndOtherPayables" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_InterestReceivableIncludedInReceivables" xlink:label="acst_InterestReceivableIncludedInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering" xlink:label="acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IssuanceOfSharesForInterestOnConvertibleDebt" xlink:label="acst_IssuanceOfSharesForInterestOnConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables" xlink:label="acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables" xlink:label="acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables" xlink:label="acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_IssuanceOfSharesForInterestOnConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_InterestReceivableIncludedInReceivables" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_EquipmentIncludedInTradeAndOtherPayables" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_InterestPayableIncludedInTradeAndOtherPayables" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences" xlink:label="acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss" xlink:label="acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss" xlink:label="acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfPermanentDifferencesAndOther" xlink:label="acst_TaxEffectOfPermanentDifferencesAndOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccountingProfit" xlink:label="ifrs-full_AccountingProfit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="ifrs-full_TaxEffectFromChangeInTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AccountingProfit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ApplicableTaxRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_TaxEffectOfPermanentDifferencesAndOther" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TaxEffectFromChangeInTaxRate" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_FinancingExpensesMember" xlink:label="acst_FinancingExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember" xlink:label="acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ResearchAndDevelopmentProjectsMember" xlink:label="acst_ResearchAndDevelopmentProjectsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember" xlink:label="acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="ifrs-full_DeferredTaxLiabilityAsset" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherTemporaryDifferencesMember" xlink:label="ifrs-full_OtherTemporaryDifferencesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="ifrs-full_UnusedTaxLossesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_UnusedTaxLossesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="acst_ResearchAndDevelopmentProjectsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="acst_FinancingExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_OtherTemporaryDifferencesMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DeferredTaxAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DeferredTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DeferredTaxLiabilityAsset" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-currency-risk-details" xlink:href="acst-20190331.xsd#statement-note-21-financial-instruments-currency-risk-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-currency-risk-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_CashAndCashEquivalentsMember" xlink:label="acst_CashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CurrencyRiskForEuroMember" xlink:label="acst_CurrencyRiskForEuroMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CurrencyRiskForUSDMember" xlink:label="acst_CurrencyRiskForUSDMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss" xlink:label="acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ForeignExchangeRiskCurrencyExposure" xlink:label="acst_ForeignExchangeRiskCurrencyExposure" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesMember" xlink:label="acst_MarketableSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ReceivablesMember" xlink:label="acst_ReceivablesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TradeAndOtherPayablesMember" xlink:label="acst_TradeAndOtherPayablesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="ifrs-full_AverageForeignExchangeRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="ifrs-full_ClosingForeignExchangeRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_TypesOfRisksAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="acst_CurrencyRiskForUSDMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="acst_CashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="acst_CurrencyRiskForEuroMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="acst_MarketableSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="acst_ReceivablesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_TradeAndOtherPayablesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CurrencyRiskMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ForeignExchangeRiskCurrencyExposure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AverageForeignExchangeRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ClosingForeignExchangeRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-cash-flows-twelve-month-and-month-ended-2017-unaudited" xlink:href="acst-20190331.xsd#statement-statements-of-cash-flows-twelve-month-and-month-ended-2017-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-statements-of-cash-flows-twelve-month-and-month-ended-2017-unaudited" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromExerciseOfWarrants" xlink:label="acst_ProceedsFromExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromIssuingSharesPrivatePlacement" xlink:label="acst_ProceedsFromIssuingSharesPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashEquivalents" xlink:label="ifrs-full_CashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ProfitLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="acst_ProceedsFromIssuingSharesPrivatePlacement" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="acst_ProceedsFromExerciseOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsForShareIssueCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_Cash" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashEquivalents" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details" xlink:href="acst-20190331.xsd#statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_RangeFiveOfExercisesPricesMember" xlink:label="acst_RangeFiveOfExercisesPricesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RangeFourOfExercisesPricesMember" xlink:label="acst_RangeFourOfExercisesPricesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RangeOneOfExercisesPricesMember" xlink:label="acst_RangeOneOfExercisesPricesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RangeThreeOfExercisesPricesMember" xlink:label="acst_RangeThreeOfExercisesPricesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RangeTwoOfExercisesPricesMember" xlink:label="acst_RangeTwoOfExercisesPricesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="acst_RangeOneOfExercisesPricesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="acst_RangeTwoOfExercisesPricesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="acst_RangeThreeOfExercisesPricesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="acst_RangeFourOfExercisesPricesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="acst_RangeFiveOfExercisesPricesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" xlink:href="acst-20190331.xsd#statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_GovernmentGrantsAndInvestmentTaxCredits" xlink:label="acst_GovernmentGrantsAndInvestmentTaxCredits" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_InvestmentTaxCredit" xlink:label="acst_InvestmentTaxCredit" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_InvestmentTaxCredit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_RevenueFromGovernmentGrants" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_GovernmentGrantsAndInvestmentTaxCredits" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-9-equipment-components-of-equipment-details" xlink:href="acst-20190331.xsd#statement-note-9-equipment-components-of-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-9-equipment-components-of-equipment-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_FurnitureAndOfficeEquipmentMember" xlink:label="acst_FurnitureAndOfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaboratoryEquipmentMember" xlink:label="acst_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProductionEquipmentMember" xlink:label="acst_ProductionEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="acst_FurnitureAndOfficeEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="acst_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="acst_ProductionEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets-components-of-intangible-assets-details" xlink:href="acst-20190331.xsd#statement-note-10-intangible-assets-components-of-intangible-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets-components-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_PatentsMember" xlink:label="acst_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="acst_PatentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="ifrs-full_LicencesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" xlink:href="acst-20190331.xsd#statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_LegalSettlementPayableCurrent" xlink:label="acst_LegalSettlementPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_LegalSettlementPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details" xlink:href="acst-20190331.xsd#statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassOfWarrantOrRightOutstanding" xlink:label="acst_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_May2018PublicOfferingWarrants2018Member" xlink:label="acst_May2018PublicOfferingWarrants2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:label="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:label="acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:label="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:label="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:label="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:label="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsAndRightsOutstanding" xlink:label="acst_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" xlink:label="acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" xlink:label="acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsRelatedToEquityMember" xlink:label="acst_WarrantsRelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsRelatingToLiabilitiesMember" xlink:label="acst_WarrantsRelatingToLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_May2018PublicOfferingWarrants2018Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_WarrantsRelatingToLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="acst_WarrantsRelatedToEquityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantsAndRightsOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses-components-of-finance-income-expenses-details" xlink:href="acst-20190331.xsd#statement-note-16-financial-expenses-components-of-finance-income-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses-components-of-finance-income-expenses-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_AccretionOfInterestOnConvertibleDebenture" xlink:label="acst_AccretionOfInterestOnConvertibleDebenture" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantTransactionCosts" xlink:label="acst_WarrantTransactionCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="ifrs-full_InterestExpenseOnBorrowings" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherExpenseByNature" xlink:label="ifrs-full_OtherExpenseByNature" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RevenueFromInterest" xlink:label="ifrs-full_RevenueFromInterest" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_RevenueFromInterest" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NetForeignExchangeGain" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_InterestExpenseOnBorrowings" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_AccretionOfInterestOnConvertibleDebenture" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantTransactionCosts" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherExpenseByNature" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_FinanceCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-option-activity-details" xlink:href="acst-20190331.xsd#statement-note-17-sharebased-payments-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationStockOptionPlanMember" xlink:label="acst_CorporationStockOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="acst_CorporationStockOptionPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" xlink:href="acst-20190331.xsd#statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts" xlink:label="acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-deferred-tax-recovery-expense-details" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes-deferred-tax-recovery-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-deferred-tax-recovery-expense-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ProvincialMember" xlink:label="acst_ProvincialMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThouandThirtyEightMember" xlink:label="acst_TwoThouandThirtyEightMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThouandThirtySevenMember" xlink:label="acst_TwoThouandThirtySevenMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyFiveMember" xlink:label="acst_TwoThousandThirtyFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyFourMember" xlink:label="acst_TwoThousandThirtyFourMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyMember" xlink:label="acst_TwoThousandThirtyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyNineMember" xlink:label="acst_TwoThousandThirtyNineMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyOneMember" xlink:label="acst_TwoThousandThirtyOneMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtySixMember" xlink:label="acst_TwoThousandThirtySixMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyThreeMember" xlink:label="acst_TwoThousandThirtyThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyTwoMember" xlink:label="acst_TwoThousandThirtyTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandTwentyNineMember" xlink:label="acst_TwoThousandTwentyNineMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="ifrs-full_CountryOfDomicileMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:label="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_MaturityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_TwoThousandTwentyNineMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_GeographicalAreasAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="ifrs-full_CountryOfDomicileMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="acst_ProvincialMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_TwoThousandThirtyMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_TwoThousandThirtyOneMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_TwoThousandThirtyTwoMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_TwoThousandThirtyThreeMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_TwoThousandThirtyFourMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_TwoThousandThirtyFiveMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_TwoThousandThirtySixMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_TwoThouandThirtySevenMember" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_TwoThouandThirtyEightMember" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="acst_TwoThousandThirtyNineMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited" xlink:href="acst-20190331.xsd#statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ConversionOfConvertibleInstrumentsEquitySharesIssued" xlink:label="acst_ConversionOfConvertibleInstrumentsEquitySharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment" xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares" xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares" xlink:label="acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IssueOfEquityNumberOfShares" xlink:label="acst_IssueOfEquityNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NetEquity" xlink:label="acst_NetEquity" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsExercisedEquitySharesIssued" xlink:label="acst_WarrantsExercisedEquitySharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionalPaidinCapitalMember" xlink:label="ifrs-full_AdditionalPaidinCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssueOfConvertibleInstruments" xlink:label="ifrs-full_IssueOfConvertibleInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherEquityInterestMember" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_OtherEquityInterestMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_AdditionalPaidinCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_Equity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ComprehensiveIncome" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_NetEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_IssueOfEquityNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IssueOfEquity" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantsExercisedEquitySharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ConversionOfConvertibleInstrumentsEquitySharesIssued" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IssueOfConvertibleInstruments" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-financial-liabilities-details" xlink:href="acst-20190331.xsd#statement-note-21-financial-instruments-financial-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-financial-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TradeAndOtherPayablesMember" xlink:label="acst_TradeAndOtherPayablesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnsecuredConvertibleDebenturesMember" xlink:label="acst_UnsecuredConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_TradeAndOtherPayablesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_MaturityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="acst_UnsecuredConvertibleDebenturesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_FinancialLiabilities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-financial-position" xlink:href="acst-20190331.xsd#statement-statements-of-financial-position" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-statements-of-financial-position" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DeferredFinancingCostsCurrent" xlink:label="acst_DeferredFinancingCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesCurrent" xlink:label="acst_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesNoncurrent" xlink:label="acst_MarketableSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionalPaidinCapital" xlink:label="ifrs-full_AdditionalPaidinCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CapitalCommitments" xlink:label="ifrs-full_CapitalCommitments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentDebtInstrumentsIssued" xlink:label="ifrs-full_CurrentDebtInstrumentsIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentDebtInstrumentsIssued" xlink:label="ifrs-full_NoncurrentDebtInstrumentsIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherEquityInterest" xlink:label="ifrs-full_OtherEquityInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CurrentAssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="acst_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="acst_DeferredFinancingCostsCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="acst_MarketableSecuritiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentAssets" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentDebtInstrumentsIssued" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentDebtInstrumentsIssued" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_EquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherEquityInterest" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_AdditionalPaidinCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_CapitalCommitments" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAndLiabilities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-key-management-personnel-compensation-details" xlink:href="acst-20190331.xsd#statement-note-7-related-parties-key-management-personnel-compensation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-key-management-personnel-compensation-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-earnings-and-comprehensive-loss-twelve-month-and-month-ended-2017-unaudited" xlink:href="acst-20190331.xsd#statement-statements-of-earnings-and-comprehensive-loss-twelve-month-and-month-ended-2017-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-statements-of-earnings-and-comprehensive-loss-twelve-month-and-month-ended-2017-unaudited" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_GrossFinanceIncomeCost" xlink:label="acst_GrossFinanceIncomeCost" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_GrossFinanceIncomeCost" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ComprehensiveIncome" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageShares" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" xlink:href="acst-20190331.xsd#statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NeptuneMember" xlink:label="acst_NeptuneMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ResearchDevelopmentGeneralAndAdministrationExpense" xlink:label="acst_ResearchDevelopmentGeneralAndAdministrationExpense" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SharedServiceAgreementMember" xlink:label="acst_SharedServiceAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SuppliesAndIncrementalCostsMember" xlink:label="acst_SuppliesAndIncrementalCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="acst_NeptuneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ProductsAndServicesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="acst_SuppliesAndIncrementalCostsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="acst_SharedServiceAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acst_StatementLineItems" xlink:to="acst_ResearchDevelopmentGeneralAndAdministrationExpense" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>acst-20190331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:59AM UTC 2019-06-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementScenarioAxis" xlink:label="acst_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="acst_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_StatementScenarioAxis" xlink:to="acst_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ScenarioUnspecifiedDomain" xlink:label="acst_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="acst_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ScenarioUnspecifiedDomain" xlink:to="acst_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="acst_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement Table [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_StatementTable" xlink:to="acst_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_InterestPaidClassifiedAsFinancingActivities</link:label>
    <link:label xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="acst_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement Line Items [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_StatementLineItems" xlink:to="acst_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:label="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="acst_DisclosureOfSignificantAccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discloure of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="acst_DisclosureOfSignificantAccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DocumentAndEntityInformation" xlink:label="acst_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="acst_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DocumentAndEntityInformation" xlink:to="acst_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of derivative financial instruments [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</link:label>
    <link:label xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings, classified as financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NoteToFinancialStatementDetailsTextual" xlink:label="acst_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="acst_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NoteToFinancialStatementDetailsTextual" xlink:to="acst_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-significant-accounting-policies-policies" xlink:label="acst_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-significant-accounting-policies-policies" xlink:to="acst_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_TopOfRangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-3-significant-accounting-policies-tables" xlink:label="acst_statement-statement-note-3-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-3-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-3-significant-accounting-policies-tables" xlink:to="acst_statement-statement-note-3-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ProceedsFromIssuingShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from public offering</link:label>
    <link:label xlink:label="ifrs-full_ProceedsFromIssuingShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-4-receivables-tables" xlink:label="acst_statement-statement-note-4-receivables-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-4-receivables-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-4-receivables-tables" xlink:to="acst_statement-statement-note-4-receivables-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NotionalAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_NotionalAmount</link:label>
    <link:label xlink:label="ifrs-full_NotionalAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notional amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotionalAmount" xlink:to="ifrs-full_NotionalAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-5-marketable-securities-tables" xlink:label="acst_statement-statement-note-5-marketable-securities-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-5-marketable-securities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Marketable Securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-5-marketable-securities-tables" xlink:to="acst_statement-statement-note-5-marketable-securities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-6-other-assets-tables" xlink:label="acst_statement-statement-note-6-other-assets-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-6-other-assets-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Other Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-6-other-assets-tables" xlink:to="acst_statement-statement-note-6-other-assets-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-7-related-parties-tables" xlink:label="acst_statement-statement-note-7-related-parties-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-7-related-parties-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Related Parties</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-7-related-parties-tables" xlink:to="acst_statement-statement-note-7-related-parties-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-8-government-assistance-tables" xlink:label="acst_statement-statement-note-8-government-assistance-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-8-government-assistance-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Government Assistance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-8-government-assistance-tables" xlink:to="acst_statement-statement-note-8-government-assistance-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_CashFlowsFromUsedInInvestingActivities</link:label>
    <link:label xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_RangesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-9-equipment-tables" xlink:label="acst_statement-statement-note-9-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-9-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-9-equipment-tables" xlink:to="acst_statement-statement-note-9-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-10-intangible-assets-tables" xlink:label="acst_statement-statement-note-10-intangible-assets-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-10-intangible-assets-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Intangible Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-10-intangible-assets-tables" xlink:to="acst_statement-statement-note-10-intangible-assets-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-11-trade-and-other-payables-tables" xlink:label="acst_statement-statement-note-11-trade-and-other-payables-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-11-trade-and-other-payables-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Trade and Other Payables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-11-trade-and-other-payables-tables" xlink:to="acst_statement-statement-note-11-trade-and-other-payables-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-12-derivative-warrant-liabilities-tables" xlink:label="acst_statement-statement-note-12-derivative-warrant-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-12-derivative-warrant-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Derivative Warrant Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-12-derivative-warrant-liabilities-tables" xlink:to="acst_statement-statement-note-12-derivative-warrant-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-13-unsecured-convertible-debentures-tables" xlink:label="acst_statement-statement-note-13-unsecured-convertible-debentures-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-13-unsecured-convertible-debentures-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Unsecured Convertible Debentures</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-13-unsecured-convertible-debentures-tables" xlink:to="acst_statement-statement-note-13-unsecured-convertible-debentures-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-14-capital-and-other-components-of-equity-tables" xlink:label="acst_statement-statement-note-14-capital-and-other-components-of-equity-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-14-capital-and-other-components-of-equity-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Capital and Other Components of Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-14-capital-and-other-components-of-equity-tables" xlink:to="acst_statement-statement-note-14-capital-and-other-components-of-equity-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-15-personnel-expenses-tables" xlink:label="acst_statement-statement-note-15-personnel-expenses-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-15-personnel-expenses-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Personnel Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-15-personnel-expenses-tables" xlink:to="acst_statement-statement-note-15-personnel-expenses-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-16-financial-expenses-tables" xlink:label="acst_statement-statement-note-16-financial-expenses-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-16-financial-expenses-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 16 - Financial Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-16-financial-expenses-tables" xlink:to="acst_statement-statement-note-16-financial-expenses-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity of short-term investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about borrowings [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-17-sharebased-payments-tables" xlink:label="acst_statement-statement-note-17-sharebased-payments-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-17-sharebased-payments-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 17 - Share-based Payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-17-sharebased-payments-tables" xlink:to="acst_statement-statement-note-17-sharebased-payments-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition of short-term investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-19-supplemental-cash-flow-disclosure-tables" xlink:label="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 19 - Supplemental Cash Flow Disclosure</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-tables" xlink:to="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for employee benefits [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-20-income-taxes-tables" xlink:label="acst_statement-statement-note-20-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-20-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 20 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-20-income-taxes-tables" xlink:to="acst_statement-statement-note-20-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-21-financial-instruments-tables" xlink:label="acst_statement-statement-note-21-financial-instruments-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-21-financial-instruments-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 21 - Financial Instruments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-21-financial-instruments-tables" xlink:to="acst_statement-statement-note-21-financial-instruments-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-24-capital-management-tables" xlink:label="acst_statement-statement-note-24-capital-management-tables" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-24-capital-management-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 24 - Capital Management</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-24-capital-management-tables" xlink:to="acst_statement-statement-note-24-capital-management-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</link:label>
    <link:label xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details" xlink:label="acst_statement-statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Significant Accounting Policies - Estimated Useful Lives and Rates (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details" xlink:to="acst_statement-statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-4-receivables-schedule-of-receivables-details" xlink:label="acst_statement-statement-note-4-receivables-schedule-of-receivables-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-4-receivables-schedule-of-receivables-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Receivables - Schedule of Receivables (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-4-receivables-schedule-of-receivables-details" xlink:to="acst_statement-statement-note-4-receivables-schedule-of-receivables-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-5-marketable-securities-marketable-securities-details" xlink:label="acst_statement-statement-note-5-marketable-securities-marketable-securities-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-5-marketable-securities-marketable-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Marketable Securities - Marketable Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-5-marketable-securities-marketable-securities-details" xlink:to="acst_statement-statement-note-5-marketable-securities-marketable-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-5-marketable-securities-marketable-securities-details-parentheticals" xlink:label="acst_statement-statement-note-5-marketable-securities-marketable-securities-details-parentheticals" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-5-marketable-securities-marketable-securities-details-parentheticals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Marketable Securities - Marketable Securities (Details) (Parentheticals)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-5-marketable-securities-marketable-securities-details-parentheticals" xlink:to="acst_statement-statement-note-5-marketable-securities-marketable-securities-details-parentheticals-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-6-other-assets-other-assets-details" xlink:label="acst_statement-statement-note-6-other-assets-other-assets-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-6-other-assets-other-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Other Assets - Other Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-6-other-assets-other-assets-details" xlink:to="acst_statement-statement-note-6-other-assets-other-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for finance income and costs [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" xlink:label="acst_statement-statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-7-related-parties-administrative-and-research-and-development-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Related Parties - Administrative and Research and Development Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" xlink:to="acst_statement-statement-note-7-related-parties-administrative-and-research-and-development-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-7-related-parties-key-management-personnel-compensation-details" xlink:label="acst_statement-statement-note-7-related-parties-key-management-personnel-compensation-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-7-related-parties-key-management-personnel-compensation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Related Parties - Key Management Personnel Compensation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-7-related-parties-key-management-personnel-compensation-details" xlink:to="acst_statement-statement-note-7-related-parties-key-management-personnel-compensation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" xlink:label="acst_statement-statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Government Assistance - Government Grants and Investment Tax Credits (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" xlink:to="acst_statement-statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-8-government-assistance-unrecognized-federal-tax-credits-details" xlink:label="acst_statement-statement-note-8-government-assistance-unrecognized-federal-tax-credits-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-8-government-assistance-unrecognized-federal-tax-credits-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Government Assistance - Unrecognized Federal Tax Credits (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-8-government-assistance-unrecognized-federal-tax-credits-details" xlink:to="acst_statement-statement-note-8-government-assistance-unrecognized-federal-tax-credits-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial instruments [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-9-equipment-components-of-equipment-details" xlink:label="acst_statement-statement-note-9-equipment-components-of-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-9-equipment-components-of-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Equipment - Components of Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-9-equipment-components-of-equipment-details" xlink:to="acst_statement-statement-note-9-equipment-components-of-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-10-intangible-assets-components-of-intangible-assets-details" xlink:label="acst_statement-statement-note-10-intangible-assets-components-of-intangible-assets-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-10-intangible-assets-components-of-intangible-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Intangible Assets - Components of Intangible Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-10-intangible-assets-components-of-intangible-assets-details" xlink:to="acst_statement-statement-note-10-intangible-assets-components-of-intangible-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" xlink:label="acst_statement-statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Trade and Other Payables - Components of Trade and Other Payables (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" xlink:to="acst_statement-statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-12-derivative-warrant-liabilities-reconciliation-details" xlink:label="acst_statement-statement-note-12-derivative-warrant-liabilities-reconciliation-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-12-derivative-warrant-liabilities-reconciliation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Derivative Warrant Liabilities - Reconciliation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-12-derivative-warrant-liabilities-reconciliation-details" xlink:to="acst_statement-statement-note-12-derivative-warrant-liabilities-reconciliation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-12-derivative-warrant-liabilities-assumptions-details" xlink:label="acst_statement-statement-note-12-derivative-warrant-liabilities-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-12-derivative-warrant-liabilities-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Derivative Warrant Liabilities - Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-12-derivative-warrant-liabilities-assumptions-details" xlink:to="acst_statement-statement-note-12-derivative-warrant-liabilities-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details" xlink:label="acst_statement-statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Unsecured Convertible Debentures - Liability and Equity Component Portions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details" xlink:to="acst_statement-statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-14-capital-and-other-components-of-equity-assumptions-details" xlink:label="acst_statement-statement-note-14-capital-and-other-components-of-equity-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-14-capital-and-other-components-of-equity-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Capital and Other Components of Equity - Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-14-capital-and-other-components-of-equity-assumptions-details" xlink:to="acst_statement-statement-note-14-capital-and-other-components-of-equity-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details" xlink:label="acst_statement-statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Capital and Other Components of Equity - Unsecured Convertible Debentures (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details" xlink:to="acst_statement-statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details" xlink:label="acst_statement-statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Capital and Other Components of Equity - Warrants Outstanding (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details" xlink:to="acst_statement-statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for impairment of assets [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-15-personnel-expenses-components-of-personnel-expenses-details" xlink:label="acst_statement-statement-note-15-personnel-expenses-components-of-personnel-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-15-personnel-expenses-components-of-personnel-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Personnel Expenses - Components of Personnel Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-15-personnel-expenses-components-of-personnel-expenses-details" xlink:to="acst_statement-statement-note-15-personnel-expenses-components-of-personnel-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for government grants [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-16-financial-expenses-components-of-finance-income-expenses-details" xlink:label="acst_statement-statement-note-16-financial-expenses-components-of-finance-income-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-16-financial-expenses-components-of-finance-income-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 16 - Financial Expenses - Components of Finance Income (Expenses) (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-16-financial-expenses-components-of-finance-income-expenses-details" xlink:to="acst_statement-statement-note-16-financial-expenses-components-of-finance-income-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-17-sharebased-payments-option-activity-details" xlink:label="acst_statement-statement-note-17-sharebased-payments-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-17-sharebased-payments-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 17 - Share-based Payments - Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-17-sharebased-payments-option-activity-details" xlink:to="acst_statement-statement-note-17-sharebased-payments-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for income tax [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-17-sharebased-payments-weighted-average-assumptions-details" xlink:label="acst_statement-statement-note-17-sharebased-payments-weighted-average-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-17-sharebased-payments-weighted-average-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 17 - Share-based Payments - Weighted Average Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-17-sharebased-payments-weighted-average-assumptions-details" xlink:to="acst_statement-statement-note-17-sharebased-payments-weighted-average-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details" xlink:label="acst_statement-statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 17 - Share-based Payments - Outstanding and Exercisable Options (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details" xlink:to="acst_statement-statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" xlink:label="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 19 - Supplemental Cash Flow Disclosure - Changes in Non-cash Operating Items (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" xlink:to="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details" xlink:label="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 19 - Supplemental Cash Flow Disclosure - Non-cash Transactions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details" xlink:to="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-20-income-taxes-deferred-tax-recovery-expense-details" xlink:label="acst_statement-statement-note-20-income-taxes-deferred-tax-recovery-expense-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-20-income-taxes-deferred-tax-recovery-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 20 - Income Taxes - Deferred Tax (Recovery) Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-20-income-taxes-deferred-tax-recovery-expense-details" xlink:to="acst_statement-statement-note-20-income-taxes-deferred-tax-recovery-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" xlink:label="acst_statement-statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 20 - Income Taxes - Reconciliation of Effective Tax Rate (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" xlink:to="acst_statement-statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for intangible assets and goodwill [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" xlink:label="acst_statement-statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 20 - Income Taxes - Unrecognized Deferred Tax Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" xlink:to="acst_statement-statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest received</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" xlink:label="acst_statement-statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 20 - Income Taxes - Tax attributes and Temporary Differences Available to Reduce Future Years' Taxable Income (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" xlink:to="acst_statement-statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-21-financial-instruments-currency-risk-details" xlink:label="acst_statement-statement-note-21-financial-instruments-currency-risk-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-21-financial-instruments-currency-risk-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 21 - Financial Instruments - Currency Risk (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-21-financial-instruments-currency-risk-details" xlink:to="acst_statement-statement-note-21-financial-instruments-currency-risk-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-21-financial-instruments-financial-liabilities-details" xlink:label="acst_statement-statement-note-21-financial-instruments-financial-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-21-financial-instruments-financial-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 21 - Financial Instruments - Financial Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-21-financial-instruments-financial-liabilities-details" xlink:to="acst_statement-statement-note-21-financial-instruments-financial-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details" xlink:label="acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 24 - Capital Management - Cash and Cash Equivalents (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details" xlink:to="acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals" xlink:label="acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals" xlink:type="locator"/>
    <link:label xlink:label="acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 24 - Capital Management - Cash and Cash Equivalents (Details) (Parentheticals)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals" xlink:to="acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</link:label>
    <link:label xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Maturity of marketable securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatements" xlink:label="acst_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="acst_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NotesToFinancialStatements" xlink:to="acst_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="acst_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for leases [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember" xlink:label="acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than twelve years and not later than thirteen years [member]</link:label>
    <link:label xlink:label="acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for a time band of later than twelve years and not later than thirteen years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember" xlink:to="acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ResearchDevelopmentGeneralAndAdministrationExpense" xlink:label="acst_ResearchDevelopmentGeneralAndAdministrationExpense" xlink:type="locator"/>
    <link:label xlink:label="acst_ResearchDevelopmentGeneralAndAdministrationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_ResearchDevelopmentGeneralAndAdministrationExpense</link:label>
    <link:label xlink:label="acst_ResearchDevelopmentGeneralAndAdministrationExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total related parties expenses</link:label>
    <link:label xlink:label="acst_ResearchDevelopmentGeneralAndAdministrationExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of research, development, general and administration expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ResearchDevelopmentGeneralAndAdministrationExpense" xlink:to="acst_ResearchDevelopmentGeneralAndAdministrationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProportionOfVotingRightsHeldByAnAssociate" xlink:label="acst_ProportionOfVotingRightsHeldByAnAssociate" xlink:type="locator"/>
    <link:label xlink:label="acst_ProportionOfVotingRightsHeldByAnAssociate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_ProportionOfVotingRightsHeldByAnAssociate</link:label>
    <link:label xlink:label="acst_ProportionOfVotingRightsHeldByAnAssociate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of voting rights held by an associate</link:label>
    <link:label xlink:label="acst_ProportionOfVotingRightsHeldByAnAssociate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The proportion of voting rights held by an associate.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ProportionOfVotingRightsHeldByAnAssociate" xlink:to="acst_ProportionOfVotingRightsHeldByAnAssociate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</link:label>
    <link:label xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NeptuneMember" xlink:label="acst_NeptuneMember" xlink:type="locator"/>
    <link:label xlink:label="acst_NeptuneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neptune [member]</link:label>
    <link:label xlink:label="acst_NeptuneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding Netptune.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NeptuneMember" xlink:to="acst_NeptuneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember" xlink:label="acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than sixteen years and not later than seventeen years [member]</link:label>
    <link:label xlink:label="acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for a time band of later than sixteen years and not later than seventeen years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember" xlink:to="acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember" xlink:label="acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than fifteen years and not later than sixteen years [member]</link:label>
    <link:label xlink:label="acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for a time band of later than fifteen years and not later than sixteen years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember" xlink:to="acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember" xlink:label="acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than fourteen years and not later than fifteen years [member]</link:label>
    <link:label xlink:label="acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for a time band of later than fourteen years and not later than fifteen years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember" xlink:to="acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember" xlink:label="acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than thirteen years and not later than fourteen years [member]</link:label>
    <link:label xlink:label="acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for a time band of later than thirteen years and not later than fourteen years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember" xlink:to="acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember" xlink:label="acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than twenty years and not later than twenty-one years [member]</link:label>
    <link:label xlink:label="acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for a time band of later than twenty years and not later than twenty-one years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember" xlink:to="acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember" xlink:label="acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than nineteen years and not later than twenty years [member]</link:label>
    <link:label xlink:label="acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for a time band of later than nineteen years and not later than twenty years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember" xlink:to="acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for provisions [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember" xlink:label="acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than eighteen years and not later than nineteen years [member]</link:label>
    <link:label xlink:label="acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for a time band of later than eighteen years and not later than nineteen years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember" xlink:to="acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember" xlink:label="acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than seventeen years and not later than eighteen years [member]</link:label>
    <link:label xlink:label="acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for a time band of later than seventeen years and not later than eighteen years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember" xlink:to="acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_CashFlowsFromUsedInOperatingActivities</link:label>
    <link:label xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock" xlink:label="acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about trade and other payables [text block]</link:label>
    <link:label xlink:label="acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The detailed disclosure of trade and other payables.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock" xlink:to="acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about intangible assets [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for segment reporting [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare" xlink:label="acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare" xlink:type="locator"/>
    <link:label xlink:label="acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare</link:label>
    <link:label xlink:label="acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of required warrants to be exercised to obtain one common share</link:label>
    <link:label xlink:label="acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of required warrants to be exercised to obtain one common share.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare" xlink:to="acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of objectives, policies and processes for managing capital [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="locator"/>
    <link:label xlink:label="acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label xlink:label="acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</link:label>
    <link:label xlink:label="acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FairValuePerSharesIssuableWarrants" xlink:label="acst_FairValuePerSharesIssuableWarrants" xlink:type="locator"/>
    <link:label xlink:label="acst_FairValuePerSharesIssuableWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_FairValuePerSharesIssuableWarrants</link:label>
    <link:label xlink:label="acst_FairValuePerSharesIssuableWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value per shares issuable warrants</link:label>
    <link:label xlink:label="acst_FairValuePerSharesIssuableWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The fair value per share issuable of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_FairValuePerSharesIssuableWarrants" xlink:to="acst_FairValuePerSharesIssuableWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfNoncashTransactionsTextBlock" xlink:label="acst_DisclosureOfNoncashTransactionsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_DisclosureOfNoncashTransactionsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of noncash transactions [Text Block]</link:label>
    <link:label xlink:label="acst_DisclosureOfNoncashTransactionsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of noncash transactions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DisclosureOfNoncashTransactionsTextBlock" xlink:to="acst_DisclosureOfNoncashTransactionsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of significant accounting policies [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WeightedAverageSharePriceWarrantsIssued" xlink:label="acst_WeightedAverageSharePriceWarrantsIssued" xlink:type="locator"/>
    <link:label xlink:label="acst_WeightedAverageSharePriceWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share price</link:label>
    <link:label xlink:label="acst_WeightedAverageSharePriceWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_WeightedAverageSharePriceWarrantsIssued</link:label>
    <link:label xlink:label="acst_WeightedAverageSharePriceWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price</link:label>
    <link:label xlink:label="acst_WeightedAverageSharePriceWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average share price used as input to the warrants pricing model to calculate the fair value of warrants issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WeightedAverageSharePriceWarrantsIssued" xlink:to="acst_WeightedAverageSharePriceWarrantsIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock" xlink:label="acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of changes in noncash operating items [Text Block]</link:label>
    <link:label xlink:label="acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of changes in noncash operating items.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock" xlink:to="acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ExercisePriceWarrantsIssued" xlink:label="acst_ExercisePriceWarrantsIssued" xlink:type="locator"/>
    <link:label xlink:label="acst_ExercisePriceWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in CAD per share)</link:label>
    <link:label xlink:label="acst_ExercisePriceWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_ExercisePriceWarrantsIssued</link:label>
    <link:label xlink:label="acst_ExercisePriceWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price, warrants issued</link:label>
    <link:label xlink:label="acst_ExercisePriceWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The exercise price of warrants issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ExercisePriceWarrantsIssued" xlink:to="acst_ExercisePriceWarrantsIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLifeWarrantsIssued" xlink:label="acst_WarrantLifeWarrantsIssued" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantLifeWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life (in years) (Year)</link:label>
    <link:label xlink:label="acst_WarrantLifeWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_WarrantLifeWarrantsIssued</link:label>
    <link:label xlink:label="acst_WarrantLifeWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated life (in years) (Year)</link:label>
    <link:label xlink:label="acst_WarrantLifeWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The warrant life of warrants issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantLifeWarrantsIssued" xlink:to="acst_WarrantLifeWarrantsIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RiskFreeInterestRateWarrantsIssued" xlink:label="acst_RiskFreeInterestRateWarrantsIssued" xlink:type="locator"/>
    <link:label xlink:label="acst_RiskFreeInterestRateWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest</link:label>
    <link:label xlink:label="acst_RiskFreeInterestRateWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_RiskFreeInterestRateWarrantsIssued</link:label>
    <link:label xlink:label="acst_RiskFreeInterestRateWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest</link:label>
    <link:label xlink:label="acst_RiskFreeInterestRateWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for warrants issued is expressed, with a remaining term equal to the expected term of the warrant being valued (based on the warrants's remaining contractual life and taking into account the effects of expected early exercise).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_RiskFreeInterestRateWarrantsIssued" xlink:to="acst_RiskFreeInterestRateWarrantsIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain" xlink:label="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain" xlink:type="locator"/>
    <link:label xlink:label="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain</link:label>
    <link:label xlink:label="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant unobservable inputs, increase in five percent of volatility would result in a gain</link:label>
    <link:label xlink:label="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of gain from the increase of 5% of the volatility used for financial instrument classified as a liability using unobservable inputs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain" xlink:to="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss" xlink:label="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss" xlink:type="locator"/>
    <link:label xlink:label="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss</link:label>
    <link:label xlink:label="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant unobservable inputs, increase in five percent of volatility would result in a loss</link:label>
    <link:label xlink:label="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of loss from the increase of 5% of the volatility used for financial instrument classified as a liability using unobservable inputs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss" xlink:to="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" xlink:label="acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" xlink:type="locator"/>
    <link:label xlink:label="acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease for laboratory facility located in Sherbrooke, Qu&#233;bec [member]</link:label>
    <link:label xlink:label="acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding the lease for laboratory facility located in Sherbrooke, Qu&#233;bec.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" xlink:to="acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BiodrogaNutraceuticalsIncMember" xlink:label="acst_BiodrogaNutraceuticalsIncMember" xlink:type="locator"/>
    <link:label xlink:label="acst_BiodrogaNutraceuticalsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biodroga Nutraceuticals Inc. [member]</link:label>
    <link:label xlink:label="acst_BiodrogaNutraceuticalsIncMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the entity Biodroga Nutraceuticals Inc.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_BiodrogaNutraceuticalsIncMember" xlink:to="acst_BiodrogaNutraceuticalsIncMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables" xlink:label="acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables" xlink:type="locator"/>
    <link:label xlink:label="acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public offering transaction costs included in trade and other payables</link:label>
    <link:label xlink:label="acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The noncash transaction related to public offering transaction costs included in trade and other payables.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables" xlink:to="acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering" xlink:label="acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering" xlink:type="locator"/>
    <link:label xlink:label="acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of broker warrants included in net proceeds from public offering</link:label>
    <link:label xlink:label="acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The noncash transaction related to the issuance of broker warrants included in net proceeds from public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering" xlink:to="acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ExpectedVolatilityWarrantsIssued" xlink:label="acst_ExpectedVolatilityWarrantsIssued" xlink:type="locator"/>
    <link:label xlink:label="acst_ExpectedVolatilityWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label xlink:label="acst_ExpectedVolatilityWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_ExpectedVolatilityWarrantsIssued</link:label>
    <link:label xlink:label="acst_ExpectedVolatilityWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label xlink:label="acst_ExpectedVolatilityWarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The expected volatility of the share price used to calculate the fair value of the warrants issued. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in warrants pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ExpectedVolatilityWarrantsIssued" xlink:to="acst_ExpectedVolatilityWarrantsIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_EquipmentIncludedInTradeAndOtherPayables" xlink:label="acst_EquipmentIncludedInTradeAndOtherPayables" xlink:type="locator"/>
    <link:label xlink:label="acst_EquipmentIncludedInTradeAndOtherPayables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment included in trade and other payables</link:label>
    <link:label xlink:label="acst_EquipmentIncludedInTradeAndOtherPayables-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The noncash transaction related to equipment included in trade and other payables.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_EquipmentIncludedInTradeAndOtherPayables" xlink:to="acst_EquipmentIncludedInTradeAndOtherPayables-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables" xlink:label="acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables" xlink:type="locator"/>
    <link:label xlink:label="acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement transaction costs included in trade and other payables</link:label>
    <link:label xlink:label="acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The noncash transaction related to private placement transaction costs included in trade and other payables.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables" xlink:to="acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables" xlink:label="acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables" xlink:type="locator"/>
    <link:label xlink:label="acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in share issue costs from reduction in trade and other payables</link:label>
    <link:label xlink:label="acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The noncash transaction related to reduction in share issue costs from reduction in trade and other payables.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables" xlink:to="acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_InterestPayableIncludedInTradeAndOtherPayables" xlink:label="acst_InterestPayableIncludedInTradeAndOtherPayables" xlink:type="locator"/>
    <link:label xlink:label="acst_InterestPayableIncludedInTradeAndOtherPayables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest payable included in trade and other payables</link:label>
    <link:label xlink:label="acst_InterestPayableIncludedInTradeAndOtherPayables-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The noncash transaction related to interest payable included in trade and other payables.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_InterestPayableIncludedInTradeAndOtherPayables" xlink:to="acst_InterestPayableIncludedInTradeAndOtherPayables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade and other receivables [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants" xlink:label="acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants" xlink:type="locator"/>
    <link:label xlink:label="acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants</link:label>
    <link:label xlink:label="acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of common shares issuable from contingent warrants</link:label>
    <link:label xlink:label="acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum number of common shares issuable from contingent warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants" xlink:to="acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfPersonnelExpensesTextBlock" xlink:label="acst_DisclosureOfPersonnelExpensesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_DisclosureOfPersonnelExpensesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of personnel expenses [text block</link:label>
    <link:label xlink:label="acst_DisclosureOfPersonnelExpensesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for employee expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DisclosureOfPersonnelExpensesTextBlock" xlink:to="acst_DisclosureOfPersonnelExpensesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade and other payables [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ResearchAndDevelopmentProjectsMember" xlink:label="acst_ResearchAndDevelopmentProjectsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_ResearchAndDevelopmentProjectsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development projects [member]</link:label>
    <link:label xlink:label="acst_ResearchAndDevelopmentProjectsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to research and development projects.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ResearchAndDevelopmentProjectsMember" xlink:to="acst_ResearchAndDevelopmentProjectsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock" xlink:label="acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of components of personnel expenses [text block]</link:label>
    <link:label xlink:label="acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of components of personnel expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock" xlink:to="acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsConvertibleConversionPrice" xlink:label="acst_BorrowingsConvertibleConversionPrice" xlink:type="locator"/>
    <link:label xlink:label="acst_BorrowingsConvertibleConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_BorrowingsConvertibleConversionPrice</link:label>
    <link:label xlink:label="acst_BorrowingsConvertibleConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, convertible, conversion price</link:label>
    <link:label xlink:label="acst_BorrowingsConvertibleConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The price per share of the conversion feature embedded in the debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_BorrowingsConvertibleConversionPrice" xlink:to="acst_BorrowingsConvertibleConversionPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TradeAndOtherPayablesMember" xlink:label="acst_TradeAndOtherPayablesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TradeAndOtherPayablesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other payables [member]</link:label>
    <link:label xlink:label="acst_TradeAndOtherPayablesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for the trade and other payables.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TradeAndOtherPayablesMember" xlink:to="acst_TradeAndOtherPayablesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccountingProfit" xlink:label="ifrs-full_AccountingProfit" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AccountingProfit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccountingProfit" xlink:to="ifrs-full_AccountingProfit-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion" xlink:label="acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion</link:label>
    <link:label xlink:label="acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercisable price per share after borrowings conversion</link:label>
    <link:label xlink:label="acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The warrants exercisable price per share after borrowings conversion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion" xlink:to="acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnsecuredConvertibleDebenturesMember" xlink:label="acst_UnsecuredConvertibleDebenturesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_UnsecuredConvertibleDebenturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unsecured convertible debentures [member]</link:label>
    <link:label xlink:label="acst_UnsecuredConvertibleDebenturesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for unsecured convertible debentures.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_UnsecuredConvertibleDebenturesMember" xlink:to="acst_UnsecuredConvertibleDebenturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based compensation costs</link:label>
    <link:label xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock" xlink:label="acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure for components of finance income (cost) [text block]</link:label>
    <link:label xlink:label="acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of finance income (cost).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock" xlink:to="acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsConvertibleThresholdConsecutiveTradingDays" xlink:label="acst_BorrowingsConvertibleThresholdConsecutiveTradingDays" xlink:type="locator"/>
    <link:label xlink:label="acst_BorrowingsConvertibleThresholdConsecutiveTradingDays-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_BorrowingsConvertibleThresholdConsecutiveTradingDays</link:label>
    <link:label xlink:label="acst_BorrowingsConvertibleThresholdConsecutiveTradingDays-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, convertible, threshold consecutive trading days</link:label>
    <link:label xlink:label="acst_BorrowingsConvertibleThresholdConsecutiveTradingDays-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_BorrowingsConvertibleThresholdConsecutiveTradingDays" xlink:to="acst_BorrowingsConvertibleThresholdConsecutiveTradingDays-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsDiscountOfBorrowingPrincipalAmount" xlink:label="acst_BorrowingsDiscountOfBorrowingPrincipalAmount" xlink:type="locator"/>
    <link:label xlink:label="acst_BorrowingsDiscountOfBorrowingPrincipalAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_BorrowingsDiscountOfBorrowingPrincipalAmount</link:label>
    <link:label xlink:label="acst_BorrowingsDiscountOfBorrowingPrincipalAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, discount of borrowing principal amount</link:label>
    <link:label xlink:label="acst_BorrowingsDiscountOfBorrowingPrincipalAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The discount rate of borrowing principal amount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_BorrowingsDiscountOfBorrowingPrincipalAmount" xlink:to="acst_BorrowingsDiscountOfBorrowingPrincipalAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_GeographicalAreasMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="ifrs-full_GeographicalAreasMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum" xlink:label="acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum" xlink:type="locator"/>
    <link:label xlink:label="acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum</link:label>
    <link:label xlink:label="acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, accelerated conversion feature, weighted average share price minimum</link:label>
    <link:label xlink:label="acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum share price for an accelerated conversion feature for borrowings.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum" xlink:to="acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AccrualsClassifiedAsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_AccrualsClassifiedAsCurrent</link:label>
    <link:label xlink:label="ifrs-full_AccrualsClassifiedAsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities and other payables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccrualsClassifiedAsCurrent" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_GeographicalAreasAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate" xlink:label="acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate" xlink:type="locator"/>
    <link:label xlink:label="acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate</link:label>
    <link:label xlink:label="acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, accelerated conversion feature, minimum time after issuance date</link:label>
    <link:label xlink:label="acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum time after issuance date for an accelerated conversion feature to be available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate" xlink:to="acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CashAndCashEquivalentsMember" xlink:label="acst_CashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_CashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents [member]</link:label>
    <link:label xlink:label="acst_CashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for cash and cash equivalents.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CashAndCashEquivalentsMember" xlink:to="acst_CashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_ShorttermEmployeeBenefitsAccruals</link:label>
    <link:label xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee salaries and benefits payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_FinancialAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_FinancialAssets</link:label>
    <link:label xlink:label="ifrs-full_FinancialAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationStockOptionPlanMember" xlink:label="acst_CorporationStockOptionPlanMember" xlink:type="locator"/>
    <link:label xlink:label="acst_CorporationStockOptionPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporation stock option plan [member]</link:label>
    <link:label xlink:label="acst_CorporationStockOptionPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the share-based payment plan; Corporation stock option plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CorporationStockOptionPlanMember" xlink:to="acst_CorporationStockOptionPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MaximumNumberOfSharesAuthorized" xlink:label="acst_MaximumNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="acst_MaximumNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_MaximumNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="acst_MaximumNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares authorized</link:label>
    <link:label xlink:label="acst_MaximumNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_MaximumNumberOfSharesAuthorized" xlink:to="acst_MaximumNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</link:label>
    <link:label xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ProductsAndServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="ifrs-full_ProductsAndServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences" xlink:label="acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences" xlink:type="locator"/>
    <link:label xlink:label="acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in unrecognized deductible temporary differences</link:label>
    <link:label xlink:label="acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to change in unrecognized deductible temporary differences.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences" xlink:to="acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ProductsAndServicesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and services [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfPermanentDifferencesAndOther" xlink:label="acst_TaxEffectOfPermanentDifferencesAndOther" xlink:type="locator"/>
    <link:label xlink:label="acst_TaxEffectOfPermanentDifferencesAndOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Permanent differences and other</link:label>
    <link:label xlink:label="acst_TaxEffectOfPermanentDifferencesAndOther-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to permanent differences and other.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxEffectOfPermanentDifferencesAndOther" xlink:to="acst_TaxEffectOfPermanentDifferencesAndOther-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MaximumNumberOfSharesAuthorizedAsPercentage" xlink:label="acst_MaximumNumberOfSharesAuthorizedAsPercentage" xlink:type="locator"/>
    <link:label xlink:label="acst_MaximumNumberOfSharesAuthorizedAsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_MaximumNumberOfSharesAuthorizedAsPercentage</link:label>
    <link:label xlink:label="acst_MaximumNumberOfSharesAuthorizedAsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares authorized as percentage</link:label>
    <link:label xlink:label="acst_MaximumNumberOfSharesAuthorizedAsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of issued and outstanding stock stock that can issued from share-based plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_MaximumNumberOfSharesAuthorizedAsPercentage" xlink:to="acst_MaximumNumberOfSharesAuthorizedAsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss" xlink:label="acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss" xlink:type="locator"/>
    <link:label xlink:label="acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-deductible stock-based compensation</link:label>
    <link:label xlink:label="acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible stock-based compensation in determining taxable profit (tax loss).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss" xlink:to="acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsConvertibleEquityIssuedFloorPrice" xlink:label="acst_BorrowingsConvertibleEquityIssuedFloorPrice" xlink:type="locator"/>
    <link:label xlink:label="acst_BorrowingsConvertibleEquityIssuedFloorPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_BorrowingsConvertibleEquityIssuedFloorPrice</link:label>
    <link:label xlink:label="acst_BorrowingsConvertibleEquityIssuedFloorPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, convertible, equity issued, floor price</link:label>
    <link:label xlink:label="acst_BorrowingsConvertibleEquityIssuedFloorPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The floor price of share payments related to borrowings converted.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_BorrowingsConvertibleEquityIssuedFloorPrice" xlink:to="acst_BorrowingsConvertibleEquityIssuedFloorPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock" xlink:label="acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of accounting profit multiplied by applicable tax rates [Text Block]</link:label>
    <link:label xlink:label="acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of reconciliation of accounting profit multiplied by applicable tax rates.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock" xlink:to="acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DescriptionOfVestingPeriodShareOptionGranted" xlink:label="acst_DescriptionOfVestingPeriodShareOptionGranted" xlink:type="locator"/>
    <link:label xlink:label="acst_DescriptionOfVestingPeriodShareOptionGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_DescriptionOfVestingPeriodShareOptionGranted</link:label>
    <link:label xlink:label="acst_DescriptionOfVestingPeriodShareOptionGranted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of vesting period, share option granted</link:label>
    <link:label xlink:label="acst_DescriptionOfVestingPeriodShareOptionGranted-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The vesting period of share options granted.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DescriptionOfVestingPeriodShareOptionGranted" xlink:to="acst_DescriptionOfVestingPeriodShareOptionGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life outstanding</link:label>
    <link:label xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss" xlink:label="acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss" xlink:type="locator"/>
    <link:label xlink:label="acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-deductible change in fair value</link:label>
    <link:label xlink:label="acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to not deductible change in fair value in determining taxable profit (tax loss).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss" xlink:to="acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NumberOfOutstandingShareOptions-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of options outstanding</link:label>
    <link:label xlink:label="ifrs-full_NumberOfOutstandingShareOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_NumberOfOutstandingShareOptions</link:label>
    <link:label xlink:label="ifrs-full_NumberOfOutstandingShareOptions-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of year</link:label>
    <link:label xlink:label="ifrs-full_NumberOfOutstandingShareOptions-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOutstandingShareOptions" xlink:to="ifrs-full_NumberOfOutstandingShareOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember" xlink:label="acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax basis of unsecured convertible debentures in excess of carrying value [Member]</link:label>
    <link:label xlink:label="acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for temporary differences related to tax basis of unsecured convertible debentures in excess of carrying value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember" xlink:to="acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember" xlink:label="acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plan and equipment and intangible assets [Member]</link:label>
    <link:label xlink:label="acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for temporary differences related to property, plan and equipment and intangible assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember" xlink:to="acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_WeightedAverageShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ConsultantsMember" xlink:label="acst_ConsultantsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_ConsultantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consultants [member]</link:label>
    <link:label xlink:label="acst_ConsultantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents consultants of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ConsultantsMember" xlink:to="acst_ConsultantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ChangesInDeferredTaxLiabilityAssetTextBlock" xlink:label="acst_ChangesInDeferredTaxLiabilityAssetTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_ChangesInDeferredTaxLiabilityAssetTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in deferred tax liability (asset) [Text Block]</link:label>
    <link:label xlink:label="acst_ChangesInDeferredTaxLiabilityAssetTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of changes in deferred tax liability (asset).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ChangesInDeferredTaxLiabilityAssetTextBlock" xlink:to="acst_ChangesInDeferredTaxLiabilityAssetTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CurrencyRiskForEuroMember" xlink:label="acst_CurrencyRiskForEuroMember" xlink:type="locator"/>
    <link:label xlink:label="acst_CurrencyRiskForEuroMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency risk for Euro [member]</link:label>
    <link:label xlink:label="acst_CurrencyRiskForEuroMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for the currency risk for the Euro.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CurrencyRiskForEuroMember" xlink:to="acst_CurrencyRiskForEuroMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CurrencyRiskForUSDMember" xlink:label="acst_CurrencyRiskForUSDMember" xlink:type="locator"/>
    <link:label xlink:label="acst_CurrencyRiskForUSDMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency risk for USD [member]</link:label>
    <link:label xlink:label="acst_CurrencyRiskForUSDMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for the currency risk for US dollars.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CurrencyRiskForUSDMember" xlink:to="acst_CurrencyRiskForUSDMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price</link:label>
    <link:label xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_ExercisePriceOfOutstandingShareOptions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation, amortisation and impairment [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock" xlink:label="acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax attributes and temporary differences, which are available to reduce future years&#8217; taxable income [Text Block]</link:label>
    <link:label xlink:label="acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of tax attributes and temporary differences, which are available to reduce future years&#8217; taxable income.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock" xlink:to="acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price exercisable</link:label>
    <link:label xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement</link:label>
    <link:label xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageSharePrice" xlink:label="ifrs-full_WeightedAverageSharePrice" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_WeightedAverageSharePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_WeightedAverageSharePrice</link:label>
    <link:label xlink:label="ifrs-full_WeightedAverageSharePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average share price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePrice" xlink:to="ifrs-full_WeightedAverageSharePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement</link:label>
    <link:label xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:label="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections</link:label>
    <link:label xlink:label="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate applied to cash flow projections</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:to="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_EquityComponentOfUnsecuredConvertibleDebenturesMember" xlink:label="acst_EquityComponentOfUnsecuredConvertibleDebenturesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_EquityComponentOfUnsecuredConvertibleDebenturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity component of unsecured convertible debentures [member]</link:label>
    <link:label xlink:label="acst_EquityComponentOfUnsecuredConvertibleDebenturesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding the equity component of unsecured convertible debentures.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_EquityComponentOfUnsecuredConvertibleDebenturesMember" xlink:to="acst_EquityComponentOfUnsecuredConvertibleDebenturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement</link:label>
    <link:label xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, forfeited</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember" xlink:label="acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability portion of unsecured convertible debentures [member]</link:label>
    <link:label xlink:label="acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding the liability portion of unsecured convertible debentures.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember" xlink:to="acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement</link:label>
    <link:label xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ReceivablesMember" xlink:label="acst_ReceivablesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_ReceivablesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables [member]</link:label>
    <link:label xlink:label="acst_ReceivablesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for receivables.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ReceivablesMember" xlink:to="acst_ReceivablesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement</link:label>
    <link:label xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, expired</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</link:label>
    <link:label xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options, expired</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_FinancialLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</link:label>
    <link:label xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
    <link:label xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options, exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationEquityIncentivePlanMember" xlink:label="acst_CorporationEquityIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="acst_CorporationEquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporation equity incentive plan [member]</link:label>
    <link:label xlink:label="acst_CorporationEquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the company's corporation equity incentive plan for instruments other than options. Including, but not limited to, restricted stock units, performance share units, restricted shares, deferred share units and other share-based awards.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CorporationEquityIncentivePlanMember" xlink:to="acst_CorporationEquityIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of effect of changes in foreign exchange rates [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement</link:label>
    <link:label xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_FinancialAssetsCategoryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets, category [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsCategoryMember" xlink:to="ifrs-full_FinancialAssetsCategoryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ForeignExchangeRiskCurrencyExposure" xlink:label="acst_ForeignExchangeRiskCurrencyExposure" xlink:type="locator"/>
    <link:label xlink:label="acst_ForeignExchangeRiskCurrencyExposure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange currency exposures</link:label>
    <link:label xlink:label="acst_ForeignExchangeRiskCurrencyExposure-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of currency exposure which impact profit and loss expressed as long/(short).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ForeignExchangeRiskCurrencyExposure" xlink:to="acst_ForeignExchangeRiskCurrencyExposure-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NetForeignExchangeGain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetForeignExchangeGain" xlink:to="ifrs-full_NetForeignExchangeGain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of financial assets [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of options exercisable</link:label>
    <link:label xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</link:label>
    <link:label xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement</link:label>
    <link:label xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of instruments granted in share-based payment arrangement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyOneMember" xlink:label="acst_TwoThousandThirtyOneMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TwoThousandThirtyOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2031 [Member]</link:label>
    <link:label xlink:label="acst_TwoThousandThirtyOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the year of 2031.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TwoThousandThirtyOneMember" xlink:to="acst_TwoThousandThirtyOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss</link:label>
    <link:label xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total financial liabilities at fair value through profit or loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</link:label>
    <link:label xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options, forfeited</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyMember" xlink:label="acst_TwoThousandThirtyMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TwoThousandThirtyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2030 [Member]</link:label>
    <link:label xlink:label="acst_TwoThousandThirtyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the year of 2030.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TwoThousandThirtyMember" xlink:to="acst_TwoThousandThirtyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</link:label>
    <link:label xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandTwentyNineMember" xlink:label="acst_TwoThousandTwentyNineMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TwoThousandTwentyNineMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2029 [Member]</link:label>
    <link:label xlink:label="acst_TwoThousandTwentyNineMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the year of 2029.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TwoThousandTwentyNineMember" xlink:to="acst_TwoThousandTwentyNineMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_SharebasedPaymentArrangementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyFiveMember" xlink:label="acst_TwoThousandThirtyFiveMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TwoThousandThirtyFiveMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2035 [Member]</link:label>
    <link:label xlink:label="acst_TwoThousandThirtyFiveMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the year of 2035.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TwoThousandThirtyFiveMember" xlink:to="acst_TwoThousandThirtyFiveMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyFourMember" xlink:label="acst_TwoThousandThirtyFourMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TwoThousandThirtyFourMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2034 [Member]</link:label>
    <link:label xlink:label="acst_TwoThousandThirtyFourMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the year of 2034.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TwoThousandThirtyFourMember" xlink:to="acst_TwoThousandThirtyFourMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyThreeMember" xlink:label="acst_TwoThousandThirtyThreeMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TwoThousandThirtyThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2033 [Member]</link:label>
    <link:label xlink:label="acst_TwoThousandThirtyThreeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the year of 2033.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TwoThousandThirtyThreeMember" xlink:to="acst_TwoThousandThirtyThreeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyTwoMember" xlink:label="acst_TwoThousandThirtyTwoMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TwoThousandThirtyTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2032 [Member]</link:label>
    <link:label xlink:label="acst_TwoThousandThirtyTwoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the year of 2032.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TwoThousandThirtyTwoMember" xlink:to="acst_TwoThousandThirtyTwoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProvincialMember" xlink:label="acst_ProvincialMember" xlink:type="locator"/>
    <link:label xlink:label="acst_ProvincialMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provincial [Member]</link:label>
    <link:label xlink:label="acst_ProvincialMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to provincial.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ProvincialMember" xlink:to="acst_ProvincialMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThouandThirtySevenMember" xlink:label="acst_TwoThouandThirtySevenMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TwoThouandThirtySevenMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2037 [Member]</link:label>
    <link:label xlink:label="acst_TwoThouandThirtySevenMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the year of 2037.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TwoThouandThirtySevenMember" xlink:to="acst_TwoThouandThirtySevenMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtySixMember" xlink:label="acst_TwoThousandThirtySixMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TwoThousandThirtySixMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2036 [Member]</link:label>
    <link:label xlink:label="acst_TwoThousandThirtySixMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the year of 2036.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TwoThousandThirtySixMember" xlink:to="acst_TwoThousandThirtySixMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RangeFourOfExercisesPricesMember" xlink:label="acst_RangeFourOfExercisesPricesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_RangeFourOfExercisesPricesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range four of exercises prices [member]</link:label>
    <link:label xlink:label="acst_RangeFourOfExercisesPricesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This stand member for the fourth range of exercise prices.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_RangeFourOfExercisesPricesMember" xlink:to="acst_RangeFourOfExercisesPricesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RangeThreeOfExercisesPricesMember" xlink:label="acst_RangeThreeOfExercisesPricesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_RangeThreeOfExercisesPricesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range three of exercises prices [member]</link:label>
    <link:label xlink:label="acst_RangeThreeOfExercisesPricesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This stand member for the third range of exercise prices.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_RangeThreeOfExercisesPricesMember" xlink:to="acst_RangeThreeOfExercisesPricesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RangeTwoOfExercisesPricesMember" xlink:label="acst_RangeTwoOfExercisesPricesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_RangeTwoOfExercisesPricesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range two of exercises prices [member]</link:label>
    <link:label xlink:label="acst_RangeTwoOfExercisesPricesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This stand member for the second range of exercise prices.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_RangeTwoOfExercisesPricesMember" xlink:to="acst_RangeTwoOfExercisesPricesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RangeOneOfExercisesPricesMember" xlink:label="acst_RangeOneOfExercisesPricesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_RangeOneOfExercisesPricesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range one of exercises prices [member]</link:label>
    <link:label xlink:label="acst_RangeOneOfExercisesPricesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This stand member for the first range of exercise prices.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_RangeOneOfExercisesPricesMember" xlink:to="acst_RangeOneOfExercisesPricesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ConversionRatio" xlink:label="acst_ConversionRatio" xlink:type="locator"/>
    <link:label xlink:label="acst_ConversionRatio-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_ConversionRatio</link:label>
    <link:label xlink:label="acst_ConversionRatio-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion ratio</link:label>
    <link:label xlink:label="acst_ConversionRatio-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ratio applied to the conversion of equity instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ConversionRatio" xlink:to="acst_ConversionRatio-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassBSharesMember" xlink:label="acst_ClassBSharesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_ClassBSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class B shares [Member]</link:label>
    <link:label xlink:label="acst_ClassBSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class B shares, voting (ten votes per share), non-participating, without par value and maximum annual non-cumulative dividend of 5% on the amount paid for said shares. Class B shares are convertible, at the holder&#8217;s discretion, into Class A shares (Common Shares), on a one-for-one basis, and Class B shares are redeemable at the holder&#8217;s discretion for $0.80 per share, subject to certain conditions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ClassBSharesMember" xlink:to="acst_ClassBSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NonCumulativeDividendRate" xlink:label="acst_NonCumulativeDividendRate" xlink:type="locator"/>
    <link:label xlink:label="acst_NonCumulativeDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_NonCumulativeDividendRate</link:label>
    <link:label xlink:label="acst_NonCumulativeDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cumulative dividend rate</link:label>
    <link:label xlink:label="acst_NonCumulativeDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The non-cumulative dividend rate of a class of share.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NonCumulativeDividendRate" xlink:to="acst_NonCumulativeDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RangeFiveOfExercisesPricesMember" xlink:label="acst_RangeFiveOfExercisesPricesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_RangeFiveOfExercisesPricesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range five of exercises prices [member]</link:label>
    <link:label xlink:label="acst_RangeFiveOfExercisesPricesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This stand member for the fifth range of exercise prices.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_RangeFiveOfExercisesPricesMember" xlink:to="acst_RangeFiveOfExercisesPricesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassDAndESharesMember" xlink:label="acst_ClassDAndESharesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_ClassDAndESharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class D and E shares [Member]</link:label>
    <link:label xlink:label="acst_ClassDAndESharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class D and E shares, non-voting, non-participating, without par value and maximum monthly non-cumulative dividend between 0.5% and 2% on the amount paid for said shares. Class D and E shares are convertible, at the holder&#8217;s discretion, into Class A shares (Common Shares), on a one-for-one basis, and Class D and E shares are redeemable at the holder&#8217;s discretion, subject to certain conditions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ClassDAndESharesMember" xlink:to="acst_ClassDAndESharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassCSharesMember" xlink:label="acst_ClassCSharesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_ClassCSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class C shares [Member]</link:label>
    <link:label xlink:label="acst_ClassCSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class C shares, non-voting, non-participating, without par value and maximum annual non-cumulative dividend of 5% on the amount paid for said shares. Class C shares are convertible, at the holder&#8217;s discretion, into Class A shares (Common Shares), on a one-for-one basis, and Class C shares are redeemable at the holder&#8217;s discretion for $0.20 per share, subject to certain conditions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ClassCSharesMember" xlink:to="acst_ClassCSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RedeemablePricePerShare" xlink:label="acst_RedeemablePricePerShare" xlink:type="locator"/>
    <link:label xlink:label="acst_RedeemablePricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_RedeemablePricePerShare</link:label>
    <link:label xlink:label="acst_RedeemablePricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable price per share</link:label>
    <link:label xlink:label="acst_RedeemablePricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The per share price of redeemable equity instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_RedeemablePricePerShare" xlink:to="acst_RedeemablePricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:label="acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:type="locator"/>
    <link:label xlink:label="acst_Series2017BWBrokerWarrantsRelatedToEquityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series 2017-BW Broker warrants related to equity [member]</link:label>
    <link:label xlink:label="acst_Series2017BWBrokerWarrantsRelatedToEquityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to series 2017-BW Broker warrants related to equity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:to="acst_Series2017BWBrokerWarrantsRelatedToEquityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsRelatingToLiabilitiesMember" xlink:label="acst_WarrantsRelatingToLiabilitiesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantsRelatingToLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants relating to liabilities [member]</link:label>
    <link:label xlink:label="acst_WarrantsRelatingToLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers warrants relating to liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantsRelatingToLiabilitiesMember" xlink:to="acst_WarrantsRelatingToLiabilitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:label="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:type="locator"/>
    <link:label xlink:label="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2017 Unsecured convertible debenture conversion option and contingent warrant related to equity [member]</link:label>
    <link:label xlink:label="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the 2017 Unsecured convertible debenture conversion option and contingent warrant related to equity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:to="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of research and development expense [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel of entity or parent [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassOfWarrantOrRightOutstanding" xlink:label="acst_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="acst_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_ClassOfWarrantOrRightOutstanding</link:label>
    <link:label xlink:label="acst_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants (in shares)</link:label>
    <link:label xlink:label="acst_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants or rights outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ClassOfWarrantOrRightOutstanding" xlink:to="acst_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsRelatedToEquityMember" xlink:label="acst_WarrantsRelatedToEquityMember" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantsRelatedToEquityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants related to equity [member]</link:label>
    <link:label xlink:label="acst_WarrantsRelatedToEquityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to warrants related to equity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantsRelatedToEquityMember" xlink:to="acst_WarrantsRelatedToEquityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnitSharesOfClassAShare" xlink:label="acst_UnitSharesOfClassAShare" xlink:type="locator"/>
    <link:label xlink:label="acst_UnitSharesOfClassAShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_UnitSharesOfClassAShare</link:label>
    <link:label xlink:label="acst_UnitSharesOfClassAShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unit, shares of class A share</link:label>
    <link:label xlink:label="acst_UnitSharesOfClassAShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of class A shares included in each unit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_UnitSharesOfClassAShare" xlink:to="acst_UnitSharesOfClassAShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ParentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParentMember" xlink:to="ifrs-full_ParentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromIssuingUnits" xlink:label="acst_ProceedsFromIssuingUnits" xlink:type="locator"/>
    <link:label xlink:label="acst_ProceedsFromIssuingUnits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_ProceedsFromIssuingUnits</link:label>
    <link:label xlink:label="acst_ProceedsFromIssuingUnits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuing units</link:label>
    <link:label xlink:label="acst_ProceedsFromIssuingUnits-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from issuing units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ProceedsFromIssuingUnits" xlink:to="acst_ProceedsFromIssuingUnits-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnitIssuedPricePerUnit" xlink:label="acst_UnitIssuedPricePerUnit" xlink:type="locator"/>
    <link:label xlink:label="acst_UnitIssuedPricePerUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_UnitIssuedPricePerUnit</link:label>
    <link:label xlink:label="acst_UnitIssuedPricePerUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unit issued, price per unit</link:label>
    <link:label xlink:label="acst_UnitIssuedPricePerUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The price per unit for units issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_UnitIssuedPricePerUnit" xlink:to="acst_UnitIssuedPricePerUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfUnitsIssuedDuringPeriod" xlink:label="acst_NumberOfUnitsIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="acst_NumberOfUnitsIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_NumberOfUnitsIssuedDuringPeriod</link:label>
    <link:label xlink:label="acst_NumberOfUnitsIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of units issued during period</link:label>
    <link:label xlink:label="acst_NumberOfUnitsIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of units issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NumberOfUnitsIssuedDuringPeriod" xlink:to="acst_NumberOfUnitsIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Categories of related parties [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfSharesCalledByEachWarrant" xlink:label="acst_NumberOfSharesCalledByEachWarrant" xlink:type="locator"/>
    <link:label xlink:label="acst_NumberOfSharesCalledByEachWarrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_NumberOfSharesCalledByEachWarrant</link:label>
    <link:label xlink:label="acst_NumberOfSharesCalledByEachWarrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares called by each warrant</link:label>
    <link:label xlink:label="acst_NumberOfSharesCalledByEachWarrant-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares called by each whole warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NumberOfSharesCalledByEachWarrant" xlink:to="acst_NumberOfSharesCalledByEachWarrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_Liabilities</link:label>
    <link:label xlink:label="ifrs-full_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DerivativeWarrantLiabilitiesMember" xlink:label="acst_DerivativeWarrantLiabilitiesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_DerivativeWarrantLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative warrant liabilities [member]</link:label>
    <link:label xlink:label="acst_DerivativeWarrantLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to derivative warrant liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DerivativeWarrantLiabilitiesMember" xlink:to="acst_DerivativeWarrantLiabilitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassOfWarrantOrRightOutstandingTextBlock" xlink:label="acst_ClassOfWarrantOrRightOutstandingTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_ClassOfWarrantOrRightOutstandingTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of warrant or right outstanding [text block]</link:label>
    <link:label xlink:label="acst_ClassOfWarrantOrRightOutstandingTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of class of warrant or right outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ClassOfWarrantOrRightOutstandingTextBlock" xlink:to="acst_ClassOfWarrantOrRightOutstandingTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for related parties [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsAndRightsOutstanding" xlink:label="acst_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_WarrantsAndRightsOutstanding</link:label>
    <link:label xlink:label="acst_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights outstanding</link:label>
    <link:label xlink:label="acst_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantsAndRightsOutstanding" xlink:to="acst_WarrantsAndRightsOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ShareIssuedPricePerShare" xlink:label="acst_ShareIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="acst_ShareIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_ShareIssuedPricePerShare</link:label>
    <link:label xlink:label="acst_ShareIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issued, price per share</link:label>
    <link:label xlink:label="acst_ShareIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The price per share of share issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ShareIssuedPricePerShare" xlink:to="acst_ShareIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfSharesCalledByWarrants" xlink:label="acst_NumberOfSharesCalledByWarrants" xlink:type="locator"/>
    <link:label xlink:label="acst_NumberOfSharesCalledByWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_NumberOfSharesCalledByWarrants</link:label>
    <link:label xlink:label="acst_NumberOfSharesCalledByWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares called by warrants</link:label>
    <link:label xlink:label="acst_NumberOfSharesCalledByWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares called by warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NumberOfSharesCalledByWarrants" xlink:to="acst_NumberOfSharesCalledByWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestRevenueExpense" xlink:label="ifrs-full_InterestRevenueExpense" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_InterestRevenueExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_InterestRevenueExpense</link:label>
    <link:label xlink:label="ifrs-full_InterestRevenueExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income (expense)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRevenueExpense" xlink:to="ifrs-full_InterestRevenueExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnitIssuanceCosts" xlink:label="acst_UnitIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="acst_UnitIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_UnitIssuanceCosts</link:label>
    <link:label xlink:label="acst_UnitIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unit issuance costs</link:label>
    <link:label xlink:label="acst_UnitIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The costs incurred related to the issuance of unit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_UnitIssuanceCosts" xlink:to="acst_UnitIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ExercisePriceFor10Warrants" xlink:label="acst_ExercisePriceFor10Warrants" xlink:type="locator"/>
    <link:label xlink:label="acst_ExercisePriceFor10Warrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_ExercisePriceFor10Warrants</link:label>
    <link:label xlink:label="acst_ExercisePriceFor10Warrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price for 10 warrants</link:label>
    <link:label xlink:label="acst_ExercisePriceFor10Warrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The exercise price of warrants when 10 warrants exercised.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ExercisePriceFor10Warrants" xlink:to="acst_ExercisePriceFor10Warrants-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ShareBasedPaymentCostsAllocatedToDebt" xlink:label="acst_ShareBasedPaymentCostsAllocatedToDebt" xlink:type="locator"/>
    <link:label xlink:label="acst_ShareBasedPaymentCostsAllocatedToDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_ShareBasedPaymentCostsAllocatedToDebt</link:label>
    <link:label xlink:label="acst_ShareBasedPaymentCostsAllocatedToDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment costs allocated to debt</link:label>
    <link:label xlink:label="acst_ShareBasedPaymentCostsAllocatedToDebt-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The mount of costs allocated to debt related to share-based payments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ShareBasedPaymentCostsAllocatedToDebt" xlink:to="acst_ShareBasedPaymentCostsAllocatedToDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ShareBasedPaymentCostsAllocatedToShareCapital" xlink:label="acst_ShareBasedPaymentCostsAllocatedToShareCapital" xlink:type="locator"/>
    <link:label xlink:label="acst_ShareBasedPaymentCostsAllocatedToShareCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_ShareBasedPaymentCostsAllocatedToShareCapital</link:label>
    <link:label xlink:label="acst_ShareBasedPaymentCostsAllocatedToShareCapital-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment costs allocated to share capital</link:label>
    <link:label xlink:label="acst_ShareBasedPaymentCostsAllocatedToShareCapital-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of costs allocated to share capital related to share-based payment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ShareBasedPaymentCostsAllocatedToShareCapital" xlink:to="acst_ShareBasedPaymentCostsAllocatedToShareCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesCurrent" xlink:label="acst_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="acst_MarketableSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current marketable securities</link:label>
    <link:label xlink:label="acst_MarketableSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label xlink:label="acst_MarketableSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of current marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_MarketableSecuritiesCurrent" xlink:to="acst_MarketableSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfMarketableSecuritiesTextBlock" xlink:label="acst_DisclosureOfMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_DisclosureOfMarketableSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of marketable securities [text block]</link:label>
    <link:label xlink:label="acst_DisclosureOfMarketableSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DisclosureOfMarketableSecuritiesTextBlock" xlink:to="acst_DisclosureOfMarketableSecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major ordinary share transactions [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares" xlink:label="acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares" xlink:type="locator"/>
    <link:label xlink:label="acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based payment transactions for the period (in shares)</link:label>
    <link:label xlink:label="acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) in the number of shares outstanding through share-based payment transactions.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares" xlink:to="acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DeferredFinancingCostsCurrent" xlink:label="acst_DeferredFinancingCostsCurrent" xlink:type="locator"/>
    <link:label xlink:label="acst_DeferredFinancingCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label xlink:label="acst_DeferredFinancingCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs, current</link:label>
    <link:label xlink:label="acst_DeferredFinancingCostsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of current deferred financing costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DeferredFinancingCostsCurrent" xlink:to="acst_DeferredFinancingCostsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NotLaterThanSixMonthsMember" xlink:label="acst_NotLaterThanSixMonthsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_NotLaterThanSixMonthsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than six months [member]</link:label>
    <link:label xlink:label="acst_NotLaterThanSixMonthsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for a time band of not later than six months.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NotLaterThanSixMonthsMember" xlink:to="acst_NotLaterThanSixMonthsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositOneMember" xlink:label="acst_TermDepositOneMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TermDepositOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term deposit, one [Member]</link:label>
    <link:label xlink:label="acst_TermDepositOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the first tranche of term deposit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TermDepositOneMember" xlink:to="acst_TermDepositOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_KeyManagementPersonnelCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_KeyManagementPersonnelCompensation</link:label>
    <link:label xlink:label="ifrs-full_KeyManagementPersonnelCompensation-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total key management personnel compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock" xlink:label="acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of unrecognized deferred tax assets [text block]</link:label>
    <link:label xlink:label="acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of unrecognized deferred tax assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock" xlink:to="acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecurties" xlink:label="acst_MarketableSecurties" xlink:type="locator"/>
    <link:label xlink:label="acst_MarketableSecurties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Marketable securities</link:label>
    <link:label xlink:label="acst_MarketableSecurties-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Marketable securities</link:label>
    <link:label xlink:label="acst_MarketableSecurties-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_MarketableSecurties" xlink:to="acst_MarketableSecurties-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation costs</link:label>
    <link:label xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SummaryOfMarketableSecuritiesTextBlock" xlink:label="acst_SummaryOfMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_SummaryOfMarketableSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of marketable securities [text block]</link:label>
    <link:label xlink:label="acst_SummaryOfMarketableSecuritiesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SummaryOfMarketableSecuritiesTextBlock" xlink:to="acst_SummaryOfMarketableSecuritiesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock" xlink:label="acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for changes in accounting policy [text block]</link:label>
    <link:label xlink:label="acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The description of the entity's accounting policy for the change in accounting policies.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock" xlink:to="acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesNoncurrent" xlink:label="acst_MarketableSecuritiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="acst_MarketableSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label xlink:label="acst_MarketableSecuritiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of non-current marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_MarketableSecuritiesNoncurrent" xlink:to="acst_MarketableSecuritiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FinancialInstrumentMaturityDate" xlink:label="acst_FinancialInstrumentMaturityDate" xlink:type="locator"/>
    <link:label xlink:label="acst_FinancialInstrumentMaturityDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instrument, maturity date</link:label>
    <link:label xlink:label="acst_FinancialInstrumentMaturityDate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maturity date of a financial instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_FinancialInstrumentMaturityDate" xlink:to="acst_FinancialInstrumentMaturityDate-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FinancialInstrumentInterestRate" xlink:label="acst_FinancialInstrumentInterestRate" xlink:type="locator"/>
    <link:label xlink:label="acst_FinancialInstrumentInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instrument, interest rate</link:label>
    <link:label xlink:label="acst_FinancialInstrumentInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The stated interest rate of a financial instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_FinancialInstrumentInterestRate" xlink:to="acst_FinancialInstrumentInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Compensation</link:label>
    <link:label xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TreasuryBillsMember" xlink:label="acst_TreasuryBillsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TreasuryBillsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury bills [Member]</link:label>
    <link:label xlink:label="acst_TreasuryBillsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the treasury bills.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TreasuryBillsMember" xlink:to="acst_TreasuryBillsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NonadjustingEventsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_NonadjustingEventsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositTwoMember" xlink:label="acst_TermDepositTwomember" xlink:type="locator"/>
    <link:label xlink:label="acst_TermDepositTwomember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term deposit, two[Member]</link:label>
    <link:label xlink:label="acst_TermDepositTwomember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the second tranche of the term deposit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TermDepositTwomember" xlink:to="acst_TermDepositTwomember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProportionOfOwnershipInterestsHeldByRelatedParty" xlink:label="acst_ProportionOfOwnershipInterestsHeldByRelatedParty" xlink:type="locator"/>
    <link:label xlink:label="acst_ProportionOfOwnershipInterestsHeldByRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_ProportionOfOwnershipInterestsHeldByRelatedParty</link:label>
    <link:label xlink:label="acst_ProportionOfOwnershipInterestsHeldByRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of ownership interests held by related party</link:label>
    <link:label xlink:label="acst_ProportionOfOwnershipInterestsHeldByRelatedParty-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The proportion of ownership interests in the company held by a related party.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ProportionOfOwnershipInterestsHeldByRelatedParty" xlink:to="acst_ProportionOfOwnershipInterestsHeldByRelatedParty-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UsedOtherAssets" xlink:label="acst_UsedOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="acst_UsedOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_UsedOtherAssets</link:label>
    <link:label xlink:label="acst_UsedOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Used</link:label>
    <link:label xlink:label="acst_UsedOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The decrease in other assets resulting from the used of those assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_UsedOtherAssets" xlink:to="acst_UsedOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PurchasesOtherAssets" xlink:label="acst_PurchasesOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="acst_PurchasesOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchased</link:label>
    <link:label xlink:label="acst_PurchasesOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase in the other assets resulting from purchases.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PurchasesOtherAssets" xlink:to="acst_PurchasesOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionalPaidinCapital" xlink:label="ifrs-full_AdditionalPaidinCapital" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AdditionalPaidinCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contributed surplus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalPaidinCapital" xlink:to="ifrs-full_AdditionalPaidinCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionalPaidinCapitalMember" xlink:label="ifrs-full_AdditionalPaidinCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AdditionalPaidinCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionalPaidinCapitalMember" xlink:to="ifrs-full_AdditionalPaidinCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SummaryOfOtherAssetsTextBlock" xlink:label="acst_SummaryOfOtherAssetsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_SummaryOfOtherAssetsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of other assets [text block]</link:label>
    <link:label xlink:label="acst_SummaryOfOtherAssetsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The summary of other assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SummaryOfOtherAssetsTextBlock" xlink:to="acst_SummaryOfOtherAssetsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FairValuePerShareIssuable" xlink:label="acst_FairValuePerShareIssuable" xlink:type="locator"/>
    <link:label xlink:label="acst_FairValuePerShareIssuable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value per share issuable (in CAD per share)</link:label>
    <link:label xlink:label="acst_FairValuePerShareIssuable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The fair value per share for derivative instrument issuable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_FairValuePerShareIssuable" xlink:to="acst_FairValuePerShareIssuable-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod" xlink:label="acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod</link:label>
    <link:label xlink:label="acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised during period</link:label>
    <link:label xlink:label="acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The decrease in derivative financial liabilities through derivative instrument exercised.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod" xlink:to="acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LegalSettlementPayableCurrent" xlink:label="acst_LegalSettlementPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="acst_LegalSettlementPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_LegalSettlementPayableCurrent</link:label>
    <link:label xlink:label="acst_LegalSettlementPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal settlement expected to be paid via common shares (note 25)</link:label>
    <link:label xlink:label="acst_LegalSettlementPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of current payable for legal settlement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LegalSettlementPayableCurrent" xlink:to="acst_LegalSettlementPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember" xlink:label="acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than twenty years and not later than twenty-two years [member]</link:label>
    <link:label xlink:label="acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for a time band of later than twenty years and not later than twenty-two years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember" xlink:to="acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds" xlink:label="acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds" xlink:type="locator"/>
    <link:label xlink:label="acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds</link:label>
    <link:label xlink:label="acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-market sales agreement, estimated aggregate gross proceeds</link:label>
    <link:label xlink:label="acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The estimated aggregate gross proceeds for the at-the-market sales agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds" xlink:to="acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_AtTheMarketSalesAgreementFeePercentage" xlink:label="acst_AtTheMarketSalesAgreementFeePercentage" xlink:type="locator"/>
    <link:label xlink:label="acst_AtTheMarketSalesAgreementFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_AtTheMarketSalesAgreementFeePercentage</link:label>
    <link:label xlink:label="acst_AtTheMarketSalesAgreementFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-market sales agreement, fee, percentage</link:label>
    <link:label xlink:label="acst_AtTheMarketSalesAgreementFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The fee, expressed as a percentage of the values of shares issued pursuant to the at-the-market sales agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_AtTheMarketSalesAgreementFeePercentage" xlink:to="acst_AtTheMarketSalesAgreementFeePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_AtTheMarketSalesAgreementTerm" xlink:label="acst_AtTheMarketSalesAgreementTerm" xlink:type="locator"/>
    <link:label xlink:label="acst_AtTheMarketSalesAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_AtTheMarketSalesAgreementTerm</link:label>
    <link:label xlink:label="acst_AtTheMarketSalesAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-market sales agreement, term</link:label>
    <link:label xlink:label="acst_AtTheMarketSalesAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The term of At-the market sales agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_AtTheMarketSalesAgreementTerm" xlink:to="acst_AtTheMarketSalesAgreementTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedMay2018Member" xlink:label="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantLiabilitiesIssuedMay2018Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant liabilities issued May 2018 [member]</link:label>
    <link:label xlink:label="acst_WarrantLiabilitiesIssuedMay2018Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding warrant liabilities issued May, 2018.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:to="acst_WarrantLiabilitiesIssuedMay2018Member-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromIssuingSharesInPublicOfferingGross" xlink:label="acst_ProceedsFromIssuingSharesInPublicOfferingGross" xlink:type="locator"/>
    <link:label xlink:label="acst_ProceedsFromIssuingSharesInPublicOfferingGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_ProceedsFromIssuingSharesInPublicOfferingGross</link:label>
    <link:label xlink:label="acst_ProceedsFromIssuingSharesInPublicOfferingGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuing shares in public offering, gross</link:label>
    <link:label xlink:label="acst_ProceedsFromIssuingSharesInPublicOfferingGross-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gross proceeds from issuing shares in a public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ProceedsFromIssuingSharesInPublicOfferingGross" xlink:to="acst_ProceedsFromIssuingSharesInPublicOfferingGross-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfSharesIssuedForOptionExercised" xlink:label="acst_NumberOfSharesIssuedForOptionExercised" xlink:type="locator"/>
    <link:label xlink:label="acst_NumberOfSharesIssuedForOptionExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_NumberOfSharesIssuedForOptionExercised</link:label>
    <link:label xlink:label="acst_NumberOfSharesIssuedForOptionExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued for option exercised</link:label>
    <link:label xlink:label="acst_NumberOfSharesIssuedForOptionExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares issued during period for option exercised.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NumberOfSharesIssuedForOptionExercised" xlink:to="acst_NumberOfSharesIssuedForOptionExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfSharesIssuedInPublicOffering" xlink:label="acst_NumberOfSharesIssuedInPublicOffering" xlink:type="locator"/>
    <link:label xlink:label="acst_NumberOfSharesIssuedInPublicOffering-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_NumberOfSharesIssuedInPublicOffering</link:label>
    <link:label xlink:label="acst_NumberOfSharesIssuedInPublicOffering-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in public offering</link:label>
    <link:label xlink:label="acst_NumberOfSharesIssuedInPublicOffering-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares issued during period in a public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NumberOfSharesIssuedInPublicOffering" xlink:to="acst_NumberOfSharesIssuedInPublicOffering-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfWarrantsExercised" xlink:label="acst_NumberOfWarrantsExercised" xlink:type="locator"/>
    <link:label xlink:label="acst_NumberOfWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_NumberOfWarrantsExercised</link:label>
    <link:label xlink:label="acst_NumberOfWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants exercised</link:label>
    <link:label xlink:label="acst_NumberOfWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants exercised during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NumberOfWarrantsExercised" xlink:to="acst_NumberOfWarrantsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingBrokerWarrantsMay2018Member" xlink:label="acst_PublicOfferingBrokerWarrantsMay2018Member" xlink:type="locator"/>
    <link:label xlink:label="acst_PublicOfferingBrokerWarrantsMay2018Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public offering broker warrants May 2018 [member]</link:label>
    <link:label xlink:label="acst_PublicOfferingBrokerWarrantsMay2018Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants issued to broker in a public offering in May, 2018.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PublicOfferingBrokerWarrantsMay2018Member" xlink:to="acst_PublicOfferingBrokerWarrantsMay2018Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BrokerMember" xlink:label="acst_BrokerMember" xlink:type="locator"/>
    <link:label xlink:label="acst_BrokerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Broker [member]</link:label>
    <link:label xlink:label="acst_BrokerMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the broker.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_BrokerMember" xlink:to="acst_BrokerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated life (in years)</link:label>
    <link:label xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option life, share options granted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" xlink:label="acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants issued to broker in February 2017 public offering [member]</link:label>
    <link:label xlink:label="acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants issued to broker in February 2017 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" xlink:to="acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" xlink:label="acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants issued to broker in December 2017 public offering [Member]</link:label>
    <link:label xlink:label="acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants issued to broker in December, 2017 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" xlink:to="acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExercisePriceShareOptionsGranted" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ExercisePriceShareOptionsGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" xlink:label="acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants issued to broker in May 2018 public offering [Member]</link:label>
    <link:label xlink:label="acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants to broker in May 2018 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" xlink:to="acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_May2018PublicOfferingWarrants2018Member" xlink:label="acst_May2018PublicOfferingWarrants2018Member" xlink:type="locator"/>
    <link:label xlink:label="acst_May2018PublicOfferingWarrants2018Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">May 2018 public offering warrants 2018 [member]</link:label>
    <link:label xlink:label="acst_May2018PublicOfferingWarrants2018Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants issued in public offering in May 2018.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_May2018PublicOfferingWarrants2018Member" xlink:to="acst_May2018PublicOfferingWarrants2018Member-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts" xlink:label="acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label xlink:label="acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts</link:label>
    <link:label xlink:label="acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in deferred financing costs to reconcile profit (loss) to net cash flow from (used in) operating activities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts" xlink:to="acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NetEquity" xlink:label="acst_NetEquity" xlink:type="locator"/>
    <link:label xlink:label="acst_NetEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US"/>
    <link:label xlink:label="acst_NetEquity-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of net equity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NetEquity" xlink:to="acst_NetEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other assets [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_EmployeeMember" xlink:label="acst_EmployeeMember" xlink:type="locator"/>
    <link:label xlink:label="acst_EmployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee [member]</link:label>
    <link:label xlink:label="acst_EmployeeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the employee of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_EmployeeMember" xlink:to="acst_EmployeeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DirectorsMember" xlink:label="acst_DirectorsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_DirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Directors [member]</link:label>
    <link:label xlink:label="acst_DirectorsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the directors of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DirectorsMember" xlink:to="acst_DirectorsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePriceShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:label="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:type="locator"/>
    <link:label xlink:label="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series December 2017 US public offering warrants 2017 [member]</link:label>
    <link:label xlink:label="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Series December 2017 US Public offering Warrants 2017.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:to="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyNineMember" xlink:label="acst_TwoThousandThirtyNineMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TwoThousandThirtyNineMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2039 [member]</link:label>
    <link:label xlink:label="acst_TwoThousandThirtyNineMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the year 2039.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TwoThousandThirtyNineMember" xlink:to="acst_TwoThousandThirtyNineMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FinancingExpensesMember" xlink:label="acst_FinancingExpensesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_FinancingExpensesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing expenses [member]</link:label>
    <link:label xlink:label="acst_FinancingExpensesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for deferred tax assets related to financing expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_FinancingExpensesMember" xlink:to="acst_FinancingExpensesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory</link:label>
    <link:label xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:to="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_InterestReceivableIncludedInReceivables" xlink:label="acst_InterestReceivableIncludedInReceivables" xlink:type="locator"/>
    <link:label xlink:label="acst_InterestReceivableIncludedInReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest receivable included in receivables</link:label>
    <link:label xlink:label="acst_InterestReceivableIncludedInReceivables-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The noncash transaction related to the interest receivable included in receivables.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_InterestReceivableIncludedInReceivables" xlink:to="acst_InterestReceivableIncludedInReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IssuanceOfSharesForInterestOnConvertibleDebt" xlink:label="acst_IssuanceOfSharesForInterestOnConvertibleDebt" xlink:type="locator"/>
    <link:label xlink:label="acst_IssuanceOfSharesForInterestOnConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of shares for interest on convertible debt</link:label>
    <link:label xlink:label="acst_IssuanceOfSharesForInterestOnConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The noncash transaction related to the issuance of shares for interest on convertible debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_IssuanceOfSharesForInterestOnConvertibleDebt" xlink:to="acst_IssuanceOfSharesForInterestOnConvertibleDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AdjustmentsForAmortisationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CommercialPapersIssuedInUsCurrencyMember" xlink:label="acst_CommercialPapersIssuedInUsCurrencyMember" xlink:type="locator"/>
    <link:label xlink:label="acst_CommercialPapersIssuedInUsCurrencyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial papers issued in US currency [member]</link:label>
    <link:label xlink:label="acst_CommercialPapersIssuedInUsCurrencyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stand for commercial papers issued in US currency.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CommercialPapersIssuedInUsCurrencyMember" xlink:to="acst_CommercialPapersIssuedInUsCurrencyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CommercialPapersIssuedInCadCurrencyMember" xlink:label="acst_CommercialPapersIssuedInCadCurrencyMember" xlink:type="locator"/>
    <link:label xlink:label="acst_CommercialPapersIssuedInCadCurrencyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial papers issued in CAD currency [member]</link:label>
    <link:label xlink:label="acst_CommercialPapersIssuedInCadCurrencyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stand for commercial papers issued in CAD currency.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CommercialPapersIssuedInCadCurrencyMember" xlink:to="acst_CommercialPapersIssuedInCadCurrencyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositsIssuedInUsCurrencyMember" xlink:label="acst_TermDepositsIssuedInUsCurrencyMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TermDepositsIssuedInUsCurrencyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term deposits issued in US currency [member]</link:label>
    <link:label xlink:label="acst_TermDepositsIssuedInUsCurrencyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stand for term deposits issued in US currency.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TermDepositsIssuedInUsCurrencyMember" xlink:to="acst_TermDepositsIssuedInUsCurrencyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositsIssuedInCadCurrencyMember" xlink:label="acst_TermDepositsIssuedInCadCurrencyMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TermDepositsIssuedInCadCurrencyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term deposits issued in CAD currency [member]</link:label>
    <link:label xlink:label="acst_TermDepositsIssuedInCadCurrencyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stand for term deposits issued in CAD currency.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TermDepositsIssuedInCadCurrencyMember" xlink:to="acst_TermDepositsIssuedInCadCurrencyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfSharesIssuedForLegalSettlement" xlink:label="acst_NumberOfSharesIssuedForLegalSettlement" xlink:type="locator"/>
    <link:label xlink:label="acst_NumberOfSharesIssuedForLegalSettlement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_NumberOfSharesIssuedForLegalSettlement</link:label>
    <link:label xlink:label="acst_NumberOfSharesIssuedForLegalSettlement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued for legal settlement</link:label>
    <link:label xlink:label="acst_NumberOfSharesIssuedForLegalSettlement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares issued for legal settlement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NumberOfSharesIssuedForLegalSettlement" xlink:to="acst_NumberOfSharesIssuedForLegalSettlement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:label xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BankersAcceptanceMember" xlink:label="acst_BankersAcceptanceMember" xlink:type="locator"/>
    <link:label xlink:label="acst_BankersAcceptanceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bankers acceptance [member]</link:label>
    <link:label xlink:label="acst_BankersAcceptanceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stand for bankers acceptance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_BankersAcceptanceMember" xlink:to="acst_BankersAcceptanceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PromissoryNotesIssuedInUsCurrencyMember" xlink:label="acst_PromissoryNotesIssuedInUsCurrencyMember" xlink:type="locator"/>
    <link:label xlink:label="acst_PromissoryNotesIssuedInUsCurrencyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Promissory notes issued in US currency [member]</link:label>
    <link:label xlink:label="acst_PromissoryNotesIssuedInUsCurrencyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stand for promissory notes issued in US currency.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PromissoryNotesIssuedInUsCurrencyMember" xlink:to="acst_PromissoryNotesIssuedInUsCurrencyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PromissoryNotesIssuedInCadCurrencyMember" xlink:label="acst_PromissoryNotesIssuedInCadCurrencyMember" xlink:type="locator"/>
    <link:label xlink:label="acst_PromissoryNotesIssuedInCadCurrencyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Promissory notes issued in CAD currency [member]</link:label>
    <link:label xlink:label="acst_PromissoryNotesIssuedInCadCurrencyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stand for promissory notes issued in CAD currency.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PromissoryNotesIssuedInCadCurrencyMember" xlink:to="acst_PromissoryNotesIssuedInCadCurrencyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity</link:label>
    <link:label xlink:label="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax relating to items credited (charged) directly to equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:to="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss" xlink:label="acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss" xlink:type="locator"/>
    <link:label xlink:label="acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in net loss</link:label>
    <link:label xlink:label="acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of change in net loss while a 5% strengthening of the US dollar and Euro.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss" xlink:to="acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:label xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CommonSharesMember" xlink:label="acst_CommonSharesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_CommonSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common shares [member]</link:label>
    <link:label xlink:label="acst_CommonSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stand for common shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_CommonSharesMember" xlink:to="acst_CommonSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LegalExpense" xlink:label="acst_LegalExpense" xlink:type="locator"/>
    <link:label xlink:label="acst_LegalExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_LegalExpense</link:label>
    <link:label xlink:label="acst_LegalExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal expense</link:label>
    <link:label xlink:label="acst_LegalExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of legal expense incurred during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LegalExpense" xlink:to="acst_LegalExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LegalFeesReimburse" xlink:label="acst_LegalFeesReimburse" xlink:type="locator"/>
    <link:label xlink:label="acst_LegalFeesReimburse-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_LegalFeesReimburse</link:label>
    <link:label xlink:label="acst_LegalFeesReimburse-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal fees reimburse</link:label>
    <link:label xlink:label="acst_LegalFeesReimburse-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of legal fees reimbursed to the counter party.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LegalFeesReimburse" xlink:to="acst_LegalFeesReimburse-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based payment transactions for the period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_AdjustmentsForDeferredTaxExpense</link:label>
    <link:label xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax recovery</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FormerCEOMember" xlink:label="acst_FormerCEOMember" xlink:type="locator"/>
    <link:label xlink:label="acst_FormerCEOMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former CEO [member]</link:label>
    <link:label xlink:label="acst_FormerCEOMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding a former CEO.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_FormerCEOMember" xlink:to="acst_FormerCEOMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AdjustmentsForDepreciationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation of equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ComprehensiveIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss and total comprehensive loss for the period</link:label>
    <link:label xlink:label="ifrs-full_ComprehensiveIncome-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss and total comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_FR" xlink:label="country_FR" xlink:type="locator"/>
    <link:label xlink:label="country_FR-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FRANCE</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_FR" xlink:to="country_FR-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_IssueOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public offering</link:label>
    <link:label xlink:label="ifrs-full_IssueOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_AdjustmentsForFinanceIncomeCost</link:label>
    <link:label xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net financial expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade and other payables</link:label>
    <link:label xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_MaturityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total adjustments</link:label>
    <link:label xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_AdjustmentsForReconcileProfitLoss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AdjustmentsForSharebasedPayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized foreign exchange gain (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_EquityAndLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_EquityAndLiabilities</link:label>
    <link:label xlink:label="ifrs-full_EquityAndLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in working capital items</link:label>
    <link:label xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total changes in working capital items</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:label="ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in fair value of derivative warrant liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:to="ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfFairValueMeasurementExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherEquityInterest" xlink:label="ifrs-full_OtherEquityInterest" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_OtherEquityInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterest" xlink:to="ifrs-full_OtherEquityInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_RetainedEarnings-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_IssuedCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_EquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of finance income (cost) [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" xlink:label="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease</link:label>
    <link:label xlink:label="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments payable under non-cancellable operating lease</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" xlink:to="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than two years [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than three years [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NotLaterThanOneYearMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AggregatedTimeBandsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_AggregatedTimeBandsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange (loss) gain on cash and cash equivalents held in foreign currencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_EarningsPerShareExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization for the period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_FinanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_FinanceCosts</link:label>
    <link:label xlink:label="ifrs-full_FinanceCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Financial expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_IncomeTaxExpenseContinuingOperations</link:label>
    <link:label xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total tax (recovery) expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
	<link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLossAbstract" xlink:label="ifrs-full_ProfitLossAbstract" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ProfitLossAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) [abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="ifrs-full_ProfitLossAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ProfitLossFromOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_ProfitLossFromOperatingActivities</link:label>
    <link:label xlink:label="ifrs-full_ProfitLossFromOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</link:label>
    <link:label xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total contributions by and distributions to equity holders</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total contributions by and distributions to equity holders (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestReceivable" xlink:label="ifrs-full_InterestReceivable" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_InterestReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivable" xlink:to="ifrs-full_InterestReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssueOfConvertibleInstruments" xlink:label="ifrs-full_IssueOfConvertibleInstruments" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_IssueOfConvertibleInstruments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of unsecured convertible debentures, net of deferred income tax expense of $129</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ifrs-full_IssueOfConvertibleInstruments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation for the period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred income tax recovery</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:to="ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:label="ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis for derivative financial liabilities [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:to="ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherAssets" xlink:label="ifrs-full_OtherAssets" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_OtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_OtherAssets</link:label>
    <link:label xlink:label="ifrs-full_OtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance &#8211; beginning of year</link:label>
    <link:label xlink:label="ifrs-full_OtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance &#8211; end of year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_OtherCurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current other asset</link:label>
    <link:label xlink:label="ifrs-full_OtherCurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_OtherNoncurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentDebtInstrumentsIssued" xlink:label="ifrs-full_NoncurrentDebtInstrumentsIssued" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NoncurrentDebtInstrumentsIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_NoncurrentDebtInstrumentsIssued</link:label>
    <link:label xlink:label="ifrs-full_NoncurrentDebtInstrumentsIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unsecured convertible debentures</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentDebtInstrumentsIssued" xlink:to="ifrs-full_NoncurrentDebtInstrumentsIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted loss per share (in CAD per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_OrdinarySharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ordinary shares [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of ordinary shares [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_LicencesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licences [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LicencesMember" xlink:to="ifrs-full_LicencesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherExpenseByNature" xlink:label="ifrs-full_OtherExpenseByNature" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_OtherExpenseByNature-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_OtherExpenseByNature</link:label>
    <link:label xlink:label="ifrs-full_OtherExpenseByNature-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other charges</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer equipment [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComputerEquipmentMember" xlink:to="ifrs-full_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_EmployeeBenefitsExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_EmployeeBenefitsExpense</link:label>
    <link:label xlink:label="ifrs-full_EmployeeBenefitsExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total personnel expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salaries and other short-term employee benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_PropertyPlantAndEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_OtherComprehensiveIncomeBeforeTax</link:label>
    <link:label xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss and comprehensive loss before income tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_OtherCurrentReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ClassesOfAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_ClassesOfAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" xlink:label="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of additional information about understanding financial position and liquidity of entity [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" xlink:to="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ClassesOfAssetsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of assets [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanSixMonthsMember" xlink:label="ifrs-full_LaterThanSixMonthsMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_LaterThanSixMonthsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than six months [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanSixMonthsMember" xlink:to="ifrs-full_LaterThanSixMonthsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of contingent liabilities [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfContingentLiabilitiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ContingentLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent liabilities [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContingentLiabilitiesMember" xlink:to="ifrs-full_ContingentLiabilitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial instruments [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_StatementOfChangesInEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial instruments, class [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_FinancialLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial liabilities, class [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="ifrs-full_FinancialLiabilitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label xlink:label="ifrs-full_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties</link:label>
    <link:label xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current payables to related parties</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of financial liabilities [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of intangible assets and goodwill [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</link:label>
    <link:label xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="ifrs-full_InterestExpenseOnBorrowings" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_InterestExpenseOnBorrowings-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_InterestExpenseOnBorrowings</link:label>
    <link:label xlink:label="ifrs-full_InterestExpenseOnBorrowings-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest</link:label>
    <link:label xlink:label="ifrs-full_InterestExpenseOnBorrowings-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest payable on convertible debenture</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnBorrowings" xlink:to="ifrs-full_InterestExpenseOnBorrowings-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_TypesOfRisksMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_TypesOfRisksMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_TypesOfRisksAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label xlink:label="ifrs-full_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses, net of government assistance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of consolidation [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ClassesOfShareCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share capital [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestCostsIncurred" xlink:label="ifrs-full_InterestCostsIncurred" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_InterestCostsIncurred-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_InterestCostsIncurred</link:label>
    <link:label xlink:label="ifrs-full_InterestCostsIncurred-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestCostsIncurred" xlink:to="ifrs-full_InterestCostsIncurred-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ClassesOfShareCapitalAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_RevenueFromGovernmentGrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government grant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromGovernmentGrants" xlink:to="ifrs-full_RevenueFromGovernmentGrants-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfBorrowingsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of borrowings [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:to="ifrs-full_DisclosureOfBorrowingsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfGovernmentGrantsExplanatory" xlink:label="ifrs-full_DisclosureOfGovernmentGrantsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfGovernmentGrantsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of government grants [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGovernmentGrantsExplanatory" xlink:to="ifrs-full_DisclosureOfGovernmentGrantsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="ifrs-full_ClosingForeignExchangeRate" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ClosingForeignExchangeRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Closing exchange rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClosingForeignExchangeRate" xlink:to="ifrs-full_ClosingForeignExchangeRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherEquityInterestMember" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_OtherEquityInterestMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other equity interest [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterestMember" xlink:to="ifrs-full_OtherEquityInterestMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_EquityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ComponentsOfEquityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_IssuedCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RevenueFromInterest" xlink:label="ifrs-full_RevenueFromInterest" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_RevenueFromInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromInterest" xlink:to="ifrs-full_RevenueFromInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="ifrs-full_TaxEffectFromChangeInTaxRate" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_TaxEffectFromChangeInTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in statutory income tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxEffectFromChangeInTaxRate" xlink:to="ifrs-full_TaxEffectFromChangeInTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computed income tax recovery</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_GrossFinanceIncomeCost" xlink:label="acst_GrossFinanceIncomeCost" xlink:type="locator"/>
    <link:label xlink:label="acst_GrossFinanceIncomeCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial expenses</link:label>
    <link:label xlink:label="acst_GrossFinanceIncomeCost-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gross amount of income or cost associated with interest and other financing activities of the entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_GrossFinanceIncomeCost" xlink:to="acst_GrossFinanceIncomeCost-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment" xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment" xlink:type="locator"/>
    <link:label xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity settled non-employee share-based payment</link:label>
    <link:label xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) from equity settled non-employee share-based payment</link:label>
    <link:label xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) in equity resulting from equity settled non-employee share-based payment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment" xlink:to="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IssueOfEquityNumberOfShares" xlink:label="acst_IssueOfEquityNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="acst_IssueOfEquityNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public offering (in shares)</link:label>
    <link:label xlink:label="acst_IssueOfEquityNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of equity, number of shares</link:label>
    <link:label xlink:label="acst_IssueOfEquityNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares issued in the issuance of equity instruments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_IssueOfEquityNumberOfShares" xlink:to="acst_IssueOfEquityNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="ifrs-full_UnusedTaxLossesMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_UnusedTaxLossesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax losses [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnusedTaxLossesMember" xlink:to="ifrs-full_UnusedTaxLossesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares" xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares" xlink:type="locator"/>
    <link:label xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity settled non-employee share-based payment (in shares)</link:label>
    <link:label xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) from equity settled non-employee share-based payment, shares</link:label>
    <link:label xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) in equity shares resulting from equity settled non-employee share-based payment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares" xlink:to="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherTemporaryDifferencesMember" xlink:label="ifrs-full_OtherTemporaryDifferencesMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_OtherTemporaryDifferencesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other temporary differences [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherTemporaryDifferencesMember" xlink:to="ifrs-full_OtherTemporaryDifferencesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax losses carried forward</link:label>
    <link:label xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:label="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses, without time limitation</link:label>
    <link:label xlink:label="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized federal tax credits may be used to reduce future income tax and expire</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:to="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:label="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements involving legal form of lease [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:to="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:label="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements involving legal form of lease [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:to="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ApplicableTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic combined Canadian statutory income tax rate 1</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NumberOfSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_NumberOfSharesOutstanding</link:label>
    <link:label xlink:label="ifrs-full_NumberOfSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding at end of period</link:label>
    <link:label xlink:label="ifrs-full_NumberOfSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="ifrs-full_NumberOfSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense</link:label>
    <link:label xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in unrecognized deductible temporary differences</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="ifrs-full_CashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_CashAndCashEquivalents</link:label>
    <link:label xlink:label="ifrs-full_CashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash and cash equivalents</link:label>
    <link:label xlink:label="ifrs-full_CashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label xlink:label="ifrs-full_CashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</link:label>
    <link:label xlink:label="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent liabilities recognised in business combination at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:to="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaboratoryEquipmentMember" xlink:label="acst_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="acst_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory equipment [member]</link:label>
    <link:label xlink:label="acst_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information laboratory equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LaboratoryEquipmentMember" xlink:to="acst_LaboratoryEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_NumberOfSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_NumberOfSharesIssued</link:label>
    <link:label xlink:label="ifrs-full_NumberOfSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total number of shares issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FurnitureAndOfficeEquipmentMember" xlink:label="acst_FurnitureAndOfficeEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="acst_FurnitureAndOfficeEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and office equipment [member]</link:label>
    <link:label xlink:label="acst_FurnitureAndOfficeEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding furniture and office equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_FurnitureAndOfficeEquipmentMember" xlink:to="acst_FurnitureAndOfficeEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_Assets</link:label>
    <link:label xlink:label="ifrs-full_Assets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets at end of period</link:label>
    <link:label xlink:label="ifrs-full_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IntangibleAssetsUsefulLife" xlink:label="acst_IntangibleAssetsUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="acst_IntangibleAssetsUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Useful life, intangible assets (Year)</link:label>
    <link:label xlink:label="acst_IntangibleAssetsUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The useful life of intangible assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_IntangibleAssetsUsefulLife" xlink:to="acst_IntangibleAssetsUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfUsefulLivesAndRatesTextBlock" xlink:label="acst_DisclosureOfUsefulLivesAndRatesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_DisclosureOfUsefulLivesAndRatesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of useful lives and rates [text block]</link:label>
    <link:label xlink:label="acst_DisclosureOfUsefulLivesAndRatesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of useful lives and rates.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DisclosureOfUsefulLivesAndRatesTextBlock" xlink:to="acst_DisclosureOfUsefulLivesAndRatesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProductionEquipmentMember" xlink:label="acst_ProductionEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="acst_ProductionEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Production equipment [member]</link:label>
    <link:label xlink:label="acst_ProductionEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding production equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ProductionEquipmentMember" xlink:to="acst_ProductionEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DeferredTaxAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssets" xlink:to="ifrs-full_DeferredTaxAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock" xlink:label="acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information of trade and other receivables [text block]</link:label>
    <link:label xlink:label="acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of detailed information of trade and other receivables.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock" xlink:to="acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average fair value of the options granted to employees and directors of the Corporation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PatentsMember" xlink:label="acst_PatentsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_PatentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents [member]</link:label>
    <link:label xlink:label="acst_PatentsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding patents.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PatentsMember" xlink:to="acst_PatentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_GovernmentAssistanceAndTaxCreditsReceivable" xlink:label="acst_GovernmentAssistanceAndTaxCreditsReceivable" xlink:type="locator"/>
    <link:label xlink:label="acst_GovernmentAssistanceAndTaxCreditsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government assistance and tax credits receivable</link:label>
    <link:label xlink:label="acst_GovernmentAssistanceAndTaxCreditsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of government assisstance and tax credits receivables.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_GovernmentAssistanceAndTaxCreditsReceivable" xlink:to="acst_GovernmentAssistanceAndTaxCreditsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_Equity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_Equity</link:label>
    <link:label xlink:label="ifrs-full_Equity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label xlink:label="ifrs-full_Equity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="ifrs-full_Equity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_CurrentAssets</link:label>
    <link:label xlink:label="ifrs-full_CurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label xlink:label="ifrs-full_CurrentAssets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_PropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment</link:label>
    <link:label xlink:label="ifrs-full_PropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="ifrs-full_PropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CurrentAssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_TradeAndOtherCurrentReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:label xlink:label="ifrs-full_TradeAndOtherCurrentReceivables-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromIssuingSharesPrivatePlacement" xlink:label="acst_ProceedsFromIssuingSharesPrivatePlacement" xlink:type="locator"/>
    <link:label xlink:label="acst_ProceedsFromIssuingSharesPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from private placement</link:label>
    <link:label xlink:label="acst_ProceedsFromIssuingSharesPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from issuing shares in a private placement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ProceedsFromIssuingSharesPrivatePlacement" xlink:to="acst_ProceedsFromIssuingSharesPrivatePlacement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CounterpartiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="ifrs-full_CountryOfDomicileMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CountryOfDomicileMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country of domicile [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CountryOfDomicileMember" xlink:to="ifrs-full_CountryOfDomicileMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CounterpartiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparties [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="ifrs-full_CounterpartiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_CurrentLiabilities</link:label>
    <link:label xlink:label="ifrs-full_CurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label xlink:label="ifrs-full_CurrentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of information about key management personnel [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CurrencyRiskMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency risk [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrencyRiskMember" xlink:to="ifrs-full_CurrencyRiskMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DepreciationPercentage" xlink:label="acst_DepreciationPercentage" xlink:type="locator"/>
    <link:label xlink:label="acst_DepreciationPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label xlink:label="acst_DepreciationPercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of depreciation of assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DepreciationPercentage" xlink:to="acst_DepreciationPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UsefulLifeOfAssets" xlink:label="acst_UsefulLifeOfAssets" xlink:type="locator"/>
    <link:label xlink:label="acst_UsefulLifeOfAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Production equipment (in years) (Year)</link:label>
    <link:label xlink:label="acst_UsefulLifeOfAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The useful life of assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_UsefulLifeOfAssets" xlink:to="acst_UsefulLifeOfAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_EstimatedFinancialEffectOfContingentLiabilities</link:label>
    <link:label xlink:label="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated financial effect of contingent liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:to="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="ifrs-full_AverageForeignExchangeRate" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_AverageForeignExchangeRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average exchange rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageForeignExchangeRate" xlink:to="ifrs-full_AverageForeignExchangeRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentDebtInstrumentsIssued" xlink:label="ifrs-full_CurrentDebtInstrumentsIssued" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CurrentDebtInstrumentsIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_CurrentDebtInstrumentsIssued</link:label>
    <link:label xlink:label="ifrs-full_CurrentDebtInstrumentsIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unsecured convertible debentures</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentDebtInstrumentsIssued" xlink:to="ifrs-full_CurrentDebtInstrumentsIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative warrant liabilities</link:label>
    <link:label xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance &#8211; beginning of period</link:label>
    <link:label xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance &#8211; end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_TradeAndOtherCurrentPayables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other payables</link:label>
    <link:label xlink:label="ifrs-full_TradeAndOtherCurrentPayables-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total trade and other payables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_IntangibleAssetsAndGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label xlink:label="ifrs-full_IntangibleAssetsAndGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="ifrs-full_IntangibleAssetsAndGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CurrentLiabilitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CurrentPrepaidExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_Borrowings-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_Borrowings</link:label>
    <link:label xlink:label="ifrs-full_Borrowings-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="ifrs-full_Borrowings-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_Borrowings-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_BorrowingsByNameMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="ifrs-full_BorrowingsByNameMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_BorrowingsByNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Borrowings by name [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CurrentValueAddedTaxReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales tax receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentValueAddedTaxReceivables" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_BorrowingsInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_BorrowingsInterestRate</link:label>
    <link:label xlink:label="ifrs-full_BorrowingsInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Borrowings, interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_BottomOfRangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of intangible assets [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity's total for business combinations [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_BusinessCombinationsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business combinations [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsExercisedEquitySharesIssued" xlink:label="acst_WarrantsExercisedEquitySharesIssued" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantsExercisedEquitySharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label xlink:label="acst_WarrantsExercisedEquitySharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised, equity shares issued</link:label>
    <link:label xlink:label="acst_WarrantsExercisedEquitySharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of equity shares issued from warrants exercised.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantsExercisedEquitySharesIssued" xlink:to="acst_WarrantsExercisedEquitySharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CapitalCommitments" xlink:label="ifrs-full_CapitalCommitments" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CapitalCommitments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalCommitments" xlink:to="ifrs-full_CapitalCommitments-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromExerciseOfWarrants" xlink:label="acst_ProceedsFromExerciseOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="acst_ProceedsFromExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label xlink:label="acst_ProceedsFromExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label xlink:label="acst_ProceedsFromExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from the exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ProceedsFromExerciseOfWarrants" xlink:to="acst_ProceedsFromExerciseOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ConversionOfConvertibleInstrumentsEquitySharesIssued" xlink:label="acst_ConversionOfConvertibleInstrumentsEquitySharesIssued" xlink:type="locator"/>
    <link:label xlink:label="acst_ConversionOfConvertibleInstrumentsEquitySharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares (in shares)</link:label>
    <link:label xlink:label="acst_ConversionOfConvertibleInstrumentsEquitySharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of shares for payment of interest on convertible debentures (in shares)</link:label>
    <link:label xlink:label="acst_ConversionOfConvertibleInstrumentsEquitySharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of equity shares issued from the conversion of convertible instruments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ConversionOfConvertibleInstrumentsEquitySharesIssued" xlink:to="acst_ConversionOfConvertibleInstrumentsEquitySharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_GovernmentGrantsAndInvestmentTaxCredits" xlink:label="acst_GovernmentGrantsAndInvestmentTaxCredits" xlink:type="locator"/>
    <link:label xlink:label="acst_GovernmentGrantsAndInvestmentTaxCredits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_GovernmentGrantsAndInvestmentTaxCredits</link:label>
    <link:label xlink:label="acst_GovernmentGrantsAndInvestmentTaxCredits-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total government assistance</link:label>
    <link:label xlink:label="acst_GovernmentGrantsAndInvestmentTaxCredits-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of government grants and investment tax credits during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_GovernmentGrantsAndInvestmentTaxCredits" xlink:to="acst_GovernmentGrantsAndInvestmentTaxCredits-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_InvestmentTaxCredit" xlink:label="acst_InvestmentTaxCredit" xlink:type="locator"/>
    <link:label xlink:label="acst_InvestmentTaxCredit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment tax credit</link:label>
    <link:label xlink:label="acst_InvestmentTaxCredit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of investment tax credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_InvestmentTaxCredit" xlink:to="acst_InvestmentTaxCredit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_GrossCarryingAmountMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossCarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SharedServiceAgreementMember" xlink:label="acst_SharedServiceAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="acst_SharedServiceAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shared service agreement [member]</link:label>
    <link:label xlink:label="acst_SharedServiceAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to a shared service agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SharedServiceAgreementMember" xlink:to="acst_SharedServiceAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CarryingAmountMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CarryingAmountMember" xlink:to="ifrs-full_CarryingAmountMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SuppliesAndIncrementalCostsMember" xlink:label="acst_SuppliesAndIncrementalCostsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_SuppliesAndIncrementalCostsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplies and incremental costs [member]</link:label>
    <link:label xlink:label="acst_SuppliesAndIncrementalCostsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to supplies and incremental costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SuppliesAndIncrementalCostsMember" xlink:to="acst_SuppliesAndIncrementalCostsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other deductible temporary differences, without time limitation</link:label>
    <link:label xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:to="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember" xlink:label="acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than eleven years and not later than twelve years [member]</link:label>
    <link:label xlink:label="acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for a time band of later than eleven years and not later than twelve years.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember" xlink:to="acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_Cash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock" xlink:label="acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about government grants and investment tax credits [text block]</link:label>
    <link:label xlink:label="acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of detailed information about government grants and investment tax credits.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock" xlink:to="acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantLiabilitiesIssuedDecember272017Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant liabilities issued December 27, 2017 [member]</link:label>
    <link:label xlink:label="acst_WarrantLiabilitiesIssuedDecember272017Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding warrant liabilities issued December 27, 2017.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:to="acst_WarrantLiabilitiesIssuedDecember272017Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="ifrs-full_DeferredTaxLiabilityAsset" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DeferredTaxLiabilityAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_DeferredTaxLiabilityAsset</link:label>
    <link:label xlink:label="ifrs-full_DeferredTaxLiabilityAsset-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilityAsset" xlink:to="ifrs-full_DeferredTaxLiabilityAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="ifrs-full_DeferredTaxExpenseIncome" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DeferredTaxExpenseIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_DeferredTaxExpenseIncome</link:label>
    <link:label xlink:label="ifrs-full_DeferredTaxExpenseIncome-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax expense (income)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncome" xlink:to="ifrs-full_DeferredTaxExpenseIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DerivativeFinancialLiabilitiesIssued" xlink:label="acst_DerivativeFinancialLiabilitiesIssued" xlink:type="locator"/>
    <link:label xlink:label="acst_DerivativeFinancialLiabilitiesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued during period</link:label>
    <link:label xlink:label="acst_DerivativeFinancialLiabilitiesIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of derivative financial liabilities issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DerivativeFinancialLiabilitiesIssued" xlink:to="acst_DerivativeFinancialLiabilitiesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilities" xlink:to="ifrs-full_DeferredTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantLiabilitiesIssuedDecember32013Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant liabilities issued December 3, 2013 [member]</link:label>
    <link:label xlink:label="acst_WarrantLiabilitiesIssuedDecember32013Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to warrant liabilities issued December 3, 2013.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:to="acst_WarrantLiabilitiesIssuedDecember32013Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashEquivalents" xlink:label="ifrs-full_CashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashEquivalents" xlink:to="ifrs-full_CashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnderwriterMember" xlink:label="acst_UnderwriterMember" xlink:type="locator"/>
    <link:label xlink:label="acst_UnderwriterMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriter [member]</link:label>
    <link:label xlink:label="acst_UnderwriterMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding an underwriter.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_UnderwriterMember" xlink:to="acst_UnderwriterMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassASharesMember" xlink:label="acst_ClassASharesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_ClassASharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class A shares [member]</link:label>
    <link:label xlink:label="acst_ClassASharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding class A shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ClassASharesMember" xlink:to="acst_ClassASharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Origination and reversal of temporary differences</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnitSharesOfClassASharePurchaseWarrant" xlink:label="acst_UnitSharesOfClassASharePurchaseWarrant" xlink:type="locator"/>
    <link:label xlink:label="acst_UnitSharesOfClassASharePurchaseWarrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_UnitSharesOfClassASharePurchaseWarrant</link:label>
    <link:label xlink:label="acst_UnitSharesOfClassASharePurchaseWarrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unit, shares of class A share purchase warrant</link:label>
    <link:label xlink:label="acst_UnitSharesOfClassASharePurchaseWarrant-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The shares of class A share purchase warrant from a unit issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_UnitSharesOfClassASharePurchaseWarrant" xlink:to="acst_UnitSharesOfClassASharePurchaseWarrant-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantCosts" xlink:label="acst_WarrantCosts" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_WarrantCosts</link:label>
    <link:label xlink:label="acst_WarrantCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant costs</link:label>
    <link:label xlink:label="acst_WarrantCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of costs for warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantCosts" xlink:to="acst_WarrantCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:label="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:type="locator"/>
    <link:label xlink:label="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public offering warrants February 2017, equity portion [member]</link:label>
    <link:label xlink:label="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the equity portion of public offering warrants February 2017.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:to="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsExpired" xlink:label="acst_WarrantsExpired" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantsExpired-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_WarrantsExpired</link:label>
    <link:label xlink:label="acst_WarrantsExpired-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants expired</link:label>
    <link:label xlink:label="acst_WarrantsExpired-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants expired.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantsExpired" xlink:to="acst_WarrantsExpired-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:label="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:type="locator"/>
    <link:label xlink:label="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series 8 December 2013 Public offering warrants related to liability [member]</link:label>
    <link:label xlink:label="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to Series 8 December 2013 Public offering warrants related to liability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:to="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsExercisedEquitySharesIssuedAmount" xlink:label="acst_WarrantsExercisedEquitySharesIssuedAmount" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantsExercisedEquitySharesIssuedAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_WarrantsExercisedEquitySharesIssuedAmount</link:label>
    <link:label xlink:label="acst_WarrantsExercisedEquitySharesIssuedAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised, equity shares issued, amount</link:label>
    <link:label xlink:label="acst_WarrantsExercisedEquitySharesIssuedAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The value of warrants exercised.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantsExercisedEquitySharesIssuedAmount" xlink:to="acst_WarrantsExercisedEquitySharesIssuedAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfWarrantsIssuedDuringPeriod" xlink:label="acst_NumberOfWarrantsIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="acst_NumberOfWarrantsIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_NumberOfWarrantsIssuedDuringPeriod</link:label>
    <link:label xlink:label="acst_NumberOfWarrantsIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants issued during period</link:label>
    <link:label xlink:label="acst_NumberOfWarrantsIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_NumberOfWarrantsIssuedDuringPeriod" xlink:to="acst_NumberOfWarrantsIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" xlink:label="acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" xlink:type="locator"/>
    <link:label xlink:label="acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series December 2017 US Broker warrants, equity portion [member]</link:label>
    <link:label xlink:label="acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding Series December 2017 US Broker warrants, equity portion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" xlink:to="acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of sensitivity analysis for actuarial assumptions [text block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_CashFlowsFromUsedInFinancingActivities</link:label>
    <link:label xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash from (used in) financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingWarrantsIn2017Member" xlink:label="acst_PublicOfferingWarrantsIn2017Member" xlink:type="locator"/>
    <link:label xlink:label="acst_PublicOfferingWarrantsIn2017Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public offering warrants in 2017 [member]</link:label>
    <link:label xlink:label="acst_PublicOfferingWarrantsIn2017Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding public offering warrants in 2017.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_PublicOfferingWarrantsIn2017Member" xlink:to="acst_PublicOfferingWarrantsIn2017Member-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsMember" xlink:label="acst_WarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [member]</link:label>
    <link:label xlink:label="acst_WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantsMember" xlink:to="acst_WarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantTransactionCosts" xlink:label="acst_WarrantTransactionCosts" xlink:type="locator"/>
    <link:label xlink:label="acst_WarrantTransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_WarrantTransactionCosts</link:label>
    <link:label xlink:label="acst_WarrantTransactionCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Transaction costs related to derivative warrant liabilities</link:label>
    <link:label xlink:label="acst_WarrantTransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of warrant transaction costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_WarrantTransactionCosts" xlink:to="acst_WarrantTransactionCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:label="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:type="locator"/>
    <link:label xlink:label="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series 9 Private Placement warrants 2013 related to equity [member]</link:label>
    <link:label xlink:label="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding Series 9 Private Placement warrants 2013 related to equity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:to="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfConvertibleDebenturesTextBlock" xlink:label="acst_DisclosureOfConvertibleDebenturesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acst_DisclosureOfConvertibleDebenturesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of convertible debentures [text block]</link:label>
    <link:label xlink:label="acst_DisclosureOfConvertibleDebenturesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of convertible debentures.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_DisclosureOfConvertibleDebenturesTextBlock" xlink:to="acst_DisclosureOfConvertibleDebenturesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xlink:type="locator"/>
    <link:label xlink:label="ifrs-full_PaymentsForShareIssueCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ifrs-full_PaymentsForShareIssueCosts</link:label>
    <link:label xlink:label="ifrs-full_PaymentsForShareIssueCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share based payment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ExpectedDividendWarrantsGranted" xlink:label="acst_ExpectedDividendWarrantsGranted" xlink:type="locator"/>
    <link:label xlink:label="acst_ExpectedDividendWarrantsGranted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_ExpectedDividendWarrantsGranted</link:label>
    <link:label xlink:label="acst_ExpectedDividendWarrantsGranted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend</link:label>
    <link:label xlink:label="acst_ExpectedDividendWarrantsGranted-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of an expected dividend used to calculate the fair value of warrants issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_ExpectedDividendWarrantsGranted" xlink:to="acst_ExpectedDividendWarrantsGranted-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_AccretionOfInterestOnConvertibleDebenture" xlink:label="acst_AccretionOfInterestOnConvertibleDebenture" xlink:type="locator"/>
    <link:label xlink:label="acst_AccretionOfInterestOnConvertibleDebenture-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_AccretionOfInterestOnConvertibleDebenture</link:label>
    <link:label xlink:label="acst_AccretionOfInterestOnConvertibleDebenture-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion of interest on convertible debenture</link:label>
    <link:label xlink:label="acst_AccretionOfInterestOnConvertibleDebenture-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of accretion of interest on convertible debenture.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_AccretionOfInterestOnConvertibleDebenture" xlink:to="acst_AccretionOfInterestOnConvertibleDebenture-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss" xlink:label="acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss" xlink:type="locator"/>
    <link:label xlink:label="acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss</link:label>
    <link:label xlink:label="acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant unobservable inputs, five percent strengthen of foreign currency would result in a loss</link:label>
    <link:label xlink:label="acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of loss from the strengthening of 5% of the foreign currency used for financial instrument classified as a liability using unobservable inputs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss" xlink:to="acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesMember" xlink:label="acst_MarketableSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="acst_MarketableSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable securities [member]</link:label>
    <link:label xlink:label="acst_MarketableSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_MarketableSecuritiesMember" xlink:to="acst_MarketableSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThouandThirtyEightMember" xlink:label="acst_TwoThouandThirtyEightMember" xlink:type="locator"/>
    <link:label xlink:label="acst_TwoThouandThirtyEightMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2038 [member]</link:label>
    <link:label xlink:label="acst_TwoThouandThirtyEightMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the year 2038.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acst_TwoThouandThirtyEightMember" xlink:to="acst_TwoThouandThirtyEightMember-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>acst-20190331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 02:59AM UTC 2019-06-26--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments" xlink:href="acst-20190331.xsd#statement-note-21-financial-instruments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure" xlink:href="acst-20190331.xsd#statement-note-19-supplemental-cash-flow-disclosure" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" xlink:label="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-18-loss-per-share" xlink:href="acst-20190331.xsd#statement-note-18-loss-per-share" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-18-loss-per-share" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_EarningsPerShareExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses" xlink:href="acst-20190331.xsd#statement-note-16-financial-expenses" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses" xlink:href="acst-20190331.xsd#statement-note-15-personnel-expenses" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfPersonnelExpensesTextBlock" xlink:label="acst_DisclosureOfPersonnelExpensesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfPersonnelExpensesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables" xlink:href="acst-20190331.xsd#statement-note-11-trade-and-other-payables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets" xlink:href="acst-20190331.xsd#statement-note-10-intangible-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-9-equipment-" xlink:href="acst-20190331.xsd#statement-note-9-equipment-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-9-equipment-" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance" xlink:href="acst-20190331.xsd#statement-note-8-government-assistance" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfGovernmentGrantsExplanatory" xlink:label="ifrs-full_DisclosureOfGovernmentGrantsExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfGovernmentGrantsExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-6-other-assets" xlink:href="acst-20190331.xsd#statement-note-6-other-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-6-other-assets" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities" xlink:href="acst-20190331.xsd#statement-note-5-marketable-securities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfMarketableSecuritiesTextBlock" xlink:label="acst_DisclosureOfMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfMarketableSecuritiesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-4-receivables" xlink:href="acst-20190331.xsd#statement-note-4-receivables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-4-receivables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-1-reporting-entity" xlink:href="acst-20190331.xsd#statement-note-1-reporting-entity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-1-reporting-entity" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfBasisOfConsolidationExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-document-and-entity-information" xlink:href="acst-20190331.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
	<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>

  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited-parentheticals" xlink:href="acst-20190331.xsd#statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited-parentheticals" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-2-basis-of-preparation-" xlink:href="acst-20190331.xsd#statement-note-2-basis-of-preparation-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-2-basis-of-preparation-" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies" xlink:href="acst-20190331.xsd#statement-note-3-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_FR" xlink:label="country_FR" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_GeographicalAreasAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="country_FR" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties" xlink:href="acst-20190331.xsd#statement-note-7-related-parties" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_BiodrogaNutraceuticalsIncMember" xlink:label="acst_BiodrogaNutraceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NeptuneMember" xlink:label="acst_NeptuneMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NotLaterThanSixMonthsMember" xlink:label="acst_NotLaterThanSixMonthsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanSixMonthsMember" xlink:label="ifrs-full_LaterThanSixMonthsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="acst_NeptuneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_ParentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_BusinessCombinationsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="acst_BiodrogaNutraceuticalsIncMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_MaturityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_NotLaterThanSixMonthsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_LaterThanSixMonthsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-" xlink:href="acst-20190331.xsd#statement-note-12-derivative-warrant-liabilities-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures" xlink:href="acst-20190331.xsd#statement-note-13-unsecured-convertible-debentures" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnsecuredConvertibleDebenturesMember" xlink:label="acst_UnsecuredConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_BorrowingsByNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="acst_UnsecuredConvertibleDebenturesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity" xlink:href="acst-20190331.xsd#statement-note-14-capital-and-other-components-of-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_BrokerMember" xlink:label="acst_BrokerMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassASharesMember" xlink:label="acst_ClassASharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassBSharesMember" xlink:label="acst_ClassBSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassCSharesMember" xlink:label="acst_ClassCSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassDAndESharesMember" xlink:label="acst_ClassDAndESharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CommonSharesMember" xlink:label="acst_CommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DerivativeWarrantLiabilitiesMember" xlink:label="acst_DerivativeWarrantLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_May2018PublicOfferingWarrants2018Member" xlink:label="acst_May2018PublicOfferingWarrants2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingBrokerWarrantsMay2018Member" xlink:label="acst_PublicOfferingBrokerWarrantsMay2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:label="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:label="acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:label="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:label="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" xlink:label="acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:label="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:label="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnderwriterMember" xlink:label="acst_UnderwriterMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedMay2018Member" xlink:label="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionalPaidinCapitalMember" xlink:label="ifrs-full_AdditionalPaidinCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="acst_ClassBSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="acst_ClassCSharesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="acst_ClassDAndESharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CounterpartiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="acst_UnderwriterMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_DerivativeWarrantLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="acst_CommonSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="acst_BrokerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="acst_ClassASharesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="acst_UnderwriterMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_AdditionalPaidinCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_May2018PublicOfferingWarrants2018Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_PublicOfferingBrokerWarrantsMay2018Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="acst_ClassASharesMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments" xlink:href="acst-20190331.xsd#statement-note-17-sharebased-payments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ConsultantsMember" xlink:label="acst_ConsultantsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationEquityIncentivePlanMember" xlink:label="acst_CorporationEquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationStockOptionPlanMember" xlink:label="acst_CorporationStockOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="acst_CorporationStockOptionPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CounterpartiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="acst_ConsultantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="acst_CorporationEquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-22-commitments-and-contingencies" xlink:href="acst-20190331.xsd#statement-note-22-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-22-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" xlink:label="acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ResearchAndDevelopmentProjectsMember" xlink:label="acst_ResearchAndDevelopmentProjectsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:label="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:label="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:to="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ContingentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="acst_ResearchAndDevelopmentProjectsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:to="acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_MaturityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-23-determination-of-fair-values" xlink:href="acst-20190331.xsd#statement-note-23-determination-of-fair-values" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-23-determination-of-fair-values" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management" xlink:href="acst-20190331.xsd#statement-note-24-capital-management" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-25-subsequent-events" xlink:href="acst-20190331.xsd#statement-note-25-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-25-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationStockOptionPlanMember" xlink:label="acst_CorporationStockOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DirectorsMember" xlink:label="acst_DirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_EmployeeMember" xlink:label="acst_EmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FormerCEOMember" xlink:label="acst_FormerCEOMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NotesToFinancialStatementsAbstract" xlink:label="acst_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NotesToFinancialStatementsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="acst_CorporationStockOptionPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CounterpartiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="acst_DirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="acst_EmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="acst_FormerCEOMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-significant-accounting-policies-policies" xlink:href="acst-20190331.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock" xlink:label="acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:label="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-significant-accounting-policies-policies" xlink:label="acst_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-significant-accounting-policies-policies" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_DisclosureOfSignificantAccountingPoliciesAbstract" xlink:to="acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-tables" xlink:href="acst-20190331.xsd#statement-note-3-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfUsefulLivesAndRatesTextBlock" xlink:label="acst_DisclosureOfUsefulLivesAndRatesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-3-significant-accounting-policies-tables" xlink:label="acst_statement-statement-note-3-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-3-significant-accounting-policies-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfUsefulLivesAndRatesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-4-receivables-tables" xlink:href="acst-20190331.xsd#statement-note-4-receivables-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-4-receivables-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock" xlink:label="acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-4-receivables-tables" xlink:label="acst_statement-statement-note-4-receivables-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-4-receivables-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-tables" xlink:href="acst-20190331.xsd#statement-note-5-marketable-securities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SummaryOfMarketableSecuritiesTextBlock" xlink:label="acst_SummaryOfMarketableSecuritiesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-5-marketable-securities-tables" xlink:label="acst_statement-statement-note-5-marketable-securities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-5-marketable-securities-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_SummaryOfMarketableSecuritiesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-6-other-assets-tables" xlink:href="acst-20190331.xsd#statement-note-6-other-assets-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-6-other-assets-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SummaryOfOtherAssetsTextBlock" xlink:label="acst_SummaryOfOtherAssetsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-6-other-assets-tables" xlink:label="acst_statement-statement-note-6-other-assets-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-6-other-assets-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_SummaryOfOtherAssetsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-tables" xlink:href="acst-20190331.xsd#statement-note-7-related-parties-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-7-related-parties-tables" xlink:label="acst_statement-statement-note-7-related-parties-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:label="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-7-related-parties-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-tables" xlink:href="acst-20190331.xsd#statement-note-8-government-assistance-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock" xlink:label="acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-8-government-assistance-tables" xlink:label="acst_statement-statement-note-8-government-assistance-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:label="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-8-government-assistance-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-9-equipment-tables" xlink:href="acst-20190331.xsd#statement-note-9-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-9-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-9-equipment-tables" xlink:label="acst_statement-statement-note-9-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-9-equipment-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets-tables" xlink:href="acst-20190331.xsd#statement-note-10-intangible-assets-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-10-intangible-assets-tables" xlink:label="acst_statement-statement-note-10-intangible-assets-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-10-intangible-assets-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables-tables" xlink:href="acst-20190331.xsd#statement-note-11-trade-and-other-payables-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock" xlink:label="acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-11-trade-and-other-payables-tables" xlink:label="acst_statement-statement-note-11-trade-and-other-payables-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-11-trade-and-other-payables-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-tables" xlink:href="acst-20190331.xsd#statement-note-12-derivative-warrant-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DerivativeWarrantLiabilitiesMember" xlink:label="acst_DerivativeWarrantLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-12-derivative-warrant-liabilities-tables" xlink:label="acst_statement-statement-note-12-derivative-warrant-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:label="ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-12-derivative-warrant-liabilities-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_DerivativeWarrantLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-tables" xlink:href="acst-20190331.xsd#statement-note-13-unsecured-convertible-debentures-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-13-unsecured-convertible-debentures-tables" xlink:label="acst_statement-statement-note-13-unsecured-convertible-debentures-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-13-unsecured-convertible-debentures-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-tables" xlink:href="acst-20190331.xsd#statement-note-14-capital-and-other-components-of-equity-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassOfWarrantOrRightOutstandingTextBlock" xlink:label="acst_ClassOfWarrantOrRightOutstandingTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfConvertibleDebenturesTextBlock" xlink:label="acst_DisclosureOfConvertibleDebenturesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsMember" xlink:label="acst_WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-14-capital-and-other-components-of-equity-tables" xlink:label="acst_statement-statement-note-14-capital-and-other-components-of-equity-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:label="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-14-capital-and-other-components-of-equity-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfConvertibleDebenturesTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ClassOfWarrantOrRightOutstandingTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses-tables" xlink:href="acst-20190331.xsd#statement-note-15-personnel-expenses-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock" xlink:label="acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-15-personnel-expenses-tables" xlink:label="acst_statement-statement-note-15-personnel-expenses-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-15-personnel-expenses-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses-tables" xlink:href="acst-20190331.xsd#statement-note-16-financial-expenses-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock" xlink:label="acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-16-financial-expenses-tables" xlink:label="acst_statement-statement-note-16-financial-expenses-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-16-financial-expenses-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-tables" xlink:href="acst-20190331.xsd#statement-note-17-sharebased-payments-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-17-sharebased-payments-tables" xlink:label="acst_statement-statement-note-17-sharebased-payments-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-17-sharebased-payments-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-tables" xlink:href="acst-20190331.xsd#statement-note-19-supplemental-cash-flow-disclosure-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock" xlink:label="acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfNoncashTransactionsTextBlock" xlink:label="acst_DisclosureOfNoncashTransactionsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-19-supplemental-cash-flow-disclosure-tables" xlink:label="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfNoncashTransactionsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-tables" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ChangesInDeferredTaxLiabilityAssetTextBlock" xlink:label="acst_ChangesInDeferredTaxLiabilityAssetTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock" xlink:label="acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock" xlink:label="acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock" xlink:label="acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-20-income-taxes-tables" xlink:label="acst_statement-statement-note-20-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-20-income-taxes-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ChangesInDeferredTaxLiabilityAssetTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-tables" xlink:href="acst-20190331.xsd#statement-note-21-financial-instruments-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-21-financial-instruments-tables" xlink:label="acst_statement-statement-note-21-financial-instruments-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:label="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-21-financial-instruments-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-tables" xlink:href="acst-20190331.xsd#statement-note-24-capital-management-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-tables" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-24-capital-management-tables" xlink:label="acst_statement-statement-note-24-capital-management-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-24-capital-management-tables" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-2-basis-of-preparation-details-textual" xlink:href="acst-20190331.xsd#statement-note-2-basis-of-preparation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-2-basis-of-preparation-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NoteToFinancialStatementDetailsTextual" xlink:label="acst_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NoteToFinancialStatementDetailsTextual" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CurrentAssets-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CashAndCashEquivalents-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_FinancialAssets-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CurrentLiabilities-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-details-textual" xlink:href="acst-20190331.xsd#statement-note-3-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NoteToFinancialStatementDetailsTextual" xlink:label="acst_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_FR" xlink:label="country_FR" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NoteToFinancialStatementDetailsTextual" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_GeographicalAreasAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="country_FR" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_Assets-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-marketable-securities-details-parentheticals" xlink:href="acst-20190331.xsd#statement-note-5-marketable-securities-marketable-securities-details-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-marketable-securities-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_FinancialInstrumentInterestRate" xlink:label="acst_FinancialInstrumentInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FinancialInstrumentMaturityDate" xlink:label="acst_FinancialInstrumentMaturityDate" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecurties" xlink:label="acst_MarketableSecurties" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositOneMember" xlink:label="acst_TermDepositOneMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositTwoMember" xlink:label="acst_TermDepositTwomember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TreasuryBillsMember" xlink:label="acst_TreasuryBillsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-5-marketable-securities-marketable-securities-details-parentheticals" xlink:label="acst_statement-statement-note-5-marketable-securities-marketable-securities-details-parentheticals" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-5-marketable-securities-marketable-securities-details-parentheticals" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_TermDepositOneMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_TermDepositTwomember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_TreasuryBillsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_MarketableSecurties" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_FinancialInstrumentInterestRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_FinancialInstrumentMaturityDate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-details-textual" xlink:href="acst-20190331.xsd#statement-note-7-related-parties-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_BiodrogaNutraceuticalsIncMember" xlink:label="acst_BiodrogaNutraceuticalsIncMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NeptuneMember" xlink:label="acst_NeptuneMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NotLaterThanSixMonthsMember" xlink:label="acst_NotLaterThanSixMonthsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NoteToFinancialStatementDetailsTextual" xlink:label="acst_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProportionOfOwnershipInterestsHeldByRelatedParty" xlink:label="acst_ProportionOfOwnershipInterestsHeldByRelatedParty-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProportionOfVotingRightsHeldByAnAssociate" xlink:label="acst_ProportionOfVotingRightsHeldByAnAssociate-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination" xlink:label="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestRevenueExpense" xlink:label="ifrs-full_InterestRevenueExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanSixMonthsMember" xlink:label="ifrs-full_LaterThanSixMonthsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ParentMember" xlink:label="ifrs-full_ParentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NoteToFinancialStatementDetailsTextual" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="acst_NeptuneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_ParentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_BusinessCombinationsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="acst_BiodrogaNutraceuticalsIncMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_MaturityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_NotLaterThanSixMonthsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_LaterThanSixMonthsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ProportionOfOwnershipInterestsHeldByRelatedParty-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_BorrowingsInterestRate-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_InterestRevenueExpense-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ProportionOfVotingRightsHeldByAnAssociate-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-details-textual" xlink:href="acst-20190331.xsd#statement-note-12-derivative-warrant-liabilities-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NoteToFinancialStatementDetailsTextual" xlink:label="acst_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare" xlink:label="acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NoteToFinancialStatementDetailsTextual" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-details-textual" xlink:href="acst-20190331.xsd#statement-note-13-unsecured-convertible-debentures-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate" xlink:label="acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum" xlink:label="acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsConvertibleConversionPrice" xlink:label="acst_BorrowingsConvertibleConversionPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsConvertibleEquityIssuedFloorPrice" xlink:label="acst_BorrowingsConvertibleEquityIssuedFloorPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsConvertibleThresholdConsecutiveTradingDays" xlink:label="acst_BorrowingsConvertibleThresholdConsecutiveTradingDays-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BorrowingsDiscountOfBorrowingPrincipalAmount" xlink:label="acst_BorrowingsDiscountOfBorrowingPrincipalAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants" xlink:label="acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NoteToFinancialStatementDetailsTextual" xlink:label="acst_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnsecuredConvertibleDebenturesMember" xlink:label="acst_UnsecuredConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion" xlink:label="acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections" xlink:label="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NoteToFinancialStatementDetailsTextual" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_BorrowingsByNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="acst_UnsecuredConvertibleDebenturesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NotionalAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_BorrowingsConvertibleConversionPrice-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_BorrowingsDiscountOfBorrowingPrincipalAmount-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_BorrowingsConvertibleThresholdConsecutiveTradingDays-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_BorrowingsInterestRate-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_BorrowingsConvertibleEquityIssuedFloorPrice-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-details-textual" xlink:href="acst-20190331.xsd#statement-note-14-capital-and-other-components-of-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds" xlink:label="acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_AtTheMarketSalesAgreementFeePercentage" xlink:label="acst_AtTheMarketSalesAgreementFeePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_AtTheMarketSalesAgreementTerm" xlink:label="acst_AtTheMarketSalesAgreementTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_BrokerMember" xlink:label="acst_BrokerMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassASharesMember" xlink:label="acst_ClassASharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassBSharesMember" xlink:label="acst_ClassBSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassCSharesMember" xlink:label="acst_ClassCSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassDAndESharesMember" xlink:label="acst_ClassDAndESharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CommonSharesMember" xlink:label="acst_CommonSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ConversionRatio" xlink:label="acst_ConversionRatio-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DeferredFinancingCostsCurrent" xlink:label="acst_DeferredFinancingCostsCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DerivativeWarrantLiabilitiesMember" xlink:label="acst_DerivativeWarrantLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ExercisePriceFor10Warrants" xlink:label="acst_ExercisePriceFor10Warrants-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ExercisePriceWarrantsIssued" xlink:label="acst_ExercisePriceWarrantsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FairValuePerSharesIssuableWarrants" xlink:label="acst_FairValuePerSharesIssuableWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment" xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares" xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IssueOfEquityNumberOfShares" xlink:label="acst_IssueOfEquityNumberOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_May2018PublicOfferingWarrants2018Member" xlink:label="acst_May2018PublicOfferingWarrants2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NonCumulativeDividendRate" xlink:label="acst_NonCumulativeDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NoteToFinancialStatementDetailsTextual" xlink:label="acst_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfSharesCalledByEachWarrant" xlink:label="acst_NumberOfSharesCalledByEachWarrant-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfSharesCalledByWarrants" xlink:label="acst_NumberOfSharesCalledByWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfSharesIssuedForOptionExercised" xlink:label="acst_NumberOfSharesIssuedForOptionExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfSharesIssuedInPublicOffering" xlink:label="acst_NumberOfSharesIssuedInPublicOffering-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfUnitsIssuedDuringPeriod" xlink:label="acst_NumberOfUnitsIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfWarrantsExercised" xlink:label="acst_NumberOfWarrantsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfWarrantsIssuedDuringPeriod" xlink:label="acst_NumberOfWarrantsIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromExerciseOfWarrants" xlink:label="acst_ProceedsFromExerciseOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromIssuingSharesInPublicOfferingGross" xlink:label="acst_ProceedsFromIssuingSharesInPublicOfferingGross-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromIssuingUnits" xlink:label="acst_ProceedsFromIssuingUnits-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingBrokerWarrantsMay2018Member" xlink:label="acst_PublicOfferingBrokerWarrantsMay2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:label="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RedeemablePricePerShare" xlink:label="acst_RedeemablePricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:label="acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:label="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:label="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" xlink:label="acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:label="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ShareBasedPaymentCostsAllocatedToDebt" xlink:label="acst_ShareBasedPaymentCostsAllocatedToDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ShareBasedPaymentCostsAllocatedToShareCapital" xlink:label="acst_ShareBasedPaymentCostsAllocatedToShareCapital-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ShareIssuedPricePerShare" xlink:label="acst_ShareIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:label="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnderwriterMember" xlink:label="acst_UnderwriterMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnitIssuanceCosts" xlink:label="acst_UnitIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnitIssuedPricePerUnit" xlink:label="acst_UnitIssuedPricePerUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnitSharesOfClassAShare" xlink:label="acst_UnitSharesOfClassAShare-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnitSharesOfClassASharePurchaseWarrant" xlink:label="acst_UnitSharesOfClassASharePurchaseWarrant-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantCosts" xlink:label="acst_WarrantCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedMay2018Member" xlink:label="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsAndRightsOutstanding" xlink:label="acst_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsExercisedEquitySharesIssued" xlink:label="acst_WarrantsExercisedEquitySharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsExercisedEquitySharesIssuedAmount" xlink:label="acst_WarrantsExercisedEquitySharesIssuedAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsExpired" xlink:label="acst_WarrantsExpired-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionalPaidinCapitalMember" xlink:label="ifrs-full_AdditionalPaidinCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxExpenseIncome" xlink:label="ifrs-full_DeferredTaxExpenseIncome-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageSharePrice" xlink:label="ifrs-full_WeightedAverageSharePrice-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NoteToFinancialStatementDetailsTextual" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="acst_ClassBSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="acst_ClassCSharesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="acst_ClassDAndESharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CounterpartiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="acst_UnderwriterMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_DerivativeWarrantLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="acst_CommonSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="acst_BrokerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="acst_ClassASharesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="acst_UnderwriterMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_AdditionalPaidinCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_May2018PublicOfferingWarrants2018Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_PublicOfferingBrokerWarrantsMay2018Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="acst_ClassASharesMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_NonCumulativeDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ConversionRatio-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_RedeemablePricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_AtTheMarketSalesAgreementTerm-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_AtTheMarketSalesAgreementFeePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DeferredFinancingCostsCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfSharesIssuedInPublicOffering-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ShareIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfSharesIssuedForOptionExercised-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ProceedsFromIssuingSharesInPublicOfferingGross-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_IssueOfEquityNumberOfShares-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfUnitsIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_UnitIssuedPricePerUnit-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ProceedsFromIssuingUnits-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfWarrantsIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ExercisePriceWarrantsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IssueOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_UnitIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_FairValuePerSharesIssuableWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfSharesCalledByWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantCosts-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantsExercisedEquitySharesIssuedAmount-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_UnitSharesOfClassAShare-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_UnitSharesOfClassASharePurchaseWarrant-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfSharesCalledByEachWarrant-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ShareBasedPaymentCostsAllocatedToShareCapital-2" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ShareBasedPaymentCostsAllocatedToDebt-2" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ExercisePriceFor10Warrants-2" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DeferredTaxExpenseIncome-2" xlink:type="arc"/>
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantsExercisedEquitySharesIssued-2" xlink:type="arc"/>
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantsExpired-2" xlink:type="arc"/>
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfWarrantsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ProceedsFromExerciseOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfSharesIssued-2" xlink:type="arc"/>
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-details-textual" xlink:href="acst-20190331.xsd#statement-note-17-sharebased-payments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ConsultantsMember" xlink:label="acst_ConsultantsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationEquityIncentivePlanMember" xlink:label="acst_CorporationEquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationStockOptionPlanMember" xlink:label="acst_CorporationStockOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MaximumNumberOfSharesAuthorized" xlink:label="acst_MaximumNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MaximumNumberOfSharesAuthorizedAsPercentage" xlink:label="acst_MaximumNumberOfSharesAuthorizedAsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NoteToFinancialStatementDetailsTextual" xlink:label="acst_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NoteToFinancialStatementDetailsTextual" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="acst_CorporationStockOptionPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CounterpartiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="acst_ConsultantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="acst_CorporationEquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_MaximumNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_MaximumNumberOfSharesAuthorizedAsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-details-textual" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NoteToFinancialStatementDetailsTextual" xlink:label="acst_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity" xlink:label="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NoteToFinancialStatementDetailsTextual" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-22-commitments-and-contingencies-details-textual" xlink:href="acst-20190331.xsd#statement-note-22-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-22-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" xlink:label="acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NoteToFinancialStatementDetailsTextual" xlink:label="acst_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ResearchAndDevelopmentProjectsMember" xlink:label="acst_ResearchAndDevelopmentProjectsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:label="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:label="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EstimatedFinancialEffectOfContingentLiabilities" xlink:label="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease" xlink:label="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NoteToFinancialStatementDetailsTextual" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:to="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ContingentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="acst_ResearchAndDevelopmentProjectsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis" xlink:to="acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_MaturityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_EstimatedFinancialEffectOfContingentLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-23-determination-of-fair-values-details-textual" xlink:href="acst-20190331.xsd#statement-note-23-determination-of-fair-values-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-23-determination-of-fair-values-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NoteToFinancialStatementDetailsTextual" xlink:label="acst_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss" xlink:label="acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain" xlink:label="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss" xlink:label="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NoteToFinancialStatementDetailsTextual" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-details-textual" xlink:href="acst-20190331.xsd#statement-note-24-capital-management-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NoteToFinancialStatementDetailsTextual" xlink:label="acst_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NoteToFinancialStatementDetailsTextual" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_BorrowingsInterestRate-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals" xlink:href="acst-20190331.xsd#statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_CommercialPapersIssuedInUsCurrencyMember" xlink:label="acst_CommercialPapersIssuedInUsCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PromissoryNotesIssuedInUsCurrencyMember" xlink:label="acst_PromissoryNotesIssuedInUsCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositsIssuedInUsCurrencyMember" xlink:label="acst_TermDepositsIssuedInUsCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals" xlink:label="acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashEquivalents" xlink:label="ifrs-full_CashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsCategoryMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="acst_TermDepositsIssuedInUsCurrencyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="acst_CommercialPapersIssuedInUsCurrencyMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="acst_PromissoryNotesIssuedInUsCurrencyMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CashEquivalents" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-25-subsequent-events-details-textual" xlink:href="acst-20190331.xsd#statement-note-25-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-25-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationStockOptionPlanMember" xlink:label="acst_CorporationStockOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DescriptionOfVestingPeriodShareOptionGranted" xlink:label="acst_DescriptionOfVestingPeriodShareOptionGranted-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DirectorsMember" xlink:label="acst_DirectorsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_EmployeeMember" xlink:label="acst_EmployeeMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FormerCEOMember" xlink:label="acst_FormerCEOMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LegalExpense" xlink:label="acst_LegalExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LegalFeesReimburse" xlink:label="acst_LegalFeesReimburse-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NoteToFinancialStatementDetailsTextual" xlink:label="acst_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NumberOfSharesIssuedForLegalSettlement" xlink:label="acst_NumberOfSharesIssuedForLegalSettlement-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ShareIssuedPricePerShare" xlink:label="acst_ShareIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_NoteToFinancialStatementDetailsTextual" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="acst_CorporationStockOptionPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CounterpartiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="acst_DirectorsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="acst_EmployeeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="acst_FormerCEOMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DescriptionOfVestingPeriodShareOptionGranted-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_NumberOfSharesIssuedForLegalSettlement-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ShareIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_LegalFeesReimburse-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_LegalExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-unrecognized-federal-tax-credits-details" xlink:href="acst-20190331.xsd#statement-note-8-government-assistance-unrecognized-federal-tax-credits-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-unrecognized-federal-tax-credits-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember" xlink:label="acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember" xlink:label="acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember" xlink:label="acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember" xlink:label="acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember" xlink:label="acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember" xlink:label="acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember" xlink:label="acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember" xlink:label="acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember" xlink:label="acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember" xlink:label="acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember" xlink:label="acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-8-government-assistance-unrecognized-federal-tax-credits-details" xlink:label="acst_statement-statement-note-8-government-assistance-unrecognized-federal-tax-credits-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:label="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-8-government-assistance-unrecognized-federal-tax-credits-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_MaturityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-assumptions-details" xlink:href="acst-20190331.xsd#statement-note-14-capital-and-other-components-of-equity-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ExercisePriceWarrantsIssued" xlink:label="acst_ExercisePriceWarrantsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ExpectedDividendWarrantsGranted" xlink:label="acst_ExpectedDividendWarrantsGranted-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ExpectedVolatilityWarrantsIssued" xlink:label="acst_ExpectedVolatilityWarrantsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_May2018PublicOfferingWarrants2018Member" xlink:label="acst_May2018PublicOfferingWarrants2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingWarrantsIn2017Member" xlink:label="acst_PublicOfferingWarrantsIn2017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RiskFreeInterestRateWarrantsIssued" xlink:label="acst_RiskFreeInterestRateWarrantsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLifeWarrantsIssued" xlink:label="acst_WarrantLifeWarrantsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" xlink:label="acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" xlink:label="acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" xlink:label="acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WeightedAverageSharePriceWarrantsIssued" xlink:label="acst_WeightedAverageSharePriceWarrantsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-14-capital-and-other-components-of-equity-assumptions-details" xlink:label="acst_statement-statement-note-14-capital-and-other-components-of-equity-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-14-capital-and-other-components-of-equity-assumptions-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_May2018PublicOfferingWarrants2018Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_PublicOfferingWarrantsIn2017Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ExercisePriceWarrantsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_WeightedAverageSharePriceWarrantsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_RiskFreeInterestRateWarrantsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantLifeWarrantsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ExpectedVolatilityWarrantsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ExpectedDividendWarrantsGranted-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details" xlink:href="acst-20190331.xsd#statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DepreciationPercentage" xlink:label="acst_DepreciationPercentage" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FurnitureAndOfficeEquipmentMember" xlink:label="acst_FurnitureAndOfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IntangibleAssetsUsefulLife" xlink:label="acst_IntangibleAssetsUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaboratoryEquipmentMember" xlink:label="acst_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PatentsMember" xlink:label="acst_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProductionEquipmentMember" xlink:label="acst_ProductionEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UsefulLifeOfAssets" xlink:label="acst_UsefulLifeOfAssets" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details" xlink:label="acst_statement-statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="acst_FurnitureAndOfficeEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="acst_PatentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_LicencesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="acst_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="acst_ProductionEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DepreciationPercentage" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_UsefulLifeOfAssets" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_IntangibleAssetsUsefulLife" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-6-other-assets-other-assets-details" xlink:href="acst-20190331.xsd#statement-note-6-other-assets-other-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-6-other-assets-other-assets-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_PurchasesOtherAssets" xlink:label="acst_PurchasesOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UsedOtherAssets" xlink:label="acst_UsedOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-6-other-assets-other-assets-details" xlink:label="acst_statement-statement-note-6-other-assets-other-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherAssets" xlink:label="ifrs-full_OtherAssets-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherAssets" xlink:label="ifrs-full_OtherAssets-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-6-other-assets-other-assets-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherAssets-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_PurchasesOtherAssets" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_UsedOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherAssets-5" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherCurrentAssets" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherNoncurrentAssets" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-assumptions-details" xlink:href="acst-20190331.xsd#statement-note-12-derivative-warrant-liabilities-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ExercisePriceWarrantsIssued" xlink:label="acst_ExercisePriceWarrantsIssued-1" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ExpectedVolatilityWarrantsIssued" xlink:label="acst_ExpectedVolatilityWarrantsIssued-1" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RiskFreeInterestRateWarrantsIssued" xlink:label="acst_RiskFreeInterestRateWarrantsIssued-1" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedMay2018Member" xlink:label="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLifeWarrantsIssued" xlink:label="acst_WarrantLifeWarrantsIssued-1" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WeightedAverageSharePriceWarrantsIssued" xlink:label="acst_WeightedAverageSharePriceWarrantsIssued-1" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-12-derivative-warrant-liabilities-assumptions-details" xlink:label="acst_statement-statement-note-12-derivative-warrant-liabilities-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-12-derivative-warrant-liabilities-assumptions-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ExercisePriceWarrantsIssued-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_WeightedAverageSharePriceWarrantsIssued-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_RiskFreeInterestRateWarrantsIssued-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantLifeWarrantsIssued-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ExpectedVolatilityWarrantsIssued-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details" xlink:href="acst-20190331.xsd#statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_EquityComponentOfUnsecuredConvertibleDebenturesMember" xlink:label="acst_EquityComponentOfUnsecuredConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember" xlink:label="acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnsecuredConvertibleDebenturesMember" xlink:label="acst_UnsecuredConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details" xlink:label="acst_statement-statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestCostsIncurred" xlink:label="ifrs-full_InterestCostsIncurred-n9" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="ifrs-full_InterestExpenseOnBorrowings-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_BorrowingsByNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="acst_EquityComponentOfUnsecuredConvertibleDebenturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="acst_UnsecuredConvertibleDebenturesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_Borrowings-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_InterestExpenseOnBorrowings-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_InterestCostsIncurred-n9" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_Borrowings-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-cash-and-cash-equivalents-details" xlink:href="acst-20190331.xsd#statement-note-24-capital-management-cash-and-cash-equivalents-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-cash-and-cash-equivalents-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_BankersAcceptanceMember" xlink:label="acst_BankersAcceptanceMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CommercialPapersIssuedInCadCurrencyMember" xlink:label="acst_CommercialPapersIssuedInCadCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CommercialPapersIssuedInUsCurrencyMember" xlink:label="acst_CommercialPapersIssuedInUsCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PromissoryNotesIssuedInCadCurrencyMember" xlink:label="acst_PromissoryNotesIssuedInCadCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PromissoryNotesIssuedInUsCurrencyMember" xlink:label="acst_PromissoryNotesIssuedInUsCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositsIssuedInCadCurrencyMember" xlink:label="acst_TermDepositsIssuedInCadCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositsIssuedInUsCurrencyMember" xlink:label="acst_TermDepositsIssuedInUsCurrencyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details" xlink:label="acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:label="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashEquivalents" xlink:label="ifrs-full_CashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-24-capital-management-cash-and-cash-equivalents-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsCategoryMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="acst_TermDepositsIssuedInCadCurrencyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="acst_TermDepositsIssuedInUsCurrencyMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="acst_CommercialPapersIssuedInCadCurrencyMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="acst_CommercialPapersIssuedInUsCurrencyMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="acst_PromissoryNotesIssuedInCadCurrencyMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="acst_PromissoryNotesIssuedInUsCurrencyMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:to="acst_BankersAcceptanceMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_Cash" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CashEquivalents" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-4-receivables-schedule-of-receivables-details" xlink:href="acst-20190331.xsd#statement-note-4-receivables-schedule-of-receivables-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-4-receivables-schedule-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_GovernmentAssistanceAndTaxCreditsReceivable" xlink:label="acst_GovernmentAssistanceAndTaxCreditsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-4-receivables-schedule-of-receivables-details" xlink:label="acst_statement-statement-note-4-receivables-schedule-of-receivables-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentValueAddedTaxReceivables" xlink:label="ifrs-full_CurrentValueAddedTaxReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestReceivable" xlink:label="ifrs-full_InterestReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables-3" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-4-receivables-schedule-of-receivables-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CurrentValueAddedTaxReceivables" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_GovernmentAssistanceAndTaxCreditsReceivable" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_InterestReceivable" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherCurrentReceivables" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details" xlink:href="acst-20190331.xsd#statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ConversionOfConvertibleInstrumentsEquitySharesIssued" xlink:label="acst_ConversionOfConvertibleInstrumentsEquitySharesIssued-1" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details" xlink:label="acst_statement-statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ConversionOfConvertibleInstrumentsEquitySharesIssued-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-marketable-securities-details" xlink:href="acst-20190331.xsd#statement-note-5-marketable-securities-marketable-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-marketable-securities-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesCurrent" xlink:label="acst_MarketableSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesNoncurrent" xlink:label="acst_MarketableSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecurties" xlink:label="acst_MarketableSecurties" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecurties" xlink:label="acst_MarketableSecurties-3" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositOneMember" xlink:label="acst_TermDepositOneMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TermDepositTwoMember" xlink:label="acst_TermDepositTwomember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TreasuryBillsMember" xlink:label="acst_TreasuryBillsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-5-marketable-securities-marketable-securities-details" xlink:label="acst_statement-statement-note-5-marketable-securities-marketable-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-5-marketable-securities-marketable-securities-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_TermDepositOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_TermDepositTwomember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_TreasuryBillsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_MarketableSecurties" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_MarketableSecurties-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_MarketableSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_MarketableSecuritiesNoncurrent" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-reconciliation-details" xlink:href="acst-20190331.xsd#statement-note-12-derivative-warrant-liabilities-reconciliation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-reconciliation-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod" xlink:label="acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_DerivativeFinancialLiabilitiesIssued" xlink:label="acst_DerivativeFinancialLiabilitiesIssued" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_FairValuePerShareIssuable" xlink:label="acst_FairValuePerShareIssuable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:label="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantLiabilitiesIssuedMay2018Member" xlink:label="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-12-derivative-warrant-liabilities-reconciliation-details" xlink:label="acst_statement-statement-note-12-derivative-warrant-liabilities-reconciliation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:label="ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-12-derivative-warrant-liabilities-reconciliation-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_WarrantLiabilitiesIssuedMay2018Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_WarrantLiabilitiesIssuedDecember272017Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_WarrantLiabilitiesIssuedDecember32013Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DerivativeFinancialLiabilitiesIssued" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_FairValuePerShareIssuable" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses-components-of-personnel-expenses-details" xlink:href="acst-20190331.xsd#statement-note-15-personnel-expenses-components-of-personnel-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses-components-of-personnel-expenses-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-15-personnel-expenses-components-of-personnel-expenses-details" xlink:label="acst_statement-statement-note-15-personnel-expenses-components-of-personnel-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-15-personnel-expenses-components-of-personnel-expenses-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_EmployeeBenefitsExpense-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-weighted-average-assumptions-details" xlink:href="acst-20190331.xsd#statement-note-17-sharebased-payments-weighted-average-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-weighted-average-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-17-sharebased-payments-weighted-average-assumptions-details" xlink:label="acst_statement-statement-note-17-sharebased-payments-weighted-average-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExercisePriceShareOptionsGranted" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:label="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageSharePriceShareOptionsGranted" xlink:label="ifrs-full_WeightedAverageSharePriceShareOptionsGranted" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-17-sharebased-payments-weighted-average-assumptions-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageSharePriceShareOptionsGranted" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details" xlink:href="acst-20190331.xsd#statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_EquipmentIncludedInTradeAndOtherPayables" xlink:label="acst_EquipmentIncludedInTradeAndOtherPayables" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_InterestPayableIncludedInTradeAndOtherPayables" xlink:label="acst_InterestPayableIncludedInTradeAndOtherPayables" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_InterestReceivableIncludedInReceivables" xlink:label="acst_InterestReceivableIncludedInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering" xlink:label="acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IssuanceOfSharesForInterestOnConvertibleDebt" xlink:label="acst_IssuanceOfSharesForInterestOnConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables" xlink:label="acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables" xlink:label="acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables" xlink:label="acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details" xlink:label="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_IssuanceOfSharesForInterestOnConvertibleDebt" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_InterestReceivableIncludedInReceivables" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_EquipmentIncludedInTradeAndOtherPayables" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_InterestPayableIncludedInTradeAndOtherPayables" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences" xlink:label="acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss" xlink:label="acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss" xlink:label="acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxEffectOfPermanentDifferencesAndOther" xlink:label="acst_TaxEffectOfPermanentDifferencesAndOther" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" xlink:label="acst_statement-statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccountingProfit" xlink:label="ifrs-full_AccountingProfit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxEffectFromChangeInTaxRate" xlink:label="ifrs-full_TaxEffectFromChangeInTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AccountingProfit" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ApplicableTaxRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_TaxEffectOfPermanentDifferencesAndOther" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TaxEffectFromChangeInTaxRate" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_FinancingExpensesMember" xlink:label="acst_FinancingExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember" xlink:label="acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ResearchAndDevelopmentProjectsMember" xlink:label="acst_ResearchAndDevelopmentProjectsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember" xlink:label="acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" xlink:label="acst_statement-statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxLiabilityAsset" xlink:label="ifrs-full_DeferredTaxLiabilityAsset-n10" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherTemporaryDifferencesMember" xlink:label="ifrs-full_OtherTemporaryDifferencesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxLossesMember" xlink:label="ifrs-full_UnusedTaxLossesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_UnusedTaxLossesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="acst_ResearchAndDevelopmentProjectsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="acst_FinancingExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="ifrs-full_OtherTemporaryDifferencesMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DeferredTaxAssets" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DeferredTaxLiabilities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DeferredTaxLiabilityAsset-n10" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-currency-risk-details" xlink:href="acst-20190331.xsd#statement-note-21-financial-instruments-currency-risk-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-currency-risk-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_CashAndCashEquivalentsMember" xlink:label="acst_CashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CurrencyRiskForEuroMember" xlink:label="acst_CurrencyRiskForEuroMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_CurrencyRiskForUSDMember" xlink:label="acst_CurrencyRiskForUSDMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss" xlink:label="acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ForeignExchangeRiskCurrencyExposure" xlink:label="acst_ForeignExchangeRiskCurrencyExposure" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesMember" xlink:label="acst_MarketableSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ReceivablesMember" xlink:label="acst_ReceivablesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TradeAndOtherPayablesMember" xlink:label="acst_TradeAndOtherPayablesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-21-financial-instruments-currency-risk-details" xlink:label="acst_statement-statement-note-21-financial-instruments-currency-risk-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="ifrs-full_AverageForeignExchangeRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="ifrs-full_ClosingForeignExchangeRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-21-financial-instruments-currency-risk-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_TypesOfRisksAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="acst_CurrencyRiskForUSDMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="acst_CashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="acst_CurrencyRiskForEuroMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="acst_MarketableSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="acst_ReceivablesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_TradeAndOtherPayablesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_CurrencyRiskMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ForeignExchangeRiskCurrencyExposure" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AverageForeignExchangeRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ClosingForeignExchangeRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-cash-flows-twelve-month-and-month-ended-2017-unaudited" xlink:href="acst-20190331.xsd#statement-statements-of-cash-flows-twelve-month-and-month-ended-2017-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-statements-of-cash-flows-twelve-month-and-month-ended-2017-unaudited" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromExerciseOfWarrants" xlink:label="acst_ProceedsFromExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProceedsFromIssuingSharesPrivatePlacement" xlink:label="acst_ProceedsFromIssuingSharesPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForReconcileProfitLoss" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLoss-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:label="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashEquivalents" xlink:label="ifrs-full_CashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:label="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ProfitLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLoss-1" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsInvestingActivities" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromIssuingShares" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="acst_ProceedsFromIssuingSharesPrivatePlacement" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="acst_ProceedsFromExerciseOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsForShareIssueCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashAndCashEquivalents-4" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashAndCashEquivalents-5" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_Cash" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashEquivalents" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details" xlink:href="acst-20190331.xsd#statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_RangeFiveOfExercisesPricesMember" xlink:label="acst_RangeFiveOfExercisesPricesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RangeFourOfExercisesPricesMember" xlink:label="acst_RangeFourOfExercisesPricesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RangeOneOfExercisesPricesMember" xlink:label="acst_RangeOneOfExercisesPricesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RangeThreeOfExercisesPricesMember" xlink:label="acst_RangeThreeOfExercisesPricesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_RangeTwoOfExercisesPricesMember" xlink:label="acst_RangeTwoOfExercisesPricesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details" xlink:label="acst_statement-statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions-1" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="acst_RangeOneOfExercisesPricesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_BottomOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_TopOfRangeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="acst_RangeTwoOfExercisesPricesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="acst_RangeThreeOfExercisesPricesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="acst_RangeFourOfExercisesPricesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="acst_RangeFiveOfExercisesPricesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" xlink:href="acst-20190331.xsd#statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_GovernmentGrantsAndInvestmentTaxCredits" xlink:label="acst_GovernmentGrantsAndInvestmentTaxCredits-3" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_InvestmentTaxCredit" xlink:label="acst_InvestmentTaxCredit" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" xlink:label="acst_statement-statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_InvestmentTaxCredit" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_RevenueFromGovernmentGrants" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_GovernmentGrantsAndInvestmentTaxCredits-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-9-equipment-components-of-equipment-details" xlink:href="acst-20190331.xsd#statement-note-9-equipment-components-of-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-9-equipment-components-of-equipment-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_FurnitureAndOfficeEquipmentMember" xlink:label="acst_FurnitureAndOfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_LaboratoryEquipmentMember" xlink:label="acst_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ProductionEquipmentMember" xlink:label="acst_ProductionEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-9-equipment-components-of-equipment-details" xlink:label="acst_statement-statement-note-9-equipment-components-of-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComputerEquipmentMember" xlink:label="ifrs-full_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-9-equipment-components-of-equipment-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_GrossCarryingAmountMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="acst_FurnitureAndOfficeEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="acst_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="acst_ProductionEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment-5" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets-components-of-intangible-assets-details" xlink:href="acst-20190331.xsd#statement-note-10-intangible-assets-components-of-intangible-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets-components-of-intangible-assets-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_PatentsMember" xlink:label="acst_PatentsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-10-intangible-assets-components-of-intangible-assets-details" xlink:label="acst_statement-statement-note-10-intangible-assets-components-of-intangible-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:label="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-10-intangible-assets-components-of-intangible-assets-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_GrossCarryingAmountMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="acst_PatentsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_LicencesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill-5" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" xlink:href="acst-20190331.xsd#statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_LegalSettlementPayableCurrent" xlink:label="acst_LegalSettlementPayableCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" xlink:label="acst_statement-statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AccrualsClassifiedAsCurrent" xlink:label="ifrs-full_AccrualsClassifiedAsCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AccrualsClassifiedAsCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_LegalSettlementPayableCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentPayables-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details" xlink:href="acst-20190331.xsd#statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ClassOfWarrantOrRightOutstanding" xlink:label="acst_ClassOfWarrantOrRightOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_May2018PublicOfferingWarrants2018Member" xlink:label="acst_May2018PublicOfferingWarrants2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:label="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:label="acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:label="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:label="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:label="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:label="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsAndRightsOutstanding" xlink:label="acst_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" xlink:label="acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" xlink:label="acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsRelatedToEquityMember" xlink:label="acst_WarrantsRelatedToEquityMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsRelatingToLiabilitiesMember" xlink:label="acst_WarrantsRelatingToLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details" xlink:label="acst_statement-statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_May2018PublicOfferingWarrants2018Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_SeriesDecember2017UsPublicOfferingWarrants2017Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_WarrantsRelatingToLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_PublicOfferingWarrantsFebruary2017EquityPortionMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_Series2017BWBrokerWarrantsRelatedToEquityMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="acst_WarrantsRelatedToEquityMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ClassOfWarrantOrRightOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses-components-of-finance-income-expenses-details" xlink:href="acst-20190331.xsd#statement-note-16-financial-expenses-components-of-finance-income-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses-components-of-finance-income-expenses-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_AccretionOfInterestOnConvertibleDebenture" xlink:label="acst_AccretionOfInterestOnConvertibleDebenture-n8" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantTransactionCosts" xlink:label="acst_WarrantTransactionCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-16-financial-expenses-components-of-finance-income-expenses-details" xlink:label="acst_statement-statement-note-16-financial-expenses-components-of-finance-income-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts-n10" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_InterestExpenseOnBorrowings" xlink:label="ifrs-full_InterestExpenseOnBorrowings-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherExpenseByNature" xlink:label="ifrs-full_OtherExpenseByNature-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RevenueFromInterest" xlink:label="ifrs-full_RevenueFromInterest" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-16-financial-expenses-components-of-finance-income-expenses-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_RevenueFromInterest" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NetForeignExchangeGain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_InterestExpenseOnBorrowings-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_AccretionOfInterestOnConvertibleDebenture-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantTransactionCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherExpenseByNature-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_FinanceCosts-n10" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-option-activity-details" xlink:href="acst-20190331.xsd#statement-note-17-sharebased-payments-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_CorporationStockOptionPlanMember" xlink:label="acst_CorporationStockOptionPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-17-sharebased-payments-option-activity-details" xlink:label="acst_statement-statement-note-17-sharebased-payments-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfOutstandingShareOptions" xlink:label="ifrs-full_NumberOfOutstandingShareOptions-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-17-sharebased-payments-option-activity-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="acst_CorporationStockOptionPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfOutstandingShareOptions-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" xlink:href="acst-20190331.xsd#statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts" xlink:label="acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts-1" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses-1" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" xlink:label="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherAdjustmentsForNoncashItems" xlink:label="ifrs-full_OtherAdjustmentsForNoncashItems-3" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherAdjustmentsForNoncashItems-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-deferred-tax-recovery-expense-details" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes-deferred-tax-recovery-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-deferred-tax-recovery-expense-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-20-income-taxes-deferred-tax-recovery-expense-details" xlink:label="acst_statement-statement-note-20-income-taxes-deferred-tax-recovery-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:label="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense" xlink:label="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-20-income-taxes-deferred-tax-recovery-expense-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" xlink:href="acst-20190331.xsd#statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ProvincialMember" xlink:label="acst_ProvincialMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThouandThirtyEightMember" xlink:label="acst_TwoThouandThirtyEightMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThouandThirtySevenMember" xlink:label="acst_TwoThouandThirtySevenMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyFiveMember" xlink:label="acst_TwoThousandThirtyFiveMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyFourMember" xlink:label="acst_TwoThousandThirtyFourMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyMember" xlink:label="acst_TwoThousandThirtyMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyNineMember" xlink:label="acst_TwoThousandThirtyNineMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyOneMember" xlink:label="acst_TwoThousandThirtyOneMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtySixMember" xlink:label="acst_TwoThousandThirtySixMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyThreeMember" xlink:label="acst_TwoThousandThirtyThreeMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandThirtyTwoMember" xlink:label="acst_TwoThousandThirtyTwoMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TwoThousandTwentyNineMember" xlink:label="acst_TwoThousandTwentyNineMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" xlink:label="acst_statement-statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CountryOfDomicileMember" xlink:label="ifrs-full_CountryOfDomicileMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:label="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:label="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:label="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised-1" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_MaturityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_TwoThousandTwentyNineMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_GeographicalAreasAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_CountryOfDomicileMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="acst_ProvincialMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_TwoThousandThirtyMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_TwoThousandThirtyOneMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_TwoThousandThirtyTwoMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_TwoThousandThirtyThreeMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_TwoThousandThirtyFourMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_TwoThousandThirtyFiveMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_TwoThousandThirtySixMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_TwoThouandThirtySevenMember" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_TwoThouandThirtyEightMember" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="acst_TwoThousandThirtyNineMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited" xlink:href="acst-20190331.xsd#statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_ConversionOfConvertibleInstrumentsEquitySharesIssued" xlink:label="acst_ConversionOfConvertibleInstrumentsEquitySharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment" xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares" xlink:label="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares" xlink:label="acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_IssueOfEquityNumberOfShares" xlink:label="acst_IssueOfEquityNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_NetEquity" xlink:label="acst_NetEquity" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_WarrantsExercisedEquitySharesIssued" xlink:label="acst_WarrantsExercisedEquitySharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionalPaidinCapitalMember" xlink:label="ifrs-full_AdditionalPaidinCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:label="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssueOfConvertibleInstruments" xlink:label="ifrs-full_IssueOfConvertibleInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherEquityInterestMember" xlink:label="ifrs-full_OtherEquityInterestMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_IssuedCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_OtherEquityInterestMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_AdditionalPaidinCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_Equity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ComprehensiveIncome" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_NetEquity" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_IssueOfEquityNumberOfShares" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IssueOfEquity" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_WarrantsExercisedEquitySharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ConversionOfConvertibleInstrumentsEquitySharesIssued" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IssueOfConvertibleInstruments" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_Equity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-financial-liabilities-details" xlink:href="acst-20190331.xsd#statement-note-21-financial-instruments-financial-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-financial-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_TradeAndOtherPayablesMember" xlink:label="acst_TradeAndOtherPayablesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_UnsecuredConvertibleDebenturesMember" xlink:label="acst_UnsecuredConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-21-financial-instruments-financial-liabilities-details" xlink:label="acst_statement-statement-note-21-financial-instruments-financial-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-21-financial-instruments-financial-liabilities-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_CarryingAmountMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_TradeAndOtherPayablesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="ifrs-full_GrossCarryingAmountMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_MaturityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_NotLaterThanOneYearMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="acst_UnsecuredConvertibleDebenturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_FinancialLiabilities" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-financial-position" xlink:href="acst-20190331.xsd#statement-statements-of-financial-position" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-statements-of-financial-position" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_DeferredFinancingCostsCurrent" xlink:label="acst_DeferredFinancingCostsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesCurrent" xlink:label="acst_MarketableSecuritiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_MarketableSecuritiesNoncurrent" xlink:label="acst_MarketableSecuritiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_AdditionalPaidinCapital" xlink:label="ifrs-full_AdditionalPaidinCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CapitalCommitments" xlink:label="ifrs-full_CapitalCommitments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentDebtInstrumentsIssued" xlink:label="ifrs-full_CurrentDebtInstrumentsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CurrentPrepaidExpenses" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_NoncurrentDebtInstrumentsIssued" xlink:label="ifrs-full_NoncurrentDebtInstrumentsIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherEquityInterest" xlink:label="ifrs-full_OtherEquityInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CurrentAssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="acst_MarketableSecuritiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="acst_DeferredFinancingCostsCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="acst_MarketableSecuritiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentAssets" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentDebtInstrumentsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentDebtInstrumentsIssued-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_EquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherEquityInterest" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_AdditionalPaidinCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_CapitalCommitments" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAndLiabilities-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-key-management-personnel-compensation-details" xlink:href="acst-20190331.xsd#statement-note-7-related-parties-key-management-personnel-compensation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-key-management-personnel-compensation-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-7-related-parties-key-management-personnel-compensation-details" xlink:label="acst_statement-statement-note-7-related-parties-key-management-personnel-compensation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits-1" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-7-related-parties-key-management-personnel-compensation-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_KeyManagementPersonnelCompensation-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-statements-of-earnings-and-comprehensive-loss-twelve-month-and-month-ended-2017-unaudited" xlink:href="acst-20190331.xsd#statement-statements-of-earnings-and-comprehensive-loss-twelve-month-and-month-ended-2017-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-statements-of-earnings-and-comprehensive-loss-twelve-month-and-month-ended-2017-unaudited" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_GrossFinanceIncomeCost" xlink:label="acst_GrossFinanceIncomeCost" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:label="ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTax" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTax-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLossAbstract" xlink:label="ifrs-full_ProfitLossAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProfitLossAbstract" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ProfitLossFromOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_GrossFinanceIncomeCost" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTax-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ComprehensiveIncome-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_WeightedAverageShares" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" xlink:href="acst-20190331.xsd#statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" xlink:type="extended">
    <link:loc xlink:href="acst-20190331.xsd#acst_NeptuneMember" xlink:label="acst_NeptuneMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_ResearchDevelopmentGeneralAndAdministrationExpense" xlink:label="acst_ResearchDevelopmentGeneralAndAdministrationExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SharedServiceAgreementMember" xlink:label="acst_SharedServiceAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementLineItems" xlink:label="acst_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_StatementTable" xlink:label="acst_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_SuppliesAndIncrementalCostsMember" xlink:label="acst_SuppliesAndIncrementalCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="acst-20190331.xsd#acst_statement-statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" xlink:label="acst_statement-statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.ifrs.org/taxonomy/2017-03-09/full_ifrs/full_ifrs-cor_2017-03-09.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_statement-statement-note-7-related-parties-administrative-and-research-and-development-expenses-details" xlink:to="acst_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="acst_NeptuneMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="ifrs-full_ProductsAndServicesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="acst_SuppliesAndIncrementalCostsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="acst_SharedServiceAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementTable" xlink:to="acst_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acst_StatementLineItems" xlink:to="acst_ResearchDevelopmentGeneralAndAdministrationExpense-3" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>p25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p25.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!XP.$ P$1  (1 0,1 ?_$ ,P  0 " P$! 0
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M)J1%6R_AI:O%PRU<J3?K)10"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M<025!<:-?."^;BGPWK5L577E79;D5[)\6:VW/&7+N>$^X-P9D&!W)@7WH+C
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M9FO@N"P^0*[[8CJUF0W71JNB?#;\-3N;IQXOQ+AJU/0^NUY3N* 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"@WIL
M? ;QQ88[,-FH,N(_&D,FK;S+H\$-LTZ%XUO'D='*,WHK+4YW&^"V!9R42?E\
MKE=Q' -'8+&5E*^PTX/LFC:(*$H^35>NC[AQ"27P,+"IUEGT&N!U% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M>;55%%4;('%$*Z=*+T<*U7'CR)\=&B.]Z-3JC[1E,QB<3&[UE)K$&->W.DN
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MY&'C>D*"\WD'^"O&W ;NX,XO<S2XO,$BV 7D1$ R7\ +_JK7/']>-U\4:O\
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M;BBHB@-[^153@O3>N.#-%F[/YG3+CE:&/A#F]HO;HR>+'9X[/WBQ%#OT411
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M<KQ8WY#D8F*[%Q,II<8P;0J$=1=.W*2W4MI3HJYLEECKKN3%5<V?H.O">H4
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M"3@J]/!+6K:[IIZ)&?036K9];1+(B>:O*=SB-H^$NWMK[NS&YH3KKDK+J?\
M - Y; NN<UP6K(B]8K=*UVOG=JJK\#G7$JML;8\)=O[>WOEMVQ'73EY7F?\
MMC0.4RKQHXYR[(B]8A\M+YW:JKT%<25FS;Q7AWC\=X@9;>C<MXYF68&,[%)!
MY0""-I<51-5_X*=*U+96Z*O0JQQ9LI\=X,8[%[S?W)C,WDH+,N5WZ5B&'!&,
MZ]=5LXEKD%R7JKY^FM/N&ZPTC*Q0Y3+C:WAWC]N[HW#N"/+>?D;A=1Z0RX@H
M#:H1%8-*(OZ?EK-\KM5+H:KCAM]1LSP[Q^U<ON#)Q9;TAS<$GO<AMU!06RU&
M6D-*(MOXGEIDRNR2Z"F/BV^IJ>)?A7CM^%C#EY"3CW,43AL'%T:E)W1QN2+9
M1Y:6M5Q9G2=-R9,?(K-J^"J;?W!$S'^*<OD%B*1=TE/:V3U H==/+;5>M7[C
MDHA&:X8<RR+)> ^*/(3I&"SN4V[$RA*>2QV/>08[JE?4J"J=75?_ .$JKN7&
MJ3@/"O!P=AMW8VV]O;87;>,C<O&&#@/B2ZC=5T=+AN$OM$2?_%JXVR.UI>YT
MK1)0BI\._"G ;(P^0QD-UV:WDSU2G)&G40:-"-]5$32B*OIK>7,[M/H9QXE5
M0>^&GA9A-@1I[.-?>DKD'1<<=?TZA%M%0&TTHG ;KZ:9<SON,>-5V-OQ(\/X
M&^]O#A)TIV(R+X2.:P@J>IM"1$ZZ*ENO4Q971RBY*<E!T<&*,.%'B 2D$=H&
MA)>E4 4%%6WQ5S;EFDCB]I>$V*VU"W)$C3I#X[E)PY).("*TK@F*\O2B=JO3
M76^=V:\CG7$E/F<KC_\ +;"Q\=(L/=^;C1+JJQV'A:!5+VET@B)=?+PKJ^[G
MP1A=O'BSNMB>&>T]DQW@PL<EDR;=ZGR"YDAVRWL1V2R7XV%$2N.3-:^YUIC5
M=CC)W^77&R,UDLM&W+E<>]E)#DF0W%,&QU.&IZ>JB*J"I<+UU7=.$H6AS>#6
M9.XV%LM-HXE['IE)F6YKZO\ >)Q\QP=0B.A%_5ZMZXY,G)S$'2E.*.-SO^7[
M&Y3<V2W SN')XV5E'.8^$0@;1.")INB:E3J^6NU>Y:JE"T.=L";F2YP/@_AX
M.W,MM_+9&;N"!EU!74R#BD;>A.KRB3B*HO6OYZQ;.VTTH@U7$DH>I5XWP'C1
MG8C4K=6;FX: X+L/$G)Y;0*VNH!4FT$E0;>2U:?<^2DBP^;.N\0=B8O>^W3P
MF1<-@%<!YF2UIYC;C:\"'4BIQ15%?@6N6+(Z.4;O164&[M?;&-VYMN%M^&BG
M"A,\E%<1%5R]U,C\ES)55:E[NSDM:PH."<\ <<Q(E-X/<F7P>&FFKDG#PG]+
M"J7M("JBJ*+^&NWN7XI-G+T%X-HNMT>$6#SVV\)M]9DJ-#P3S;T4T-'G3Y0J
M*"X;NI5]JL4SNK;ZFK8DTET&Y_#"5E\V_EH&ZLQA3F +<N-$>16"$!TIH T7
MEK;RC2F:%#29;8Y<RR_V=L_"[1P+&$Q $,5E2,C<+4XXX:W-PRX7):QDR.SE
MFJ455"*K;WAKCL)OC-[N9F/.R\X.EZ,:!RV^L)=2R:OT/*M:ME;JJ]#-<<6;
MZD3GA;BV_$(-\8V8_CL@8Z,A%90%8E"J6+F"J7N2(EU1>E$7IJ^L^'%CTURY
M(J\WX)8^3GI>:P&<R6V96275DF\:Z@MO$O%245]E5O?A6J]PXAI,R\.LIP6)
M>$^-#9[.VX>8RL3D2.^ADVY1+*60MU4B)>"BJK?1:WX:SZSY3"->EI$GNTO"
MN%A,\>XLEEINX,\K/=6I^0(55IE>*@V (*)?R_\ ZTOF;4)0A7'#G=E(W_E^
MP#&0F]TS65AX'(N$],V_'D<J,X1=(JHIKT>2WFX7K?N7&RGJ8]!==#;3P1PB
M>&[VPQR$I,>[)[UWNS?.1>:CFGV=-N%NBI[A\^4%]%<>)9;P\*\+NC:N,P$J
M2_'+$<E8$]E11X#9;Y:%Q32NI.GX:S3,ZV;ZFKXU90:\CPJ=>V["QB[KS8SX
M$AR4SF$D_P =7'>"H:6TF"?HBO156;681/3TB6;FR_#3'[:R<W-/Y"7FL_D
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@/F&;_S#;)PV9FXF5%R!28#QQWB;::4%-M;*HJKHK;\
M%>RG97LDU&IYK=U5.-31_N<V!]SR?U+/VU:_3[]49]Y3S']SFP/N>3^I9^VI
M^GWZH>\IYC^YS8'W/)_4L_;4_3[]4/>4\Q_<YL#[GD_J6?MJ?I]^J'O*>8_N
M<V!]SR?U+/VU/T^_5#WE/,?W.; ^YY/ZEG[:GZ??JA[RGF/[G-@?<\G]2S]M
M3]/OU0]Y3S']SFP/N>3^I9^VI^GWZH>\IYC^YS8'W/)_4L_;4_3[]4/>4\Q_
M<YL#[GD_J6?MJ?I]^J'O*>8_N<V!]SR?U+/VU/T^_5#WE/,?W.; ^YY/ZEG[
M:GZ??JA[RGF/[G-@?<\G]2S]M3]/OU0]Y3S']SFP/N>3^I9^VI^GWZH>\IYF
M[!_S#[)FP\C+:B9!&\8R$A]"::15$W091 LZMUU.)^"LOLKII::FEW57.^AI
M?W.; ^YY/ZEG[:M?I]^J,^\IYC^YS8'W/)_4L_;4_3[]4/>4\Q_<YL#[GD_J
M6?MJ?I]^J'O*>8_N<V!]SR?U+/VU/T^_5#WE/,?W.; ^YY/ZEG[:GZ??JA[R
MGF/[G-@?<\G]2S]M3]/OU0]Y3S']SFP/N>3^I9^VI^GWZH>\IYC^YS8'W/)_
M4L_;4_3[]4/>4\Q_<YL#[GD_J6?MJ?I]^J'O*>8_N<V!]SR?U+/VU/T^_5#W
ME/,?W.; ^YY/ZEG[:GZ??JA[RGF/[G-@?<\G]2S]M3]/OU0]Y3S']SFP/N>3
M^I9^VI^GWZH>\IYC^YS8'W/)_4L_;4_3[]4/>4\Q_<YL#[GD_J6?MJ?I]^J'
MO*>8_N<V!]SR?U+/VU/T^_5#WE/,W9W^8?9,.%CICL7(*UDVG'HZ"TTI(+;I
M,KKNZEEU O1Y*RNRNVUIH:?=526^II?W.; ^YY/ZEG[:M?I]^J,^\IYC^YS8
M'W/)_4L_;4_3[]4/>4\Q_<YL#[GD_J6?MJ?I]^J'O*>8_N<V!]SR?U+/VU/T
M^_5#WE/,?W.; ^YY/ZEG[:GZ??JA[RGF/[G-@?<\G]2S]M3]/OU0]Y3S']SF
MP/N>3^I9^VI^GWZH>\IYC^YS8'W/)_4L_;4_3[]4/>4\Q_<YL#[GD_J6?MJ?
MI]^J'O*>8_N<V!]SR?U+/VU/T^_5#WE/,?W.; ^YY/ZEG[:GZ??JA[RGF/[G
M-@?<\G]2S]M3]/OU0]Y3S']SFP/N>3^I9^VI^GWZH>\IYF]A?\PVR<ODV<=&
MBY 7WD-0)QII!_AMDXMU1U?("UF_97JI<&J]U5N-313_ #.[ 5$7N>3X_P#T
M6?MJU^GWZHS[RGF/[G-@?<\G]2S]M3]/OU0]Y3S']SFP/N>3^I9^VI^GWZH>
M\IYC^YS8'W/)_4L_;4_3[]4/>4\Q_<YL#[GD_J6?MJ?I]^J'O*>8_N<V!]SR
M?U+/VU/T^_5#WE/,?W.; ^YY/ZEG[:GZ??JA[RGF/[G-@?<\G]2S]M3]/OU0
M]Y3S']SFP/N>3^I9^VI^GWZH>\IYC^YS8'W/)_4L_;4_3[]4/>4\Q_<YL#[G
MD_J6?MJ?I]^J'O*>8_N<V!]SR?U+/VU/T^_5#WE/,?W.; ^YY/ZEG[:GZ??J
MA[RGF/[G-@?<\G]2S]M3]/OU0]Y3S']SFP/N>3^I9^VI^GWZH>\IYFX?^8C9
M 8=G++$R'=GI#D4!Y36O6T .$JIS;6LXGEK/L;S&AKW58G4T_P"YS8'W/)_4
ML_;5K]/OU1GWE/,?W.; ^YY/ZEG[:GZ??JA[RGF/[G-@?<\G]2S]M3]/OU0]
MY3S']SFP/N>3^I9^VI^GWZH>\IYC^YS8'W/)_4L_;4_3[]4/>4\Q_<YL#[GD
M_J6?MJ?I]^J'O*>8_N<V!]SR?U+/VU/T^_5#WE/,?W.; ^YY/ZEG[:GZ??JA
M[RGF/[G-@?<\G]2S]M3]/OU0]Y3S']SFP/N>3^I9^VI^GWZH>\IYC^YS8'W/
M)_4L_;4_3[]4/>4\Q_<YL#[GD_J6?MJ?I]^J'O*>8_N<V!]SR?U+/VU/T^_5
M#WE/,?W.; ^YY/ZEG[:GZ??JA[RGF/[G-@?<\G]2S]M3]/OU0]Y3S-V'_F'V
M3+Q^0G-Q,@C.-!HWT)II"5'G4:'2B.\>LO&LOLKII::FEW56F]=#2_N<V!]S
MR?U+/VU:_3[]49]Y3S']SFP/N>3^I9^VI^GWZH>\IYC^YS8'W/)_4L_;4_3[
M]4/>4\Q_<YL#[GD_J6?MJ?I]^J'O*>8_N<V!]SR?U+/VU/T^_5#WE/,?W.;
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M($6RJ@JJ<4Z.CS50>:STJ.I=)+<ANME7SJGEH#TC=(!0B(@'@**JJ*? E^%
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MWWOXG-UV.8H#P_97XEH#[SO7'[6@8&>UDX>&BP%P<5S#I'!EO*EDS"Z+9O\
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M6U-HT5+CY%J6R-JMFH:L6M$G:J>G$^1(MT1?/7N/(>T H!0'[.\)/_&NW?\
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M51441)=&E*UDP*W&-JF:98GJSB41$2R="5Z#B>T H!0"@.BW+_VWM'_<9/\
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M<LJJV8% * Z+;_\ VINS_80?^-"N5_NK\_Y'2OVLYVNIS% * 4 H!0"@% *
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M0"@% * 4 H!0$\#^;#_6_=6LVV*C73HK1#V@% * 4 H!0"@% * 4 H!0"@%
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MIH#P5$DN*H2>=%NGXJ \!QMQ-39B8HME450DOYN% #, %3,D $Z2)41$_"M
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M=M9HB(16Z-2IQ6U !:: S,&Q$W.+A"*(I*G1J5.G\- 8E&C&\+YLMD^' '5
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M>!\"U)S-3;_>$NNFUM?P=%:Y.9,\=(->5LR)*DY W)\T8>4=5Z?CFW !APE
M6R15%OG()""(J(YQJJXXDTO:[;F2'(0\A*QKJ1VXBMQ.0C:LLD1 .EUIVUM:
M]%JBMH.)+G^^.M)$;PC>9B.BO/!Y]IH45%X)I=$M7GNG12OQ@/X&A&VKB\AB
M2C9?"MLN(+C#*2'&Y[S31IPY<@Q(A05)=(_HU79IZ,G&5JB1=DXMMF$WCWY&
M+<@QEA _")MHS8)44@<10(%4B35J04+5Q1:G-^)>)8+@<<F + M 3..6,41!
M!>L+9"H+8BOUN/2OEJ<G,EC2#Q<#"67WK4YS.XKC;72W)5=5^CV_A_%3D(.3
MF[,S4:<XN(%S2$.+$QDT)B,*P45M6T.2TK9\U>-^JG%.%JZ*Z\3#J_ Z;$8:
M0P_E)62-N1)R3@@2@BZ>[--(TV%EM:_7(D\Y5AO:#21J0=CXZ(]%/OLU\(++
MT:"P^Z)-LL/ARR 40!O8>@B52^&U5W85"ZQL!G'XZ+ 84E8B- PTIJBDHMB@
MIJ5$3C9*PW+*E!LT*3L?RTGX@_?2LO=%1!6B"@% * 4 H!0"@% * 4 H!0"@
M)V/Y>3\D/WTK+W1405H@H!0"@.8S8'$WQMO*V56'0E8MTD2Z";Z"\RI? I,*
M-;K]K1A[IE8.S=PIC5VNIQ?\.+,61WW6YWKNRR.\]VY.G1JU]77K]GR7K7-3
M/B3B]O M]Q8;.YB.^ G&8>A3HT[!N==458]B49*6X:B4AZGDXUFK2-639IEM
M"9G).0F;ET1BF,,0V8F/>->6S'=5^ZO$(*1&[9533:R6J\XV)QG<RQ>SLCC=
MRY3+LY&1)21$99AC,D./:G6T._>$LFH!4DT67AQH[II(*L.3.'@\_,W-C\SE
M(\''>[6GVD&$X;IR%?1!_B&3;.EL;:D'BMZCLHA!)S+,M@@;L3+9<A(0S.3D
MRHZ$EE5@51AHK?Z0M:D^!:9/!=$*=3J*P;% * 4!U>,_Y>Q\A*\U]SK78V:R
M44 H#GI>,<.4Z:.@B$:K9=5^/X*[UOH<VB+W2YVS?[7JJ\R<1[I<[9O]KU4Y
MCB/=+G;-_M>JG,<1[I<[9O\ :]5.8XCW2YVS?[7JIS'$>Z7.V;_:]5.8XCW2
MYVS?[7JIS'$>Z7.V;_:]5.8XCW2YVS?[7JIS'$>Z7.V;_:]5.8XCW2YVS?[7
MJIS'$>Z7.V;_ &O53F.(]TN=LW^UZJ<QQ'NESMF_VO53F.)*SC'!:?'F@NL4
M1/:X=9%\U1W+!%[I<[9O]KU5>9.)Y[I<[5O]KU4YEXA<2:I976U3S+J]5.9.
M)[[I<[9O]KU4YCB/=+G;-_M>JG,<1[I<[9O]KU4YCB/=+G;-_M>JG,<3SW2Y
MVK?[7JIS'$]]TN=LW^UZJ<QQ'NESMF_VO53F.)Y[I<155'6T5>E>M=?Q4YE@
M]7%.JMU>;5?];U4YDXCW2YVS?[7JIS'$>Z7.V;_:]5.8XGGND[WYK=UZ5ZWJ
MIS+![[I<[9O]KU4YDXDKV,<)I@>:":!5%7K<;DJ^:HKE@B]TN=LW^UZJO,G$
M>Z7.V;_:]5.8XCW2YVS?[7JIS'$>Z7.V;_:]5.8XCW2YVS?[7JIS'$>Z7.V;
M_:]5.8XCW2YVS?[7JIS'$>Z7.V;_ &O53F.(]TN=LW^UZJ<QQ'NESMF_VO53
MF.(]TN=LW^UZJ<QQ'NESMF_VO53F.(]TN=LW^UZJ<QQ)8F-,) DKH+:_!-7E
M%4\U1VT*D0^Z7.V;_:]57F3B>^Z7.V;_ &O53F.(]TN=LW^UZJ<QQ'NESMF_
MVO53F.(]TN=LW^UZJ<QQ'NESMF_VO53F.(]TN=LW^UZJ<QQ'NESMF_VO53F.
M(]TN=LW^UZJ<QQ'NESMF_P!KU4YCB/=+G;-_M>JG,<1[I<[9O]KU4YCB/=+G
M;-_M>JG,<1[I<[9O]KU4YCB/=+G;-_M>JG,<25<8YW40YH71PEOUK<43X*G/
M4L$7NESMF_VO55YDXCW2YVS?[7JIS'$>Z7.V;_:]5.8XCW2YVS?[7JIS'$>Z
M7.V;_:]5.8XCW2YVS?[7JIS'$>Z7.V;_ &O53F.(]TN=LW^UZJ<QQ'NESMF_
MVO53F.(]TN=LW^UZJ<QQ'NESMF_VO53F.(]TN=LW^UZJ<QQ'NESMF_VO53F.
M(]TN=LW^UZJ<QQ'NESMF_P!KU4YCB2M8QQ&'QYH+K0>/6X6*_FJ.Y8(O=+G;
M-_M>JKS)Q'NESMF_VO53F.(]TN=LW^UZJ<QQ'NESMF_VO53F.(]TN=LW^UZJ
M<QQ'NESMF_VO53F.(]TN=LW^UZJ<QQ'NESMF_P!KU4YCB/=+G;-_M>JG,<1[
MI<[9O]KU4YCB/=+G;-_M>JG,<1[I<[9O]KU4YCB/=+G;-_M>JG,<1[I<[9O]
MKU4YCB2M8QP67QYH+J04OUN%B1?-4=RP1>Z7.V;_ &O55YDXCW2YVS?[7JIS
M'$>Z7.V;_:]5.8XCW2YVS?[7JIS'$\]TN=LW^UZJ<QQ/?=+G;-_M>JG,<1[I
M<[9O]KU4YCB/=+G;-_M>JG,<1[I<[9O]KU4YCB/=+G;-_M>JG,<1[I<[9O\
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M% * 4 H!0"@% * 4 H#-CZ4?P_D6HRHPJD% * 4 H!0"@% * 4 H!0"@% *
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M!^8X_FAAH3^U,L\PD/F]47.02MGS5+5IX==+(7F2MUCP_P R,VGQZ'T?#?\
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M+@M0UD*BO*TEM6F]DXWX)=;(G"ICPTI]J@Z]U^0S]Q'JW=^.T_M_$L:Z'C%
M* 4 H"TC?0!\5<WN:1)4** 4!5/_ $Q_*6NB,LPJD% * 4!K9$\@$)XL<TT]
M.0?_ &[;YJVTI*MNN0H9(B=/!*JCQ(SE6-ZY7&/;@C;FCQE=P,!O*+(QRN<M
MUEWF(C>AZY YJ:LG&RWO73TTXCQ,<VIGP),9N7<[.9Q$'<42&RSGVG3@E#)T
MB8>:;1Y6'^9P-5;OUPMQ1>%1U4-KP*K.=?$V=O[ES60W7E,-D<<WCVHD6/+B
MCS>:\HON.-_QE'^&*_PKZ1O;STM1*J:%;-N"G7?V>2"&Y>YQ/\)'.2&B:G>_
M<DI'=4E]EIYO'1:^GRWK7IJ8_J)S>_@=\J654\W"N)T% * 4 H#-OV'/DI^5
M*C*852"@-?(1$F0)4-2T))9<94T2ZBC@*-[?!>JG##11X39,*!L!G9<I\YD$
M(CD)YZW+(P<4KD@HI:537PK5LDVY&%2*P:.U=C9S"*S&D9\9^+BL%&C1NXQV
M7E%0T KL@;F2@GFM?RUJ^1/PU)6C7B:D/PJ9C;9VU@TR9DFW<D.3&1RD17E%
MPSY:CJZOTG3=:KS:MQNB+'HET-?)>$3TES,0X>X)$';>X)*R\MB 8:,B<-45
MP6I!+J;%S3QX55FVTU0>+?71E\NQHH[J7.LR%::3#^Y&H2 BB#:%<7$-5OP3
MA:U8]32/.37#6?(YUGP>D18.V6\?N%Z%.VNS);B30CMES#DGJU&V9$.E.(J/
ME3S5OUYF5N9]+;78F;\((XX)B [EG7IZYEO/9#(FT.J1(!;J&A%1 %4X)Q6U
M/6UF/"!Z6GSDL-W>'1Y[<C&>CY/N,@89X]]MR,U+%6'"4E)KF\&G./M66LTR
MPH@MJ2Y-!?"9YC#[6BXS..0LEM574B9'D XC@2+\P2:(M/0MDXUKUM7*W)Z>
MBA[$R^&N1B9G(S<'G4Q\/+R.^38CL&/+(7B1$<)AQWB&NW19;5/532E;%]/7
M1G>5Q.@H!0&;GL-_$OY5J(IA5(:N29R#T,V\?+&%+54T23920@HBW7^&I BW
M3ATU5'B1G*8[PY=9V@_M>?EREPU5'(,AN.$=Z.\+RR$<1=;B&J.V5+IY+5T>
M7ZI2,*FD$Y;?W#"3)9YZ;[[W,L$H.+1MD(K30J6I+ I.)J)RQN$J]"<$J<DX
M6R+Q>^[,<GLO<.1E868[N 4D8E@$5IR&#[#DU$L<S1S&DU_J73J^3C55TITW
M(Z-QJ6DK&;O*/%2)GF6930$,MUR #C;RJ5T,6^:*MD*<+:E1:RG7H::?4UH^
MT)4#;)87%916)#[CSTW(R& D&\<E2)\E;U-"*D1\+>RG"CO+EHG&%"*AS9><
M8VUAMI'+3)XH94=N;)Y(1E;Q\1.9RC1#/F*ZXV(73R*M;YJ7;Q)P<)'79:/F
MWT;7%9!O'FBES5<CI(0D6UK)K;TJ->7)6S^UQ\I/=VN3!6?5H\B\(MQ_P971
M]DX#W<W#R$<<H0NNR7),L4(SD/K=UU;61%+HLG0G"N:[:G&&N7CKU/7D_,]Q
MZCOCMZ7TJJ5=E6OVKY?S(\%LR-@(>2;PSC<27/D./A)Y*&C0D6H&N6I)K%M+
MHG%*F+MEC3XZ-LWWOYBW=7QO,G>E*I1RB=-7,:-^)+M3;D_!,/QWLDDZ.ZZX
M^ =W%DA=><5QQ=2&=T52X)Y*N#"\::;E? Q^4_(8^ZLK5Q\+)*OW<I55"\$7
MU>@^49L?2C^'\BU&5&%4@H"GRV[,-C&,BXZX;KF,9)Z4RRVX:II%#T:D'1K4
M21=*E>RW7A6E1LR[)&8;HP9%"!9/+<GH"Q@-MT%57%T@A*0H@*1)84.U_)3@
MR\D:;^_-M-OQ66WSD]ZE+"ULLNF(.B)D2$J!9;*VHKIO9?PU?39.:)"WI@8X
M6R$QJ*X1O(+8J;J<MAY62<)1!-*(2=>_ ?/Y:<'X#FC;_P 283WL.)24A9 R
M(!9$'"12 $<(>8@JW<05%5-7"IQ<27DI@T\?O#%2<G+QC[H1YL>6]%;:74J&
MC((Y?6HH"$HW+1JO9+U71Q)%93!.&[=N&P;PS44&W 9(>6[S%<<%2!!:T<PM
M0HI"HBJ*B*ODJ<&.2,Y&Y,.T^L7O(K+T:@95#1%)6U=!M3TZ1,@2Z"JZK>2B
MJR\D:$+>V+*$U)R+C</G!&5ML2-TU=DQ^\<M $-6I!OI1+ZD]%5XWX&5=&^6
MZ-O",8UG-J$P =CF*$0JVX6@#(D14;$CZJ*=N/"IP9KDB";NK'M1#EQ"24Q'
MDLQYAHAB( Z]R","4=+F@UXZ55."\:*C([%VJ66R^2LFA0&:_0C\I?R)4!A5
M!Z*7)$\ZT!\Y#Q2BGMB$\&1A%N-^:S&>@(J:D$YW(-$:U714:X]/PUW]'7;0
MY>IIYEC(RN]'I.XY.-DPRCX.4;+&+?CE=\&H[;Q(LD7$42+6J(NA42LI5TGQ
M++UCP+' [H<S&91MD4'&OXB%DXXDG\5"E&XBH17MP$$\E9M2%\RUM+^1:Y7-
MXO$M [/D(SS%TLM(A&ZZ7ZK30(1N%\ HM956]C3:10;FW+,B8,<IW]C;0:72
M!K+1T==>($NV* #PZ-:)T<3^!*W2LN-_@9M;2=B#<6\,Y$V?%E0XK;.Y)D I
MY1G;N,QFV&4>D..(BHJB/ !2_$B3X:M:)V\B6LX\SHUR[<?;B9F;=&VH8S)/
M+2ZV1I'#TC?T)>L<=8-SI)2KXD8?48)C\H3XQTFML)#+6Y#6]Y HI(FA+<=2
MH7F&M>D_(SZB),IXA8."PLAMF7D(X1F)K[T-E#!IB5] ;BF;=M=N")?X;46-
ML.Z)<UD)#V>PF+8=.*"(YE<H2+I48L8=(MN*BV1''G!0N/0*U*K1LK>J13O[
MX<R.:Q 8P9D6!*B9*0+K['*:E U'0F76B74JHA=9$72OEM:M>G"<^1GG+1TF
MTI<F;M7#S)3BNR9,*.Z^Z5KD9MB1$MK)Q5:Q=19FJO1%M631F'T;GQ)^6H#"
MJ!0"@% >*ET5%Z%2WIH#GV=B;>:<P+J-N&YML";QIF=UTFEOXMD1#TKUA\R\
M:WZCU\S/!:>1-'VAAV)C$I$<<*-(F3&FG"0F^?/6[QJ.GC;B@>9%6H[L<4>3
M=F8&8>2)]H].4[N4AMLU;$78GT+[.C2K;H\.LB^1*JNU'D'1$,C9,23$5B3E
M,D^^CS$AN<Y($GVSC$IM<O\ A\H;*O'J77RT]3R0X%OC,>Y!C*R<V3/524N?
M,(#<XVZMP!M+)\59;DJ4&W4** 4 H#,/HW/B3\M0&%4"@% 8F8-@3CBZ6P12
M,O,(I=5]% </ WGGI."P+D9IA[,[I?D.XX'T((\>&&IT2=Y?7/0P@]"W(BZ:
M[.BE]$<U=PO,O-K9Z?D7<KC\FRTSE<-)&-*[LI*PX+C8O-.MZ^LB$!<17H5*
MQ>J4-;,U6T[E)E=[;C;;SN5Q<*(]@MMNFQ,%\W4E22CB)RE84?X8(VA6'6BZ
ME3R5M8UHGNS+N]6MD9S-W;BE;J?PV#7%-L,PHDQMW)&\+CO?-:B("VOD0*BH
MN,N0[.81O[@W-D8N7C8/&I#;GN1EF39N0<((K#2'RA32*B9FXY=!'4G!%5:E
M:*)9;6UA&U-7>ZQ8:P%Q/>-"K/*0LGE:OT59T<=-NG547'QDKY>1SL3?&?<V
MECMSS6XS,0LJ,>2D=#5M['NO+%!\.;UQ_B$+B><?CK;QKE'D85W$G?JEE5/-
M7$ZB@% * M(WT ?%7-[FD25"B@% 53_TQ_*6NB,LPJD% * 4!H9Z9E(>'ER<
M5!]Y9)L%6)!UBVCCBK9$4R441$O=>/15JDWJ1MQH<1!V]E\IM;<&'G8V9$S>
M=C.'.S4U8W+=E**"VV L.O$#3? 0&UD%//79V2LG.B.:JVFO%EA"C[ASN>V[
M)R6(=Q#&W@>=DF^XR:/2G6.[H,?E&>IM$(B4BMY$M67"3AS)5+:TV/,2[GU\
M1)V4D;>FQ\=/AQ8(R''(BH!1G'C)PQ!XBT$CB6LBK\%+1QB0IY3!3M[<W,6U
MVMA.8MP8[<T5/.<QKNJP F=Z0D37S><HH@:-'3QO:M\E/*3/%QQ/J!+<E7SK
M>O.=CR@% * 4!FW[#GR4_*E1E,*I!0"@% * 4 H!0"@% * 4 H!0"@% 9N>P
MW\2_E6HBF%4@H!0"@% * 4 H!0"@% * 4!FQ]*/X?R+494852"@.:R.T'IV1
MR,A9J1XV0BO1766&R SYK2-"3Z\Q6W.5:X+H0O)JM6U>$8=9(9VS\K/E0I$O
M* :1EAFXTC3@MH<-WF*K(<[2'.1$0]:&O#A55TO .K9MCM>2SCL9'BS!"1C)
MKDUMTVE(#YQ/:P($,5]F0J(NKI2_P5.>K+Q-9=D+R<@TDVW?H<Z'JY?L=^DE
M(U>UQT:]-O+5]0G K<)@-Q0]X')>85R!WJ08*:HC+3;C* CS)"[=77-""0$U
MP15X^5=6LG4BJY+-S9TYR:Z191 @'/=RC++3""^W)<95H+/*:BHAJU>Q=5^"
ML\UT+Q-)KP^FA%F >19=DR^[?QW&'B42B@8HZA+(YJ.JKFO6)I9?)9:OJ$X&
MP&P]&3.4<L)3;Q-O/%):,W^\-QQ8YHF+H-HI:$/BVJHM[+4]30O#4GQ6S%@2
MX,COG,[D<8]/+MJ[M!*%TZEMJU:_@Z/AH[R%2#0;\. ;..O>6GP1H8\QN0RX
M0F 2''Q4$!YM!+^,H]?4G0MJOJD],DF;1R0Q,A':D"ZUE9,9#CL@K+++8R.<
M^^H$X8\PPX%RT%%6RZ;T5U^X.IV1+=57SK7(Z'E 9K]"/RE_(E0&%4!%LJ+Y
MJ YC_!7_ /",3;W?/Y62U)[SR_:Y4OO6G1JX7]F]_AKIZGU28X:01RMHYQR3
MFVX^9;B8O.OD_)!N*I2P1QH&3!M\G= W%O@7*NEZ*ZTTV'%ZZ[DA;5RD++MS
M<!-C0HP0(^-[I)C'(1&HIF0*! \S9;';BBTYIK4<7.A-NM,2910G8K(37F]3
MD69C6'#=CE[*J+S1";9%YK\4Z:E)\&6T&O%9W'D,2(0L@]'%.8P\F<QR$^8+
M;26D381=(K;4J*A>5*KA/_HR*6C5?\+< Y@ Q@NR1DLXWW6U/20^VJMHA**N
M-,N-MFB&XI:%2WDZ*JS.9\R>FH@N3VTU_A!S;;3YB!PCA))<4W236VH*:ZR4
MEXK>VKX*QR^J37'2#$MM*N0[YWGIQ*XC1H\Y:N;>_P"S^.KST^<CB<%E-H9:
M%DQ1F$]D'L?CH$7$.+";E1I#L1M4_BD3@=W'F6NA+_I(M=E=-?,YNKD[?$8B
M;)G9S(9EE&G<D@06FA)"TPV6M*Z22_!QUUP_/:UZXVMHDCHEO)H8_8V58<Q:
M3,R,J+AHLB#!9&,C1*T^RC FZ?,+4X BG0B(OFK3R+73<RJ/J='@\;[KPL#&
M<SG=QCM1^;;3KY0(&K3=;7MYZYV<N3:4*#>J%,P^C<^)/RU 850* 4 H!0"@
M% * 4 H!0"@% * S#Z-SXD_+4!A5 H!0$$^,4J!*BBMBD,N,BOF5P%%/RT3U
M#/G&!8R;FU]B9W&PRG/;=:>@Y+&MD /**M=T?Y?,4 4VW6472I)=*]%HFR?B
M<:S"?0OL&UGX;F:W [B'%F9R?&Y6*YK2/,Q&FPCHXZ6I6]2)J<(1)>'#IK%H
M<*=C2G5QN5&0Q&ZHD'=6VH6*.6UN&5)?Q^6%QH8S(9 41[O"$2."K2ZE1! M
M7"M*U6TYV(T]5U-G=^%:E0'\*WL\LM*[D$/'Y@DB"VBHT@ 9O&:/M<HN/ 57
MS5*6UF8%EX003MJRX.=Q>3R&%_Q:T&&:Q<Q$1AQT93!:N=IDD Z'4(A4KW2J
MKRFD^.H=8<Q.A,UMW=4#PPC;;BAIRDTEB/$VXA#!BRWR)RQJJ:DCL%H'3Y;6
MJ<JN\^ XM5@VO$:#&C[&C[?@ C:3)./Q>.83R(C[=K?(;;(E^*IB?U2RW7TP
M=L5KK;H\E<CH>4 H!0%I&^@#XJYO<TB2H44 H"K?T\X^N"=9>"D*+^6NB,LC
MZOZX?/'UU2#J_KA\\?70#J_KA\\?70#J_KA\\?70#J_KA\\?70#J_KA\\?70
M#J_KA\\?70#J_KA\\?70#J_KA\\?70#J_KA\\?70#J_KA\\?70#J_KA\\?70
M#J_KA\\?70#J_KA\\?70$C>G0YUP]E/TA\Z?#492/J_KA\\?75(.K^N'SQ]=
M .K^N'SQ]= .K^N'SQ]= .K^N'SQ]= .K^N'SQ]= .K^N'SQ]= .K^N'SQ]=
M .K^N'SQ]= .K^N'SQ]= .K^N'SQ]= .K^N'SQ]= .K^N'SQ]= .K^N'SQ]=
M .K^N'SQ]= .K^N'SQ]= 2.:=#?7#H7](?.OPU"D?5_7#YX^NJ0=7]</GCZZ
M =7]</GCZZ =7]</GCZZ =7]</GCZZ =7]</GCZZ =7]</GCZZ =7]</GCZZ
M =7]</GCZZ =7]</GCZZ =7]</GCZZ =7]</GCZZ =7]</GCZZ D8T\U.N"]
M/00KY/CJ,J(^KV@?/'UU2#J_KA\\?70#J_KA\\?70#J_KA\\?70#J_KA\\?7
M0#J_KA\\?70#J_KA\\?70#J_KA\\?70#J_KA\\?70#J_KA\\?70#J_KA\\?7
M0#J_KA\\?70#J_KA\\?70#J_KA\\?70#J_KA\\?70&:Z>2/7#VEXZA\R?#4*
M8=7]</GCZZI!U?UP^>/KH!U?UP^>/KH!U?UP^>/KH!U?UP^>/KH!U?UP^>/K
MH!U?UP^>/KH!U?UP^>/KH!U?UP^>/KH!U?UP^>/KH!U?UP^>/KH!U?UP^>/K
MH!U?UP^>/KH!U?UP^>/KH!U?UP^>/KH"0-/+<ZX="?I#Y_CJ CZOZX?/'UU0
M.K^N'SQ]= .K^N'SQ]= .K^N'SQ]= .K^N'SQ]= .K^N'SQ]= .K^N'SQ]=
M.K^N'SQ]= .K^N'SQ]= .K^N'SQ]= .K^N'SQ]= .K^N'SQ]= .K^N'SQ]=
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MA J$*]!"J*B_A2@/: 4!L1_H)/R$_?2LO=%1KUH@H!0"@% * 4 H!0"@% *
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M5(BCLJ1+Q555M+JM<GN=%L;50I.Q_+2?B#]]*R]T5$%:(* 4 H!0"@% * 4
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M?[N%%5V^)X?A]MP\D<TA?T./][<@(\21"D(M^:K/0JT?8X^7+7>8G2?@5?\
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M^^E9>Z*B"M$% * 4 H!0"@% * 4 H!0"@% * 4!/(^@B_(+]]:RMV5D%:(*
M4 H!0"@% * 4 H!0"@% 3P/YL/\ 6_=6LVV*C73HK1#V@% * 4 H!0"@% *
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MK?(N<?%?:7RUT1EF&HO.OIJD&HO.OIH!<^FZV_#4 137H55]- >W<Z+K?\-
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MJC+OTZ'<XQUQ[&0WG%U..QVC<+SD3:*J\/A6N3W.BV-FH4S#Z-SXD_+4!A5
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MA1VGVELJB8-B)"MKIP5*XW<MG2JT1:UDT9A]&Y\2?EJ PJ@4 H!0"@% * 4
MH!0"@% * 4!F'T;GQ)^6H#"J!0"@.*?;?=\2LTR-^<[MIL('DXE(>0[?ZZA7
M5?8O_(Y_U/X'-X[)XS([.\/\'!?!S,QIV.[Q  D5^.N/0N]D\VG6;0-*HJDB
M7O\ #71IJUGX:F$TTD=!NW-XDLUM7+)+:/%8S+R8F2E(2<J/(.*XR".DO -+
MBZ55>A5K%*N&O&#=FI3\SF<[*C2,QF-R1W$?V_%SN!67,;76R0P@(9#J$ET(
M&2=!").'#X*W5:)>,,PWJWX2C+?CK.:G;GR&'<'(0H.'@,S7XI(\V9-Y!)1M
M"070R&.)$2)T7ICT23Z_X"^LQT-W?,J-NG*N?X9DMY(V-N9?FNQ#1P1[X#8Q
MVE(%5$-Q054'IX5,:XK7JBW<O3HS;#,X?/9'P^9PDEN4[$(IDAIDD(H\=N"3
M)H\(_1KS#$-)66]3BTK264X@V(&?V\7BS,:9R4-5/#QXK38/-<7QENJ30HB^
MVE^(IQJ.KX;>(5ER^1O[9O\ X_WIR[\C5C4/S<_NJZOV--9O]M?F:K]S.NKF
M;% * M(WT ?%7-[FD25"B@% 53_TQ_*6NB,,PJ@4 H!0&+C;3H*#H"XV7M :
M(0K\:+PH"-B%"CFIQXS3)JEE)ML 54\UQ1*2 Q$B1R<*.PTR3RZG2; 04R\Y
M**)=?CI(,0Q^.!Q' B, X*W$Q:!"1?.BHE[U99(/4@P4E+,2,TDM4LLE&PYM
MO-KMJ_'4EB">A10"@% * S;]ASY*?E2HP850* 4 H"EG[5A3-T8K<G-<9GXM
MI^.B!;0\R^G%MR_&PEUDMY:TKPFNIEUUDMC88-P7#;$G014!Q436*%P+272E
M_@K)HX*!X.8J*4".YEILK#8N9[P@8IP6$$'T-7!(WQ;1YQ$(KV4J[/.WX:G)
M8EU.JVMM?&[:QA8^ 3K@./O2GWWR0W7'GSUF9DB"B^;HZ*YWN[.6;K5)%@L"
M KAN+%95QPA-P^6&HB#B)$MKJJ>15J2RP>.8_'NND\Y%9<>,4$W2; C(46Z(
MI*EU2DL05,W:,.;O'';GD2'#>Q4=V/"A6'DB3_MO7MJUZ>%:5XJUU(ZZR20=
MJPHNZLGN577'I^299C:3MH9883@#=N/6+K%>H[S5(*NLEU630H!0"@,W/8;^
M)?RK40,*H% * 4 H!0"@% * 4 H!0"@,V/I1_#^1:C*C"J04 H!0"@% * 4
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M0?OI6'NC2(*T04 H!0"@% * 4 H!0"@% * 4!.Q_+R?DA^^E9>Z*B"M$% *
M4 H#!U7$:-6A0W4%5;$ETBI6X(I(A62_EM0'-8_<NXGY^2C2<5%9;Q%DFN-S
M#<)=;'/'EBK :N"HBW5*VZKJ85F>X+=L^:_#9GXYN+[Q@%DH9L2%?3ECH50=
M16VE OXB6Z47C2U("L0X[>F2.)BLCD\6W%Q67)H(\MB3SU:.1]"C[9-M**&M
MAN*E9>FJZ+5)[!6.MKF;% * 4 H!0'5XS_E['R$KS7W.M=C9K)10"@.2G_SS
M_P LORUZ:[')[D%:(* X+?&TMY[G"5AG'L5[ADN"3,MUIU9L8$5%401.HI<%
MZUTX5UI>M==9.=ZMZ>!:;BVC+R.0VH_%> 6-ORD>?YREK<;%I&TTV14U</+6
M:WA/S+:LQY$&2V&WE-Y3\KD48?Q,W$IC5CDBDZ+FO5S$NFE+)T*BWO562*PN
MH=)<E*>P-Z+MW;4-9\)_)[:G$^P_(YQ-.L"BBR)V'5J1%LOP>6M>I67YF>#A
M>1<3]M[LR[6#/*.X]N7BLLW/<[FCPM%';!4TBAHJ\S47Q5E62F.A75N)-*)X
M9.P?$M=SQ)+0X9U'W'<:NK6,B2WH=4$1-&DU1"7C5>2:QXD6/ZI*N5X:[RB8
M&?M;$S<;*V[,5U(I3VW.]0Q?6YHV0(0K;R+6EDK,O<G!Q"V.AW#LB?D-N;<Q
M,>0TCF%DPGGG7-2"811TGH1$);KY+UBMX;?4U:DI(WLCMB5+\0,9N-#:6%"A
M2(KK!W5Q3>*XJ*64;)Y>-16^F"NOU28[9VO+Q.Y-S91UQHH^:D,O16V[H0"T
MVHJAHJ(E[KY*6M*2Z"M8;.FK!L4!/'^@D_(3]]*R]T5$%:(* 4 H#A<AM7>4
M?>V2W'@GL83>1C,1B9R OJH\GRIRDMQ7X:ZJU>,.3FZN9113(F]'O$[-CA7(
M;4YS"Q&IBR0=5@M::2)HAZR*!74;]*=-:3KQ4]3+3Y..ALR/"O+,8W;N/B2(
MN0AXF.\S,@SU?".X\^2FLE!96Y*"DND2J>JI8]-Z&QM[PUS&+7:".RHYIMU^
M<[*4-:<P92KHY:*GD\MZ6R)SYEK1J/(\E^&66?@9<6YK#.0>SWO[%.*ADV*C
M;2V\ED7CQOIO19%I\('IO^)98O9>6FY?,9K=3L4Y>5@^ZQAP4/DM1N*DJD[U
MB(B6_P %9=TDDBJKF65>T_#/<.*P6<CS,J"YG(1&\=CL@QKNQ&8!1:Z4$D6Z
M\;5J^1-K30E<;29ELKPXS&&W-#S,L8# ,0'(3[4,GS-UQ5&SYF][1'9=7FI?
M(FH%:-.3Z/7$ZB@% * GD?01?D%^^M96[*R"M$% * J#W7@&YCT1V5RG&.8A
MN."0-*3*:G !TD0",$7B*+>O.^YQIM-[?MN?2K^([FV-7K65:-$T[?5]K==T
MGX-J"*9NIAB?C(K<1]YK).-MC,T\MD.<"N!Q+B1*(W5$3AY:E^Y2M50_J\?#
M4ZX/Q%KX\EW>M7B5GQWL^+A[;*7N]_ ES>9R6.%QV/BCFQH[2OR7T>;:1!&Z
MD@"5U,D1+VX)\-7-EM355E+S.78=EBSM5ME6.]K<:KC:VOG&R_?\#?BSH\F
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M3;:KM&FYT2*BHBBMQ5+HJ>5%KV'PFH/: 4!/ _FP_P!;]U:S;8J-=.BM$/:
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M6WA.O[>9/PU.XQ6YX_1<6UYVI-8\4VTTNEJ&TQ,DGAX&$R0\K-Y/'O"0-BB
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M%3I14K)HSTEYEXT 057H15^*@-')99N"] CJV3SV1D)&9;%414ZI&;A7_1;
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M\W/QQ7E;IP[L,!%.G)QD08Z_&HDE>O%7G6.C_@>?(^+GJC+,[>#;D?PDPO\
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MVR6^Z]FW\S:K9P,U^A'Y2_D2H#"J!0$$R%#FQRC3&0D1S45-IQ+BJBJ$-T^
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M@NVMEP/U'DPY;VJ_I=7RKX;[/K_ O9.2R)[ EY'*,=WE^[W7G6HKUELC2DA
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M-7$;1WOW[:?O1((0ML$32=W<,G'6U:Y:.+J%$3V133\:UG'V^6:<HBAW[O\
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M@&DO,OHH!I+S+Z* :2\R^B@&DO,OHH!I+S+Z* :2\R^B@&DO,OHH!I+S+Z*
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M+T)^6H4PTEYE]%4@TEYE]% -)>9?10#27F7T4 TEYE]% -)>9?10#27F7T4
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MK(*T04 H!0"@% * 4 H!0"@% * G@?S8?ZW[JUFVQ4:Z=%:(>T H!0"@% *
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M?\O8^0E>:^YUKL;-9** 4!R4_P#GG_EE^6O378Y/<@K1!0"@% >72]K\4\E
M>T XK0"@"77@E ./1^*@"HJ<%X?!0!;^6@"HJ=*4 H">/]!)^0G[Z5E[HJ(*
MT04 H!0"@.$VXQAX7B5E8T!&&(O<(XMMM$""I*2*2)9>)7Z?+7S.W5*]S95A
M+BC]A^3R9\OXG%?)RM?U;RW.T?P7\"DP,S/9W.1B#(S1M/?6<Z,EMN*45HU1
MMMEF_,U=6RIIZ*\V&^3+=?5;[G.ND>2/K?D,';=IV]D\>/\ M5X+@W=7LM7:
MWVQ\]SIHJKE_$.=-TZXNW(W=(Z>193Z:G;?"@]6O97_<[AV\,:CYO<^!F7MO
MQ=,>U^YOS?\ X5TK_'4X9R7*R6'P>8FYIU^?-S32/8DS!6VT;=)!T-6U!H2W
MSJ^:[.]*7M9NSNOI^?0_75PTP9\^#'AK7'3M[1D2<N:K>VSG_ M=X[BF,S\C
M/Q4S(<S'SFX[AG(9;A@6I$)D(OTCB6OUK5W[O.U:UJ.WTVC=1\(\3YWX3\92
MV/'CS4Q1DQ.RBEGD:\+/)]M?@3[BSV>QF5S&W6I3JS,R[&<P+RJ2DT$@]+PB
MOZ*!9;5K/GO2UL:;F[7'Y[G'\9^.[;N,.'NG6O#!6ZS+_,Z*:M]9\3Z4TVK3
M0-J:N* H*N$MR+2EM2KYUK["4*#\'>W)MQ$^!G5,B@% * GD?01?D%^^M96[
M*R"M$% * X;-S94;-21VE*DS<X1H4[$*G/QXDJ)Q?<<44BJJ?J'?_06NM5IK
ML<V]=#=WH_*G1<;M<5Y4W<!HW.1HE5&H;*(Y,)"X+94_ABO^E6:::]"VZ=3/
M-X3(1\J[G\-DXV/=B8Y(AQ9+/-9Y31*Z.HD<;)M/)>E;:0PUK*-F%G7LOLQG
M(B"1<CD\<X_'BZNOS%95?X:+8B1%LJ?!4=8M!4Y1S$8HCFU?#@("CS^]P2CB
M%KIH8/O2\./!-6O\=='O8QX(TFE:/PE@M"J>\RRK0Z?_ %/>"9.Y\.G7TJOP
M5?Z_E_@3^DV)9QO\ [^"4H][7(9$7Q6VM72(>Z<.FZCHT?BJ+[JE_I9]&B(\
MD2.CWTR- CORT%-7XZXLZHFH!0$\#^;#_6_=6LVV*C73HK1#V@/G[[#T;<6X
M-PQ 4Y6(G,$^V/2[#.(WWAOX51$UC\*5\IU:R7R+>ME\UQ4_]3]ICR5R=KV_
M:W<4S8K0_P#+D62W"W_W7Y,CP4UR1C,)!CRSC0<MD<FKLM@D!PQ;=<<;;!S]
M'F7\G'A4PW;K2J<5M:^J^+_F;_(8%3+FR6HKY,.'!%;:I-UK6UFO'C^[4CSH
M/.P<ECWI\E^'B\MCPC2E=7F(CY-JXVXXGMJTI7%5XI4S)NMJMMJMZZSUC^1O
M\?:M<F/+7'2M\V#*[5XZ?2K1:J\.4:I:,^@BRD:&K(...<ILD%UTE-Q;(O$C
M7BJ_#7U4H4'XIW]3)R:2Y/9*%\D<*S+S,+8$7-)D),K(Y,8;;KKK@H#(/.("
MDVA)H;)!*VLO+Q6OF*UZX%?DW:W'Y3^VY^POAP9?R5NW].E,6)Y&DDYLZU;B
MT:V4_P!*\-$33Y&Z</B\HZ9.Q8A#&",Y)E!,?8-U]&GG4-$]A +4FKH6M7ME
MQUL]EINY:UALY=OC[/NLV))5O?ZW;C1XZV5:\JUCK*C3='N0.=B\EEX,/+2I
M0,X.1+:!YU'7&GT*PFA)UKK:XWZ/)PID=J6M56;_ -MO?Q)VRQ]QBQ9+XJ4=
MNYI1Q7BK5C:-O)_QU+$<L\>3VPRW+4DEP'WY+8E?F68;4#)$Z>M>R^>NWJOE
MC4[U;_@CPOLZK#W-G3[,M:UTV^NTI?*"J@/Y7*Q=GQG,E)8'(09+N0=9/2ZZ
MK8MJG7XJBW7VDXUPI:UUC3LURJY\]CZ/<8\/;W[NZQTMZ>6BHFOIK/+P_P -
MC/(.[EG9C,PX!2->+%EJ"3<QN.($3*&CSS9HJO:R7C?A9+5<CR6O95GZ8C6/
M#=]3/;4[3#@PWR<(R\G><=KS]4<:M/Z(6T:RY)9CD_(RLX$[)NXU<3"8)MJ.
MX(-*;S!&Z\:$BHX"GU$OPJW=KN_*W'C5;;:K5^?0YX*X\%,#QXJY?6R6EV3=
MHK=*M5_E<?5IJ7VS_P#M/#?[E'_^VE>KM?[5?_%'QOS7_P#-S?\ U+_^YEQ7
MH/F$Q?R(?[4OW4K/B7P(:T04!1[UDSXVVY3V/<-J6),HVXTES34\ E9++^BJ
MUYN[M98VZ[Z?S/K_ (+%CR=W6N5)TBTI[?:_\3G).0S,2=(@2)TP<*QE1:DY
M%+E(;C'&1Q$YH@JH"O+;4B<.BO':]ZMU;MP5]_&(_P"I]S%V^#)CKDI3'Z]L
M$UI_2[J_'[6]^&L>.YK0$R+^:VOD,L_+$2[\PS(+6"F/,3NO,$1X$\'M71-2
M=-9IR=\=KM_U?]OWG?N'BIV_=8L-<?\ ^59K1PX?J<==J/:)XO8Z#-37PW7&
MC3)<J#BEC(<4XJ%9Z7S;$VXHB=[!:P+P6]>K-=K*DVZUC2/%R?&['!5]E:^.
ME,F;G%N7]-..ZEKQ_JW13P7,Z43'3)$Z6ZY+S?=G&3MH:CMNO"FCJZDNEKDJ
M^:O/1WBK;>N2/@I9]/N*]LKY,=:8TJ=MR36]KNM'KK'R^)6PGLIB]N\B(_)
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M%'HG,51,0)%/6.GJDB6K>1:/]H,T>I]0K@=B>/\ 02?D)^^E9>Z*B"M$% *
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MCO3#>O%7MC^OC"^I6:U2T3B"^KU'QQ0"@% 3L?RTGX@_?2LO=%1!6B"@% *
M4 H!0"@% * 4 H!0"@)V/Y>3\D/WTK+W1405H@H!0"@% * 4 H!0"@% * 4
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
+4 H!0"@% * __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>p29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p29.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &L SL# 2(  A$! Q$!_\0
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M128W(LB!PIQQD ]JFUR\O-/T6_NM/L&U6^A@>2"Q658C<2!25C#M\J[C@9/
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M+EY[:%\ROR]3;HHHJ"@HK N/'>@VGC6T\(RZE&GB.[M'OX=/VL7>!6VM)G&
M,\<G)P?2N3N/CMI5M\>+7X5MI&K'5;C3CJ*ZDMN/L84 G:6SGHI^;&,D+G)K
M14Y2V72_R(<HK=GI=%%%9EA1110 4444 %%%% !1110 4444 %%%% !1110
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M65%W@]PRJ[?0BO/O!_P&_: ^'?A^V\$>'?B?X>@\'69,=GJESI;2ZI;P;LA
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MUO>#OV0M7TKP[\4M3\1>+(_$?Q(\>:7/IUQJKP>3:VRO&5551>2H^3/ X10
M,<]4ZU&S=UJH][Z6WZ6.>-.IIH]+]K==NMRA^R?:?%SXH:3X)^)?B[XB;M"-
MG)$OAJSM !>*JR1":XESS(7^? '\*CCD5Y?X6_:M\<^&/V.O%?C&\U636O%D
MGBJ30M,O+Q$(M]T<; [0 #M42$ C[Q&<CBOKO]G_ .&U[\(?@YX9\':A=P7U
MYI4#PR7%L&$;DR.^1N /1AU]*\)T']ANZD_9I\3?#+7=>M#J-]K<FMV&I64;
MLEO+M0(&5L$YVNIQV?CD5C&K1E.7/:W,K:=+LT=.JHQY;WL^O70\H_:4^&?C
MSP%#\&9_%WQ*O/&PN_%5B9[.\M(T6WNLY+0R+\VS&Y=I]CQTKL_BI\7-=U#X
MY?$30/$WQ8N/@YI/AVTAFT"WA@C7^U-T98S%G!,HW #8IYS@<JV=[Q1^R[\9
MOBE:^"F\<_$'P_=R>%]6M;R&SL+&18[A(S\\LDI 8S$!0 %"\MZUY3XXUI-=
M_::^)^L7?Q0L/A-J&GSP:?!I_BK28M3^U0PIA9X!,NV.-B-ZJF2=Y)ZUTTW&
MHDFTVD]EYKI;]#&2<-;-)M;OR?G^IJ^(/BY\8/#O[#*?$76/&&HQ>*M6U. V
MS/900-;6WF.@"A4&X2*%?+#N,<=?0_B[XZ^(^H?M,?#?P#X5\:-X8L_$7A@S
MW<SVD=R$<><[RHC#_6%8P 2< X.*Y_1_#_Q'_;6_99UC1=;U#3H+I=? TOQ#
M+:/;0ZG9P\B<1!<@,2<$*!QC&0:]IUK]G_5M2_:0^'OQ'34[)--\-Z(^EW%F
MROYTKLDR[D.,8_>CJ>QK&4J<&U))-<W3R5NAI&,Y)<M[>[^>IY;X ^)OQ+^&
MWQ1^,/PWOM;G^)5WX?\ #C:_H<UY;JES)+Y<;+ 0G+!C*HQG^'C&[%>/+\:/
M'FL>%? FJ^&/CKJ&L_$;Q1J<=CJ'A*"PMY!8K(7WE82A\OR\*,L "#D$ 5]#
M?$[X6ZY\._B/\7/C1"[:K97_ (2;3K?2=++I?I($A4R!]I"A?+9LC) YQQ7R
MSX+\>:W\'/A;H6K> ?C1X<\2Z_+% L/@R+PO%)?2R2N"\!F"F9MI9LEL9P<'
MD5O14*BYXI-NW32]M>CMKZ>IE4<H/EDW;7KTOIU7ZGZ#?$WX7W/Q(^">L^!;
MS6I'OM0TS[$^KR1*K/,%&)71,##,H)5<#!(%?*OAGXW?%']C_P /^'O"OQ=\
M"6NI^ K%HM.M?%&B.'$2+_JRZ\AB N1N$;''<U]9>,O#GB/XB?">73+36[GP
M)XFU"SA9K_3P)'LIOE9T7)&1D%"00<$X(-?/6M?LO?&CXOV^E>&?BK\2='U3
MP-974=S<1:39&.\U#9G:LC;%"YSU!/7."0*X,/*'*XU6N6^VM_56.NM&5U*F
MG>WR^=SC_B]X/\4^)?V\/!MAIOQ'U'36U+0[B_TV^@LX7.G0E9LPQJ1AU81_
M>;GYO85Z;;^//%VD_MN^'/A]/XDNK_P^O@];FY@D1%6YN5\Q3.P X9BH. <5
MK?&[]GGQGXB^+_@[XC_#C7](T36M#T^32FMM8@>2 P-O 90H.2!*PP<=%YZU
M!\5OV>?'^L?%#PC\3_!'B;1-/\<:;I0TG4EU2UD^Q7:$,6=57<R\N_R_[OS#
M'.OM*<XQ3:^%K;9_<9\DXN32>Z?R..?]H;Q)X+^-_P"T4^H:A-JF@^$-&AO=
M,TF7:(DE,49 ! SAG;GGN:\D^+'A_P"*'BO]C+4?B7XH^)]UJ,.NPVU[<>&O
ML,0LQ!)<Q^4D;#E&7*-D>A4YZU[UX)_9!UU?%7Q2U/Q[XJM?$J>/-'6PNYK.
MU-M)#)M )1/NA4P ASD[03SFN2N?V0_C+K/P8NOA7J7Q(T(>$;-%33OL]@_V
MBY5) \<=PY'R(IYPFX_*HR16T*E&$DXM*SC?3HEK;3N9RA5DFFGK?KY]=>Q<
M7XC^*O@W\2_@7<WFL3S_  T\8:%9Z/-92A?*LK[R(Q&X.,J&)C/)Z>;^':?!
M7QMXI^-GQJ^*>LQ:]>6GP\T60^'-(M;8($ENE $UR"5.64C*YR,2C@XKGOVT
MM#TKPW^Q_IGAK66-WK]O_9NGZ-]C_P!9)J$85 8@><;!+[X)[XKVO]GCX51?
M!?X.^&_"HVM>6UN);Z4<^;=2?/,V>_SL0/8"N:I*'L>>WO/3[G>_Z&\(R]IR
M7T6O_ _4C^#/P-L?@K_PD']G^(]>UQ-;O7U*Z369H9 +ISF65?+B3#/QGJ/E
M& *\!_X*">/-,U*]^'WPGOM9MM%L/$6I17VMWMS,(D@L(GP-S'@;FW$>\0'>
MOLFOGO3?V7?^$@_:*\6?$GQ__8WB>PN[1-/T;1Y[7SX[2%2OS.LB[=^%/3/,
MCUA0J)5'5JO5?GT_S-*L'R>S@M_R/(/@+\1O"'@/]M#Q7X5\(Z]I>J>#/'-I
M'J%B-+N%DAMKZ-26B^7A20LQQZ&,5T]CXD^(G[37QQ^(NA:!X\NOAYX0\#W*
MZ:@TNVCDN+VY)=6=V;^$&)^.F"HQG)KKOCK^R/8^+I/"&M?#:T\/^!O%?AO5
M4U"&ZAL%@BG08)23R5!/S*A&<\;A_%5'6OV=?B/X&^+?B7QQ\(_$^@Z4GBO9
M)K.C^(+>62 7 R3-$R#).6=L''+MU! '7[2E/WT[2:MKKJO\T8<E2/NM:7Z>
M?_!/,/VJ/#?C72_%G[,^C7GBVWU7QJNM7$*^(YM.5(S*9;;RY6MU.#M!7(S\
MQ7MFNX\#^)/B#\(_VMM&^&?B+QU<^/M!\2Z+)J,<VH6L<,MK,GFD[=G8^2PQ
MTPPXXR>E\7?LX^-O&NM?!;5]<\8V.M:MX*U234=4O9;/[.;P/+$X2)(QM&U8
MRH)QG@GO73^*/@;JFO?M3>#OBC%J-I'I6B:/-ILUBX?SY'<3@,IQMQ^^7J>Q
MJ?;0<%"33TETZW=K:#]G+F<DGNNO2RN?.'A']K#QIX1_9M^+7C'4]1?7]<TW
MQ5)HVDM>HI2W5A&%R% R%!=L'J0!TJAX?^/GC'P=K'@K5--^(/BGXD75_>P0
M>(?#^H^%I[:V6*7_ %DEO(85V>6>  ><@],BO7O!/[%7D_!OXC^ ?%>KV]S%
MXHUN35[:\TY6W6C?(8V(8#)#)R.A!(SSFMGP-\-/VA]+N]!TO6_B7X<_X1K2
M9(0]U8Z8TFH:A#'@>5+Y@"KN P64[N^2>NKJ8?WN6V_X6]'Y]C-0K>[>_P#3
M]5^IF>"?B]KOPS_:0^*'@GQ[KT]]X?736\4:#=7:J##:*&::)2 ,A06 SV@)
MSS7E<G[37Q'\%_LMZC\3]1U"2?7/&WB)K3P];74*O#I-H3)M94"_,0(Y ,YS
MB,X/.?9_VNOV5;[]H?\ X1Z^T#6X/#NMZ>)[.XNI@^)[*9<21G;U[X!XP[<\
MUUOQ<_9KT/XG? ^S^'-M</HD&E1V_P#9%Y"NYK26!=L;XXS\N0>02&/(/-91
MJ4+0E);VOIM;_/<U<*OO)/:]OG_D?.?@3XW>*?"WQ2\!6>E^/O%/Q/TS6KY-
M.UVSUGPO/9):F0JJW,,C1+M56;)7)X'/7(Z;P3KWQ,_:@^*7Q&OM#^(UUX!\
M,>$]3;2-+LM/LXIQ<2H6!EF#_?!V@[3V8 8QD^E?#_P/^T%!XBT7_A,?B%X;
MD\/Z;(#/'I.F,UUJB!2-LS2*!&3U)3O7+V7[,WQ+^'/Q,\8ZA\,_&^D:#X3\
M7W9OKZWU&Q:XN;&9BQ=[=?NL<NQ&X@?=!!VYJG4I7=FE*V^ZW_PI7MY$*,]+
MIVOM\O7]2E_P3361?@+K8E97E'B:\WLHP"?+AR0.U<W^UY\0O#GBG]I#X7_#
M?Q#KFGZ/X6T:X'B+79M0G6.%V4$P0L3QDJI&/2<'M7N'[*OP*U#]GOX>ZEX:
MU'58-9DN-8N-0CNH59<QNL:J&!'WOD)...:YOX8_LHP6?Q*^(7CCXD0:%XRU
M;Q)>*]I#-9BXBL;=<[4'FK][;L7('2,<\FH]K25>I6;]/G_D7[.?LH4TO4\U
M_8P^(&@>&OCI\4_AAH6MV6L>&KJ[;Q#H%Q8SB6'8^WS85(XRH:,8_P"F3FN7
M\ ?\@?\ ;:_Z^+W_ - O*]R^(/[*<3?%WX>>/OAQ'H?@Z]\/7#+J-I#9BWBO
MK9R RXB7&_895R1_&/[M5O#G[+FN:)9?M P/K.GN?B/+</8%5D_T02"<#S>.
M<><OW<]#6CK4G>:>ZC]Z:_17(]G45HM;7_%?TCHOV)<_\,K?#W R?L,G_H^2
MO&_^"<%C;^(5^*/C/5XUN/&MYXAD@O+B89FCCVA]H)Y4%V?('78!_"*^D_V?
M_AO>_"'X.^&/!^H7<%]>:5;M#)<6P81N3([Y&X ]&'7TKQ[QG^RCXP\*_$S5
M_'GP3\:V_@W4-;8R:MHNI6_FV%S*229!\K;226.-I(+-@@'%8*I"4JL.:W,]
M'\_U-.2453E:_+T^1QG_  4=L;?P]-\*_&>D1K;^-+3Q#'!:7$(VS2QXW[21
MRP#JF,]-Y_O&LG3/"/BOQM^W-\:--\,>,&\%(UC9->:A;V:W%TR"&#:D18@)
MENK<G P.N:]*\%?LI>+_ !/\3M(\>_&OQI;^,M1T1O,TG1M-M_*L;63((DY5
M=Q!"M]T$E5)) Q1K7[.WQ3T'X[>//B9X"\6^';"X\016]O%INL6<LL;QI&BM
MYCKRC!H\J5W Y((KHC5A"'LE)72>O35IVV,I4Y2ESN+LWMUV9Y9:_'[XC>'_
M ((_'WPWJ_B5[[QA\/+VWAL_$D42I+-#)<[ 6&",X1NN3A\9.,UI?%O]I;Q1
MI>@?!+PA;^)+SP]=^*- MM7UWQ/:Z<U]>+&802(H44_,[*^2%XRIX&:R?C1\
M-=-_9U_9A^)5MXP\6VVL?$KXB7*WDTBJ4^UR)<QL8X4ZE4\QF+8'W^@&!7JF
MI?LVZ]XR^'?P9\4>&=:'@_XD^#]$M(K>:\A+PR(UNBR03+U ^\.AX9P1SD:-
MT5:;2LV];:?"O+:_E\B;5=8IZI+\_P [')?!S]HS7_"_B[QOIM]K6N_$+P1I
MGAV?7[/6]:T>33KF"6!<R6K%XUW[AR&(ZX [UH?!/P_\:?CMX'TSXG3?%^;P
MU=:M<M<6F@VFEQ3:?#;)*4\MT8@L6"-SG(R,DGFO6O /P\^*.L_V['\6O%6A
MZSHVJ:<^G'P_H-@8[<!\AY#,X$FXJ2NWISGL*\X^'_[/'QR^%&DQ^"/"WQ+T
M&U\!V]RTEI?W6F--JEK$TA<QJA'E')+<D]6.,< 8.=-\W*XJ6GFK=>GZ&JC/
M3FNUK_6_ZGG/B[P)XQ\0?\% KC2;3XEZII-[)X;DN[74H;*%GM+9I686BH?E
M* G[Q^8]_6O4]2\=^+&_;<L_AX/$EY'X<F\'M</!$$7_ $C$B^>/EX;@'TR.
ME:/Q9_9Y\?:C\>]+^*/P\\3:-I6JKI/]D7L.MVSR)Y>YCYB! <DY'RG&"HYY
M(KH#\!=9F_:JT_XKS:I8M80>'QI,MFB.)6E^8EUZ@+ENYS2E5A**;:^&VW7[
M@5.46[)_%^!XYX(_:?\ $OP_^ OQAMO'&IG4/'_@*^ET^*YG50UP9V*6DF ,
M$;]QZ?<45D?$SXV_$+X6> _@]X&U;Q7?Z=XI\50-J&O^)O[/-[=V4)(;R88$
M0Y8!BO"Y&SJ,DCTKXO\ [&9^)G[0FD>.8=7@L_#DK6DVOZ.P;.H26S$QG@8(
M*[%.>@!(ZUV_[1'[/]]\6+_PKXH\+Z\OACQWX5N&GTS4)8O-A=6QOBE7NIVC
MG!X+#!#&J53#\T79:ZO39VT7I?7[A<E;E:[:+S5_\CQSX)?&_P 86_Q0U?PK
MIFLZ]\3_  Y<:'-?Z=J&O:)+I\]M?QJQ%N[M&F]'VCD]V4#&#GG/V:?B_KOQ
M&\9:1_PD_P ;]2T+QW_:+C4O NK:-'!;2Q!VQ;P[@,.5 P0=X/&TXR?H?X=^
M$?C>NI:E?^./'?A\A]/DM;+3-"TLM;Q7!^Y<N\FUV*X^YG!R>E>=ZA^S-\3/
MBCX[\&ZE\3?$/A&YT_PKJ,>HPWV@Z;)%J5^T9#*DKMA44D#(3CCIG!![2B^9
M.RTWW[_W;>MK!RU/=M=_UZ_YGLW@+1?B58?$CQK>>*M>TW4?!UU*AT"QM8-D
MUJG.1(=H[8!RS9(R-HXKT>O./ 7A7X@Z/\2?&NJ>)?%EKK/A34)(VT328;<(
M]BHSD,VT=L#JV[&?EZ5Z/7F5/BZ=-O3^KG=#;_,****R+"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N$UK7/AGH/
MB:275]0\)Z=XAA(9Y+V:UBNT) ()+$.,@@_E7=U^>GBZV^%]Q^W]\3!\5FTE
M-!&BVS0?VO*8XS<>3:8VD$9;9OX],UUX>DJKE=O17T^1SUJGLTK=7U/T TS5
MK+6K..\TZ\M[^TDY2XM95DC;Z,I(-6Z^'?V,UTKP_P#&/XQZWX*>[L_@=#"L
MEK<71D%M]H0*TCQ;^2J@3<]=I3/:NO7]L[QCJ7A&_P#B+I'PIDO?A99ROG4Y
MM6CBOYH$?8\Z6Y'W0<\9['G@D7/"R4W&&NV^F_3U\B8XB/*G+S\]NOH?6=%?
M.WQ!_:NN(?%_@SPE\./#D/C'7O%&DIKEL]]J"V-LEFX8HVY@2SG8WRC!&._9
MOQ&_:>\4_"WP+X(U;Q'\/ETK6]>UY-$N-*EU1)!;@[OWR21J0P.W(!P<&LEA
MZCMIOYJ_W%NM!7UV/HNL/1/''A[Q)K&K:3I6M6.HZGI,@BU"TMIU>6U<D@+(
MH.5)VMU]#7G7Q2^/4_PZ^,_PT\"QZ-'?1>,))XWO6N"C6OE[>0FT[L[O4=*\
M%^".O:SX7^,W[5NK>']%3Q#K%IJ5O+!ILETMLLV)+C=F1@0,+N;WQCO50P[E
M!R?:Z^^PI5DI**^?W7/MNBOB;]AWXQ>,[/X)7VM>)_#K3>"-/BU/5I_%+:HL
MUQ*\;F1XA;'YNF\ YQ\OO7I_P7_:(^(OQ>FT/6XOA=!;^ M8F>.+58->AEN+
M9%+ 230X''RD%1R,_FZF%G3E):67FOZOY"A7C)1?5GO.N>(M*\+V/VW6=3L]
M)L]P3[1?7"0Q[CT&YB!DX/'M6):_%SP+?74-M;>-/#UQ<3.(XX8M5@9W8G 5
M0'R23Q@5\Z_\%//^3:4/_4<M?_0):R_@?)^RE\0/%^@Z3X0T2PN/%T:+=PC^
MS[N(K)$HD+!G 7(*YZ]N]7##Q='VKOUV6UNXI5FJGLU;IN?95%?.DG[7UGX)
M\<>/_"_Q(TF+PI=^';-M4T^>*Z\Z/6+3)"F+<J_O"2H"<\EAGY#69XL_:Z\1
M> /@1X4^(_B+P$+1]?U>&UCT6*^9IX[.1'=923&,R,$R$P.&7)!R!E]5JMI6
MW_4OV]/778^GJ*^9K7]JSQ=X;^*OA7P[\0_AG+X-T+Q;.;71M1.HQW,HE+ (
MDZ)PC'<@*Y^4L/O8)$VJ?M1^+_%7C/Q7I'PL^'2>,M.\*SM::EJ5YJJ62RW*
MYW0VX(.X@JPS[=,$$GU:IV^=U;[]@]M#^D[_ ''TG56XTNRN[J"ZGLX)KFWS
MY,TD2L\>>NUB,C\*^?=6_;8\+VGP*T3X@6.E7NH:CK5W_9=CX<0@7#7X)5H6
M;' !'WL'(9<#+ 5K>%_BQ\9KJ#5X]?\ @S'87L.G&^L#;Z_ \%Q(&4?9G?'[
MM\$G."/E-+ZO4BKO3IJTA^V@]%J>[45\6?L%_%3QUK?@_5;W7?#\;>#Y=3U'
M4+SQ5<:NK/!)M5VB\@C=M'][..370I^V=XPUGPKJ?Q"\/_"M]1^%NGR2!M4G
MU:."]GAC;;).EN5^ZO/&>QYX.-)82I&;@K.WFOZOY$1Q$'%2?4^LJPX_''A^
M;Q=+X6CUJQ?Q)#;_ &J32EG4W*P\#S#'G(7YEY]Q7B_Q._:P31V\!:3\/?#[
M>.?%/C:U6_TNQ,XMHX[4KN\Z5B#MX#<<8V/DC'/DWP:U[Q'XB_X*#:_=>*_#
M7_"*:XO@_P J>P6[2ZCXD@PZ2* "K#!]1R#THAAI.,ISTLF_Z6X2KI248ZZG
MV[15#7KN^L=#U"YTRP&J:E# \EM8M,(1<2!25C\P@A-QP-Q&!G-?&?[%/Q2^
M)?BKQQX_>]\(I<Z'?>*[N35-3EUI2=(?9D6\<1&9%4A5W*0.?:LJ=%U(2FGL
M7*HHRC&VY]MT5\J_\-?^-/'#>(]8^&/PLD\7^"?#\[P7&L7&II:R7;1C=)]G
MB*DL N".I((X!.*]S^#/Q<T3XX_#O2_%^@^8EG>!E>WG $D$JG#QOCC((Z]P
M0>]%2A4IKFDOZ\^PXU83=HLUO$'Q$\*^$[Z&RUOQ-H^CWDPS%;W]_%!(X]0K
M,"1Q6]#,EQ$DL3K)&ZAE=#D,#R"#W%?F9H%S\-/"'Q<^(ND_M+>%]1D\1ZQK
M$LEGX@O$GDMOLI.$\LQMN5><AU!P,#Y=N*^I=5^+GAW]G?1?@IX2\":;;Z_X
M3\57RZ99WHU N(8FDC_>JV&\S)F8XR.F..W34PG+:,+MO[GI?1W,(8CFNY62
M7W_-'TC17D'B[X[S^&/VCO!/PP71H[B#Q%83WK:D;@JT!C64[1'M.[/E#G(^
M][5Y3HO[8GQ!^($'C"+P1\(I-<N_#.IW-I>7$FJI%;&*(D+LW ,\S;6.Q1P
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MV^'U['\>/!NI_"3P#X^^&-BMZ9/%MGKR-#I1@!&Z.,.Q\TD!@,<#*D 8)'Z
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M_9Q_Y^[G_OL?X5<HH I_V<?^?NY_[['^%']G'_G[N?\ OL?X5<HH I_V<?\
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M!/0T"9KT444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY6W_ (%GVJAHW[%JZ1#X<C_X2YI?['\?2^.<_P!G@>:7Q_HW^LXQC[_/7[M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBL3B$Y1]R3MUTMSZK39\JO?N@C)MD]]XWODU^_TK3M!FU22SV>:Z7"1@!E#
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MLD=PN=KH<_* 2?E&%]J!'J5%%% @HHHH **** "BBB@ HHHH **** "BBB@
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M:*.1TW&.-MC@ ;1W!KW[]G670&\ [/#WQ*O/BE:?:&E;6=1U&.]N$+ ?NF9
M-H&.%(!&30!UNO>"TUSQAX7UYKMH7T-KEE@" B;SHO+.3GC'7WKSBS_9O-G#
M %\32/-I4=O#H+M9+BQCAN1<*)0&_?DD*I.4^5>,,2U>U?3K7RUI_P 6O']M
MJ[>']9OK_3]2O/[.6_GNK"WC72I9[\V\GV1@"LD13A'E#\@'))*@ ^@_ OA
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J'B";4;
M?0=2ET>W@N]72VD:SM[F0QQ2S!28T=@"54M@$@' -7ZR_%%O=WGAG5[>P+"^
MELYH[<JVTB0H0N#VYQS0!\+^(-)\1?'SQ-XATZ;X>_"OQ#XE::&?58]'\<SI
M?1R0H\*,_DX9"$D>,^H.UN@Q]L_#C2)O#_P_\-Z9<:59Z%/9:=!;OIFGRF6W
MM2D87RHW/+*N, GD@5\/^ ?AS\7_ (<WGPEO=&_9PL;#4?!5K-:ZC>V7B;3H
M9=;\VU,3F1AR,RGSOF+\C\:^\/#.H:CJGAW3+S5]+_L35+BWCENM--PL_P!E
ME*@M%YB_*^TY&X<'&:!L^1?CQXC^+?PK\1+;GXW7EY<:Q+<7&F>&?#_PYAU2
M\2U5QDMB091 Z*7;&3VZX]9_9!M=-N?AQ>:];ZOI_B#5=4OY1J.I6OAR/0I_
M-B.PPW-LG26,[P2>3N],&N(_:TU"/3?B5X5E\*S>/+?XFC2KD1R>!]+M[\G3
M#+'Y@N8YV5"GF^7M(.0Q]Q7H_P"RGHL>B_"^8'1_%6DW]WJ=S>:A)XRBCCU&
M]NI"&DN'6-BH5B0% Z!<>Y Z'LE<K'H7@F.Q\00II^@+:3N6UF-88!'(_))N
M1C!/4_/755\<>%?A'XHTV2]N+GPG>R6T,MC+J=C)! !.(M2>>2WM]K?Z8FQR
M_F3?.=BC.6*@ ^NM+M;"STBVATN*W@TU(5%M'9JJPK'CY=@7@+CICBLKX>_\
MB7I'_7$?S-8OP7T*\\._#^.VN[!M*$E[?75OISA0UI;RW4LL,15254K&Z#:#
MA>G:MKX>_P#(EZ1_UQ'\S5?9(^T=%1114E'QWXJN!J7_  5"\&1!"W]G>"IB
M6QT+-<<_^/8_&OL2OCO29)-2_P""HVM8CRFG>!T0MZ;I(R#^<A%?8E V%%%%
M @HHHH **** /BCX&_\ &,G[9WC3X52_Z-X1\>(?$7AU3Q''<?,985[#A9%Q
MUQ%'ZU]KU\5?\%/[C3_!_@+P'X^MKS[!XV\.^((I-%D5,F7(WRHV.B_NT;\,
M?Q5Z;^Q]^V)I/[5VAZPT>CR>'M>T=HQ>6+3>=&R2!MDD;X&02C @C(XZYH'Y
MGT11110(**** "BBB@ KX-_X*J?&[Q3\-_#/@WP[X4\1R:')K$EQ-J T^X,5
MXT4801@%3N6,EGR1U*X[&OI?]I;]HS0?V;?A^^N:FIO]7NF-OI&C0M^^OK@C
MA0.H49!9L< CJ2 ?)_V6_P!F?6;K7;[XQ_&=(]:^)7B"/,&GW48:'1;5AQ"B
M'(5]IP1_"/EZEB0:[GAG[#_[>4?@_P (IX:^-.M:Q$EQ/NT/Q%JEO)+$\.-K
M1O-RQ"N.&((&2"P %?HGX=\3:1XOTB#5=#U2SUC39QF*[L9UFB?Z,I(JGXH\
M >&O&WA]M#U_0-.U?1RNW[%>6R21*,8^52/E([$8(KY;\1?L S^!-6G\0_ 7
MQ]JOPRU9SO;299FN=,G/965LD#_>$@]J T/L.BOS%^-W[?/[0G[/^H6W@CQ;
MX;\,6GBJ%5NFU>)&FBOK8DA&1 X"Y*L">.F-JU]G?LH_M+:5^TI\+]-UP2V%
MEXE56CU/1K>X#O;R*Q7<$)W!&&&!/][&3C- 6/;****!!1110 4444 %%%%
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M$8(ZTWX>_P#(EZ1_UQ'\S2^"/",?@CPTFF)=2W\QFGN[F[F55:>>:5Y97VJ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOW23C!.>_2L/P;\7M*\16;F_EATRZC(!61L(P/<$_P">E=G:ZQ8WP!MKVWN
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MD9 KU/\ 9K^%?[86@_!W1;;2O%>@>&=+&]K31_%5L\M];Q$\!OW3%%/)"$Y
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M]I:!7M%E?8K1R#YF*9!.XD$ ].H_4^@+6"BBB@04444 %%%% !1110 4444
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M35(!-9W,5S$?XHG##]*]'"YCA,;=4*B;6ZV:]4]5\T4I*6Q9HHHKT2@HHHH
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M=M^7IL_4^W_LS*^),'/,?;1H8J]G!R48SE_,KVY>:_>R:Z+;ZF_X1/QC8_\
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MXS)*I7#L<#YFR>!4<?PU\(Q:;J&GIX6T9+#44CBO+5;"(17*(-L:R+MPP4
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MDJ![5'=?"_P;>ZI=ZE<>$]$GU&[>.6XNY-/A:65XSF-F<KDE3R"3Q7DGA?\
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M^[894YV"OMBSF-Q9P2E9$+HK%95VN,C.".Q]JKFDURMZ"Y4G>VIYS]C^,?\
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M6[J0R:E>1WMR3X?A35$@D2:'E+<&WD=E>-5;;"[G=P] SW?['\8_^@QX&_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAKH:EIK<=T]@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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5W[;_  H_M:U_OM_W[;_"KE% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>p30a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p30a.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &G S0# 2(  A$! Q$!_\0
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M$VHJ[.UHKY:T?_@H-X.NM0L1K'@[QIX:T2_D6*TUS4M*_P!%D+'"G*,Q(/\
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MQZH?1114%!17%?%SXO>&O@CX-G\2^*;M[>P2188HH4\R:XE;.V.-/XF.">P
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M\V^.OVX-"\%_$[7_  -;^!?&'B;5]%*?:6T.Q2X3#(CA@ ^X#YP,D#FM*/\
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MAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.FBI1C[W](****Y3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDD/<$[?E/#;6[;7;^#EPP\?;.C._R[=PE6E[-5(_UY'V%X+^(7AGXC:?-?\
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M1_"T4=RU^M] 9H3'N'WD .X9QQ@UK'"KV[HMWM?;R(E7_=*HEO;?S/L7P?\
M$;PK\0K>2;PQXDTKQ!%'_K&TV\CGV9Z;MI./QKHJ^!OAAIOA+QM^VAX;\1_
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MP?PW^VE#8^ ?B1>^.?#K:#XN\ ND.J:/:SB2.X:1_+@,,A_A=\#G. 0<D&O
M?VK/B!\6O'GP1\'ZIXV\&:+H7AW5-<LKVQFT^^9[F#='(8XYXVSG<C%LJ1C;
M@@$XK6E@YRFHST5[;KUT[F=3$14;QU?];GZ-T5%<R20VLKQ1>?*J%DB#!=[
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MV.I.ZN%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^_W_ -:KE% %/S[S_GUC_P"_W_UJ//O/^?6/_O\ ?_6JY10!3\^\_P"?6/\
M[_?_ %J//O/^?6/_ +_?_6JY10!3\^\_Y]8_^_W_ -:CS[S_ )]8_P#O]_\
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M:CS[S_GUC_[_ '_UJN44 4_/O/\ GUC_ ._W_P!:CS[S_GUC_P"_W_UJN44
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M/^?6/_O]_P#6JY10!3\^\_Y]8_\ O]_]:CS[S_GUC_[_ '_UJN44 4_/O/\
MGUC_ ._W_P!:CS[S_GUC_P"_W_UJN44 4_/O/^?6/_O]_P#6H\^\_P"?6/\
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M ._W_P!:KE% %/S[S_GUC_[_ '_UJ//O/^?6/_O]_P#6JY10!3\^\_Y]8_\
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M-/\ &5]%I^B3:?$TXN99#A> ,J >"3C:>#@UKZU\7O#>@_%#P_\ #ZZN)O\
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M6 "KN4$YZL, T >KT4@(8 CD&EH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ^5?^"BU[)J?P?\-^!K9W%UXT\4:?HX1,Y*&3S">.P9(_SJM^T%J-YXN_
M:(^'?P7'B*^\(>"9-$GUK5)M+O#9SWB1;TC@$P(*JOEY8#J"?0$?1OBOX:^&
M?'&M>'=6UW28M1U#P]<F\TN:1W'V:8[?G ! )^5>H.,5B_%3X!_#[XW#3_\
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M^E7;NZM:NX4.5P0#D*O!!'%;NI:99ZQ926=_:07UI+@26]S&LD;X.1E2"#R
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MIUMH\.DQV-N-,AB6".S\L&)8U "KM/&  /RI/[!TSRQ'_9UIY8E$X7R%P)
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M &O,--^,WCCQ@;."PU73]*F70K^]GG2R$\<\MK<-'OCRPP'"CU ^;@\8]_\
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MRI.]CHOC[PM$6.D^%O%VH:3I:DDB*U_=S)"#Z1F9D [!0.U>X5Q_PI^'%O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5^;'Q6\47FD_'CQ_8:IX1MKOQ%J$6JVWAOP^G@.WN8YKD26YL
M+O[0T3&X,P:X:1F;"8(ZXK])Z^'/BAK/Q"\/:K\5?"<EGXEN?$_B35EN_#WB
M:T\2P6VFZ9;(P:SRK2!K=8\GS4V'S=IZ[A0-'VUIJRIIMJLT,=O,(D#PQ?<1
ML#*K[ \"K-5]/\W[#;>?*D\_EKYDL8PKM@98>Q-6*!!1110 4444 <UX#_Y!
M^I?]A2\_]'-72US7@/\ Y!^I?]A2\_\ 1S5TM5+<F.R"BBBI*"BBB@ HHHH
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\Y/'6BZ)X6^
M-WC72==\'_";Q5KVN>()[ZT?Q5XGVZ@(YBODPNIC(CXQM0D8#*.>I_16\O+?
M3;.>[NYX[:U@C:66:9@J1HHRS,3P  "237P#XX\.VFM>&O$E_I/CKP OP@^)
MWB*X1O$NNZ+<MJMM<S,RRQPR;1&54Q,(Y9-H7 P> :!H^^]-B-OIUK$T,=LR
M1*IAB.4CP -JGT'2K-06-JME96]NCM(D,:QAW.68 8R3W-3T""BBB@ HHHH
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M26_A47!TG4/$?]C65H3=NHGB?</,D;E7&. (S7T3^SAX</A/X1Z3IA\&6_@
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M[)_PR'A_^RCX?W#(8WC3O]IW#OOST_V1\OM7+6GC,53<:$>3SD]?N5[?,]G
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M\17/.A5I_'%HVC5A/X97.MHHHK U"BBB@ HHHH **** "BBB@ HHHH ****
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M.QRP!9B57L,8/7/'U74XN4)5.6D[Q2LAX>,E"\UJ]PHHHKB.H**** "BBB@
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M^@K8_P#@0G^-')+L'MJ?\R^\TJ*S?^$FTC_H*V/_ ($)_C1_PDVD?]!6Q_\
M A/\:.278/;4_P"9?>:5%9O_  DVD?\ 05L?_ A/\:/^$FTC_H*V/_@0G^-'
M)+L'MJ?\R^\TJ*S?^$FTC_H*V/\ X$)_C1_PDVD?]!6Q_P# A/\ &CDEV#VU
M/^9?>:5%9O\ PDVD?]!6Q_\  A/\:/\ A)M(_P"@K8_^!"?XT<DNP>VI_P R
M^\TJ*S?^$FTC_H*V/_@0G^-'_"3:1_T%;'_P(3_&CDEV#VU/^9?>:5%9O_"3
M:1_T%;'_ ,"$_P :/^$FTC_H*V/_ ($)_C1R2[![:G_,OO-*BLW_ (2;2/\
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M1\;:+J?B+PKJ6FZ-KLWAG5+B/9;ZM;P).]LV0=P1_E;@$8/K7Y[>-/BQ\2?
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ML[>."")((8U"I'&H55 Z  =!4E @HHHH YKP'_R#]2_["EY_Z.:NEKFO ?\
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MD< ?=/P]BLH/ /AJ/3;>YM=.33+9;:"\.9XXA$H19#D_.%P#R>0:^?\ XV?
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MH_X5#K/_ #VL_P#O]_\ 6KUJBC^T*WD']AX3S^\\E_X5#K/_ #VL_P#O]_\
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MUA>"SEG'F,RJ Q12$!+ 98@'-5''5Y.T5=^@GDN#BKN_WG)?\*AUG_GM9_\
M?[_ZU'_"H=9_Y[6?_?[_ .M6[XH^.7@WP=XVA\*:IJ,\6K.UNDK16<LMO:-.
MQ6!9YE4I$9&!"[B,TSPK\>/!?C3QA)X:TK4;B;4O](%O)+92Q6UZ8&VSBWF9
M0DWEMPVTG%7];Q-KVT]"?['P5[7?WF+_ ,*AUG_GM9_]_O\ ZU'_  J'6?\
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M\_\ 1S5TM5+<F.R/)/&'PWU/6O$%W>026RQR-D!Y<'K]*Q?^%0ZS_P ]K/\
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M6I_LH:[<?L]K97&J:IXA^(%OX4CT73M/U"[MUM-+9O)\^*!D101B(+O=F.$
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M_*C[/+_SS;\JY#I(Z*D^SR_\\V_*C[/+_P \V_*@".BI/L\O_/-ORH^SR_\
M/-ORH CHJ3[/+_SS;\J/L\O_ #S;\J (Z\R_:0\#ZS\1OA+?:#H,"7.I37^G
MSK%)*L2E(;N*5SN8@<*C'WQQ7J/V>7_GFWY4?9Y?^>;?E50DX24ET)E'F3B^
MI\O?&3X)>.O%WQRN]>TBPMY]*O)]'D@NO[12"SC6TE+R?VA:$;KMAEO**_=R
MO3%=+X'T'QSJ?QUN?$WC#P,+#3K1;BP\/S6NJ6K6NEVCX9Y#"IWO/.R@,V,*
M" .]>^?9Y?\ GFWY4?9Y?^>;?E6_UB3CRV6UC+V*YN:Y'14GV>7_ )YM^5'V
M>7_GFWY5S&Y'14GV>7_GFWY4?9Y?^>;?E0!)8_\ 'P/H:TZS[.&1+@%D91@\
MD5H5+&@HHHI#"BBB@ HHHH *_/OXJ6GQ=\/_ !J\=Q6]KKU]J'B"VU+3]+UB
M/Q+%;Z9I]O.]N;&41EP;=H%CFW\;G)XR&K[XU;6+#0=/FO\ 4[VWTZQA&9;J
M[E6**,$@ LS$ <D#GUK\\_&7AG1-(^*'Q"FUGP9\)O&5U?\ B&ZNTOO%'CF"
M&^BC8@+"\; E NWA.-H(7G&2#1^A^FK*FGVJW$RW$XB423(,*[8&6'L3S5FJ
M>CA1I-B$CBA7R$Q' VZ-1M'"GN!V/I5R@04444 %%%% '-> _P#D'ZE_V%+S
M_P!'-72US7@/_D'ZE_V%+S_T<U=+52W)CLC)NO\ CXD^M158N()&G<A&(SUQ
M4?V>7_GFWY4 >&^'])\<>"?C=\1K^'P4VL^'/%FH6$L6JP:M;0FVCCM4@D9H
MG.\X(8X R<5R7@GX+^/+&Q^&'@?5-*L;/P[X!UPZO_PDD.HK)_::(9_)1+<#
M?&S><-^\X&TX)S7T_P#9Y?\ GFWY4?9Y?^>;?E73[=]E_P ,K?D8>R7?^MSY
M>\&_ _QS\/=2\>WVGVUO=_V3I5[I'@&#[2BXCNKF2X=G).(RA:)!NQE8\"L_
MPC\&/BU\ ;/6H_!W]D^+)]1\+VVGP20QQZ<MKJ%NP2*619)6\UO+EE8R<;C&
MH(&:^L?L\O\ SS;\J/L\O_/-ORJ_K4W>Z3O_ %_P1>PCTN?+?_"I_'.O?"_P
M=\/M/\,+X*L+#68-0U75=:OK;53>>3NN&EEBBD!E:6Y"%ER/P J3PU\"/&.B
M^"(O#VK01:O;:3J4MM ^GS1V\MWIQO8;Z.2 ,^(6#H\1C9@0NT@G: ?J#[/+
M_P \V_*C[/+_ ,\V_*E]9GM9=_F'L8GF_P %_ =_X'T.9-15()I(K>VAME96
M>.&!65#*RDJ9&WDMM) PHR>:]$J3[/+_ ,\V_*C[/+_SS;\JYY2<GS,VC'E5
MD1T5)]GE_P">;?E1]GE_YYM^5241U@>.YO$,'A6_?PM8VNI:V%'DVEY=-:K*
MI(#A90#L?;NVL1@,!FNC^SR_\\V_*C[/+_SS;\J:=G<35U8^5=#^&7Q1\-_#
MCQ%I<6@3W$?B+6;F]N((/%*0Z]#&T<8C=[_;Y<K%T8,"21&5 STIEQ\./B9;
MZ/\ #OP=J/@:QUWPAH-C9S:NFAZC:V8U.]@8-#%()""8(B Q '[QQG@<5]6_
M9Y?^>;?E1]GE_P">;?E75]9EO9?C_F<_L5W9\S>!?@KXVTGXE>&(=1L+*'PS
MX9\1ZUX@CUM+U9'OQ>K((H1 !N1E,S;BW'R\$YKZ5J3[/+_SS;\J/L\O_/-O
MRK&I4=1ILUA!05D1T5)]GE_YYM^5'V>7_GFWY5D:$=%2?9Y?^>;?E1]GE_YY
MM^5 $=%2?9Y?^>;?E1]GE_YYM^5 $=%2?9Y?^>;?E1]GE_YYM^5 'A/[1'AW
MQKXTU#2] TCP=_;O@J=5EUZ2TU.VL[O4%5BR66Z4@K#N"LY'+ [01SGF+'X+
M^-F^(5I:2:19VOA=?'H\>'6!?H6B0VVS[#Y &XR*_&\?)M&?:OIW[/+_ ,\V
M_*C[/+_SS;\JZ8XB48\J2,'24GS-GF?PA\'ZUHFL?$'7_$L$<6L^(/$$LT++
M*LI&G1(L5FF1T 0,VWL7;/)KTBI/L\O_ #S;\J/L\O\ SS;\JPE)R=V:QCRJ
MR(Z*D^SR_P#/-ORH^SR_\\V_*I*(ZLZ?_KS_ +M1?9Y?^>;?E5BQA>.8ED*C
M'>D!?HHHJ2@HHHH **** "BBB@ K!\?:)=>)/!.NZ38QZ;->7ME+;PQZQ;_:
M+-G9" )HOXX\GYE[C-;U% 'YT^,K74)/B;K7A[Q!<?!'4_%EG9S7^ISR> +B
MY$4<%N)7$D^"&D6$ [!EL8&.@K[X\!,DG@;PZT4MC-&VFVQ633(C%:N/*7!A
M3^&,_P *]A@5\*_M%:3X1F^)OBK4-*UGXAVT7]KSV6J:)X;M[=X]1NGTX-J+
MVSR,&CV6D48E;!Y90O4FONOP&VCOX&\.MX>&- .G6QTX#/\ Q[>4OE=>?N;>
MM V;M%%% @HHHH *YGP5_KO$G_87F_\ 0(ZZ:N9\%?Z[Q)_V%YO_ $".J6S)
M>Z.FHHHJ2@HHHH **** "BBB@ HI&8(I9B%4#))Z"N.L?C/\/M3O;>SL_'7A
MJ[N[B00PV\&KV[R2R$X"*H?)8DXP.: .RHK)\+^+-&\;:-%J^@:I:ZQI<K.D
M=Y92B6)F1BC@,.,AE(/N#6M0 445R^K?%#PCH.N_V+J/B/3;+5?-MK?[)/<J
MLGFW!<6\>"?OR&-]J]3M.!0!U%%%% !1110 4444 %%16]S#=1[X94F3)7=&
MP89'!'%9_B3Q5H_@_3UO]<U.UTFR::.W6XO)1&AD=@J)D]V8@ =R: -6BBB@
M HK+UCQ-I/AVXTN#4]0M["75+H65DMPX3SYRK,(U)ZL0C8'?'%:E !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 <O\ $[P[J'BSP%K.DZ5%H\VH
MW4(6!-?M/M5B6# _O8OXEX_/!KX)\1^=>>/O%^FZS=? _4/$&BV]QJFO7\WP
M^N9TC\IH_/+S[3YDBF5"P&XC)SR#7Z/5^<_QJTGP0OC[Q+J4&L_$=?#%QJ^L
MVFL:#HD$#07$2""76KB*1B'2V#I$LHY)8$+@&@:/T-TE=NE60W0MB%!NMEVQ
M'Y1R@[+Z>U6ZJZ6UJVF6AL=OV(PIY&S[OE[1MQ[8Q5J@04444 %%%% '-> _
M^0?J7_84O/\ T<U=+7-> _\ D'ZE_P!A2\_]'-72U4MR8[(****DH**** "B
MBB@ HHJ.XN(K6WDGGD2&&-2[R2,%55 R22>@ [T 245QVG_&;X?ZM=0VMCXY
M\-WMU,2(H+;5K>220@9(55<D\ ]*W_#?B72O&&AVFLZ'J-MJVE7:[[>]LY!)
M%*N2,JPX(R"/PH TJ*** "BN8N?B=X2L_$)T*?Q%IT.L?:HK'[$]PHD^T21F
M2.'']]D!8+UQ@]"*Z>@ HHHH **** "BBH[>XBNHEEAE2:)NCQL&!_$4 245
MD^(/%FC>$X[%]:U2TTM+Z[CL+5KN58Q/<2$B.),GEV(.%')Q6M0 445EZIXH
MTG1=5TK3;_4+>SO]6D>*Q@F<*URZ(79$SU8*"V.N ?0T :E%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%97BSQ!%X2\+:SKEQ&TT&F64
MU[)'']YEC0N0/<A: /@OX]^)]#/QB^(L^B_"2QUB<VU[I>JZK=^*WTV6Z,-K
M;S7?E0#A&:%H4WC#2JC@<9K[G^'-]#JGP]\+WEO!:VMO<:7:S1P6))@C5HE(
M6,D E #@9 X XKX,\:>*?&?Q8T^[?Q%\//A&\UQH2?$"2:[>XG:ZM8TV0VSE
M2K"Y"$J7W%=I QQ7WK\/=;M_$W@'PUJ]G9KI]IJ&F6UW#:( ! DD2LL8QQA0
M0/PH&SH****!!1124 +7,^"O]=XD_P"PO-_Z!'6=X#^+FD?$#4);.QM;^S<V
MJ:A:/>Q*BWMHSLBSQ;6/REEZ,%;#*=N"*T?!7^N\2?\ 87F_] CJELR7NCIJ
M***DH**** "BBB@ HHHH 1E#*01D'@@U\K?#_P"'7A*U_;<^(<$'A?188K'P
M[I-U:QQZ?"HMYC)*3)& OROPOS#!X'I7U55./1["'4Y]2CLK>/49T6*6[6)1
M+(B_=5GQD@9. 3QF@#X!^'OQ(^(/Q)\._"O3Y?B)KFBOJVC>*KR]OM-\@33O
M:7K"WSNC(&U0!P < C(SFE\(_'CXI:+X>\.^)!XLU#Q7J?B3X;ZKKATN]MX3
M!#>VFT0O#''&IS@$LI)WG/J,?>-GX-T#3_LWV70]-MOLR2QP>3:1IY2R',BK
M@?*'/+ =3UI]CX5T339+*2ST?3[62QB:"U:"U1#;QL<LD9 ^52>H& :!W/E_
M]B/QWXY\8:AJ3Z_XPLO%6AW&D6E\D<FO6>HW]M=O_K"4MXT,,+\XCD!*%",Y
MS7E?C*"37/A_I5Y+?36.OZM\?A#=:A&%-Q;O'<RV\&W>",QPQQ;0P(&!P:^]
M-#\)Z'X8:Y;1]&T_26NG\R<V-JD)E?\ O/M W'W-<YI'P?\ #^C>+/$&MQ0^
M?'K5Y!JDVFW*)+;0W\:[/MD2E<I*RA Q!YV \$DD ^.+/XR>-8]:@^'OB#XE
M:CH'A2V\?ZSX=N_'LS6\5ZMO;6D<]K;R3O'Y2/([N-Y4$A,#TJ3P-^TQXI34
M/"EUXL\;K::)=>&?$<=IJMXT=I!J\MK<[+6Z ("F5H^<+UQD#FON&Z\$^';Z
MROK.YT#2[BTOYOM-W;RV<;1W$IQF212N';@?,<G@5)J'A'0M5M[&"]T73[R"
MQ(:TBN+6-UMR!@&,$80@<<8H ^0/V8?&7CGXJ?$CP>-7\>ZP--L_ VEZ[=Z=
M'Y134+F26>-C*Q4L!@ D*1D@9Z5H_M2?$+5M%^.MSH;?%.]^&^AP^ +C6[<V
M\]O&MSJ$5TPC3]ZAW%EZHF&8+@=Z^L=+\+Z-H<JRZ=I-CI\BP+:J]K;)&1"I
M)6,%0/E!)(7H,FN*U[X$^'O%'QA@\?ZNB:I-#H7]AKI5[;136NW[2+@3892?
M,## .>E 'Q?KO[2GQ!U?0=:U_7/'TW@#Q+H/A70M7T#PW%# D?B*YN8M\[/$
MZ%YE9_W8CC(V9SV.>S?XR>+&_:&M;36O'>H6MEJOB"WT.WTG0+FTE2Q\V ;K
M2ZL)$6XCD#EF^V(TB# XQQ7VCJ'A?1M6U"QOK[2+&]OK$[K2YN+9))+<^L;$
M97\,4C>%=$;Q -=.CV!UM8_*&I&U3[2$_N^9C=CVS0!\@_L?:IXG\$_!?6X_
M!^G3?$C68_%FI6U_I6I:]!9MIRK/)A^8B0TG#,I')8L,#BO-_C]\0=1\;>(/
M&MIXE\=RZ3>Z/X]T?2=/\!^9 L4EF)()!<["OFN2Q=O,!QA<=" /T-T_0M-T
MFXO+BQT^ULI[V3SKJ6W@6-IW_O.0,L?<\U2U+P/X<UG43J&H:!I=]?E50W5S
M91R2E58,J[F4G 8 @9X(!H"Y\5Z!\>O&4GQ$T/4F\>S7GB?4O'=[X<U+X</'
M"T.G:7&91Y_DJGG!HUC20R[L,&Q]>>\%_M&?$#1-!\<7*^.+GQKXJ7PG>ZU:
M+8S6>I:1*R3*HN81&B36AC5_^/>9,-M.3D8K[]C\,:/#KDNM1Z38QZS+'Y4F
MHK;(+AT_NF3&XC@<9INE^%-$T.[O;K3='T_3[F^;?=36MJD3W#>LC* 6/)ZY
MH ^!;?Q9XM\7?LT_&"X\2^,+'Q)I%CH=GK6DW']O6>I:C8:@A\Q7+6\:>4K2
MQJ45AE2I7)YK[_\ #UU<WV@:9<7B>7>36L4DR8QM<H"P_/-<;XJ^!?A/Q5I-
MMH_]G0Z3HG]I0ZG?:;I<$5O%J;Q-O2.X"KET\P(Y'&XH 21D'T*@ HHHH$%%
M%% !1110 4444 %%%% !1110 4444 %%%% !7YP_%[Q=H$?Q!^*EYI'P=TS4
MK"5K^+5]0U#Q;)9/=I8W%N;TK;K_ *M7D,+.BX:9%)(.<5][?%'QQ%\,_AOX
MH\6S6S7D>B:;<:@;=#@R^5&S[,]LXQGWKX0^)&N^+?$MKK]YXK^'/P@NIO#=
MC%XYU,;IYCJ4<RE5BC((VSB.U=7+%E;;%P10-'Z%Z/,+G1[&8+$HD@C<+!_J
MQE0?E_V?3VJY532;R/4=*LKN%/*BGA25$Q]U64$#\C5N@04444 %%175U%8V
MLUS/((H(4:221NBJ!DD_@*Y+X?\ Q1TWXAR7,=I8ZAILT5O;WJ1:C$J-/:SA
MC#.FUF^1MC\'# J0RB@"[X#_ .0?J7_84O/_ $<U=+7-> _^0?J7_84O/_1S
M5TM5+<F.R"BBBI*"BBB@ HHHH *CG@CNH9(9HUEAD4H\<BAE92,$$'J"*DHH
M ^1?A5X)\,:3^T[^T;)8>'M&M)=&MM%FT]H+"%39.;"1BT6%_=DGD[<9/6O'
M_#?Q0^(GCKPKX94_$?7-%EC^$^H^*IYM/, :XO;>]D5#)NC.%*@*VW!(7&1S
M7Z&PZ)IUO>7MW%86L=W?!5NYTA427 4;5$C8RV 2!G.!5*W\$^';1$2#0=,A
M1+5K%5CLXU"V['+0C"\1D\E>A/:@=SX.D_: ^*?@_0[_ %6U\4WWB?4=<^$M
MOXU6UO;> II]ZUQ%"[VZ)&N(DC=VVMNR5R<U[?\ L7^+?&GB0^*4U_Q78^*]
M!6.RN-.D_MZTU6^MWD1O-69[9$"HQ4,BLN0-PR<5]$6OA?1K&>":VTBQMYK>
MU%C#)%;(K1VX.1"I XCS_"./:C0?"^C>%8)8=%TBQTB&5_,DCL+9(%=C_$0H
M&3[T ? EOIL_B;P%\";DZI=:5K_B#XGZM<ZGJ=HJ"YCNFFO(V8;U90ZHB(,@
MX"KQP*N:#\:O%VN-X8\'>*_BI?>#O#T.L^)-/NO&F;:"[NVL9$%M#),Z&-&V
MN6/ +A0.O-?9?A?X/^'_  GKFN7]K!Y\.IZG_;26-TB20V-ZR[9IK?*[HS(?
MF;!QN+$8W'.W=>!/#5_ILNG7/A[2KC3YK@W<EI+91-$\Q.3*4*X+D\[B,T!<
M^#?"_P"U)XVGT>YU3QAXM_X1][[X1ZA?Z8UPT=I%>ZG'>3QP74*L!F9XDC8(
MO][(7!KTO]E7Q5XT^)WQ:N)]9\>:Q/I>A>%?#=^VC#RC!>W%YIA,LDK;-WWQ
MYF%(!8Y/ Q7U=JOA'0M=^R?VEHNGZA]C!%M]JM8Y?)!&TA-P.W(XX[5+I?AS
M2=$FDET[2[.PEDCCA=[6W2-FCC7;&A*@951PHZ <"@#XQ_:C^*VN>&?B]\0[
M./XK7G@.VT+P5!KFCZ=%-;HE]J DF"Q%94+2!]JJ43!.X>F*Y7QA^T9X_,WB
MCQ%=>-9_#/C/09=!CT+X=1QPK%K(NHH&FW1.IEF+M+* 4(\O9^-?8-Q\"?#N
MH?%[4?'^I0QZK>7FFVVG+8WUM%+!#Y,CR)*FY20^7/.:[6\\+Z-J&L6FK76D
MV-SJMH"MO?36R//"#U".1N4<]C0!\8:+\5/$^J?M&7?A[5?B5J,MKKFMZEHU
ME!X9NK.:WMHEA?;;RVKQK<VEQ"5+?:,2(S*,Y4YK5_8EUSQ/X6_9;\'1^#]'
M;X@SS:C?1ZI:WFO0VG]BD7# 1JIC)Y'[PH><N3G# #ZYA\*Z+;Z]+K<6CV$>
MM2IY<FHI;(+AU_NF3&XC@<9J;2]!TW0_M7]FZ=:Z?]JF:XN/LL"Q>=*<9D?:
M!N8X&2>>* /SN^(GQ U+QWX\TNX\1>.)GUJP^-%EI-KX!9X(X[>S@F(AG6/;
MYNYLY,N[:V_&.E;WP]_:"\;7FJ^#]:?XCM?>)O$=SKEOXB\%W4$4EOX<BMDG
M,4ODQIYT0A,<98N29 QQS7W/=>"?#M]JS:I<Z!I=QJ;-&YO9;.-IBT9S&=Y7
M.5/(YX[5/9^%]&T_6+O5K72;&VU6[ 6XOH;9$GF Z!W W,/J: N?GKI?[2'Q
M"\*?"_XB2VOC/4?%'B^S\,VNKK,)K/5=-3S;M(9;ZVF@16@"HS-]EGCRNW<<
M@&M76/$WB_4OV:?B/JFL^*K'Q0OA_5=%U7PI?1Z]::QJ-I=_:(LK+-;(B_,Q
M^0%0=LK+R!7WCI'A#0?#Z7J:7HFG::EZQ>Z6SM(XA.QZE]H&XG)Y.>M<MKWP
M/\*ZY_PC]LEA%I6C:3J:ZN='TR&.WM;RY3F)IU51O"/APN0"RJ3G&* N=\A)
M52PPV.13J**!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5=5T
MNUUS2[S3KZ%;FRO(7MYX7Z21NI5E/L02*M44 >#_ /#"OP&_Z)MI?_?R;_XY
M7MND:3::#I-EIFGP+:V%E EM;P)G;'&BA54>P  _"K=% !1110 4A&00:6B@
M#S?X9_!YOA_JB7<^LG54L],CT738Q;"$P6:2,X$AW'S),E07PHP@^7))/3W/
M@FUFO+BXBOM2L3<2&62.TNVC0N0 6P.YP*Z&OG_X*Z+JMC\1O-N+#4K;4!::
MFOB2ZNHI4ANKAKY&LB';Y)2(?-VF/(5& ..!3NT#2>YZW_P@\?\ T&M<_P#!
M@]'_  @\?_0:US_P8/72T4^9D\J.:_X0>/\ Z#6N?^#!Z/\ A!X_^@UKG_@P
M>O+_ ($V.G_\+ \4WVFVVLZ3:>7]D6UU:WNUFOV29S)?3O,H4NS,50*2WEC)
MX8*ONM',PY4<U_P@\?\ T&M<_P#!@]'_  @\?_0:US_P8/6]?33V]C<2VUO]
MJN4C9HH-X3S& )"[CP,G SVS7BW[.NG^+]/\3?$&3Q=I.HV5]?75I>/<W=RD
MT$LS6RB1+?:2!$FT*H'0 9^;=1S,.5'I?_"#Q_\ 0:US_P &#T?\(/'_ -!K
M7/\ P8/72UD^+H]1F\*:TFCMMU=K*9;-L@8F,;>6<G@?-CK1S,.5%#_A!X_^
M@UKG_@P>C_A!X_\ H-:Y_P"#!Z\W_9AM]4TW1]5T^ZL)HK&)+247MYI<MA<S
MWCQ'[4DBR$F4HRI^^_B+L,MMS7MM',PY4<U_P@\?_0:US_P8/1_P@\?_ $&M
M<_\ !@].^)"WS_#WQ,NF6]U=:BVF7*VT%E+Y4[R&)@HC?^%\XP>QQ7F_[+^D
M7FB:+XCMY(+A=.-]"]G</I\^G02_Z+"LGE6LY,D>)%;<2<.Y9ACFCF8<J/1O
M^$'C_P"@UKG_ (,'H_X0>/\ Z#6N?^#!ZZ6O.?C1H<^K6OA&XM+:YN+JR\3:
M9-NM2^8XOM*"5F"GE=F<[L@#-',PY4=#_P (/'_T&M<_\&#T?\(/'_T&M<_\
M&#UY'X9T75H?CL+J2PU1-4_MC49-0U!XI1;2:2UOBTC\T_NW D\K"*=RE')
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M6D0"MUYDP%Y#%ND_9GTCQ!H6C^,+3Q#I^JVEVWB">Y%QJTZ2O=&2*)GD0J2
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MZ\GTR33IKH-#&TIDAD^;<LA9-Y^]M[D%B<S#E1VG_"#Q_P#0:US_ ,&#T?\
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M$/A=JC>)Y/"EGK+RPZM?1+'F.2./#C]XK!?WJD=.]6--\:>+-:^$_CK4=/\
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M+K6O&'BFZUZ^U"WT2ZU>&]AT^&>(P7RQHFUI!M+##+R,KGTX!KVVBF!YK:?
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M#0%TUO%DWA*WA>UF#IMR(Y21)@A0!\HZXZC/#$>B^&?A7JUOXLTO7_%'B?\
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M''MCKUKN***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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DN3T;\J**+!</MR>C?E1]N3T;\J**+!</MR>C?E11118+G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>p30b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p30b.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &Y V,# 2(  A$! Q$!_\0
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MUR74$MI9UC_UCQ0%2S #G R>QP<@?1/PK^)>C?&#P#H_B[0)&DTS4HO,19
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M"FL>)/$O@7XHZ#<Z>-)N9($3Q!H[3Q7*C(\V,!69=V,J2!D%2#SQXG^S#X?
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M;G//2I[_ $'3-4TU=/O=.M+RP7:%M;B!7B&W[N%(QQVXXKE/@O\ &/P]\=O
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M,UNCF C&"F1\IX'3T%:-%/F?<5D9NN>&](\46JVNLZ59:M;*V]8;ZW29 WJ
MP(S[TEQX9T>\CL4GTFQG2Q(:T62V1A;D8P8\CY>@Z8Z"LCX<?$[PW\6O#\FM
M^%M0_M/2TN9+0W'E/&#(A 8 . 2.1ST-<O\ M&?'W3?V<O <'BG5-+NM6MI;
MZ.Q$%FRJX9T=@V6XQ\A_,5<85')4TM>Q#E!1YWL<GK/[-]_K7[6-K\4[B]TZ
MX\/IHS:7-I4\;/++F.13D$;2OSCJ>W2O;=#\.:3X7LS::-I=EI-J6W&"QMTA
M3=Z[5 &:^6(?V_+RYACFA^!_Q"EBD4.DB:>Q5E(R""%Y%?6&GW9O]/MKDQ/
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M8U_OO_WU0!/14'V-?[[_ /?5'V-?[[_]]4 3T5!]C7^^_P#WU1]C7^^__?5
M$]%0?8U_OO\ ]]4?8U_OO_WU0!/14'V-?[[_ /?5'V-?[[_]]4 3T5!]C7^^
M_P#WU1]C7^^__?5 $]%0?8U_OO\ ]]4?8U_OO_WU0!/14'V-?[[_ /?5'V-?
M[[_]]4 3T5!]C7^^_P#WU1]C7^^__?5 $]%0?8U_OO\ ]]4?8U_OO_WU0!/1
M4'V-?[[_ /?5'V-?[[_]]4 3T5!]C7^^_P#WU1]C7^^__?5 $]%0?8U_OO\
M]]4?8U_OO_WU0!/14'V-?[[_ /?5'V-?[[_]]4 3T5!]C7^^_P#WU1]C7^^_
M_?5 $]%0?8U_OO\ ]]4?8U_OO_WU0!/14'V-?[[_ /?5'V-?[[_]]4 3T5!]
MC7^^_P#WU10!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA.=%UK3]8%N0LWV"ZCG\LG. VPG&<'KZ&@#6HHHH **Y3Q/\5/"G@SQ1X?\
M#NMZW;Z=K>OR&+3+.7=ONF!4$+@8ZLO7'6K'@/XB>'/B=H;:OX8U6'5K!)Y+
M:22+(:*9#AXW5@&5@>Q X(/0@T ='1110 4444 %%%% !1110 4444 %%%%
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MD#'<>^6'%<]K7[.'BC7/VP-"\=7%M;'P;%X0;0KR07*^<)6BF1@$QDC]X.:
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M_L@_%!?'?P6\3MX!\$>$H?"&H0KJ%EH,RI<W4:-$7NII>DK,%8A,D@[LGY^
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M4$\1>+--;[1X>\ ^'UT![R/F.34)69GC5NA*+)(&QT*CU% 'UM11102%%%%
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MQR#1D?LAPZ?KWQ1\9^+X+[X=Z7>7VF6MB?"_P]U.&\B1(I)&^U7)CPOF$R;
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M(RI.!G'H* N;5%%%!(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/0<5ZO6.(E2G).DK(UHQG%>^[L****Y3<**** "BBB@ HHHH **** "BBB@
MHHHH *^>/VW/#NI^)/ACH=O::-JGB+2H==M[C6M)TW4DT\75BJ2>8DLS.FU-
MQ0\'[P7IU'T/7S]^VQX53Q)\)]/N;B_T""RT?6;;4;C3?%%VUKIVJ*H=!:RR
M Y!+2*RCD%D7/% T<W^Q[X.\/>']<UF^T'X/:M\.8[RPB<:E?^(!J45Y&7RJ
MH!-)@=6##@X/-?4M?)O[%_@+Q+X>\1ZI)XMNM!T[6_#WAS2_"4GAS1K\74\,
M</F31W%V0<*[B;Y .-N?2OK*@&%%%% @HHHH **** "N8\,_\C9XM_Z^8/\
MT0E=/7,>&?\ D;/%O_7S!_Z(2J6S)>Z.GHHHJ2@HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>I:CX>TFWO+R9K622-5AAF98QDQ[W] ?EQT/:\&W;D?]:_Y'-]82OS+^M/\
M,^[B<#)X%<SX+^)GA7XC-J0\,:]9:Z--F^SW;6,GF+%(<_+N'!Z'IGI7F_@W
M5O'_ (X_9@NYO&*W'@_QPVGW45S/';1^8I0N%E$;90%T49'0%CC'%?.OP?\
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M2ZY::.ER_EVZ7#_O)V'41H,LY'?:#BDZ]2I*+ZIW7X?Y%*E"$7Y_U^IXU8?
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MDIL&<R$$DCWR-KQ=^RGXRUW6/%MU;7.DK'JOC[3O$\'F3N"+6!7#AODX?+#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OB_P 9>+KN/XO>)M2E
MUR/PUJ.H>,K;P8NOW'EAM&TF+3UNY! TH*1O.[-\Q!R3WVBOM"O)/'WP#'B+
MQ7>>)?#^N)X>U/44A35+>\TR'4;&_,/$,DD$F,2H/E$BL#C@YP*ZL/.,)/FZ
MF%:,I)<IX%\(?B!K&MZSX8\6Z')_PFGC*3PYXB75+>-XDFO;>VO%32UN2@55
MD)4JK, 2&D]#7G?PCD\7>#?VIHKN_P#!NN1^/=2\%WU[JDFH/ S3WDDS/]H"
MH[ 6ZLB0(@^8!5XZU][^ _!__"'Z.8[F:TU#6;AS+?ZI;:?%9&\D+$AV2,8R
M <<DGCDDYK;.EV3:DNHFSMSJ"Q^2+KRE\T1YSLWXSMSSC.*Z/K48N24='I_7
MD8_5V^5MZH_/?X,^.C>>,O@!-;?$[6]?\1>(+^_N/%6D7&M/*D<JQN4$EOG$
M0'("X (4'' -:VO>*-?O?@O\9?C3HUY=:=-XL\00:9::K9[C-::);S+;B:,C
ME2?GR1TZ]>:]]\._LF10_$BV\6^*/%]WXK-B]U)8V)TVUL41YX_+D>9H$4SM
ML) 9N17L^A^#]$\,^&;?P[IFEVMIH4$1@CT](P81&<Y7:>H.3G/7)K6IBJ:D
MG%7V^Z[=ORZ$0H3LU)V_X:U_S/@K3_%OA7X;>._CIK/AWQEKWB30++PGI\<.
MLZ9JJWU\K22HF(KEPP^5I!\QSL!./N@!GP[NO$OCRY^+'@/PWXKU)8SX4M]9
MTM;/Q9+J\D5_&R-\EX A!<_+(B?*"Q'; ^][7P;X?L;62VMM"TVWMI(/LSPQ
M6<:HT62?+( P5R3\O3DUEZY\/X#X9O;#PH]IX,U22T^R6NJZ?IT+/:)NW81"
M ",Y.WIDYZU/UN+Z:Z:ORM_D/ZO+OIK^-SP+]C?QUX@^.WB7Q5\3-4NM0@T=
M;2RT*PTR:9Q )XX$>\E\O.W<92,-C."15SP+JGBG2]6_:.U?PMHUKK_CJ+Q)
M%%::?>3^4LT"6T A#,2.!&TC*,C)XR,YKVSX0_"_2_@W\/\ 3/"FDR37%O9A
MFDNK@YEN)G8O)*Y]69B?88':DL_AE::7\5+_ ,;Z=>SV4^J6*6>JZ>JJ8+UH
MC^XG;/*R(I=,@X*L 1\HK"5:#G-I:=/DU^=C6-.2C&[UZ_,\N_9>\;>)/%^L
M>)#XUU_6Y/%L4,#7/AK4-"_LRVTQ27P8.6\X,01YF\DA1TXKR/X^>)OAKXT\
M>ZK\'=.U7PYX.T:\U--8\<^(+^\BM6EE1PWV: NPWSLP&YAP@![Y%?;_ +]Z
MP+SX?>%M2NI;F[\-:/=7$K%Y)IK")W=CU))7)-*%>,:CG:WH.5)N"C<^(?BE
MXHT'PWX@_:PL->U&SM=2\1:5I<F@QW+C?J,7V1DC^SY_U@#[!\N<$9[9KL?B
MA\+8-%\$^"=5@7Q!;^.[S1[&XO8[.1C;6S:=99DOY8]O,\*,R1+N :5XL@[3
MCZXOO"NB:I=V5U>:/87=S8X^RS3VJ.]OCIY;$97\,5J=>#R*OZU\/*MM_N2_
M0GZOO=_U=O\ 4\+_ &3_ (J:9XY\)W'A_2O#UKX?LO#MK8BWBL-06^@:"X@\
MV(&4*O[X#/F*03N.<G=FO=:S]%\.Z5X;MI+?2-,L]*MY)&E>*RMTA1G/5B%
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MI+F4R"(^ZJ4!]P:PJ<KIN[3>FRMWO^AK"ZFM^N_R/7:***X3J"BBB@ HHHH
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M_@9<?_'*A?\ 9,^%CL6_X1DC/9;^Y _]&4*OCU:T*?3OT^7WC^K\./>M7_\
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M@4QOV(_A_P#P7>N1#N%NX^?_ "'4>WQSWI+_ ,#_ /M1_4<@Z8R:_P"X*_\
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MOF_]B+PWIVB?$#Q3/I7C#P_X@\_1;(ZL^C:\NHOJNJ-))-=7[H&/DJKS>0O
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MO_7S!_Z(2J6S)>Z.GHHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-GBW_KY@_P#1"5T]<QX9_P"1L\6_]?,'_HA*I;,E[HZ>BBBI*"BBB@ HHHH
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M^;[_ /VS^]GZ":9X5T71;VXO-/T>PL+NXYFN+6U2.27O\S* 3^-:M?GWX?\
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M-(UC7]+T3PUKNG7%YIEOJ6E:YX@U5;^XU/1A-+# P"JHMU#(Q$6.C Y-?8]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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C 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>p31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p31.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'G UL# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BO/;_ /:&^%^E:E<:?>_$'PU:7UO*T$UO/JD*/'(IPRL"W!!!!!KL-!\2
M:3XJT];_ $75+/5[%CA;FPN$GC)] RDBK<)15VB5*+T3-*BN5^'_ ,4O"GQ3
MLKV[\*:W;ZW;6<_V:XDMPV(Y, [3D#G!%=54N+B[-#335T%%%%(84444 %%%
M<CXP^+W@?X>WD%IXF\7:+H-W-CR[?4+Z.&1@>AVL<X]^E4HN3LD)M+5G7456
MTW4K36+&"]L+J&^LIT#Q7%M()(Y%/1E8'!'N*K>(O$ND>$=)FU/7-3L]'TZ'
M_67=].L,2^F68@4K.]@OU-*BN5\%?%7P;\2%E/A;Q3I/B Q#,B:?>1S.@]2J
MG('N1754-.+LT":>J"BBBD,***Y7P3\4O"GQ&N=8M_#6M6^KS://]FOT@#9@
MDRPVMD#NK=/2GRMIM+85U>QU5%%%(845P&L?'_X:>']6N=+U/Q[X=T_4K60P
MSVMUJ<,<D3@X*LI;((]ZZOP_XHT;Q;8"^T/5K'6;(G N-/N4GCSZ;D)%6X2B
MKM$J47HF:E%%%04%%%% !145S<Q6=O+<3.(X8D+NYZ*H&2?RKGOA_P#$GPS\
M5-#;6?"FL0:WIBS-;M<VX8*)% )7D Y 9?SI\KM>V@KJ]CIJ***0PHKQ7XU?
MM4^&O@OXQ\-^%;FRO=7U[6;FWB^SVJ;4MHII#&DLDC#'+ @*,D[3T[^U5I*G
M**4I+1[$J49-I/8**XKQ5\;/A_X&UA-*\0^--"T74GQBTOM0BBD&>A*EL@'U
M-7/%GQ2\)^!O":>)];UZSLO#\C(B:CO\R%RWW=I3.<X/2ER3TTW#FCKKL=31
M5?3]0M]6T^VOK.59[2YB6:&5>CHP!5A[$$&K%04%%%% !1110 456U#4K32;
M*:\OKJ&RLX5WRW%Q((XT7U9B< ?6N+T#X^?#7Q5K TK2/'GAW4=29MJVMOJ4
M3NY]% ;YC],U2C*2ND2Y):-G>T445)045YPW[2'PJCNFMW^(WA>.=6*,CZM
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3([@$,MHQ&" >BEQ*P]0V>]?0>].I"I*\?>6CV^1Y'NQA*"L]'JM_F>_:?\
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MUQB\OM.BEEXZ99E).,=ZVM8\*Z+X@T-M%U/2;+4-'954V%U;I) 0I!4;"-N
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MC'Q%XB^#=]8ZW8V_AO7-2M;S1;5K7,MI<[8<2S-R'&9> .V1BO4?VPO!NO\
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M8P(/!KB-1TGQE^R9^TUXY\<VG@G5_'/@;QH/.=] A,US:3E]Y5D'HQ<<X!#
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MQI]CKVF:)K&B:P8-.OO[*B*K&))O,$BJ!O9DC"[CD@\\U] _LVZ7>Z'^S_\
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M?%&O:=JW@2QT)FTK0+6S$-PEP;@)&KS8Y#,6!//W\]JY;_AISXL-\/'^)_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 56U*Q34M/NK.1F6.XB:)F7J P()'YU9HH \T_9_P#@3H_[
M._@23PMHE_>ZC9O>27IFORADW.J*1\J@8^0=NYKTNBBKE*4Y.4G=LF,5%<L=
M@HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ,$DUQXW 3KUFZ$4FE'F79L]/*LXIX3"I8J;<7*2@WJW&-O^&7W'VM17SO\
M!GXH_$2UL_%>M_%JS?0M$L+9+B!Y;+R ,D@JO=CP!MY.2/6N4L_CM\7_ (WW
MUU)\-/#UMI7A^%S&-0U *68^[,=N<<[5!QGK7F?V?5YI+F5H[N^FOF>\\ZPZ
MA"7++FE>T>7WM':]NB\V3?MO^!/%VN6%AK6GSR7OAJQ3%QI\(.8),G]\0/O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?L7^"6TO3[C4)]+MM'U&:UMXRTIBCA4.57J2 V3[ U6\4?$S0OVC/CI\'!X
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M:WJ5I'D6UQ>6BRK!(XQ@D#'7K_P(Y^N: "BBB@ HHHH **** "BBB@ HHHH
M\K^+7QR;X>^)]!\)Z)X:O/&'B_6XY)K72[:XCMD$48)9Y)9.%'!QP?NGVSBZ
M9^T%XF\1^&;Z;1/A;J]YXJTO4!8:GX=NKZ"U:W!1V$R3O^[E3*[?EYYSC&">
M9_:LD\('Q-X;7QUH.LZ=I$<$DEIX^T&659]*N"2/*(B1F 8!2"<C)Z<$C2_9
M'\8^*/%6C^+(M6U'4?$7AFQOQ#X?\0ZM:-;W-_;E26+ @%@ORX<C)W'TP #/
M\"_M:Z_XU\&ZSXO_ .%77ECX5TRSO;F34VUF!PTEO&S&+R]H?+,NW=C SGI7
M5>*OVD[;PO\ LXV7Q9?0I;BWN;>VG&EK<A67SI%0#S-N.-V>G:O,/V:_"NH>
M)/V+_%F@VT#IJ6H?VQ;012KL+.X8*.<8R2!7FGBKQY:>.OV3=#^"VDZ=K$OQ
M)466G3:))IDZ/ T4REW=RNT)A<YSWYQ@X /H'7/VH-<A^)'B+PGX>^&6I>*_
M[!M[:ZO;FQU&%'5)H5D4K$X!<_,1A22<5>_X:PT&XL_ &M6>FW$WA3Q5?-I<
MFJRR"-M,O,X6&>+!ZG(SNP ">1C/DVD_%30O@G^U=\6)_$8U#%Y8:9!9)8Z?
M-<-<R1VR;E78I /3J0/>M+P'\'[RX_8S\<V/BW29]/N]6?4?$-O8."+BT;;Y
MD''57#1*<=<-@]2* /<O#?QDC\7?&+Q)X(TO29+BS\.V\;:CK?G 1)<2<K;J
MFWYFQDDYXVD8KTBO#OV,_"L/A_X"Z)J#^=+K&OM)JVIW5UDS3W$CG+,3SP%4
M?AGN:]QH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO?W365C<W"6\MV\,;2+
M;P8\R4@$[5R0,GH,D#GK5BB@#YNU>U_:%\5V%QX@O/&GA/X-Z,B&==.DTY=4
MGMH1S_I4\CK&& ^]L^4>IZUM_!CQE\39]6L;?7K_ ,,?$SP?J D6W\:>$9%B
M^SR("=ES!O92IP5#1,<-@,O.:^?M6^(?B?\ :&U3Q)X9\.QW%UX?\26L^J0Z
M!J6KVMW<!;2ZB4O",'[&^\1G[+=!HG&]=T9R*^F?V8O 4?@OP!<WC2:D^I:]
M?/J5^NIZ3'I,D<P5(2@M(ODB 6%?NDACEMQW9H&>O4444""BBB@ HHHH Y7Q
M!_R/?A+Z7G_HM:ZJN5\0?\CWX2^EY_Z+6NJJGLB5NPHHHJ2@HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** &LBOC<H;!R,CH?6G444 %-553.U0N3
MDX'4^M.HH 2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBLW6]<AT*W669'=6[
M)CV]3[UE5JPHP=2H[) :5%<C_P +(L/^?>X_\=_QK<T37(==@:6%'15_OX]3
MZ'VKDHYAA<1-4Z4TVP-*BBBO0 **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JOJ
M%O)>6-S!%<26<LL;(EQ"%+Q$@@.NX$9'49!''2K%% 'S)I=E\:OA#JM\-/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *Y'XC?\@R+ZG^:UUU<C\1O^09%]3_ #6O&SC_ '"I\OS0F>;U
MZ1\.?^0;+]1_-J\WKTCX<_\ (-E^H_FU?#Y'_O\ #Y_DQ(ZZBBBOU$H****
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M\:?M->#=&U[QSKVKZ3<M=B>RO;^26*3;:3,NY6)!PRJ?J!7QS7T/_P $_?\
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MXL\ ^+KK4/%FK^.M/A\2W5KI7B'54V"]M$2,*\2D A=VX'.?F#8]!Y#^WO\
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M\31YGC;_ )]]!_[_ $W_ ,37544<WD'+YG*^9XV_Y]]!_P"_TW_Q-'F>-O\
MGWT'_O\ 3?\ Q-=511S>0<OF<KYGC;_GWT'_ +_3?_$T>9XV_P"??0?^_P!-
M_P#$UU5%'-Y!R^9ROF>-O^??0?\ O]-_\31YGC;_ )]]!_[_ $W_ ,37544<
MWD'+YG*^9XV_Y]]!_P"_TW_Q-'F>-O\ GWT'_O\ 3?\ Q-=511S>0<OF<KYG
MC;_GWT'_ +_3?_$T>9XV_P"??0?^_P!-_P#$UU5%'-Y!R^9ROF>-O^??0?\
MO]-_\36SHK:JUN_]K)9I/N^46;.R[<#KN YSFM&BE<=@HHHI#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ^,?&UQ^T''^T!J'AX^*_AM'8:Y!N
M\/:-KRRRI<11/,Y*0*2_G)'@R.0$.%V]#CVG]E=M>OOA_?ZOXA\?:7X_N]3U
M2:=+G0\_8+% %C^RP X(5"C'! (+?B?'_P!J7Q%>?!;]H#P_X]\.:YX,D\3Z
MWI4>@)H/BL3><%$[%)K9X@60,TI1MV <=3SCT_\ 9&\(/X5\*>,);[5]&U'Q
M%J7B:\N]:M/#R,ECIM[MC22UC# 'Y BDDCDL3SU(/H>[4444""BBB@ HHHH
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M ,G#ZS_V+=S_ .E%M7QM7V3_ ,$K_P#DX?6?^Q;N?_2BVK^B\?\ [M/^NI_
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M -&+7Y=E7^_X?_''_P!*1_9G$_\ R),=_P!>JG_I#/#J^R?^"5__ "</K/\
MV+=S_P"E%M7QM7V3_P $K_\ DX?6?^Q;N?\ THMJ_HO'_P"[3_KJ?P'A/X\?
MZZ'ZM5XK\;/^1DMO^O5/_0WKVJO%?C9_R,EM_P!>J?\ H;U\WE_\?Y'1GG^Y
MOU1YW7TCX'_Y%73_ /</_H1KYNKZ1\#_ /(JZ?\ [A_]"->AF7\->IX7#_\
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MTCX'_P"15T__ '#_ .A&O0S+^&O4\+A__>)_X?U1NT445\Z?>!1110 4444
M5M3U"#2--N[ZY8I;6L3SRL!G"JI8G'T!KYO_ .&\_!OVCR_[#UK9OV[ML73/
M7&^OH/Q9I<VM^%=9TZW*B>\LIK>,N<#<Z,HS[9-?GE_PR9\5/M>/^$6?;O\
MO?;+?'7K_K*^>S3$8RA*"PL;IWOI<_3N#\LR',*=9YQ546FN6\U#36_57/T9
MTO4H-8TRTO[9BUM=0I/$S#!*LH8''T(KY2_:0^+OQX^$/C?P]!I%SX#F\/\
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M7.&!(.02*;X,\$Z1\/\ 0UT;0K9K+3$FEFBM?-9TA,CL[+&&)V(&8X1<*HX
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)/-W@"WWACEHRQ 8@<=>R:R@@\3>$_#FL:@^A>']074;FZCTWQ1=W*7-S$L
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M6N+J3?++([&2265N[L[,S'CDGI6=XD_X1#X9^%-8U"XT:QM-+GPU[!964?\
MI6]@A+( /,SOYSG@FO&?&'[/NMAM4M_#NG0V7AY[[2K^31[*2!4OO*@FCN!Y
M<JM%NWM Y\P8?RADY -8NN_L^>)3H\=A#X9_X2#S=,LK;3;K5]1MS<:"T5T\
MTR950I#*Z &(?\LPA^4 T*G!N[GO_7<3G)*RB?4VGZ=IVAV=O86-K:Z?:Q ^
M3:V\:QH@ZG:H  ZGIZUF^&9_#5YH3-H7]FG2)II8F%FB+"\H=DD4@#!.X,#Z
MD5Y;\1?ACK>M_&32/$.G:%;WB1M8JVH7ES%)##%%,S2CRV42Q2;6;:86VN6
MD7 KSSQ'\ _%3> 8/#&G>#]-^R6]UKC(+::UC+37$A:TN09$8)&$8JVU1*I1
M<?+UF-.,DKSW*<Y)Z1V/H2"3PGHGFZ+I&E6,LVDW$$SZ5I=K$&M'F8JDWEC
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M?-G)\PK_ +W6J]G"+]Z6W]=Q<\I+2)]!V4UKK45E?W&GM:W,<D@MTOXE$\3
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M HHHH 15"C"@ 9SP*6BB@ HHHH **** "BBB@ HHHH *0* Q8 !CU..3110
MM%%% ",H;&X X.>12T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>p32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p32.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'B YL# 2(  A$! Q$!_\0
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M$N!U(1L,1[@8KMZF%2%1<T'=>1MB<+B,'4='$TW"2Z233^YZA1115G*%%%%
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MN"",X9F)QG'6O?/VA?CQ/\ ]%TC6#X.U?Q3I<]R8[^XTL _8(@/]8PQR23@
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M@.SPR%XM?W&)5^<X-X< >M7'"P4[2CHY6^5F0\1)QO&7V?QT/HOQ+^V+X_\
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MI  T*A@P.2<C&.,UW/QN^(GC'P'I^EQ^"? -WXZU?49FA41SK!;6F,'?,YZ
MY..@X.2.,^F5\D?MK_%[Q+X#\9^ -"_X2#4? GP_U=I/[9\4Z5:F6XC(.!$K
M!3L['(&?FSR%(/+3OB*RNE^/1?>=$[4:;L_Z;.E^%7[3WBS6OB3K7PT\=^!X
M?#GCVUTYM2T^"TOA):WZA<A _.PG^]DCALX(P? ?V?\ XH?%C4/VHOB[J-C\
M/;34M7N[JSM=:L9-91%TI(F:(!'/$O"G[O\ =]Z;\"K73Y_VZ/#FJZ#JGB[Q
M+X=N]!N!:Z_XN\UI;TK'(':)Y%4F('@<#G=6M\)_B?H_P#_;,^,UAXRBU"PG
M\4ZG#_9?E64DHF5YG96^4?=VRJ<CT/<8KTO9QASJ$+MQ3MKWUZW.+G<N5REH
MF^W8^_****\ ]8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBODKX\_\% _#WPT\;6/
MA+PG81>+]4%VEMJ-RMP4M;0L=OEAU!WR9SD#@8(R3D#:E1G6ERTU<SJ5(TU>
M;/K3KP>145O:06BL((8X0QR1&@7)]>*FKQ;]HC]HIO@O<>&="T7P]-XM\:>)
MKAK?2](CF$*MM*AG>0@[0"P_7D $U-.$JDN6.XY24%S2/99K>*Y51-$DH4[@
M'4'!]>>].\M=Q;:-Q&"V.<5X?\$?V@?$/C;QUK?@/QWX'N/!?B_3+9;T+%-]
MJL[F D#<DJC:#EAQDYYYRI ]RHJ0E3?+((R4U=$,EG;R*BO!&ZQMN0,@.T^H
M]#4U?)VK_MD^,O%_BCQ#9?"'X6W'CS1?#T[6]]K$EX+>.61<[EA7'S=#C!)(
MP=O(SZ]^SG\?](_:+^'_ /PD>F6DVF7-O<-9W^FW!W/;3J 2N[ W*0P(.!UY
M ((K6>'JTX\TEI^7KV(C6A-\L6>IU!<6-O>;3/;Q3[>5\Q V/IFO(?VC?VHO
M#?[.>FV"W]M<:WXBU1MNG:'8_P"NG.0-Q.#M7) S@DG@ X./'IOVO/C=X>M5
MUSQ#^SWJ-OX:QOE:UNF>YAC[LR;"1C_:5?J*=/#5:D5)+1[:I7]+BE6IQ?*S
M[%"A5"@ +C&.U)'&L:[4547T48%9/@_Q)'XQ\*Z3KL5E>:=%J-K'=):ZA%Y5
MQ$'4,%D3)VL,\BMBN9IIV9MOJ17%M#=Q^7/$DR9SMD4,/R-2*H50 , < "EH
MI#(EMH5F>58D$KC#2!1N8>A/>O'OVFOV=5_:)\*Z!HJZW_PCZZ5JL>I"5;7S
MM^U'39C<N/OYS[=*]FHK2%25.2G%ZHB45-<LMB-+>*.5Y4B19'^^ZJ 6^I[T
MYT612K*&4]F&13JIZOJUEH&E7FIZC<QV6GV<+W%Q<S-M2*-069F/8  FHW++
M8 4  8%(T:2%2RJQ4Y!(SBOCJ+]N3QI\4-6OX_@W\([_ ,8:)8R>7)K%],;>
M.0_[(P ,CD MNP1E1TKV3]GGX[ZQ\8X=;L_$/@+6/ NNZ+(D5W!?H3!(S D>
M6Y"DG R1C@%3DYKIGAJM./-)?BK_ ';F$:T)NT6>PI&D>=B*N3D[1C-(D:1@
MA450>3M&,T^BN4W(8K.""(Q1PQQQ9SL5 !GUQ4GEH7#E5WC@-CFG44 >/?$#
M]GX_$KXW^"O&^L:Z9-%\**TMEX?%M\KW1)/GM)N[$1D#;_RS'/)KV&BBKE.4
MDD^A,8J+;74BM[6&U4K!#'"I.2(U"@GUXIZQHK,RJJENI ZTZBH*(H[6&&1Y
M(X8XY)#EV50"WU/>I&4,I!&0>H-+10!&88S&$,:E!T7:,4YXTD4!T5AZ,,TZ
MJ^H/<QV%RUG''+=K$QACE8JC/@[03V!.* +%-2-(\A%5<_W1BO!_V3?VG)?V
MCM(\2C4=#C\.Z[H-ZMK=6,<YE&U@=K<@$'<DBD<_=Z\UD6_[9FF3?M92?!S^
MRT%JH-LNL_:.3>"+S#'LVXQU3.<[A73]7J\TH6UBKLQ]M#E4KZ,^D:BCM88E
M<)#&@<Y8*H&X^I]:\*_:D_:6NO@&_@[3-&T*'Q'XC\3WQM+2SFN#"H *KN.%
M).7DC ^I]*]WBW^6GF;?,P-VWIGOCVK*5.48J;6CV-(U$VXI[!)"DT9C=%>,
MC!5AD'\*/)0QA-B[!T7' K$\?^()_"7@3Q'KEM%'/<Z9IMS>Q12YV.T<3. V
M.<$KSBOFEOVQ/$@_8S7XQ_V)I?\ ;1O?LWV#]Y]FV_:_(S][=G'/7K5TZ$ZB
MO%=4OFR95E3T;\SZS90RE2 5(P01Q3(;>*VCV0QI$G7:B@#]*QO ?B";Q9X&
M\.ZW<Q1PW&I:=;7LD<6=B-)$KD+GG +=ZW:Q:L[,T4KK38:L:QYVJ%SR<#&:
M%C6/.U0N>3@8IU>0_&?XH>/? OC7P)I?A/P%-XLTG6+SR=5U",MBQCW(,Y48
M3AF;<_R_)CW%0@ZCY43*?*KL]:C@CA9VCC5&<Y8JH!8^I]:1+:&.5Y4B19'^
M\ZJ 6^IKA_%/QFT+PG\4O"'@&ZCNY=<\3)<2VAAC4Q1+"A9C(2P(S@@8!Z'I
M7"_'K]H+6/A/\6_A)X3T[3;&\L_&6HM9W<]UO\R!1+ F8]I SB5CR#T%7&C.
M;22WU_K[A2JJ*;;\CW>FJBKG:H7)R<#K3JS?$GB33/!^@:AK>LWD>GZ580M<
M7-U,<+&BC))_P')Z"LK7=D7>QH*BJQ(4 MU('6@1JK%@H#'JV.37QQ9_MO?$
M+XH75Y<_";X,:AXF\-VLC1_VK?W'D"8@\[1C:#C^$,QY&1VKW']GKXW:E\:M
M!U2;6?!.K^"-7TFY%G=V>I(?+:3&3Y;E5+8XR"HQD=<YKIJ8:I3CS27XK\C&
M->$W:+_,]4,$;3"4QJ90-HDVC<!Z9IPC56+!0&/5L<FG45RF]V-6-58L% 8]
M2!R:)(UE0HZAT;@JPR#3J* N]QD,,=O&(XHUB0=%10 /PIL]K#=!1-%'*%.0
M)%#8/KS4M% <SO>^HE(J*K%@H!;J0.M.K@O&GQFT+P-\1/!7@N^CNI=8\6/.
MEE]GC#1QB)0S-(21@'.!@'O51BY.R1+DHJ[.[=%D4JZAE88*L,@TD,,=O&(X
MHUB0=%10 /PKR3X]?%#QY\.;_P 'P^"_ 4_C6'5+XP:C)#N_T.(%<$[?N[MS
M'>WRKL.>M=%XX^,VA> ?'G@KPCJ$=U+JWBR>:&Q%NBLB>6JEFD)(P/F & >]
M7[*32:ZW_ GVB5XM['=)&L>0JA1_LC%)-#'<1F.5%D1NJN 0?PKR7]H#XH>/
M/ALWA0>"? 4_C<:E?^1?F'<?LL7RX)V_=W9;YV^5=G/45Z[4N#C%2>S*4[R:
M6Z&QQK$@1%"(. JC %!C1F#%5+#HV.:=14%78C*&4A@"#U!H50B@* H'8"N'
M^-5CJE_\.]232_&,?@(Q[9;K7I(5D-M;*<RE=Q 5BH(#'I]:\X_8XUGQ;X@\
M%^(+_7-5U;7/#,NJR?\ ",:EKZ!;^ZL ,"63 !*L1E2P!()[8K94[TW4OL9.
MI::A8]^6-%8E552W4@=:=116)H0"RMQ.9A!$)C_RTV#=^=221),A21%D0]58
M9%<-\,?C-H7Q9U+Q=::)'= ^&=5DTB[DN$54DF3[QCP3E<@\G!]J/C=\9-#^
M _P[U#Q=K_F26UN5BAM8,>9<S-]R-<\9."23T )[5I[.7-R):DNHG'F;T.\H
MKXZF_;@\<^!GT/6_B3\'[OPIX$UJ=(8-7CO1-+;AQE3)'M!SM!;:=IP#@$C%
M?84,R7$*2QL'C=0RLO0@C(-74HSI6YNOS(A4C4ORD;6-O)<"=K>)IUZ2% 6'
MXU+)&DT;)(JNC#!5AD$?2OG;XH?M/>)+#XNW/PS^&?@0^./$VGV:WVIR7%\M
MI;VJ,%8+N;JQ#IW'+@#/..[_ &??C8?C?X1N]0NO#][X7UK3;M]/U+2KP$^3
M.F,['(&]?? (((/3)<J-2,.=K3^K:!&K"4N5;GIB6\4<:(D2*B?=55 "_3TI
M1&@<N$4.>K8YI]?,'[47[;%C\!/%FD>%='TF+Q)K\[))?QM.8X[&)R FX@'Y
MVSD#L,$_>%12I3K2Y(*['.I&G'FD]#Z?IJ1I'G:BKN.3M&,THY -?,?Q<_;4
M7PW\19_AY\./!U]\2/&EL2+N"S<I;VK#&Y68*Q)7/S=%4G!;.0"G2G5=H()U
M(TU>1]-2Q)-&T<B+(C#!5AD'\*(88[>-8XD6.->BH, ?A7RYX&_:N^)$/CS1
M/#'Q&^"VL>'/[9N%MK74M,8W,*N?[_&T*!R2'R "<<5]34ZE*5)VE^=_R"%2
M-36(5'/;Q749CFB2:,]5D4,/R-245B:#?+0%3M7*C XZ"FM;Q-,LS1(TRC"R
M%1N ] :DHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*^"_V]/AEX5^%_@CP!
M:>%-"L]#M[[Q@MW<K:ICS93&WS$GG Z = .  *^]:^,OVG?@3\>_CWK$%E&?
M!%OX;T?5VU#2',]PETZC(C$WRLN=IY"XYKOP4N6JG*5D<F)CS4VDKL^S:^$?
MVIM<\0?&CX^:9I'PCT=KSQM\+TDU2[U>2<)%N;8WV1$(Q(Q(4<D9.]>F37UQ
M\)'^($GA>0_$F/0HO$'VE]B^'C*;?R,+MSYG.[.[/;&*\$\;?LZ_$_X>_'+7
MOB9\&M6T21_$D875M#\0AQ$9,@ET9>O(W=5();J#BGA7&G4=VKI:=OZL%?FG
M!66G7N4H_P#@H+IFH?"G2=4T[1(Y?B%/K%OH5YX1NIVAEAN'W!G4;2QCRN!Q
MP3M/(Y^O>W-?">L_L6_%S6?&UO\ %R3Q)X3A^*4%_#=IIEM8LFF%4&#N?;N9
M^G)7/!^;."/MG2+C5[CP[;3:C9VUIK;6X,UM#,9(%FQR%?:"5SWP#CM2Q,:*
M2]B_7_+T\PH2J._M#R'X[?&3PI^R[X(:WT31[-?$VL2,NC>'=)ME1[R[?"^8
MT<8^Z#MW-C)X49)%4_V+O@7J?P.^$\D7B%PWB?7;MM5U*-2"('=0%BR."5 Y
MQQN9@,@ U\^VO[,/[3,/Q8OOB1-K'@G4/%EP"D-U?/).MBG9+=&B*Q@#*CC.
M"><DD_57P#L?B[8:;JZ?%K4=#U*\,L9L)-%4J F#O#_(HZ[<<>M:58QIT>6$
MT[[]W_P$13;G4YI1:ML?-NJ6T.M_\%2K.+Q $DAL=(232([CE2ZVI=2H/<.T
MS#W7/45]"?M$?M"7OP#LK74%\!:UXKTIH)9[S4--P(;%4*C]ZVT[<[N"<=#6
M'^TY^RNOQNOM%\4^&];;PE\0]!(.GZP@)5U5MRQR8Y #$D,,XW-D$'%>7>+/
MAC^UC\4/"=[X*\1ZYX&MM$OXOLMYJ4*/YTT9/)P$P"<=E7\*M>RK>SE*2LE9
MIW7S1+YZ?.DG=NZ:,C]J[X[>(O%'PD^"/C?P3>7OA>\US6DEBM_M+!2>BI-L
MP)$W 94C!!/%>V_#;]GW7_ACI'C34M5^+&LZMX@UZPQ+K&H!3!ILRJY:>*)V
M*!06!P< ! .!TX3XI?L@^(]7^$OP>\&>'M4L;U_!FH1W%W=WQ: 3(#EBB@-S
MDG )].:]T_: ^&=W\8O@[XG\'6&HC2;S5+81Q739VAE=7"OCG:VW:<=F/!Z5
M,ZD.2-.F[)MWTZ7T'&$N:4YK6RMZVU/S\^+WC;0O@M:V'B?P%^T+X@\<_$6S
MU"/[=;7%U)/8WD9W%_EP4V@@?*7;@G'."/9_VA-;\4^,/VM/A+X7T3QEK7@[
M3_$WAXF[;2K@C:K?:'8JI.W>57:'QE>".@JAXD_94^-OQ ^ MG\.;[_A _#.
MGZ,D'V:/2XY3+J<L9VAYI,8C^4LQ8*2S=0 37K?BK]G?Q/K7[2WPF\?03Z>-
M$\+:1]AOHWF83-)LG7,:[<$9E7J1WKKE5I*SYDVE+MVTZ6,(TYNZM9.WYZ]3
MP?2? WB^S_:>U?X VWQ4\6+X(N+9-:FNGO-VI;1#DPI.1\BLSC=@8(4<9SG>
M^"OBSXB^ _%/[0/PPT37=2\9WGAC3GN_#DFKR?:+E9BORH"WWB=Z?+]TLG &
MXU[/:_ /Q'#^VA>?%9IK#_A&IM&%@L8E;[3YGEJO*;<8RIYW5D^&?V??'_A7
MXZ_&/QWI.I:-8OXILEBT6>??,8)ALPTL>T# VGH3VX/2LI5H25FU\*_\"NKE
MJE*+ND]W]UCP+]E_Q-X7\6^*/#?_  D/QA^(/AWXKI? ZEH^M7C+:7S^82;=
M%=2H##"[6(;D@+G%?1'_  4+O=0L?V4_%AL&=!)+:17#1]1"UQ&&'T)P#[$U
MQ.O?LZ_%[XZ>-O!=U\3X_!6DV'AF^2]EU3P^DK7^H;""$RP^13M&1D8/.. *
M^J_&G@_2OB!X3U;PWK=O]KTG4[=K:XBS@E6'4'L1P0>Q -9UJL%6A43O;5K>
MVO1Z?\ TITY.G*!Y]^R5IVE:9^S9\.H]&2-;631X)I#&!\T[KNF)]_,+Y]Z7
M]JKXMWOP1^!/B7Q7ID:R:K!'';V9=0RI-+(L:N0>H7=NQWVX[U\_^%?V=OVC
M?V>5N= ^&'C/0=>\&O*\EK:Z^A62UW$D\;3CKD[6VDY.T9->E>'_ -FWQOXV
M^%7CCPY\8?'K>)KWQ1L>.*SA MM)=#N1H,JI.&"$KA5^3U)8YRA257VLIIQO
M?K>URHRFX>S46G;Y'BNI? GQMI/[-X^,<?Q>\8'Q^FDKXBD5M0)LBAC$IA\K
MV0XY.W(^[CBL_P",7QT\8?$OP-^S)K^C^(;[PEJ_B;49[&^N--<JAE$T%NTA
MCSM<;MS!6R!NQ792_ /]I2^^&*_"&X\2>#T\%+ NGG7U68WS62X BV8QG: N
M,#CC=WKJ_B;^R#J5U9? ;1O!MQ9C2/A_J*W-Y)J$K)+.OFP2.ZA5(+,8Y&(X
M&6%=BJTU).I)-W=O2S_7H<WLYM/D32LOON>2>/?!7C7X1_M%^%OA?X>^+'BR
M71O']HO]H7NIW8N+NW*R,9'@<C$;LL9 8#(WGKQCMO@N_B#X)?MH:A\*$\7Z
MWXI\):AHO]HQ1Z]=&XEMY=H8$,>GW6'  (89&1FO3OBO\!/$?C;]J/X9?$.P
MFL$T+PW \=Y'-*RSL29#\BA2#]\=2.]/F^ WB.3]LZW^*HFL?^$;CT0Z>8O-
M;[3YFQAG9MQC)Z[JR=>$H6DUK%W];Z?,T5*4972VE^!\Y?LO_#;Q5^TYX4\;
MP^(OBKXNT_2-*UR>WL[/3KTAQ,5!WR2-EG0 KB/( (8\9KNOV5_B)XM\?_ C
MXE>$?$/CZ70-7\(WS:?'XSN-LCP09/+M(0#CRY!N+9 <<Y ->5_L@VWQK_X1
M7XAR_"J\\,&UF\0307%MKT<@E@EV+B>)UX/! VMD?*#@\UZXW["&KVO[+.N^
M [?Q+#/XUUK4DUJ_U"3>MM<3*>("<;MF.=Q&=_. .!T5W!3E"<DM5;3;N_ZW
M,:2DXJ44]G?S['B7B3XD:#\$O'W@?5?AG\;O$/Q!U6XU6.TU^PU.ZDN+6YA9
MAN894)SR!AF(R"",<^I_%IO'WCC]N2_^'_AKQWJ/A/2M3\/1_;'AD=Q#" KR
M-!'N"K*VT+O&" S<U;\;?LQ_&?XL>$?!^G:T/ OAFT\,7]M/;:/H<4JK/L&U
MY7D((0A?NHHP<G)&!7K0^ _B/_ALX_%7SK'_ (1K^Q/[/\OS6^T^9LV_<VXQ
MGONJ)5J2]ZZ<K2[/72W2Q<:<WI;2Z_X/4\6_:-\2>(/V9? GPV^$>@^+]>N)
M?$-]<'4/%!C:YU);7SEW)"H);=B7 VG/R  C<:QO ?C"_P#AQ\:/ 4?P]U?X
MG^)?#>K7BZ?X@T_QEI]S)%&KLJK<([( A!8L?3;R<$BOI/\ :D_9XO/CCI/A
M[4O#VL+X>\;>%[W[?H^HR*3&'RI*/@$@$HAR <%>A!-9/P]TS]I75/&&CS>-
M]8\&Z)X<L7W7EOHMO)//J(P1M)?A >NY2I!['I64:T'1UM?6]]+O[ON[%RIR
M532]M+?U<^:/B/XV6Z_:*\=:5\;/'/CSX>V*7?E>%I] E>#3UMPS!)6VJ2Q*
M^6=P'4ON(Q@??7PWCAC\ Z MOXBE\6P?8XRFN32+(]\I7(E++P<_YS7SW\8O
MAS^T!\1+7Q3X1DC^'NM>$M9DD2SU#4(9DN=.@<D !,$&15QAN3N&<] /<?@I
M\-(O@[\*_#?@V*\;4!I-KY+W3+M\URQ=V SP-S-@=A@5AB9PE2C9Z]EMMOMI
MZ&M&,HSE=:=_ZW/C33/$=I^RE^W3\1A?E;;PUXFT:XUN-3\JLZHUSQ[^9'<(
M/]X5YA=_#;6-+_9ATG]H+R3_ ,)K_P )D?$TUS@[S:O*(U!/7;YRJWTD-?4/
M[<7[(VN?M'W7A34_"]SI]GJVFB:UNGOY&C#V[D,N"JMDJP?CC[YKW#6O@_I6
MI? VX^&D:K'I;:)_8\3$?< BV(_U! ;ZBNKZU",837Q.REZ+3\3#ZO*4I1>R
MO;U?^1\I:?KMK^TY^WUX8U&P;[5X9\&Z#!JBE>4\V2-94Y_O"2XB!_ZXGTKG
MOB-\8I?BY^T=XV\.^*?$7CC0_!'A28V5GIO@6VE,UQ.I*-+/)&K$#*N1N'3
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MHT 7**I_VDO_ #[W'_?HT?VDO_/O<?\ ?HT 7**I_P!I+_S[W'_?HT?VDO\
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MH;(4')X(/L#S7Y^^(/!4>B?";]H76[3QGX%UJ#5-/T][O1? C.+.TE^U1[)
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MLA *F40>;@\XD&>:]3KRZB49-([H-N*;"BBBLRPHHHH **** "BBB@ HHHH
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MA/:Z1H\6I:EJQGQY$TKD0VXCQR60%\DC@=*]'KFE%QM<V4E+8****DH****
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M ]M=QZ);>9#(I5D)0'!!Z'!Z5R&@_%#X-_%?Q[H[W7A-5US4@9-$UKQ%X:,
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MZF94^\T3,H64#!.4+< GH* /7J*** "BBB@ HHHH ***;)(L4;.[!$499F.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ.:>.VB:6:18HU&6=V  ^I-
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M;7_)J_Q#_P"O%/\ T='6M+^)'U1$_A9^)>Q?[J_E7V7_ ,$K5"_M":W@ ?\
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MGP[-T="L9+9[E8XG>:YEN&$48(CB5I&8I&FYMJ+A5W' YH&.^)W_ "(.M?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK\?_ /@I-_R=/K/_ %X6?_HD5^P%?C__ ,%)O^3I]9_Z\+/_ -$BO6RO_>/D
MSS\=_!9\NK]X5^['[-/_ ";M\,?^Q:T[_P!)HZ_"=?O"OW8_9I_Y-V^&/_8M
M:=_Z31UWYO\ ##Y_H<F7;R^1Z51117S1[84444 %>'_MM?\ )J_Q#_Z\4_\
M1T=>X5X?^VU_R:O\0_\ KQ3_ -'1UK2_B1]41/X6?B97V7_P2M_Y.$UO_L6[
MC_TIMJ^-*^R_^"5O_)PFM_\ 8MW'_I3;5]CC_P#=I_UU/F\)_'C_ %T/U8HH
MHKXD^G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M35_B'_UXI_Z.CKW"O#_VVO\ DU?XA_\ 7BG_ *.CK6E_$CZHB?PL_$ROLO\
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M;030&R1%MRWF(5SO+MTSTQ7V^*QE"I1G&,M6CX"AAZL*D92CHC[MHKEO[?\
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M=-MM)M5M[2+RH5.0N2?U)JU152J3FK2DV9T\/1I/FIP2?DD@HHHK,W"BBB@
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MW_'Q%_OC^=?36@_\@/3O^O:/_P!!%?,MM_Q\1?[X_G7TUH/_ " ]._Z]H_\
MT$5V9E\,?F>7P]_$J>B+]%%%> ?;!1110 4444 %%%% !1110 4444 %%%%
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M?_HY*_(U_O*_Q?J?VY+_ )%#_P"O?_MI^J=%%%?KA_$84444 >%?##]F;_A
M_C)KWQ!OM8AU:[U;SY/LJV[Q1V4C2$(;=?,*JOD;4<$$LR[@5'RU[K110!\H
M?M_?\BWX2_Z^;C_T%*^**^U_V_O^1;\)?]?-Q_Z"E?%%?F>=?[]/Y?DC^M>
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MIL:+'&J*,*HP![4ZIE.4W>3NS2G2A1CR4U9>1^1?B3_D8-1_Z^'_ /0C7?\
M[,?_ "7;PC_U]'_T!JX#Q)_R,&H_]?#_ /H1KO\ ]F/_ )+MX1_Z^C_Z U?C
M^&_WFG_B7YG]PYI_R*<1_P!>Y_\ I+/TUHHHK]=/XC"O#_C)_P C0O\ UR'\
MA7N%9M_X=TW5)O-NK1)I.FYLUUX6LJ%3GDCR\QPD\91]E!V=[ZGS1;?\?$7^
M^/YU]-:#_P @/3O^O:/_ -!%9MIX:\.73R_9K>UF:WD,4GE2;C'( "5;!X8
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MOTP_DH**** "BBB@#\VOVN/^3@/%/UM__2:*O((_O"O8/VME)_: \4\=[?\
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M\ ?@;XJ^&/BWQ3K7B/Q$NK+KDSWZV=I=3>1:W$K_ +U-CC]Z D=N%F<[^'!
M&,^Z444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!SOQ&UBP\/?#_Q-JFJ6#ZKIEEIES<W5C''YC7$21,SQA>Y901CWKX#
M^%W@N7X=^,OAMXX\0?!U[3P5K.JV<.@1#QA+J0T:6Z'^C2I:MP<;AZE1D\$"
MOK7]J'X0^!/'_@FZ\2^.K35+VS\*:?>7ZPZ7?S6S.@C#R+B-AN)$0 STY]37
MQ5\'_#/P^T35?#VO:GX!DT;4[/Q5X?M-)L['QA=77DQWT8EBF'S;960%-T8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWC => "/E[<\UV8>48WNTGIO^/<YJT92M971C>#_ -L3Q3XBTWP+I6E^ O\
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M**]0^1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO'UMXK@WM+\EM'NS&WR?ZSYAP,CCK7M7Q\^'^N?$CP*-*T&31'N%NHYYM/\
M$5D+FQOHESF"3@M'DX(D3YAMXQG-=%65&<H+IU^Y&-.-2*D^O3\3Q?XV?M;>
M+O"_P;U'Q!HO@+5_#OB'3]5@T^\AUR"-X(%=AAT=7VS(_*!HR<-UXP3ZGI'[
M0]M>_$23P5?^&]2TG7(/# \37,5Q)$P@7<%-N2K',@)ZCY?>O%X_V,_&%U\!
M?''@V77=*TN\UC4[?4M)T>TFN;C2]*\J0-Y2/*/,VOCGY<#"X!KJ_$OP)^*&
MH?%#3/B#I6I>$[37M1\,?\(WXAMKI;B2VBR^\S6N &<CC"N5^[R>>"4<.URI
MKKW\K?J)2K7N_+]?^ :-O^V=H^J^"_ .KZ-X2US6]:\:270TSP_9^4;GR[=V
M6:1V+!0HVY'//M@X\:^%WQAEO/AK/J?B_4?&,C7?Q:.F6,-KJ+07-MN ,=O/
MECF!>0T0.,UV7A?]DWX@?#GPS\([WPUK7AV;QEX'34;2:+41/]@O+>ZED<X9
M5WAE#GMR3UXY32?V/_&=IX&L])N]=T2XU./XD1^-9KB%98XG@ &Z-5*DA]V<
M#)&/XJU7U:*:B^OZO]+$/VTK-KI^B_6YW'B#]M#PWH/B[4[ >']8O?#6D:LF
MAZIXI@$?V.TO&;;L*EM[*I.&8#CWXS9@_:VL=1\>:IHNE>"O$>LZ)I6L_P!@
M7^OZ?%'-';W8.#N@5O-\H'K)MQQ7F=U^Q'J6E_%#Q%J=AHW@'Q1X>UW5VU5K
MCQ3;W37]B)'W2PQB(A'7KM+$8SDYK1\7?LH^//$OQ:C\00ZGX7TQ8];74H_%
MFFPS6>MK:AL_8WCB AFX 7S'))QR.U9\F%Z/I_7]?@R^:OVZ_P!?U^)[]\7O
MBM9_![P_IVLZCI]S>V%SJ=MILTEL5'V;SGV"5]Q'RAL XY^85YSJG[97A2S_
M .$VAM-.OM2O_#&O6OAY[.!H]]W<3R&-3'EL8#)(.?[GO7H/QX^&;?&#X1^)
MO",4T=M=:C;8M;B;.R*=&$D3G ) #HI.!G%?/_AG]AN\T'QA\)]:?6;25=!
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M_P 0KRXM(M,U/1KR.T@U"*WU6)$:XM)MPBG38[#:2C @X92,,HR* -#XG?\
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M&V[1Q]:Z(XR$IU().\-_QV^X\:MPUBL/A\'B:DXJ.)ORW=K6Y7[U]%=25O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 55_LNRWW;_8[??> "Y;RES, -H#\?-QQSVJU7R5KGQ2\
M0>!_VH/$>KZEXBNAX"L=2L-%OM.GE)M;1;JQ\R.X"]%Q+'@G_;]ZY,1B(X=1
M<UHW;TT>I]%DN45\XE7AAYVE3@YVU]ZTHI15NK;5O,^H;GPKHMYIT&GW&D6$
M]A;D&&UDMD:*,CIM4C _"I[S1=/U+[-]KL;:Z^RN)(/.A5_*<=&3(^4CU%?)
MOP?^,'B*S\<>-_%WBW6;Z3P_=>%F\56>D3RL8K.W:YE6!$3H&:*-.G4O2?LV
M?&:_U+6/$>A:GXW_ .$KOM6\/+XCMY$N?,&FW)#BXLUY^79NC(4< *:X89A1
MFX+EMS7[=-OOZ'U&)X/S+#PKU%5YE146[<V\_B2=K>[]IZ76USZO7P[I2ZLV
MJ+IEFNIL-IO1;IYQ&,8WXW8_&K-EI]KIL/DVEM#:P[F?RX8PB[F.6.!W)))^
MM?%'[-/CSQ3K7BGPK$?$/BV7[3X=O-1UJ/Q5=B2"\Q\L,FGAB6PK_>(QP*9I
M/CWXAZEX3^#.IZ3XBU2]U2+0=2UR\LI+AF&L?9[B,M#+_?+1%U4GH<8J(9G3
ME!34'K_G'_Y+\#JQ/!&,IXB6%GBH^[97=[?#5:OV7[IV[*2>FJ7VK#HFG6[7
MK16%K&UZ<W3)"H,_!'S\?-P3U]:IQ^#?#\=G-9IH6FI:3*JR6ZV<8C=5)*AE
MQ@@$G&>F37R'XX^+&N>)/#/BW4/#_B+6KFQO/'.DVE@-)OC#<-:3VL3&"!R<
M1EBWT#'GO7TW\&-+O=)\#Q1ZA%XC@NI)Y)&A\4ZBE]>)S@ RHQ7:0,@ \9-=
M-'%0Q%1PC'1=?FU^)X69Y'BLGPD<36K^])I<NS^&,M4W?W;I;:-;K0ZB[\-:
M1?Z?!8W6E65S8P$&*VFMT:./'3:I&!CVI;SPYI.H7MM>76EV5S=VW$%Q-;H\
MD7^ZQ&5_"O*OCY\7O$WPPU#1%TK3M/M]%N5D>]\0:S#<RV=LP*A(G-NI:+=D
M_O'&T8KFO&O[0GC*QN/'.K>'-'T&Z\+>"6B34A?W,HN[TF))'-N5&Q0%<8+
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M9\G#.0,G '&/*K7PW\2-8O--N;R[\3:6#+I-O-;QZBC!;=HG%ZS%0 SYVY<
M,#@K@Y-5[@?%2"?PA$+;7I9K-K=);A9D>.:,:@R2_:%#JNX6H1MS!RV_*A6!
M)IQE+1S)3BM>4];^&?A#3/"%O=P:5XDN]>BN'-Y+]JF@F=GE8L9F>.-68M@@
M%B1A0!P*MW/PQTBZ74 [W6+[6;?7)<2#_CXA\G8!QPG[A,CZ\\UY5X \%^*_
M"_@/Q:D&G76G:S)X2LK2P,;()/M<4-T-JG.-RLZ=>,D59CM/'O@_5@R+XBUS
M1+>]5O+,Z7%Q*LNG%6Y9AN1;G!P3\I.1\O2'%\SM(I2T5XG;:Q\#/#FMMJ33
MR7R?;YKV:413!0&NK=()MOR\?*@(]&)//2M;Q-X.LO%>LZ5/%K=YIFKZ&':)
M]/DB,BK,FP^8LB.,$*<<#D'%>0Z+X1^(^J2:++JNI^);-GGTVUO4AOE11;'3
M1]K; /#?:1@N/F!^Z0"36?HOA_X@VWB?3-2GM/$*:]<VFBP27B31"SD\FXG%
MW]L ;YCY#<'!RS#;@U7(_P"?87,OY3V*/X2V":T-1_M?6 LES!?7=FEPL<%Y
M=1*JK-(JH#N.R,LJE48HN5/.7WGP?\/:E#<6]]%+?V5QK+:Y<65T5D@FG*;0
MKH5PR A6"G^)0>U>0>'?#OQ5U.:"#6]3URU$VIVRZF+67R]JA[@RR02[L+$5
M\I=J   *>&W5V7B6S\;3?%5?LAUD:>U[9BVDMYT73EL/+Q=B9<[O.+;]IP3D
MQ;2 &I.,D[<XU)-7Y39TKX>^$/$7@W4]%\.ZB8]"DU.69H]+>)H()@P\V!4*
M-&8]X8M&RL-S-[8(_@+H-OI\EE!J&KPQ/865CN%TK.IM)C+;SAF4GS59C_LD
M8!7 KSB/2]6\ _"?X6>'[@^([26?4IH+^STJZ)OW7[-=R!%;=G 94;"GHM0R
M6OQ8OM6\+6E_;:VA:TL[?4;B"Y3[/)&\4JW#2;754D4M&"0K-N&Y2HJN66MI
MZ$\RZQU.ZO/V??#-^L^FG7]:6\GCG>_:.\B$]Y#/<&9A*/+^[YH?:5"XRPSC
MBMKPK\*X=/\ $GCW6-5AM9&\43"-K6W=FC2U6+RP"2!AY,L[A>,D<G&3Y9;:
M+\1]-\ Z#9:3;ZU:Q6NAZ1;WMO<SDW.^.>87JHP<MO*B+E3G9C:<XK3T'PW\
M2%O;"]O]4UVY>UFT>-%\T0PS6[RNMX98LG+K$R[B3G<H8<YH:E9^^":NO=.M
M7]G/0_LGE2:WKMS*LEHT-Q<7$4C1+;)*D*!3%L90LSCYU8YPV=P!JAJ7P/\
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MS*REQPV<#'!^#]#\=:?=2W$]MK46I7^MZ;?W[R3JT+0G2U28("Q5=MPC!E
MX3JN*H^%_#WC>\N/"UQKMMXHN8]+\26\SSW%V$DDC:TFCDD>$2'"+*T6\!V3
M#,4 7(HM);3V"Z?V3T%_@3X/U[2_#C032SQ:1;R6MM=*8+CSH'<,\;>9&ZD;
ME'*@,,'!'-=%XJ^%NC^,+R_N;V2[CDO=.33)/L\H4")9O-!7@X;=W].U>8>%
M[/Q_'JFA_P!O+XH>86UO]G-A/"+=)!+,;G[8&.&RGE8R#QC9ALT>%;7XD1_#
MKQ=!(NO-JN;;[+<WT\8NIAN'VH0HS,L<FP'!#F,N04"@&I<97^/;]6--?RG:
MWGP#\/:A'JD,]YJDEG>6]Y;PVOVA=E@+IQ).T'R9!9P#\Y8#H  2*N^)/AGH
MWQ NM*FO-8O[I]&D1"+>XC^::-T?+X3,<F5&3'L)#%3P<5YC<>'_ (B:KIUY
M]GN_%%E9V]CK%QI"27BI=M*/LQLDN3D[R7%QM5B?D(#^E5-5L_&/A_7$LK"Z
MFTF[\6>(;RR>VCE59%@EC@E;4(U!/,2P3)GMYH]JKEE?X]1<R_E.X\1_L_\
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M'++6].B2V$0M[J[E:**U&#\Z;S'AF^;AB2>WKM]X%\/ZEXDM?$%UI-M/K-J
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? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>p33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p33.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!U0.$ P$1  (1 0,1 ?_$ ,4  0 !!0$!
M       % @,$!@<( 0$!  (# 0$               $" P0%!@<0  $# P(#
M! ,,!P8$ P<#!0(! P0 $042!B$3!S%!(A1183)QL=&2(U-SLW05%C:!D4*R
M,S4(H5)R-%0WP6(D%X)#5>'2TY2T)1BB=5;P\<*3.!$  @$" P8$ P<$ 04!
M  (#  $"$0,A$@0Q05%Q$P5A(C(S@7(T\)&AL<$4!M%"4K(CX6*"<Q7QXD-C
M)!;_V@ , P$  A$#$0 _ /5- * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0'GSJ*4C:?65W>.X\
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MX46ZIWWK$]7=R*YE64W[?\?[>]2])U;G6JZ8+*M]'Q=-NQ&!UEW!G<A#VH]
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MI9$ ]:E?B2)^F]UK!'47(S4;B7FX'4N]FT5_37+VDG-RLXR4Z8KBJ&KRLEU
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M2LSN*W!)4;>TQ*#G)MX&/U!Z7979D[ [SVU*R^X9^,FMI+8E.+,>\NMU5 T
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M54K>N6[4'1U-6$YRV4-]Z2]3)F\6LI R\$<=N'!O(QD8S:JK:JJD*$%[JGB
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@([(;DV]CCY<_)1HSGS;KH"7Q
M56]9(VI2V)F&>HMP]4DOB7,=G,-DK_=\YB7I]I&7 -4]U!5:B5N4=JH6MWH3
M]+3,VJ&04 H#&7*8U%5%ELHJ<%17 [?UU;*^!3J1XHJ:R$!TT!J2TX:]@B8J
MOZD6H<62IQ>\OU!84 H!0$/(W?MN/G&L$].;#*/(B@PM^U>P5*VE"7N15NM8
M7?@I96_,;L.W7Y67>47TUO,W*Y;'8F [/R+XQXK*7-PO[$1$XJJ]R)5YS4%5
M[#!I]/.]-0@JR9\Q&8QN8@-S\<^,B*[[#@W[4[45%LJ*GH6ENY&:JMA.HTUR
MS-PFJ21F5<P"@% * 4 H#5NI>^@V1M9W/G#6>+;K3/EQ<1I5YI:;ZE$NSW*R
MVK>>5"ER>55-E:?$XP/E8!($-;KP1%2_%?56.A<Y6?7#+36IV4VWM"7F=KXT
MS"1EQ>;94T:_B&PR2*1B/;\%;/[=+!RHS!UGM2P)23UFQ"+M&7#B%)PF['EC
M-Y%31M8SZ*@\MUNQ<=2V]KN6J*P\>,2W56'!DMNGJ"&%W=MW:\>"4Z?GS.ZB
MX@)'9;MJ=)-):DMJX<.RJPM5BY<"93HTN)%;YZRXK:>\<3MN1#*1Y_E%,F"X
M@C%!YWE 1CI6]UX]J<*M;L.46R)W5%T)[=VXMV8E^,&#VRYGVW1(GW0E,QN4
M2*B"*HZGBU7[JI",7M="TI-;%4@M@]4\INK<^4P,G;IXPL.%I\GS+<@ ?4D0
M6;MB@J2^)>!<+5>[948IUK4K"XY.E#Y$ZRXJ3U1>V(,,AY:FR&45Q.6<EMI'
M39T:>U.*>UVI1V'DS!75FRDWO#?</;Q)'%H9,U6T?>1UT8\>.PI\M'I+Y(2-
MB1^$$05(E[$X+:ENWF+2G0Q=O=16LA*C,3F8[;,YQ6(&2@2AFPG'Q'6L<G$%
MHVGM/$1,/%W+?A5I6J;"(W*FY5A,@H!0"@% * 4 H!0"@-19Z@!_W+?V/*@E
M'<\DDZ#.5Q"&0-T0A0-***BNKO7LK+TO)F,>?S91CNH Y#J-DMFQ8*FWB8H2
M)N3YB:!<=TJ+*-Z>VQ?WO31VJ04N(4ZRH;+%RF,ENN,Q9;$AYG^*VTX!D'^)
M!553]-8VFBZ:/BY7%I-2"LQA)R\4BJX'-7O]B^K^RF5TJ*HJF9+'01$ILIF*
M)KI!7G!;0E]":E2]$F]@;H7'I,9A@I#[H-,"FHGC)!!$]*DO"HH26?O;%^2\
M]YQCR2]DKF!RN*V]N^GM]=3E=:$516QD(#[[D=B2TZ^S;G- 8D87[-0HMT_3
M2C%2A<IC$FI!68PDU4ND57 YMNWV+ZO[*4>T51K>[^H</ R5A,MM/2FQ;.6_
M)?&+$C"\JHTCSZBXNMU170V($2VOP3C62%K-B4E.@VQO]O*RV(4UAEAV:)EC
M9D.2,V%*Y27=!M\1;5'03BH&"+;BE[+9.U3$1G4VZL1D% * 4 H!0"@% * 4
M H!0$;N;-)@]NY+,JRLA,=&=DJPA:5/E"I:=5EM>WHJT(YFD1)T530,)U5W]
MFL9%RF-V \_CY@HY'?3(QAU JVOI(4+N[TK/*S%.CE^!B5R354CHCF;P[7,Y
MTZ.TK)"V\AO-IH,O9 KKP)>Y%K7RLRU1?DS(<5A9$I]MB./:\Z8@"7_YB5$H
ME4FI;+*XL(8S2F,##*VF2K@(TMULECOI_MIE>PBJ*F<A ?D.QF9+3LEBW.8
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M)#9<:'2T*(B:01+:1X)P[*PQN26*9E<$]J+3O3O8SK,UES"1%9R)M.3FD;1
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M<F;F0WG(S@<\VE425H$4;((MBE[+5I:FUTW"*92WH-0[T;DW%T.N5S3NB@%
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M-15?<_525O3UKF?(B%_6TRY%7B6MI].]T8?J0&8FGYV,XP92\BIBFN0\'C1
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MB9QP<AN#)/#+?)0PN-E#>QP,5J9;,57N=/42KWU;4R54ES^\K96]G6*U3.*
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M@8R,X*XO,MQ\SN&(G%=6(,A8(D3L%XC ?7IJT)TMM[U@OB5E&LZ?; [%6H;
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H#"S6&QV:QC^,R+9.PI*(+S8F;:DB*A6U-J))Q3N6IC)IU1#550NX['0<;
M8@0& C0HH"U'8;32  *61$2C;;JPE0R*@D4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * B<SM7 9J7 E96(DMW&N<Z&AD?+!RZ*AJVBH!JBBBIJ1;=U6C-K9O*
MN*>TEJJ6% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!%8G:N Q.1R&2@
M1$:GY0^9.E$1N..+=51-1J6D44EL(V1/15I3;5'N*J*6)*U4L* 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@/CABV!&5]((I+9%5;)
MQ[$XK0$*.\L >'9RS;SCL20\<:.(,/$^X\V9@;8L('-4D5LKII[$5>R@)/'9
M&%DH+$^$ZCT20".,NI=+BOJ6RHOI1>*4!D4 H!0"@(C+;OVSB);<3)9)B+)<
M1%%IPN-E6R*5O93UK6*=^$'23HS=T_;K]Z+E;@Y11+"0D*$*H0DEQ).**B]Z
M5E--JA]H0* 4 H!0"@,')YW$8MR*U/E!'<FN(S$ KW<<6WA%$1?35)W(QI5[
M38L:6Y=4G"-5%5?@C.JYKB@% * 4 H!0"@% * 4 H!0"@% 1T+<>"G92;BH<
M]F1DL;I\_$;-"<9U\1UHG9>@)&@% * 4 H!0"@% * 4 H!0"@% 6I4R)$:5Z
M4^W'91417'2$!NO8ER5$H"X!@X F!(8$B*)"MT5%[%14H#[0"@% * 4 H!0"
M@+9R(X.@R;H"\[?EMJ2(16[=*+Q6U 7* 4 H!0"@% * 4 H!0"@% * L1Y\&
M0ZXU'DM/.LK9YMLQ(@7T$B*JI^F@+] * 4 H!0"@% * H>?98:)U]P6F@XDX
M:H(I[JKPH"L2$A0A5%%4NBIQ146@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4!I3>U\[#QN.=8;9D3\9EY^1&*3JM@ZU,
M<E(@\S06DD;E(7LVNEO70$[M'#R</MZ) E$!R0YCCZMW4$<?=)XA%5LJH*N6
M1;<: S4FDN6*#I32+ O:[\;J:C:WZ*FF!%<3+J"10"@.=[Y^YRG3<#BF&2W'
MN)L R<MTKA'B@EN:YJ6R6'V!'M7C7/U.6KC'USV^"/2]JZJA&]<;Z-E^5+^Z
M7!?JS'GN2F]Q1]OM9I_'8O$849,1UEP 62ZVNA",B0D,40>(U63>=0S4C&/W
MF2THNP[SMJ=RY>HZI^5/'#AS-EZ9SYN0V/BYDYXY$IX#5UYQ=1$J.FG%?<2M
MG1R<K2;VG+[W9A;U<XP5(JF'P1L];)RA0"@% * XEO*?D9&X(V6R6)GMNL96
M.SC )JS7E6B55%M=7B>?--7N(B7KC:B3<U*2?J5.7]6>\[;9A&R[=N<&G:DY
M8XYGQX1BL#.W-F\F\[O&:>9DXV3AQ::Q>/;=1D5!P$52)M?;(E7M3LJ]ZY)Y
MWF:<=B-?0Z6W%:>"MQG&Y5RDU78^.ZAU+!N..X7'NN$IN'&9(S);JI*VBJJK
MZZZ=MUBN1Y+512NS2V9G^9FU<P"@% * 4 H!0"@% * 4 H#6^HNX\IM[9^0R
M>)@/9+* "-PHK#9/%SG50!,@!%)0!5U%ZDH#SUL7<9[3RO423B8V1>R;>$:F
M^9R$5QMPIC;9./OR0/\ A\QUQ3 2[4H2;CL[+[EB[_Z?P7=V3,Y#SV)E9+(L
M/&T0<\F-:(/+$5T"7LB5[*BT!WBA H!0"@% * 4 H!0"@% * 4!SOJ[BMB-L
MPMS[QYLZ+B4<:@8%=+C$N5)32 I'455UY;6#CP[:$FD85W?VQ]E;+VA'>:QV
M=W3DWQ Y ^9#&12N_P @0)40S 51+*MKW2@-YZ4;IW3F<CN_'[@DLRGL#E/(
M1W8[/(!0!H54M-S7Q%QXJMJ Z%0@4 H!0"@% 6Y4EB+&=DOEH88 G'36ZZ0!
M-1+P]")0'EW'=0,/N'K7M/=TO*@@RI$R+'QWBM!BZ.3"!SA_%DN.$96[+HG=
M0DV2?U5ZF.X&3NZ)/AQL0[N(,)%Q*Q4-UM@9"-$ZKREQ,[*BHH\+\+4!Z"H0
M* 4 H!0"@% * 4 H!0&-E(/G\;*@J^[&24R;*R&%076T<%1U-DJ+8DO=%M0'
M#=F;9V]'ZD19NQ8RM;;V9!DQ,]FQ[<G+,?X&M$1'S:7QFY;@O#T4)/F'ZF]3
M)4+9>XI&0A)BMXYL8B8MN*B.1HO,,="/J:ZE) \2J-TX66@.^4(% * 4 H!0
M"@/.']2V]X&5'+;-3(I#:P\0)<B/Q1R=/<45CQ@X6Y;39*Z?KTIW4)1M$??N
MY<SFL#MW9N2B1($?;P9F5.?CK(21H+D#' 5)M1'4"ZB3C0&Y]&]T9C=/3K%9
MS,&#F1E\]7C;!&Q\#Y@-A3T"*4(9NE * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H"+'\SN?8@^M*K;BN\E*J6% * B)^S
M]JY"4<N=B8LF2[;F/.M 9EI1!2ZJG<B6K%*Q"3JTFS=M=QU%N*C"<HQ6Y,AM
MU;'=R34*/BV\;'C0VR:;;E0T?5I%["95"'3I]%K5AO:;-11RT7%?D;N@[HK3
ME*X[CE)U\LZ5^;B3NV<$Q@<%#Q#+A.MQ T<TDLI*JJ1%9.RY*M9[-M0BHK<<
M_7:MZB]*ZU3,R3K(:HH!0"@% 6)<"%,1I);#;Z,."\SS!0M#@^R8W[%3TU64
M4]IDMW9PKE;551\C4=X=/Y>XL@X:RH;$1]L6G#6$#DP 3VD;D*2*FKW.%:M_
M2NX]JIRQ^\[/;N[QTT$LLW).OK:C\8FXQ8[<:,S&:NC3 "VVB\5T@FE/[$K;
MBJ*AQ;DW*3D]K=2Y4E!0"@% * 4 H!0"@% * 4 H")<VSB!E93(Q8;#>6RS"
M,3)9AKYHM@H-HZ*KXQ%%[/10'.-@=$YN#WE&W-DBQ,9<>P\S#A8.*Y&;<.0F
MDWGU=-PKZ> BG!.ZA-3KM"!0"@% * 4 H!0"@% * 4 H#4MZ],-L[RFX^;F"
MEC(Q>I81Q9+D?ED:HJFG+5/'X4\7;0&O;OZ5QPV>SC,/!DY^5&R SHY3\K(8
MELEHTDY'FDCI@262P^SV]]"3*Z,;!R^T\=F'LNC;,W-SRFK":><E(P&A $"D
M.^-T^%R):!G1*$"@% * 4 H J(J67BB]J4!!9'9.WLAN'$9^0PJ9'"<[R! 6
M@$YXH)Z@3@7!.%^R@.0[BZ+9_+;N<;@8AC#X1W,-Y-_(#DWW63%L]9&WC=(M
M@^[V$M[)W4)J=[H0* 4 H!0"@% * 4 H!0&-D\>QD<=*Q\A3%B6T;#I-$H&@
M."HEI,>(K9>"I0&E[8Z*[0VU+B/XF1E&FX1*;,(I\@HMR14+4PI<LD75QNE
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MU\N'R:.M*]R]?-(%M9!U77V: WI+V2_%>]: 4 H!0"@% * 4 H!0"@% * 4
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4!HO7+_:;<OV9/K0K-I_<1BO>EGB>NP<X]*?TD?R?<GVJ/\ 5%7/UNU&YI=C
M._5HFT* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@-"ZU8MS);+1@7(JM-S(S\B!-DI#8G--'K.&3ZJB#S$3A[E C1N
MB#4YK-0"R18[$,8S&/8F!C6<A&E2)2O2_,H2@R9((-#X12]^*K0EG=J$"@%
M* A=RY>?"+&P\<C7GLI*\LR[(0B:;067'S,@ @(O"RJ(B$G%>V@+NU<R[FL#
M%R+S0LONZP?;!5(4<9<)IS2JV73J!;7[J ^C^9W/L0?6E5MQ7>2E5+"@% 0V
MX9,ACD<EPF]6K5I6U[6KE=RNRAERNFT$/]Y9'_4.?KKE_NKO^3(-IQYF<%@S
M52(@%2)>U5M7HM-)NW%O;0DR*S@4 H!0"@(3<_\ #C_XB]Y*Y'=MD?B" KBD
M&Y8__(1_HQ]Y*]5IO;CR1)D5G H!0"@% * 4 H!0"@% :#UY_P!H]Q_0M?\
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M\$(D6Z\;]M<76ZN["Y2,J(][V#M.EO:53N04I9GCC_4U6+N?<)RF +(.J).
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MOZZ B=G[0WM^+W=V;QD8SSX05QL.+AVW1;Y1N"Z9O./>,RN"(*=B<: W^@%
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M?KJVO2N1YO4>Y+F5[?\ YU#^D_X+47O0R=+[L>9T>N6>C% * 4 H!0"@% *
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M7,^L=F^DM_*4;!_.^#^V->_4:7W8\RW=_I+GR,]/G$B..<UQELW4TKK(44O
MJJ'%4OX5553T5Z8^2EV@% <US7\XF_3'[]=6UZ5R/-ZCW)<RO;_\ZA_2?\%J
M+WH9.E]V/,Z/7+/1B@% * 4 H!0"@% <&WSTXWKDMWY6?"QA/1)#R&RZCC(Z
MAT"E[$:+VI7#U.DN2N-I8'T+M7>M+:TT(3G226.#X\C[L3ISO3&[OQ<^=C29
MB1W5)YU7&2THK9)>PFJ]JTTVDN1N)M8#NO>=+=TTX0G636&#XKP.\5W#YZ*
M4 H!0"@/+O4/\\YS[6?O)7FM5[LN9]8[/]);^4IV!^=\']L;]^HTONQYD]W^
MDN_(SU)7ICY,* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@.==7LIO^!'@G@8V+<P*N#]^/95T6VD;5510>Y@J L$GMDGB1;6H28O3
M*%NJ+N29'F,;=PF,CQ1)W X%1)PWWR0FI+_@ Q'EB2#W+>@.GT(% * PY;L[
MS3,=N)S8;R&DF4CW+)KAPL*)J*_I14M0'.V5:;VOB(^2D.-X),[D6,F\\^XB
M)';?F(P+SY%KT<T6TN16[$6A)N'3]V8[M#''+)PW%$^4;UU<)A'21@B4O$JJ
MSH6Z\5[Z$&8/YG<^Q!]:56W%=YPOK5^?I'V9C]U:\[W#W7R1],_C'T:^:1I4
M/_.1_I6_WTK3CM1W;GI?)GKVO6'Q@4 H#F&0_F$KZ9S]]:ZT/2N1YB[ZWS9)
M[0_G8?1G[R5BU/H-G0>[\&;Y7..\>9^JG^X&8^D;^H"O.:WW9'U/L/T5OD_]
MF:7D_P"6R_H7/W5J-'[T/F7YFQW3Z6[_ .N7^K.<U]"/AR.^_P!)'\YW+]FB
M_ONUHZW8C:TNUGI6N>;ARHO;+W5]^NPCRK)O9O\ .D^B/WTK!J?0;O;_ '?@
M;U7..Z* 4 H!0"@% * 4!Y4WA^;<W]ND_6E7E[_N2YL^O=N^FM_)'\B2Z6?[
M@8;Z1SZDZRZ+W8FIW[Z.YR7^R/3->C/E@H!0"@% * 4 H!0"@% * 4 H#S;O
M':6ZI&[<R^QAYKK#LU\VG08<(2$C54(51+*BUYW46)NY)J+V\#ZAVWN&GCIK
M:=R":A'^Y<#*Z>[5W/$WMB),K$S&([3RJX\XPX("G+)+J2I9.VK:6S-7(MQ9
MA[QK]//2W(QN0<FMBDN*/1%>@/FHH!0"@% * \O=1/SUG/M1>\E>:U7NRYGU
MCLWTEOY2C8/YWP?VQKWZC2^['F6[O])<^1GJ2O3'R44 H#FN:_G$WZ8_?KJV
MO2N1YO4>Y+F5[?\ YU#^D_X+47O0R=+[L>9T>N6>C% * 4 H!0"@% * C-SY
M=</M[(91$0BB,DZ(KJ74J)P%-(F5R7@GA7C0$)TOS^XLYM9J3GXR1<BP2Q9
M$ORRO,(@/*\" V#9*XBJ@AJ&UN- ;=0"@% * 4 H#R[U#_/.<^UG[R5YK5>[
M+F?6.S_26_E*=@?G?!_;&_?J-+[L>9/=_I+OR,]25Z8^3"@% * 4 H!0"@%
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ME>W_ .=0_I/^"U%[T,G2^['F='KEGHQ0"@% * 4 H!0"@% * 4 H!0"@% *
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MN?\ 3DVJ(RC97=)1;0 4"YKIH5R*]D7AV(!N- * 4 H!0"@% * 4 H!0"@%
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M1J_0K/XC)9R%'Q47'2'F<.^6=R<&$S&()7G-+(JZT I\LRFKEIV:46@9W6A
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MKR]_W)<V?7NW?36_DC^1)=+/]P,-](Y]2=9=%[L34[]]'<Y+_9'IFO1GRP4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0'(=T=%LWE]Q9#*,Y&,TU,>5T
M&S%Q2%%1$LMN'=7)O=OE.;DFL3V>A_DUJS8A;<)-Q5-Q3MOHIG,3N#'9-[(Q
MG&H;X/&V N(1(*]B7X4L]OE&:E58$ZW^3VKUF=M0DG*--QV"NL>+% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@-=WUOS [)PHY?-*ZL<W1CM-L
M!S'#<)%)$%%44]D57BM9+=MS=$4G-156:OM#^H#8FZ<_&P4%N:Q-EZDCK)9
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MGU)UET7NQ-3OWT=SDO\ 9'IFO1GRP4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0$3N?;.,W+BUQ64UGCW'
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M]Z;33LQM*<K5J<IMRIF>94P2=,%XXLL;BZ;[CR^3#+/!!DR9< (61A'*G1V
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M?&NPM=[#=A-1S1:\U7C2.3UYL-WA6NXVP5511532JIQ'T>JMDXC/M"!0"@%
M* 4 H"S*F1HC7.DN(TW>VHO2O=5HQ;=$4G<C!5DZ(L1<WBI3R,L21-U>P.**
MMO1=*M*U)*K1CAJ;<G1/$S:QF<4 H!0%+CC;39..$@-@BD9DMD1$2ZJJKZ*
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M\:F(WL/<C.8=S2L/R6QW.[-7"F\'EG(CBH@3 #4B(ZVJZDU+W=E56GFI9O\
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * A9^1W UN3'
MPXL 7L0^#BS9RFJ*T2<033I6]]*_\;=]TE1\2K;J1,S?3^/R.3C.PG)B1'7B
M;1A6P48\:+'?=(U<,=17D+:U65NJ15SH6<IO]P92^3CN#C&1FH]-5 53.)%5
MY4:!31;B7#Q)9;+4JU]X<R2+>C0MS9'D7R@0N:WYY29!LWF%0#;\1BH^-=(J
M7!51?5>O3)SD<WU,C\R0^]"-G'1(;\F2\I"K@O1Y"QR:$$[4(D\)7]VU6Z1'
M4,AKJ)#<\JGD7D5]\XSAZV>4!@8!87E-&W%7F(2("W5+]Z6J.D.H7LGON+CY
M$UIV&[IBRF8+;Q&R#;LEYH7D!"(TT(+97(CLGHO4*W4ESH6$ZD8\D%Q(4@63
MAE.$W.6VI(#)O$ "1HIZ4;424+HB^KC4])D=0HS>^GHKRC"C<Q8XNF^T[8>9
M;'G,;$"1?#Q%$)52D;==OVQ#F9T3>*.Y''8Y^"XP_.8:>5Q2;1M"=;4] :B$
MG=.FQ*"+;A4.W@V2IF%-ZDP8;'.>@OBAO2VHXJ;(JZ$ E%]P+G_>2P OB)>Q
M*E6FR'<*W^H^,9GNPTC/.'[,105M><[K::Y?M?)EKD"GCM;C>UJ*TZ#J(^%O
M6>QF58EXQYF&+43GHJM<QAV3*=C:B5#^4 E$%30G9Q]5.FJ;1GQ*(O4W&3'>
M3#AO2'GG ;@@!-?+:C<&ZKJLUI1DB47++IM[E'9:"N(N,;V>C[2QV:GQ#=>F
M*0N@UH;;;5-:_*&X6@$L&FZE92LE';\S2&?"I4N^7&V\DZ_CU0(LQN'#07FM
M3W,CA(OXB1$5!/L2_OTZ>S$G.6L=OS[Q=4QC&Q".3 :AO> C=&<P+WC!5\&G
M59;7H[=/Q(4ZE47?SDU_'MQ<:X*2IPPY O.-BXR),./(1-B1$)IRO$!(B^[1
MVJ5Q"F7L1O4)J,"S$D2&T;;<FS/D@1GG:E#6.OCP"Y*-T1%3UVB5NA*G4Q\7
MOS[VS$"'%85@'7#&4+BB:J"QE?9)LVR(>-N/;_QJ7;HB%.K+@;\BO.$!1WX:
M,RVX[B.(TIZ3YB7-O5S&T^15>(]EK7[G3&<I9ZA(\C(!B)7F)7EBALJ;"*XW
M,!YQHU7F6'PQRU(O%*=+Q&?P,29O>7-&$F(%UOSLC' XIBTA,M2U=4].I3$C
M^145NBIZ+U*MTV^)#GP)+%[R2:XTRQ#D2D2Q3)*(T", X^XTVI#KN2?(DJZ;
MV'BM5=NA93,1CJ5&DN(Q$QLA^69HC3(N,6("9=>%SF:^7918)."KQM5G:\2.
MH9(=0(!QGIX0I)8F*PC\N>B!9I2C)+0%;U:U^3(;JB6U*B57I/9O)SDEMK<<
M?.Q7GFF28..[R70(@<2Z@+B*)MJ0$FDT[%X+=.ZHG#*3&527JA84 H!0"@%
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M^J7OI]=%%L-I'U<OCA0R=?;::%107G# 0/4*&BBNKT%3*Q4O'-A X31R&Q=
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M3H2I)E.&W%CLKCX4UDT:#(@KD-ITV^8X':A"($?=QMVIWV6DHM.A"DF53L]
MBQA?#7,UNHPVU$'GF3FE2TV'@EA156ZI11;)<BN%G,3,CQ'V)3>F<V+L4#)
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MJF=$S$"3B&\N#FB XPDE'7$TV:4=>HD7LL-5<76A*>%2QA]PPLJ;@,MOLN
M/(W(:)HB:=OH<%"[1+2OK3O1*F46B%*IE%D\:*.J4MD48+2_=P4T$O&Q\?"O
MNU%&34LSL[BH01S?D!_U9M-QA%4(C5XQ;!11%XCJ-+JE2HMAR2,GSL-)*15?
M;\RJ*J,:QYBHB77PWOV5%":E"Y3&(R3ZRV48 E;-U7 TH8\5%2O9%3T4HR*H
MI?RD-F7"BD2J[/4TC**7%>6',*Y)P3PI2@J1#F^\(&DD"2XWRW7W76V2(6FF
M'B8<<<MXK(8+V(O#C5^FRN=$Q!R<.<<D8Q:_*.HRZ5N&I6P=32O[2:'1XI5&
MJ%DZF%'W1C'\G]WMH\JJZY';DJT21S?915<:%SLU#I7U714[4JS@Z5(S*IG%
MD\:*.*4ME$9+EO*K@IH/^Z7'@OJ6JT9-476Y,9QQUIMT#=95$>;$D4@54NB$
MB<4OZZBA)A8[<&'R&,')QY3?E% 3,S)!T(2(J<RZ^!>/8M6<6G0A2353+29$
M)T&4?;5UT.8VVACJ(/[PI>ZCZZBA-3&F9W$1,<[D79;7E&4-2<$Q)%5M%4@&
MR\2\*^%.-2HMNA#DB^F0A\N.X3P-I*T^71PD!34DN@BB]JV[JB@J5-38;KQL
M-/MN/-?Q&A,2(>-O$*+=.*4H34Q?Q!B/O!^!YD.?&9\Q(74FAL$+0NLKV%45
M.Q:G*Z5(S(RDFPR<:;1]M7'QYC((8ZC#MU"E_$GK2HH34H3)XTA0AELD*FK0
MJC@*BN)P4$X^UQ[*49%44M96 8MZGVVG7&^:C)F"&@VU*JHA+V)VJE,K%2B#
MG,9/;8>AO@_&DMB['D@0JV:$JHB#QO?P^BI<6@I)F0,V$3C;0R&U==0E:;0Q
M4B0>!**7NMN^HH*EB;G,-!;=<ES6608-MMY3,4T&\2"V)<>"DJ\+U*BV&TCY
M.SF&@-/NS)K+#<5!*0IF**V)JB"I)>Z:E5+446PVD74R4-+\QT6DYJ,@3A@B
M&9"A(@<>-]7!.VHH*EJ-G,9+<4(CX2$!YV.\;9"J-NLI<P/BBW3U5+BT*HNC
MDL<3;3@RF2;?+0P:."J&?9I!;^)?4E11BIDU!(H!0"@% * 4 H!0"@+2Q8RR
MDEJV/F4!6D=MXM"JA*-_1=$6IJ*&I+M'<B8)<&WD(R0(S2,Q$5E2)T0= QYZ
MEJTV;!0N'>NKN1*R9U6M#'E=*%O ].&8KW,RQM30Y9@+ \T6TUS'I5B$C+6*
M(\@V*_9ZZF5VNP1M\2UDNFI283333S0N))R#TD-&@'AR!DMR5$)>8V!:4+W>
MRBNX_=^!#MDGE]H2)>9QDZ,ZR 0A9;<-T"<=4&'4<MXE("U=RV0A7Q(2]E5C
M.B:+..)#AT[S MQP.5#=& $-F(V;1J)MPGW'4YR*2\31Q$X=BI?C5^JBO39A
MR=EY2!*QL>.PW.)XX92'48LU%2-/*6:,.$?R0:75%!LJ^%/T2KB=?MN(R-$@
M]TV>3%Q84=V*A#%D0Y)N,JJ)YEP3*2RB*EGDT]J]O#CPJ.KC4GIX&/N/8V;.
M'D/+FS+9M..)&T$KQGD'&W"1Q5) L"BO9[2>BIA<6'VV"4&2A;-R?W/(C-O1
M6I$K(CD'& ;)(R"* /*#]L+\M#4QLNJ_9>J=15^!.1T,+#=-9,!B-KE,',CO
M1'!E"TNI!BM$THBI*I6+5P2_9PJTKM2%;H8\#IO+B(X]DWFID;E:9$2*V:$Z
M(PWXQZ!)=*$YSD5$1$1.Q*EW:["%;XE3.P,Q*P&-62\P.9577\A(D KI(Y(Y
M?[-U:/0#0 0DBHMN!);C'52;X$Y'3Q+Q=-I'.R#BOM/E(<<<C&\KB%\M+&6H
MN<M06X$"(!W*WHM=%=78.F9,S8N0>PV.B<^(](AQY45U'F/D-,NUW  -*(XW
MILBV\5U[+U"N*K)<,#)QFQ_(Y2//1X''&9CLDWE#Y9QIR&D5 ,^U5U"AKW5#
MN55"5"C(D-DYB9D,M(56(&N5D"B2%91QYSS3",#S+KI)K]K2O:J)Z*MU$DO@
M5R/$JA=.,DSSC.3&UR!GMD(@X2-A.CLM#H(R4E4#CW6_:A+V4=U?D%;93*Z7
MOON3=<L#"4VO+,T*X&;#;!@HHGB;TM<$4OT<+T5X.V22;&<;RRS&#CBPK\T^
M0K2V!J;'::5!TJ/%#9U+V70E[%JO4P)R8EF+L2>SMJ7BR>B\YR3&DQ11I5:#
MRI-$@&2_*&A<FUR55%%M=;5+N*M0H84*,GTZ<DL&K+S0OGD)<YT5#2#HRQ-O
M2XMB52;!SPE;]5%=_(.V8<_IAD93[Z)-8\L4=^.QK;,G-+L4&&Q<\2"2-DTB
MZEN1>GA5E>2(=MF1D^F\G(SY\EZ6 )/;)44-5V73B)%4!1+:V;)?2I)V]E^-
M0KM$';J92;)R18+*14?BPLE-EA.AO1&B1F,ZT#0"H@JHJ_P5OV=M5ZBJB<CH
M8K/3%&6W&&Y0)'0I#485!55J&Y$<CLL)QX\LWS+UHM6ZQ'3,J/L.0C[$MYV.
MDIH\8>MMM?"D 5%P0)?$B.76WHJ'<_4G(6,IT]F3)>9<!^*TUD6WD;%6B-5=
M=)HQ(]2DHV5FQ:"L7;I14HKM*!PVEK-=.\ME<G,E.S(P-26Y "B-%J3S$-(Z
M J(HB0MF.K4J:E3T62IC=21#MMLS9.Q')F0*9+.,8N$9G'Y:D"$< (?AU=R$
M"JGJX557*+[<2<A1 V-D8>39F"]$<1J*++B.-$2O.#$&-X]:EI3P74@M<?"J
M=]2[B:"@ZFPS<2Y(S.+R"."(8]'T-NRW+G @I9>ZUJQJ6#1=K$U<.FA,XQ8T
M>4(/O8Z7 ENES"$RD."XV8B1+I0%$KH-KW]59>KC\3'T\#-E;"9<PV;C-JRF
M0RSLH_-$)60)#W-0#1%OP2R+:JJYBO EPP96WMK-QGF9N.\C"F,M/QN2B.N,
M<I\@<YG'26L3:[.Q4]%,ZV,G*S+E;?RIRGYC,X4F.XM,>,@@LJ/(1$K]A5$_
M:OI2H4E^(<648'9XX19D>-*<D8^5'::Y4E>88N,@K2*BH@II5I %4M^S24ZB
M,*$6ST^DL_=K8/QU;C1\<P^ZK2\YLL:YS-48D7P(\O K^[QJW5V_'\2,AG-[
M6RD'9[&#Q+[$:1=$F2!$F];9$JO:%#Q X:<-?%4[>VU1G3E5DY6E1$)D-K9)
MK<&,2-!:<:-S'./&#:JW$;QYK<&7C)-(J/[.F]U]?"RFJ/XE7'$EY>U'9N8E
M-R0$\:_-#(D1<4<$H)0G&."HHJG T7T+Z:JIT7VXDN-66HG3EHL?'C92<4M^
M+*DR0DHS'4C20]S4U\]M[Q(ED)1M=>-'=QP"M\2_+VA,G9>9-G%&?:=COQFP
M$' -UMTA-H'R0N')4.!-V)>WA13HJ(EQJRSB-JY"#D8/,+F($R3E)CZ$9"AN
ML+%;8 G2-T_"6I2+T>M$I*::_ A1H8$'IKD!RS<R?*C2&6WFG#;1DD1WE.ON
M:B!5Y8DO/[!&R6[[U9W53 A6\2N+TYG1I$ AD17&HYPS<,VB5T$@OFZ(1UO8
M1,3LJ=WZ>!W4%;)Z5A,RWFI4[%RV6&LBD=)G-;4W \NJI=KCI76"Z?$G!>/'
MLK&I*E&7HZX$.]L/*/8_[J.:PF/A,3&L4J-GS=4MHV0YZZM*HT#JIX?:[>'9
M5^HJU*Y'L)E_#Y>='QPS3CM.P)K,GY'60DVT*II\6E4)5*J*25:%J-EC<>T#
MS$V3(%\&>?CU@IJ#4NKGB\FKBFIM=.DA[T6IA.B^)$H5+.&V6<7,,Y66L8G
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MB.R!?;0SYG+UMBG$;<5'4JU$;28<V9K>>W,N9QL69,;;9'(M,R76XZ@#S<F
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M0E94O943NI-)1HN(C5NO@1<#J%FGL64EQ^.YS68AK)98)&XCTAY6S9>UNH/
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MH[;04T4P-\PG9,Z-,9=8=BO3&VB%LS!X(9>/EDB>(]/%13]'8M';84RN-OW
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M%5<*;2V:NPC8^^V6(KQ95I2?9D2&16 +D@'6XH";[P<$+0TIZ#_YDLEZL[?
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M*^YK5PG=*N.%P3LT\+<$O4.39*5#!8V3C$Q\2.W.FJU$$4Q[R/(CC+?+5M1
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MU-@;<%C&M-M&"8MM68YZD,B;4D,A<5Q#U:C'4J]M^^G5>/B,B-CK&7% * 4
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M2>>4ADFI4EL1(]*-7YXW5/9]D;\933?@0TZ$[F\-N$LQ'* KY1V@B!#D))4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
%* 4!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>p34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p34.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!T0.$ P$1  (1 0,1 ?_$ -8  0 " @,! 0
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M<2.L/$+1%_DK%LU[B39*;=PVZ.\5$YT!<"7\%:MBM7BC-;U?!E@KF;% * 4
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M6E1M3&AEV2<$K630H!0"@% * 4 H!0"@% * 4 H!0#%,<,=O8H!0"@% * 4
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M4\,%-Q157'%]TS55IT]W:UF^0S5VU2+'Q%XBZA:XC0]#P+O%TK"=C)*DWZ6
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M'-TW=XR-1V7<KQ*:;G!2:(<!PW9;<:]#S?XTEQ1Q6+YVWP/2+-8+)9(G4[/
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M!0%=UOK[3FBK<Q<+\ZXU&D.[AHFFC=53R$>"H"*J=$%KICQ.[A&+W5>)/LO
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MZ@TZX6<Q+<D"[%)15.78BX8+72E[6HMCU1FU56SW+1EXX;IPMEKJ"9HC3LN
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!T)ADC1PFQ)P>Y-4153WEH#O
M0'1&64<5Q&Q1Q>4T1,R_AH#L0 :8$*$B<F*8T , ,5$Q0A78HJF*+^"@.$;;
M1!1!1$#N4P39[U '&FW$RN ACCC@2(J8_AH#D@ L,PHN')BG)0 A$A421"%=
MBHNU%H#AMMML4!L4 4Y!%$1.TE <H (2D@HA+RKAM6@" "$I(*(2\I8;: $
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MR.K.Q":/>KN\>L.+CAE!C#IX\]<WU%5=5YFUB>V2FUZ#D* 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * FM$?7C3?SM _:FZ\O6_M,[=/]:/T2K\\?2% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% >/_ &K/Y12/U^%\LE=^E_<K[3&7Z7[#
MXSK](?*% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 8Y'YN[_8+^BN6;Z+>Q
MFJ?4O:=P[@?>2NE>"(^)S5(* 4 H!0"@% * 4 H!0&)O_'>_W?[M<:?7;W?H
M;M]*,M=C H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#T+@3?;/9-?A/N\MN
M%#2#,;5]Y<HYW&E0!Q[)+R5Y>KH[4A<T=L#2>IWX+ZEM^GY&K),N>-O?D:>F
MQ[<Z19"*4656@;5/QU5-E.JH[;=)^9##:)]A==%<1])VRW\*WKQ<!??M#EW:
MN:DI.NQ$EJH1W'$VEE3%%V<B5Y\N"S=X7&#K6Z^6>\W/I?IVU7?1EO>NUD.)
M%OIW.0Y;GYLQ([9 0JZY+EN.94=S(I-(FQ=M9\.S5G%OIC6/T1=R32E<2N:6
MOUEO&IM<RKWJ 2D25=2RQKC<)4.VRVBDF:@^ZPJ'NQ#*0-HJ(N-=<E'6M4E[
M86IBK3;EGHT"_P!AO.J;U+M-[C-QV=!=5D7.'OE;B/-/*A$B%B^B-YD),>EA
M[M>9T=:I-?UG5--__*5RP:ZTAI27P^M-XOL>^R;,=Q.=>(I.28\09P$# BZJ
M(9(*ETL$Q&NE\5KJ[2B8T]AE72:DQ/:WTY8KIHN)(N5G>AP+T=QDE:79T[JS
M3H$V3ARI1N+@YGS$T*8IAC56*UE9P^$:PAN2C4AM02],V/0NM8,/4T"Y7.[W
MN-<X+5O<,B%A'U,5SJ(IO!3:2"JY>S6Z*UKU;JTDH)9I)ZECU=J[2KVJ==7A
MK4<*7"U'I1R-:60>4C;?W;0=7,%3 '#(5)!3\.VN6/';;50_EL:M=2WW$5J>
M^6.](UJFW:\&QVQNP-VXK P1K.1YMO*L1(O1!6G"Y3Q_V5O'1U^5UE[IGL]I
MFUD]9[#S?A%=+?:N)6G;C<I 1(,64AR)#BX  Y"3$E[&VO7U-6\;2..)Q8]&
MXC:AU)=K1?6G.*%FN5F>5UYFR-(B/.-"YO&61)&!7.F IW7X:\N"E4U\C3YG
M;(VT]20M'$/3C?$7AW.>OK8VZW::&+=72=+=MRNKNBH._P!?,0\M9MAMLNHU
M=M"JZE>PPZ!UGIN1HNPQ'+G;(5WL%TDS9IWB5-CJ2..*XW*92,;:220>ANS7
MW-B<K-BLKMPX:[(_")2R:7<:;&I;)JO35PM</4\+2MU#4SUZ=D.J["CR8[O<
MNLKTBS O2%LEQK3HZ63=79;8(K)KC&IJ.7ZTW#06O;(WK 94PKHU/B3KD9QG
M;@PTT@N;H$S8DX0X(//LQPQJJC5ZO;V=G8'9.K4GC%?0/** 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * FM$?7C3?SM _:FZ\O6_M,[=/]:/T2K\\?2% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% >/_:L_E%(_7X7RR5WZ7]ROM,9?I?L/
MC.OTA\H4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!CD?F[O]@OZ*Y9OHM[&
M:I]2]IW#N!]Y*Z5X(CXG-4@H!0"@% * 4 H!0"@% 3&F=":RU+UV18+0_<F(
MY@V^XRK:(!J&9!7.0\U>*W45QY+)]WZ'=8G:J@G/8OQ8]5IG;9\)3SU.\>7M
MW#V+\6/5:9VV?"4\]3O'E[=P]B_%CU6F=MGPE//4[QY>W</8OQ8]5IG;9\)3
MSU.\>7MW#V+\6/5:9VV?"4\]3O'E[=P]B_%CU6F=MGPE//4[QY>W</8OQ8]5
MIG;9\)3SU.\>7MW#V+\6/5:9VV?"4\]3O'E[=QKW#A-Q,MT%^?-TW+8AQ05U
M]XE9P$!Y57!Q5IY_'WCR]NXV/8OQ8]5IG;9\)3SU.\>7MW#V+\6/5:9VV?"4
M\]3O'E[=P]B_%CU6F=MGPE//4[QY>W</8OQ8]5IG;9\)3SU.\>7MW#V+\6/5
M:9VV?"4\]3O'E[=P]B_%CU6F=MGPE//4[QY>W</8OQ8]5IG;9\)3SU.\>7MW
M#V+\6/5:9VV?"4\]3O'E[=QK0N$_$N<CZQ--RW4BON17\%9Z+S2HA@N+G*.-
M//X^\>7MW&S[%^+'JM,[;/A*>>IWCR]NX>Q?BQZK3.VSX2GGJ=X\O;N'L7XL
M>JTSML^$IYZG>/+V[A[%^+'JM,[;/A*>>IWCR]NX>Q?BQZK3.VSX2GGJ=X\O
M;N'L6XL>JTSML^$IYZG>/+V[A[%^+'JM,[;/A*>>IWCR]NXV+;H;C+9)C]L@
M6:=$DWN$^S(CCU=5?A@H(^*XFO117 QY%VUBW68K1*>AI8;+M1K>Q;BQZK3.
MVSX2M^>IWF?+V[CGV+<6/5:9VV?"4\]3O'E[=P]B_%CU6F=MGPE//4[QY>W<
M/8MQ8]5IG;9\)3SU.\>7MW#V+<6/5:9VV?"4\]3O'E[=P]B_%CU6F=MGPE//
M4[QY>W</8OQ8]5IG;9\)3SU.\>7MW#V+\6/5:9VV?"4\]3O'E[=P]BW%CU6F
M=MGPE//4[QY>W<$X+<65V?1:9VV?"4\]3O'E[=QK6_A1Q+N,;K4+3DM]C.XU
MO!5G#.RX33@[7$[DP5*>?IWCR]NXV?8OQ8]5IG;9\)3SU.\>7MW#V+\6/5:9
MVV?"4\]3O'E[=P]B_%CU6F=MGPE//4[QY>W</8OQ8]5IG;9\)3SU.\>7MW#V
M+\6/5:9VV?"4\]3O'E[=P]B_%CU6F=MGPE//4[QY>W</8OQ8]5IG;9\)3SU.
M\>7MW#V+\6/5:9VV?"4\]3O'E[=P]B_%CU6F=MGPE//4[QY>W<:TWA/Q+@BP
M4O3<MI)+[<5A55GI//+@V"8.<I+3S^/O'E[=QL^Q?BSZK3.VSX2GGJ=X\O;N
M'L7XL>JTSML^$IYZG>/+V[A[%^+'JM,[;/A*>>IWCR]NX>Q?BQZK3.VSX2GG
MJ=X\O;N'L7XL>JTSML^$IYZG>/+V[A[%^+'JM,[;/A*>>IWCR]NX>Q?BQZK3
M.VSX2GGJ=X\O;N'L7XL>JTSML^$IYZG>/+V[A[%^+'JM,[;/A*>>IWCR]NX>
MQ?BQZK3.VSX2GGJ=X\O;N-VP<,.(=EU+8;G=M/RH=OCW:WJ_)<5I1%"EMBF.
M4R7:JHG)7#J>KI?&TI.F+"U9,^ZZ^0>T4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4!X_P#:L_E%(_7X7RR5WZ7]ROM,9?I?L/C.OTA\H4!>N#&F;%J/6BP+
MY&*7 ;@RY1,"X;2D;#><>F"H25YNJR6K25QDZX:IO4E+?8M :YLMZ^CEID:<
MU'981W-J,4LIL67'8PWP8N")MN(BIEPV+6'>^-K<]U6XY&E6MDXT:(I_@WK&
M.%M60<%ER[N0V[8P<H$>?Z_EW1@WAGR"IHAEAL7LUM=55SQTG\C/@LB%T%J+
MJ=^EB#1MZ<EM0+B(GB:OONDR"-#ATT4P6NGC5E+^XSX;U[B5O/"#5-HM5PN4
MN3;""T9$NT9J:TY(BN._X;+K:?\ $+F$56L5ZFMFDIUX:&GA:4F]IS36C[-H
M5G6^KHC]W2XRW(5ELD=Y8P.;A/RKS[PH1((JF5$'_IV9ODM:^RND<66M4J[F
M1IV&V:TOP,:%M#MI9;BE)NC4Z8+D:,C2KG>ZRX@*+*#AW>W'DK6]XZ_.Y]Q-
MJL]#D>$6LG+];K-&&)+<O##TJU38\D'(<EN.)$[NWQZ.8<N"HN&WEIYFNUOE
MQ'@N8-Z/P-UG)*+N)5I<8G)D@2AN+"LR)&)(L5DT5<[XJ"XBFSW:R^KJN?P*
ML#-&T<(]67*$W.)R!;HKDQZVJY<);<;+,85!)E4/:I$2X#EQ_!6K=35.-7I)
M%A9BA<*]6/R[JQ*2+:6[(^D2XS;E);BQ@D%W#2.EBAD2;4RX[-M5]16%&L\@
ML3[3NSPFU>MQNT*:,6UC9$:6XSI\EMB("2?S?*]TA/??B9:CZFL)K60L3F#<
MMFANLZ3E-E#B>4!O[%J'4*ST1AO.VJJT@#BT;989D=S>]4MFBW=MF(*J:>\F
MIO"^W636NJK,,=C4,*VVN=*BBD]&GXO5T#!Z0C0_X@9L4:5$Q2N:ZAVI5_3+
M78:>-)M<="N1>$&M)-K9FMA$25)BK<(MG.4T-Q>B(BEOVXJKG45%%5.=4YJZ
MOJ:)Q^?88\%P=[+P<U?>+?:YT9VWM-WMLW+0S)F-,O22;(@)IIH^D1]''L<F
MVI;JJU;6NG'0JPME*>9=9><9=%0=:(@< MBB0K@2+[RI7H3.+1TJ@QR/S=W^
MP7]%<LWT6]C-4^I>T[AW ^\E=*\$1\3FJ0]-T78M(-\,+CJF\:?=U!.8N[=N
M9CLR7XRHTXPCF/Y)#Q5"[(UX\M[>(JIQI)WQU6V6C<U9P1ENW[=Z2;W4-;7"
MNTR#<GP;>@C-)05MUPD%,&LJD2E@J#4Q]4MOS<VM.TM\.NA6;?PGU+.*482[
M8Q"C2RMS-QD36F8LJ4/_  HCA?XR^ZB85UMU%5SY\#"Q-F&!PMU;*>N[4D8U
MH"QNI&N,FYR&XK 2#[AE'"Q$B/E3#9AMQPJOJ*J(UGD%B?:6#BAPVZAJ._K8
M8S,:TZ=M]MDW!I'5)4*6V J3:JIY\SI*J[<*Y=/GFJW<;-FLF+5QV%?C<+M7
M2KA:H+#+).W>VI>6'%>$&FH*J2*](</*+:#DZ5=7U%4F^3CWF%B>A-Z4X/G=
M+K=H4V\VU6;?:G[DS)ASV'6C(15&E4TS8-B8_E55$44]]*YY.IA)I/5QP-UQ
M2WJ0C?#*_%9SN[DRV1X*N2&H3C\YIOKJQ/\ &6)FV.B/,N*8\U=/'4Q#^'#V
MF?"<25*NYR% ?2/V3/\ (=3?KT?]GKXW6?NOW'NQ?0CWBO,;% * 4 H!0"@%
M 5KB9_+W47ZB]_14? JXEEYD]ZJ04 H!0"@% * 4!5]!]QJ+Y_N/]X*B*RT5
M2"@% * 4 H!0%9N/\QK!\UW7Y6%4[2]A9JI!0$%>]:Z<L=\L]ENDGJTV^DXW
M;5(5W9&UEQ CY!4E-$''E6HV6#9?U+:F-2Q]..F8W23$=N#8Y?R>X9- -2/'
M!%0EY*2(*DYQWX=!(-$D3'+<VYN7+XW#?.VB>.7!9*)EPQV9L,*FY%VLL<S7
M.F(>H;38)$Q N%]9*1:EY67@'D0747+F+\5.>K)(-E-2VI=4'IA"/RL$(;D0
M9%W?5R=5E%S]]G3DI(@E:I!0'(=V/OI0%5X:?51/G"Z?Q*14J5EIJD% * 4
MH!0"@% * J^OOS>P?/\ ;?E%J,J+15(* 4!2+OQ?TK;+_/L)1;I-N5L5M)H0
M(#TH&]Z".!B3>/**UG<6"XP)(S83$QIMP&Y#8.B#H*VX*&*$B&"[1),=J+R5
MHAG027D15]Z@ B1$@BF*K0$+I75=LU/;WY]N%T&8\M^"XCPH);V,>0U1$4NC
MCR5$Y*T3-4@H"M<0_JZS\Z6G^(L5F_ U7B>D5P.HH!0"@% * 4 H!0"@% *
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M,E,D 4%%,MI$N")BJ\ZT!WH!0%:XA_5UGYTM/\18K-^!JO$](K@=10"@% *
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M1/4?1L_25K:\.MN78^3,&G/KUK3^W:_V*O2CY)::H% * 4 H!0"@% 5CB?\
MRZU'^H/?T5&"S\R>]5 H!0"@% * 4 H"K: _P]1_Z@N/]\*B*6FJ04 H!0"@
M% * K%R_F3I_YJNORT*H"SU0* 4 H!0"@% * 4!R'=C[Z4!4^&/U33YQNO\
M$I%1 M=4"@% * 4 H!0"@% 5;B!^;Z?_ -06SY5:C!::H% * 4 H!0"@% *
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MK[U?&Q^L=4[)._:NQ?R,[F7E>6OWAT% 5;B!^;Z?_P!06SY5:C!::H% * 4
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MR7F\SPLNQD+,J?DGL-X."+SY4VU+X:V<OC#7N9<?4WI7;5_+N5O?7@:0Z3L
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M0^A8\7S9/GM^7_)%4G/Z*^\:% * K'$_^76H_P!0>_HJ,%GYD]ZJ#E"5.1:
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M7"_5V?DQJ@V: 4 H!0"@% * 4 H!0"@*MISZ]:T_MVO]BJ(%IJ@4 H!0"@%
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MN,=M&#=9,,Q9VP4FU1%V@0+M%=OND&3=4A5]._7C67]NV?L597$K+16B"@%
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M73SEE:JM6-W?_P <>XX?:Z.E[4ON\/2%773BXW2J]FZ'WI%@KWGQA0"@% *
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MRZ*&TZ"H0D))BBHJ<J+7Z9--2C^-WI:EG6RBRT:?8=ZID4!5]!]QJ+Y_N/\
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M;/\ 7/\ 7,?I^.7\V>WU6Y?]:]WZD]PJXJE:":L=\=4K42Y8LHMJQE7\4O\
MNO[OO5Z?3_4-GR7^GL[O^#Y/^U?ZHNH3ZCIU_F_JK_?_ /=^OM/>1(2%"%4(
M21%$D7%%1=J*BI7Z,_DC33AG-"%7U]^;V#Y_MORBU&5$_<Y[-NMTNX/(1-1&
MC?<$-I*+8J2HGN[*SDNJU=GV';I>G>;+7'7C>RK\="OZ=U'J>Z1F[A(MD1FU
MR8Q28TEJ7O%!4',#;R9>5>=1[FO-@SY+K<ZK:U/']3['J/IW28+O'7)>V6MU
M5ITB>;KK\)XFU#U?;&K+;YU\G0H+\X,PB#XDT2HJI^3)5Z2=E:W7J:JB=W5-
M]YPS>D9;9\F/IZ9,E<;_ +=5[5V&R]JW2S#0O.W>(#1@K@.*\"B0(612%47I
M=+9LK;ZG&E+LOB<*>D]79[5BNVG'TOC$Z^[4Q3]1 U*M!1GH;EMN"ND[*-]!
M7=-MY\[")L<P_&["5F^:'6(VV[_T-X/3G:F7>LBRX]L55>UN(M_;W%>M_$:3
M<X<V= 2W(PS*;CQV7I*BZK9.JWO'=B".=$Q;1.6O-3K7=-UVQ,<>_M_@?9ZC
M_7*8+TQY/%W.CLVJ:2JS%>UQ_4RV2=06&-<@MDBXQV;@XJ(W$-T1=52[E,JK
MCBO-V:]ELU%;:VMW(_/8_3^HOB>6N.[QK^I)Q\0WJ*P.7-;4W<8YW-%5%ABX
M*NXHF*IE1>5.QRT6:CMME;N0MZ=U"Q>,\=UB_NAQ\3&WJG33DQN$W=8IRWB(
M&HZ.BID0DHJ*)CRYD5,*BZC&W&Y2;MZ5U5:.[Q7V+5O:XCB:MNUI8I^H9MB9
MD-K+AJ A^4%5>)14G$ 4_P"RRX%6*=52UW1/5?C\CT=1Z+U&+IJ=1:KV7GL^
MG6%/_EV&#B']76?G2T_Q%BN]^!\JO$](K@=10"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0%+XI?F&G_G^V?+U:\26X&6Y6F#<FVFY8$2,.(\R0&;9"XB*B$A
M HER*M:S8*Y$E;L<\8_0WTO5Y,#;HU\RARDY7L<F%-/VO/&<('#=B(8LNF\Z
M1Y7=IB1*2J8KV"QK/E::/6:][[?U]YU^XYHLI25XE;:QIP:4:/O1P>GX(1E;
MB C+HPRM\=PLSB R7(BBJ]+!=NVH^EJJQ71[=J[="U]1R.\W>Y>)XC7";>V-
M#O"L=NAM6\&F^E;658BGBJ8"0HA[$V+FRUK'T]*JL?T*$8S]?ER/(V_W;;K>
MU</A)T33EJ&8], 70>D.*Z^@/O"V9JF55)M#0%V)V*SY3'N=M9>KU?Z3!M^I
M9G14>UUJH7RUE+CQB3I]%K)N%95DUQ=!_>J\ZKN\;3*"[U2S]$=B)CR5/)8H
MB.V>+F5WS)K[KU&[=*^EUC;7;#U?RQ&KUX<3N>FK,;D@U8).MHXC[8N."V6]
M'*X6[0LB$2<I(F-5])C;;CZIG5QKQTX&:^IYTJK=]$0XK/RZK6)A<N!DD6.V
M2'6''FB-8R C0;QQ&_R2XMYFT+(65=J9DK5NFI9IM<.]]G#0QCZ[+1657&Z9
MT4Z\8<2I[8-^NYXQ0"@% * 4 H!0"@% * 4! <0?J#J;YIG?LQU'P*B6MG^6
M0OU=GY,:I#9H"'U1JFW:<@-2I8/2'I3PQ8$"*&\DR9#F*BTR"J.*X(JJJJB(
MFU5J-P5(U+%JB^3K@,*Z:6GV7>-DXU*=<C28ZY<,0,X[A[LUQV(2;>S1,06%
M'&R,P$Q4V\-X"*BD./)F3E3\-4@1QI34!,5-$0E!"15RKR+ARX+V: (XVIDV
MABK@8*8(J*0HO)BG*E :5XNCD&VR942*5SEL-HXW;F'&Q==151$RJ:H*=G%:
MA3<5UL=VCA"V;O< 1(A*N&*BFW:J>Y5(<HXTKBM(8JZ*(I-XIF1%Y%4>6@.U
M * J^G?KQK+^W;/V*LKB5EHK1!0'"HJHJ(N"\R]BHUH"MZ@:O"M97LKT85S(
MX X*G-TDK\?ZWCZO;%XMC3F4OU(R $2(D$44B78B)M5:_-)-N$0N5J"[[L%E
MD#;8HB"T@IF5$3G7FK]]Z;3J]J\5JM4M*QK[^1HDJ^P!0%:XF?R]U%^HO?T5
M'P*N)9>9/>JD% 1]XT]9+TVVU=883&V54FP<4LJ$J88X(J;:Y9<-,GU*3V='
MZAGZ9MX;NC?&(/FCB-;X5NUM=H4%D8\1ET1:9#'**9!7!,<>=:_*=;15RV2T
M1_<O]<ZC)FZ#%DR/=>U=7[V3?!BQVB\ZGDQKI$;F1PB&X+;F."&A@B+L5.9:
M]'I>*M\C5E*@^7_NG79NFZ2M\-G2V]*5RAGT#;+5;K5$&';F!C1052!D%)11
M27%<,RKA7Z7'CK1150C^.]5U>7J+[\MMU^9MUL\XH"KZ#[C47S_<?[P5$5EH
MJD% ?(W&C^:-_P#_ !FOV=NOH8?H1Y,GU,I-=3F>F_9V_F6W^HROZ!KAU'TG
M7#]1]15X3U"@*S<?YC6#YKNORL*IVE["S52"@% 8I R";5([B-N<RD.9%]Q:
MX=17(Z_XVJV[U*!3KR%PZVIS007%1$0A3HJB=BOP/JE<_BSF46?+@XY&68[8
M,U9@%##.\"XIBF*)S;:Y=!7,\J>)3=?C4%SB!,%O&4X)N+RH X"GPU_0>EKF
M5?\ +9.W<H2_F:,]>D"@.0[L??2@*KPT^JB?.%T_B4BI4K+35(>4?:4^H43Y
MR9^2=KT=-]1RS<#YGKVGE.#[@O>6@/L-G25EU)I"P,78776&8,4@9;=-L%)6
M Z1(*IF5.;&OB]3TU,KBW"3]!Z7ZOGZ)NV':K-<75-_F?/FMK7#M6K+I;H0*
M$2*^3;($JDJ"GNKM6OR758U3):JX)G]S]$ZJ_4='CRY'-[5ED[PDTO9M1ZBD
M0KLT3T=N*3H"!DVN=# 47$?<):]'IW3TRW:MP@^5_MWJF?HNFKDPN+.Z7"=(
M?,^A;+9H5FMS=N@JYU1G'= ZX3JBB_BH18KE["5^FQ8ECKM7 _C?6];DZG(\
MN2-[XPHGX=IO5T/(5?7WYO8/G^V_*+4946"XF\W DFQ&ZZ\+9*$/,([U<.XS
M%T4S<FVLW;57"GN.O3UJ\E5:VQ2OFX[>_370\[L=ADIJ YEEL<W3UM6')"Z1
M))(C3[Y@HM"RTAFG1+\;8E?,Q87OFE72L.4^U]Q^SZ[KZ^65,^;'U&7Q*.EJ
M\:U3^9VM"[.S4A1M]XC#8X$>*\ERCV)QB\,@+!NML//EE3))4 %5V](55>RE
M>=4NMM4GN5->'">\^H^HPW>;):U?"MU*MC;WJKM6JG6DM]FC4=Y8]+6^#<+_
M *=NEO@N%IYBRN167)("2@X+RCE/E3.J(6U.6O7T]%:]+57R;(U]I\3U3J,F
M'I\^+)=>9MU"LU5O5.LZ=W UM,Z<OD8=%"_"<;&W3+F<M"38TV]FW2EV$+'9
M6,&"Z\.5]+M)W]3]2P7\XZW3\3'AV_\ 9UC=\.TX'35Y'AXU 2 :3TO"/DP@
MIGW*2U/.O]7+MIX%_ B-=_\ $K]3P/U)Y-Z\/P-LSIN\.(]LDK9HTVT7Z\19
MMC?N)W.Z%,C71L&C:W#BCDWCADB@K&')VJZXJNE[)U;W6F=.'_!\_K,E.IZ?
M%?'FKC\+#LM1NRMN4S"2UW\_B0TB%JRXWRW.O6QV-U&]A(=;9C,M1Q80U3?)
M(QWKQ&.TN;LUP=,MKINL1>>"B.<\6?3QY^CP]/D5<BMOZ=U3=[.SM'T[(VU2
M?#MY'9-*W0='.,C;22Y+J#K8H@)O=RDA%1S'EPR?[*OE[>%P^;Q)_,C]5Q/K
M5;Q/\7E=G'3=LX>V2PV>),@<0-0$[;G5B74H[T2X  JP*-,Y30RQ11)2V8(E
M>G%5US7E:6B'V<#XW69:9?3L"62N_%N5J-O<YM*A=J@V>(?U=9^=+3_$6*]E
M^!^>KQ/2*X'44 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!2^*7YAI_Y_MGR
M]6O$EN!(UZ#B* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * @.(/U!U-\TSOV
M8ZCX%1+6S_+(7ZNS\F-4ALT!2.(D6;&O&E=5M17IT/3LJ25RBQ@5U](\R.K"
MR&VAZ1JRNU1';E5<*RRHC2UM<;YJV)'T?=CGVV3$F=<CK -MJ(Z$8NJN%*=;
M D(W\.@J_@J3KH6"L</[5!3R,A3TCZF@Q)*7>WMVEYB:XZ48QD-W"8IF+@J[
MTQ,^Z)$RU$BLSZ;TP%ML7"RXVNWI#OTC%BXS4;)'B%VV/KEE&O24-Z ;#V)@
MF&%5+@)XF'AU:HJ2+ ,N>D75L'?%>(06EYJ<Z\33@R0G3E,A<:,US"9=$E0<
MN%1(,1M(P87V=),J/;5'4$^SMA-?4"*6Y@^*HV2KB>4$1,H<B(FRD:"=2=D-
MZ69U_J(M;P.N29+D+Z,F_%=E"L,6 16HB@#F1P9.=7$' N1>2KVZD[#%I=J#
M;N(Y1H#<:]K.EW!^9/<AO1[M;5-",D?DF.1Y@B_)-XX+AERXHE%Q#X'J];,B
M@*OIWZ\:R_MVS]BK*XE9:*T04 H!0&NS;X3#I/-,B#A<I(G]'8KR8>APX[N]
M*I6?XTY V*]8% * K7$S^7NHOU%[^BH^!5Q++S)[U4@H!0'GVH^#%COU[EW>
M1<)3+TLT,VVT;445!0=F*8\U?,S^ETR7=FWJ?L?3?]TZCI,%<-:4=:*)<R;N
MB^%MITG='+A#FR)#CK),*#R @HA$)8]%$7'HUTZ7T^N&VY-L\OK7^TYO4,2Q
M7I6J5MVD]_/VETKWGY@4 H"KZ#[C47S_ ''^\%1%9:*I!0%4O'"O0%YN;]SN
M=H"3/DJA/OJZ\*DJ"@IL$Q'D%.1*Z++9*$S#QIFG[$^%WF%OXZ1X2KXU^8\*
MO(D=/\-M$:>N*7*S6L(<Y )I'A<=)<AX9DP,R3;AV*S;)9J&RJB7 LU8-"@*
MS<?YC6#YKNORL*IVE["S52"@% * Z/,-/-JVZ"&"\HK7+-AIDKMNIJ#K'C1X
MS:-L @ G,G/[ZUGI^GQX:[:+:@9:[@4 H#D.['WTH"J\-/JHGSA=/XE(J5*R
MTU2$+JO2%BU7;0MMZ:-Z(VZ+XBVX32[P1(47,.WD-:U2[JY1+53XE3^[]PP_
M0I/C;WPUT\Q<QX53A?L^\+U146#)P7_[M[X:>8N/"J>@PHC$.''AQT46(S0,
MLBJXJ@-B@BBJO+L2N+<G0\WU'P0CWN^S;L5X-@IKJNJRC"$@X\V;>)CVJ^1G
M]*62[MNB>[_D_=^F_P"[VZ7IZ85B5MBB=T3_ .DDM!\*V=)79ZXMW(IBNL$Q
MNB91O#,0EFQ0S[VNW2>GK#;=NG3D>'U[_:K>HX5B>-4BVZ=T]C7)<R^5]$_)
M"@*OK[\WL'S_ &WY1:C*BT52"@(ZZ:<L%V-MRYVZ/,<:3!LWFT(D3EPQY</<
MKEDP4O\ 4DSV]+ZCU'3IK%DM1/C#-YIIIEH&F0%MIM$%ML$01$4V(B(FQ$KH
MDEHCR7N[-NSEOM.]4R* 4 H!0"@*UQ#^KK/SI:?XBQ6;\#5>)Z17 ZB@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@*7Q2_,-/_/]L^7JUXDMP)&O0<10"@%
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MP?C4IN0AE>XA\0M"RM"WZ-&OL-Z0]"=!IH'$4B)4V(B5&U!4F6#VF</<$_\
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M/U33YQNO\2D5$"UU0* 4 H!0"@% * 4!5N('YOI__4%L^56HP6FJ!0"@% *
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M=/UE<KBJ9_#/5O\ 7LW055LMZ3;@DW+_ "X&:Y?S)T_\U77Y:%7J/@%GJ@4
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M!GL&H]1S=<7^V2(6%M@&PT);YM=QBTIH65!S'OEP7EZ-:Q9KVRVJU\JCW?\
MQ.77^G]-CZ'#EK?_ "75G]+^;YHYZ;?S-GB1]6FOG.T_Q)BO8^!^>1Z!7,T*
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * IO$[\TT]_J"V?+U5Q#)JNA@8K0
M&.3'9DQW8SXYV7A4'0Q5,1),%3%%1=J5FU59-/@S>/(Z65J_4G*.S8 VV+;8
MH+8(@@*;$013!$3WJJ4*$9M9MR^+.V*]FJ08KV:"!BO9H(&*T H!0"@% * 4
M H!0"@% * 4!7^(?\O\ 4_S3/_9G*C!+VS_*X7ZNS\F-4&S0%-OW#:'=]>6C
M51RB::@""SK<@XA+=BJ907#7'8L<W35-BX[.Q4@IGF</+/==63;_ *@:8NX.
M1F(5KA2&4((C3:D;I)F4LQO.'BJX)L1$I!#2C\/;K97[L6C[NS8X<^4Q.CVY
M88OQFWA:W,@"#,"[I_ #Z"B0DF.*XX4@IB/A8L^)<Y%YNQNZFN4R-<1O4)D8
MR1)$ -W$6,R2N]%L<4+.2Y\RXT@22=ML.NS<=\OZDCS(RQWF BP8 Q!<)T%!
M'7R-Q\E4,<4%O*F-((:6A]*:_P!-0+-9WK_;IECM+3<=61M[K<AQEH<$1'5D
MF(E[N2B128T/I9=,69VW+(24KLV9,5X0W>R9(-_)AB7<9\,>>B(1ENX7Z<Z[
M=;EJ"'$OMUNTUR6Y*D,"N[9P%MB,"$IJ@-- B<NU<5YZ04E-%:8+3%C\BC)Z
MS"CR'RMJ95%68KKBN-QUVEFW6911>QALHB$]5!5M.?7K6G]NU_L51 M-4"@.
M"$2%1)$(53!17:BI4M5-0^ *[==)MN8NP%R'RJP2]%?[*\U?FNO] 5OFPZ/^
MWL]W(PZD-"T[<I+RMDVK( N#CCB8(GO=FOC=-Z1GRVB-J7%O\:F55EMMEEA6
M\<6QSO+W3Q[2_!V*_7=%Z9BZ=?+K;F_QH=$H-^OHE% 5CB?_ "ZU'^H/?T5&
M"S\R>]5 H#0O-ALE[BC$O$%FX10-'19D A@AHBHA(B\^!+5K9K@1I/B0WLMX
M;>K-N^(&M^-?FS/AUY'"\+>&RI@NF+=\0-/&OS8\.O(LS#++##;#((VRR MM
M-BF B )E$43L(B85S-G>@% 5;0'^'J/_ %!<?[X5$4E[WINP7UEIF]6YBXM,
M$ILMR01Q )4P4A1>?"MULUP,NJ?$B?9;PV]6;=\0-:\:_-F?#KR'LMX;>K-N
M^(&GC7YL>'7D6<401013 11$1$YD3DKF;/,.+'"<+Z#E[LC:!>@3-)C#L24B
M<Z=AW^][]?+Z_H/$^>GU?K_R?N/]6_VE]*U@SN</8_[/_M_3V'D6AN']XU5>
M"AM 4:+&+_U"48K@TF."C@N&)KAL&OC]+TELMHX)<3^@>M>O8>AP[V]UK?35
M?U=_L[SZ<L%@M=@M;-LMC*,Q64]\C)>4S7\8BYUK]1BQ5QUVUX'\3Z[KLO59
M7ERN;/\ +N7<1-R_F3I_YJNORT*MGC+/5 H!0"@-2X6N'/;RR Q).Y<382>\
MM>/K.@Q=0HNM>?:B-2=+;9H-O'\B.9U>Z>+:2_!7/HO3<73KY5-N;X_\!*#>
MKZ!10"@.0[L??2@*GPQ^J:?.-U_B4BH@6NJ!0"@*].X=Z#GS'ILW3\&3,D&K
MC\AQD2,S7E(E7E6MK+9=IETJ^PP>RWAMZLV[X@:OC7YLGAUY&_9M&:2LDHI=
MGL\2WR3!6C>CM(!*"JBJ*JG-B*5FU[/BRJB7!$S630H!0%6X@?F^G_\ 4%L^
M56HP6*?'>DPGX[,@XCSH$#<IM$4VR5-ABA8IBE2R;32<'7!D5+JUJJZ3^E\'
MW%8B:*N[US;N=_O*7.5#C/Q;?NXP1Q!) Y#<<RJ6<L/>2O+7IK.VZ]MS2A:1
MQ/MY?6,-<3Q=/B\.M[UM>;.T[7*2Y(J-\T7<H1V2W.-29D&T6\F8\R+!:G@Y
M(<=4B0X[Q8-X"@X$O+V:\>7IK5VUU:K7L4Z^P_0=%ZQCR+-D3I2^7)+K;);&
MU55A1>J^;MT+?INP7URY6C4E\-MFYQ[:<&5!;!$3$W<XEB*Y15 1$443#'DK
MV8<5]U;W^K;$'Y[U'KL"QY>FP)O%;*KULWRK#XZO7@WV&&S</3MOT<QG([Y!
MDS9*_DU'>]<S=%.DN7)F]W&ICZ/;MU^EO\SIUGKZS>/\D>/3'7C].R.[63GV
M>G]$F]/]?3,%P\H=9W:X8;]7LF7-[N&.-/*?X]D_U3^<C[^O-OJ-G'%LB?\
MKMF8]YMQ=)W:W7B9(M-W2+:KA,Z_+@G'%T]Z2HKJ-NJ2((N8;<17#FK=>GM6
MS=;15N6H//E]4Q9L-:YL6[+CILK96:4?TS6-77V^TB&>%KH7-F8Y<67>K7,;
MFV\L5.MN8'F5IZ2IJ1"B;!P1$KBNA^:9X6GAK[V?0O\ [,GB=%2RW8O#C?\
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M H!0%7XD?5IKYSM/\28J/@5'H%<S0H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MMG[%65Q*RT5H@H!0"@% * 4 H"M<3/Y>ZB_47OZ*CX%7$LO,GO52"@% * 4
MH!0"@*OH/N-1?/\ <?[P5$5EHJD% * 4 H!0"@*S<?YC6#YKNORL*IVE["S5
M2"@% * 4 H!0"@% <AW8^^E 57AI]5$^<+I_$I%2I66FJ04 H!0"@% * 4 H
M"KZ^_-[!\_VWY1:C*BT52"@% * 4 H!0"@% * K7$/ZNL_.EI_B+%9OP-5XG
MI%<#J* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * I?%+\PT_\_VSY>K7B2W
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MC08$+"=R X]BB4!LJVD=3_1N3JB#,LMYDS)&H+A+B-1+=(=!YIX@W9 _E%G
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M'TM">-Z%&?/#.ZRVX6')B8(2X=NO"STHS4!6;C_,:P?-=U^5A5.TO86:J04
MH#&\^RR.9XT;%=F8EP2N67/3&INU5=X*CJ%YEZXD;1HX"B.!"N*;$K\'ZWEK
MDZEVJTU"X$9ALSC;5S8-PD !)<Q+L1-BUQ]+R5IU-+6<)/\ @0N;,F.^BJRX
M+B)RJ*XU_0</48\OT65HY&C+78"@.0[L??2@*KPT^JB?.%T_B4BI4K+35(*
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M&@DL=71#&4^0R!CFI*)(HIN4+E3+C@M>&OIEMD:2MO\ 5;YH_P#T_GJ?7O\
M[!1Y=TMUMO\ Z*?)N7%:_/'!S$HE)6EWW=)O6AEMMAY]X7B;5YQT$_+"X?Y4
MD0L50>QRUZK]&WT[QI)-N>+?;/$\&+U6M>M6>S=JUK'TI/Z6E\J<?GP,E]TW
M*>B,PK3NVHF+W6$>-2<3>AE0@<=&0J)WPIACV4J]3TEG55QQMUF>.O>U8QT'
MJ=*W>3-+O\L0H6CG55=/<]8Y&HUI*Y"Q,CGU<AG6IF";ZJJF#[+1-XHF7I"2
MECCCCLKE7H;Q9/;\V-5GO2CD>B_J^)VI9;_\>>UX['6UD^>C4<(.)E@ER)UE
M:<:%A7&=S>6V,39./&(76Q4\H;2<3###D4J9.EM:U$U&D6CA"U6OM_5EP^H4
MICS63=HM.-VTLK73JW$OA7\TC?N^FY=VN[C[\M8T(8A16 :$#(M_CUA31P21
M,4043#;7?/TELN1MN*[841V_5Q1X^C]3IT^%5K7=DW[G,I?+]$;6I[6Y-6T6
M"^0IC4B4W$G&3$>,\ZZ19FDBD2";>(%CG%4)4V8%7+!TN6ED[*MM$M>S;RT[
M?U/1UGJ'3Y:.M'?&MU[)):6WI:6^;L>G;\I'%HB\#;W(PI$>.1!6&1ND7Y D
M?-U";Z!8YT-,>3!4KSOT[)LV_*YIMU[-6]-.\]J]=P/*K_/55R;]$OF6VM8M
MKV1WZ,G+79)T.^R9:"TU!>WA& GO2<=-1Z:9@$FNYZ2(:HM>W#T]J97;15<]
M\OX:=^I\GJ^NQY.GK3YGDK'9"24Z:6:MQT>U-$_7O/CB@% * 4 H!0"@% 0'
M$'Z@ZF^:9W[,=1\"HEK9_ED+]79^3&J0@.)>FKGJ71\FTVPF1G&_$D,]9(@:
M7JLEM]1(A$U3,C>')4:DJ9I72W:]O^F]06:YV^TVY;E;WXT-Z'*>>_+O"H#O
M4-AK*"9N5,5]RIJ"5LNEX6GK#NK%;8$2\##%K>M- P#LAMI$%77&PSJ&\3%<
M4JI"2I^Q*U+H9;,4R4M\)E7BN"2Y6X\J*6_ZUU?/N\.L]/N*FW0NXGK/I.<[
M<]0R]2-Q9+.HH5NC3(C:DXV1QXQM2A7,(] C/H<^'8HD22NVO@[.BV>]VUZ\
M$X^=TB7335U-%=?C+ 9;;C)(%<N\R(WNRV](.?&IM+))7+3G$+533%IU0MJ@
M6$7FG[CY,.0\_-2.XCHLHCP-BPV9@BGM(L-B58;$H[\3.'D[5<JW2+=+""2H
M=NOJKBBOVB28./LAE1>GF:3+CV5HU)$S>U+HE=0ZALI2RW6G+*TZ\Q%CO.L/
ME.-$:9)":R*(,LYL,"Y2HT$SC3^AST[K";<;6Z2V6[1&QN+$E]Y]])T8L&GA
M-U7%(29)0+$MF5*)"2W5HA5]._7C67]NV?L597$K+16B"@"HBI@NU%Y4J-2"
M$N6FF'L7(F#3O*H?B+\%?G>O_P!?ID^;%\MN78_Y?H2#2M^F'S+/,7=MHO\
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M@VZ]9H4!6N(?U=9^=+3_ !%BLWX&J\3TBN!U% * 4 H!0"@% * 4 H!0"@%
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MPIEQ[>"8I:2XUP.@H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0&@
M=ZL)NRHISXI.PP4YS"NMJ30)RDZ*KB ^Z5:VVXP248DU!I=(:W!+E!ZD#RMK
M+WS.Z1]=BCO,V7.N/)CC5V6F(9-R->WZLL#UAAWR3(9MD2XMH\VLMQMK'$<=
MI*655RIV:ML=MS7& K*)-MR?IY'H\%V1$WTQO_E8I&UF>:7;^3!5Q,?>3"LQ
M;B64:6I+_IRQ1VNN[A7U<:6)!S-"\9..BUG:;-45<JN8JJ5JE+6X$M9(YNVI
MM/6T9DL38E3H:LM2V(YM%)!'W1:!#3',*8FB]*E<=G"[ [)'2?J+1%F"9-?E
MP8YP2!N<8$UO6B>-!$7$'ICF)>>JJ7M"U([51NG=--#*D-G+AI*%E'Y0*XUO
M$8%$5''$5<<B(N.9=E9VVCM-2C7'46FU;E2'94)JW-9!Z\4B.K+F^Q+!50NC
MTL>ZY5Y*NRW?)-R-TY5D),QNQE1HFW<2)M<I/K@T>WD5Q>Y7GYJS#+*.(LJP
M2Y<IF(]%D2V5RSFVB;-P"5,N#J"JDB[,.E1JR6H31%ZDUCI6UVN9.DR(TLK6
MXV!Q@=85P)#A9&@7.2(V2DO*2IAM7FK=,5FXYF;721KV[6NEKD=U)\HD>+;G
M66)DQ]^,K925!#R8YE[C'*A%RKCEY*ML5E'>%=,EI5UTO&D"$F7";DM,D^VV
M9M(Z+ IG(Q%5S9,!QQ39LK"K9\RMHPP=0Z0N#-KD1YL,TN ;^TB1MBXXA<JM
M 2H6..PL$QQY:KI93H].(5DS'<)=A&\I"D1FDZH"7:9,<46VF%12;9<<)<$4
MR5#PQY,JKV*)6B?<&U)LR-0:32/&GR;E ZNXI+#EN/,Y"45025HR+!<%5$7*
MM14MPAC<C7NNH=.6ZYQ(!JP[<KF^VPL8":W^#PE@Z8*N=0P##'"K6EFI[$'9
M)D@[=[&-P;MKLV*-P545F$3K:/*N7,F5M5S=SMV)R5G:XF-"RN!H3]5:.MC$
M^Y/W"& PB!NXO-FV1MD19 !W(JDBX[$1:TL=G"@CLEJ;7E33027V>MPAD[M)
M<EO>-(>Z%$)'C3''*B;<R[*FVW>)1J2=4Z,086\GPG@G3$B1" VW1*9E4LJ*
M*DB&B)_1V4JK'?71\!N1L1K_ &1_JH2)$5B;/3%B(;[!N.9"5$R92+>8*GXN
M.%1T:]PW(CK-K&QW2ZHSN$C2R;/=//;M"/)*?C;H%QS*JE%(\.Q^&M6Q-(BL
MFS<NKFD#L,AF;*B1K/.%R,Z[OFV&R[H7 1Q%%,R8%C@N*8+4KNW:<2N(,ZS=
M,MC%@%(A",]$.'&(VORZ+TD)L%7\ICRXIC4BW'702CI)O=B1QXV7HDJ=;R!I
MYH7F$=8WIHW@2D2;OEY%PQY$VT5'\0VC5@:ITK<%9=A/Q7HJD_'ZUO&10'(S
MP-JT@DJ&N+A)AE3#D[X<=/'9<2*R9(RKQI^.)#*FQ&A==ZL:.NMBA/**8M+F
M7:>54Z/+6%6SX(TVCO,F62WLLQIC\:(S(7<1V7B;;%PE_P"& DJ(2KV$HDWP
M#:15#XDZ8"X';(S+3K@SPLL<!>C CCJ@IO(@D:*+;2)AM3I%L%%KMX%HGNDQ
MXBX%E6\Z87K$U9T)?)Z[F5)WK7Y!57#(X>/Y/;S*M<MMN$/4U*-5K4FC5EO6
MUN;#WC$<+F\"$VC:,&2Y7U+N,,1QS>\O.E79>)A\AN7 [Q+_ &<[JQ%B;HVK
MHRY*B3XY ;3YLD@O#F#E,4(5QYTQ[%'1Q+[ K*3;Z[86]XN_BAF)UQU<[:8E
M&5-\1;>5I<,ZKW//68L64/+=@:>?8Z_%!YEOK,EK>MH0-*B+O3''%!5%3I+L
MILMR$HQA==,R]Q "9"D=:;WD:*+C1[UL57I-@BKF%%%=J)S5=MEKJ24=CN.G
MEN35O.5$\J-XHQ$5QOK ]%"7(WCG3H;=B<E3;:)["RI(]S4>A[+9U5)\)FV6
MQQJ(0MN 8L.$:-M@2"I*)9NSMY5[-;V7L^#EF=U4C?>G:;???AO2(;LAD$D2
M8QFT1@""F#K@*N*#E5.DO-64K+74U*-.U7G3FHBG)'"/,BVQT6$E?DGF2S,@
M]BV0J2941Q$7W4JVK:L=Y$TS.[?])/6U)3MR@.6U#W:/F\R3&\!,V7,I9,PH
MF.%39:8AR-R@XE3K%;A:E(V+@7Z4RUOF41P777FT!LR7'!0R-HF*<U$F_<&T
MO>:-\U;:($Z9"E6V3*9AL,S+G*:::<999<(Q W$4T<++N25<H%@B5JF-M)ID
M=DB5MESMMS<G)'#-U*0D9\R$<",6VWA(515S#E='!:Q:K4&DY(^7K&UQ[J[%
M2))?2*ZU%FW!EI#98=D95!MPLR.+W8*6020<4S85M8FT9=E))&[8!BC=#.*D
M5@<0G$K:-@(KAL=78*(ONUB+<#6G$P+<=*++B/+)@++GX% <SL[Q_F165QS'
M_NU=MH[="2CNS>=-2WWG&9T*0_ !2?,'6C-@-N*FJ*J@G17'&CK9=CU+*.IW
MO2JMQ[@<^#NY1;J)+)UG*Z0EW#;BKTE0N9%Y:;+<(9)1T\MV%L<DYZ)#SO.P
MF&WGF/RJ@650%$+E7%,0Y4YTILMV"4:$;6%C\JE9B82*(/R(^\<W8,[R+U;#
M#;^.4L$#W4]ZMO&XG\=O\B;E,$S)F6/JTJ1)?C=6CJK<QYPF\C9"FT72)<!5
M,_(79KFDS4HU6=2Z7\HP;;'FQBEW-@WX+;1 2.LL8"J@H[%1,VS\.'(M5TM#
M<<";D2PM-#ER@(Y$RC@B)@/83W-E8DT:[EKMSCK3IQFU<8>60T65$P>4";WF
MSE+(9)BO9J[F2#:J%% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M*J1)1X\>,R#$=H&6&TRMM-B@@*=A!3!$K+<FC)4 H!0"@% * 4 H!0"@% *
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M)VTH!O&^^3MI0#>-]\G;2@&\;[Y.VE -XWWR=M* ;QOOD[:4!7JI!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
00"@% * 4 H!0"@% * __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>p35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p35.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!E .$ P$1  (1 0,1 ?_$ ,H  0 " P$! 0
M       $!0(#!@$'" $! 0$! 0$!              (! P0%!A   0,# @0#
M P<'!PD&!@$% @$#!  1!1(&(3$3!T$B%%$R%6%Q(Y-5%A>!D=%"TV164I+2
M,Z,D**&Q8G*R5'0V-\%#4W.T-8*SXS0E".1CPT1U)A$  @(! 04#" 8) P4
M P$   $1 @,A,4%1$@1A$Q1Q@9&A(E(%%?"QT3*B4\%"8H(S)%0E%N%R-/&R
MTB,&DL)#-?_:  P# 0 "$0,1 #\ _5- * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MJ$TVH"HBH\E%+614I(@R.-'-X'S: GFT5&W5%%(4+@NDN:7K) 8C1X[?3CM
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M3<<99QK+J1@S)L3O:UE,"3GX5O*XDR=8)=8:* 4 H!0"@% * 4 H!0"@% *
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M.&@$*&_ZJZ+IN7 ?"HJG"Y>.I5HE\Q<*YF'2[6N95#3<!$9SK\#M\//U.O\
M+IU?+4Z>W&S_ %*U]F=IUVYLE"G;"S4['R0D1G,=,)F2R:$"Z6315$A6W DK
ME119)\2[.:L^:X_:>%3*=OF$1_H[AQCWQMKU+ZI,Z,1MYOK>?S:7%O\ Y.5>
MAW<6['H<E52NTPA3OAL+ R)4HVL)M_>&2@G)><)18B",EE@77"7W!(A&Y+PX
M4:EOBZHQ.(X*Q'RN6B9,MSS(4E),,]T8/T[PDJMJB=!+@J\-*JG-."UM:Q'^
MUAN9\J-TC'X'%CW;9C W$RHQG766T(A>]*Y# U<%%6^A7K^9/&L3;Y. A+F.
MNS2;^:V+,EXB:P;:89%Q\1J.YZU'O3#8A?ZI"1(MU1.G[*Y5Y>;7B='S<NG
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M V'ZFH41/+IKI=/VI^[&GZ"*QI'WMY]TKQ'I% * 4 H!0"@% * 4 H!0"@%
M* 4 44)%$DNB\%1>2I0'F@=.BR:+6TVX6]EJ : N*Z4N*6%;<D^2@/%::4T<
M4!5P> FJ)=$^1: ], ,5$Q0A7FBI=* ]H#%&FD$10!T@MP2R61?DH#SH,*I$
MK8ZB5%);)=53E?YJ2#U6FE<1Q0'J(ED.R:K?/0 FFB,7" 5,?=-4153YEH#T
MA$A421%%>"HO%%2@(.3P6-R3,5B4UJ8B2&I;30^4>HPNIO4B<T0O-;VI5*S1
MCJF3C #%1,4(5YBJ71:DT: NA:4U(ED6W%$]E ! !32(H@^Q$X<: \;:;;'2
MV" //2*(B?Y* $TV1"1 A$/NJJ(JI\U !::%440$5%-(JB(ED]B4 Z36E!T#
MI1=2)9+7O>] >H H2DB(A%;4MN*VY7H"L=V_%+<3.>:,V)@L%%DB%M$AE5U
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M^9: \-EDRU&V)%91NJ(JV7FG&@(F/PT"!+GS(X+ZG).B]+=);J1 V+0)\@B
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M@-Q8/,-/!FI.5P1L._$&,@0NO@\%E:<CDVV*V+S(0<N5J.R:V0PJM/;H,/W
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MW%KU7+Y9DY'\,]RAA9#!*W(F#/B-PU)Q$TXV$:DWQ\%76JJ->3P=^5K?*_\
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M3)?F?#ZBRVW'>8P[ /"H&NHM"\T0B54O7'/9.S@]/1T=<:3+.N1Z10"@% *
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MG5*FN*J<I),08+!@J[U5CM*ZJWZF@=5_;>UZSN,<SRJ?(9!OKJ:* 62@% *
M*B+S2] :HT6/&:Z3#:-MW4M*<KDMUK;6;U9%**JA(VV2UK<*PL61: \TC[$H
M(/;)[* 4 LE +)[* 63G0"R7OXT LB\Z 4!YI'V)00>V2@%D]E +)>_C0"R7
MO;C0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M@% * 4 H J714O:_BE ?/8F=W!*4,6[E@@R\.S+#-Y VVE174<Z$,U$] )U
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M-_\ \%2?S/\ [*GC,OY;]8^1='_45_#]I%RO<K?+^+F,/;/D,,NL. X\J/6
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M5UZ:S6NTY7^(45E&J+N/(9D,B\P:&T:7$DY+7GM5IPSVTNK*5L*'?'_MC/\
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M 4!!FJB9#'JO+4[_ /+6@)C;K;H(XV2&!<1(5147YE2IK964IR@950% * 4
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M?J)'[.GC\7'U,?XYUON?BK]H_%_M[]J+]1(_9T\?BX^IC_'.M]S\5?M'XO\
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M84_F^SU#^S?M_B'^(#]R_L*?S?9ZA_9OV_Q#_$!^Y?V%/YOL]0_LW[?XA_B
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M?V%/YOL]0_LW[?X@J]_T15582(G%57H4_FNSU#^S?M_B/E^Y]U;DW!):7+2
MDE#,FF!9$4;UDO%00>!*MN=?,S9KY'[3F#]9T/08.FJ^[7+S:N=O^AV^V=K=
MX]OQ'&\1'B,!))'75=)DG%6UD0E+CP]E>W#AZC&O92U/@==U_P ,ZFR>1V?+
MHHF"Y_Q ?N7]A7;^;[/4>+^S?M_B'^(#]R_L*?S?9ZA_9OV_Q#_$!^Y?V%/Y
MOL]0_LW[?XA_B _<O["G\WV>H?V;]O\ $/\ $!^Y?V%/YOL]0_LW[?XB;L+=
MVZ7-V3ML[E::+(M-=<GV= H*"(*@+H3S71Q%O?ARJ^FZC([O'?:CS_%?AO35
MZ>O4=//(W&N_;KZCZ/7T#\R* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MQ=)2M4HF#Z'5_&L^;):R;JKJ(6R.!U->D^2* 4 H!0"@/EN&_P"O.9_X/_\
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MU(2=)$2RT!#VILR/MXW7 ENRW#99B@I@TV@L1M73119!M"/SKJ,N*T!T5 *
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M4LBH2E[RKQJ+W_\ 9.Z2JU]B.PW0L[DY<+&P(NV)'KH45Q9!3F5CM1GFHQ
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MW;#V!N3<VUY6-FY!J!MOX[*D/0EB%ZTR9E]5-+YFB")D*<4"]O&LR956TK;
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MT/E1?>,T2M56]AC<&YV5&9=9:==!MV02@P!$B$9(BDJ"B\U045>%(-DVU@%
M1/BV.^+?".LGQ%&/5^GL5^AKZ>N]M/O<.=;RN),G6"76&B@(SF3@MY)G&&ZB
M3I#3C[+-EN3;) +A7M;RJZ/CXUL.),G<2:PT4!'@SFYC;C@-NMHVZXRJ/-DV
MJJT:@I"A(EQ54N)<E3BE:U!B9$W-#P4K"2ASS8.XED%?EBYJ4-#/G520>)(F
MGEXUM&YTVF62C4G0WHS\1A^*J+&=;$V%%+(K9"BC9.%N%8RD;:P"@,'WA98<
M>(2(6Q4U$$4B5!2]A%.*K\E$#&))"5%9D@)@#P"X(.BH&B$E[$!<17VHM:U
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M 4 H!0"@% * 4 )+BJ>U+4!R";!=#:>"Q#,] R.WC8>@SU:U-JZP*AYV=27
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M34*H:(0K94X7XHM:#4QCH+,V3.:;094Q&TDNW55)&D403CR0;KRHV]AD$C2
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MC;>T)0;JPT4 H!0"@% * 4 H!0"@% * 4 H#3-F1841Z9+=%F+' G7WC6PB
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M!3%?3BXKXMEI5$-0M4]T^63>\U@BX#>,]KM>]NC)*LV5$9FON(B"WU/3O.B
M^5$%/*")>U;;&N?E0K?V98E2>XV.QSTV;(ARF7($EZ03#71*#(;85QK1K-WK
MAJ32MQOR7E>B5&X0]I&&%[E-MX]K[P0Y$%P,..7]6YTB20RT((\8@T1*!:W$
ML"HG.EL6NG&#%DX\"+N7N+D6]M9I&X,C!YV-CDR4!)'1=UL*:!K30KH:A(D0
M@+E=*VF)2MZD6R:/<RPF]T</"S!XYQDW&8LAB%/GHXR(M29*!H%&B-'3%.J&
ML@%4&_R+;%A;4FO(DS9 [B)D<C,AP,1)?&,<ED'T-A$5^+J10=;U]1A'"!4
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M&0;\-O*0LK'@M36BR,N$#)Q& CN(3;"*+X*((0WLM[IRIWRCA'8;W99!M/=
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M(]P6SMN8)XW\9$Z+QMBQU#<=>(606XM KI'H;1?U1LE+9';:%1+87-04* 4
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M.S.,:/'2W <QL%F)$Q9B*"X8LQQ%UT[*5M3G(?"WRU%VGKO+JFB\J"A0"@%
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M/=0B?U:=)Z@3CRLE1;%5.-Y2O9ZFZ5N[?;8X7&-O+)R.2QYY=^7"@"]H'Z(
MC@R3P)H0W;DXI7Y)9+UBI75\'&T.UM$;9VZM_NMSGA=8P[^+P$;+R\>['ZY+
M*)9'494M::6U].B>*I14KY9<&NUO436-T[KSDS(.8J7#Q<?#QH+YL2VU,'SE
ML))/J/:A5IL1+0A"G.Z_)4\E5$ZR;S-["+#WOO3(;H=2#!==Q,;+%C'HPQA5
MI([:H#D@I2N(2."2ZM&BVGASXUKQU5==L&*[;\Y],KSG84 H!0%9N./EY.*<
M8Q+RQY;BBG5 @;- OY]!FV^(EIY*H+54:G4FTQH4<#:C[6"RV.:QT6%*R#)
M<V0Z63*2Z0J.J7UFP)T>/%")>"JB6JW?5.?T$JNC*.1VYSV2/(SGV\=B9SK$
M%J%%A=0XY.X^2LD77UT,KYE^C1$'RCXK5K*E"U?^I/=MDB7L7<N0ER\_)*&Q
MG2F8^5"A@;KD9 QVM$;<>4 .[O6/S(WY>'.L61+3=KZS71O7>=%M/!Y.%*S&
M4RJLCD<U)"0ZQ&(C::!E@([8(9B!&NEJY+I3BM1>R<);BJIZM[RFPFQ\O!39
MO6=8+[OK-6;I(EU>I:, Z5Q2]E/C>U5;(GS=I*HU'844S&S=D'B\P[*A)(0<
MG#=9D+)1HFYDTIK9-FRRZ6L;HA"0IJ\%X5::O*\A+7+J6/;/;N:&!MR1E8_I
MX^)QB^E:/RN++F.$KIDVOF#ILB(IJX^<JS-=2XWLW'5Z28Q=B;MCGB,6)02P
MN(S195N4KCJ27&C-X^FK73T(8J^O'79;>%'DKJ][4!4>BW26NR\3O+ QPQ4B
M' =Q_JY+Q3 E.]7IR'S>2S*L(.I-:);74Y+5MJ51-:%7W"V#N;<$S*>D*'*B
M3\>D2&DYZ0VD)Y$-#<;9:$@<5W6/F)45+>*<*K%E58\I-Z-DG,;$S4[$[NBM
MN1P>S[,5N)J,]($Q'!H^HJ!P34*VLB\*RN1)KL-=&T^TBY?8N[G!RV,@%!+%
M9;+QLR4E]QX9#:MOL/.LHV+9 7&/Y"U>/%/&MKDKHWM2@QT>J[3LMTXAG+X@
MX+^/:R;3A@117W28'R$AB:. )DA"2(J6KC2T.9@Z64HB[2QVX(#<AC)ON/1D
MT>B%Y\9+@(E]0JZC+!$G*VO47RU5VGL%4UM*G'[-S,/M^U@K09&18DN24;E
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M>-DK>1S&\SF426K3K;S0.M$AM."A 8K="$DNBHJ>"I4%&5 * 4 H!0"@% *
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M@% * 4 H!0"@% * 4 H!0"@% * 4!2[LW"6#QK3[+"2ILR2Q!@QR+I@3\@T
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M.&W.RA/O$R1"[K(&F$$#N:@R2W*R<DJ:XU";>TVUW.FXJL/E\QG.YC3Z/6P
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MLK<AQZ0IO 3K<<[ HL1F7CUD*IK+2@"7Y$JJT5G.Q&.S143MVR,KN2&?K<Q
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M$4X(B)P1$KR'H/: 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MA[>VDS@B$(N1G/066U9B8Y]T388;NBH(6 7%THEAUF5DX5MK\VXRM8+VH*%
M* 4!"S&(@Y?'.P)HJ3#MEN*J)@8$A 8$G$2 D0A7VUM;-.48U), =("-U*R(
MFI>:V\5K#3V@% * 4 H!0"@/$$4551$12XDJ>*_+0'M * 4 H!0"@% * 4 H
M!0"@/!$1OI1$NMUMXK[: B9?%1LMCG\=*(TBR4T/BV2@IMW\P*2<=)IY2MX+
M6UM#DQJ24VV#;8MMB@-@B" "ED1$2R(B)6&F5 * 4 H!0"@% * 4 H!0"@%
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MS1L%E!@2#FQ79;,C&.FYTD8($(7P-+BA=3RE?FEJRU%$HU7<PRXG[QV] GK
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M"A(B_*EZXVK#@ZU<J2=4FB@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% .% * 4 H!0"@% * 4 H!
,0"@% * 4 H!0'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>p37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p37.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!I0.$ P$1  (1 0,1 ?_$ ,L  0 !!0$! 0
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M-!V!Q?&6X]\;%74T(S7EW6335G$Y['*CM:[1I-.NUB-0Z=BC:#4-T@7--28
M[#(9,_$XN7;E_P#HM>XIGEQ/G9][;&<QYF_UIVRW61^D:33U3262'5%+UU]Z
MN;<\-.W=PL-C<P=L).S=NWK/3T(VYVX7OJSLQLR]"T)]\_JZ;[SU]ONCB\&@
MK[:US&RPEN.:1I] '-NR[%AJ<N?TYAK3/:Z59KB @(" @(" @(" @(" @("
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M\@D NQ:,-_HXE.IO%IC&V4:-9C+U5<S<0$! 0$! 0$! 0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0<Y3
MZ"L,&MZG6<?&^N:NG%++C)C#PVAH&#,-A_-CNK2=2>7E[%.2.;/:Z-9KB @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @Y^TZ&L=LU1==3P\:6\7=K65,\
MTF<-C9AECB;@,C?1&SO+2VI,UBO9"D4B)RZ!9KB @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @M<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MA
MT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.
M@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.
MI]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L
M.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AY
MT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#A
MU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/M
MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/
M.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<
M.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]
ML.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.A
MYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#
MAU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/
MMAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT
M/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@
M<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I
M]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@<.I]L.AYT#AU/MAT/.@-94!P+
MI01W1EP_XH+J @(" @(" @(" @(" @(" @(" @(" @(" @("##O-WH+/:ZJZ
M7!YBHJ.,S5$@:YY:QOK.RM!<<.\%-:S,XA$SB,N$_F'[(_ML_1:KY);^%U.#
M+OZ<3^8?LC^VS]%JODD\+J<#OZ<3^8?LC^VS]%JODD\+J<#OZ<3^8?LC^VS]
M%JODD\+J<#OZ<3^8?LC^VS]%JODD\+J<#OZ<3^8?LC^VS]%JODD\+J<#OZ<5
M]O;SV7.H9*]MV<:.*5D$DW5JG 2R-<]K?T>.UK'%1X:^<83WU>*Q_,/V1_;9
M^BU7R2GPNIP1W].)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7R2>%U.!W]
M.)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7
MR2>%U.!W].)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7R2>%U.!W].)_,/
MV1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7R2>%U
M.!W].)_,/V1_;9^BU7R2>%U.!W].*_#V\]ETU+4U45V<^GHPPU,@IJG!@E=D
M9C^;_"=L4>&OP3WU>*Q_,/V1_;9^BU7R2GPNIP1W].)_,/V1_;9^BU7R2>%U
M.!W].)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9
M^BU7R2>%U.!W].)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7R2>%U.!W].
M)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7R
M2>%U.!W].)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7R2>%U.!W].*_3=O
M79;4LJ'P7=TC:6(SU!%-4^A$'-87'&/G/ 43TU^">^KQ6/YA^R/[;/T6J^24
M^%U."._IQ/YA^R/[;/T6J^23PNIP._IQ/YA^R/[;/T6J^23PNIP._IQ/YA^R
M/[;/T6J^23PNIP._IQ/YA^R/[;/T6J^23PNIP._IQ/YA^R/[;/T6J^23PNIP
M._IQ/YA^R/[;/T6J^23PNIP._IQ/YA^R/[;/T6J^23PNIP._IQ/YA^R/[;/T
M6J^23PNIP._IQ/YA^R/[;/T6J^23PNIP._IQ/YA^R/[;/T6J^23PNIP._IQ/
MYA^R/[;/T6J^23PNIP._IQ7Z/MY[+JV5T-+=G2R,CDG<T4U2,(X6&21VV,>J
MQI*B>FO'8F-:L]JQ_,/V1_;9^BU7R2GPNIP1W].)_,/V1_;9^BU7R2>%U.!W
M].)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU
M7R2>%U.!W].)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7R2>%U.!W].)_,
M/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7R2>%
MU.!W].)_,/V1_;9^BU7R2>%U.!W].)_,/V1_;9^BU7R2>%U.!W].(?\ <1V1
M $F]G ;_ .RU7R2>%U.!W].+(K^WCLNH*N2DK+LZ&IBR\2,TU22,[0]NZ,C:
MUP*B.FO/8F=:L=K'_F'[(_ML_1:KY)3X74X([^G$_F'[(_ML_1:KY)/"ZG [
M^G$_F'[(_ML_1:KY)/"ZG [^G$_F'[(_ML_1:KY)/"ZG [^G$_F'[(_ML_1:
MKY)/"ZG [^G$_F'[(_ML_1:KY)/"ZG [^G$_F'[(_ML_1:KY)/"ZG [^G$_F
M'[(_ML_1:KY)/"ZG [^G$_F'[(_ML_1:KY)/"ZG [^G$_F'[(_ML_1:KY)/"
MZG [^G$_F'[(_ML_1:KY)/"ZG [^G$_F'[(_ML_1:KY)/"ZG [^G%?J^WGLN
MHWQ,J;LZ)TT4=1$#35/I13-SQOV1GUFG%1'37GL3.M7BL?S#]D?VV?HM5\DI
M\+J<$=_3B?S#]D?VV?HM5\DGA=3@=_3B?S#]D?VV?HM5\DGA=3@=_3B?S#]D
M?VV?HM5\DGA=3@=_3B?S#]D?VV?HM5\DGA=3@=_3B?S#]D?VV?HM5\DGA=3@
M=_3BG!_N![)YYXH(KT72S/;'&WJU4,7/(:T;8N4J/#7X)[^G%Z(L&H@(" @(
M" @(" @(" @(" @(" @(" @(" @(" @(" @Y3M7_ /6NIO\ +JC]F5KH^_'G
M4U?=E\,#<O9>8(" @("#HJ;_ ->7'_-Z/_#5"SGWX\R_\/I<ZM%! 0$! 0$!
M 0$! 0=%8O\ 2.JOB6__ !2SM[T>E>NZ7.K100$! 0$! 0$! 0$'0:5_<M2_
MY/+_ (FG5+]GG7KV^9SZNH(" @(" @(" @("#HM"?QFK_P JNO\ ^OF6>IN]
M,?>O3?Z)<Z-P6B@@(" @(" @(" @((R_HW^ ^)!TW:-_K2X^"F_PL2STO=A?
M4WN;6B@@(" @(" @(" @(.BUM^^VG_);9_AFK/3[?/*]^SS.=6B@@(" @(,V
MR_QNV_WNG_:M46W2F-[]!5X3U1 0$! 0$! 0$! 0$! 0$! 00GG@IX))YY&Q
M01-+Y97D-8UC1BYSG'8 !O*1&1H]-Z^T9J:>:GL-WI[A/3C/+%$[TPPG#.&D
M N9C^$-BTOHWIOC"M;Q.YGZ@OUJT_9JN\W:;J]NH6<6IF#7/RLQ QRL#G'?W
M JTI-IQ&],SAFPS1SPQS1G-'*T/8[=BUPQ!VJLPE-!K+GJ2SVRYVNUUL_"K;
MS))%;HLCW<1\+.(\9F@M;@S;Z1"O6DS$S'8B;1#9JB6%>KU:[):ZBZW6H;2V
M^E:'5%0\$M8TD-Q.4$X8E6K6;3B-Z)G"U)J6Q1W.@M;JR,W"Z1OGH*=N+G2Q
M1@.?(,H(R@$;3L4\DXF>R#,-DJ)$! 0$'*=J_P#ZUU-_EU1^S*UT??CSJ:ON
MR^&!N7LO,=A2]E&M*FQLN\4$&26F=7P4#JB-M;)2,WSLIB<Y9XUE.M7.&D:4
MXRMVKLOUA=+''>*2" PSQ2U%'2OGC95U,,'Z62"!QSO:W_Z);6K$X(TYF,L2
MGT)J&HTG4:KB;3OL]*&F=PJ(C.P.EX+<T )D;B_=F V;5,ZD<W+VHY)QE=LG
M9[J&[69UZC=1T-LSOC@J;A51THGDC&+V0"0XO([R6U8B<=I%)F,N9&T8K11T
M5-_Z\N/^;T?^&J%G/OQYE_X?2YU:*" @(.OH.RG6=?9([O3P09)Z=]92T+ZB
M-E;/31>O-%3DYW,'PK*=:L3AI&E,QE"S=EVL;S98[O0P0F&I9+)0TTD\<=55
M,I_TKJ:!QS2!F&U+:U8G$D:<S&6)2:$U#5Z6JM40-IW6FB;FJ?[1'QV#B<(8
MP F08NW9@%,ZD1;E[412<9;'3W97J"_TU'-;KA:#+7#^ST4MPB95$XGT3!M>
M';-RBVM%=^?4FNG,\'*5U)-15M11S%IFI97PREAS-SQN+797#>,1L*TB<PI,
M+"E @(.BL7^D=5?$M_\ BEG;WH]*]=TN=6B@@("#KM/]E>L+]:H;E014[8:L
MR-MT-141P3U;H?T@IHGG&3*LK:U:SB6E=.9C*&G>S+5VH*(UE##!%$Z9]+3,
MJZB.GDJ*B,8OAIV2$&1[>Z$OK5K.)*Z<RL6CL]U/=K7<[E210""T-G?<(99X
MXZB,4S<TIX!/$]'=CEPQV*;:M8F(XHBDS&5S2O9OJC4]"^NMK::*C;.VDCGK
M*B.F;+4O&9L$.?UY".XE]6M9Q*:Z<V<]7T-7;ZZHH:V)T%92R.AJ(7>LR2,Y
M7-/@(5XG,9A28PL*4" @Z#2O[EJ7_)Y?\33JE^SSKU[?,Y]74$! 0=3I?LVU
M3J6A-=;VTT5(Z?JE/+65$=,)ZDC'@P9S^<?AW L[ZM:SB6E=.92L?9EJZ\25
MK(8(:,6^IZC4/KYXZ5O7"<!3,+SZ<IPW!1;6K!73F5+)V9:OO-=<:"EIX8JZ
MU/?'6TM3410RM=&"Y^6-QS/  WM!"6UJQ$3Q(TYEC:5T+?\ 4\5346X4\-'2
M%C)ZRMG930"24X1Q![][W]P!3?4BN]%:3+57>TW&SW.IM=R@=35]&\Q5$#L"
M6N'?&(((V@C>%>MHF,PK,8G$L-2@0$'1:$_C-7_E5U__ %\RSU-WIC[UZ;_1
M+G1N"T4$! 0;O2^D+UJ6:I9;A#'#11\:NK:N5E/301DY0Z25^P8G<J7O%=ZU
M:3+8CLOUC]Y)]/OIHHZRFI^NU%2^>-M(RD(Q%0:@G)PSRJO?5QE;NYSA4=EN
MLCJ!]C-/"V>*E%PDK'3QBB%&1LJ>LXY.&>5.^KC)W<YPI+V7ZRCU'#I_JT3Z
MNHI^O05+)HW4CJ0#$U(J,<G"&&TIWU<9.[G.&KU/I.\Z;JX:>Y-B<VJB%11U
M5-*V>GGA<< ^*5GHN&*M2\6W*VK,;VG5U1 01E_1O\!\2#INT;_6EQ\%-_A8
MEGI>["^IO<VM%! 0;"PV*ZWZ[TUHM-.:FX5;LD,((&X$DN<< UK0,22JVM%8
MS*U:S,XANKKV9ZMM];:Z00P5YO4CH+9/;YXZF"65AROC$C3@',_"QW*E=:LQ
M/D6G3F$KIV7:QM]9;J3@0US[K.ZDHI*">.IB=4L]>%SV'!CV?A!V[;R)&M6<
M^0G3F$;]V::HLG4G575)Z>OJ#10U=+5130-J6G!T,LH(;&YO=S;$KJUDMIS#
M!U7HR^Z5J*2GO#(6OKH!54SH)F3L=$7%H=GC);M([A5J:D6W(M2:[VC5U! 0
M$'1:V_?;3_DML_PS5GI]OGE>_9YG.DX;5HH[!W91K1MB=>#3P9&4HN#Z#K$?
M7FT9_P#N#38Y^&LN^KG#3NIQE;INR[6-3I]M\BIX3 ^F=70T9GC%9)2,.#JA
ME,3G=&.5)UJYP=W.,IT793K.LL<=W@@I^'-3.KJ:A=41MK9J5GK3QTY.=S/&
MDZU8G!&E.,EK[*M972RQ7:DAI\E3#)545%)41LK*B"+UY8:=QSO:/A2VM6)P
M1I3,9<@M6;-LO\;MO][I_P!JU1;=*8WOT%7A/5$! 0$! 0$! 0$! 0$! 0$!
M!Q/;5;+G<^RS45%;(7U%9+3 LIX@2^1K)&/D8T#:26-<,.[N71TMHC4B99ZL
M3-9PY2KU[H6Y"2XZ;M=3=KI9=/U;A<+>U\#Z.(,:!1ESF^C,\CT6Y'%N&."U
MC1O&RTXB;>ORJ\]9W<'ETE]K*G2^N:"&X/J[34:9IZ]L(J*RLC%4:AK)7-EK
M"7F08Y9,F#,>X",%V<D1:LXV\WD_!E%MDNAU+7ZJ?V@RTLE\%CDA9:3I=U1-
M71QOA,;#.(*>F9)!4F23,R42;1X%E2*\F[._.[[06F>;>N6Z>]055MOL5RKW
M7%^O:JT&%]5.ZF-'(^3&$P%W#RXC?AL2T1B8Q&.3/I3$SO\ ]3362[AUZT;<
M:FKN5RUC3U5ZFU);9))W.AJ64L_#BBBE!BA<6M#8PP;1W"KWKLM&R*[,*Q.V
M..U"S:KNCZ:_FANE0::OT?75\L(K*VJ='7Q.&&>:IPPJ8VOP?P0UHY%-M.-F
M8_CCLC=^1%M^WL>^:'TW1-[/Z2WUDM1<H;M1MEN#J^9]1)(:N%O%:7/.QNW
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M)!TW:-_K2X^"F_PL2STO=A?4WN;6B@@(-WHNT7:\:FHK9::P6^LJG.8*TRF
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MO;D# 8X]U 0$! 0=%8O](ZJ^);_\4L[>]'I7KNESJT4$! 04+6DXD! +6G>
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M-,;"U_KMRC X;L1AM02<R-X >QK@TXM#@#@1N(QW(#V,>TM>T/:=[7 .'O%
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M]P^)0**00$! 0$! 0$! 0$%$$I/7*@44@@(" @(" @(" @(*OWCP#Q*!12"
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MU1\QUHB(TZ[OMA;Y-TTS,ZU]\[OQE[ O*?0" @(*CU7>YXU HI! 0$! 0$!
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M[Y?3:7NQYH7E#00$! 05'JN]SQJ!12" @(" @(" @(" @JW<[P*!12" @("
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M!!7(_+FRG+RX'#WU&3$J\*41"7([A$Y1)@<I(VX8\J9[$\LXSV(J4" @ $G
M#$G< H @@D$$$;P=A02X4O,=T2F83RSP(XI)9!'&POD=L:QH))\ "3."*S,X
MA$@@D'81L(1"3HI6,8]['-9("8W$$!P&PX'NIF$S68VHJ4" @("#9:<_B\7Q
M9/V;ECK^Y+JZ+^;'I^YU*\][P@(" @(" @(" @(""Y/^E=[GB""V@(" @("
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M:=C,P [YQWJO?3B9X1[6OA:\T1\4S_VM?7TM$ZW1U]+&Z &9T#HGNSXY1B'
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MC<, UV;'*\$''<NG3U;Z,6C&)M';Y_*G.&8W4D@B;%P?S89D>S.0'?FV,!(
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M8>))O/&0,LKFY72.+3ABTN)&S8-G>43>9V9D0.Y5&;>/WT?J8/V+%U=9[_\
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MO.F ZQ'W_>\Z8#K$??\ >\Z8#K$??][SI@.L1]_WO.F ZQ'W_>\Z8#K$??\
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M^T==(^.)DC2QN<EP&[$#N'OJFIHS6,RVT.KKJ3B(EF]8C[_O>=98=)UB/O\
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M[QLPP:YP&]3RSC/8C.W#,4)59O/@/B4"BD$! 0$!!7\ ^$*!12" @(" @("
M@(" @J/5=[GC4"BD$! 0$! 0$! 0$!!5NYW@4"BD$! 0$! 0$! 0$!!5F_W#
MXE HI! 0$! 0<WKK^&0?KQ^(Y>!_<7\FO[OPE2^YQ(!.. QPWKX_#)1 028Q
M[W!C&ESW'!K6C$D]X!3$3,XC>*!KB<H!+N0#:HP#FN:<' @CN$8%)C H@(""
M61X8)"TY'$AK\#@2-X!4\LXSV"*@$&91?NEP_4M_:L71H>Y?]L?^4)AAKG0(
M" @("@>G63^#4'ZAGB7Z%\M_X]/VPWC<S5W)$! 0$! &\>%0,U0D0$! 0$!
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MTOUN?17^Z5,$5BO,E#>/2I:M\<-2PQ-XA;FD8"-C]F<!-T3F(WP;YW]DO5M
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M'%C>#Q,-PQQQ[ZMK6Z>UYG-9F;7Q\.Z.7/VWDX6W?=H%S&MA+9'2AS\7>AA
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MECP>PU _.9FO&)Q![JRC4M68_P!/XNR>ET=6+3OC4QG$[^7<ZCL3&&LGC_\
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MA7L?*/>MYGYW_P#87\K1_=;[GN2]Q^7B @(" @N3_I7>YX@@MH" @(" @("
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M,!R(& Y$# <B!@.1 P'(@8#D0,!R(& Y$# <B!@.1 P'(@8#D0,!R(& Y$#
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0W!QQ\2"Z@(" @(" @(/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>kpmg.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 kpmg.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@ 0 "C P$1  (1 0,1 ?_$ +<   (# 0$! 0
M      8'  4(! ,! @$  @,! 0              ! 4  P8! A   0,"! ("
M"PD+"P4      @$#! 4& !$2!R$3,2)!46%Q(Y,4%587"(&A,D)R@K1U-I&Q
M8I(S<]/%%D:&4J*RH[,D-'15=C?!4U2D&!$  0," @4)!P4! 0       0 "
M Q$$$@4A,5&Q4D%A@<%"<A,S%'&1T2(RPH/PH6)#%>&2_]H # ,!  (1 Q$
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M,)Z0_3XKKSILBI&9LB1$2KTJJKGCS<7<HD< XZRO4%K$8VDM&H*Y]5NW7H[
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M>>!IL5)QPD$!3I557)$QHR5G0%L2D[36O#I<2*?EG,89!MQ6ZA-;%2$40E0
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MVC6KDK5RP:=3Z9,E0J:QJ5UEATP5Y]=19$(JBY (8LRK QA)(!)VJO-,;W@
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&BF(HO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>exh991_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh991_01.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MP  +" != /8! 1$ _\0 'P   04! 0$! 0$           $" P0%!@<("0H+
M_\0 M1   @$# P($ P4%! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H " $!   _ /9J***********************************J:IJ5
MIH^F7&HWTHBMK9"\C'T'8>I/0#N37.>#O$FN^+';5'TV'3=%.1;K+EI[C_:S
MD!5_ Y[>M==7->*_'.E>%4$4V^[OW7='8VXW2L.I8C^$  G)]#7/>"/BU'XO
M\1MI,FF?8M\1>!A+YA8KR0>!CCG\#7HU%%%%%%%%%%%%%4]5U6QT73I=0U&X
M6WMH1EG;^0'4GV%</;^,_%?C"Y9?".DPVFF E3J>HJV&YZHHZ_3GWQ7G\GB?
MQPGQ$&B6?B274)ENQ"&50(G.1NR@X '.?0 U[AXD.K#0;HZ&%.H!?W*L 0QS
MTY(QQWSQ4/A*/7(_#\*>(I%>_4E6V@< <#D$[B<9SQUZ"MJBBBJNI:E9Z1I\
MVH:A<+;VL"[I)&Z*,X_F0*F@GBNK>.X@D62*5 Z.IR&4C((_"EDDCAB>65U2
M-%+,S' 4#J2:\YD:Y^*'B"#REEC\(V$A,K,=HU&13P .I3IU]^_3T=$6-%1%
M"(HPJJ, #T%<?XX\;MH;Q:)HT#7NOWPQ;P(,^4#GYV_(G'MD\5SUYH-C\/O!
MFIZYJ]W]M\17T#1?:I6WMYCKC:F>PZD]< ]N*RO@1X;82WGB*YA91M\BU++@
M-GEV!_ #(]Z]HHHHHKG?$?C;2O#LB6K&2^U*4XBL+1?,F8]?NCH,<\U/X?O]
M?U(O=:II<.F6KJ#! 92\_P!7X 7CMU%;=%%8'C'QAI_@S1_M]Z#*[MLAMT8!
MI6]L]AW/:K'AF[UC4-&CO-;M;>TN)SO2"$D^7&?NAB>K>N*R?%'Q!L_#^IV^
MCV=I)JVKW# +9P. 5STW'MG_ .OTKJ86D:!&G18Y"H+HK;@I[C.!GZU\W_$W
MQC)XN\4&UMKC&F6C^5 "_P"[9LX,A^OZ"O0[OQE=2Z1!X5\ VAU*]@MT@EOK
M5=MO;X&"58\9XR"3CW-;/P\^',/@Z*2\O7CN]6GX><#(C7^ZN>>>Y[UW%%%%
M%%>7>,[R?QMXWL_ ]AEK"UD6?57&0,#G82.V"!_O,/2O3 (+*T RL,$$?5C@
M(H'<GL *X2XN+CXF71LK%I(/"T#C[3<[2K:@P/,<9_N @9;O7=6EI;V%I%:6
MD*000J$CC08"@=A7.^//&MIX,T1KARLE[."MK!W9O[Q_V1D9_+O7,?#NSCT#
MP_=^-?%ESY=_J3&0RW7RNJ '  /=L$@#J-N*H_V-J?Q;\16^KW\4EGX6MF(M
MHG.U[@ \G';=QD^@P.>:]'U76M%\):4DNH7,5E:QC9$N.3@?=51R3]*S/"WQ
M!T?Q:;\V27$$-AAGFN$"(5.><YXZ'KBN/\=_&![&V$'AJ$N)MRIJ,L?[ML<$
MQ _>P<C)&,CO76?#>3Q)=>%TOO$UT9KB[;S859%5DB(&,[0.O7\:ZN21(HVD
MD=41 69F. H'4DUYYJ/C'6/&-Y+H_@+:L47%UJ\HQ''SC"<')]_R]:Z+PIX)
MTSPK"SP[[J_F ^T7LY+22$#WZ#D\#\<UT=%%4=9UBQT'2YM2U*<0VT(RS'J?
M0 =R?2O-/#6D7GQ+\3+XRUZW:#3+1@NG6A *R $G)SU&>2<<GCH,5T7Q(\?P
M^#-+%M9E)-5N5Q!'P1$/[[#T]!W/T-9_PO\ !7]B!M;UF83ZY?QB0!WW/%&P
M!.<\[B>I]L>M7OBWXCF\/^#)4MB1<7[&W5@#\BD'<<CH<<#ZUS/P@^'C6T;>
M(-<LHRTR#['%,,LBG.7*GCD8Q[9]:]:@M;>U4K;P1PJ3DB- H/Y5+111117-
M>._%2>%/#TEQ'\]]<?N;*$<L\AX! QSC.?T[UF^#-%M? ?A"34==EA@O9]UQ
M?W+G)R3D+GJ<<<#J<XI?(O\ XAIF]AET_P -$G;"6*7%]@D9?ND?&<=3]*["
MTM+>PM(K2TA2""%0D<:# 4#L*6ZNH+*UENKF58H(4+R2,<!5 R2:\&MK6\^,
MGQ FGN#-#HUH"H9,9CC_ (5!(^\QYY]_2O2+'X3^';=XVO9=0U40L&BCOKDN
MB8Z848';H<TWXB^.CX*LK.STNW@GU&Z(6& @D(@P,[5P>>@_^M7D7Q"2:W-N
MFN7\M_XCN!YUVOF#RK)3]V-5'&XC!/T'KFNG^'WA6XD\(/J'B:=K;PY$6NA9
M ;/M1QP\A')7 P%[\?CF^$+ _$_X@R7VI6ZQZ98QAEMH@%C1 ?W<0'H223Z\
M^M>[WU]9Z3I\MY>S);6MNFYW;@*/\]J\]CDU+XK79RL^G>$H9!E6&V34".>O
M4)T_QSTJ?$3QI??#J6QT3PYIMG:VLEMO$C1DX.=N ,@9  R3G.16EX;T#QYJ
MPM[WQ-XHD@MR XM;((CN."-SJN /IGZBO1**:[[$9R"0H)PHR3]!7B/BO3_'
MGC[6Q=)X=G32K)_]'L[MA") .[ L"21QQT' [UV/@?7O&U[.MMJ_A&"PL%.P
M21_Z/Y7&>(V)+#Z>M6-?^$_AWQ'K+ZI>37ZS2',BI/E6]OF!('L,5SNK? BR
M>)&T;6;J&<-AC=$."OH-H!%=QX2\,S>'_#HTO4M1DU9F<NS3C*C./E .?E^O
MJ:Z&BBBBBBFLRHA=V"JHR23@ 5X5?0:A\6?B'=W.AWBV=OI,:BVN'R/NMP1C
MH2=S ^@%<OK \7>#O$=K/KHEN)K:0R0&\8SPRX[KDX/7V(XZ&O4O#GQOT&_M
M]NN*VF7"("S!&DC<]]N 2/Q_.O0-)U:RUS38M1TZ8S6LV?+<HR[L$CHP!ZBO
M,/C#XDFU"[L_!&D2A[B[E3[2%<#DG"1GTYPQS_LUW_@WPS#X2\-6VDQ.)'3+
MS28QO<\D_3L/8"F^,O%EGX.T*34;G#RGY;>#.#*_I]!U/M7G?@C0=<O3J7Q#
MUFS^V:D\#R:;;2*<NVWY6 [#^%?S]#5;PM\+M9\1>(9=?\;1-'%)(7:W=_WD
MS=@<?=4=.N>*T?CEKZV&CV7AJT9$^TXDFC5?NQ*?D'L"P_\ ':ZWX8Z"N@>"
M+*-[1K:ZN1YURK$EBQZ$^GRA>*J_$OP-J7C6TM(K#4DMA;EF:&7.R0D#!X[C
MG\ZYC1?^%L^$;*/28=%L]2M8<1P,SJ=H]B&4X]V%7H/ _B3Q?XJL]>\:QV=M
M;V:J(["!BV['.#R1]X\\G.,=*]0 P,#@4M%%%%%%%%%%%%%%9WB#39]9T"]T
MVWN_LDMU"8A-LW;0>O'N,C\:PO GP]L_ \4[0WL]U<72J)F;Y4XZ84?4]2:Z
MBYL[6]B,5W;17$9_@E0,/R-<Y-\-/!D]U]J?P_;>9NW84LJY_P!T';^&*Z=$
M2*-8XU5$0!551@ #H *Y?2_AWH6E^)KCQ$!<7-],Y=&N)-XB)&"5]SD]<X[8
MKJJQM<\):'XDGMYM8L1=M;9\H-(P49Z_*#@]NOI6NB+&BHBA548"@8 %.KC-
M;^&&C>(O%7]NZI/=7 VA3:%@(R , 9 W8SSUZUV*(L:*BC"J, >@IU%%%%%%
M%%%%%%5[N_L["/S+V[@MD_O32!!^9K,E\:>%H%+2>(]+ 'I=H3^0-4S\1?"[
M2&*UOY+Z7LEG;2S%O7!52#COS5>[^(UI;J?(\/\ B&Z;&1Y>F2*,^GS8K!O?
MC#<6>IP:>W@W4DGNMOV>*=Q'))NX&%P>_'6O2H7>2"-Y(S$[*"T9()0XY&1P
M<4^BBBBBBBBBBBBBBBBBBLV^\1Z'IJDWVKV5O@;B))U!Q],YK"_X6AX8DWBS
MEO+]EZ"ULI7W?0[<?K0GBOQ-?1F33O UV$)&UKZ[CMSCU*\D4L<?Q&NHW:6Y
MT"PW?<1(99F3ZDL!G\*>GA;Q#=;'U/QI?A\'<EA!% @/ME22/K^E,C^'&EM*
M9K_5-:U&0DY:XU&0?A\FW JY'\/_  C',9O[ LY';.3,GF9SW^;//O6C'X>T
M2)%2/1[!%484"V08'Y5>BBC@C6.&-(T48544 #Z"GU%);6\LL<TD$;R1?ZMV
M0$I]#VJ6BBBBBBBBBBBBBBJ>H:OINE1>;J.H6UFA. T\JH,^G)KG)/B;X>:5
MH=-6_P!7D7C;I]F\H)] < ?KVI_]N^+M2MHY-+\+)9^:>)-4N@I0=B8TRWX9
M!IDVD>.M291=>)+#3(A]Y=-LRS/_ ,"D)QVZ42?#G3[V4R:QJ^L:H2>4GO"J
M'T&U HK4TSP7X9T9M]AHEG$^<[S&&8?1FR16RB+&H5%"J.@48 IU%%%%%%%%
M%%%%%%%%%%%86J^-_#.C(YO=:M%=#M,4<@DDSZ;%R?TJ@OC>XU+8/#_AO4M0
MW#)EG3[)$/\ @3]3] :8LWQ#U R 6NBZ/$[$*9'>XEC''/&%8]?3I2#P3JFH
MQJOB#Q;J-ZFXL\%L%M8VR.AV?,1^-7-.^'WA32YQ<0:-#).,?O;@F9LCOER<
M'W%=#'%'#&(XD6-!T51@#\*?1111111111111111111116'>^*(8II+;3;"\
MU:ZC<QNEK'\B..S2-A5]^<^U9Q/CS5V8;=-\/V[8 R3=7 &>3V0''UZT^+P%
M;SNKZUK.JZS@$>5<W&V'G/\  @ []\UJ:;X5\/Z/_P @_1[.W.=VY81NSVY/
L-:U%%%%%%%%%%%%%%%%%%%%%%%%%%)C%+11111111111111111111117_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>exh46_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh46_01.jpg
M_]C_X  02D9)1@ ! 0$!- $T  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ L ! 1$ _\0 '  !  (# 0$!              4& P0' @$(_\0
M4Q   0,# P,# @0#!00'! 0/ 0(#!  %$082(0<3,10B05%A%2,R<19"@1<S
M4I'2)&*4H0@E-'*"P=%#4['"-41D<Y+3\"=%572#DZ*5LK/A\?_:  @! 0
M/P#]4TI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I7PD#&?VK[2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*5A8CAEU]P+=475!1"UE03P!A(/@<>!\
MY-9J4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I0G&."<TI2E*4I2E*4I2E*4I2
ME*4I2OBOTG'G%<'T?U0U=?[M-MZ7--F?%NCL(0>PZAU]II20XXE1=*4G"N K
MR1CYXD;OU*U39=?7+2EPML)R=(8[E@6PPZ43%%0]KAW':$ISN/@;2<^ <NJN
MHNH=/ZZC:;EKL#.ZU(N#DMU+NS?W-BD!(5D9((3Y/(\\U)S>H%Z:N>G]+M6N
M*G6-R:6_(;<=/IH;22H=Q1&2H*V^U((SGDBM37G4?4NAK*W)O%B@/.>O:@!U
MJ2H-/]Q"E!U *2I."G!2<_8GS5GNM_U&U?7K1:+;;9DAF+%?6MV2II*.ZMU*
ME$8)*4]HG Y.X55]+=2]1WVS7FZHT];O1VMR7'>VSEA7<81N\%O.U7@>2,<B
ML$?J]/38=$7R?:(+-HU#)$5^0):O]C45$)SE !! /.0!@_'-2'4#JA-TG9M0
M79JT19L&VSF8+*O5*07U*0"Y_(0-BE!/G!PKD$8JSZ+U%=;W+FMW&WP&8S(P
MU*@S%/H6L+4A;9W-H(4DI&?(YX/FJ;(ZJWE6K-36*W6"VO2;.\AEL/7);2IB
MEH6M"&QV2 LA!X40,_-27]ISL;JO'T?<[2B-'E-GT\X2-VYWM)<[:D;1C@D9
MR<G&/G$-&ZSR)ZM<O6ZQL+A::BIE(<=F%*IB%#<E20$':DH2I0Y/E/C)QI,]
M=9/X?<E/Z=:$Z/9FKZRVW,6IIQA>S*5++0*%@+_PE)/&?!/26M7-1.G36K+Z
MTB(QZ%,YYME9<VI4D*"02$Y/(&,#DXJI)ZK2X-LTW>M161B#8KZZVRR\U,+S
ML=3@W-EU';2 "GDX4<?>LC'55R/>M76B^VEJ#<;*TEZ*RW)4\;@%G#>P; >5
M%"?!P5_:ODCJE*M74:SZ7O\ 96X[=Q::_P!M8D%Q#+ZTDAE0*!GE)&>."./-
M/[49;U\U)&A6B*Y;[5;'+G'DKFD&6A)4GA(0=@W(6.?@ ^#7G1O4B]ZECQI4
M>T6E<=^(92T,W!:G(84AQ30>':QA9;(R"2/./%:FB.M3>J[>GL681KNF<Q'=
M@/R\%++Q 0^E6SWC!'&!Y'/(SD7U0U*C5K6FU:,CINSEM-T#!NV3VP2-F0T1
MW.#QXS\UTZ5<V8%D=N=S(BL,,&0_N.>VD)RK/[<U4[=U/L,KIB=<.J=8M:&U
M*6VH N)6%;.WC."HJP!^X\5]M>L+[):LLN3I535ONJT!IUF:'7&$K!4E3R-@
MV\ 9VE0!.,U56>M3C-ONESN^G#%M5MNYLTIYF<'EI>! *@@H3E/(\'/VJ0N'
M5.<SKB]:7A:>CR)MM;0]W';D&4/)<V=M*<MG#BBXD!)^3Y-?;OU3F0=5P["U
MIYHRI-M1<PJ5<1'#;9X*5Y0=JPK(Q\_7XKU<.K'X/==,0[_89%O1>DM)4ZM\
M'TCJU*2$. @?*?/[^,<[*^IR7NJBM$VVTJDO(CN/*EK?[;>4I)VI&TY]V$DY
MP#GY&*T=$]5Y>K!;7X6FE)A2WU,J4)R%NLA*BE3BFMN=@5@%0/\ ,*PVSK3%
MGQ-2M_@S\>]6/*G;<^^E)>0%;5+0O'(!S\?3ZUN7OJA<+/>K=;9>DI:'KE+<
MA0E*E(2'EH(!5R,A!SPH^1@XYJ^Z<N3UWLD6=)@2+<^ZDE<61C>V02"#C@^,
M@_((J2I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*^. E"@ "<'
M@^#7"].=+M6V*5=)$*18&Y<V?(EM32IY;L(/X"P@;0%' &-W&0.*W-=],M2:
MP$RXRYT*/J"+,:=L<AE]P-PVD')"D[.5J/)/.2$^ G!QW?IMJ:^:TA:AOC&G
MIRV;2FW.1ER'4A;B5E?>2OM$I.XYP!]L\U(RM :G_B&SZT1.MTC5D-#T>5&5
MN;BR(ZW%J2VE83N04)7@**23@9^^YU'T1J#7NB_1W&1:XEU8FMSH;;(6MELH
MR-BUD97D*/N"$_\ =^MCTS;+PJ\W*_7YB'&G2HS,1N'&?4\AM+2G%9+A2G)4
M7#X2, #R>:J>@M#ZBL>@=766X)MIEW9Z5(BEN4I:4E]&-JU%H'VG^;"LY\#Q
M1OIG,E]"1HJZF#^*1XZFHTAI:E-I<2LJ;7DI"D\XS@<#/FO'4+IE<+IT>CZ1
ML+L9V=W&W7Y4YY8[C@5O<=*MJB5+7D_^(\_%3_3NS7NS2?2.6JVV2P--.+1#
MB2>_OD..!94#VT;$I]P"1_C^P H Z>ZHA=3=0ZM8L%IG29<I+]M6[<BVJ*4H
M6WN7^4=P4% E(^W/&:W=2]*[UJMR<;O)9CS$R+=)CSV'B%*<;;V2%!(2-F02
M0/&0/%8)'3G4B+EU-5"MUM;AZA@-0+>D2S^4EIH-)W#;P"D[L<XVX^]2?]G,
MR-T,DZ>@66UQ]32H"(<EQI:4AY2<)WJ<VY5P,X(^WWKZYI35^HM+6[2-[B0K
M39&;6J))D1Y?J5ON):"&B$E"< *&\C/. ,UISNG6I=2Z<TCI*_MV^)9;$\TY
M(EQY!<5+2R@H0E*"D%!4"<DGCXS4WKC0]UN_6#2>J(4:"NWVMLM2=[Q0\X%;
MQQA)!",A0R1R3BL/4+IO-UG*U A:F827?1.VR:EY1<9>9*RI6P)&.'5C]1/S
MQQB,:Z87Z#J[64RV"UHM%VL@M4)E4EP.-E#2&T%1[9 &$D_)\5\Z?:#U;I*&
MW'BPK,R_(;";K*3-6OUA;2[L*4]D;5*4X-RR2<)S@FMV#TK>W=/[R[VHVH;&
MW'BSRVZ2B2RVG&"<#)! 4,C[? Q(2M(7E77R+JYF.P;.W;/P]PE[#A45*5O"
M<<@9 Y.:L'4BVW:]Q+9:;:ROT$F6@W%]M;06TRD[L)2X"%94$Y!!]H4,'-<L
M9Z1WYVVZYT@XM3>FKJ^)MOG/.-EQM\*2I6YM&WVJ*1X P .*LL*SZ]DW[1JE
MH=M,&ULEF[-HGAQF8$ ;"A(YR2#G<E)P<9.*H3'235R%7*^-0HZ;ZSJ%=WB1
M9,A+D:4TX1E#B<D)6G&0K[G!S@B8=T'J.;UBNFL[AIQ]3#C<5Z(PU/80M$EE
M+(PLY.4'8L?.01P#C'B_:#U9J#J%9]0W^Q%]N-:&V9"8,MIH^J"U.@(W+_2E
M12DD^<$X/%2VK-$:DUW;I3&H;6Q%EOVIP-/-NH*(\D2"XR@85G] 2E2@,<FL
M5@T%J#3G4ZSWF/;7)D.+8UPY<KU#0<DRUJ<=6[@J!P5JQDX//TK2Z/Z(U9HB
M%&"K M-Y<?[$F4J8RJ.(JGDN*6$A945@!:0,#E0))Q35/2:YZFTG&N+<%RUZ
ML@S93K;:G6OSX[TA;A:4M!(_2X0,GSN&,*S5PZI6&^W77&@IUGM+LN%9Y:WY
M;B7FD (4$IPE*E@DX!/T\>:ZDG@#C%*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4KSW$=PM[
MT]P **<\@'P<?T/^5>J4I2E*4I2E*4I2E*4I2E*5K7*=&MEOD3I[R6(D=!==
M=7X0D#))JN-=1M(.J4EN_0B4A9/N(QL25+'(\A()QYP,U(C5EB,>UOBZ12S=
M%AN"L+XD*/@(^IK7_CC3/H7Y@O<$QF)!B..!T$)>'EO[J^PJ7MMT@72W(GVV
M9'EPE@E+[+@6@XX/N!QP0?\ *H>'KO2LV8S%A:@MDB0\@N-H9DI65) ))&#\
M $_T/TK8:U=IUVVFXM7RVKMX>$<R4R4%KNG&$;LXW<CC[UC?UKIAB:N&]J&T
MMRT.=E;*I;86E><;2,Y"L\8\UEN>K=.VJ:8=TOELAR@ HM/RD-J2#X)!/&?C
M/FMJ-?+5*E2HT:Y0WI,0;I#3;Z5+9'G*P#E/]:CW-;:5;#9<U+94!P!2"J<T
M-P)(!'NYR01_0_2LR-6Z<6$E%^M2@I"W$XF-G*$9WJ'/A.U63\8/TK8:U!9W
M;8W<6KK!7;W%AM$D2$%M2B<;0K."<\8^M:_\6Z=]4F+^/6GU*G TEGUC>\K)
MP$A.<YR,8^M;MUO%MM"6U76X1(27#M09+R6PH_0;B,^16*+J"S2RQZ2ZP'^^
MM337;D(5W%IY4E.#R1D9 \5MRYL6&II,J0RR75;&PXL)WJ^@SY-:T.^6J;W?
M1W.%([2=[G:?0O8GZG!X'WK;B2X\QKNQ'VGV\XW-K"A_F/W%>&I\-V6Y%:E1
MUR6QE;27 5I&<<C.17M,J.L+*7VE!'*B%@[?W^E?6)+#Y(8?:=( 4=BPK@\@
M\?!KZI]I&[>ZA.W]65 8_>O/JX^0/4,Y*@C]8_4? _>O:WFT'"W$).-V"H#C
MZU\0^RM6U#K:E?0*!-9*^$A()40 .237SN(V;MZ=OUSQ7T+24E04-H^<U\#B
M#G"T\>>?%?.ZV4J4'$83Y.X<5[) !)( 'R:\*>;2<*<0#]"H5Z2I*L[5 XX.
M#7DO-#&7$<^/<.:] A0RD@CZBOI( R2 *4I2E*4I2E*4I2E*4JA:PZIV'35V
M<M :N=VO3>TN0+7$5(=;"D[@5> ."#YSSXJO]0NIP<Z0QM2Z*DE$RX2F8T/O
M-)W=PNX6A23\X2L'&?J/K76&WD=SLJ=;4^$A2D \X^N/.*XSTNO$2Z=:NH$R
M;-C^L6^FV0(RG4EPMQP0Z4I\[=Q!_P _.*[72E*4I2E*4I2E*4I2E*4I2OBD
MA:2E0!2?(/S7'K7)B+TUU=4I;#B6;A/W;UC"2(R!@_3D$9_<?%5N*Y/%FZ,"
M==K0_$5,C=AIE@MK 3%6#E:G%!6"=IPD<E/@\5HPFH,F*I4+4C-IU C5ET>M
MMP4$K8[F2%-N[CC"T' ^?&,_/7.D=S<N&AP_,@Q8+S<F2A]<50,=]P.J[C[1
M_P "U;E9/U/Q@US[HC>$L:1TTFX:BLJH/=DI;@K9Q+[BG7-BBHN*XQN/"4X2
M?.!FL,>7;;9U"A7UQ0;Z?7.X."$2\GTXN.W'J"GX0HI<"<G&\%>!E)K:L-T,
M2^:\EN7NR1[.WJ'=,9F,]UQQM#36\((7YXP!L)R/.?$OH>3IUJUZYMVJY,-N
M<]=9@N;<EP)6ZRM1#7T44EHI"<?TK:TA<+99.I'4),^6S#21"DH]0K82PF,E
M._*L$@%)!^A_>H&[16[9T?T$7&FV)"[C:"O>D(4K\Y*@%$X(P#_3G[U8IL2#
M$Z[V!AB/%82Y99K@0A"4Y<4\T5*Q\D^[GYY^]5O2%ID-ZJ1T_>0LVO3MQ<O"
M%J!*5Q5>Z,UGY(<<6>?_ ''WK'I=!%RUN[)<L*[ C4KKLSUJ5%X!(;)*,''"
M@DI^_P#E5IZY-./'1"&&X[CIU"R$B0,M_P!T[^H?2J=K^SRKC$L\.WBS-:F%
MWD34JM((2A]F,MQ@*YR%*0AL'(Y!''@UXCWYS675#ISJ%Y*F[6^[*8A1WDE)
M2I$19>64GC/=5L'_ -UD><U[Z7Z2FWB3:[QVK9$MULNMS6N0PM1E2PIYQ':6
MDH 2WGDC<<@#@5,:.N#EG_Z.4=VRJ;CW9Z')$% 0 IU_+A2$I&=RL)R/VY^E
M1=S@6NW=+M!WG3C,=&H528"HS[*?SI+CJAWT*5^I04%.%0/T.:V]1:6-KZE_
M@%I;BQ[#K=M2[@T$84V8XR\$8&!W4+"3]"5&M?44N/H+JQ+U)'8,:PQ6(UNN
M3,9& &W&SV5A XPE: GCGW_3BJEJ.)*?M'4V5>V&W[K(>LS[K3H'Y'<<2>P5
M8. E)"#QGC/S5QUAI9A6F[@Q<;%8=/7.5<+:B.NSO!2PWZII'>2=B"E:2ZM(
M6$9]V.:R69A.INID?3NN+:Q(O%KLDEJ4Z6R$2VR]'[;R%?X5C>"GX)<2>"<R
MO2+2.GV[MJ:<S:(#,RW:CEIBO,M)2IE/;0G8"G&$X6H;/'/C-;'7"?/EQ&=.
M67\1$M]I4QQV#&6\IHH/Y"5;0<)6Z!DG^5M8J+N5^CZXN/31BYI4U8KRS)?E
MQ%\-OR6D)VL.#Y"5=P[3PHI'G%5SJ-&MS-GZF6>W:?CPXD)=M7A#V6U.+6DA
M3;6P!OVJ(40?/]:U7HS*= =8%AA%K82 VG3_ .I-O6AL?F 8V_F'#@4GCQR2
M*E=96&!;>GFL7W],6JUN+LP,9<5U"C+\%3I;VIP6UELYQQNX/->]5:8@P=(:
ML3*TK:[!WX3*&A;Y0<5*2'DE2RC:C"D'MX44Y!5Y^*@]9:CN5VZ:2=+S%NJF
M:?*&+VZ01WRB0TVRGZD.A6\X(R$''G%3EQLGK>J&O6H6E['>$(B0$%$UQ+08
M06U[B@;#R0/\2/TIY\5LJ+^E]9ZBU/IML2=.LKCM76!'2"EQA4="Q*;Q^M:=
MQ)\[TD_(%1EVTW85=$K'=D6B 9#K\%M#Q8"SV%3DD!(^ H+)('G<0<\5T7J
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M10H!92LIPLI40%;2<$\U[D7W1\JW(U0\Y;Y#$=XQ6IW8[B^X%E&QL[2I1W<
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M[267YW::<?=2RUAO<MQQ1X2D %1/R<> "3P":W7(L=U6YQAI:N.5(!/!R/\
M(U%W>59+8_'CW%ME"[L^(Z 8Y6'W-I(2H@$>$G]7P*SZ<O-LOEK1+LCP=A)6
MID$-J;VJ0HI4G:H C!!'CXKY8K'$LJ99C%:WYCZI,E]S!6ZX?DX '
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MBOMSI"94@. JWNI& OSP<$CC'!(\598,2/ B,Q83#4>,RD(;::2$I0D>  .
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M TM-PWZ9-P;?>#3\13Q(QVR,J" -RB2GVD$9YQJ7?J<XQI95PCVP(E+B71U
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MPXQ?"=[F\;EM)SR00C)'SM^U05\M^BHD^(B[?A\23#MSK;"5/EGLP]NUS !
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M-#V(<*U D(Y3CYSD'%;NFM W>Z6*#(>]):2U:)MI9B"*ZD;'R"EY25N%:5'
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MLQ65M/J4DI)=;6@I60%*P3R-Q^M;FG-!:?L=E1;D6Z))1A0<<?C-Y7N65J&
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M36L()W<$[N#[%?\ X)^AJ-UQU M6F[&W-CS+;,DO=I3$8S4-J?;6L)*T<$J
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MRV0DJPD\H*O/!^#4/?\ 54N/JR-INQ6]F;=%Q3.>5(D%EIAC?L!)"5$J*@0
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MU@-LH<2C8I>Q2-Q5[5#&#6>R=6+JZ_I^-/M,9!GHAL+<[RBI$A]@N#<E*"E
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MVJNKUR7#95/>CB(X^4Y4IH$G8?MDFHS2NB-/:4<?78+>(A>&U6'5K"4Y*MJ
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MVL6>T_Q! NXFR9@?&5LI)4$[MN3G<!CP-OWJP7'IYJ!?5^]ZQ788LUIYR,]
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MG.3YK:?Z<Z3DH<3(M#;R7(C<$AQQ:L,MD%"!E7MVD @C!!YS4Q"B6?2MC[+
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M14D)"QC&$K"?"#R2G&.#BG734TYJ6XU8M6S7-/OW.UL1K@7&W5!UY:Q(9"U
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M0A:VD$+C@JQD#&0DYY\#SBOB;EJ:+:2($S4LF5.TY#F2RXVXXIMP/H1([2"
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MG&0A*BPL%2,)2,(]V2%[\>2*[?H%,DZ7A/S;N]=G9+:7_4/);2<* .W\L!.
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M4:9DVUJ08LG<V_'?QGMO-K2M"B/D;DC(^E3,,R'8#)F-ICRE-CN(;7O"%8Y
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M1%2A+C:>X0LJ]J@"1R#]3BMO36CKI:[GIEB1IQ268-[N3TEYKTY;6R^AT(4
M% [,.(&,9]OC@5J3.EU\CV#4<&*PT^Q!)8L3*70VI<5R0B0^WNSA)..T,@?H
M^AS5[Z<V$V;1-U:;LLJ!ZMU^0(,I]#[A4I(!!"<-IR0?:#C!!)R37+%].[K(
MTY!:F:25(FL:.<MS9<$=1:G;_P LA17D%/*@KX!X.2170^H]JNUST;I6,BTR
M+BMJ2PN:T"VX\C:TH%6UQ7;6=Q .\J SNP2 :Y_IG1U[8:ML>^Z)E7,>@8BQ
M%NRFVEVZ0P\M15W$KRAM64KWHR3C&","MUW2>HW;??XK6F7FM3I]:57M$M+;
M<]IQY+@;!!W*4M [8W8"!X/Q6&\:2DW"4N3#TU/A:<?NML<-J:8[10EM*Q)<
MV(Y2"DI2< %6.*2])S;=J5EAK2<^3/A:@1)BW%GEH6[M[&V@\I6Y.T  I^.5
M?.:K#%@O;5JGM2M+ZBC-RF;8=L2*L8=:DY>/L4I2B&R1O6=RL9XRFK(]9I<.
M0J(_IN_S]'1[O/C_ (9'9=WA+C;?9>2E1&]L*#N#G"2K.<XK=M]AO#G4B*JY
MP=6QW&G8;MO>CK:<8;CI90EQM]]0*L@A>].?>3P.<U=^K-@NTJ?:KGIU@ORG
M4N6J4V7%)0EAY) >4 ?_ &:\*XYP2,U1%6[4L334%Z\HNWXC O$"U,&*9"B_
M%CNY7(6A)/"P5DD\$)3SG K!&L?=N,"SOVF_1V6M67"1)4VS)0A,=:7PVM+B
M,  A:!E*OGG-=;Z/N37.G%E_%/5^J2AQM7JT+0[M2XI*=P7[L[0GD^?-7&E*
M4I2E*4I2E*4I2E*4JE=8KS=K!H.9<-/KCMSDO,-)6^,I2''4-Y\'Y4/(\9JA
MVS6=VTI?[V9T2,NP/:A?8?D*DK4\VX88>PA!&-@[9^1^K@"K9TNUU>M72I(N
MNF95LA*81*B2U(6EM:% 8;)6D;EC.<IX(_;F#T;:O[06-3W6\7.Z-347.5 A
M&-,<9$!#:MB2A*" 5?S$G.>!XJ01U"F6^5V7(2)=EMMP9L<ZY=[#WJ5)0.X&
ML$=O>M"3[MWN)P<<ZD/J=J28F,6-)1\RVI:H^ZY8&Z,YM<"OR^ 1^DC))&,
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M!,:G(<;;0HEULY22% C&?BJ[>M(2+=%O\]B$YJF\WUM,*0E]QJ.VAC:H 8P
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MP!"CR3D9Y5XQ2SJ>;JV9T^F7F:Q.>8U%/82_M0A*VD(1M/M !R#P0 #74/\
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M6LC*5)!"P?W!JR]0-'S-3:.C62%=&XSK+T=TR)$?NESM*"QE*2@ E203CCR
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M1X1&VV'"E145#*<< D\ @DD IS<-.:BMFHX3DJSOK>9;7VUE;*VE)5M"N4K
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MH?86MQ"'6E*:P%I"@2CZ9^E>@ML^%(/.//S]*^A2"K 4DJ^F:!2% $*21^]
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M$'@&NW:7O,9^Y7/3\2VR82;*EEE)6E(:6A2?9VRDG@!/@X(&..:X]J_2\O\
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M_'+AL>:@,E6QK<D1%!3>/9]<Y_>LS730M:B%W1>Y'=%W<N^PLI(WK9[.S/\
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MM.%07CN$G*3C&?// XK5N'2.^R;W/G(O=K*I)EM!Q^$XMQ+,ALH*,]T ! (
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M#A&S&PA.#SGGC/S+: US/U3-9B.V]F-*BMO?BS7<),-U+RFVVQQ[MP0M7..
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M')!!"DD'Y!KUJ._Q["+<J4Q(=3.F-04*92"$+<5M259(PG/_ /PU+**2GE6
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MW*5]K!<;:[03PC])3@'YP!^]:Z.D\-<:+%FW>;)BLN3UK:+;20ZF7GN))">
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MI1QM<5P,<\G/S,(Z77(V^U1I>L)DW\-G194?OQ$!*&V"2AO:@I]QR 5DDD)
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M?\<K_BG/]5?!;6!X7+_XIW_57W\-8Y]\K_BG?]5/PYG_ !RO^*<_U4_#F?\
M'*_XIS_53\.9_P <K_BG/]5/PYG_ !RO^*<_U4_#F?\ '*_XIS_53\.9_P <
MK_BG/]5?/PUCC\R7P<_]J=_U5Y7:HZ\Y<F<_28Z/_@J@M,<(">Y,P/K,=)_S
MW5C-DBETN=VX;B,8]>_CQCQOQ61-JCCPY,\YYF.G_P":O2;8P!@+E_UE.G_Y
MJ^BVL  ;Y7'UE._ZJ?AS'^.5_P 4Y_JI^',?XY7_ !3G^J@MK &-\K_BG?\
M57PVU@Y]\OG_ .U._P"JL?X/&Y_-G<Y_^NO?ZJ\-V.*@I(?N)QG]4]\^?W76
M4VF.<_FS>1C_ +8[_JKU^&,?XY?_ !3O^JM8V&*0 9%SX^EP?_UU]18HJ#D/
MW(_]ZX/G_P"*ZV3;6,8WRO\ BG?]58UVB.I)279V#])CP/\ _=7URTQUD$N3
M1C_#,='_ ,%5A_ HN<]^Y>0?_I!__77PV"(3_P!HN?\ _49'^NLZ;4PE. ]-
MQQYENGQ_XJ]"VLA&WNR\8Q_VES/^>:^FW-$?WLK_ (ES_P!:^?AK.[=W9>?_
M -I<_P#6OHMS0S^;*Y_^TN?^M??P]K_WLK_B%_\ K7D6UD*)[LO)_P#M+G_K
M7K\/:_\ >RO^(7_ZT_#VO_>RO^(7_P"M/P]K']Y*_P"(7_ZUA>M27%)*)DYK
M'D(?)S^^<T9M2&_U2YSOW7(5_P"6*]N6UM:,!^8@_5,A>?\ F:Q*M&1@7"X)
M'SA[S_4BO*;.I))%SN//U<2?_EKY^"G()N=R(^G> _\ *LJ+:M#7;3<9V/J5
M()_S*<UZ<MSCC7;-QF@?5)0#_F$YK&+4L9_ZRN'*=OZT_P"GS]ZS^B=R#^(2
M^!CPW_HH(;H)_P"L)7/V;_T4$-T#'XA*_J&_]%##>)_^D)7C_"U_HK"Y;9"U
M93=YZ.,82EG_ #Y;->$VJ6%9-]N1'^$HCX__ ,6:V#">/_Z1EC_PM?Z*^&"]
MS_UE,&?]UKC_ /DKX8+^21<YGV&UKC_^2O#UNE.) 3=YK1'RA#.3_FV:P_A$
MW_\ 7]S_ /X<;_\ %5]%IF \WZY']T1__P 57U-JEI"LWRXJ)&,E$?C[\-5D
M1;I*6]INTY2O\92SGQ_]WC_E7Q%MDI&#=YRO')2S_P"3=9A"?&/^L91P,?I:
M_P!%>/02,Y_$Y?[;6O\ 17LPGSG_ *QE#(Q^EK_17AV!(6 !=)B,?*4M?^:#
M6,6R4%9_&9Y'T*&/_P 769F"^VZTM5REN)0.4*2UA?[X0#_D16]2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
0I2E*4I2E*4I2E*4I2E?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>exh46_02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh46_02.jpg
M_]C_X  02D9)1@ ! 0$!- $T  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ L ! 1$ _\0 '  !  (# 0$!              4& P0' @$(_\0
M2Q   0,# P,$  0#!0<# @ / 0(#!  %$082(0<3,10B05$5,F%Q%B.!,T)2
MD=$7)%-48I*A")/!-')#8[$8)29$<X+P)T55@^'_V@ ( 0$  #\ _5-*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*5KW"=$ML54FX2F(L=) 4Z^X$(&?&2>*C;VF1=[,TJQ7IJ"V\I*C.:0A[+9_
MX>[*<DXY((QGBHGIQ=9\K2;DR_R0ZAJ1([4YQ"6A(C)6>V\0 $@%&#G !'/@
MU9;7<X-VB"5:IL:;&)*0[&=2X@D>1E)(K;I2E*4I2E*4I2E*4H0"02.1XI2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*U;G;H5UB*
MBW.)'F15$%3,AM+B"1XRD@BH;5VF%7O3!LEMN#MECJPA2HC2#_*'EL)4" D\
M C'CCP:V-/6)RV6EV#<;G)O*72=RIC;0 20!L"&T)2$X'C'R:D;=;X5LC>GM
ML2/$8W%7;8;#:<GR< 8S6U2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2OF
M/=G)_:OM*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*54K_<K
MA%Z@:6A,2=MOFIE!]@-@[E(;"DJW>1C/CCS_ $K0ZN:N<TWIR8U:GVF[VY"D
M26"O![2&FRI3F#P3G:D ^5*'D U;;!*,ZR0)*G4NK=80I2T^"H@9_;G/%;]*
MY5:M37C6_474UEM-S<L]ITZIMEQQAA"WI+RBK.2X%!*!L(P$Y/W66Y]24:(:
M:M^KR[/NC;;LR6]!:0$,1/4%IIY22H'G<@;4[CG/'%?9_6K3D*^S+88=W?7&
MDQXBGH["'&U+?&6RDA>2#CZS^E?4]:-/.VJTS8T*[/FY3G+:U'0R@NI?1CV*
M3OX)R,<GR,XJ#E]65734.DGM/ONMV>?%N3DR.]%!>2Y':W;,9\@_ //'/-;5
MHZT66WZ7L#]^D3)<B5%;D2I;40-H:2MPMA:D[O\ %QA&X_.,5-7'J_IZWZK<
ML$J-=&Y#4]FWN2#&RPEQU.YO*P?!_P _TP#6=?5K2[=SN,5UV6AB") <FEG_
M '=2V DNH2H')4G>GXP?@FI/3>O;1J"PW*Z042PFW%2949;7\]LA.[&U).<I
M((P3]><BH2V]9M(7!328\B9O>B&:TE450+C8<[?M^U;@1CR<<?%0$[JXNSN7
M/OM+N:CJ-%GCM1HBT]A)""I*^25+QO(P.3C]<;FE>J[;FMKOIS4A#4@7=5OM
MZV(C@0H;0I*7%Y("SDC''CP*W>L&MKII&[Z3CPI5KB0KM,5&DR9S2E!A(VG?
MG>D 8)\_YUHZ'ZL-OZ?DS]5%M,87HVB%<(;"^U.)SL6E'N*0<><D9^:]WSJN
MR]<=)G2RV9,&X7Q5GFF0RM*FU) W;>1@C(\@@U.)ZM:-4W(<1=5*0T 4$1W/
M]Y!<+0+/M_F#N HRG/(^N:G9&L+'&TD=32IA8LP1O+[C2TD#=MP4$;L[N,8S
MFH1[JOHYFW1YKUS=2R_,<@( B/*7ZA'YFRA*"H*Y'!'.1BL-[ZJ:<8TLS=+5
M<!*=G1Y+MO0B*ZX75,I45%2$C<E*2/=G&/L5BMFNKC<.AZM:HBQ47$6YV;Z?
M"E-91N)'!S@A/WQFJOH'K+(N,UT:G1;F[:BSM79V=!2O9%W>6G05*]WUCD\<
M?4]JOJE'C6^Q3=,JCS6I=^9LTMJ2TXTZQOW9.P[5)4, ^X<@BLEDZKV5-CDW
M'4=T@-I%QDPV1"8D*.UH!2MR%(WY2GW*.-H&.:R,]3[8WJ#48GW.VIL=MCQ'
MFW&6WU/GO $$^W:L**D[>WN\\U+P^I6DYDVVQ(]UWR;@,L-^G=!_M"V O*?Y
M9W@IPO:<C%7"E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5
M"76PJGZELMW$UUD6T/#L(0"E[N)"3N)Y&, \5#W_ *>VO4EEGP]1=NYRY"7T
M,3Y$9I3\1#F=J6SMXV9&#]C/FK/9K;%L]JBV^ RTQ%CMAM#;: A( ^@.!6Y2
MJ++T"N-J^X:DTQ=U6F?<FTMSFU1D/M/%/Y5@$@I4.?!P?D'YA]7=(8VHI*9#
MEZF)??@"V7!YQM*URF Z'?(VA"\C&[!&#C' K3F]$HKUWFSF+V^RF1-@S$L%
M@+2@14J2VWR<D8(R?TJIW_I;=].S-(1K$_(N*&]1.75^6(H(B[PV.4!?*<I_
M3C/(JU0>B<>"FSN1+TZF3"8G(<<5'!#[TI!2MW&[VD9&!D\) S\U#73_ -/J
MY]DMUM5JR2EF#"3$;2J$A: 0\7-Z4E7M)]H.#DX\X.*EKWT9E7:]S;D_J1*5
MR;K$NNU, >Q<=M2$ISW/D*!)X\?KQMP^D"XL/4]I:U)+3IV]J?>] (S94RZZ
M,$]TY44C (2,?E&3YS;>G6E'M)6/T$F>U.<]H#C4-N*D)2D >U'DGDDDDDD^
M/%5+3O1&P6.ZV>>PLJ<M]PE3@GM !P._D;/.<-E*"G]4DX&>,%QZ.OS'Y[J=
M0!AQ[4:-1,*3#W=I:01VSE?N'(YX\>#GCP[T:?7JE-Y_'V@1?A?>R+?C*N!V
M]W<SC \_9)QS5EZD:"=UE>M-3%3(S<6SR52%Q7HY<$C( *2=PP,#'@^:IZ^B
M]RC:;78;9J4?A<:YMW6V-28Q68JDJ)[1(6-R.<\ '/[FM6#T3N\<6E+U[A/^
MCU$Y>G%AA39>2O8%)X5[5>U7R1R/JL5NZ$2X&GI-H5-L<Z+@M-=ZW=MYYDNA
MW:Z^D[P01P4^/UP +I,Z?W-WHNC1C-W;-P3'2R)C[7>2,+W;<*R< >T'R  ?
M(JEP.BM]M[5M;CW:W+3#U.;_ )4AQ(4GV (QD\^T_/UR?-?(712^0;+9DQKG
M:S=8+,^(X5MN=EQF4%\X!!"DE9_3Q]5=[;H6YP.B9T4W-BKGF"Y"]44D-C>5
M9..2<!7_ (^*U)/2Y5QZ*(T1-DQF):8[;9E16_:I;:@4*(/)SM3GY\U7W>C=
MT<<$U5QA&>[J"/>GVP%!D(82I*&D<9!(4<G]OJM&#T4O\"7"NL:ZVE5VBW:9
M/"'V5N1W&I*$)6A0X.1M/Z'/QBLVJNB-UO\ <M0S5W:"R[,$%4,(8(0VJ,@)
MPI'@(5R=HS@X\XYWE](;BO5>GKPRY9;<[;W6WG'+<TIA7#JUN-A(X6A04!E1
MR/<><XKM=*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*K5SUQ8[9<UV^6]+$I+J6-K<!]T*<+?<"$J0@A2MGNP"2!6QIO5
MEFU(_+9LTLON1 VIX%I;>T. E!]P&<X/CZ(J=R,^:KE]UI9+'=$VVXORDS5,
ME]+34)]XJ;! *@4((P"0#]$C[%2UFND2\VUF?;G2[%>!*%E"D$X)!RE0!'(/
MD5NYH"#X-8I4EJ,TMQY6 E)60!E1 &3@#D_L*Q6J?'NMMBSX*RY%E-)>:64E
M)4A0!!P>1P?!K:I6E=+I#M:8RI[P93)?1&:)!.YQ9PE/'V?Z4EW6#$<BMOR6
MTKE/^E9&<[W=JE;>/G"%'^E;M*4K4AW*%,ES8L62T[(A+2W(;0K):44A0"A\
M$@@UMTK3B7.%,ES8L64R[(A+2W(;0H$M*(W *^B00:^6F[6^\,./6J;'F,MN
M*96MAP+2E:?*21\CZK=J+<U%96UN)<O%N0IN0F(L*E(!2^K\K1YX6?A/D_52
M+[S;#2W7W$-M(!4I:U!(2!\DGQ4?9]06:]I4JRW:WW!*?S&))0[CQYVD_8_S
MJ3I2E*5\6I*$*6LA*4C))/ %:]LGQ+I 9FVZ0U*B/)WM/-+"D+'V".#6S2E:
MT:?#E2I4:-+CO28J@F0TVX%+9)&0%@'*20<C/Q6S6*5(8B1G9,MYMB.TDK<=
M=4$I0D#)))X 'W6"-=+?*D(8BSHKSZV$RDMMO)4I3*CA+@ .2@GPKP:R/S8L
M>3&CR)+#4B2HI8:6X$J=(25$)!Y40 2<? )K8I2E>77$--K<=6E#: 5*4HX"
M0/))K57=;>W;6[BN?$3;W$)6B27DAI25<I(7G!!R,'/-;E8DR6%R7(R'VE2&
MTA2V@L%20<X)'D X/^59:4I6)^2PPMI#[[32G5;&PM825J^AGR?TK+2E>5N(
M;*0M:4E1PG)QD_0HVM#B0IM25)/@I.17Q#K;F[8M*MIPK!S@_1KTA:5IW(4%
M)^P<U]I2E*4I2E*4I2E*4I2E*4I5*Z@K0F^Z&"D+5MO>\[4D[1Z5] 4?H;EI
M'[J%<TUN],@Z\U9<K5+N#,J/-LR6V8JE8<2<AW*!PX @G@\#SP<5*]()]VNF
MKY+E[O5R_%XX?;N%I7#>0TV2X=B]ZUEL#&-@;"=PSD'!-?>JES9M_5NQ.KU
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M=ZB+NN1E C!1.5C_  !?;)_2L?4&_6NSQQ=K$_%%S(CQ'IC"0Z(L1Q]"5.J
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M&T*Y4WGV^Y/(SBN<W'7NMK8EN)^,VF<[+9MTI$U$,!$;U+W;+2DA?(\J2?)
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M*7M,V=Q*5+4 N&VK!7^<C(^?FLHT3I<7-JXC3MI]>UL+<CTB-Z"@ )(.,@@
M8^L"MVU6"S65^7(M5L@P79*BY(<892V7#G)*B!SR3YJ!9M.@]8721<6H5AO%
MP;+8>?#;;SB<<H*CR? X/R!QQ5@N%AM-Q9G,SK=$?;G)2B4%M ]\)_*%_>/C
M/BHR%H+2<%YMZ%IVUQW6W4O(6U'2@I6!@*R!YQGG]3]FM*X]/M#-VXF?IVT)
MAQ4.+*G&$A*$JY62?Z9R?&,UO6G2NE>Y$NMJM5NY0AR.^P@;2 @)0M..,[,
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M@QV4.)5G)*-R59QCE/Z4TC+N6J&;G"&I[]"U2[%EMRX:V5):AOAT=I:21A
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MT>/)KMU*4I2E*4I2E*4I2E*4I2JC?]=6V _=;? D0)-[MS3+ST.1,3& 2XK
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MH;:#@[FS.2$))R!GSM !P/H5ATIK^W7IF B?V;=<9[TEJ/#4\'%+##BFUJW
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M\>,_Y5O.MMO(+;J$.(/E*@"#_2H]VZ6X7EJS%25S5-=_LI1N[;8. M7PD$C
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M;"E@A+VQ6S"R@J (3G'/T:\1NIFEI423(8G/J[#K3):]$^'5J=!+00WLWKW
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MK7^EWG;6TU=V5KN828H2E1W;E%"=W'L)4%) 5@DI(\@U97W4LLK=7G8A)4<
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MY_A&]"@3X&.3R*O=*4I2E*4I2E*4I2E*4I2E*4I7EQM#J=KB4J3YP1D5Z
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M</N!:F@DI1Y(.#@CC Y.*W==:?N4S5VK-9:(?:5J*PSD-O,LKSZN-Z1GN-J
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M+R%$=TJ6?=N"0M0(( ">03S4CU4O%RL6D?Q"T/MLR$3(K:M[87N0M]"%)&>
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M<DNX:>0, )2\4D$;3[#NX!%:]TUIJ=%XU$Y;[TS^+0%3VV[!Z<N+<;0E19=
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M==6M7<0D(2H+*MP(2 D8/CCQ4S*T[:)5B399%OC.6I(0D15-CMX20I(V^."
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MM>F+GIIEW5R;@ROL)6(+*&79"5R5-I>#;J"7T* VDME)3@K ((JZ=8W$B]Z
M;-R7#4Y>N E2!N_D.\^Y)'DA/U[_ +QBBMZ\U!%L;,J/=2W-7"NJKA:^TSMM
M"XR%EK:-@*<*#:,+W!6X''S72VKC<K?TAG7J3?E3)RK8N>W,4VTE+:BSN 2
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MMOY!)#B/"0$GX%3/4R-,>UMI9V+%N+L5N+<1*<BMNJ2@*8P@'9QN*O \Y\5
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M%D/H+:(ZLDY0E27E 'Z0>?-3?1-QQW2UP4E*A;OQ>=Z#<1RQWUXQCXW;P/T
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M;8BF&)ZUN22'W"MQ2A@G>5;AQXP1CXQ4Q!B1X$-F)"8;CQ64!MIII(2E"1P
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MJ;0%A)'!.Q.!QQA;Z;:MBZC@.IBV^5!@20I+GK2SWVS$+!*FPV<NYY*U*)/
M&!FMR)T[U#9+%81;;=;Y,QJQOV>=&,GMH"W D"0A6WDG8 <C.W ^*Z-T^AWJ
MU62W6B[PXC+$"W16$/,2"X7'4HVN @I& -J<'YR:M5*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4K$N5';
MD-L./M)?<!*&U+ 4K'G \FDF2Q&0%R7FV4$A(4XH)&2< <_))Q66E*^%0&,D
M#/W7VE*4!R,CQ3-*9'V*4I2E*4!SXI2F1]TI2E*4R*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4KE?48:5>U+$@.2K5#OHEQ;C)ER'$I=CM
M-*!3M4H@A2MNP)'PM2L?>YU)NVCYEJ6W<OP6Z7!2W;?%8FN)+;;_  %[B?[,
M)X*E<$# ') -OT6U'CZ3M$>'/_$6&(K;*9F_?W]J0G?N^<XS4S2N"]?]07A<
MUI6FX\YU&E76KI)=8;!:4ZGDMN*R" EHJ4< YWCQBM;J1U6O3$FVRM)7*(S;
M9NGG;L$OQ@Z0M&2$CD')_*<Y P3CS45J3JYK"%-D/0Y=N0Q$L$"[.1G(V_N+
M=4TE:0H$$#+F?G _SJ3UEU8U'9=67ZW1W[?VX5WML5EMQGE3,AI:G,G=\$)Y
M_7]:SQ^IMUN/4F5IY^7 DVF4JXQ/Y#0*&NPT%)(4K!4H@D*!!3GA.<&K-T&O
M$:W?^GZRW2XR0(T2-(=>=4?RI2\X3_D!BJKTHU3>XW52\6_4B)T8ZFCBX0FY
MC"VTL/(3A32 2-P"<<CSL'S5[T==;]8-.0V=3F7J2XRYD@+DVF/W&XP[F-JR
M5#A))^. ",>W)_/FHI;["]9PPTF'#5JWL-WQ+JP+2 O(PE(SM(!\' /QXKHF
MI-7W736N=;R+/'B3)C2+:$ND+6XXRI"U*VMET)6I*4J(" DGDG.,U7IW4B3;
M>H+6HN_&[ESTS$'J6V750V'')*4J>6@D*"$@$<\Y"1\U?_\ U0OOM=%')#4@
MKD!^,?4Q_8#D\J&"< Y^SY\FJ[JCJUJ#24NXVRV0K6NVV2V0).7D+[BT.%I!
M1D* S[S@X^/!JT/=5+J=3ZH1%M\)RS:>4I,IE3A1+4D,J<#J,G!25)VA(23S
MG-5I?6G5B-(1KPNR6T&4_$#"R5!I3;_<!3@+*MR5('NQ@\C:#6U=.H^JKE;K
M&S&_#K?.7JQ5CE*1O4ASM*R,<Y2E1&%#.2/W(K0M74F?I1=XG/PHWX&=7R[?
M<Y!=>=6S^7:XE)4=J3@C'@'&!S5ED]5-11]31K&G3[+]PCP6)UR92X4$!U20
M4MJ4<#8% DG()! QYK+U>NDZ5U)T'I-<J7 L5U<==ENQG5-&24#(8W)PH \
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M&<:9M )2A.1$1G"  GG'P ,?59'M!Z4?W]W3MJ5O83%5F,GW-)QM0>/RC:G
M_0?5;$_26G[C9HUHG6>%(MD;'9BN-!3;> 0, ^, FM&;T[TA-+AE:>MSI<91
M'65-#W-HV[4G[ VIQ]8K9.B=-&^B\JLD)5T#09]2IO*M@3MQS_T\9\XXK1;Z
M::,:A+B,Z<M[49<A,I;3;>U*G$YVD@><;C@>!G@5F<Z?:3=A*ANV*&N*J:+@
MII224F0!CN$9\XX/WSFMF/HS3T>-/CM6I@,3I0FR6SE0=?"@ON$$_FW '/Z"
MOMXT=I^\WN)>+G:H\BY10$M/J!W  D@'!P0"<@'.#SYK:U%IZU:CA)B7J$W*
M90L.(W$I4VL>%)4"%)4/L$&HT:#TW^&+@*MB5L*>1(*W'G%/=U'Y%]TJW[D_
M!W9'Q6K(Z9Z/?8M[*K*TANWH<;C!IUQOMAP8<_*H9*@>2<DU#ZAZ2V%W3%S@
M:;A,VZX2;>JVM25..+#;1.=I!5XS6YICIE88.D&[5>+7$FR'X3$6>XM2W0]V
MT@ )*SN2D$9 & #R.:V%=+=&D1,69*#%:>9:+<AU!"74E+F2%945).TDY.,#
M/ K+'Z:Z285$V6="D14H2TVX\XXV-B2E!*%**5%*5* )!(R<&L5NZ5Z)MJ'T
M0M/Q6DOQ%P70%+.]E:MRD'*OOY\C P>!65CIII!A0+=E9(]#^&E*G%J28^<]
MLI*L$9YR><\YS65OIYI9%N9@BU)5':E)FIWO.*67TC"7%+*MRB!P,DXP,>!4
MIIK3=ITQ$>BV*&F(P\\I]Q"5J4%.* !5[B?.!4O2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E55W6<)BXWOU2D1[59]C
M,F6LDY?6$J#:4@<X"D^.25@ 5\<UK!#UGD,+;D6>YR#!;EMJ.6Y.5 (6DC@$
MI4G["L CG(M=*5S=_6&KVM3-6-.G[.N<Y;EW%*/Q%P I2X$;-W9(W>X?I^M;
MNANH<*_RKA;KFY"@7J'+DL*A)D;E%#*]I<&0#C^GP?BK/9-0VB^I>-FN42;V
M<=SL.A>S/@G'@'&0?D<BJ+8]?:AN,EY2[-94Q&KNY:BE-T(?46W-JUH0IL!0
M"0I>-P.U)J[QM36*4VVY%O-N?;<0XXA;4E"@I+9PXH$'D)R,GX^:UDZUTPJ
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MT-<9O5BKPA]$KW>G6E6[VD#!!4!C)SS^F?%SZ875^-K.#&E1DV^8EURS-+)
M8<?*5OA1 R$E2<#'("U8JS],-/R;0Q=7Y]F1:GY[R7'&C<W)ZUD)"=REK\<
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MI2E*4I2E*4I2E*4I2E*4I2E*4I7()/15$V3+7/U!(?:DHE-J_P!V0'2'G$.
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MEZ,J0?4I4[%4I2=KKBU9&Y(Y&_Z^*K&F.EKZ=/SK1J*+8DA5N-K9GP4+,EQ
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MMI:@>6T)Q@#X).3]U2+ITPO-WN#T^7>($.Z(MRX+5Q@1%-O22L)!6_E9\!)
M"3GW$A0P*QV?I;>K7+9=9N]J"!>F[NIMJ"M 01'4RM*27%9R%9!/R,G.2*A7
M^B^H784U#E^M;TB3!3"6\J$XE;NV0'DN+7W3E1(P<#    Q5SGV5J_\ 5BUS
M'($QHV>*KU<A;!3'E*)0IE"5'\^Q6]8(_*4\^:D>I.E;KJ8VD6N?#8CQW5F5
M%F,J<:D(4@I&X)4DJVYR$D[2?/BJ..DE\_ ;C;W+G;%KDVJ!;4.!EP8,5S<%
M$;B.<GC[ /V*EK9TZO\ $O\ ;U*NEN59H5Y>O#84PM4DJ>2YW&U*R$D N'"L
M9\<?%6GJ-HY6K8=N3&G+M\R%)[J)+8RL-J0IMU ^MR%J&?@@'XJH'I([!TS<
M;7;)C3P>ND:3%3+*BF-$9>#J8X\Y )<Q^B_TK;.@[XJ8\XJ1;U-'5*;\D!:T
MJ[01MV'V_FX3^GG[KJ=*4I2E*4I2E*4I2E*4I2E*4I2E*4K@%EUU=-%0;G+?
MAM7#3:KY=([:@\LRDJ;+SHP",%&&RGSD>?TKI'3?4U_U$F0Y?;0Q!BJ;;?AO
M-/H5WD*SGVA:C@8&%<!7T*I]^U#>=,=0M:W2#%CS+9%8M[TQM^0X' @A:3V4
MX*=W&><9Q]GC,.JMX5>9\&-8V9[@8EN0T15+/<4P\ELIWD!*\A6X[,X(V\FL
M:.K-WDO,PK-96+U/#3K[HB+4T A#H;VE#F%-K)SD*SMX_,#FODK5MRU%JW1T
MR.VF'9OQ^1 "$OJ[KJFV'DJ[B1["DJ22!R?:#\U?M::E?LLNR6ZWL,O7*\2C
M&8]0M2&D!*%+4I1 )\)P!\DC]:HB^J][>;,>!8("KDPQ/7+0].4E+;D-Q"'4
MIVMDJ!"@4_OSC!KH;VHMN@UZD9C;@+=^()CK7MR.WOVE0!Q]9P:YZ>KMSA".
MU=M-(3-N,>-+MC,6670ZAY>T)6=@*5C!5A*59\5)6SJ!JFX76UVQ.C4QYLF.
M[(>3+G%D-I;>0VI0';)((<2H9 /)&.,FOZ%U#>&WXK[C;ERU%=C<E]EVZN"(
MEJ/(*?RE!"% E+8"$\C)/U4NUU8FW",N59-/-RX;5E1>G779W:*&U!S*-O;.
M5!32A_YXK&]U:N41E]^?IIIEB/'ASGBFXA13&DN%"5 ;!E8(.4^./S>,YKMU
M:>MUTOD55E:=1;XTV2VIN9N+@C;-P7A!2@JWD@!2B,#<$YKU%ZK2GG1;W;"E
MF]R5Q$PHRI@+3HD-N.)*W-GLVI:<W82KD #.>,T[J5=HLF/;TZ2F.WM$82IL
M%MQ2RV@NJ;';6A"DKSL4KW% QCY) L75+4$_373^Z7FT-QUS(S:5)$@D)&5!
M). #DC/BJ])ZH/Q-:1].RK0SWW5*9_DS>XL.IC][\H1@(/*05*"CC.P"M+_:
MW._ K?<G--".F?$>N,=,B>E*5Q6FD.+5N"3A9WX2@^<$DIK-:^K,B[W.'&M>
MF+E(:66&I3B4.'TKSK:7 E1#90$H"TA9*@0<X2H#-1EKZM7:/8=,R+U:8"7[
MSW2EY4TLLY#FU* LME(7@D[5$ A/"E$XKIFM;XO3>FY=U:B.3#'V%32 HX25
MI2I9VI4K:D$J.$DX2>*HD/JO,N!CIM&GE7509:>DJ@/J>; 6XM [:PWA7#95
M[^W]<$$"R],M17/4D"\2+JW$;,6Z2H30CJ4<):<*?=D#GCS\_0JB6[7-WT_J
MC50E0G9]D.H40C+<F\Q%.MLI0E+9!)1N5DX(QG@&KAH77LC5%P;@N6E$.8RV
M^JY,^I[BH2T/%I"#[1N*]JU \#"?G(K4ZC:CN\.\3K-#2RS"5IV=<#+0\I#[
M;C>U*2C P,%0^?G.1M 5"V+JNY!L$&->+7+7=%0;>Y&4'.\9GJ$J 6KMI44G
M+:U$ *./ )XKHNBK\]J/3[-PE6R5:WEK6A4>2A25#:HIR-P2=IQD$I!P?%<.
MOVK]06>/JF?$N-[5(MNI%16GWTI<@,QMS1*'N"0D!:N1A0RGFNGN]2&6[FVG
M\-><M"KF;.9Z74?_ %6. &_.PJ]N[/GXQS4(QUGB&VW62]99.^ B,ZIIB0T[
ME#[W: *LA(6E7E.3@\9\XU=9:[O$IFV(@0)%L]+?H,*YK]4C+:EK05,^W(6D
MI6G)2?G'WCL8_*/VKDDZ#>1U.B:>&K[TAF5:9,U:D=H%+@>0E.T%! 2 LC'Z
M#FL&GNH4NPW2YPM1HF38'XQ.CHNJG&MK?::+H:V A6 A"N< 9XY\U;NGFO$Z
MS>F!NS7& RTVV\V](;(0ZE><#.,;Q\I&0,CDUFEZS6-4O6BW6B7/:B/,1YTA
MDC_=UNC*?:>5  I*CQ@*'GG%&U/U25==+ZLBVIJ9:;I M_K6G0XVM: '=A2L
M#.Q>1@I.2 ?(-7!_7X3<+@W%LEREP(*GF7IK6S8'FF>ZI)!((21A(61@J./U
MJO:[ZA+?TC<567UMMF-VJ)>F91"".TXZ!MQSS@$$$>#4A=.J<:!J6;8_PN2J
M4RB1V2IQL%U3+/=.4YW)01X61@D'ZJ*A=:H[=ILKERLL]VX2H+$V6S!;[O92
M[D)*1G)SM*L>0G]>*WU:VEW?7>DD6A$IFP3)4Z.M]?;+<SM-+Y2.5C"T':>
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M3#\H96MWVDI:4K:%+W8)2,G=SG-3>E=(V+2C<A&GK:S!3(4%.=O)W8S@<DX
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M:VK6Z@MK0K".4;2H8\\GGQ4MHK1\;2;+C,.YW::P4I:9;G2NZF.VG\J&Q@8
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MX 0X\XL(4OU?"EC)YYP58W8XSP!5G'4?5;[_ ."6^UP9&HF#-#J@ AA[L.A
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MQU +1<0D=M*D!>XD*4G&<$GF0LNOM1+LL&0Q.<G75FTW@*BK:_M)##R.P<%
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MMDN"^M:&I+2F5J;("@% @XR#SS6&Q6B)9++"M<))]-$90PWOP5%*$A(W'Y.
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M*4I2E*4I2E*4I2E*4I2E*4I2E*4J(OFI;/8DN&[3V8P;0EQ>[)V)4L(2HX\
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M3E6?R > 15WZC7'^$M*6Y-HG-VY<RX-,KDH;907"X5*6HJ4GMH4K!)64D<G
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M))SD\"OFB5V8V=QG3JPN)'DO,N':I)[P62YG('.XG../JIDMQUN!)2V7&SW
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M)\AZ,6-J6%;AN 4XE2L%*A@#/'[59K/>[==[5;KE!DMJBW!M+L92CM+@4G<
M ><X\CR,&I J0" 5)R? SYK[N3NV[AGSC-$E*P%)(4#R".<T.W'Q55::@Z3F
M3$6VTW%Y$\R+G*?0[W&^ZD)R"7%^U2AC &![3XK'I?7<#4=QML.+"FM+GVA%
MX;6\E&T-*4$A)PHG?D^,8_6O%Q18M(:C8N+=KD*N.HYK<)V4U[\+V$IW;E>U
M.$?W1Y\BKCE/V*<8^,4]OZ5H/W,-76%"1#E.HDH<7ZII ++6W'"U9X*L\<<X
M-8(]]BOZGEV)+3Z9<>,W+4M20$*0M2DC:<Y)RE6>/C]JE'E=MI:PA2]H)VI'
M)_0?K5'C=3+5,TW;;Q MUUE_B3CK<.&TRCU#W;"BLA)4!@!"O)YP ,D@&[17
MA)BM/!#C8<0%A#J2E2<C."#X/Z5&V:_1+M/N\-AI]MZV21%?[R-H*BA*P4\\
M@I4#FI;*?TID?8IE/Z4]OZ5':BM$>_V*?:9;CK<::RIAU3*@E>Q0PH D'R,C
MQ\ULVZ&B!;XT1M2W$,-I;"W,;E!(QDX &>/@"HN1J>U,Z@MEG+I<EW$/]A3:
M"ILEG^T25C@*'UYKW:=.P[;>+C=$2)DB5-4,F3(4ZEE/^!H'A"<\X'SCZ&)J
ME*4I2E*4I2E*4I2E*4I2E*4I2E*5Q?\ V;:E=TI<=,/NV,0F0]^'7$H6N2L+
M?[W;<& $I) "BDDG XK7D=-]22&VBFV:=B"5ZA,YN/,D!T]QI+8<]24EP_E)
M* $@C )4,U(ZFZ52WXD2%IR5Z%#]O5#N+CKI<:<Q%+"%ALC^UY2.X"D[4D'.
M<5'JZ?7YVUE<BPVUB[%UI?JK?>7_ %"5-MK2' XZD@CWE/;4,;2K.<C'6=/P
M[A!TQ AW!Z,_<V(R6W'6F^VTMP)QD)'@9^!C] /%</7TQUI)M%RCRHMG#SUM
M1$2$3"&W%MRDO>UL-!+:5)R !X\J))-?H"*75PV526DM/J0"XVE6\(5CD X&
M<'YQ7$XF@+XJ%88MSLT-Y%K@76-N,A#G<<?*>VI((&,X4/C -8=+=,[W"U';
MW[W;&9[2/P]]$I=T=;]&['92VH%E)VN\H)23C\YSY(KJG4>VR[QH#4%LMS7=
MFS(#T=E&X)RM:"D<G@#FN?6W2DF-:9T5G13BG9]M;B3W+C<$."0M/"=J0ZO"
M05K6>4GV@)R<8@UZ!U1#L$*V*M?XHU:+JN0I2)J8[MW96A:0XI942EQO<!A1
MP4X \8$E9-$72R:A1'&D8,RSR1"<B.+G!?X.6<Y1N7_,7@G<-O!)(. :AY6A
M=4/VQ=H&G VS'@WN*F2);.Q]4IS>R4I"LA(('G&">1]SUMT#(O4NX1;OIY5L
M@S-,1[:IUQ3"L2D+<)5M;6H[AN0H*\>WSXK0O.@=32K-9;C=82KK=52'%7:%
M"F(9+@+*64%"W/:=J$<A1Y[B\'FK]+TZI/295C3:9!6JWIB&#'GCNI1C';2^
MO )2"?/M.,>#7OI':+I9M.S(]YCH8=7.<=9/;;;<<;(3A;J6E*0'"=V=IP>#
MP2:HVM=*ZBFZINJDZ<7<VY%XMTZ)<FWXZ3'89[?<;PM86"-JR-H(.\U$W716
MHG=/J;8TZ^JX,W&Z/,(W178RFWWDK0AUMQ?*%@CW).Y!1G%;EQTA?WH6HHDS
M2$:==74W%<>\-2&VTO)D-D(;V[PHJ!*$^\;0EO(.<9UKUTREA=K:CZ13+MLF
MU1X[\1B:U$$66E14XXZ4YW!6494V5*);'GBI%[15X:N6QK3I*$:R;O(DMO,8
M],4C<H96%<*\IQDYX!J.5H34QLL>(;&57"W0KG&?EAYC%U]0%!L#*LGDI6KN
M;<%)QDU(Z5MUWZ>3Y-S3IE:83MLM4(QX[[#?<D#*72$I4=RP5@>,J.<$^:ZU
MK".Y-TE>8T>)ZQYZ&ZVW'.T=U100$^XA/)QY(%<1B:&U#;Y3:XFFBS:FOP=Z
M5"0XQB9V&UI?1M#F"L*6A7. KM^3QGJG2VSS+/9[FF7%$%B5<I$N)"R,QF%D
M%*"$DI!SN.U)P-V*I.O;%+G]1KS(E:?U#,MTFS-08[MLE]@+="G%$*(=1[<+
M ]X(R#Q]UY.C-4L6-46\6(7&YR-/,6^ ]&4V$VR4A2^<[ALQN:5O1Y+9Q\5L
MHT9=V-4R;H;,^].;U- =1.2E(4J.&4)D.)R<A"B%9'SGGP:C6]'7HVZW6ZX:
M;O13!MUS@OR(CC"2YW9"5MAOW^Y.S=@$8YQ]D=7Z.09MOTQ):N%M1 6J:ZM&
MUCTY?0<8=+.XAHGD;1@<9 &:JG4K0%^N>HKN[ISL-Q;K'8F.ON[5*9F122T$
M)./[3* 3R $KSY%>HUAND2^6*ZR+1($R5;[G(N:8R4K"7W^TM+)5GG 24 _.
MT<\UZZ566ZVW4&FE7&VRHR8NE&X#RU-X2E]+V=A(XSA).?\ 7FQ]9+0J[6:R
M@V]^XQ(MU9DRX[+?<6M@)6%@)'*L[@,#[^:Y3*T5=66X[%RLFHI=A>2\FU0X
M"VE/6[,A2VDK4Z3V\ME W@@IV[237Z&O#27+%-:=)4E4=:5>XI)&T_(Y'[BO
MS#8;+<)6BH$_3]BO"XS]EC,77<EX"8ZIUD]Q"-X4\$MI7G:0%).W(!Q4GI^S
MZOC+@0[5:+K#=BIOK4=Q]@LMM!Q(5&Q@[$@DG'/!R <"K/H%!T[J&ZWJW:+U
M!%AKM,-I4<QOYSKX>6'3[UY4H;DDGY *C\$]P<<#;*G%!1"05$)25'^@')K@
M6AK&ZW$Z7"Y:>N(DV\S4RN[ <'IQAPMA2B,)RI2<?'[8KM.E+ZQJ6Q,72(Q)
MCM.J<1VI+>QQ"D+4A04,GPI)^:XW?;-<$ZQNEZA6^[MS?XIC%IU##ZD&,(R4
M+7M!VJ05)(*L? _2L6D],7>^-VVWRVKS;YBX$MC4;\GNH2Z^5#LK0HX2M062
ML*0<!(VY (%8K!IK6DV[PC=8'IHUQC--RLJ6>RN" &U+.?\ \,OGC&4#YYK#
MI70]QO\ 8;M$G)U/#O#MKV/^M':C"<E>X.(5G+BBK=[P<;%$'S@;%_M>I'[?
M8[A>8M\CQKNX\Y<XML:4\Y$5VD(CCMI.<!*%$^<+5SR!4AIJW?@>H;Y>KVG6
M$M%FMT)Z,7R\5.X94ET;4D-N+ V[AS@Y/G)KM$"9'NEJCS(BBY%E,I=;404E
M2%)R#@\C@U^;[7IPOPM/6R5;+]&]&;XF4XAN4WVR2%M8<2.00E.-IPH@CW9Y
M^Z>&JKE>; J_3]6Q7O26Y4$Q(JU(= 0.^EU6X)2=^\K[@R4A/Z _IJE*4I2E
M*4I2E*4I2E*4I2E*4I2E*5QNTZXO4_4EWANZHL$1V)?%6R/;78*NY(0"@@[P
MZ2DD%0SM(R#_ $Z#:]:62Z75-L@R7')^]U"V#'<2IHMA.XN I&P>]."K 5D8
MS7N[ZPL=JE.Q),]"IS:VFS$:!<>*G-Q0D(2"22$*./I)/BHQ'4O3+EO>G-S7
M5QF8:)[BTQW/:RIPM[L;><*2H$#D8.<5HR.H467+D1H3JH)AWJ-:ENRXKI1)
M4O:2AL@<*() )X'!. H$S#&O=/.PO5>M4AD2'XJE.,.(V.,I*G=^4^P)2E1)
M5@<?J*V]+ZML^IQ*%HDK<<C%(=:=96TM&X;DG:L [5#D$<$55])]2H,N^W>S
M:@FPXMR9NLF'$;2VM(<:;2""I1RD+QN.,C(' J;B=0]+RX3LJ/<][;9:&WT[
MH<7W02T4(V[EA8!*2D$'!QX-2QU%:DZ<-^5,0FT!GU!DJ!"0WC.[&,_^*B#U
M%TEZ=F0+[$4PZYVTN)W*2#NV J(&$@JX"C@$^#6RC7&FE7"7"%XBB3$0XX\E
M1*0E+9PX0HC!VGS@G'S6H-;VV=+M*;/<[:XQ(EKC/A]:T.A26BLI0C;G>."0
MK&$G/T#(MZOT^Y"C3$7>(J+);=>:="_:M#7]HK/TGC)_6M.9KO3S=E=N#%WA
MJ2'%L(W*(_G)!)0H8W# &3QP.?%9],:E;N.@K;J2ZEB"U(@HFODK_EL@H"C[
MC\#[KY#UQI>;"F3(=^MTB-#V]]QIX+#>[\H./D^!]G@<U@7K_3OKK/%8N")#
MEU=<98+(*DA38)7O/]W!PG!YRH<>2,5IUO;4:;MEPU#<[3%=F)4I)CR>XRH!
M>W<E9 R.4@G& 58SXS--:CL[MY_"6KE%7<L*(CA8*CMQNQ]D9&1Y&17B\ZHL
M5DDMQ[O=H4)]P I0^\$D@G .#X&>,U6QK.;<.HDO3=DCPG&[:63.4^ZI+BD.
M)*BIO (.WV#!\E7QCF6.N+&W>;S;I$KT[EJ#/J''4[49=_*E)^5<I&/DJ &:
MQN]1-(,IB*>U%;FA+!+.]X)WX7L/GZ5D$?&#GQ6'_:;HDL=W^)[66]N_<'QX
MSC/_ //BO;FM+="N]X1=;M9(]LA)CX<,LAU"G 2 XD@)3GC;A1R,^*VG=<Z6
M:M;-Q<O]N3!>*DH>+XVJ*3A7^1\_7S49<>H%N,RY0+3(A.3[=)C,2$RG^RC#
MJAPA6#N7@\#Y.!FIXZHL0N[EK-VA"X-I*UL%T;D@#)S^H')'D#GQ2S:HL5[E
M/1K->($]]E"7'$1GTN%*5>"<'Q4C.F1H$1R5.?:CQFAN6ZZL)2D?9)X%0+FM
M]/DVA,2ZPI1NSRX\(LO)4EU:$E2AN&?&,']2!Y(K5T/KNV:FL;<IZ1!ASTM.
M/280EI<5'0A:D%2O!"?;G) \U)'6.F4QFI"M0VA,=U:FD.&8V$J6G!4D'/)&
M1D?&:]:DU3:-.+MR+O-:CKN$@1HX6H#>H_O\#Y/ZC[J)T-KN!J2T]Z6Y#M]P
M0J1W81E)6MM#3JVRL^#M]A.<8J8;U7I]R )J+Y;%0RLMA\2D;"H#)3NSC..<
M?5;[-RA/VP7%B7'=@%LNB0AP%LH SNW>,8^:H&G>H=MU5!E/W1NV0]+R@N.Q
M*>N31+RMQ26G$<;%E/N !5[2.?BK?;)6G[.(MBMTFW1"VD(8@MNI2H)P5 )1
MG/@$_P"=;LV[6Z!)CQYT^)&D2#AEIYY*%.GZ2"<G^E:XU'9"[,;%XMQ<A_\
MU*1)1ECG'O&?;SQS621?;1&3(5)ND%E,8I2\7'TI[14,I"LGVY'(SYKTB\VQ
MR4Q&1<8:I#Z.XTT'TE;B?\21G)'ZBL[[L6V6]QYU3,6'&;*UJ40A#:$C))^
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M^/->H?4BPRV4.,^N]T>7(*%1E!:?3*"7D*!Y"P2!M/G(K+:^H-CNMY8MMO\
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MGG$02EI2(NXH0E'<RDDK62HJ/D#&!6BKI)*WI?9U"&9GJ+@XMQ$(%):F$%Q
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MD2;#M$!VV16T0BTZIE2FRDK7W"DJ :2.$C/->-<=.IFH[U=9L:[-1$3(D5M
M+)4MI^,\IYI8(4 4DJPH$$_1%3VB=.3+3.O=VO#T9V[WAUIR0(J2EE ;;#:
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M]*V4=0)C=O8U0] M29K^G8+Q>#.%MJ>D]M6]94#V@2%[<CP>?FI!_6^J+*Q
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M+W;[2'BDC< "H!:ANQM37C3?4&;I&RJ1>K>J1:D_BST>4)BGI#ACR5#:L*'
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MK/;+9 "4[<G "<')R#6K-Z26":R4R)5T[SJ9"94A$C8Y+[^WN=TI !SVT<
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M;7IY4F:VA.]M24]E1)]A)6GE6 ,_-;$K6T)*+A'@I:F7F PP_(MXE-ME =\
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M+M'EH4S%LEQARVE)?A2Y4AN/#49#KP#:&P ZVGNXVJ"?R@C;DX[LRV&F4-@
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MK*DE10=HP$D>[\W %1C.B=5F\10[9X*'6[Z[=57A$L%PM/-NIV$%.XEO>D?
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MSAM?D!P@>5A*W$@_ 616'0>C7]),IC&_W"XV^.UZ>%&D);2F.WG(&4@%9&
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MLX2PTE!1X\DI!S^OQC-;'5K0=XUFX46ZX0V(BX+L93,I+B@'%$%+@"% $C&
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MFEH?2E*% $DG!!)2 $G@@_/2M"7ZYW67?[?>HL-B7:I2&,Q'5+0M*VD.I_,
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MYN9E3;SNP9;26QO0DNH!)*#Y]O%7'5MRF6?3=PN-MM_XC*BM%Y,0.]LNA/)
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MJ*O:0A:BA8V\H6$J&1QS5>ZF7Z]LZNLEBM"Y\6/(ARIKTJ$F.MS+6S"0'CC
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M0PRB!;UQK''".&]ZDEYQ(QX(*([>/C-=LZ$I0= ]]LDHDW*>\G(Q@&6Z!_X
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M<,XSS7W(^Z9'W3(^Z^;DXSD8KYO2#C<,U\[K>[&].?K-?.^T"!W$<_K7PR6
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M8_\ P&O^P4])'_X#7_8*>DC_ / :_P"P4])'_P" U_V"GI(__ :_[!3TD?\
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8I2E*4I2E*4I2E*4I2E*4I2E*4I2E*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>exh46_03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh46_03.jpg
M_]C_X  02D9)1@ ! 0$!- $T  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ L ! 1$ _\0 '  !  (# 0$!              0% P8' @$(_\0
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M.Y*BE0R/H@C^E3*AOW2"Q<8T!Z4RB;)2I3+!6-[@3C<0/) R,_S4RBB$@E1
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MAR$ZX$".E2&U!0"4)4#@$!9)QD@U6W#\8-RB,:BM^I)-RBW>U/QG1'>=;,-
M:*U+[>6PL+[A7Y]QXR #71>MT-4O3UC):FKC,7J&])7#2LN-,A1WK&SW# /E
M/(^/L:7)AWRT:>BWNU.W.6(EX>B0(\N6[OD0Y'Y+>[<<DI=<"DE0)V@?S74K
MQ9%,]-IUECKD27$VQR,A:W%%UQ7;(!*LYR3_ .]<(N,-],,SK)$U!%=AZ5B&
M&4B6VOU*9*MR%#(*L%?Z3D8.0",5N.E57N7U1DOW*=J%AU$]Y34,0W1%>A*3
M^4I2U*[:0$X]H 6%Y\Y-;%UE2XJ=HPM.SXO:NBW5S(<,R%1T",ZG=C8M(R5)
M'(^<CQD<[L$>XVY4@3FKPO1\O43TB=<PP[%E2TK9]CCB4;5A'=VI)2E(. ?!
M(J#J"YZK;M<!23J3U,2,78KA1)6IYL3E!"E(0 .X&4(*BZ3[5 ;23FMAD.2D
ML3KVW)U6Y;SJ!<><TE4D%%OR5!3;8PL#=MRI/.TJ' X&X]!&/3Z7NZ W/;:5
M>9CC(G-.MNEI3FY"CW/<<I(.>>2<\YKE%ZN6HO6ZA>88U:RJ9!ND=#88F**'
MP\%,>\>S].=NQ*0E/!4HDU<A=[@WB2P@:C>TUZNUR9J0)+CJD.1UEXH4?>4]
MSM%:4XP!C:.173>BS)CZ-?:+$UA(N<Y;8F(<0XIM4EQ:%'?[CE*DG/SG[S7)
M6)NH7)UV"W]76QN9%F-J6F%*?5'=]8C9E15A6&RKEH(P@X"E*\=<Z12I;VB5
MN3H\I"TR7P@NONNAY(6<+;[OO#9_NI5R /)\UQ!=_P!0IMEX4S(U6TN3;&5-
M91,<=:DB7[P5E(2%[%'.P!'P <<[)W;E:M4SW+?>-12F8VHH46.W)E2'6O3N
MLY=W D[QN"@2KA.W@IJE<N6HDZ3O,R9>-4,WY$4-38:(SZ$L2.^C"D+4LIY"
ME;0T DHSN  S6PHNRX5]NEIEW74;NFVKPD/RTR)"G6VU1$E #B?S @OI<!VD
M $ < UK5J?O4:T:?BKNNHK/ 3&?,)42 ^XX_*]6ZI27$A205J3VRD. H(4KQ
MS6P1)\J?U!TXN\.7D7^)J"4W*CK2\J.Q'++R6"A(RV I*D#>.3E63@<;]UB8
MCO+T?ZI^2PV+XSO6R^ZUA&Q>22@C'.WD^,G'DUSMJ1=$MR+K)O>H5V;^T\BW
MW#;-<Q&A)6OMJ21A2!N* 5I.=N!XIZFYRWXL25JF\QK?Z>[.Q76I2VW7XK*F
MS'<4H\D_\3W^5)3\@G.T=';E-5?HD>9>I]R7<-.Q+H^F6\7 A]2B%]L>$ 92
M"D?L?O,'JH\;5K?44QNX7.'*<TFZN$IIUW87T*<)VX]H( 1Q]D?)YI+K=[B[
M(N\P:NNT5<#\%>0RT^"@=_8'B4E.% @DX.4@Y./BHE]NU[M\219E:HN,6T1[
MU-B.W5TO/N,I[;:F$K<;*7 -RG<$'&4A)XXKK5W$F7T4G%^5+D2S9'%&1L,=
MYU89)W;>2@J(SCSSBN3-W^<BRICP+U<(<V)9[>[IYAM:]EP<Q^<@H/\ Q3OP
M@IYVIP1CFNH]>&G'>DE\4DR4NMMMK/IE*! #B=V<$92!DG/&!^U:#?\ 4[SE
MTNL&WZIFQH7XM9VXS@D)#@9>2 ZD%8*CP"3GD$$G/(J);=0W&WRH2XNJ9]RG
M-W6Z6N- DRTK#S:&7E1]PP"M16EK"R<^X <&MJZ#72Y7.5/7,U,]>&C&:4Y&
M<BNH,1[PH*6X3A9PH%"?:-N1C/,37C+\MCJ^IU4@3V+<RB&(ZE!Q,?L%8VG_
M  J<[NX#SM.?BM3N&HD1]47"\6/4SZ6X"+&V0AY"D2TK=6AP/9!)VH6H^1C.
M?HUM'2?4.H;QK=W\5OZ%.),AN=9#&<*XQ"SVR20$H2   H?J!YR>1T?4^@[)
MJ27)E7)N3WI$5$1Q34A;>4H<#B%8!QO2H9"O(R1\UPJY)DZ?UE.DZ<N,6XVR
M=J)(N.F9P0N0'P_COLC.X_I"P1C 'NSM.*VSWR_V=K432+S<$./ZS1#NKRE(
M"XL592@.DE.4%82$A>=H"1@ ^<L;J-J]^U:98N]\-CA2Q-#%\<:"D2%MD]DN
M\8V\$<#W9!P161&M)6GNIU_+TTQ;9+OD!JXW.*E&48C$!*D+!VI4L<G *=JA
MYX'ZG0I*TA2"%)(R"/!K[2E*4I2E*4I2E*4I2E*4I2E*4I2E<RD]4'I#NHW]
M.V3\4L^GE*1/EF5VE*6A.Y:64;3O*1G.2D'X)\UM%GUUIJZV>#<F;S!98F,A
M]I,A]#2]I.WE*CD>[*?YXKYJ/6EJLS\R$J0PY=8\!<\1%/);*T). -RN 5'@
M9_>IMFOEOD6ZTK4[$AO3XZ)#,4OHW84D'"<'"L9QE.14MB[6Q^0EABX0W'U%
M20VAY)42DX4, YX^?JJW7NI$:0TG/OKL5<IF&D+<:;4$J*<@'&>/FN5:IZL:
M?N%DN2=2::N.^U-Q+J(I>2-[;BD=MU*DK'(+B>#X./D<=2>@6"\WBT7*4&UW
M:(TI^&%O%+C25@;CLS\C .15E.NL=BWR9,;;-<984^EAAQ!6X$@\)R0.<8R2
M!^]:?;^J%ODNI+UMN4.)VX;SDE]M(0VW)2>VI6%$@;AL/T2#^G)'0<"M+U'K
MA=DNS$-W3MV?1)F(@1I""PE#[RF^YA.]Q)Q@*&XC&4D>?,[3.K$WR\7.W.VN
M;;GX+4=U29FP%0="\8"5*\;"#S_''-6,VQVJ?>85SEQ6G;A!"@PZHY+>[S@>
M,\><9'./-6A4D$ D GP#\UY"VR$D*00H\<^:B76Z0+1#5+N,EJ/'2I*"M9_O
M*(2D?R20!7F!/<E39[#T%Z,W&=2VVZX4[7P4A6Y."3@$XYQR#4XE &24XSBO
MN!^U0[Q<HMIM$VY3%8BPV5ONJ2,D)0"3_P!@:@:2OKFH+>J6NUS+<@["V).P
M]U"D)6%I*%*&/=C^0:F76\6ZTQTOSY33+1>;8"B<_F+6$)3Q\E2@*F)=:4X4
M)6@KQN*<C./O%4VH]1,66)'?2PN8AV:S"6&%(RTIUP-@JR1P%* ('/[5>#:?
M&#3<G)&1GZK!.EQH$-^7,=;9C,(+CKJR E"0,DD_  J)$NGJ;LY$1"DB.F.V
M^B:4I[+FXJ&U)SG<,9(QX(JRRG]J>W..*CW&9%MT!^;.=0S%CH+CCBO"4@9)
M-:T.H%@$M,5UY3$HOL1BT]M0M+KR"XE!!.0=@R<_P,JR*K[CU2LD1^Z*1%N4
MRV6IT,7"Y164N1XR^,@^[<K;GW;4JV_-;O#DQYD1F3$=;>CO(#C;B""E:2,@
M@_((JHONJ;99F[B'E.R),")ZUZ+%;+CO:R0"$C[(/^7U5O"D-RHC$EM"T)>0
M'$I=04+ (SA23R#^Q\5F]O[53ZAU!#L*H F,3'!,?$="HT=3H0H^-Y3^D$X
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MB:P"78[3Z5.( .TDI!R,'C^:\7G45ELBVD7F[0("G02@2I"6MP'DC<1QR/\
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MDFPY%^4EQ<QA^.$MJBK"D;%**MG<V<JX"C[?DU&E6_7$'3NIXT9V[]W3^^-
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MG8IM2W6DN@X! &%*X\?^U:?#OEUM>H;5(_'+K.T:+I+8CSW5NO&2A<5)2DE
MRX ]O"%X/@XXQ4'2]SU3>X$9Z/>;[^*1M*IG,QBX4H?FH6ZC"PM)WY&TD?/&
M2.*RW.X0[T=(")J.^J8E7YA:7Y:2A<99BNI<0VMQ.2K?C/&U)< &*U^9U%O"
M=.V1<?4$[U<:(Z[O6X=KY1,6V%$I2KO*[:?<%$) (5Y(JZNFM[XQ<M1NVJ_2
M[@VON+;D11W6H3 E-I7W(^S<TM#97M5X6 5<G%=-Z42Y<_14]Q.HG+^"ZX(L
MQ+"T8&P>U*G.7 %$^X_/'Q7(G^I=^?TN3$U ^;G&TLM^24)1N:G-R$;@H%)
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M,U%;6I *TEM3XR"E(4K/UP0?W^*R2=>Z6C6V#/D7N&U#G F.XI6 L X4<>0
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M]I! 4Y[3CD)0DCZK>NF]@DV*U2_7P+= ERY"GULP77'ADI2,J<<Y6HD$YP
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MF\Z[N6G-.2X4!NTQF7IDF1'+ZU./!10A"-R0  G<5$YY  \FO;VN&].0NSK
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MD)0HE2RE(&58YX%2[7T]GZ2@V&4^L7QFRP9<1<&)&"790DN[CMWN!("1C@_
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M0<C!('/["RB=4=1OV^X/&UM!$&6TW(DHA.DM,+C=WN>G[G<5A1 /(.T[MO!
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M&93'92XPDA#:>0D?L"3_ )G[KT- Z7_#A 598:X8DF8&EIW /$8*QGP2//\
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M*4E(]R5 _I)!YY!P<U-3H/2R+PS=6[% 1/9:0RAU+0&$)3M2,>.$@ <<  ?
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M@%2E'!SPHC]SJMOZ!WANSZEB2K_!4[>+;'BEQ,=PE+C2T*!)4LY20C!_G@
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M9<"%+"-A=9W<@%24J1SQS]5SM.B%2+C8W7-&W!BTK7<G7HDHM/%"G(Z DEM
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M6[9*<0XTI]$82DK;7'[BDD(\H<.">>,_%:!:+;?(UA$IZ/K5V0E45F_QUH"
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M*PV2&S\JP,X\$CP2#S5JZ7*X:>A-N:COS+Z(=[=7VI;@6I33H7&*U#*OTDD
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ME14@!*5[AM4< YXKVQU1TF[<'8?XDII;7?"UO1W6VTJ8R74;E) W)"2HISG
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M"I2C@\ $\5,A2!*BM/AMUH.)"MCJ2E2<_!!\&LU*T^^=2=+V.Z3[=<ILEN9
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M!K&[TYBF[NR&+E,9M[TU%S<MX"%-JE(2 '-Q&_RE"B,X*DY^3FO9Z5,-6J+
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M>V=U$1Q+86O>I/MV)Y25YX(\?-9M#:GNU\ZF3VYS$B# <LD:9'AN/H< WNN
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MK4VD+2EQ+?<+9 .[=M_;&?;G/%5:NM&FTQEOF'?>VF(B>2;>L?[LK_\ #?\
MH!&"?D^,CFI[O56P-WQ5L4S=<(F(@N3/1J],TXXE);W.> %;T@?R/ YJJTEU
M"6Q8";ZN5=KHN7/V-0(P*Q'COJ05E(( "1M'G)R,;CS5RGJ?8''926!->0U;
MD7-IQ#0VRF5D)26LG*CN4$XP/=Q6!WJO86YJX@AWMQY,IR" W;G%!<A R6DD
M#E6 3QQ@9) KQ-ZQ:/A0+9,?G.AF>SZA/Y?N:;W%!4M/D84E0P 3[5?521U0
MT^N?(A-(N*WV5R&03$6E#CK*"XIM"U825%() SR*N]!:C&K=(6R^)BN1!-:#
MO97R4Y_?Y'T:GWV[0[);ES;@M26@I+:4H05K<6HA*4)2.5*)(  ^ZY_H'J+^
M(7"X1+WZI#SUY?@V]I4)32T)0PAW8X.<* 4KDGG%9Y/5"!.7Z:T-SD-R;1(N
M+5Q5"<<0SVU%'N; W'"@K(X\ ?-2HO4RP0D62!=KHEZYS68VYQF,M*-SR1VR
MH<]O>3P">,C.*OM+:PM&J%O)LZY+J&TAP.N1G&VW$%2DA2%* "@2A0R/JMAI
M2E*4I2E*4I2E*4I2E*4I2E*4I2E<[1ICIW<+K<6(RK<N=.#K4B/'GD'*P0YM
M;2OV*(SN*0"<G/DUAUUTY8FL./V(-1'I-RASK@MV8\TE2(Y!R@)R$KPD#(Q]
MDY%3&^GVC;_9[>_';7*CY6^U-8FN=Q\.\N%3J5;EI7\@D@U]FZ TE%>"YBG(
MYE7*/,0E<Q2$KDMC:TE(W <  !(\X'T*^KZ4Z9<BN-.HN#KB@P&Y+DYU3[ 9
M*BWVW"K<C&]7@_.*DQ^FNG6)<-]+,E0BJ:=0TY)6I"G6UJ6AU0)]R]RU$J/)
M)YS6YUI^INGMFU'<+E,N"YH>GP4V][M/E +*5[P /@YSS^YK!=>FEFN4V7-<
ME71J?(D-2A*8EE#C3C:.V%((\91[2/! &:BWWI/8+P%AV1=HZ7(B(;P8ED=]
M"%E:2LG)4H**CDGG)SFI:NG4!5OEPS=+MLD71-W*^XWN0\E25  [/TY2DX.?
M'FO4CIQ97[Y<K@X]<>Q<LJEVY,DIB/.%&PN*;'E13CYQP#C/->M(Z"MVE[N[
M<(URNDN2J&B$!-D)<#;"%$H2/:#@9/DUN.021D9^JT>-TXMT6]-W%FZW1$A$
MZ3<4I"F<=U] 0O\ _!Y*<>!G^<\5L6DK#'TQIR#9H;\A^-#1VVW)!27"G)(!
M*0!QG'CXKQJ_3<35-G_#ISLEA"7FY#;T982XVXVL*2H$@C@@>0:UIWI;:7@
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M:5%+2M_Y82" G<%9(.<8S4@]3-01KNIR>FRM69%ZF6E14VXE:4LLN.AXKWD
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M;:D-Q@4)!6"V%+PG)P2=N."<UI,SJ5K)ZROSF[I'@/1-.INRF#&;67G$R5M
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M+](M;<IKN=H.N-I4DC(Y&_\ [5IHU;K5W5#.F(UZM:G/Q)V$+L;?N0Z/2>H
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MI2E*4I2E*4I2E*4KX%)*B 02/(^J)VD CD?%4=TU)%@:GLUD=8D+DW0/%IU
M!;1VDA2@HYR.",<'S6"_:JC6J\L6Q$"?<)BVTON(AMA99:4O8'% D$C=\)!.
M 3C K8]H^J;1D\>:;1]55:IO4+3.GYUZN*73$AM]QWM(WKVY^!_6K0!*L*QS
MCC(YKR([*5.*#2 IS]9"1[OY^Z^&,P4(066]B""E.T821XQ]51ZKTG"U(Q$;
M?=>B^GF,S=T=+>75M'*4KW)5E.?C]O-71B1RA"%,-%".$I*!A/\  ^*^M1([
M24AIAI 2=P"4@8/C(KT^PU(1M?:0ZG.<+2"/^]>'(<9Q04Y'96H)V@J0#@?7
M\5\$&(EYMX1F0ZTG:VO8-R$_0/P/VJMB7&T:E7=[=VTRTP'_ $LMF0P=N_:E
M>,*&%#"@<C(J:F!;G[<(B8L1R"/8&0VDMC!\;?'!'BHFH!9;;;I=RO$>(F,T
MT ZXXR%$H!!"?&3SC ^\5K,NP6#J! ARH@=B1XMR3(>;,(-*?<8*D['4.(R0
M,GC%;%=S9K/#A"7!:$8K1!82W&WI;[A" G"0=J#D _'W4&+?K!."FHS3P4;@
MY;MS<)P%$A*25'(3[0 /UG _>I>B[% L-K<9M\R3<%NNJ6_-E/\ >>?<&$$K
M7\D! 3^VW%6I8@R'G\M1W7>$.Y2"K[ 5_GD9KX]"@)0IQZ-&"4*[I4I X('Z
ML_>/FM7TY%L\O6MZE0Y\Z3-MA3#5%>]K$'>VVHI93M& H)02<GQQ\UM4R!#G
M%DS8K$CLK#K7=;"]BQX4G/@\GD5!7IFPN!T+LML4'D!MP&*V=Z000D\<@$ X
M/T*RJL-H4S#95:H!:AG=&08Z-K!^T#'M/\8J!KS37]K=..6A4Q<-IUUIQQ:6
MPLJ"%A83@\8)2,_MFIC.G+(RW#0U:+<A,-9<C!,9 #*CY4@8]I_<5GC6BVQ;
MC(GQK?$9G2  ](;92EQP?2E 9/\ 6OLFT6Z5%=C2H$1Z,ZYW7&G&4J0M><[B
M",$YYS6!W3UE>N0N#UHM[D\*2L251D%T*3^D[L9R/@YXK-;[/;+=(D/V^WPX
MK\@[GG&&4H4Z>3E1 Y/)\_=8)6F[)+F+ERK/;GI2UH6IYR,A2RI'Z%%1&<IR
M<'XK"YI+3KC 8<L-J4R'S)#:HC92'3Y<QC]1P.?/%3+Q9K9>H7H[Q;XD^)D*
M[,EE+B,CP=I!'S5=;=%:8M>/P[3]JBD.(>!:BH2=Z,[%9 \IR<'XR:^R=%Z8
ME,=F1I^TNM>H,O8J(@@O'RYC'ZCCD^34O^SUF_&A>/PJ#^*A ;$SL)[H3@C
M7C(&"1_%5[.A-)LH?2UIJSH#X6EW$-L%87^L$X\'ZJR@6"T6]$A$"UP8R)*$
MM/)982@.(2G:E*L#D!/ !\#BL=UTU8[O#C1+I:+?,BQB"PR_'2M#1 P-H(P.
M../BK-;+3C!96VA3)3L*"/:4XQC'UBH3EEMCC:T*M\7:N-Z,X: _(_\ Q?\
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M!"BKMXW<*42*M9:+W%N>HY$2/J1EN;=H4B2ZU&EJ*H2XON4A (.0[C<E)W
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M4/6V_6E1O+,/@)2V^5M+4D%2A[VS@@A.""!62)U<]7&BO1M+W18F,2GHH+[
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M4 N$!/O3RG!.?XP:C-=7]+N6E5Q#DI,8J;2RI;6T/E?<*0A1.W)#2S@D$8Y
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MP'[BS,B1FY:E-N=IM"$*>24CW)+85Y(.1G.T5Z1T;TXB-V$2;OVO3IB;3-)
M92X'$-@$8"4J''\G.:]:MT$_<(]RML!#$BWZAEH?N[DUXA324]L992E'*MJ
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MN2&TH024J1A.X*!4HYR>3XX%14]/&UMVL3-07N:];YK4UMZ2XTI2E-H4A*"
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M93_I7Q%FMJ$X1;XB1]!E(_\ BOB;):TN]P6Z&'/&[L)S_GBO0L]M'B!%'_\
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J4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>exh46_04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh46_04.jpg
M_]C_X  02D9)1@ ! 0$!- $T  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ L ! 1$ _\0 '  !  (# 0$!              4& P0' @$(_\0
M3Q   0,# P,$  0$ P0'!@ / 0(#!  %$082(0<3,10B05$5,F%Q%B-"@5*1
MT1<D,Y,()51BDJ&Q-$-3<I3!TD1C@K+"X? U9'-TE;/Q_]H " $!   _ /U3
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E1L2_6B9=I-KB72"_<XP*GXC<A"GFAQRI .0.1Y'R*YE*ZA(G=8].V
MV%>[>BR]R9$=83(3W'I"$ #<-W WDI2".2A1YRFNCS=3V2#J")8YESBLW>6G
M>Q$6O#C@YY _L?\ (U,4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*5A1$C(DJD(CLI?4"%.! "B/HGS\"H"5
MHJRO:GM5^;B-1YUO4\I/8:0@.J=3M)<]N5$>1R.2:LA0DJ"BD%0\'%?:4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I51U/=IBM8:>T];'S&7*2[.E/! 41'9*!
ML&00"M3B03\ *\$@BJ0M63(EGM5Z8F7)^WF]NVN='N+;?<2%R%-)4"@<;%[0
M!D@I)SS@UUFE*YOUA7>K=&@7.SZBGVY*YT.$8S+;"FR'7PA:SO;4HJPH8YP,
M>#6TYJLZ2NK&G;FF_P!_FN,+FB8W$:5L8[FWWAO;^7*02$?(/W6M%ZNV5R#+
MDR+?=(PB.Q426W$-;F$R.&UN8<.T9&"#[DGR!7O4W5W3FG5/HFIEEUMUUL(3
MVP7 T4A:D;E@* 4K;@>XE*@ <5NZ(OLF\:OU0WZY<JU-M09$%*FTI[:'FE*.
M, $YP#[LD5FUMU%L.CI:8UW<=+_8]4MMD))0UOV;R"1GW9X3E7!., UY@=1;
M3/OR[-%C7!=P0X4J;[2>&PWO#_YN6E# "AY) \FHV'UBTO(C)E/_ (E"AN1S
M)9D2H:D(?2'$MD(\E1"E)&,?/US66-U7L$E+"8[%S?DO//1TQV(I=7W&D!:D
M^TD?E4""#C!\^:VHO4NPS)<)F#ZR2B3'8E%]IH%MEM[=L+F3E(]IR<83\XS6
MA$ZQ:5E]Q++LHN?R2R@MIR^'20@I.[ SM_K*<9&<9J]6J>W<[;'FLMO-MO(W
MA#S90M/Z*2>0:Y;9M<W"7JB;)ER)S,-BZ/VABSHB-*,I:4@I*5[@H+2 M2LG
M9M(\>38&>JVG9$^U0HK=TD2+AG:AJ$M79VN]I?=_P;%<*^O[BMKJO?Y>FM.1
M+C#=6V$W*(T_L:[JE,K>2E:0G!))!., GZKS:>I-EN<V)"99N+4V0[(CB._'
M[;C;C+8<4A:2<I)2H$9\UKV3JG8[W*A,VQBXO&4TT[D,#^4'=^S>-V0#VSR
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M8]2D=M2TI_.<>Y92,)'-26G=?1[Y.;@L6R:U-]7)B2&72@*C=C;N6O!_*2M
M&,YWCXJY'\IKE=JZA& RS;XMIU!>;A)N%PC(0\Y'"TN,*RI!5N"0D ^WR<)^
M>,R-MZH,7A$-VQ6*YW)E;,=Z66-FZ('R0D%)/O(P2K;X'/Z5IZ*UK(8E"UWC
MU4Z7-O=TAQGLM@(1'4I24JQC^A.!P?'.*AM==5';CTWGSM'Q+BB6+8BXN2$E
MI)@H6M24[MQ()/;<X2#P">.*FWM?,V*XWXR8][N"FKI$MX8'8VMN/-)*.T=R
M?:21G<2<J^O&1/5RVN0$.LVFYKF@32_"(0EQCTF.\"2K:2-R< $YS5[L=S:O
M-C@W2.VXVQ,81(;0Y@*"5I"AG!(S@_=<\?ZR6^/;O6R+'=6&5NK884ZID)>6
MA3B7 %!9 ">V<D_:<9S6N>J=K;>DWTMWXPV[&W<3!4TTE(27U-E0!.[N \')
MVX'&34G_ +5&&[CZ2=IV\PMD]FWO.O!DI96\$EDG:X20H*&< [?FH#0O4V5"
MMYB:D@7F4ZN;<&(L]2&0F0IA;A#0PI.%!""-R@E)((S5BN'5BTP83<IVUW=;
M3L&'/;#;3:EJ;E+V-@#?^8*X(_RS7AKJU;!=)<*?:KI 5"C^HF&0&@J*GM*=
M)6V%E>W: -R0I.Y03G-:D3K58YFUN-:KR]+7,;@MQVVVE*6XXA:T85W-N"&U
M \^TCG YK:@]7[(^VR]+M]VM\1UB6\E^2RG;F,3WD$)4HA2<?6#X!)K7A=:+
M),C[X]MNCSQF-04LL]ETJ<=2I37N2X4>[81^;VJX./-;%BZH-W_4NG[=:[1+
M[%P8E.2%O*;2N,MAQ*%(*=W."3G&>"G&><3'5S4<S2G3^ZW:VM*<EM(2ALA*
M5!M2U!(60HC."KQSSCC&:@+'KMJR)?AWMZ\W!#<UN._/?C,(1 6Z$%$=Y3:L
M%2=R<K2"D%0!.:M.E=90]33IT:!!N;:8;CK+C\B/L:+C;A0I"59Y((S^Q^\@
M6:E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E5?5.BK=J2:94R1/8<7!>MS@C/;
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MHMBQ$F-]EQOU3V$-;]_;;]^6T%0R4HP#\BLDKISIJ5ZM4B&^MZ2MEU;QF/\
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M6Z;DT^\) 6 EH-!.[<//)6@#'W^E:FE]8LWEJ]O3(Z;9'M4YR XZ^^G:I;9
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ML]<F.'"4;^WNV;L9\\9Q_:O-IUM:5V*Q2KU/@V^9<H;$D,+?  [B1C!/QN.
M3Y/%;K6K]-OWP6AF^6URZAQ;7I$24EW>D>Y)2#G(YX_0_5:SMTT?JJ9^#/R;
M-=I*,N"&Z6WCP2"H).<X((R/%:>O=9P-%VZ.TPJWJFJ<9;:@N20RKMJ6$;DC
M!SC.<8&<'GBMMC5]OBMW%V_W.RP66)ZX;2Q/2H'"4D!9.-KG))1S@8YKRSU
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MAK(2H*4 >2-J>.>/*NEE^,R]]R)IUU,LS9$>:MU\OM.24.9; V[0 IP^\#.
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M0[I,ND.RHGQD:F?N7X4I]MM,MAQA+07R2G<E0*@%8\_=1[G36\"^L+<TRAR
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M^E5F%HV?>M;:GDWCU<.Q.7:--:BJ#93,+++82K()(3O;!(XS@>.:PSNBT.;
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MN(<2<@94H% R3Y_2K#;="2+?=)<N/J.X):F/)ERHR6V@AU\("2K.W(2K:G*
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MN*+2DD  !3BO=N.X  IY)JN].;-J)K0]CU/%CVU4JVV)4.VQ</.+?4M:"KO
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MIMS*D+ QN22><X)&#56N6O+Q%DWRXMMVHV*SS7H;\9PK3*7VV"YN0K.TJ4O
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M##!>#^&F]A[@! 4",$<*4//A1'@U9(42/!A,Q(;#;$5E ;;:;2$I0D# 2 .
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M"0M]I);X3C"TJ7[5\^TD&IVZZIO]BE7>,[J-^5=K7*A,P8+K3*3=&7E-[G"
MG<HDK6 4$!/;'ZYW;AJ;6$"[ZEM##LJ7*LXD79#RF6MLB(I@^G8 "1D]W<"1
MS_*5SSBH"T=0[HA5K3+UM;Y=JN,R.EZ>RV@J@(4VZ2A:U-);27%MI&%#*1N_
M0UT#_H_2&7^F,3T\A,@)F3@5@@DYENJ&=O&2"#QQSQ7SKB=MHTRLS$P$IU!#
M*I:@DA@95[_<"D8.//&:I;&N[O <2+AJ<&V%-WBQKBZVRD2BR&BPZD[0E2\K
M<3Q[5;/!JJ:PUH[J313XOU^2T]':LK[$,%IM$_N%I;SIX]VU>\83@)[1!\G-
MF1K[4;NH;LW"O3+TNWOW1+ML)8*7DM)5Z9#*0.ZI1(]P^<*Y' J-5JN?=+3;
MI$K6Z)4$W>U+=6P4-F(%*7W$O+[:4CE*3L()2?.1BOT@V04)(5N!'G[KE4YP
M2M4]3571YR,J%:6&8S^4H+49;3BU*23XRX%Y)_P)^JHMOU-(BZ3MC;&I'[8P
MSI=B5;'&B@IF3AD+8Y!+A00A':'/N/'BN@].+C=+WKC43D^_/E-O4PDVA/;*
M&E.QFEJ"CMW>UP+2.?(5GYKHMX>D1K3->A-=Z4VRM;3?^-822E/]S@5^?M/Z
MOU%.TQ+EQ-<,2+NZ8ACP5Q\*3-)PJ*HJ2 GN$$% _)@J!V@D^=2=2;DQHBWR
MH6J2S=U19TF2EU+30:DM*1_N^2A6=A5M#8&Y8()4$G)SNZTO\RX3KA&U<6H4
M6?:&T,,MQU-*3+;;#F3@D@;E$#/D$Y..-R#JR^2)=NM3NLEQFF[]<;4_<"U&
MWN-M,]QLJ*F]F[/&0!G//-5TZSU"Q(:O[JT&_)TE_,66L'M_B(1ZDMX/':R[
M^7'Z8XKJW3/5;3S!BW75%MNSLN8XW;W&'2LK ;2XIO?L0E93DGVC@$ \BNCU
M^<5//3=4N1%:@>;GC7;C;:U*:4Y'1Z)824I4D^?RC(*?:, '.=^W:[NTUFU2
MC?H2'W;%=B9KK+7;[K#X0T^HI22 1[E)'MXSCBNA='K[*O=FN8GRY,J3$G*8
M67EM.AO^6A6U#K0"74^[.[ (W;2.*V.K>H)6F],QY<9]41EV='CRIR4I5Z1A
M:P%NX4".!QD@@%0/Q7/I.KYO\N SK=:X;5OFS8EZ0TR@3GFG/:P2I&Q80C!4
M48WY//!J/E]3=018DM=UNK-JG+%D?9B2$-(*4/X$E("TY*?S$DY*<'D8K/9]
M0*@WFYP?QQNS6V?JJX"1<&^V=I0RVIMO<L%*"KD\@\)(&,\7_H$\A[I#IQ3:
MPXD-.(W @YVNK&>/VKWU.O$BT7C108EM1VIEX3%>#B6SN0IIP\%8)!R ,IP>
M<?-<M8ZC:KA6*'<OQM-V=G6ZYN)8,9E/:5'>2A#H" %*.PJ64G@@< 5,W*\H
MG3-&*9U8QJ*-_$[ 9DEMM*FTJB.9;4I"0A2MQS@ $;D@_%04GJYJ"!9[4I-Q
M9F7D0;IZV"M#16EYF0$-K6E !20V%JV\ A)_>ODC6+UCU%JA^RZCBSA+F6IA
MZ]/+9"6V5,.DK*FT% &Y(1N*"!OY\ UVOIG/FW'2$5^YW.'=9(6Z@S(9RTZ$
MN* (5M2%'  )  )!Q4%U@><C2]%N_BSUMBF])2^M"D)24]EU0W%23\IQCP=W
MWC'%]0]1+G?M-WFVW&\1)<>7;&Y\<J4RTI#J9K:4I2E."@%)!"5J*\#)*<D#
MH\764N?;M+39$UI<Z1J409<-R,WN@$I<'8Y&X*3MQW/*@HGP:B[1KW4S*+9*
MFWR%*]?"O"D,.QT--H=B*PV2H8/(R5?&!Q]U;.CFH[OJ9Z9)FW9,^WMQ(I3_
M "FFUID+1EY)"<$)20 "0,Y/)QFKQJ^Y_@NEKM<^ZVR8D5U\..(*TI*4$@D#
MDC(\"J%T8U?<]07;45ONLX3!"$5Z.M99[NQYHK(5V?;P<<<D9P2?)ZI2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2O+C2'0GN(2K:0H9&<$?-?%--J<2XI"2XGA
M*B.1^QKPJ*PK=EEL[B2?:.2?->E,-*V;FT'8"$Y'@'ZJ+1J6U*OMPM!D]N;
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M6LX5G!7DY^" ,\X5)F7%V)ZQW4;MO@Z@A3$N 3EE$94;:K8I2>XO^=CX\DD
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M]X1D$*QP#Q7RW.W)Z5IEA&J]1R[/.N4CNOHCR(NUHQL[ IU2G"E*P/<3P5D
MY'&+2FH=03X%G:U7)U+&>,1DVU^"TZ527T/*#J'@!M4I24MC^: -I*O))J=Z
M?3+_ #M;NF^WBXIEH>EHFVARWO!A+)4KM*[BG"T$@!.U2$Y5D@YY4+)T.NB?
MX$L-LDF099CO/-;FE;/3I?4AOWXV_E*,#.<<XQ72*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*8%?-H^A7W ^J^8'T*;1]"FT?0K[@?5  /
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M,_>*E+GTE:OV@XUDU%+C/W&)+=EQ9S,8I#)6Z7"G:5$E)R4D9Y&/D U)=0-
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MD58Z4I2O+CB&FU..*2A" 5*4HX  \DU$:9U19=4,2'K!<8\YMASM.*95G:K
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M2>,'SBJ]I^%J%_3-DU!*U.[ZMX,SI[2D-^E+"@%+;0 G*0$^%9R2.3R:U_\
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M4E*&'3A#RC\(SQG_ "!'-;DGJQI2/<Y<%<U:G8XD9+;96%*825.H '.0 ?(
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M*9TQMTFYS+BBZWB)/D2C+0_$>0VIA2FTMN!&$?E6E"-P5GE((P>:N#5LCIM
MMKH7)B]GL+$A9<4XDC!WD\J)&<Y\YJNVO0D:VMQXC-YO2[1'P&;8X^@L)2/"
M"=G<4D?X5+(QP<CBHM?2FS+M3EM7/NBH:83UOB-J=0?1,.X[B6SLR<A(3E>X
M@# (YSFF],K7,_$?47*YDSQ!+Y"VLE47!;/_  _)(!5]XXP.*A]/].7+B+S_
M !2Y.1$>NLV7%@H?0&T!X*2'0I W!6UQ8P5<$DX\5LQND%LC3&I*+U>EN-OP
MY *UL^Y<8$-9PT.-I*2!C(_7FL4SI[M<M5A9AB98&[@J[O3I<@=]ETN*6II"
M$(&4J*B"2?RJ4/JK_J*TQ[]8+A:);CC<:<PN.ZIH@+V*!"L9!&<$_%4R;TJ@
M2HUR9-WNJ!/APH;B@IK($50+:A[/S$@Y^.3P.,8XO3AJQ7G^((,ZYW*?&>ER
MX\)QQEMM;D@?S 5=O=R0G!*CC:D>!BISIIIG^&+"^AZ-'BRYTMZ:\RPHJ0R7
M%$AM).,A*=J> !D$@#-:.I.G$*^7BZW'\0EQ')[4?<&-@V/QU*4R^#C.Y.[&
M,X(\UDBZ#<;O=@NTR_W&=.M7J<N2 @]_O(2E0("0$ ;$X"0/!^2349'Z5,QH
M=MCLWB5M@PIL%!4V@Y1).5$\>4G&,?7ZFM=[I$T];'X#E\E^F=ML.V$!I (1
M&6%MK''YLYS\<^*RW[I0U=[G,G*ODME4J89BVPRTMO)9#)]JDD9"4IPH@E)R
M1YK ST>C-P2P+]<"OT<2,EX);"D.15$L.CV^4A121X4///-=!L%NDVV$MN=<
MI%RDN++BWW@E/. ,)2D )3QX'R2?FJ=%Z</Q+W;IK-[/IH%REW&/&7%!VF0'
M-Z-P4,C+JSX^OUSI:?Z52+ B*FTZGF1$^G$:8&F$?[RE)5L4G=GMK"5%.X>1
M\"K9U#TPYJ_2[UG;G""7'6G>_P!KN%);6%C R/E(YS4=-TG>[O&D1;[?HDB%
M)+29$:-;RPAUH'^8@Y=4<KX23GA(QCG-0T?IA,B+MCT#4:VY=N0Y$8==AH=!
MA*4%)86E1]Q04C:OC&!D&I.RZ D6:]S7H.H9IL\YSU,F ZVE2G)!0$J7W?("
ML!13CD_('%5I/1AURW*AS=3.O(1:4V>.4PT([;2'4N-*5S[E)* #X"A]5:/X
M!]4=5(O-P3-CZ@89:?0(_;*%(:[96#N(YP".."!R:TI?2]E,>Q*M-T=BW"UL
MNL&5(81)]2'5!;BG$JX*BL;]WP2?-6+4.FWKKI%%D;GIR$MH<>FQTR@^E.-P
M=0<!6['."#SD$5]TMI1BQZ/&GUON2HQ2ZA142,)<*B4)R24I&XA(R2 !R:J3
M72MTZ818I6I9;\-E3 CCT[:2E#+B'$!>.5J_EH3N/](\9)-;?^S8(GO2_P 5
M>4%WX:@+2&4C+@1L#>2?& .?OFJUH_I9+N.@X,35#[\*:Q$FPV8R4-$14R%J
M"SE)(62C&.<#)XSXL+O2N,XS*B_BDD6ZXB*;E%"!MDK8"0%)/E&X(2% >0.,
M>:^6G2,F[:AU3>[I;A9I-QA_AS"!($@XPI*Y! ]H4M(9&.>&QGS6"7TE1)LT
MNW*O3J6G[3$M&X1T[@B.LJ2L\\J.2*V1TSD,1;U @:CDQ[3<3(<$/TZ%!I;Z
M5!?OX44;E%03D<@<UKSNE3DB N.B^EM?H+=#;7Z4':N&YW&W"-W())RGCSP:
MMNK]/2-1Z1>LXNCD20ZE 5*;;!W$$$A2,C*58(*<C()&:J.G>E+ECN]NN$:]
MH+L.X/S D04(04/H0AYH)2H)2#VTD$#V\\'S5CZ@:/7JY%N;_$$QV(KJEN,.
MQP^T^%(*1E!(&Y.=R2<@'G!JH-]'GT:<GVK\>9/J8,"$'O08*!$<*T*P'.<@
M@$<>,U-::L#TOJ;=M4RK;*MR$QQ!2V\XG$EU*B#)"$J4 "@(2DDYQD8^3/:K
MTPY>[QIVY1IWHY%GEJD#+7<#J%(4A:#R,9"O/Q]&J5;^DDJ&Q:VCJ%MQ,*#<
M81*H)RYZM1459[G&U1&!SD#&1G-?)'2!Z0PRE>H0'HULA08SR80W-N15[VWC
MN60H$Y!1@9!\_-="TM:YUJMA9NEQ3<9BEE:GD1DQT#@ )2A.<#CY)/)Y\8I3
M?3&:S.5<(M\CLW%J\OWB(Z(!*&R^DI=:6DN>]*A\@I(\ULV'IJ;/J6T7=JY-
MN+B*FNR$*C8,AV4L+6H'?A !2D 85P.2<YKSUM@72=;+";,Q,6Y%N29"WXC/
M><9';<1D(#C:B"5@$I4"!GR.*@-/]-;G*TXZ%/Q[*[<+:JSRV/2E6Z*"OMK2
MGNGM.[5G/O6.<D$\5,HZ5I:#EN9N8_AUV>Q<G(CC)4_W6DM@!+P6,)5VDD^T
MGS@C/&31_3>7IV^620+^F3;K.Q)AQ(QB;7.PZ4J"5N;\**2A/(2,BLO5#IP]
MKF0DF\(C1O1NQ?3OQ/4(0M?AYL;TA+@'&[GCQM/-1[G2R:^EX2K[&=[UZ:O#
MN(*TA6QD-%O_ (V1N SNSQSQXQM:.Z<W.PWZR3)FHFY\.S0WK?#85!V.!A93
MM"G O!4D(0,[1D#Q\UO=0]#2M67&#(CW")"]-M+;_I"J5'4%A16R\E:2DD#!
M204_)!J(@],;G NT1^+?HWH8#MP<B1W(14K_ 'L$D.+[@W;5JR, 9 ^SD;ED
MT!=;8K10-ZA+1IN(Y$QZ)>9"5I2C_P"+[<)2/OGX^!&6'I;>+!#MBK3J.*Q<
M8T1^ ^ZY +K;C#CRG1A!<X6A2C@DD'/(^_=[Z5S+C.G3OQ>&N:JXM3XRI,$.
MH]L<,+0\G.%A:4@DC;@^,5XN72VYS&+@W^+P&Q,L;EH(:A=I#96\IS<E"58"
M4A6T#SQDDDFK5HC2DS3EWO4ER;&>BW(LNEE#*DJ;=0RAM7N*N4G9D#&>?/W<
M*4I2E*4I2E*4I2E*4I2JUU#U+_">EWKF&VUK#K3""ZK:VA3CB6PI9^$@JR?T
M%4;674'4FEX#Z7VK++G1D2Y"Q$2ZX5M-)0I)4V%?R00OW*4HA/M W%0K,[U*
MN0GEMN+$]/\ Q%#LZ20LJ4V\REQ1QD86G=]8X/%1<7JM?5GTDJW1F+U(?8CL
M0%LK;6TI9>5N*EK#;J"AD[5I6D*4<';73-"W2Z773S#^H(3,"ZA2VWV&GDN)
M2I*B,Y2I0&1@XR2,XJ-O6E[S,O<F=#U$N-'<>BO)CJ8*P@-'*D9"QE*O.,>2
M<[A@#FO2*"UU'1JN[ZODSUW>/=78C329CC/H&T ; A*%#:H$J]WR4_O6\>I%
MQTOK*SZ/+#,^&W)@VKU2W2M]T.M</K4"4H.4D[%>Y0Y'%:]GZTW67>;3 =M4
M-1F7*XP"6U*3CTR4E*ADG&=W.>!C-:\+KG<9-GCH_"F$7N3<6[:F.4. L.%&
MY0<;/NX/M3@^[SQ@I%Q8TK+UC%CWZX/7.Q7*4U&4]!1)7AAUEPE1]J]IR,@<
M#SE0)X$SU0U7<-)VZ%)@6\26775)DR%(6M$9 23N6E *MI. 5>$YR<^*K_36
M[SG[GJR:VT9S3]VB@(;E!:&D.16%*6V2>4@KS@8R,D?55W7NM[U-TOK"T7:W
M*M4IBUF:TMI;B%-D/! 1OX"SX.]!VGD<@9-^T45IU[KIHNN*0EZ&I*%+*@C=
M'&<9/ )^!Q41(ZB79&JY4%%H@JM<.\L6EY\3%%T]UM*DK"-F."H9!/Z#[J#U
M-U9N\/3/K6;=$CKNEFD72U.!Q3A;#>TX=3M W;%A0P2-P*3\$S,GJ3/@ZKME
MBG6R,OU+\:(\\Q(6I2%/-J6%D!&$ $ !*RE2LD@8&:Y]IW7%YB])D6N\QE!J
MX6BZK@W%$UQ4CN1^XH]WV@I.",$*)]O/GB]L=0+G;I,*QJMK"I<FW0G[8Z](
M5_OBEJ0AT* 3D%&XJ.,\<U;M>:FFZ;:L_P"'VQJXO7*>B E#DGL!"EI40HG:
MKCVG/%4N'UA?;A-S[W84Q+<IF:"XS,[J^_$W=U 3L&4G:=JL_'(%;1ZFWEN&
M\N9I94)PR6V8RY+SB&G@IM:^ 6@ZI0*-NU#:LE0/C)&@SUH>>MIN3.FRNW,0
MH,Z6[ZT;VT25E&$HV>Y22E7R 0.2GQ78_CFN(V;J#<])VJ;^,6J7+@&==6X<
MY^;O4ZMA;ZTM'()2C8UL2HD\I.1C!J3U+U-NJ+<Z+-;(C<Q,>URDJD22I.V8
M[V]I2$9RDC'['/D;3:>I]W-ET<W.D,R%$3(:%HB2RRH%3Z$_GVY*<GD8]PR.
M,UBTYKE=XUU=-.J@LQC!#A47).'R$J2$J[)0,H6%%06E2@ !G!(%:&L^I3NF
M+S=8SEB<E0;8U$D2)3<E(4&WW%-@ALC)4"D\9Y^2.,X)?5%U,EM<6SH=M$F7
M*ML2=ZHCN264K.%("#M0HMK2% J_+G&*F]#WFX:DZ6VZ[W+M,3IMO[RE,+(2
M"4G"@?Z3\_I]FJ!8M;O633EINUP;N%SFLZ.;N:RN<4H?PI&_*""-_NSW.21\
M5,'JI=F)DM$[3<9F-"E06I+B;B5E+4L@-*2.WRH%7N!( ^"?-:<35]R@7N#$
MM[#;,:7J6?%G+ES5OC#;*G/Y:B/8DX)V@  IQX)-;UHZJW"X0&YRM,N-0IR6
M?PU]3ZDH><>=2VVVLE VG"TJ)3O  4.<<S_3"1<'Y&KTW?*9+5Z4CMB2M]MM
M)C,* 0I8!"?<3MP ,FH+3/4.^W)]R$JU6]ZX/3KBU&2)BFVTM15A!W*V$E1*
MD 8'.23C&*MFC-5.ZJAVZXP[8MJTRXA>,AQY.]MX+V%DH'G&%'=G'%0MWOLF
M9JW4\5M]]%OT]:TNN,L.=M3[[R%J&58R-J$C&/E>3X%:6F=0OMR]!2FGY;EK
MU- #99EO]];+R(X=0K?P25)2L*XP2 < YSM:CZFHL>MF+"];4+;=E1H8>$H=
MPK?X20T$G" < J44\^ <5DTCU#EWR_P+?,L"H#$YJ4N/(]6EW<J.Z&U@I"04
MC)R%$\UDUMU#_A;4,>WNVQ+S"Q'*WC)"%X==[64M[3D))25%12/<,$GBH>]]
M2[R-,76]6/3J'+<U'D+BS7Y/M[C+O;5W&P,C."I(!).T@[?-734VHU::T@N\
M7.(%2$!I!C,NY"G7%I0E 60.-R@-Q XYQ5!U?KJ\R;;,M#=O1;;W&N]O@R0U
M.)0IJ0M)!:=" K*DY2?:"G)/.!FU7:Y2= :/@K4U.OCRI;48A^6E3H+SNU([
MB@-P25I2,@$C!/R:@X'52:NXLQ[GI:1$;,N1;GG&Y;;VV6TT70V@<%04A)]Q
MVC) _6H<]9)]PAO"T6>$)K4^WL$+FEQLLRG"E)W)3^<;<$#(!.<JQBI9?5T>
MJNG8T[.D08;<Q29+15A:XP45A64!*4DH6$J"E$D<@$XK5/4.0+FS=I]CNL)(
ML,FYLQ#/:+;S2%-$*4@9 7A0P21M!(P?CQ&U_-U*O3$F,VJ I.I!;)+4>4'F
M9#9BN.Y"@$E2>4'P/'S5ZUCJ)=MDPK1;8AFWBXH=4RP'PSM0VG*UE>%8Y*0.
M#E2A\9(YAHG7;D6#:ILMR[W%U&E57!;:I(<0X1(""5)"2HN#P5\X2#QFMZ=U
M"NLJZ:8NMH@^L:D,7 .0(=Q0J.[V@TH.=P@> I7!3N!X('.)9?6&$N"]<H5J
MDO6F&S#?N$A3B4*C(DH2M)".=^U*@5<C&>,\UZ_VNQV+B\BXV67$MC4^5;E3
MB\VL=V.A2U#8DE6"$'G[K31UH9%LD2Y.GKC%0AQE+3DC+3"DN@D%;JD@(P1@
M^0,IYQDC)_M2NC3M_E/Z:4NVVN!#FJ2Q)2MT!Y)4HGX(2!_3G\A/.1B^:9U
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MXK31U&O\)&I Y=A.>M$"1+MY],@-W9KN*3W\@# :QM(0?=M*O&*V8^N[XJ5
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MDO4-KC05PK=&D:NN$26B-'5MEA#"U;EDK\J*3G'&<'^G!Q]![]=($32E@>]
MY:)\6X.Q@RVH.LJ9DX]RRHI4#O/ 2,8%3O5>$)O4K0+0M\.XJ6BX@QIBMK3@
M#*2-YV+\<D>T\U'7;4]PZ=V"RLV^!9(4:2IUB5!#RW!;I;GO2LJ"L".E2T[P
M$C:%#'D"I*=KW4S.IIL6':XDNVVEZ/'N#JE(8W]QM*BXVI3N1RL!*-BMW(W9
MQ6C)ZBZHCZ,C:E"-//1)S$23'90M?<1W7TMK:4"KW;0XG+@P H$;>>,K>K]2
MW#J';;8)$)B U?IT%U+;!R^RW%2Z@*)5PH;R.."0#C P8JQZ[F:6TCIJ8;=
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M8]$^N4P4M@!IU0 4L?KP/\A]5@O\G1]R>:EWB=!6NTI1-0ZJ5M$=+F4I<R%
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ML'.,**B< C/)J(ZFZC7(U.[#NUW1;T6S4=J1'MZUMI2^P5M.*?.4[CSNY!
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MS"O$Q$H1XT22PH(:2HAU"BH_RU$8) (!]P!YKK-*4I2E*4I2E*4I2E*4I0D
M9/BH;46HH5CLXN+H<DMK=;8:;C86MUQQ80A*<D#)41Y( ^:V;'<5W2ULS'H,
MNWK7D*CRTA+B""1S@D?&00>1BM_<,9SQ4).U''AZKMEA5&E.2+@R\^AYL)+:
M$M[=V\YR/SIQQCFIP$'Q7S< <9IN'V.*P2IL6(&C*D,LAUQ+3?<6$[UJ. D9
M\D_ K/N'W3(QFH72FHXFIH#\R"T^VRU)=BY>"?<IM12HI*204Y! .?BIL$'Q
M6NU,C/29##3[:WXY"7D)4"6R1D _61@_M6P.17PX^:T+_>(5@M$BYW1WM1&
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M1^#;766YB7F9#29&>TZIIU+@0YCG:K;@XKF$_IOJR=>)-[D1;*9*[GZ[\/\
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M[+[32-Z%(/M*2VH%*L>U?'S7<])V[\(TS;+?Z=$81HZ&NPAY3R6\#\H6KW*
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M$/TT<J8X+:%)6-K2U <D'/&<UO=1MT'5^AKW((%JA3'V92U'"65/,E#;BCX
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MENPF^ZIB,RI:W$]P-9;X 6-Y"202 ?)JUM36'("9I66HQ;[I4\DM;4XSE04
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MUYUU*T'(.X%Y0((P< _H9"5TROJ[VU*8NEM3&5)MDU\*:<WER(@(*$D*QL4
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MF6_%C3(STICAUEMP*6W_ /, <C^]9I,AF,WW)+K;2,@;EJ"1DG &3]GBM/\
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MW*SD 8,D_H6_MWYZ6&;>B%_%C5\WB44D1TL]M7MV8W?U$9_O\U4-&:*N6L-
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MJ0HA&<(4% D82X<9Y%1YZ<ZG@:<E6O\ #8]S<EZ5%K[_ 'T ,/I6\I*!O()
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MQ7Y4#/E1^!6Y0\>:U!<H1N*8 EL&:MGU"6.X-ZF\@;PGSMR0,^.:VZ5J2[G
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MX#G%7G8G&-HQYKXIIM:LJ0DG[(J+U!>+;868;ERRA$N6U#:V-*7EUPX2#@'
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M2A*3(PT7&R%).,DG('['CBI7J8S(MO7G1.H[NVLZ5CQ76%2% J:BR2'/>O\
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MXW8_D*2L#"2E0SN'N45@<YXB-%P[S-.A;+9KA>[>W)TY)2^X7'4^G?!5L(R
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M//\ :L7^TW3(N4""J6XA^864IWLK2EM;J-[:%DCVK((]IY&1G&14;9M?KO\
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M[EYMQMY+13@<8"LC(SG(((QSZU7U&7IK6-T@38*%VN#:&[@76W/YJW''BTA
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M\.O$*/,MXVDLOIW(]O@G/U499K?I6]JB:@M,:VS5)3VV)S24K.$$HP%?.WW
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MI-Z%%B.6*&J/&97'93M/L:7DJ0#G.TY/'ZFO;F@],.)D!=FC$OH:;<5R%$-
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M,+CDO)*U>XMAW8D*5G!) -1,!ZYAJ!<[A*OJYK-CO,1B8DR-_<;D992?.5%
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MSMYV[JYXB+(GKL1N!OCUK1JEU5N<69(6(/86 I9'N">XK:E2^=I\[2<W?KI
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M7<>0 HA!Y3N!"P2 0 ;7)T9=[K)5<[5I^1;Y,O4PGQYJ0TAQB&N($)6<+"@
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M1WFI+#;T=Q#C+B0M"T$%*DGD$$>0:]TKRM:48WJ2G)P,G&3]5ZKP76PHI+B
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MD.)CC<_N!4I)"02H8"E$8\ D^":E],0++ L['\,Q($:UR )#0@MI0TX%@$+
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M[A65$' 3M^!6A;Y5S:THNXM2=:INS2K:[=$24O\ ;:=1(2F1VTD94%(+A*4
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M7;GW$M,...'"$I*B?H"OSYTKO4>W:1TU'N-[G.]EAQIRV-V]7<C+42>Z%@9
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M /GK_P!:?AT?[?\ ^>O_ %I^'1_M_P#YZ_\ 6GX='^W_ /GK_P!:?AT?[?\
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M@<^3_K7S^&[3_P!B1_XE?ZT_ANT_]B1_XE?ZT_ANT_\ 8D?^)7^M!INTC_\
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G*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>exh46_05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh46_05.jpg
M_]C_X  02D9)1@ ! 0$!- $T  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ L ! 1$ _\0 '  !  (# 0$!              4& P0' @$(_\0
M31   0,# P,$ 0(#!@0#!0(/ 0(#!  %$082(0<3,10B05$5,F$C<8$6,T)2
MD=$75&*3)*&Q""4T<L%#<X*2TB9$4V.4X?#Q9'2BPO_:  @! 0  /P#]4TI2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2OB3G/!&#CGYK[2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E",CY_I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*U;K<8MIMLB?<7@Q$CH+CKA!.T#]AR?Y"L-BO$*^VYN=;'''(SA(
M2IQE;1.#@^U8!\CZJ0I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4J*U,[>FK6I6FHT"1<-PPB<\IIO;\G*4J
M.?VQ4%K1=M7HEE.O%F(VZ61(5"=>"6GP0H%*T *"0L A1P.!FL?3PWM&A7>[
M(?GRT+D"WO7(%M;S(6H,*=XW<I"224[L'.*L6G%7I=O)U&U;VIN\X3!<6MO9
M@8Y6D'.<_'U4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5\4H)*00>
M3C@9K[2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I3&:4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MJ,>O]I9EM1G;E#2^X7$I07DY);&YP>?\(Y/U4BRZV\TAUE:7&U@*2M)R% ^"
M#\UZI2E*4I6!$R,Y+=B(D,JE-)2MQD+!6A*LX)3Y .#C^1HY,BM2V8KDEE$I
MX*4TRI8"UA/ZBE/DXR,X\9K/2L3TEAAQEMYYMMQY6UM*U %9QG 'R< FLM*P
MPI<>=&1(A2&I$=P90ZTL+2H?L1P:S4K%%DL2V>[$>:?:R4[VUA2<@X(R/H@B
MLM:\Z=$M['?GR68S.X)WO+"$Y)P!D_)/ %;%*B9FI;%"?6Q,O5LCO(.%-NRD
M(4D^<$$YJ50M*T)6A04E0R"#D$5]I6*5)8B1W9$IYMEAI)6XXXH)2A(\DD\
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M$M+.U#I24I6#M("L!1&WYP>?2];3(,HQYNHKA'DF=9I#$>2@-NJCNH:$C>D
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ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2AQCGQ7SV_M7S",YPG/G-??;^U?,(
MPG \?M49>[E;[9"+TIHO)86W_"89+RT%2MJ3L2"0,_/Q@_526QM6<I22H8.0
M.17O@_1K7;$-2W66_3E:  XA.,IXXR/CCQ64--9)2VC).20!R:^*6RPUE2FV
MVDC&20 !419[I9[\]<F82$NKMTTQY"78Y1L?2$JR-P&>%#"AP?@U-Y'V*\%M
MLYRA!_H*T$3H/YYZWI:4)WITR%K["@E2"HI'\3&TG(/MSG]JWF6VF&PVPA#:
M!X2@  ?T%5XZMLZKI:X#R)+<NZ.28\9+T1:=Y8SW <CVC@D9QN'(S7G3NCXU
MB?OS\:?.=?N\I<MQQ\MJ+#B@$GMX0,# 2,'/Z1^^<&@#9[0U*TA:9$MYRPI;
M2Z9*1N ="EIPH !7'T,#Q\&K;Q^U:%SNC5OD0&7&)3QF/]A*F&2XEL[2K<LC
M]*?;C)^2*V8DN+,;4Y$D,/H2M32E-+"@%I)2I)(^0001\$5F]O[5CC26)3/=
MBO-/-;E(WMK"AN22E0R/D$$$?!!%:%\OD&R& )Y<'KI3<-GMM*7EQ?Z0<#VC
MCR<"I3@<<5Y2E"?TI2,G/ \FBDH6"E82H?1YKYL;*]^U&_&-V!G'_P#)-1UX
MNL&S194M]"W%-I0MUN*R7GBDJVI.Q(*B,Y^/@_1J10EM*0$)2E(\ #&*]83]
M"F ?@5H7NYP;+;'[E<G$M18Z<K7MR1D@  #DDG  ')) K!9[] NEO]6@/16^
M^8Q1-95'7W K;MVK ))/ QY^*ANG3=F>9NERL\JXS77Y;C,AZXJ674*;6H=H
M!0!2A)*L)QQN/W5N6E#B"E82I)&"",@BJE/Z@:;B2)C3[LEQJ&[V)$EJ"\ZP
MRYD#MJ<2DI"LD<9X/!P:MNU"CG"23^U??;YXKYL0#G:G/\J]9'V*\X1])XKX
MMII>-Z$*QXR :=EK&.VC&2<;1Y/FOGIV<$=IO!24GVCD?7\J^)C,(+92RVDM
MC",) VC]OJO;K:'6U(=0E:%#!2H9!'\JP^AB>W_PK'MQM_ACC P,5X7;8*PT
M%PHR@UN[>6DG9GSCCC/S6TE(2D)2  . !\5]I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4J ZA+<:T%J1QAQQMY%MD*0MM90I*@TH@A0((.?D&N F)>7K?#?MLC5
M9LT@6HSG75R^Z91<!D+1G^)L#)R2GV9Q@Y'%D-KO$"]RX$=>I%7N)=H@M3ZW
M7W&%6W^$'-ZB>VH =W=N]V2/V%0-L5J&7;W'=&S[[*U!'D7=AXOR)#C/ITE]
M+ !<_AE87V]N"3G.> <9KDY=$05.:=EZJ9LRQ:P^IY4@OMRN^ _C<-W#0)6$
MDIR1Q6;4-N?TK)UZU:W-1&XJ_&KAR>[)>6ZTDMA:BL922#O&#R0% <9J:0[?
MEZK(=>OC=^3?U H27S$-J()R$Y[6 C_%C?OP/-8ND#MY9O\ I3U\_4#XGV>2
MN:B>IY:.\AY(;X4"$':%_1('SG!P7A$NSZRU?V6KLW#D7J#)N3C!D F 6$A2
MVUI) PY^K9A6T$# 3Q<-)2-0'IWJIZV.R9;Z9$PV%R85+<<9"?X))5[E#?NP
M5<D8YQS7-;\W*NFFYWXYS44NQ1XEODS4R79*G6YJ93?=2G<=^0UO4I*<@':1
M@@8WX3DB'JV;=;-(O#"I.JVF41E]U+;S"X@"E.-J'(*DD;U#*=OG@U'Q)%\&
MDI\IV\:P3>@Q%]?',60V(T@26PLI4HG*E)4X=K8V;1D@>T'I_4.*Y9>G42)
MO-P8#;S8];(4\\I0Y/\ '6V4N!!/!4DY''QQ7-;E<K^NQ7%4-[4D>1_99MYE
MOU#[JQ)$M8W!6!E2D[?(W;3R/-22')EKU))<BW?4KK,2\VU#"'7I#Z#'?:0I
M_>D^4\+\@A) QC)K9B3YXFV!<A5VDO1;Y>DY6RXMSM;'@U@J'R%-A))Q[L#]
MJA N5^3;IC:YNJTL.BU.H4$SMR5]\ID@N*&20WG=M"4DCA/&:NB].J=N_4*V
MVR;=8;T:+ ?A3W'G@7'&6E_K=..X,D!0)/!_;B[:55/D=.9]YGMS6[C=V79_
M8BJ[CK(6W_"0T"<;@@(XX&[/W7.=-P;\T;.TRW>'6&+_ !PY,0)C:9#'86ES
MN,N$E&U00%']&XDCY%:>F[?/T]'L+K%EU)&99E7>/<8[+$A95W2HQS@?J3^G
M"TY /.03SIVU_4J9NE')L'5:)<7\<S,4J)+6'F.V4O?IPE("B=VX*4I7NRD
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MJ2HJ4,)6$DYS4O!ZDV]^XHM\JV72'.-Q;MCC+R6E%IY;)=3N*'%#:4@\C/\
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MD/)RK<I7./&!CC-:MUZ>7>Y2(<Z1JEQ5VMZV%P):HG]R4@][*0X H.[L*'&
M /@5C>Z6N/P;W9G;_(3IJXE]U$!#" MEUTE2B'3DE(6HJ"<#GR36:3T_O4VT
MVY%PU:])NUOFLS(TM<) ;06T+1@M X)4EQ63D<[?@8K0MG2-RW0TLLW]U:S
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MQD0KBS,F6N;-;MT9UHL20@MX223NWC<G!X')S]#='5RU_AH5R]!*4W)B,/\
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MIDO+&%.!K].X\\_]1Q6?46CX-_N:9TN5/;=3"?@!#+H2CM/ !S@@^X[4\_\
M2*@W^E%AD-%#TJ[*(9BLM."5M6SZ;/94A20"%#<OGYW'-9IW3&SRS'4N;>$N
M-Q9$-UWUBE+D-O$%P.%0.[)&<< <<8  R3>G%K?8@HCS;G#<BV[\27H[J4K>
MB\?PEY21CCA20%#X(JN6[IJJ1K;4#TX38>FW1!3'A,R4=F2(Z-H#B<%0 (3@
M!0R/.:GX?3*SQ) 4S)N"8S+K[\*)W$]F$Z\"%N-#;G/N40%%21N. *UXW2BS
M-0&(;LVY/QF;.]9$I6MOF.XK<<X0/<,) (^$C(/.==?2&TKFB3^7O@6'(T@@
M2$8+[  ;=(V8W  #'Z?VJ6TYT]@V&797X]RN;YM+<EIA+ZVR%)?6%KW80,^Y
M*2,8Q@5BUKTTM6KKH[.G3KI'6[%1$=;BOA"'$(<+B,@I/(6<\?US7C_AA:E6
M:=;W;A=G%29XN@E^H2E]F2!CNH6E(P<#'((K0O'1ZSW9*A-N^H%J=B^DDK,W
M*I*0X7 5DI/(4HX P/ Q@5?)EJCSK$_:9I<D1GXRHSI<.5.)4G:<G[(-5>)T
MST_ .^W-O17A:?PZ76U J2SDG<,@^\E1RKY^:T)?2.RRV(S3\^ZGTT"/;V%I
M=0E;26%A;3B5! (<2H9R/.3D&I"+TYMS=S@3Y=PND^3&9?86J6^ESU"7@ YW
M/;])2 $[0-HX\YV]$Z)B:1W(AW&ZRV$MAB,Q,D]Q$5H'.QL8&!X&3DX2!GBM
M/4_3BWZAN=TF/W&Z1OR4=B/):CN-[%!ES>VH!2%84"3^W)XK4N'2JU3+M)NB
M;G>(MT>F>M3+BOH:<946PVI*,(QM4E*000<[1^^;?^';3IXVEJ5+0@L%CU)<
M[CW(P5E2P<J^<D'FJK;^G @V>WVQK5&HA#M[1:C-I=81VQL* <I:!44@Y&XD
M @'R!6HOI#8_23HL65<8<>6EA9;C.);2U):QLE-X3[7>.2.%9Y!K+)Z71'WX
M<PZ@U"BZLMN,OST2@'I+2U J;4=N$IR!@("=OQSS7MSIA"5J(71N\WEEI-P1
M=$PD/)[(?2@().4E1"DC!!5]XQ6SI_IY%LDJQ/,W6XO"SMR&8S;Q;*>V]MRD
MX0"<;$X.<\<DYK%)Z6V%VR7>W,F5&_(7 W/U#+@#C#^[<DMG'M"3DA.".3]U
M9M-V==FMGIG[E-N3ZEJ<<E3%@K63^R0$I &  D <?9)-%?Z.V]^UQ8+MYN9;
M83/3O :2M1E_WA)"!X/C'\CD<5\1TC2VBX$:EN3CMP2TF6E^/&<8>"&^V 6N
MUMP$XP/C:/WST'3MI9L-AM]IBK=<CPF$1VUNJW+4E( !4?D\5(4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*5 Z_Q_8346<8%ND'GQ_=JKBAU;<(^AA:M0VVUSVH
M,2R3(NU;N"TZZAL%P\'N)4G=D8!SX^#TFP:JO$GJ-,L5T;APXK:7E1VE,.I=
M?0DHV.-NDEMP$*.X#!2<#!\U"WWJ)J*V:CO33=MM+]HM-SAP9&'G!(4B0E&U
M:1C;D%Q/\^?YU'6W65[U UI>YWZS6<P9%^3#A^FE/=UMU D(6X> ",(X!SD$
MY&<8U_\ C3=;=;T72]V>"8$AFX>F1$=<+G=B+VD+*D@ *_;)&,_L)C4-ZO1E
M6!&H[5:G%B]PD1W8LUT##J%?Q E/NRE06G"QM4/ZUK1^J6HFX$>Y7"RV=-OE
MKGQF"W/4E0>C!TY65I"4H5V5#.>."<9Q6FK5\[4OX%5TC)B2H.J8<0EGNM(=
M"X_<_0K"O\>/=D' /S5BZB/WF)U)TPYIEJ,_<'+;/"F9DAQME:4*8(X2""KD
M@<?/)XJ)A=89<ZUS+C'M+ 8CKM1[:G5%13,(2H9Q^I"CP?!'P*U-4]09L^T:
MJA7*U14?C^3!,A]B24"0AM+@4E(W)/Z@I!P. 2/-2MQZGW:!JB;$=M,#\1"O
M+%I=>$H]]7>0E2%I1M">,\C=_+QFM:U]5-37*RO7:-HR0NWN1D2HKJ"5DI+J
M4D%*<J60VHK.T?X2,?-96>J=R?78%-1;5Z*YJ"$S5+>$=Q9D*;[25[/X;@0D
M*VN!)).T<BK'K#6=PM]\EVBP0H<F;"M:KM(]6ZIM*FPHI"$;4GW$I/)X''W7
M-=676;J>;J:]1U-M,VW3,2[VX*>=2Y%<6EUW=A) W$ @@\':@'(R*]6F]Q^G
MBY,W\7%]6]88LQ3Z)KRFW''9 :25)7[4@E25+4.3R?FK;>=::SM\R/8V[1:9
M6H)*WW&#'>W-+8:0V0HH6M!25*< QN. "K! Q5WTQ-O=P0F3=HL"+&=BLK0R
MR\77$/$$NI4H>TI!P$E.<\FJ2KJ-=%O0IT:)#7:9MX>L2&=J^^R\@N)2ZL@X
M*2IOE. 0"#D^*LG2S4%[U3I:+>[W%MT5J<TV]%:B.+6H)(YW[@,'/( SP?)\
MU<:4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*^$$D')&/C[K[
M2E*4I2E*UKE"8N5NE09B"Y%DM*9=0%%.Y"A@C(P1D$^*JTCIII>0%!Z \L*8
MCQSF8_\ H8.6A^O_  D9SYSY\FI"UZ,L5KO3UVA0UIG.K==*ER'%I2MT@N*0
MA2BE!40,[0,U7[5TZ8.MM07Z^!N2B;-8EQ&$/.AM"FFPA*G&\[%*!3N!(.">
M/ J:B:"T_%A6^(S%?#$":JXQDF8\>V^2HE62O)_4K@Y'N/')K61TUTLAF,U^
M.6MF/Z@--N2GEI D9[P(*R%!63G.:\0>F6EH$6+'B0'4(C2VYS9,IXJ[K8(;
M)459(3N.$DE//BH;272^&W:9+6KX[<Z6^],44)F/.L-HD+4I7;0K 0K:O:5)
M /!.>34S!Z9Z9A/(=CQI@6B6S.RJ?(5E]I.U"R"L@G!P<^?G.!4GJK2%JU.Y
M%=N0E(?C)6AMV+*<86$+QO02A0RE6T9!^JB[OTPTI=9+;TFWK;[;++ ;C2'6
M&]K1RWE*% $I^"1Q7@]+M-+;N#3K4YUF8WV2VN<\0TV7 XI#?NRA*EI2H@'G
M ^.*VG^GNGWY*Y#K,I3SDUBXK49CN5/LC:VL^[X&./!P/JM6/TMTM%1+3"B2
MHOJ%;P6)KR.P=X<RUA?\/WI2K"<#*1Q@ 5]8Z8Z=8<B+;1.'8*5.)]:Z4RE)
M=+P4\G=AQ7<45Y/.3CQQ4GJC1=FU-*8DW-E[U#3:F.XP^ME3C*OU-+*"-R#\
MI-:DWIWIZ9(N#KD>2G\A$3 D-M3'FVUL)X2WL2H)2 ,C@#A2OLU]_P"'>FU
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M0A!(<2@G*TJ((&.<84>#7FVZKFS6[>O\,DF3$>D+2S/8=*%H5@-IPK"RKGW
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MM)"1VFW7UK2D[>"<*R?YX^*M%:MU=D,6R6]!CF5+;:4IE@+".ZL [4[CP,G
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M2E*4I2E*4I2E*4I2E*4I2E*4I2E1FJ(#MUTS=K?'4E+TN(['0I9( 4M!2"2
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M8"@^_E*@% YSC',5I?J)=F[=9508"%VA&F)-W<;ESENOK4TO: 72@Y/ Y/\
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M  V0DGC(SN_:JMUVN<J#'L;49RYLMOONI6[$+X1D-G:E?8_B%141M2" 2.2
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MA2EE(01A(R3CK70YUA-KU!!3,F2)<2]34/(E/+<4@%]91RKQE.%?OG/S4/\
M^T'J2796[=%@W*7 ??BRW6E-K4RA3J$I*<K2E14H>[#>,*SE1 '/3=*7-%ZT
MU:[DVXEU,J,V[O2, DI!./ZYJ5I2E*4I2E*4I2E*4I2E*4I2E*4I6*7(;B17
MI#Q(::05K(!)  R>!R:HJ.K>DUP)4L3LM1X34["=JU.)<64!* DDE07A)'C*
M@,^<2%GUC*DWV):[OIRXVER8RX]'=><:<;6$;24J*%$I5A6<$?!YJSMSHKC7
M=;DLK;W;=Z5@C/UG[KZJ9&2EM2I#02X<()6,*/[?=:ENOELN3<AR%-8>;CO*
M8=4E8PEQ/ZDD_M_]*W4RF%% 2\V2LE*0%#W$>0/Y8-:LZ\6^"TTY*F,MH=>3
M&02K]3BC@)'[_P#]?BL5GNJYWJ_50G8*F93D9 >6@]Y*3PXG!/"AR <']JD4
MO-J&4N)(R1D'Y'D?^1J,U%>C9F8ZD6RXW)Q]T-):@M!:AP3N45%*4I !Y)'.
M ,DU":&UZQK!+3L.QWN'#>:6ZU+F,MI:7M6$E.4K5A63X(&0#CQ5OWIX]PYY
MK[O3]BM&)<52+I.AF%*91%[>V0XD!I_<,_PR#D[<8.0.?NM[</NHFY7^-$3)
M3';>N$J,MI#T6& MUL.$!*BG(P,'<?V!-2VX?=1FI;TSI^PSKK(8E268C9=6
MU%;[CA2/.U/&?O\ E6OIS4L6_2[G'C1YK#D!U+:_4L%L.!20I*T9\I(/\^/'
MBO6L-20]*6!^[W%N0Y%84A*PPC<H;UA ."1QE0J9"A]U4-0]0+;8IE\CRXLY
MQ5HAM3GRTA!"VW%*2-F5#)!2K(./'&:N / ->4N(4G<E:2G.,@_.<8_UK[O3
MG&1F@6DG 4,_5"H!)42 !R2:P09L:?#9EPGVWXSR0MMQ!RE:3X(/U6QD8S\4
M) \FM!RXE%Y9@"'*6EQE;QE)2.R@I4D;"<YW'.0,> :S2)\2-)BQY$AIM^4L
MML-J5A3B@DJ(2/G"4D_TJ'OMQMNDX[DT0UN2KC)0TEF.$]V4^H82D%1 S@?)
M  !J4L]P_)6N--5%DPR\C<6)2-CK?[*'P:W001Q7S</NL4MAN9$>CN$]MU!;
M5M.#@C!P?BM+3EGAZ=L4*T6_N"'#:#30<65J"1X&34D"#\TW)^ZP)FQE3E0T
MOM&6EL.J9"AO""2 HCS@E)&?V-;!(!QFL$Z+'GPWXDQI#T9]!;=;6,A:2,$'
M]B*RH"4)"$ ) & !\5HV2Z"ZPU2/1S86'5M!N8UVUG:HIW 9/M.,@_((K?W#
M[H5 ?--P^ZT;JBW2A&B7(LK#KR5,LN*QW'$>\8'^+&W=C_IS\5O C'GBF1CS
M7Q24%7(!)XHE"4%12D J.20/)\<_Z"OI2"02 2/'[5]2 D  8 ^*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I5)ZIZ5DW_ $L&K"W%1=(DB/+CAP;$N%ET+#94!P#@
M_P!349JYS4FL-%7>UP].S;5+<C$9F26DAQ84DEI!;6K(4D*3N.T<CSSBIWW0
M,RX7P3&-.*:L\NZ6M]5L6&"AL-I/?=4C<4CVE+9">3M/!!R8*[:+OR8\5JWZ
M4E=R'+GB"RM,=<4L.2RZAM:=^6@ $E+B#E.,8QYD6- R9%PC1+MH\R&$ZKE3
M)3RDLEMZ*ZEW8K.X**05HXP,8\<8K4GZ*U676;;:K$_$5!FWI<>XI=92V$RV
MG>R4X5N RI(/M!2<8SBMH:06NS6^8QTW7"5&G6]<V(7&7') 9WI6I#>=A&%#
MW9!6"<C YWTZ1O#EFO\ /A69:+];=4/7FU-RDH2'T**-R0K. E2=WUR$GR*T
MM0=-9B+W;8<N%>+A;U165-R;8J.CL30\MQU2BXDEM*U+"MZ,'"=O.,5WUQ6Q
ME2B%*VIS@#)/'P*X;%L>H'N@]IM@M=S:F1IFZ;":0VAYQCOJ4H(2Z"A7"DG:
MH8."*U[#H6*G46F6YE@OR[-'B2W4IGI25-.]Y+C06EG#:,$.%*!P,@8R:KIT
M'+<L2VQIZ[AY[22TJW(=!5<4*PT%ISRL#].<@#QBK!?;%=[E+O;LJUW:0E]5
MA<;5VW4DK:7_ .((QSD(4<D?TY%0NH]*W9<.Y6F!I:[/6UN7=#!2ION(;*T-
M!HH0M8"05=Q27.2GG R:W'-/W9,+4;J[!=S=[@BSRFY B<J[/8[R5+2=Q5E*
MU%)^ONIYZQ7A_5"GG;;/%\1J,3$7(-DM&U[3_"W\#;LR@M?JW'./D:?3'2LR
M!=-+)N%FGH0_;)K5V]2VZMM9+Z2RAP+XSM"L#X!_>N[,1F8ZG5,-(;4ZK>X4
MI WJP!D_9P ,_L*_.6J;#>53=;-V_3UUEM3TO)$I49;<A!5+;.Q"@2EY"@G<
ME6-R$IP2!P?=TTM<52KC9[=INZKL8O*WV MLK0VA4,)"D(=4$JR[N.XGV'W?
M-8V;+J63I:],2M/W@S9&DH4%"7FLJ=D-+7N259//\1)YP<9X&#79^H42[7GI
MW<H]C;6W<I$8;&%K[:E#(*VMP/M44[DYS@$URF^:0FS&HTF'HNZV^Q.O/F=9
MXTB,IXN+80@.H:7N:2D;5)X(5[MPQXK75I'4K&K-/OLZ>N2&;=-MZ^^7F)"U
M1T,=M86\5!64DE.U"0D^Y1W<5H1]$ZA;M8#6FYR[>S(AO/MK;CHG2&T=_+2L
ME33Y;*VU!:TC?CGD CL^C+ (?39-E,.4RRIE]IN+<'4O.);65;4KVX2!M(]@
MX2/;GBN.VK2%Q8TG;X=UTI.>C_@##BQFV1NBW(*.7L ^PK)2>Z<?H\@'GKFI
M[;J*1T??M\9U3FIOQK;:U-K +KP2GN *(QE6% $C'-<O9T?.&GF(VEK3J*WW
M-5P,N!,N;;+:8+B6U=PAIE 2VA0&P#: M1W?N=Y=H=<BVH0--7^TPO[,S;>]
M&BLJ[K#REH4$I)X*B0ZH+.-Q/)RK%:&G-(3V-5:2GR]-J>C0+U(2N4U"4QW&
MU14I;>4PL_P@' ,X 3N25#R,] ZSVA%X=T<ART/7)IB]-OR.W&4\&F A8458
M!XR4<?/].*'_ &8OI; 5:IZ+\@W5-UG-MJ2B9'<0OL(;4,A8RIG8CRCMD82,
MYZ?T@L+6G^GUK91#?B3'F&W9C;ZG-QD=M*5DA>2.4_&!^U<'1IN_L0;QC2]\
M8,ZU+;4EN.LK]6F6%C>XE16ZK;N/=.,@\ #QVOI=:5674&L(D>'/BVM<IA^&
ME]*PV0IE.\H*R23W LJ^<G/S52AZ2E2^J5Q>U! O[ZG9CY:D-]KT2X;C93L6
MZ1W-H'':S^KW 8)J-.B=51='W%+D9X2K2&K7%])M+TN"B1W77$).$E;B-@VJ
M'N+:O\YK29T<MUZR1EVK4S]F+=S>+<U@M%!4VVIM);9 #:=Z5[4$^<GC(JR]
M)[5/B:RA3KS9IJ)#^FX$?UCT98*'F@M+R5J5^E7"?/ZN",BOG5&S72X7[427
M+?=9+[\!@:=EPPXI$62E2MV2GAHE10HK5@%(QGC%372K3JXVJ-572[1;BBYB
MX.)9>>4\EE;2VVBLMI4=I!<0KD#X&.,5I:BM"Y/5-]=ULE^E[W83UIN,%?\
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MZTK4G4MN*4(#A(<X*2<9'^;'SC.WYQ6W*ZAZ3B7UJS2+["1<G7$M)8*\G>H
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MD;T_!>U$Q=X8C2VF;JM+*#+945*0E*597O&4J4>%;@>2.-K64"[*8M3]R=U
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M1</M#7!1R>!6Y)BW:&[<Y+%TUBXF*W;)L=M7J7 7EK/?&"D;P$8RC&U// /
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MR<#[@6A3>SWGMAH#<0,*W_/&P-3W-VX_A$WBY*N3-VNL%QH)4%%DLNF-E0&
M2H-E"B?OR,XQ: N;]W&F]/0=23F/5:45[N\"MF8EQ&<$@$J2 M..0 DCX-8K
MIJ36(T?&O$V5,M4=,F/9I[A25AD-=P/RO:-PW.[4;AX"?W%7W2;2IF@8FH+M
M>#<;E;XTLQ[LJ,I"=ON =#1QNPE( 41[ADC]7.KT2OTZ[6V[IDRY%RD,=I0D
MF6E^,\I3>?X2MB5(R1E3:AE&17,H>M]3(T]?;E.U:ZS.$5*I,+T2MUOD!]M.
MT[T[49"EH"1^H#/D$U:DWNY6K4*VUZUFS6X>HHUN#3ZX^UQF0TA2M^U R0LN
M!)XQLQCS56AZOOERT\I<C4SMY7-MEW;ND!?91Z-ME+@9<.Q"2VI1VI]WG<,>
M!B57K*\QK(6[?=50Y5OM=L>LEN;2VI-T"VTAU.T@K7SE&$D%. ?WJYHN6I(N
MK;GI^9<)@9;*[TU/(:.R&II2/3GVXRE[D$@Y2.:YU!UEJ*3I[U;VN)/J'=+.
M7W:A$9)3(95A+8_A\)41A0Y)(/(\5-6_7FH;KK..V[JB':6B]&"+<IL.KD1G
M&$*+K>&O=DJ4K>5;4!)R  28:YZNU#)T+)]3JB1.7<=*NW I:;9:4RMMU""4
ME*<X4DKW>?!(QCC]%Z=DL3+% ?B2DRV%LI*'TJ2H.#'ZLIX/].*D:4I2E*4I
M2E*4I2E*4I2E*4I6%$2.B4Y)0PTF2XD)6Z$ *4!G )\D#)_UHB*PB4Y)0RVF
M0X E;@2 I0&< GR0,G_6LU*Q2T,N1G42DMJCJ20XEP I*<<@YXQBJ7&TUTV=
M"/2V;2"PXTIU/;BQCN;'"E# Y3P<GQQ4$^WTY@F9(NVG=)QK<F3'BQI2&8SH
MDEX)*?:E.4\JSS\ J\<U[T;!T#J5VYLN:/TW#EQ+A(@I8<AQU+>#1 +B1M!*
M3G^F/-3C6D^G#C3SK5@TBIII?:=4F%'*4+S^E1V\'/P:T[M9.E]J7&:FV+2C
M:Y4H0FT" P27C_AP$\$#DY\?U%2,[0.@(T12YNE],QV.$EQR P@#/ ]VT5KN
M=.^G)D--+TUIP/.)RVCTS0*T@>0,<\?->4=..G)P4:9T\?8701';_2/*OY?O
M7ASIUT[DPLBR6<1E'8%LD(&?H*21@\?!^_NM@]+-#)2D_P!G("$HY&T%('^A
MKZ>F^B%H#OX:(4?JWAQ6#Y.<[OW)_J:RN=.=' *6JSL(2?)[JTC^ONJ&MVGM
M$3M4W>Q-V-U$JVML.N.+>5VW Z%%.PAPDD;%9R!X^:G8FA-*1IC;T:W-HDL+
M2ZDA]PE"@<I.-WV/_*I+6.I(FE-.2[U.9D/Q8NTN(C)2I>%*"<@*('&[/GQ3
M4>HXMA>M+<IF0[^2F(A-J9"2&UK!*2O)!">,9&?CBI"=<(L QDRG4MJDNAAD
M')*UD$@#'[ G^AJ/TCJ.+JBSBXPV9$=OO/,%N0$A84VXIM6=I(QE)QSXJ:2I
M*A[2#_*J@[KR,F7=F6+->9*;4_V)CK+3:@VK:E60"L*4-JDJ]J3P?Z5;@M.!
MR*!Q!2I06DI3P3GQ6,R6 -Q>: V[\E0_3]_R_>H>YZFB1A,;@-KN<V(II+T6
M,I.] <4 "2H@8 .X\^*F!)8.?XS>0K81N'"OK^?[5&:<L-JL*IZ;0EQ)ER%2
M9 7)<>RZKRKWJ."?VQ6^U<(CLN3%;?0I^,$EY(/Z-PR,_P!!G_3[K2FV2U3K
MS N\MH.S8:2F.M3BMJ-WR$9VD_1QGZ-2H<0<X4#CSS6G'N!>NDV$J'+93&2V
M1(<0 T_O!.&SG)*<8.0,9'FMW<G&<C%:S<^([/?A-R&ERV$)<=:2H%2$JSM)
M'P#M5C^59U.)#16/< ,^WG/\JK]EU="O6BO[36Z+.>B%EUY,9+8,A?;*DE*4
M@X*B4$ 9YXJ=C/I?CLN[%MEQ 7VW!A:<C."/@BLI('D@4W)^Q3<G[%1,>_1G
M]32[&EJ0F7&CMRE+4C#:D+*@-ISR<I5\?%2VX?8IN3]BF1C.1BF1]UB:EQWI
M#S#3S:WV-O=;2H%2,C(R/C(YK*2!Y- 0?!%#M/!P?VKXXD*3@\?1^J@]&Z:@
M:4L+-IMZWG8[2W%I5((4O*UJ6<D 9]RE'^M30::]I#:/9^GVCV_R^JI>D9.G
M8-VU.6+A+7-1<$1IKMR?4HI<7RTTV5G 1EW"4CY5\U<S'8*"DLM[=NW&T8Q]
M?RJ(U-?[;IN+'>G-N../*+,=B.R7772$E12A(Y.$H4?Y#^5;UJ?B7&V1)T9G
M:Q)82XV'&MB@A0R 4D9'GD&MU*0E(2D )'  ^*^TI2E*4I2E*4I2E*4I2E*4
MI2E*4H0",$9%<+N72O429A%HN$:+$BS'H\%*4X*+?+W*D@_]25+]@XQVQ]UZ
MOV@;PB?J1VT6-A<15ZM=PB1M[24R&F$(#B4@G"3[3^K&?OFM*5TZU!(D.28U
MJ1!N$B_W&0N<A;/=1&?86AM94#D@*6#M'(V^,@5C=Z?Z@N5KD!C3S-E4S86K
M<[$2\ULGR&WD+2I.TD;0$*PI>%9<QX!K:.DM23;\N\R=,J:']I(]V3&5(84L
MM>E[2QG=MRE823SR.1DBKKU4L$^YW/35QCVA-^M\!Q\2[2I:$]T.-%"7!W"$
ME2#GSSA9Q7.I>A]3MZHLTF)I@,0H,JV2$-Q933@2TTC:M"W'5=Q2T@E.$[4%
M*<G)-:;.B-2,PH-F=TM-=9M\>\Q'I$>6RT)+4A>]H-*)X&%#A2<9SQYQY_L'
MJ!^(PNZV"?,M+C\M'HXB8T60HN=GMR'&R2VA7L6DE!!& H 95GK74*P7"X],
M46N!&,B0UZ53L)QWN&0VVM"G&2M6-VY*2,G&?VS5 G:"]9<XV=-R6].2[^V^
MFW!L 1V/2*;=6I 5A"5N*3P/A.<?%7WJU8?R>DX-KBPI;S2)+>/3LMR R$I5
MM4XRYPZC. 4_OG.17*W]%7=\S[@_I1QB[1H=E]"B.@;&G6G,O!H[N E!P>?L
M<^:G(>D+P]>HK4BSNIO+=SEO7&[*">W.@N)="&RO_'PIM/;(]NSX'-5M_3^I
MY6D7H*M,7AE]G3#%K4I:6R7I+<A!RG:X24XR02/ /'P;)/L%YDZQ:DS].3)E
MR:U&S<&KJE"-J( 2 EH**P4[3Y1C&058/FK[U0LYN+NE)2;,;L(%W;>>;2VA
M:D-%IU)4 L@8"BV3S\ _%<G:T5J!N"ART66="O4X7EN1)!#94EU2EQ]RMWM!
MX ^03\<UT?HK9#:6;NZ+5>K6F2IK<S<C'2.XE)"BVVPD)">1E1Y4>?@DU_\
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MCR XMM2FSN!6G/\ $^#CD5UCIE9'[#I^4V_:46QQ^4N3Z9,Y<QSW!.2XZO\
M4LD$\<8QY.2:+I/2UXMLZ1,EZ-*KLY?95Q8F+G-=MAI]:@2H)7E1#:UC;MP3
M\_-:;&@-2"/J2-'MC$:-J"*Z6VER$A%J<[CA+*=BB>VZDI*MGR3QC@8HF@[]
M!F6N]P]*H*F9"S,M,N\F2Y)"H_:#G=7E(*!D)'^4G[&/>H-%:I0Q<&+1IJVJ
M8GVB#$#+,I"6XA8>6LMY7RL[5 !7@D9X\5(-Z0U FYA7X1( U:F\^H$AH_\
MAU)(4 -V<C/C]^!6.Y=,+RN-K*WV]YIBW.-R%61K("4N20E3X4/\(RE2$GC
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M+INYB08,J0[V)#$58](Z#W'O[L %()!!SGP!R:DM:7]K36GGKBXR7W-[;+#
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M(SA6.%$#R,XR/D9JA7WI]J6_6^[R)[EF3>)S$*&&VGG>PEJ.\75*)*<E:B2
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MEI9E!\J&Y"BI(Y3R<D\\9P.BZ/TA?;-U+O%[DK@JMERM\1E:4NK4XVZRWL(
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M<!2DC+B@$I 4<<9XYK<U[I=[5,&#'8N1@F-+3)4%,!]M\ $=M;:B H<YY\$
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M7;1R !P?OB*NFG-0V;6MA] ['ER9-VN5P0\8;O982ZQ@)=4DG') !RG/UYK
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M$J)!Y(YQ7.[;J*9:G--BSQ5VB-$3?'9EF86%M+DL$*4A)2/<@J6H) '&1@9
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M5],E#82-J2I VE8).<<J/">.E6+4]Y<Z+7R\6_UDF\1!)2TI\HDY6A1!+:T
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MBX ;*WBRH-.!:=P*%XPH8(/[@Y&1S7W4VL;+IJ0TQ=Y2VW%MJ?(;8<=[;22
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MC(YKWU:NT^P]/;Q=;1)3&FQ&PXAQ2$K ]P!R#YX)JN6G6IML:[7.7?9&I;7
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M.Y)&0<'D?R/-;0SDYQCXK[2E*4I2E*4I2E*4I2E*4I2E*4I7EU"76U-K!*5
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MPO8H$X)2,$8Q47/ZDW&[6:^RTVXMV1.G(]W;,6<IB6GNEP* 7LPE0+:@,'_
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M/:W[\;00,[@"%>00/JM*-H#2=IM-QMSL<J@W1]MV2W,EN.AYU&TI5E:B=Q*
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M7/6HJ2X"G'\<E0V^/&U0P<FL]NUM=6=4NO2=23'&4WZYV_TN6EH[+453B-J
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MJNUU%TTMY]AI^:1&D"&\L6V3VFG=P3L4OM[4\J3Y/S5F<M\-Y"4N16%I"^X
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M+1<;_$MD5:'H\VW?D&9@6GM.([B6]OG.25)Q]YJQQ6HT1EJ)%0RRTT@);9;
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M%(4X">WP21@8^\G%1$CIAK&:Y<$RA:$N2K=<(*Y+<YX)4IYQ+K:TL[-K0RD
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MQEU/JV_FSLVZ[:BDOV299+BJ-,CQ5)$Y\%24,J*V\J 1@9 &<YS70VK<_/\
M_94:@PXKDB2O3Z0AA*=RU+" < ?>1XK5TE=8MUTSH"/9[@E<ZTVAQR6EE04N
M*4Q>T-XVD)5O/ 4.=IX.#5$T;U-UM)MD*9#NSFH)TFR3I<V&IAK_ ,&XRM:6
M5 (2"-V!P<[O],8[AU4UA!T9?I4.]KDB*BU.,7!33*MKK[25/LGV;3@DG&,I
MQ@FNO]%M0S=2,:O@WBZ"[?CKP]#:>*4)*F,#;G8 #SNY%4^UV^T2_P#VE-2V
M23%A.VTZ?9BB(X$[>"TH(2@_0&>/&,U%-=3-6/2=9K<O<" Y:TW$"V.I2IYC
MLMY84@=KD%0(*EJ(.X  '&=F;J[6MNT]T_N$C5[3CFJ9<5"P(#*4QVEH&_'!
MW$%23GC!S\' @])]6-5W5R(BX7B-)CW"SW)W8(K22VMA+FQ9X/)V9(/MP?%1
MD7J-JJVZ;LJ+/>HEOCITPY<C':A1PCNHD.("4C;[<@ $?L>,\B?OW6:^1]06
M)#%YAH:>3:G)<=+3:4MI?0%/;BL%2OU A2"$I!&<DU%:@U',8:UPJ??&YLEK
M5<=@PYC#2T)92I(0X$*3D<)QD<>W(YR3;8?4W4;VL%QER4H9=N%TAO0]K6(+
M,9I)0\%%.<Y))W%23X &,5FZ(]0=2:@UC;+??KPS/CSM/FY*0(S;9;>#Y1M!
M1Y]H)(/^@KOM*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4/BJ]I/25MTN]=W;:7RNZRU39)=<W[G5>2/K^56&E,"E:DNWLR(<
MQA [!E(4AQQH +Y&-V2",C/SFH?06D(&B=.QK-;')#T>."E#D@I+FTJ*L$I2
MG(RI1\?)J<$.,&E-".T&E'<4;!@G[Q]U[98:9*BTVA!4<J*4@9/[_P"M>/11
MO4^I].SZC_\ 6[!N\8\^?%%PXRU.*6PTI3HVK)0#N'T?L5Y5 B*;:;5%8*&C
MEM);&$?R^J\HMD%!240XR2D$##21@'S\?->3:;>0 8,4@# ':3P/./'[UZ7;
M(+B0%PXZ@ D %L'A)!3\?! (^L47;8*U.*7#CJ4XH*62V"5$# )XY(KX+5 3
M.>FB%&$QY :<?#2=ZT#PDJQDC]J]QX$2.L+CQ6&E@;0I#820/KBMFE*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2N;V*XSE
MN]24R+G,=3"F+:B[B/\ PZ3&;< 00/A2SY\8'[U&QNJ1LMOCQ;A;+E<'(%MA
MS+E.2XR0VTZGETC*5*P02<)_>II75"W)D15&#+_&2YSMLC3@IO8[)1N&T)W9
M"24*2%'C(YP,&LFANH\?5ESBQ&[3/@IF6X7.*[(4V4NM;@A7Z%$@A2AP<9YK
M5N'4M-HO6H(MUMKB(]OFQH$9;+B5*DNNM!W&"0$X2<_R!^>*Q(ZLQWY,&/"T
MW?94B3&<EJ;0AI*FFT/%I95O<&0""<C(((/WC53UG@JA*EIT[?"R+<+L#AC)
MB8RIW^]XQQ[3R<C -;<OJ!'L]RO<EU-XGL"1;XS$9+302#('M+1)!()/.XYS
MP.*^W'J[:K?9%W*1:KJE+#LAF6TH,I5%6R0%I6HN;"HE2=J4J45 Y X-:ESZ
MC%Y[43*VI]NA6N9 91,CAIQQWO*0<%"E<!06!XR$DGSP)_\ XBVS\FA@Q)H@
MNRG(+-P*4=AV0V%%30]VX'V* )2 2D@'QG'H;J5;=87!J)%M]TA+D0A<(RIC
M24!]G<$%2=JE>%$#GSG(R*SW#J!;85[5!<BSU1FYB+>[<$-I,=J2L I:4=V[
M)W)&0D@%0!(-1VA+W?-0WB\3WWI4>WP9LF#Z!R,SM<[:MJ2A:5%06"D[MQ*3
MN& *KTGJM+;D::NKMMN$>U36KD9$%,<.O*["D;% C(X3N)]P'"O/%6E?572R
M;U;;:)I+LXLH0O  0MY(4VA22=P*@0<[<#(R16MU/U1,T_J'3$9NZLVRW7!4
ME$E]<?NJ1L;WI(Y^^/!\U]MO4&WVNR6U_45V1+_(H?>AS&(BVD2$(RH(VGPZ
M4^$_XB..:WY_4W2]OO$>V3YRHTQTLH4AU!3V5NC*$+_RJ(\_7&<9&?AZFZ;$
M9Z2IZ6(B&FWTOF(X$/-+=#27&SCW)W$#(^"#X(->;EU%MT:\Q;;&ASY4A=S5
M:W]L=8##@9+V3Q[@4 $8XQDY %--ZW@NIMD>XW'U$JZ2)B(CK<)QELAEQ84@
M[OTJ2$X]Q&<$BLJ.I>EUR8# G.I<FEI#95&<2E*G>6TK)3A!4"" K'!'V*^#
M5Z[' 4K6 2W+<DO(CMV^,\ZIUI )W[ %*& #D^. ?G%3-]U/:K' BR[A(6EN
M4H(CH;:6XX\HI*L)0D%1. 3XXQ5?D=6-&L1V7UW92F78[<H+;C.K"6EJ*0M1
M"3M 4D@Y_21@XK.>I>E6XC\EVX/-MM2A#4ER(\%]U2=R0$%.["DC(.,'XJ/;
MZC1+C?\ 3)LTF,[8;DW.]2ZZVMMUE<=()!"L;<9.0H9J1/4O2Z+?+FNS9+3$
M5+;CG<@OI5VW%;4.)24;E(4> L#&?FL]XZ@Z;M$A3$Z<ZE\.J82VB*ZM3CB6
MTN%"-J3N.U:3@?>/(-8H?4K2<QB2^S=1Z=B,F6IY;#B$*:) W()2 O!(20G)
M"C@C/%8$]4M)JCQW1/?*Y#KC#<<0WB\7&TI4I';V;@K"DG!'.X8K/9^H%JO6
MJ(EGM:)$A,JW)N;4M+2@TIM2L#DCCP?/SQYJ&U7K>7#UG)MD60W;X5KCL2Y;
M\J"ZZA\.+6"@*3@)]J#@\[EG:/!%2TGJ7IF)'?<F2I3"V)+<-UA<)X.H=<3N
M;26]N[W >TXP?BI6ZZLM-KMENG2G)';N&/3-HC.+=<R@KX; W#"02<CC'-1/
M_%#2/?8:%T62\VPZE0BNE 0]PVI2MN$I)XR2 "<'!J1A:TLDU]QF,_(4ZBX&
MUJ28KJ2) 25E/*? 2"=WC'.:^7[7&G;!=V+7=[FW&G/!"D-*0HY2I6T*R!@#
M/!)/'SBM-/4G2JF7EIN2]S2FT]DQ7@ZYW,]LMM[-RPK!P4@@XK.C7^F5JMR6
MKFEPSP@L%MEQ0][A;3O(3_#RL%/OQR"/(-/^(&F/42V579I"HS3CZU+0I*%M
MM_WBD*(PX$_.TG&.:W--:NL.IUR46&YL3E1]I<#>> H921D<@X/(R.#]5XU%
MJB+9KM:K4M#ZY]T4M$;:PM;:2E.<K4D':,E(_KGP":K>@.JEDU%IIJ9<9T*)
M<FX@ES8Z%**64E6WR1SS@8&2"0/D9MU@U!;M10G9-FD=Y+3A9<2MM3:VG  =
MJT* 4DX(."!P0?FJ+HW75\O[=KE+_L^EJ2\ZT[#;><]2E+:E)6M(/G].<8\$
M#.:M\;6FG9,;U#-UCF/Z=4LNG*4):2LH4I2B,#"@1@\Y'BM?_B!I?\6+A^6:
M]/W2QC8ON!8&XI+>-X(3[CD<)Y/'-;7]L=/]AY[\K'++(84M8)*4A[ :.?I>
M1C[J+B:]M]S>C"V28R6_R;EO=$P+:4YVT+*PT-ON4%(\'X"O!Q4HSK+3ST*-
M,;NT5420EY;3V[V*2U_>'=X 3CG-;5DU%:;Y'D/VN:V^W'7VWO*5-*QG"DG!
M3P0>1X-4_4/5.T0C;'+7)B2HKEP9B37'5+:[#;J7"ET93A23VU8/@XX\YJ<<
MZ@:5;AQ):KW$]/*!4VM))&$J"%*5@>P!1"258 ) /-5^X]0IT.\72&(,1QN)
M?(%J2L.D;FY"6R5'C&Y._P >/_K;-3:@%HDVJ#'93(N5T?+$9DKVC"4E:UJ/
M)VI2"3@>2!\U"HULMMEJ8^U D6Q5V7;')$*47.P"X&VE+!2!DK*4J2#[=P(S
MSBSSKS;H$MB+,EM,R'VW'FFUG"EH; *R!\X!!-1#W4#23#T=I[45K;=D!M32
M%2$@K#@)01SX4!P?Y?8K=&J;$;RJTBZP_P DG(,?NC?D)W$8^P.2/(')I8M5
MV"_RGH]CO-ON#[*$N.(BR$N%*3X/!\57]2=1[7;),^'$?B/S;?+B1Y;;KX;#
M:7W4(*@<')2%@D<#]ZG$ZRTVJU-W,7VV?CG%*0B29* VI2?U *SC(P<U.-.(
M=;2XTI*T*&Y*DG((^Q7JE*4I2E*4I2E*4I2E"2/ S2E5*ZZ):EW.X2X5VN-M
M;N82+@Q&*-LG:D)SE22I"B@;24$'&/D U5Y'3J1<==7D/N2(6E)-MB0_31^U
MLDI:*_X2L@K2D!0'&,@D9J<;Z;6QNYF0W*EIB)G+NC,'V%EF4M)27$Y3N_Q*
M.PG;DGBO>ENGT;3MQLTJ/=9[_P"+MR[8VVZ&\+:4L*]V$@Y!2G&/K^=:VH>F
M,"]7:X7 W.XQ7Y3[,Q)8+8[$EI(0AY"BDJR$ IVDE.%*XR<C=AZ&]->(MS-\
MN4B4U!>A.+?[:R^'%!94KV\$$)P!A( QC%5^/T>BLP&X?YR<6$V-VQ$!IL%3
M*U%6[./U#@?O@?OG-+Z3LRN\7+[.)<<MZP"TV4I,,81QCG<<DYK3N?1EF=*N
M#XU'<&3->FK<2EAE02F4$AQ*0I)VG"<;A[L$C(K9E])D/Q;BRB_S$JGF(Z^I
M4=H[GXY1M=X P3VTY X\^34DCIPRFX[_ ,K)-K1<7+LS *$[6Y*\^[=Y*0I2
ME!/V?VKSHSIPC3%RLLMN[.R?QEK7:DH6T$[VR[W K@\$82/GQ_IZE].&'[W+
M?1<G6[3-N+-UDV_M!6^2WM(4'"<I22A!4G'.W@@$BIW1VG5:<CW)I4SU7K9[
M\\GM!O8IU6Y21R<C)./FJDWTN>0(;?Y]2V(@N*6D.1 2$2P<I)"AG:23D^<X
MXXQ\TYTNDV"ZQWX6HWDQ5(C^M9$1 +ZV4)0@H622V"E"0H#.<?&:F];:3N=\
MU!IZ[VF[Q8#]F4ZMM$B$J0EPN(V*W8<0<!)X'W4/?^G5WU!:U1KQJ9+KJ>Y(
M97&A&/V)?M#+J-KA(#82?:2<E2B3XQC_ .&=Q5JL7A[43+B9895<F#;&SWW&
MT!!4TM2BID*2D @9_8C@C$WTNN9T?-TS+U09-H0P(]M:7!2"P$K2MLN*"LN%
M.P)XV\9^^/<;IW?6KB;H]J" ]<U7ANZJ5^-*4<13'6V!W2?TG*3G@CD')K8?
MZ;/W#1_X>XW9+<QNZ.W)B=#8+:FNX\MQ:0%*5@E+KB,YX"AYQS]<Z;NL:UD7
M6V2[>U;IBF%R([\!+SK1:2E/\%Q1PD*2A(.0?&1SR)+J?I*7JVWQ8T1<%':*
MU!<A*PMIS'L=:6@A2%I//!P02#6+7&B)5_L-B:CS8R[K9W$/-NW&,)#,D]LM
MK#J">=P43D'(/(JMWOIE>Y[-Y0B?:D_D+,BU[41BRA"N\IQ2PE/A/\18 R3X
M)).:B]=Z;O5IOJKLRJ-(=NE]M<AMIJ,\X&>P@H47"G)V>#GCS4M<.E,RX2(Z
MI%QB]J5^3<N7;:4DE<QH-_PADX"0D?J//GYKY,TG)M425<=7-.7X_B$Z?:C6
M>&M3CS*E>Y:TDG"CQX.$\^:V+'T]NT2/H1YZ1$5+L_J)%P+HRI]Y]HI/N2.<
M%1&3YP*@T]&KK(L=MM<RY0$-1+4N I:&U.;G!)2^VO8H %(*$@@YR"H5+V_I
MM>F;KI^Y//Z>9?M[DEQQJ!;S'9_B,AH;4I.2?*B5'Z  %;?3SIQ<])W>RRE7
M."\S#M/XI]"(JDJ=2EY;B%I._"3E?.0?!^\C<U=T_E:DNNH77K@RQ#ND"-%0
ME#*BXRXPZ76W#[L*&Y1R,#@#GSG3D]/KS.NZ+S,N5O1=7+C"DOEF.L-EF,%;
M4)!7G<HK422<>!CC-6#J/I>?J>-;6K?/9C(CR"X^S(;6XR^@H*<+2E:2K!.X
M G!(YJA0^E6HHFEY]H-RM+W?A0(;;A:<2$B*Z5@J3DY*@H_U ^#Q/Z3L[-TZ
MHWC4C=OGPH[+8CJ3*9+29$Q)4VI]M)Y(#>$;O!"OVJ6U-I"9>]5R99?CM6R5
M9'[2]^HO N*!W)&-N!C[^:I[72N](LK4,+TNR67V%%,.W*C"8A (47EH.[<H
M[#A.![,<@\>+1THOD*%9X7K+8R;<?X5QB%UE]"3)4ZI!2/:MM258V*.$D9R<
MUG<Z5W9RPP+0_.@O1K1'GQH#A"PMU,AM32>[QQL0L^,[B!XYK<1I[5^FYCMV
MM#-GDREVZWV_TQ+JMQ9*M^#@8![API7C'-6_5=CN4Z^Z?NEI7"2[;G'>XF2%
M>YMQ&T[2GG/ /U7,AT>O,G3ELL\QZTMM1+4Y!4XVM:PITR4/I46U( 4C+2 4
MY'"E?0!Z1TXTY)TY:9+<R!I^#)?=[A9LD7L,#"0!G/*B<$Y(XSCXJIZ,T5J;
M3MM@Q4P-+)EL2W7S<4+6MX-N/*6M"<M#DI5LR5>!G'U&GI3?7(^HVE2K0TG4
M47NSTH;)2B<EU2T*;&P9:(("@KDG)\DYV('3G4EK5:KI:6]*0;O$6\EV&PPZ
MB(^VXVE!*E<K*LH21QP./O.3473W4TN-+8M[FG]DZ+ 0^5H<9#3D5PKPVE (
M"#P!R, >#YK:A:"O\:=%(=MJXL?4SM^!4ZYO+;J'0MO!00""[P<X.,\9K%<.
MDS\MK6;#=R2Q'NH4;8@ D1"XM+KP4. 0MU">!X2,?L+%T]TI+L-IN+<V!I^%
M*E$91;&5]I>$8RLJP5<YX^!\U2K=TMU RY;%%VWQHD2Y0)PMZ)CSS+78#G<[
M2EHW(2HN I;R0G!YYJ,N_2'5<UB?&;DV9,:8F?E DO-[5OOEU*E%" 7  =NQ
M64@C=[O L$WIUJ"9,N$IPVIMR9=;9<"A$APAM,9" XD'MCDE'''SSXJT:ZA.
MQ]7:1U, ZJ);')$64EL;BEN0E*0X1G]*5H1GS@$G'&15YFG;C;K+=-/N-1W)
MFHM0JFL^F6M?:CJ>;<<<7E*0DH2G[P5%(!R<59^H.F[Q<[]IF\V#T2Y-J7(2
MMF6XIM"T/-;"<I2K]/!QCG[%<HM^E+DY<)^ARW:)5Q_LK"MTMU4I1$?#CP[B
M 4940E2#CVX)1Y!R+C&Z>WR-)CVQ!C.6B'?U7YB:N0HO*SN5V"G;P2I1!7DC
M:?&>*VNG&BM1:?G:87<T6PM6ZVRH<E;$EQ2EJ=?2XDI!0 0 D>2/U' XK%J3
M0M\EZCU9(A1K>_#O$BV2VR_+4@A45:"I"D=M0P4H/.?KCY$->.FVI5W:1<68
M%HFM&Z37DP')KK*'(\A#2<E2$C:L%K)&% A9')KL.F+>JU:=ML!;49E<:.AH
MMQ@H-((2!A&XD[1\9YJ3I2E*4I2E*4I2E*4I2E*Y'/ZE:A9FSD,V2"N+^7=L
MD-:)"EN./I&Y*E(VI&W:E>0%9W #CS6O-ZJ7YFR7=U5AB1+I9(/K[A&DR">"
MXM*4M[0>2$%62>,@8/.).5U)GL3)[*K?%2F'>8-L6>XI7LD(0HK'M!*@5@8Q
M\9J.MW5:_7&WRKG"TC)?M;D0R8+J%$J5A83A8Q[O:HK(1DC81R2*W-(:^O6I
M-7V&/'39EVB7 DR'UQG5N*);=2@$92"@^Y/L4,C<H'D#,GK3J!)LDZ]HMUN:
MF1[!%:FW+>Z4.%MPKP&A@@D)0I1*B!X'V1%:5<GZEZL:C=GONI@VHQ%PA'EO
M( 2XR5@*1@)4%!65 ^"$CD<U#WO4VII=RD$!K,+5[-OALL25-!Q'I\E#N$\H
M)4%$D*\G P 3OO\ 5^X+CQ6[5I23<;F&77I<5AQ:PV&Y"V"$+2V0K*FED%6T
M8 YR0*L'5"]SV8>F+=;7W8'YZY,PGI2/:ZPTI)6K82"$K(3M!/C/'->;JVO0
M,@7"/<;G<8LU3%OCVV;,6\/4N.I0E?=7N4E)W>[R..!\5'N]4YJ)+-J1IWN:
M@-P<MCL834AI#H9[R%!PI&4K3XX!&#QXSJ0>L4AVU/7"9IMV.P+5)N3($M*E
M.>G6$/)(Q[0"?:H_J / .!6U-ZLNP%/Q)^GUP[GMCNQVWYB RMI[?M6IP [<
M%!20 H[B  <YK65UE*H4.5&TU+?:<M!O$C$EM)8:2Z6W!A6"H@CC')SX'-65
MK7:UZDF615J<1/9GLQ6VU/#+K+B%.=\8& D)0OC/E)'!Q5HU#=$66P7&ZNM+
M>1"C.25-H("E!"2H@9XSQ7.FNKX"6$R-+7I,EZ.F<B.V$/+5%5@)<2$$Y)._
M"?/L.<9 ,_=>IFG(P#%LFLW:ZKE-PD6^(\@O=Y9("5 D; ,*R3C&#\\5J2^I
MC41DA_3]X3-CPUW"=$*4!R+'0XI!6<J&_)0HI"<Y SQQG >K=K5=?3Q[7<WX
M27XC+D]M+9:1ZI"5,*QOWD*WI'"<BJZSJ6ZS=1RI\^=?84*/J5-F:C0TQULN
M)]@2EP'*@-V2I0.<+P/&181U8BGMJ1IG42V79RK:PXEEHAY])=!2G^)S@LJY
M\#YXJ1TMU'@:BN-OB-6J[0_7(?++LMM"4%;*MKC>4K)W Y^,''!-;6H]?6S3
M]^8M=PCS$J>6PV)&U(:W/+*$ ;E!2SD>[8%;003BH6V]8+#*=3ZR%=K9%6)1
M1+F,)2THQB>\G*5$Y 'U@^ <\5MZ.OUQN_4"_LR6YL6W-V^%(CQ9B&TJ07"]
ME2=A.00@9W'(((Q7NX]3;-;+])MERCS8O91(<]0XE&Q:&&^XXH)"M^W .#MP
M2DX)Q4'JGJ*XU$M$HQ[GIUMNZPVYPN4=M*5QG4*5^O*D_P"'G!"DD8.#Q4O<
MNI\&WI@A^PZ@]1+@.W%,<1D=Q#+9PHK!7A)P0K&<X(!P>*R(ZH6-U:78[$]Z
MUAR.P[<T-)].PX\E*FTK)4%#A:,D)(25 $CG'ECJC9ERX,>3%G0W)4J5"Q([
M0[+L<$K"\+.,@<8SG(^Q4,UU%9M5ROESNSUP-K<BVUV'!<:;#C;DCNC8",#G
M8DG<HXYY^!GF=36+SI>2YI^!=_R"XDE["$-)7'0T=I=RLE"AN(VXW;OK@X6W
MJA&A6*V_D(=QN$EJ';C.DQD-A"7I24]L84M).XG)P"!D5)::ZIV'46K#8;:B
M6M\ATMR,(+2^V<*_2HJ3^VX#/Q43K_6MTCMZ@CP(\NW_ (>3;LRTAMWOH>>0
ME:0GD_I4<<9X\C(K=G=7M/VZ&E<Z//C2_4/1E0GDM-O)4TA*UD[EA.,+1C"L
MG>, UDZDZN?C]'YFJ],REL+$=J5'6XR"2E2D\*2K]E?S^JC[7K1-M9OET<O%
MWO\ :K<TA4EI5J##T?<2=XREO<D)2HJX)&,U*3>JNGXEH1<G$RC&?DN1H:OX
M8$W8,J<:4I824?\ 4HC)X') KW!ZHV.XO0DVV-=);4GTX6\U&.V,7R0V'02"
MG.#X! &">",X9W5*U,Z?9N3$"Y.J?C3)+3!:2E7_ (4D.I5E6 01^_'BM(]1
MV8:Y=UN*;IZ5FRQKB[;6X:"IE"W%A3V[=D\#E.>$I)Y).):]=3;%9W'434R0
M4+0VDCMA+BBUW5!*BL#VH(*LD8W) R2*Q-:KDNN-ZJ:E(.@S:%RW2MC:ZAU*
MLY'.XG:% IP ,>3GBQ:;U)%O]MD38S$IEEAPMJ[R![L)"MR2DD*3A0Y!/S5>
MA=4K#);FE35QCN1O3E++\?:X^'U;62A.>=Q\ X(^0*PN]6K"TAH>CO+DAQ^1
M%3&:@J<<+K !=3A.0=N[R"1P:\-]9M%KGR8JKD6^PTXZ7EH_AJ#9PL CG(/Q
MCGXSD4M_6+2UP0!"5<)$E3ZXZ8S$53KJG$M]S: C(.4@D'..#G&*RP^KFE)+
M#SZI$R-&;@_D4O28CC2'6=R4DHR/<0I24X'R>,U@A]9-*S5--1%7!^4Y(<BB
M,S$4ZYW$HWXPC/E/@C@X/T<;VG>HD346I[?;K5!E.09ML_)(FJ3M2 5[0@I\
M@Y"@2?D8&?->YW42WV[4E]MMQBRV(UJ8CN+E]LJ2ZX\2$MH Y*C[0 .22H<;
M>9S3.I(.HF99A!]F1$=+$F-);[;K*\ @*2?L$$'P0:HVC.J4 PUQ-63NU<67
M)H5*]&MF,ZB.ZX%;5'*2H(2%$ G^IJV:*UQ9=9)F?A772]$*.\T\V4+2%C*%
M8^B <?R/BJMHWJI;7H*8VIY:F+B@S"N28;C,9Q+#K@5L6<I*@A(40"?G^53,
M;J;IMYMQ:W)D=QMV.VII^&ZVX ^K:RO:4YV*/^+X^<'BODSJCIF(XZTZ].5(
M1+?@AEJ"\XM;S20I:$A*3GA22/L'/P:A>H_5.':]#RKCI>1ZJXF&W-8(AN/-
MH;6K"5.XP$!6% ;B.?@X-374S5LG2=GL,]LLH:E72-%E;V5.D-+R5[ DYW<<
M>?Y&MJU=1--W1^WLPY;Y=G%Y+27(KK>%- EQ*BI("2G'(.#5BLURC7BTQ+E
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ME!4H@ )^5'))_E52F]*'+M%?MMZO"'[.AR:]#:9B['FG)/<W*6LJ4%;0ZL)
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MZEJ)IN3'N,BZW2ZKO#]UA1BW%B[CM>1OR2G+64 9RHD$FNU,M(9:0TTD);0
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M<%0!.02,"I%&L=4+<O\ <H+C+X*;:N/;BR%N,H>:0M8;_B)#J\%>!D%1Q@\
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MQE(SD^.!7%K1<;I!5<K7?)-^MM_9L,I["Y[LB)<' E*A)CN[CL*<$E  QO\
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MM>I?=*TH2I0!(2E*#_50.#@56]"36K^O2T1 ND:/+TR[(:=%V=6M!2ZTDA6
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M %#E0+LY9Y%I;7<"Q#=@)]609P><#:E#V':$$DJ\\#/CFK-KO43FEM-N75J
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M0R8[S[D="EN-D8*%$C)!'!!^.*A3I;0LBY/V0VFT.3$PFDNQ"T"1&"_8"/\
M*%)X_<5M?\/=([EJ3IVV(*VW&E;& G*7/UCC[^:]R=!:4DH"7[!;E[66HX)9
M&X-MXV)SYPG Q_(?0J0+EETI:(S"W85JMK92PRE:TM-@DX2D9XR3_K4+'Z8Z
M*CH4AC3-L;"DE*MK(R1N"L$^< I! ^,<8K/-Z?Z4G)E(EV2(Z),@2G=P/N=
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M+[["E?J"7/.U63E/@Y\5F_L#9Q;41 J9N]:BX.R3(47GWT$%*EK\G&!QX
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MJ6G>""1]8.:U[;TY@P;_ &^\_E+H_.B&0I2G5MD2%/X[BE@(_P"E  24@!(
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M1D?[5D58[4I14JVPBHC:26$^/KQ^PKU^&MA&/Q\3'UV4_P"U?4V>VH45)@1
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GI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>exh46_06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh46_06.jpg
M_]C_X  02D9)1@ ! 0$!- $T  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ L ! 1$ _\0 '  !  (# 0$!              4& P0' @$(_\0
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M2,*06TAM.#M/<6K)Y2?BNGZ\NM]TGTLF7%J[1YUV84V4S%Q0EM25O)2,H2K
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M#"F^X%'[)Y/S7FU:NN9U'8[=:H\:)"N&H;I&FH,AQU3G92LDI4K] )]V$XY
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MKD<^:^EQ"3@J -?0H*) ()'!_%5>WZU@SM%S]2HC2D0X:)*UM*".Z0PI:5X
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MKL72D:->-0W)J9,#][;;;?&Y&UO8@H24>W(.#\DU7ATHM'TQB"NXW8LQ[>Q
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M+.Y85O4I*^,<YY-:L;0D]N+*,/3EQA7AEN\"9*2ZD(F-/][LM(]Q"\E;:AP
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M^*;:;??9]RM%LN%ZU/%MJYUP$1]E3J'EQ4%LL=Y92?D+P5X4I.,^37=4@)
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M>RH@@J65)&5$Y/X\5<']#3$ZW=OUOU#*AQYG95/A(80H/J; 2"E:N6P4I2%
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MI+13Z81RTX>2"4)!W >?BHBY=*+RI#<JW7*WBY2!<TS1(;66<33E1; .[VX
M 4>?/'BMW3/3F]6K45DG+?MK(@,QV'Y41QU+DQIN-VNVZT?8??[@YG< ,8YJ
MW=1=.2]06^UKMCK3=PM5Q9N4=+Q(;=4WD%"B 2D%*E#(!P<>?%5.T].[M&U7
M9K^^JVI?%UF7.>PTXO:@O,)92AL[/>0$Y*E!.23]ZO>N+(YJ/2%VLS$@1G9D
M=3*'2G<$DCC(^1]Q\C-<NG:$UW<9DN?,.G&Y$@V\.,QY#R$K3&4X5;5]L*:4
M=X(4GD8P#\U&Q.ENL(]KF1G!8E%5GN5M:+,APG=*>[@4=R/ \'DG'W^=FX:
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M)+>[ VJ"%D$[?TG..*\1^IUHESFKHQ=7?H@LK]R<BB"2H):>#:W"X#Y2<I*
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MBI27-Z004!*QPD'*0%8\#-0L'I08,L2&-02W%YN"CWF&SE4M"0L^P)'"D)4
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MYG\Q2.1C'/\ :KS.AUWE)FK<U' <E2XDB$])7 67GDN.)7O<7W<J4 D # 2
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MY%;-*4HHA())P!6%,N.J(927VC&"2ONA8V8'DY\8KTU(9>44M.H6H *(2K.
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MUWZU(0^A+C15,;&]*CA*D\\@G@'YK:1?+2N*_)1=(*HS"^VZZ)""AM7]*CG
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MM+>]LN$I<6A"E)2M62HA)P":H74+I]?I6HKO+TVW%3%>5'OC6X)W&XQMP2@
M^.X-F5<?I/W-1&J^G<^8U/2]8#.FNZ<?(>24% N3CZG2$Y4#N!4<*^!CG[[=
MTT]?U7B\W!&GI<F Y<;9+?A+6V5S66XZD.IQOPI27"A6"0%;?GYA-7Z.=N<6
M8B'I.[,ML:<*;6AW<ZXS)]0M:4E040%A*P1R=N2 >#7Z'CJ<-H;44.*=[ )1
MG:HJV^.?!_>OS%%L-]1:9N[3=]C)E1K>X6F8[J5%UN85.[B%E:UAK(+BL$_
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M_'?"&%A7<["E.^Y)2VM&,@9&#QFISJT[/9M=H7&;G.VH7%OZJB"E:GE1<*R
M$'<4[]FX)YVY^,UQ#L7YFW0X:GM2V2QEZX^E6Q;93KZ9*I2U(*@%(7DMJ3M4
MK(SO!YSB8O*K_;YNJWFS<6H#MVAHNDD1'5N%GT(2IS:TI*BGN8W!M?&/)'G%
M*3?[.RF5 ?U!.OJM.NM09LJ/(0X\M,A:E;F]Q 4&N4ASW$[<^[ K<M[DJ=(L
M<5C5VJ7+7<[LIDN!J3%6TGTJTJ0E;JUN$!SM\DX2H^T\'&VQ>[G]1EP[C<[L
MWIMO4\R+,FHD.!QAD1T=A)7^I#9<W94, $ ?.:B9VI=2VFTO2+Q<KPWZC3EQ
M1;W%E:"\\B23'7A/APM;3D\D>?FK+IG4-QD]5+<R[=IDV/(2C+#,@I].!#W;
M7HY3@H*E;@Z#G<0D^!5WZKW63:X%EQ)>@VF3<6V+E.95L5&8*5>[?_("L(25
M? /D>:YU9+W?KQ>-+6=>I[E&@2Y=U$><R6^[.CLK1Z=9*D'.05<C]0&><YKJ
MO5"Y7.S]/KW/L86;A'8W-J2C>I(R-RP/DI3N5_:N'?XIM]JU'J239]2RWH4R
M?;$&Y+?!2^@1W2I"GL?PTY3^I*5'.$@<\:L7J'?[EIE<YG5[Z)5LTXN>ZRR&
M3ODMR5(2',HS@IV9'&<_'S8;AK>?;KE=;([K%]\&X0$MRB&&U(0^RMQ:2YMV
M-(RD>["R!P 2<U&R.J%[?T_8TMZF89N,JT/.-NMKBIWSDOA #Q<]H2$GPD G
MW'X&)F\:LOL2_P!X@PM21VU?6+/;TR RPI24O,9=41M]V2<C[8.. 16M<.HM
M[AVR#$D:D"71-N\0S6V6 ^\N,HI8W)4.VE)RDJ.!X3R 2:[?I-Z2_I>TNW"2
MU+FKBMJ??94E2''"D;BDIX(SGQQ7%=.ZENOUE5G_ ,3R(0GWZZ-.3'4,.*8[
M1(::&Y&$E8!5A0\-D)QFNK=+KY.U)H.UW6Z);3+?#@46@0E82XI*5@'X4E(5
M_>N37MR;,N]S9>OKCDQ&MHK$-N0VE8B_PDJ2H)&TE.,X3G!*,\DJ)\N=1]5K
M99M3%WM#4]E,U9N4W9';DEB2MH @Y2!M0%*"><*&,?/>X+ZY-M8?66M[C25D
MMG<C)&>#\BN#6C6FHT:8T\S8%62VI?LUPNCC3-N/;W,.\(;0'$A(5NY)^<GY
MK(OJ)J"+.N=R3+96S+%ICLQW6\,PW)+/<*RHK' Y!R1DK3D@"I.]=0=6VQN-
M;I)LZ+P6)C@7&:7+$EUI3?;C]MM66UJ#F#DD XQGQ66[ZDU;<6M5V^9"L2HE
MJLS3\Z+(9=5WE.QG%K;3A?C<G'GQQG/-8X^H=8"1J1[3S]K>CVVR6^3#MJXR
M]B2M"EJ2"E8.=J5 ??V#C!)OW3S5"]6VZ1=FNV+4ZXEN"K84K= 0.XH\D8W[
MP,?T'S5MI2E*4I2E*4I2E*4I2E*U+O/:M5JF7"2EQ3$5I3S@;25**4C)P!Y/
M%<]?ZUZ6BPXDF>FXPD20'$)DQ]B^R<;7MI.2@[N",G@\8&:D?^J=A%V5 4S<
MTE,MV!WU0UADR$)W%L+\;B!D#YK4O?5RR6_3CEUC1IDO-J3=F6@C9W&E.!L9
M)\84H9X.!SSXJ2'4JQ?5Q;%)G)F;PSL,97^<6BZ&L^-^P9Q_;.:AM/\ 4R+>
MCI^XOR?HT&="ERE1)492NZEHC*P_PE(2,D@CG/[&I8]4=,MQ),B6]-B".&5+
M;?@O)=*'5;6UA&W<4J/ ./) .#Q4YIK5-KU%;9,Z ZZAF*ZIF0F2TIA;*T@$
MA:5@%/!!Y^#4,>I^E41)<I^>XRQ'81*WNQG4]UA2@E+K8VY6C<0-R<@9&>"*
MEU:MLZ-,)O[LAQJVJ(2E3C#B%E17L"0V4[]Q5P!C)S6E_P!0=.*0HM3'G74R
M%Q%,-1'ENAU RM/;""KVCR<8&1GR*^2NHFEHS$-]5U0N/*:0^AYEI;B$-+5M
M2MQ24D-I*N,KP,@CX-1VK.H,6VZALUGM;S$B6_=&H,Q"FG%!M"T*6<+&$[P-
MIP23@^*EHFOM+RVXKD>\,*1*8>DLG:H;VVBH.*Y'\I2K(//%0%RU\\WZA^U/
MVNX1D7:!!#;16'&VY!0DE><#?E>1\8\\\58-&7^7>7-0IGM,-"VW1V$VIHDA
M:$H0H*5GP?>0?CBM2\=1=/0M/7JYP[A'G*MD94E;#3GN6!G;CCE*E# 4,C_2
MHRT]0O1Z'=U1JMVVM6Q90J,[!<4K>%8]A"P/<%9&<X(&>/ W;'U$M,_5%ULT
MN;;HKK+[+4$F8DJG)<90Z%(2<$_K XR#Q@U9H%\M5PG2H4"Y0Y,R*</L,O)6
MMHY(]P!R.01S\@U5%ZTO+U^U';;9I^)*^BN-H4I=S[2GRXV%H"4EH@$YQ@J
MSCG[69C4EE>5L3=K>71)]&IL24$ID8SV>#^OS[?-9&+]:'U34L72"XJ$=LH(
M?2>P?LO!]OCYQ7J/>[5)90['N4)UI;9>2M#Z5!2 <%0(/*<\9\5#W#6=M2[<
M8EH>BW*Z06V7G8J9*&\(<5@'>KV^.<?E/]0J>1<(:RX$RF"IM8;6 X"4+)P$
MG[$GXKW&EQI*W4QGVG5-*V.!"PHH5]CCP?Q6>E1M_L=NU!!3#N\?U$9+B7@C
MN*0-Z3E)]I'@X/[@'XJ2' I4'J+2=CU&[&=O5N:E.QMW9<)*5H"OU *20<'
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M+Z+TA3R%^I((.]LD#:<%1(5Y\ UBG]'%/S7G&KLIN+]2<?CQTIVI8AOA7JF
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MR4$( ]Q)S\U&:AUUJ?4O337L*[SVE^DMULF=QAD,J2)*4*6SP3E/N\^?(\'
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MEN*"4)&2HG  K"F;%6PEY$EE3*DE06%@I('DY^U0^N-4QM(Z>>N\IAV0RT4
MH:4D*PI83GDC(!4,XR?Q5@J&TYJ&-?A</3LR&#"F.PG$O!(*EMXR4[2<IY'Y
M^X%3((/BH35FI(FF(D*1.9D.MRIC,%/92%%*W5;4DY(]N2,XR?Q4WFE?,C.,
M\U$#4,,ZM_PZ$O>O]'Z[<4>PM[PCA7R<GQ7W5=_B:8L;]VN*7U16"@+[+96H
M;E!.<?;)YJ7'BE1U[O,.S0)<J6YGTT9R6II'+BFVQE12GYQD?ZBLMFN+%WM$
M&Y0RHQIC")#6X8.Q:0H9'P<$5N4K&Q(9D)4IAUMU*%EM10H'"@<$''R#Y%9*
MBYU^M\&_6RSR75(GW)+JHR.VHA?; 4L;L8! .<$U*5&W:]P+3*MT>>_VG;A(
M$:,-BE;W"DJVY ('"3YQXJ2JMRM=:9BSW(;]YBH?:<#3G)*$.$X"%+ VA>>-
MI.?Q5DI2E*U';G!9N3-N=F1T3WT*<:C*< <6A/E03Y('WK;K#-EQX,5R3-?:
MCQVQN6ZZH)2D?<D\"M2SWRTWI"U6>YPIZ4?J,5]+H3R1SM)QR#_H:D:T+M>K
M79D(7=[E"@(6<)5*?2T%'\%1&:]NW6WM6Y,]V=%1!4$J3)4ZD-D'P0K.,'(Q
M6Y2L+$N/(=>;8?:=<95L=2A8);5C.%#X."#S]Z.RH[)6'7VD%""XH*6!M2/Y
MC]A^:RI4%I"DD%)&01\BOM*5\*@" 3R?%?:4I2E*4I2E*4I2E*4I2E<Y:T#<
MD:7UU:E72+OU')DOM.)84!'#R @@C=[B ,_'-0U_Z3S[E<)-R;N-M5,WP76&
MI$0N,%3#+C2T.))Y0L.J\<C Y-=)TK;';18HT.3Z(/H!4X(4<,,A1))"$#PD
M9P,DGY)S5;U9I>ZW'6]MOL(6R1'@P7HR8LM2AN6ZI!4HD(5P @<?GX^8/4'3
MV^7V):^]*M$.19LR+8(C!2VR^'04)(*>6TMI"<#&222.$XQN]-+C(U!=7)*-
M/NVVZN&6X^]%+LR(ZIM*%H:60 4G:"%G!3]O!K!_@+6#^CDVR9,L F6WT:;>
M['86WWQ&=2M)>7C*,A &$9 ))YS@?+!T_P!3V[4,6\/NVE;S=XN%P6RAUP)[
M<IM"<!11G<DI)Y'.?/&*SL=,[I(T=I&%*N#42[VDK8ENLK4XEZ*[D/- X2?<
MG9@X&"GC[U]A=-ID+J#)N*85BE6UZXBY-RI0<,J,=J06T)&$'E/M43[03P:Z
ME<4..6^2AA#;CJFU!"'#A*CC@''Q]ZXC;>G>IFW+&W(C,FUP[O$EB(],#ZXS
M33;J5)2Z4@K;!6G8A62 #SS4+>>F>LY.FS;H]LA#N1I;6UN:EHI*YBWTA:@G
M*T;5@! (3N!)XQBYOZ6U"_*ENJM;;9?U5&NP"):<!AM#:5*/'));/&.=W]JZ
MXKE)K\\O:%U2;%=8S-C>1%66!'B//QGG8Q$E+K@CNY'\+:D[4KY"E?;),$S*
M8N/4.:A<%J=;6[M/5"9C28ZY*I+P["MZ%.A91D*.-@P.=Q2G-7CHWHJYZ:U'
M99$FP?3&T:;$.8X@LX<EA\$E6Q1*E%/.[[<?BKSU?M\^Z:#FQ+5;47.2MQE1
MC*Q[DI=2I1 *DA1 !(23@G@Y&0>5:=T%<4RUQK[I25+AMS;I*95*$5:=CS2"
MTG:E6T'<E7M"=H401XS47-T=J5_2CUKN>DIEUGR+9;&8#Y[!]$6 .\TI2U#9
ME0404YW!8K]-I.0"00?L:X++T/=UWN>[:;5)@ZB7?9<Q-W"]K?I%H7M1NW9(
M45(!2!P02?%6#H7I^1:%S7Y%MO\  ?=CM-RQ<C'0VM].X*4TAE(W?.7%<J!3
MYY-3_6:UKNNE(S7H9$Z.S<8DB2S&25.EE#J5+* GW$X!X3SC.*YQ'T[+@26T
M7>SWF9H=Y<T0+:AMQ]R&I0:[*UM\K3G#VW<?9W!G;S47=[3J^VV6=$GVJ\W&
M[7&P6UKN14K<2)#+JBYO<' 6E)3SY..,^:VOI=W1J W>RVZ^,7A[4-P:;>D1
MY 0B.N.H-$A7M#1<*#GQQY&.)WI+ +>O($Q-AOEN<%@5'GO3XSJ0Y,[R"LE:
MN%J5MSN'ZACGC O'6RW2[KTOOT.W,/2)+C2"EMA&]Q0#B2K:/DX!QCG/CFN=
M2K3.@V._7^PO79NTVJ;'N5IBSGY"5R VD&0WM=._8YR$A0)W#(&#D]AT7;I5
MLTY%9N+A<GKW/R3O*P'7%%:TI)_E!40/P!7/>IUL4K6TN>FSSY:G=+S8C+\:
M.XZ.\>0@E(."4[@,^2KBN=FTZDMMK;A6:%J9FWJMMID71"&'W'%.C(?#8<_4
MK!:"FTGPDC P0.X=)8BX6C([2G;RXUW%J9-W0&WPC/ V 90CSM2KD#'Q@"J=
M8%W!&IK8JVBYR%]I"/1,I?;;D%3Z#EMYOVH=2$DJ"P4E!YX!KF=Y%PMMCG6R
MV1M20)J)EY=4IM$Q32WMY4P 6^5+*-I2K=L'N4H*.:F$72X2+L[=Q=K\V^S<
M+,&FEKD)9(<:1ZG<UC!3@.9^ 0?&>=.3.F*O%HN<G_$BM21(]W%S;;;>7V7>
MTH-]A*@6A@#V[/(P3GYQVB]WB=+3:T7^]L1'+S;T-NM/2"I+#L=?>PXXG<H%
M83R0!DY  .*FES7G=8::@WF?=7KS;]4%HL/A90F&&W$,.X_0K=["7/.Y:OVK
M]!2TNKBO)CJ"'BA00H^ K'!_UKD/2^\Z>@: @Z3U*ZRB_,K5'FVMX9D.O=TJ
M*P@>Y:5$A>\ @CG/!Q #55T4X]*.H);=Y2NYM7:V%U&RW,-H=+3P04^S:4LX
M6<A6_P G-0#FH;TWIV5-7KVY&4SIB)?BT7F/_BE';V^$<-GV HX)*QR<U8;A
MJ:]M:KNJH&J9#\B+>XC<:RX:6'XSK+:W> D+VI"UJ2K. $<Y)S51<ZG7EBS7
M=V-J_>^];HLR)O<84YWE2MBTE."&_9C+>5;1@YSFKHO4U\M\?4,M&H)MS@Z5
MO;)DY2T794)32.XE6Q('M4I2@1C(20<_%^BVF2C3<34&H9"1J&%"D/I>D(3L
MAJ<258.T#(;'MS\C=]ZT.B=^N-WAW6/>;A)G38BF=ZW RML[V]P4TZTE(4A7
MZ@"D*3D YKWUC6&G](.W)32=.)O"#<N\/X8&Q7:+GQL[FWSQG;FM+6]VLMIF
MLS=-R(L>YSI<.UW&X12E?I(ZW%86K@H"LY2"H'&\9XJL(U5JYV\P;&WJ)+:/
MJ-RA_4U1&G#):882XE>.$[@2I!(P,I_<5%MW.;J.1;[W=)33RWM$2);S#S+3
MK*UI6@D%LIY"E(W$#G( S@8K%J?6$J\=/IUNDSXMM;A62UOB)Z5M*9JG@DKV
MI4.$)("0$ ;3GSP*L:]=ZIE7._/P[OI^/%M\JXP_1/J/> 9;66E)1MR5'M[R
M=^TI)P!BHFZZUU8O3<EB=>VFY$FW6BY-R(T;LJ8]3(#:V_)R,#.[V^2.!4O>
M=47BT7G4D.T+@,7!Z],1$NM0D%]Y/HTNJ5C<$J6 !E3BDI" ?' J#E:FDW-3
MFHWHMO=N#N@%RY#;\?>R\0_DH4D*!*3A0QGC</-336H-9HF:SE6)Z$XBU6JW
M2(MM=B*[6%-+6M#>U?"L _?)VC@#GIN@M0N:IMDF[-EM5K??4+>I+2D*6R !
MN5D\DJ"L8 X J!ZNZTN.DV8R+-Z1<IR/)DEMYAQY12R@*R E20E.2-RU*&T8
MP"354E=4M2B7*>C1;2JV0OI"GPI#G<6)@3N"#O !!5QD>,9'DUGCWV7JC7>@
MKQ(9A)M[LRYM1$(0KOMAMIQ'O658]VTDIV@IP!D\UVBA\5\224@D8/VK[2E*
M4I2E*4I2E*4I2H?64B3$TC>I,%]4>6Q#>=:=2 2E:4$@X((/(^15 C=4VK)I
MVT&^1+K/EJLT6[39;++?;;;=(2I1P4_I4? 'C[\UORNJD6VNW@7>W.1D1;F;
M;$/J6!ZM0;"R05N)".#GW$#"D\E1P*_=>I4NXJND[3<Q:+=_A*1>HR'64;VW
MVG%)Y!&?Y<8R15C3U5T_ O5KL%REK-S>;82ZX0A*4NNH2I *=P5[@K.4I*1X
M)%?+QU6MT6QS;C M=TEH::2]'5V0EN4VIP-I<0LG].XCSA6"#@@BI-?4>R-N
M.M/(FMOLSXUM=;4SRV\^E*D;N< >X GX-5[574^/)T?J-[3#DF)=8$ SV%S(
M9"'6TKQN2#Y!P1S@C(.*L'5"\7"S:;@R[;<XEL6N?&8>D26>XA+;JPA1QD 8
MW!62?C^]5G275J+]/>3J5TR'4W"3!B3+9"==:N"64A1<0E&\C@G/)!VDCC.+
M6GJ/IHR'FC+>0A#;SB'EQG T^EG_ #>TO;AS;@Y"<^#6O;>J6D[BR\['N#P2
MVVTZ Y$=0IU+AP@MI*<N9/'M!YK'(ZLZ-CQH[SEU7E\K2AI,1Y3NY"PA2"@(
MW!04H I(SSG&*S:7ZDV&_P 2U.H7)BO7-+SD5A^,XE3B6N5D';@@#!\_./-6
MF'=(<RSLW6.^DV]Y@24/*!2"V4[@HYQ@8YYJMZ#ULQJ>S7*?(CKM_H7UI<;?
M&TI:VAQMPY\;FE(5^,D?%?3U)T>EEYQZ_1&$-+;0YWR6B@K&49"@" 0<@^,5
MZMNJ-'2;M%-OFVU5PGMI4TXV@!;H6G>E)5CR4Y4$DY(YQ69G7^DW6WUHU!;0
MEEQ#3A4^E.U2SA/D^#\'P:SVC6NFKS*8C6J^VZ7(?2I333,A*E+"3A6!G)Q@
MT:UIIEY+ZF[];%!AQ+3A]4C"%J.$@\_)!Q^QK"G7>FG'K.W'O$1_ZNZIF&IE
MU*DNJ3G."#]QM_<@59J4I3 ^U,#[4P/M3 ^U*C+O8+7>)$!^Z0F93L![OQBX
MG/:<Q^H#[U)TP*8'V%*8'VI@?84P/L*8'V%,#["F!]A2OFU.<[1G[XIL3DG:
M,GSQ7SM-XP$)QX\5!6#2T2RWB\W)J3*D2+H^'W0^4$-D)"0E&$@A.U*1@D^!
M4X66BDI+:"#Y!2.:A=0:8B7N1#7(DS&&6'-[L>,X&VY0SD)>&,J2#SC(\G.0
M2*FW&D.M*:=0E;:@4J2H9!!\@BL4.)&A-=J''9CM9SL:0$#/WP*]R&&I#*V9
M#2'6EC"D+2%)4/R#6HQ9;4Q;EV]BV06X"P0J,AA :4#YRD#'_BOB;':4MQVT
MVN"$1T*;92(Z,-)4,%*1C@$>0*PN:9L3@]]EMAPVID9BM\(4"%)\>"%*!'SD
M_>L,G2.G93<9N38K4ZW%06V$+B-D-))R0D8]HR,\5DD:7L,F:_+DV:W.RGV3
M&=>7&0I;C1&"A1(R4X^#6#_!NFNTZU]!MG;=83%<3Z5&%,I.4MD8Y2"!@?&*
M^2-%Z9D(=0_8+6XAUQ#SB514$*6@;4J/') . ?@5C;T+I9IMUMG3]L;0ZP8J
MTMQD)"FBK<4' _25<X^_-:]^TB'&0[I9R%8KKL;CJGH@H=<],G'\(9Q@8  \
MXQXJ?LEKBV6T0K9;F^U#B,I8:1YPE(P/_M4?J72-AU.[%<O]KC3EQ=_9+R<[
M0L84/R"/(/' J)/2_1WII$=-D90Q(+)<0AQ:0KM?Y?A7\M9X?3K2D/4*KY%L
M[+5T+JG^\E2AAQ7ZE!.=H)^<#GYJV4I2E*4I2E*4I11(' S2E*4I2M*]V]-V
ML\ZWK>=81+96PIUK&] 4D@E.01GGY!JCRNE-NDVU<%=XNH8596K&1_!_R6U;
MDJ_R_P!?D'X(/C."/5SZ7Q9<J1*C7V[PI:IHN##K!:S'?[7;6I.4<A:?U).1
MQQBO4_IDQ+,]2K[=5.3;.Y9W7'BAQ2DK<*U.9(_5E2A@82 <   5ZA=-&8EX
M3-:O=Q2RZE@S8@0UVY;C2 A*R2DJ1E*4A000#CFM-CI2AO3TRQKU)=G;66TM
M06%[,0DI<2X,8'OP4( WYP <>37RZ]+%W&]N3G-23T-NRX=Q=90RV.Y)CI"0
MLJQP%!(]HQ@\_@0T3HJ_$@S8S6J'E>J@N0%K=A-J44*=[@4HY!4O).5$DGCP
M!BNA:JL$R^VJWQD7!N.]&E,2EN*C]Q+I:6%@;=PP"0/DUXONF%W+4>FKFQ*:
MCM6=QYPL>GW]WN-EO 5N&S 4?@_\T>[]-E6O3+[29K\V%:6)YM$-B*HOMKD-
MJ2$J4%'N;=Z@GVCR"2<5H6SI9.O^E[1,NMS3%O$2V0X\ " I B%E07AYM:SW
M#D;3G:"!P.:N5@T/+@7ZV7:==(\A^+&DQUM,P@PVKO+;5[ %':$AM(YW$Y.3
MXQ4;GHAUNQZ<T.]&F3O3RQ(:NL:/V&8\8J(>;<5O)WK;4ZG  !WIX&,UT?65
M@>ONGTV>*ZU'A/.-HEI*3[XP4"MI.",;DC;GX!-4C4>@7K$=37'3,=A=NG65
MV))M0;<><F.A*]BLE?)&X)QY*21]JK6F-,WV^6V7!+$<N=^!+7<IL64R7O3K
M!0R4.@'(" "4Y W'.2:LLOI?-<U)>UM.V;Z)=7Q+6X["WSHR]B4*2TX3A((3
MD*\IR0D#@U!#I'?6]/MV]#>E>]&=B(;D-1UM.2F674+W/+VJ.XAL#8GVY).3
MQ4I(Z:7R2N0'%VQEN1J.1=5J:?7N3'<CED ?P_\ ,&XJQP.//.:T(72R_,65
MB(JWZ23(CN0T=UDN@R66)"73W"I"L$]L#:,CW*.<#!EH.A-10M8P[RTFU=EB
M]39?93)6G_MY#2$9_P O]8V$[<8)(]PY-=,L2[DY:(RKXU&9N13EYN,LK;2<
MGA)(!/&*WZ4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I499+[;;YZTVJ6B2(<A41\HSA#J<;DY^<9'BM/3^L+#J
M&?+A6:Y,RI47EUM(((&XIW#(&Y.01N&1^:GZ5H7R\6^PVURX7B6S#A-D!;SR
MMJ4Y.!D_N:P(U)9G'+8ANY15JN:2N$$.!7J !DE&/( YJ6I4+J'5=@TXIE-]
MO$"WK>.&TR'TH*OR 3X_/BI.#,C3XC<J#(9DQG!E#K*PM"AXX(X-9Z4K&^^S
M'96](=;::;!4M:U!*4@>22? H\^RPRIUYUMMI(RI:U ) ^Y)K)2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4J$UFQ>96FIL
M?3+L=FZ.I"&G7UE"4 J&X@A*L*V[L<'G%4'I(J?IM.H(=[M#5OBNWOL1$Q"Z
M\%*4V@?* >WA*<+/DDYQCG-I*>+UU<E7>R/&=8W+3Z93JXBF?1K0[PTA2@"=
MQ[BB""1M'@8KJ=*I?6)R,WT\N@G%KTRRTVX'3A*DEU (/XQFN36FP:GZ>ZT<
MLUE95<].MQIMUL>_<LH=[*AZ<G_ZE)_?R.2:J;G4O5D?2]ZEPM02WRW9HLN1
M(="%&)<524I6RD;<)!1N_AX. GXYJ[],-<ZUF1=3)MS8UE(B2(G;0_*:BJ;2
MXP5.'<$A) 6,!/&.:R=/YR++ULU[(UZ['MT^:AERWJFN)2DQP%%26W#A)"1L
M!Q_22?!K3U[J^=IN7*BZ,G?2+&S9C=K:AEE!3/D.2@%)3W$DE/O)"48_4".,
M5#:NZC:RC:DOPB:A7;419=J;1 <C,N!"I+674*)3N]I2>,_?)!KH'3/7MT=T
MY>57N8U<YL75*K)&<=4VP7FRXV,Y 2DJ"5.*  R=H%5CJ!U6U/'OK5IMKT*T
M-.7&=&:N$G:TVX&4(+8*G,I"=ZB%''./:1FJMJG4UZGO]47;C=&'A&M5N6BW
M*2EQA06&U**$K )2DN*.<9.X9^*^Z@OUX=/4A,R[1^S;K3;^Q:W66E,K:6E*
MRD(\X258R/ZAGXJS6CJSJ(:CAQDQ8J+8U=8=D%O:8(<6EQE2E.I)5D8*00/&
MTC//-.FO5;5=\U]IRW7*9;Y%LN3T^.M+4;8L!A)4AS=N/*C@8 QC[DYK]&4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E* 8
MI2A /D4P*\!EL)*0VG:3DC'!-?4-(;)*$)25><#S6.3$CRMOJ6&GMIRGN("L
M'[C->9$*+(=8<D1F77&%;FEK0%%L_=)/@_M6*1:+;)4LR($1TK.5%QE*MQ^Y
MR.:C+AI"SR_0]F*B$8<Y%P08B$M[G4@CW#&% A2@?GG@@\U)3;/;9[+34ZWQ
M)+31"FT/,I6$$?(!'%8IM@L\Y3YFVJ!(,A ;>+T="^X@$$)5D<@$#@_:L<G3
M%AE%PR;);'NXVAE?<BH5N;004H.1RD$ @>!@5Z&G+(FZLW--HMXN+".VU*$=
M'=0G&,!6,@8X_:M2'HK3$&9'EPM/VJ/)CK4XRXU%0A3:E#"BD@<$_BK!2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E/%*4I2E*4I2E
M*4I2E*4I6A>XDJ=;EQX-P=MSRU)_[EI"5K2D*!(2% IR0",D'&?%<0DWK5C'
M3K5E_8U?<%/V6X3HJ$/18R@XVTX6T'AL'=X)\@\C SQ=W^K=D@PI'U"+<HLV
M-)3$5$EH;9=6HM=W?[EA(24<Y4H?;&2!4S)U4S=^F4[4VG7EI08#TF.MUK"D
MJ0E1Y2?LI.,54=(:Y>DP6;DY>I=Y]-:A-N-M9@)#J%JVX[9 2#@ASC)) &/S
M9/\ J?IPV55V2Z^J"7&F6'0@;9+BT;]C9SA1 R%<X!!!/!K'$ZKZ8FPX\F&[
M,DMN-I=>#$93ABI4X6QW0G.WW@C'/@GQS6XKJ)8MP0T9CKRI<F AI$=6Y<AA
M!6XV,XYPDX^"1YJ(M_4!N28%WEKE0;>[8G+JY;505J= 2M&5ASY "L!('(.[
MQBIUW7U@:+85*<)=9COMA+*E%8?W%L# _40A1Q\ $G YK<A:NLTW2:M21Y*U
MVA+:G5NAE94A*"0O<@#<"D@Y&,C!K75KO3J2^#.7EEAB4H>F=Y:?(#2D^WW;
MB<<9P<@XP:K4#7,^5>-.18TNV36+E<I\-YQJ,ZWL#+:UI "E9W H 5P0><8Q
M4_H74[MUZ?1=07U<5E9:==D+82H-(2A2@2 23@!->K?U"TK<&ICL2]15MQ&V
MW75DE("'/T$$@;@3P-N>>//%:Z^I&G"[9D1Y3K_U26N$T4L+';<0"5AP$ H(
MX&" >1QC)%MDR&8L9V1)=0TPTDK6XM02E*0,DDGP,559.M8$M=M%@NMF?#T]
M$5],B3L7M*"HAM(Y4Y@I(!X(.:A?^KEA?EVEZ)+ABR27IC$F=(?#884P!C \
M$+R",D'!!QS5P<U386Y,".Y>;>A^>D+B-JD("GP?!0,^X'XQ6>UWZT79]YFU
MW.#-=9&7$1WT.% R0"0DG'*5#^Q^U(E^M$Q;*8EU@/J>*@T&Y"%=S;^K;@\X
M^<>*@;'KRVW/55VLRGX37I%1Q%?$M"A-[K>_^&.,D>,#/D5B=UL]'OUDMLBW
M,_\ O2XRX*7&IB7.T&4K6E:@!Y4E&2G.4YP:MD2?#F*>3#E1Y"F5;' TX%E"
MOLK!X/X->E3(J9!CJDLA\([A;*QN"?OCSC\UC^IP.?\ O8O"TMG^*G]2AE*?
M/DCP/FLWJ&>X&P\V7#D!&X9)'GC\9'^M0FD-3L:BTW&NZVC!0^XXV&GUC<DH
M<4W@GQDE/Q]ZF_5,;W$=]K>V,K3O&4#\_:O8<0I:D)6DJ3C< >1GQFH6PZC9
MO-WO<!B.^V;4^F.MU>W8ZI3:5Y003QA0\X-396D$ J )\#/FH*=J:+;9,TW-
M'H[9&:;<%Q=<1V7"M13L'.[<"/MSD8KQ8]4,7;45]M"6'6';4ZTTI;A3AXN-
MAP%&#R,$5)W"ZQ(#\6/(>2),M2D1V<C>\I*2LA(/X2?Q_K6KI&_QM3Z<@7F$
MEQN/,;[J$.XW)&2.<$CX^]3&1]ZI#G4FTA?<9A7:1:_4"+]49B[XI<*PCA><
ME.XXW ;>/-7?(^XID?<4R/N*9'W%,C[BF:9'WK3O%SAV>V2+A<G@Q$CIWN.$
M$X'[#DGX ')-8-/7N)?H'JX29"$!Q32VY#*FG$+2<%*DJ (-2>13-*5'KO,!
M%]19E2$_4UQS*2Q@Y+05M*OMC/%2%:-HNT"\1UR+7+9EL(<4RI;2@H!:3A2<
MCY!K<<6EIM3CB@E"05*4HX  ^34?8[]:K\RZ[9Y\>8AI>QPLK"MBL9P1\9!!
M'W!!'%2612M:?<(=N0TN?*8C(==2RVIYP("W%'"4C/DD^!Y-;-*\+>:02%N(
M20DJ(*@, >3^U89$^'&9;>DRX[33A 0MQP)2HGQ@D\YK8"TE12%)*AY /(KZ
M0""",@TI2E*4I2E*4I2E*4I2E*Y^WTZ__P /U)8'+P^IN\S'Y:G^RD*:+JPM
M:0,X(SG[>:UKKTQ7+O4J\Q;[)B7=4EJ3&DH80H,E#'94@H/"T*3Y!Q@^#5JG
MV%^9HN78W;D\[(DQ%QG)KR$E9*TD*5M3M'R< 8Q5<BZ+U+&LK-M9U:RRU%A&
M'%5'MH;*3LV!:SW"5$#) 24C=M/Q@Q'_ $B<CP'H=KOIB,,W!-SMJ51>\(CQ
M04. [UGN(7N4=IP03YK>3TZO$:],W:W:J5'N+T00[@[Z!LAY(<4L%I.0&B-R
M@/U<8SD\G CIA-;U2W/1?&A;&KR_>$1?29<4MYLI<2IS?C'N.#MX^<UOZ4T!
M-L\ZR.3KE#F1K?:'+.II,-3?<;*D$')<5@X0 >.>?&<"*7TC]/I6+ MUT;-S
MA3S-BR9D8/ME ;4TVRMLGE"6BE&?((W#FN@Z>M;D'3[5ON'I'E[5!P,1PTR0
MHD[4H'A(!QSD\<DFN>:9Z.M66[V.>JZO2%P2MM\*3@/L(*3&:QD@!HH0<CRH
M$_-;5LZ?76WW:R2T2X+@@W>X7-P$*!4F2E8"!QY3W#S\X'WJ9TWI6Y6KI8=-
MOO1'+@(K[ =;4I+9*RO"B<;A^KGBJ8]TMOSJ+6XB1:695JM5MCQL%:T+DQ'2
MY[AM&&U9QD<CSCC%2#W3V]IU-$U*PNW?4E7KZC)BEY890UZ;T^U"]F5* ]Q)
M2G)..,9,_<K7>=<=+;A;+RVQ:[M.;=:';WEM.%GMJP<*P0$D@@'DY'Q59BZ#
MOR!9WE6?3422S>8\Z4(3SGO;:0I.=RT$J5EPD#@) \G/&*Q:(U-:+E94FWVZ
M3%MLZZO)>,KE:)&2V=I3P<J((R> 3SQ4%I?I3J"VR;2;I:X%Q:7%A-/]VY.M
MI@+C\;@TC"7A@!8S@A6>1G-=-Z5Z;>T_9I8N-LAP[D_-DNK<8*5EQMQY3B 5
M 9X"\8/V_-4F_P#2^_KNMRDV*XMQ&HT\S;.@<=LR$I3+"OL![U) ^5'SQC6U
M!TXNJ)VHC9[.VIIZ79S;EAYM*T-1=H<P21MX1P/DG_3(WI#4HFP646MQAE.H
MKK.7(2\RKMM/H<2TX!OS_P#-Y2,GVG\9E^B6C9FGE*?NM@7;;@U";@N2E70R
M1*"#P4(!(0C@GG!!5C&*K%PZ>WIR^:F<GV.1<WW79\B#<#<$):*'F5)0UVMV
MXJY2C"L(P,YXYC;CTSNALMU8A:80F:Y8+8U'(3'3MFM*_C$*W8"PDC*OG!Y.
M!G9ME@^NZZU#Z"R.BX1=6M3?JR4M!,=MM#2G&RK=N)4-PV@$$JR3P:S6W3-^
MBV2V_7]*R;I&3!N$)4$%E:X[[TDN(=3E>-JD*"=P.4[?SSO6[2CS>K=.VM5P
M@29TJV,,ZE;2H.+48A;6A1!S^HJ#9*L920:@6] :E99U"6K1<W=0)[H>GJFM
M(8N#*WTN*0C "U*4V%)PLX1X!&0*Z7T?MCMOG:L=&G9%@M\V<B1$CNH:1[>R
MA*L);40GW(4<?D<GG%,OV@-56N]S)FE(\),>U7(W&TH*$!3AE!*'VSXVH1[R
M!QD%/](K7U)TZF1(FJK99[&X]'-OM"(RPAO$E<=W<[M)/ZBDX]P&3GFMN9I.
MX2-7S;VSI:7'E)O=KD15CL)4S%;90EY*2%D #8I*@//M\_%UZE6=Z7J_0]V1
M9571BW2WB^&T(4MK>T0A>%$<!82K(.00, G%<?M>A]20-.6YFR6>Y0;E)T^Z
MQ.<2=JG7A);5VUE1VA1:0X$D\>_'@UU[I;IP0-,WJ,S'OEOCSY#BVV[F6 XW
MN0 I2&V0$-ISG"1]L\9J.Z:W&1IW2ELT===.W95T@D1"6X2E17DA7^<E[';V
MX.XY(5P1@G&:I#MU^5(BEZ%>&=1QW+D+W*;0_P!J5'4ATM]M8]JR26MB4<I(
M/ QS$2+!/C:;E+B1=4IE'2L66@$S23<@I2<X_P#U$Y3[,D 8.W J5G>IGZOU
M ]:)&HG+Y&O<%4)I*I'90PIF.I\+21VT@I*R4JP1A(P.,U!Z7J-B%=S#1JQ@
MR;<G +,WN-2A-05;W,;5.!LJ)4A*48XP?-7:>FX6^#JBX6V3>7&=,WMB7$C/
MRG\RF"TT'6MRSE:5**R <@*'V/-ZU+%U#9.CMR;MKDN9J/TRW5*;6I;G<6K<
MYV^<^T*5M ^P KFETERW^XG3]WU$SI-^[6MEA\R)'=0M2EB2E+BR5; G&X'(
M"OVQ5[ZWVQB+T<=@E^:_Z941#;BWW"ZYM=1DK4DY4=H43GC(SY (K<V;=A?7
MFHDF[_78UZC,VN-ZEY3#]L(1N6=QVN@H[I4LE2@0,D8%6_HN7IMIN5TDWFXW
M!YR=*8[,A\N-L(0^L("01D$HVG/R"*IG2W5LV=U0;C/76:]#FQ9N^/,<<*P^
MV^G:"@I"&U!!/M;)&!D^163J)J"XQ];:HB0]33X-RB,P'K/:T.HVS'5%04D-
M[=RTDX"@#\DG@#%>NVK]0JBZHG.:NEV^[P6KBEZS)@K/92G/95W"=J$X",+
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MSC[J)^2:PWF)8I'2/3:KO;85TN+EG:C6]B9R"ZXRCGG].-H)7P0 ?%?8J/\
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M]MR+8F7<VV;<5/K82AR0VL$A12G"@<94!G'GFI)R3%:=#;K[*'"0 E2P"2?
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MCBJM(ZJWV/9(EW,&U/QKK9Y=W@MH6L*8].E*U-.JY"SM5Y 3[@1C'-9)NO\
M7D6Y2(*[-IU3\>SF]KVRGB%,A1 0G* =_M/GCD<_%;D#JE.N;<2Z0;?&39%W
M5BTO-O+4)*%NH00O@8P%. 8P<@9!YK0'4S5OT6+<7[/98[4YYQF(/4.NN*+9
M=W?PDI"U9[:<%/ "MRL#(&M=->72\V+5$IV''=LHTS"N:(B)*V'4J?2X5 .)
M&3^GR"/TI_J-6B3U$E,35K8M2';+'O#5C=?[Y#W>5L3O2WM]R M:4_JR>3C[
M^-&=2YM\O-FB7"R,PHUW1+,5YN:'E;HR]JPI.T8!^""?'(%=,6L)05$\ 9)K
MERNJSC=I9NKMD5Z"X09,^V%,G*WD,C>4N I ;4IO*P,JX21YXJ\:1NTV]V-J
M?<;6NV..DJ;96\ETELX*593XR#X/(JM/=10F=&#5K6JV3)SUKB3B^D)<E-[Q
MM4G&4H4MM: OGD<@ @FG1]>:@3-L%^E0'I#<G3LJ>];HDI(9_AN,$NDKP 0E
M2A@9.<#P21;4]3V'[RF);K'=9T3NAA<IALJ#;A:#@!&,!.%(!45  J^W-3F@
M=5KU?:!<Q9IUMANI0Y&7*4@E]"D@[@$J./MS^*A[MU0M=OUDWIYN)*EN^H1$
M>>CE*@T\M(4E)3G)&" 5>$E0S\X@Y_65"M-7&XVW3UR0XBU.72%ZTMI1(0A:
M4+/L62 E2TYS@D9Q]Z7/7TVV3[Z_'AW&1.9CVUSZ=(=CI8;$A11N;4#E1W$@
MY5C(&#BK,QU"B.W65;#:KFW<(\]F IA8:W$NH+@< #AR@)2HD_@XS@U=:I3G
M4>U,W95NE19L>2FZIM![O:2 ZM&]M7Z\[%)((.,G.,9XJIIZH^EUI)D2F[HY
MIQVV19+:$QFR(W<?=:[RE YV*"4$<J)"LX&#B4N_6;3L*ZW&VQT29<N&F0/X
M2FMJW&$%3C>"O<G !]RDA)P<$U!(ZFSX6HHUQNL.XFTN:::NDB PVTHQE%XA
M3V=WZ-H!QN)P1[<Y M,_JUIR)>'K=F0^ZV7D;F.VK*VD[E)V[]XX! 4I(22"
M-WBK!H?5+&K[*BZ1+?<845P(4UZUH-EU*D)6%)P3E.%8S]P:CI?4.T0]3ILL
MMF8P5.+9$QU"4L%Q#9=4GE6[ 0"=VW;\;LU$3NJ\(1HB[?:+NZY)DQ&V@[&+
M8<9D+PEU))P00#@<'.,@>:V(^OX5N5--TE39A<O+ULC-,VY84AQ+>\,@#)42
M <*.,Y^ ,UL2>J.FF+5'N"7I3T=R.N6YV8RU*CLH7VUK=3C*0E>01YX. <'%
MSCR6Y$-N2V3V7$!Q)4DI.",\@\C]C5-8ZHZ8>:<<1)E !#+C251'0J0EY10T
M6D[<J"E @?\ '-6BQ7>)?+8W/MZG%1UJ6@=UI32@I"BA0*5 $$*21R/BHVU:
MTL5UO9M,&879H[P [+B4++2@EP)64A*MI4 <$^?WK:U-J6U:9BQW[S)+")#P
MCLA+:W%..%)4$)2D$DD).!CGQ4&>I^D=EN4F[I5]1'_;!+#I*_X@;((VY20L
M@$'!'SXK3M_4JRPK% DZBO<!R3*9=DH<@QWBTXTAPI*DIPI7'&0>1R? S4[(
MUMI]BZ1;<NY-^IE*;0T4H6ILJ<3N;27 -B5*'*02"1XS5<9ZAZ89LEKF:MO-
MC<EJ+K[#L9"U-D(<4WO;"@5 @<$_?=\59&M:Z<>N,>"S>(CDF1L#24*W!16C
M>A.X<94GW 9R1R*Q].[_ "]2:<,ZX,LLR4RY,92&=VW^$^ML'GGD('_\\5+7
MR]6ZQ1$R;M+:BLJ6&T*</ZUD$A('DG / ^U1LO6VF8;,-Z3?+>VS+:2^RXIX
M;%-J( 65> DD@ G SQ69_5NGF);D9Z]6]#[:%.+2I](VI2D*43S\)()_!!\5
M&7/J/I6!9I=T^L1),2*6DN*C.!P@N'"!P?GG_0_:K8P\W(8;>86EQIQ(6A:3
MD*!&0143=-4V"TRQ%NEZML.2=O\ "?DH0OW'">"<\GQ1>J=/MS),1=\M:949
M"G'V3*1O:2G&XK&<I R,YJ(U3KVTVBSV^7"FVZ8NY24Q(9,M*65K)Y4IP;L)
M2 <D XX'DUO6^^6V[6MV)>7+:S,],57"W*EMO=E!&%!>#@IY\D8YK):+CIFW
M6J)'M$ZT1[=_EQD1WFTMYR/:C!QY4.!]_P TM=_#L>ZR+NW'MD>%,7'2ZY,;
M6EQ"<8<)!PC.?TJY'SYJ2>N<!AM"WIL9M"TA25*=2 H$@ @Y\9(_U%9')L=#
M_IP\TJ5L*TL!8WJ ^0"?'Y\5%Z)U$UJO3$&]1X[L9J6E2DM.D%20%%/../BI
MRE*4I2E*4I2E*4I2E*4J UWIU.K-+S+*Y*5$;DE&YU* H@)6E> #QSMQ_>LH
MTO8E69%J=LUK7;DJW^E](WV=_G=LQMSG\5D=TW8WE22[:+<X9+*8[^Z,@]UI
M/Z4+X]R1C@'BM56B],K@18*K#;##BK+C#/ID;&U'R0,<$_/W^:7#1FF[BY+<
MFV6 \N6A#;ZE,IRXE&-@)^R<#'VP*V-.:<M^GU7)5N:#9GRUS']J4I!6H '
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M@H2O;N "4\X-;T#3.K%:VL]YF:9EMO,7)AY]YIZ,0MHQ TI2E%SN%85Y2"$
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M9*5.;"C*T\[4E101A0!/%[LU_G+TB]>[_;F8.QE4H,QI!D99"-X.=J?=C(P
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M ,D\55;EH>QW*ZS;B^)B79X0)2&IKS;4@(3M 6VE021MX(QR/-6?:VE(2$I
M    XQ6#T,4SFYO:29+;190LD^Q!.2 / S@9^^!]JV2$J(S@_:H:;?8<>1&:
MCLR)RG)@A.&&WW1&64[B7<?H2!C)/C</O6_'7!N,1STZH\F,5K;7L(6DJ2HI
M4D_&0001]QBLKT2.^I!?8:<* 0DK0#@'@@?O6%ZU6]][NO08KCNY*]ZVDE6Y
M(PDYQY \'XK5N]^@6J0VQ)+ZY+B0H-1X[CR]F]*-Q" <#*T\GXR?@UJW:RV!
M%O#,J'%9CF0F9VFF@DNNM_Q,[4C*E>W) R2 ?(S6U"?M&KM/1I;;;%QM,UM+
MK8>:W(<2>02E0_\ N*]OV"SR'8;K]K@N.0L",I;"26,>-AQ[<8'C[56;O)Z?
MV>ZOHN3-E8G,NB>^HQDDM.*SAU:@GVJ//N403G\U+P]*Z4DV<M1+'9W+9,2V
MZ4(BMEMX 902,8./(^U;,?2M@C/QWHUEMS#L=3BV5-1T(+9<2$K(P.-P !^^
M!GQ4<[TZT<\VPAS3-I4AAOM- QDX0C?OVCC@;LG^Y^];,71>FXJV51[-#;++
MSDAL)1PAQQ.U:@/&2D8/XJ2M%FMUGM:+;;(;,: @$)8;3A !))&/[FHE.A-,
M(A/Q$6:*F,\A#:VP"!L2K>E Y]J0KG:,#/Q4U<;;$N5M=M\YD/0W4=M;:B?<
MG]_/]ZK2=(:2^J1XO;!N<<.RD-F>Z7R'4]I;JLKW+R $;E9QC (K7;T'HN6E
M^V-1TN^D@IM;T9%P>):C$[TM+2',@'R,\X^<5F:T7I"ZMW$LM>L3(>91*4BX
M/+/=C'" 2%^U2".1P<CGFO$GI;I"2\MUVUNY67SM1.D(0GOY[H2D+ 2%Y.0
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MSO;CG#RBHN, )0 $*2D#GD$@_)KJ_3RZ2[_8?KDHN(C7)?J(3"PG+4? ".0
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MB%*>'\Q//M R#R!G Y BNJIN;.II<Y E7>RQH 3)B6V8IB9:E'>1*0D*'<R
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M?^DW&'.["MCOIGDN=M7V5M)P?WK4U+&L(,*YZB,)H6]WN1Y,M:4!E9XR%$@
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M':FO3[^SLB-I[6\87MP.-PX.//S6S9;-;+'$,6S6^';XQ45EJ*REI)4?)PD
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M4RRM_MMI*W"A.-Q2@94KR. #R0/D5[MLIF9;XTJ.E:&7VTN(2XV6U $9&4D
MI//@C(K9KXI*5)*5 %)\@U$7ZZ6S3MN:?G)*&=Z8[+;+*G%J4K@(0A ))./
M'Q]A41<;19]?:+Q#<=C0[DP-LEED-O!LJW$>])(R<YX^35A:L]N:899;@Q4M
M,K[C:$LI 0O^H#& ?R*Q_0;1M6DVN#A:.VH=A/N3G.T\<C(!Q]Z@=-VBVV/5
MD]MRZRIUZFLAU#<G'\"*E:MK;82D!* I9_/C/@5;UH2XA2%I"D*&"",@C[5!
MHT?IMMR&XW8+4AR'_P##*3$;!9]V[V<>WGGCYYJ01=8#EW=M:);*KBTT'UQ@
MH;TMDX"B/L34*[T_T>Z75.Z9LRBYOWDPV\JW$%6>/D@5$/Z<L^J8"WM*7&-
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MMI7+D-,(4H("G5A(*CX S\G[54T],-%[98;L4="9B^X\$+6D*.\+^%<#< K
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M<H3$@M2TK,A#R]H.!D$-A/)\G;R5"I&<J^/6Y?J7-1/7DV:W.:<>:2_M]1L
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MY(F:!T[(0R\P'+>PH-OJ*EI';'"E8&3^<<UR1W6.J7(@D7B=:YMHGW.XV1R
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M!\YKZ5))()&0,D9^*';X.*<$?!%,#["H^_W:#8+/)N=T<[4..G<M025'D@
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MTLM^I+C;)4>0U ;@L*C(B^@CR& V3DE#;J%)0K('N ^ *G[1H33-LBPFF[+
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MN<IZ].7*0](:=1<'GU$(0^X6]J73\H4GW#S^^:X\[<-5IM%W[#FK&'I=O0X
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M'5NGBAQIO3DI4B,_!DQYCSKK*&U25OH<2"C*S_$*2A6,[4G=R<2#'2ZZ(O\
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MZ2Q'><9<4>RAY*T.*03@D#*2,X)%5>X:*U1.N-RE/LV@*E7JV7,=N2OA$=*
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MG+=I&S6]=R6Q'=4;BRW'E=^0X\'&T(*$I(6H_P I(_.3FM*Z]/=,W2#:H4F
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M'"0DDH5OVXR@#[4C:KN#VJK-$O&J741;?J.X6]V7N8:#R41PII+@V;"<J4C
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M@J*XO_;('843DE''M.>>/FOD;2&GHKC2X]F@MK:?7);4&1E+JP M8/\ 4H
MGYK?LUIM]D@(@VB%'A0T$E++#80@$G)X'YJ&DZ!TM)CEE=DAI;,A<HAI);/<
M6,+5E.#[AP1X(X-6-B.RQ&1'8:0VPVD(0VA("4I P  . ,?%4^)H#1;C4N-#
MML8MAA5N?:9D+PEM2@XIH@*XY(./.,#QQ6[$T%IB)>V+Q'M#"+DRA"$/Y43[
M4;$D@G!4$\;B"<?-2&I-.6S4D>,S>&''D1GDR6>V^XTIMU/Z5A2% @C/!SQ4
M='T'I]B8Q*]/+>DLK[B7),^0^K.Q2!DN+5D!*UX!X&XD8)-1@Z3Z23%ML=N%
M(2BWI+3)$Q[<62K<65G=E;>?Y#D>?N:WF.G6F&+K/GM6]279W<+S8?<[14XD
MI6M+>[:E:DJ(*@ <$_<UH-]*-+H:>1VKDHNML-J6JY2%*'97O:()7D%!\$>!
MQ\FI,Z#L*K9?K>Y'>=C7Q9=FI<?6HK64A.X$G*3A*?'V%8KWT_LMVN-OFDS(
M;T-CT@]%)6P'H_PRYM/N0#R!4IJ33S5[B1&/6SH!BO!YMR$X$'(24[2""E22
M%$%)!%9;!88-AT[%LD!"A!CM=E(4K*E#Y)/R2223]S5,8Z16..U;6X]QOC"H
M3!B!;,TMK>C;MPCN%(&6P<X\$9/-2#W3>W/09L1<^X=F7=$W=P#L\/I4% #^
M'^G*4\>?;C.,Y(Z<0$3&I2+E<PZW=7;PDA37^>XC8K_Y?Z=I(Q^?VQI1.E,&
M-:46Y%ZO"HR;;)M?N+.XM/KWK)(;_5D  _8>/.<%LZ1PX5TASEWZ\/KBS&YR
M4++02IU+/:4580"0I/D9XYQC-9+=TEMT6%#@OW>Z3+?&MLBU)COEK"F'L;@2
ME .1M1@@_P O[U[F=+8TZ%*;GWVZR9KPC-HG.!GNMM1U]QIL8;P1O)421E1\
MG'%6?36FV+!,O3[$J0]]5F&<XA[;AM92E)"=J1QA(\YJ%'3FWIOKLYN=.3"<
MG_556[*"QZL>'1[=PY]Q3NP5<D5,Z,TZK3-ND1#<9$]+LEV5O>;;04J<45K
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MKT.WPB7WTNOA14 5^ G (_!/XJ\],-/N::T5;H,HK5-+:7)*G%;E%P@#!/\
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M$>3(:+9*PE*L@'RDA:2#5'ZO-R57>QF9$O<S3BFI#<ANSI6IYN0K8&7"$')
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M)VA1^3CXK\]N=4-6NZ8O5]8G6)D-QY2T6]QP.28RVW0E([82" $\*WD\J!!
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M<)#:$RDE,_LHY,A 3G]6/!&<8.1Q6XYT@T^I]]PS+P XU*90@S"4LMR#EU*
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MX!Y&.:N-*4I2E*4I2E*4I2E*4I4/J/4EKTXRTY=GUM]W=VT-,K>6H)&Y1"4
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MN82W^C9E."C(.2!D>,<W+I]9IEBT?#C7&0Y+NRT=^6\Z0"X^KE6<<8!]HQ\
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M)4I2_?@IVNMJ]J5\Y0$DCYJG3=3WFX:.E;KK*FKEZ7N/UN.^D)]%-2V A(2
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M. M140KASSM&%)XSFOK6K7M-7"0&85O]2+39(K,MQ*@$AYQ;>7B%8V))4K@
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M::9E =I:O?NQDX( )'/! S4O;]?P9MR-O;@STSTW-5K7'6E 6A26BZ72-_\
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M"'8R8BLSI"B&DN!Q*02O(VJ ((Y&.,5O1M"::M.H57]J.MF:HI*E*DN=M3F
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ME*4I2E*4I2E*4I2E*4I2E*4J/O=EMM\BHC7B#&FL(<2ZEM]L+ 6GPH _(J0
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M&_J<_P!I?_%/J,;^IS_:7_Q3ZC&_J<_VE_\ %/J,;^IS_:7_ ,4^HQOZG/\
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MCU[&0,^:S?5[=G_XZ-]_\P5[^J0/_P![%_W4_P#-/J<#_P#>Q?\ =3_S3ZG
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LI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>exh46_07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh46_07.jpg
M_]C_X  02D9)1@ ! 0$!- $T  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ L ! 1$ _\0 '  !  (# 0$!              4& P0' @$(_\0
M41   0,# P,# P,!!00&!P(/ 0(#!  %$082(0<3,10B03)1814C<8$6,T)2
MD1<DH=$(4V*4L=(E-$-5<I+!-9.BPN'P\50816-D@X2RL]/_V@ ( 0$  #\
M_5-*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*5H0KS;)\V1#@W&'(EQR0\PT\E:VB"4G<D'(Y!'/R*YXY;KW&ZK6
MJ(WJ^Y26GA(N4N I#266HX]B$ !.[!4M(&2>$*/FKZYJ.R-WU%D<N]O3>%@%
M,)4A >4"">$9R> 3X\5*TI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5K1[?#C2'7XT2.R^\27'&VTI4LDY.2
M!D\G-:,*Q,1M2W*]EQQV7-:9CX7C:TVWN(2GC/*EJ)Y\G\5O+@0US4S%Q(ZI
MB4[4OEL%P#G@*QG')_UK9I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*  $D#D_-*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI5#UQU&9TQ>1;6;3/NDEN.F4^B(VI1;:4I200 #N5[%G''"2<_!BU=62J\)A
M,::N+J%W-ZT-O=YE.^2VG=M"2L$ @$Y.,?DU,1.HUOF:6:NL6)*=E.PWYJ;>
MD#NJ2PL-O)"B0DE*CCSS\9JKV/J0C^U6H)*Y$F;;YGZ0FT0QM22N2TI6T9(Q
MG&XDGC!^U3\3J;%D7"#%7;)3!=N+]KE..K0$PY#:"L(60KG>D921D?UXK6C]
M6[>]/M\;]'NP,@L!\AM"O2EX;D;P%$XVE"B1G 4,\Y PV/6DW4/4VSM0T3(U
MAE6F3*:2Z6BB6$O-)0\D))6,A1^K'!''FK1JK64;3\Y$-,&;<9?IES768:4%
M3,=! 4XK<I(\G  R3@X'!K3L746V7[4:;3:(-TDI[#,DS4L#TZ6W6BXVHJW9
M&0".1G(Q7O5.IF;%J>*W(>N"FQ;)<TQ&&6UH>2UVRHY)"@L \ <'<<^*V=(Z
MUM^J)+L>)%N$1]$5F8$3&.T5LN[MBT\G(RE0_D5BO&OK5:=41K',9FI>??:B
MID!M/:[KH)0C)4%*)QR4I(&1DC-1,3JU8Y4:0\S O)2U#?G)!B@%UMESMN[/
M=R4GDCC@_?BK+IO5,'4+[C=O0^0B+'EJ<6$[=KZ2I"<@GW #)'_:')S4/>>I
M-GLTV[1KA&N#2K8_&9?66D[</G#;B3NY1NX)^#\4N74JR6YR0)3-P#<=]3+S
MP8RV@)<#1<*LXV[SC ]W"O;@$UO1M<VB1/?@I]4F8S<A:U,J9(672@N @?Y-
M@*MWC )K)K?6=IT;!9DWA;N7U%+33205N$#<K&2   "221_J0*@O]KNE5*0I
MEV>]&4F,M4IN&XIEM#Y(;4M>,)!4-O/SQ\'&^YU)T\U>7+<X[*"D.O,=\1UJ
M:4ZRC>\@$ G*$\DD8\X)((&*W=3M/3XCSK9FM.MOLQTQGHY2ZZMX99VI_P"V
M 2,D8P<XQ4?+ZS:2AV=FX2G9S2'%.I+*XQ2XCM*"7"0?(2H[>"<D'&<'&MJ_
MJ.@7:P0],N/O(>O,6%+E)BE<<I<Y4T'#P%[2D\9QX\\5-]4;[/T]#L<NWK=V
M.W5B/):98[RW6E$Y2D>=QQ@8^_QY&&W]4;#.<A(:;N"3)1)4>ZQV^RN/GNM.
M;B,.)Q]//'/CFK$SJ.&K28U%);E1('I?6+2^T0ZAO;NY0,G./CS5=1U3T\J.
MI91<N^F2(BHJ(:W7@Z6BZE.U&[DH!(_@CR#67_:AI<VN+<&I<AZ*]$$Y2F8K
MB^RQN*"XX /8D*"AS_E5]C4!JCJDJ.+B+/%7MM=TA1)#SL=;B'FGE-A7;VX]
MV' 4^<CD YJQKZEZ8;L[=R<F2$,*+V6S#>+S8:.'2MH)WH"#C)( &1]Q6W:=
M=Z=N]]_1[;/5(N 0'"A,=S:$E 6"5[=H!2H$<\_&:\:HU_IO2\\PKU.<9E)C
M^J4VB,ZZ4L[MO<.Q)PD$')^/FODGJ'IB-<4PG;G^ZK.'$L.*:)#?=VAT)V;M
M@W;<YQ\5I-=5M&O0DRV+LMV.K.%M1'EX2 @J60$9"!W$94?:"<$U(G7NFQ=G
M+:JX[9* ]RIEP-J+(RZE#FW8M2!]24DD8.1P:R:7UMI[5,A3%BN E.I81)QV
MEHW-*) 6G<!N&00<9P>#@ULZUOR-,:3NU[=:6\F#'6_VT))*B!P./ S\_ Y/
MBJ)I;J'(93<)VL+Q9&K4S#:E)[4.3&?;"W"D*6AS/M)&T;<YQGP:G3U8T."
MK4,5/(!W)6G9E12"K(]HR,9.!X^]6'3.I;1J>&]*L4U$QAEXL.*2"-JP <8(
M!\$$'P00166_WRW:?@B7=I'89*MB<(4M2U8)VI2D%2C@$X )P#4<YK?33;D-
M*KQ$Q+;;=96%904K.$$J\)W'@9(R>!6C-ZFZ+@W&1!F:CM[$J.X6G4..8V+"
M@DI)\9!(R/BMI.OM++MR)R+U%5&4\M@*223O0,K&WR-H&3QP.?%)FO\ 2<.2
MS'E:@MK;SS0?;29"?<V4E06#GZ2$DY_YBM25U*TPU'@O,W 2$3)J(#?:0HD.
MJ2% $$ @;2%?D$8SFO5MUQ;46E^??+I9V&1.?BLN1I!<0L(4< Y ]^!E0&0/
MO6Y*UWI6(XPW(U#:VUOMMNM)5)1^XAPX0I//(./(JR5$?VFLOZT;0+I#-S&<
MQNZGN9 W$8SYP0<><'/BO5CU'9K\N0FR72%<#'V]WTSR7-FX93G:3YP<?Q6-
M_5-A8N;]N>O$!$]AM3SL=4A(6A"1E2B,Y  Y/XYJIP>K%AFW> &ID)JQRX#D
MQ-P?DI;PM#J&^V4'Z2=X(R<G.,<5<7M0V=BZ,VQVZ047%Y(4W&4^D.*!&00G
M.? -9;5>K7=RZ+5<8<TM8[@COI<V9SC.TG&<'_0UOTI2E*4I2E*4I2E*4I2E
M*4I2E*4I50U-H&WWZ_LW@SKI;YH9],^8$CLB2SN*NVY@9(R3R"#SYK6'3:W"
M>Q+3<;D%,W=V](1N:*0^M.TCE&=@&<#.>?/ Q56.F,RWZAMEKM\VZIT['M,N
M*J<76.ZE<A]+BT8VY.0E7NV\;A@\58%=*K.EV>Y&E3(ZGO0JC;-F(:XB-K*T
M>W)/)SNR""147J'I^X]:V=-M0$W.)=9XN-VN\AQMM:'4N(45!M*1DK2DH&W
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MIV'#7@$BWRFSW7%9^K8% #\[OQ677^DM3-:GUL-)6F<W!]%;F&4MM* DLM;
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M/W0A#<@L("E8]VX).[A12 =JL9QRB]48S-A7+NUKGMS(]KB7-]I@-+"T/JV
MMD.$$!05P2#C[GBOMPZM6:W3+@Q-MUU81#EF 9#J&D,NO\$-I6IP#)2=WNP
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MTCD;MISD9&=IP>*SL:T;MSEJM5_:=5J!YB.J6U!84XVPMU6P;L$[4E84,Y(
M')\9W-8:VM.DW8+-S3.=DS0LQV(D1Q];FP95@)!\ YJ,=ZIZ81!9FHDOO0E,
M-27GVF%J1%;<5M0IXX]F2#P>1@G&!FL%]ZBVU4#43-ND3&'K?&D$W%N)ZAEI
M;21N( /N*2I/M.,\_ )J.O?492(5]9:5)MR;9&A/_JZX1?;6'E<GM @@%(XR
M>,DGZ>;,K7=F;O:;8M<DJ,H0/5!A18]3C/9[@&-^/Z9XSGBL.ENHUAU-/CQ+
M=ZY+DE#JV%R(;C*'NTK:X$J4 "4DC(^,UM7+7-BM^H$6:1)<]8IYF.K8TI2&
MW'MW:0I0& 5;3C^F<9%:%KZH:5N<A]IB<\VEEA^0IZ1%=9;*&5;7=JUI 44G
MR!G%:^A=;.:HUKJ:"UN%L@LQ'(H=B.1W3W X5%07RH':D@X P?ZUHZIZG-6]
MV:W#9=83;+Q$M\UZ5$<*"VZ4[RV1@$@+!')XYP01F8>ZFZ5:M$6Y?J*W(T@N
M!(;C.J<2&R XI: G<@()&XJ Q5BGWRW0+4S<9,E(AOEM+2T K[A<(" D)!*B
M21@ 569G571D,,^JO2&BZWW4I4R[N"-Y05*&W*0%)4"3C&.<5*C6^GOU1Z J
MY-(?:"MREI4ELE*"M:0X1M44I&X@$D#S4:_KVU3DQD62[0T/FXQX;J)C#J5$
M.>X)2D@'*T E"C[3YR16GJ7J;:&+'J)S3\QB9=+7"?EI:<:<#3O:)"MJL +
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MK .4C>>0$GPD<#[5&+Z4:=42XF7>4W /IDIGBXN&2ASM!HD.$DC<E("OO@?
M %GGZ;MLS22]-R0\JVN1O2$*=)<*,8^LY)5\Y/.>:ASTYLJIJY#SDYY+_95,
M9<>RW,6SCMN.C'*@4I/& =HR".*F]2Z>AZA:@)FKD-K@RD3&'&'-BD.)"D^?
ML0I0(^QJL/=*[)(:CL2GYTB*T]+>++BT%+AE AT*PC.#N5C!&,_@8G=%Z4C:
M4A.1HT^Z3@O: NX2E/J0A(PE"<\)2.> /GG-5^=TGLEPE2I5QF763,<0$,25
MR EV( [W4]I:4@Y"@,%140!@<9%97.F=M>E(D/72[O2!$DPW%NR$N%U#X 65
M;D'G"4@8P!M'%8$]*X'>MQ<O%V?8MS:4Q&GE-*[*DL=D*2KM[A[>2D':5<D9
MK$.DUO;A0X[=ZNS8CV==C*@IK]V.K<!O';P2G<<8QX&<XJPPM%VZ.YII]3LE
MV786#&COE82IQ!;""'-H 4, ''C(!K6TUH1C3U[D2X-WNOZ>MQQYJU*>'IF%
MN'*BE( .,E1"22!G@9 K3UETWBZIG7F3)N<MA5SMZ+8M+:4$(:2YW,IRG.XG
M(R2?/C@5&?['X)N[TU=\NJDNKF*+.&=H$E&UT9[>3X&,G@) &.<_9W21J3#0
MPC4=U94;8S:WW$(9R^TTLJ;)]GM(W$>W' '.<D[DKIHF1#N;:KY/1(DW87F/
M);2A*XKX 2,8&%)P,84*L\>P%>EY%FO,^1=/5-NM2)#P2A3B7,Y "0   <#
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MK7EOW<#*2!YR:R7CI]J<WV0;?"LKD1^;:KBXZ'E1TI5%2E*VT-A"C@[ 1DX
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MS&1)0HNL.NAK.[@!:5J2"GGZA@FHS6&L;S>K7 @PK:_ E*U"U:+@TB?VU ;
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M059)2I*@0!\9\<UXN^N)=PZBZ2AVD36+.Y<Y,-Z2%-%F:IMIS>D $K]BTCG
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M))DR@IMQUMR/Z-TOMEI(6X5-A.0 D@[O&",'FMMKJ!IMY1#,\N 2(L8E+#A
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MO9+-R4A<P-Y;+Y3@)W%)!/"0//@8K7FZ)L$R5,DRH16[*>8D/'ON %;']TH
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MBH;VQW-P2 /</JXQ4]$Z;S+;"TTJU7_L7:S0'+9ZI40*;D1U 82IO?P4E*%
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M.4F1!"V0XW#2EWO=O8>%)+I62/D$#XJXZ L$JP6EYB>W9V7G7=Y9M,,1F$#
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MYVT(E/0W+F$KVM.- Y*O9MVE0*>%Y\''-2'6"]S;'H_=;'C'E3)<> F2 #V
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M ^^XYZ?U&U)_;#I2I+1(2<%0QDGY54O:KH_?NCPN+3T]N3(M2U)><"4O[MA
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M@<\D3477&K'KBU994"UP+PH2Y.]Y7<0IAE#91[&W5;5J+HR-YPE).#D"H_\
MVKWDZ:EW!,*WEYG3T.]I1A>TEUQ27$9W?9/'SGSFMA[J5J95NOEWB6*(NSP4
MW!"777DH*'(H7C("RM>\MJRD(24Y'*AS4;>NH6KG$F&P;1%E&59W$/,H=<26
M9;A!00<'(*,%7&4JX"3R+]U>O5UT[TUN]TM#S#5QCM(PXMLK"=RTI) SY&XD
M9R..0:K\SJ)=83MRE.1H+MMM%TCVF:D!2'G%N!L*=;RH@)"G1A*LD@$Y'BK'
MU4NUVL]@M[]B=8;D.W2'&67FRL%#CR4D<$8SD G[$XP2".;637-RTC>+\J:P
MW+L+NI9T92C(6J0VM,8/ ("O;L]A&-WE7&,<W[IKJZ^:GV/W:RM0(4J(B9%>
M3(2HJW'E&W<20 4G?P#GP*@-4=0[UI[56J&51H\R%#%NC0HS>0M3TDK *E?R
M.1]DIQC)-$:_UJY<[+:TZ6@,7*?ZL%,R6II)2SVE!8"4K*0I+F-IR<_@<QL7
MJOJJ8S;78^G;.E-RCS7H_<GNC9Z5S:[O_:^1C:!\^2/%8974M<0W?5$"S=V0
MY8;7/2PN<O:0\ZI&PIQM2H;CR!S@>.:EY?4V^QT383UE@-WF+<?1*;:?<D)6
M/3A\%M"4!QPX(2<)P/J. *@[MU#N5]TSJ:8_!CJL[.GH5Q$1J8ME[+V]2L.I
M&>-I'&/I'W.+=/ZD/PI,]V/:VW[';+E'M,I[U*C(2MSMCN);V'<E)<2,9R>?
M&.<>B.IEPOU_M\&XV-B%&N"IS<9YJ87E*7%<"5[DE"<).>#G.0> ,58=6:KF
M6R]Q[-9+4W<KH[#>GEMZ28Z TV4IQNV*RHJ4 !C'DDCYH4&\2NH^O[8&'Y,7
M3RK(Q=64QY[D=Y#BG5#<4H&U9!04%))2!DYR<5;^H^NW](3;=';MS#C<M*SZ
MJ;),:.%I*0&NX$*"5J"B1OVI]OFHQ75;TK27;C:0TRBZ3K=(<;D[NV(S:W"X
M!M&[*6U<<8-1^J]8:AFZ;@36;-)MI7<;8_#5'GH6F<RZ\G+2E #:HI.%)Y3R
M/<15^T/J->I;9*?D0C!EQ)CT&1'[O="7&U8.U>!N!X.<#S5AI2E*4I2E*4I2
ME*4I2E*^*4$^3BA .,U\PD#XP#46N_14ZI9L*D/B8[$7-0O9^V4)6E!&[_-E
M:>/L:DRVVIKME*2V1C:1QBO02E.2!C[T4E*MI4 <'(S\&L<AAF0V42&FW6_E
M*TA0_P!#6A=[W;;*PXJ;(;::9""]CGLH62E*U@?2C(/N/ P?L:W418W[2DLM
M?MY+9"1[<^<?:O/Z?#VI'I6,)7W .V.%?YOY_-8VF;<)1C--Q/4, /%I(3N;
M"\@*QY&=BAGYVG[5GE18\MDLRV&GVB02AQ(4DD<C@UHR7X#%\@QG(I,U]I99
M=3'*@A",9!6!A/U\ D9YQ6W<&H;L?_TBAA;"2%?O@%(/P>>*P/V2U2%K6_;8
M3JUD*4I;"5%1'@G(YQDX_FH*\Z#M%UOMHN+K+2&K>MY?HQ':++ZG4A*E+!3D
MGVIYS\5/_I%M]2J1Z"+ZA3794[VD[BW_ )"<9V\#CQQ4->]&P+C:6;5$<<M-
MK[A5(B6]"&FY2",*;7[<A)^=N#^:EYUDM4]XNSK9"DNEOM%;S"5DHSG;DCQD
MGBL#FG+#VY'<L]M[;S:6WMT9&%H2/:E7'(  P#XQ6BQ#THY=)%L9@6OUD**E
M#K0BI';8<*L(SMQM)W^T<>>.:SV-.G#=Y[-ECP&[C;TMQ)/88"%M(VA2&R0!
M[=N, <"IAV+'>?:>=8:6\SGMN*2"I&1@X/QFM0V*TER Y^F0M\ $1%=A.8X(
MP0WQ[>..,5%/Z3TC;84B0[8K/'C-1W4NK](@!+)RIP'CZ3R2*SN7#3D'1B)+
MKT)G3(B("5+P&/3J2$I&#_A((&/SBL7]A=**CN,_V>M19=9;86CTR<*;1RA)
MX\#XK['MVE[7J[NL1;;&U'<6E'>E"4OO-HQNY\D#*<_T^U25^L=KU!!]'>H$
M>=&W!8;?0% *'@C['\BH'4-FT3:=.-Q;["M$2SH>"D)?2E">\?!!\[S]QR>:
M^L:?T7J>.])C0;5<&5L)@.K:PH=M)"@TK'@#VG:?%1^J>E]FO"&!!8AV\B5'
MD2?]U#HE)924H;4"H>T X_BI]S1>F'8\1AW3UI<9B)4B.AR(VH-!7U!((XS\
M_>O2-(:=:0H1K%:F%;TNI4B&V-KB00A>,?4G<<'XR:T+9HQIJPW6!=I[UUDW
M0$2YC[+6YSV!"?9MV82$C VD9Y.<FK!#ML2+:&;6VRDP6F!'2TH;@6PG:$G/
MD8XJ#_L?I)$=NS_I-N2V7!+3%V@%2D8 <QY.W( /QP/M6U=+CINZ195JN<RW
M2&%OIM[T=UU)!>4 4M$$_6000/-:TK0.EI<-B+*LD1YEEU3Z XDJ.]0PI1).
M59  .2<@ ?%?4Z"TLA<)2+)$0(;:6F4I!"0A)W)"D@X4 22-P."2:UI6E-%Q
M)KC4RW6M$B[J<:[+Y![Y5[W$H0HXR=H4=HYV@GP*\S>F^EG+,B!%L=O:2PI;
ML;+60VZI."H\Y5G"003R !6A:^ENGUZ:M%MU+;X=UD0(2(/?[:FPXVC.,IW'
M[D^3@DD8J6<Z>Z27,FRU6&%WYC:FWU!) 6E0VJX!P"0,$CDCS6"%I#1EW@/&
M)#ASHCJ&XKBD/J=20PK"$YW'E"@<?(.?N:FM2Q+(_IV1!U"(J;,X@,NIDN!#
M>W@ ;B1CG&.<YQ43;]*Z0>O*I4&)#=N$#M,.['BLMJ;2.WW$[L%:4XP5 J Q
M@U.7^QV[4%N,"\1DR8I6ES85*20I)"DJ!20001Y!J"_V<Z7]0A\VY:EHGJN@
MW2GE R5 )+A!7@Y  QXQ\5ET5I72M@7,>TI#BLEQ9:>4R\IP)*226QE1V $G
MVC S\4O6B=,:AFW%^XP$2),MA,67AY:0M*?<C<E*@-R<Y2K&X?!%>;7T]TU:
MYUOF0("V9,$/=EP272<N@!Q2LJ]ZB$I&59/ ^PQK,=,M+QVH3;,.4D0VI#+)
M]<^2E#^>Z/K_ ,143GSG!^*QJZ6:35%>C&WO=EV&U 4D3'Q^RTH*;3]?&TI!
M!\^?@UYN/3?1URN3ZID13EP>=]6X?6O!Q1*0V3PO(24@)(\$ 9S@5Y_V3:1$
M(Q$P9*&%1$P5I1.?3W&4J)2A>%^[&2!G) ./&*WG.GFGG;VFYN1WR[O:><:]
M2YV7G6@ VZXC.%K3@>X_89S@4M.@M/V25:Y49$E+MN6^J,IV6XH)4^?W>"K!
MW'GGY\5NZITC;=2/19$Q4IB9&"T-28CRFG A8PM!(\I4 ,C\<8->+3HRTVG4
M"+O!2^T^W!;MK;0=/:;81]*0CQQ]_P FO&K=$VO53R%W1R:$=OM.M,R%-MOM
M[MVQ:1P1D _!_-13O2O3;MX<N+R9R]TI<P13+<].EU:2EPAL';[@3D?.3\$B
MM>/TEL3-M1":G7HMM/LNLK7-4XIE+*RMMI!5G:V%<X^<#G@5:=+:;B:;1<DP
MWI#QGS')SRGRDGN+QNQ@#C@><U-TI2E*4I2E*4I2E*4I2E<SZUV>?=D6 -1[
ME+M+<EP3V+>TT\YA2,(66G4J0M*3GC&1D$<BN;7#2,^/!N[PMFI53(T>U"WN
M.+=6\ AP!["F@$]P-8"MOC"@">2?5YAPK7?H,"Z6^]-V5.II!CL-LR,O1E0L
MG8E)W.)[B23@'C\'!W8UGU/%MC<6VL7DS_T2Z,6UUQE:5,MK?0J.VMXC"'"V
MV<9((.T$@XK/(T^;M;=23+,FY66T1X<:7$%Q+L?9<6-ZE$)60=FP)0L_23D@
MDC(]7JQ72X.Z8D79B[*-SC7.?<(T14@--+<:0IEH]LC!3[0,XR4G[XJN,0=4
M1K4RU;&M3B5*T]#D7,J0^IQQ]$E)>2@K( <[6X! (RGC[5O1;$B2FV19J=;/
M6A\7!:4OHD1P<--J0GMM\H3O[FQ*_.#C@@&<TBAN,U?)^H(5S;DS=*1%/R9C
M+P0KML+2^E:E8"5;@/:2#\CR:D[A&U.UT"TVTP)OZ@TS"-P;8;*I'IP!W$I0
M,**@G&4@@G!&:I,^TW$1$1FY^L'+:JUW5Z.7$R8I#B=BV$;$G(PH.[0KW$)Q
M].!6);%^:D7:?'8OR9]QM5G=EOM,OE:FAD2]HX"EC(]@(5RK:1S4S9X:[CJ7
M25K.H-4JML@37TNEQ^*IQ.6EL@@DJ"-P="2LA1"3\8)MO5J9<(VK;2U!D71E
MERS73N&(7=H<#0+1(3P% A92<9R/XKE\WUCVGV8USFWR9%<LEFN\P/29*U(?
M$E"7U YRG#9)*1]@K&1D7&U7:[2M3P6XDN\LW9J^);$-];W9=M!;X<V+X.4I
M!*U>\.$@GG%2W4^YOQ]<MQKM-U#;K6JWI7;'[.EU6^8'?>A:49"U%.P)2L%.
M"KY-0RKW>%:E;=,Z[Q[]^OKBR[>MQ78;MFU6'4M_0$A 2KN8SNR"3P*J=NN=
M]>M,9]S5FHE.2=,2Y[G^\XVRF'"&P/;E.0%9'E6.<UN2M67B5=9[T/4UP_6F
MXUFDVVU-/)+<QQU"2^GMXRI.%9.,;<Y/@5J7F\ZANNE-5)N&HIYNR(<UJ=9&
MHK@+"DKRD[Q[4HV8'M&%I5SGDUOZYO:Y]FUNS'OLB;:8T*RR(A+P]K9> =5P
M,J!'N)(/D?BIQ>KI(U'=6&=0NJTZ;O 87.2\C?&C.PRM.%8]H4Z$I*CSR?GF
MM!6J+Z\A41[5,R)&9MEVD1I*"UW)C4=Y CO'<C.5)WY(P%!)(QR3T74-QO%P
MZ.0[]9)[J;HW!CW-182D>I"4I<<;P0<;AN&!\X'C(-!3J+4\YN_%R;=;;%CQ
MI.H8CSO;),1;)2PTH%) ]Z5+VE)P!@G[UC6-P%PT]=YDN]*[KNC+>XTPIY(;
M?6I:^Z4C&3@I' ^3S\8[)TON\J5?=7VJ1>G+LQ;WXZXS[A:*PAYA+F/VP!MW
M%6./'&3BN1:?E..Q=+-HU2]&N:7[ZI^0IUI;[*DJSM]R2 2 %'<"<*., C$W
MI[7U]O5ZT^W-U+#M;CD:VO(9<4D"Y!T)[VU :))*][?M6G84YQYJ\:SE,6OK
M#I:X7]Q#-C$"2Q'D/'#+4Q2D>5>$J+84 58^0*U[[J&VN:@@1;!>46NSW>3(
M7/O$1:=KDIMIL(;0XL*;!*1DD#GMD>=U<VG]0=6RM/.SW]2*MTF+IMB[B.TT
MRGO/>H6V"K<G(2M/;44C'U # X,C=M8WB#/NT!G6RU0VKS:FS<%&.HML26E%
MS!V[0D* 4., #YY!C-5:^O\ !LLIB/JF0IR$9ZX,IP(;]>VTXE+:^X$'NJ![
MB=B$A) *BH8&9QO7%RDWXSV]8!=O1J&' ;CMKC]I4=]E"U[CM!.T[MJL_P"%
M7DU=.GS^I']62+/>KA,?&GEO)D2%A*4SP]M5&) 2![6]^<?XL5#W/4$RS/=2
M;XE03/CW&);D/K;"O1Q"AK]P?=*2ZZO'C/G-5FU7I5MO=W-IU S<R_K"W1ER
M7NPZ7FEL(23E*0G/"@%)P<H/YSLG6FJHMMCRY.J&EQ9]\DVHR7F&66H26G'0
MD]U+:P"O:@ J2H8'YW5(V375WD7+T-WUA:H;\.+$=8>::2MF[[GUH=4G<@*.
M0@( ;Q[E9&00*C;+-?N4K2RY]Y>DS1K&:UM=4VI<<!$I*1@)!&0$X!R!QC P
M*NO3^\:FG:LEV&\SGG7K$[(]>^8[:6Y:'"E47;M2-OL*B<'.4\^>-/4NN;U'
MNNHI$"4RD6.YPX3=H4VD*FMOAH%16<J!RM924X [9R#S5EZ73[W=XUVN5WNC
M4J*J;(C18Z8R6RP&9#K>2H$[MP2GSXQ^:H%OOVHE+L]LM%UA6X2IU[1(6U;V
ML)].Z=AV@@!1SR<<YR>>3#W_ %M+U=H:4+U<XMN]-;K9-7%4V@":75(6XX-V
M2$@X2-I&"#G.0!8)VI;XS<KJS9YEMM[\C5R+3W?0I7N;<BH4E:@%#>H'G)/.
M / Q4:GJ9K"(]>;C*>LKT2W&;$5;U.AI]QV.TLA:6L%0W%&X@J("5<>.9"X:
MDOS_ /9]+>L($AN==(/[D%I*%H:>9=40X#E.W>V=J<DD#W9K[;K[<-)V^XWM
MEYH:=B:JGMW5H,[U!EQS:EQ)'(VK(R!Y!_%3S+UT@ZWT',G)8:NM\CR6+HVP
MWM2M*&NZWN\Y+9]H5_VCX!Q6IK_7EZM5SU6];7HK,?2[<1U4-YK<JX![E7NS
ME &0E)&?<#G(XJQ=.KWJ._7>_NW1^W"U0+A(@,M-1EH=7M*"E945D8 44D <
MD9S\55)74342V8DV,J F/<9UPMR(G8)=B*80Z4+4HJ&XY:RI.,84,?FGP;UJ
M"-&L^HH-T@/7=C1*I\A^5'+AD(0ZA0;4=X]WD%1)Y*O;D\7-GJ+J.YWB4NU,
MVEJ!#F-0WFI2]JL.-)4'/K"R2M8"4[,*2#[L^-.%U!UC$TWIC4VH'[$W9;PD
MAST\-TJBE3*E-*42YSEP $ ?( /-:R^H5SU%IB,]<[3 6_$N-OASH;T=?[,T
MS"E02=_^%*6U#SRM.>.*W+WU6O=BN5Q:N4>$VE"UMQ65,JVJ29+;*'DO]P-N
M( 62M)[:DJ(3XRH7[3UYO\C3%YD7=BW-W6&X\EE++@*%)"=S9<"5KV$@C*=Q
M^X\BN:N=4]9(L2[@J-IX[=/M:@&$/<H)VK;P5 Y)Y!\)\>[.:EW>I%SDZO9M
M#\6 Y9YTEVW'M(<*FE"/W<J=.$J5Y!;">!C*@>*K'3+J5.MW2IN4B/'7$M4>
M);DQW<B0N0ZI"4NJ4I02&<+!&<9P>0.3V'I]=K_=;;+.JK6U;IS$@MH2VXA0
M=;P"E92E:]AY^DJ/C.>:M-*4I2E*4I2E*4I2E*4I6-V0RRMM#KK:%N'"$J4
M5'[#[UJKN]M2N,A5PAA<DD,)+R<ND>0GGG'XK3EPK'?+K%=>]-*GVETK:VN9
M5'61@G /!QQS4K*DL1&2[*>:8:'!6XL)2/ZFN?=2[Q9I%TM6GI>GAJ.6K%R3
M$#C:=B4':%@+4 M65'"?D!7];I>[W;+''8>N\MB(V^\B.T73C<XLX2D?U/\
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M.8Y8M.2F-4.Q+M%T]=Y+L@EIUY+B'FU]M04DX'MW'(*B-W(\BSV#7^H[WKN
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M"5*20,X^,XR/D9%56VW*_P O2+6GF]/7&VWM$$Q5R5[!&CK#12'$. G>-P&
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M)2@96K"02$I!!*CP/DU,MNMNLI>;6E32DA25@\$'YJMQ=?:8E19DAF\1U,Q
ME3IY!PI12DI!&5!2@0"G.3P,UY?ZA:38AQI3U^@H:D]P-;G,*4IO&].WSN&1
ME)&><8KRCJ+I!;4EU.HK86HS:777/4)VI2KA)SX.3QQ\UGCZZTO)M;UQCWV
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MD]E+L=+* GVX6KV[B<#S\XS70]&7&[7.TN/WVWM09*9#K:$M*44N-I40E8W
M$9'W'.,C@BJ1<="WR5>9T;_T>NSR;^Q?4S%.J#[6Q*-S01M(Y[82%;A[5'CX
MJR]+M/RM.Z6;AW2+#8G]]]QQ49>\+"WEN#*BD$D;\57=<:-O]ZO>KW8*+?Z>
M[V%%JCK?D+24+"UE16 @X&'58QGE(\9XZ#8&9,>Q6]B<AI$MN.VAU+2MR H)
M .#@9&?P*Y OIYJUM1BHCV"9;H[]T<:3*DN_[PF7O(2M 1[0"K! 5SDG(P,Z
M1Z5ZC#,22MBVSFH[LAM%IGSW7-L=Q#20/4A 42DM< I^A6W/'.[$Z>ZIMKL:
MVL1[1(MS5^BWI,I#Y8[:4(;0IE+6Q7"0DA)W?2 #72.I%MN5VT7/@V5J*[/<
M[>Q$H#8<.)4?(4 K )22"-V,BOS_ *C@7K2=WMZ)K=N@3)5QN5P97,NH6DMO
M,H;4@N.H"=PR,$G)P?C.96#I+4-U@66;I^RENU-"V%AMZ>VA2D17>2Z0C+IX
M)2K.S8K*4Y.*L,#0U\1<].N3K*PY'MUVN\I:0ZTM/:D!9:(22.=RQQ\;<\5I
MZ6T)JJWC2S2K:J*]%9B,3G526G8SC3*UDI6WRK>-YV*1]^2!FNE](K9<K)H.
MVVF]0TQ9<%)8.UQ*PZ ?K&W@ _ \@>?M5(U+HZ^SM1W!"+.F3;7M3V^[EY;S
M6UQAMIM#B=A.<C8<@^<C&>:K+?3;4#4U;T_37ZI;7W9\<VQ-U](&6WI =2[E
M"L%)3A*D>?8.#7>7+.W)THJS/ -M.0O2+"%*4$@HV'!/)_D\U3- M:JT]IRU
MZ6>L*5J@($9-T,IOTRVTG 7MSW-Q3_AVXSQD#FJ0YT_U Y9HD)RR8E6F'=&%
MR4.,8NJGT*2WC*@1E2MRNX!@IX)\UI7/II<U0+H8&C6&Y7Z1:H\8)5'22^VZ
M%2"#OX5M(&[("MO^+Y\6G3\B_P!_U&[8[$A-RB:O7+-S6IM 2AMM.Y@J22OW
M$X( V_N$YX-:D;0>I56I425HY\I<5:5+;+D/MI].^X74 !SZ=B\ G<I0Y4<D
MU)W2R2;$V]Z)F-:M2M:F=DZ?B+4V.]&>V-+2VA*C[-JBM0P,8R17>-/VF+8K
M'!M=O;#<6(REEM('P!C)_)\D_)-<<&E[M$E"8YIIUR!$U%*GR(*4L'UD9Q*T
MM+0E*B%%O(5L5@_;FOFCNGRT:MLRK[II;EMCQYKL?OEMQ$#N2P['9X5DE"4K
M.1N +@&>!5^ZOVRZW/1X;L<837F)<>2] *@GUC*%A2V<GCW >#P<8^:YU<-.
MR5R&Y;VA)O\ 9Z5#F,-6A#B'78TAU84'U(*MK94 0-BCL&/&2!"R.GMV#K[E
M]L$BZ3VF[$A,QL)4I2F5#U2D'=G.P;<\$XK!)T[%@ZFLUKONG9(M*M279R/!
M0R5!R,N/E';0D\IR,[1X .17EO05]8E6R+>K!>)L,L,?I@@O,I-O6E]U8;==
M4%*;VI6DE:/.W;[L#%GM>ES&O%KC'23K!BZJFR'9"(B0TN*XE_804DY3A;(P
M0,8Q_A.([0VE)%OFZ"@2--RXR8TF[-70B(KLK2ZE24*6H#:4D%"03\# XQ6=
MS0^I(FD;G#](\X+*Y^GP41E)[\R$J2E]Y22H$;E-=M&#G);7GZL5TCH_:F;3
MIF0W%B7F)&?EN/MM75MIIT;@,[6FP VC<#A.!\GYJ\TI2E*4I2E*4I2E*4I2
ME5+7>K)>FYEBB6^T?JDF[2'(S:/4I8"5);4YR5 CD)/_ .7Q5;:ZM)5IZ?<W
M;(ZT[!M[DQ^,9 )2MM]3+K6X#&4E&<_((XI>>J[UMD7E0TQ+D6ZU2&X\B4B6
MRG"G.R6SL)!P0\#GQ[3G\>XO5)Y^Y(L2].OL:K5)6Q^FNR4;-J6@Z7 \!M(V
M*3P!G)QXYKS$ZP6^9(LK;%N>;3<4)5F6^AA25=U32T("CAQ2%(5N"3G&, YK
M09ZX0WHDR:G3UV%O;C-RF9*FR&UI6ZEL;U;=J/J"N"H;0?D8KH^D;V-1:?C7
M1#*64O[\(2\EX8"BG(6DE*@<9!'P15/U<N\P]>Z5@L:BN34.\ORT/-MLL8:2
MB.I:$H);)'(\G)/]*B;5K>1IS65YM-]=N%RB?J4."BX.=M*&5NQ4*"2@8/N6
M%'A.!N'/VM.ANH,76$]3,*V7!F,N,)<>6ZV.TZC<$XW#(2OD':><'/W IL_4
M5W<UWK"TN7W4,1,65$9@>AMS3[3??;1RXHLD!(6<G<M/&<&K@WU!8.JY6GG+
M5.;GQG<N%90$"-M*O5;MW]WGV_?)QCSB6?UA:$6J!<6WUNQ+@VVN&XEM02^7
M%)2V@$@84HK2 %8^2< '$&KJ5%86VU<+'>H4E<>9([+[3:3B+CN '?@YW I4
M#M(^:KUUZIIDV^_2&&+I!M4.W0+@B?%;8<=2)!W#V+4001@?3QA?/TU;5]0+
M<W=[C;78DY$N#+8B.(*$$J[J2M+B0%9* A*E$^< \9!%?-$=0[/K*<]&M2)2
M2B.B4AQP(*'6U$@$%*E;3P,I7M4,CBL,OJ99(-_>M=Q:G0RV))$AYH!MSL(W
MN;1G>0$Y(5MVG!P2>*TI'5NR18LE^5 N[(CHBN+08X4K9).&E#:HYS]O(\8S
MQ7MOJWIS]7B6V5ZJ'*>VH<1)2E"HSJD;PTZC=N2=OE0!0/&[-:\/K3I"6TX6
MI;G=_:[+)"=S_=SLVX5@9QX44D?(&14YJ/6K5KT!(U/&MTQ]"$C;%<;+3FXK
M"!N!&0,G['CFJ[:.HY8UO>[1?$RA&$^)$AJ3#4$L*>82L(>6,@$K44C\_@UL
MWCJY9(5FN4V+&G27(D5$Q+*F5-]YI;O:2M*B/I*OZX.<5.ZTUBUI>T6R:[;Y
M<E4^9'AH9;3[TEU0'(^X&>/D@#YS57TCU*BO2KC U6\&I+=PGLLO"*M$<M1L
MDC><C>$)*R,_?^*MFC];V75;\UBT/.EZ(EMQQMUI3:MCB=R%@$>",_D8Y K0
M1U-TR7Y25S'6V&&EO"2N.L,NH0XEM1;7C"_>H)X\GQFOB>I=B)CH6)S<AV:W
M;UQW(JDNQWG,%L.I/* H'()X(!YR,5XNW5+2]H0I=PEOM)2\\THB,XK:&EE"
MW#@'V!8*=WR00,X-9(G4[3$N\BVLS'B[ZE4,NJBNH9#R4;]G<*0G)2"1SR!D
M<8S@1U7TLJ#)EJD3$,,.1T95">*EI?\ [E:4A)44JP<''Q^1GXKJ?:')MB9B
M1YSJ+F_(8<6J.MLQ"RG*^XDC<D@E/D  $J)P.9O2.K[;JMM]RU)F=EI*' X_
M&6TEU"\[5(*@-P(2?'CYP>*A3U6TRF)<)+KLQMF&P91*HJ\NM!WL[T #)&_C
MX\Y\<UM(ZC6-QB2IL3U269@@^C,-Q,AQTH"QM;("B"CW9\8!-:V@M9.3^F:M
M3ZB5VTL^J<?4B.I&UMIUQ.0CE7TH_GS175;2B$1'')LAMN1M(4N&\D-I4O8E
M3F4^Q*E9PI6 <'FL%[ZMZ<MMNN$I@S)GI%;0&HCNQ[#H9)0YMVJ <4$D@GGC
M[5AU/U*TVN%=8D2Z16KG ]SGKX#ZVF%)4C.\!(.?>,8.<\_!J?N.O=.VZX/P
M7YB^^SO"NW'<6C>A!<4T%I24ES8"K8#NQ\5%V7J!!NSMJFB=&@V^5:%W1R++
M9<0^AL*2.YO.$! R0?OP4DCFI(]0]+)@.S';J&6&G&VG.\PXVI"G!EO*5)"@
M%#PK&#\&OB^HNE4VUN?^K(,9?<.4LN*4@-J"7%+0$[D)22 2H #(SY%2]\U%
M:K$TRNZ2PR'@HMI"%+4L)3N40E()( Y)Q@#S6C_;?39E1V$W>.M<CL]M2,J1
MET9:!6!M25C&T$@G(QYK7;ZAZ5=EOQ&;RP[*9#Q4TVE2E99R7$@ <J2 3M'.
M.<8K6@=3=,2+-;;C)G*@HGQTR4-R6E)4VVI02%.8!" 5$ *)VD^":\0]?6N*
M_<TWZ\VIM+=S<@Q@QW,Y2VE?;7N'+@R<[>/ '/%2:]<Z91"A2UWF((TQ <9=
MW':4%6W<3CVC=[<JP,\>:K=WU=9M/ZOM-ETZQ;/5W.Y^GN*66BA:5%I3F\E(
MPI7 SDDC<*L=WU(U:=2*CW"?:8UM:MZYKW>?*7T .)3OVXQV^<9)SG@5ELEX
MTSJ><[+LTNV7.7;B65/L%#BV-PR0%#D X^.#@_:J?<^KMH;N5L$5]ANVJN4B
MWSI$P+:+1:;6K*!CG*D;>><D8%6%.M+>N\!:+M9#8S:_U'O>K_>V[\;]F,=K
M'^+.=W&*DV=4VN9IJ;?+2^+C#C-..'T_*E%"22@ _P"+C&#\U6M%:]DWUB//
MG1;:W8I$%<W]2BS2XU'*2C++Q4A(2L!9/G_"KCC-6$ZUTRFV&XJOMM$$.E@O
M&0D)#@Y*<Y\@<X^W/BHNY=0K.F9<H%KGVY^XP6XSS@DR@PR4/+ &',$$[>0
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MX&3@A2"4D$8((/@U4T]2V%WEIA%LD?I;]R<L[-P*QM5+0#["GR$E25("ON/
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M.[I;Q*U,#]HDE>24\?S@9S6A<='6W3SESOFEV;;;K[*)(?GN.*C!2E N'9N
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MN'=;;>87[N0@+[AQR$\GQSJVF0F7J#2VV$U"=CZNN<9Y##JU)6L,/%:\J/\
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M8B-Y#B,[%\I^I))P?C-?-):=_L_'E]ZXS+G,ENAY^7+V;UD)2@#"$I 2 D8
M'W/S6W>;#:+V6#>;7!G^G5O9]4PEWMJ^Z=P.#P/%?8UCM4:[/W6/;8;5S?3L
M=EH82'7$\<*6!DC@>3\"HS5$/2OJH[FI(=J<DSR+<TJ6PA:W]QR&1D9()&=O
MCC-'-"Z4<:6VK3EHV+4A2@(;8R4I*4G@>0"0#\ D5.MPHK4%,)N,RB&EOM!A
M* $!&,;=OC&.,5%,:0TY'M,BUL6&UMVV0H*>BHB-AIPC&"I.,'&!Y^U>AI6P
M#T6++;AZ(J5%Q&0.P5?44<>W/SCS5)U?T@MM[G0G+<;;;X,:,8R82[4T^T@%
MPK*VP<;%$DY/(/''WL5MZ<:4@MPB;)!D2HB& B6^PE;Q4T@)0LJ(SN  Y_C[
M"MV#HK3-O<9<@V*W1ULAQ+9;CI3M#F=X\>%9.1XK$QH/2L>"N$S8;<B*MY+Z
MF@R-I6GZ3C_L_'V^*T;UHS0D"(_<+Q:;-$BI<4Z\_(2AIL*<4G)43@>Y03G/
MDXJS76U6^]6IVWW.*Q+@/)"5LN)"D*'D<?@@$'XP*A(?3W2,-]I^'I^W,/-+
M+B'&F0E25%.TG(^2./\ 7[U&WOI[T_C6U+]WLEHCP(3:DAQX!MMIM2B2DG(
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ML1;-.;0@0XBBHIF=EQ@!25*Y#A21D*)!Y(SD'[5HSQI=F]-V2;"A>OO"5O\
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MC7*?!NIFW":5[26TLJ8;" 4Y)#9;R..4'[@U%6CISJB):K#!F0[9(3:;9<X
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M3Q'HA;[I0W$4VGO%">1M*PO?]\C/Q55N-FU.J->BU8]1-F;"?0ZTRRX%*?\
M5H6DJ<"B7EA 7A>$C!"0,589EKN-OOMQ3#LU^G:09N\:2]!#+ZEO,JB%)*$N
M'+@#N"I(.<XR.*\S+#=S?(#;K>MVK=Z=A=G2P4.N,J2XI2T2'%Y[:OH.2<;/
M;R4XKO&HTSEZ>N:;.4)N1C."*5_2'=IV9_&<5^=IK%^7I.XNVEK5,9?]G&FY
MX+<L/.70.IY1GW*40%[E)RD@C)Q7Z&TQ;HUJL<:+",LL %Q/JW%N.^\E1W*6
M2K.5'R<CQ7)+M&U [JR0REJ\)U +^T]&D,AWTBK6=NY)5_=X"$J"DJ]Q7@CR
M*IUDT^?T_2EMFV_4$-V"N]IDI;;E(*EJ]S8#B,82I(21@X41CGFM[3Z]17";
M957U6LF7_26XP%1&5X6I"$ID)>4K"4$N!945@;DX\X&>A]![8IG3TNYR9%Y=
MFR93[:DW%]]6UM+[A;*4.\C*%).?)^^<U&];%W87^U-&5?(E@?B/-]^SL.NN
MHE[DE!4&U _2%;3R K.0157-PO*=4VIFZKU&Q?3J9IA2E!UMAVW%OVIR@]DY
MVY4!D[MV*T&;K>VK2S$=?U,F=&T_=H\M21*&):' IDE9'*AD[5 Y]R02<XKQ
M*>F1IUVGJ3J%,VXV6S;9+"I*3P0E]2E!*L 9]W!6,JVX))K#"=DSKC8_[47+
M4$6!$N%XBBX,IDLJ2VH,J92'%9<"5;58RK=QC->G9VKXS)G.FX'4 TK$3(=0
MP5/AKUZBX<#!+@94DG!!YSP>1U[HJXX[IV<Y^M7&\Q%S%+CR9L9YG""E/L;[
MRU.*0DY&Y1\Y&3BN@TI2E*4I2E*4I2E*4I2E5S66KH>E&X!EP[C->G.J888@
M,=YQ:TMJ60$Y'P@__HYJJR>M>D8\V7%=7,+D9IYU6UM*B2R"74[ K>DIP>5)
M2#@X)Q6V.K>GQ)4R]$O;';>9:=6];W$):[V TI9/TI42 /G\5\_VQ:.%UF05
MW'88S3SI=P"AP-$AP) )5D$' *1N_P .X5&PNIHA:@U0K4#4UFTQ)$&/&08N
MU;!?;)RYSPDJQ[B>,@<5>F[['N-KO#T!QY @K>CJ>[)5^XV/<4#_ !X.1Q\I
M(JF,=5[%9K1 1>YTZ9*-MCW!^4U;5I1VG> ZH)R$ GXSQ5PU1JJW:;BQGIXE
M.&25!IJ,PIUQ82@K4=H^ D$FJ7K?J9'1;;>-*OO.RI#]O47O2*6PAJ0Z@!+B
M_""I!)&>?'W%9[OU 2]K2RVNSR%I@O&<W)?5$6I*U,,DGMK\*V+&" #D\?>L
M%NZB)?L*8YENNS%6)5T_6$V]?IQPK"^V,G P3C\8\FI[_:!9;:FWQKG.<=?6
MU'+\IJ*L,-*='[9<5R&MY\!1J3M>LK-<[GZ"&])5([KK&51'4([C>=Z=Y2$Y
M&"<9Y )%:]RUQ:K9J&?:[@)$=,&$F<_*6ROLA!*@ %8P3[3_ ">!D\5(Z?U)
M;+^J6BW.N%^(L-R&'V5LNM$C(W(6 H9'(..:ASU)TFEN4XY=@VS&;#JW7&'$
M-ELN=O>E12 M._C<DD?FL\/7^FICT1J/<=[DJ6N"TGL. E]*0HH.4^T[3D9Q
MD<C-2,;4MHD:?7?$34)M* LJDN@MI 0HI4?<!QD$9^?C-5FX=0]+VYB-<(R5
MNKEW!NVN%N&M#J'%@*_<24A0PDA6".>,9S6/0O4NVWQ<R%=9<*)=XTB8E3""
MH)#+#JD;MRN,[0%$9!P<X J5/4?2"89E.7^$VP'0R5.+V864E0&#SRD$@^"/
M%2=VU78;1;HL^ZW:%#ARD[V'7WDH2Z-N[VY//'/%15WU[9FK?=A:+C!F72'!
M>F(C%W 7VTY(R/L2 <<C/-8-,ZV1<4+DW*39HD-%LB3G4B6>]'4\G<0ZE0 "
M3D;3G)^W(K5U-U*MD3]&CV*;;9DN[ON1XZW7]K2%(2HG>4@GZ@$8QY5^*G4:
MM@Q[U;;'=G$1;[+A*F&,E6]* G 4-_&>2K!QSM/BM^Q:AM&H&7G;)<8L]ME6
MQQ4=P+"3YP<?BL#6K+ \_$99O$%UV6\N.PE#R5%QU RM P?J&1D56[)U+M=Q
MUI<;.[,MK,1*(OZ=(]4"9RW>YN"0<<I*-N!GG^<5,6_5L1,*Z3+W/LT.+$G.
M1$.MSDK3A(& LG&UPYY1R1Q49:>H]IF:PNEFDRK='89$/T$DRTGUQD-J6-@X
M' 2,8*LY!^<5,ZFU=:]/S[=;YC[8N-R[B8;*UA <4A!5@J^ 3A(\G*A@&HS0
M'4&TZITI'NCLZW1Y0B)E38R9*28B3D^_." ,>2!6^Q)TG=XZ]2,"T3DPPI1G
MH0VZIG8,GW@$@@<XJ)M&K-172);;O%T['58+@XR&CZM7JVV7% !Y;8;*<;5!
M6T*R!R3YQ/JU;IY+T]I5YMX<@(+DH&0D=E()!*N> ""#]C6NSKK2CZVT,ZCM
M#BW'A&0E$QLE3I\('/)_%>6KKI&5JL=J;97=1H:4UE+C2I*6TD[DY^H '.1_
M/YK;CZMT[)BN28]]M;L9M[TRG42VR@._Y,YQN_'FMB'J"SS?2^DNUO?,M!<C
MAN0A7>2,Y4C!]P&#DC[5G7=+>B$U,7.BIB.D!M\O)#:R>!A6<'/Q6"-?[-*?
MCL1KM;WGI"2IEMN2A2G0,Y*0#D@8/C[&M"]3=*WRS3(MVGVF7;0M+<E+DE!;
M2O<"E*CG@[@, _(J5,UA,:5Z);4AR(G"F6W 2E6W<$G[$@CS]P:B=&:MMVI]
M+PKPP_&:#T9$EYD2$K,?<G<4K(\8^<X\5.0Y4:=&;DPWV9$=P90ZTL+2H?@C
M@UA;NUN<;4XW/B*0E?:4I+R2 O\ RDY\_BM.3J:TMS8T%$^*Y.E,+D1F4NI_
M>0G )!SC&2.?Y^QJ#E]0($.Q.2'VVQ=V[4NZN6Q$EM:TMH *AO!VGD\'/."1
M5CM-WBW"VVR45(87<(Z'VF'5 +(* HC'R0#SBHQS5D4:[BZ9;;2Z\]%=DEY#
MJ2&BVI *%)!R"=X/-66F!]A2F*8'V%,#["F*$9\U$7_3ENOSMM<N3;JUV^2F
M7&[;RV]CJ00%':1G@D8.1R:E@!]J^X'VI@?84P/L*>*4I2E*4I2E*4I2E*4I
M2E5O5^FW;_.T_):G"*;3/$[:6>X'2$*1M\C'"U<\_%5*?TLF.VF\6>%J>1&L
MDWO]F$8B%ACO;MX*LA2TC>LI&1@D$[L8K8N'31^6;F?UE*?6N6US!B[@GT>"
M ??SO4 3XP..?-:#_2!4FVW.R/:AD#3D@NJC0VXK8<84M>\!3IRI:$K.0GCX
M!)Q6"]Z.N=LL^I5W)<C5$W4;3$-;<.(F,&7&VU)0\K+AVI!VDD9P>0,<#H-G
MT_\ I.C&K'"?"76XI:]0M&[<ZH'<ZH9&25$J/(R2>:Y[.Z0SY=EDV]>H(_[]
M@CV)3AMYX2RO<',=WR05#'\'XP;/U!T7/U;%L[2;JQ'3$*S(:=BEUE\J1MW;
M-Z<*2<E.20">0<53X/1RZ0H"8+&HXR8CH@+EA4 J*WHFP-J1^X-H*6T@@[N<
MD8S@25MZ872V3[.B+?(BK-9U3##C.0E%T)D)4"E:PYA025<$)''G/FL4#IC>
MH%ABVV/>8*DBP.V.07(RSN!WE"T>_P!N"H9!SD# Q\>G>E<]R-<8)NL5-OO+
M$-NYH$=15N82E*BR2K"=Z4I'.=N,C-7BP6!^W,-]]]E;OKWYJ^TA2$GN;\)P
M%>XC<.5;O'C."*SKOI[/U)?YTR)=68D>;;6H;@4RI;C;C3RGFEH(4!C<1D$'
M(&/GB8TAIJX0;M>[W>GXOZM=0RA:(8/9:2TDI3M*N23N))/X'QD\ME=&=5.P
MYH5=+(]-E0C#<DK2^%N[9#;J'%DE7)#>"  $YP,BI;5NFIZ$7:V2FW_U&_WQ
MNXVJ7;&W'!"<0EE&]U1&U  05<GD%0'C%7S56BF;GTX7I6U.)A(::91%61N2
MA3*D+1N'R,H&?GS57G: U!-N[VH''K4U>';E!EF*EQPL!N.A:<%>T$J5O)SL
M&,!/YJ'N/2*]7.W-V^3-A,L*EW:0XZTZI2P)84&\)*.=I5[AD>.#]LMLZ8WQ
MDV5Y5OTG ?B76+,D"W!Q >0REP$Y*?J/<X3C"=OGGB_ZWLEPNMQTJ[;6HBV;
M;<Q+DA]PH_:[3C9" $G)_<SCCZ<9YJ@0NE]YM[UYCLP]/2(ZA.7!G/%SU:O4
MI7^VO@I3@N$%P9*DI QR<>;ATRU'/ANH<-K0XW:[5':2I]:D./PUEQ05A"2E
M"BI2<@D\9QS@2%LT3>8M[T?<&[):(#<&;*E3&(LI2R@/,AK.]2<N+^2>. !S
MYK;ZF:%O.I-3/2+8Y%1#G6*39WW''"E3"EJ2M*P #O!*=I''&3GXJ7T5IVZL
M:HF7^\QHL!YZVQH!C1GRZE2FE+*G"=H_S )\G .?.*K&I^EUZFWF\3K-=VX0
M]:W=+4C*@&)2MJ7U+ \A24G !\N+S\5@U#T[O7J-0-VF'&=BR&[.U!4N2$+
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M3/N2HUKCM35PVUR);10[M.$J"DJ(]V>!G-3JKE!3-$-4V,)BD=P,%U/<*?\
M-MSG'YK[ N$*XM*<M\N/*;2K:5L.I6 ?L2#YY%;-*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E0NI8=\EIC"P7.' *5*[_JH1DA:2.,
M.(P1_6M2Q:>F6&+$M]NN*#:(D 1FH[S&5]X'APK"A[<<; !^#\5DZ?6&1IC1
MMKLLN0S)=A-=KNLMEM*@"<>TD\XQGGS5AI7.>K.A+CK*XZ:E6^7 939Y1EJ9
MF,EQ$@^W"%8/"2 H'^:KTSI?J6?%TU'D76TL1;)=(\R-$CM.]MEEE( 0E2E%
M1)Y))/' KF>MNG]]TJFUL]B),6^]<W'Y;++X;2U)2V@L*6A*B"070.!^#FK3
M#Z37K4UL=GE,.PMW/3S-G]"XA9<B;'6U;L'DY2V>"0?<,_-;M]Z)7F]1ITF1
M=+<U=IDJ$XH-I7V4-16BVD#/)4K.23X\#/FMA[H_?UW%R2FXVQ*5ZJ&I,8<\
M9/[?CR,^?G\5":FZ=3+3I?\ LP\Z_(NEROZ[G99L",X?2.;T;B\YG"3L4HCC
M'L4<D@5V74ND43^FUPTK:W$QDO0%0V5NY4$DIP"KY//)/GR:YA=NCFH+E;T,
M.W"V!V998EFG.960TEEY"^XT"/<2E &#M]W/XJV=;-"W?6FC[99;&J %1I3<
MA;LYU8&&TJ   2K=G=SG_CFM3JOTOD:AAZ<.E$VZWJM,E;JH!4N-'>0X %C<
MR I)P,9 _P 1K#H_I9(M'4 W6X0[(_:462/;F64[UEMULH.0EP'"<I."5$\
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M0ZVM0;^I#HPXG^""1CQR?O6Y8='V*P/*=M-O1'6J,B(HA2E9:0,)2<DY _\
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M _TK/'9:C,-LQVT-,MI"$-H2$I2D#   \ 5[I2E*@+]HW3E_GL3KU98,V6R
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M["AN25$&J=K[75SM?4YN!$O)C1&;A;X[S+RD("6G >Z0C!*TD+1^X2D)4 D
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M ",;594C8O*O83G-=.Z:WFX2[_JNTW*ZJN@MKT<LR'$-MK*76$N$;4 #:"2
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MB3U'U(;?:[TAV"IB[IN"$VQ3!WP51T.K2HJ"LJ_NTA8('*N,5T7I?-O=UTA
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M6A16%)2>V00<$Y P?CQ&T5(;:BN7W2$JX6EB^W1]R"E#:UAE_!96$;L*3XR
M<@C..*T9?3Z^IL-P@NV1Z1+&DE06RM274I<]2IU# 7\J0C8 1QE(Y. :DG-*
M7N=J:4\U8KM"E*+<FR2@N.S'MS8CA 9<V[EIVJWY:22E1.>.55*](+'+MNL(
MTE>DYEE0FPH@S'W&VTI?F(<!6LJ"BI>[R%GSS]JUKAIN\/:Z?6JV3%7PZ@:F
MQ[TA'[;=L"1N8[GP-H6CM_*E!7R35JZ):=C6S1I==M<R%<Y2G$S$S0L+7^XL
MIR%'&-J_(_CG%<EE6/4JM/MVZ3IV^K>AZ=GVIQQ#.Y+LDNI4T4D*R4_(('R?
M(S6Q<M.7&-,NK-ILNH?[/EZW29D5N*5JE98<2XI"'TJ0XM+BFU+01SM'(*<C
M'?=)W!JW3XT>U:J>3&TZ/T_O%UUX2A*4IK<6\(WI04$)&2D<<E-2=UM,^7J/
M5MP8L%U6)*;4[(<$%QI<N*C;ZQI!*1E1]N4 Y4 0,\U[8TP_-U+9XLFVWQ.D
MW[M+]-%;:D-)CQ%1TI"5@8+3:GAD)., 9P!6LS9K^=/WZ)'T_J*/JYF+(;FW
M,/*;CW!'?"AVCD]Q90%)0,#:"1\BHZZZ=N/]F&HUNTUJQ^#.E270U.C-*4R^
M6 E*C%1L0V@J) 6HG:4%0 *@:RJTM>+H@+E:?O:+[*L]I;MLQ86GTLIH%+KC
MBPK#>//N&X@D8R<5NW^PWF8BX^LM%_=L*M27!V5'AQ$+>6EQ* R\AMU)#B 0
MOD#C<% \5UW0-U;CEG2;D.\LRK;;V'2[<"EPJ0O("2XDX4I.,'@>#C.,UREW
M233=W1;W=.W!MI>KY$J2Y'AN);5$4TZ&R'&APD=Q(\CE1'P<05FM>K9UNTZU
M>VM9,MM0VVH1@Q_W&7VWW H.EP?M$CMX61R@8Y&175>L78%[T,Q/DW)N$]-?
M;DH@NOI6Z@1UJP0S[B-R4YXX&?C-4*P6+4TF:4O*U$942PON6WU#LEM'J4R'
M%1@X<ALK#1;RE1QS@C(-2=KL5RU1'N42SO7Z!$?L+8DJG+D-K3=4KRDA3A!)
MX(7M]I&W\5( 7Y]G2NH;FQ=85RN=[CN/P6%O%+$9+"F]JT#*0"H;SGY7C[U4
MXTN\1+%+VJU"^LR;8\9SJ9C;BLRBI;3S2B0' V3O+9*",?.,RZYM_5=5)6N^
MLZD9NDW]02E4CTR[<&W2VIL?1C^[""GW[OR:D>BHN<*_VEF;(O11*TVT[,1/
M]0M/K$N8P"[PA01D%*< ^?BJUKU^XN7+6[*5WB>Q(AW!I+:Q(;,96P(0E3?+
M3C2C_=J3A65$G/.->=.G6YVYV^-*OZK6IZU/9*I:VV>XPXITKV_NELJ"/8@I
M&=HR.16NW/ES-.MBY_J$BXMZ.ND-SU<5U*U.J= 0@E8R5;4X\GZ3R37<^GVI
M+?+@6RQ-J<1<XMIBR'&E,J0G8I &4DC! /!P3CQ]ZXQ=M1WEG6=S=:N&HH\)
MU=VC2=C,EY<?:WAA83@-)PI)*-O.,E2^<#H_2AZ7/T;?X,SU;BF75LHDHFON
MMO@M).YAQ9#B1D^"24J*@#P .76:?/8TQ!C.7._6\1]-H7:D(6^CO7-)/<;(
M)_<4%)0D-G*<*.!YKIO5AJ:[I713UU]2VZU=H+ER5#=<3VT[27#EOG 4.#_&
M,'%<Z@7:9:)#ESMMPO2$R;C?U.Q&MRDA(0M;*@TK@JW%!!5R2H#QQ4?;[H]<
M(ZD7VX75^T1KK:9Z7C(E*2A"TJ[JPXK:H^\)/  "OI Q7<M?2)C6IM"LPIDB
M.Q+N#C,AM"RD.M^F=7A7SP4C'YKC;FLKXG3C#;U\N#%RC:?NHF?N*RW,:6%,
MI45#^\P,8\X.*L,R]W&VW%<%O64M0D:27<TS)92XE#RWTA+@2A.0G!4!@':D
M?.*KDW5\F;9I5MO%XG1;<[;[D(TAJ69#4V8G"4M-O[<NM!*CA)\DG.2D5NHU
MK-@VYQF!>W3 8M=C#_8V+5!8<R)#B0!D$(",E62G<#]JWI4^.-:Z2E)UE<I-
ML<9NOI;BXL(;604%*$DC:YM"E#<<YV#'BHRWZ\NKFBV')>I7K=(CZ;3<;>\D
M-!-PFA3F]LE22%D$-H[8Y]Y/VQM_VLU*-3+N,W4;\:/&U!;K>Y:CV0VA#[*%
M.A9VYX)4!D\;5?(-=]L5YM]^MZ9UGEM2XBE*0'6CD922"/Z$5(4I2E*4I2E*
M4I2E*4I2E4+J1JZ1I>_:5;;3(=B3GI"9#$6*J0^Z$M$I2@)R?JP3@?'D &O,
MKJ[H^*Q >=N#G9EH;<WAE6&4K64)+O\ D]R5)(/(QS@<U>9;R6(CSZB4I;;4
MLD)*L #/@<G^!7/H_52P6VR6I5WN$B9)?MR+@N1$MSW;6R5;5/8 .Q(()()R
M!_3,TOJ)IE-X%L3<0N4I0;24-+4VMPH#@:2X!M4LI((2#DYP!GBN=P^INH+@
MFQNLJ8C-7Z2^Q'2JSR751>V'%9R%#N9"6\XQ@E9/"2*N]IZEZ=<@.^ON\<RX
MD9+\A33#J6W1N""M@*!+B"OVC;N)RG[C/M?4JQKNEL@1!/?=FNOL%28+N(ZF
M0"L. I!3@E(.1QG)P.:^:=Z@6MZUVX72Y,OSY%M7<U.1(;Z&%LH)W+1N!( Q
MX)W>..14E#UUIZ7<84%F<H29@'9#C#B$J44!?;W*2$AS:0=A.X#XJ=N<^+:[
M?(G7!Y#$2.@N.NK/"4CR35;'472P@)EO71+#1D>D*7V7&G$O;2H(4A20I*B!
MD @9R,9R*BI74F$;[ITP'HS^GKG"F3')A2O<V&-H/'Q@J(((R-I\5;;1J*U7
MA;*;;+3(+T9,QO:DX4RHD)6"1X)!K7U+JFW:>F6>+<%K2[=)/I6-J21NVE62
M?@<?\17NV:ILETN3EOM]SC2)B I1:0O)(2K:HC[@*X)&<&OFK]3VW2=J1<+R
M\6HZWVXZ2$E1*EJ ''_'^ :@=,]0;9<K]<K+<I=LBW1J<['BQ4R,N2&DI2H+
MP0.2%'@9\'[&I?2$_2SR94/23UI*&5A;S-O+82DJ PHA''('GYQ^*DKW>K98
MH?JKS.C0H^=H<?<" 3C.!GR< G'XK45JS3R2X%7RV)+8;4O,ML;0Y_=D\\;L
MC'WR,5IQ=>Z9D1;M)_6(;,:URC#E.ONI;2AP <9)Y&3@'Y(./%;CFK=.MR&F
M'+[:DO.EM*&S+;"EEP9; &<G< 2G[_%>]/ZEM.H7[FS:)C4E=ND&+)"% ['
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M;6&I;D9*US6UH4$JPA14" DJ&#M/(SBI*7=[9#4A$N?#84LH2E+CR4E14<)
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M=H+;<8+(RWV^7,8RI2B3C P*Q6O16HV+?T_AOPFD&S2):I;K<A*PA+B%I0I
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MQ-9>?::)(3M;V@CCDDE:?X&2>!4&GJA=S<I++NGH\9B$_;F9B')NZ0CUFP)
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M;Y0?4I*<I4>5(2E.X\ '[8K9M_32ZIMND@[I6[EK]50]<HTAQA:=H:2EPAM
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M.XDLE.\[MVT\+1C!.2H ?)K&>L%M$LM_HEZ$9OT7?DJ;;2ECU0';W)*PK.2
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M0E37IE[VG0<'*@<YSP<G\5)*Z>2%3+=-<U',?FPV938=?8:.Y3Z @J"4I2E
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M$!'[('M!&[<<^<8Q\UCO/5+5\O2U[O%KLC,"TF$^["GO+0I2%(44XVAPE:B
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MH.H9=FD277FC:Y)DM-M);*%J*2DA84E604E0XQYSY (G%18[B2%,,J!3L(*
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MD))8<*LH"DI Y!V^1S7BY],6X$FSS]#R&;;<+:Z\M*9Y=EM.AY 0L*!<W X
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M7_>%_P#.GZ>U_P!;*_[PO_G3]/:_ZV5_WA?_ #I^GM?];*_[PO\ YT_3VO\
MK97_ 'A?_.GZ>U_ULK_O"_\ G3]/:_ZV5_WA?_.OGZ<UG/=E?]Y<_P"=??T]
MK_K97_>%_P#.GZ>U_P!;*_[PO_G3]/:_ZV5_WA?_ #I^GM?];*_[PO\ YT_3
MVO\ K97_ 'A?_.GZ>U_ULK_O"_\ G7S].:R3W97/_P#,N?\ .OOH&LC]R3Q_
M_'7_ ,Z\_IS>XGO2\8^GOKP/SYS_ /HKU^GM?];*_P"\+_YT_3VO^ME?]X7_
M ,Z^"W- ?WLH_P#]PO\ YU]_3VO^ME?]X7_SKPNV(5],F8CG/#ZCG\<Y_P"=
M$VT!9*I<Q2#X07B /ZCG_4UB7:-P7BX7!.XYX>^D?89'_P"6O:[6%$DS)O(Q
MP]C%?/TOWY]?.VYR4=T8/XSC/_&BK5E2ML^>@$@@!T'&/R03_K6/]&. /U.Y
M<#']ZG_RUD1:D)V[IDY>/.7R-W\XQ_P^U/TI&U0]7.Y.0>^?;^!_^7-9$6UM
M* DORU$#&XR%Y/YX-8Q:DACMF9.*O^L+YW?\O^%>F[6VC&9,U?&/=(5_]"*]
M_IS62>[*_CU"_P#G7E=L;41A^8G'VD+Y_P"-8S:$E( FSP1_B#YR?'_Y_P!:
M-6E*![YL]S_XGS^?MC[_ /"O/Z.K*B+G<1D8QW4\?_@U\19L*RJXW%8^Q>P/
M^ %94VPH4DMSYR<#'+@5G\^X&B[<XL8-QFCG/!0/_P 6L/Z*<8_4[G_]\/\
ME65NV+; Q<9QQXW*0?\ Q37IZWN.IVJN,P#.?;L2?]0FL9M2SYN5P^/"TC_\
M6O LI'_[TN?_ -\/_+7M%J4DI/ZE<#M\9<3_ ,?;S7Q%G*=V;E<59&!N>''Y
M\5]3:2%9_4;@3G/+H_\ #&*"U+&W_P!)3SC[K2?]?;S7M=M6M("KC-X&.%('
M_@FB+:XE0(N,TD#')0?_ ,6OB;8M(2!<IWM^ZD'YSS[>:]*M[BD;3<)F.?';
M!_UVUZ]$[Q_Z0E\?AO\ \E$0G4I"1<)9 ^X;)_\ \*\BW. D_J,WG/RC_P M
M9/2/?^\)7_RM_P#DIZ1[_P!X2O\ Y6__ "4](]_[PE?_ "M_^2OAAO$?_:$K
M_P"5O_R5X7 ?4%8N<Q)(X(2U[?X]E81:I6TC]<N6?OLCY_\ ]5%6N422F]W%
M.?@(C\?ZM5F$!\ 9N<PXQR4M<_\ X%?%V^0HI(NLY.#D@)9Y_!RW63T;O_O"
M5_\ *W_Y*>C=_P#U^5_\K?\ Y*>C=_\ U^5_\K?_ )*\(@R M15<Y9!QA.UK
M _CV5Z]&]NS^H2L8\;6__)7A<"0I*PFZ3$%7@A+/M_C*/_'-8OTN9A7_ *;N
M&3CG8QQC_P#I?->H]ME-*)<O$]X$>%H8&/\ 1L5[=@2%MJ2FZ3$*)X4E+61_
MJ@BM?](F_P#O^Y__ '<;_P#Y5L18$EF0''+K,?0/_9N)9"?_ ,% /_&I"E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
4I2E*4I2E*4I2E*4I2E*4I2E*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>exh46_08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh46_08.jpg
M_]C_X  02D9)1@ ! 0$!- $T  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ L ! 1$ _\0 '  !  (# 0$!              4& P0' @$(_\0
M3Q   0,# P,# P($ P0&" $- 0(#!  %$082(0<3,10B015182,R%D)Q@3.1
MTA<D4J%456)RDI0()31#DZ+!\$6#L=$U4X*RX6-SH\+#_]H " $!   _ /U3
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*^'.1C&/FOM*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I5*UIU#@Z5N2HDF')D=F*F;)6TI [3)<[8(2H@K.[^5()
M_N0#=0<@&E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E0-RM5XDW^'+AW]R);6MI>@)BMK#^"<Y61N3G(''V
MKF?6G2&H+]JB%<;1!=??AQT?29#!:2(LOO!2E/[SE3>U(Q@'&%<9(KIFH[/=
M+O;8K,*_RK/);(4Z]#::5W..1AQ*L#//'_.IQM)0VE*EE:@ "I6,G\G'%>J4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2OBE!*2I1 2!DDG@56]&ZOCZK,Q<&WW%B(R1VI4
MED(:E)).%M$$[D\9Y X4/O6>3JNV1]90],%Q2[I)C.2@A R&T(('O/QG/']#
MXXS/4K2OER:L]FG7*0VZXS$86^XAH K*4I*C@$C)P/O6EHW4D/5NG(E[MK<A
MN%*!4T)" E9 )&< GCBIHD#R13(J!@:JML[5]TTTP7OJ5N9;?>W(PC:OQA7R
M?%9KKJ2UVJ]6FTSI26Y]U4XB*T?*RA.Y7]./^9%>=8ZFMVD=/R;S>5.H@1]O
M=4V@K*=R@D<#\D5*1)3<N&S)9)+3J$N(R,$@C(K2L-[BWR/(>A)D)0Q(<C*#
M[*FB5H.#@* )&?FI/(^XI2E*4I2E*4I2E*4I2L8+OJ%)*$!D)!"]WN)R<C&/
M'CG/S62E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5K7-T,6Z2\J
M.Y*2VVI18;2%*<P/V@'@D^,5RW1# TY<K]=['IN\0;!-]*ANU>G[:TR"M277
M4,Y]B DMY/SM40,#G7M6E-66WJQ:I\R9#G1'$SGI$E,-Q.U+BF=J">YC?A*4
MIXP$MGS\=CI5<ZD)D.=/M2-0FGGI3MND-,MLMJ6M:U-J"0 GDG)%<IT%=]1V
M[I19-+6G3][C:B]*^PJ1*@+:9BJ"'%)45J 225; /Z\_GEZHEWT]HB%*O+6H
MHY-U@B9!E1>W'DK;[I<22"I:PI(RI>TA1*>%')&"9 G3]"6N/I!J\WZ:RW*]
M7*B-.AN/(*T*V;" L.)2$ +)\<!)R0.V],H=T'5J_7.YV^>TB79("1(?CK0A
M3J6T=Q.XC!4"H9'G@CX.*AU<L>JM43+AJ^QPG._89[+5MC+B/B6OM*&Y3:?!
M0M3BE$XY2VGD<BHGJS&U#J=W4<F1IZ_24W*TPE6=A$1Y0C+"T%]*D@80K._.
M[R,8SQ5KM.B;LSU/8:;CR4:6NL6+=) 7E(COL8_1Q@!)4M0)3QD$\<8JAVZV
MZB;M=K9N]JU,O3YOMQ1.:B,OI?0'&D)CO)2?<4IRHI." 4_?&;5IRTZD_P!L
M6;I(U.AEA41=N>5'+B'HP:*5H><)"$'!RL8R5>!D#/Z/I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I4;?;';;]':
M8NT1$E#+H>:R2E3:QX4E0((/)Y!^:R6>TP+-&5'MD9N.TM:G5[>2M:O*E$\J
M4?DDDUO4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E:]RC*FV^3%1(>BJ>;4V'V" XV2,;DDYP1Y
M%<03#GJ_VF$:HU$DZ?),3$]9VI]'O(.[@^Y1.?(('VK?L/5XVW341B_6R6JZ
MHA6]3(#H>7-,A!POV9(Y0M1 "E8YP3Q72-":C<U3IUFYO6R7:W5J4A4:4@I4
M"#C(R 2D^02!D? JB]4Y\V/U"T[!;F7]$"9!EK>CV=9[JU-%LH( ^?>0?[5N
M,ZU?TQ:]/0I5OO%P5=8H7!?FK2EYV2M6Y,5WCV+"5?N5Q[%?:LLOJQ"CZHE6
MM-JN+\.&XIF9.88<<;86EO>O.$XVIX!.[()\8YKVUU*?1;8=QN&G)<>#.>AH
MB/)>0L.(DD!"CXPH$C<GG&>":Q'J%+N=_BP+9;'$Q.]<8LMQ;B4NA<4 ?I\X
MY*AR:T[%U/@0=/6<R6;F\Q(L;ET8ES7$*<DEK 4R2G +IR#P,<U+6[J6S.U/
M'L[=FN(*GU1'G^V2AAY*-R@H@8V@Y1NS^X'C&";K>9PMEIF3BP_($9E3O983
MN<<VC.U(^2? JAZ?ZK0;TLQHEO>>N?JTQ41H[S;@<RSWBM+F0G 1G.2"%#;\
MBHQ&N94/JI,MSZ)[KLVW0G(5F<4VE:'%%TNXP2GVI3E1*OC )]N99/5:VMW:
M1&G6RXQ(3%Q=M:Y[G:4T)"&U.%)"5E>"A.0=OXX-8I'5>/%MS\R58KFRVFVF
M[1P2T3(C!0"EIPO@@*2HI.#@_-;;?4FWS[G/M,)B0J6S+:AA;2VE9#K2G0\G
MW'VI0A1.1GVD8)XJJ:5ZMM6O1E@%Z1<+O=7;>W-EN,)05!"W2A)VY!4>%'"0
M>$_D5*Z@U](?U9IA-F]8U8UW.3#E2BAM3,KM-.[T@9+GM6V<$  [5>1C.TKK
M!9V6TN2[;=([3L%BX,.+2UM>:><#;6"'/:I2CX5C !R16#_;/:5QX98L]W>E
MR7GV4PTA@.;FMNX))<"7"=Z=H;4HGG XKJ*#N2#@C(S@UQ^5U&O+T^S3F;1<
MV(J;O.MKUN8##ZYH:;=P4G=E)2MKGE(\_N&#4XCJW8UNV79&N'I[HU'=1)4V
MA*&^^K:VD@J"E'=@'8%;<@G YJ:Z<:M<UE9'[DNV/V]M$MZ.A+RD$K#:RG/M
M4>>,'\@XR.3&Z^UG+LM\C6.)"="IMMF2A< ML)CEI(.=JCSC<"<_<<'G$!I'
MJ[!;T?"=U4F='NC=MB2EJ?90WZWN@(#C>#M"2O(YV@>>!XO^C-3P-6V<W&V!
MP-)=6PM+@&4K3Y *24J'(PI)(/P:J'4F^7.V:WT[;V+Y*M5LGQ93CRHT-$E>
M]KMD8!;40"%G/QP/'SEMO4"/:;5:6[R].N,BXQU28,I,1#)F@K]C*4;A^MM4
MCVX&?(^0/<[J]IF#J%RTR7'VULE2)#V$J2PM+>]25)"BO@#&X)VYXSFO?^U&
M"@P_566^142Y<6(TMZ.D)(D EIS(61M.T@C]R21E(K&.HYGZ@@6NV6B:M#RY
MS4EXJ:!87&(0H ;\'W*3S]E#SSC'I[J'#CV2S)F_4I8E65RZMSY 929"6@"X
M@A*N' % X Q^>#6Y%ZH6B3J>+8T19WJGGO3+4$)(8>V[BA8"BH8_:58*<_/S
M5HU6ZZQIB[.QWUQWFXCJT.MXW(4$$A0R",CSR*HFE^IB!IJ/]6MMX]>Q A/J
M6ZVW_O27_8'@I*MJ$[DJ)*]F!S@5M6SJS:KF;4F%;[B\[/25!M ;)0 \IDD>
M_P#4PI))V;L)]WBNB.+*&E+2A2R$DA*<95^!FN:M=8[&NV(FN6Z[QTNH6XPF
M2RVSWTHSO4A2UA)VD $9!RI( .:WFNJ=C<FVIGT]Q0Q<G&6F)+K';;*W6^X@
M840HC;Y4E)2"0"16K9M9R[YU)M4:$W.8L,NT/RV^^VT$22EYI*'4$$K *5'A
M6WA23BKS?KHW9K2_/>9D/H:Q^E';WN+)(2 !_4CDX \D@#-4M?5BS=N-Z>#=
M)3[RY309CLH<(7'QW 5!>S@'.0K&/GQ4/KKJ<ES33$O2"Y:U%=O>=EH906V6
MI#B<(<"CD**"> DD93XR*ZWGVYJC'J5:@Q'=])<,/+G- !M!(7$W=Q. OR=B
MMN,YQSBM>+U7L+\53JF+DPM349Z,R]'VKEID*V-%L9YRKCDC[^.:A;#U/3;X
M5\>U.9GJ$7>5'C1'$L-NM--(;44$[@@[=^,[B59&-V14L.KNGU)E.MQKJN)%
MC-S'Y(B'M-M+;4XA1.>-VW:/R<5X9ZIL2-06RW-66YH3*9DO.K<2C* RE).P
M)4>X/<.4$@\;=U&.KUC=9D$P;LF0R_'CJBI82X[N?05-<(4K&0DC!((/! K'
MJ/J9&=TE->T^Q<EW@PYCR(Z(Z"[%["BVM;B5'&$N#&.2?@&MS16OF+DS8[9(
M1+DW9V%&7+?2V@(0XY'#N5 $$ C^8)VY(&<\5;=4W;Z%INZ7;TZY(@QG))90
M0"L(25$9/'Q7,(O4^5;]2O/:@8FHM+MH@SO3L,H=$,N+<2MQ2T\[/:@\DJP>
M$^<6>)U1T]+U]_"3"W5W N.,AQ.Q2.XV"5H("MZ2,'DI )!P3BK'K&]'3FE;
MM>1&7*$",Y)+*% %00DD\D@8P,_?C@$\546>K5B0_:XMR1(C3)@82XC:E89=
M>2%-MG"B25 Y! ( (S@D XX?6*QS$0U1K5J)Q,[?Z,BVKQ)V)4I6P^#P@_\
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MK0#W3CVJ)"O@\\U,Z)T%<-/WN'.GW_ZBW!MQM<=OT@:5V=Z5(*U!1W* 3CP
M>#QSF_TI2E*4I2E*4I2E*4I2E1VI+HBR:>N=U<;4XW!C.25(3Y4$)*B!_E5
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MN,N)*%H4,A23P01\BJG!Z::1@6]<*'9VF65/)D I<7O0XDDH*%YW(V[E8"2
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M2T8R@C"PIPA:5[N1QC_\^:UWS6;JM3_09L$.P;';)$. 8GZ(*VEK4EM(6,<
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MW>@J0,925((YX_=7N]=-[9<)&GT,M0(]KM;JW5P1#"D2%+;*"2=PP<'(/)R
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M*DG<DY20>" ?Z@'XJMZ@Z;6&Y)O,F%$9@WFY1G6#."2YL4X@H*^V3M*B#@G
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M9L45F.ZIYR0HR%=^.AYO" G;QN(/N_IXYZ)2E*4I2E?"I(6$E0W$9 SR1_\
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MVDI)&\Y"<YP3@'D<#7-]NI9@C6;C#R&+SW3&,=PJ,=8+&%*:R<H)YVI*DIR
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M8[+332G7'W%>$(0D$J/!^/ )/%>;'?K??5RFXS<AMZ"M*'6I,=;*VU%(4.%
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MIPR$!*6595R&\/<'/E!\U>M:6N1>M*W2WP9<B',?84EB1'=4VMMS&4G<.<9
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MM.0-+/6^3(O0=4R_(#BV<(& GV<[E+]O_9PHD<8KH+"W!#;7+2A+P;!=#>2
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MF<$)<0>^LC<@%+F0E.X)(R#\#;E],+ZZU<!';T]#]78)-I[43>RVVZ\\5E0
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MPVETX:<62GVH43@$XK:C]4-./79R"I<]GMO/1E2'H3J&>\TDJ6V%E."O"5'
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MG]$A*6P#@<$'SD_.")!WI=:7WXKLJ5*D*0Y-=D]P(/JU2D=MW?A(Q[,) 3C
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M1T2N'"LA8#A"<A/"<9R<UL7/I;(G"\E5\92JX-6U'$$X0J&H*!QW.0H@Y'&
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MPP,<9Y3GGD<\UXD=*[A]1AS&8&CG [$,27%?@*4Q&_56M+C"/YE?J84%;=Q
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M-VYR/^@E(9(:4K<G &WW)!.#SCGBN?V?4UVA=(EVB?&M<ZW#2[-RC,NQ%E*
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M1UMAUQ_O); 27$HVH!'O7E0)3Q@?/BL;O4R,VY<)?TJ6O3T%<EE^Z((4E#C
M)6"CR$DC:E7R?C'->TZ]GH>:@2],2X]YE/=J%&5(06Y*0V7%+#O@!*1A7'"B
M!SFH]'5MAU<0,6"XN)5&<ES%]QH"&VT\6GBOW<["E1]N<CQ^(-KJ)<DZQE7:
M3;;BFS?PXW/C6]#B'"YOD!*72!P@[2-V2=H!/P:EX?6!B>U!1;;%+G39<N9"
M;:CR62V7(Z LD.E024*200H?G\9WK7U2CWI,!RQ62XW%AUF._,4SM*X:7B0C
M<C.5$;23CPD9YK+I/JC;-3ZI-HML*:IE0=+4T(W-+[:L*W8Y1DYVY\_@\5T"
ME*4I2E*4I2E*4I2E*4I42UIRSLSKA-:MT=$NX)V2WDIPMX8QA1\D8J"C:5T/
M=&Y<>-:[8^B&DVQ]"$?X*4J2Z63]D@E*MOCFMG3-CTA)=:OVGHEN?6HJ2W-8
MPO)'L40KGW>W:5#DXY-33=FM[5YD7=N,A-QD-)8=?!.Y:$_M2?CC)_SKEVH>
MF&G-4L%O2$BS,-PI;Z9;"H_JF3(6$;RK:M)2XD #@\;CD9QB[:6T+:;$RPXX
MTF9<D0S!<F.)(+C)45EO;D@(R>$\X&!FM&U:*Z?7&S3K9:K/9I%N3+_WEIA*
M5)3(1\$CPI.<8SQDCY-2+W3_ $L\TMI=FCAIR,B&M""I*5,H.4MD XV@_']?
MN:3= :7G1)L:99H[[,Q\27PX5**W0,!>2<A0'&1CBOCO3[2SL>0P;,PEE^.U
M%<;;4I"5--$%M&$D8"2 1BON-)Z.N3KSCT"U3+P\G<IY[8J2X $C]Q\^!^21
MGDUI7C1>C(\5Q=T8:BL/25NK<<G.,A;KQ2%@JWC._:D%.<'&,5-WK2UDO=LB
MV^YV]E^'%4E;#7* T4@I3MVD$8!(_H<5C8L>G]/Z8?M@CQ8=B"%AUIY?Z00K
M]VXJ/ Y_I4!:- :#E6-,:S1([L)#Z)"'HDUQ2T.)3A"DO)7O20DX&%< \<5(
M+Z=:64EQ/TO8A<%5M4EN0ZA)CJ5N4C 4!RKDGR3Y->)G372LQ3BG[<Z2YV"L
MHFOHW%D -J.U8RH!*>?)VC.<"O<SIUI>;>3=)-N<7,,D3"1+>#9>"=N_MA>S
M)3P>/</.:BQT^T#!2+(8S++LA2'V6%W!WO)+9)06<KWH"23@(P!5CNUOL=V?
MMOKG4+>MTA,F,$RE)*'4@@$@*&[@D85GR:B5=,=*.18T=VWN.L1_5;$+DND?
M[R"'@1N_FSG\'QBO">ENE4/.OMQ9R)3CC;QDBXR"\%H!2E25E>Y)VDI.",CB
MO'^RC2(9B-MP930C=P(4W/D)64.*W+0I07E2%$G*22/<?N:L.I--V[4-N8AW
M!MU+<=U#["X[JF7&5H_:I"DD%)P2./@FJ_&Z6:6BLN,QXTM#:XTB(4B8Z?TG
MU;G1DJSR><^:^.=*],+<0H-7!L)6PZI#5P>0E;C.T-N*2E0!6 D#=YX^_->E
M=+=+&/=(Z8LM$6XI<2ZPF8[VD!Q04YVT;MK>X@9V@<<>.*L5ZT_;[UIMZQ7-
MMR1;WF@RXE3BMZ@,8.[.<Y .?O5?@=,M/0;LS<6/J1DLR#+07;@\X.\6^VI9
M"E'DIX/_ /(5I/='])N6Y$'LW!$4,F.M#=P>1WFRM2PES:H;P%+41NSC)^.*
MM5ZT[$NUOB1'7IK*8J@IEQB4XVXDA)1RH'*N%'.[.<\U7T]*]+-Q7HT>-+CL
M.HCH4VS-=2G#!RU@;N"#S^223S6'_9%H\O.NF#*RX)"0E,Y]*$(?!#J$I"P
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MTB:QB1;I:DQK]/8G)2ZA84T4'*D[@/'P..1SQXKW*Z0ZC??G+,ZU8?U0SJ!
M+CIVH0%@MGV^?<GD?8_BM2%T4OT.SV\M2[6;E!F7!:&0^XEEQF4UL.5]LJ2M
M!SCVG(^1\8+ET N4B'%A,7>(EAC3XM7=4%;U/"07]^W'"-WMX.<<\^#L7SI#
MJZ^6G6 FS+$W.U"8!4E#CO;9,8 $YV9)./& .?BLL[I1JF3JY=V!L:63J*'>
M=AD.9V,H4E2<=O&3D$?%5#H_W8W5J#'>L;[A9DS4,A$Y)1;D.%:RHQ]G<0%
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M%I9<;*FP=BC_ ##['D\U%)&GF+DJP(8M[<N4RJ4J&EE([C8(25J&,'D@<_\
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MW>8CUPB1& \]ZEE;[;[32EL[4D @N ;0?=P"><&I$8 .,8H=IP3@X/'XK[3
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M=TT#;].ZD97ZA^0Q$N$>/(:6LM(04+8:*0T%'A*TD$$*62,\V[2%CN43JO\
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M7G$LM+<7G:@%1P"3C^@JCQNJ^CI$63);NC@CQXOK5K7$>0"R%!!6G*!O 4H
M[<XSS6XGJ+IA2XH-P6D2'A'0M<9U* XI1"4J44X1N(.W<1D<C(YK&SU+TL\K
M].>Z4%UEE+ABO!"RZM3;92HIPI)4A0W@E.1YY%>IO4G2L)I*Y5S+>YY^.$^G
M=*RXP<.IVA)/M_I_2L<?J?H^1%FR6;RVJ/#CIE.N=IP)[2B %I]ON&5 ';G!
M.#BM5[JOI=0B"WR9$U;]P;MQ2S&<W-N+&X%0*00-H)!QS@XS@XSVW7EO8MDF
M7>[E$= N$B*SZ&.\LE+:C[2C!45)'[B!M'WQ66;U.T=">C-R+[&"I#;3S92%
M+24.'"%D@$!)/&3X^<5:;C/BVV ]-GR&X\1E.]QUQ6$I']:K,GJ1I.+;1/EW
M=N-&[YBGOMK;6ET)W;%(4D*2K;@X(YR,>:L#MXM[5E%V=E--V[LA_OK.U.PC
M(5S^"*K4KJ7IQJ/#=9DOR#*FI@!M$=86TZ1NPXA0"D\#.",GX!K1T!U,M=_A
MOLW>;;8-YCN2@]%2^,);9=4DKY\>T!1SX!SXJ6=ZC:19B^I?U!;V6 YVBIUT
M(PO;O .<8RGD??XJ9GWZU6^Q_69MPC,6K8ESU2W &RE6-IW>,'(Q_6HJ/U T
MI)@2IL:_6]V+&*$O.MNA01O44))Q\%0(!\$BM&TZ\B!F_O:D>A6QJVW5RW(4
M73A82VE84<@<E*B2 .,?/FK:B?$7;A/3)9]$6^]W]X[>S&=V[QC'.:K_ /M"
MTB8?JDZCM*XW=#/=3*0I.\I"@,@_8Y_'S6^_JNPL7AJU.WB FXNX"(Y?3O).
M,#&?)!R!Y(Y'BM>9JZSFU/2;9=K1)>,5V4PE<U"&W$MDI4HKYP@*&TJP<5J7
M#6]JAVE1=NUA1>_2AY$-ZY-H2I:F]Z1N/.T_"L>.:D(VJ;2$P6;A=;5&N,E+
M8$;UB"2M:00E/(*LY&#CD$'YK:;O]F<NBK:W=;>NXI)!BID(+H(\C9G-8[Q=
M50+K:8H$+MS%N)<6_+#2T!*"K*$$'N'( (!& <UH7#7FE8,"?,>O]M4Q!9#[
M_:D(<*4$X!PDDG)( 'R2!\UOM:FL+LJ'%;O-M5)F-!Z,R)*"MY!&=R$YRH8^
M14$V_P!/G;V;\W*TRNZ %)FI>8+@ &3[\Y\?/VJQF^6@/,,FZ0 Z^E"F4>H1
MN<"\[2D9Y!P<8\XJ,EZYTO%;8<<OMM4V]+$%*VWTK >P3L)!.TX!SG&*^W;6
M^F+5 N<N7>[?VK:#ZM+;Z7%M'.-I2DD[L\8QG/%>H.IHC[UT>>E6MNTPTM+1
M,3.0L*2M&[<L>&QXQDG<#FMAW5.GFH$><[?+4B%)2I3+ZI;80Z$^2E6<''SC
MQ4G#E1YL1J5#?:?C/(#C;K2@I"TD9!!'!!'S4._J_3[<>Y.HN\!\VYE3\IMF
M0A:VTISDD \<C'/S4=T[U3+U59%769&MK$%Q*7([L.=ZA)202I*_:G:M'@CD
M9S]JAHO5JQ3+S:TQ9<'Z',C2'C<79(;#3C3C:.VI)&!GN)(R<\CBKS]9MGU-
MJW?48?U!ULNMQN\GNK1_Q!.<D?FMJ4^U%C.R)"TMLM)*UK4<!*0,DD_;%0&A
M]86W5^FA>H!6S&"W&W4OC8IHH)!"L^.,'^AK>;U)8G8Y?;O-L6P%;"XF4V4@
MX)QG.,X2K_(_:L[-XM;\PQ&;C"<E!L/%E#Z2L(/A6T'.W\^*\,WVT/11):ND
M!R-O4V'4R$%&Y.24YSC(P<C\5HEC3=TO\2ZAV#)NL)A18=0^%*::5PH@ XP?
MDX^U;K5_LSL;U+5VMZXY46^ZF2@IW 9*<YQD#G%81J>R&\P;4BY15SIS"I,=
MM#@5W&QCW CX.[C[X./!K>GW*!;D;KA-BQ4D%67W4H&!Y/)^*1KE E*4F+-B
MO*2VEU0;=2K"%<I4<'P<'!^:\HNUM<A^K;N$-<7)3W@\DHR/(W9Q7INXP7)2
M(S<R,J2MONI:2ZDK4C_B SDC\UZG38<!I+DZ3'C-J4$!3S@0"H^!D_-:,'4=
MFFNSVXUQBJ5!?]-(_4 V.;0K'^1_Y$?!K=3<(2Y8BHEQU2BCNAD.)*RC_BVY
MSCGS7R/<H$@N"--BNEL;EAMU*MH^YP>!4#J/64&TMV5R*$7%JY7)FW!R.\@I
M:+A("E'/(&#P*V+]:=,ZJ9C(N[,"X(0Z4LE2P2%XY"2#G.!R!\"I%A%KL%OC
MQ6O26^&C]-EO*6T ^<#QSY/^=;2Y,=#Z&%O-)>6"4ME8"E >2!Y-:%[N_H;5
M<)%O8%QF1$%7HVGD)6I6,A)*CA.?S6^B0V0WW"EMQSPVM0W9QG'GR/Q6C=K_
M &FT1UO7"?'90AQME0*P2%K4$H3@<Y)(K8NERA6NUR;E<)#;$&.T7G7E'VI0
M!DFH>T:F@WR\WBT)96CT*60IQQ2=KZ7D%22C!)\ ^<'\5NZ8L-HTU;1;+#&;
MBQ4**RVE14=Q\DDDDG\D_ ^U2]*4I2E*4I2E*4I2E*4I6.2L-1W'%!9"$E1"
M$E2N/L!R3^!7!;'TSN^KNG-G9OCK,)V';7X<)B1%=0ZTMU8"EO!2@>$HPE(
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MR<$Y_I_0;\K0NHY$G4D%-J@+>F29TN%J!Z1M<9$A@H"-B?=N3[49/M"1D9(
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M#O9AQV)UB<N#\@IVAUY,@M;4G.$X"22/NKXXK>LFO+W=>L<^T1I5N58(LMR
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MMS=@*'MP"3Q4B.HLU<YVW,Z7GN76&TV]/B)=25,H6]VP4$<.9 4L?M]H'@G
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M^_:3_P#HH8TS<#Z]0'V[2>?^5>O3RO\ II_^$FGIY7_33_\ "33T\K_II_\
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%I2E?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>exh46_09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh46_09.jpg
M_]C_X  02D9)1@ ! 0$!- $T  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ L ! 1$ _\0 '  !  (# 0$!              4& P0' @$(_\0
M1Q   00" 0($ P4$!P8% P4   $" P0%$082(0<3%#$B05$5,F&2TB-5<8$6
M)#-"4I&A%R548G*3"**CP=-SL;(U0X+1\/_:  @! 0  /P#]4@
M
M
M
M
M
M                 'QZ]+'*B*JHF])[J<RX3XB7LWDN-^MJ56T.25[,]'R%
M=YE=85[LEWV=MKD[IK2HJ:7LITX
M         *0G'^-U,#-=EJ6<E,MMR/<VY=EL(SW73$>Y>E.Z^Q7>*\#AQO,K
MO(9JE&F[4D5.K2WT,:]R+)*]51-O>K6]D1$:B?-552SU^/X^OG)LO&EGUTJ*
MUZNMRN9I4:G:-7="?=3V3_[J2P
M
M
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M3?=$*UP[E[.522RTL9=BQNE=7O2]'EV$1[F+T]+E5%VU5TY$72HO;9:
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MEI-WGP.X_-QKP\HT+V-;C\BU\BV6=+$5[NMR-<JL54=\"-3>U[(B?(OP
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M*J>:[2+V37STBIWWV+?A\K0S5".]B+D%VG)M&30/1[5TNE[I^)N@
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MYU^&6.:)LD+VR1N3:.:NT7^"GL
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MA\=#0Q=:*K3A3ICAB:C6L3>](B?BIM@
M
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M7H=I%TOT72HNOQ0R@&IC<E4R4<SZ4[94AFDKR:]V2,<K7-5/JBI_[^RFV
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MP;D<O2UNFM55.G>"+[-[&<AS<G5Z#,9FQ=H=6TW77I8QVM)KJZ%7^>_F='
M                             ,"U*ZWFW%A9ZIL:Q)+TIU="JBJW?TVB
M+H\Y.A5RF/GHY"O'9J3L6.6*1O4U[5]T5"/XYQC#\;;83#465W6'(Z5^U>^1
M4]MN<JN5$^2;TGR)D#0UOW-?(4:^1H6*5V)LM6Q&Z*6-WL]CDTJ+_%%-/CN
MQ?',<E#"4HJ=5'*[HC3W5?FJKW5?;NOT0E-)]!I ![  :&D^@TA#<HXSB>44
MX*F<JK9KP3ML,9YKV(DC=]*_"J;UOV7L3.D*YG>$\?SMR6UE,>DLTT;8INF5
M\:3L:[J:R5K51)&HOLCD5/\ ,E[V,I7\9)C[=:.2C(SRWP*FFN9_A5$^7RU[
M:[&VQC8V-8QJ-:U-(B)I$0^@
M
M
M
M                                        'QJ]2;TJ?@I]
M
M                                                         145
M-HJ*@
M                    !X5KEF:Y'JC$:J*S7NO;2[_S_P SV
M
M                             ?$:B*J]^_XGT
M
M
M
M
M
M
M
M
M
M
M
M                                 'Q$UO:JO_L?0
M
M
M
M
M
M            ?$14]UV?0
M
M
M
M                                                       $5%WI
M?;W                                            1$3>D]^Z@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                          'E
M6;D1W4Y-?W4]E/0
M
M
M
M
M                                 !IY?)TL/CI[^4LQ5:<+>J261=(B
M?^Z_A[J:/%.48KE=&:WA)Y)889E@D\V!\+F/1$545KT1R=G(OM\R:
M                                   -9;]1+#X/4P^>Q%<Z/K3J1$]U
M5/H<]9:AY)<L<OR\C4XEA6OGQL2]V6'L:O7;=]433DC_ )N^;5+'X;4)Z7$J
MLM^-8\C>>_(6VKK;99G+(YO;_#U(W^#4+0
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MJ;I5[J=7\/\ C"\:P[TNV/69F[(MK(W%3O-.[WU]&-336I\D1/Q+.
M                                #!!;@L6+,$4B.EK.1DK43[JJU'(G
M\=*B_P T/SOXB^'#,IXSS4N/5<:J9##27;E6^^1L#W^>QO4WRUZHW*J-=U-^
M;5WO:G2(N V\_D\3D>=_8-MV.^*&I3Q_PH[2HB.EE5SW-3>])TIM$5?8Z.G9
M.P!6>(\4;QW*\DO):6P[,WUNJBQ]/E)T-:C-[[ZZ57?;W_F68
M                            !?8K7!9FVZN7N:>DDV5M->CDTNXI%A3^
M73$W7X%4Q#VY'_Q%9^>-ZN3%X*O2>W2Z1\DJR^^_IT_Y_@=0
M                              !1K-3DO&\QDIN.XVKF<9D9O4>FEN>F
M?5F5$1ZHJM<CF.5.I?FBJO9=]M_P_P",S<>IY"QDI89\QE;3KMV6)NF=:HB(
MQO;:L:B(B;[_ .9:@
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M#YZ*;6OM&W^6+]!XFQ\\C=-REV-?JUL._P#6-3$[%6E1$3.9)O;79E?O^/\
M9#[*M:U]N9+?UZ*__P 1ECQ\[$T[*WGKK6W-A_S[1GM:,RLU]I6T7ZHV+?\
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M>U_QJ_\ ::/3VO\ C5_[33YZ>WM?Z\NO_I-,3JN1TG3D6)W[[KHOS_C]/_\
M?(]1UKR?VE]'?],*)_\ V>_3VO\ C5_[336=4RRN5692%&[72+5VNOEWZC/3
MKWXY4=:O1SLUW:V#HVOUWM3>
J                                                    /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>exh46_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh46_10.jpg
M_]C_X  02D9)1@ ! 0$!- $T  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ L ! 1$ _\0 '  !  $% 0$               4! P0&!P((_\0
M4!   @$$ 0($ @8%!PD%!@<   $" P0%$082(0<3,4$B4105,E)A<8&1E-'2
M"!8C0E23H1<D,V*2L<'"\"9#<G."-$138V2C&"4U-J+#U/_:  @! 0  /P#Z
MI
M
M                        *-/K4NIZ2:Z?9_C_ -?,J
M
M
M                                                 " Y#R6&%S."
ML*UG7J1RMR[:%Q&453IS5.4TGM]3;4'K2U^*]X>X\0K6ER)V,+*I4QT,A#$U
ML@JL5&G>3BI1I]'JU\4$Y?.27LVMW
M           (+(X;(W6?M+^WY!>VEG1Z?,Q].E2E2K:;WU2E!S6]I=FO1:T0
MOB%8W][G^%5+''5[JC9Y7Z3<U:<HI4*?DSI[:<DWWJ)]D^T7^3U>?#LQ2S5U
MB*%E+ZJN.34N0_6"G'HC3714E2<>KJZ_-IM=EKI:>_8W[*X7+W7(;._L^275
ME84>CS<="VHSIUM2;EN4HN:VGKLUK1L(
M
M
M
M
M
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M9?\ A[O3[&\@        'EPBZD:C3ZDFEW]GK]R/12.]?$TW^"T5
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MISCN4WN,HTVEVW'J]7HWP
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M$U3Q6/I5K:M3L+2%6U@Z="<:,5*E%^L8/7PI_)&8
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MX7)N1\P_G%QY\IY11XE5O[RG&TP&+MU>7$XN26Z\]I:[M/V_!M=OH<
M   I*48ZZI);>EM^K*@                        T#Q7Y/DN,2P#Q^0Q=
MA0R%[]#K5LA;3JPIKRYSZ]QJ0UKHUKWZO;7>.X=XGT[G&PJ9^*G"KEWA[3(V
M-&<K>]GM*-1+XO+3;UWDUM/O\MOQ'+\5ELA"SLW=2J5)W$*<W;S\N7D3\NH^
MO6DNK:6VMZ>C80# S&9QF%MU7R^0M+&@]ZJ7-:-.+U^,FCB.$YYB<?XT<DO,
M9&_R]'D5M:*S5G;Z56I04H3474<%+2:EM-K3?R)C)Y&MS/Q:XWC[NUJXZUXY
M;2S61M[BI!^76E\%&,G"3CM)N?KZ,C^1^+T^2\IQ_%.!7D+6%]7E;2SDJ+K)
M=*W+R*?];7IURU%=_P S=L#X4\5Q61H9"="OD,[1J1N'D;RZG4N)32:4F]]E
MZ_"EK\.QOYQC(T+KQ<YM>8ZI.I2X!@J_D7,(/7UG>0DG*#?_ ,*/9?BU^*Z<
MSCUQ'POY=5X[DI3AQ;,W#K8>Y<4J=K7G)]5H]>B?VHMZ7JCK9QWQP\6)<5M+
MS$\94+G/QI==:KVE3L(RTHN?SG)M=,/=M/\ !QW%K3'>$/AC7YAR^FJW*[Z#
MKW5>O\5Q6K5.\:";[K79-+Y-OT(3P+XY><TY?/Q#Y/3\^=-SE;5:D6E.M):_
MHT_^ZI0^"/LY.3[Z3.^X_.8S(Y+(8^QOJ%Q>6#C&ZHTYJ4J+EMQ4ODWI]B1
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M+:5ARC$5):WTRN8PE^J33]S:*-S0K_Z&M3J=D_@DGZ^GH70
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MR1G\A\$^0Y:\QM2CE<3C;/'6/T"E9X^->C"I3ZG)Q<NIR74WJ3VVTOFS"O/
MO)W.9JWBLL-1L:M*C3J8NVRES0MJCIQZ(MJ-+J]-^LF]N3WW-\X]Q7/\;LE;
MX7BW![5)_P#=UJZWV2VVZ3;>EW;??1(U+3FCMZE!<?X7*A6ATU:;NJRC-=^S
M7D::[OU^9J^:\-KS,]3O^"< E/MJ=*YKT9-_C*%!/_>:O<^"->G4JRL^'8>V
MJ2:U4L.2W=+2]UJ=)_)?K/5MX7\[LE_^49+.X^F_LT5RAU8Q[>Z=NO3])M7"
M<9XIX"\G/,5WGK=*4:=&XR-*FEO7=R5!R;6OFEW]/4W)YSFB3_['6;>NW3F8
M_P#&E_UM?CKPN0\RC)JIP>+27K3RU*6_RW%'BGRGESWYOA_>Q_\ #D[67;M_
MK+O^XR(\KSS<>K@6=2;TW]*LNWX_Z<?SLSG;_L#R'T?_ +Q8_P#^@H^79R,8
MN7 .0^FYZN+%Z[>W^<=_\"=XYE;C+V,KB[P^0Q-13</(O?+ZWI+XET3DM=_G
M[$J                           "#YER:QXG@ZV2R+E+35.C;TEU5;BK+
MM&G3CZRDWVU^GT1K/%>)9')Y:CRGGLJ=;,4Y2E88^F]V^,@_:/WZK7K-_DM)
M'0CBO.;+)5_%N_RO$ZE)YO#86VKJU4TE>J56OYEO-)_UHQIM-^C46:+'Q!RO
M'.$T[K!U*5E4NHY/+RMW;TU-OZ=*,/-<VEKIZH],-SW%>R)?E?BCS"SRM^L%
M?XF\G+*TL;C\8K9N=PJMO&:DJG7Z0<H]]:;?=Z:1!<3Y'R3CUM5P>!ECJ.;E
M7R%YDLGD)QU?5J5PZ>^J<XZ7;XDMM)IKW/HCB61O,GY]S=7N-K4:E&WJ4K>T
M?5*@Y4E*77/J:DFWN+TOAUZ[.3U,O;XSGG/LQQQXJ=[<5,5;6M>--UNN5524
M^B,&O,F];TG%-I=4DD]>Z'BIRNYL+=V]KA57CC\E>5W6C43;M*[@THQF^GJ2
M7;JEI[[M+O/^+MQ#.^#N/R5Q0Z:EQ5Q]=*$VO+\VK34DGV_JSE'\F85[A:6$
M\3+3B_'/I4,1F\1=._M5<U94[5IZA67QJ4.IR</A:WVUK6SUXH5KO >'N+X9
MC;^_K92XM?*G>T:%6O6A2I16ZCC34YKJGT0WW[2??:V6;ODO\Z<3X49B'F4;
MFZRO17I2<H]-6-"M&<))>RJ0]^^DBE]XB9/*\;S]A<XNTE?8VRR/UU;4KBK1
M\F-/X::IU$FTZD6Y)_ZKUK1>NO%2MQVXH6E;$4XXJVQM.Y4ZE>4:E>"MG5GY
M,I+IJ.'2HN+EU/>_1,VSPYYEE>45;F&7X[6Q$8TZ=:A6ZYSIUXR3]'*$'M:^
M37=:9O                                   #>EMG-.&4?Y[<LN^87K
M\W$V56I98.B^\4H-QJW.G_6E).,7ZJ,?Q.E@PHX['V]]5OX6=K2O*R4:EQ&E
M%5)KLDG+6WZ)=_DC7N<PXCA./5\KR?'8V5A:0FEYMK";_I'\4()KNYM]TO5O
MN:)X5^&EE>Y*^YCR?CV-M+C(N+Q^*5O#R[&W6G!RCK7FO2DWZI_+;2Z15X1Q
M6K8PLZG',/*TA6=Q&@[.FX*HUISZ=:V_F2MKB[&TNKNYMK.WI7%XXNXJ0II2
MJ],>F/4_?26ELA%P#B:PEQB(X#'PQMQ55>K0C245.:EU*3UW[/T^2[>G8Q:7
MAEPVC*H[; 6ENJE*K0G&AU4E.%1[G%J+2:?R^22]$B1R/#L'D>/V>#O+-U,7
M:='DT%6J14.C['=23>NVMOV+W'^+87CU2O5Q-A3H7%QI5J[E*I5J)>BE.3<F
ME\FR]# V$.15,Y&G562J45;RJ>=/I=-/:CT;Z>S;?IZM_,U^U\,^-6M>VK4*
M%ZJEO?/)0;OZ\E](:U*HTYZ;>WO?KM_,D[_AV%OJ6=A7M-+.0C#(2ISE3E7C
M&'0DW%IKX>W;YLAUX6\9=W"M5H75>BNANUKW52I1G*%'R8SE"3:<O+^';]?<
MD^&\)P_$(UEB(W4I5(QIJ5S<SKNG3COIIP<V^F"V^R^9LP
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M,3DLGXC9'F63Q]7%T98Z&*M+2O.,JTX*HZDJLU%M1VVDEMO2>]=CH(
M                           .;\B\/<C2Y'<<AX%G7@<G=:=[;U**K6EX
MUKXIT^W3/2^TN_ZVW@W.#\7<BO*K\LXYC*4M*56PL)U*B7?>O,>M^G_7K+<'
M\*\)QF_^MKNI<YOD4MN>4R,_-J[?KT)]H?H[Z[;.@
M
M
M                           II]6]]M>A4             $+RKDV.XS9
MTZV1G.56M+R[>UH0=2M<S^Y3@N\G_@O5Z1IM_P HYKCZV+O\CB\-:X^_OJ-G
M3QGG5*E[JI+6^M?T?5%;FXZ:2C+XCI@
M         +-W=6]G0E6O*]*A1CWE4JS48K\V^QJ%YXI\+MYSA3SUM>5(?:C8
M1G=M?GY2D67XK\4I][JXR-G#>O,NL7=48?[4J:2_2S:\'FL9GK&-[A;^UO[6
M795;>JJD=_+:]_P)  T;Q3\0:7!K/'T[>QJ97-Y*O&WL<=2J=$J[VDWU:>DM
MKOI]VE^*RN&\7KVUS+/\FJPO>3W,.F=5+^CLZ;[^117M!>[]9/N_9+$P*_G/
MSK(9NI+JQV%G/&X^&NTJVE](K?FG_1+Y=,_O&]
M                C\]F;# XRKD,M<PM[6GI.4MMR;[*,4N\I-]DEMM^AJ4;
MOF7*7+Z!1CQ7%;^&XO*2K7M9?.-+?12_]?4_]5&1:^&7'/-A<9FA7S]['O\
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M<UE%>5%S](;WOJTT_37K[HV<
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MN&NX<5R7*LPG]:\FNY7TW)::I;?0OR>Y27X21V,
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M=-+]'[BMEB^6YRYIU^27]OB;!-2^K,7*4IS]]5+EI/7X0C'\VC=TM+2
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MJL87%.SH0O*T*]S&"52K"'1&<M=VH[>D_EME\
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M4C1C3^G-Q^-NG--QCI[<5T_:6S[ BU**E%IIK::]RH
M                 !H&>4^5^(5G@TF\/@U3R5_W:5:XEU>12_%1TZC]MJ!O
MZ[     -)IIK:?9IGCRJ?E*GT1\M>D==CQ5M+>K-RJ4*4Y/WE%-_]=E^HO
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M%>K!)*3W'JCOIAU*+2DHZ?J;F
M "(M^.XVAR>[Y!"AO*W-O"UG6E)O5.+;48IO26WMZ]=(EP
M
M
M
M     #Q4FX2II4YSZY=+<=?#V;V]OT[:[;]4>P
M
M
M
M
M
M
M
M          &TEMO2
M:3336T_9E(QC"*C!*,4M)):214
M
M
M                                            \RIJ4X3;EN.]:DTN
M_P U[GH
M                         %))MK3:T^_XE0
M
M
M
M
M
M
M
M
M
M
M
M
M                 "D8*.]>[VRH
M
M
M                                    !YI5858N5.<9I-Q;3WW3TU^M
M-'H             HM[>VM>Q4                             ))>@
M
M
M                                               *3ZE"3@DY:[)O
M2;_,1WTKJ23]]%0
M
M
M
M
M                     "D9*45*+3BUM->Y4
M  'FC2IT:4*=&$:=."Z8PBM)+Y)'H
M
M
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M%&4DHU:;;]$I(N           : T!I     :         T-#0T-#0T
M  TI)II-/U3+:H45%Q5*GTOU72M,I&VH1DI1HTE)>C4$>ZE.%1:J0C)?*2V6
M_HEM_9Z/^PA]$M_[/1_V$/HEM_9Z/^PA]$MO[/1_V$/HEM_9Z/\ L(?1+;^S
MT?\ 80^B6_\ 9Z/^PBL;:A&2E&C3C)>C44BZ
M
&    ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>exh47_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh47_01.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ L(! 1$ _\0 '  !  (# 0$!              4& P0' @$(_\0
M0Q   0,# P,$ 0,"!0,$  (+ 0(#!  %$082(0<3,10B05%A%3)Q(X$6)$)2
MD0@7,R5BH;$T0U-RP8+1\&-S@Y+A_]H " $!   _ /U32E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*5RO\ ZD[O<[)TY3-LEPDV^6)[#9>CJ"5;
M5$@@_CG_ .!53N\G4"NGA<L^I;K&FW.\MPHR93J7I$92776,%0 ]JUM@XQQ[
MO/.:W=>J>H;_ */T3(@SY=OE(N,:VWEQE(0IQ]:EI*.1@$):*R ,#NIK;UE?
MM;GJMK6T:2GWE^7!3">ML)H!Q@*7VBYW=PP$84OR0/S5\TE=+S(Z_:BM=QN4
MA4.+:H\A,)*_Z+;JTMA>T8SC.2,_9K4CW.7KKK+J*PN7F?$LMHA-.1!:Y:F"
MXXM*%=U2D_O'N( )*>.0:J#.K-97/I5_BJ->'US=*W5<>X-M$!NYQFE)*E$
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MTG/<5W2A6W"O<1R?(SQFN9=2]$7#7<^992@VZQ0K<$1%&.VXT\^L\E(W@I*
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MIOZ[G8#!:<6II]*@M.Y6T!"L$@G/C)^#C] Z9M#-@L$"U1BI3<1E+6]1RI9
MY4H_))R2?LFJMHR%(E]0-7ZC=:<9B/EBW1 M!3W4L!6]S!\@K6I(/R$Y&0<U
M4-7=.]67G4ETF)7:'H[J9[<9;LIY"T-R(H:2C8$%"<*2DDC)5Y_%>'.F6ID(
MCR(SUM$N$U97&6U2'.V\]"2X%H60CA![G! /*02!5ZZ7Z?NNGK1=Q>_1^MN%
MUDW'9&=4XAL.J"MFY24DX.?CQBJ9=.G.H[OIZ^JFHLIN]VO$2XO15.K5%[;
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ME)PPRVVH [E>!YR2< >T?ZA6?36KK5J*3*C052&Y49*''&)4=;#G;7G8L)6
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MTN@OKW<D;2GV;>%$GP*FV^GDB9!UDQ>)T<JU"MF0E<9I2?3/MLH2%@%1SAQ
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M.V3N5X (Y.!53MVN[Q,4WJ"!>H3-]D6*V+4R(Z'!/=$N0VIG ]P42KPC!S]
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M^70(M"M9 AR_180E17&'GELO15+4D.;-N=Z2,@$@Y&>!4;J/6=PN>@_2:DU
M_"8=T[/6PZ%(;_4Y*'G&>TLE."0A"?:,$E9_MTCJ'?;K9NF^E%6B2B$S)5&9
MESW'"TB.V6B05+"%; 5!*=VTXS^<U29>K+^VSIZ3)UFX]:GF6V+W.@(0EN&/
M4E#4A"EH!/<V*25;<8!6.",[;.M;_P#XKN(MNI%W.Y,ZCDV]FPX9*5PTLJ4%
ME*4=P * &_../YS&6/7.I7X;(<U@V^J?-MS+B(J4JD0W'G"AU"BXR$-G(/\
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MCHB?-?E0[=?WKF^+?*;2GM,-1TAI)]N1G:7#S_JK5Z'R6U:DTLRE:5$Z*:4
MGD#$D@__ +*C;A)G6SK/JUVUW65&N[UTM28]J1LVSV%-H2\LH(W*2A 6=P("
M<&IGIAJ?4=ZZ@%%WN[;,G=*;GV/MN+5'"5J#1_8$M< >XJ.\*^\8QW_4-[&N
MK@EN[2V+Y%OD:-;[$EW^E+@+#86Z6P,J&%.**SPC8>1C%6K_ *>FT'IO&?\
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M<B'H.U7"UWFXQ;C;=)S'"ILX4'DRF\MK*DG@*_T^>.>/-^T[?[U<>I$95RU
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MOZ:%J?:IUSU/>KG-MTAQ]IR0IO!"FBWM*0G PDGD8)/D^,>M)=,8NF+Q9+A
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M6U*#BL>Y*D((//U@# JP3NF&F)KUR6]%?2B<F/O::D+;0VIA(2VXV$D;5A(
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MI:*2K:1XY_YJIQ]77O2D[5MFL3C<RWV^YH8MR[@7I:SF*MYUA&%;E[%( Y4
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M%NPE6Y9*,9C*.2UQ_IS\5I7'2D>?=[*\ZM*;9:&U^FA(1MPZ4%L+W9\)0I0
M \G.>!4_!BLP83$2*C9'8;2TVG).U*1@#)Y/ K-2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4JOZOU!+L+,94
M"Q3[PX\5[DQ2A*6DI25%2UK( ^@/DU1;=UH:F:+EZI_PO>6[0TQWV7E*:VO
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M0=JL6B=17&W3;Q'9M]OER8L-FXNH98=].D)*0%9X[>0"2 5JXY&.?W@3(/\
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M&X7"=$C(:E3U)7)<3Y=4E.U)/\ 8K1C:3LT;4ESOS$0HNER:2S+=[JREY"0
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M3?'M(SCX'Q\5I+T+IER1>7W+/&4Y>0$W#.2) !R-PSCR:T+?TMT3;U23%TY
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ME#:05*4HX  \DFL)AQ'(/I3&87#4G'9* 4$?6WQBOL&%%@,!B#&9C,@DAME
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MM;F\ND>W!2 ?ZO\ IS\@XG=0+U$FZ71%O=ORM5MS+@J2E#D@1Q;RPZ6.W_\
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M9" DYSVFT)3\Y*<D<FNEZ,TG$TPFXO,RITZ;<G_4RI<U22ZZK:$C(2E*0
M  *LE*4I2E*4I2E*4I2E*4I2E5G7NL8FB[?"ESH4V8B7+1";1$2@J[B\[<[U
M) !(QG/DBEBU)<+G)89DZ8N=M)==:?5*<9PUM2E25#:L[TJW8!3G!!SBK"9#
M #A+K8#8W+.X>T8SD_58_70_2"7ZJ/Z4IW][N)V;?O=XQ^:^N3(C4AEAR2PA
M][/:;4X I>/.T>3_ &KTS*C/NO-L/LN.LG:XA"P2@_2@/']Z2I<:(E!E2&6
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M(AC8E"E(8VNG8D^T[O/ SYY\U3M':'OD!VTHF:?;97#D7GU$EE; 2^) !:4
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M^HVDV(%OF.WN,EB>X6V#A62H'"MR<90$G 45 !)/.*SOZ[TPQ<I]O=O,5,N
MTIZ4WDGLI3MSN., Y6D8\DG K1Z=ZYCZR:U!(82RB%;;@N(V^E9PZA*$*WD$
M#:?<01^*CM4]5]/6_1][O%GFQ;D];@@=@**=REK"$'QDH).=PR" <&O%WUAJ
M6VZ;TX\F#8Y=TN]Q3!0MJ4ZF,4K2M:' =A5@A'(^/S6)CJ-,9FW"RWV+:K5J
M""Y%*TN35+COLO+2GN-J" K.20$D#DC)QS5GD:\TM'E3XSU^@)?@ F4GN@]G
M"DI(5]'<M(QYR0/->)74#2<2#"FR;_ :BS"H,.J<P%;3A6?H \$G&#YK"WU%
MTP57SOW1B,U9Y:84AUU8"2ZI(("<$D\DIQYRE7'%;*]>:50JU)5?K?FZ@&$
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M3LAMB)0AW@OKN+EJ$(0R9'J4)WE&W.!E.#G/@\XYQ#Q^J<27JJ))9FI;TO\
MH4JX2DNL$/,.LNH2L*'[@I(*@4@>?OBI5GJM92XRS)@W>%*=DQF$QY48-KV2
M%%+3W[L=HJ!!.<@\$9(SXO?5[3EEC=V:)847Y+26@&PI2(ZRAQT96 4!0(&#
MN5\).#6>+U7TM*U9&L#$Q2I$E8:9? ':6Z4A?;\[@<*')2$D\9SQ6S?M7Q;!
MJ.[_ *C/D&);[0FX.PFX>[:CN*!=2YY4>,;? QG-2&C-96[5L>X.6]J8PY!?
M,>0Q+9[;B%;0H>WG@@@BH"'U;T_(1/#D>Z19,4-%,63&V/2.ZO8UVTYSE2N
ME6T\Y( YK,]U/MS;21^CZ@7,2EQR1#3"R]&;0L(4XM.[E.XX!059P<9P:S?]
MRK*+KZ53%P3&5*=@MS^QF.Y);!*F4D'=O]J@,I )20"34)=>K,=W1RKC:;3>
M6YDN%(E06W8[>XM-M!?J2"YCM#>CR<G. #6SI?J;%=A:2B7IB>)]WA1E*F"-
MLCJD.,=TH!R"3@$^T%(R 2#62V]8=+SH[LG%QC14P57%MZ1%4@/M)6$*[8\J
M(44C&.21C-?+SU:M-DM0F7BU7B \7'4>CE--LO%#:4J6XG<X$K3A:?VDDDX
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M>I'QI>;WUL6\14;X[CJ^X27<Y6E+A4H)P/(!) YLV@--3M-6Y]FZ79JZ275
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M5$ ?'V:@]4Z#N]HN%L-DFOONS]7.W<R$P"Z((=86GWIW>Y (2-Q*?-3;/1R
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M3QS4%TECQ]4]9-=7ZY(=>DVZ1&$$NJ4E4<+:6E2=H.W&.,$'GGS6QH<QF?\
MJ2ZEOR2TA,>+%*%K( ;"FFRLC/C) )_^:QW/K%<FM4H=M\=B5IU5YCV=##;*
MC(>#K'<[Z5;L8R1M3MY'R*:;Z@ZO>G:FMUX>MK$O37K7)K\B.IJ.I.U'I,J!
MR K^HLD G:D?)&:9>=:W75&EI,'43L21)M>H[48\EIO9W$NG<"!_ 5CP<'GY
MK?8UOKPQ>HVH;9=V'V;'>ELKMSL7?MBMG:2V=XV^T9(QSM)SDUW+IU=KA?M,
MHN]QV=N<\[(A)#>Q0B*62QN&3[BC:3_-6:E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*5AG1(\^&_$FL-R(KZ"VZTZD*2M)&"D@^016E*T_9Y41,
M63:X+L=,<Q VMA) 9.,M@8_;[4\>/:/JOE@T]9].QG(]AM<*W,.*WK;BLI;"
ME8QD@#DX%2E*U)UL@3WHSTZ#%DNQE]QA;S25J:5D'<DD>T\#D?0K!=[#:+R[
M'<N]LA3EQMQ95)92X6]PPK&1QD<'[K&O3-B<!"[+;% LB.08K9RT""$>/V@@
M$#QP*DD,-(CI80TA+"4[ V$@)"<8QCQC'Q4:C35B195V=%EMB;2L[E0A%1V%
M'=NR6\;?(!\>:^?X9L/>+OZ):^Z7D22OTC>XNH!"',X_<D$@*\C/%;=IM<"S
MQ/2VF%&@Q=Q7V8S26T;B<DX  R37F[VFWWAAIFZPV);33R'VT/("@EQ)RE0S
M\BHQG1.F&6&646"V=IE3RVD&,@ALN_\ DVY'&X<''QQ6*=H'24Z+!C3-.6IZ
M-!2I$9E49!0T%'*@E.,#)Y_FI638[5)C0(\BW1'&(#B'8C:FDE+"T#"%(&/:
M0.!CQ6"1IBQ2;C+GR;/;WILQGT\A]R.E2WFN/8HD<I]HX/T*UF-%:88?@O,V
M"V(>@M%B,L1D;FFR""D''CW*X_)^Z\1-!Z3AQDQXNG+2TRE],H(3%1@.ISM7
MX\C<K'UDXKW_ ((TOVHK2;!;$MQ9!E,)3&0 VZ<96.."<#/W@?585: TJJW+
M@_H<(1%R53%-A& 75#:I?'R4\'[''BO=ST+I>YJ=5.L-O=+L=$1>60,LH4%)
M1Q_I!2D@?@?52-PL%IN+<!$ZW17TP'4/10ML'L+3^TI^L5#(Z<:/0&@G3T )
M:9>CMI[?"6WBHN) ^ =ROXR<8KQ<.FNCKBS":FZ?@O-PF4QF 4GVM).0@X/*
M0?@YJ:OVGK3?[,JTWB S*MJMN8ZAA'M(*<8\8P/%:]KT?IZU6B5:[?9H3$"4
M"F0REH8>R,'?G]W''.:CT=-]'(MLJ C3MN3%E);2^@-#+G;_ &;CY)&?.<UY
MTWHU5LU/,O=QGB?(+7HX"?3(9$.)NW!D;?W8.!D_"1^<RFI-*6+4RHIOUKBS
MS&45-=Y&[;G!(_() R#P<#CBMRW6:V6V7-E6^!%BR9J@N2ZRTE"GE#."HCR1
MD^?NHFZ:"TG=9[\VYZ;M,N8^077GHJ%K7@ #)(YX _XK)_@S3R+RB\1[1"8N
MS;09:EMLI"VP$[$XXQD)X!QP./'%:&F=$,V^VWAB_P H7^7>%@SY,F.A'J$I
M;2VE)0GVX"4C^Y)^:D&]%:7;0XA.GK1VW%-K4DPVR"IM)2A6,>4@D _ -1NI
M=!0KHQ.1:GDV1RYK(NCT.,T5S6BA25-K*DDC(4<*'(//-6Z,PU%C-,,(2VRT
M@(0A(P$I P *R4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I4#JZZ7BU167K)9V;GRI3Y>F>F2RA*2=V=JB2?  ']Q5&A=4[BJ
MSZ=N]WL4&U6B\R6&VI3MS"TI;<;=6I2LMIVJ2&T\'@[_ #P:O,G6.G(L2W2I
M%[M[<>X@&(XI](2\#@92<\C*AS^16IKC5$C3KMCCPH#4Z3=IPA-AV064-DH6
MO<I02HXP@^!6*-K2-!@K?UB[:+$2\MEG-S0ZAW8G*L**4X(.04XSQ^16W%UU
MI66Q->B:BM+[,)I+TE;<I"DM(/A2B#@"HVY]0K4G]$78I,&[L3[NBTNN1Y*5
M!A2D+7GVY!/L'''FI1>MM,(F3XJ[];42("%.24*D)!:2D@*)Y\ D _1X\UM2
M=3V*,S,=D7> VW#:0](4I].&D+_8I7/ 5\??Q7AW5>GVC;0N]6\?J6/1_P"8
M3_F,X *.?<,D#CY(K)?=266P&,+W=85O,E10SZEY+?<(QG&3^1_R*@=&=0+9
MJ&X7.V/2(46[PYTJ+Z(20MQ2&7"CN8X(!QG&*S:AUO"MS]F1;UQ+B)UV:M3Q
M9D@F.I:%+R0 <G"1P<<*S4EH^_*U#;94I<81BQ.E0]F_?GLO+;W9P/.S./C-
M0#'4JSOZYGV-F7!7!@6Y4V5/3*24LN)>[:FE#P",@^?G&*L<#4]BN#:%PKQ;
MWPME4E.R0@DM).U2\9SM!X)^#Q7@ZLTZ)4&,J^VM,F<A#D5E4I 6^E?[5(3G
M*@?C'FM6)KS2TFVFX)OUN:AB4N'W7Y"6P7D*(*!N(YXR/L8(X.::]U;%TC86
M;C([*P_*9B-=UX--[W%A(4I9SM2!E1.#P#Q633&HDW&S19%U<MD6:\^N-VHT
MY#[:W$E6 A8QN)2G=MP" >1P:@=,]1#>Y6E&%6OTYOD>8\?ZX7V%1UI24\#"
M@=QY&/%7&3>;9%5)3)N,)E4;9WPX^E):WG"-V3[=QX&?/Q6O-U+8H*%+FWJV
M1D)>,=2GI3: '0,E!R?W $''GFM#66L;;IJRW.6J1%D38<5R4F")*$.NA*%+
MP >>0DG.#P":S-ZD8E)A"WKAOOK<:1*8,M*7(H<05#*>25<<)XR,GXK?BWRT
MRYRX42YP7YB 5*8:D(4XD X)*0<X!X_FO<"ZVZX.+1 GQ)2V\%:67DK*<@$9
M /'!!_N*AV=61)]P@HLST&;!<D2(TJ1ZM*%,N-#E*4$96<^<$8'/(K;.K-.X
MR+]:C[D)XEMGE9PD>?D^/NMQ=WMR+NW:USHR;DXV7D12ZGN*0/*@G.<?FO$F
M^6J+=XUJDW&(U<Y*2MB*MY(=< \E*2<GP?\ @_58H&I+)<9KD2WW>WRI+;?>
M6TS(0M249QN(!\9&*B=(ZV@ZIU%J"WVI3$B):O3[9C#X=0^74*4<$<#;C'G_
M (K+*U[I>/!N<LWN"ZU;5!$L-/)6IHE80 0#Q[CC/W2/KS33Z[N!=XB$VIQ+
M<E:W4I2"I*5 @YY!W 9'SD>:V96L=-Q!",F^VQKUH0J,%R4 NA9PDI&>02",
M^.*TE:T@2;HN#:I5O<>BW1%MFIDR>T4*4V5X;&#O7\!/&2%\^TU),ZJL#UPG
MP6KS;U2X"%.RVA(3EA*?W*7S[0/G/CYK-8[_ &B_M/N6.YP[@VPOM.+BO)<2
ME6,X)23\$5HM:JMT: ]*O=SL\)D27F6G!.0I"TH4?).,+P,J3SM.>:V;OJ6T
M6G3+NH)DYD6=#27O4MJWH4E6 DI(_=DD 8\Y%1L#6]I?U1<+'(F0H\QI]MF*
MVJ2G?*"V$.[DI\X]Q'&<[:EK9J&SW2Y3;?;;G#E381Q)89>2M;1R1A0!XY!%
M?6]0V9R[FU-W:WJN8W Q$R$%T;0"?9G/ ()X^:T_\9Z9VSU&_6Q*8#G:E%4E
M #*\D;59/!RDC^Q^JJL3JE$N>J)<6S*M,JQ6Y*%W"XJN2$%I"V]X=2G!"D#(
M23N!"LC''-J<UGIANV,W%S45H3 >4I#4@S&PVXH>0E6<$CZ%?).M=+QERD/Z
MBM"'(J%+?09C>YM*3M45#.1@\?SQ6=S5-A:EV^*Y>+>F1<$!R(V9"<OI/@IY
MY!^/OXK)#U)8YT]V#"O%ND36DJ6XPU)0M:$I.U1*0<@ C!^C6K_C/3)MDFXI
MO]J7 BJ"'WT2D*0VH^ H@\$_'W4HNYP$6O\ 4US8R;=VP]ZHNI#6PC(5OSC&
M/G-4K5_42+$C6AO2TNR7*;=7W6(RGIZ4,%3:,J3O3G*BHH0$_:Q4GJ76L73T
M2.Q< RW?9,!^8S!+WM6IEO>M&_'C/ ..<$XIIC7MDO&D&[X_<[='2U'9=GI$
ME*DQ'%H2K8I7WE6.?)_-9=3ZPAVOI]<-5VPLW.)'BJE-=MW"'@/@* ..>/%1
MVEM97&<GU>H8%IM5I<BIEHDHNJ7"V%%.Q+J5(1M)"N""1E)'U4U#UEIJ;/9@
MP[];'YCSBVFV&Y*%+6I&=P !SQ@_\5H7W7UCB62^2K5<K=<YML@/3C$9E)4I
M26PK(.W./<G;XX-;4'65G7#L)N4^'!GWB.T]'BNO +45I!PD'SR<?DU((U#9
MG'H[+5T@N.R'EQVDH?2HK=0"5H&#^Y(!R/BM0:STT;;+N OMM,*(YVGWO4)V
MMK^$DYX)^!\_%8VM2&3>+:FWQVI=@EP79ANK3V6VRDH 2>-N%!60=V?:>.":
MD;!?K5J&$J98Y\:?%2LMEUA86D* !QD?."#_ '%25*4I2E*4I2E*4I2E*4I2
ME:-]:DR++/9@H9<E.,+0TEY90@J*2!N4 2!_8US^%H6[-Z-Z>6J0+<J1I^8P
M]+'<4IM2&VG$91[.5>Y) ('\U4(O1V_P8-M0#9;F4PGH,B+-??2P@+E./)6D
M( W\. *0K .T<\5?.J>DKCJ-G3B+7!LT]JVS?4O1;FM2674]I: G 0O/[\\C
MX%1<31%Y5^D)59],6N'#F/R/10%K+;8<CN-[@2VD%16L' 2D )\DGBG:CT-=
M]-=-YDFX)@*3!T<_9WA'<)*WBZE25C*1D;4YYYR<8^:LD705\N5^C:ADHM\%
M;UXA3W(;4A3B&F(\=UO(4$#<XHN\C & .36NUHB9;(]M9U2F C3-A,_?*96X
MZ]-:DA:=JV@CV !T[CN5DHSP.:U;3H&]7/IQ;):);DJ]"X,3PF4\N)ZB.RDM
M,M*6V-R#VL+SC.\Y->IO2J[)=85"MUC,67%3#DP')<H,P@EYQU*@0H&1RYR%
M;<J2"-N>+7U7TS>[Z]:W-.,--SF4K;]<9?;+*5*02A;124O-*VY4@\Y2DBH2
M'T^OS%T5,91;VGT7*]S6G5KWC_- A@J3MY\^X?0^?%1M@Z>:J:N4&3-AV^.V
MU=;;.6A,Y3YV,QW&E@$H3@@E)"0-H!P/&3T#2&GKE$TK?;7<%"'(F3I[C+T=
MW>I*'W5K0L' PH;_ !^*Y@GI=JZXP&FI;%KMSD"S1[6P(\U>V4IB2AT*44H!
M0E82<X)(/-32>F%W>L=O7&;M]ENRYCYF)8E/R,Q)* B0DN.*)6X2$K!X 4D8
M^SLZEZ?WJ1.OMMM<>"+3>)$)]NX%_8];DL=H%"4;"5##0VX4 "H^.2:Y*Z3W
MY%B@,.08MP$25<&5P$W-R*W)8DN[PZ7$ $$#VE!W I_/%=$U+I"?-T7IBT0F
MX)=M<V!(=0IU8;V,*2I24%04H\)P-Q_DU4UZ U(-;)<;BPU6EO5/Z_ZDRMJB
MVI@-EL-[3RDI\Y&<C'DD36D]&7N'=-$RKBU#939X]Q1)2U(*\K?<24;?:,C"
M<\^,XQQ67J)T\EZHO[KL.2U$M]PM_I;@M*BEXN-.!R,M&!C*5DY)_P!(Q\\0
M_P#@J_VAZT7-VV1-2R7H,F-=(BGTM)3(D.)<6Z@KX*>"@_.U*<#XJ/B=*;S&
ML&K(CHARYLRP1+="E+4"ONH9<0Y[B,I2=R1G/(%2%NT7JAF):[=-BPI MU_B
MSQ<NZ@.RF$A6XN )&5HR$@_(QXQS$2= W"PQI]RN$> S"0[?)4N4TX4N(8?;
M/:_8C<KY.!RGX!KW_P!/DYU[4L]N8W;9<L6F)',ZUSD26&VV!L2A6U(VK65*
M5@DG"?  &9*S:*U!'U5:'G;3$;M]LN]VEEQ,I)]0W)"E-JV;>,;P@@G/M^N*
MJHZ-WPVI32[59S(.DA:DD*2-DT/$]S.WSLQ[_)-7*!H"]1NI;EUD1HLV Y.;
MGHENW%Y*XQ$?M*0&$X0HC&$J/A*CG/Q[USHG4EYZCV^ZPFK<JUQI<"3N,CM.
M$,K65A:0V2L^_*25  9&.35=8Z0WS]&CQ$&!#EJAWB/(DLKY69+R5,A1VY4G
M:,'Z!/\ %7KIQ8+[ U+J6\WVW6ZW"ZM1 W'AR2]VRRVILI/L2 /! &<9JC6K
MI=J^/^IE\6/<_;416]LI>PNMR^\DAL-!+2"#C"<X//))J:O?3W4TZ1>933EK
M2X]>(UZC->J?0%K3'#+C2UH"5( QN2M.3D#(%1URZ57N3IZY0H\33\-Z59?1
M-I8==4EI_P!2ITX4M)400KE6<[O@>:E)/3N_NWQ+H<MYA(U3&OR5%]>\MIC]
MMQ)3LQNW $<\Y.<5'W/IOJ:99$VMQ%N(ML*Z,Q9R9:R[.,IMQ"0ZDH&S]X4H
M[E94D?VN/3K2=PTY?KW(F)C"++AV]AHM.%1W,,E"\C:.,G@DY/XJ"MV@;LQ)
M@B3%@/,-Z@N=S65.X*6GT.I;P-IYRM)/U@?V],Z$O:?^GE&CEB/^M(B=G =_
MIJ(=W ;L>"!CQ\UGUAHF\WB[6ZY0V(#3J+Q;;B\@O$$(82H.(W!//)&/O\8K
M4Z2=/[MI6_%VZQ8Z_2Q7(J+D;F^^Y*2IP+&&5>QH<94.><8^28*RZ<FZGU?J
M>,RS&9AQ=4/35W'OY?94(R6PVEL#()W9W$X SP3BL.G.E-\A+LZ95K@!ZU3(
M23,-U??$F.RHE12TL%+7PK:/]1.,"K/?M"WR2[JYZ(Q;B)ER@W&"TMXJ#HCA
MO<TX"D! 46^.2 5?C->+)H>^G5T;4$R';XC;]W7/?MX?[GIV_1F/[2$ *4I7
MN5X'M3R36M"Z<WEF[LR'HEJ<9_6;M<% O'*&Y#:DM >SSN5D_7'FJV.EFM6&
M-.1F6K(MNVQX&YQ,E3)+C#Y<4E1#94X"#QG 3S@9.3+GI5>GV?2D0H:7E7L.
M2FGB5MB6?Z/&T%6!P1D<5FN^B-77=FVW"7:M/QYUN?9<,.#,=8,\)96TI2Y"
M$I4@@*&P8. % D@U.W#0EP>Z2V^P06;? GP7VI;<)IUQR*HMO]T,E:\K*3P"
MK[YQCBHO3^B-0M]0H&I9<&&Q'?N$N;)B>JW&+W(Z&DX]I"U$MA1(('('Q4_U
M*TO>[S?K?.LB(KC2+7<+>^EZ06B"^A&Q0PA60%(Y'Y!^*IDSI;J!Z+'0PW!9
M=B6ZSI2E$I;29+\/N;T+4V M(/<&U8Y!0D_Q9Y>B+H[T7O&FXT:!%NMP;=/9
M1*=<:0MQ>X[G7,K6KDDJ(Y)^N:JS_3B^/:%N]DA:1TY9Y<JU(AN2HT\J5+<0
M4E*E)#20/]9).3X&?FMQ?32^JOAE=FWI;_Q1"O&_O>X,-,A*P!M\[AXXS_\
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MI+OZ1&4H)BI<(2\I!.4^TIR 5'.<9Q7F?U5TW#EH9'ZC(0IQAKOQH+KC6Y]
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M.U)64CW _N'WQE1U4F6U[3T^_MXLUT@SIX])"=<<[2'4=E6!D@!E>Y1.!_'
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MCP6T-("O)&:BH_1!;5A>M:[[&4RPZR];\6AA(;4T3L,C',C@D'<0#DGS5O\
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M2$[4CV[E*/.3SYJL+Z3VAVU.6J1<+F]:T17H<*,M:,06W1A7;4$[E'' *RK
MX\$UG=Z:Q926WKA>KK*N:+A'N GK[27-S*2EM&U* C8 I?&WRHG-0XZ)V?L7
M!A=YO3C,N$_!V+6T>VVZ^'U8/;R3O&<J)/-3DWIK:IMPG2Y$N<I<R?"N#B0I
M('<BI2E &$_M(2,__&*QVKIA:+<Y9E-2YRE6M<]36Y2??ZLDN!7M^/C&/'.:
MHM]T!J6VW6##TC#EAJ#!C0X5T<GQBVCM;BE3S*V5*R%+6?8>1CQ75]3:8:U
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M.1D>1^1509Z3Z?C1[RW#7,85=+8+4\M+@40C8$*6,@CN*"4;E'.=@/WG>E:
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MQW^]WR2Q*B38,]H6^\0D*#B5NM?MR4JRA:4J*5#R1M\;:V;YHBVW"%>F8:1
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MQD-]MA(*7"DI*@?O:2/XJO1]/],RF3%CV[3Z/7/NVIU"$(07G0H+6SQR5!2
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M:JU!'U)/7;M5OPX;-QM<8,)9CJ0AJ4@;UY4@D^"1DXSG^*B+KK35;%K:M/\
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MQ\?'U41I/2D33:[LXR\[)>N,YZ<XZ\E.Y)<()0" /:,<"IH1(R4I"8[("<8
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MX5G>E0""LE.2!@&M/5O41UO6&F[?9A(;@&]*@3IBVVS'>VLK*VTJ*MV4G&2
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MF;M<[G+FWA-R:N3DLMMMETM-*:;;*4IP$I2H^.223GG%:\/I\WIM0E053+O
MMX?5;+&2TA#!>X<2%JQN&"L *. %$<UBL?3!$?I[;;0Y+=@WB+)%P;F,+[IC
MR "E.-W"TI;(:P1@I'@5O+Z=R?7QIK&J[NS)4PB/<G$I:S/0@J4G/MPV05*
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M/R/!YY\X&*GV.HDZRC6#MLC6Q,L:ED1"J1*==2M*&%*W!&[.[^FE.$X2,Y.
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M$6I [I[3WM!7[<_6?KXJ$TKT_N,+4%MDOVUB)%,>Z*PE:%F J2^VXTVD<@E
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M>H;]/A6V&^R+]%O<=M4A*!.2A@-K9.4G:0<J!5P3_P B^=-+/,M%HGKN,1N
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M2G(!.#5CA72%-ES(L20VZ_#4E$A"3DMJ4D* /\I4#_>J+U!UM<[3JR!IZQ"
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M'ND;S\ #;_)S6TC0-]AR+VS;+_%8M%W6]*DQE0=SGJ'&=BMKF_ALJPO&,C&
M><U"7+I3?7M.M6B%?+<VR[8HEEF%^&MPK$=2U)4C#@QN[A!SG'Q4B>FUV3J!
M#K5XM_Z,U<G[FW&=A*6Z%OLK;<1O[@&S^HH@8R.!\5J/]*;FYI>-9TW2$$MZ
M<78UK4PHY4I:5!P>[@>WQS58>BW:+KY3%LB!YT72/*3!E6B8TE;C328ZY"9"
M5=G84[E!2@?C@G%=*UQHB9?]0LW2%/88_P#2I=J>;>:*\I>2,*201@A0'!SD
M9K:T#I2;IQ]YR;,9?"K= @I2T@C:8[:TJ423SN*^/& *G-6V&+J?3-SLD\J$
M:<PIA2D^49'"A^0<$?Q57MFFM42-,2M-ZDN%I=MB[>NWA^(PXE]P%!0%*!5M
M2<<G&>?JJU,Z::EN:HMRN=UM7ZY:H\5FW.,M.=I99>2[N>!.?<4@$#QYJ+D]
M&;L^1/DN:<N%S7<)LIQB=$<=B;)*DK)"2=P6E2>,8!!P?DGH.H=)SW+?IARP
MR(C5TT^M*F$O(+<9U):+2T%*,[!M4<8!VXQXJ,TCH.YV'4UMNJY,!:2U/,YM
MM*D@.RGT/'M#_:DMI3S@XR?Q4CJ73-Y1K1G5.E'X GJA_I\N-/WAIUH+WI4%
M(!(6"2.000KXQ6K?=,:D<O\ $U!;'K2[=5VURV3&9/<;8*%+WI4C 4<I.0<_
MN'U52B]&KC @W"!#N,5<5YVSJ;6]OW[88'<)XX*L>T#@>.*\RNEFI9$MB(95
MH%JA1;O%C/[W.^XF8GV]Q.W *5$Y(/('C->ATWUE+FNWB;*L3%U9-O=BQV5.
MJ96N(7,)<) .U0<SD#@@<<<V:TZ:U:CJ#9]0W=^T/)3!DPYC<8K0EL+=#C?;
M!'OQM )5CR343J;0>JKEU3BW]F1;G+3$G1Y3#;KZT*0A+2FW$; DI*LDJ"SS
MX ( J*B=)+^G2]NM#TNWI7#LHB)?2ZL@R4S$2$@IVC+9" DG.>3P>*OW3JQ7
MVU7#4L_4?Z:A^[RT2DM07%N);PRAL@E24_[!\54K)H/4\63:A+;MFR+>[E<%
MN-REG+4AIP)X*![MSI!_"?SQIZ9Z=ZLM,K2*4>@B_IL./'ES8TUP*>;;4XI;
M"VBG8XD[AA7!25*/-87.FVK[;I*#;[4JT2Y3NG7;!,0^^M"&@HJ(=;5L))]Y
M!! SA/UQG8Z77N-?KDH1=/2XLI#LAN?+#BY+#SC ;4T@?M"<I&%^0D^#BNH:
M"M<JQZ)L-JN':]7"@LQG2THJ25(0$G!('''U5)MFA+TQ:.J$1Q4)+FI)$ER"
MKNJ4 EQHH'<]OMYQXS\_WC-7],-276+9(L&ZVXQ;= A,!N0' E+[#B%%8">%
M!021[N4XP/W$UNV[IG=8UP4AVXQ7+9!<GR+8 %ATN2TJW!X^"E)6O&WSQFM&
MX]+;]*@AE,RUA?\ A)K3^X[_ /S)<2HK\?MP#CYSCBJY'E3V.JJV;3!@36'-
M0JF+@R(TQF0PX4".M])P6BC9O6%J.#G@ D 6?J39[S?^I4BSV80TLW+32X<M
MZ47 &6EOX4IL)&%.8/"21XY-;$?IS=XMP<M+3D)6F'+NS>_4*<4)2%M]L]G;
MMVD%38]^[."1CQ7BW])YAMUD@7*>QV(EIN-L?7'*@O\ S*P4K1D8R$YSGY^Z
MTM20;];.G[%GOTF"N_MJ89T^;7&=4ZN0P?Z;CBE9'(P5 C:$[^3GCI^F[5(L
M,6W6F*EA5IB0PT72HAY3H(Y(Q@A0W$G.<_S4/K+2\^[Z[T1>H:H_I[*_*7)2
MXLI44NM;!MP#D@CYQ5>OG3^\W'54RXI?B(CN:BMUU0.X=_9CLAM8/MX)/('(
MKQTKZ;SM'7UQ4B-8UQ(R'&6+@AM9G2D*5N'<).U&,D';^XC/%2,#3NJM+7V\
MHTN+3*M%XFN7!2IKBVUPGE@!>$H2>XDD @92?.3SFH^ZZ#OSUVNEOC&W+T_=
M;JQ>'Y;BE>I8<;+14A",8(461@[AM"CYK2B=+;TS$@LKF6]1:A7B,X0MS 5,
M<*T%(V^$\9\'D^:K-NTO>)^L=4:.2(?HU6VRQKA*4I2%)0TV2I3*<>_)24\D
M8R#S@U*WKI7JNZ7.]O2I%H>%P@SX2752'@4!YU"VB48*4[=N,)'."25$U\U]
MIF9:F-53I+[1O-Z?M[MB1#2MQY,R,V G_3CRD\^-I5G%='E:26GI5+TI 6RA
M]ZUNP@ZL%*"ZXVI*G%8^U**CC[JDCI7>@XY_GH*D*E65X9*\A$) #@QC&5$9
M'\\XJ*?T%(L,N[7K7USA.V>9!F6V4XRI];I3(D!:"A!"@DCA.$X \\\FK=H"
M+?=,Z/THA<!<ZYW>4ER\N.@H<9WMJ45JP,90$-HP<> /)J7O&E[C-ZBIOC+D
M9$ 61^VD*6KN%QQQ*@< 8VC:.<YY\57;/H/4&G+7HMVV.V^;=+)!=MK[#[JV
MV'$.E!+B5!)(*2A)QM]PR..*@VNCMX@Z?N-NB3X#QD)M"$*<*T >D<4MS(P>
M#N]HY_.*Z9H6P3+"WJ!$Q;!]==Y,]DM**L-N$$!0(&% YX&1^:Y_IOI9?;79
M3;Y$RVN!&G9UE;6V5@J6\\5H601@#'G'(/W6Y#Z7W-+2VI$^$A)=LSH4VE1/
M^22D+!SC]Q3Q]9YK9T-TWEZ9U>J88^G7(+;LA]N>F'BXN=U2SL6OP G>1N&2
M0 , 5ZU-T]NUTU#J"?$FQ&4RY-ON4):MQ*),7 "'$XP6U8\@Y&?!Q5BZ?Z=N
M%ID7VZ7PPTW6\RDR'F8:E*9:"6TMI2"H J.$Y*L#)/XJWTI2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4P,YQS3 SGYI2F*4I2E*4P*4P
M*4H1GS2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2O*G6TN(;4M(6O.U)/*L><5B3,C+0
MM:9#10@@*4%C ) (!_L1_P BO4B2Q&+7J'FVNZL-M[U!.]9\)&?)X/'XK(I2
M4E(40"HX&?DUX1(96\XTAUM3K1 6@*!*<\C(^,UX,N,&5.F0UVDE0*]XP-N=
MW/XP<_6#7E4^&D JE, $I2,N 9*OVC^_Q]U[]7'VJ/?:PESM*.\<+R!M/YR1
MQ^:S4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I47<K<[)NT"8RXR@Q6WDCN(*CN6$@'@CC@Y_D55;?H2;#MC<5J
M[H;6W"?@I6E@K2 XAL!S:I1]P4V#@Y!!(\G-;LO2,EV\IN3-P0E7JFIBF7&=
MR2ZA#K9.01Y;6VG_ /Q)Y.35@N%M,YVU.NNA+D&0)'M2<+/;6@C&>!_4)^?%
M1=PTLW*NTFX-.I9=>?BO+2$;DK["TJ"C]+(!1N'QC(.*UXFCF!"2);43U2)\
MBX;6$J#+CCJ7$>\**B04N'(! S^*AX73"/"B2HC5Q>=C2$14 /MI46C'" VM
M/&,GMIW#&#YJ?E:5C-VN1 M[$8Q94X2W6904I",J"EEO:00HJ!4#GA2B?'%6
M:E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5\2D)&$
M@ 9SQ7VE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
HI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>exh47_02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh47_02.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ K\! 1$ _\0 '  !  (# 0$!              4& P0' @$(_\0
M0Q   0,# P,$  4# P,"!0$) 0(#!  %$082(0<3,10B05$5(S)A<19"@20S
MD0@74F*A)31RL<%#4X)CDM'A&";P_]H " $!   _ /U32E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2ASCBE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I5+UWKE6D74O/V.?*M+(;5.GM%*41TN+V)VI)RX=V,I3X!!^0*N@Y
M -*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*AKG:9TN]P9L:^SH<5C_ '8+3;2FI'.?<5(*A]<*''UYJ"UY
M&U)<9L>+:K+:IUN9V20N;<%L!3Z22D*0EM6Y*2$JQD9('US,ZFL3]]C16V[S
M=+0MI16I5N=2@KR,85N2<@5.TI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5$76_P8$M=O
M$B.N[F([,:AK=#9<0C )*CPD9(&3^YYP<947NWAN-ZF9$CO/I;4EI<A!)*P=
MH'/NS@XQYP<5E7=[:BW&>N?$3!'!D%Y(;'./U9QYX_FMQ"DK0E:%!25#((.0
M16H+K;S.=A"=%,QI.]Q@.I[B$X!R4YR!R/\ FL35]M#R@EJZ05J*TM@)D()*
ME#*4^?)'('S65=T@(E/15S8J9++?=<:+J=Z$?^1&<@?O7EN\6UR-(D-W"(J/
M')#SJ7DE+1'G<<X'^:C-$ZF:U3;IDMEE+:(\Y^&"AT.I<#:L!:5#@A0P?\_-
M3$BX0HTIB-)EQVI#Y(9:<<"5.8_\03D_XJM6/7UHN+<?U:_PZ1)N4FUQV'U
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M5!MY8X22LX&?DD>/&U>.LEA@V.\3X\:>\[;FVG?3NLEI3S;C_92M.<G!4#Y
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M4S&6X Y)!+2, 9)(Q\<;D_XVM::XMFD766[DQ<'ENQWI21$C*=PVUM[BB1P
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M;GWS.<GVT+0TL(,@+<0%-DG@!6['Q6E,ZR18L1#:K'-7?$R9$61;&W$K6R6
MDK.Y.0H86C&/.['&*Z9:IJ;E:X<YMMUI$EE#R6W4[5I"D@X4/@C/(K:I2E*4
MI2E*4I2E*4I2E*51M=Z#<U+=%3X5V-N?>MDBT/DQP\%,.D$[<D;59 YYX)&
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M-H$Z[R[B[<KCW9-UB7<I!;VI=CI"4)'LSM( SDD\#!'.=%?26WMQ(B+=?+Y
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MS<0YI/T<MEE-ZF7=5Y]J6E-O(>+8!W;E.;G0DC P$Y^B=.?I'46HK1;@;._
M=L%LBP2TZ4!4UYJ0PZL-'=@HQ']JE;<E?['%MM-FO%TM/42XF)(MK^HDJ3!C
M2E!+K>V*EE*EA.=A*AGR3@"J3*M$N^6C0TVS69Z2PUIB=;5]I"<Q9)CI0$*'
M!20I*T_SQ46YH._1-/I:M%EG1HB[79G;E$8"$N2UMEWU" E84A3G^WE*A@@
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M01]UZI2E*4I2E*4I2E*4I2E*5R_JBS'?U]I%#MA:OKJX5R2B(M32<G#'.7"
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MKK.O]DN%I3"6B,W)CR$R7%((0\$#<C:DY(*/!QG/D5SQ'2J_(TLFV]^W*?\
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M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*\E!+J5[U
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MTJNT(7)""M4<N@*2 D*.?X20K'T<^*]V#4-HU"R\]9+C&G-LK[;BF%A02?\
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MMP]I]I4 %$*P>*UH?5NUR(JG%V>\L2%JAIC1'$LEV5ZK=V2C:X4#.Q9]RDX
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MK3W$J>.5A!VX SG&0?-:\_IVP_.N4R'?;W;Y$]+(=].ZWL*FDI2D[5((.0D
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MT\HHX)3^8L$#))3GG.*E[%U-E3KU!M,^QIB3G;L_:9"42@ZEI;<?OA25!(W
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M8+DIE,IZY%M3"5-QW@X^X59=;1^<-I"CA8&.,CHVFNH4>;K-VRSA+;D3'/\
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M(4XZI>Y2$! //CVI&?O%05XZ:6&[7B[7*2Y=&W[JVEF:EB>ZTV^VE.T(4E)
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M2TXV'/<?<G8EUQ10G*1O4$'.1MJO7+6NH;=JK63;%SB*;:NL*!"B/1RZL%;
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M"SR+=<FA)@2DA+C>X@+3D'&0?'%?GEW36GQTWZN2&[-:DRX%WGM17$QFPIA
M0WM2D@92.3P/WJ9NO435-ID3[('H"Y#%Z9MZ)J6D1VFFUQ0[M]ZBD>["4E1Y
M'[XJ]C5]VB=&)>II;<"7>HD)Y:TPEEUA3K94G((\@%.58/&#@_-474^NM2VG
M3X,#55LN\]>^0@PHK.]#:8BW=KF5[$C>@GC*BGQR:U+7J^9$F:HU!&1&8GW.
M/I[OR=@4W&#Z"%NJ&>4H"CY./&>*G;EKZ[6JXW* [J.T3&&;#-FL7!#*$(5*
M;=2$(/O*2H)4,I'FM%&J7;9)U9=VIC<:;<%V4;FF$.'>ZRG<D!2DI!(SA2E
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M%"5C*4\#&XC_ !SSS7)4R[O>]964.7UP3&]77:*RZ4I<,5"6%)2$I/QM' /
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M6LE/=RIET;]Q!3N)QSCR:I</6FHGK %B^RALTK=9 =4E!4M]B06VG,A/ZBD
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M=;4M+36U(0%]KW8ROR0<<W;J?HXWW4^AVQ91<+! ]8F6PG:$(26 &@4DCC<
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M\Y7U6U$N7I!U,N.VB4J$S<8YBH#8[[KB.[W%+"AN" I(2" /)Y ,O!UKK"9
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MR67$H:W'>-@.2<']_'D0\KJ7J5V/$M,*Z(@3T*EEZX7I,>,"\SVSZ?*0MM8
M<"B4 %2?!2<U;M$ZXN<W6BV[]=X)MDI@KB>D[3D8E#32G 7,AUM:5*5E+B>0
M1X(YZ[2E*4I2E*4I2E*4I2E*4I2E*4J(EV&+(U"Q>"5IE-QUQ' ,%+S*B#L4
M#]* ((Q\CP:CWM#6).F)6G[;#:M=KEJS(:A(2WW4DC>D\?W ;2?.#P15F0A+
M:$H0D)0D8 '@"OM*T9=GMLRXQ9\NWQ'YT7/IY#C*5.-9\[5$9'^*R0[?#A/2
MW8D9EEV4YWGU-H"2ZO 3N5CR< #/[5@@QK5^+7"9#9B_B)4EB6\A([F0D*2A
M:O/"5)('T14'JNS:+8F,WC4UJLRI;S[3#<N5$0M:G20EM.XI)SX ^JEIVFK+
M/N\6Z3;7#?N$8 ,R%M K1@Y&#^QY'T?%>?Z6L #>++;@&PZE($9  #O^X/']
MWS]_-5^WZ;Z?3],2G;?9[&NR**N\MF,A*"6%*222 #E)"P#_ #CS66S1])6*
M).UI;'&(UKFP(Y<>:3M9##25=M02!D>U0'\)2.,5*S-*:;NS#IEV:WR6Y+Z9
MKF]A)[CH3A+AXY5CC/U4C>;1;KW!,.\08TZ(5)669#8<02#D'!XJ+8T1I>/%
M5&9L%L;CJ87%+:8Z0DM+5O4C&/TE7./NL5GTFB'?+A=)\I,UUYCT4=OTZ&T1
MH@45!D ?JY."3Y"4\<<[6AOPI.D[:WIZ49=J:;[+#Q5N*PDE)R<#/((K?9M-
MM9=:<9@Q$.,...MJ0TD%M;F2M0XX*LG)^<\U'Q-':=AK97%LT%I;7>[:D- %
M/=_W,?\ U?/W667$L=DTH_%E1XD;3\6,M+K*D#LH9"3N!3XVXSQ6K"TKI9_3
M";9%LUM78Y(#PCB.GMKR 0K!'G&,'R,#ZK:N>GXS^D)FG[:&[=%>AKAM=EI.
MUA*D%((1X.,^*AK-T\TU;-*L6F;:K9*9;2TN2M<5*4ONMI #JDDGG@^2<9-1
M[3_3*T60RF?Z=BVJ2%VWNH0VEIU.2I;60,%.2HGX')-6O35BL=BA%.G+= @Q
MG]JSZ1I*$N<8"B4CW<?-?(KECNLNYQV$0I,B.^A,U':!*74A*D;\CE0&T@_&
M!6R_9K7(?6\_;83KRW&WE.+80I2EHX0HDC]2?@^1\5C.G[,9$M\VFW]^6 )+
MGID;G@/_ #.,J\#S49=M4Z<T[?&K?+<#%PG%M2@S%6O]2NVA3JD)(2"H;05$
M9Q@>*RW!.G+),M_J8,./(N$Q3+"T0P2N0X@E1*DIX*DH.5'&<8)I9V-,WV/"
MN%MA6Z2W;W'(\5T1DCTZD**%I;RG*<%)''''%2=YM-NO<!<*\08TZ&OE3,AM
M+B"?O!^?WJ%EV/2:X\72<BSP#$4A4AF#Z/\ ) 01E0PG:%94/G)R?/-23FF[
M&ZRIIVSVU;2F$1BA45!26D'*6R,?I!Y \ U!ZNZ?6C49MJ'(\)F-'N*;C)8]
M(A:9B@VI!"_')"A[N?TBI6=H_35P3'3.T_:)*8S?99#L-M8:1G.U.1P/V%?)
MFF+:8[BK9$@V^XA3SL>:W$;4MAYT86Z,CE1XS]XP:UNGK5JBV63!M$_\07$F
MR&YL@IVJ5+4LN/;@ !G<L\#@< >*E'=/V=V89;MJ@+DE],GNJCH*NZD%*7,X
MSN ) 5Y K73I+3B%SUIL5J"YZ5)EJ$1O,@*.2%G'N!/)S6IJ^-I:VV6?==26
M^ 8#,4,2''(H=_("@0V0$DE.[!QX!YKTW:=,761<X*K/!?6R\VN4AZ -JG.V
M-BLJ3M60C R"<#CCQ6PWI+3C41Z,W8K6F.\UV'&A%0$K;W%>PC'*=RE*QXR2
M:AM/Q+9(OESU8+NJ>W'2] 83V0VB TVH=YL  %1WMY*C\  <>?&HM+67J*K2
MMY><8F6J*5RVV'XW<;EH=;P,A6,>0H9'D"MO5=LTA:H"+I>[7:VQ%2W'CO*@
MH=<:YPTAI(23D*(VI2/)X%1G3*-9+SI>YN^I=OIN$E0N4BX0>QZEU*$H*2TI
M( 2E*4IQC&4GR<U<K?:;=;;:+=;X,6-  *1&9:2AO!\C:!CFJW<[-HG3=IMT
M&;9K7'M\BXM-QF1!"T&4LD(. DX5\;CX^ZG?Z<L>((_![;B"=T3_ $R/].<Y
MRWQ[>?K%9X]GMD=]IZ/;H33S166W$,)2I!6<KP0.-QY/W\U@N^G+'>7FWKQ9
MK;/>;3M0N5%0ZI(SG *@<"O-QTQ8;G"C0[A9K;)B1B%,LNQD*0T?_2DC _Q6
MPY9K6XX7'+;"4X7$.E2F$$E:!A"LX\I'@^1\5%W"TZ7L-NN=VDVFV1H[3+TB
M6\B$DDHQN<*MJ<JR$\^<XK-!L&G)%CB,1;-;#:N)##'HT!M)4,[@@IX)!^L\
MU7;XYH&>UJR'.:@-.,1PS>'4Q.VXE"Q[07-G). 4@$GP1\59]*7NV7RU]VS%
MT,1W#%6VZRME;2T8!0I*P""./BIBE*4I2E*4I2E*4I2E*4I2E*4I2E*5^?M2
MZAO3/4"\?A=QO2 GU\141:UK]Z87<84TV$;$#<A12K)4HY^.*V=+WV^:?M#;
MUYF7B=#EV^TR;B]+6I3D#OH>3(6C"<I"2EG(YV@E7W5^Z3O)D1M3OMH?#;E]
MEK0MY*AW$^W"DE7E)'@CC' \8'&[Y-N5XGS+8;E=;GLO,)_U<1QQQM@>L. 6
MUMY8>2GX&4[4@XYYG1?KI&!M^I;]>;=:H[UVBL7#>4../-OI$9*U[<J/;*BD
M9]Y^\"L-FUGJ5N4S;K_,N+5X=N=F>]/V59##C30D_I21L*RL$$C!^CQ6EZ]^
MUZ.MUMDN7.!II3][27XO<2IQX2'"PVX4IR$J"E$ \*(Y\8J]1V)#O_2Z(S,6
M0Y*5I@LA@(/<*_3[<;?.<_%4^XWR^0=/W=RPZ@N5UTVF5",BZ/%3ZF$+#BI.
MQ;(0L(3^2#LY0%*QC''1- S;C(Z0.R7+R[-E"/(,>X&,ZVLI&[MJVN^]>.,*
M5^H 9SY/*[/>]3PK8YNOM]E0IEIM-QN#[ZNZ]$0\X4R5,$)]NU ^ 2,$^1FN
MK]&[A(GP+YLG2[G8V9W;M<Z6I2G7FNV@J!4H J"5E20H^<'SBN+3[]<+!TKT
MU'M5PN\*X-Q9\YI+3I;:<4F42 0$*+JAN/Y9(3MR3\9EM1WJY09>MG(%QF16
M96H(WK9!+P5'A*BC8X.V-Z$E20G<GX %6#IE(O=]U;88ETU+=ID&'8T3T.,A
M<5$Q8E/-I4ZE:0M0* @\XW8!.<U(=85__P"SW-MV7):2O1]R##*58;=<P-R<
M?)V\_P#[HJFB\7*UVVZ663=[VJ&IRSHBO":ICL*>BJ4M*WDH*D-Y0.$C.< 8
MW&H]6K]33M.1;D[J"[M2(FG&9RD-'MI5(1.+14M(3E64CD'@_-=GZW,RI>A4
ML,+E)@/3(R+BJ*G<Z(9< =*1@YXQD8/&>"*Y]:KI(C7FVW+4+5PGZ9B(N=LA
M25PE=R0TH1RWN;0@8*MCR =J00G_ ";<D:ATU_T]0D)3)3?8=N8;=#2.XZTG
M*0L@<Y4ALJ/SRFN77&Y(AL:F38+KJ*3'FW-A46X(D/MEY(@#:7'THWK 6@I2
ME)!44@$X\V2R7#5$V1I!I-QNCJ=5VZ&I]QQU;:H;L1252BE/&P.(]N0.2?W%
M6+I[<)RNK.HH<J7<[BUF2I+G=?#$4=X;6G&7/8E0 PA;?"DY)!\UH:NAW9GJ
M%KZZVANZBXLZ?95;U-*=#;B@' L)3^A:D[@0#G"CD#)-127)C^HK$=//7^[:
M81>+<H/S5/2'6I&)"'_<Z"H(">WN_M220,'-+>9ENM]G9NQO=NTXY=KS^(N0
MN^PXEU3ZE1RI3>%A!R<$'!) -:;R>I*;1;6VUW-VYW:TM2$*+[R4QGHKF_#@
M&-JGF2A"D?W+SGP34] G:D5>H,Z;*O#,>[6NZ7%4<E8$0*+?IT;<$)6EL XR
M<**\#G)KK=UU#9K-=5+N.I9<-4&R3B7EO*>45N 24-J"=R"4C! QCFNH]'+F
M[<M,W5Q=U>N3XN,A38D)=2MAM2MS39#J4JX21SC'/!XKDUIO.HX-CN<FZ72_
MO7:4A#<ZWQXDID1)'J4I4XI\]Q*$A(4,,I *!D '!KQ8KQ>9EGM3>L;KJZ-;
MTQI0C2+6B3WGI*9)"$J4$E2_R@G;W.#DYR?$YTYB3;;KY<E#EV:1,U9=VGHZ
ME.)84SVBM+A1C;DJV85^PY\BI/\ ZD;A<H?X6FT/7)B4EAY]EV,X^$!Q*VL#
M8T@[UD%6 LA &[()(Q#"ZW2Y]0'';-=KO)N;>I4,HAJ=<##=L7&;6ZI39&$^
M3YP0<8&:I*9M\NW39QZ-<[W>/6V"0F[-R''7T(>#R$,; 4_K/NSCR,D_==*U
M9>=0LWS7'8?NKEC1-M/<[/<WLPEH_P!2J/CD*/SM]PY(P0#58UG='X;=D.FK
MEK)R'&"78KTSU +B3,2%82$;EX;"Q^=_9C ).:E;2U*BZMGN6]^]!U-RO+MU
MAJ[QC"(KNJ:5L(V[BOMD;/<=Q\BH>XO:@CVS1$=%TO5IB1]/PG((AP)$E;LL
M8[K92A24[L!*0ET%&U1\>:Z9_P!0,,S],:?:4F66?QZ"7S&*TJ2WOPHDHY &
M?(\'&.<50M43+FY9]5,N7:Z1PSJAWT[;ZI:4/,(83AKNM^]M.[)21[2I(X(S
M4A N3SEX6_<%ZXC7UEE"K? C=Q:%Q##"MJRH%M2PLN;E*]Y6!_%4[2ERNT\Q
M[7/>N4J.W?[%*C)D)D.ELJ"B_E;HW<*3[N G=NV@#BNY=9/4P-/0]1PI$M"[
M!,;GNQV'B@2F0=KC1'@Y2HXS\C'S7*]7Q]40%:?8N%XO=K:<MWJFGF&9,U7X
MDX^7%,X;6G)"2E*0YE&-W'S6G<[]>&M:ZECM2=1QB_"NK:V5B4I7<0VDLK01
MEM )"R@M^$\$DJ '<K%;7[5T[[6G7)3\]<)3\95P?<=6I]3>4[BX<@;L<< ?
MM7';*;E(M,!#M_U2ER3=84>YH+4B.IIXAT/)"RM7GC=V\-C"" #4#=;I=I>@
MT6[4ZM0>D-INC4'9ZDN/3DOJ2RAXH&Y8[6W&_P!IRK.?C](:.G-2;)%CH2\A
MZ)'8:>0ZRMLI46D*Q[@,\*'C.#D>017"^J#1E)ZM,):G%;\RT*:[+;@[B4AE
M*RD@8(&%??C-?HBWLM1X$=IA3BV4-I2A3KBG%J '!4I1*E']R23\UL4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E:LB869T6,(TAP/[\NH2"AK:,^\YXS\<&MK(^Z
MPR9,>''<D276V6$\K<6H)2/CDUE4 K@@'YJOZLU=:-+P)<JXO%:HJ&G'6&,+
M>2AQP-I5MR/;N/G]C5AR,9^*4) \TI2HO4U]A:;LK]UNA<3$94A*RV@K(WK"
M!P/W4*DRH!.XG \\U#Q]2VV5J%JS175/R78(N*'&T[FBR5[ 0L<')\?L,U,G
MD<U4+WU!LUJODJSK8NTR?$;0\^W!MSTGM)7RDJ*$D#.#_P 5:($I$Z#'ELAQ
M+3[:74AQ!0H!0R,I/(//@\BL]1D2]Q96H;C9F@Z)D%EE]TJ3A)2Z5A.T_/\
MMJS_ (J3H2!YJLWQBTZ=<NVL9C4N0_%B*+A2M3I::2 5AI!.U.=B2<8SM&?%
M6"));EQ6)#1/;>0EQ.X$'!&1D'Q64J 4 2,GXK7G7");XKLF=)9CQV@"XXXL
M)2G/ R36.!-7*?G-N0Y$81G^RA;P&'QL2K>C!/M]Q'.#E)XK<R/NOI('FHG4
MMA@:BA-Q+EZ@(;<#S:X\EQAQ"P" H+0H$<$_/S7W3MA@:?AN,6Y+V'%EQUU]
M];SKBL8RIQ9*E<  9/  %>;;J"'<-0WFS1P[ZNTA@R"I("/S4E2=ISSP.>*E
MP01Q2F1C.:B+/8(%G=NJX8="KI)5+D!QPJRXI*4DC/@82D8''%>=(6VTV;3T
M6V:>6E5MA;V&PEXN[2E1"DE1)Y"MP(^",?%3-1L2[LO1D.R6WH3BU.A#$D!+
MB@V2"0D$Y!"=P_8CQ6/2=^B:GTY O5N2ZF)-:#K0=2$K /V 3_\ >L%SU3;+
M?/MT13BGW)L_\-!8PL,O]I3NUSGV^U/[GD?S4[4%JC5$'3IA,R&Y,J?.<+42
M%$0%O/J RK:"0  .2I1 'R:]::U'&OR9P;C3(4F"\&),>8V$+:64)6!P2DC:
ML'()'[U-U$Z@T];=0)BINS"WVXSH>0WWEH0I0\;TI("Q^RLC]JE%N(0I"5K2
ME2SM2"<%1QG ^^ :^[D[@G(W$9 K[7GN(+A1N3O SMSSC[KX7FPA*BX@)4<
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M*:CMA#F7&'PK+9&<*;(PHG/[U':_LE\G]6[?<8=DF%B%*MZD3FFPX5M!2R\
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MA3X2G<HH&?< .3C.!S41>]4PV;5&E6FXV=]4A;2FR_,2AM;*G4-J6E0SG]0
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M/I=4\J0H-_[J5+6I6S[ QCXGY72R1)N6IT&XI8M$QJ0JUM-@E4.1);VON$<
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MF0E#KC+B#&>[K2FP%.;V]F] 2%))*@  1]U8I-QAQK8NXR)3+<!#1>5(4L!
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MM:-SFW:@J2VLA*B#[3Q6YIC5UEU.Y);L\IQUV.E"W&W8[C*MBP2A8#B4E2%
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M9*T+2,)*=AY/!Q[JU-<=1+G=K.VFR6ZX6M,:9;!.?>?].^PM]UM78+>,GV*
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M?+I<0>-F5G*A@X ^L <577>D^FW[3(MTM5RE1G6VF$]Z6I2F6&EI6AEM7E*
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M<:/F1HD>5IVW.L1'5O,(6UD-J6K>K'[%7)3X_:MEK0^FFM1&^MV>*F[%TO\
MJ #D.%)25 9P"0>2!SY/->[SHS3MZN[%UNMIC2;@QL[;ZP=R=BMR/GX)./Y(
M\$T9T7IME"$HLD':AIYE(+0.&W5%3B>?A1))'[UDTSI.PZ82\+!:HT$O)0EQ
M32?<L(&$A2CR<#QFEKTEI^TW>;=+;9X,6XS01(D--!*W 3DY/[GD_9Y->)NC
M=-3[9"MTVPVV1 A',:.['2IMKX]J2,"OK>C=--P)$)NPVQ,20RB.\T(R EQM
M'Z$JXY ^,^*UUZ!T@N B"K3%E,-#I>2QZ)O8'"D)*MN,9P ,_L/JLS.BM,,I
M>2UI^U)#T9,-P"*CWL)QAL\<IX''[#Z%:\SI]I"9!@PI6F[2[$@Y],TJ,G:U
MDY5@8^3R?L\U)7G3EFO5L:MUUMD63"9*2TTML8:*1@%'_B0..,<5&S]*&;J"
MR27)++=FLY#T6VM1@D!\(4A*RO/Z4I60$ #G!SQBIF\6>W7IEAJ[0H\QMAY,
MAI+R H(<3^E0SX(R>:U&-*6!@1@U9X"1&#R6?R4GMAXY= ^@KG/W2S:5L-EM
MDJW6BT0H<&45%]AEH)2YN&#N \\<?QQ6K8-":5T]-]99-/6N#+P4AYF.E*P#
MY 5C(S^U8F^GND6T3D)T[;-DX;7TE@%*D[@K: >$IW *P,#(SYYK:M&C=-V:
M0R_:;';X3K)<+2H["4%!6 %XQXR$IS_ J/E]-](OM7(-6*!$?N#+K+TF,PA#
MN'![B%8X/S_-3LFQVZ7!A1)L5$IB$MMU@/Y<*%M_H7D\[A]^:UV-*6!B:W+9
ML\%N4W(=EH=2R I+S@ <<!^%* &3\XKU<-,6.XNSW)]IAR5SVDLRE.M!7>0D
MY2E6?(!Y'U6"V:-TW:KJ+G;;);XMP#?:#[3"4K"=H3@$>.$@?P*)T9II-TG7
M+\#MYG3D+;DO*825.I6,*"L^0H#G[^:^6S16FK7&98M]CM[#3,A,M 0R,I>2
M"$N9\[@"0#\ X\5MP-.66WWF9=H-KAQ[G,_^8DMM!+CO\G_[_?S6L]H[3;]^
M-[?L=N=N^Y*O5KCI4YN2,)5DCR/OSX^A6NO0.E%M6UI6G[<6K:HJB([(PR2K
M>=H^MW./&>:S+T5I=;T]YS3MH6Y/_P#FU+AMJ+_N"O?D>[W)"N?D ^:V+EI>
MQ72Y0;A<;1!DSH./3/NLI4MK'(VG]CR/H\UXMFD]/VN2)%OLT"/(#CKP=0PD
M*2MW'<(.,C=@ X\X'U6M%T)I2*U):CZ<M*&I*DK=0(J-JRD[D\8\ \@> >:]
M*T781>K?=&+<Q&F0I#TMM4= ;W.O(V.+7@>XD8SGS@9\"I)=DM:[Q^++MT-5
MT[78]664]WM_^&_&<?M4;;]#Z6MS;B(6GK4TAQU#Z@(J.5H)*%>/[221]9.,
M58J4I2E*4I2E*4I2E*4I2E*4I2E*4I2OSWU%ESIEWO,=R\KW1]7VEF+&<0VO
MTP4TTH.)21GDJ)YR#M/')HOJ5=VM KN$C4K+5[ML:6]Z<Q&PF<6)7:2I9^-P
M&-J,'))!XQ70NF%SEW/46NC-NKDH,78,L1%J21':[#124@<A)*B/HE)/DJ)H
M6F)3EL7IF:P_$EN7'5UPAJ=<C-*<:;+LG(2X!N&[:E6<_./'%>X.O[\W/>ME
MXU$W'<<GM,/7!MJ,J-$96)"D.-.#(4E9:0C#@RD@Y.2*V']?7:+JJR0(VIV+
MLP'[?&F+3$:89>2^IQ)<"LE140E) 1A(_P#WJL_2),Z3T>+5M?:BSB[<$1GP
MA*T)5ZE[8K;\C.//FJJ]U'U0[HN3=V"TPXA^#9W2^E+2(TO=B6ZI2DD!.Y24
M D%((SR*CKIU0U%;+?!+VH++(G1=KLQ$,M/-J:5,2UEQS@9"%8PVD<@J.  *
MZ1T]OEQO%UU--NEY9-NB79^UQH8:;0E)2I.Q7<_4I1SC'V:Z!2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4K1=LUL=
ME+DNVZ&N0MQ#JG5,)*BM PA1.,Y2"<'XSQ6-5@LZV4LJM-O4TG=M08R"D;OU
M8&/G)S]UM,P8C$M^4S%8;E/A*77D-@+<">$A2O)Q\9\5IQM.V6*VVB-:+>RA
MJ09:$MQD)"7B,%P #A>.-WFL?]+6#T<V(+);!&FG=*:$5 2^?.5C'N.?DUED
M:?L\F4W)D6J [(;" AU<=!4D(.4 $C(VGD?5?%69J-8W[=82W9PM*^TN*P@!
ME:B25A!&TG)SR.:Q6C3L*WZ>_!W@9\=SN*D*E)2HR%.**W%+&,'<I2B1C'-?
M5:7L*X\>.JRVU3$=HL--F*@I;;)!*4C& "0,C]JVOPBV[5)%OB *?3)4 RGE
MU)!2X>/U @85YX%;U*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2JOKJXZBMT,O:<B6U;;+#LF1(N#B@V@( (0
M$I]VY62=W@!)SY%;L:Y7&Z:0BW*W1&HEQE16WTQYY4$L*4D$I7M&3MR>.,D8
MR/(T>FFHI6J-+(N4T02X9#[(=@N]QEY+;BD!Q)R< A.<$YJTTKE/4WJ/-TSK
M*'88TFSVQ,F"93,V[M.EA]W?M#(6E20@X&2I1(&1QSS,Q.IEI3?[C9KH5195
MJM[<VX/[%EADJ3N*=^,8P00<\YP,FM@=4-)_@;MT7<E-M-O(CEAR.XF07%C<
MA 9*=Y*D\C Y&3X!JM,=8H;VN%Q6PT[I?\#1=D36F7%/*4MY+:4! Y.2K&-N
M<U9.JVO&]":4;NJ(HF2Y+[<:+%6YVNXXOQDD'& "3Q\8XJ$3KJ\Z6UK"L6O3
M:U1KG%>E19T!M;:6BTDJ<;6E2E$@)&0H8_CZDE]7='JLMQN46Y+?;A0_7%'I
MG6U.M;M@4C>D;@5X3D9 )YQ7BT]2H$^[M%Z5!A6LV--W<1)+B)30*L$J24A.
MP#YR23C P0:DGNI.E&+<B:_=0TRN5Z()<8=2X'RG<&RV4[P2.1D<Y&/(KXUU
M,TB\W;5LWA#@N"E)CA#+A)*7$MG< G*/>I*?=CS5QI2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4JKZVM%_N[<=FQ7.VPXX
MR7VYD-<@.^,#VN(&WSD'(/%9O0ZF3:5LHO5O5/[#:42'(!*>Z%$N*4@.#*2,
M )!!&"<FFA=.*TS:'X[TE$F5*ENS9"VVNTWW'%;E!",G:D? ))_>K%2N>Z\T
M9>M2RY[2+A9WK+,CI9]'<[>9'IE@*!=:4%C"CN'GY _S7)/1!E;NH(S5W<3:
M;O9XEN4E;>YYMR,E"6UA60",-C<,9))P16%SHS/=;9NCE[8&I6+A"G-%#*A$
M'IFTM)24$E1W(3DG/GP ,YS:NZ.3=2:@_&UWR/"N"+?&89,6*M*&9#+P<#B4
M]SE/!&T\C((/'-RZC:'3KK1K=IN,M+%Q:4W(9F,M\-2$?WA!/Z3DC&?!\YYJ
MFZPT+?+LBZZFU=+@3)ULLTUBV0[8PXE 6MI67#N425D>W:./'S5/T)TEN&JN
MG$)VZ340"Y85VR(P(RT.-DR.[N=W'GW)'@#(/\59;MT5N-Y,DW*_,J[NFF;&
ME*&5 (<;6VL+&5'VE3?(\\FOC_1>YSI#5QFWB&W=5WR+=G^PROM!##>Q+:,G
M.>2<G[KY Z-7F% L,9F[VY,FWSG9AN+;+K<EKN.A:DM$*VD*2"DI6".<UW*E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*5A?EQX[T=E]]IMV0HH90M0!<4 5$)'R< GCX!H_*CQW6
M&WWFVW)"RVTE:@"XK:5;4CY.$J.!\ _59J4J!F:RTQ"E.QINHK-'DM*VN-.S
MFD+0?H@JR#4E;[I N2GTV^;&E*CJ"'@RZE9;41G"L'@XYP:W*@UZOTVBX& O
M4%H3.#G9,<S6PX',XV;=V=V>,>:G*5KPYL6:7Q#DLOEAPLN]I85VUCRE6/"A
M\@\UL4I6M-GPX)CB;*8CF0ZEAGNN!'<<5X0G/E1P< <ULUHMW>VN/H9;N$13
MRWEQTH#R2I3B!E: ,\J !)'D5G$R,9QAB0SZL-ATL;QO""<!6WSC((S^U9Z5
MHQ;O;9;S3,6?$?==;4ZVAMY*BM"5;5* !Y /!/WQ6>;-BP6TN39#,=M2TMI4
MZL(!4HX2G)^23@#YK['EQY*751WVG4M+4VX4+"@A:?*3CP1\BOL.4Q-BM28;
MS3\=U(6VZTL*2L'P01P166E*5JW"XP[<&#.DM1P^\F.UW%!.]Q7Z4#[)^!7F
M[W.%9K:_<+I):BPF$[G'G3A*1G')_DBMP$$ CD&E*U8]QAR9TN''DM.2HFWU
M#25 J:W#*=P^,CD5M5K"?$-Q, 263.#7?,?>.X&\XW[?.W/&?NMFHR\:@L]E
M4V+S=H%O+F2@2I"&MV/.-Q&:WXS[4F.V_&=0ZPZD+0XA04E:2,@@CR#]UDI2
ME:LFXPHLV)#DRF&I4LJ$=E:P%O%(RK:/)P.3BMJHB+J:QRKP[:8UXM[MT:)2
MN(B0@NI(&2-F<\#S]5+U@GS(]OA/S)S[<>*P@N.NN*"4H2!DDD^ *RM.(=;0
MXVH+0L!25).00?D5$2=4V&+>V[-)O-O:NKF-D1<A(=.? VYSDY&!\U,UJ/7.
M$Q<XMO>DM(FRD+6PRI6%.)1C>0/G&X?\UMUY=<0TVIQU24-H!4I2C@ #Y-0,
M;6NF95JE7.+?K8_ BM]V0\U(2M+2?M6#QX^:GTJ"TA22"DC((^17VE*4I2E*
M4I2E*4I2E*4I2E*4I2N4:CN+D7J?J:;,4XRW:-+%Z$M+?=*=ZUEQQ",C*LMH
M'!'@ GFJ3'U7*O/277*Y5Y%PF68Q9<"3WVW76UJ::=;.Y"0,]T*&W&1[D9.,
MU^@[4Y(>M<-V:WVI2V4*=0/[5E(W#_!S6U2N5:QLMF8ZH:$A)@P6V9JKJX^U
MVT@/J6R"HJ']Q))\YJFVB;.T]U!O;UFG*1 <U*BV?A24M]I__0@C"B-P4"A(
M'('C]ZLO1#55\U'-<?O-_MDX288?7;V70IZ$Z%X*2D-)[:<'&U:EJRG()&35
M3TO.AHU!J\2[KI"/#3JV0J1%NC <ENH"F_\ :RO[20GVGW9K+,U?J>5>5M(U
MBN)&E2KU%0AN/'_)3$W*;4E2DY)P$@Y^,\@\UDNFOM2N2I*XE_0P]%LUMN,:
M$&F2F<^]^MKE.X[^  D@@D5MPKY)@N/08MX398=QU=<F9]R1VLQ=J%N)1N6"
MA*E%*1E0)P>/BL4;6>LEQ;4$W-;HOK;UL@2TQFE)$MJ5M$C@8VK9WKP3C\LX
M'(KY/ZB:K9UCJ(LS[2&[<_,CLV1UW,A]+;"E-*0R&NX2I02K>'-I!( !&:MG
M134MYOPN'XQ?+5=T"/'D-&&^EU;*EA6Y+FUI 2"1PDY4,$'/FN?IU)=-2'3T
M&ZWL.79G44)U,EH1GHZ$N-2@A;"D 9"MAPEP;D\9S2Z=4K^WIFS2$:@+5T;B
ME^4VF*PEMY(G=C>M2\DDI!]C8'.Y1(  J9@%H:]T^M*T\ZPNV"K \QEYQ_G%
M;/5:XS[+U(NETM-X9MLV+I=#S3;C*'/5J3)<(9 5_P"1('M]W(Q6:T:[U1/Z
MD^DG/6ZTPV9K<-RU2GT]YQ"V0H+0@-E945'A07LPD@C/N.YJ;66H6^J+MKA3
MK9;[=;Y$)#D:8\$KG-/\*4A/;4I1W$)3M4D I.X$'BM]/-07"TVW34."F$4*
MLMXE)]0D)PXW))3ESRE'W\?/P,8IFM-2.Z>_$'+O;+A$[5GW,NM1W5)DNK;[
MWM3X ^,C(*CC]((FK1<KK:=:+1"ND=ZW7'4LR)(LYCHRE!0I9>WC*L@IR<X&
M%?YJJZ;UC?+7H_1MHLTZVVIENS_B/J)[W;1*4)"DJ8&6U[L)'*4X7E:2#P0;
M_P!4[]=K/U$TJ;?*>$<6ZY23"20$2W6V@4-G/DDGCZ^*R]-]3W&?J6WPW=0)
MO\6X65-S<4EII'HW2I("?8 0E04<!65 H//FJI'UYJ1B_7.5)U EV)$O=RMR
M[<(;;A;BL-.."1[<+)24I3@D \?)S4+9>H6HKB@VN'JMQ2GKY;(B9N(SKR6I
M,=2G$^U)0,.#  !*2"G)Q5AAW:XVG4USMS^JI$M].JX$,M3O3J<4RJ.@Y2D)
M&W>K(RD#]'&%;B8ZZZTN*[+J.<_JUR/>X[,U+VG78;:TQBV\.TOE&4IV;1N7
MG>5\'/%2FH=6W]OJ/?(T'4^Q%NEVM$*T=AI29B9(2'1D#N* !*L@\?P!52O'
M4J[SXFL&86HG51%1&9C#F]IIU@?B 84E.T?E#MD9"BH\A1(W%(NFF=97R;U7
M>M\O4$)J(S/=A"V/.)+LB.&0IMYMM#625'WE9<VX)&T<4U9K2\VS4746-%N*
M(;<&19F8CHC-J[!D$)=4HD#=Q\JSC Q5DT;?;K+T5K3\0N9FS+1-G0V9G;0A
M92V@%)4$@)W GX ' XKD"+Y=;>U&O]KOSPGPM#192WGNT^9"O5*RVXH@\>4Y
M&%<#)SG/0=/:QU'=.K;L!R[VV+"9N$F$Y9GGTE];3:"6W4-AK>"<;RHN%)!P
M *V-,/V^/U-ZAJUJ[#;D%R/Z03RD),+8K:6]_!3G?G;\YS6A>]1SK!*GP--W
M!<6'9&+8W:+0E+2A<FG2$GW. N$^4#:1@IR<YX@(^M-834P'!JIYM$]R\[TM
MQ(^(Z8?N;VDHSSP"59X/@'FLEXZB:E*!+CZB3%=;TS;[LS!1'84F;*=5A;?N
M3O(5C&$$$9R/&#DO_4G4$2Z:A3'OK0#42ZJ8CXCDQWHR4[4A&"OVD+!4M6%C
M)"0,5NLZQU2Q;+J[^-OW%5D1:KQ,4B,R%.Q7DE4AD;4@;0E)6"!NP,9-='TC
M!<OEELM]U#W')[3[]PA=W"3';>WAM*@G )#*PDY^<_(S5<Z*ZKN=_F76%?+H
MJX3(K##F]GL+BK2LN8<:<:2#[@![%^Y./GFJ-#G-V"2B)89L&\6R3%NDBS3(
MPVSK4X4K<6EQ))W)SQN4,YX(\5YMVN[RWHKN-ZK6S(MVG(<Z"72PZ;I(._NM
MJ*AN7M4@,X20K)R25$&MR_ZRFW?3VL&;QJ 09K*+I%7ITQ4**F4QE%I>[:'$
M XW;R2DE02,9%7SHY>IEYA7-%PN1]=#4B.;5ALI@H"?RU!:1N<[B<+W$XY(
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MW'*"5 #+GG*U;CYQ._\ 49>[K:YD+\'EWF*^U#7)08BWDM+4EYK<"EM)"U!
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M(2 "25$8&!Y)P,G.-?3_ %(AW*^0+5<[1=+'*N+2GK?^(H0D2TI *@G:I6%
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M4I2E*4I2E*4I2E*4I2E*4I2E*4I5:F:YT]#OZ+-(G[9ZWDQD@,N%!>4 0UW
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MXVP5@+6E.-R@GR0,C)_<5L4I2E*UWYL6/(CQY$EEI^2HI8;6L)4Z0,D)!\D
M$\? K8J->OUH8O3-G>N<)%U>25MPU/)#JTCY",Y/S_P?JMF5/AQ)$9B5*89?
ME**&&W' E3J@,D)!\D $\5LUHW.[VVU=O\3N$2'W20CU#R6]W\9//D5N,NMO
M-(=96EQM8"DJ2<A0/@@UZKXM:6T*6M02A(R5$X 'W6O;+A#NL!B=;9+,J&^G
M<V\RL*0L?8(K%>;O;[)"5,N\UB'%2<%UY82G/G'/SP?^*U)NJ=/P8D25.OEK
MC1I:-\=UZ6VA+R>#E!)PH<CQ]UF&H+.J'"EHN<-<6:\(\9Y#R5(><)("4*!P
M22#P/HU)TI2E:\J;%B.1VY4EEER0YVF4N+"2XO!.U(/DX!.!]&MBM.Y72!:V
M@[<YT6&V03OD.I;''GDD5FB2H\QD/1'VGVB<!;2PI.?Y%9JUI4^)$D18\J4R
MR_*64,-K6$J=4 5$)!\D $\5LTI2M2UW*%=H2)ELE,RXJU*2EYE86DE*BE0!
M'T01_BO,V[6^#-C0YDV.Q*DI6IEIQP)4X$#<LI!\@#D_587-06ANQ)O3ERB)
MM"D)<3,+H#12H@).[QR2!_FI.E:$Z\VRWR.Q.GQH[W87)V..!*NTC&]>#_:,
MC)K<8>;D,-O,.)<9<2%H6@Y"DD9!!^146QJ>QOOMLLW:"MYR4Y"0A+R25/H&
M5M@?^0 Y%;HN,)5T5;1+8-P2UWS&"QW WG&\I\[<\9K:I2E*4I2E*4I2E*4I
M2E*4I2E*4I7(-;+D.ZTUPAP*66-'J]$S@X4%EWND8!).4-CC]N*A].3A=M$:
MIMCEV<O&EVM.M.F:XMM?II!967&4K0D)]@2VK&"4D\GG%=:T%(F2]#Z?D7//
MKG;>PM_)R2LMI*C\_-3M*X9JJY0K/U G2[=<[7=&I5UA-7&PS%!,IJ0GM);?
MC<[CMW-J(P1[58/G$2]U$NMRTRS;%7A1OJXE]:FQ64)2\A;0=]/G:-S:PE&4
MX()\\^:WY.NK^AM^1:[J)UG[MG4A\--N!EQ]U*7HF\#"\(*5;C[T[QD^#7V1
MKW5/XWJ53-R@HF6UV>TUIU:T*?>2VT5-+0V&@O!]J]Q<(() &<5@&L%O7[1(
M1K^1<+<]=AZI\-LLH;48Q(CK<2@(7E85E.,@+2."$JJ>ZE:AG::UU<YL2YN%
MUO3;C\2WN;2VIQ+ON4$8W*(2-Q .<)^JG] 7R=-U/>;9^-_U!:&XD:5'N6QH
M*;6YO"F5%I*4D^P+'M! 7SGBN,P+K<G[;IJZ-ZFD_BT:TWYUR4KLN.-K;<0K
MMD*&!P >>0#P0,8N%LU[J6ZZTM"%WBUVJ,XW;W!;YCP09K3[25.*:3V2IQ6]
M12DI<2$ELY&":VNMFO[GIC65JC6R]"(T@1W)$5:&4MK0X^4*4I2_<OV@\( V
MXW*5R!6BQKS4Z[D5L7N/)[DV[Q%P PU_I6HX<+;^1[N"E .[@[A\D&HR3U&U
M5&M+2HFHV;@F1#MDER9Z1E7I'I#H0XS[0$>,J .5#!R<59+KJO4MIO%RC&^=
M^5:)=OB,V]^,RVJ[(?*$J=R "#E2]O;( [9R#S6S)UW?&6M4-3WQ >TVU,<F
MOHB]Q!*SF%M2?U#MJW'D<I&>#57TCJZ=J#5FE&KU<(]P<A:AD,-R=T=2MIMY
M4D;FL).5+4/:.< 9)%7;J9JF[V[4<R%$O;-A8A6=5SC+>9;6BX/)4H*9)6#[
M0 C(1A?YF<^*\=*G%7W66J[G<U)$M#D-9@.):68KBH;1)"@-P()<1Y^#\YJA
MKFW&\:J885?7&IC.N+C'8>6A+JHC:8RPD)2KC&/&>/FOL?JOJN[P+"ZS=K':
M7#;TRW%S7 RB>L2'&U)0DMK*QM:&4ME*LKX/Q5RZU+VZZZ?@+L:'<SS_ /&!
MF.!V4Y)Y'^/WJK=/]226K!I^Q1+Y^!07'+F7+JVRT67'FWLI;CEP*;#)#BE#
MC.$8&/-:ULZNWZ3?-)IF79F,N4]!CSH*V&FVRE]+A+@W9<5N ;6%)*4)W '=
MGB5L^L]12-/Z5E7W51M\6^2Y;<BX>FC-MQ$QPZ$H2I:2C+A0#[@3[2!BI73=
M^DV'_IKL]SM#B ZW'9:5(VI<#"5/!#CN!P=@*E8/ V\^#5;N6H7[QU,T[:CJ
M94VSQ[X1"NS2XRNZ50R5-92.VHI4L(_3G#N/-7/JG-LEEZ@=-/Q5ZWPK>R]-
M"O4*0AMMOTJDCSP$[M@_G%5*V7*7;M7W&XZ6?:A:2O.I;:Q$4&T%J4HH4)):
M!X 44@;D\DC@\&LSFM-4G3S\UV_=N/*U))M3DQ[L,,V]AM3@00L-*V[R$I*U
MA6.,8)S4I9-:W*5>8D2]ZS@P7&FX!C^GBI4U>@ZHI<4@+2%G) 2"V0$_JP0<
M56.GVKKJ[IRTP']9JMB7F+G+5<'?3N*,E$C"8ZNXA7 2KND?J(6,$ "I^TZM
MU3>[=>;B-1Q[5(AVV \($EIAMIMY]E*CO6I)4DDY*<\94G((&#?>E>J&[]8D
MMR[DY(NJ'GTK:E%@/X0Z4DX9]BTCA.](P?V/%<KOMQE7#J).M[E^4Q,;U?%;
MB-E+:U1D&$O"T(4. 3QSP2/LG/UKJ)J.5"TZRUJFU6]:K7ZLS)ZT-HG/)DK:
M4C';5O(2V,H04*RL$'C%6?K=)CHU?TZ]3*L\=7J9:B;K@QP#'(RL$I.,X \>
MXC^*C)>JYD.)8;;IZ^6-E4N/=G)<BP,-+C]YAM+K93N!'Z5)"O/)(S\B,E]1
M=40M/7N<[>FUR#9+7>F-D1LI8+[NQUM*?E.,?J)Y)Y%;J;_-F:TL,.?=F;X+
M=J1;4.<VAMHOI-N6M2/;A)VK6$Y'[9YKS:]8ZKN_X>FP:A;G7J[VR8_(MRFF
M2+3(: +:=H&Y(WY:/<)))S\8K-,ZA:GGZ4C:@A/MVVTW6Y-Q6Y,W:R(#2&L+
M4M9:6$[WTK1N4E0''C((U(^O=8.7ZVQ)&HK"RAIF(XEPN;&KN%.J2XIE)84M
MPD)"0&RC!.X;@0!<.IVI[G8M:6%MBZEBV++(>B13'7(<6M]*!O:<PM;:@2G+
M9W)))YQBN=:-U/+TKH8@7YR) =MUVDMH1%;>5'>:N(0E;:2 5;@\KA9P-N>
M#6S8]3/:BU?I0W*Z,W1<*\7F&B0.TLK8$3*"KM@)5PKR!@X^?-2P]_\ TB1R
M@CVVILYVA6,. DX\<8^>..:Q7?7VH(:9D>VZCBS[.+Q'B(U"^6FFFTKCEQ:"
MZAM;8 7M3O+9QNP>>18KOK#4$#HO:[S&FP;E<77VH\JZ1\HCH;+Q0M_*F\8
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M+?;)V@Y4/=M'GZKEC<[54.&ZU'N&HY(DVRRS MUQU:T/N2$)>"3C(&TD%/\
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MI"EJ.!DG@8_YJPAUDO*:#C9=2 HHW#< ?G'U7F1)CQXS\A]UM##"2IU:B $
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M6G6$RDJ5(W>J9*%+#@&WVCVX_NYX^*E[/JB%+;M<6ZNQ+=?9T42?PI<E*GD
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MH)'(21SP*\7/IUJ6_P!T@7B<BTVV=$<MK1C1GE.M/-QGRXIW<6TD*.["4XX
MP5<\=J' XI2E*4I2E*4I2E*4I2E*4I2E*4I2E*K$K7>GXUR1!=F.%Y=P%J!0
MPXM/JB@+[>X C.U0R? YR1BH<]6M+_@PNJ%W%4)Q:DL+]"ZDR4I3N6ML$ J0
MD>5>/CR0*DXG4+3LR>S$B2GWUO("F7&XSBFW5%GO!"%A.U2^V0K:#G!^^*B8
MO5S3*[%9[G-<EPTW)GU :=CKW,M;@DN.8'#>X@!?@YR,@$BP:>UE9]17:X6^
MT.29#D!:FWWO2NI8"TJVJ0'2D)4H'X!/V,\U]N^K[5:KNU;7_5NRE%L.>FC+
M>2QW%%+9<*00@*((&?HGQS41(ZIZ2C/SVY%P=1Z-L/*5Z5U0=1W$M[FMJ3W!
MO4$Y3G_CFL5NZH6>;,NK*8-Y:1;HK,ESO6YY#A+KBD);#93NW$I3C[W''Z58
MRQ-?6F?-MTF/=4-0'HDMY<1Z&X'RIA20X2?[-F% I(R<C%:4_K!I=G3=RO$%
MR9,1":8>+/I'65N(>7L;6D.)&Y)5D;AD<?QF<AZ[L<I\L-N2DO"Z?A';7%<2
MKU&PN8P1G;L!5N\8JTUS*5U5AB5;Y#+,ANT?B$VWRU.0W5NE3#:E;V@@'<G*
M#G@_O@@U+M:YMK=PNLEZ\QGK6S BSFF68CA=0VZ2$JW<A>\X 2!D?/FK-8;O
M%OEM3.@A\,J6MO:^PME:5)44J!2L C!!'BJ[J'6GX1KFQ63TR5PIRRQ)E[Q_
MIWEI4IA!&<^_MN#Q_P"/W6_<=;6"W7-<"7.4B2W)9AJ 8<4E+SR2IM!4$E.2
M!GSQE.<;AG39ZCZ:?B/28\J8ZRT]Z?<W;Y"NXOW9#8V9<QL7G9G&.<<5Z8ZC
M:4D/VYJ/=T.JN :+!0TXI/YN>V%J"<-J5@@)64DGC%1R>K^AU,.O"\K+;:%.
M%0A2.4)44J4GV>Y*2#N(R$_.*F).O--1KJBW/71 DKP$D-K4V5%ON!'<"=F\
MH]P3G<01QR*A)75O2W]/7"[6V1(G-PF67U-IB/-J6VZO8A2=Z!N259&4YQ@@
MU>')T=JVJGO.=J*EKO*6ZDHV(QDE0.",#SGQ7-H'52*[J^[-2"ZW86+=%E1E
M.0G6GW'77%(2E*5#*]_LVX3R?X-3<OJ?IN':%3Y#LM';>=8=C&,OOM*; 4YO
M1C*0E)2K/TI.,Y&=ZRZZLU[OAMEJ,N40VESU3<=1C^YM+@3W/ )0M)P?O'GB
MMG5NKK7I7T*;H9:WISBFHS,2*Y(<=4E.X@)0"?'-14GJ;IIAB"^J1*7&E1&Y
MY>1%<4AAA:MJ''2![ 3GS]$G@9J4TEJF-J5^^-Q&74"USUP%+6#M<4E*25).
M,8R2,9/C/R*Q7G6%C@WUBQS2^Y)?<;95LBK<:;6YGMI<6 4I*L' )_?@5IKZ
MEZ7:]8J1->99C,+E=Y<5T-O,H4$J<:5MPXD*4![<YR",CFO!ZG:7-M=F-RY+
M@;E>C+"8;WJ"YL[APSMWD;/?G&, FO+FNH<N[.0(LI4%4:XQ(BG)$-Q:9/>:
M#J6T>-I(/ZCXQR.16S9]?V6Y2W8A5(CR4S)<)M#C"_SE1B>X4* P0 ,^?V\U
MA1U+TVY)0EN3(5#5;?Q7UHBN]@,9/)5MX/M5P><C'GBIS3.I+9J6(_(M+SBT
MQWE1WD.M+:<:<3C*5(6 H'!!Y'@UJ)UI9E:M_IM+L@W,*+9_TSG:#G;#NSN8
MV[NV=V,^*E+S=X-F89=N+P:2^^W&:&"HN.+4$I2 .223_P#<^!59;ZH:6>7#
M1'E3GERW%MM)1;9))*'$MK)_+]H2I0!)P*Q1>JNE)$*Y2Q+EHCP%,I=4N$]E
M0=44MJ0@)W*2I0(! KW&ZE6>9-L<:%&N;RKI)?B >C<2J,XU@+#R2,HQN'D<
M#)/BK'J2_0-.VTS;FXX&RM+3;;3:G7'G%'"4(0D%2E$^ !5?A]2M/S7H#$47
M-V7,<6T(R;<^7&2A:4+[J=OY825HR58P% _-2FLKH;3&MC@N#4'OW&/&*G(R
MG^]O6$]H $;2K.-YX'U4<_U'T^RY.05SE>D>],5(A.E+KW=[/:;5MPM>_P!N
M!_/C)KPWU,TPNW3YJI4EIN PW(DI=B.H6VA;BFQE)3D^]*DG&<8-9G^HFG(]
MXGVV1*D-/PF7GG5*BN["ED)+H2K;[RD*22$Y\U@@]3M,S84J3'D3=L=;#9;7
M ?0ZX7_]G8A2 I07SC ^,^*P2NK&DXC,-V1,D-MR!N45Q7$>G3W5,[G00"@=
MQ*D\_(/P":M]WND*SVJ1<KE(0Q"CH[CCIY '[ <D_0')^*YQK?J@TQ9F$V R
MF+FY=H]KDMOP'%R(?<2I868_ZE$I3E..#GYQ5^AR'[/IE,C4]PC./1&"Y,F)
M;[+9"025[<G;P,G_ /X57%=4-/-0WGY2;G'<;6RE,5V"X)#H=.UI:&P"I25$
M$ X\C!P>*N<&2)D*/)2V\TEYM+@0\@H6D$9PI)Y!^P?%9J4I2E*4I2E*4I2E
M*4I2E*4I2E*4I7"'&;PKJ/($&R.[E7M,STTNT.EA VI95)3+2Z&@2TDK'L*M
MQV\GFK!_VC2QI_2,6-.@OW#3S3D=#D^WA^/(;<_6%L[P01@$$*\CZ-; Z;7)
MO5UHO(O4)]%OD-NMH<MY#B&Q'[*VD*2X$(0HE2]J4#"CSNP*BX_2:YQXMAV7
M.S.2K?!_"73*M8D-JCI65-.(2I7M>3DY/*25>,#!OVA=-.:8C7AER4F2F==9
M-Q1M;*.VEY>[9Y.<'//'\5&W32-U&L9-[T]>F8"+BB.U<678H>*TLJ."VK<-
MJBE2DG(4,'/D53&^C,R+IZZV6%=K8W!=3LAJ%K0F0@>H0[^:\#N7@)V@<9R"
M? J?UCT]NMUNFHIMGO3<(W>+#96A;2CA3#A5C<E0.Q25*20.>?..*B;5TGN4
M..TAVZ6XK::NS:2Q%6V"9I202"L_I*?&?&!GC-8+MT<F7#37X;^+1VW4V"!:
M$J[*BDN1GR\5GD<'@8_D_M4U9[$JX=6+I?4L2FDPX:&5+>96W'?GX4@O-I5R
MH);PC<#C"L9)R:O.EG;N_IZ$YJ-B.Q=R@^H;CDEL*R>4Y)\C!QDXSC)KGULZ
M:7*#<H*_Q&,N%#N%SE-M[5!2D2T* SSC<E2C\8P3\UH6CI/<[?;9+3DNUS%.
MV*':#'D-+++A965**OD @X!'()SQBK_TZL$[36EV;=<YZILA+CBP2M2TLH4H
ME+2%+RHI2, %1)X_P*EJ;I2U?8EZFO.QDZJE2_4P[GA?^F"%)[(V[O[4I _D
MFJ;=V+PKJ8XVB")<Q=PA3G(KMMEMH<=8:2UWFWTK[0;Y4H%8)RD @[0*MT_I
ME<'])6B&F19I5SM=QE3FTSH9>B/AYQQ12MLG(P'."#D%(K1@]()%LU7'N<$:
M:=8>,=<SU%I25L+:P,1!G:VE21MYR1@')/-;4/I;<H^FUVG\3B;39KI;4K2T
MH$+EO]P+\_I2 !CSYK5MG22=:M0+DQ%Z?=BOI;<=D2[?W9C3J64MJ2TX3[6U
M% 5]C)Q]UZ5TIN_]+&TBZPRINR1+<TX6U\O,/ET*5[OT'A././\ BNFZCL_X
M]I:Y6>4]V_70W(KCK:<;=Z"DJ S^^<9_S7+1TIU%-D/W"ZWVU_BK3$%J$J/#
M6&DJBO=Q"G$E9W9Y! P.>/'.S<NDDN=>OZC5.LYU"_(<=DB3;C(B*;4TAL(#
M:E@Y3VTJ"LY))^#BIFQ=/I]OUI;[Y(ND,^EC]APPX7I5S1VDH"7@E>Q24D%2
M<)!' ' YG-7Z47?[_IBYHF)CFRR7).PM;^[N;* ,Y&,9S\U1X_2.Y1+'^&1+
M^REF9:$6:X[HRE;VTJ64N-Y62E6UQ:<$D<YXQBKCTZTC(T>YJ!CU;4BW3[BN
M?&3VR'&MX&Y"CDA0&U(& /!SYXU9&D+NSK2YW&U72&U:+TIE5RBOQ2IW+: @
M]I84,;T@ Y!QR1S50D=([S-T\S9IEV@&-:[>_;;6ZAE86I#I1E;WNQD)1MPG
M@YS^U;FHNE]TGSKY(C2K6ZBXW!$U#<EMQ*F2F.&DJ0ZA04A:2-P*?/CYK?A=
M/[Y&N2G7;S%EL.SK=-><>97WG%QVD-N'.[ W=M)'!QD\UK(Z=ZB@W5BX6J[V
ME+\6[SY\?U,1Q:0U+R5I6 X,J22<8('W6I'Z1W'^F8UCE7:&N-^#"V/N)C'=
MO0\IUM20HD%() 4%>0#C&>+GTRTO+TK97XT]5I#SSQ<+=K@IBL)X \#E2CC)
M)/[# %04C05^7U*8U*F\6]V.Q-+[:)$9Q3K;"F>TIE)#@2$^5#"?U*R<XP<O
M71F2]I^T&&W)#L>YLRTR68;DH1RWE04M#9#F"<)RD'S\>:B.E>G+V\];+O<$
MQX,:$U/C,(1&=9<?3(=;=[Y0XI2DY4E7M7S\XYXT;;TBO[";GZJ_6UQZ:F$7
M9 AN%QYR-)[P<<*G#N4H<'!'P!@#FR0- 7*VZDC76#<8>4WF9<'4NL*.YF2$
MA2!A0]X"<!1R/VXP;!U!TP_J2WV]5OE(BW2US6KA#<=25-]U&1M6D$$I4E2D
MG!R,Y^*AM(:&N-GU8+_/N$-^3)3+5-0RPI"2X^I@CMY4<)2F.@<\GD_/%@UM
MIU>I(EK91)$<PKG%N!)1NWAEP+*/(QG'FN=W'I5>95ROLM,BPA%Q5EV*J.[Z
M>7^>EP+>;WX#B4IVA2,$DDDY-:ERZ.7^39W[>UJ2*43[8W FNRH[CS@#;ZW4
M!M1<!P YLRK)P@??&W<.D]^F:ENET7?[>KUK,^+O<A+4]V9" E"%*[F,-D )
M  & ?E1K?E]*IKCDV<Q?4(NQ_#GHCPC80W(B-J1N4DJ.Y*]ZO;\9\FO-SZ87
M:?>HEY>O-M<NK\<1KFZ];$.IP%J6E4=*B0VI(5L!.<@ G)'-[USIQ&JM(W&R
M.2%QO5-A*'D $MK20I*L'R I(R/D51IW3:]7*='O,V[0$WS\7AW%XM1U]@MQ
MFU(2VD;LY)6I1)/SCX%= U=8H^I],7.R35K0Q.84PI:/U)R/(_<'FN>RNE]W
MO<Z#<M17N&NYPUPFT+BPU)0IB.\72""O.]:L9.<#' KK-*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I5 NW5G2UJU')LTN4X'XZ7BXZE(* MION+;\[MVWGQ@D8!SQ
M6NKJQ;)-F=G6NW7)YQN5!9[$A@L*<;E+2EMU&[RDY5C[*<< YKTYU BP):([
M3DRZ.2M1FR$*9#7I%E.XI&$C<E(Y!\G)Y.*T;;U2BV;1<6YZM<6[,D3)K2$1
M&AE33,A:-^"0,)2$YYR<\ DXJ1D=6]/(G(CQH]VFH<=0PA^)"4XTIU;276VP
M?_)25 CC'!R12=U>TM#M-IN#K[_8N#)D;=J0N.V%A"U. J'Z5920G<K(. 0"
M:RL]5-/R;H_ BB<ZXVX^PA[TY2R\\RC>IM#AX4HI!(QY_P C.4:_'_:56N%V
MB8VD0?6>A60%GCCW?^)\[L?IYQ\5L7+J'9;;,$>8B<V&RRF6_P"G5VH2G0.V
MEY?A).Y/WC(S@<UN:SUE;=(1TO71J:XV6W'E&,P7 VVC&Y:CX &Y/SDYX!J+
M<ZG:?1J V<>O7([Z(O=1$662ZMKNH0',8)4GD#Y_XJ2TYK:TZA<MJ+=ZHJGQ
MG9;0<84C:AIP-K"\_I4%'&#]&M>7U!LD2?>(SYF);M((E2O3J+"%A*%=O>!@
MKPXG"?DG YK4;ZH:?>MHE11/DO=UUE4./%4Y(2II(4O*!\!*DG/CW#')Q6U&
MZBZ>D%K8^^GN7)JU)WL+3^>XT'4#!&0"DCD_-1L#J';;]=[*BU2;C'COS'8Z
M>];5AJ?M;=)#;B@  DME14,^,'SQBTKU"@ZA,"[F4_;H#T.<_P"DD1CM<;8=
M0DO]T@8PD_I&?UG_ ,>?3'5[3<B$X]';N3L@/ML(A(C9D.[TJ4A249Y24(6K
M[ 200#Q5HO.I[?:+'%NDP20U*4VVPRAA2GG%N?I0&\;MW[$<8.<8-4F]Z_<O
M<K3]OTE*D1';FN4TZ^NWJ>7%>8V@M.H_L]RQN)\ <><C:Z@:\E:=9NEK8CJ5
M>(]@>NJ9:65*8"T9&"/@$I)&3]#G-;,+JE8E6B5)D_B#4B(ZU&4P_#6P\^XM
MO>@H;7@X4 HC.. <\<U]U/U%AQNF1U58%-RQ*V,P@Z"$EY:PV L#D!*B<C_T
MF@=U%I1PW?5>IH,S3K$1Q<TF%V%M.93L[>TDJ!]PP>? &2:\JZJV=L*:>MM[
M;N"9+<14!4/,@+<25-DI!(VJ"58.?@CBL=IZNZ?N4=]]N-=V6&;:_<^X_$*
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(E*4I2E*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>exh47_03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh47_03.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ KX! 1$ _\0 '  !  (# 0$!              4& P0' @$(_\0
M0!   0,# P,$ 0($!0,"!@(# 0(#!  %$082(0<3,10B05%A%3(6(T)Q%S-2
M@9$D8J$(L24T0U-RP>'P8Y+Q_]H " $!   _ /U32E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2JU'UC!=U6; Y%N,:2H+[#TB,IMF24?O#:C^[;YSC!'@FK+2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2H2
M%;KTSJ27-E7T2+2XG#-N]&A'9/'/=!W*\'@C^K\55'V+I=NK]JN$:W76%"M;
M$J+,>DJ1Z>2A806^TD+)R5 $JP#A.#XQ5MG6^[OZ@A2XU[]-:V0>] $1"C(.
M#Y<)RD#@\#X\\U,TI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*B(%_C3KK<X;"'"U
M;BEM^6=H9[A 46P<Y*D@@GC R!G.0/1OT)-]C6I:RF1*94_&7Y0^$$;PDCY3
ME)(..%<9P<2M*P3Y(A09$I3;SJ6&U.%ME!6M82,X2D<DG' 'DU0XG4]$NY3(
M36E-2!Z"XVU,W-,8C%Q 6C?ATG!20<@$#YQ5MTE?6=2Z9MMZBM.L,3F$R$-N
M@!:4J&1G'%;5WN#=ML\VXJ0MYJ*PM]2&L%2@E)40,G&>/NJOH_7#^I3;G1I>
M]0+?/C^I8FR"PIHH*0I.=CBE)R#QD"K?ZAD*">\WN*M@&X9*L9Q_?'Q6K>[H
MS:;//N#R5.MPXZY*VV\%:DH25$ $CG@UDM]P8FP(<I"@A,MI+K:5J&XA2=V/
M/G!^*V\C[%>4N(6"4K2H D$@YP17T*"@"D@@^"#7QQ6U"E %1 \#R?Q5*N_4
M:WV</HN<"X,28]F-[>8*4%3;04$E!PK&\$X^OS4U=]3Q+7$LTA]F0M%UDLQ6
M>VE)V*<!(*\G 2 #D\_C-3@4" 000?!S7W-5YW549-YN=K:A3WY=O$53B6FP
MK<E]2DI4GW>!L459Q@ ^:GW%[$*4 5$#.T>34#:M4,3KQ'M;L*;#GNV]-Q+<
MA*1L05["@D*(W@^0./S6:RZBBW:Z7V"TTZTY:)"8[RG<!*BIM+@*>?&%CSBI
M&X3XENA+F3I#3$5&"IUQ6$C) '/]R*S[T;PC<G>1D)SSBOJEI3C<H#)P,GR:
MQKE1T-..K?:2VWD+65@!./.3\5Y5,C)4RDR&0I__ "@5C+G&?;]\?5:UEN#D
M^&'941<%XNNH##CB5*PA92%922.0 <?&<5N*?:0XVA3J$K<SL25 %6.3@?-?
M5NMMJ0E;B$J6=J03@J/G J&O&I(MKU'8;,^T\I^\*>0PX@ H06F^X0KG(R <
M8!\5ISM8-1]1S;)&MD^;-C169A#';VK0XZ6^"5#E)2HG.. <9J1DWQL2%1[>
MRN?(9E-1I3;*TA48+2%;UY(X"5!7'.#Q4KW$;RC>G>!DISR!]T4M"0HJ4D!(
MR23XJ+_7HO\ %*+"$.F6N$9P< ';+86$8SG.<J'QC'S4F76PZ&BX@.$9""H9
M(^\5]"T%12%)*@ 2,\C/BOH4#X(->5.MH4A*G$)4OA() *O[5$:8U#'U"U<G
M(K#[*8,YZ OO!(WK:5M4I."?;GQG!_%361]BL:7VE*2E+K94K. %#G'FO,J5
M'B,.OR7FV664%QQ:U!(0D<E1)\#CS2-+CRFFG(SS;J'4!U!0H'<@^%#\'[J+
MU1?TZ?C1W3;;E<5/.]L-P&0XI.$J45*)("4@)/)/D@"JA9.K,*[6^!/1I^_1
MH,^3'CQ9$AE ;<#SH:"]R5D#"B,@\\@@$9QT0R&0T'2\WVR<!>X8)_O7M:T-
MH*EJ2E(\DG KZE25#*5 C[!KSW6^Z6^XCN ;BG<,X^\5K76Z0;3 ?FW*4S&B
M, %QUQ6$H!.!D_W(K;R/L5Y4\TDD*<0",9!4.,\#_FO>156UAK*-IUVUQFH,
MNZS[F7?2Q8105N!MLN+4"M21@)'WDD@"K+'<+T=MQ3:VBM(44+QN3D>#CC(K
M)2E*4I2E*4I2E*4I2E*4I2E*5P(:=N[MBOMH;93/G0=6JO$RV+6E)N,)2@X
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M**DE2,#>D*R1D_/D>?%W?;'4V4BZIO9A?Q"V\W<6&=S2RIA# C%:7,I2'"/
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M!#B9"UGLE"%+SL2X$N8)) ']6....V:T7UW1B7+-8[G*CW'3L^U,".4GL/\
MZ@\M*7,K&T!.!D9^AFIRZZ<U"-=Q9[&DY[+@5V9$MG#JGVE0NV"MSN>-_E 2
M$C;G))Y@Y&AKVQI);#6FKBLR=.PG9[:FBZIZ6U-05#!5DK[6_"01QQ5UBV:[
MLWR';6].W5,1&JD7=$C8$LL1%QPG83O)W DA20".#XR*J+?3:<Y:$J.F)I>5
MI:8VH.).[UZ'SV205?O"?V\G@C%=?UY;KM<>F-D1Z*5,4RY"?N=O227Y+*2D
MNM>1E7R1\X(^:H]FTM+3KW2LT:>GM:<9O$]^'%7&"/T]M3#24%2!_EI+R5J2
MGX&#\U^@J4I2E*4I2E*4I2E*4I2E*4I2E>.RUWP]VT=X)* YM&X))!(S]9 _
MXKZ&FPZIT(2'% )*\<D#P,_[G_FO5*^*(2DE1  Y)-5RTZZTO=WVF;;?(4AU
MY;C;:4.<K*$!:L?8"5!6?&#4W;+A$NMOCSK;(:DPY" MIYI6Y*TGY!J+MVJ+
M;+U#,L1FPQ=F"5^E0]N66P![B,<'G]OD @_-9KOJ:R6:1V+K=(D-T-I=(><"
M=J"L("E$\ %1 !/S45)ZBZ1BRKA'?OT-#]O4$249)+:BH)V^.3N(&!DUAC:G
MT+IV(RJ/=+);8]S/KD!+B&A(+AP7<<9R>"?QSXK)(ZCZ4BR[M&F7F-'<M;R&
M)(<5C"EI"@!\GY''RD_5;\*3IJP::7=8*K;;[&\/6JD,A+;2^Y@]S(X)5D<_
M/%5\=3[(G4[41ZX6UNRRH+4F'<3*&'W%/+:+8'X*1SGCG/XD[UKJSQF[[$ME
MP@R[[;(CTE4$O85E"-V#@'\9QDC-:FD]:2;UJ@6F1 :80NRQ;NAQ#I4?YI4"
M@C \$>:SV_7$!6L+OIZZ2H$*;'E-L0VE2!W)(6RAS(2<'.5$<?535MU+9;G=
M9=LM]TAR;A$R'X[3H4MO!P<C\'@_1X-?7-1V5N^)LSEUA)NRDE8AEY(=*0"H
MG;G/@$_V&:C'-?Z53^G%N^07D7"7Z)AQET+27MI5M)' XQY^5)'R*PZHUM$T
MUJRT6R[N0X=NG1I#YG29(:"%-EL;,$8.>Y]_'BM<0>GS&HIEY[&GD7F*ZTN1
M+PUW67'>&RI7E*EYX/DYJ=O^I+98I=JBW*4VQ(NCYC1 XK:%N;2K&?C. /[J
M ^:KO3KJ1:M5Z93.DRX,2X,L*?G1$R KTR4K4G<H\8'MSSXR,U:[%>K;?[:B
M?99K$V&LD!UE61D>0?HCZ/-<VTQU5N5RFV#]4T_$BP+S*>A,.Q;CZAU#K9<!
MWM%M)"?Y2O<"< C-7Q&L-..2YT5%\MRI$%"G938D)RRE/[BKG@#Y^OFM!_J/
MH]BT,7-W4, 07UK::="\[UIY4D <Y''&/D?=:;VOX;W4.T::M,B'*+Z9'JSN
M5O9+: I(3QM5Y((SQ4SJ36-@TU*C1[W<V8CT@;D)7D^T$ J5@':D$_N5@?FH
M"#K*X7;J1.L5H1:W+?:U(1.2ZZM,HA;:5AUL8VE *DI(/).3D<9C[GKK4_\
M%&J(%AT[ N$.P*9#Y7.+3[H6RET[$["G(!(Y4/ J8L&OK;=F$W;U]MCV%RUM
M7 %][9(9W+6E1<2?:$ I"<@_N"ASQ4BSKS2KRH26]06U2IJRW''?3EU07LPG
M[]PP/OXK7O74;2EHCW9R3>HBW+4@N2F&5AQU&%!.-HYSN4E/X)&<5N?QMIKU
M\"";Y $R<A#D9DO#<ZE8R@@?]WQ]UKGJ'H\"03J:T 1U]MTF4@!"LD8)SYRD
M_P#%62-(9E16I$9U#K#J XVX@Y2M)&00?D$55(VNK3"LWK=2WBRP]TB2RVIF
M7O0L-+((!(!*@ ,I&<$XJ7O]Y3$TG+O%ND6]2$QC(9?E/[(ZDXR%*6 <)QSD
M5H2M>Z;A7"[0I]UCQG[4VRY+[IVA =_9C[)X\?ZA]U,1;U;95E%XCSH[EK+9
M>]4'!V]@SE6[Q@8/_%46U]1X^HKU/AVIZRO6IFXQ8(DOR2D24/,E2DH&,*<W
M I"?!&?JI#3\OIS8';O(L#VF[>XP0F>Y%+3?;]Y2 LCQ[LC!^:E5:\THERWM
M_P 0VM3EPQZ1*)"5%[*B@%.#R-P(SXR"*TIO4_1L2(J2K4$%UE,IN&I3+F_8
MXX2$YQX'"CN\82?JMP:OMUOM+L[4=RM4%D37HB'$R@I!VN*2D$D#"\)]R>=I
M!YP*S2-::9CRHD9^_P!K;D2PV6&E24;G Y^PI&<D*^#\U8#XS7/NGG4^T:FT
MZJ9<IEO@7%AM]Z5%]1GLM-.K07#D [<)!.1QN&?(S8;5K/35W$'].OEOD*G*
M6W&0EX;G5(&5I2D\D@$$C' (J)T_?;);)$J!;']/PM,P8/JVS'DI2I'\UQ+J
MBW@!+84D^[/[LU+QM9:;E09,V-?;<[#CO)CNOHD)*$N*QA.<X).1C'FMZW7R
MU7*VN7"WW&'*@MYWR&7DJ0C R<J!P,#DYJ'<ZAZ0;B(E*U):Q&<?,9#OJ$E*
MG!MR ?G&].3X&>:WWM5Z?9N#<!V]6Y$UQXQT,*D)"U. )44 9_=A23CSR*TH
MVO\ 24JW3)[.H;8J%#=#+[Y?2$(6?V@D_?P1P?BHG4O4VRVY_3\:U38%REW:
M=%CI9;DC>EEY1'> &20,?C-7VE*4I2E*4I2E*4I2E*4I2E*4I2E*5@GH==@R
M$1@T7U-J#8>!*-V.-V.<9\XKBEHZ?ZPM\JS7",W!VVB:I<.U2[@XZAII<<M*
MVO["K:"04H(.$C&?BKKTIT7/TC;6D7&:T\]Z)F*MEG*FT*;<>5N2I6#@AT<8
M&"GYS7F7I*ZO]3K'J#?#]!!5-"T[RES:\VTE. $8)RA6<G/(Y/BN<]9IJ874
M666$0%^HM\5N1#D*D-.S2V^74!HMM+2HDI",\$9(_-6^1I35+NG):82+>U*F
M7\W4LKDK;4(ZT@E'=""6W KC*1X!P>:KJ^EVIGM%/65Q-K2]^AR;>VYZI:QW
M5RNZG)*,XV?/)S\?-;EQZ>ZC)O+*85NE1YDV-.9?:N3L62PXW&#6YM0;(2M*
MD@@G(*5$$5=;WI^Y3>ET6S3XL6\71,>.B2E3YCI<<04%2T+"?:H$%23CR!7,
M[CTRUQ=-,7*%<7X,F=+LJ8*7W9144K3,+H2H]L9/;(!6/*AX^:D+OH/5\W5%
MV?\ 1V[T<INY,-.LSE-)"'V0EM1:#?"\I 4O)))SX2*M^B-*7:UZQ;NUQ1';
M83IZ';"EMTK5WFU**OZ1[?=P?GZK0U/HF\7C5,YGL1199UTA71R;W\.M>G;;
M3V@WM.2HMCW9QA1_L?73;0MQT[?2[<X4!:8@D(CW!,Y]UQU#KF_AE7L9/^K&
M=QQ^347K;0-^ONL+W^DM?IMONL5UF7+,L.-/YC=M"BR4[D.)4 DE)P4#G).*
MCK9T]U%'U!IR^)L5OBOQ;DA4N.+J])*FPRMHN]QW. -P*6TC., GZN74FQ7N
M;J2T7.S6V-<FFH,R \R\^&MA?[>'.0<I&PY YYXS53M>EV&NHFG;):KHU,;M
MMMC)U EM(.]R&$B*5\G:I1<*L')PW^,UT;6%JN4R^:4GVQIA]-MG+=?;=>+?
M\M;#C14/:<E._./G'D5R971_4C]AB0>] CN-6-R&5!Y1'J/7HE)&0D*V$-X*
M@<C/ ^^G],]/S+!:KBJ9;X<"3-DF08[,QZ42K:E.YQYWW+4=N<X&!@<^:YMI
M;I;?V).FU/VBQ6>9;+HNXR;Q$DER3*;4MPF.0&TD@AP))*CPGQ\45TXU<JP0
M;+'9M['Z Q<4PYKKP=$Y4@+" 6RGV8"\G=D;@, BMK2G3?4\/4MLN-Q:@(::
MOCUU=(G.2'-KD4-;2I205$*'G\GXQ4[I31.I;1J:R"2;2Y9+3)N+S<A+SAD/
M)E*4L ME&U)2I6,[CD5.=0M,2[H)[EDM\&1.NMO5:9+\R2IM++!WE*DH"%;B
M"XHD93GCGZ]].=+7#3$^^-RULO0GS%$5[O*6\L-1FV"7 4@ GM!603G<?KF#
ME:=UG UAK*586+*N'J!3!1*E2G N-LCI:)+0;(4<@D#</C\U7KGT<N4:PW*T
M665'>CKTVU:&')"BA2GDR%NJ4H '"3NX\_7YJ9U-H6\2=8F='M]ONEOGPHL2
M0B9,=;3%4RI1"RA/#R?=G:<<CXR341<NG^KW-!7K2;<:R/1T-21"N#CJE29(
M=?[H0<@!L^=QR02$_P!ZW;CH34LR3?8)8@"#J"3"GOS%2"I<%;0:WMI&T%S'
M:&Q7MQGG%>'=!7^+TU9MB8;<J\M7>1/;7$N!CK8+BW2E:%J00HX<P4J&""JN
MA:+EW=<>1;+Y;O3R+<AAGU;>.S,):25K;&!M 5D8Q@?^!SJ)TSO;,:Q-;("$
MPKA=Y+B4O*.UN2VZEH))3D\K3G/U\U9KII*ZS.A"=)!#";N+.U;\![#>]"$I
MSNV^/;GQ^/S43J;1]]F7/5,A%JBS8]S1;W64IN*H[S;K'G8H(.U8/N2K.,@9
M^:ECI+4%TZ+N::O=PC+O[\53:Y&W^7NWE20K:!GC"2H#GDU6UZ%U9=M3.7BX
MQ;3#[E^MES+*9:G=C4=HMK /;&2>"/[GZYTVM :R;G/S(C4"*B+<&;E'MRIR
MW8SSZ7'"YL)1N:0H.%6T[L+Y %2\/0NH)VIY=QN;%GMK4S3LFUJ3;R3Z=YV2
MMQ. 4C=A*@2KC*L\<U78W3#4L>TVX-6BRLSK;+MCN]%P><5.3&6HJ)4M.&P0
M4D) ./=^*L471VI+#-A7F'%AW-^//NCCEO\ 4=L.-2WMZ5I6H8"T@)R".05#
M-1#?2N_L::>MK?Z=W51;6A"PZH!*F);K[J![20D!P!)^=HX'QU_3\^?/;GBY
M6U4!<>4XPU_,"P^V,;74G P"#X(X(/D8-<?@=-]7V[2MO@PDV?UD>WW:*2\X
M5HW2I"'$<%!"AM1CGP3R"!S]MO2[4[-AOCB'X4'43EX3=K9)]4N3V2IM+;B%
MK4@*/L*QGY./KF2U5TQN4ARYQ[&(B8*M)_H4<O.D+4]W=VY7!XQR5>2355UW
M99VD+FB[SEV]A,RY6=45QR6IIMHQ(SG=[CA24IW<H3D'.[.,U=>F257WI3?;
M? C--./*ELIDID]]F6ZZDK4ZAP(3E.]PIX3@%) SBHG4G3*[R6=.*1;K5=A&
ML3=HE0I4YZ.TA:=JNX"V/YB2H<I4!G:G&#XI=BN*F-;FV6M%JGK3>7G(L5J0
MZAZ*ZMI,=;JF%-D]M("UX4O&U1Y/%3EHZ9:T8:D(E-6[<\_:GW5>N*TK](ZH
MK2A/:2&TD$$)'"<8&<G%IO6B-2.:K<7#:M\FV/:BB7PRGI!0ZVEMM+:F2G:<
M@!&4\_-==I2E*4I2E*4I2E*4I2E*4I2E*4I2E8Y+R(\=UYS=L;25JVI). ,G
M ')JBP>JVG9&G;7=W3.9:GQU2NT(KCBV&4JVJ=<"0=K8/]9X/QFKO'F,2F8[
ML9U+S,AONM.-^Y"TD @A0XP01C[JN2KW/L$RZR-2KBJLY+(MIALK5(=<5N"F
M2V"HK5D)(VCD*/T:T)/5;2$6WQY<JY.M)>#I[9B/*<;[1 ="T!)*"C(SNQ@<
M^*]M]4M(+MDRX&ZE$2(^W'=4N.ZD[G!ELA.W<4J'A0&#@UA<ZLZ0:M3%P<GO
MI9=6Z@H]&\7&2T0'"X@)R@)W)R5 #W#[K?/4;2PU"FQBZ)-S4OM!I++A&_9O
M"=VW;DI.0,\_&36_9-7V*^/0FK5<$2')D94QA*4*!4RE>PJY''NXYP?^*UI>
MO--1-0?HDBYH1<N\F-VRVO:'5)"DH*\;0H@C SD^!S46.K6CEVU,]BY/OQ%+
M4@.,P7U@[4[EJX1^U(Y*O ^34H_KO3[5Z8M?K%NRGMH266''&PI2-Z4*<2DI
M"E)Y"2<D8XY%1&G>H]JO0:N!N$>%;5VG]25'EM+;?;0'"DN%1]NSC''D\YQ6
MVGJ9I8VIVX&<\EII]4=;:XCJ7@M*=ROY13OP$G<3C '-3-SU39;;8X]XDSD&
MW2"@,/,I4]W=_P"W8$ E61SP#P"? J(E]3='1%0Q)OL5OU;33[)(5A3;F=B\
MXX2<>3C'SBL-VUW&9UW8=.VUUF0Y+E/1YAV+/9*&%N !8]F[*0"G)(!\5O7K
M6^E-.WDV^YW2)#N+Q;4ML@Y]_M05D#C.,95CX_%8YG472T*1.9EW1+/HT+6X
MXII?;4$$!P(7C"R@D!0224YYQS51=ZK)N^KF8&EY4%%J8ABX3)=QBR$)4TEQ
M27 E6 $82E2@I0*2<"K.UU/TFNVRIR[DXRQ&=;:=#T5YM8+F>WA!3N(5@X(&
M#@UB>ZL:,8F-Q7KNIM]820E<5Y."I 6E!RCA92H$)_=\8SQ6:7U-TG$LUONK
MUS4(,YLO-.)CNJVH"PA2EX2=@2I0!*L8-9T]0],JU$;(FX+_ % /KC*28[H;
M2ZE&\H+A3L!V@GSX!K3'5+2QCRGA+? 9[7:2N.M!E!TE+:F-P'<2I04 1P<$
M^.:DT:ULR]('4K;K[EM&4D-L+4Z%A>PH[8&[=O\ ;C[_ !S40KJQI-NV1YKT
MN6V'D2%A@PW2ZCL$!X*2$G:49YS\ GQS6KKCJ3'M:K2Q85)FR)5P@L.K].XM
MEMF0L<EQ/M2LI(*03GD'!J4UMK1-CDR[7$8<7=19Y5T96ME2F1V0,!9'V3]C
MQC(*DYQ6KJ7IZ7I]ZX.S%AV*A@/L>F=2X7'DCMI;;4D*7O.0G .<''BI)&NM
M.JTB=3+N*&[,D[''EH4"VK>$;%)QN"@H@$8S46YU7T8W$3(5>#M4^J*E BO%
MPNA(44]O9NS@@CCGXS6VKJ-IA-Q=A&X.!UON)*O3.]LK;05K;2O;M4XE()*
M2H?6:\776]L4Q:U6N[PD*EJAR 7FG%!R,\Z$)VX'"E\A.?D<C -:>HNHEJ83
M<HD"XB+-@O--N/R8+SD?_/;;<2%) "B"X$\'A1&> :EG==:?9OXLSLY0F]X1
ME*[*^REXI"DM%W&P+((PG.36A#ZIZ.EIF+9O">U%BF8XXMEQ*2T%;5*02D;\
M*P"$Y.2!YJ8@ZLM,O3+]_6Z]$ML<.%Y4QA;"VMA(5N0H!0Q@_%574G4V"+'W
M-.N+,]5PC6]29,)[?'[RO:Z6,)6M.W)2!C=XS4NO4\FP(TW;-3A$B^7F0Y%;
M7;HZRSE(4H+4%'*!M"<C)P2?@$BO],.K=JU+IAN1>I;$:[LQ%S)C:&7$-(;2
MX49259W8]N0"3E0_M5LM>KX-]TY<;GIU+LU^&EQ*H:VU,O!Y*<AI2%#<DGCR
M/FJ'I#JE.7I1_4FI%VR79DLL*#EI;7WF7W'-BF'&E*4K*21SQGXJ[(Z@Z:5?
MF[/Z]29JUAH;V'$MAPH"PV7"G:%[3G:3G\9JLZEZLV]-N+FF7/42&YD1"C)B
MNI;=8=?2T7&E':%CE0"@2,CY%6G^.+0[HRYZGAK>?MD!MY:E]I3?<[8.=F\#
M<#C (X/W5/1KG4UJB:;OVHV;0+#?9$>.F/&2X)$(OI);*UE12X <!6 GSD?5
M3PZKZ0<8E.1[DX\(\5V9@1G$]U#6>X$%20%*3CD Y'S7JWZV@3%SI4^=!:LZ
M;5&N!CNLK3(92YOR7,\$' "4@9SG[&<O^)6DF;5ZQ=R+#"'O2]IR,ZAU+FPK
M""T4[@2D$CCGXS6+6NMDPNE4W5VF'8LQ CH?C+=2HMJ"EI3E0!!XR>.,$<U2
M4]2[]%O*;7(CV:5,:OUNM;]QAMK+#[,E*E*V>X[7$;0""H@9\5?5]2M+-/7)
MN1<'&/T]"W7E/174)*$+[:U()3_,"5D))3G!J6TKJJSZJ8DO6.49"(SG:=W-
M+;*58!'"@"0000?!J;I2E*4I2E*4I2E*4I2E*4I2E*4I2E8Y#?=8<;SC>DIS
M_>N.6?I?J6SVF(U#NUI5--F58I)<9<+?8"E*;=0,Y+B=R@0<).?C'/1XFG/T
MW35IM5HEN1EVMEMJ,ZK<I)"$;,.(W#>",\$\'!&" :AM2:8OU^;A2GKE 8N-
MMN")T!M#"U,H"=Z2ESW K*D+.2-N".!YS5)?2.Y2)%PF*N\0S;C%NB))$=26
M^[+2A(V#<2$I2V!R23Y^:T-<Z"N=LL<^3'=]?)GRK(V6V8RU=OTRDH4LA.24
MG]WX K/J7I%?K[;+A'=OT)L71^5)F,".OLAUP-I;4@!0)*$M)'NR,J4K&>*W
M1TQN46ZL7-5QBN)8O,2[.(#2R2AF)V5I2!DE1/(J8Z3:>1#N&H;XVS,8AW&2
M3;F9:%-K:CDEQ0V* * IYQY0!&<;:@H^E+K>>HFK6'66XUA5>85P<?<2M+KR
MF665I2UP$E)6G"E9.,$8R<CQ+Z47UWIS8=,,WJ&A$*-*C2D+;<+3Q=!V.#:I
M)RC)P#E.59P<"IK3^AM2Z?O+:[3?8#%HE+COW"-Z/<ON-M(;4EDDX2A8;2.0
M2!X.:A(72*Z/V9-MO%S@AI.G7+$E<5I9*27DK0X0H\\)&1D<_BMV^]/-1ZDM
M%N?U)*T[<+S;W7.S&<AK,%32T!!2H9[F_@*W9X(QCYJ;ONC;O+T38;)"GP6W
M(3K1E)2RJ.R^T$J2IM(:4%(3R" #R$X)P353F=([R_I!VT"YV\/JLD.U)=V+
M"=T>2IT*(^BD@?W_ !4K9NGE]M^M(DE<RV.6*->)=Y1PX))7(;<24$?MPDN<
M'/(^*B-1V&Y:EZJZRL;*([5NN-MMZ93[V\*2TE;A);P,*5Y3@J'G/."*QR^B
M\[;J*-$=L!CW!N86)CD(B:E3Y)"%N9/L3N/N3@D8!&*L=_Z;S+W=+N7YK#,&
M;IUNS(+9474N)65A9!X*<GQY(K2D=.]27B]1[W?;A:A<V9%M(;B)<#:F8KRG
M59)YWJ*CCC Q^>)&[]/KC/U&9XFPT1_XDC7P(V*W;&HH9*/K)QGZJK7CHW?;
MCI9BQ_KT-N*3,4^UVW>V5NR>\AP)2L;E >W"\@9) )J?>Z6R94Z4Y+N,9<>3
M>UW5QM+*@2A<0QU-@[N#[B0:U%]*KY.T?'L=YU+$F(MBF#:TJMB"RD,@I3WT
M$GN902DC(&.>35E5HNY(Z;+T[$NL2+/6=Q?C04L1P"X%*;#2",(*<I/.X@DY
MS50M_1B=%MBX1O<0-&/=F$)9B*;2@34) X[AX04^/K \C-9W>E%Z0B)$AWN
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ME12&/4!&\-A?R2D$C /CXXJ)/5J XPV6++>&Y1N<6W.19;(:=0'P2AS:">,
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M[2BRY%2EQY#K@;0I"2O@%1'"MIP?%9W.K]E$1I3=MO+MR7-=@JM:64"4AQI
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M :D=Y!)2@%1SN!)))W$_0JX3-";]:.W^!>IT%$M;+D^&TALID*: ""%%.Y'
M 5M/N QQ5UI2E*4I2E*4I2E*4I2E*4KF^HNHTNV76Z+BVEI^Q6:7'AW*4J04
MO)6[LY;;V'<E/=022H9YQXKFYD:BNC%PO+;T@2I.J#:$(1>GV$.,=_;VBE*/
MY8&Q("T85A:B?HV*U=3)-@F2[/&L%TN%FM7JXZIRW)#ZTNL)4I0<>6WLV92I
M .\JX&16>Z]7;Y"MEJ<9TH)=QN,07-J)$=>D$1"&PGE#.>X5+(P0$C RKD5]
MNVLKG?\ 5&F7K<RN#96-2_ICBU2%MONNICNEQMQG;MV \9W'E'CG(O'5"_W/
M3FF6YED8COS7)T6*E$A12C#KR$') /G=C/QG/.,&(:ZB2?XACMR+6RW8I%U<
ML34I,G<\9:"L<M[<!LEM0!W9\'&#4WU U6YIF/:VH4-$VYW68F##:<=[3?<4
M"=RU8)"0$GP"?%<TNG5&ZWJ1/L\:,+:XQ9;HJ>6GB7H\J.=@[2P!G!P0<<[_
M (*<&1M?5B1:[&^S?[9BX16[:VSM?6\9)E()25;&U*"AL6HA*5'ZR:D].]2[
MO?KK9+9&TNJ-,F1ES)(FR%,]IEM]+2U(26]RL[MR=P22*ZC7+M0=4YMG?E-N
M:8<S!B";+2]+#:TMF4Y'!0-A"\]O>,E(*5#Q7F3U2GQHJV7M/,_K(OS=@$=,
M\EDNK:[J5]WMYQ@@$;?^:@HO5%2]33+U,3*8@V_3DEV5:DNE:4R69?;5M. %
M9(VA8^/.*G)O5*XVBXKM]^TZS&ELN0W'^S/[K;<20X6^_N[8Y0L *20/.0<5
MAOW6(VR*RMC3LJ7(?[[[++2UK*XS;H:2YE#:MJED^U*@!]J!(!,=9/5:DEVZ
M'I>ZR8T?U;:GVT+*@[';WJ0H;-@R04#"R<XR "*M_375XUMIL79,9B.DN%L)
M9E!\< 'D[4E)!)!2I(((^B"8>=U)+%VF!FRNO6.!=&[1,N'? 4V^O:,I: )4
M@*<;!)(.5< XK1Z(NW6_P)&J+S+G=R2]*CHC^N[T9:$R%!*TMX ;4D)[?'D#
M<1DU$]3M;WMJX:BM-M8].W:I%H+<AF26W75/OIR@C'[5 *3Y^#G.>,]PZU)@
MVY*7-/O&]HD2F9$!+Y<#0CD!:M[;:L@E20,I R3DC&3T5=_0K1B]0,QWDM^A
M,U+#Z2VL#M[]J@?!^#5 TA;+O+TA8]83=87(2WT-7.>A;J51%,$;ULI;&$H
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MHWDJ<2%I.\*2DG"=R3M)Y\@\BN%Z5939%:<NS<2UQT-:L=C/28BRFX*2IYQ
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MA.[Y*B>"*Z!J.WRGNBVE(#]FG2UI1 ;EQRTXMQA*4)W*6RV4J7@C&P$<D$\
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M;<[:LA6Y0&\#D<9Q47HO0VJ(=J3#BVIRT34:<N=M3)WH;2)3DE*FU!2%$\I
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M23A.4G;M' P , 9.Q.Z17'^(;_*@G3I9N"IDAJ8_$49J')#:T]LK' 0%+SN
MW8XK(]TNOB78T^+.MPN,%BTJC-N!1:<>B(=2M*SC(0KN\* R,9Q6EJSI=K&_
MZ??@N7&S)]6Y.>>CI6\VVVM]T+0K> 2X$@$;2 ,D'D@5?.G.EKGIZYZEF79Z
M*ZY=9+4E/IU*PDAE*%#"AQ[DG')XQXJ%U59H]]ZPV1,1<D&-%[EW"6U!I;;3
MJ'8R"HC;N[ON '.T*SCBJ[<.DU_1=K^_:#IM*I;TN3$N4AEQ<M*I 7EM0Y0
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M4L/%*RI 4  G(&1R0,XYK,QU@TJ\].0AV41&;6ZA8:"A)"7$M_R@"225K2D
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M=-[GI]ZTR+?J-OU4.WR(#BW( 4ET..EU"@G?[=BB.,G(3\9KI!"^R0%)#NW
M44\9QYQG_P#=<VB=,Y2>F3VDI=[:=6J<)B);<,H"?^I$@I*"X<^X*&=PX(^N
M=>Y]*9+US?NUNOK,6[+N$J6AUZW)?;2T^AM*FBA2N2.TDA61\\5/ZZT5)U1T
MW7I5N[B,XXVRTY-7%2LJ"%)43VTE"024CQ@#X%1=RT%J.]Q5,W[5D60D2XLM
MM$>TI80%,NA9*OYBE**@D)SN  '@UJN=-9$.2U<U7/U:X4J[3TQVHNTN^L0?
MY0.\X*23S\\>*KNE>EMXNVFK#.OET;AW2+!MS$=DP%)].W'<2Z6W4ES*U%20
M-P*?&<<U9Y>@I$!]3YDJFV*!<G+_ !K:PP3+7*(4=G=4YM*-RUD)V@Y(!5YS
MH:5Z8-O:)NL28F3;),^>9D-*E!QR AMTKC((R4J"?)3R/>4YXS6Y<^EUPF.P
MIJ-3(1=VV78TA]5K96TZTM04$I:X""DIR%9)R3G.<5;M3Z;<O5KM4-NX+95
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MMI5L="TA2"%**3P>!D9S4% ZIS+A93<(UNMZ4-18OJ0[-([,QY\MF.0$$E2
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MHL6X7 @R7VTX+F/_  ,^3C&3R<UF<TW9G'ENN6V*IU<M$]2B@9,A "4N?_D
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M,MB:^I;A06RO?M1N5[!PD^W'N3N\U+:8T;HLP8\^P08SL1U3TAEYIY;B%%Y
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M9:4'\!M ';*"0L*YSQ?^DNIKA>-47^'<[TBZ;&TR(YC%I<=+2G7 D@I 6VO
M2DMKR1LSDYXZFKE)YQQYK\W1M;:IFZ0L+\2^*MSATQ/NKW8BL$./1W $Y"D$
M)2?& !4]%US/N-UE.3=4KM$[M,IA61J,VYZM+L1"PZ@E)6<.K7[@2D!OD>:B
MIO5:[/V9I=KOT,O#3,&=)=0EIPQY2I*&WBI/P=KG*3XP.!\V"\WO5MJO&KV8
MMYE7/^&K4Q,:CF*RDS''$/9WE*<X3M"L)P3MQ_>"MNO-12TVRWS-5V=5ON,Y
M2%7F(MJ1Z9'IU+2RX5-(;"EK3P"D* R#R0:ZET56%])-(E)! MC"<@YY" /_
M -5\ZK7*1:K19WXBF4N+O4%D]UI+F4K?2E03N\*P3R.1\8\U3-%:TO\ /UX[
M'N5V9<@KU%<[,W",=",-L-EQ"PL>XJ'"3Y!'YYKM%<'U3(G3=4ZKAR;VXV8V
MH+(W;FWPVL15*+2BXVD__DKCY&<_-0LCJ5K)<*/":NMLB/-.W!M5SFJ;C)?7
M'>V)2=R%(SM(44I"21X(P:_1%J?<E6N'(?"$NNLH<6&R2D**03C(!Q_< _BJ
M!U+U+,MFHH-M3J&+IB NWOS#<9+*'4N.H6V T L@'VJ4H@>XX&/FJL[KW4+U
MQDS8MUC=MO4 LZ+/Z=.7&"@$2 >5Y(/<_P!.T&JO*ZO7]&DFY$6]1'9Z=+-S
MW<-MJ4B7ZIMM1*0.#L6<I/'SBK1J346IM-:P@0W=1O79@-I2B/%;C!QY]8=6
ME#[>W>E"@$)"VSP$\C)S4AT$U9?=2+E+O=\MER0[$8DAB,Z''8KBL[DKVMH2
MV/'\LE2A@\GS76KBX^S;Y+D-ONR4-*4TW_K4!P/(\G\U^:=0ZIO5RT1/WZD7
M=FKEIV3,N48-LH_2WDJ;PU[1E(5O6WM623M)SQ7Z%TE;8]MLC CK2\X^E+[T
MGMMH5(<*0.XOM@)*B D9 \ 56^K=[EV>/IYJ)>4V5%PNB(;\PI:/;;4TXHD=
MP$ Y2GG!KD$KJ-K4M6F.B_VN"CLRG6+I/4F.U<"U+4V,_P I25_RT@[$;2=^
M0? ,CKN?>M06&[2I&IEM1XNJ(UN;A,L,%ML!]DI7N*2LJ!5NP3SCD>14JO4E
MVMVH)K=LN:(:X6HFK<-.HB,MB2PZ4%;_  DK*E;UN;@0..1YJ+@ZGUF_:=%3
M7=8O(_7E3$OCT,7#79;=4"C*1YV#.X_[BM.;U&U(C24E^==8DT2].1+PDN0V
MBF.ZJ4EE2 GPI)SR59((R/JK7J35^HK=U!=;CWM'Z4SJ"W6LP3':(+4E@+42
MO&[A1XP1X.<UFZ?ZRO=^UK!BR+]:EM SQ/@)?CJ6E;;RT-):2D]S&T!1)SP,
MYYKLM?G^SW>ZV/64YR%< 8%QUN[;'X"F4%*@N,%=S=^[(*4\ @?><UA@:XOT
M;3>@KFJYL1;<]'0J=%A,1PXHJDI;!+*L'M$$I_ED$$YP<8K]##Q7&>HNM]26
M_J";3:)EKML>*S&?2BXO! G!:R%[!VU*7C 2 A25!1S[LXJKHUGK26A3Z-3!
MA,EB].!I,)D]KT:\-["1G)S@[L\#[YK=N6O=2/\ >G1;^S#5'M=HN#%M].V4
MS5R20XW[AOP3@#:<C<*\Z=OMRAMQ;)!NHL<:YWZ]%RZ%IMSMJ;>4I+0#GM!5
MDGD'A/'X]6W6FMIJ;.A<_:O4\=#%N>:BMJ;8?:?V/N#(Y2MA)>&[(YP/%;BM
M4ZGGZI0S%U*N-$?U-,L09$-D]EMME2PH%0)*@4^3P0?%0"NJFKYUATL8D^U0
M)#]N7-?F3G4,MRUMR%-*1@H5GVHR4HVJRL8/&*G[5K/4[VK7$S+W',-V\72T
MMPT1D#8&65.-K"^%*4" /HY_(J\="9S]QZ5:?DS+BNXRE1QW77%A2TJ_TJ/D
MD#'GFI+J=?I&G-(O3XCB&%F1'CJDN)W)C(=>0VITCP=H45<\9 SQ7(-.ZJD:
M6O\ -CKU'%?A2KS=/52W$,H0ZM,-AQI1*0$I5N!&!PKG(S4'+U[?E6B=>Y%X
M;>F*TA#EHBO--J9<=5)*7%]O&"1@YQ]_0 J[W/7.I4]39<%FZ6:WVZ%<6XJX
M<UY*5NL*:20XE';*U$J62%)6$C9A21R3/=&]5W"ZKN,+4EV3*N;99*4@,J:.
M]M2LLNM8#B5!*E!)&](!SGS74:4I2E*4I2E*4I2E*4I2E*4I2E*4I7Q:@A"E
M*.$I&2:IVC=>Z3U1+$73\G<\M!EH0Y#<C]U)."XC>E._D\D9\\U+N::@N:N;
MU"X7%2VX1@H:.WM)07$N%6,9W;DIYS\>*F"TV70Z6T=T)*0O R ?(S]<#_BH
ME^ZVB5J!W33Y;>N!AB8N,MHJ26"O9DDC:?<,8SG\5)-PXK:&$MQV4)8&&@E
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MGOH<6IP24I6H[P@([>[^D*/&*ZST85-/3RWBY*G+>0]);0J=N[Q:3(<#>[<
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M%@T&SJ&]J[\JX=E,R6UZCNOEG>4I"0M7M;!4O"1@#G%70NM!"EEQ 2DX*LC
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M#NT**\U;KE+AWJ-;Y'?6@& IU!4'@5 ^,8)&.01D$&KB_JG3\>VQK@_?+6W
MDG:Q)7+;#3ISC"59PKP?%;-XO=JLJ&EWBY0H"'5;6U2GTM!9^AN(R:\?Q#9O
M5R8OZM;_ %49!=?9]0C>T@ $J4G.4C!!R?L5@8U5IV4IM#%]M3Q=7V4)1+;5
MO6?Z1@\GGQ7VRN6&UK1IZSNV^,Y%1D6]A: II!YSVQR!SG./FIFE*4I2E*U+
M5;(5IB>EMD5F+'WJ<[;20E.Y2BI1P/DDDUMUJ6JV0;1!1#M4./"B-DE#,=L-
MH3DY.$C@<DUMTI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4J,U/:S>]-7:U
M)?,=4Z([%#P&2V5H*=P'XSFN3N:0UG(M-K1(L>F&Y,&3$0X8SI0]*::0X@K+
MQ02V,*3A(!4$E8SSBL6E>F6H$V*9 O A1''],-V9IYI_O*8<2IX< H'M4EQ)
M.#G.0,^18^F.G-16_55XN^H+=;+>W*@Q(;;,.27>6 M.[]J0 0H$#G' J"=Z
M>:B1;+B\TQ;US!JY6H68@>]DIC_[2E%.$J.5$9! ./[U(:,T)=HFM&K]=H,!
MJ+*,U]V#W [Z-QY<<H"3MPK_ ",G&,*42*V=::8OUPZD6ZXV: VU%Q'3*G*E
M(4AQM#BE%#D=23E0!.Q:2""L\U25],]:7"+$BOQ+3#%KLGZ1'=,M3HDEMYI:
M5*2$C:A8;VD$G 4<CXJ=G:)U!?;S9+O+TW8K7VFKEWH++J5%MQYAM#:UK"<.
M+*FSE0 P"/.*^=2;:_8>@>G;9<$,KFP5VIAQ'< 05H<:!&X\8X/)XQ6BSHG5
M<74+>HXUAC%<J7/)M?KD)$1$AAE"5J4 4_N945!()]PQGFO=OT/-LFC[R]?[
M/;TNQ=(-P4R4*0ZL/LHD!1!QD$I6CG\ <XJ&L6@KQ?=,V>_P;7&AI8@6E2+<
MXIM7ZLF/EQ2ED':G>%I W<Y1[L"MN7T]U$9;,R%8$,ORY[TUMI3T=V/ 0ZMD
MK8?:4/>E7;WDMDE*B=OY^.],KJF?J%<_33]T5NDK:DIO:D":A]S=M;:5[4+2
M,9W^TE QG.1;X-@U.GHC>+4Y;X9ODA,GT\5QIA&Y"UDI[@0.T72DY/\ 25'G
MYJJVK0%^?E0V;IIAKT;4ZY/A<E^.Z4AYC#:BE/ ]X'"1YYP !6E$Z?ZNMD%E
MI6GF+J^_;;0VRXJ4R@VU<0I4ZUE63[SN.49&?-=/ZC:>N-XU#H^;;HR7409$
ME+[FY 5'#L=2$N@*\[5%)P.<@56NE6CKS:KO8')UD:LXLMM>M\J0AQM1NBE*
M;VK&PYVCME65@'*L8\D:=TT9?52M6O)TU&D"Y7^/+;<WL*=5&2E*5*1O]J5@
MHW>[X6<<U'670VJ+8JS^KTG:[NP;=^E*BS9:%I@*;D.+0_DI]R5)4DD)&[*1
MX^+#8]'7ZW3[=O@(4RWJZ?=E*2\@!$9QI]+:L9SR7!QY'S5>L?3W5MLL.F B
MUV]VX1(=YC.MONH4AI<A96R5_P"I/ !QR-_]ZQ:>T1K6)'97*T_$6N/=+?<
MT[/:'=+<4L.@;$;4 '"L8\<#.*LG3'0-WT[JQ3EV@1WV82I7I[NY<7G''DON
M%>$QR=C9Y&X_)'&>36O<>GE^EZMG/"-!_3EZIAWP/+>Y<90UL6C9M_<"/G@Y
MJ$O'2S42X\/O6Z->FL3HRX*;J[#2RA^474*WH WHP0%((SP,9QQ<>L.F+W>+
M/9&M/VXRKA%;=;2\B4AM#"E-A'O0Z%!UH\A0.58'&<U2+ATWUG,U),E2+7;
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M0PEEJ,_#2@%6 R\2IU&,\A1)//W4):.F-MBZZN5^FM1Y#*DPTVYC"QZ;L-E
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M22X[(2\A6">4C: 1\\_?%[T#I^_6R\:BNNI'[8N5=EL+[< .;$%MKMGE?)R
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M4I2E*4I2OBDA22E0!!X(-1MALD.QVYN#!2KTK6Y+*%G=VD$Y#:3_ *!G 'P
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MG[4_98UHEP(TJW1TMH;8DMAU(",;>%9R1@<UYCZ9L49I3<>S6UIM3:F2E$9
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MA:=WT<C(^<B'U+H)5LLVHTM>INLJ]0(=OBLQHVTLOQFE!IU2\D)3OVJR<!.
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MN<<=M\.M)< 'R#A8X_YQXK1OVKYK.I-11K<A*HNG+5Z^6@@9?>6A:FFLD^T
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MIY!][+7=/\L>X IS^01C%5]O7]W;U9/O#L)X6M>GXTZ+;U3D!M279!2EY:B
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M[O-M[L%1)R5>]7/_ !BM&W]+;% =@O,RKPN1#==>;>>G+=7E;1:()5G@()
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MK;"%%(4 "H *X(.1D8(K25K"Q#2S.HD3N[9WM@:?9:6X5E2PA(2A(*B2H@8
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M]U$WJ_1+1/L\24'2[=)1B,;$Y 7VUN>[G@80?OG%;TN9'B%M+[J$..[@V@J
M4X0DJ(2#Y. 3_M4?I'4,/5.G(%ZMR76XLUONMI> "PG)'(!(^/NI@$*&001]
MBJ5 ZB09\R0S%M-[=:CSS;7I"(H4VV\%A!SA1. 2.<>#FKIN'V*^Y'W4;8KU
M$O<:0_!+G;8DO1%]Q)2>XTLH7P?^Y)J2R/NF1]U&7V]Q+(W#<G!_MRI3<1"F
MFE.!*W#A&[:#@%6$Y\94*D\BE,C[ID?=1.G-00=0L37K<I91$F/07-Z=O\QI
M6U6/QD>:ELC[ID?=,BO*UI0A2UJ"4I&22< "O,=]J3';?CN(=8=2%H<0H*2I
M)&001Y!'S7R1)8C=OU#S;7<6&T;U!.Y1\)&?)/U66F:9KPZZVUM[BTI*SM2%
M'&X_0_-:=CN0NUK9FB++A]S<.Q+;[;J,*(Y3_MD?8(-;^12JSIW6<#4%WDPH
M$:X=IM*E-3EQR(TD)64+[;@\E*@00<9\C(YJS9'W2E*4I2E*4I2E*4I2E*4I
M2J3>;-<I'5K3EW9B%=LB6Z6P_(WH&Q;BFRD;2=Q_8>0*Y^KIM?5ZB1.CP(\.
M0=2W&<J>E;9=3&>94EM>0<GW$>WSP,BIOHMHJ?IR:[)O%E7"N#<-$!R8JY^H
M3,V'A:&QPE.!D%7N&XCQDG=7:;WI#J+J*_V>QO7Z%J%$=3H8D--.Q764% 20
MXI(4A0(.0<CGCQ4/KC1]_N]VO,AVP1;B[>[.S"9>$E&+1(25[E!2]JRC+@7E
M *B4?M&:BX732YG4T.3<M/Q)3:-2/3)$IPLE3\8Q0A+BAG.%. JV^0><?-0:
M-,SXKVGM/7#33%SO9TI,A+CEU@B/ND(2AQ2R1[$A7E&5 $X'FI%W0NKF=9P9
M/Z-W&825LF='?CCU*/T_LA2BI0<*E. #:KV@ 8^5'0B].W+!I*\JO,:/9&DV
M*VOM/A;82+E&2M:B4I5[E[L G^K)P37;.F]MDP=,-2;FD"[7-9N,["=N'G<'
M9C_L3M;'V$"N,L],I$C4C4NYZ19?CO:ENDF3N2UE<-;1[.3G]I7R!\'GCS6-
MG2NIXMJT4T[H]<J1;85O4J2VIE3S2F9B7'&\N+&TA ( 3YWG)P,"[=-+.E6O
M;TN.N+(L-G>>5;'&,%*')FQUYO(XRC&.#X<_XWNI>F;K=]=:>GVF*=S5NN,1
M,Y.W,-]UH!IPY.< A7(!QG\USO373J28,%NYZ3N/<5=;>+BB:[&=9>2TAU*W
M$H;2D% WC*E94K=\X)K>3TU/\3!YW2K:X[FJ)+CBRVVI)@JBA* H$\MESG'/
M@Y'C.A;]#:G59(+#]JE"6C1$ZUJ*EIXD%9[39.[Z\? _]LO\%S[?:YMMC:5E
M^@EJM'?0VVE8*PRX7W0V5A+A"]B5;\IR0H@[:BK?HC5R+,TM-EFM7!S2/Z:E
MP]LK0XB2I2FCD^TK9PE)Y_</&#CKW12R&S66X=J%?+?#DR>ZU$NO80ILXPK8
MTRD);23\?.,X&>>=JT6Y<-1V^/<=,S5Q3JFZ2)SBF2$.L.)=+2RH'E.%(&>/
MKXKU8+'=AIU;%T@:D94]I!F"X['947T.)D. H2"1E02I)VYR4BNE=%V)L/0B
M&)]L%O[4A\,MI9<9[C>\[7.TLE3>[SL^/C'BJ'+L^H695KZBHBS7+B;JMY^T
MH@*]2F(YA@MG!R=K3;:\$8W GYJ.F/N+UA(:N\34!C)O$YV'<&FG"Q(4^TAM
MEH.(7@84",8\H2" 2JM*9H2?&TSI .PKY'AR;9FZ" PJ3)1/4VV.XMM1R#A*
M@%#]JOK=FL\NR:A7JF_NW&'JURY]B48CT=E!8<85$*6TN/)/*@?_ *:.=^%"
MM2%I6XPY;TUNTZD"H_Z#+B)*Y*]KJEH]9[2HY5M&%9SMQ\5DN]CU,JYZRDRH
MVJE7KT]Q2V]#8"8K[:TGTX2M*MZR!VPE"1E)SG@*K)<-*S(TB2P;-?I=MA7B
MS3E(V/NJ>3V2'UIW*Y(4?<$DX(&<>1T_K6U)E:3M[46V2[@ERX,]YMAMUTMM
MX42M;3:DEQ(( VD@9()X%<9GV#4URTC%<_2]3B[0-,-)8"N^VI,UN64@@ X*
MPC) .3M(-6P6V[+ZI6^1<;'=WIK6I''Q<0PM<<0%1U(: 7G"<%0R.,'=5ZZE
MVUV5K/0LXVN3<(<25(2[V6]_96ML!M:N>$A0R5>!7']/Z(U):]+,Q;%:;E N
M,O3B4S2@%M3C@F J;W*.T.]K>$Y\ _1KL71&V?I>EY;+<"^6^(N:MV/'NX90
MXE*DI)VMM );1NW83_<_-4'23,RV:LN[\JRZY5+=U')E,,Q@MN ZTM6U*U[B
M$8P2K/\ VCFJ_%T!.5;4>KT_<^^Y#O9DIRX2XX'!Z,'!Y(!5L']R*SS+;.N6
MI;E#,2Z/:H:MMC7!?2AU0@R,'NK<5^U' R=WG:1R<BK$_;)B6X+U[M-T=TTC
M4-V?GQD,.E:DNN+5'=[2/>M&5? /D''&:C[79-5,'3,6<]+$G4<=4*:V\\KN
M,,,O]U*U<_O,?+9^<E.><UYNEEU2-3ZHDQAJ1.HBY.,)3,<>D=84A?8R^5!)
MPG:D(_<%@'&,FKET1LWIH]T==:U!Z9YQAY,>]0Q'2T\E.%%I!)5G]N5>">03
MS6GTP:F-]4]1K<BW)R-($ETRYK$AE;*N^D)8.XEIQ)3RA2.0E.#C.*\Z[M=U
ME]4X[\M6H404"(JVN6J+W4!27#W4N+\-9W<E7"D<<XQ7.XVDKVY8(LF?%U49
MKVGKA(E9D3-QG-ND1@0%<*P3M0!@CG!K?O;ERN^L[Y%@N7Y6I8[-F<LX0J2&
M8RU(!?+H'\M.4E6>X.?<!SFI>%;;G&0A-[M=V7I=S4EW>GQV(SZG%I6HF.X4
M-C>IK.X\ C)2?S7FUV;4T5_2L&9*N.-1QC#E-OOK#T9IA_NI6<G*5F/_ "U8
M_JQG.:U7-+W"=J6<_<V=3!4K5,^(.V_*0@V\QU+1@)4$ALN[?<,9\9P*CF[?
MJ2;8-'#4/\6LE%I"&'84-3S[<P/K)"\D%"BVEH!2_;C/(YJ2@6>^?Q))F3(F
MH''IT^^Q%EU4A2%1^V2P-N=B4$YVD 9.,9Q72M)A<?H3&1"@W-$AFR*0(I#C
M,DNI:(*4;@5)45@[3CY!'&*X[9+7<U1X3+ULOQLT;4EOF%D0Y;>QE4525%*5
M$K(#N-Q!\^["0<5U_KF)3FE;>Q%AS)+3UQ91(],V\X&VL*)4MMDA:TY"1M!
M)(R17'IK&I;GHR*XI.K!>[?ISN-X$MHF2B84C*> M81G@Y)&#S@5T:S0;K_B
MV_9%O2Q9D.IU,%+D**MRVRSZ<^?;W M83P/;XXJ:ZRV]4M_1,GT$F8S#O[#C
M_8;6LMME#@WD(YP%%'/_ .JY@NS7B98])Q)D?4JXJ;9>A*2I<I)4ZE94R',$
M*R2 4A7GC /%?&K;JB/IV\LVIC4"GI5FM$J;W$O.*D.;E>J#9=(.\H(RC(/M
M*1CBNM]&XWZ?H@HQ>O3"2\MG]5:*'BV3D;6\E24>=J3S_P BN5Z>L_H]'Z*_
M4K3>AISU\\WB(EF2' X2L1UK:'O*!@>!C)!/(J<Z:Z>N$C5]G&I8UX5&AVI4
MB%ZE;R4M$3'"R',';W0TI&4J)..#XKNM*4I2E*4I2E*4I2E*4I2E5B9K[3$.
MZ3+?)NS+<J(RX^\DI44H2V,K]V-I*1R4@Y'U66UZUT]='XC$*Y-KDRGG8[3"
MDJ0X7&T[UI*% *20G!Y X(^Q6JGJ)I=;MN;;N?<,\-EA2&'5)/<<+:-R@G"-
MRTE(W$9((K>L>K['?;F_;[7.#TMEOO%!;6C>WN*=Z"H +1N!&Y)(_-2%XN\"
MS1FY%TDHC,N/(CH6O."XM02E/'V2!4)==9VA%KN3D"[V]$N.J3'29.[MH?8;
M*UI6!SA(&58^/%53674FVVJ%>)-K9@S=16JU1YO><00R6GW$C:'/W ?M5C@'
M*?SBV1=?:8DVL3D7B-V3(,3!W!9> R4!!&XG'/CD<^.:^2M4:/N4/NR[E:94
M:,EB9N=*5I:#B]K3G/@E7 /D'ZK>L6J+5?+K>;=;GRY*M+XCR4E.,*V@\?8Y
M(_ND_P!ZPG6NF1?A9/UVW?JQ66_2]]/<W@9*<?!_'FM0=1M'KB.26]0V]YA#
MH8WM.=P*602$IVYW' )XSX->[5J31\*W2!:KA:(\*,PF:ZF,I"$-MN$D.$)X
M]QS^23^:^0]6PV(=SEWNZ69F/'N+D)I;$@D C&UMS(&'>>4C.*AM ]0?UZRP
MKG>)%E@,NV]V<Z@2B'&TH?6V5X4,=K"?WDCGXJQQ]::9DVYZ?%O]K?A,N)96
M\U)0M*5J_:G(/DY&!4E:+Q;;S ];:)\6=#R1WH[J7$9'D9!QD51O\6;";W9D
MB=;T6"YQ'WV[D])#0#C3B4%O:H <[OO/'BKDYJ*S-WIFT+N<--T>1O;BET=Q
M8P3P/[ G\@$_!J'UMJR58+O8+9;K4FXS;PX\TTE4D,)26VRX<G:?(!K:8U3'
MA6H2]6K@Z?6I:TI1)G-E*DI.-P7D ^1QY&:W&=3V%YJ6ZS>K8XU$*1(6F4@I
M9*OV[SGVY^,^:C'];6Y=YTY#M;L>Y1[P^^P)4:0E:&E--*</C.2=N,?%2)U5
MI[,H&^VK_I"!(_ZMO^220D;^?;DD#GY.*@S8]!62[R;VMBR0IK3^YV2XXA':
M=<&<G)PE:@<YX)S^:L:K]:$38\-5U@)F24!QE@R$!;J3X4E.<J!P>16U)G1(
MKS34F4PRZZ%%M#C@25A(RK /G Y/U45==1QX[,-5N>M\QV0XSM0J:AK+2UA'
M<23G=YX _<> <FH*Z]3+-#NT*&R]'=;7='+3-><?#0ANI:6YE0/D';CR!^>,
M5=69#+\=$AAUMQA:=R7$*!2H?8(\BM$Z@LPMSL\W:W^A97L<D^H1VT*XX*LX
M!Y''YJ*T3K&)J6R,SW#&ANNA]Q,?U*7"6FW5-]W/&4G;G.,#-2R+_9W)'81=
M8"G^UW^V)""KMXSOQG.W'.?&*Q,ZGL+\27+8O5L<BQ #(>1*0I#(/C>0<)S^
M:\*U9IY,6#)5?;6(\Y?;B.F4C;(5G&$'.%'/'%;UUND"T11)NLV-"CE00'9#
MJ6T[CX&20,FH]_5VG(]J8N;]^M3=N?.UF4N6V&G#])5G!/!\5'7/7-K;G/6^
MV3+=(N$<Q5O-ORNRA+3ZPE*@O!"CCD)'G*?]0K?CRM.1]3SDLR[:W?Y+;8DM
M!Y/?6AL$IW)SG "SSCP:DK7=;?=V%/6J?%FLI5M+D9Y+B0?K*2>:AFCI:)JN
MX2FI%O\ XB<9'J4]\*?#: /Z,Y2G !. ,\$UJ=/-8OZQB.STVM,:TK2ER)*3
M+0\74G/M6@<MK P2GG]PYSQ4M U589\!$V+=X2XJWUQ4NET)2IU*BDH&<9.0
M<8\C!&00:V7;Y:69#K#MS@H?:3N<;4^D*0..2,Y ]R?^1]TBWRU3'D,P[E"D
M/.!2D-M/I4I02<$@ \X((-:T/44/](A3+O(A6UV0T'2TY+;4E.<#A8.%#) R
M/L5BC)TY!U1/D,OP6K[.;;]2GOCNN(;2=A*,^ DGG'BOEAU3"U \P[9WH\NU
MOQE/HEH?&20O:4]L^['GW>.,5AC.Z35<Y&I(\NU.2RD1')PDI4$C@]O=G"<X
M' QG JP0Y<>=&1(A/M2(Z^4NM+"TJ^.".#6"X7:W6Y2$W"?$BJ7^T/O)03SC
MC)^ZQOWRTQY3D:1<X+4AM!<6TM]*5I3C.X@G(&.<_5;,6?$E[?2RF'][8=3V
MW K*#X4,?!P>?Q4:S? +I=F)Z8D2)"4REN0J6@ESN)_J1Y;]W S^[R*DH$Z)
M<(PD6^2Q*CDD!QEP+22//(XJJZ1UF_J-BUOHM:8[$QV8TLKE(W-=AQ3>0G@J
MW%)\?M^?BI#3K.F8<J?(L;T%4F;(Q*=;D!Q;CO)"2<D\940GP,G J=CR&9*"
MN,ZVZ@**"I"@H!0."./D$$&M&3?K6PF?F=&6[!:4](9;=2IQM*1DDISD?[U$
MZ!U1+U7;E7!ZU"#"<0V[$=3*0^'D*!)!V_L6DC"DGP?!-3$:^VF40(UT@O$E
M0_EOH5RD J'!^ 03]9KTN]6MM40+N4))F *C OI'>!\%'/N\CQ]U$:-U=$U*
MU*2.U&G1Y4B,N(7DJ<PRZILKQ]$I_MSC-6:E*4I2E*4I2E*4I2E*4I2N6N:(
MU?'B:CM=HO=KC6N:Y+DPW51UJE-NR"5%"E9P$A2E84 5<#^U05CZ5:ELU[C7
MF)+L@G1[J[-;:6I]QLMO1DLN!2C[BH;<C[R<GZ]0>E>HV'=,LKE65#5L2AN1
M/C+D-276@\M:F=@.Q22E0 *CE)*B/BMC3>AM2=/X+SMB@Z:G.16FXL4,0^S)
MEMEY&Y3[OPI* <;3@DE1!P!72M;6$:FTI<[/WO3KE-%+3P&>TX#N0O'_ &J"
M3_M7.T='5MJU"LW7OO72TR(P4ZC@3I"-C\DCXW!+?M!P!N%:^H.D]ZFV^]PX
M=T@%JYV6%;E=]*P6W(RA@I(_H4"L_>2*DIF@]0QM13+]9W[2N8+O^H1H\E3@
M0MHQ!'4A:@DE*N-P(!\56+GT;U"F%,CVB;9L7.$AJ9ZCNI#3R9:Y/\H)!RC<
MO;[N0!\UU'1]CNEFO^J'IBH*[?<YHG1U-+670HM(0I*TD8 ';&,$^?BN8V&P
M7'5&I[_#8,1NT6_6ANCTGOJ+_<:::PVEO9C:3QNW<84,<<S]OT!?K#8-$.6Y
M=OEW;38DH7%<>6VQ(2\"#A>TE*D\8)1]CC-?+9THD0T:4!GLCT84W=VVTD)E
M-=XR6VD9'[4/<#./85#YQ6%?3W4MMN#EWM;UMDS&=2RKQ'B/.K0TZR^UVB%D
M))2XD$D$ CSYS47 Z2ZB393%DR+0EXZ;GV?"'G%)[S\@N(5DM@[ ",GSGX/F
MHS7FGIFE)K=ZN$FT1ENS[8]$==4^6FG(L9:%]Q:&CLW$[1D'(_TGQTCH>XZO
M0:&W(R6FT2G^V^EQ:TRPM9<4\DK0A6U2UKQE(\9'!%4B-TTU.--6VWOLVPN0
M=/W*S@^I40XMXI#:_P!G (3GYQ4E;>G5XM^M6)9@VR?$=E1IZYLF6[W(BVVD
M-K0AH )62$':LXQN.<X J9ZOZ3N.I;KIB1"L\&\1+<Y(<DQ)<GL)<WM;$@*V
MGP3G/QM%0-QZ?W:YP;3&1IVSVJ+!A76*U$:EEY+)?:2&U;B@9)6%DGXS\FJQ
MJW1=PTKHV=-G1X/I_P!"M%L<;0L)"I+<E.]7*<?(P3YJTV?I[?'=4-7N0PS:
M6I%RDREPV) 5Z1"X!CI4G:D)*BOW''QCR14*=#N-:?A0]?,PK#9;+:)%H=N3
M<M&)P<4@-JVX&T!20L!7.\CCS6RK0NH+EHG3%YD15W2]*?-PNEO5)5!7)+K
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MOMU]B/39!4EMH9"E*3G*>1PK S@\XY\45U(T@A,I3E_A-IC;>XI:BD84O8%
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MUM9>"FD)0IL8.W!"00?SX&.8]OI5>&M(MVM%Q@F2FRW&TDJ2K83*?2X%Y'C
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8I2E*4I2E*4I2E*4I2E*4I2E*4I2E*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>exh47_04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh47_04.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ KT! 1$ _\0 '  !  (# 0$!              4& P0' @$(_\0
M01   0,# P,$  4# @4#!  ' 0(#!  %$082(0<3,10B05$5(S)A<19"@5*1
M"!<D,Z%B<K$E-,'10U."X73P\?_:  @! 0  /P#]4TI2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4JK736]M@:\LFD\+>N5S2ZOV?I82ALK!7_[MI 'GYJTTI2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4J$B6>
M>QJ25<7+].?@O(VHMJVVNTT>/<E00%_!\J^35#7TUN<3J?8[_$O4N5 ;GS9T
MMN06P6B\UL2E&$;E#A*>2<)2,8JZW?3TV?J6WW1C45TA1HN-]O8+?8?Y)._*
M2>?'GXXP>:L5*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*^$ D$YX.?-?:4I2E*4I5'@ZT$25JPZ@=
M:1&MES1!B)CLK4Z[O8:<2@(!45K)<(PD?'BMT]0]+)MB+@N[LIBJC"6I6U1[
M;9<#>5@#V>\[<*P<A7^E6/B-96Z$W='[K=H;C#$[TK28D=U3B26TK#:DC<5K
MP2K*1C'P,&HRU]183MVU-^(/,,V>W""J*^AMPN/"2T%)!1C<5%1 "0,G./-9
MKEU)L0;CLVZ>V9,ZW29\20^RX(Z$L@[BZ<!20"#D>1M(X.,[\S7>G[4BW-7F
M\0VI4MIMP=L*4C"\ +) .Q!/A2L#@\\&MFWZTT[<+\NRP[M'=NB%NM*CC.=[
M?ZTYQ@E/R,YK?U"[=FK?FP1H<B:7$IVRW5-MI23[E$I!)P/BN6L=2M4?T3<M
M32[98V8$22J+D2720M$I#*BH;?TD%:@0>-HR.:OCFO\ 2S=F%U-ZBF 7E1@X
MC*OS$@E2-H&<@ D\<#GQ7K6>K8^G;#%G1VA/?GOM1+>RVL!,AYTX;&_D!)\E
M7/ XSP*TX%_OELD3EZXC6BWVIB,A]-PC2E%H*)PI"MZ4D'QC'G^3BMM>O])M
MVQBX.:AMJ(CZEH:<6^D;U(&5) /)4,C(QGD?=?;?KW2EP;FN0]06UUJ$TEZ2
MX'TA#2%>%%1XQ_GSQ6)/432*[5^)-W^"N#WS&[J%[AW DJ*<#G(2"K^.:VY>
MM-,Q)T.%)OUM;ES-ACLF0G<Z%_H(&?"O@^#6XUJ&SO*9#-SANEZ2N&WL>2K<
M^D$J;&#^H!*LCXQ623>K7%==:DW&&RXTIM#B7'DI*%.'" 03P5'@??Q47?=0
MNV^>IJ(F#(:;AR7W$*E!#O=:""$!."<$+Y/]N4\<U%:0UZ=07VV6U=M$8SM/
MQ[Z%A_?L[BMI:(VC./\ 5\_0JQS-2V2%>XUGEW6$S=9/_9B+>2'5_P )SGX/
M\U!ZFZ@V:VZ?OLVTS[==9]JB.2G(3,M._""0<XR4\C'CS4[ OUODP$R')D5I
M0::<>07D_D]P H"OK.>,XS6>YWBVVI(5=+A#A!0*@9#R6\@$ GDCY('^16-R
M_P!H;NK=L<ND%-Q<;[J(I?2'5(\[@G.2/WK-'ND"2MA,>;&=5(07&0AU*NXD
M>5)P>0/L54]5=1K9992HD4M39;%RAV^:UW@WZ;U!]JR2,$ <X_\ (JRF_P!G
M%O8GFZP!!?5L:D>H1VW%9(PE6<$\'@?51^M]3_TQ#MSC=ND7*3/FH@L1V%H0
M5.*2I0RI9  P@_-9+3J%Q=O>DZCMZM/*;=* B;*94%IV@[@I"B,<D?X-;[-[
MM3S3SC-RA.-LI2IU2'TD("AE)4<\ CD9\U!W_6T"VO6)$)3%Q3<[HBUE;$A)
M#*U(4K)QG)&W]/!YJ9<U!9FI$AAR[0$/QTE;S:I" II(\E0SP!D<FOLJ_6B'
M'D/R[G!88C!!><<?2E+07^DJ)/&<\9\U\7J"S(5;TKNL!*K@,PP9" 9(X_[?
M/N\CQGR*B;;K&-Z&X2M1"/8F8UQ>@-NRY*4MO[#PM*E;?(!X^"E7G&:\Z\U>
M=,6.!<85N5=Q-ELQ&FV'T-[BZ<(4%*X()*1_G/BO.G-<P;DS=DW9K\$FVEY#
M,YB8^WAE2TA2#W$DI(((P<^<BK"JZ6]#D1M4Z*E<L9CI+J07AY]@S[O(\?=9
M(TV+*=?:C267G6%;'D-K"BVKZ4!X/\U2_P#F&MW4C]O@Z>N,NWQ[@BUOW!E;
M12T^HISN;W;P@;N5XQQ\^:E=8:UMFFM,W:\E:9R+8I"'V(KJ%.)4I:4!)YX.
M5>#]58^^T%%"G$)6$[RDJ&0/L_M6-B=$D.*0Q*8=6GRE#@)'^W\BLW<1M2K>
MG:K&TYX.?JOA>: R74 <\E0^#@_^:T[W>+?8[<N?=Y;42&@I2IUPX2"HA('^
M20*V^^UW0UW4=PC.S<,X^\5 ZNU?;-+PYCLU:G9,:"[<#%:QW%LMD!:DY('!
M4/)^:FHDQF5!:EH4$M.(#GN(]H(SS6?<G9NW#;C.<\8J!T[JB+>W[PVVTY'%
MMGJMZEO*3M=6$I5E!!Y!"A^]2[$Z*_+DQF7VUR(VWO-I5DM[AE.?K(YK8!!
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M@YY"L @GQ\FI6[=.;X(T^#;)5M>AWJT1K5<%2BM*XY:06^\R #NRE1]A*<$
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M2%$9/@G/W6K$ZK6>0S(3^'W9NY-2F88MBFFS)6XZ@N(  64CVI62%*!3L4"
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MXF6MQK>$#CV#X*OC /\ <*D%=1K&BZ^C4FX=@K=:;G)B+5&>=:"BXTA8!W+
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M4"&U K4 H \'Q6S9^F2[;J6U3A>E.6RU3)4R#!,5(+7J$KWH+F<J 4M1'&?
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MAY4GG@D_!JS=;](:HU'<,Z>M\)^,NWA@O!Y+#_<2^EP)6LI)4WA/"01[B2?
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MZ6@U;&VY3J7%%02\_P E83G P$YP,^,5JW[I:[=S='GYEN=D/7L7B*B5"[S
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MQ=-M+6*8F1;K>XG8%!IEV4ZZRSN!"MC:U%*<@D< <$CP:P1.E>CHMKN=N1:
MJ%<4H1(:<?<4"A"MR$))5E"4J)(2G %9V^FFD6KBF>W9T"6B6W.2YWG3AYL8
M0O&[' /CQ^U5C0G2.);+C=KAJ9MB=+D727.BI;D.J::0^,8+:L)W@;AN SSY
M\8F8O2'14>$[$1:5F.[#$!Q"I3WN9#O="2=V?U_/G QXXK5O_3I46UW./H40
M(+]Y#<:YN7 O/A<9+*F@E W<*2%<?!^:O=FML>T6:%;(:-L6(PB.VGZ2E(2/
M_ J&T_H73>GW83MIMC;#L)#S<9>Y2BTEU>]8&2?*O]AP.,U%L=*=*,-Q$,Q)
M:#$G.7!EQ,UX+0ZY@.>[=G:K:,IS@_Y->;-TGTE9KC FP(+R'H3LA]D*DN*2
M%OI"7"03@Y2 ,&O$;I'I%BSW*V*A2'HT]+3;A=DN*6AMI6YM#:LY0E)Y '^<
MU\3TAT>FTJMR84L,&X"Z!7KGNXF2!C>%[MP./WY\^<59]5:8M.JK2;=?(@DQ
M@H+0=Q2MM8\+0H$%*A]@U7W>EVFY<-3-W3<+J\IQMPRILYUQ\%M64 +W I )
M/"<9SSDUYD=)=%R(QCO6@EKUCTX!,EU!2ZZD)<P4J!"5  %(XX\5[@=+-*6^
M;;9$*"^T+?L++/JW5-;F]W;6I)40I2=RL$_?\5OZ-T'8M'O27+&P^UWU*(0N
M0XM#04K<4MH)VI&>>!6!73?3!NEQN @*2_.2^'0EY80E3Z4H>6A(.$+6E*05
M)P34UI33]NTK8(EELK2V;?%"@TA2RL@%14>3R>2:@$]-+ C44F[-":V)4A,R
M1!1)4F(\^""'5M#@JR ?K(SC-52#TE<G=0]4WC4KV^U3YL6;%B1I)[;I9! #
MZ"D9P0DXR1R:LB.E.F4WZ3="U*47C(6(I?/8:<?2$O.(3_:I0&"<_)QBO>E.
MF%@TM>X-SLZIS;D."JWM-*?*FPRIQ3A!!Y)W*)Y-;6H= 6R\:A%^9EW.U7DL
M>F<EVZ1VENM9R$*!!21D?6?WX%1EVZ2Z?NTB*_-?NCCT> _;DK7)*U*0\%AQ
M2BH$E9[BN<X&?'%:<CHKII]AEI4F[#LL1([:A)&4)C?]LC*< _?&">< \U[9
MZ/V:'<V[I N%U;N#$V7<F5*>3M$B0A*%DX3DCV)XS]^:HN@^C]]#,FT:K)38
MI$1QB>@RVWE2WBH+2ZV4M)4C"]RLK4H\@?==CL&DH=IT](LS\N?=8DA)0X;D
M]WE*04!&SP $X'@ >2?FJ8KH9I==DN%M<DW1:9K4>,I\NM]QMEE04VVDA&-N
M4IR2"3@9-7C5>E;7JO3+UCO;2Y$-Q(&XJ_,0I/Z5I5\*!YS_ +\$BJ^[TV9N
M%LGP-0ZAOMZBRHIAA$IY"0TCCW!*$)"G,@'>H$\?SF//1C3ZVV?43KM(D(N+
M%S7(==;[CKC*-C2%$( V)3Q@ >?-?+=T9L%N;LWI9MT#]JN;MS8?4X@K*G-N
M]!]N-IV)^,\<$5NP.D]@B:'ONE5.S7[;=Y3DQY3JT]Q#BMIRDA('!0DC(/[Y
MK#%Z26IN?"N,BY7.3<V+K^,.R5%M)D/;=N%I2@)"<#PD#R>>:Z/2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4JD0>HEI_ 'K_=Y#%OLKLMR-!>
M65*7(""4J5M )&5(<( S[1DXYQ)P]3H=U@+*XEI3,J"+A;Y32]R7VP0E8/[@
MJ01C(*5?L:LE*C=1R+G%LTAVQ0FIUR&T,L/.]I"B5 $J5@X !)\9.,#FN7N=
M2]61]/ZAO<G3EH,"S&5%?+-P<6OU#!VYP6TY;4?'R/)J]0]?:8E:?=O*+W 5
M 9<##SJ'0M*'< [,CR>?CR.:GH-PB7"W,SX4AI^$\V'6WD*RE22,@@_54*RZ
MZU%?K<S>[)IB)+T\_*[+3@N1$E;0=[:GPUVBG P3MWYP*LXUIIHS;E#-]MR9
M-M05S&U/I26$C&XJR> "0"?@\&M>'U!T?-ELQ8FIK0_(>>$=MMN4A16X1D)&
M#SG(_P \>:W&=7:=>NB[:S?+8Y<$!PKCIDH*T]LD+R,Y&W!S]8->8VLM,R;:
M+BQJ"U+@%PL^H]6@-[\9V[LXS@9Q]<UM?U#9B 1=K>08YF#_ *A'+ \NCG]
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MK0E09>;*MZ%JSD*QM'[X_:O/_$+8;U>KA'_!=/2IC[45"HT^,E*UMNB2VI2
M5+':]J<[DC)SC( -7#I-;)-JN.M6YUJ?A.RKT[-;>6A(0^TX 4;5 \D8.1\9
MJA7O3=W=ZEWNXITQ/_/$YD2& A29#2X>UO+JE[@2I. @!*4DCY.:C6]'385J
MU$Y*CR+2PW9K9<(S\QQ26S<&$E2BLE1RLD!*O/'\5V/I7"E,:2;GW)*F[C>'
MEW22V5%7:4\=P;&?A*-B?_Z:YMIG3]WMFJUK3:+FPI>M)DQ]Y(4&UPW&70VH
MX.%)RI'\57FM 3WK#%4]8[R)[]MO*I!4\[E3H>4J$E7O_4!RD'CD?-;T^Q:G
ME:ML<R\MZG"#'MGHG(3*'2RM"?\ J$.K5RR2HDJ5G"AP<X KN>E=10=46LW"
MV"0&$O.1U!]E32@MM12H84,\$$?^/((KD5^L&LK5J2XR].079+5KN:[A!+[N
MX2TRVT(<:'TEM7=6<^!MQ\FH[76D;NWIK4=L3"N]SCQG;*EO9W'>^VT$AXMI
MSR<[BK'WD^,C*QI6^1M5*N=JMUSC2UZI=<2ZI2^T(2XN-Q1G;M*\ G&>!G.!
M4 ]8]2R]+J_!(&I8VHFK2\U?'9 = DR$N-E);*R0ZK*7""V<8.#C(%65YB5=
M]5(O\RP:A<LIU%%EL-.L.AU"/0.-EP-YRE(?[9)XQ\\5WNE*4I2E*4I2E*4I
M2E*4I2E*4I2E*5IWFYP[-:I5QN3R6(<9LN..*^ /H?)^ !R3Q5,E]4[3"LR[
MC.M=_CH:=<:D,N0"'(X0E*E+6,X"-JTG()SGC-28Z@6'OEDO/A0NC=GY95CU
M#B M _@@CG[/.*BFNK6G'+2_<NW<D1 \VQ&6Y&V":I:EI3V23A7+:_)& ,G%
M6/3NJ[5J#2R=06QUQRW%"UDELA:=A(4DI\Y!!&!_C-5R+U:T[)MS<I#%W#CD
MP0$Q?0K+Y>4UW4C8,^4<_P#ZYJ-UAU<ML;0[URT[ZF1<7K<[-CH](IP,!!*-
MSP! 0D+24\GR#YP:N#^I&+-H1G4-_#C33<1J1*[3*E%*E!.?:,GRK_ \^*U[
MGKBS,,71MJ:42X;WHU[HSBPA\M%U(*0,J&SW<?'SFJQ?>I+-MTJJ1#Q/OO\
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M;XT]Z_VI$*2X667S+1L<6#@I2K."1669JG3\*3(CS+Y:V)$='<>:=EMI6VG
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M%!=4XEQL9_4DJ/"@0:^1^GUZTO>KKJ"UQK%<)+!F3(:C%4)DEQXJ5VEKSM2
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MR([0#*5#*>XM00C/[;E#/[50==ZHO%HC:ATS'D.N+MVF%71=V#X3)+^\@<#
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MI0R%@A6XIQR.0K]C4U?>L%JL=E@7.X62_H9E1C,4@1V]T=CN)0%N>_ R5IP
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MV\E^(L(=;6VL+2I)((X4D?%4J?T?@W:)<E7N]W2==YBHZQ<\--/,%@DM[ A
M3P2<D@D_? J"UQTTN^HM:V:*Y-NB[,FT28DV[E<<NK4ZK)04$< @>4H&,C!&
M#4K)Z*6IRZLS&+M<8Z(S]O?BLH#92QZ1!2A()23@[B3^YSS6[#Z30H.A]2:9
MA7BY,Q[W-<F./I*0XV5[-R 0.4D( .?()K3'16V"RNV]-XN2,WMN^M/(0RE3
M3Z4[< !&W&,\;<>.."#[5T<@"XW&Y,W>:W<I-V-W9D;&SZ=PA04@#&%)*58(
M/T/\Z,KH1:'+3;K=&NLV-&AVQVV@(0@E?=7O<<)(_43\>!\5U#3=J18M/6RT
MLNJ=;@16HJ7%@ J"$A() XSQ5<T!H1&C[MJ.>BYR)SE[E>L>#S:$['"5$XV@
M<>[_ ,54HO0NW&9<'[K>[C<!/M[]OD=P)"U!R1WDKW\G<DX\YS@?'%;T[I(J
M\6FQP=1ZDF71%J<6ILN164A2"V&P@@)^ "<DDDG/UC0N71$7#34:R2-5W5V)
M&MJ[>TEU"%I&74N)7CCE(2$?>T 9'S59.@]8-=5WKQ':+Q3+C)84_;HKK#D9
MM"$%Q3I<"VU8+G"4;LXP<>.I=/.GHT1(DMPKY/D6<J<,6VN(;#<8+4%'W!.Y
M6#G&3@!1XSS6[J_3\K46HM-I6 W:K5+%S=7N&YUY (:; \X!45$_L!SDXW-<
MZ78U99FX;LEZ'(CR&Y<64R$E3#S9RE8"@0?H@CD$USCJ#TQN;NE[G+@7B?=;
MZ]:G8$I"FFD_B&Y14@8  ;"%*) 3\<'/.9<])VWKTN>B_7*+"5<4W=J VVT
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M'$G>O=A;:2\M03M!Y *L#G2G]'7Y43:+\VF0BUV^WH48>4;XCH<2M2=_(5@
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M.1^UE/(X!YY\BJ;;NB\RVIM@BW.SO+;B,1)3DZTHDJ3VB=KC!4?82%8(.1D
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M4VE#H4DI*E)2@J.00$^?BHQO7NJTNZGG-7^.;LTB8AVQX6ZY$#;NQ+J4!&U
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M\PIWC/N/\8!K7O$J_P ^7KAF.N_]EZV71M,.0Y*<PIMYM*!G ;!V=PI",^W
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M 3@>U )QG \8K2TOJ73^IG9K5HWEZ*$]]M^$Y'6E+F<':XE)(5M5S^QJ?##
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M2D!7N(^:KN@A=+WK:VPKC=M1BPM^MF6S=(>:,EEN0UV.\2 I607OU')2E/\
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M5*V+=3E(!7[3S^H<'U8-%ZN8AOM/V"4VX-+7*UH*I+'N?<D*6VGVK P4D<X
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M^T_!O5E-L?2IEE)0ME<<[%QUH(*%MG^U22 1\?XXK?5#C*E>I5'9,CM]KNE
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M=(5NG2(;L9IZ)%(4\DON);1[<^259Q\BK 94?LATOM!HG 65C;GQC-1^I[_
MTY;1-N2U;5N)99:;3N<?=4<);;3_ '*)\#_\9J+TKK-B_P ZX0I%HNMEEPFF
MWUM71MMLJ;65@+3M6H$9;4#R*M 6V4!84DHQNW9XQ]U\0XVI2TH6@J1PH C(
M_FO)?8#8<+K6PG:%%0P3G&,_>:]DH! )2"? ^ZPW"2B% DREMK<2PVITH; *
ME!(S@9P,\5IZ?O4.^V2V76)N;8N#")#*'@$KVJ3NP1]X^LU$ZNUM"TW/BP5P
M;E<9K[:GRQ;V ZMME) 4ZH$CV@J XR?H&O<!JPW?4MNO\=X_B_X7^4T7-JO2
MNJ2H*4W\>Y'G[!'Q5F!21D$$?=0]KU##N.H[U9F&WTRK3V>^I:,(5W4%2=A_
MNX!S]&L>KM40-,1&')R9$B1)<[,6'%:+K\AS&=J$#SP"23@ >2*^:2U1 U-&
MD*AMRHLJ*L-2H<QDLOQUE(4$K2?L$$$$@YX-2DNX18KS3#SR!)>2M3+&X;W=
M@RK:GR<#'BO-K>:F06)J(KD54IM#RFGV]CJ24CA8^% <$?&*VBE"A@A)'T15
M9U?K6U:5G6V'<6I[TJX=PQVH<-R0I0; *SA )X"@?XJI6^)HS6FIGQ NMWFH
MELLW=V,B8Z(3Z=VQ.4'@^YH H\#&"/(KJO ^J\.M-O(*'4)<0<':H9'W7O ^
MA2E*4I2E*4I2E*4I2E*4I2E*4I2E*54^J6E7=9:-E6B+*1%E%;;[+CB2I'<;
M6%I"@.=I*<''-0FIK5JS66DY]MN$"VVEX%EUE(EF0B0ZTZE>U>$IPTK8!\JY
MR0,8-OB6"##G7"XQ8R$3YVQQT[B4]Q*"@*'T=IP2!DBN11>G&IV=)M6TQ+8N
M4YIN7:''522>TZM:R@I.S)!"AD\8Y\\9E;MH2]Q5-FVV^W7%J9IT6-]AYP-I
MBN#)[N<96@DG< -V4I(_:Q=+='3M)S-0&<ZT\W+7%##B%<K2U&;:)4G'M)*"
M<9/FI/JEIV9JG0]PM5M>2U,<+;C6]:D(64.)7L4I/N 5MQD<C.:H;G36[/61
MB39X\?3M]1<C("O7NS5AIUH,OE;KA)4HIRH 8'L1\YK'/Z9SFNH"7XUN$RR*
M=@NQ7#<W&$6\1DA.TLI_[@QDIQ\J() )J&M/2B_0M%+M/X?;T3'--S8+CB%H
M'<DN2 XV%*P"<)2.3P*[#I.Z2I#TFUR[(_:E0&(Q02I*VEA;>2E"DX!*%)4D
M@#X!\$5R&5HG54B\WV5<M-HDL3H4V,XB#.8C;RY(;6E36$YR4ISEPG*LYP#@
MVVR:<O371V^6F[VKU$V8)(3#94Q&?=;6<#>ML=H.D<E0R"<9^:ICFD-:&VSD
MITXAYRXVB?:6UK=C-/LH<<"FER-OL4H@JR4>< GFIFQ:1U%:+LV)&F(-QD*]
M*_'O+SS:G();C-M+: )W$A25E.#MRLD_-;'2#1-VTSJ>U2G[2FVP?Z68ARPA
M;>%SDNDK*@DG<H@D[N?.,U&ZCT-?W+G?I$6RN/-JU(W=3Z>0TRN=&],$!*%$
MY"D.95M6 "3D$U]LO3=]N/<DS-)-)+>G51( D2&I2VWB[)5VPL\A6UU )&$C
MP#@"H-WIA<VQ<GH6E66Y(BV,PU(#"5-.M+2J24*W#:K PHYRK]Q75=<V6Y3^
MH.B[A"A.R(,!%P$E:'@V&RXP$HSR#R<C(!Q4#T?TS>+)9M20A;E6MEU"$6]Z
M2VTB25!LC\TM**5A!*0%\*5@Y%4-&@]6O178]MT](M$M&FVK=+D!V.GUTA$A
M"W?>E2B>Z@*&Y0\G"N*G[+H6<WJ;1$G^F9:+1%N,Z7*:GNQ75L+6PVEMS:C"
M$#N)*@EO/*0HX)P(RW=.[\YI_3,&YZ>+Q@Q;ZE;;RV%I0Z^O='."HC)QP1X.
M,XKW9>G>H&Y=C5>;'-ERT0[:&9B+BVA-O<80$K2YDE1VJW+ ;R%;L'')J=Z.
MZ8OMGU5;W;GITVYN%97+=*FEUDB9([R%=T;25JW!).5 &M67HW4O]6K0W8E*
MA_U@B_">F0R$&.62V1M*@O<#R1C^,U7K=TNU1$T9#MT2T-0[@JPOL3EI=: D
M.F:VX&5J2225-)6D*Y W8SYK+<-#7VX2YES;TE*@V-=V3)596'8R'G&C$0R%
M)1E364KW*PHCR<<\U>>DVAUV344^7<K"8X9@P&($F8\U)?3L;<2L=P<I4 4I
M.T!/'&14-JO25SE:IUQVM/.R!<I5GDQY;7:2'&67F2\WO)!"O8I6/H#GQFJ7
MSI[>W&7H<BSW0Z=;OMR4F#;&XREAIX)[#K:7,H"1[D_!3N)&*Z-JO3-W&EM"
M3X\23.FZ:D,27X#L@/NO(#>Q>%X 6ZD'<#QD@X\BLVN7KCJJQQ'6--73\.B7
M..Y.ARFT)=G1D[MZ$M;CN2%%"MJL;L$<_-$9T--D26A.T_.-B>-Z<BP.1Z5E
MQ#!8:4@*PC*T.E*<X!(\?%?NFE;A9-+W9Z1:[DQ#FV:RB<EQ:BIZ4);8>!.[
ME>W(\C@XXK=U#HV[NZ;F0[9I2>+1(E3GK9&6WW'(.8[:4#M*< 1N<[JM_N*?
M( *ZE)FE;K*U3'U FPW=-P;O%G<2^XXH+3&["1(QA9PG((4/WP:LO273^S5E
M\AE;4NPZ?6_!@+"RXEX2BB0M*O@E"2A'SY-9NI-CG/\ 4G3D^V6F1<1&5&;+
M;L;_ *9A'>)4XV\E04TXD<J&"E20D'/BMSK! 5/N,3%HOK<F,P78%\L@WOL/
MDD%E21SL4 G.<IYYQYJEW2PZT=NESNDVUR3=)NG;>V^Y%V_F*;=2J4P"#PM2
M-P 'GX-9/P%2YKCL72EX=T$_<T.*L_IRRM/_ $I07 PHI5VPX4G;Q[@5 <"O
M$*PWB%K!J6[8+M_2V;>R];U%3SY"&'0VX5@^\-J4G>GP"1YVUT/J+$EP=:Z2
MU6B)*GVZU^I8E,QFBZXR'D !Y"$C<K!3@XR<'@>:YEKY,MZ\R-4/0[C;[1>;
M]:83;0;=:E2&6DN=QPMH/<RK<4A)&X@#C.*P?TM=_P 3L,C\.O*K7W;X+8A*
M70N(TZ@>F#F3N;SA9&[!&0#]5NW)BZC3MA:U%;]2.LJTJQ'A"*E[NL709"MZ
M4\I<.484O &U0^37B-:M21]0MW&ZHOCMZB72R-+=0I]QH(5&0)92$G84%?<W
M$# SSC-7CJQ"F2^HO3U4-RY1$)7.:7.AP^^(Y<:2E.[*%)3DY&5#@9/&#5,O
M6DU:3E:@LNGK5=G;?&TU'9:>C]S<ZI4M:W<K0.3[U*4A&"4[@,<8C(MIN\W\
M*M[L74C=H87>P&^W,C)*>VE<;VE17MY.T*)Y!')XKM?2JZ2)VB[''N+=P%R9
MMD5<ER6PM!6M2"#[E#W*RA6?GD'Y&;C2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*TKS:H%[MSL"[16I<)TI*V71E*BE04/]
MB ?\5NU\<0EQ"D.)"D*&"DC((K0L5EME@MR(%D@QH$-!*@S';"$Y/DX'S^]2
M%*4I2HV^6.W7UJ*W=8P?3%DMRV?<I)0Z@Y2H$$'(J2I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I7E"TKSL4%8.#@YP?JOJ%I6"4*"@"1D'/(."/]Z^TIXKX% ^
M"#7VOBE)0DJ40D#Y)Q7VE*4S2F1]TI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*5 Z^N<JRZ(OUSM[1=F1(+S[2>/U)02"<
M_ QG_%<XAWV?:;;IVRV>Z6FU.NV$W=Z9=4%P2GB4%94H*3S[EK4KDG(^C4]I
MN>N'UBO=EAH'X7,M3%X44#"$R%.*0HCZW@!1^RDGYKH]*Y7_ ,3@W='+LD 9
M+\4#/_\ D-_')/\ @'^*B(!E:0A2G;+8M*Z?NL^X0H334:0J4A3*W0V7'$I[
M>2%+.#@<'!K+I[J'JQVZP(=WC6@JE2[C;0&F7&U!Z*A:TN'<L@)4$@;?/.=W
MQ5+ZA:VU'>.F/:OR;2IJ\6F-=V50$+;4P!+C)*%A2U9R'1A0QR",&NC7GJ#>
M(LF\S(K$(VJTWJ/:GHSC#GJ7$N%I)<2K<!^IWVC:<A/GD5#_ /-:_,6R^JE0
M(*KAI^,^FY-MMK"$R2_VXX25+_[:D9623X'D5YN/4K6\"7$M#NGHBKU,<D*C
M);+3A<:;:0H M"1A*R5Y_P"X?:,A)KK%IN$Z5I:-/DPFVKDY%#JXB7@I*7-N
M2@+\8SQGQ7#GM6ZDU+?M'9%MC:BBW-UI<-UE]A,5:H;A*7DDDJ!Y*5).% ?'
M.)E_JY>PWH^4U MABW1N&J<TDNN.M=]XM;@0-J$\<;B2HD@#VDUH:%D+.H]+
M%:WE*&IK[%&7"04;758(SS@I&,YQBNA=85RDV&T"W$>L7>H*6@IU3:%*[R>%
ME/.WCFJK.ZG:D0VW;(5DCR]1MRIS+[<8*=:4F,$<H!4E0W%YL9).WW$@^*Z8
M]=I+6CEWAV'V9:()E*BN+!VK#>XH*DY'GC(S7+E]4M5^DL[<33D2XW6Y6X7E
M$>&MQ03%5L"4$E(PLE2LGP,#SFI*5U,NYN;7H[3!_#GKC*M2 ](5Z@/,-.+4
M5)2DI"=S9'DG&#\\1>K^IZUZ3"Y5E0^S(TS&OZTIF+9Y6\VDM!21D ;LA6><
M8(P<U+7_ *C7RT/:D>_";>];[9,9MS&V0X7WGWDLJ;R@-D;</<X.?;@#Y,)J
M/J-J&Z:9O%G;L:K5?46B=/DJDN.,!,9O*$N,';OW*)R H)QM.?C/4-'RU_\
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ME*4I2H/5^FH6JK8S!N+C[;;,IF6A3) 4%MK"D^001D<C%3"66D[-K:!V^$8
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MAP+;2VL(<4XC;N;"5* )4!BM=>OK3;W;V[=;K#,.&]';;3&9=6\GO-A2$J2
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MR,*"G4!!;6O">4# 4A)Y\UY=Z47M4.Y+9A6MAR9I^9 3']8Z\IN2\^' HNN
MJ6<9)5QSX&.:W&>F=YCZYDSG8D2X1G7TSFIK]SD)++@8#>STX]BCD$!9\)5X
M.-M;^FM"W^);M(19\>)O@6*9:I;X?W*2ISMAL#CW) ;_ ,9_;FY]*K/<-/\
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M!7N:VX_5DY!.1XK)%ZQ:6DQE.-JGJ<#S3*8[48O/*[J%*;4$-[CA021]@X!
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ME['2$_:U<IVD D9\8W;'TR@6;4D&YQ;I<E1;>Y)=A6YPMEF.7QAP).W?MY)
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MIW7')2T2"8[BO;D+[8Y*@/;@G[J]])G9*NHFLG+G^("3,8M\EHOMK2VMOTR
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M#E6E3RB@QIZ0VZA044X(R1R1Q@\@@U(IDL*2I27FRE"BA1"APH>0?WJ!=U-
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MY.U*V%NA!4C .Y7)"1]^:KT?J;(7=$PW;4TE2M4+T\"E\GV!HN![]/GP-O\
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M;%,*<4TED,M)1W06UA 2%E*LC<M1'QCS;>G$EAZY/JTR_,5$TTW&M0NDA"W
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M*' 7 ESA6"H<8/\ %0=UZ+1K@PR@ZCNK2NR42%);95WW#),E3GN0=A+AR0G
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MY2HX5P>#]&HR\=4+=9M03;5<;7=&EL,2'F5A+9]2&&^XYL3OW ;2-JE!(5R
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MZ.U 95\C6VU3_P 7C]IZ8VA*Q(:/!&X>?')\\?M7U_I[I-]&URQPRG?O("2
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M]<DRI$52E3(+<!3C$EQL&.A8<0E.U0 &[!X\_P 5\GZ TY*A3694>1VY,_\
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ME*4I2E*4I2E*4I2E*4J+U#>(%DA(D7(K*5N!MIIMI3KCKASA*$)!4I7!. /
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M][<:4VFX^E0IU.1@95P2!QQGG%:NF],L6JR/P9[HNCTQQ;\Y^0T@"2ZO&XE
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M:3T\JY"X*L=L5.#78$@Q4%8;V[=N<9QM)3CZX\5Z1I>P-K"V[);$K :&Y,5
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M$HBND*4C=N3W G;[<*S[N#P<$UOZ,TW&TMI^+:X[KDGL)*#(>2D.N#<2-Q2
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M#;;=VM\2<AI6]"9+*7 A7V-P.#^]0.I;KHO3+L4:@?LT!U;QELB0$)5W!Y=
M\A7@;OO S4A&L&G)=JD-QK3:UV^YI#KR$1T;)(/N"E #"O.<G[KV]I:P/^E[
MUDMC@BM%B.%14$--GRE(QP#CP*C((T5=-33V83=CE7Z.M#LH(0VM]"V_:A2O
MG*? /E/CBL&H]+Z<OD"X:>BJM\*Z*C/D&.ALR(R9&0XX$^0%G()XW<\UKZ!Z
M>,Z7NLF[2I,67='6?3!R+;VH3:&MV[;L;\DG&5$GP,8YS+:V7I ,PTZV78PT
M'"8Z;HIH#?C:2D+^>?C[K-I_3^F8JH]SL%MM3:O3AAF5$:1RSY"4J3_;\\<5
M(WJSVZ^0C#O,&-.B%07V9#86G<.0<'Y%:;6E+ T\TZU9K>AUI]R4A26$@I=<
M&%K''"E#R?FO$;2&G(H;$>QVUL-QE0T!,=/M842I38X_2222/')K;L%@M&GH
MBHMBML2W1E+WJ;BM);25>,D#YX%8=0:8LFHEQE7NV1IRHY):+R,[<^1^Z3@9
M2>#@9'%;$&RVRWSY<Z# BQYDL(#[S382IT)&$[B/.!P*D*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I7/>JEODR;WH><S!DS(\"[]QX,-J<+6YI:4+*4_VA93D_ _S
M7)+7IJY?T]<_Q&VZP7J!XQ6KI^0I+#ZQ-05K;6@[G#V^Y[DG 1YQQ5RGZ-?L
MFHKM)M=MN!A1EVIN"W'E22@,+<+4H!"5X40V"3GQP?YU=)6Z^P-0Z7C>FO0M
M\/45W; >[Q0W#[:PR5*5^I!.-I43GXJM6NV7JUVY4B-9]2NJGZ;E^L:<7)WN
M/"2E+8.\DI6&]Q"4X)!.,Y&=[2L"6G4&FU2[5?C AWBY=E:XDM'92ZTV63A6
M5);)W?JR!SD^<X+:Q+9TGI=.J&]2/Q%:?>3%+#<DO-7$N$@*"!N"MNT(*ACV
MG%;-L;U2SJR-.OTB_+N,>ZVB+ALOF.4N10)/L'Y93OR5*QP1YYJY]6E*_JBV
MHO(O"=.*MTGMN6TO@HG!2"V5=GG.W=MW>W.:C^D4*YJZCWZ=J9J:U>%V>UAQ
M2BM+3KO:/>R![%*2K:/G!*L8R:A[LY?G-8:C2]<+_%N[;TLQ8\6*^IEZ$(ZN
MUA>_LI&X@Y">YO& >:KLQO4L.W(G1I^KB\S:;/<"%R9*P93CX3(!2K.?83E&
M".,XJ=BW:X.]1IC$"[7N3=V=5*97##SJXR+;VD*<W(QL !)Q_<#C'[ZAFR8.
MD]+Q;S+OELMXTQMA*B%YDBYI4!L7LPHJQMVI6-I]W!-6'3C&J3U#AV6\3KAL
MD)C:AD*3*4$M[65-NQL;N$&04*"0-I3D<XJFM#4!TFX_)O6K6[FY8;E+4V9+
M^3(9D;8X'''MW$@8SQGC%3+EVU;,ZC0A/NLZW*4F(Y$AM1WW!)84P Z?:0T/
M>5%16-R-HQQP:FY)U"]H"1$F3KW/_%=*"X2DRW77<.HEH1QG] +9.X#R!G^>
MO=8;FFW].+.BWS;BTW*>89:DQY+C)V]M2@770E2PD[1XPI1P,C)-5^Y729>_
M^%1N=>)$E<UV(T'G5 I<4I,A*<GC.?;YQSYYS7J\:KE:>U)>;2Y=IC?_ -4L
M_P"')<RXIZ*KM)?5NP200%[B3G(\\UH:+6%:LT2 E647_4(42DC;N[BAY^P1
M_O4IU)U7(MO52VL(N,Z Q%<@AQ#CZD,O-N.D.;&DIPY[?U*4?;M&!DDU5F=3
M:KB,.7"WWF[3YTR%?#Z9[:MII4=X!A3:-G!VDGYW>/VJW=#WX4K76JW[9<I]
MTBK@6])E3%N+4IP=[>-RP#P3X^,\<5$:+=DVYFUKBW"YA4O6DMF2V5K4A31[
MY&X$<!66S\9)!J,LFI;W;(C=QF7/4-P]=:+J76FU%2T.,R EHM!0(2I*%*.[
M!R/.< 5XT;/NESNNF&IKTN;'AZJ<],ZZ7WBF.82B#W'4I4I.Y1Y/_P 8KINM
M47&7U+M,.-.NC$=%J?FML17E-M/R&G6RA#F/*2"002,BN21;A=KG%TTJZWMZ
MZ.(U':G)<1<60E4)_<L.;EN>.1@H3[1MR, \[R]7ZBCW+4<NZ:CGQ9\1$U$B
MRQ8CCJV4[B&'$J4.VA(2$$.8YR<Y-8%ZZO#>DG7Y&HW U"NTIC$>;_U$AD-(
M*.RZMH!U25+)"5 ;Q_%6#2&IM0SNKA9N5^]*3.D,_@CZ'>XJ,$$M*2@)V 82
M%]S(YR#G(%>=5:AN%HZCZY,>[OQ6R]9X[Q*TGTD-?#TAM)!QM*@-Q! *R3\5
M?>F%RG7&%J6-^*+NUMAS5,6Z[%:5K?06TJ(RE(2K8I13N'!QCXYXA;KG<TV6
MS7>'J">W<X>C9LPOAQI]7<;>0>TLE!]N0,@^X?I)J_6'5^I+AU?1&GWJ) A!
MU+;=I4E:URXZF0I#S8#>.59)7O\ ;C:1XSAUU=)%HU]JV1;KZ_ NX3:S#M[:
M6U&X$J6DHV%)6L840=I&,Y/Q5;U%KW5\>XZLDC4,>%*AIG,HL_;6IUI" 2RZ
ME!:VI&U(5W"LA6[&,X%2EYUIJ>TVF7$;U!WAZ^$B3=)@0DPFGHJ73N+;9"$J
M7[0HH. ?\UA:EW*7)G7"YWMF?=F]$/OI4RRCL2RVZ\$K"'&]RAD(7G !."/:
M<5=-&W>1,ZH6LS[NX5R](PI28I6A*'G5+<*U)3C)/MS[?L_&,0;^L[[_ %<Z
MMN[NBZ-ZC%I_IM0:"503@A\#&_.T]SN9V_&,5,]#825])Q/CW!4N<XF8TU(4
MEK>Q^<X=J5I2#@JPL[B>3GQ@5RZZ:@N]N7;M26K4+JYD;2%LD2'UI:>,DJFE
M"VW%;? *U D84=HR<@FN@Z6UIJ&?U4?C7"[VR+%%SDVS\%=<)?+:$E3;J&PU
MD9"=Q6I920K'!P*W;4Y'8Z[:Q7K!R&VA4&(+.9FT),<!7=[95]+(W8^_XJ-N
M^H!8E7*V:3O#5DL=KL)NUJ0E+;B)[BG'%* 4[DEO*0D!)2??P<;:CI&M=8R;
MQ&'XY^%IE7R%:S"5"948Z9$)+QR3[MR5D@ _/G=X&S;M9ZCN=NTTT_JIJUKE
M"[I?F+C,?FJBO)0V<*&T9"N<#X_S6I!ZGZB?U!I1$BX)9$A=MCW*&Y'::;0N
M0TI1P5$NJ4>",;4IX'N)K+I[5.O;W84KA7QI^Z7*QR;E%91":3V76)*$!"<@
MY"TJ(]P//C%=)Z:ZI<U1;Y%^>DANTW"0EJULNI"% ); 7R0"HEQ+O'TGCBKQ
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5&6>QP;/(N;T!I3:[C),R1
ME94%.E*4D@'QPE/ J3(!\U#VC3=MM-TN%QB-O&=/(+[STAQY1 *E!"=Y.Q *
ME82G &?%3&!]4P/JOFT?0K[@?5,#ZI@?5,#Z%,#ZKYM'T*^XI@?0KY@?0K[@
M?0ICG-,#Z%?-J=Q5M&X\9QS7Q2$+QO2E6#D9&<&ONQ._=M3NQC..<5Y4TVLJ
M*VT**AM.4@Y'T?VKZVVAIM*&T)0A(P$I& !]8K&8D8IP8[.-I3C8/!Y(_@UD
M[;>\+V)W@;0K'('U0M-EQ*RA)6G("B.1_FOBFFU%14V@E0VJ)2.1]&O*XS"T
M+0MEI2'!A:2@$*'C!^Z^]AK=N[3>[;LSM&=OU_'[5]0RT@I*&T)*4[1A(&!]
M?Q7CTD?U1D^G9]24["[L&\I^L^<5Z8898;+;#3;:"2=J$@#)\G K +9 #?;$
M&*$; WM[2<; <A.,> ><5F$9@2"^&6P^4[>YM&['UGSBM:ZV>V7=#:+M;H<Y
M#:@M"9+"70E0\$;@<'BO4RU6Z<J,J; B2%1E;V"ZRE9:5]IR/:?XK(J#$6X7
M%16%.%8=*BV"2L# 5G[ X!JMWW0]NO.HK-<9:(ZXEN1(3Z!R*VMITNE*BHY'
M!"D)5D?(_>IZ59[9+EIE2K=#?DIV;7G&$J6-BBI&%$9X))'T3FM:[61,F"6K
M4^+1+ "$3(S#9<;;WA2TIW)( 5CZ^<^166U6.W6NSVZV18K?I("$(CI6-Y1M
M& 03_=^_GDU)4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E>'V^ZRXWO4C>DI
MW(."G/R/WKG?2E^1'U!K&QRYEX>_#YC7IVKH[WW$LJ:!"P[D[@M060DGV@ <
M'(K"TN19^N;$)Z\79<.[6U^0W'DN=R.X\E8REH>&]B/H<A7))S73:5J7>XQK
M1:IEQGNAJ)%:4\ZL_P!J4@DG_85Q[I'U5-R3K5.II<=:[6I=T;<CK"T>C4C=
MM2?G9C:?W.*^:AZPWMC1$:]PM+*BF?.AL0')$@+;D-/@K"A@#"@E)24GA)4#
ME0'.;_F;^$:IU5$6Q/FW(W>%:X<%V2@1^ZZWP$+"<H'M659W'@?)('V7UVA>
MBM[]LLDB6N3;)%R<0I]+?8#!4'$$X.2"A6/OC[J?L_5!F[:KL]FB6IP"X08\
M_N/2$-K2V\VI8*6SRX$X 44G()\&J1UPU5)LW52QP9%^OEJL2[6])EBU %9*
M2LA0RE7UR?@#XJ2MO5:YZ:Z?:3DZM@FYWR\LNR&DPU)'<80D+"CCC>4*3[4^
M2?CQ4A<^MD*/+<]!8Y\VWM3(T!R7O2UA]].X("58)VC]7C!Q\<U(/=7;:B]1
M[<FVSE*<OZ]/*<)0 EX!)WXW9*#N'[^>/@PFF^K01$A1_17V^W"XS;BQ'1LC
MI<"H^%=OVE*=NTC!Y/GS6\WUOLR=32;1,M\V.(<=QR8_[7!'=;:[JVU)22?:
M I.[P5)(&?-8- ZXN^INKKT=YN3!LK^G6KBQ!?+:B"IT;7,IR1E*O!/_ .*W
M8]]O,G_B!NVFS=7V[.BPB6TPEMOV.EQ"-P)22<9)Y)&?VXJ(L'5LVC2]D8O,
M2[WR\N6+\=E2&4,)2EC<K>H^Y ]N, !).,>34[-ZT:8CW6%&;,E^(\F*IZ8E
M("(_J4[V I)(4=R>3@';D9_;[:.LECNFKV; Q;KLVX[.?MJ9+B&NT7VAE0X<
M*L8YR4_(_?$5U^O6K-'Z>N6I;+?DQXK0CL,01%;6-ZED+6I2DDYP4XP<<<BM
MF1KUOIO':@ZWOCMYF2E^J9=#;3;C,0AM)4XD; <+*\!(*B/ .#B0?ZPZ?;EW
MEAJ#?) M*GDRWF(16TWVT%9.\';A0!VY//[5&IZ\Z8\N0+XTD>E4M:XJ=K;<
M@ MN$A9]I!!^^?%97NJ=OLE]U6F\2YDJ-;[A$@HCL0 #'4ZA6/=O/<!*3S@8
M\8.16VKK-IE.G1=PU<U)]3(B&*E@=]*V$[W-PW8&$>[SG'QGBL<OJS;GM2-6
MFU,R7XSMA=O:K@VUN2TV "@[21P0%9SCDH'R<8[-U=L,?3MC=NEP?FNO0F)$
MR:B,&FV XL-!QY.[V N'&!G&"?'-2;75K3#FJ38.Y-3-%P-K*S&5VN_C(3O\
M<\@?P?C!J_TI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I6"X
M1&I\"3#D=SLR&U-+[:U(5M4,'"DD$'!\@Y%0]KTG;K7!,:&N<E2WVWW9"YCJ
MWWE((VA;BE%2DX2$[2<;<C&#6.U:,M%MU#(O;:93]Q=+A0N3*<=2P'%;EI:2
MHE* 3R<#]O'%6.E1>IK'$U'99%KN!>$9\I*BRX6U>U04,$?N!43<]!6.YZJ7
MJ"8T\Y.<@JMKJ"Z>T['5G*%(\$'<3_('U4(YTBL+VDV].OS;R];F)+<F*%S"
M5Q2V3M2T<>U(!(^3@^> 1[D=)--NKNCR%3VID^8S<#*0_EUF0T24N-J(.#R<
MYSG-8D='=,-L1V4&X):9M;MI2D2",M.E2G%'CE:BLDGQ^U;ELZ86>#>[/<3-
MNLH6AM#<"+)D!;,?:REK*1MR"4I!(S@G)QFI"\:#L]WUI"U/-$A=PBQ5PDM[
MQV5M*"PI*T$>[.]7_BH5?2.R-Q[0W:Y]XMCEH>=<@O1I65L(= "V@5A7L./'
MQDXJO=2NETAZ;#N6DS-<DO7J'/FPU2&TQU=K.Y["AG>0!G!Y\X-6%_I%8G=4
MIO?K;JA2;H+RF(AY'8$K"05XV;B#M&1NQYQBLEEZ3V&SW2T3XDBX]ZV3)4UD
M+=24ER0 '-PV\C &,8_S6=OIG:4:@U#<1*G>DOR2)]M*TF,ZHH*"K&W<#A1/
M"O/^,>=$=,X&D[\+NS=;M<):;>FV(]8XV4HCI4"A("4)Y& ,DGYK)J'IXQ<]
M7IU+;KQ<K-=5Q?1R'(9;/?:W!02=Z58.1Y&#5+U/TUG7/J/%BV]$VW:5&EU6
M54J.MI6T%9_*(<RH@HQR!G..?-2TKH?IUZZ1'T2);<%H0^_"&THD&*@H9*E$
M;A[3@X(S66U]'X5MO]ONC%YG+5$N\F[AEQMLI4M]*4J3D ' V\']ZLG5#1+'
M4#2KEBESGX4=QU#JW&4I4H[3D#G]\'_%:>H.GC-XO%FO";G(BW>!%]&Y)0RV
ML2&C@D*0M*D@[LD$#@D^>*P-]-&$V36UM-VDJ1JA]Z0XHM(_Z=3B=I"1CD8
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M^ GP4^WYP>C:6LCMMZ/ZHML6!?$(?1+$6--0VEY0<:\-M-@);3O*L(^.3QG
MJ4*-<ST_F6Z-!UXJZ#3CD/L3&RB*VZEI..T!@E6](2G'.":Q*TC<+?>G9%MM
MUZ3Z:[6>3&*G)+B E:4^K7@JPKD'?_L<5HVV!.NLZ?(LK5Y<N3$^])N#Y#ZF
M7(I+Z&VD;CL4K?L 2CD$9QP:RS[5=8UFM35VM=^5*8TI":L0A-/J]+<4-G>%
MI1PA>X-Y*^-J<?8JS0+-J9G74ZTM/[DMI5J0/>H40)+T=3"6"/&SO)<< /&
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M7>=Z9$6.PM\=E:3W0E)40DDX).#\U]TW>XM^L-LNL7<VS/C-RFVW,!82M.X
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MF0,$K!*N%8!&,XQ5>O&A+I#O.G--SY#3ULD.WIN-.90ONH3*CN$E[C:%!3A
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MC2F4/M*(QE"DA0/^Q%<_M?5-,BV1G9.G;M^)2GY*8\",&W''665[2\"5A(2
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MQ47.Z<1)0OJC<IB7KC<&KJRO",PY3:4I0M& ,CV)X5D<?N:^V3IXQ U%#O\
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M5*@MQ&P5.X:+O]Q &4CYJ'L_5FU79B6Y%M5ZW-6U%U8:,8%<IE2MN6P%'PK
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>exh47_05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh47_05.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ K\! 1$ _\0 '  !  ,! 0$! 0            0%!@,' @$(_\0
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M)_X>7R_T;TR7$NI4&%I_FXRH!Q0W#\5\="T--V;5#4<)##>I;BAM*?VI2'>
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MI2E*4I2E*4I2E*4I2E*4I2E*4I2H;%J@1UQ51X49I45M3+!0V$]I"MNY*<>
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M&Y[1_-6A"PZP6S\$.;LD_!('FJ9GIWJ#T]N=F2(DBYNVNYLW-_N$=R3*#>W
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MHC=G>E(/@;<C )-?<?JM8GY[440[RA2W(R%+<A*2AH2" PM9/[4K5[1\Y!R
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M1S&7%0LM>/&Y6<^?S6PU9JU%BG0[=%MLN[724VX^B)%4VE0:;QO62M20![@
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M:Y1B2 M&,+VI5P?D84*MZ Y\4R*9%,C&?BHUREB!;I,M3+[X8;4X6H[96XO
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MDU0P=4-7'1L;45LM\Z6U(82^U$;2COJ"L<8*@G(SS[O@U?[AD D GX- I))
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M)2MUY3KLOOI2\!E6[N8 24C\#ZK[U/8;L[89C5BL-W1;9$V;(MB767U.0_\
MM6PD!D*2I!<>#I2I>0CR!E0KM;['>Y.HQ?)EHOPG"X6(MO.)="DM]E(E$IW8
MQPH+XX)YK8=*K%(@:QN\!>%6K3CLB/ <2\I7<]4I$@I5SR6TE*><GW?%0->0
M;DYU4+]LM=RG%Z-Z=?<B.):91V'AW&I"5;,96$J:6.58(' (R=FTS>=/Z15&
MBZ<N;J)=CM?JXI0Z4B2F0KO** H%2DHVDM@C(X/&:_=,:>U.+&VW*M5U+[%B
MOD++[!2=ZWDJ90 <\$8V@$C@XR!7HNHK;<E_^'J-;HD.<;JFT1&DQV0M#R7
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MG'$.*RKL[0"1CD@']HJRUKIRYR]:W[NV.X3+M+F0GK'>&FPIN$TC9W$ES/\
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MPJ:A0"EXP$*R-XW9 4.#BK![4%G8NJ+8]=8+=Q7C;%6^D.*SX 3G/-?NHKW
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M>2"!\*!X_JJ?THZ?SM,WUMRZ6M*GX++T9N[&ZO.^I0M86-D=1(;R<E7(]V2
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M1@\__;_FOJE*4I2E*4I2JO4-_MFG8K$B\2A':?>3':]BEE;B@2$@)!))P?\
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M=G/%97H>8CG1F!"N <B1R)J%!U[MJ+0?<W*"DJR  K&<Y'WX-6/3.+I^)?\
M49TO*LR8,@L*9A6R0A: A*""^I*"0E2U**>/(;23R3CT.E>.]>5/+U)T]BW$
MI_A23=0W<4+SVW%^WLI<^"@G=P>..:E:Y<M.B517M$V^W0KS=IT*T2'HC2<1
M&77%[7EM)PGR% $CDX'(&*Q<CJQJM^'I]$25;FG9+%V+[QBE9>]&E:DN)3N
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M6G5E+A4D_(&T@@^<\&MP[U&TJU:8UR5=,PY!="%)CNJ4.T<.%2 G<@)/DJ
MJKZG:WF:8D:9;M2K247B2I@OW!U2&4#ME05N3\'&/\BI%JUW&B6=$K5=QLZ%
MOR76(J[6ZN0W("$Y5M&W<5 A8(P?V_FIT/J)I.9$F2H][BJCQ(R9;SAW ):/
MA?(Y'QQG!X//%54_J7;7;II^+I]Z-<$3[I^G2?<I*X_\I:\[2,_TC!/!'C/F
MK!SJ7I!OUN^]- 0T+==/;<QM0H)64G;A822 =N<?-64W5]AA-R%R;FPD,%I*
MP,J.71EL  $J*AR ,G%1?X_TMW("!>8Q,Y*%L*3DI(6HI1N4!A&Y0*1N(R00
M.>*FW755EM5VCVN?<&F;A(".VRH$D[U%",D# W*! SC)!Q5'TGUXQKC0T:^R
M.Q$D'?ZIE*SM8(4H#*CC^D _YKO<=9MIUEIZR6OTTMNXN367WDN9[#D= )00
M/G<0#GQCQSQ(TOJQF?TZM>J+P6H34B$W*?P24H*@.!\GDX \G@5\0M9VJ7/=
M=:O%M_2VX"YBPLJ0\V$.J;6M6[ " 4J2<@$*!S7U+Z@Z4AMO+DWV$T&74,.!
M2\%*UI*T)QYR4@D?=3TZILBM+IU&+DQ^B*;#HEY]A23C^^<\8\YXQFJQ_J/I
M"/:(]SD7^$S#D!PM*<44*7VR L!!&XJ22,IQD?55^ONI%MT[;(SMNDPYTZ0J
M*MN,'>5L/.I0'!C/&%$C[Q4O5.NX.EM6P+=?GHL"URH3LA,U][;EU#C:>V!_
M9><__L:MY&J[%'OD>SO72*BY2$A33!7RH']O/@$_ )R?C-4!ZBVR)U'N&E+Q
M(APG4-QE0EN/85)4Z%93@C&04CYYW"KA>MM-(NDNW+O4-$V*E:WFU.8VA"=R
M^3P=HR3C.,'.*Z2]8Z<AM*<EWRW,-I;:>4IR0E(#;IPVO)/[5'P?%0IO4#33
M.FC>F+U;WH:^XAA8?&'G$ Y0GY)X_P".?%43_4I$/1&B=17%N)$8OK\=J2MY
M[8W&2XRMPJW'SC9CG[K4P-9Z;N#4=R'>X#R9$9<QH)>3E;*#A2P/. 00?K!^
MC7Y<]7V:WPK-,<EH<BWB2U$ANM'<EU;@)1@_1 \U1=-NHL#5=K!FR(46[),A
M;L1#N=C33RF]_/.,!).<8R.,$5I;/J>R7F#)F6RYQ9$:+GON)7@->W=E6? Q
MSD_%4T?J3I:7<K5"@W-J2]<7W6&NW_2IMON*W9P0-I3SC^H?WJ1'ZA:1D0'Y
MS>H;:(;#J67'EOA"4K4,I&58SD D$<'!QXJ'J#J1IZWZ3-YAW2)(#[+ZH2<J
M/?6T%;DX R "G!..*_;!U#LLR/8XUQG1X][N$)J4N(@*4$*6SW2DJP0#M"B
M3D@9KE/ZHZ718I%P@W1$@!*@SL8=6'5A&X8 3DIQC)' SR154GJ8\QTFT]J:
M3!;>N]Z[$:-$;7L0N2Z2$C)SA/!/SP*MXE\U#8I,QW7)L[=E:CAU%PA!Q/\
M,*PD-%M14HJ.>-N<G'&3BNQZF:/3 9F*O;*67ENMH!;6'"MO!6DM[=P("DD@
MC/N'W7VCJ1H]<*X3&[_"7$MZ6U27D**D(2X=J%9 Y!/&1D9XK\<ZEZ/;LZKH
MJ^Q?1I=4R2 HKWI3N4-@&[A/NSCQSXYKJYU#TFW=8UM7?88FR0TIIO<?<'0"
MV<XP H$8R><C[%2H6K[)<FXGZ=<6G5S77H\7*5#N.M [T\C^G:<_VJMM.MXS
M-OT^UJXM6>_W9&40#N)"BH) \>W)4D>['*L>:_-5:HN+6IXNE],1X3U\>B*G
MN+G+4EEAA*PC<0D%2B5'  QX))^R];-:=M+;G4!R):IRW74I1&*WT.-H/^J,
M)W!.""21QD9J8=?:6%^19OUJ+^IK6VA+()Y4XD+0,XQ[@01SSGCFL=I?J5+O
M^H$.HEV:+8%7)VV!E]E],M3HW!L)4?8HKV%7CVCCDU<2^HT).O(=HBR8KEL]
M),?FRE)6D,%@ISAP^Q0&5!6,X*3G%3W.IFD&[>)KEZ:0P7S&]S3@7W=N_;LV
M[@2GD<<\8J#>^I]B94[%MUQ8$A=K5<X\UYI:X>P9 *EIY^#X^B//%7'\;6)N
M;"MK]TC"Y2DMAM*0KMJ6XDJ0G=C *@"4I)"B/ K,:1ZC.72SV.Z7:3;(S<JV
M3)LB(VAPNJ[+@&]LGC: %9!YY&/!JZM/4[2MRM;LYJX+;0RRP^^VY'<2XVEY
M02CV[<G*CCVYJUU1K"Q:6+ OL],0OI4M [:UG:G&Y1V@[4C<,J. ,CFN#>O-
M,N:C_047>.;MW.SV,*_?LWA.[&W)3R.>><<@U36?J'&O?4EFP6=34JVJMCTM
M4H(<22XAY+>$D@)4GW'D9Y'GBH]LZDL-7[6+&I'X5OMMCF,1$/87E9=&4E7D
M?CCZ)/%6[?4;3;\NQL19BY";PM]N.ZVRHH"F1[PLX]A'Y_N<#FJB\=4+>XBT
M'3#S,XR;O"@R \TXV4L2%%(>0"!N2<>U7[3@\FI</J'#@VR=*U.M,935TE06
M4Q6'7E.(94??M2%*X2,J5C _%3W>HVEF[JS;_P!42N2\E)04-+4VHJ;#B$[P
M-NY2"%!.<D'@5%T]U.TW>+*W<%2E0\V]=U6R^TL+1%2HI+GCD C^G/QYR"9G
M\>6*3>7;+ GARZ]I2FP6'"T5=ON!/<QM*MA"MH5G;S4W05XDZ@T58[Q.;:;D
MSX;4EQ#0(0"M(5@9YQS]FKZE*4I2E*4I2E*4I2E*4I7*6'C$>$7M^HV*[?<S
MMW8XSCG&?JO.[/H*YQ>G^DM/OW".E^RSHTAQQH*V/MLN[]N#SD@#\9%9N?T@
MN2I#\MAZQ3Y#\^>ZXQ<XRW&0Q)=0Y[=I"DN)V?!P<D9'FM'KW0MUNR='_H:[
M-BPJ*RU/85V73VNVD!M' 3@DX^,#%?$?1FHY-RTW-N3VGXHM$N2ZF-;(RVVB
MVZPILD D^_<M2O@<_=8G5_3NZZ=Z636U2&9@AZ:5;%-L-K+CCOJ X%)_\N,C
M'FM'$Z>7ZXW^TZBNTBVQIJ+BS,?CQMZD!IN.6DA*B 2L[B22!C@<XYXIT1/M
M,""UJR0Q,TS88\N.RJ&R\_+E-R$]H!QM*3X0L@[=V2 H^#46W=.+G=.EMF0L
MMO7UN>BYE%X0IL/)2@LMH>"1N2H,[!QR%)SYR:_3T;EHNUMF-L:;<06H[<J.
MZR^6HI94I0,=(7[\A7(</*AN^<5IM<Z-OEWU]9;U8WH<%N,&D2)8D.)?4TE:
ME+:4U@MN)(5[<X*22>:@:%Z;7?3>EX$!VX,F9"LTJW-JC.K;277GNYOW8RG;
MM0 0,\GC@5RTQTWOMIU):+DY+MW:A3;E*6A#CJRL26D!(RO*LA:2223Q_P 5
M?0=(W"+T<BZ5E,VV?.8A-QE-N..(8=VD?UI&])P,A0&0<&L'>-#:AMND+@_=
MU^O!L,JU!EDNS)"%/2=[7(2%.!M&T%7!.TG:<<\="6C4E_N#<AQB$M$>[PKC
M)N"TRF!)#;*V2A"'FTG<E(0K(&TE7GZV4+0^H8/1QW3$.?"8O1>==0^DJ+>%
MR5.XW;=R3M5C<!D'D>*H[!TPU#;I$%2W;4AJ-)NKVU$AYTD2F@EL%2QE1"O)
M)\ 'DFHEPZ7:N%F1;H+]D=;ELVLS%/O.I4R[#" 0UA!W(4$ \[2"3]UM^HVF
M;Y>KFV_9$VY;3UJF6I_UCZVRT'RT0X@)0K<1VS[24YXY%4#'3&XV_6$"3&39
MKC:4^C4Z[<.\9#*X[2&PIM"5;%*(;20I7*2I7D<5WUGT]O-YU7>GXB[8;5>V
MH+4EU]:P]&$=PK)0@)*5E7&"5)P?O%5]QZ9:BN,=-C<E6IBRQ)4^7%FH*S)6
M9#;R0A:-H2-I?42H*.[:.!S5,OI5K*5'6F8JQ(4(=LA(2S*=4"(CZ5[B2T/*
M0>/NKJ1T^U3&NTVZP/TA^0N9<>S&>DN(;]/+#?OW!LE+B2WR ""#P:M5:+OS
M'3[0EOCBW/7C3DB,^MIQ]2&7NVTMLI"]BB.%YSM^*RMZT2[$CV;3\28^-33[
MA)ERC':6IEB)+W"2D.;0 E(QM)*5%24G R /1]?Z9GW9G2_Z$8K2K/=6)I:>
M44(4TA"T%(*0<'"^!CG&*\W>Z.WZ7;+1;7Y4!EF,U>677VG%*41+5N:4$E(_
MLH9\>*UN@=$W2SZ9U%%N-JT['E7!CLAJ*Z^ZV^0VI.7EK.[:<@;0/:,_)XSN
MGNFNLK?>+'<'IMM4BVRI :BO2W9/88=C(:]KJD!3A24DA"L#&!N%5NG^D.K8
M4UMZ9*M"QZRTR7,2GG"?1K5NP%(PD*2>$#"1X& *N7NF>JFWY$V%.LYER!=(
M:VG^X6TQI;Y>"TD#/=!.",8(P,\<_EFZ6:E@:FL5P>N=J?C6\1 4%+HVI:BE
MA:$H!VJW;BH*5[O \#%3&.FVH;?IS3#-MGVO]4M<*5;7P\EPQULOD$J0!R%C
M:C\'D?56+W3%Q[I;I[3:K@VFZ6)QF5$F!LEL/M$E)4G.2DY(//SFI=VTYJ[4
M=G>;ODVS1I<9]B7;VX2'%-=YIS>"\5\E)P!M X\Y)QBA/3*_2+V+])N4%NYR
M#<')##>]3*%/QFV&PV3@X3VDDDCG/C@5D]>Z O.GNF%P4ZN+,+.GX%I#<9#B
MUJ=:E!>X#'*3O/QGCQ6AOG3?5E\9N,Z1(LK<Z[2=TV"AY],?M)C=E #@ 63G
MW*3A(5P#P.82>D>I/T&5;S*M&9$2RLE>]SVJA8"_Z>00,@^<\8'FM)TULS$O
M7NH]0PTRQ90ZK].1(CJ9 >>"#*6A*DI5@J;;&3QG?CR:L>I.E+[?;_99NGS
MBN1" Y.7*>9D-I[J%*0$H24.H(1RA?&<>*E:KTS>$:TBZNTHJ [=4P#:WXMP
M6M#3C!<[@4E:$DI4%?@@@_&*@:@TYJ^<N-<V#87;L] ?MTR.ZIQ$=+3B@I)0
MK:I2BG&#D *SG P!5%:NDMTM&P1[G&D]NXVF4%O[MRD1&$MKSP>5$' \ 8YJ
MPLG3J[Q(=E9F2+8X;?J)^\*VI4H+;<#OM&0/>"Z<'Q[0?Q5(UT>O3]M8L<ZZ
M6YNS0+?.M\-^.VOU"TR%(4%.I.$Y!0,X/.3]U8Z:Z:7B)=+/<9C>G+>]#N"I
M;S=K86$O#L+:!)5SN)7G'A(\56'I/J1&F8UI9F6D[M.O622XI;HPKN*6VM(
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M0QP/;YYYXGWCIA=)@,O-AES6;K.ELQKC'4]%<8D[<I6/(6G:,$<?'SFIVG-
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M37:4E*]V%8X*DGVDY!!&<C/Y9NK=GG0HS\R#<H"GXDJ<A+[.$EE@G>0K.,X
M./S6UDWF+$TZY>II7%AMQC+<[PPIM 3N.X?8'Q6-T3U%1.T1>+UJAI-NDV>0
M\U/91[^V =R, 9SE"D>/)S7W+ZKV*-=W[2N'>EW1F2(BHS4%2U%Q2%.) (]I
MRA)4!G./CSCL]U6TFQ<9D.1< TY%:=<6M0!2HM %Q"2"<K3D#'R<@9P<<FNK
M.G7^VB,U=9,E<A441H\);K@6E"5G(3GC:H'/C@_1KO:NJ>F+E!F3$2)3$2-!
M_42[)C+:#D?)!6C<,J 4-O\ ?&,Y%06>LFE7Q&3&-QD2I#KS*8K$13CJ5-)2
MM>4IS@!*P<_W^C5I8>H%OOVK6[-;&)#[#EK:NB)H0>WL<)VI/'!( /\ R/(K
M9TI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4K*]1=+RM66:)"A7!F XQ-8F]QV,7PHM*WA.W>GR0.<^,CYX^M5Z57?[SI>
MX":EA5EF&64=K<'LME!3^X;?W9SS65N735]AN>&;FN196I4BZP[2(P"TREH7
MQW<\HWK4H)V@@D<G%4NC^EDRY].K8SJ><XS=F;?'9A)$8)-N4VH.)W))(<4%
M@9S@$#&!R3KM-:"EVO45LO5PO8GS8T21&>VPD,(<[JVU H2CA ';''N)R3FL
M[*T 0SI_23C,V;!ASESQ/0REAEF,I2RJ.M05E:U$X.!R%9.,5Z'K*PKU':V+
M>9#;44RF793;C/=3(90L+4T1D8"MH!//&1@YKS[6W3M%NC:EE:=B 6J[6UJ!
M(LEM@M E8<_^81DA.Y*%J]H )QG<#@B!HG2%]NFJ8]ZN/>A18,],U/K8"6)$
MMPL.-.;@EU7 26MI)^%<5;HZ1 "_P!=PW8;B'5L,-PV_41W'%;S_ #SE2D!>
M5!/'G!.!S/L_3VYLS;+.NM]C/R[=*=D[8MN1':<WL*:'M2<@^[<3DY/'%5L'
MHZW_  RU:+G>5NA%F%HWL,! .U_O(=PHJY!"1M/!Y^^)$#IC<$7&R7"??HRY
M5O7,*D1K8AAE8?92U[4I/! 2#D[LDGP*^M+]-+CIB?'EVF^L]UJPM6@J>A[@
MIQLDH= "Q@<G*<G^]>GTI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*$@ DG ')J#:KQ;[M:D7.VS&9-O
M7N*9#:LH(22E1!^@4GG\5$TOJBRZJB/R=/W%F<PRZ67%-$^U8^"#_?(/@_%7
M-*I]0ZEL^G5P4WN<W#]<\(\<N [5N'PG., _WQ4F%>(,ZZ7"W17]\RW]OU+>
MU0[>].Y')&#D<\9J?2L@[U*T@U<7(2KY'+S;H86I*5*:#AP CN ;-V2!C/FM
M?2E*KU7JVINT:V&8SZ^2RJ0TR%94MM) *A^,D5^HO%O7>1:42VE7$Q_5]@*R
MKL[MN_\ MGBI]*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2LMU!AWR?:X\:Q18$QI;X];'ER5QPZS@Y2%I2K&3MR".4Y'S6
M<Z**D:>Z9VBWWZ(Y"E)1)D)82TXM7;#JEG(V#"O?PGR1C&? D]+N[)OVL;N@
M./VVZ3&9,2:]%5'6ZGL)3LVJ )0@)2D$@9)5Y.37H=*\WZOV6'J>X:5L%U94
M[;Y\J2AS"2=BQ%=*%@_"@?%>7,MZZTYIN]QIXD&0U>H%ON%RB[D*7;D-I3WD
MJ'NR4E(4I/(&?!!(K;G>];&-I]M-QU BUN1;RZS(:4XEQYII#BHRW%XR3[4>
M>2"/NO1;+-ZC:CZ?VUN$W;O2SK#A5Q?>6B9ZE4<@*V[<#^9CGY'-0NBE^L<'
MIU9M%WV&\F_-J6Q)M+D!Q:PKO*.]2=I&W!"BK. .:S.G=1:P:O%W,F==C/$*
M[/7>,HJ<;@*1DQ2VDY""<<!.=PYP?-8V1J37$73ETFKONH@XBSP+HTI;JR#(
M5(;0H#C]NU:\H\'Y!P*TG4'6NIDZ]U<Q9KU<O5P7K6+1 94=CBG$I4XDMI'O
MR"3@YJU-UUA==6ZZ8D7V=&>B)N3+%J98>RZR&3Z9QO VHY&=_E1..<BJIV9>
MD=/].0[,_=5Q'-&2BM3"5*VR$X)1O R"-JDX^ACZJ9<KYJJV0,:3=GOLM:%8
M>97V=X1(#R0X4KV\K2WO(&?CQQ7(:CU;)A1HUAN][FV-6J&(3-Q1N<==BJ1_
M.'=QDI2K@*^/OBO7NA%QN=QZ>1EWYZ<]<6I,AIQR:A27"D.JV9R 3[2GFO0J
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I@4\TP/JE,#ZI@?0K\VCZ%9^UZ0M=LU=>=21$O"Y79#2).YS*#VT[4D)^#C
M'_']ZT.!3 QXI@8Q\4  &!P*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I5#K&)=95N2NSW:1;51RIYT1F
M&W''TA)PVGN)4$Y..=I/Q7CUNU1K!GIUI35,F_R[DJ[SH+;D)$-A*_<\H+0V
M0$C"T@#"CP?ZAFM/.ZUVR':XKSMIG?J2U2 _;@I!=8##O:<S@X4K=^U(\_@<
MU;]5-3RK;HVTW*R2Y$43Y\-GO-1@XZ&75@*VMJ2KW;3P-I.>,560-;)T[8O6
MR7M57P2KFU:HL:XPF8LD/*;W#@I:RE60,J%?-EZSP9[[C,JPW:$M,66^GN=I
M0<<C?ZS2,+Y(^"< U!OO51VX6^*+3%NEDGIFVUTMSV&_Y\.0^$;A@KP"-P^%
M UII74J+'GO-_I%R<@^I>@1IJ.V42I3:5$LH3OW9)0I"20$E0QGQGB]U;T^W
M8DW4ID"*J#'F@J+:0"^M2&VB2K"5DH5G)"0 22!51+Z[Z;C6^#)<8D[G^XIU
MKN,Y:0VYVU*2=^'?=DI#945 $@<5O=1ZHAV&':I4EB4['N$QB$A;3>>VITX0
MI8)!"<X'WDCBL3JSJ9:I.D9SD)^[0WDMS%..1$,J?B^D=2AS*5*V@DJ2 #G(
M5\53ZQUM?;;JBX0X5Q=2TW>[-';06&RE#$A)[B<[23N*3DGD<8(KTW66J8FE
M(4.1,C3)1F2T0F&8B$K6MU8.T8*@.=N/-9@=6+:[9X<^)9[U)4['>ER8[;*
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M;5!O&0<#/D8( \Y%9J1U3APRJ-.LEX9O*G64,VT(:6Z\E[>6UI(7LP>VO.5
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M*@C*CG=DJR3N\C%=M9]/52XEVM\./,FKU#<F9DB;W&VDV[9VTE:>0HG8E6
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MW.*<VI&2$(W$[4 DG:,#FHM[Z=Z>O-YDW:2W<&;E)0EMV1%N,A@K0D8""$+
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M6^"S-CP/4MNVWUA<6DE<=&XI6YDJ'<!SR<&O)Y5JU [IYI-J@ZI9N?Z=V]1
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MR=[*G7E+(=.T?N2 -JBD#%>I=/1<KUT\N-\G1\7+4*%S$1>X5(0@M!#2!NX
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M;#;-'RKO;;A&DR"Q(5%94APE;C(.Y*TI&Y ! !) QD9QFM/;)PNFE(D^4AI
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M!D-EP-O(]AW I<)4@A/(X5YK:=-M)3-*R=0)E.L.QIDEIR,4*)7L0PVU[P0
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MEV0@K;!YSC;M).,#</SCMJO7$/3L]<)5NNEQDM13.?1!:0OLL D;U;E)^0<
M9)P<"N>FM?V_4NHY=KL\&XOL16T+<N7;2(IWMH<0 K=N)*5@_M__ 'J.OJ3;
M&UW%YRWW46B$F1NNH8"XRU,JVN(24J*L[L@92 HI.,XJ,[U2MT/<S=;1>8-R
M[[+*+>XRA;ZP\5!I8"%E)2HH4GSD*&#\9C6[K%8Y<=]YZVWN$VS&DR"J1% "
MC'_UFTD*.5I^O'YKZC=7K.],AL.6J^1DR);,3NOQ0E""\,LJ)"C[5^!CGR2
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M$J4L+QN5A9*TI)("CG' KG(Z8JN%RAW6]7QZ;=XLF&\F2(R&\MQEK6EO:/\
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M;0$(4G_:H!*3G[ -1HW3>T-SHTZ3*N4VXLS6YWJY+^YQ:T-J;0E6 !L"5JX
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M6DX2H;AE&?/R?L8KH^N[M8X]VA673]O7?)>IW[>3%;/:==2PAU;J@MQ.5JY
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ME<> U:X!ENKMX9QWUO;<J!2H8P1D\'.['S5M-T9HYV\0Y$NS6G]20&Q&4II
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M8$9.&0$AL)* G;X_:I2<XS@D5/TWINSZ9BN1K% 9A,NKWK#8.5$ )&2>3@
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MEK$AM<9M:>V@ 8PHK_=N&T< '%5UAZ)7J-?[++N-SB^DB/W%3XB/.MNE$E)
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MLAM0=)W )"@OXX/)..35'ULMSC]XUEV6;H])E:7:1&0REU;3BDO.[TX2-I4
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M6AYK#Z9@+!2D'E8;_:.> ,9P*_H;5[$B=TRO##<:1(EOVIU"6$ ]Q;BFB D
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M)1%::6?&4Y4V3BLU<.GU_E/.V]4*.X&[K,N;5Y<D)WN-O-N ,%.-P_U$H/\
M3M1GZ%4,CI?J>;IN1%>M41$D:3BV9D&0A6)++Y)4#\ CW9_P>:FWGI?J%Z\Z
ME*(3$SUZ)[T>X+N;B=BI$930:]/^W<"4IW$XVCQD 5O-0Z,E3>DC>GK8EJ%.
M3'CEQEI7:0\M!0I;:EIY 7M*2H?>>:\_/2Z[R69A.GHD5M^U71EN._</6+1*
M?[90X5K'[BI*CE.,9^\Y_7NG>JA!FL?IK3RGT61T.&4WNWQ$MI=2<@<G:HYS
M@X'W7;6]G-@BZEES6H4>\*OK=YT_(4XT');V&QZ=*!A1Y"DD?2P?NO3M)M/Z
M<39M-K@/O!4)<E^Y(QVE2 I)=W#R%+4X5#[Y^C6)UMTYOD[55YN&G'HT9IWT
M]WC%8!/ZFP%(2.<X0M!3N.,D@<^<T&I.E-][=X:@QV9RI&FFX:7EN("G)YE*
M><7SR.5*7G\_=28O3F]C65VE3;2):);\F8U<5W,I2V'H_;+7IP.5#)3N)QC^
MP%5[_3G4TFR,*58(B+E'L5KAH27F1A^/++CH2H<#<D!61P<XR:DW'IA?GG=4
M=RV(FS9+5R])<W;JK"Q)0I*4=CA(("D@DG:.V"/BMWJK35Q/3&#:=/VR&F:A
M41;T?:TG;M6A3BD;@4=P8)"B#SSS6!TQT_UA8XL8KL%GNB7XKT!V)<Y8<0P#
M,<D(=5[2'!AW!2,'*0:TMBTCJ6'JB&^];H7HXVH+C<B]ZH9<;?:<",(VD@Y6
M!Y)_Q6%U/H6[:8T$N3/8ML5M&GS:7@T\K:F0Y.0M+A*4<I ]Q4?R#Q6]Z-71
M=X_BUV+$B=Z4\B4J:S-3+CNO*;V=L*2V@#:&T$CD^_).361MG3;63#=P>N-K
MBON2&;>E*8=U##C3L92B%M?RNV@9((1C  QR:W5TTWJ1SIEIJUKA6V7=8+L=
M4I#1;:VI1P2PHHVH7C W!(P"K;@XJAGVF?IG_P .<:U:BAQ1,@N1FBQWTK0[
MB6C:"I0P-P_XS76U].KFYJ^WWF?:X+41V]2;A(A*4AP1VEP^RD8 VJ)6 HX_
M!\BHENZ<7INZ:>7-MT1Z+"NMYD/!3B" U)2KM* /GDCCR,5^:1T+J:PHLK4C
M3]FN27+=!B/N3'4J_3W&'%J*PGG?G?N&T@[DC/W6?789]@O_ $_LTS3\>Y2^
MU?4^A4ZT$+;<=WI]QXQM6.//D5:P.F>J8=XTV'&6'V;0[;%>H1)0@.AIM:7B
MOV[U*3N(1DXV^!G-;KI(Q=M-6.QZ3O%I>;=8@O/KF(<#C*5!\@-DC^HI6%#\
M _58'6>E+^C6%VU!=;<A-AB*N,E3D>0AI*V%P@V"4H27%.$I.XD_[<<"LQIN
MW3=6+<@6YF*_=H=M@*[\*[-O,/-PW4;8REM)_E*<)*L[O+8..,UJI'2^\2K5
M+;;L,6,M^QW",TV]</5+:DOO)6E2G% >X@*R1P,UJ;3%O^C]2S[@K3R9\6Z_
MIK"WF90[K*@A#"LIVDJ /N)R!@9J9U,T=<-07]4R)"BRF18)\!(>4D$/N["W
MC(/RD\_%9M>A=2PHEY_3+1;<3&[1ACO-I4DL((>[9*"E*PK&%D?D<@511>E6
MI5662Q,M4)3Z=.SK='*Y:75)D.2ENMJ"BD8.U7[N/SBFI-,:EMU\NNH+O;&O
MTB*Q.4\\U,0V%-.0PC?L2@K+F4^Y9*B3CP #5'I^TW#4<=^):X\>==(L&V[U
MP;LTJ.\W%<P&EN,X+:U9*P3G_3' QSZ3H'14^T7VWW*5IYN.TS F9;=G)E.I
MD.2$N)W+/E1"5'<. 5G\U<:F;N^O^E,23;[>[ N3SD>:;?(?+:E=IU*RT7$X
M(W!/"N/(/'QD9G3J[W&QQG(>G8=GG1)#]U:9>N"IBGGEJ3NBO*)P6W,**^<8
MVC!]U=9W3J^3=475Z1;([S5T>$QF>NYN(_3%JCAI20PG 6I.,)5]$>,4B:8U
M7$LUB=&D+,W/LLF"HHB2T)<G!EIUI2MY2 D . @')Y5^,PXG3_5*+6M#]G@F
M5+M5[AK E)(C.RGBZT02GW YV_& 3G'BM ]TSN4AO2 1*CQFVK9&ME^9.5B0
MRSL<2E'QG>E:<_[7%?BN%OTA=K!K2\7J39/U<,RIET@S1='$KPXW@1TL'VA7
MA&X\;0/G%>M6N4J=;(DMQAR,M]E#JF7!A394D':?R,XJ32E*4I2E*4I2E*4I
M2E*4JHU)?K?8&(SEP[JW)#H9CLL,J>==7@G"$)!)P 2?H FJ"7U.TW%;CK<>
MF%#C"93Q3#=/I&5$@+?]O\L9!'NP>"? S7W$ZEZ:EZC59&94@S$O/1BI45Q+
M7=:3N4@.%.TJV^X $Y'/U7[9.HUBN[D%#0GQUSRL1$R8;C9?"6@[N3D<I*#D
M'Y_O5>]U$CI=D72,H2M.MZ?5>4=ME0>44K((Y/' \$#!!R:GP.HUDEW>WVQ2
M+@Q-F-M*"7H;B4M+<;+B&EJQ@+*4J.,_TFJU?6+2;EEN=QM\B7,$&";@6DQ'
M6U.LA6PJ1O2D* 5@$C@?-:JY:HMMML,6[35OM1Y1:2RV6%EYQ;F-C8; W%9S
M^W&>#]53'J9IDIMH;DRW7K@M;;+#<%];@4AP-K"TA&4;5$ [L8JUO6K;59[Y
M M$Q<DS9NWMI9C..)2%+"$J6I*2$ J(&215%_P!3M-V^R6V7=;N'53FWG65Q
MX$C#J6U;5D(VE0QP#G^_BOB1U)T_<;%/G:?O<5"H:XQ>?DQ'BA+;K@2#MP%*
M"AN 4.,^?!KXM_4-J+_%3VHE-M1K;>?TN(F,PM;CV6FUI2$C<5+)6KP/ JXB
MZ_TY+F6F+$FNR'[HPB3%2U%>4%-*)"5J(3A"<C&58P?-=[WK6Q66^1K3<9:V
MYCY;'M86M#?<44-]Q8!2C<H%(W$9-0&NIND78\Y]%W'9A*0EU1CN@'>X6DE'
MM]Z2M*D[DY&1YKG(ZIZ.CVMNX.W<B.MYQC'I7BXA;8!<WM[-R D$$E0 &1]B
MI=SU[IV+-<MWZO':GD!*%.-.*9#BF^XA)< V9*<*V[@2/'FJR+U+LT1NV1[U
M.;5(>LHO+\R*RLQ@UN2@K&<J *E$C(X .<?.NMUZM]RFRHD&2EZ1%2VMY"0?
M8'$[D9.,<CG%<[CJ&U6V:N).FM,R4Q7)I;5G/9;QO7X\#(JGEZUM2GK.+?=K
M?LFOQTGO;\N(?;6IH-X'[E;<C/& K\5FI76"SINUB4PYMLDURX,R)+K*]Z%1
M0G]J1R0=V?'CZ.:T+NN+3"EW>3<KU:V[/$CQ7TK05%;:7BH)4L^"E7MVX_.?
M(JTM>J[)=;%+O-NGMR+=$[@?=2E0[9;&5@@C(('/CP0?D5D[-J/4NHH=CU!%
ML%K<LDR0A3;;KI]6Q'6K:'^1MSM]Q2#X/DU;M]3=&N,3'DW^(&8:T(><5N2D
M%9(202,*22D@*&0<>:ZR.HVDH]I;N;U\BI@K>6PES"C[T<K&,9&T<DXP*KM9
M=18%GO%EM%ME1)-TG3XL=QE>\[&75 %04D;=V"" 2,CGFM!8=7V"_P!PE0;/
M=&)<J*-SK:,\)W%.X$C"DY&,C(J._KO2[%VG6Q^]PVYT%I;TAI2\=M*$A2CG
MP< @D Y%<8_472<BV2[@Q?(JXD5;;;JP%9"G/V #&3N^, YYQ4+1&NV[YHV[
MZAN"$,PX$J6C<RE1W,LJ.%[3SDI'C'GX'BJBR]6[5-UA(MTMU,6W.Q8+T!U;
M+F]Q<C=PL@%*!G8!G R?)R*V%NUA8KC?G;+#GI<N37<RUVUI"NVH)7M60$K*
M20"$DX/FJ[3NHI]TUUK"RR6X@A68QDL*0E7<6760X=V21QG P!518.I]DCZ?
MM+FIYT6%<YD82ELQXSNQ#:G"A*C@*V)S@$J(Y^JFR^H$"U%\SY!F!=[%H:3#
MB.[F5E*3M<SG<0"593P01@>:L5=0-+H=FMN7=I!B-J=<*VUI2I*5;%%M13AS
M"L).PJY('DU#T'JIO6XU*AV(VJ%;[D83*7&5H+B VVO*T. $*RH\$#P*SNC>
MI-SO,>?=)S5J1:X)EJGQF7%"7;0R5;4NI).\J"2<@)'_ !6GM74C3-P9LI_4
M!'D79EEV.P\A04.[D(2H@%(42E0 )Y*3C-1[=U3TK-LJ[H9SC$5,I^*-["RI
M1:/N6$I!.S&%;O "AG!XJXA:CTY=;^F%$F1)-T80HH*4;B!M05!"\8/"T$@'
MPH9K\GZTT] OB+/+N;3=P6ZAGM[%$)<6,H0I0&U*E#P"03\5TLVK[#>F9[UJ
MN;,EF""9#B =C>-V?<1@XVJ\?55O_4G2!MSDXWR.(K;K;*E*2L$+<3O;&TC/
MN3R#C!'BORU:YT<XEO\ 3;C%2F1'>GCMLJ0%-MJ(=6?:.00<@^[\5?3+[;(5
ME1=I4M#=O<2A2'2"=^_&P)2!DE1(  &22!BLQ-ZF6(?I+5M?<DOW9<EB,0RH
M!MUE&Y274G"D$< @@'GG R:A=/NJEEU!I!FXW6XQ(UP9A-RI[:4+0AK<<>W=
M^X9XX)Y('DBK#_JCI$1(;YN:MTMUQAM@1G2\'&U)2M"FPG<DI*DY! \U;ZFU
MA8=,*93?+@B*IW! V*7M25!.]6T'8C<H#<K R1S4-74'2OZA*@N75I+L=+RG
M"MI8;/9!+H2LIVK* #N"22,<BOI6KM(VEA]P7*W1F@EJ2Z6P ,/?Z:S@<[\<
M'YJ,OJ1ILR[(S'G"0B[//L,NMI44I6TG*PKC*3R/(_-?5HZE:0N\QF+;KVPZ
M\\A;C22VM 6E"2I125) ( !-2-1ZHCQ]%MW^UW& U%>,=3,N4AQ3*D..('A/
MNR0K _)&>,U]#7FF/XB%B_68WZJ7C'['/#H3NV%6,!6/C.3X\U-N^J;)9WY+
M-SN<>,[&C"8\AQ6"ADJV=P_^7=QFLWK#J-;=-:BMD65*C)MJU/MSWR%J5'<0
MRAU"0$@Y*DKSCGC%3XNLH#MVN;BKO:U6:-;X\Y*T%7<0ES>>XI7[2@@)VXY\
MY\BLY>NKMH@WZQ=J6R+')3-3-<>C/)D,N,(;4$!H@*!]^2"D\8Q7I<*4Q.AL
M2X;J'HS[:76G4'*5H4,@@_1!KM2E*4I2E*4I2E*4I2E*4K+ZXTP]?E6F;;)J
M(%YM,DR8;[K/>;!4@H6E:,@E)2H^""#@YK*7+IQ?IBKB5:ECNN7R B!>7'H/
M[TIW@+82E0"#M<4G"MWP>37[;^E;T&_,W%J[MX:ODF[I;,8GVNQPR&S[N2,9
MW?.?%5UHZ27>URH4Z%?K?&EPY:WV&&H"_2-)6R6G-C?=RE2LA7"@D$<"IMMZ
M5SXE@7:G+^V\TO3CUC4OTI"BM:U*#W*SX"B"GYQG/P/E/3"]*U+9;O(U%$>5
M;E1%);<@K5L[32FW$-'NC8A>\J/!.[&20,5 _P"CDY=D$%Z\QE+&G'[%W$QU
M)&Y;Z74N8*CQA.",^>?Q6YU7INY7S3]F;:G1HUZMDF/-0]VE*86\V,*!3G=L
M4%*&,Y&1S5-I+I]-L>L6[\]<&'5/"<[+90A03WI+C2\MY/  92.>3C/SQ)UK
MHVZ7[5UHND*9!B-0E-*#X;<3*;"7-SB4J2K:M"TX24K! Y(YJH;Z;78)LI<N
M4$KMUON4/(:6 LR5>P^?"0!G_.//$%_I1=W--2[9^KPBMVSVJV-J+2L),1S>
MI1P<D*)5C^]3[GTYO,A-]3$NL-M%QOB;H6W&UE"VNREM33FU0)Y 4 #@E(!X
M)J;TUT)=-+2;4Y<9\.2B%9A:BEEM8*BEXK2O)/C:0"/OQQ4J?I"^,]0)5_T_
M>(<2+<T1V[BR_%+KA2SNP6E;@ 2%;>0<>>?%>8ZPZ>:CL%GN=T<FQKK*>5!8
M04-NEU:T7 .AQ?*OA9R$@  # XYM]1](]17MB<XJZ6QI^[N2WK@RGO!E*G&D
M-M%&""K:$9.[ )5G!P*TU@T+J&QW&6U"N=K%GG=N3)2Y&6M\2 PEI8;5N "%
M; <D$@$@?=54?1DO3B[)<]1R(3UI@Z7&GKHTRAYU:QD>YL)3N5DA(/ .":L.
MGUJU%IC1-F<C1?U"Y7">VNY>N)0\B,<-I/X6VTAO(5Y*5?)K2=0-&'5CEI<;
MN#D!V&ZXEQ;:<EV.Z@H>:S\;@1A7P0#\5D(O263;X5B8C7),I<#4#-S4[)4K
M*8K*%-M,(\\I04CG _<:Y67IA>X#]H0Y-MRHUN=NR4+07 XIJ8,I)&,!04>1
MG&/!S4%SI1J%JR7&''EVQU^1;;-$0MQQQ([D)P*63[#PH)X///D"MQI+1TF
M=;M7AQAR-?[B[(;2PI64LK:2C"L@85P?&1^:CZ)LFLM/0;=I]Y^R/6.WI[+<
M[<ZJ2XRD80DM$!*58P"K>1QXYXP#?236"FYHE7"U.O2&H*%O*E2%EQ4:5W-Q
M"DD(!03[$X2D@  #FI>I.D^IK@S>&H<VV)CW*YW*8XRM]YOV2&4-M$J0G)*2
M@J*/VG(\XJ6GIQJL72#_ #K+^G_JL"]25%YTO)>9:0VXVCV84V0C*22"/!J9
MTVZ?:GT]KL7N]R[=*:5;GH3KC3[RG%J5([J5!"D[4#;@;4G ^ ?-5VJNF.JK
MQK*Y7!$RU*@/Q[C'94XZXE:$28R6TI[81L&U:<E0)*@23R *DSNF6HA<3<+?
M/MPDQE6N1%;=6YVW'(K3C:TN83PE0<X(R?P,5J=):.N5NT/?[-=)454FZ29K
MR5,;BAH/E1 R0"<;C\"LG#Z7:C7;YQF3[2U-EQ[4P4M!Q;;9A.A6<G!.X)3]
M<DCXR;K0?3F9I?5TF9OLR[:%R'&'T1#ZY8>65EMQTG]J2>".58&< 8JRG:9U
M!;=87J]:5DVU2;TVR)3-PWX9<:04)<;V#D%.,I./VYSSQGKCTDF*MK\6!=F4
MJ5IMJQH<>:427$.]Q3IY^<GCXS\U/D:"OJ539,6Y6]<US4B;VSWVE[$MAH-=
MM0!\A(XQYP,GGC/1.C=RB6N9 BR;$R(Q"K9+1 *9+I3(0^A,EP'E(4@).T9/
MGXQ6YZ9Z=OMC.H)>I'[:Y.NT[UJD0$N=ML]I"",KY(]G_P#? R;G36_W:[^N
MO:[%'G)MLF"]<+>E:7+@7FB@=YO:$@))W<$G('@<55/]+-8R5Z94]<+046=J
MVI;:[[X0VJ*H[BD!("RL8.Y0!'[1@<GE(Z-7O]'BL@V":_$FSNU'FJ?,9<60
ML+W*VX4EU)'QP1P2:UVCM#7JRZW%R4JV0+6AE33C-N>=#<SV(2@JCJ&QM2=I
M]R5'(P,>:YW7I_>)%WO$*/(A*T[>+G'NTAYU:A*8<;4V5-H 3@A7:3A14-N3
MP>*O]%:3GZ;T!)L8FM+G+5+6T^$DH0IUQ:TG!'QO&1CX-8+2_2O4\*8J7<YU
MJ4ZY<;;<'=CTAU2E1TJ2X"I?)*@00?'G@ "H-ST,Y&%DTL93KEY?NLJ6Z]$:
M<"$6V2I?J$*64E(R $XSG=M(^Z]1ZC:9E7ZQ6]%E<89N-JG,7&&A[(96MH\-
MKV\A)!(R/'%8QOIQJ!>H8>HG7[2Q<3.F2Y,5LN%I*7X[; 2A6 2H!O<5$#)/
MBJM_HS=Y.GX5L>N%OVQK(Q !(6M"I#,GO)44X&6U#*2#SSX-7NC.G%VLVIK#
M=I/\/1DQ$3!(C6J,MAO<\&P"D')4?Y?*E$'G'P*MM6Z/OTC6AO\ IJXP&3+@
MBVS&K@RIU*&PLJ#C0!P5#<?:KVGYK,O=*[],M[=AG7&WFR0Y$Z3#DH"_4DR$
M.I2A:<;<)+ZB2#S@<"HC?2C4[S$CU]PL_=<C6J,D-!W&(;H4221_4!\#R?\
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MD:ZNR&([4 M-*=<[X<+2P0YMVGM+!]V4J&"!6KTGJ%C4>FHUY88?8;>"\LN
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MR=@?[Q4I"DX5G]I'C:3\X(CV[HW;X<.0S^J2M\BSOVESMMI0A/=>+JEMIYV
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M?@6DYP0<'%?BW$(3N6M*4_9.!45F:5R9S;T=YAN,4@/NX#;H*0HJ2<^!D@Y
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MY"2G*R> ,X .>*.X:5O=GUSI9,:SW*6BUN06%SF4+=[[1;<#ZNXI0#:-ZN4
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MJ-Z3M%)&WR%\[?'.:SRNE%_;A6DN08%Q[=MD6J1 =N;\=A(4^IQ#H+8&\$*
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M:BT0'$H5C"U)) *4Y.>/(-?'3[5DC4UVU2TX@)B6Z:VQ&W1W&'0E3*%D.(<
M(4"H_ JQ?UK8F+T;6[+6) D(AJ6&'"RE]8!2T70G8%D%/M)S[A]BI.F=3VO4
MS3SMF=D/,M*VJ<<BNLI4<D>TK2 K!20=N<541];VJ'$G/W:[QG4MW-Z T(L9
MW<'$<]DI&XK< !R4C!^!6BLEW@7RT1[I:I*),"0G>V\C.%#)!\\@@@@@\@BL
M_#ZD:5EV^3.8NA,6.IE"W%1W4Y[I(:*04Y4%$$!2<@D>:[1-?Z9EIB*8NB")
M33[S>6EI]K'^KNRGVE/R%8/XJY=O5O;T^;VJ0G]+$;UG?"21VMN[=C&?V\^,
MU6-:VT^Z'BBX)_DHBN+RVL>V20&"..=Q( QX/G%16NHVEG6YS@NJ4MPBV'EK
M9<2 %K[:5))3[DE8*=R<C(/-:*WW*)<')B(;P=5$>,=\ $;' D**>?PI/C[J
MDD:[TU&NLBWR;JTU(80ZMPN(6EL!I.YP!PC82@<J )(^17Y;M>Z8N4=;T.[L
M.(3(:B\I4DEUTX;2 0"=Q\$<8!/@5PD]1])QH+<MZ\,AA;KC)(0LE"D$!>\
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M9K5S@J>C(+[ZGMS*,YRDJ*?<<$8S5F_TWN TY>[<A=HE+G7HW1LO(=:#(V(
M*"V0IMP*1N"D\<D?/%:.E5_])*M;U\CR[9=_0NW:0]W/5%V.E 66SX/<[2<E
M1R,D\UVMG3W4.GOTB="DVR3)M3MWE!LH6 ZJ3E30  &,$ *''GBO07V;E?-!
MN,RH[,*[SK:4.,+42AEY;6"DD<D!1QD? KSZ9TUOTJRP(9E6M+K.D7].N*"W
M".ZL-@+'MY3AO\'GQ5CK#I]=K]-GR69D%I4K3"['M5O(#JW I2^!^W P/G\5
MWM]BU/IN_P!ZNL%FVS_UBXP>XTE2D%J.AE+3JN?!&-P&59&?FM#K[3TN_6^
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MC3HR4UK.9>K?J";$A3UMO3+>AIM2774(2A*@LC<D%*$@@><?%9MWHU#>T_\
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;4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>exh47_06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh47_06.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ KT! 1$ _\0 '  !  ,! 0$! 0            0%!@,' @$(_\0
M0!   0,# P,$  4# P,#!  ' 0(#!  %$082(0<3,10B05$5(S)A<19"@3-2
MD1<DH25B<@A#L<$TT5/P@I+A_]H " $!   _ /ZII2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI6??U.T=4HL,"*[,DH 5+=2I*6XJ2,IW$G*E$8(2D$X()P",Z"E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME4J;1/&IUW,WV88!;V"V=IKLI. -V[;OSD9_5\UYG=- 7AW7#KT>V15-N7UF
M\-7XOI$AAH);#D?;C<0>V4@ [=I&?%>C7S3\RYWVV3X^H;G;V(:@IR%&V=J3
MSG"\I)Y\<'QXQYK04I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5G=4ZLA:=EVF*^V](DW
M&8S$0VR 2WW%;0XO/A(/^3\9KGK_ %<QI"U1Y+C E2I3XC1HYD(8[CA258*U
MD)2,)/)__)%:""ZZ_"CNR&#'><;2I;)4%%M1&2G(X.#QD<5VI68U%K2V6'56
MG;#-7B9>EN(9.X (V)R-W_R)"1]DU=RKI BS&(DF;%:F2,]EAQY*7'<?[4DY
M/^*S/3W7]NUA:!**!;9?J'HQAR'D%PJ:/O*<'W ?8_>M'%O5KEK=3$N4)]32
M=[@;?0HH3]G!X'[U\-WZT.LLO-W6 MIY?:;6F0@I6O\ VI.>3^PJBUKK^T:9
MTA,U VZU<X\<)5VX;Z%*6DN);)'., K&:UR5!201]9K*,ZZMC_4)W2304N4U
M;U7!<E"T*:2E+G;4@D'(4#Y!%7#&HK+(COOQ[Q;G6(X!><1*0I+8/@J(.!G]
MZ[/7BVL.(;>N,-M:PE24K?2"0K."!GYP<?Q7VS=(#T9Z0S.BN1V24NNH>24M
MD>0HYP"/WK]5<H*0@JFQ@%HWIRZGW)^QSR/WJ,;_ &L:B38O6-&[*CF5Z<'*
M@V"!N/P.3X\GGZ-6=*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4KR_5_3F[7._BZV_4DT*=N4*2Y'<;9V,M,JS["6R<C*B 3C
M).<YK1:S9G7>RN0/Z6CW1M]QR.MN7)0A"4%)"7LX)P<^!A0R:M=&6E^Q:2L]
MJERE2Y$*(U'<>/\ >I*0"?XXJYI7B74;IOJ/5[]ZO+$QR'>8DUA=FC[V@RI#
M&"AQ2MI6DDN/G&0,D9' J:UI>^S>ID34-_TW$FQY4.&3NE(W6J2RHDE.<E0R
MI1&SS\UEM&]-=;V"3*,EB!(AW"/<651^\@JA*?.Y*T.;05;L)!'^?V%;:^BV
MJ&[0J"AN';G7]+*M;S[3J<+D^K[N%@#)"D#85<^:GQ^E&J9MKO%Q:;8M%W_%
MX=SM,1Q;:T,+:2$+4K;N2 H<X!.=B<URD=$KU;] ZUM<#MSI4EU,:SH<<0DH
MB^H0\K<K PI1'(_]@^Z]IT38[C9G]0NW.4)'XA<#+8 45%MLM-HV'@8P4*\9
MXQSG->*=2M/W5R[ZOU-(T^[9K0YIQ^U!3,EE"GI"I0*%>PYVKRG.X9()!K,6
M+3$K4$"[,62WSW+FBYPI]Q@*$=E#T9*'4)0V2I: H')VK)!P#BKS4O1Z^2&K
MJU;M.-NQ_P"G6;?!$J8TZZW(3(2K]9Q@AO<<X _M!^*^QTKUG$MVIF[;;V66
M';[#N,> F0T&Y3#07O1C)0GDH.%#!V>.!7QJCHY>I:;>W:+$YZ./8941MJ=,
M8==:?6ZXIM.[(']X((X3G&>,G9:+T5>[?UC@7V\6=I<4Z=8BF2%H<,:4A*$J
M&2=Q) 4G<GR%?S7ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4KX?9;D,N,OMH=9<24K0M(4E0/D$'R*BVJTVV
MSLJ9M-OB065JW*1&92TDG[(2!S4VE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E?FX9QGFOVE*4I2E*9&<?-*4I2E*4^:4
MI2E*4I2E*$X\U\N.(;05N*2E ^5' KZI2E,@FE*4I2E*4I2E*4^:4)QYI2E*
M4I2E*4I2E*4I2E*4I2E*4I7D$W3%BO?76_?C5KC/I198CX6XG!#G<=3W 1@A
M6$I&[R GS5)T^US=H%H?@H6)MM9C7B3;9<K*UNLQG&PQE6[W)PM0SG)VCGYJ
MYA]2-1W#5<>+ M<-5JC>A;N+CKS39"I+:5[TJ4\" .XG:G8LJ((R#6BZ@Z@N
M=HUKHR) ?"8<I4UV6P&2XM]+4<K"4XYSGZ^2GSC!A:(UK>;E>=/MW<VQZ'J&
MVN7*((3:TKB[>V2VXI2B%\.XW )Y2?:,UC.I%VO4R\:[@.3&50K=-L*(3)00
M&UK?0O<2#SG)S]X3C&.;2Y]0]:"-&MUHMULFZA,NX,+"$;67!&6A(P''D;<]
MP9.Y1 22$G/&[U7?KU"T)&NMH@MN7)Q#"W60GU):2K!<*$(4.Z4@DA*5#.."
M?G&6+J3J&^WJ,W:(ENF6MEN"9DI.UI*P\,N.)[CR5H"<@)26UE12H9%<].=2
M-676V+DHMELDORK2JY0H\4+"TE+X:*5;E86<'< "G)&/G(JYO4"2Y*NESB)M
M;MVBZ7GRFIJ(SK3K*FI 265M+4=I!VD@YPH'!(/-PC55]MMOU-.9@VJ9?(EF
MM]S<<;:6@RDJ#NY*@"2"E*%;<<9)K]NG5*[N"(K3=N8N;=UER$6M3(W%UEAD
M*<40IQL$ES<D85^E)("C@'3ZJUC<K+TFD:H5;6&KHS';<<AN/!Q"%E:4J3O0
M<$#)Y%9&Z=3-10[==HSB;*U?;?<'8NQ#3SR9"$1@_P#EH!"LX."HD #GG@']
ME=1KW!N$BXJ;BOP'D69M$4Y!95*)WJ"OGR?(^$_1S9W/76I9%U9M5@BVA,MZ
M]2[4EV872A(:8[Z5$)YR4A0(^\8\\3.GVM[_ *IOCRE6-"-.%R0PW,#B0IM;
M2RCW#>2K=M4>$C;_ .[S7/6/4&Z6JX:C5:84*1 TTVP[<6WG%)>>#H*CVL<)
MVIYRH'<<@8QFN732W,WC5^JM13T=R?$N[\.,]W'4K0T&T#MJ02$E.TI(&.#D
M^:RUXO\ J*[WJV.(<BKDP]:R;?$96XII!:;C+P%E*3D<$DG)YQ_$^/U=OMV8
MLPT_IY$N6N&B9/:W^Q*>\XTK:LJ2$@%I:MQ"O@8^:M^O,=4QO1L9,-V>'[R&
ME1&YBHO?26'3M*P1CE(/^/WKE"F732%AM<&S:?:M,JX2Y6^+<;BY,2QVVE+"
MDK!42%):SMR,$G^:J(76*\N:8<NK]LM8>>M#5UBL)?<&$F0&%A:MOV0H8^\<
MXS7.]:LNDOJ#IVUWM+#,JSWU2'EP5K[+Z%05NI.#SD!6"#G_ ,U/'4S4[UEM
M5TB6RV/M7N#*EV]E!=*VU,CN!IPC]14V%#(P H8_GO+ZL395O:E:>MS,QN?.
M:@V]Q 6Z'%>G[SRB!C.TY0 ".4J_VD5R/534JKK'@-Z1<$J-'8D7-@N J;2X
MXI)(5D!("4;\JSG.#M()JZU7-N'3NR/R[=NF-3;F]*E298>>:@MK2I0RE&Y8
M1E*4Y'"=Q.,<5=:VU8_9-&1+W:V8DQ4E^(TC>\4M%+SB$;@H))(]X.<>.?VK
M,6WJ#J&Y79&G6H%KCW]N3,COO.+6N*>PVTL% ]JB5=] Q_;A1Y\523.I\RZV
M5DWFT18MHN=K<(;DH>*)CH;>#C*'D\(.YL8"@"I))!S@&NN>N9TBTW)PP[>Y
M8F-+6V>FU/-E3>]Y>1R"#@# Q^P\<YUU^Z@WB'<[Y+AL0OP:Q7*-;I,5U"_4
MR.]VP7$*SA(274X&U6X \CBOWIYKZ]ZCU%;D7!BVM6NYQYSD=M@++K2HTA+1
MW*)P0H+\ #Q777VOKCIW6]IMT,VU^"\_$CR6-KBWT=]Q2-ZE@A+0&$D A17S
MXQFJ#_J]>+8'9M\MT%=O<@SY,=N(I?<"XLCM865<85E/CQ^^<"YZ6?B?_4WJ
M#^,R(STLMVU:O2I6EH9:<QA*B2#@#.#@XK,:FO.H;O>+40]&[L77"H$(K:4E
M#;:(Z^%[2-X^?(YR,CXE.]6=3.P[*BUV)F9<?0B?<$H!#2DAY32@A2E)[8]B
ME;E;@. 1\UZ!U+U!>K!IZ-.L$-E]:G@)#CK+CZ8[6Q1*^VT=R^0D>WP#GP*R
M1ZG7G\0==:B6F1:HDFVQI/8<<+C@F-ME+C:E # 4X.",D#G;59:>L-_FVMZ[
M/:?:CVJ8&Q;7WUAH!;DA#("SN)6!W HJ 2!MQ\@U?R;[<+7J$/WF!9'M01['
M<'URX\QQMGMLNLD((4#L!"TJ.<E.#@X-9>)K*X:LG:45=6&X\VWZK;B+4PVX
MRAQ*H3K@.QSW#]0'N\X!XSBM_P!6-5W?3$&(JPLV]Z4ZB0\4RMZBI++*G"E"
M$8))QC<2 G(SG(J9(U%<7;?:;E 5:Q&5&9EW"*^XI+Z&W!E);^,Y"@ H#<1C
M(K'.=2=2-Z4MUY]!:'OQYV,W:6&75%QDO%7#P40E6 /(4@%7''FC/47535TT
MXS>K-"L\6:4LR'Y06M!?[RVU-)6@J2THI2E20O()5MSQFK_I7K*[:GD7*/J!
MB'!GQ4-+,%#3K;S6[=G=ORE:#@;7$'!YX&.<1)OFI;GJV#([]O6[ U'<H4(/
M-+;2EIN*YD+ /O\ &0?OY&>)\+J_<ICND5LV^$6+JW",MM!6MQA4AU3><CVH
M3[00#DJR>.":WG3BX7JZ6&?(O4B*\^+E.884TT4A+;<AQM(4,\XV'D8XQG)R
M:\51JS5+SFE]3/R;>]>!8;O*.]A:&E(:6@A)0%#GVD \#P>?-;:W=2=3W75S
M;-ML<9=B8>BQIRW'6VG$%YI"]Z5+<22 7$@)"#N X5DX'SULB*G]0>G\5%I1
M>0ZBX*5!=E%AMS:VT05*P1QG(X\UPN6I;QHC3T&WZ>LUKMZV[;<KK*B29;DI
M,<L*0M3:5)/.[N\#( R/K!ZIZIWM%LN:GH-L,UN/:Y<4)4OM[)C@1L6?)4G.
M<@#/UQS1O:PG2^I.F'[Y'9$RQ2KU$E+@[BW(2W$0X%)222.% ;220<_>!<O]
M2M5Q;&S<E6^T2S<K.Y>H#$;N*+3;7;4XTZ<^Y6QSA0"1N&,'-?=[ZIWB3!C.
MZ3B1):;M<U0[0\ILJ2ZTVSN<60I: HEP*0 %#P?)&#\V_JCJFY7IB)&TRTCT
M/ITWAE3[:BA3A(44.]P)2$E)X(.2"GVD&O:*4I2E*4I2E*4I2E*4I2E*SEWT
M-IB\75RY76QP9<UU"4../-A6]*? 4#P<?O\ M]"N&J;+HZ>($'4L2T+$9IUV
M*Q)V)"&DI <*4G'M VY^!Q]"N,.P:'N-WM$N'"LS]Q@PVW8"FMA6U&/^FM"1
M_9YVG&!\5:2XVG[]>FVWQ"F76R.I>"0L*=B+6D[20#E.X#.#YQFOVR:4L5CG
MRIMHM<:)*DD]UQM."<G<0/H$\X&!FDS2EBFW1^XR[7%>FOI:0ZZM&2L-+"V\
MCP2E0!!\\#ZJ/<M#:8N<-42X6.!(C*E*FEMQH$%Y1RI?\GY^_FIM]TY:;[:4
M6RZ0FWH*"DH:!*-A3X*2D@IP.."..*JI^DM&V\P;M/M5JBBS-!+$IY*4)C-I
MSCW'@ $D@GP3GS756AM*OQ$M"RP"P8QBI[:,89*^YL!'@;_=Q\\U]1-$:9A-
M+#-HBI"XKL-Q2\J4MEQ6]Q*E*)*MRN2222:BZ+CZ*:4IK2+MH=6W'3%6(<A+
MJ@TV3A*L*)(!4?/RKGS4^YZ.T[<[%'LTVT1%VN,4EB.E&Q+1'@HVX*?GQ]G[
MJ3*TY9Y6G/P!^WQU6;M)9])MPWL3C P/K JNN6@=+7-3JI]DB/J=D>K65@G<
M[L""H\_*0 1X..17)WISI)R,Y'59(W9<BMPU)25)_*;4%(3P>"" <^>/-=+9
MH+3%J>B/6^TM1W(DA<IE25K]KJVPVI?)Y)2 .<UTLVF=,)O+NI+1"AJG2MQ,
MMA>Y*B>%* !VA1Q@J R><FNM[T=8;Y<43KI;TOR4I0@GN+2EQ*5%24K2"$K
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M6ZW:C?B7:&J.@N,QMQ;0Z,<H&Y*3M&!R<?.?;-%RIKVG;8F^/MKO2XJ'Y+8
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ME*4I2E*4I2E*4I2E*566^]VZY7:YVV(_W)UL4A$ILMJ3VRM.]/)&#E//!-6
M:;!3A"1M&U.!X'T/^!4*=(B6OTSBXZ]SKB(J"RP5E.XX&=H]J1]G %2UQF%J
M*ELMJ42DDE())'(/^/BN;<"&U)]0W$CHD>X=U+8"O<05<^>2 3]XK\=MT%Z
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M-#O4.-<8:%J[DR.\8^4*"7,*2!W-I."$$D'S6V]2E^*\J$XVZZA.,9R K:"
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M%91L3S_J['3D!(*4[?&*MX_3R(Q?G+HBY3 M=X-Y+>$;>X6"SL_3G;@G]_\
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MVT(#89><6WL6=VW> 0 2 H GSQQ5CHS2;VG(ZV7[]<KHVEE,>.F24)2PTG.
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MU+#<=Q:5[$Y\;2D!/T/.:DL]-K#&U.F^,JGMK"D/*B)EK$5;R$A*7E-9P5@
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MZ;<B'(5;Y [SDAL+<:0UORM20>/<D<^XC::IX74V4Y N&I%V6WM7MK2HN"G
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M)B+>9LY4AYIEIS9*<97RM8*$X96K*0HC<GC'F_ZX6YR[:YZ<1VK7;+E*<5.
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MWL4O!X4% \CYR?DYK*:3Z6:>M]TD0-2)T])E3&$NHM,*(6&2EI>>\4*6M2E
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MSIY6N)TS7%T@,ZAE-MR6IS'8[J4EM28J5M%IK:=HSDI<*B5G<=H%;=4PO?\
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MG&^XA3BRVI 7@$$+\IX/WQ7G$*%?H^C##M-KU#&[>AC'].J.^WB=W<*"0?\
M[A]Q '.W&.,5(M.GKK;M5&6W"U($1[Q:E,%;TMU"6GHZ?5JPI1"ANW!:CG;X
M)%?6A?Q72VIKKJ'63FID2(+4A=T4+?F(\V7/8H.A9[@2,$;4^T!0X -:_KBT
M_+<L#L&/<9RFPZXW"98?4Q)4>V$A3C)"FG!G*%GVCWYQ66=BZD6G5"6(&I4Z
MW!F!$QIQ:(BHZE%300I1V%6P!*-HRE1YQBJ2_/HM4F$]:7-26_0\N[0&W&5&
M8TZM?;D&0E"2.Z4%(1N X*N1XX_)MLU8];[.E<K5$2PE<E5K,2(Y)DMGU)+
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MD$IY*\ C<>1S4J';[Q;-23Y\<WR.N9?[XV\EKO=HQ_3J6A81C:"5I1A8&20
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M5("0V2%Y"@",%*LY'Q5(.INCC:&;F;XPB$Z\J.E:T+2=Z<;LI*=P "@2H@
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MY8MQDVE^SR0_%+^6G%)5E&%IVJRG&3G@^*KVNE$D29#CUY96EV=:YFT12/\
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M!1X(XKU746H4Z6=L$>4R[(B3I(@KF+<2"TX4GME8QSO4-N1C!->=2NL%OO\
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M3(9<AR%8*=ZC[2 -WA7D 8(KC;^H]SMFGK#:-+Z;:_$Y2)[Z8P4X^C:S(6C
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MH?I P4XY!R:Y1-?:ZB=.[!KN[S;4Y977X_KXT:$KN(CJ6I"W-V[]62G@#_\
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MM&U31;4ONI*5*!(V@%!(4#D$9&#^L]1(MZG:?>:9OUJ@R;B8C+KK#/:G+V/
MH/N4H)!;SD8.<?OA<.J[*-.R[Q L%U?@I#2HDE:4)9EA<A+'M4%':=RL[5[2
M1SC%2X&MX]OGW5FX.762!?&;;^:RTA,1;S;90C*5#<@%0&XY.58Y'-1M2]9-
M.:>:CKG)DCNOR&MI+:5!METM+= 4H;D[@=H3E2@#A/!K6:GU-$T_:HTQ;+\M
MR8ZB/$C1P.Y(=6"4I3N( X!.20  :S<OJG;XT!B2JSWDK3&,V>P8X2Y;F I2
M2MY*B/E"\!.XD))'&,S8O4BSRW5(C,S'"+BU;DD(3A1<:[R7A[O]+MY5N/.
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M$$A.>-RDYXS6=L74ANS1)EMO:+[=)EMDB&Y-7$9;+\AQ:>U'2E"\*<*7$C(
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MRV3<94Z'+$A2 N*Y%2"I/M40KDCD'QXS7IE*4I2E*4I2E*4I2E*4I2E8V^Z
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M:?;WX,UI+\1]LLNMKY"T$8(/\BLC%Z8Z;8#:G&YTIYIZ.\V_*FNNN(["BII
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M'Z8!I& %!);4D#;@@CC!\BK%C2]ACW5BYQ[-;FK@PT&&I"(Z$K;; P$I('
MX ^!QXKO=+%:+L\V]=+5 FNMMK:0N3'0XI*%C:M(*@<!0)!'R.#5/J&S:-MM
MI?E7RSV1NWI+*7%/PFRC*,-M C;_ &[MJ?H' Q71RV:5L-PLVRU6R%,4I4.W
MK9A)"F\I6M2$*2GV)(WGX!)/R><WI")IBX,2DS+HUJE6HWUNJ7+BH4V]Z8);
MP4! 0-FU/) R>16PMVE=/6Q]MZVV*U1'F]W;<CPVVU(W !6"!QD 9^\"O@Z0
MTT6H+1T]9RW 4I<1'HF\1U%6XEL;?82KDXQSS7[_ $EISUKTS\ M'K'BLNO^
MC;[CF\$+W*QD[@2#GR#S4:);]+7.:EABU6UZ1I]Q,=K="2/1*VI4E+1*<)PD
MI/LX'%?5C@Z7N#Z[C9[?:W'XTV1F0U%0%HDD['E;L9WG;A2O) ')%=D:0TTW
M&FQT:>LZ8\XA4IL0FPF00=P+@VX40>><\U\R-(6-Z\0KHBW1F)\20J4EYAI*
M%K66RV=Z@,J&T_?]J?JKZE*4I2E*4I2E*4I2E*4I2OYVU>NXP.J^LW;3<)\*
M^ONVA=KAH7M;N P$.Y1C\Q"05;B.$\D^*T_3^Z7B1U%G,W?4$LOIE36U6==N
M>&UH.'LK+A5VPC8E)2H)&[?@E1K7=5KE/MECM;MKD.,/N7B"RHH3DK;6^@+3
MX/!!.?VKS:5>-1M:W9E6B\W.<I=[N5N$%T@QDI0P7$(*0D'(7M ).0!P>3G+
M-W>;>-$7"1>-32Y+3LNUJ?9]/(:,22);?=&]SA) W'8C"1L20!GG2:ADW"UW
MWJM<--3Y(FQW+:TL)W.!II2&PZ[M')(2%\C) "JB0[_)9L=H1J#5E^58)/JO
M2W2UQY*7%2 IM3+)4M*G'!M[F"H84002<5;6N[R8FI;B6KC<VI$O5L%+S$@
M$QW8:-H4G;@9((X__I@?'/:9.UW;/ZGMMO5<I;FGX\N3&F/H"_7=Y*%1TCCW
MJ;!?R /*$?>*T/0:X29]GN:G[\J\M"0DMJ+4@!@E W-]Q_W+.021R$YP., 0
MNJU^DPM6*@S;W*L5L;L[DV#(CJV>HG)7@-JX._"=I#?]VXY!P,5.C9FL=07:
M'=+M=+A'<8N<:.Y;VTA#"$&"EV0%C;R-ZL J)P1@'/)KXUPU-:>G&DI%FN#S
MC%RCR;2EEE"<,RG5+$5[D;AM5A*N<#SCCGWV"PJ-"CL././K:;2A3KGZG"!C
M<?W/FOY_B7^7 DSHMQU%.@6M[5$]FZ2BXA*X#0[AC)"E#+:',)]QSX & :]3
MZ17&==-%,R+C(=E@29#4:6Z,+DQTNJ2TX>!G<@).<<^?FO(]</JD:IOT-VYR
MP\WK"T*2P7 KL-%MK#B$%)QR3SR#@<<<Q=0:MU2QIZUPV-3_ (>VB7<6/Q6:
ME9+CK,DH9;6MM"LGMG<$E.%D?MBOZ)LS\EZP07Y&'):XS:W/86]RRD$^T\IY
M^#XK^=K%K'54Z!?I;VJ&&KDJ*#^&(2XIZ)-3*2E#10I 2VE16&B-Q)2=W.":
M[G4MPFWC0L]R^7$37+C<A+@J<;0VU,0W[(@.TY05$(3DDJ"L@@GCC9M::HFV
M1R7_ %<TY(E/VQ#D>*G>_!<<?"'TK"V@EKRH!!W'VY\>;O35^NDS6VAH]XOL
ME26I5YB=Q1;29*FG$I;0YM&TDHYXQG@BO3>K=VN5DT#<IUF*T26^V%/H0%F.
MT7$AQT#G.U!4KP<8SC KR:Y7(S[];[9_5;TVR1-31$0;H7V5N%2XCI6WO*"A
M>U11@X/^ICR!7] )C-1;>8\-M$=E#92VAI(2$#'&!X%?R? N,ERU62XV[4\P
M72'H^?,,E"VEN!]MQ#G942DX&4X(_5CC/)K?V?6-]N74MM,C4$>"E,J.VU:E
M)4LS8CC*5;T(2D@DJ4I1<"O;MP<)\^B=:;Q<+!TRO=SLTE46?'0V6WDI2HHR
MZA).% CP3\5YOJ*]7^PZ\A6-6L%1FHRXST9RX>]=S0XXONC8VSA9Y"  4[0D
M'YR*&#K.7-"H]XU7*[3=W@R'+A%EL+CAE:W@"E7;';&4HRVL$C8/A1%6UOU!
MJ-4NS723J.:^)>LE6=412&>TF.A;P&W#>X$@ $YY'_B@U-J^7/T3?)$O5UV9
MO^](N%E;0$(M^)R$X"P@;0$';R3OSDY\5H7M9W5]=[;<OBF=.KU-Z*1=([C8
M5$B%A)04+ PD*6 "O'&3X-4L_5&JKG'FQHNIK@W A6ZZ2H<MC8E<M$9U(8<<
M7L)(5RDE.-^WSR:]_P!(:D@7^$E$6<S)G1V652T(X4VIQL+3D?&0<C_/U6+Z
MUW<6VZZ0CS+[-LMGFR)+4U^(]VE%(844^[!(]V/'//W@CSRQZ@U==8%S>-SN
MCEYM>FFIT6*A>P.NJ[X"W&]OO44%I>T_W;<_%<KC<7;C.M5NL.I;C=+(Y=;2
M]^(2'^X]'E.+=2ZVA:QY[:0K;C"3\#.*0=17^X:>-OGW29,0_IV_1U(=P5/.
M,NJ2V3P,KV<9_P#^U(1J*[P-.27M/:DGW*SQC: 9)4A8:D*>"7XZ5A(RG9L)
M '&<'&2*FVZ[7"W:MN[:;Y.1.D:[9CNP7'$D>D4V-I"2,A*AP#G!#8QX.8$W
M5^HC%ER8VH):M2!N[M72T)4A2;>AI#I9=0C;E."AH!7.[?YYKT7I!<KF[=[O
M;KG<Y=R[=OMT[N2E)*D./MK*T@)2G"<H! ^,UWZLWAR!>=-PIUY?L&GIJGQ+
MN3#R&E(=0@*:;*U)(2%87_. ,_>;Z4W2]:DU?&-YO5QQ#LT:4(S:DMM2%*<>
M0'%IVY.]"6G/(P5?6 -EU=O,G3]LL-S9ENQ(;-YBB>Z@92(RE%*]_P#[>1_G
M%>0,ZNOM_,1H:CNL>,\_?G4.QREI;B&.VXP"2@X2$D^,<'%7&B=<7B5JW39U
M#>/2KEP8 8ANL/8FAYC\Q: CVE8=SE2N$@? S61A7R\3.F]U5=[]<IKEWTG)
MENL2W4J"7FY':3VP "G*<Y']Q^\5HK]=W[7!#;6I+O"2-/1YFGW$+&;G*PHE
M"\)PZK_11LQ^DY 'FOMZ^7OT>I;[.O%Z::B:@1;+A'COY1;X)#2ENH0$YW D
MIW<D)*B.1FH5\U#<V9%IB0M87=BPR6'%VNZRX<EQV5(]1^@);PIW#82$]P$*
M"E'!XQ0ZTU#=[U=]76I%PN3T!<=]Y4:2XK<PN/-:45!&P!H!L**4@GVE*E')
MXW-AU!=T7VV&%?IT[2\C4[<:W2GU;S+95%=4ZDJ(!4A+H 2?L'S@8JM+7B:S
M%T=:;5<I"&IB]1M/-QSY<0I:VS_(W9&..:B:;>OT70VD7-.7:[2V[W!-E6V7
MSM@3B4GNISC&U"7LCX*?NOZ:91VV4-[E*VI"<J.2<#R3]U_.UWN.OK7/DQ8?
MXS/1:9<FUK=4X?\ N1+&8CW Y+14@*/QN3CYQ\7Q^='B:IMU\U%=C$L>H+0!
M)4^4+2RHM!:BK'(]Q7_(!KZCW*^6R]N/Z?G2E.3KW?H[<-:AV77$M+<9PD@>
MXN <G/GZJJ1JF]IB6ZXVC4]TE6Z-'M\J_+DN*(B2?4-H=:)VC:"E;A4CX",G
MXJ_C7IRXZSL5PN=UNJ+<UJF<U%*NXVE;2XP4RG;M!4DJW ?&"1XK^@Z4I2E*
M4I2E*4I2E*4I2E*KX\\O7J9#5 E-)C(0I,MQ*0T]OSE*#G)(VC.0/(\U/R/L
M4R/L5G;!JMB_(BO6V!-<BO29,5;ZDI2EE3*E))5[LX4I! QGSSBI:M01$ZM1
MIXMO^L7!5< YL':[:7$H(W9_5E0XQXJ9*N,2.8Z%O-EZ2%>G:"T[GR$E1",G
MG@$U]P)7JH,>0XP[&4ZVE99?P%MDC.U0!(R/!P3S\U(R/L5QF2XT)M+DM]IA
M"W$M)4XH)"EJ4$I2,_))  ^2:K=,Z@BZACS7HC;S:8DQZ"L/)VDK:44J(&?&
M1Q5R,'Q2J6XZ=A7'4$"[S'93CD('L1^^H,)7R X6P<%8"E $^ ?XJZR/L57R
M9;2+I'@*A/N)EMN.*?2T%,IV;1M<5\$A7''.T_5?5XN'X9;UR41)4S8I">S$
M0%N'<H)R!D<#.3^P-3 E&XJ"4[CC)QR<>*+2AP +2E0!! (SR.0:^O%?(2A)
M40$@J.58'D_O7XM#:RDK2E12<IR,X/V*AMR&6;NJ$U#>0MQHR5R$LX:)R$X*
M_&_]O.!7Z]-;3>(L-422M;C2W4R4LY:;VX!2I?\ :H[N!\X/U4TX((."*^&6
M6664M,MMMM)_2A*0 /X%=*H=77^WZ:M29DV.[(+KJ8K$>.V%N/N+. VD' R?
MW('%2K5>8<^PLWA:'8,531<4)S?86R!YWA7Z<8/[5SM6H;?=KS>K3&+AEVEQ
MMJ4A:,#\Q 6D@_((/_BI-GGINEO:FF'*AE94 U,:[;J<**<E/QG&1^Q%3=B,
M$;4X^>*K+%>K7?!._"7T/^@EN0Y&U)';?1^M/(\^[R/NK/:@%7M3D^>/-?N$
M^..?C[ID8^,5'9AQ&9DB6RPTB5("0\ZE("G D$)R?G&3C^:@W>P0+M=[/<I8
M695I=6]&*5D *6@H.1\\$U-5<(B+DU;U/MB:ZTM]#.?<I"2D*4!] K2/\BI1
MP/.*_/;XXJG=O\-C5<73Q:>]9)B.S4+"1V]J%H2H$YSNRL?'^:N,)!SP":@W
M2;^'AAQN#)EJ??0PKTR$J+84<;U9(]@^3R?V-0+EJFVP;A;(B5*E/3YJK>GT
MQ2L-.I;4X0YS[<)2>.3XXJ[<0VXC:ZE"TGX4,BOK*1]5RC2(\Z,'8SK,B.O(
M"VU!:58.#R./((_Q46_7:)8K)/NUP44Q(3"WW2D;B$I&3@?)XK)1>I$>5.CQ
M&M-ZB,Q>U:VO3-E3+2E!*7E8<Y;))P4[OT*XX-;O>C:5;D[1G)SP*J+K>V(A
M?:B1G+C.C%DN1(Q27$(=64I6=Q  X4?/A)JW&W_V\_\ FOWVDCP2*HM6ZFMN
MF;;+E3SW'6(CTSTK>TNNM- %PI!(S@$9_D596J:Q<+7$FL#8S(:0\A*L I"D
MA0SCYP:EX2<' XY!JG>T] >U+'OCRI#DQAHM,H4^OLMYSE:6\[0L@D;L9P<5
MSOFIHEGO-AMC[;SC]X?<CLJ; *4%#962K)SC"<<9KHB^%&EW;S.MTN(IIEQY
M<-P)+P" 24@ D$D)XY^14.T:LAW&V*N,J*_;K:I$=UJ3,V)0\EY*2@I(4?!4
M$G..?&:TGM_:A2G!!2G!\\>:':2,XR/%?M*4I2E*4I2E*4I2E*4I2E>']3=+
MWBZR^HY@6F4^F=#M3<=2/:7U-NE3@0=P_2DC_/\ Y@M:%O%FAW>?IVSI1<K+
MJ-R;9H[OZ'8KK2&W$).2=IW*5]Y0*KM5:*N=IO\ IV+;-/S'V[2BV=NY16 Z
M7-L@JD'<5#M?J)*4)RK/)VCB\TM8;[%F:0)MLUE46[7I3CBV\);2[W>TM7TE
M14G!K*0M.W"*F48&B;JS<4Z;7 N1<95MFRE26BMSN!:>]D!Q9PH%0&WZ%?EC
MTQ?(L_3SLVP7542+=+P& (026&7V$=@A"20TC>5$ <)(-?$[1=XGZ/MS$VQ7
M)Z7#T84QTAIQ*FYB7@4I(!QW .0,9\_MB=<7.QKAI^\VJ^K81>H$M5U$3N-M
MA,=#784X'>,.J&1@G.[()KU7K1:G;GI^SK;A29S4&\PYC\>,T7%K:2YA?L'*
ML!1.!]5YHK3.H&M2.W*PVVXQ;M.N%];5*+:VTAM32S&*B24I27-A"L<D9K6_
M_3_9G+1'NVZW:A@=Y+!>;NC;;3??2DI<+24 ;LX25.']?'R#7J=VCF7:Y<=)
M<2765H!;4$J&4D<$\ _N:_GR1I)R1/C1&[+JG\%5-NZUQI*.TTVOL)[92AK_
M .V5@["3[CN..>8L.RWJUZ0EAJP7I^9<=/6TSDK0^>])]0H.ES!"U*#:AN0D
MY*01P*DZ9MM]BNZ?A>BO[4>(N_-N Q7VD=I:=T?CD#.?: 3@\#D5!MMBO,'3
MBA&M6H$//V"T.O)"'RM<Q$P]S.>=P3C(^$_M5\U9KC%ZB2[J]#O*7AJE24RP
M'U-I@JAJ/_Q#8<*>?&0,G KGT78D1-86)=]8ND*8NRN16DR674IF/AU3BWBH
MJ*2KMJ3]^58/ S=]:_3JUSIIBY-W25!D6ZX)$6 'UJ6\.SL.QKG@J\G@''C%
M9:%I/5R[1JR;/BW1W4L>W6Y$5\ON@N9CI3*2U[@E2\!2<CG=SYJ6FR7%]%UU
M!HZ)=&;):9,2Y6VWRDOMN2'6TJ$EI*5G>$J3M'((*@,?-6-PLMY@2";B+YA[
M3-P=E/V\./AF6^\EQ26P2 5)"EA(X)"1^V*;2L#5;Z8BK!#G0QZ6\,,OD2&&
M'G"AGL/*:=)+65;@$GY0HCBH,BVW>5!BHTU U,RUZ. Q>4*3*;6N8)39<(42
M"I00'=ZTY&%).?..VJK;<K=:G(<:#J%UB)=IR8=O4Q*<:EME36P!Y!*T+P5E
MMPY3PO)KV7J@W>)/3V>FQM/^O*6U+:8<*7BT%I+J$*3SO* L#'.?'->0W?32
M[K(BLVRW79>CEZFMSL:.IB2A3:>TX)+B0<+;;RI/)P-P5BO5NM5MDW+I3J&#
M;HS\J0Y& 0RRDK6O"DD@ <JX!X^:\Q<T[*1U&FWF%9KTSF]V41G4,O( C>G2
ME_</&T!)2HG.. :J[Q'O!T?I9;T/4<Z8Q)G%,*1'DE#Y,H]O+B2'&W0V04+4
M"G:%#[S_ $!K2YRK-I2Z3[=#?G3F6%&/'9:4XIQP\(&U()(W$9^ADUXS9;#?
MNGEWN=N5)D.Q[Q8EJ5<;=;5I;C3&4%*'%$K*=ZDY))*<J"?&:S-I5<+X_$@W
M:+JJ/-EFSID6UUF4WEEE0;DO;@K)0=XR>#X-7,[2NH8.N[K^$(U Q<6 ZU97
M([.^$(WIMC2''UJ]J4J3R@C.[!Y)R*2SZ5NSEFM"$V?5[*)-^MHNC$MGM(*$
M(=$A:$MG=L5N!4XK&XX_Q86+1FI+8+8-.0+E:[E-L]UC2'U]S8A8=5Z5"BLG
M9A(&WZSGGFOFP:0EO-V=EJP:H8LSUZB^NBW!AME(2EEY"U!ID#V$EO<XK]1P
M<?)N>CUEOL#4ND)-[LEP0W'M,^ '7F2/3*]65-A1."D=H82?D' ^<7O_ -2%
MLN-WL\");K!,N9[<E:)$5LO*CO!O\OV;A@DY_,()3C &Y0K/W33ETF:J@WV)
M9KNB<C4EJ=4^XE>Y$0Q4I>XR<)W[@O'^>*F=+;/-A=0;/)EZ>NL2X(MLN->;
M@^TKMR99=:5W X>%)5L401\$#XXW'5JS7&3^ 7O3\$S;O:IA2AH.%&]I]!:6
M"1_:"I"C^R#7F,31FJHT6TH?;FONV>^6^U-*:"D!V"P\IQ4DCZ5O2#DJQVS@
M\UVC:/D2[XF%.L5P4TYK.9-F.EA8;<C+;=#:M_ 4C"D@G/\ =CGD5!%DNK=F
MMS&JK+?I,9-E?C6MJ,RZZY!FA]P))VD[5%!:V+40 $XS4JUP-5Q[I"M5SM][
M?EHU0W<79*&W%,",J'L)[OZ<;R<I!XY_SZ'_ /3U$E6[I3:[?<+=,M\V*IYI
M]N4T6U*7W%$J /D'/GYP:\98L=]>7K9I6E[ZTBYV24SVE1G"ER6F05(4I:E$
MNJPI)"_G) &U-;2Y:-N(O-Q&D[8[;Y2='LQH$A;"VPW(WN!2$N'A"]BP,9SD
M@_!-4EOTOZ.#!?5I35=QTPJ:LW.TS(S+;A<[ 0AUN,T$A201RKR3[N2,U-O6
MEI3*;ZF'I:Z,/R+7:!$(WR"V&I(WM*<2<E82$$@'@(/.,$RTZ=N,7J7*OLFU
MW +1J<J:F[%;6H2H2TK5DG:&]Q1D_8Q4+H8VU"UK:57&UW:)=I%LD,^J<AA+
M5Q67BZI];R5GN*V;!D@C*CR<IJXZZ6&Y3]6+EP+-,G(=TQ/@H=C,%S:\H92D
MD>,C<!_\JRDC2=\CPKNQ"LMW;LP<LDF9$CL JE)3'<$CMMN H<4%]DK01SLP
M:]NZ36Q=IT);X;C=V:0G>6FKJXA4AMLJ.Q*@@!*,)QA _2,#XKSE>B[];X6J
MX@MOJK7:(\Y-B9:=6A<GU9#BAE)W9; *!@@G<1]&J#0NFKS!UAIU";)=(MLA
MZ@ERD]R$6&FF7(:4I(2%*"1O2H>?)YY)KM-L%P?TM8T7/2UXN5L_"KBPU!5&
MWN19JWB6W5MJ.1[,A*_(S\9J+-TM='=.:F:?T]=7FQ_3ZDQ_3$K=0RTV'DMC
MPHI 6"!GFMEHW3+4;JG-M<1E*+%:G?QZ.V"?R7Y+7:#11X&W8\O]MX\?.FZR
M6U^X6ZQJ5;9-VM$>XI=N<",DK6^QVU@#9_> LH.W]O!K%].-%R/ZYAR+M876
M[)$CRI-K3,;&86Z8%L-C_8L)"CM^$E(S\5[K2E*4I2E*4I2E*4I2E*4I4.1=
M+?&GL09$Z*U-?_T8ZW4I<<\_I23D^#X^C5?=]56BV6BZW!<UA]NVQUR9#;#B
M5K2E()/&?/! S\U6Z6UHW<[?'DWMF)9S,6GT(7/;<$M"DA22V1@D\X*<<$'S
MYJ]<OEI;E.QG+G"3(:2I;C2GTA2$IQN)&<@#(R?C(K\-^M CQ9!NL ,2E;8[
MGJ$;7C](.<*/["JK6&L[?IVQWN<TINX2[2QZB1!CO)[R4<<J'E(QSDCP*DOZ
M@[T&!+LC4>YM/2FV'RW+0GLI5^I63PI2<CV<$YXK$Z91IV^ZG>OD324!JXLW
MJ5 D2G74)6EQD*_.2G&%+)'QR 2<\5O[-J.SWJ(B3:[C&D,K"U)*5X)"%;5'
M!YP#\U9K<0AHN+6E+:1N*B< #[S66U3K6%:+7!D6[LW21<):84-IJ0E*'72"
M<%SD) "3D\_Q6@M,B3+MS#\Z$N!)6G+D9;B7"V?K<DD'_%=E26$J*5/-A06&
MR"H<*(R$_P D$<?O6<UUK.!I+3ETNKH]:JW!LOQ6'$]Q(6M*02">/U9Y\XK2
MM.MO(W,N(<3DC*2",@X(KY$ADNEH/-]T DHW#.!YX_R*Y/R8+L5P/OQEQU_E
M+WK24G(_2?CD'Q6=TQHG2.E;C*F6"V0H4Q2=CJT*)*4J((2,D[0<#@8!P*F(
MBV^X7*%?;I 5"N4!;\6*M]](.Q1VDC8LI(4$ @'D?0-3X=S*VISD^/Z!J*^I
ML+>=04N( !#F0?:#GPK!X\>*G=YOMI<[B-BL85N&#GQS42]3)$"W.2(4!RX/
MI4@)CMN(0I0*@"<J(' )/GXJ85I"DI*DA2O )Y-?+[[4= 6^ZAI!4$@K4 "2
M< <_))Q1Q]EMQMMQQ"7'"0A*E %1 R<#YXK["DG&% Y&1@^:^7'6VU(2XXA*
MEG"0I0!4?H?=9Z[:QMUOF1(Z-\I3MR3:GE,D8C/*;[@WY(XVX\9_4*OG)4=I
M+1<?:0'2$ME2P-Y/@#[-=-Z=^S<G?C.W/./NH<":[)F3V'83T9,9P(;=<4@I
M?!2%;D@$D $D<@>*^-01(5QLLV%<8R)L60TIM<8D#O C&T9(Y/ '(YQR*H=#
MV:Q6*!%E1+:BT3KDTC<S(D]YX8&>WO4I1(3D\).,DUVO6KT0=0N6.%;WY]R3
M;7+BAMMUM 6$.(1V\J(PHE8//&*T*YL=IV.S(>:9D/Y[;2U@*60,D 9YQ^U5
M=IU"S>)4-=J[$JT2HSCZ)J'P,J2L)VALC<1R?=X&,?(JQ9N<%]MYQF;&<0RK
M8XI#J2$*^CSP?VKM$DL3(Z'XCS;["QE+C:@I*A^Q'!KXG3XEO;2Y/E,1FU*"
M$J><" 5'X!/S7Y^(0_6)B>KC^J5X9[@WGC/Z?/CG^*_7IT1DN!Z4PV6RE*]R
MP-I5^D'ZS\?=0Y-V[5VCQ&F4NL*2X9$@/H C%*4J 4DG<<A7P..,^153;]<V
MFXZD8M4-P.LR+<FXL30M/9=07"WM2<Y*LC_S6C5+C)E",J0R)*D[PT5C>4_>
M/.*Y7&Z0K; DS9LEMJ+'95)=63G:VD9*L#DC'U7=B2S(BMR674+CN(#B' ?:
M4D9!S]8K,ZIUDBTR+7$M<%5YGW(/+CLQWT("D-)!6=ZCC.5) 'R3^QJMTGU&
M9U 7IJ[:NWZ<]Z6;I*E-)2IQ#O:4A:<Y02K]/)R/JMF[<H34QF([,CHE/)*V
MV5. +6D>2$^2!]U2V/5<>^W!A5J#,BROP/6-7!+Z1N.\IV=H^X# SN/&<CR*
MMEW>VH8E/+N$1+,4XD++R0EDX!PLY]O!'G[KLAV-/AJ4RMF5&<21E)"T+!'C
MZ(Q6"T'!TA99$!^/9[/8K_=&G2F/&=0Z=B%84E*TC;C].0,#/'.*W%JNMON[
M"GK5.BS64*V*7&=2XD*^B4D\\CBOQN\6QQ,A3=PAJ3'5L>(>2>VK.,*YX.>,
M&N;E^M#<'UKEU@(A[E([ZI" C<G.X;LXR,'/U@UG+QKGTE_FVJWP&YKK5F%X
M8=,M#33R2X4;"M7"1P#NY&#_ !G3+N]O9F1H4F=$:GR$[FXRGDAQ8_\ :G.2
M.#X^J@S=7Z=A05S9%ZMZ8J'TQ5.I?2H)=4<!!P3@_M\#)/ -+??P8UTD7I,2
MV1X<M<=+JIJ%I4@8VK41@()S^D\CC[KYMB=-6!EQ=O<MD%JX.F6I:7$)#ZW#
M^O.?=D_/_%3=17RWZ=M+MRO$E,:&VI"5.*^"I02D?\D5V3=("IR829L4S%)W
MA@.IWE.,YVYSC'-3*4I2E*4I2E*4I2E*4I2E*\<U!HBZR^J,ZX2K.[=K5,?A
MR(\E-T$9,,L@ A2 -RL$;AMSG.#CG&>M?32^P;'<618VTR)%AN\%7;>9!<=?
MD[V$DY&?:/). ..*L+SHB].V^8@:91/_ !33C%M:;4ZPV;7(0%@_W8V%3FXE
M&XY3_%?<+IK=X\+4SJH49ZZ*O3$YAUWM[KE';#*E-*7R4!:FU'!^<9&":K=4
M:!O-XD0)W]&J:M[S$EA^QQ+JTP6G''TN%Y;H&"%A/N2C)3M&,^*@:CZ;ZNN.
MI[^N)96HT:9$N,=+J'V RZ70DM''^H5$H 4I>?=@C:!5PSH2]/7#\8;T\+<R
MY=[0Z+4AQG+:(Q(<>.U6SD*\ DX3_BIE@T=J!O4-MF2[2MMEC5MSN#FYULXC
M/-K#;@ 5X)4 1Y_;%4!T@ZU:M,VA$6/8M3+DR[8\TGLER1 ?+A<=2$$JPE*?
M:3C!!&.:]AZDV25=>G]PM5F:2M[8WLCD@!Y"%I4IK)X&]*2C)_W5Y>[H^YS[
M[#N+6CO16B3J"')7:W1'/8:;86VZ\I(44)W**.$DDAO)\XKWEY2DLN*0A2U!
M)(2G&2<>!D@9_DUX=>],ZD&J[PV=..W"/.OUNO")C#S0;:;9+86GWK2K?A"O
M \'_ !5->=!:DG:)O]C1I2,Y?RA;3E\4\VERY!4M#HP<Y.4)R=Y&"D 9KUKI
MQ9%V*3JIA%K3;(#UV+T-IL(2VIKL,IW(2DX *D*.,#S7D&F;"_?-4WPVBPJ;
MD0]57&1(NQ#:$N,=M:#&"MV\E2EI.TC:!SFK=C1K]ELNBE3]$"ZP8UF7%GVZ
M,S'6MN:M+([ZD*4$J4>VH%>21GXJ;9^FE]CR[ U-4U(@SX41.HBZO>2]#*5L
M[>?=N.$$X\()^:I+]I"]L:,0Q_3TR5=!=KE(BL!B/)C[77"4)>0M6 A:3^M)
M"D\G^91TAJ"([*G7*PF;:VM4/7*5:F0ASU;"HR&T+;03A00O)V*P3C(Y JF?
MZ87E]RX*F6!4F$JS7,VR*YVEF$ZZ_NC,CW8"T@DY'"<D \5Z?U)LEYNO0V79
MX,9V7>W($=L-;PE:G 4;CDG&1@GS\5D;MHF\O=4C?&;*X G4<!],T*1O$1,0
MH=P=V0C?C<,<\<'&*TW7NS7>_6.#!L]E_% I3Y64I:4ME986EL@.J"1[E<JP
M2,<<X-8B-HN_2;TQ>YFG9)GM7"QNMR''&RZAIMEL23DKXY3A0^?WYK3](K"A
MK5UW5'<9?L=@4["LZVCN1MDJ3(< /CV MH&/C-<^J6F[G<-2WAXV-R[MS[0F
M':)+023;)84OWDJ4"@;E(7W$C/LQ\#-''T->/6.VV\65<\.:IC7"9-+3/9F1
M_3;5*4"=QPL+)3C@K^<FL[&Z?ZB=LM@;ONG[M.BLPY,%N'&DL(<BN^L6MM14
ML'8V6RTG>V=P"/&.#Z]TJTW^%7/5URN%I$6YR;N^$2G %..QB&RG"_)1G/G'
M(\5@5PIL_6VI[Q9(\BX,V[5-OFK3#*"IYI,(H6E!*DI..Z,C/BOS2FB+E+UF
M+EJ/2K@CH8N<EA$GLN=E]<WNL@$*(W;2<'Q_CFOF%I&]-Q.FI:L<M5T@1(T>
M0),=ER/'2ET*6K>5!;3J<;@0"%<)QY%44S0NI)%AN$=C24J/=$Z>>MDN4%,8
MGRO4,K[H4%[E[DI4<J&><5Z(C3=T>UD@7G2K%VCK>BRX=RD/('X<E#2$N-$<
MJSN2I02G*5%62?)K,:=Z>:J_#;;$$!%FDM:4F694D+;PB07D[5'8<X4,JW $
M\DGFN5PZ?W>ZN-R8.C&;1"2BVQ9=N)82F86I06ZYM2HI*0D8RH[B":W/382M
M)7:589]HD1F[S>;G+@]LMEMAA)2I&4I5[$D$XP, X!Y4*_.JVG;A<=36ZX"P
MIU':A;Y$$PCVB8[[A24O@.$)\)VDY) \#DU^=)] S-.WRY2]11(<J8B- 9B7
M$I2MPEN*EIW:?U)&1CG&17+J;T^NFH=4//6CT[$&ZV[T]Q>)2'$NL+#D=200
M<DJ]I..$@_.*K&.G]_<N&F;C.AQ5720S=7;T\VM*4-/26DAM&,DJ2G:E'&[&
MW/S657TPOLS23+"]+,HFQ-,HMS*5JCY$M,HJ4M!S[2I.5[\C.[[S6FDZ,O$G
M4LJ,[9U>L?U W>FK^ WAJ*-F6%$J*]X2%-A 24D'/@FLG#Z?ZL?TNJ#(T^^R
M[!TO-LX6X^TH2'R\E;>P!15M(!P2!_@5[#J6V7!WH\Y;;-9F/7*M[3:;8[M2
ME(PG>W[2$Y"=P SM) SQ6$T)HR^PM6Z<7==.O"%;9-U<$J0J&>V'U(6R0EM7
M!!"\[4@ J..*HX_3:_M:'TW$?T[(6F)<)ZKE;8DF.RX^AXJ#;Z5E102E!",$
M@X) P!FK^T:%NUON!C/Z48F,2&XZHDY^<A:[4$10T6B3[ED'<04C:2O)_:#9
MM!W^)I5,->FU-R?Z,E6=P!]@[Y2G,H3G?X/*@? W<X-5.J-+/:6M6YRTP8(D
M2;"&65NLM-3)+ <4^E0SM\<'>4@D9!/&?3.@;D8Z/N#,>"J(^U<Y!E#<TM*W
M5D.$I6T2E0"5I1YXV8^*PVE^G=\M=MT>BY:;1+,.'=X<EEM]I*FB^Z5-'?NX
M!3D;DDE._P >:WW1.Q72P6>YQKG;E0(YDI]&A\,&2II+2$CNJ9]BB-NT*_40
M!FO&=5:8U%;M-ZJG:@T\S"C2;<RPOM.1DQ^^F>%)"$)Y(*5@A:_=^K/D 6VI
M+"Y:=8V&?(TD1#N5\=>CZ>1Z=:@$P0@G 5V@5+25XW? ^>!V9Z7ZK1IN;!,!
M"RO2CMO;;<E(5MD+EJ>0R#X]B2!N\9Q@_-:QC2=_@:SD/.Z9MEZ9E*AOQKC)
M?0D6Y3+*6U)VX*R>"I.W@D\D>:Q]LZ<:HA6:^![3;;BY*;0^F.E<5"5.QI!+
MJ&T)]H24$X*N2#R22<: Z"OD&1(NS]G:N+ U-(O#EG2XVKOLN,=M)&XA!6A1
M*@%8\<'-54[I5>IMAN;)L<(.R+7-3!0ZXVI4-QV5W6V 3^G:@GW).T%2@..3
MZ'U+TY=;YTG9ML*$F5=F/1N^G6X@%:FG&U+2%*.W.$J&<XK-M:.OPU,TV;,E
M*E:@1>Q>NXT.S'P-T8@'>5  M  ;=N#GXKVJE*4I2E*4I2E*4I2E*4I2J2[Z
MKL5GN#4&YW2+%E.;<(<7C;N)"2H^$@D$#.,D8%9+4'5>T6NYV]M#C'X<;F_;
M)\I]90(ZVFBOVC!W9("?YXK3/:VTTS^'=R\PP+BA#D97<R'$K.$'/@ G@$XR
M>/-=[)JNQ7VX2H-GNL6;*BC+Z&%[^W[BGDCC.0>*B0->Z5GRI4:%?[<\[%:6
M^\$OIPA"3A2B?&!CGZ^:CIZDZ.-K1<3J* F(MQ;25+<VE2T)"E)"3R2 0<8^
M1]BN5IU]:K_<HS-BN5N6RF<["DID.%#JU);4H=@>%Y(S];02*F.:^TLVW<%K
MO<-*8&/495^G*]@(_P!PW^W*<\\>:DHO.G'K4C58E0/0]CVW)6T -9\;SR!N
M^/O]ZB.=0M(M6R/<'=16Q$.05I:<5(2-ZD %20/.1D9'GD?=6-^U-9-/)C*O
MEUAP$R5;62^Z$[SQXS\<CGP,BH]NU''+<QRZ3;6PA$YR&RIJ4%!6T9"59QAS
M )*!G&*^G]8Z;CS'8K]]MK<AII3RVU2$@I0E&]2O/PG"C] Y\5VFZIL$$.F9
M>K='2T6TK+LE"0DN EL$D\;@"1]@5RMNL--W20EBVWZURGE,F0&V92%J+8."
MO /@8\U6VW5FBXSD5NTW&U)-WFJ;;,0IVOR2@+5N*>-Q3M.3R<I^Q5@QK/3+
M\-Z6UJ"U*BLN):<>]6C8A:OTI)SC)P<?>#7Z[K'3;5F8N[E^MB;6^HH:EF2C
MM+4,Y 5G!(P?^#4A6H[*FZ-6U5TA"<ZR7VV>\G<IO&=PY\8Y_C)\"ONP7^TZ
MABN2+'<8L]AM9;6N.X%A*A\''CX/\$&K.E*4(!&#XJ):;9!L\%N%:H<>%#;S
ML9CMA"$Y.3@#CR2:ETI0\U"L]IM]E@IA6>%&@Q$DJ2S';#: 2<DX''FIM*4I
M2E*4I2E*4I2E1[A!B7&*J-<(K$J,K]33[86@_P @\5]Q(S$.,W'ALM,1VQM0
MTT@)2D?0 X KK2H]P@Q+E$7%N$5B5&7C<T^V%H5@Y&0>#R :2(,22]'>DQF'
M78RM[*W&PI32L8RDGP<$C(J12E*4I2E*4I2E*4I2E*4I2E*4I2O*]6:"O%PN
MNKVH'X>];-51F69#TEPI=A*0@H*DH"#W!MP4@J3A0^CFH\#I[?HNH(C^^W+@
M1K]*NB27UE:VWHZVP"G9@*!(^3Y)K/PNCM[AMV0EO3]Q(M\:'-;N"WE(CJ94
MHA;(3@+!W'VJ Y .>37J'3/3TO3.GY,&?Z<O+N$N2E3"B04./*6G.0.<*'%>
M1:(TO>M6:;0_#1;HK5L<O3=OD*>+BWGY#KJ/S&RC"4I"C\JSP<?6FTUTWOEM
MU1;KI(,%++=W5<G6Q,=?6D+@]A0WK3E1W\\_!^/%2K)H34$*]0%OF N)$U!.
MN?>3(7W%LR&GDCVE'"DET#&?CS5#;NDMP@6:1"=LMFFO1641HLW\3DM/R$AY
M+F_."&%#:%>T*RL><<'8_P!)ZB>Z5VZTSYL:5J.&\S,*W%'M/+:D!Y+:U!/(
M(2$E6WS[L55VSI_>7=?6S5%P1!C!4^3,F0&Y*WDM!<1,=(02@!9)3N42$^<#
M.,U<:XTO>Y.L(U^L35KN 7;7;2_!N:U)92AQ:5]T82K=^G"DX&1CFHHT1>3,
MA.K7;4I9U-^,*#:U %CTY:P!MX7DYVYQ_P"ZJN5H'4QA:ILC*;$];+JY<9#%
MQ?4OU+1E-J';V!.!A9&5[CE(QM^JR/T[U=-=<FW&/9X[STRSR>PB6M>U,,D+
M!5V_*DX(QGSBIL'IUJ"-=K9-]/:%"/-O<AQE3ZMA3+![2>$9(SP?&!XS7+2V
MB]5VV79)*X;"(EON2E,0'YH?7&85%4R2'=@*TI)!2D^X) &?JLLO3G5Z8<AF
MXV^TY6Y:G2GUI+9,62M:TH0&@&TJ2HX0.$@@<DG$^)T[U)8[@NYP8-INA,VY
MI_#I,@H:5&EK2I*\[" H!.%)P<I. :_8W2VYHOLI^YVNS71J4XF45_B,EAJ.
MOTX:4TB. 4$#!"%GE*3XX K3],;!J'3#LN-,C,&V2'T!E*I0=>BMI9 P7-B2
MZ-P"4@\I3CD^!Z/2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*5\..MM %QQ" 3@;CC)K[I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E>5]2
M;/(;UC:M3K]#=HD%Z-'3:W$.!YA2W0GO-*2O!42M)(4@C#?!'FKCK7;8USZ=
M7CNH:<DQHKLB,')*F0A:4'\P%/\ <D$D9!YP.,YK6:<<+VGK6Z1(!7%:5B0<
MNC* ?>?E7W^]6%*_E^;9H^I^MG4"%?;=%F6)MZ-ZR6^Z0Y;V?2.'N-<83E:4
M9.>,#VJ!)3I-7]7;U8]438=K1:Y%EMUPM<,9:6IV0U*94LJ"PO (V<>TYR/K
MFFO'4"\/6_6\F[)C7"+!U7'MT2(H.(2RA#F H%"@2<I2K&<;@?(( T\[J?JA
MB'KN[-1;*Y:M,S)$,-A+O>>4-@;)]VT %1*OO& !YKT#I]>;W-T]*DZOC,0G
MX[R]KR%-A#L? 4APA+BP@[3R-Q\9S@UY?HG6UT1UK4J[)F-V;5D8^@$EE;3;
M:F5+[26RKA6]K:LXQE3H'Q7=CJ=KGUUZ??LT)-M@1[F^Z/1O8CJBA80V7]^Q
M964C)2/OCZZ2NJ.KFM%::NB;?:'+CJ5YINWLLH6H-Y05*"PM:022$@84,;CY
MP 9MKZDZRNVMV+-%TU&:$-,/\78<=;*F@\E14ZVYW0%)0=O 0HGGD'&<@KKC
MK!=IASVX-@0F9#GR6VE-O%31B%6X*]_NW!/'C!^\5ID]7-1W.]:=MVG--LS9
M$JU1;M-:+@2>V[C<&U*4 -N1R0K.<8&,F-I_K#J"ZZMM=O7 M2(-SF7*"T4[
M^XVJ*@*2M1*L$'<,@ 'C@_%:_P#^GN_7W4W3*'>-32$2)4I]]3:PWL/;#A !
M^#R%8Q\8KTFE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*56N6&TNWM%X<MD-=V0WVDS%,I+J4?07C.*X2]*V"8MM<NS6]];<A
M4M!<CI44O*P5.#(X4<#)_85<TI69NF@=)W:;(F7+3EJE2Y&.\\[&2I;F!@95
MC)X %=G-%Z9<D.ON6&VJ>=<:=6HQTY4IH8;)X\I' K\DZ)TS*DS9$BQV]QZ8
MZV_(6ID$N.(_0H_N/NI[%AM$=N>W'M<%I$]2E2TMQT)$A2O)<P/<3DY)S7*U
MZ:LMJLSUIMMKB1K:\E278[;8"7 H;3N^\CC)^*^9&E[')9M;4BU0W46LI,'N
M-A1C%.W:4$\IQM3X^J\XTWT6C6W4294Z3'DV]I3RDM(2^E<D.A84A\*=4VI.
M%G(2A.X^>,@^A7+1^GKE8XMFFVB(Y;(JDJCQ]FU+)3^DHQ@I(R?'V:_?Z/T]
M^*0[D+-"3-AM!F.ZEH MH'A( XP/CZ^*X-:$TFTA"&M-VA"4-.,) B(&&W,[
MT^/!R<C]S761HW3DB3;'W;+!+ML0&H9#0'90,%*0!Q@$ @'@$9&#7['T;IJ-
M/;FQ[#;&IC;SCZ'D1D)6EQ8 6L$#R0!D_M4K3NG[3IN"Y#L4!B#%6ZI]33*<
M)*U'D_\ X_@  <"K2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E8C5&K;W8[M!C?@<%<:X7!%NB/.7%2%+4
MIM2]ZDI95M3[%)\DY_:N#.OTP-8?@.K/PNTR7(T9QA"9A<+KKKCJ-B<H3D?E
M#G Y6D>2*GR-?V*U6M4R^W: TCU;\4*BJ6\D%M1R#A.04I *N, YYQ6M;6EQ
MM*VU!2% $$>"*S,76<*3KM_3*&E]Q$=3J961VW'$%/<:'VI(<;)QG]7QBI,O
M6.G8;_9DWB&T[W'FMJG!^MI(6XG^4I()%0QU$TD8*9HOL0Q5.EH.9."H)"S\
M> E225> ",FIS^KK!'N;EO?NT1N8VVIU32EX(2E 6HY\<)(5CSCGQ4"'U&T?
M,DMQXNH;>Z^XM#:$)<R5*60$8_DD 'P<U-<UGIQJ;/B/7J"U(@H4Y)2XZ$=M
M*2 HDGC ) /T2,U =ZCZ43$C2FKS&DL2)J+>A<<]P=Y8W)2<>..<_5:ZL\_J
MJVP9EV3=KG:HD:"XRVI:Y82ILN)R Z% !!/P,G(YKX=UUI=FS,79R_6]-N?4
MI#4@O#:I2?U ?QCGZ^:BV?7$"9=KO$F.1XC46XM6Z(ZIX$2UN,(=2$_N=QP!
MG.*[W_6]CM5DDSOQ."I:/4-M(4\!W'F0K>WQDY!3@\'%0+#KV!(M[D^]W&QP
M(J8D*00F<%%HOHW8<*@D)!)]I^1SQFKAC6.G)%K;N3%Z@.07%K:0\EY)2I:$
MJ4I(^R$I4<?0S5K;I\2YPFIENE,2XCHRV\PX'$+'C(4.#6(OG5*PVVXPF43H
M2HHN3MMN#[K_ &Q#6VRM?((YR4;?(SGC-:!_6FFV&[8X]>H26[FD*B*+@PZD
M^%9^ >!DX&2!YXJ[ER6(<1Z5+>;8C,H4XZZXH)2A(&2HD^  ,YK,)ZAZ66S:
MGF;NPZQ<I:H3#B<X[J4E1"L_IX \_P"Y/P<U\0>I&DY=L@SQ>H;4>:\MA@N.
M %:DKV'CX&<<GCD?=?>J-<VFT,7F/%FPI-\M\%Z;^'E\!:NV@KVG&<'&#CR
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M0F/ ;D.38I<>BN1FDM[HQ\84$@X5P#S@^*YL](;J---VIVYPL(LEPMB5)0K
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M&:[-=567=71;&FRS5*4^W#E.-_F&*^ML+*5! *2E)4E*E;N#GC S7I*SM02
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MUGX/8?3&;9D7=R]29TMU!6A2G%N*92@)!4%E>"?]I5GXKU+QXK"7CIG;KIK
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MT !>X<A60%;@<@\@YJNM>@-.6R;;YD6"LRX*GG&7G9#CBRMY(2XI94HE:BD
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,4I2E*4I2E*4I7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>exh47_07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh47_07.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ L(! 1$ _\0 '  !  ,! 0$! 0            0%!@,' @$(_\0
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M1AN*<CAU2QN*Q^\';@82.$[LX-6$'J9IV<QOCJG]TSTVT1EPG$/EY2=X_34
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M"%'<,E6 2H 8^QJPTOH%=BZ<S](&[&3$>;DLQWC'"%,MN[N" KWD%:CGC.?
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M9V$M#K;DAY677"I0W#:?;M X7^*W%\Z6F^2%)N%S2(CFG4618;9(7W$NAP/
ME6,92/:0?'FHR^FEYGZJMNI;O>+>N[19D5Q08B*0TIAE#HV@%>=ZB\HY)P,
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M-J4Y(2 D )2E( '  JRN4"'=(;D2Y1(\R(YC>S(;#B%8.1E)!!Y%0(^E[!&
M$>QVMH .)PW$;3PX %C@?W  '[XYJRAQ8\*(S%AL-1XS* VVTTD)0A(&  !P
M /M4.?8;1<+C$N$^V0I,Z(<QY#S"5N-'.<I41D<@>*^[/9[;967F;1 C0FGG
M5/N(CMA"5N*QE1 ^3@<_BORZV2UW=;"[K;HDQ3&_M*?:2LM[D[58R.,@X-5+
M5DTF)KUG;MUK,D6]MAR+V4D^DW*"$D8Y1N"L#[U<62SVZQ6YN!9H4>#";)*6
M6$!"02<DX%56HK3IA-SA7Z_Q+>)K"VV(\N2E.Y*E+PA()^=RN/R<U\NZ#TJ]
M?';R]8+<Y<W5;UR%L@J*MNW//SBOFWZ TK;D1TP+'"C=A]$ILM(VD.H!2A61
MY("E 9^YKI%T1IN*ME3%HBI[*7T(!3D!+YRZ,'@A1\U7)Z6Z,;A(B,6&.PPA
M:G &%+:)*AM5E22"01Q@G&.,59VK1>GK3?'KQ;K6S'N#J2@N)*L '&=J<[4Y
MVISM S@9J7JN+9YNGIL?4WIOHZT?]P9*PAL)R#DJ)&,'!SD8.*AV[1>GX"H#
MD2 $NPG5R&'5.K6L.+1L4HJ4HE1*0$^XG@#[5H5H2XA2%I"D*&"",@BL3&Z4
MZ+BMNHB61$;N("%*8?=;5@+WC!"@1A0!!'CQXK]M&@-&J<MMPMD-IY$+VQU-
MREN-;DJ5[BG<4K6%%?N()R5<YI_TKT4(DR,BPQT,REH<<"%K204*W)V$*R@
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MG/M"3O &/'D^<5Z9TSU3>]1>N3?K2B#VT,OQGD* #S;B2?V%14,%*AN. KR
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M:2DH;SG8,#A.><>*SU_OFD9U_8TS>VXTZ<7$[6'X9?;;<4A2DA2BDH0LI"B
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MAWVX7:).:NLVXRVW%2W'"I; >66MH42 G:K@C&<_/FO--'661;&=/.JT]?\
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MBG/IBS[S;DNO/I'?4T^A+*%X "E*0K^3CBMET?NL:,U=[*[,92E-[N"+4P5
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MI;:U--E;>=BBD93GSC[5]);0A2E(0E*EG*B!@D_FN2(<9"7DHCLI2\HJ< 0
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M_P"BHY1G*B"1C /.>!I8_5ZRNZC:M:8TLQ536;8;@HH[8E.-E:&R <\X(SC
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M%[OJ)<=HM-EUP+<2"A &2HY/  ^:@VJ^M72:$0FB[;UQ6Y;,]#B%-/!9(PD
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MB.QFY4AIER2YV6$K4 7%[2K:G[G:E1Q]@:D4I2E*4J+=+C#M4!Z;<I+46(R
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MW>X&CL'!2I?VJDZ&R]1R-5SOZAO%R?E=AT3[<_"?2W'>#OM5W'%E RDD)2T
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MDJVQW[Q&2[<D-.10-R@XEPX;5D#"0H\ G&?BI&C]56W5=@-XMJU"&'7FBIS
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M9MQ"%N> I140,\Y^W%7$3JOI&5(N+#5Q47(0W8#9/?'<#?Z6,[R7"$@#DDC
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M.Y"U$'D';_BM_P#41:K[=WTFQ6.YRWX4#NQID5?['3*9*DH2,*"^VA1SSP2
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M:ZAZL7,BSKAI]N1;F5NA].RW]U 3E+9]R@5*!5C_ .W-=%=:H*%W9TV6>N!
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MD1G$I]<RR $!P[<A7QN3@X)''Q::0T2FP7VY7>3=)-RG3&TL!QYMM!2TE2E
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MC82 E6$9"RM6,\I \FKUGJA,D:@8MS5E2VZY=FK6J*^\42&TJCAY;Y2$J&T
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M<EGLIV/J7^\K3C"BKYSY^:\VU'TACWB^..A^T,6AQ+;?8%DCJD,(0E* AE_
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M')QO2">"!D'.".17WJV_Q-+Z<GWNX(=7$A-%UQ+*0I9 ^PR*M6E)<;0M(X4
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M+;@24A2&P" 3DC/V)Y_FN/TFW>N=F_3XGK'4=MQ_LI[BT?[2K&2/Q73Z?"]
MJ#Z2/Z)22A4?M)[92?(*<8P<FC5OA-*RU$CH.4G*6DCE(P#X^!P/Q7['@Q(S
M[[T:*PR\^K<ZXVV$J</C*B/)_FOU4.*N,N.J,RJ.LDJ:+8*5$G)R/'GFL9+Z
M=,S;XY*F7JXO6U4AN4+8M+*FTK0I*@ LH+@0%)!"0H >/'%:QVSVQZW&WO6Z
M&Y )W&,IA);)W;L[<8SNY_GFOUVU6YV:U,=@1%RV4%MM]3*2M"3Y2%8R!R>!
M7$Z>LI:#9M%N+88]*$F,C 9SGMXQ^S(!V^,BNSEHMKEP;GN6^&J<VWV425,I
M+B4?[0K&0GD\>.:C*TS8E1RPJRVPLECTI1Z5O;V=V[MXQ^S/.WQGFI2K7 4(
M@5"C$0P4QP6D_H@I*"$<>WVDIX^#BN$33]FA[/2VJ SLC^D3VXZ$X9SGMC _
M9DYV^*YP-,6&WM1VX-EML=$=SO,AJ*A/;7C&Y.!PK'&1SBN[-CM3-W=NK-LA
M-W-U.QR6EA(>6/L5XR1P/GX%5[NB]-.O7)URQ6U3MR!3,68Z<O@G)W''.2 3
M]R :F)T[9DL364VJ &9J4HDH$=&U\)3M 6,>X!( &?BN,'2MA@,1&8=G@,MQ
M'C(8"6$_I.$8*T\<*P<9\XK#:NZ/P;Y,B^B>M<"V,,".B(JRQWRTG<2KMK(!
M1G<3SNP<GY-7EUZ>PW=.N62R.M6J#,(3<BB,EQR:WLV*2I1/"B ,KY-:J?:;
M?<;2NUSX4>1;EH#:HSC84V4CP-OCC _XKS[6/22!>$Q&;(;3:(+)6M<-5G9D
M,J<5C+B4G;M7A*03\@"KNP=--+6B/;/_ *1#ESX+33:)TAE*GB6QA*MV."/Q
MXX X Q:-:,TVS&:CMV.W)8:CNQ$(#"<)9<.5H''[5')(_)K\&B]-BY">+) $
ML-=CN=D9V;.WM^W[/;_''BOMW2.GWM.LV%VT0U69DI+<,M#MI(.X$#[YY_R?
MO7VSI6Q,R6Y#=IA)?;D.RT+#0REYP8<6/_<H>37Y9])V"RM36K19X$)$W/J
MPRE'=SGA6!R.3QXY-=HVG;/&T]]"8ML1%FV*;]&&QVMJB2H;?&"23_FH-JT1
MIFTOLO6ZR08[K+RI#:T-#*'%("%*!^"4@"J>\]/8TEU,:U&';K/+FIN%U81&
M*G9;J7$N)PLJP@%2>?:>"<8K=TI2E*4I2E*4I2E*4I2E*4KS/46GKHYU&?G.
M:>BW^U3FH:&W'I"&OIRV'%J*L*!)!WA7M&24X/'-><Q- :O$RY3'M/%M:F8[
MJ66I,9*''F+AW]B,'.%()PI?NR#DC(%6%WTIJB3;;[-5I:6W<YMY>GQ642(L
ME#87&0T \VM6Q:%'<%?*?(S\R)/3^_3(,^)/L49\/:MAW,IWM%A48-MI=*4J
M5G: E8VD9(/ -46H;6_:TPK++M0;"Q?4MPE/1<,1I#H##J$+>0@8WC&#D *3
MCG(W%ULJ[]T-T_ TG DX9=@J9:<4V'$I:?1N62%;3PE2LI)!SQYJ]Z86&38M
M1ZZ5+LXB>ONQF,S$]O;):4A.$Y!W92H+)! Y6<9R:P,71DF%Z'ZEHQ<NSQ+O
M<U3(#;+#GK \M2HTA*"K"@A.$>[!3NXX%:QW3-T:Z'Q;([;UR93;K+BH!<#J
MPP):7.SDD E+0V^<9&!D5B;KH"Z.6N*HV*<-,O7.8^;%"1%$B*TZVA#2@AS+
M>04N$@'*>]D'(.-[JFQ7!OIMIR S;IDYF _$5<+<M]+SS\9'[VU*X2Z0=I(X
M"MI'S6#T%H:YQ[Y#E772S@AQHUR?AQG>VD,O&6EV.!M5A"MI5@_%9^W::OZM
M.:A@.Z3N0;GLVE_TR8J6FPXS(!? RLE2MO\ >HE2\$GXJ_UCHZZ(O.M&K9:+
M@W;ID^V2%^ECI=]3#;:"7&T)4=JB%\E!\@'R#5-?M(W8:1?MDFPW^[0%V=QF
MR-R8R''(<COK*BXA!PVHI*-I_M0-O'(K^D[-,]2R6C'DL+82A"P\V4@DH!]I
M\*QG!(R,@U84I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E5]VL=JO':^K6R#.[1W-^I82[L/W&X'!J<TVAIM+;2$H;2
M,)2D8 'V KZI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*9 \D4!!\&E,C[TI2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4KR/K1IFUNW+3,]UM
M\RKA?H<.0L2G1N9(4"V %82#C/MQSSY.:J94N?HCJ!>DZ>"'[5#B6AAR)*==
M><*'9+C>&U*7P1OSE61P*TFD=>7_ %#K1V.BR)1IH2I4,3<IRE;*E)!W=S*B
MHI/M"!MX.5#QA=36^_7?JUK./I=$_P"L,/VQ46X)G;(]N06@7.XT5^\+"5#:
M$'/X^=0_U-O,6Z:A9=BVQUB! N,I@L!XA2XI1PITC8K=NY2G)0>"<U6ZAU7J
MU"YD/4+-E=AKTO.NKL6(7DI6$[0E)=)"DG!(XQY/X(M4]3;L[=X5ML.G79S4
M5F"JX%O<K8F0V%Y2HD ;$X/NSN\<8)J^Z>:PN&I+M=(-X1 @R(X*A;TAU$MI
M/<4D*6%@!22 DA:./=_SY_I?J+,T;IT19T!N7;DQ+C+@.MRENO.EF6I 2X5#
MPHK2 <DX&3G.!H8W4/5\B;9K2K3L*'>9[\MI(GNN,MK0TVE:7$@!2@"%$$'Y
M3YYXI;[UAU K3FHKM:[$MJU-17'(%Q6RYM2M+P:_4W)"5;LE0VDXQ@YYQJ)W
M4FX1KK)6+9"58[?=&+/.?$E9>#[@;RI"-F"A*G0#DY."0*I^HNL;KI'JK*EQ
M4^NML;30F2(+LXLH2!*VJ<0G:H*=((2,[<\\_%7<KJ3<&M8S;&Q8X\A:&9*X
MR43LN.*90E8"PE"@C?NP!DJ&,E(!%<YO5N.FT-3K?;');<EN$W'6VM2PJ5)"
ME=DI0@K]B E2B$D^X )SQ5I(Z@N0.G3^I+O8YL26T[Z9,!;;B5/.EP-H*=R
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M_3[FX/;^UC;_ .[.[VXS721UKL2<.1+7>YD-(BJ=DM1TI0T) _2R%*"B2>,
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MU2CDH6H><A0&"!FI>G^G$NUZ#U#8$WE$5Z[%PH5;V5-L0@I 3AIM2U$ D%1
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MSP8EQEY[\AED)6YDY.2/N0"?N>:ST[3/3_5NI+BJ0BVW.]MI#<QMN85.-@<
M+0E?MQSY ^?O5V-%:<#Q=1:8Z%E]B3[,I'<83M:5@''M3P!XK,W_ *6VRY:C
MTY)8;;8M-N7.<DQ$N.I4\N2 20I*@1[@21X(./%:"ZZ:TG%@W!ZYP;=&A28K
M4&2MXAMHLI)#:.2 G!5@8P<X^PJHNG3R.;$BPV<1F;/+DH>NIEER2_)2@H(
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MCCXB-DI91(?4XH#D[4E1\ #@#P!_-4D;IEIMB%'AEB0]%8AR8(:=>4I*FWW
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*E*4I2E*4I2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>exh47_08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh47_08.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ KT! 1$ _\0 '  !  (" P$               0% P8! @<(_\0
M-1 !  (" @(! P0! @4$ @,   $" P0%$082(0<3,10B05%A%3(C4G&!D18S
M0J$(%T-B\?_:  @! 0  /P#ZI
M                    '%JQ:.K1$QW$_/\ ;D
M
M
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M:?\ ,SVD
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M9SQCQ>T_LB8B?GKKN)M'<=]QW^%5YC]0M'A]KF>+P[FII<GQ^K@V[9^1I?\
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M>??VM/6CG]/1QZ]L5[7G'EP4GN+Q-8[I-NH_F9KW\0@[?T_\JY;R;3\@Y/\
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M9]<]O>])G^:^W5H[_$Q$MVPT^UBICBUK16L5]K3W,]?S,_S+L
M          #IEI[^G[[5];1;]L_G_$_X=P
M            %;J<UH[?-;O%ZV6<FWITI;8]:S-<<V[]:S;\>W4=^OYZF)_F
M'7C^=T]_FN4XO!&?]5QOV_OS?#:M/^)7VKZVF.K?'YZGX6@Q8]G!DSYL&/-C
MOFP]?<QUM$VIW'<=Q_';+V$S$1W,_#7_ !;S#AO*<N[7@]G)LTU9K%\WV+TQ
MW[FT1-+VB(O'=;1W69CX1>8^H'C/#[7)ZW)<G&'-QM]?'M5^SDMZ6SQ,XH^*
MSW-HK/X[Z_GIM43$Q$Q^)^0'%K5KU[3$=_$=JOQKR'B_)N.G?X/;KMZD9+8I
MR5K:O5Z_F.K1$_"U  8L>S@R;.77QYL=L^**SDQQ:)M2+=]3,?QWU/7_ $90
M                    0>>V-K4X/D=GC\,;&[AULF3!AF>HR9(K,UK_ -YZ
MA\S<;J\KF\"\/OQ^OS?(;^WFMR?*UP5S4Q;L;EK8IO.>GXR8H]9^?Q'S\Q$L
M/,<_RW&:V3:Y3DN6XG)R//\ (;\ZN]39I]G6QXNL$6FE;7KB^Y>D=UCJ?;_^
MK-Y+A\LU=;;T^,Y?R3DL/$^-XL/ZK4G->V[M;.6+QDI:)F9I6)CN?S%:=1'R
ME<[L^8<EY%H<%DV?(\>/5Y/0X[[V&N:M9P4QQ?-GR>D?NMDMU,3,_MBOSU^Z
M5+P^[Y'QN'CN6U>.\AQ[N]L<GS6YCOCV+1><5,E=;7MWW\?F9B?S$Q\S/2\\
M7Q>3\OM<!Q&/G?*M3'I^.7Y+DLF+[D9-C/DS6M&*)R5_;?YF(GKOJ/C^T;'S
M7D7/>'\QS%/*^7UN8VM.<5].FML5P:^Q3+ES7Q^_IUCF,.*,?[9[[F?:>[0W
MOSSD]C5__':OK7E,?)<SBQ:^'#N[%K;%,NSDB?MS?XM,5BUHB)^9K6(G^6I\
MSD\IXG;WO$/%+<OJ8>+C0XWB*4B_IER9+_>R[%[S$]TK7'-?6;>L5F8_GIK^
MCFS<YY;I\AMZ>YFCE_(]SD\F",,Q;)BX[!_P,4UF/S:UK1U_?Q^86M?)_.>=
MX/:WM7DN6I>O!;/([<ZV*:X\>?)>)U\&']O^ZM8CO^>IGY[;E]/>1\ZYOS&=
M3D<^W@U.*S:L[UYK6N&W>A7[F"(GN;7^]>+3,3U$?/\ RPK_ #SRKRSD/->=
MX;Q_;W-3;U]O2T>,U]>D3%O;URY]G+\?-(KU7YF*]3_?:G\:\K\KY3S7AKSR
M_(X^,YKR7;O@PVI,XZZ6O$1Z3^9B+S:(Z[B(FO?SW\7'UOYC-I_4K3SY-G>Q
MZ? <)FYC'@K[?9S[7M;'B_$3'<3/S,_Q\?S+2_%/(O)O N YSCM&^6V+A^.T
M=6,<XIG7UL^S,Y,NQ-HK/?I[]3W/S/\ $Q'QZSX=R_(\=]*/).>Y'R#/RE:5
MV=C4SSCO:,5*UGTBE[TI.6/B)]O6*S,SU\/-^%^HGF/ 1S$\ORM]S-QG%:&'
M+CVZ1&/'L[-ZVC-;JL6FN.ENK=S\S\?U,2<GG7-\=J:O(8_-O]2OJ\S-N3PX
M<==C%@X[+,8ZY+7IBK69K,>T=?$^W\]-L^F&YL^0_5SGMO-Y#O<EI<'HX-/6
MC-2N.,ULM:WR99I%8BOS6L?CN?\ I'34</U0\DOSF7F=#G+[W"4V>1W,G'1K
MX[4IQ^'NN&TWK3WB;WBU:]S\]?\ 5WQ_4WRV:<UM_P"O\?UQ_ :NQDIDP4IA
MKM[62MZ>MOYBF._K$S;UF8B9_E8[OG/F/#ZE<&[S.CZ\OL[=N,WL^;5K]O6U
MZ3/<WZC%[9+32([F?6/S\PNOIMR7)[OUDSX=K?T^1OK^,:M>2W=:O5-C/.2<
MF.T=?M_V9+=3_,?,==]1[8                    !,=QU*%PW%Z7"\=BT.
M+UZ:VGB]OMX<?Q6O=IM/7_>94?EO@G"^4[/ZCDHW,>:VO.IEMJ[63!]_!,]S
MBR>LQ[4F9GXG^YZZ[ELFIKXM35PZ^O2*8<-(QTK'XK6(ZB/_  R@->Y7Q#C>
M6\BTN7Y#)NY[Z<TR8=6VS?\ 35RUFWKE^UWZ^\>T_/\ T_IL(  #K]NDS:9K
M7NT=3\?E#YC1MO\ $[^I@V+Z>7:PWQ1L8ZQ-L<S7J+1$_$S'^?Z5?@?BNMXA
MXIH<'KY;;--7%]K[V2L1?)7VM:(GK^O:4+SWP?7\KT=/#CSUTLNKL4SUF<%<
MV++ZQ,13+BM^V]8B?B)_$]3#GPSP'A_&O%M/A+8<7(8M?+?8B^SAK,1EM:;3
M:E>NJ1W/Q%?Q'_E9^+>-:/CFOLUU(MDVMO+.QM;62(^YGR3_ /*W41$?U$1$
M1$?B%V
M                                                Q4MGG9R5OCQQ
M@BM?2\7F;6GY[B8ZZB(^.OF>^Y_'7SE
M                           !&Q\AJ9.1S:&/9PVW<-*Y<F"+Q[TI;OUM
M-?SU/4_/^$D      "9ZF/B?D                  '%K16.[3$1WU\N0 !
MY#PGZNWUIC8V8]<V3)R6";Q$>UM>E-*<=)[[GU[F;?'\VG^Y[]>
M                   !HV+A]RGU=C?G4M_IL<?L7C9K:(K&;).K3[<Q^>_7
M!-OYCY_MO(
M
M                                              QQFK.Q;#^[WK6+
MS\3UU,S'Y_'\,@
M             3\1_8
M
M                                                    !W'?7?R
M
M
M
M
M
M                                             #CO]TQ\]Q'?X<@
M
M
M
M      .MJ4M:EK5K,TGNLS'^V>ICN/\ M,Q_W=@
M&.^6:YL>.,62T7[[O'7K7K^_G^60
M                            <7M%*]S$S\Q'Q$S^9Z<@
M
M
M
M
M                     .F;'7+AOCR1[4O6:VC^XE1>!;VWR'B^KEY*\WW:
M7RX<LS6*V[IDM6)F(ZZF8B)_'\M@                            ">^I
MZ_*%P^#;U]&M.1RX,VU,S:]\&*<=)F9[^*S,S_\ ?Y30
M
M            <6[ZGUZ[_P N0                          (GL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M5GJ>I_'Q*3K9\6S@QY];+3+AR5BU+TM%JVB?Q,3'YAD
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M$37JLS'<_$QL/AW$7X'QCCN+RWPY,FKBC';)AQSCI>?YM%9F9CO\_F?E<
M
M
M
..                _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>exh47_09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exh47_09.jpg
M_]C_X  02D9)1@ ! 0$!D &0  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" ./ L$! 1$ _\0 '  !  $% 0$               8" P0%!P$(_\0
M6Q   0,$ 0(#! 8#"0H*!PD   $" P0%!A$A!Q(3,4$4(E%A%18R<8&1(T*A
M""0S-5*CL<'2%R4F-$-B<J*ST6."DI6RP\33U/ G15-SA9/"559D969T=92D
M_]H " $!   _ /JD
M
M
M
M
M
M                                &IOMY90XS=+M0HRM6CII9VQQ/14D
M<QBN[=IZKK1".FN7W"Z9 VV5MRI;S35=ICO$-;31)&D7<_L="YJ*O&_L[YX=
MM>#HL-;2SU$M/!4PR3Q?PD;'HKF<ZY1/(R
M                #R1C9&.9(U',<BHYJIM%3X*:ZPV&TX]1.H[%;J2WTKGK
M*Z*FB2-JO5$17*B>ND1/P0P,6Q:GL5375KIWU=RKE;X]2YJ,VUN^QC6-X:UO
M<O">:JJKM5V9MNQZS6VXU5PMUJH*6NJE5:BHAIVLDE57=R]SD3:[5=KOU-H
M
M
M
M
M
M
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MK*<W?691-#J]P)% ZIA[%:Z./L:U'-VB/^QPO/;QSM5Z\
M                    :Q;!;%R!+XZD8ZZ)#X"3N<JJUG/")O2+RO*)O2ZV
M;,    &BRK&H,CCIDEK[I024[G.CEM]6Z!_*:5%UPJ:^*<>FB_C5AH\=M[J6
MB=42J^199IZF9TLLTBZ17O>[E5TB)]R(B<(;;2<\)SYE/ALUKL;K6O+T^ 6-
MB]VV-7N\^/,+%&J:5C536M:]/@6EHJ57N<M/"KG/:]R]B;5S=:5?FFDTOR+X
M
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M]I'7/ZP7*FKFRU;Y*/P8/#6&!==K'<^\J?']J^F[
M                  (GU!RYV-4U)2VVC6Y9!<GK#;Z%JZ\1R)MSW+^JQJ<N
M7[OB1=O3*_7EKJK+,_R)*]Z+J*RU'L5/#O\ 5:U$57:^+N5+_3>]WNV9?=,%
MRVM2XUE)3MKK?<5:C7U5*KNWWT3]=KN%7U_:O32.]1+^F+8-?+VO;WT=(^2-
M'>2R:TQ/Q<K4_$T?0W&VXWTUM+)-NKZZ-+A62N3WY)I4[U[M^J(J-_ GP 7R
M.<=%FMH*?*["Q42.U7VICA9O[,4G;,WT_P"$<GX'1P
M                   "F1[8HW22.1K&HKG.5=(B)ZG/.FD"Y'=;AGM:QW=<
M$6EM3'II8:%CE[7(GHLBIWK\NTZ*<NOR*O[HG%O 3WTLE6LZ]VOT?>WMX_TO
M_/!U$YC^Z8:YW1#)^SS1D*^6^$GCV=!L:L6RV]8=>'[/'VZ\M=J:,T '-\"=
MX?5OJ= CF^'XMNF1$XTYU-I?^@BG2
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M12(BHCF.3:+S\45"^ #%H;=14$E2^AI*>G?4RK-.Z*-&K+(OFYVO->$Y4R@
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M."[XT7/Z1G"(J\^2+Y'B3PKY2QK_ ,9"ON:GJ@1[5\G)^9Z
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ML1+[D50ZXU2>?A-7B*%/73&:32^2JJ'1
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M7:BN<[JN2SW:IM<=4]W<Z>.)R=KG.]7:72KZJF_F3T
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M?(WV,6"WXS9H;9:8G1TT2N=M[U>][G*JN>YR\N<JJJJJFU
M                    .>XBY)NLO4!^VKX--;(/)=HO9,__ .I#H0.39*C.
MHW4FDQV-$EQS')&UMU<G+9ZK_)0;]>WESD_!3K(
M                   !JL@O<-D9;UGCDD]MK8J)B,UPZ1=(J[]$TIM3G&#.
M3^['U-;M-HEL76_3V=QT<AW5++EQ/'.ZAC]IOM>_V2V4J)M99W<(NOY+?M+\
MD^9>Z98A%AF+0T"R>T7"9ZU-?5+RZHJ'\O>J_?PGR1"5@
M                         $+ZG*B-Q7:ZWD%'KY\N)H<UH7):OW0-U@<O
M;'>[)!4,77#I()'L5OWHUZ+^)-<GR"V8O9*F[7RK924,";?(_P!5]$1/-57T
M1#G_ $[ME=E^4+U#R.F=31K"L%BH)$]ZGIW<K,_X2/1?3R;QSQKJH
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M.8_N?:CZ7MN69$^'M==K]4RQO5NG+"Q&L8U5]43M=Y<<J=5
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M0           !L;3X@              BV6/UD^%1\>]<I5^?%%4_P"\E(
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M,X:J;Z;3N;I%]V\4RKSZ:^*>I6W,,O25&OZ<7)(T>B.<VY4B\;Y5J*]-_L_
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M_5G)E3^4E"FO^D5V[,'UM934ZXUD5/XS^Q99Z5K61<?:<O?Y>G&R5
M                         '",P8^7K3D/LZ8R^=ECIEC;?F]T?=WRZ1O*
M:]-K\/0Q+YG5^M$E12XW=++';+;2VEM/#2TB30*D[_!<C7^(BJUJIMNO--)Q
MYKE4G4'+I*VFQV.NM7T@M^N%H?=*JE56K'!"V9K_  VO:B.T_M\U3W4V:&FZ
M@7+Z9JLT6V1ONL6&/>L2(O8]T=>Z-9-;WV+KOUO:)QOU)7=>H608Y<ZF&JKK
M?=K30/H:NMN$-*OZ.DG>YCTTQ^D<U6]R+I?=5=IQSAW[J9EC);12TK+/05E3
M:TNRK6R,@B<U\SD9$Y9'II6QHU7=JJNW<:0V>$]0<AOO426CJ)+.RS^VU=![
M-[3&D[%BWV.:WN[WN7M<J[:B=JHJ>7/9      #G.<XO=KGU4P"_436RVRU2
M5+:IG>B.C\2)4:]$7S3:(BZY\N#HP            !K+U8K=>_!2Y0OE2+:L
M1LSV)SKS[53?DGF:_P"I=CX[:>I9KU96SM5?OT_D+A5E5%18Z[2[7^,:G_O#
M%?T\QY[U>Z.Y]R^J7>K3_K?FI=;@ME8Q6,?>&L7S1+U6:_VIZF#V?L5GBWKL
M7]7Z;K=?[4\BP:T1>+X<][;XC5:[5ZK/+CR_2\>2<H>MPBV-^S6Y#^-]K5_I
ME+:8+;FZ[+ED;>=K_?RL7?._61?V!V#43EVEVR1OR2]5/]LI?@E&Y%U><F:J
MHJ;2\U'&_P#CAF#P-5%^G<E77";NLJZ_;\_4J=A;'-5%R')-*FN+@J?U'LF'
MR.5.S)LCC1$UIM4Q=_FQ2AN&S-1$3*\F_&IB7_JRM,1J$553*\CY3M7<T*\?
MC%Y_/S*UQ6K\'PVY9D+?7N[J=5_;"4-Q2O9.LK<RR/N5=Z7V16_DL&@[&+Q^
MKG&0-Y7_ "%"O_9CQ^+WER:3.L@3[J>@_P##'B8O>DW_ (=9 OWTU!_X8J7&
M[XC6I'FUW541459*6C555?)>(43C^L]9C]_9(YR9G7O141$;)14JHGS]V-%_
M:>2X_D#U569E71_!&T-,J?M86_H#*>_?UTDUK7;]&0:^\+8,I5NDS-Z+\?HR
M'82Q96U4UF*N1-?:MD//Y*A1%8\P8Y%=F,+TUI4=:8^5^/#RM++EZ:WEU,OO
M=W\4M\N>/M^7*?/CS):W?:G<J*NN50]!&<AOM3;LOQ2U0)$L-TEJ&S*Y-N1L
M<#GIV\_%$WY\$F -!=Z/)IJYTEIO-KI:3M3MAJ+8^=^]<JKTG9_T32Q6OJ&J
M.2;)\?;M=HL=FD77'*<S^@I[9U$8]Z2Y-CLC$7W'+9Y-JGS1)TT>K1]15FE5
M+SBZ1JJ]B+;9UXUQ_EO5?/E3UM-U&\3W[EBG8J(J]M#4(J+KE$_2^6]*:B]8
M5D%YJDJ[I28#7U:1*SQJJR/E>GGVHCG2*NN?Z3SZH92^25LU+T_=$K(6(OT/
M*JJD:[8U4\3R9KW>>-\:USIK_P!,<EO]5;JBNEPZ)*6JGK)*:*URK%52RL[%
M=*GB)WKI$YX7RVJZ-U]6<PI8U]BH<!=(VF2A:JT$T6Z?E5BX<[3-Z]SRY537
M.P'*I<=K++2PX58[?7HK:V.UT,C5FC77<S?"(JIW-[M*NEX1#87G'LPO#Z!+
MA8\ JH:->Z)*ILTJQ*BI_!JK/=X;_1YZYN4EARRGO"WI;!@JWJ1B,EJXG31R
MO32(OO\ AJNN$X^"(;QM1GWAM5UNQ?OURGM]1I/YDICJ<_\ \I;,6:GRN,_'
M\S]Q"I\]SJX7FJMEDMN,HE%41Q3UZUD\E.Z17:6F:OA(OBKQM416M]>>"9-K
M^H"TRN^@<;\;:IVK=IDXVG_X?U38==,ZBB=)46#'6HFU75XETUJ>:JJTZ:_:
M0;*NI.15'3BZWRTT-B?;O"D@;74%Z>^1DJKX:=B.ITV_N5-)Z\:\T4EECN74
M""T44%3BULDFC@8Q\L]\=WO<C417.U O*\JOF9\-WSEW\)B=G;SK^.W?G_BY
M5+=\W9KMQ.T2;7]6]NX_.G0YIC75?*&8M?<AKK#35E&MX?2T<*W-K)555;&V
M")J1+WZ=M=JJ*NUXTAK<GRKJ-AZ?6+(*9'SI+'(ZWP7./V>.G<]K5;X21]RK
MMZ-\3O73E3S3@ZU'>\V='&YV'6]JN3;F_36U;\OX'6_QU\RXZ]9@V+N^J5&]
M^D5&,NZ?+S58D_\ *!;UF*.;_@E1*BIM52[IMJZ\E_1%'T]F'<J?4R+2:Y^E
MH^?]0N-OV5+]K#D:ND7^,XE3>_+R,JTWC(*FX-BN.-)04B\NJ%KXY-<+^JU-
M^B?F8]5U%Q.EFF9/>Z1L<,K:>2H[MP,E5'*D:R_81VFK[N]IQOS3<L:J.:BM
M5%1>45/4                           @V8,1_4S %7S8^N<G_P#7U_63
MD       '*^J^371UY@Q.T6J^2P3PI47&MMU,DCF4ZJJ+%&JN:B/=I45V]M1
M=HBKY3'I[<+'<L2H7XO&D%LA1:=M.K.Q\#F+IT;VKRCD7>]\^O.]D-RFMR#/
MKK=L;QAL-'8*5R4E=>'3R13,J$<USFP(Q4[E8WA=JB*Y=+PBHZWD43<EZB08
MW2U,GT;8Z-C[M*]^]12(O[W5R\JLK48KU5=HUG"^\XYY06JLN.,8[36%T-"F
M3Y957JF9-%W11PQ(]\2+&BI[B^'&[2*=RQOZZQUL<>2?5^>C[-.FH5ECD1R)
MY]CD5%15^::^9*>Y.Y&[3N5-HAC7:K906JLK)E[8Z>%\SE7T1K55?Z#AF#X%
M=KMT@P&HL]VIZ:YTM2Z\.=5Q+-%*^7O<BN;M-N;WHJ?-/Q,C-</;2W;"J2_5
M/TU77J]QNNE55,:C9TAB>]D38_)L6]Z8G"^NU4[JB(U$1$TB<(6:U9$HYUAE
MCAE2-W9+(WN8Q=<.<FTVB>>MI]Z')NE%MJJO+*R_6FKN"8VL3Z=\U7522K>*
MCN3=2UCE5L;$[5:U6ZVGR)Q>K]503^TV^:T+9J"1[;M45%0Y'P=J(JM:B-5.
MY$7:[5/AHAW5&]5EPQ?!V103VZMO5ZH$6GD<J/B:CO%<CM:\D:FTT2KJ?C-=
ME..QT=KJXJ>HAJ&5'A5"O2"I:W:+#,C%158[?*?%$X.<XQ14_4IEJJ*ZS6VT
M8;C<[TDMZM;N6MC;VNWQVI W:^?+E3E-';J*H@JZ."HHY&2TTK$?%)&NVN:J
M;147X:+P                          (5E>O[I."[^-=_L4)J       "
M&Y)D]]H[Q/:K+B=97U#HV.IZQTK8Z/G?=XDB\M[=?91'*OH9?3O&9,7L4L%7
M4-J;C6U4M?6RL3M8Z>1=O[$]&IPB)\C0X7:LKQ;=FBM=IJ;8^OJ*EUR6O>V1
M8Y9G2+W0^%R]$=V_;UPB^1 ,:M=^RN[]0[?;Z2FH;5=+_-2W&Z^.JS)!$UC%
MACCTFU<BJG=OW>YW"Z0GF?6>6SW3";[9K;4U=#CLDT#[?0L[GI!+#X2.8S];
MLTWCX*I.[+<$NML@K6TM72)*BJD-7$L4K>=>\U>4\C%K\?HJW([7>Y/%97VY
MDL43F.TCV2(B.8]/5-HU4^"HAINL-?);.EF4U4'=XS;?,UBM72HKFJU%_#>S
M;X9;VVG$+);VM<QM+10PHUWFG:Q$Y\N>#$RS%VW^YXY7)4^!-9JY*QJ*SN21
M%8YCF?+:.VB^FO(TF572O=U;PFS6VL?%#X5977"!KM))"C$9'W)Z^^[A/EOT
M*.L\]U^A*&@MU%=IZ"MJ4CN4MKB\6H93HBJYK6HJ+MZZ:KO1%<OP)-3MJ),-
M6.PTGT55>QNCHH*N-$2G<C52-'M:J\(J-X1?(AO2_ KM:;3;FY=5TT\U(KY4
MI:7O6.2=Z[=/.]R[FEWRBJB(W?"*J(J;#.\;N]ZS_!+A0LI_HRTU%145CWOT
MYJNC1K$:GKO;OV%76=]X^J<%-8Z"MKEJZZ"&L91?PS:;N[I59RB(JHWMVJIK
MNWM"]TAQ:KQ3$%I+DD;:VJJIJZ:&)>YD+I7=WAHOKVII-_'9-DX\@
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MZJJJJFU
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MODDRIYJQ<TJ(5KJEU#[&UZTKZ)4C8_NTBLG1J(JZ1=L5RKY+PA(
M
M
M
M
J                                                     ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>kpmg_sig.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 kpmg_sig.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ^ *0# 2(  A$! Q$!_\0
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)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6739423184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Acasti Pharma Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001444192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">acst<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="nump">78,132,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6739346592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Financial Position - CAD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,521,000<span></span>
</td>
<td class="nump">$ 8,223,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">11,865,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Receivables</a></td>
<td class="nump">1,586,000<span></span>
</td>
<td class="nump">759,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other Assets</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">104,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DeferredFinancingCostsCurrent', window );">Deferred financing costs</a></td>
<td class="nump">179,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">1,115,000<span></span>
</td>
<td class="nump">406,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">37,331,000<span></span>
</td>
<td class="nump">9,492,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other asset</a></td>
<td class="nump">557,000<span></span>
</td>
<td class="nump">555,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Equipment</a></td>
<td class="nump">2,813,000<span></span>
</td>
<td class="nump">2,821,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets</a></td>
<td class="nump">7,743,000<span></span>
</td>
<td class="nump">10,065,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">48,471,000<span></span>
</td>
<td class="nump">22,959,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">16,429,000<span></span>
</td>
<td class="nump">6,697,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDebtInstrumentsIssued', window );">Unsecured convertible debentures</a></td>
<td class="nump">1,817,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">18,246,000<span></span>
</td>
<td class="nump">6,697,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Derivative warrant liabilities</a></td>
<td class="nump">16,263,000<span></span>
</td>
<td class="nump">6,426,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentDebtInstrumentsIssued', window );">Unsecured convertible debentures</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,612,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">34,509,000<span></span>
</td>
<td class="nump">14,735,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">129,318,000<span></span>
</td>
<td class="nump">73,338,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherEquityInterest', window );">Other equity</a></td>
<td class="nump">309,000<span></span>
</td>
<td class="nump">309,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionalPaidinCapital', window );">Contributed surplus</a></td>
<td class="nump">8,280,000<span></span>
</td>
<td class="nump">6,956,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Deficit</a></td>
<td class="num">(123,945,000)<span></span>
</td>
<td class="num">(72,379,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">13,962,000<span></span>
</td>
<td class="nump">8,224,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CapitalCommitments', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and equity</a></td>
<td class="nump">$ 48,471,000<span></span>
</td>
<td class="nump">$ 22,959,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DeferredFinancingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DeferredFinancingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of resources: (a) controlled by the entity as a result of past events; and (b) from which future economic benefits are expected to flow to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of future capital expenditures that the entity is committed to make.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDebtInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current debt instruments issued. [Refer: Debt instruments issued]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDebtInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of present obligations of the entity arising from past events, the settlement of which is expected to result in an outflow from the entity of resources embodying economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDebtInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current debt instruments issued. [Refer: Debt instruments issued]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDebtInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2017-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2017-03-01&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6749245376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Earnings and Comprehensive Loss (Twelve Month and Month Ended 2017 Unaudited) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses, net of government assistance</a></td>
<td class="num">$ (426)<span></span>
</td>
<td class="num">$ (38,366)<span></span>
</td>
<td class="num">$ (15,669)<span></span>
</td>
<td class="num">$ (7,227)<span></span>
</td>
<td class="num">$ (7,653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(292)<span></span>
</td>
<td class="num">(6,649)<span></span>
</td>
<td class="num">(4,027)<span></span>
</td>
<td class="num">(3,265)<span></span>
</td>
<td class="num">(3,557)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Loss from operating activities</a></td>
<td class="num">(718)<span></span>
</td>
<td class="num">(45,015)<span></span>
</td>
<td class="num">(19,696)<span></span>
</td>
<td class="num">(10,492)<span></span>
</td>
<td class="num">(11,210)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_GrossFinanceIncomeCost', window );">Financial expenses</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(6,551)<span></span>
</td>
<td class="num">(1,808)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeBeforeTax', window );">Net loss and comprehensive loss before income tax</a></td>
<td class="num">(769)<span></span>
</td>
<td class="num">(51,566)<span></span>
</td>
<td class="num">(21,504)<span></span>
</td>
<td class="num">(10,607)<span></span>
</td>
<td class="num">(11,376)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Deferred income tax recovery</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and total comprehensive loss</a></td>
<td class="num">$ (769)<span></span>
</td>
<td class="num">$ (51,566)<span></span>
</td>
<td class="num">$ (21,504)<span></span>
</td>
<td class="num">$ (10,478)<span></span>
</td>
<td class="num">$ (11,247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Basic and diluted loss per share (in CAD per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
<td class="num">$ (0.97)<span></span>
</td>
<td class="num">$ (1.01)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares outstanding (in shares)</a></td>
<td class="nump">14,702,556<span></span>
</td>
<td class="nump">54,290,295<span></span>
</td>
<td class="nump">17,486,515<span></span>
</td>
<td class="nump">10,788,075<span></span>
</td>
<td class="nump">11,094,512<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_GrossFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_GrossFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph ab<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 90<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, before tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 91<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_91_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2017-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=32&amp;date=2017-03-01&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2017-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2017-03-01&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2017-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=33&amp;date=2017-03-01&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6750958080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes In Equity (Twelve Month and Month Ended 2017 Unaudited) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Issued capital [member]</div></th>
<th class="th"><div>Other equity interest [member]</div></th>
<th class="th"><div>Additional paid-in capital [member]</div></th>
<th class="th"><div>Retained earnings [member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in shares) at Feb. 29, 2016</a></td>
<td class="nump">10,712,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Feb. 29, 2016</a></td>
<td class="nump">$ 61,973<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,875<span></span>
</td>
<td class="num">$ (39,628)<span></span>
</td>
<td class="nump">$ 27,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and total comprehensive loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,478)<span></span>
</td>
<td class="num">(10,478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IssueOfEquityNumberOfShares', window );">Public offering (in shares)</a></td>
<td class="nump">3,930,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Public offering</a></td>
<td class="nump">$ 4,509<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment transactions for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Total contributions by and distributions to equity holders (in shares)</a></td>
<td class="nump">3,990,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total contributions by and distributions to equity holders</a></td>
<td class="nump">$ 4,603<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">732<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Issue of unsecured convertible debentures, net of deferred income tax expense of $129</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares', window );">Equity settled non-employee share-based payment (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment', window );">Equity settled non-employee share-based payment</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in shares) at Feb. 28, 2017</a></td>
<td class="nump">14,702,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Feb. 28, 2017</a></td>
<td class="nump">$ 66,576<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">5,607<span></span>
</td>
<td class="num">(50,106)<span></span>
</td>
<td class="nump">22,386<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in shares) at Feb. 29, 2016</a></td>
<td class="nump">10,712,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Feb. 29, 2016</a></td>
<td class="nump">$ 61,973<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,875<span></span>
</td>
<td class="num">(39,628)<span></span>
</td>
<td class="nump">27,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and total comprehensive loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,247)<span></span>
</td>
<td class="num">(11,247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment transactions for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">674<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Total contributions by and distributions to equity holders (in shares)</a></td>
<td class="nump">3,990,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total contributions by and distributions to equity holders</a></td>
<td class="nump">$ 4,603<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">818<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,730<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2017</a></td>
<td class="nump">14,702,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Mar. 31, 2017</a></td>
<td class="nump">$ 66,576<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">5,693<span></span>
</td>
<td class="num">(50,875)<span></span>
</td>
<td class="nump">21,703<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in shares) at Feb. 28, 2017</a></td>
<td class="nump">14,702,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Feb. 28, 2017</a></td>
<td class="nump">$ 66,576<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">5,607<span></span>
</td>
<td class="num">(50,106)<span></span>
</td>
<td class="nump">22,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and total comprehensive loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(769)<span></span>
</td>
<td class="num">(769)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment transactions for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total contributions by and distributions to equity holders</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2017</a></td>
<td class="nump">14,702,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Mar. 31, 2017</a></td>
<td class="nump">$ 66,576<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">5,693<span></span>
</td>
<td class="num">(50,875)<span></span>
</td>
<td class="nump">21,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NetEquity', window );"></a></td>
<td class="nump">61,973<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,875<span></span>
</td>
<td class="num">(50,875)<span></span>
</td>
<td class="nump">15,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and total comprehensive loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(21,504)<span></span>
</td>
<td class="num">(21,504)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IssueOfEquityNumberOfShares', window );">Public offering (in shares)</a></td>
<td class="nump">10,667,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Public offering</a></td>
<td class="nump">$ 6,169<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsExercisedEquitySharesIssued', window );">Warrants exercised (in shares)</a></td>
<td class="nump">178,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Warrants exercised</a></td>
<td class="nump">$ 456<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment transactions for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">929<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ConversionOfConvertibleInstrumentsEquitySharesIssued', window );">Issuance of shares for payment of interest on convertible debentures (in shares)</a></td>
<td class="nump">89,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Amount</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Total contributions by and distributions to equity holders (in shares)</a></td>
<td class="nump">10,935,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total contributions by and distributions to equity holders</a></td>
<td class="nump">$ 6,762<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,025<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2018</a></td>
<td class="nump">25,638,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Mar. 31, 2018</a></td>
<td class="nump">$ 73,338<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">6,956<span></span>
</td>
<td class="num">(72,379)<span></span>
</td>
<td class="nump">8,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NetEquity', window );"></a></td>
<td class="nump">66,576<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">5,693<span></span>
</td>
<td class="num">(72,379)<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and total comprehensive loss for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(51,566)<span></span>
</td>
<td class="num">(51,566)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IssueOfEquityNumberOfShares', window );">Public offering (in shares)</a></td>
<td class="nump">51,612,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Public offering</a></td>
<td class="nump">$ 54,124<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 54,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsExercisedEquitySharesIssued', window );">Warrants exercised (in shares)</a></td>
<td class="nump">772,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Warrants exercised</a></td>
<td class="nump">$ 1,733<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares', window );">Share-based payment transactions for the period (in shares)</a></td>
<td class="nump">4,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment transactions for the period</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,041<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ConversionOfConvertibleInstrumentsEquitySharesIssued', window );">Issuance of shares for payment of interest on convertible debentures (in shares)</a></td>
<td class="nump">105,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Amount</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding', window );">Total contributions by and distributions to equity holders (in shares)</a></td>
<td class="nump">52,494,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Total contributions by and distributions to equity holders</a></td>
<td class="nump">$ 55,980<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,324<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">57,304<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">78,132,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 129,318<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">8,280<span></span>
</td>
<td class="num">(123,945)<span></span>
</td>
<td class="nump">13,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NetEquity', window );"></a></td>
<td class="nump">$ 73,338<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 6,956<span></span>
</td>
<td class="num">$ (123,945)<span></span>
</td>
<td class="num">$ (43,342)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ConversionOfConvertibleInstrumentsEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity shares issued from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ConversionOfConvertibleInstrumentsEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from equity settled non-employee share-based payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity shares resulting from equity settled non-employee share-based payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of shares outstanding through share-based payment transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IncreaseDecreaseThroughSharebasedPaymentTransactionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IssueOfEquityNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in the issuance of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IssueOfEquityNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NetEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NetEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_WarrantsExercisedEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity shares issued from warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_WarrantsExercisedEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from transactions with owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in equity resulting from the issuing of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6749208208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Changes In Equity (Twelve Month and Month Ended 2017 Unaudited) (Parentheticals) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome', window );">Deferred income tax recovery</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax relating to amounts recognised in other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph ab<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_ab&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 90<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_90&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxRelatingToComponentsOfOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6751046368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Twelve Month and Month Ended 2017 Unaudited)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Cash flows used in operating activities:</a></td>
<td class="num">$ (769,000)<span></span>
</td>
<td class="num">$ (51,566,000)<span></span>
</td>
<td class="num">$ (21,504,000)<span></span>
</td>
<td class="num">$ (10,478,000)<span></span>
</td>
<td class="num">$ (11,247,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForAmortisationExpense', window );">Amortization of intangible assets</a></td>
<td class="nump">194,000<span></span>
</td>
<td class="nump">2,322,000<span></span>
</td>
<td class="nump">2,323,000<span></span>
</td>
<td class="nump">2,323,000<span></span>
</td>
<td class="nump">2,517,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation of equipment</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">505,000<span></span>
</td>
<td class="nump">349,000<span></span>
</td>
<td class="nump">189,000<span></span>
</td>
<td class="nump">221,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Stock-based compensation</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">1,041,000<span></span>
</td>
<td class="nump">929,000<span></span>
</td>
<td class="nump">588,000<span></span>
</td>
<td class="nump">674,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Net financial expenses</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="nump">6,551,000<span></span>
</td>
<td class="nump">1,808,000<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">166,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Realized foreign exchange gain (loss)</a></td>
<td class="num">(12,000)<span></span>
</td>
<td class="nump">581,000<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDeferredTaxExpense', window );">Deferred income tax recovery</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(129,000)<span></span>
</td>
<td class="num">(129,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLoss', window );">Total adjustments</a></td>
<td class="num">(418,000)<span></span>
</td>
<td class="num">(40,566,000)<span></span>
</td>
<td class="num">(16,102,000)<span></span>
</td>
<td class="num">(7,332,000)<span></span>
</td>
<td class="num">(7,750,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Changes in working capital items</a></td>
<td class="num">(328,000)<span></span>
</td>
<td class="nump">8,090,000<span></span>
</td>
<td class="nump">3,583,000<span></span>
</td>
<td class="nump">1,120,000<span></span>
</td>
<td class="nump">792,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(746,000)<span></span>
</td>
<td class="num">(32,476,000)<span></span>
</td>
<td class="num">(12,519,000)<span></span>
</td>
<td class="num">(6,212,000)<span></span>
</td>
<td class="num">(6,958,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from (used in) investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities', window );">Interest received</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">384,000<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">146,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of equipment</a></td>
<td class="num">(24,000)<span></span>
</td>
<td class="num">(700,000)<span></span>
</td>
<td class="num">(455,000)<span></span>
</td>
<td class="num">(2,503,000)<span></span>
</td>
<td class="num">(2,527,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments', window );">Acquisition of short-term investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,765,000)<span></span>
</td>
<td class="num">(12,765,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Acquisition of marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(23,753,000)<span></span>
</td>
<td class="num">(26,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Maturity of short-term investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,030,000<span></span>
</td>
<td class="nump">22,030,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Maturity of marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,933,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash (used in) investing activities</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="num">(12,136,000)<span></span>
</td>
<td class="num">(411,000)<span></span>
</td>
<td class="nump">6,908,000<span></span>
</td>
<td class="nump">6,888,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from (used in) financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Net proceeds from public offering</a></td>
<td class="num">(34,000)<span></span>
</td>
<td class="nump">57,892,000<span></span>
</td>
<td class="nump">11,065,000<span></span>
</td>
<td class="nump">5,044,000<span></span>
</td>
<td class="nump">5,010,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ProceedsFromIssuingSharesPrivatePlacement', window );">Net proceeds from private placement</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(40,000)<span></span>
</td>
<td class="nump">1,882,000<span></span>
</td>
<td class="nump">1,872,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ProceedsFromExerciseOfWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,011,000<span></span>
</td>
<td class="nump">384,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Share based payment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(44,000)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
<td class="num">(18,000)<span></span>
</td>
<td class="num">(18,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash from (used in) financing activities</a></td>
<td class="num">(44,000)<span></span>
</td>
<td class="nump">58,862,000<span></span>
</td>
<td class="nump">11,406,000<span></span>
</td>
<td class="nump">6,908,000<span></span>
</td>
<td class="nump">6,864,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Foreign exchange (loss) gain on cash and cash equivalents held in foreign currencies</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
<td class="num">(58,000)<span></span>
</td>
<td class="num">(49,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(801,000)<span></span>
</td>
<td class="nump">14,298,000<span></span>
</td>
<td class="num">(1,549,000)<span></span>
</td>
<td class="nump">7,546,000<span></span>
</td>
<td class="nump">6,745,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">10,573,000<span></span>
</td>
<td class="nump">8,223,000<span></span>
</td>
<td class="nump">9,772,000<span></span>
</td>
<td class="nump">3,027,000<span></span>
</td>
<td class="nump">3,027,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">9,772,000<span></span>
</td>
<td class="nump">22,521,000<span></span>
</td>
<td class="nump">8,223,000<span></span>
</td>
<td class="nump">10,573,000<span></span>
</td>
<td class="nump">9,772,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">6,778,000<span></span>
</td>
<td class="nump">1,896,000<span></span>
</td>
<td class="nump">1,583,000<span></span>
</td>
<td class="nump">7,584,000<span></span>
</td>
<td class="nump">6,778,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">$ 2,994,000<span></span>
</td>
<td class="nump">$ 20,625,000<span></span>
</td>
<td class="nump">$ 6,640,000<span></span>
</td>
<td class="nump">$ 2,989,000<span></span>
</td>
<td class="nump">$ 2,994,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ProceedsFromIssuingSharesPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares in a private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ProceedsFromIssuingSharesPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsForNoncashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsForNoncashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2017-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=4&amp;date=2017-03-01&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737302864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Reporting Entity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory', window );">Disclosure of basis of consolidation [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Reporting entity</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Acasti Pharma Inc. (<div style="display: inline; font-weight: bold;">Acasti</div> or the <div style="display: inline; font-weight: bold;">Corporation</div>) is incorporated under the <div style="display: inline; font-style: italic;">Business Corporations Act</div> (Qu&eacute;bec) (formerly Part <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1A</div> of the <div style="display: inline; font-style: italic;">Companies Act </div>(Qu&eacute;bec)). The Corporation is domiciled in Canada and its registered office is located at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">545,</div> Promenade du Centropolis, Laval, Qu&eacute;bec, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">H7T</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0A3.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation is subject to a number of risks associated with its ongoing priorities, including the conduct of its clinical program and its results, the establishment of strategic alliances and the development of new pharmaceutical products and their marketing. The Corporation&#x2019;s current product in development requires approval from the U.S Food and Drug Administration and equivalent regulatory organizations in other countries before their sale can be authorized. Certain risks have been reduced for the longer term with the outcome of the Corporation&#x2019;s actions, including its intellectual property strategy execution with filed patent applications in more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div> jurisdictions, with more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div> issued patents and with numerous additional patent applications pending.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation has incurred significant operating losses and negative cash flows from operations since inception. To date, the Corporation has financed its operations through the public offering and private placement of Common Shares, units consisting of Common Shares and warrants and convertible debt, the proceeds from research grants and research tax credits, and the exercises of warrants, rights and options. To achieve the objectives of its business plan, Acasti plans to raise the necessary funds through additional securities offerings and the establishment of strategic alliances as well as additional research grants and research tax credits. The ability of the Corporation to complete the needed financing and ultimately achieve profitable operations is dependent on a number of factors outside of the Corporation&#x2019;s control.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfConsolidationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for consolidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfConsolidationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737358720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Basis of Preparation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Disclosure of basis of preparation of financial statements [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Basis of preparation</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(a)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Statement of compliance:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">These financial statements have been prepared in accordance with International Financial Reporting Standards (&#x201c;IFRS&#x201d;) as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;). Beginning in fiscal <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Corporation&#x2019;s fiscal year end is on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31. </div>Fiscal <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> is a transition year, and includes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">thirteen</div> months of operations, beginning on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and ending on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017. </div>As a result, for comparative purposes the above financial statements and corresponding notes to financial statements include <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> unaudited periods: the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017 </div>and the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 28, 2017. </div>The Canadian Securities regulator permits, in the transition year, the presentation of a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">thirteen</div>-month period for the financial year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The financial statements were approved by the Board of Directors on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 26, 2019.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(b)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Basis of measurement:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The financial statements have been prepared on the historical cost basis, except for:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 18pt"><div style="display: inline; font-family: Symbol; font-size: 10pt">&middot;</div></td> <td style="text-align: justify; padding-right: 5.9pt">Stock-based compensation which is measured pursuant to IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,</div> <div style="display: inline; font-style: italic;">Share-based payments</div> (<div style="display: inline; font-style: italic;">Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>(e) (ii</div>)); and,</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 18pt"><div style="display: inline; font-family: Symbol; font-size: 10pt">&middot;</div></td> <td style="text-align: justify; padding-right: 5.9pt">Derivative warrant liabilities measured at fair value on a recurring basis <div style="display: inline; font-style: italic;">(Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div>)</div>.</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(c)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Going concern uncertainty:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation has incurred operating losses and negative cash flows from operations since inception. The Corporation&#x2019;s current assets of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$37.3</div> million as at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>include cash and cash equivalents totaling <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$22.5</div> million, and marketable securities of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$11.9</div> million mainly generated by the net proceeds from the recent Public Offerings. The Corporation&#x2019;s current liabilities total <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$18.2</div> million at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and are comprised primarily of amounts due to or accrued for creditors<div style="display: inline; font-size: 10pt">. Management projects that additional funds will be needed in the future, after TRILOGY phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> clinical trials, for activities necessary to prepare for commercial launch, including the scale up of our manufacturing operations, the completion of the potential regulatory (NDA) submission package (assuming positive Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> clinical results), and the expansion of business development and US commercial launch activities. The Corporation is working towards development of strategic partner relationships, as well as actively seeking additional non-dilutive funds in the future, but there can be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurance as to when or whether Acasti will complete any strategic collaborations or succeed in identifying non-dilutive funding sources. Consequently, the Corporation <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>need to raise additional equity capital in the future to fund these activities. In particular, raising additional capital is subject to market conditions and is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> within the Corporation&#x2019;s control. If the Corporation does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> raise additional funds or find <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more strategic partners, it <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be able to realize its assets and discharge its liabilities in the normal course of business. As a result, there exists a material uncertainty that casts substantial doubt about the Corporation&#x2019;s ability to continue as a going concern and, therefore, realize its assets and discharge its liabilities in the normal course of business. </div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div> <!-- Field: Page; Sequence: 10; Value: 9 --> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The financial statements have been prepared on a going concern basis, which assumes the Corporation will continue its operations in the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the ordinary course of business. These financial statements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments to the carrying values and classification of assets and liabilities and reported expenses that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be necessary if the going concern basis was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> appropriate for these financial statements. If the Corporation was unable to continue as a going concern, material write-downs to the carrying values of the Corporation&#x2019;s assets, including the intangible asset, could be required.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(d)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Functional and presentation currency:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">These financial statements are presented in Canadian dollars, which is the Corporation&#x2019;s functional currency.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(e)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Use of estimates and judgments:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">The preparation of the financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>differ from these estimates.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">Estimates are based on management&#x2019;s best knowledge of current events and actions that the Corporation <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">Critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements include the following:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 35pt"><div style="display: inline; font: 10pt Symbol">&middot;</div></td> <td style="width: 5pt"></td> <td style="text-align: justify; padding-right: 5.95pt">The use of the going concern basis of preparation of the financial statements. At the end of each reporting period, management assesses the basis of preparation of the financial statements (Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>(c)).</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">Assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the next financial year include the following:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 35pt"><div style="display: inline; font: 10pt Symbol">&middot;</div></td> <td style="width: 5pt"></td> <td style="text-align: justify; padding-right: 5.6pt">Measurement of derivative warrant liabilities (<div style="display: inline; font-style: italic;">note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></div>) and stock-based compensation (<div style="display: inline; font-style: italic;">note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></div>).</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(f)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Use of estimates and judgments (continued):</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.6pt; margin-bottom: 0pt; text-align: justify">Also, management uses judgment to determine which research and development (&#x201c;R&amp;D&#x201d;) expenses qualify for R&amp;D tax credits and in what amounts. The Corporation recognizes the tax credits once it has reasonable assurance that they will be realized. Recorded tax credits are subject to review and approval by tax authorities and therefore, could be different from the amounts recorded.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6604915088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Disclosure of significant accounting policies [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Significant accounting policies:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The accounting policies set out below have been applied consistently to all periods presented in these financial statements.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(a)</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Financial instruments:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">A financial instrument is any contract that gives rise to a financial asset of </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> party and a financial liability or equity instrument of another party.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(i)</div></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Non-derivative financial assets:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The Corporation has the following non-derivative financial assets: cash, cash equivalents, marketable securities and receivables. The Corporation determines the classification of its financial assets at initial recognition. The subsequent measurement of financial assets depends on their classification.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Financial assets and liabilities are offset and the net amount presented in the statements of financial position when, and only when, the Corporation has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Cash, cash equivalents, marketable securities and receivables with maturities of less than </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> year are classified at amortized cost as they meet both of the following conditions; they are held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms give rise on specified dates to cashflows that are solely payments of principal and interest on the principal amount outstanding. Cash and cash equivalents comprise cash balances and highly liquid investments purchased </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> months or less from maturity.</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0.25in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <!-- Field: Page; Sequence: 11; Value: 9 --><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(ii)</div></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Non-derivative financial liabilities:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The Corporation has the following non-derivative financial liabilities: trade and other payables. Such financial liabilities are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are measured at amortized cost using the effective interest method.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The Corporation derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(iii)</div></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Compound financial instruments:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Compound financial instruments are instruments that can be converted to share capital at the option of the holder, and the number of shares to be issued is fixed.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The unsecured convertible debentures are compound instruments and have been separated into liability and equity components. The liability component is recognized initially at the fair value of a similar liability that does </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> remeasured subsequent to initial recognition.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(iv)</div></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Share capital:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Common Shares</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Class A Common Shares are classified as equity. Incremental costs directly attributable to the issue of Common Shares and share options are recognized as a deduction from share capital, net of any tax effects.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(v)</div></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Derivative financial instruments:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The Corporation has issued liability-classified derivatives over its own equity. Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit and loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and all changes in their fair value are recognized immediately in profit or loss as a component of finance expense (income).</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(vi)</div></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Other equity instruments:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Warrants, options and rights over the Corporation&#x2019;s equity issued outside of share-based payment transactions that do </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> meet the definition of a liability instrument are recognized in equity.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(b)</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Equipment:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(i)</div></td> <td style="text-align: justify; padding-right: 5.9pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Recognition and measurement:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Equipment is measured at cost less accumulated depreciation and accumulated impairment losses, if any.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Cost includes expenditures that are directly attributable to the acquisition of the asset, including all costs incurred in bringing the asset to its present location and condition.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Gains and losses on disposal of equipment are determined by comparing the proceeds from disposal with the carrying amount of equipment, and are recognized net within ''other income or expenses'' in profit or loss.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(ii)</div></td> <td style="text-align: justify; padding-right: 5.9pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Subsequent costs:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The cost of replacing a part of an equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Corporation, and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the day-to-day servicing of equipment are recognized in profit or loss as incurred.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <!-- Field: Page; Sequence: 12; Value: 9 --><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(iii)</div></td> <td style="text-align: justify; padding-right: 5.9pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Depreciation:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Depreciation is recognized in profit or loss on either a straight-line basis or a declining basis over the estimated useful lives of each part of an item of equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Items of equipment are depreciated from the date that they are available for use or, in respect of assets </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> yet in service, from the date they are ready for their intended use.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The estimated useful lives and rates for the current and comparative periods are as follows:</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-indent: -9.05pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div> <table style="border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Assets</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid; text-align: right"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Method</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Period/Rate</div></div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;Furniture and office equipment</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Declining balance</div></div></div></td> <td style="font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20%</div></div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> to</div></div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 30%</div></div></div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 28%; font: 10pt Times New Roman, Times, Serif; text-align: left"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Computer equipment</div></div></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="width: 30%; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Declining balance</div></div></div></td> <td style="width: 20%; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="width: 7%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></div></td> <td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30%</div></div></div></td> <td style="width: 7%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Laboratory equipment</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Declining balance</div></div></div></td> <td style="font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30%</div></div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Production equipment (in years)</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Straight-line</div></div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></div></div></td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></div></td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Depreciation methods, useful lives and residual values are reviewed at each financial year-end and adjusted prospectively if appropriate.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(c)</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Intangible assets:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(i)</div></td> <td style="text-align: justify; padding-right: 5.9pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Research and development:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss as incurred.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Corporation intends to and has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized includes the cost of materials, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use, and borrowing costs on qualifying assets. Other development expenditures are recognized in profit or loss as incurred.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Capitalized development expenditure is measured at cost less accumulated amortization and accumulated impairment losses. As of the reporting periods presented, the Corporation has </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> capitalized any development expenditure.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(ii)</div></td> <td style="text-align: justify; padding-right: 5.9pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Other intangible assets:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Patent costs</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Patents for technologies that are </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> longer in the research phase are recorded at cost. Patent costs include legal fees to obtain patents and patent application fees. When the technology is still in the research and development phase, those costs are expensed as incurred.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Licenses</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Licenses that are acquired by the Corporation and have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(iii)</div></td> <td style="text-align: justify; padding-right: 5.9pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Subsequent expenditure:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditures, including expenditure on internally generated goodwill and brands, are recognized in profit or loss as incurred.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(iv)</div></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Amortization:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Amortization is calculated over the cost of the intangible asset less its residual value.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <!-- Field: Page; Sequence: 13; Value: 9 --><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets from the date that they are available for use, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are as follows:</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Assets</div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Period (in years)</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Patents</div></td> <td style="width: 1%"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 7%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 7%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td style="width: 7%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">License</div></td> <td style="border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8 </div></td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 14</div></td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(d)</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Impairment:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(i)</div></td> <td style="text-align: justify; padding-right: 5.9pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Financial assets:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The Corporation assesses at each reporting date the expected credit loss for calculating impairment of financial assets and recognizes expected credit losses as loss allowances for assets measured at amortized cost.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(ii)</div></td> <td style="text-align: justify; padding-right: 5.9pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Non-financial assets:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The carrying amounts of the Corporation&#x2019;s non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset&#x2019;s recoverable amount is estimated.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the &#x201c;cash-generating unit, or &#x201c;CGU&#x201d;).</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The Corporation&#x2019;s corporate assets do </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> generate separate cash inflows. If there is an indication that a corporate asset </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">be impaired, then the recoverable amount is determined for the CGU to which the corporate asset belongs.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">An impairment loss is recognized if the carrying amount of an asset or its CGU exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Impairment losses recognized in prior years are assessed at each reporting date for any indications that the loss has decreased or </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset&#x2019;s carrying amount does </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> exceed the carrying amount that would have been determined, net of depreciation or amortization, if </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> impairment loss had been recognized.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(e)</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Employee benefits:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(i)</div></td> <td style="text-align: justify; padding-right: 5.9pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Short-term employee benefits:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">A liability is recognized for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Corporation has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the obligation can be estimated reliably.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <!-- Field: Page; Sequence: 14; Value: 9 --><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(ii)</div></td> <td style="text-align: justify; padding-right: 5.9pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Share-based payment transactions:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The grant date fair value of share-based payment awards granted to employees is recognized as an employee expense, with a corresponding increase in contributed surplus, over the period that the employees unconditionally become entitled to the awards. The grant date fair value takes into consideration market performance conditions when applicable. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. Share-based payment arrangements in which the Corporation receives goods or services as consideration for its own equity instruments are accounted for as equity-settled share-based payment transactions, regardless of how the equity instruments are obtained by the Corporation.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(iii)</div></td> <td style="text-align: justify; padding-right: 5.9pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Termination benefits:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Termination benefits are recognized as an expense when the Corporation is committed demonstrably, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognized as an expense if the Corporation has made an offer of voluntary redundancy, it is probable that the offer will be accepted, and the number of acceptances can be estimated reliably. If benefits are payable more than </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> months after the reporting year, then they are discounted to their present value.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(f)</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Provisions:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">A provision is recognized if, as a result of a past event, the Corporation has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as a component of finance expense (income).</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(i)</div></td> <td style="text-align: justify; padding-right: 5.9pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Onerous contracts:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">A provision for onerous contracts is recognized when the expected benefits to be derived by the Corporation from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Corporation recognizes any impairment loss on the assets associated with that contract.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(ii)</div></td> <td style="text-align: justify; padding-right: 5.9pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Contingent liability:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">A contingent liability is a possible obligation that arises from past events and of which the existence will be confirmed only by the occurrence or non-occurrence of </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> or more uncertain future events </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> within the control of the Corporation; or a present obligation that arises from past events (and therefore exists), but is </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> recognized because it is </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> probable that a transfer or use of assets, provision of services or any other transfer of economic benefits will be required to settle the obligation; or the amount of the obligation cannot be estimated reliably.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(g)</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Government grants:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Government grants are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Corporation has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Grants that compensate the Corporation for expenses incurred are recognized in profit or loss in reduction thereof on a systematic basis in the same years in which the expenses are recognized. Grants that compensate the Corporation for the cost of an asset are recognized in profit or loss on a systematic basis over the useful life of the asset.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(h)</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Lease payments:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease. Lease incentives received are recognized as an integral part of the total lease expense, over the term of the lease.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(i)</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Foreign currency:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Transactions in foreign currencies are translated into the functional currency at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the period, adjusted for effective interest and payments during the period, and the amortized cost in foreign currency translated at the exchange rate at the end of the reporting period. Foreign currency differences arising on translation are recognized in profit or loss.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <!-- Field: Page; Sequence: 15; Value: 9 -->   <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(j)</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Finance income and finance expense:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Finance income comprises interest income on funds invested. Interest income is recognized as it accrues in profit or loss, using the effective interest method.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Finance costs comprise interest expense, accretion on borrowings, unwinding of the discount on provisions, impairment losses recognized on financial assets, transaction costs for issuance of derivative warrant liabilities and changes of fair value of derivative warrant liabilities. Borrowing costs that are </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> directly attributable to the acquisition, construction or production of a qualifying asset are recognized in profit or loss using the effective interest method.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Foreign currency gains and losses are reported on a net basis. The Corporation recognizes interest income as a component of investing activities and interest expense as a component of financing activities in the statements of cash flows.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(k)</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Income tax:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Income tax expense comprises current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they relate to items recognized directly in equity or in other comprehensive income.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> recognized for temporary differences arising from the initial recognition of assets or liabilities in a transaction that is </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> a business combination and that affects neither accounting nor taxable profit or loss. Deferred tax is measured at the tax rates, enacted or substantively enacted, that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously. A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> longer probable that the related tax benefit will be realized.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(l)</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Earnings per share:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The Corporation presents basic and diluted earnings per share (&#x201c;EPS&#x201d;) data for its Class A shares (or &#x201c;Common Shares&#x201d;). Basic EPS is calculated by dividing the profit or loss attributable to the holders of Class A shares (Common Shares) of the Corporation by the weighted average number of Common Shares outstanding during the year, adjusted for own shares held. Diluted EPS is determined by adjusting the profit or loss attributable to the holders of Class A shares (Common Shares) and the weighted average number of Class A shares (Common Shares) outstanding adjusted for the effects of all dilutive potential Common Shares, which comprise warrants, rights and share options granted to employees.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(m)</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Segment reporting:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">An operating segment is a component of the Corporation that engages in business activities from which it </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">earn revenues and incur expenses. The Corporation has </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> reportable operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The majority of the Corporation&#x2019;s assets are located in Canada, while </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> major production unit, with a carrying value of </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,831</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> (</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 - </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,077</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">), is located in France.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <!-- Field: Page; Sequence: 16; Value: 9 -->   <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(n)</div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Change in accounting policy:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Adoption of new accounting standards</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The accounting policies used in these annual financial statements are consistent with those applied by the Corporation in its </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">annual financial statements except for the amendments to certain accounting standards which are relevant to the Corporation and were adopted by the Corporation as of </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2018 </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">as described below.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(i)</div></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Financial instruments:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> Financial Instruments, replaces IAS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> Financial Instruments: Recognition and Measurement. IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> introduces a revised approach for the classification of financial assets based on how an entity manages financial assets and the characteristics of the contractual cash flows of the financial assets replacing the multiple rules in IAS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39.</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> Most of the requirements in IAS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> for classification and measurement of financial liabilities have been carried forward in IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> also introduces a new hedge accounting model that is more closely aligned with risk-management activities and a new expected credit loss model for calculating impairment on financial assets replacing the incurred loss model in IAS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39.</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> The Corporation adopted IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> as of </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2018 </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">and assessed the impact of the adoption on its financial statements, and determined there was </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> material impact. The Corporation does </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> apply hedge accounting.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(ii)</div></td> <td style="text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Amendments to IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> &#x2013; Classification and Measurement of Share-Based Payment Transactions:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">On </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 20, 2016, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">the IASB issued amendments to IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> Share-Based Payment, clarifying how to account for certain types of share-based payment transactions. The amendments provide requirements on the accounting for: the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based payments; share-based payment transactions with a net settlement feature for withholding tax obligations; and a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from cash-settled to equity-settled. The Corporation adopted the amendments to IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> as of </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2018 </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">and assessed the impact of the adoption of IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> on its financial statements, and determined that there was </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> material impact.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Future accounting change:</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The following new standards, and amendments to standards and interpretations, are </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> yet effective for the period ended </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019,</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> and have </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> been applied in preparing these financial statements.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">New standards and interpretations </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> yet adopted:</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0">  <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(i)</div></td> <td style="text-align: justify; padding-right: 5.9pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Leases &#x2013; IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> Leases (&#x201c;IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16&#x201d;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">) In </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2016, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">the IASB issued IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> a new standard that replaces IAS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> Leases. IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> is a major revision of the way in which companies account for leases and will </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> longer permit off balance sheet leases. Adoption of IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> is mandatory and will be effective for the Corporation&#x2019;s fiscal year beginning on </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2019. </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">The Corporation is assessing the impact of adoption of IFRS </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> and currently there is only </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> lease that will be impacted by this new standard and the impact is expected to be minimal.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737302576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">Disclosure of trade and other receivables [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Receivables:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: center; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid">Notes</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-weight: normal; text-align: left">Sales tax receivables</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 14%; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">618</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">470</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Government assistance and tax credits receivable</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">872</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">282</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Interest receivable</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Other receivables</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Total receivables</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,586</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">759</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6592009280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DisclosureOfMarketableSecuritiesTextBlock', window );">Disclosure of marketable securities [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Marketable Securities</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.65pt; margin-bottom: 0pt">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.65pt; margin-bottom: 0pt"><div style="display: inline; font-weight: normal">The corporation holds various marketable securities with maturities greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90</div> days at the time of purchase as follows: </div></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-weight: normal; text-align: left">Term deposit issued in US currency [US $20], earning interest at 2.23% and maturing on March 13, 2019</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Term deposits issued in US currency [US $2,020], earning interest at 2.50% and maturing on various dates from April 8, 2019 to March 12, 2020</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,696</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Treasury bills issued in CAD currencyearning interest at rates ranging from 1.83% to 1.90% and maturing on various dates from April 2, 2019 to July 25, 2019</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,196</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Total Marketable securities</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,892</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; padding-left: 10pt">Current marketable securities</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,865</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 10pt">Marketable securities</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DisclosureOfMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DisclosureOfMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6591972592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Other Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherAssetsExplanatory', window );">Disclosure of other assets [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Other Assets</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.65pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.65pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-weight: normal">During the year, the Corporation owned a reserve of krill oil in which amounts are expensed as it is being used. The following table summarizes information regarding activities of amounts of the krill oil usage in the R&amp;D production processes and for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">NKPL66</div> manufacturing for the year (see note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div> (a)):</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-weight: normal; text-align: left">Balance &#x2013; beginning of year</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">659</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Purchased</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">68</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">970</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; border-bottom: Black 1pt solid">Used</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(105</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(311</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Balance &#x2013; end of year</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">622</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">659</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> <div style="display: inline; font-weight: normal"></div> <div style="display: inline; font-weight: normal">Current other asset</div></td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">65</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">104</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Other asset</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">557</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">555</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other assets. [Refer: Other assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737274768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Disclosure of related party [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Related parties:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Neptune Technologies (Neptune) Acasti&#x2019;s former parent company, owned approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.5%</div> of the issued and outstanding Class A shares (Common Shares) of the Corporation as at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019. </div>Neptune&#x2019;s ownership reduced below a control position, following Acasti&#x2019;s U.S. public financing activities in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2018.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(a)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Administrative and research and development expenses:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">The Corporation has significantly reduced its reliance on the support of Neptune for a portion of its general and administrative needs; however, it will continue to utilize their IT support for the near term. The Corporation was charged by Neptune for the purchase of research supplies and for certain costs incurred by Neptune for the benefit of the Corporation, as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></div><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"><tr style="vertical-align: top; text-align: justify"><td style="text-align: justify"></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br /> months ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br /> ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br /> 2019</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br /> 2018</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br /> 2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, </div><br /> 2017</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; text-indent: -8.25pt; padding-left: 8.25pt">Research and development expenses</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left; padding-left: 13.65pt">Supplies and incremental costs</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 13.65pt">Shared service agreement</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; padding-left: 15.3pt">Total</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; text-indent: -8.25pt; padding-left: 8.25pt">General and administrative expenses</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 13.65pt">Supplies and incremental costs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">211</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">239</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">293</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">277</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 13.65pt">Shared service agreement</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">121</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">325</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; padding-left: 15.3pt">Total</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">245</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">360</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">618</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">577</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Total related parties expenses</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">245</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">387</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">678</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">42</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">636</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 16.3pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Where Neptune incurs specific incremental costs for the benefit of the Corporation, it charges those amounts directly. Neptune provides Acasti with the services of personnel for certain administrative work as part of a shared service agreement. The employees&#x2019; salaries and benefits are charged proportionally to the time allocation agreed upon within the shared service agreement. Effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 30, 2017, </div>the laboratory support, the corporate affairs and the public company reporting services previously provided by Neptune as part of the shared service agreement were discontinued. The Corporation is now incurring incremental costs and expects to do so in the future, partially offset by reduced shared service fees. The account payable to Neptune amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$44</div> at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>is non-interest bearing and has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> specified maturity date. These charges do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> represent all charges incurred by Neptune that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>have benefited the Corporation. Also, these charges do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> necessarily represent the cost that the Corporation would otherwise need to incur, should it <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> receive these services or benefits through the shared resources of Neptune.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Historically, Neptune has provided the Corporation with the krill oil needed to produce CaPre for Acasti&#x2019;s clinical programs, including all of the krill oil projected to be needed for its Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> clinical study program. However, Neptune discontinued its krill oil production and sold its krill oil inventory to Aker on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 7, 2017. </div>In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Acasti purchased a reserve of krill oil from Aker that will be used in the production of CaPre capsules for its Phase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> clinical trials (see also note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div>). The Corporation is currently evaluating alternative suppliers of krill oil. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>a reserve of krill oil owned by the Corporation was physically stored at Neptune&#x2019;s facility.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(b)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Interest revenue:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 7, 2016 </div>Neptune announced the acquisition of Biodroga Nutraceuticals Inc. As part of this transaction, the Corporation pledged an amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2</div> million (&#x201c;Committed Funds&#x201d;) to partly guarantee the financing for the said transaction (&#x201c;Pledge Agreement&#x201d;). Neptune had agreed to pay Acasti an annual fee on the Committed Funds outstanding at an annual rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9%</div> during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11%</div> for the remaining term of the Pledge Agreement. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 20, 2016, </div>Neptune fully released the pledged amount. The Corporation recognized interest revenue of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nil</div> </div>for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$89</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">thirteen</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nil</div> (unaudited) for the month ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$89</div> (unaudited) for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 28, 2017.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</div> <!-- Field: Page; Sequence: 19; Value: 9 --> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(c)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Key management personnel compensation:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">The key management personnel are the officers of the Corporation and the members of the Board of Directors of the Corporation. They control in the aggregate less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1%</div> of the voting shares of the Corporation (less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1%</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2%</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>).</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Key management personnel compensation includes the following for the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">thirteen</div>-month and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017 </div>and the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 28, 2017.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br /> months ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2019</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2018</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, </div><br /> 2017</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Compensation</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,641</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,754</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,510</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">146</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,364</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Share-based compensation costs</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">940</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">826</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">619</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">78</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">541</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Total key management personnel compensation</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,581</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,580</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,129</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,905</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2017-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2017-03-01&amp;anchor=sect_Disclosures&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737243536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Government Assistance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGovernmentGrantsExplanatory', window );">Disclosure of government grants [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Government assistance:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br /> months ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2019</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2018</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, </div><br /> 2017</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Investment tax credit</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">588</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">409</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">103</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">95</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Government grant</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">227</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">37</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">190</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Total government assistance</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">595</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">409</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">330</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">285</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Government assistance is comprised of a government grant from the federal government and research and development investment tax credits receivable from the provincial government which relate to qualifiable research and development expenditures under the applicable tax laws. The amounts recorded as receivables are subject to a government tax audit and the final amounts received <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>differ from those recorded.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Unrecognized federal tax credits <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be used to reduce future income tax and expire as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">$</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; text-align: left">2029</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2030</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2031</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2032</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">431</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2033</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">441</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2034</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">436</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2035</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">519</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2036</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">286</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2037</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">315</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2038</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">324</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid">2039</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">329</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,167</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGovernmentGrantsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for government grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2017-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=20&amp;date=2017-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGovernmentGrantsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737335744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Disclosure of property, plant and equipment [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Equipment:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0.5in; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Furniture and <br /> office equipment</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Computer <br /> equipment</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Laboratory <br /> equipment</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Production <br /> equipment</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Total</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Cost:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%">Balance at February 29, 2016</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">336</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">398</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">Additions for the twelve-month period (Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">186</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,484</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,678</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at February 28, 2017 (Unaudited)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">522</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,484</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,076</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid">Additions for the one-month period (Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Additions for the thirteen-month period</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">186</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,527</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,721</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2017</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">522</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,527</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,119</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid">Additions</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">192</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">181</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">383</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2018</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">714</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,708</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,502</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid">Additions</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">219</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">497</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid">Balance at March 31, 2019</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">68</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">933</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,968</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,999</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Accumulated depreciation:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at February 29, 2016</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">52</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">56</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">111</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">Depreciation for the twelve-month period (Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">129</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">52</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">189</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at February 28, 2017 (Unaudited)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">185</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">52</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">Depreciation for the one-month period (Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Depreciation for thirteen-month period</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">140</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">73</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">221</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2017</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">196</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">73</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">332</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid">Depreciation</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">107</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">239</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">349</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2018</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">303</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">312</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">681</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid">Depreciation</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">180</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">317</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">505</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid">Balance at March 31, 2019</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">483</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">629</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,186</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Net carrying amounts:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.1in">March 31, 2018</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">411</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,396</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,821</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid; padding-left: 0.1in">March 31, 2019</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">450</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,339</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,813</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 28.35pt; text-indent: -10.5pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Depreciation expense for the periods end <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">thirteen</div>-month and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> has been recorded in &#x201c;research and development expenses&#x201d; in the statements of earnings and comprehensive loss.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2017-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2017-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737185120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory', window );">Disclosure of intangible assets [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Intangible assets :</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2012, </div>the Corporation entered into a prepayment agreement with Neptune pursuant to which the Corporation exercised its option under the License Agreement to pay in advance all of the future royalties payable. The license allows the Corporation to exploit the intellectual property rights in order to develop novel active pharmaceutical ingredients (&#x201c;APIs&#x201d;) into commercial products for the prescription drugs market. The license Agreement, together with the Corporation own IP, allows the &#x201c;freedom to operate&#x201d; for CaPre, which is currently the Corporation&#x2019;s only prescription drug candidate in development. The Corporation believes that upon the expiry of the last licensed Neptune patent in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2022,</div> the Corporation&#x2019;s expanding patent portfolio will cover CaPre, and that it will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> require any license from Neptune to support the commercialization of CaPre.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Patents</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">License</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Total</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Cost:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 55%">Balance at February 29, 2016, February 28, 2017 (Unaudited) and March 31, 2017</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,330</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,692</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">Additions</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at March 31, 2018</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,330</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,692</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">Additions</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid">Balance at March 31, 2019</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,330</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,692</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Accumulated amortization:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at February 29, 2016</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,425</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,787</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Amortization for the twelve-month period (Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,323</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,323</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at February 28, 2017 (Unaudited)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,748</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,110</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Amortization for the one-month period (Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">194</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">194</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid">Amortization for the thirteen-month period</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,517</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,517</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at March 31, 2017</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,942</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,304</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid">Amortization for the year</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,323</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,323</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at March 31, 2018</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,265</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,627</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid">Amortization for the year</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,322</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,322</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid">Balance at March 31, 2019</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,587</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,949</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Net carrying amounts:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.1in">March 31, 2018</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,065</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,065</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; padding-left: 0.1in">March 31, 2019</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,743</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,743</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-weight: normal">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-weight: normal">Amortization expense and impairment loss for the period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">thirteen</div>-month and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017, </div>and the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> have been recorded in &#x201c;research and development expenses&#x201d; in the statements of earnings and comprehensive loss. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2017-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2017-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6634879440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Trade and Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Disclosure of trade and other payables [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Trade and other payables:</td> </tr>  </table> <div style=" margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-weight: normal; text-align: left">Trade payables</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,064</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,420</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Accrued liabilities and other payables</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,319</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,479</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Employee salaries and benefits payable</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,054</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">754</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Legal settlement expected to be paid via common shares (note 25)</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">990</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Payable to Neptune</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Total trade and other payables</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,429</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,697</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">The Corporation&#x2019;s exposure to currency and liquidity risks related to trade and other payables is presented in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737212576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Derivative Warrant Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory', window );">Disclosure of derivative financial instruments [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Derivative warrant liabilities:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The warrants issued as part of the public offering of units composed of Common Share and Common Share purchase warrants on both <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 9, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 14, 2018 (</div><div style="display: inline; font-style: italic;">see note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div></div>) are derivative liabilities (&#x201c;Derivative Warrant Liabilities&#x201d;) given the warrant indenture contains certain contingent provisions that allow for cash settlement.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Warrants issued as part of a public offering of units composed of class A share (Common Share) and Common Share purchase warrants on both <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 27, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 3, 2013 </div>are derivative liabilities (&#x201c;Derivative warrant liabilities&#x201d;) given the currency of the exercise price is different from the Corporation&#x2019;s functional currency.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The derivative warrant liabilities are measured at fair value at each reporting period and the reconciliation of changes in fair value is presented in the following tables:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Warrant liabilities issued <br /> May 2018</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Warrant liabilities issued <br /> December 27, 2017</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-weight: normal">Warrant liabilities issued <br /> December 3, 2013<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">1</div></div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">March 31, <br /> 2019</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; font-style: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; font-style: normal; text-align: right">March 31, <br /> 2018</td> <td style="font-weight: normal; font-style: normal">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">March 31, <br /> 2019</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; font-style: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; font-style: normal; text-align: right">March 31, <br /> 2018</td> <td style="font-weight: normal; font-style: normal">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">March 31, <br /> 2019</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; font-style: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; font-style: normal; text-align: right">March 31, <br /> 2018</td> <td style="font-weight: normal; font-style: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; font-weight: normal">Balance &#x2013; beginning of period</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,405</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">209</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Issued during period</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,272</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,873</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-indent: -4.95pt; padding-left: 4.95pt">Exercised during period</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(722</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">)</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; text-indent: -4.95pt; padding-left: 4.95pt">Change in fair value of derivative warrant liabilities</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,696</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">532</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(21</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(188</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; border-bottom: Black 1pt solid">Balance &#x2013; end of period</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,246</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,017</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,405</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">Fair value per share issuable</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.81</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.82</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.65</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.01</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <div style="display: inline; font-size: 8pt">(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>)</div> <div style="display: inline; font-size: 8pt">In order to obtain <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> warrants must be exercised. All unexercised warrants expired on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 3, 2018.</div></div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0.75in; text-align: justify; text-indent: 0in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0.75in; text-align: justify; text-indent: 0in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></div><div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The fair value of the derivative warrant liabilities was estimated using the Black-Scholes option pricing model and based on the following assumptions:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Warrant liabilities issued <br />May 2018</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Warrant liabilities issued <br />December 27, 2017</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Warrant liabilities issued</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">December 3, 2013 <div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">1</div></div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br />2019</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br /> 2018</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br />2019</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br /> 2018</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br />2019</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br /> 2018</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; font-weight: normal">Exercise price</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">$</td> <td style="width: 8%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.31</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.26</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.26</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.50</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Share price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">$</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.35</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.02</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.02</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.02</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Risk-free interest</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.52</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">%</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.23</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">%</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.56</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">%</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.19</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Estimated life (in years)</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">4.11</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">3.75</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">4.75</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">0.68</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">94.58</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">107.57</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">95.15</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">133.86</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <div style="display: inline; font-size: 8pt">(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>)</div> <div style="display: inline; font-size: 8pt">In order to obtain <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> warrants must be exercised. All unexercised warrants expired on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 3, 2018.</div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of derivative financial instruments. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDerivativeFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737279760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Unsecured Convertible Debentures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBorrowingsExplanatory', window );">Disclosure of borrowings [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Unsecured convertible debentures</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Concurrent with the Public Offering described in note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,</div> on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 21, 2017, </div>the Corporation issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,000</div> aggregate principal amount of unsecured convertible debentures maturing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 21, 2020 </div>and contingent warrants to acquire up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,052,630</div> Common Shares (the &#x201c;Private Placement&#x201d;). The principal <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be prepaid, in whole or in part, at any time and from time to time, in cash, at the sole discretion of the Corporation<div style="display: inline; font-weight: bold;">. </div>The debentures are convertible into Common Shares at any time by the holder at a fixed price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.90</div> per Common Share except if the Corporation pays before the maturity, all or any portion of the convertible debentures. Should the Corporation pay all or any portion of the convertible debenture before maturity, then warrants become exercisable at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.90</div> per Common Share for the equivalent convertible debenture amount prepaid. The contingent warrants will be exercisable for the remaining term of the convertible debt for the same price as the conversion options. The unsecured convertible debentures were issued at a discount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.5%</div> to the principal amount, for aggregate gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,930.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-weight: normal">The convertible debentures provide the Corporation an accelerated conversion right whereby the Corporation <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may, </div>at any time at least <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> months after the date of issuance of the convertible debentures, accelerate the conversion of the debentures to Common Shares in the event that the volume weighted average price of the Corporation&#x2019;s Common Shares on the TSX Venture Exchange is equal to or exceeds <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.65,</div> subject to customary adjustment provisions, during <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div> consecutive trading days. </div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The interest to be paid on the convertible debentures under the terms of the agreement is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8%</div> per annum, payable on a quarterly basis in cash or Common Shares of the Corporation or a combination thereof, commencing on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017. </div>The decision to pay the interest due in cash or shares is at the discretion of the Corporation and the number of Common Shares to be issued will be calculated at the current market price as at the close of business on the day before the interest payment is to be made. Payment in shares shall be at a floor price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.10</div> per share, with the difference between the amount payable and the amount computed at floor price payable in cash.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The proceeds of the Private Placement were split between the liability and the equity at the time of issuance of the Private Placement. Both the conversion option and contingent warrants are considered the equity component of the Private Placement. The fair value of the liability component was determined through a discounted cash flow analysis using a discount rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20%</div> that was set based on a similar debt and maturity considering the Corporation&#x2019;s credit risk excluding the conversion option and contingent warrants. The amount allocated to the equity component is the residual amount after deducting the fair value of the financial liability component from the fair value of the entire compound instrument. Subsequent to initial recognition, the liability is measured at amortized cost calculated using the effective interest rate method and will accrete up to the principal balance at maturity. The interest accretion is presented as a financial expense. The equity component is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> re-measured. Transaction costs were allocated to the components in proportion to their initial carrying amounts. The portion allocated to the liability was recognized as a reduction of the debt whereas the portion allocated to other equity was recognized as a reduction to other equity.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div> <!-- Field: Page; Sequence: 24; Value: 9 --> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The split between the liability and equity component portions of the Private Placement are summarized below:</div> <div style=" margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid; vertical-align: top">Liability component</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid; vertical-align: top">Equity component</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">Total Private <br /> Placement</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-weight: normal; border-bottom: Black 1pt solid">Balance at March 31, 2017</td> <td style="width: 1%; font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,406</div></td> <td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">309</div></td> <td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,715</div></td> <td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Effective interest for the twelve-month period</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">366</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">366</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Interest payable during the period</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(160</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(160</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Balance at March 31, 2018</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">309</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,921</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Effective interest during the period</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">365</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">365</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Interest payable during the period</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(160</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(160</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">Balance at March 31, 2019</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,817</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">309</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,126</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6630502576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Capital and Other Components of Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Disclosure of share capital, reserves and other equity interest [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Capital and other components of equity</td> </tr>  </table> <div style=" font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(a)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Share capital:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Authorized capital stock:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Unlimited number of shares:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 30pt"></td> <td style="width: 20pt"><div style="display: inline; font-family: Wingdings">&Oslash;</div></td> <td style="text-align: justify; padding-right: 5.9pt">Class A shares (Common Shares), voting (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> vote per share), participating and without par value</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 30pt"></td> <td style="width: 20pt"><div style="display: inline; font-family: Wingdings">&Oslash;</div></td> <td style="text-align: justify; padding-right: 5.9pt">Class B shares, voting (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> votes per share), non-participating, without par value and maximum annual non-cumulative dividend of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5%</div> on the amount paid for said shares. Class B shares are convertible, at the holder&#x2019;s discretion, into Class A shares (Common Shares), on a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-for-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> basis, and Class B shares are redeemable at the holder&#x2019;s discretion for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.80</div> per share, subject to certain conditions. There are non issued and outstanding.</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 30pt"></td> <td style="width: 20pt"><div style="display: inline; font-family: Wingdings">&Oslash;</div></td> <td style="text-align: justify; padding-right: 5.9pt">Class C shares, non-voting, non-participating, without par value and maximum annual non-cumulative dividend of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5%</div> on the amount paid for said shares. Class C shares are convertible, at the holder&#x2019;s discretion, into Class A shares (Common Shares), on a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-for-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> basis, and Class C shares are redeemable at the holder&#x2019;s discretion for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.20</div> per share, subject to certain conditions. There are non issued and outstanding.</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 30pt"></td> <td style="width: 20pt"><div style="display: inline; font-family: Wingdings">&Oslash;</div></td> <td style="text-align: justify; padding-right: 5.9pt">Class D and E shares, non-voting, non-participating, without par value and maximum monthly non-cumulative dividend between <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.5%</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2%</div> on the amount paid for said shares. Class D and E shares are convertible, at the holder&#x2019;s discretion, into Class A shares (Common Shares), on a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-for-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> basis, and Class D and E shares are redeemable at the holder&#x2019;s discretion, subject to certain conditions. There are non issued and outstanding.</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(b)</td> <td style="width: 5pt"></td> <td style="text-align: justify">&#x201c;At-the-market&#x201d; (&#x201c;ATM&#x201d;) sales agreement</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 14, 2019, </div>the Corporation entered into an &#x201c;at-the-market&#x201d; (&#x201c;ATM&#x201d;) sales agreement with an underwriter B. Riley FBR, Inc. (B. Riley), pursuant to which the Corporation&#x2019;s common shares <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be sold from time to time for aggregate gross proceeds of up to US <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30</div> million, with sales only being made on the NASDAQ Stock Market. The common shares would be issued at market prices prevailing at the time of the sale and, as a result, prices <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>vary between purchasers and during the period of distribution. The ATM provides the Company with a flexible alternative for raising additional capital. The ATM has a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> year term, and requires the company to pay a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3%</div> fee to B. Riley when any sales are made. As at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> securities have been issued in relation to the ATM. Costs incurred in connection to the ATM of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$179</div> have been recorded as deferred financing costs.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(c)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Public Offerings &#x2013; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 2018:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.95pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 9, 2018, </div>the Corporation closed a U.S. public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,600,000</div> Common Shares at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">US$1.00</div> per share. In addition, the underwriters fully exercised their over-allotment option to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,490,000</div> additional Common Shares at the same public offering price. This offering generated gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$24.7</div> million (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">US$19.1</div> million), which resulted in net proceeds to the Corporation of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$22.6</div> million (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">US$17.4</div> million) and a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,090,000</div> Common Shares issued.</div> <!-- Field: Page; Sequence: 25; Value: 9 -->  <table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"><tr style="vertical-align: top; text-align: justify"><td style="text-align: justify"></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> October 23, 2018, </div>the Corporation closed a Canadian public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,750,000</div> Common Shares at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.28</div> per share. In addition, the underwriters fully exercised their over-allotment option to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,812,500</div> additional Common Shares at the same public offering price. This offering generated gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$27.6</div> million, which resulted in net proceeds to the Corporation of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$25.4</div> million and a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,562,500</div> Common Shares issued.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(d)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Public Offering &#x2013; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2018:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 9, 2018 </div>the Corporation closed a Canadian public offering issuing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,530,000</div> units of Acasti (&#x201c;Units&#x201d;) at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.05</div> per Unit for gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10</div> million. The units issued consist of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,530,000</div> Common Shares and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,530,000</div> Warrants. Each Warrant entitles the holder thereof to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share of the Corporation at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.31</div> at any time until <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 9, 2023.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 14, 2018, </div>the underwriters exercised their over-allotment option by purchasing an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,429,500</div> units at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.05</div> per Unit, for additional gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.5</div> million. The units issued consist of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,429,500</div> Common Shares and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,429,500</div> warrants. Each Warrant entitles the holder thereof to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share of the Corporation at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.31</div> at any time until <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 9, 2023.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The warrant component of these Units are Derivative Warrant Liabilities for accounting purposes due to the warrant agreement, which contains certain contingent provisions that allow for cash settlement (note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div>). The proceeds of the offering are required to be split between the Derivative Warrant Liabilities and the equity-classified Common shares at the time of issuance of the Units. The fair value of the Derivative Warrant Liabilities at the time of issuance was determined to be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.3</div> million and the residual of the proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.2</div> million were allocated to the Common Shares. Issuance costs related to this transaction totaled approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.8</div> million and have been allocated between the Derivative Warrant Liabilities and Common shares based on relative value. Resulting from this allocation, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.7</div> million has been allocated to the Derivative Warrant Liability and is recognized in finance costs in the Statements of Earnings and Comprehensive Loss, whereas the remaining portion of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.1</div> million in issuance costs was allocated to the Common Shares and recognized as a reduction to share capital, in the Statements of Financial Position.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The fair value of the public offering warrants at issuance was estimated using to the Black-Scholes option pricing model and was based on the following weighted average assumptions:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">May 2018</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; font-weight: normal">Exercise price</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">$</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.31</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Share price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">$</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.82</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Risk-free interest</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.21</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Estimated life (in years)</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">87.40</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The weighted average fair value of the public offering warrants issued in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2018 </div>was determined to be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.39</div> per warrant. Changes in the subsequent measurement of fair value of the Warrants are recognized in financial expenses.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As part of the transaction, the Corporation also issued broker warrants to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">547,975</div> Common Shares. Each broker warrant entitles the holder thereof to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share of the Corporation at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.05,</div> at any time until <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 9, 2023. </div>The broker warrants are considered to be compensation to non-employees under IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,</div> as stock-based compensation, and are thus accounted for at fair value at issuance date and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> subsequently revalued. To determine the fair value of these broker warrants, a Black-Scholes options pricing model was used based on the following assumptions:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">May 2018</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; font-weight: normal">Exercise price</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">$</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.05</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Share price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">$</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.81</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Risk-free interest</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.20</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Estimated life (in years)</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">5</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">87.40</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The total value associated with the broker warrants amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$283</div> and was recorded in contributed surplus.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</div> <!-- Field: Page; Sequence: 26; Value: 9 -->  <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(e)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Public offering &#x2013; <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 27, 2017</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 27, 2017, </div>the Corporation closed a U.S. public offering issuing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,900,990</div> units of Acasti at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">US$1.01</div> per Unit for gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12.6</div> million (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">US$10</div> million). The units issued consist of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,900,990</div> Common Shares and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,910,891</div> warrants with the right to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share of Acasti. As part of this closing, the underwriters&#x2019; also partially exercised for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nil</div> consideration the over-allotment option for warrants, which were issued for a right to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">892,044</div> Common Shares at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">US$1.26.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Warrants forming part of the Units are Derivative Warrant Liabilities for accounting purposes due to the currency of the exercise price being different from the Corporation&#x2019;s functional currency. The proceeds of the offering are required to be split between the Derivative Warrant Liabilities and the equity-classified Common Share at the time of issuance of the Units. The fair value of the Derivative Warrant Liabilities at the time of issuance was determined to be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.9</div> million and the residual of the proceeds was allocated to the Common Shares. Total issuance costs related to this transaction totaled approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.5</div> million. The issuance costs have been allocated between the Warrants and Common Shares based on relative value. The portion allocated to the Warrants was recognized in finance costs in the Statements of Earnings and Comprehensive Loss, whereas the portion allocated to Common Shares was recognized as a reduction to share capital, in the Statements of Financial Position.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The fair value of the public offering Warrants at issuance was estimated according to the Black-Scholes option pricing model and based on the following assumptions:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">December 27, <br />2017</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal">Exercise price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.26</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Share price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $0.97</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; font-weight: normal; text-align: left">Risk-free interest</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.22</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Estimated life (in years)</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">5</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">93.52</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The fair value of the public offering Warrants issued was determined to be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.60</div> per warrant as at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 27, 2017. </div>Changes in the fair value of the Warrants are recognized in finance income or expenses.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As part of the transaction, the Corporation also issued broker warrants to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">495,050</div> Common Shares. Each broker warrant entitles the holder thereof to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share of the Corporation at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">US$1.2625,</div> at any time until <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 27, 2022. </div>The broker warrants are considered for compensation to non-employees under IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,</div> stock-based compensation, and are accounted for at fair value. To determine the fair value of the Broker Warrants, a Black-Scholes option pricing model was used based on the following assumptions:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">December 27, <br />2017</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal">Exercise price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.2625</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Share price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $0.97</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; font-weight: normal; text-align: left">Risk-free interest</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.22</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Estimated life (in years)</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">93.52</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The total cost associated with the Broker Warrants amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$406</div> and was recorded in contributed surplus.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div> <!-- Field: Page; Sequence: 27; Value: 9 -->  <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(f)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Public offering - <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 21, 2017:</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Concurrent with the private placement described in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,</div> on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 21, 2017, </div>the Corporation closed a public offering (&#x201c;Public Offering&#x201d;) issuing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,930,518</div> units of Acasti (&#x201c;Units&#x201d;) at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.45</div> per Unit for gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5,699.</div> Each Unit consists of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> class A share (Common Share) and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> half of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> class A or common share purchase warrant. Each whole warrant entitles the holder thereof to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.15</div> per common share, at any time until <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 21, 2022. </div>The Units issued as part of the public offering are considered equity instruments. The transaction costs associated with the Public Offering amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,190.</div> The proceeds and transaction costs were allocated to share capital.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As part of the transaction, the Corporation also issued broker warrants (the &#x201c;Broker Warrants&#x201d;) to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">234,992</div> Common Shares. Each Broker Warrant entitles the holder thereof to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share of the Corporation at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.15</div> per common share, at any time until <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 21, 2018. </div>The broker warrants are considered for compensation to non-employees under IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,</div> stock-based compensation, and are accounted for at fair value through contributed surplus. To determine the fair value of the Broker Warrants, the Black-Scholes pricing model was used. The total costs associated with the Broker Warrants amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$144</div> and were allocated to share capital.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The warrants issued as part of the Units of the Public Offering and the broker warrants include an &#x201c;Acceleration Right&#x201d;, related to the Corporation&#x2019;s right to accelerate the expiry date of the warrants. The Acceleration Right clause means the right of the Corporation to accelerate the expiry date to a date that is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div> days following delivery of the acceleration notice if, at any time at least <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">four</div> months after the effective date, the volume weighted average trading price of the common shares equals or exceeds <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.65</div> for a period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div> consecutive trading days on the TSXV.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Furthermore, as part of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2017 </div>Public Offering and convertible debt transactions, a total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60,000</div> Common Shares were issued as equity settled share-based payments for services received from an employee of the previous parent at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.57</div> per share for a total cost of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$94.</div> The equity settled share-based payment costs have been allocated to share capital for a cost that amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$85</div> and to debt for a cost that amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$9</div> based on relative value.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The value of the broker warrants was estimated using a Black-Scholes option pricing model and based on the following assumptions:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">February 21, 2017</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; font-weight: normal">Exercise price</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">$</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.15</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Share price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">$</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.70</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal">Dividend</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Risk-free interest</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.79</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Estimated life (in years)</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">1.00</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">112.09</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The total cost associated with the Broker Warrants amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$144</div> and was recorded as contributed surplus.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(g)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Issuance of shares:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The following table summarizes the shares issued to settle the payment of accrued interest on the unsecured convertible debentures with the corresponding amount recorded to share capital.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; color: #00528C"><div style="display: inline; font-style: normal">&nbsp;</div></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"><div style="display: inline; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"><div style="display: inline; font-weight: normal">Accrued interest as at</div></div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"><div style="display: inline; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"><div style="display: inline; font-weight: normal">Share issuance date</div></div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">Number of shares</div></div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">Amount </div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">$</div></div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; font-weight: normal">March 31, 2017</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 35%; font-weight: normal"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">April 7, 2017</div></td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,496</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">June 30, 2017</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">August 15, 2017</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,885</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal">September 30, 2017</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">December 27, 2017</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,783</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">December 31, 2017</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 27, 2018</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33,605</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal">March 31, 2018</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">June 6, 2018</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,348</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">June 30, 2018</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">August 21, 2018</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">51,807</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; border-bottom: Black 1pt solid">September 30, 2018</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">October 31, 2018</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,723</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">195,647</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">257</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr>  </table> </div> <!-- Field: Page; Sequence: 28; Value: 9 --> <table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"><tr style="vertical-align: top; text-align: justify"><td style="text-align: justify"></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(h)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Warrants:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The warrants of the Corporation are composed of the following as at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 28, 2017:</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">March 31, 2019</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">March 31, 2018</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">March 31, 2017</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">February 28, 2017</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">(Unaudited)</div></div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">Number <br /> outstanding</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">Amount</div></div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">Number <br /> outstanding</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">Amount</div></div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">Number <br /> outstanding</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">Amount</div></div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">Number <br /> outstanding</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">Amount</div></div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Liability</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 28%; font-weight: normal; font-style: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">May 2018 Public offering Warrants 2018 (i)</div></td> <td style="width: 1%; font-weight: normal; font-style: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: normal; font-style: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">10,188,100</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; font-style: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: normal; font-style: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: normal; font-style: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">8,246</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; font-style: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Series December 2017 US Public offering Warrants 2017 (ii)</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">9,801,861</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">8,017</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">9,802,935</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">6,405</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; font-style: normal; text-align: left; text-indent: -10pt; padding-left: 10pt; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">Series 8 Public offering Warrants December 2013 (iii)</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">18,400,000</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">21</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">18,400,000</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">209</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">18,400,000</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">187</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">19,989,961</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">16,263</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">28,202,935</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">6,426</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">18,400,000</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">209</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">18,400,000</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">187</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Equity</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Public offering warrants</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Public offering broker warrants May 2018 (iv)</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">547,975</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">283</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Public offering U.S. broker warrants December 2017 (v)</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">495,050</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">406</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">495,050</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">406</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Public offering warrants February 2017 (vi)</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,904,034</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,904,034</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,965,259</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,965,259</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Private Placement- contingent warrants</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">2017 unsecured convertible debenture conversion option and contingent warrants (vii)</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,052,630</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">309</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,052,630</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">309</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,052,630</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">309</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,052,630</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">309</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Series 9 Private Placement warrants 2013 (viii)</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">161,654</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">161,654</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">161,654</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Series 2017 BW Broker warrants (ix)</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">234,992</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">144</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">234,992</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">144</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">3,999,689</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">998</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">3,613,368</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">715</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">3,414,535</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">453</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">3,414,535</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">453</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 25pt"><div style="display: inline; font-size: 8pt">(i)</div></td> <td style="text-align: justify"><div style="display: inline; font-size: 8pt">Warrant to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share of the Corporation at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.31,</div> expiring on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 9, 2023.</div></div></td> </tr>  </table> <table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 25pt"><div style="display: inline; font-size: 8pt">(ii)</div></td> <td style="text-align: justify"><div style="display: inline; font-size: 8pt">Warrant to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share of the Corporation at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">US$1.26,</div> expiring on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 27, 2022.</div></div></td> </tr>  </table> <table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 25pt"><div style="display: inline; font-size: 8pt">(iii)</div></td> <td style="text-align: justify"><div style="display: inline; font-size: 8pt">In order to obtain <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share of the Corporation at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">US$15.00,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> warrants must be exercised. Warrants expired on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div></div></td> </tr>  </table> <table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 25pt"><div style="display: inline; font-size: 8pt">(iv)</div></td> <td style="text-align: justify"><div style="display: inline; font-size: 8pt">Warrant to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share of the Corporation at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.05,</div> expiring on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 9, 2023.</div></div></td> </tr>  </table> <table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 25pt"><div style="display: inline; font-size: 8pt">(v)</div></td> <td style="text-align: justify"><div style="display: inline; font-size: 8pt">Warrant to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share of the Corporation at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">US$1.2625,</div> expiring on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 27, 2022.</div></div></td> </tr>  </table> <table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 25pt"><div style="display: inline; font-size: 8pt">(vi)</div></td> <td style="text-align: justify"><div style="display: inline; font-size: 8pt">Warrant to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share of the Corporation at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.15,</div> expiring on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 21, 2022.</div></div></td> </tr>  </table> <table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 25pt"><div style="display: inline; font-size: 8pt">(vii)</div></td> <td style="text-align: justify"><div style="display: inline; font-size: 8pt">Warrant to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share of the Corporation at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.90</div> expiring on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 21, 2020, </div>net of deferred tax expense of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$129.</div> Exercisable only for any portion of or all debentures paid by the Corporation prior to maturity.</div></td> </tr>  </table> <table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 25pt"><div style="display: inline; font-size: 8pt">(viii)</div></td> <td style="text-align: justify"><div style="display: inline; font-size: 8pt">Warrant to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share of the Corporation at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$13.30,</div> expired on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 3, 2018.</div></div></td> </tr>  </table> <table cellpadding="0" cellspacing="0" style="; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 25pt"><div style="display: inline; font-size: 8pt">(ix)</div></td> <td style="text-align: justify"><div style="display: inline; font-size: 8pt">Warrant to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> Common Share of the Corporation at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.15</div> expiring on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 21, 2018. </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">117,496</div> warrants amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$71</div> were exercised in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">117,496</div> warrants expired on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 21, 2018</div></div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 0; text-align: justify">&nbsp;</div><div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Warrants exercise:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">During the year <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">771,400</div> warrants offered as part of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2018 </div>public offering were exercised at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.31</div> per Common Share of the Company, resulting in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.0</div> million of cash proceeds. In addition, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,455</div> warrants offered as part of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2017 </div>U.S. public offering were exercised in a cashless manner to acquire <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,074</div> Common Shares of the Company.&nbsp; A total of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">772,474</div> Common Shares were issued as a result of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,855</div> warrants being exercised. During the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">178,721</div> warrants offered as part of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2017 </div>public offering were exercised at an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.15</div> per Common Share of the Company, resulting in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$384</div> of cash proceeds.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737279760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Personnel Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DisclosureOfPersonnelExpensesTextBlock', window );">Disclosure of personnel expenses [text block</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Personnel expenses:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br /> months ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-month <br />period ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2019</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2018</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017 <br />(Unaudited)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, </div><br /> 2017 <br />(Unaudited)</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Salaries and other short-term employee benefits</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,144</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,281</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,491</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">214</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,277</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Share-based compensation costs</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,041</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">929</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">674</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">86</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">588</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Total personnel expenses</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,185</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,210</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,165</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,865</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DisclosureOfPersonnelExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DisclosureOfPersonnelExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737322688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Financial Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Disclosure of finance income (cost) [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Financial expenses:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0.5in; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br /> months ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-month <br />period ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2019</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2018</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017 <br />(Unaudited)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, </div><br /> 2017 <br />(Unaudited)</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Interest income</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">475</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">119</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign exchange gain (loss)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">279</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(32</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(180</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(177</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest payable on convertible debenture</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(160</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(160</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(17</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accretion of interest on convertible debenture</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(205</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(206</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(22</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(17</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Transaction costs related to derivative warrant liabilities</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(653</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,134</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of warrant liabilities</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,287</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(344</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(53</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(22</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(31</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid">Other charges</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(19</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Financial expenses</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,551</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,808</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(166</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(51</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(115</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737171056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 17 - Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Disclosure of share-based payment arrangements [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Share-based payments:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>the Corporation has the following share-based payment arrangement:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(a)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Corporation stock option plan:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Corporation has in place a stock option plan for directors, officers, employees and consultants of the Corporation (&#x201c;Stock Option Plan&#x201d;). An amendment of the Plan was approved by shareholders on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 28, 2018. </div>The amendment provides for an increase to the existing limits for Common Shares reserved for issuance under the Stock Option Plan as well as certain changes to the minimum vesting period applicable to options granted to directors and employees under the Stock Option Plan. The plan continues to provide for the granting of options to purchase Common Shares. The exercise price of the stock options granted under this amended plan is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> lower than the closing price of the shares listed on the TSXV at the close of markets the day preceding the grant. The maximum number of Common Shares that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be issued upon exercise of options granted under the amended Stock Option Plan was increased from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,940,511,</div> representing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20%</div> of the issued and outstanding Common Shares of the Company as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017, </div>to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,494,209</div> representing <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15%</div> of the issued and outstanding Common Shares of the Company as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 27, 2018. </div>The terms and conditions for acquiring and exercising options are set by the Corporation&#x2019;s Board of Directors, subject among others, to the following limitations: the term of the options cannot exceed <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> years and (i) all options granted to a director will be vested evenly on a quarterly basis over a period of at least <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">eighteen</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div>) months, and (ii) all options granted to an employee will be vested evenly on a quarterly basis over a period of at least <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">thirty-six</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">36</div>) months.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The total number of shares issued to any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> consultant within any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div>-month period cannot exceed <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2%</div> of the Corporation&#x2019;s total issued and outstanding shares (on a non-diluted basis). The Corporation is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> authorized to grant within any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div>-month period such number of options under the stock option plan that could result in a number of Common Shares issuable pursuant to options granted to (a) related persons exceeding <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2%</div> of the Corporation&#x2019;s issued and outstanding Common Shares (on a non-diluted basis) on the date an option is granted, or (b) any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> eligible person in a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div>-month period exceeding <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2%</div> of the Corporation&#x2019;s issued and outstanding Common Shares (on a non-diluted basis) on the date an option is granted.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The following tables summarize information about activities within the stock option plan:</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, 2019</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, 2018</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">Weighted average <br /> exercise price</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">Number of <br /> options</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">Weighted average <br /> exercise price</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">Number of <br /> options</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Outstanding at beginning of year</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.81</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,284,388</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.58</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,424,788</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.77</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,173,523</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.75</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,121,500</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.77</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,167</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.84</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(407,067</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.89</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(199,800</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">Expired</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18.06</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(62,100</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Outstanding at end of year</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.25</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,046,677</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.81</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,284,388</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Exercisable at end of year</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.56</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,613,200</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.92</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">591,113</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"></div> <div style=" margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-month period <br /> ended <br /> <div style="display: inline; font-family: Times New Roman, Times, Serif">March 31, 2017</div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended <br /> March 31, 2017</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-month period <br /> ended <br /> February 28, 2017</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Weighted <br /> average <br /> exercise price</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Number <br /> of options</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Weighted <br /> average <br /> exercise price</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Number <br /> of options</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Weighted <br /> average <br /> exercise price</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Number <br /> of options</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%">Outstanding at beginning of period</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 8%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.52</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 8%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">454,151</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 8%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.59</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 8%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,427,288</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 8%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.52</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 8%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">454,151</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.69</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,300,400</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.69</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,300,400</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.27</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(190,138</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.50</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,500</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.29</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(187,638</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid">Expired</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.38</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(139,625</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.38</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(139,625</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid">Outstanding at end of period</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.58</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,424,788</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.58</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,424,788</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.59</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,427,288</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid">Exercisable at end of period</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.44</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">238,482</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.44</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">238,482</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.49</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">240,982</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0">&nbsp;</div> <div style=" margin: 0"></div> <!-- Field: Page; Sequence: 31; Value: 9 --> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"><tr style="vertical-align: top; text-align: justify"><td style="text-align: justify"></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-month <br /> period ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-month <br />Period ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br /> 2019</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br /> 2018</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br /> 2017</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">February 28, 2017 <br />(Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; border-bottom: Black 1.5pt solid; text-indent: -6.75pt; padding-left: 6.75pt">Weighted average fair value of the options granted to employees and directors of the Corporation</td> <td style="width: 1%; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.51</div></td> <td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.22</div></td> <td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.40</div></td> <td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.40</div></td> <td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> options granted during the month ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> options granted to consultants during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">thirteen</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,167</div> options were exercised during the period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 (</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nil</div> for period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nil</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">thirteen</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017). </div>Stock-based compensation recognized under this plan for the period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,041</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$929,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">thirteen</div>-month and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2017 </div>amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$674</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$86</div> (unaudited), respectively and amounted to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$588</div> (unaudited) for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 28, 2017).</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The fair value of options granted was estimated using the Black-Scholes option pricing model, resulting in the following weighted average assumptions for options granted during the periods ended:</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-month <br /> period ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-month <br />Period ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, 2019</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, 2018</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, 2017</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">February 28, 2017 <br />(Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Exercise price</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.77</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.75</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.69</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.69</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Share price</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.73</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.75</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.69</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.69</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Dividend</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.10</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.21</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.87</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.87</div></td> <td style="white-space: nowrap; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Estimated life (in years)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif">5.78</div></div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif">5.89</div></div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif">4.94</div></div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif">4.94</div></div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Expected volatility</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">85.35</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82.4</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">123.5</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">123.5</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The expected life of the stock options is based on historical data and current expectation and is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> necessarily indicative of exercise patterns that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the options is indicative of future trends, which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>also <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> necessarily be the actual outcome.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify; text-indent: -17.85pt">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The following tables summarize the status of the outstanding and exercisable options of the Corporation:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="14" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">Options outstanding</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">Exercisable options</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td colspan="3" style="white-space: nowrap; border-bottom: Black 1pt solid">Exercise price</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Weighted remaining <br /> contractual life <br /> outstanding</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Number of options <br /> outstanding</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Weighted average <br /> exercise price <br />$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Number of options <br /> exercisable</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 5%">$0.77</td> <td style="width: 2%"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 41%"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.77</div></td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.26</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,898,523</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.77</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">348,197</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>$0.78</td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.58</div></td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.86</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,000</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.50</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">518,750</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$1.59</td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.71</div></td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.90</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">273,333</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.65</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">233,333</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>$1.72</td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.88</div></td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.21</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">790,833</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.77</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">292,500</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">$1.89</td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.50</div></td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.97</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">308,988</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.57</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">220,420</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.91</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,046,677</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.56</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,613,200</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 10.65pt; text-align: justify; text-indent: 0.1in"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <!-- Field: Page; Sequence: 32; Value: 9 --> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic;">Share-based payment transactions and broker warrants:</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The fair value of share-based payment transaction is measured using the Black-Scholes option pricing model. Measurement inputs include share price on measurement date, exercise price of the instrument, expected volatility (based on weighted average historic volatility), weighted average expected life of the instruments (based on historical experience and general option holder behaviour unless <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> entity-specific information exists in which case the average of the vesting and contractual periods is used), and the risk-free interest rate (based on government bonds). Service and non-market performance conditions attached to the transactions, if any, are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> taken into account in determining fair value.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(b)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Corporation equity incentive plan:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation established an equity incentive plan for employees, directors and consultants. The plan provides for the issuance of restricted share units (&#x201c;RSU&#x201d;), performance share units, restricted shares, deferred share units and other share-based awards, subject to restricted conditions as <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be determined by the Board of Directors. There are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> </div>such awards outstanding as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> </div>stock-based compensation was recognized for the period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 (</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">nil</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-month and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">thirteen</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31,&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>).</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737236096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 18 - Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Earnings per share [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Loss per share:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Diluted loss per share was the same amount as basic loss per share, as the effect of options, RSUs and warrants would have been anti-dilutive, because the Corporation incurred losses in each of the periods presented. All outstanding options, RSUs and warrants could potentially be dilutive in the future.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2017-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=33&amp;date=2017-03-01&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737253264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 19 - Supplemental Cash Flow Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory', window );">Disclosure of additional information about understanding financial position and liquidity of entity [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Supplemental cash flow disclosure:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(a)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Changes in working capital items:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br /> months ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, <br />2019</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, <br />2018</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, <br />2017</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, <br />2017 <br />(Unaudited)</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">February 28, <br /> 2017 <br />(Unaudited)</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Receivables</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(738</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(553</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">193</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(40</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">233</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid expenses</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(709</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(103</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">247</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(33</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">280</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Assets</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">37</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(659</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred financing costs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(179</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid">Trade and other payables</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,679</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,898</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">352</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(255</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">607</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Total changes in working capital items</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,090</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,583</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">792</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(328</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,120</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <!-- Field: Page; Sequence: 33; Value: 9 --> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(b)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Non-cash transactions:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br /> ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-left: 10pt; text-indent: -10pt">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2019</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2018</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017 <br />(Unaudited)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, 2017 </div><br />(Unaudited)</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left; padding-left: 10pt; text-indent: -10pt">Issuance of shares for interest on convertible debt</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">120</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">137</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">94</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">94</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Issuance of broker warrants included in net proceeds from public offering</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">283</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">406</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">144</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">144</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Public offering transaction costs included in trade and other payables</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">132</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">381</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">381</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">416</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Interest receivable included in receivables</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Reduction in share issue costs from reduction in trade and other payables</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">109</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">109</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Private Placement transaction costs included in trade and other payables</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Equipment included in trade and other payables</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">216</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">288</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">288</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">269</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">Interest payable included in trade and other payables</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of additional information that may be relevant to users of financial statements in understanding the financial position and liquidity of an entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 50<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_50&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737359728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 20 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Disclosure of income tax [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Income taxes:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Deferred tax (recovery) expense:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.95pt 0pt 0.4in; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right; border-top: Black 1.5pt solid">Twelve-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2019</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2018</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017 <br />(Unaudited)</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, </div><br /> 2017 <br />(Unaudited)</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left; text-indent: -7.35pt; padding-left: 7.35pt">Origination and reversal of temporary differences</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,599</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,241</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,240</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">163</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,077</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid; text-indent: -7.35pt; padding-left: 7.35pt">Change in unrecognized deductible temporary differences</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,599</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5,241</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,369</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(163</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,206</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Deferred tax (recovery) expense</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(129</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(129</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.65pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Reconciliation of effective tax rate:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right; border-top: Black 1.5pt solid">Twelve-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2019</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2018</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017 <br />(Unaudited)</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, </div><br /> 2017 <br />(Unaudited)</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Loss before income taxes</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(51,566</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(21,504</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,376</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(769</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10,607</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic combined Canadian statutory income tax rate <div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">1</div></div></td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26.68</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26.78</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26.87</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26.80</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26.88</div></td> <td style="white-space: nowrap; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computed income tax recovery</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(13,758</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5,759</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,057</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(206</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,851</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Increase resulting from:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -7.15pt; padding-left: 21.55pt">Change in unrecognized deductible temporary differences</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,599</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,241</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,369</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">162</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,207</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.2in">Non-deductible stock-based compensation</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">279</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">248</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">178</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">155</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.2in">Non-deductible change in fair value</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,677</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">92</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.2in">Permanent differences and other</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">203</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">178</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">166</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">154</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 0.2in">Change in statutory income tax rate</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">201</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">198</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Total tax (recovery) expense</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(129</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(129</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.65pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></div></div> The Canadian combined statutory income tax rate has decreased due to a reduction in the provincial statutory income tax rate.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; text-transform: uppercase"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div> <!-- Field: Page; Sequence: 35; Value: 9 -->   <!-- Field: /Page --> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><div style="display: inline; text-transform: uppercase"><div style="display: inline; font-weight: bold;"></div></div></div> <table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Income taxes (continued):</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Unrecognized deferred tax assets:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the net deferred tax assets, which have <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been recognized in these financial statements because the criteria for recognition of these assets were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> met, were as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">March 31, 2019</div></div></td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">March 31, 2018</div></div></td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">March 31, 2017</div></div></td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Deferred tax assets</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 55%; font-weight: normal; text-align: left">Tax losses carried forward</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,695</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,670</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,293</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Research and development expenses</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,362</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,927</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,220</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Property, plan and equipment and intangible assets</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">766</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">567</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">435</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Financing expenses</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,852</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">116</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Other deductible temporary differences</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">378</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">768</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">522</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Deferred tax assets</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,053</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,048</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,470</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">&nbsp;Deferred tax liabilities</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Tax basis of unsecured convertible debentures in excess of carrying value</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">67</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">122</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Deferred tax liabilities</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">67</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">122</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Net deferred tax assets</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,040</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,981</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,348</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.55pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">On initial recognition of the unsecured convertible debenture equity component on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 21, 2017, </div>a deferred tax liability of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$129</div> was recognized with the corresponding entry recognized directly in Other equity. Consequently, an equal amount of deferred tax asset related to unrecognized tax losses was recognized with the offsetting entry in the Corporation statement of earnings and comprehensive loss.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>the amounts and expiry dates of tax attributes and temporary differences, which are available to reduce future years&#x2019; taxable income, were as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">Federal</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">Provincial</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; border-bottom: Black 1pt solid; padding-left: 0.2in; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">$</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">$</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Tax losses carried forward</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; font-weight: normal; text-align: left">2029</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">714</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">714</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">2030</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,627</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,620</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">2031</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,071</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,063</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">2032</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,262</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,241</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">2033</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,854</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,825</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">2034</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,598</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,598</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">2035</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,595</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,459</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">2036</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,494</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,494</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">2037</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,584</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,456</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">2038</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,340</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,270</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">2039</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,447</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,447</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">89,586</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">89,187</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Research and development expenses, without time limitation</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,617</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,036</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Other deductible temporary differences, without time limitation</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,875</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,294</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr>  </table> </div> <!-- Field: Page; Sequence: 36; Value: 9 --></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737349840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 21 - Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Disclosure of financial instruments [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Financial instruments:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">This note provides disclosures relating to the nature and extent of the Corporation&#x2019;s exposure to risks arising from financial instruments, including credit risk, foreign currency risk, interest rate risk and liquidity risk, and how the Corporation manages those risks.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(a)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Credit risk:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Credit risk is the risk of a loss if a customer or counterparty to a financial asset fails to meet its contractual obligations. The Corporation has credit risk relating to cash and cash equivalents and marketable securities, which it manages by dealing only with highly-rated Canadian institutions. The carrying amount of financial assets, as disclosed in the statements of financial position, represents the Corporation&#x2019;s credit exposure at the reporting date.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(b)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Currency risk:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation is exposed to the financial risk related to the fluctuation of foreign exchange rates and the degrees of volatility of those rates. Foreign currency risk is limited to the portion of the Corporation's business transactions denominated in currencies other than the Canadian dollar. Fluctuations related to foreign exchange rates could cause unforeseen fluctuations in the Corporation's operating results.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">A portion of the expenses, mainly related to research contracts and purchase of production equipment, is incurred in US dollars and in Euros. There is a financial risk related to the fluctuation in the value of the US&nbsp;dollar and the Euro in relation to the Canadian dollar. In order to minimize the financial risk related to the fluctuation in the value of the US dollar in relation to the Canadian dollar, funds continue to be invested as short-term investments in the US dollar.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The following table provides an indication of the Corporation&#x2019;s significant foreign exchange currency exposures as stated in Canadian dollars at the following dates:</div> <div style=" margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: normal; border-bottom: Black 1pt solid; text-align: left; vertical-align: top">Denominated in</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">US <br /> $</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">Euro</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">US <br /> $</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">Euro</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-weight: normal; text-align: left">Cash and cash equivalents</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,369</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,024</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Marketable securities</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,696</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal">Receivables</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Trade and other payables</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(13,251</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(131</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,924</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(627</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7,170</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(131</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,132</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(627</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">)</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 23.4pt; text-indent: -9pt">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The following exchange rates are those applicable to the following periods and dates:</div> <div style=" margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">March 31, 2019</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">March 31, 2018</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Average</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Reporting</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Average</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Reporting</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-weight: normal">CA$ per US$</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.3122</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.3349</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.2834</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.2900</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">CA$ per Euro</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5192</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.4975</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5008</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5898</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 9pt; text-indent: -9pt">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Based on the Corporation&#x2019;s foreign currency exposures noted above, varying the above foreign exchange rates to reflect a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5%</div> strengthening of the US dollar and Euro would have an increase (decrease) in net loss as follows, assuming that all other variables remain constant:</div> <div style=" margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Increase (decrease) in net loss</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">364</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(88</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">)</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.9pt 0pt 20.5pt; text-indent: -9pt">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">An assumed <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5%</div> weakening of the foreign currencies would have an equal but opposite effect on the basis that all other variables remained constant.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div> <!-- Field: Page; Sequence: 37; Value: 9 --> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(c)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Interest rate risk:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market rates.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation&#x2019;s exposure to interest rate risk as at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>is as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 60%; border-top: Black 2.25pt solid; font-weight: bold">&nbsp;</td> <td style="width: 40%; border-top: Black 2.25pt solid; text-align: right; font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="font-weight: bold"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">Cash and cash equivalents</div></td> <td style="text-align: right; font-weight: bold"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">Short-term fixed interest rate</div></td> </tr> <tr style="vertical-align: top; background-color: White"> <td style="font-weight: bold"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">Marketable Securities</div></td> <td style="text-align: right; font-weight: bold"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">Short-term fixed interest rate</div></td> </tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 2.25pt solid; font-weight: bold"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">Unsecured convertible debentures </div></td> <td style="border-bottom: Black 2.25pt solid; text-align: right; font-weight: bold"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">Long-term fixed interest rate</div></td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The capacity of the Corporation to reinvest the short-term amounts with equivalent return will be impacted by variations in short-term fixed interest rates available on the market. Management believes that the risk the Corporation will realize a loss as a result of the decline in the fair value of its cash equivalents is limited because these investments have short-term maturities and are generally held to maturity.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(d)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Liquidity risk:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Liquidity risk is the risk that the Corporation will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be able to meet its financial obligations as they fall due. The Corporation manages liquidity risk through the management of its capital structure and financial leverage, as outlined in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24.</div> It also manages liquidity risk by continuously monitoring actual and projected cash flows. The Board of Directors reviews and approves the Corporation's operating budgets, and reviews material transactions outside the normal course of business. Refer to Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>(c).</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The following are the contractual maturities of financial liabilities as at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018:</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: normal">Required payments per year</td> <td style="font-weight: bold">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Total</div></td> <td>&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Carrying amount</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Less than 1 year</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1 to 3 years</div></td> <td style="font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Notes</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-weight: normal; text-align: left">Trade and other payables</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,429</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,429</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,429</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Unsecured convertible debentures</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,143</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,817</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,143</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,572</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,246</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,572</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: normal">Required payments per year</td> <td style="font-weight: bold">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Total</div></td> <td>&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Carrying amount</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Less than 1 year</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1 to 3 years</div></td> <td style="font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Notes</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-weight: normal; text-align: left">Trade and other payables</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,697</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,697</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,697</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Unsecured convertible debentures</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,303</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">160</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,143</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,000</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,309</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,857</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,143</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr>  </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The Derivative warrant liabilities are excluded from the above tables as they expected to be settled in shares and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> by the use of liquidities.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=sect_Scope&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737209552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 22 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">Disclosure of commitments and contingent liabilities [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Commitments and contingencies:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic;">Research and development contracts and contract research organizations agreements: </div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Corporation utilizes contract manufacturing organizations related to the development and production of clinical material and clinical research organizations to perform services related to the Company&#x2019;s clinical trials. Pursuant to these agreements with manufacturing and contract research organizations, the Corporation has the right to terminate the agreements either without penalties or under certain penalty conditions. For agreements which contain penalty conditions, the Company would be required to pay penalties of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$109.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">During Fiscal <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Corporation entered into a lease agreement, for its research and development and quality control laboratory facility located in Sherbrooke, Qu&eacute;bec, resulting in a commitment of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$79</div> over the remaining lease term, which is committed in the next year.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic;">Contingencies:</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.1pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.1pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.1pt; margin-bottom: 0pt; text-align: justify">The Corporation evaluates contingencies on an ongoing basis and establishes loss provisions for matters in which losses are probable and the amount of the loss can be reasonably estimated. Refer to Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,</div> Subsequent Events.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737233408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 23 - Determination of Fair Values<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory', window );">Disclosure of fair value measurement [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Determination of fair values:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.1pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.1pt; margin-bottom: 0pt; text-align: justify">Certain of the Corporation&#x2019;s accounting policies and disclosures require the determination of fair value, for both financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic;">Financial assets and liabilities:</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">In establishing fair value, the Corporation uses a fair value hierarchy based on levels as defined below:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 36pt"></td> <td style="width: 20.7pt"><div style="display: inline; font-family: Symbol">&middot;</div></td> <td style="text-align: justify; padding-right: 5.9pt">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1:</div> defined as observable inputs such as quoted prices in active markets.</td> </tr>  </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 36pt"></td> <td style="width: 20.7pt"><div style="display: inline; font-family: Symbol">&middot;</div></td> <td style="text-align: justify; padding-right: 5.9pt">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2:</div> defined as inputs other than quoted prices in active markets that are either directly or indirectly observable.</td> </tr>  </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top"> <td style="width: 36pt"></td> <td style="width: 20.7pt"><div style="display: inline; font-family: Symbol">&middot;</div></td> <td style="text-align: justify; padding-right: 5.9pt">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3:</div> defined as inputs that are based on little or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> observable market data, therefore requiring entities to develop their own assumptions.</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">The Corporation has determined that the carrying values of its short-term financial assets and liabilities (cash and cash equivalents, marketable securities and trade and other payables) approximate their fair value given the short-term nature of these instruments. The fair value of the liability component of the convertible debenture is determined by discounting future cash flows using a rate that the Corporation could obtain for loans with similar terms, conditions and maturity dates. The fair value of this liability at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>approximates the carrying amount and was measured using level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> inputs.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic;">Derivative warrant liabilities:</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">The Corporation measured its derivative warrant liabilities at fair value on a recurring basis. These financial liabilities were measured using level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> inputs <div style="display: inline; font-style: italic;">(Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div>).</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>the effect of an increase or a decrease of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5%</div> of the volatility used, which is the significant unobservable input in the fair value estimate, would result in a loss of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$569</div> or a gain of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$598,</div> respectively.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">As at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>the effect of a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5%</div> strengthening of the US dollar, would result in a loss of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$405.</div> An assumed <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5%</div> weakening of the foreign currency would have an equal but opposite effect on the basis that all other variables remained constant.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6619290352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 24 - Capital Management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory', window );">Disclosure of objectives, policies and processes for managing capital [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Capital management:</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-weight: normal">Since inception, the Corporation&#x2019;s objective in managing capital is to ensure sufficient liquidity to finance its research and development activities, general and administrative expenses, expenses associated with intellectual property protection and its overall capital expenditures. The Corporation is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> exposed to external requirements by regulatory agencies or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties regarding its capital, except for certain covenants included within the convertible debentures <div style="display: inline; font-style: italic;">(Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></div>).</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Since the beginning of its operations, the Corporation has primarily financed its liquidity needs from funding provided through public offerings, private placements, from the exercise of warrants that were distributed to its related party&#x2019;s shareholders, from a rights offering and from the issuance of options to employees. The Corporation defines capital to include total shareholders&#x2019; equity, derivative warrant liabilities and unsecured convertible debentures. The Corporation&#x2019;s policy is to maintain a minimal level of debt.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The following table summarizes the cash and cash equivalents of the Corporation:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;">  <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 12pt; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-weight: normal">Cash</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,896</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,583</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Cash equivalents</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Term deposits issued in CAD currency</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,100</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Term deposits issued in US currency [US - $3,250]</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,193</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Commercial papers issued in CAD currency</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,693</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Commercial papers issued in US currency [US - $1,099]</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,418</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Promissory notes issued in CAD currency</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">498</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Promissory notes issued in US currency [US - $798]</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,029</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; padding-left: 8.75pt">Bankers acceptance</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,334</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Total Cash equivalents</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,625</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,640</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Total Cash and cash equivalents</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,521</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,223</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> </tr>  </table> </div> <!-- Field: Page; Sequence: 39; Value: 9 -->   <!-- Field: /Page --> <table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Capital management (continued):</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">As at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019, </div>the term deposits, commercial paper, promissory note and bankers acceptance have maturity dates of ranging between <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 25, 2019, </div>bearing interest rates ranging from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.76%</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.40%</div> per annum, cashable at any time at the discretion of the Corporation, under certain conditions.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">As at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>the term deposits, commercial paper and promissory note have maturity dates of ranging between <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 2, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 11, 2018, </div>bearing interest rates ranging from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.26%</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.72%</div> per annum, cashable at any time at the discretion of the Corporation, under certain conditions.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 134<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_134&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6661800928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 25 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Disclosure of events after reporting period [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;">  <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25.</div></td> <td style="width: 5pt"></td> <td style="text-align: justify">Subsequent events</td> </tr>  </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 15, 2019 </div>the Corporation announced the annual grant of stock options to its employees, executives and directors of its stock option plan (the &#x201c;Stock Option Plan&#x201d;). The stock options were granted by the Board of Directors as part of the Corporation&#x2019;s annual performance review in accordance with the Corporation&#x2019;s Long-Term Incentive Program (LTIP).&nbsp;An aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">644,117</div> stock options were granted to certain employees, executives and directors of the Corporation under the Corporation&#x2019;s Stock Option Plan. Subject to the terms and conditions of the Stock Option Plan, options granted to directors will vest in equal quarterly installments over a period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div> months and options granted to executives and employees will vest in equal quarterly installments over a period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">36</div> months. Each option will entitle the holder to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> common share of the Corporation at a price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">CDN$1.28,</div> until <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 15, 2029.&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 10, 2019 </div>the Corporation announced the settlement regarding legal claims made by its former chief executive (&#x201c;CEO&#x201d;) officer with respect to the termination of his employment. Pursuant to the settlement agreement, the Corporation has agreed to issue <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">900,000</div> common shares at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.10</div> per share to the former CEO.&nbsp; In addition, the Corporation has agreed to reimburse the former CEO for legal fees of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$64.</div> Furthermore, pursuant to the settlement agreement, the Corporation receives a full and final release from the former CEO on all procedures in connection with the termination of his employment. This settlement has been accrued as at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019 </div>and the expense of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,054</div> is included as part of General and administrative expenses.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2017-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=10&amp;date=2017-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6733287632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DisclosureOfSignificantAccountingPoliciesAbstract', window );"><strong>Discloure of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Description of accounting policy for financial instruments [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">(a)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Financial instruments:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">A financial instrument is any contract that gives rise to a financial asset of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> party and a financial liability or equity instrument of another party.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt">(i)</td> <td style="text-align: justify">Non-derivative financial assets:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation has the following non-derivative financial assets: cash, cash equivalents, marketable securities and receivables. The Corporation determines the classification of its financial assets at initial recognition. The subsequent measurement of financial assets depends on their classification.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Financial assets and liabilities are offset and the net amount presented in the statements of financial position when, and only when, the Corporation has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0pt">Cash, cash equivalents, marketable securities and receivables with maturities of less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year are classified at amortized cost as they meet both of the following conditions; they are held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms give rise on specified dates to cashflows that are solely payments of principal and interest on the principal amount outstanding. Cash and cash equivalents comprise cash balances and highly liquid investments purchased <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months or less from maturity.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0.25in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <!-- Field: Page; Sequence: 11; Value: 9 --> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt">(ii)</td> <td style="text-align: justify">Non-derivative financial liabilities:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation has the following non-derivative financial liabilities: trade and other payables. Such financial liabilities are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are measured at amortized cost using the effective interest method.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt">(iii)</td> <td style="text-align: justify">Compound financial instruments:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Compound financial instruments are instruments that can be converted to share capital at the option of the holder, and the number of shares to be issued is fixed.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">The unsecured convertible debentures are compound instruments and have been separated into liability and equity components. The liability component is recognized initially at the fair value of a similar liability that does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> remeasured subsequent to initial recognition.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt">(iv)</td> <td style="text-align: justify">Share capital:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic;">Common Shares</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Class A Common Shares are classified as equity. Incremental costs directly attributable to the issue of Common Shares and share options are recognized as a deduction from share capital, net of any tax effects.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt">(v)</td> <td style="text-align: justify">Derivative financial instruments:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation has issued liability-classified derivatives over its own equity. Derivatives are recognized initially at fair value; attributable transaction costs are recognized in profit and loss as incurred. Subsequent to initial recognition, derivatives are measured at fair value, and all changes in their fair value are recognized immediately in profit or loss as a component of finance expense (income).</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt">(vi)</td> <td style="text-align: justify">Other equity instruments:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Warrants, options and rights over the Corporation&#x2019;s equity issued outside of share-based payment transactions that do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> meet the definition of a liability instrument are recognized in equity.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Description of accounting policy for property, plant and equipment [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">(b)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Equipment:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt">(i)</td> <td style="text-align: justify; padding-right: 5.9pt">Recognition and measurement:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Equipment is measured at cost less accumulated depreciation and accumulated impairment losses, if any.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Cost includes expenditures that are directly attributable to the acquisition of the asset, including all costs incurred in bringing the asset to its present location and condition.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Gains and losses on disposal of equipment are determined by comparing the proceeds from disposal with the carrying amount of equipment, and are recognized net within ''other income or expenses'' in profit or loss.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt">(ii)</td> <td style="text-align: justify; padding-right: 5.9pt">Subsequent costs:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The cost of replacing a part of an equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Corporation, and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the day-to-day servicing of equipment are recognized in profit or loss as incurred.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <!-- Field: Page; Sequence: 12; Value: 9 --> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt">(iii)</td> <td style="text-align: justify; padding-right: 5.9pt">Depreciation:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Depreciation is recognized in profit or loss on either a straight-line basis or a declining basis over the estimated useful lives of each part of an item of equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. Items of equipment are depreciated from the date that they are available for use or, in respect of assets <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> yet in service, from the date they are ready for their intended use.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The estimated useful lives and rates for the current and comparative periods are as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-indent: -9.05pt">&nbsp;</div> <div> <table style="border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 10pt">Assets</div></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid; text-align: right"><div style="display: inline; font-size: 10pt">Method</div></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 10pt">Period/Rate</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><div style="display: inline; font-size: 10pt">&nbsp;Furniture and office equipment</div></td> <td style="font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">Declining balance</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">20%</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"> to</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"> 30%</div></div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 28%; font: 10pt Times New Roman, Times, Serif; text-align: left"><div style="display: inline; font-size: 10pt">Computer equipment</div></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 30%; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">Declining balance</div></div></td> <td style="width: 20%; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="width: 7%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">&nbsp;</div></div></td> <td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">30%</div></div></td> <td style="width: 7%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">&nbsp;</div></div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><div style="display: inline; font-size: 10pt">Laboratory equipment</div></td> <td style="font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">Declining balance</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">&nbsp;</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">30%</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">&nbsp;</div></div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 10pt">Production equipment (in years)</div></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">Straight-line</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 10pt">&nbsp;</div></td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">&nbsp;</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">10</div></div></td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt">&nbsp;</div></div></td> </tr> </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Depreciation methods, useful lives and residual values are reviewed at each financial year-end and adjusted prospectively if appropriate.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory', window );">Description of accounting policy for intangible assets and goodwill [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">(c)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Intangible assets:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt">(i)</td> <td style="text-align: justify; padding-right: 5.9pt">Research and development:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Expenditure on research activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized in profit or loss as incurred.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Corporation intends to and has sufficient resources to complete development and to use or sell the asset. The expenditure capitalized includes the cost of materials, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use, and borrowing costs on qualifying assets. Other development expenditures are recognized in profit or loss as incurred.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Capitalized development expenditure is measured at cost less accumulated amortization and accumulated impairment losses. As of the reporting periods presented, the Corporation has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> capitalized any development expenditure.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt">(ii)</td> <td style="text-align: justify; padding-right: 5.9pt">Other intangible assets:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic;">Patent costs</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Patents for technologies that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer in the research phase are recorded at cost. Patent costs include legal fees to obtain patents and patent application fees. When the technology is still in the research and development phase, those costs are expensed as incurred.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"><div style="display: inline; font-style: italic;">Licenses</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Licenses that are acquired by the Corporation and have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt">(iii)</td> <td style="text-align: justify; padding-right: 5.9pt">Subsequent expenditure:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditures, including expenditure on internally generated goodwill and brands, are recognized in profit or loss as incurred.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt">(iv)</td> <td style="text-align: justify">Amortization:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Amortization is calculated over the cost of the intangible asset less its residual value.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <!-- Field: Page; Sequence: 13; Value: 9 --> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets from the date that they are available for use, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Assets</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Period (in years)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Patents</td> <td style="width: 1%">&nbsp;</td> <td style="width: 7%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 7%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td style="width: 7%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid">License</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8 </div></td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 14</div></td> </tr> </table> </div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory', window );">Description of accounting policy for impairment of assets [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">(d)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Impairment:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt">(i)</td> <td style="text-align: justify; padding-right: 5.9pt">Financial assets:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation assesses at each reporting date the expected credit loss for calculating impairment of financial assets and recognizes expected credit losses as loss allowances for assets measured at amortized cost.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt">(ii)</td> <td style="text-align: justify; padding-right: 5.9pt">Non-financial assets:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The carrying amounts of the Corporation&#x2019;s non-financial assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset&#x2019;s recoverable amount is estimated.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the &#x201c;cash-generating unit, or &#x201c;CGU&#x201d;).</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation&#x2019;s corporate assets do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> generate separate cash inflows. If there is an indication that a corporate asset <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be impaired, then the recoverable amount is determined for the CGU to which the corporate asset belongs.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">An impairment loss is recognized if the carrying amount of an asset or its CGU exceeds its estimated recoverable amount. Impairment losses are recognized in profit or loss.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Impairment losses recognized in prior years are assessed at each reporting date for any indications that the loss has decreased or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset&#x2019;s carrying amount does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> exceed the carrying amount that would have been determined, net of depreciation or amortization, if <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> impairment loss had been recognized.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Description of accounting policy for employee benefits [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">(e)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Employee benefits:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt">(i)</td> <td style="text-align: justify; padding-right: 5.9pt">Short-term employee benefits:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">A liability is recognized for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Corporation has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the obligation can be estimated reliably.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <!-- Field: Page; Sequence: 14; Value: 9 --> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt">(ii)</td> <td style="text-align: justify; padding-right: 5.9pt">Share-based payment transactions:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The grant date fair value of share-based payment awards granted to employees is recognized as an employee expense, with a corresponding increase in contributed surplus, over the period that the employees unconditionally become entitled to the awards. The grant date fair value takes into consideration market performance conditions when applicable. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. Share-based payment arrangements in which the Corporation receives goods or services as consideration for its own equity instruments are accounted for as equity-settled share-based payment transactions, regardless of how the equity instruments are obtained by the Corporation.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt">(iii)</td> <td style="text-align: justify; padding-right: 5.9pt">Termination benefits:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Termination benefits are recognized as an expense when the Corporation is committed demonstrably, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognized as an expense if the Corporation has made an offer of voluntary redundancy, it is probable that the offer will be accepted, and the number of acceptances can be estimated reliably. If benefits are payable more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months after the reporting year, then they are discounted to their present value.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory', window );">Description of accounting policy for provisions [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">(f)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Provisions:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify"></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0pt">A provision is recognized if, as a result of a past event, the Corporation has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as a component of finance expense (income).</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt">(i)</td> <td style="text-align: justify; padding-right: 5.9pt">Onerous contracts:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">A provision for onerous contracts is recognized when the expected benefits to be derived by the Corporation from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Corporation recognizes any impairment loss on the assets associated with that contract.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt">(ii)</td> <td style="text-align: justify; padding-right: 5.9pt">Contingent liability:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">A contingent liability is a possible obligation that arises from past events and of which the existence will be confirmed only by the occurrence or non-occurrence of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more uncertain future events <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> within the control of the Corporation; or a present obligation that arises from past events (and therefore exists), but is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> recognized because it is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> probable that a transfer or use of assets, provision of services or any other transfer of economic benefits will be required to settle the obligation; or the amount of the obligation cannot be estimated reliably.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants', window );">Description of accounting policy for government grants [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">(g)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Government grants:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Government grants are recorded as a reduction of the related expense or cost of the asset acquired. Government grants are recognized when there is reasonable assurance that the Corporation has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Grants that compensate the Corporation for expenses incurred are recognized in profit or loss in reduction thereof on a systematic basis in the same years in which the expenses are recognized. Grants that compensate the Corporation for the cost of an asset are recognized in profit or loss on a systematic basis over the useful life of the asset.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Description of accounting policy for leases [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">(h)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Lease payments:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease. Lease incentives received are recognized as an integral part of the total lease expense, over the term of the lease.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Description of accounting policy for foreign currency translation [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">(i)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Foreign currency:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Transactions in foreign currencies are translated into the functional currency at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated to the functional currency at the exchange rate at that date. The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the period, adjusted for effective interest and payments during the period, and the amortized cost in foreign currency translated at the exchange rate at the end of the reporting period. Foreign currency differences arising on translation are recognized in profit or loss.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory', window );">Description of accounting policy for finance income and costs [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">(j)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Finance income and finance expense:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Finance income comprises interest income on funds invested. Interest income is recognized as it accrues in profit or loss, using the effective interest method.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.95pt; margin-bottom: 0pt; text-align: justify">Finance costs comprise interest expense, accretion on borrowings, unwinding of the discount on provisions, impairment losses recognized on financial assets, transaction costs for issuance of derivative warrant liabilities and changes of fair value of derivative warrant liabilities. Borrowing costs that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> directly attributable to the acquisition, construction or production of a qualifying asset are recognized in profit or loss using the effective interest method.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Foreign currency gains and losses are reported on a net basis. The Corporation recognizes interest income as a component of investing activities and interest expense as a component of financing activities in the statements of cash flows.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Description of accounting policy for income tax [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">(k)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Income tax:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Income tax expense comprises current and deferred taxes. Current and deferred taxes are recognized in profit or loss except to the extent that they relate to items recognized directly in equity or in other comprehensive income.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted at the reporting date, and any adjustment to tax payable in respect of previous years.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> recognized for temporary differences arising from the initial recognition of assets or liabilities in a transaction that is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> a business combination and that affects neither accounting nor taxable profit or loss. Deferred tax is measured at the tax rates, enacted or substantively enacted, that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously. A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer probable that the related tax benefit will be realized.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Description of accounting policy for earnings per share [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(l)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Earnings per share:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The Corporation presents basic and diluted earnings per share (&#x201c;EPS&#x201d;) data for its Class A shares (or &#x201c;Common Shares&#x201d;). Basic EPS is calculated by dividing the profit or loss attributable to the holders of Class A shares (Common Shares) of the Corporation by the weighted average number of Common Shares outstanding during the year, adjusted for own shares held. Diluted EPS is determined by adjusting the profit or loss attributable to the holders of Class A shares (Common Shares) and the weighted average number of Class A shares (Common Shares) outstanding adjusted for the effects of all dilutive potential Common Shares, which comprise warrants, rights and share options granted to employees.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Description of accounting policy for segment reporting [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; text-align: justify"><td style="width: 35pt; text-align: left">(m)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Segment reporting:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">An operating segment is a component of the Corporation that engages in business activities from which it <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>earn revenues and incur expenses. The Corporation has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> reportable operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The majority of the Corporation&#x2019;s assets are located in Canada, while <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> major production unit, with a carrying value of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,831</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 - </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2,077</div>), is located in France.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock', window );">Description of accounting policy for changes in accounting policy [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left">(n)</td> <td style="width: 5pt"></td> <td style="text-align: justify">Change in accounting policy:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">Adoption of new accounting standards</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The accounting policies used in these annual financial statements are consistent with those applied by the Corporation in its <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018 </div>annual financial statements except for the amendments to certain accounting standards which are relevant to the Corporation and were adopted by the Corporation as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2018 </div>as described below.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt">(i)</td> <td style="text-align: justify">Financial instruments:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,</div> Financial Instruments, replaces IAS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,</div> Financial Instruments: Recognition and Measurement. IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div> introduces a revised approach for the classification of financial assets based on how an entity manages financial assets and the characteristics of the contractual cash flows of the financial assets replacing the multiple rules in IAS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39.</div> Most of the requirements in IAS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39</div> for classification and measurement of financial liabilities have been carried forward in IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.</div> IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div> also introduces a new hedge accounting model that is more closely aligned with risk-management activities and a new expected credit loss model for calculating impairment on financial assets replacing the incurred loss model in IAS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39.</div> The Corporation adopted IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2018 </div>and assessed the impact of the adoption on its financial statements, and determined there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> material impact. The Corporation does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> apply hedge accounting.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 40pt; text-align: right"></td> <td style="width: 35pt">(ii)</td> <td style="text-align: justify">Amendments to IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> &#x2013; Classification and Measurement of Share-Based Payment Transactions:</td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 20, 2016, </div>the IASB issued amendments to IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,</div> Share-Based Payment, clarifying how to account for certain types of share-based payment transactions. The amendments provide requirements on the accounting for: the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based payments; share-based payment transactions with a net settlement feature for withholding tax obligations; and a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from cash-settled to equity-settled. The Corporation adopted the amendments to IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2018 </div>and assessed the impact of the adoption of IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> on its financial statements, and determined that there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> material impact.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Future accounting change:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">The following new standards, and amendments to standards and interpretations, are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> yet effective for the period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019,</div> and have <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been applied in preparing these financial statements.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">New standards and interpretations <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> yet adopted:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 5.9pt; margin-bottom: 0pt; text-align: justify">&nbsp;</div> <table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt"></td> <td style="width: 35pt">(i)</td> <td style="text-align: justify; padding-right: 5.9pt">Leases &#x2013; IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.25pt; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> Leases (&#x201c;IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16&#x201d;</div>) In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2016, </div>the IASB issued IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> a new standard that replaces IAS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,</div> Leases. IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div> is a major revision of the way in which companies account for leases and will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer permit off balance sheet leases. Adoption of IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div> is mandatory and will be effective for the Corporation&#x2019;s fiscal year beginning on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> April 1, 2019. </div>The Corporation is assessing the impact of adoption of IFRS <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,</div> and currently there is only <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> lease that will be impacted by this new standard and the impact is expected to be minimal.</div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for the change in accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DescriptionOfAccountingPolicyForChangesInAccountingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DisclosureOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DisclosureOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for finance income and costs. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2017-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=20&amp;date=2017-03-01&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for the impairment of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for intangible assets and goodwill. [Refer: Intangible assets and goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6675108464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DisclosureOfUsefulLivesAndRatesTextBlock', window );">Disclosure of useful lives and rates [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="border-collapse: collapse; min-; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Assets</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid; text-align: right"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Method</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Period/Rate</div></div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;Furniture and office equipment</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Declining balance</div></div></div></td> <td style="font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20%</div></div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> to</div></div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 30%</div></div></div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 28%; font: 10pt Times New Roman, Times, Serif; text-align: left"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Computer equipment</div></div></td> <td style="width: 1%; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="width: 30%; font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Declining balance</div></div></div></td> <td style="width: 20%; font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="width: 7%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></div></td> <td style="width: 7%; font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30%</div></div></div></td> <td style="width: 7%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Laboratory equipment</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Declining balance</div></div></div></td> <td style="font: 10pt Times New Roman, Times, Serif"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30%</div></div></div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Production equipment (in years)</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Straight-line</div></div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></div></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></div></div></td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></div></div></td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Assets</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Period (in years)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Patents</td> <td style="width: 1%">&nbsp;</td> <td style="width: 7%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 7%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td style="width: 7%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid">License</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8 </div></td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">to</div></td> <td style="text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 14</div></td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DisclosureOfUsefulLivesAndRatesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of useful lives and rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DisclosureOfUsefulLivesAndRatesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737270304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Receivables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock', window );">Disclosure of detailed information of trade and other receivables [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: center; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid">Notes</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-weight: normal; text-align: left">Sales tax receivables</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 14%; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">618</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">470</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Government assistance and tax credits receivable</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">872</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">282</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Interest receivable</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Other receivables</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Total receivables</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,586</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">759</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information of trade and other receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DisclosureOfDetailedInformationOfTradeAndOtherReceivablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737331184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_SummaryOfMarketableSecuritiesTextBlock', window );">Summary of marketable securities [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-weight: normal; text-align: left">Term deposit issued in US currency [US $20], earning interest at 2.23% and maturing on March 13, 2019</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Term deposits issued in US currency [US $2,020], earning interest at 2.50% and maturing on various dates from April 8, 2019 to March 12, 2020</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,696</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Treasury bills issued in CAD currencyearning interest at rates ranging from 1.83% to 1.90% and maturing on various dates from April 2, 2019 to July 25, 2019</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,196</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Total Marketable securities</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,892</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; padding-left: 10pt">Current marketable securities</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,865</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid; padding-left: 10pt">Marketable securities</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_SummaryOfMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_SummaryOfMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737325808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_SummaryOfOtherAssetsTextBlock', window );">Summary of other assets [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-weight: normal; text-align: left">Balance &#x2013; beginning of year</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">659</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Purchased</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">68</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">970</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; border-bottom: Black 1pt solid">Used</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(105</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(311</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Balance &#x2013; end of year</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">622</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">659</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> <div style="display: inline; font-weight: normal"></div> <div style="display: inline; font-weight: normal">Current other asset</div></td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">65</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">104</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Other asset</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">557</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">555</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_SummaryOfOtherAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The summary of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_SummaryOfOtherAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6745119456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory', window );">Disclosure of research and development expense [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br /> months ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br /> ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br /> 2019</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br /> 2018</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br /> 2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, </div><br /> 2017</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; text-indent: -8.25pt; padding-left: 8.25pt">Research and development expenses</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left; padding-left: 13.65pt">Supplies and incremental costs</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 13.65pt">Shared service agreement</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid; padding-left: 15.3pt">Total</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; text-indent: -8.25pt; padding-left: 8.25pt">General and administrative expenses</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 13.65pt">Supplies and incremental costs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">211</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">239</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">293</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">277</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 13.65pt">Shared service agreement</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">34</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">121</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">325</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid; padding-left: 15.3pt">Total</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">245</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">360</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">618</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">577</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Total related parties expenses</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">245</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">387</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">678</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">42</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">636</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory', window );">Disclosure of information about key management personnel [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br /> months ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2019</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2018</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, </div><br /> 2017</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Compensation</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,641</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,754</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,510</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">146</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,364</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Share-based compensation costs</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">940</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">826</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">619</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">78</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">541</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Total key management personnel compensation</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,581</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,580</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,129</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">224</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,905</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6631480288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Government Assistance (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock', window );">Disclosure of detailed information about government grants and investment tax credits [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br /> months ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2019</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2018</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, </div><br /> 2017</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">(Unaudited)</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Investment tax credit</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">588</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">409</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">103</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">95</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Government grant</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">227</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">37</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">190</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Total government assistance</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">595</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">409</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">330</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">285</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">$</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; text-align: left">2029</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2030</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2031</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2032</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">431</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2033</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">441</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2034</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">436</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2035</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">519</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2036</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">286</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2037</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">315</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2038</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">324</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid">2039</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">329</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,167</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about government grants and investment tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DisclosureOfDetailedInformationAboutGovernmentGrantsAndInvestmentTaxCreditsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737181952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Disclosure of detailed information about property, plant and equipment [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Furniture and <br /> office equipment</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Computer <br /> equipment</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Laboratory <br /> equipment</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Production <br /> equipment</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Total</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Cost:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%">Balance at February 29, 2016</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">336</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">398</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">Additions for the twelve-month period (Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">186</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,484</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,678</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at February 28, 2017 (Unaudited)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">522</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,484</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,076</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid">Additions for the one-month period (Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Additions for the thirteen-month period</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">186</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,527</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,721</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2017</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">522</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,527</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,119</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid">Additions</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">192</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">181</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">383</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2018</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">714</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,708</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,502</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid">Additions</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">219</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">497</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid">Balance at March 31, 2019</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">68</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">933</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,968</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,999</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Accumulated depreciation:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at February 29, 2016</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">52</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">56</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">111</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">Depreciation for the twelve-month period (Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">129</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">52</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">189</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at February 28, 2017 (Unaudited)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">185</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">52</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">Depreciation for the one-month period (Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Depreciation for thirteen-month period</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">140</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">73</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">221</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2017</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">196</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">73</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">332</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid">Depreciation</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">107</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">239</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">349</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at March 31, 2018</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">59</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">303</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">312</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">681</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid">Depreciation</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">180</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">317</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">505</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid">Balance at March 31, 2019</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">483</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">629</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,186</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Net carrying amounts:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.1in">March 31, 2018</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">411</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,396</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,821</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid; padding-left: 0.1in">March 31, 2019</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">450</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,339</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,813</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2017-01-01<br> -Paragraph 73<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2017-03-01&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737275776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory', window );">Disclosure of detailed information about intangible assets [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Patents</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">License</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Total</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Cost:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 55%">Balance at February 29, 2016, February 28, 2017 (Unaudited) and March 31, 2017</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,330</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,692</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">Additions</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at March 31, 2018</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,330</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,692</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">Additions</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid">Balance at March 31, 2019</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,330</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,692</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Accumulated amortization:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at February 29, 2016</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,425</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,787</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Amortization for the twelve-month period (Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,323</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,323</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at February 28, 2017 (Unaudited)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,748</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,110</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Amortization for the one-month period (Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">194</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">194</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid">Amortization for the thirteen-month period</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,517</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,517</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at March 31, 2017</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,942</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,304</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid">Amortization for the year</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,323</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,323</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance at March 31, 2018</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,265</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,627</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid">Amortization for the year</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,322</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,322</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid">Balance at March 31, 2019</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">362</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,587</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,949</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Net carrying amounts:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.1in">March 31, 2018</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,065</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,065</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid; padding-left: 0.1in">March 31, 2019</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,743</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,743</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2017-01-01<br> -Paragraph 118<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2017-03-01&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6735526976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Trade and Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock', window );">Disclosure of detailed information about trade and other payables [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-weight: normal; text-align: left">Trade payables</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,064</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,420</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Accrued liabilities and other payables</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,319</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,479</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Employee salaries and benefits payable</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,054</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">754</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Legal settlement expected to be paid via common shares (note 25)</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">990</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Payable to Neptune</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Total trade and other payables</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,429</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,697</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The detailed disclosure of trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6750576752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Derivative Warrant Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities', window );">Disclosure of maturity analysis for derivative financial liabilities [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Warrant liabilities issued <br /> May 2018</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Warrant liabilities issued <br /> December 27, 2017</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-weight: normal">Warrant liabilities issued <br /> December 3, 2013<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">1</div></div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">March 31, <br /> 2019</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; font-style: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; font-style: normal; text-align: right">March 31, <br /> 2018</td> <td style="font-weight: normal; font-style: normal">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">March 31, <br /> 2019</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; font-style: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; font-style: normal; text-align: right">March 31, <br /> 2018</td> <td style="font-weight: normal; font-style: normal">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right">March 31, <br /> 2019</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; font-style: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; font-style: normal; text-align: right">March 31, <br /> 2018</td> <td style="font-weight: normal; font-style: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; font-weight: normal">Balance &#x2013; beginning of period</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,405</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">209</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Issued during period</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,272</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,873</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-indent: -4.95pt; padding-left: 4.95pt">Exercised during period</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(722</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">)</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; text-indent: -4.95pt; padding-left: 4.95pt">Change in fair value of derivative warrant liabilities</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,696</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">532</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(21</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(188</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; border-bottom: Black 1pt solid">Balance &#x2013; end of period</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,246</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,017</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,405</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">Fair value per share issuable</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.81</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.82</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.65</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.01</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_DerivativeWarrantLiabilitiesMember', window );">Derivative warrant liabilities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory', window );">Disclosure of sensitivity analysis for actuarial assumptions [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Warrant liabilities issued <br />May 2018</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Warrant liabilities issued <br />December 27, 2017</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Warrant liabilities issued</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">December 3, 2013 <div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">1</div></div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br />2019</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br /> 2018</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br />2019</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br /> 2018</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br />2019</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br /> 2018</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; font-weight: normal">Exercise price</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">$</td> <td style="width: 8%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.31</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.26</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.26</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 8%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.50</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Share price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">$</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.35</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.02</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.02</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.02</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Risk-free interest</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.52</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">%</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.23</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">%</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.56</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">%</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.19</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Estimated life (in years)</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">4.11</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">3.75</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">4.75</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">0.68</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">94.58</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">107.57</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">95.15</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">133.86</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2017-01-01<br> -Paragraph 145<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=19&amp;date=2017-03-01&amp;anchor=para_145&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis for derivative financial liabilities, including the remaining contractual maturities for those derivative financial liabilities for which contractual maturities are essential for an understanding of the timing of the cash flows. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_DerivativeWarrantLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_DerivativeWarrantLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737252976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Unsecured Convertible Debentures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory', window );">Disclosure of detailed information about borrowings [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid; vertical-align: top">Liability component</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid; vertical-align: top">Equity component</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">Total Private <br /> Placement</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 55%; font-weight: normal; border-bottom: Black 1pt solid">Balance at March 31, 2017</td> <td style="width: 1%; font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,406</div></td> <td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">309</div></td> <td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,715</div></td> <td style="white-space: nowrap; width: 1%; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Effective interest for the twelve-month period</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">366</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">366</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Interest payable during the period</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(160</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(160</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Balance at March 31, 2018</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">309</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,921</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Effective interest during the period</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">365</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">365</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Interest payable during the period</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(160</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(160</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">Balance at March 31, 2019</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,817</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">309</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,126</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6749590752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Capital and Other Components of Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DisclosureOfConvertibleDebenturesTextBlock', window );">Disclosure of convertible debentures [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"><div style="display: inline; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"><div style="display: inline; font-weight: normal">Accrued interest as at</div></div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"><div style="display: inline; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0"><div style="display: inline; font-weight: normal">Share issuance date</div></div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">Number of shares</div></div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">Amount </div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">$</div></div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%; font-weight: normal">March 31, 2017</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 35%; font-weight: normal"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">April 7, 2017</div></td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,496</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">June 30, 2017</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">August 15, 2017</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,885</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal">September 30, 2017</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">December 27, 2017</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,783</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">December 31, 2017</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 27, 2018</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33,605</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal">March 31, 2018</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">June 6, 2018</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,348</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">June 30, 2018</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">August 21, 2018</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">51,807</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; border-bottom: Black 1pt solid">September 30, 2018</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">October 31, 2018</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,723</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">195,647</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">257</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ClassOfWarrantOrRightOutstandingTextBlock', window );">Class of warrant or right outstanding [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">March 31, 2019</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">March 31, 2018</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">March 31, 2017</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">February 28, 2017</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">(Unaudited)</div></div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">Number <br /> outstanding</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">Amount</div></div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">Number <br /> outstanding</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">Amount</div></div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">Number <br /> outstanding</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">Amount</div></div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">Number <br /> outstanding</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-size: 9pt; font-weight: normal">Amount</div></div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Liability</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 28%; font-weight: normal; font-style: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">May 2018 Public offering Warrants 2018 (i)</div></td> <td style="width: 1%; font-weight: normal; font-style: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: normal; font-style: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">10,188,100</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; font-style: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: normal; font-style: normal"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: normal; font-style: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: normal; font-style: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">8,246</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; font-style: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="width: 6%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Series December 2017 US Public offering Warrants 2017 (ii)</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">9,801,861</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">8,017</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">9,802,935</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">6,405</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; font-style: normal; text-align: left; text-indent: -10pt; padding-left: 10pt; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">Series 8 Public offering Warrants December 2013 (iii)</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">18,400,000</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">21</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">18,400,000</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">209</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">18,400,000</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">187</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">19,989,961</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">16,263</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">28,202,935</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">6,426</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">18,400,000</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">209</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">18,400,000</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">187</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Equity</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Public offering warrants</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Public offering broker warrants May 2018 (iv)</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">547,975</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">283</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Public offering U.S. broker warrants December 2017 (v)</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">495,050</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">406</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">495,050</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">406</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Public offering warrants February 2017 (vi)</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,904,034</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,904,034</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,965,259</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,965,259</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-decoration: underline; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Private Placement- contingent warrants</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">2017 unsecured convertible debenture conversion option and contingent warrants (vii)</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,052,630</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">309</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,052,630</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">309</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,052,630</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">309</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">1,052,630</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">309</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Series 9 Private Placement warrants 2013 (viii)</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">161,654</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">161,654</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">161,654</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">Series 2017 BW Broker warrants (ix)</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: bold; border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">-</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">234,992</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">144</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">234,992</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">144</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-indent: -10pt; padding-left: 10pt"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">3,999,689</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">998</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">3,613,368</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">715</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">3,414,535</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">453</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">3,414,535</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-size: 9pt">453</div></div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"><div style="display: inline; font-size: 9pt">&nbsp;</div></td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsMember', window );">Warrants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory', window );">Disclosure of sensitivity analysis for actuarial assumptions [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">May 2018</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; font-weight: normal">Exercise price</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">$</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.31</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Share price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">$</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.82</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Risk-free interest</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.21</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Estimated life (in years)</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">87.40</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">May 2018</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; font-weight: normal">Exercise price</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">$</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.05</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Share price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">$</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.81</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Risk-free interest</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.20</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Estimated life (in years)</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">5</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">87.40</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">December 27, <br />2017</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal">Exercise price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.26</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Share price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $0.97</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; font-weight: normal; text-align: left">Risk-free interest</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.22</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Estimated life (in years)</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">5</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">93.52</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">December 27, <br />2017</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal">Exercise price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $1.2625</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Share price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">US $0.97</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; font-weight: normal; text-align: left">Risk-free interest</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.22</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Estimated life (in years)</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">93.52</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">February 21, 2017</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; font-weight: normal">Exercise price</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">$</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.15</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal">Share price</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">$</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.70</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal">Dividend</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Risk-free interest</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.79</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Estimated life (in years)</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">1.00</div></div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Expected volatility</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">112.09</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">%</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ClassOfWarrantOrRightOutstandingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of class of warrant or right outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ClassOfWarrantOrRightOutstandingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DisclosureOfConvertibleDebenturesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of convertible debentures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DisclosureOfConvertibleDebenturesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2017-01-01<br> -Paragraph 145<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=19&amp;date=2017-03-01&amp;anchor=para_145&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737216992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Personnel Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock', window );">Disclosure of components of personnel expenses [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br /> months ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-month <br />period ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2019</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2018</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017 <br />(Unaudited)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, </div><br /> 2017 <br />(Unaudited)</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Salaries and other short-term employee benefits</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,144</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,281</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,491</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">214</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,277</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Share-based compensation costs</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,041</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">929</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">674</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">86</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">588</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Total personnel expenses</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,185</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,210</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,165</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">300</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,865</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of personnel expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DisclosureOfComponentsOfPersonnelExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6751066800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Financial Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock', window );">Disclosure for components of finance income (cost) [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br /> months ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-month <br />period ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2019</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2018</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017 <br />(Unaudited)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, </div><br /> 2017 <br />(Unaudited)</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Interest income</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">475</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">119</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign exchange gain (loss)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">279</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(32</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(180</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(177</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Interest payable on convertible debenture</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(160</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(160</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(17</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accretion of interest on convertible debenture</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(205</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(206</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(22</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(17</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Transaction costs related to derivative warrant liabilities</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(653</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,134</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value of warrant liabilities</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,287</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(344</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(53</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(22</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(31</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid">Other charges</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(19</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Financial expenses</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(6,551</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,808</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(166</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(51</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(115</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finance income (cost).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DisclosureForComponentsOfFinanceIncomeCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737350560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 17 - Share-based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Disclosure of number and weighted average exercise prices of share options [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, 2019</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, 2018</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">Weighted average <br /> exercise price</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">Number of <br /> options</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">Weighted average <br /> exercise price</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">Number of <br /> options</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: left; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Outstanding at beginning of year</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.81</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,284,388</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.58</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,424,788</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.77</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,173,523</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.75</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,121,500</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.77</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,167</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.84</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(407,067</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.89</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(199,800</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">Expired</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18.06</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(62,100</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Outstanding at end of year</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.25</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,046,677</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.81</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,284,388</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Exercisable at end of year</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.56</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,613,200</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.92</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">591,113</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-month period <br /> ended <br /> <div style="display: inline; font-family: Times New Roman, Times, Serif">March 31, 2017</div></td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended <br /> March 31, 2017</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-month period <br /> ended <br /> February 28, 2017</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Weighted <br /> average <br /> exercise price</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Number <br /> of options</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Weighted <br /> average <br /> exercise price</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Number <br /> of options</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Weighted <br /> average <br /> exercise price</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top">Number <br /> of options</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%">Outstanding at beginning of period</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 8%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.52</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 8%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">454,151</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 8%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.59</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 8%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,427,288</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 8%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.52</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 8%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">454,151</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.69</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,300,400</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.69</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,300,400</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.27</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(190,138</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.50</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,500</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.29</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(187,638</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1pt solid">Expired</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.38</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(139,625</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.38</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(139,625</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid">Outstanding at end of period</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.58</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,424,788</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.58</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,424,788</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.59</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,427,288</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1.5pt solid">Exercisable at end of period</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.44</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">238,482</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.44</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">238,482</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.49</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">240,982</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-month <br /> period ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-month <br />Period ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br /> 2019</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br /> 2018</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">March 31, <br /> 2017</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">February 28, 2017 <br />(Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left; border-bottom: Black 1.5pt solid; text-indent: -6.75pt; padding-left: 6.75pt">Weighted average fair value of the options granted to employees and directors of the Corporation</td> <td style="width: 1%; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.51</div></td> <td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.22</div></td> <td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.40</div></td> <td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="width: 10%; border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.40</div></td> <td style="white-space: nowrap; width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-month <br /> period ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-month <br />Period ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, 2019</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, 2018</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, 2017</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">February 28, 2017 <br />(Unaudited)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Exercise price</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.77</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.75</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.69</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.69</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Share price</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.73</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.75</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.69</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.69</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Dividend</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.10</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.21</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.87</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.87</div></td> <td style="white-space: nowrap; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Estimated life (in years)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif">5.78</div></div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif">5.89</div></div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif">4.94</div></div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-family: Times New Roman, Times, Serif">4.94</div></div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid">Expected volatility</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">85.35</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82.4</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">123.5</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">123.5</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">Disclosure of range of exercise prices of outstanding share options [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="14" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">Options outstanding</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid">Exercisable options</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td colspan="3" style="white-space: nowrap; border-bottom: Black 1pt solid">Exercise price</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Weighted remaining <br /> contractual life <br /> outstanding</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Number of options <br /> outstanding</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Weighted average <br /> exercise price <br />$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Number of options <br /> exercisable</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: center">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 5%">$0.77</td> <td style="width: 2%"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 41%"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.77</div></td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.26</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,898,523</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.77</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">348,197</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>$0.78</td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.58</div></td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.86</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">775,000</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.50</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">518,750</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$1.59</td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.71</div></td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.90</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">273,333</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.65</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">233,333</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>$1.72</td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.88</div></td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.21</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">790,833</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.77</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">292,500</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="border-bottom: Black 1pt solid">$1.89</td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.50</div></td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.97</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">308,988</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.57</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">220,420</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.91</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,046,677</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.56</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,613,200</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the range of exercise prices for outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6733257600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 19 - Supplemental Cash Flow Disclosure (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock', window );">Disclosure of changes in noncash operating items [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-<br /> months ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, <br />2019</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, <br />2018</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, <br />2017</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">March 31, <br />2017 <br />(Unaudited)</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">February 28, <br /> 2017 <br />(Unaudited)</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%">Receivables</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(738</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(553</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">193</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(40</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">233</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid expenses</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(709</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(103</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">247</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(33</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">280</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Assets</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">37</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(659</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Deferred financing costs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(179</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid">Trade and other payables</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,679</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,898</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">352</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(255</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">607</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Total changes in working capital items</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,090</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,583</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">792</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(328</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,120</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DisclosureOfNoncashTransactionsTextBlock', window );">Disclosure of noncash transactions [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Twelve-months <br /> ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-left: 10pt; text-indent: -10pt">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2019</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2018</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017 <br />(Unaudited)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, 2017 </div><br />(Unaudited)</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left; padding-left: 10pt; text-indent: -10pt">Issuance of shares for interest on convertible debt</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">120</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">137</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">94</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">94</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Issuance of broker warrants included in net proceeds from public offering</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">283</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">406</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">144</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">144</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Public offering transaction costs included in trade and other payables</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">132</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">381</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">381</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">416</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Interest receivable included in receivables</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">96</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Reduction in share issue costs from reduction in trade and other payables</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">109</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">109</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Private Placement transaction costs included in trade and other payables</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Equipment included in trade and other payables</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">216</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">288</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">288</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">269</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1.5pt solid; padding-left: 10pt; text-indent: -10pt">Interest payable included in trade and other payables</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of changes in noncash operating items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DisclosureOfChangesInNoncashOperatingItemsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DisclosureOfNoncashTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of noncash transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DisclosureOfNoncashTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6750581680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 20 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ChangesInDeferredTaxLiabilityAssetTextBlock', window );">Changes in deferred tax liability (asset) [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right; border-top: Black 1.5pt solid">Twelve-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2019</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2018</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017 <br />(Unaudited)</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, </div><br /> 2017 <br />(Unaudited)</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left; text-indent: -7.35pt; padding-left: 7.35pt">Origination and reversal of temporary differences</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,599</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,241</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,240</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">163</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,077</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1pt solid; text-indent: -7.35pt; padding-left: 7.35pt">Change in unrecognized deductible temporary differences</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,599</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5,241</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,369</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(163</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,206</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Deferred tax (recovery) expense</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(129</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(129</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock', window );">Reconciliation of accounting profit multiplied by applicable tax rates [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Thirteen-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">Month <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: right; border-top: Black 1.5pt solid">Twelve-months <br />ended</td> <td style="border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2019</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2018</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">March 31, </div><br />2017 <br />(Unaudited)</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; vertical-align: top"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">February 28, </div><br /> 2017 <br />(Unaudited)</td> <td style="text-align: right; vertical-align: top">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: left">Loss before income taxes</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(51,566</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(21,504</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(11,376</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(769</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(10,607</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic combined Canadian statutory income tax rate <div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">1</div></div></td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26.68</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26.78</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26.87</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26.80</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26.88</div></td> <td style="white-space: nowrap; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Computed income tax recovery</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(13,758</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(5,759</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,057</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(206</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,851</div></td> <td style="white-space: nowrap; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Increase resulting from:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -7.15pt; padding-left: 21.55pt">Change in unrecognized deductible temporary differences</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,599</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,241</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,369</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">162</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,207</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.2in">Non-deductible stock-based compensation</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">279</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">248</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">178</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">155</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.2in">Non-deductible change in fair value</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,677</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">92</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.2in">Permanent differences and other</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">203</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">178</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">166</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">154</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; border-bottom: Black 1pt solid; padding-left: 0.2in">Change in statutory income tax rate</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">201</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">198</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; border-bottom: Black 1.5pt solid">Total tax (recovery) expense</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(129</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(129</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">)</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock', window );">Disclosure of unrecognized deferred tax assets [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">March 31, 2019</div></div></td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">March 31, 2018</div></div></td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-top: Black 1.5pt solid"><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">&nbsp;</div></div><div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: right"><div style="display: inline; font-weight: normal">March 31, 2017</div></div></td> <td style="border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Deferred tax assets</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 55%; font-weight: normal; text-align: left">Tax losses carried forward</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,695</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,670</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,293</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Research and development expenses</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,362</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,927</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,220</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Property, plan and equipment and intangible assets</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">766</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">567</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">435</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Financing expenses</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,852</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">116</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Other deductible temporary differences</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">378</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">768</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">522</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Deferred tax assets</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,053</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,048</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,470</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">&nbsp;Deferred tax liabilities</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Tax basis of unsecured convertible debentures in excess of carrying value</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">67</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">122</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Deferred tax liabilities</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">67</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">122</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Net deferred tax assets</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,040</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,981</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,348</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock', window );">Tax attributes and temporary differences, which are available to reduce future years&#8217; taxable income [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; text-align: left; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="6" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">Federal</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">Provincial</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; border-bottom: Black 1pt solid; padding-left: 0.2in; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">$</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-family: Times New Roman, Times, Serif; font-weight: normal">$</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Tax losses carried forward</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; font-weight: normal; text-align: left">2029</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">714</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">714</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">2030</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,627</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,620</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">2031</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,071</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,063</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">2032</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,262</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,241</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">2033</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,854</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,825</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">2034</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,598</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,598</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">2035</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,595</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,459</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">2036</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,494</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,494</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">2037</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,584</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,456</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">2038</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,340</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,270</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">2039</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,447</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,447</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">89,586</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">89,187</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Research and development expenses, without time limitation</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,617</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,036</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left">Other deductible temporary differences, without time limitation</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,875</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,294</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ChangesInDeferredTaxLiabilityAssetTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of changes in deferred tax liability (asset).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ChangesInDeferredTaxLiabilityAssetTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of unrecognized deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DisclosureOfUnrecognizedDeferredTaxAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reconciliation of accounting profit multiplied by applicable tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of tax attributes and temporary differences, which are available to reduce future years&#8217; taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_TaxAttributesAndTemporaryDifferencesWhichAreAvailableToReduceFutureYearsTaxableIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737274192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 21 - Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory', window );">Disclosure of effect of changes in foreign exchange rates [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: normal; border-bottom: Black 1pt solid; text-align: left; vertical-align: top">Denominated in</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">US <br /> $</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">Euro</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">US <br /> $</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid; vertical-align: top">Euro</td> <td style="border-bottom: Black 1pt solid; text-align: right; vertical-align: top">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-weight: normal; text-align: left">Cash and cash equivalents</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,369</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,024</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left">Marketable securities</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,696</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal">Receivables</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Trade and other payables</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(13,251</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(131</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,924</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(627</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(7,170</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(131</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">)</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,132</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(627</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">)</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">March 31, 2019</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">March 31, 2018</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Average</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Reporting</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Average</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right; border-bottom: Black 1pt solid">Reporting</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-weight: normal">CA$ per US$</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.3122</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.3349</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.2834</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.2900</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">CA$ per Euro</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5192</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.4975</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5008</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5898</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1.5pt solid">Increase (decrease) in net loss</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">364</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(88</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">)</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Disclosure of financial liabilities [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: normal">Required payments per year</td> <td style="font-weight: bold">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Total</div></td> <td>&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Carrying amount</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Less than 1 year</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1 to 3 years</div></td> <td style="font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Notes</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-weight: normal; text-align: left">Trade and other payables</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,429</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,429</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16,429</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Unsecured convertible debentures</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,143</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,817</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,143</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,572</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,246</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18,572</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: normal">Required payments per year</td> <td style="font-weight: bold">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td>&nbsp;</td> <td colspan="2" style="white-space: nowrap; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Total</div></td> <td>&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Carrying amount</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Less than 1 year</div></td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1 to 3 years</div></td> <td style="font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid">&nbsp;</td> <td style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Notes</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$</div></td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: right">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; font-weight: normal; text-align: left">Trade and other payables</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,697</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,697</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,697</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: bold">&nbsp;</td> <td style="width: 1%; font-weight: bold; text-align: left">&nbsp;</td> <td style="width: 10%; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Unsecured convertible debentures</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13</div></td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,303</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,612</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">160</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,143</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,000</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,309</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,857</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,143</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the effect of changes in foreign exchange rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2017-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=21&amp;date=2017-03-01&amp;anchor=sect_Disclosure&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737226784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 24 - Capital Management (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Disclosure of cash and cash equivalents [text block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 12pt; font-weight: bold; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2019</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-top: Black 1.5pt solid">March 31, 2018</td> <td style="font-weight: normal; border-top: Black 1.5pt solid">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td colspan="2" style="white-space: nowrap; font-weight: normal; text-align: right; border-bottom: Black 1pt solid">$</td> <td style="border-bottom: Black 1pt solid; font-weight: normal">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-weight: normal">Cash</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,896</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 1%; font-weight: normal">&nbsp;</td> <td style="width: 1%; font-weight: normal; text-align: left">&nbsp;</td> <td style="width: 12%; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,583</div></td> <td style="white-space: nowrap; width: 1%; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Cash equivalents</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Term deposits issued in CAD currency</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,100</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Term deposits issued in US currency [US - $3,250]</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,193</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Commercial papers issued in CAD currency</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,693</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Commercial papers issued in US currency [US - $1,099]</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,418</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Promissory notes issued in CAD currency</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">498</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; padding-left: 8.75pt">Promissory notes issued in US currency [US - $798]</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: normal">&nbsp;</td> <td style="font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,029</div></td> <td style="white-space: nowrap; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid; padding-left: 8.75pt">Bankers acceptance</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,334</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: normal; text-align: left; border-bottom: Black 1pt solid">Total Cash equivalents</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,625</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="font-weight: normal; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: normal; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,640</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: normal; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1pt solid">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Total Cash and cash equivalents</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,521</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,223</div></td> <td style="white-space: nowrap; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6733360560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Basis of Preparation (Details Textual) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Feb. 29, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">$ 37,331<span></span>
</td>
<td class="nump">$ 9,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Total cash and cash equivalents</a></td>
<td class="nump">22,521<span></span>
</td>
<td class="nump">8,223<span></span>
</td>
<td class="nump">$ 9,772<span></span>
</td>
<td class="nump">$ 10,573<span></span>
</td>
<td class="nump">$ 3,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets at end of period</a></td>
<td class="nump">11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">$ 18,246<span></span>
</td>
<td class="nump">$ 6,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 35I<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 35M<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 35N<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737667808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Significant Accounting Policies (Details Textual) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Assets at end of period</a></td>
<td class="nump">$ 48,471<span></span>
</td>
<td class="nump">$ 22,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_FR', window );">FRANCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Assets at end of period</a></td>
<td class="nump">$ 1,831<span></span>
</td>
<td class="nump">$ 2,077<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of resources: (a) controlled by the entity as a result of past events; and (b) from which future economic benefits are expected to flow to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2017-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=13&amp;date=2017-03-01&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6750330768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Significant Accounting Policies - Estimated Useful Lives and Rates (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=acst_PatentsMember', window );">Patents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IntangibleAssetsUsefulLife', window );">Useful life, intangible assets (Year)</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DepreciationPercentage', window );">Furniture and office equipment</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_LaboratoryEquipmentMember', window );">Laboratory equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DepreciationPercentage', window );">Furniture and office equipment</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_ProductionEquipmentMember', window );">Production equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_UsefulLifeOfAssets', window );">Production equipment (in years) (Year)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Licences [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IntangibleAssetsUsefulLife', window );">Useful life, intangible assets (Year)</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member] | Furniture and office equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DepreciationPercentage', window );">Furniture and office equipment</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Licences [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IntangibleAssetsUsefulLife', window );">Useful life, intangible assets (Year)</a></td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member] | Furniture and office equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DepreciationPercentage', window );">Furniture and office equipment</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DepreciationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of depreciation of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DepreciationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The useful life of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_UsefulLifeOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The useful life of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_UsefulLifeOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=acst_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=acst_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_ProductionEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_ProductionEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_LicencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_LicencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6750614128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Receivables - Schedule of Receivables (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentValueAddedTaxReceivables', window );">Sales tax receivables</a></td>
<td class="nump">$ 618<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_GovernmentAssistanceAndTaxCreditsReceivable', window );">Government assistance and tax credits receivable</a></td>
<td class="nump">872<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">80<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Total receivables</a></td>
<td class="nump">$ 1,586<span></span>
</td>
<td class="nump">$ 759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_GovernmentAssistanceAndTaxCreditsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of government assisstance and tax credits receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_GovernmentAssistanceAndTaxCreditsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentValueAddedTaxReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current value added tax receivables. [Refer: Value added tax receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentValueAddedTaxReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest recognised as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6749056192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Marketable Securities - Marketable Securities (Details)<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecurties', window );">Total Marketable securities</a></td>
<td class="nump">$ 11,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecurties', window );">Total Marketable securities</a></td>
<td class="nump">11,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecuritiesCurrent', window );">Current marketable securities</a></td>
<td class="nump">11,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositOneMember', window );">Term deposit, one [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecurties', window );">Total Marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecurties', window );">Total Marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositTwoMember', window );">Term deposit, two[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecurties', window );">Total Marketable securities</a></td>
<td class="nump">2,696<span></span>
</td>
<td class="nump">2,020<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecurties', window );">Total Marketable securities</a></td>
<td class="nump">2,696<span></span>
</td>
<td class="nump">$ 2,020<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TreasuryBillsMember', window );">Treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecurties', window );">Total Marketable securities</a></td>
<td class="nump">9,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecurties', window );">Total Marketable securities</a></td>
<td class="nump">$ 9,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_MarketableSecurties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_MarketableSecurties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TreasuryBillsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TreasuryBillsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6750866848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Marketable Securities - Marketable Securities (Details) (Parentheticals)<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecurties', window );">Total Marketable securities</a></td>
<td class="nump">$ 11,892<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositOneMember', window );">Term deposit, one [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecurties', window );">Total Marketable securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositOneMember', window );">Term deposit, one [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_FinancialInstrumentInterestRate', window );">Financial instrument, interest rate</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositOneMember', window );">Term deposit, one [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_FinancialInstrumentMaturityDate', window );">Financial instrument, maturity date</a></td>
<td class="text"> <span></span>
</td>
<td class="text">March 13, 2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositTwoMember', window );">Term deposit, two[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecurties', window );">Total Marketable securities</a></td>
<td class="nump">$ 2,696<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,020<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_FinancialInstrumentInterestRate', window );">Financial instrument, interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositTwoMember', window );">Term deposit, two[Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_FinancialInstrumentMaturityDate', window );">Financial instrument, maturity date</a></td>
<td class="text">April 8, 2019<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositTwoMember', window );">Term deposit, two[Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_FinancialInstrumentMaturityDate', window );">Financial instrument, maturity date</a></td>
<td class="text">March 12, 2020<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TreasuryBillsMember', window );">Treasury bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MarketableSecurties', window );">Total Marketable securities</a></td>
<td class="nump">$ 9,196<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TreasuryBillsMember', window );">Treasury bills [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_FinancialInstrumentInterestRate', window );">Financial instrument, interest rate</a></td>
<td class="nump">1.83%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_FinancialInstrumentMaturityDate', window );">Financial instrument, maturity date</a></td>
<td class="text">April 2, 2019<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TreasuryBillsMember', window );">Treasury bills [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_FinancialInstrumentInterestRate', window );">Financial instrument, interest rate</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_FinancialInstrumentMaturityDate', window );">Financial instrument, maturity date</a></td>
<td class="text">July 25, 2019<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_FinancialInstrumentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The stated interest rate of a financial instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_FinancialInstrumentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_FinancialInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maturity date of a financial instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_FinancialInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_MarketableSecurties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_MarketableSecurties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TermDepositTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TreasuryBillsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_TreasuryBillsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737111920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Other Assets - Other Assets (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Balance &#8211; beginning of year</a></td>
<td class="nump">$ 659<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_PurchasesOtherAssets', window );">Purchased</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_UsedOtherAssets', window );">Used</a></td>
<td class="num">(105)<span></span>
</td>
<td class="num">(311)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Balance &#8211; end of year</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Current other asset</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other asset</a></td>
<td class="nump">$ 557<span></span>
</td>
<td class="nump">$ 555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_PurchasesOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in the other assets resulting from purchases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_PurchasesOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_UsedOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in other assets resulting from the used of those assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_UsedOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6739945344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Related Parties (Details Textual) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jan. 07, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties', window );">Current payables to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=acst_NeptuneMember', window );">Neptune [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ProportionOfOwnershipInterestsHeldByRelatedParty', window );">Proportion of ownership interests held by related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties', window );">Current payables to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember', window );">Parent [member] | Biodroga Nutraceuticals Inc. [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination', window );">Contingent liabilities recognised in business combination at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestRevenueExpense', window );">Interest income (expense)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember', window );">Parent [member] | Biodroga Nutraceuticals Inc. [member] | Not later than six months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember', window );">Parent [member] | Biodroga Nutraceuticals Inc. [member] | Later than six months [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Key management personnel of entity or parent [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ProportionOfVotingRightsHeldByAnAssociate', window );">Proportion of voting rights held by an associate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ProportionOfOwnershipInterestsHeldByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interests in the company held by a related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ProportionOfOwnershipInterestsHeldByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ProportionOfVotingRightsHeldByAnAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of voting rights held by an associate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ProportionOfVotingRightsHeldByAnAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 3<br> -IssueDate 2017-01-01<br> -Paragraph B67<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=3&amp;date=2017-03-01&amp;anchor=para_B67_c&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRevenueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRevenueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=acst_NeptuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=acst_NeptuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BusinessCombinationsAxis=acst_BiodrogaNutraceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BusinessCombinationsAxis=acst_BiodrogaNutraceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_NotLaterThanSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_NotLaterThanSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanSixMonthsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6750740288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Related Parties - Administrative and Research and Development Expenses (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 426<span></span>
</td>
<td class="nump">$ 38,366<span></span>
</td>
<td class="nump">$ 15,669<span></span>
</td>
<td class="nump">$ 7,227<span></span>
</td>
<td class="nump">$ 7,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">6,649<span></span>
</td>
<td class="nump">4,027<span></span>
</td>
<td class="nump">3,265<span></span>
</td>
<td class="nump">3,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=acst_NeptuneMember', window );">Neptune [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="nump">577<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ResearchDevelopmentGeneralAndAdministrationExpense', window );">Total related parties expenses</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="nump">636<span></span>
</td>
<td class="nump">678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=acst_NeptuneMember', window );">Neptune [member] | Supplies and incremental costs [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=acst_NeptuneMember', window );">Neptune [member] | Shared service agreement [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ResearchDevelopmentGeneralAndAdministrationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of research, development, general and administration expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ResearchDevelopmentGeneralAndAdministrationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2017-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2017-03-01&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=acst_NeptuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=acst_NeptuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=acst_SuppliesAndIncrementalCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=acst_SuppliesAndIncrementalCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=acst_SharedServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=acst_SharedServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737714848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Related Parties - Key Management Personnel Compensation (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Compensation</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="nump">$ 1,754<span></span>
</td>
<td class="nump">$ 1,364<span></span>
</td>
<td class="nump">$ 1,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation costs</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">940<span></span>
</td>
<td class="nump">826<span></span>
</td>
<td class="nump">541<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Total key management personnel compensation</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 2,581<span></span>
</td>
<td class="nump">$ 2,580<span></span>
</td>
<td class="nump">$ 1,905<span></span>
</td>
<td class="nump">$ 2,129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2017-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2017-03-01&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2017-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2017-03-01&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2017-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=24&amp;date=2017-03-01&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737224144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Government Assistance - Government Grants and Investment Tax Credits (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_InvestmentTaxCredit', window );">Investment tax credit</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 588<span></span>
</td>
<td class="nump">$ 409<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Government grant</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_GovernmentGrantsAndInvestmentTaxCredits', window );">Total government assistance</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 595<span></span>
</td>
<td class="nump">$ 409<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_GovernmentGrantsAndInvestmentTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of government grants and investment tax credits during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_GovernmentGrantsAndInvestmentTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_InvestmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investment tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_InvestmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government grants. [Refer: Government grants]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2017-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=20&amp;date=2017-03-01&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6740827872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Government Assistance - Unrecognized Federal Tax Credits (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unrecognized federal tax credits may be used to reduce future income tax and expire</a></td>
<td class="nump">$ 3,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember', window );">Later than eleven years and not later than twelve years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unrecognized federal tax credits may be used to reduce future income tax and expire</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember', window );">Later than twelve years and not later than thirteen years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unrecognized federal tax credits may be used to reduce future income tax and expire</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember', window );">Later than thirteen years and not later than fourteen years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unrecognized federal tax credits may be used to reduce future income tax and expire</a></td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember', window );">Later than fourteen years and not later than fifteen years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unrecognized federal tax credits may be used to reduce future income tax and expire</a></td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember', window );">Later than fifteen years and not later than sixteen years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unrecognized federal tax credits may be used to reduce future income tax and expire</a></td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember', window );">Later than sixteen years and not later than seventeen years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unrecognized federal tax credits may be used to reduce future income tax and expire</a></td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember', window );">Later than seventeen years and not later than eighteen years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unrecognized federal tax credits may be used to reduce future income tax and expire</a></td>
<td class="nump">519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember', window );">Later than eighteen years and not later than nineteen years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unrecognized federal tax credits may be used to reduce future income tax and expire</a></td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember', window );">Later than nineteen years and not later than twenty years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unrecognized federal tax credits may be used to reduce future income tax and expire</a></td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember', window );">Later than twenty years and not later than twenty-one years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unrecognized federal tax credits may be used to reduce future income tax and expire</a></td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember', window );">Later than twenty years and not later than twenty-two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unrecognized federal tax credits may be used to reduce future income tax and expire</a></td>
<td class="nump">$ 329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_LaterThanElevenYearsAndNotLaterThanTwelveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_LaterThanTwelveYearsAndNotLaterThanThirteenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_LaterThanThirteenYearsAndNotLaterThanFourteenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_LaterThanFourteenYearsAndNotLaterThanFifteenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_LaterThanFifteenYearsAndNotLaterThanSixteenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_LaterThanSixteenYearsAndNotLaterThanSeventeenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_LaterThanSeventeenYearsAndNotLaterThanEighteenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_LaterThanEighteenYearsAndNotLaterThanNineteenYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_LaterThanNineteenYearsAndNotLaterThanTwentyYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_LaterThanTwentyYearsAndNotLaterThanTwentyoneYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_LaterThanTwentyYearsAndNotLaterThanTwentytwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6752207360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Equipment - Components of Equipment (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,813<span></span>
</td>
<td class="nump">$ 2,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_LaboratoryEquipmentMember', window );">Laboratory equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_ProductionEquipmentMember', window );">Production equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,339<span></span>
</td>
<td class="nump">2,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">$ 3,076<span></span>
</td>
<td class="nump">3,502<span></span>
</td>
<td class="nump">3,119<span></span>
</td>
<td class="nump">$ 398<span></span>
</td>
<td class="nump">$ 398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">2,678<span></span>
</td>
<td class="nump">2,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">3,119<span></span>
</td>
<td class="nump">3,999<span></span>
</td>
<td class="nump">3,502<span></span>
</td>
<td class="nump">3,076<span></span>
</td>
<td class="nump">3,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Furniture and office equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Computer equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Laboratory equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">522<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">522<span></span>
</td>
<td class="nump">933<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="nump">522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Production equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">2,484<span></span>
</td>
<td class="nump">2,708<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">2,527<span></span>
</td>
<td class="nump">2,968<span></span>
</td>
<td class="nump">2,708<span></span>
</td>
<td class="nump">2,484<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation for the period</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment [member] | Furniture and office equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment [member] | Computer equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment [member] | Laboratory equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">483<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation for the period</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment [member] | Production equipment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Balance</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation for the period</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2017-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2017-03-01&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2017-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2017-03-01&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2017-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2017-03-01&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2017-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=16&amp;date=2017-03-01&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_ProductionEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=acst_ProductionEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6752631536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Intangible Assets - Components of Intangible Assets (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
<th class="th" colspan="1">25 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,743<span></span>
</td>
<td class="nump">$ 10,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=acst_PatentsMember', window );">Patents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_LicencesMember', window );">Licences [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,743<span></span>
</td>
<td class="nump">10,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,692<span></span>
</td>
<td class="nump">$ 24,692<span></span>
</td>
<td class="nump">24,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,692<span></span>
</td>
<td class="nump">24,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,692<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Patents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member] | Licences [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,330<span></span>
</td>
<td class="nump">24,330<span></span>
</td>
<td class="nump">24,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,330<span></span>
</td>
<td class="nump">24,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="nump">$ 12,110<span></span>
</td>
<td class="nump">14,627<span></span>
</td>
<td class="nump">12,304<span></span>
</td>
<td class="nump">9,787<span></span>
</td>
<td class="nump">9,787<span></span>
</td>
<td class="nump">9,787<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="nump">12,304<span></span>
</td>
<td class="nump">16,949<span></span>
</td>
<td class="nump">14,627<span></span>
</td>
<td class="nump">12,110<span></span>
</td>
<td class="nump">12,304<span></span>
</td>
<td class="nump">14,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization for the period</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">2,322<span></span>
</td>
<td class="nump">2,323<span></span>
</td>
<td class="nump">2,323<span></span>
</td>
<td class="nump">2,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment [member] | Patents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">362<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization for the period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember', window );">Accumulated depreciation, amortisation and impairment [member] | Licences [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="nump">11,748<span></span>
</td>
<td class="nump">14,265<span></span>
</td>
<td class="nump">11,942<span></span>
</td>
<td class="nump">9,425<span></span>
</td>
<td class="nump">9,425<span></span>
</td>
<td class="nump">9,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Balance</a></td>
<td class="nump">11,942<span></span>
</td>
<td class="nump">16,587<span></span>
</td>
<td class="nump">14,265<span></span>
</td>
<td class="nump">11,748<span></span>
</td>
<td class="nump">11,942<span></span>
</td>
<td class="nump">$ 14,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill', window );">Amortization for the period</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 2,322<span></span>
</td>
<td class="nump">$ 2,323<span></span>
</td>
<td class="nump">$ 2,323<span></span>
</td>
<td class="nump">$ 2,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2017-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2017-03-01&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2017-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=38&amp;date=2017-03-01&amp;anchor=para_118_e_vi&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=acst_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=acst_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_LicencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=ifrs-full_LicencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6748997136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Trade and Other Payables - Components of Trade and Other Payables (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">$ 4,064<span></span>
</td>
<td class="nump">$ 3,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccrualsClassifiedAsCurrent', window );">Accrued liabilities and other payables</a></td>
<td class="nump">10,319<span></span>
</td>
<td class="nump">2,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Employee salaries and benefits payable</a></td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_LegalSettlementPayableCurrent', window );">Legal settlement expected to be paid via common shares (note 25)</a></td>
<td class="nump">990<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties', window );">Current payables to related parties</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Total trade and other payables</a></td>
<td class="nump">$ 16,429<span></span>
</td>
<td class="nump">$ 6,697<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_LegalSettlementPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current payable for legal settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_LegalSettlementPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccrualsClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current. [Refer: Accruals]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccrualsClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 70<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6611604768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Derivative Warrant Liabilities (Details Textual)<br></strong></div></th>
<th class="th">
<div>Dec. 03, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember32013Member', window );">Warrant liabilities issued December 3, 2013 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare', window );">Number of required warrants to be exercised to obtain one common share</a></td>
<td class="nump">10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of required warrants to be exercised to obtain one common share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NumberOfRequiredWarrantsToBeExercisedToObtainOneCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember32013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember32013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6749738800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Derivative Warrant Liabilities - Reconciliation (Details) - CAD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Balance &#8211; beginning of period</a></td>
<td class="nump">$ 6,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Balance &#8211; end of period</a></td>
<td class="nump">16,263<span></span>
</td>
<td class="nump">$ 6,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedMay2018Member', window );">Warrant liabilities issued May 2018 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Balance &#8211; beginning of period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DerivativeFinancialLiabilitiesIssued', window );">Issued during period</a></td>
<td class="nump">4,272<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod', window );">Exercised during period</a></td>
<td class="num">(722)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability', window );">Change in fair value of derivative warrant liabilities</a></td>
<td class="nump">4,696<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Balance &#8211; end of period</a></td>
<td class="nump">$ 8,246<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_FairValuePerShareIssuable', window );">Fair value per share issuable (in CAD per share)</a></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember272017Member', window );">Warrant liabilities issued December 27, 2017 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Balance &#8211; beginning of period</a></td>
<td class="nump">$ 6,405<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DerivativeFinancialLiabilitiesIssued', window );">Issued during period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod', window );">Exercised during period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability', window );">Change in fair value of derivative warrant liabilities</a></td>
<td class="nump">1,612<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Balance &#8211; end of period</a></td>
<td class="nump">$ 8,017<span></span>
</td>
<td class="nump">$ 6,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_FairValuePerShareIssuable', window );">Fair value per share issuable (in CAD per share)</a></td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember32013Member', window );">Warrant liabilities issued December 3, 2013 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Balance &#8211; beginning of period</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DerivativeFinancialLiabilitiesIssued', window );">Issued during period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod', window );">Exercised during period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability', window );">Change in fair value of derivative warrant liabilities</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Balance &#8211; end of period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_FairValuePerShareIssuable', window );">Fair value per share issuable (in CAD per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in derivative financial liabilities through derivative instrument exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DerivativeFinancialLiabilitiesExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DerivativeFinancialLiabilitiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of derivative financial liabilities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DerivativeFinancialLiabilitiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_FairValuePerShareIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value per share for derivative instrument issuable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_FairValuePerShareIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the fair value of a financial liability that is attributable to changes in the credit risk of that liability. [Refer: Credit risk [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2018-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 10<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-02&amp;anchor=para_10_a&amp;doctype=Standard&amp;book=B<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Effective 2018-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 10A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_10A_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInFairValueOfFinancialLiabilityAttributableToChangesInCreditRiskOfLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedMay2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedMay2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember272017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember272017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember32013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember32013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6740987280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Derivative Warrant Liabilities - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 09, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 27, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 21, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price (in CAD per share) | (per share)</a></td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 1.2625<span></span>
</td>
<td class="nump">$ 2.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedMay2018Member', window );">Warrant liabilities issued May 2018 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price (in CAD per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WeightedAverageSharePriceWarrantsIssued', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_RiskFreeInterestRateWarrantsIssued', window );">Risk-free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.52%<span></span>
</td>
<td class="nump">1.52%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantLifeWarrantsIssued', window );">Estimated life (in years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 40 days<span></span>
</td>
<td class="text">4 years 40 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExpectedVolatilityWarrantsIssued', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.58%<span></span>
</td>
<td class="nump">94.58%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember272017Member', window );">Warrant liabilities issued December 27, 2017 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WeightedAverageSharePriceWarrantsIssued', window );">Share price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_RiskFreeInterestRateWarrantsIssued', window );">Risk-free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.23%<span></span>
</td>
<td class="nump">2.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.56%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantLifeWarrantsIssued', window );">Estimated life (in years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 273 days<span></span>
</td>
<td class="text">3 years 273 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 273 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExpectedVolatilityWarrantsIssued', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107.57%<span></span>
</td>
<td class="nump">107.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.15%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember32013Member', window );">Warrant liabilities issued December 3, 2013 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price (in CAD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WeightedAverageSharePriceWarrantsIssued', window );">Share price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_RiskFreeInterestRateWarrantsIssued', window );">Risk-free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.19%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantLifeWarrantsIssued', window );">Estimated life (in years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">248 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExpectedVolatilityWarrantsIssued', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133.86%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ExercisePriceWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ExercisePriceWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ExpectedVolatilityWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the warrants issued. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in warrants pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ExpectedVolatilityWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_RiskFreeInterestRateWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for warrants issued is expressed, with a remaining term equal to the expected term of the warrant being valued (based on the warrants's remaining contractual life and taking into account the effects of expected early exercise).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_RiskFreeInterestRateWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_WarrantLifeWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The warrant life of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_WarrantLifeWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_WeightedAverageSharePriceWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the warrants pricing model to calculate the fair value of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_WeightedAverageSharePriceWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedMay2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedMay2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember272017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember272017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember32013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember32013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737634736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 13 - Unsecured Convertible Debentures (Details Textual) - Unsecured convertible debentures [member]<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Feb. 21, 2017 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Notional amount | $</a></td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants', window );">Maximum number of common shares issuable from contingent warrants | shares</a></td>
<td class="nump">1,052,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_BorrowingsConvertibleConversionPrice', window );">Borrowings, convertible, conversion price</a></td>
<td class="nump">$ 1.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion', window );">Warrants exercisable price per share after borrowings conversion</a></td>
<td class="nump">$ 1.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_BorrowingsDiscountOfBorrowingPrincipalAmount', window );">Borrowings, discount of borrowing principal amount</a></td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings, classified as financing activities | $</a></td>
<td class="nump">$ 1,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate', window );">Borrowings, accelerated conversion feature, minimum time after issuance date</a></td>
<td class="text">120 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum', window );">Borrowings, accelerated conversion feature, weighted average share price minimum</a></td>
<td class="nump">$ 2.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_BorrowingsConvertibleThresholdConsecutiveTradingDays', window );">Borrowings, convertible, threshold consecutive trading days</a></td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_BorrowingsConvertibleEquityIssuedFloorPrice', window );">Borrowings, convertible, equity issued, floor price</a></td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections', window );">Discount rate applied to cash flow projections</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum time after issuance date for an accelerated conversion feature to be available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_BorrowingsAcceleratedConversionFeatureMinimumTimeAfterIssuanceDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum share price for an accelerated conversion feature for borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_BorrowingsAcceleratedConversionFeatureWeightedAverageSharePriceMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_BorrowingsConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_BorrowingsConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_BorrowingsConvertibleEquityIssuedFloorPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor price of share payments related to borrowings converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_BorrowingsConvertibleEquityIssuedFloorPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_BorrowingsConvertibleThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_BorrowingsConvertibleThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_BorrowingsDiscountOfBorrowingPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The discount rate of borrowing principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_BorrowingsDiscountOfBorrowingPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares issuable from contingent warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_MaximumNumberOfCommonSharesIssuableFromContingentWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The warrants exercisable price per share after borrowings conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_WarrantsExercisablePricePerShareAfterBorrowingsConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The discount rate applied to cash flow projections for a cash-generating unit (group of units). [Refer: Cash-generating units [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2017-01-01<br> -Paragraph 134<br> -Subparagraph d<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=36&amp;date=2017-03-01&amp;anchor=para_134_d_v&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 36<br> -IssueDate 2017-01-01<br> -Paragraph 134<br> -Subparagraph e<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=36&amp;date=2017-03-01&amp;anchor=para_134_e_v&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfDiscountRatesAppliedToCashFlowProjections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=acst_UnsecuredConvertibleDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=acst_UnsecuredConvertibleDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6750655984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Unsecured Convertible Debentures - Liability and Equity Component Portions (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Effective interest</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember', window );">Liability portion of unsecured convertible debentures [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
<td class="nump">1,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Effective interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestCostsIncurred', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Balance</a></td>
<td class="nump">1,406<span></span>
</td>
<td class="nump">1,817<span></span>
</td>
<td class="nump">1,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=acst_EquityComponentOfUnsecuredConvertibleDebenturesMember', window );">Equity component of unsecured convertible debentures [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Effective interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestCostsIncurred', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Balance</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=acst_UnsecuredConvertibleDebenturesMember', window );">Unsecured convertible debentures [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,921<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Effective interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestCostsIncurred', window );">Interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Balance</a></td>
<td class="nump">$ 1,715<span></span>
</td>
<td class="nump">$ 2,126<span></span>
</td>
<td class="nump">$ 1,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest costs that an entity incurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=acst_LiabilityPortionOfUnsecuredConvertibleDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=acst_EquityComponentOfUnsecuredConvertibleDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=acst_EquityComponentOfUnsecuredConvertibleDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=acst_UnsecuredConvertibleDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=acst_UnsecuredConvertibleDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6780098272">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Capital and Other Components of Equity (Details Textual)<br> $ / shares in Units, $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="7">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 14, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 23, 2018 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 14, 2018 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 09, 2018 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 27, 2017 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 27, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 21, 2017 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>CAD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>CAD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 14, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 27, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds', window );">At-the-market sales agreement, estimated aggregate gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_AtTheMarketSalesAgreementTerm', window );">At-the-market sales agreement, term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_AtTheMarketSalesAgreementFeePercentage', window );">At-the-market sales agreement, fee, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuing shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,600,000<span></span>
</td>
<td class="nump">$ 17.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (34,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 57,892,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,065,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,044,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,010,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DeferredFinancingCostsCurrent', window );">Deferred financing costs, current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,000<span></span>
</td>
<td class="nump">179,000<span></span>
</td>
<td class="nump">$ 179,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfSharesIssuedInPublicOffering', window );">Number of shares issued in public offering | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,600,000<span></span>
</td>
<td class="nump">16,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ShareIssuedPricePerShare', window );">Share issued, price per share | (per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ProceedsFromIssuingSharesInPublicOfferingGross', window );">Proceeds from issuing shares in public offering, gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,700,000<span></span>
</td>
<td class="nump">$ 19.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IssueOfEquityNumberOfShares', window );">Issue of equity, number of shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,562,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,090,000<span></span>
</td>
<td class="nump">19,090,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfUnitsIssuedDuringPeriod', window );">Number of units issued during period | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,530,000<span></span>
</td>
<td class="nump">9,900,990<span></span>
</td>
<td class="nump">9,900,990<span></span>
</td>
<td class="nump">3,930,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_UnitIssuedPricePerUnit', window );">Unit issued, price per unit | (per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ProceedsFromIssuingUnits', window );">Proceeds from issuing units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 12,600,000<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="nump">$ 5,699,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfWarrantsIssuedDuringPeriod', window );">Number of warrants issued during period | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | (per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2625<span></span>
</td>
<td class="nump">$ 2.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,407,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,653,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_UnitIssuanceCosts', window );">Unit issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfSharesCalledByWarrants', window );">Number of shares called by warrants | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantCosts', window );">Warrant costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 406,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_UnitSharesOfClassAShare', window );">Unit, shares of class A share | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_UnitSharesOfClassASharePurchaseWarrant', window );">Unit, shares of class A share purchase warrant | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfSharesCalledByEachWarrant', window );">Number of shares called by each warrant | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice', window );">Weighted average share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares', window );">Increase (decrease) from equity settled non-employee share-based payment, shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment', window );">Increase (decrease) from equity settled non-employee share-based payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ShareBasedPaymentCostsAllocatedToShareCapital', window );">Share-based payment costs allocated to share capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ShareBasedPaymentCostsAllocatedToDebt', window );">Share-based payment costs allocated to debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsExercisedEquitySharesIssued', window );">Warrants exercised, equity shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">772,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfWarrantsExercised', window );">Number of warrants exercised | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">775,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ProceedsFromExerciseOfWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_May2018PublicOfferingWarrants2018Member', window );">May 2018 public offering warrants 2018 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,246,000<span></span>
</td>
<td class="nump">$ 8,246,000<span></span>
</td>
<td class="nump">$ 8,246,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfWarrantsExercised', window );">Number of warrants exercised | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">771,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ProceedsFromExerciseOfWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_SeriesDecember2017UsPublicOfferingWarrants2017Member', window );">Series December 2017 US public offering warrants 2017 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,017,000<span></span>
</td>
<td class="nump">8,017,000<span></span>
</td>
<td class="nump">$ 8,017,000<span></span>
</td>
<td class="nump">6,405,000<span></span>
</td>
<td class="nump">6,405,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember', window );">Series 8 December 2013 Public offering warrants related to liability [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,000<span></span>
</td>
<td class="nump">187,000<span></span>
</td>
<td class="nump">209,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceFor10Warrants', window );">Exercise price for 10 warrants | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsExercisedEquitySharesIssued', window );">Warrants exercised, equity shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfWarrantsExercised', window );">Number of warrants exercised | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_PublicOfferingBrokerWarrantsMay2018Member', window );">Public offering broker warrants May 2018 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_PublicOfferingWarrantsFebruary2017EquityPortionMember', window );">Public offering warrants February 2017, equity portion [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | (per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfWarrantsExercised', window );">Number of warrants exercised | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ProceedsFromExerciseOfWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember', window );">Series December 2017 US Broker warrants, equity portion [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember', window );">The 2017 Unsecured convertible debenture conversion option and contingent warrant related to equity [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,000<span></span>
</td>
<td class="nump">309,000<span></span>
</td>
<td class="nump">$ 309,000<span></span>
</td>
<td class="nump">309,000<span></span>
</td>
<td class="nump">309,000<span></span>
</td>
<td class="nump">309,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,000<span></span>
</td>
<td class="nump">309,000<span></span>
</td>
<td class="nump">309,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncome', window );">Deferred tax expense (income)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember', window );">Series 9 Private Placement warrants 2013 related to equity [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series2017BWBrokerWarrantsRelatedToEquityMember', window );">Series 2017-BW Broker warrants related to equity [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsExercisedEquitySharesIssuedAmount', window );">Warrants exercised, equity shares issued, amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsExercisedEquitySharesIssued', window );">Warrants exercised, equity shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsExpired', window );">Warrants expired | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AdditionalPaidinCapitalMember', window );">Additional paid-in capital [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantCosts', window );">Warrant costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment', window );">Increase (decrease) from equity settled non-employee share-based payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=acst_UnderwriterMember', window );">Underwriter [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfSharesCalledByWarrants', window );">Number of shares called by warrants | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">892,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">892,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsExercisedEquitySharesIssuedAmount', window );">Warrants exercised, equity shares issued, amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=acst_CommonSharesMember', window );">Common shares [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_UnitIssuanceCosts', window );">Unit issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=acst_ClassASharesMember', window );">Class A shares [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfUnitsIssuedDuringPeriod', window );">Number of units issued during period | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900,990<span></span>
</td>
<td class="nump">9,900,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedMay2018Member', window );">Warrant liabilities issued May 2018 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | (per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_FairValuePerSharesIssuableWarrants', window );">Fair value per shares issuable warrants | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_DerivativeWarrantLiabilitiesMember', window );">Derivative warrant liabilities [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Total financial liabilities at fair value through profit or loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_UnitIssuanceCosts', window );">Unit issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantCosts', window );">Warrant costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember272017Member', window );">Warrant liabilities issued December 27, 2017 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfUnitsIssuedDuringPeriod', window );">Number of units issued during period | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,910,891<span></span>
</td>
<td class="nump">8,910,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_FairValuePerSharesIssuableWarrants', window );">Fair value per shares issuable warrants | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=acst_UnderwriterMember', window );">Underwriter [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfSharesIssuedForOptionExercised', window );">Number of shares issued for option exercised | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,812,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,490,000<span></span>
</td>
<td class="nump">2,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IssueOfEquityNumberOfShares', window );">Issue of equity, number of shares | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,429,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfUnitsIssuedDuringPeriod', window );">Number of units issued during period | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,429,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_UnitIssuedPricePerUnit', window );">Unit issued, price per unit | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ProceedsFromIssuingUnits', window );">Proceeds from issuing units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfWarrantsIssuedDuringPeriod', window );">Number of warrants issued during period | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,429,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=acst_UnderwriterMember', window );">Underwriter [member] | Warrant liabilities issued May 2018 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=acst_BrokerMember', window );">Broker [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfSharesCalledByWarrants', window );">Number of shares called by warrants | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantCosts', window );">Warrant costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=acst_ClassBSharesMember', window );">Class B shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NonCumulativeDividendRate', window );">Non-cumulative dividend rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ConversionRatio', window );">Conversion ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_RedeemablePricePerShare', window );">Redeemable price per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Total number of shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at end of period | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=acst_ClassCSharesMember', window );">Class C shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NonCumulativeDividendRate', window );">Non-cumulative dividend rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ConversionRatio', window );">Conversion ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_RedeemablePricePerShare', window );">Redeemable price per share | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Total number of shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at end of period | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=acst_ClassDAndESharesMember', window );">Class D and E shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ConversionRatio', window );">Conversion ratio</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Total number of shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=acst_ClassDAndESharesMember', window );">Class D and E shares [Member] | Bottom of range [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NonCumulativeDividendRate', window );">Non-cumulative dividend rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=acst_ClassDAndESharesMember', window );">Class D and E shares [Member] | Top of range [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NonCumulativeDividendRate', window );">Non-cumulative dividend rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=acst_ClassASharesMember', window );">Class A shares [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Total number of shares issued | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding at end of period | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="25"></td></tr>
<tr><td colspan="25"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Warrant to acquire one Common Share of the Corporation at an exercise price of $1.31, expiring on May 9, 2023.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Warrant to acquire one Common Share of the Corporation at an exercise price of US$1.26, expiring on December 27, 2022.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">In order to obtain one Common Share of the Corporation at an exercise price of US$15.00, 10 warrants must be exercised. Warrants expired on December 3, 2018.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Warrant to acquire one Common Share of the Corporation at an exercise price of $2.15, expiring on February 21, 2022.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Warrant to acquire one Common Share of the Corporation at an exercise price of $1.90 expiring on February 21, 2020, net of deferred tax expense of $129. Exercisable only for any portion of or all debentures paid by the Corporation prior to maturity.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Warrant to acquire one Common Share of the Corporation at an exercise price of $13.30, expired on December 3, 2018.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">Warrant to acquire one Common Share of the Corporation at an exercise price of 2.15 expiring on February 21, 2018. 117,496 warrants amounted to $71 were exercised in November 2017 and 117,496 warrants expired on February 21, 2018</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated aggregate gross proceeds for the at-the-market sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_AtTheMarketSalesAgreementEstimatedAggregateGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_AtTheMarketSalesAgreementFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the values of shares issued pursuant to the at-the-market sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_AtTheMarketSalesAgreementFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_AtTheMarketSalesAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The term of At-the market sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_AtTheMarketSalesAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of equity instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DeferredFinancingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DeferredFinancingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ExercisePriceFor10Warrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of warrants when 10 warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ExercisePriceFor10Warrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ExercisePriceWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ExercisePriceWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_FairValuePerSharesIssuableWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value per share issuable of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_FairValuePerSharesIssuableWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from equity settled non-employee share-based payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity shares resulting from equity settled non-employee share-based payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IncreaseDecreaseFromEquitySettledNonemployeeSharebasedPaymentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IssueOfEquityNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in the issuance of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IssueOfEquityNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NonCumulativeDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The non-cumulative dividend rate of a class of share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NonCumulativeDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NumberOfSharesCalledByEachWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares called by each whole warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NumberOfSharesCalledByEachWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NumberOfSharesCalledByWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares called by warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NumberOfSharesCalledByWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NumberOfSharesIssuedForOptionExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during period for option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NumberOfSharesIssuedForOptionExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NumberOfSharesIssuedInPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during period in a public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NumberOfSharesIssuedInPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NumberOfUnitsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NumberOfUnitsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NumberOfWarrantsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NumberOfWarrantsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ProceedsFromIssuingSharesInPublicOfferingGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross proceeds from issuing shares in a public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ProceedsFromIssuingSharesInPublicOfferingGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ProceedsFromIssuingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ProceedsFromIssuingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_RedeemablePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share price of redeemable equity instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_RedeemablePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ShareBasedPaymentCostsAllocatedToDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The mount of costs allocated to debt related to share-based payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ShareBasedPaymentCostsAllocatedToDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ShareBasedPaymentCostsAllocatedToShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs allocated to share capital related to share-based payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ShareBasedPaymentCostsAllocatedToShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ShareIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of share issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ShareIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_UnitIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred related to the issuance of unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_UnitIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_UnitIssuedPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per unit for units issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_UnitIssuedPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_UnitSharesOfClassAShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of class A shares included in each unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_UnitSharesOfClassAShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_UnitSharesOfClassASharePurchaseWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The shares of class A share purchase warrant from a unit issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_UnitSharesOfClassASharePurchaseWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_WarrantCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs for warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_WarrantCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_WarrantsExercisedEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity shares issued from warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_WarrantsExercisedEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_WarrantsExercisedEquitySharesIssuedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_WarrantsExercisedEquitySharesIssuedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_WarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_WarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_g_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as &#8216;an accounting mismatch&#8217;) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity&#8217;s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 8<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_8_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_May2018PublicOfferingWarrants2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_May2018PublicOfferingWarrants2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_SeriesDecember2017UsPublicOfferingWarrants2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_SeriesDecember2017UsPublicOfferingWarrants2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_PublicOfferingBrokerWarrantsMay2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_PublicOfferingBrokerWarrantsMay2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_PublicOfferingWarrantsFebruary2017EquityPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_PublicOfferingWarrantsFebruary2017EquityPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_SeriesDecember2017UsBrokerWarrantsEquityPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series2017BWBrokerWarrantsRelatedToEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series2017BWBrokerWarrantsRelatedToEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_AdditionalPaidinCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_AdditionalPaidinCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=acst_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=acst_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=acst_CommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=acst_CommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=acst_ClassASharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=acst_ClassASharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedMay2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedMay2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_DerivativeWarrantLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_DerivativeWarrantLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember272017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_WarrantLiabilitiesIssuedDecember272017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=acst_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=acst_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=acst_BrokerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=acst_BrokerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=acst_ClassBSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=acst_ClassBSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=acst_ClassCSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=acst_ClassCSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=acst_ClassDAndESharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=acst_ClassDAndESharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=acst_ClassASharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=acst_ClassASharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6753325520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Capital and Other Components of Equity - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 09, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 27, 2017 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 21, 2017 </div>
<div>CAD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>CAD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | (per share)</a></td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 1.2625<span></span>
</td>
<td class="nump">$ 2.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_May2018PublicOfferingWarrants2018Member', window );">May 2018 public offering warrants 2018 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="nump">$ 1.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WeightedAverageSharePriceWarrantsIssued', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_RiskFreeInterestRateWarrantsIssued', window );">Risk-free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantLifeWarrantsIssued', window );">Estimated life (in years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExpectedVolatilityWarrantsIssued', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember', window );">Warrants issued to broker in May 2018 public offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WeightedAverageSharePriceWarrantsIssued', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_RiskFreeInterestRateWarrantsIssued', window );">Risk-free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantLifeWarrantsIssued', window );">Estimated life (in years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExpectedVolatilityWarrantsIssued', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_PublicOfferingWarrantsIn2017Member', window );">Public offering warrants in 2017 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WeightedAverageSharePriceWarrantsIssued', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_RiskFreeInterestRateWarrantsIssued', window );">Risk-free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantLifeWarrantsIssued', window );">Estimated life (in years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExpectedVolatilityWarrantsIssued', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember', window );">Warrants issued to broker in December 2017 public offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WeightedAverageSharePriceWarrantsIssued', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_RiskFreeInterestRateWarrantsIssued', window );">Risk-free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantLifeWarrantsIssued', window );">Estimated life (in years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExpectedVolatilityWarrantsIssued', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember', window );">Warrants issued to broker in February 2017 public offering [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExercisePriceWarrantsIssued', window );">Exercise price, warrants issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WeightedAverageSharePriceWarrantsIssued', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_RiskFreeInterestRateWarrantsIssued', window );">Risk-free interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.79%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantLifeWarrantsIssued', window );">Estimated life (in years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExpectedVolatilityWarrantsIssued', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ExpectedDividendWarrantsGranted', window );">Dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ExercisePriceWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ExercisePriceWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ExpectedDividendWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an expected dividend used to calculate the fair value of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ExpectedDividendWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ExpectedVolatilityWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the warrants issued. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in warrants pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ExpectedVolatilityWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_RiskFreeInterestRateWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for warrants issued is expressed, with a remaining term equal to the expected term of the warrant being valued (based on the warrants's remaining contractual life and taking into account the effects of expected early exercise).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_RiskFreeInterestRateWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_WarrantLifeWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The warrant life of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_WarrantLifeWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_WeightedAverageSharePriceWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the warrants pricing model to calculate the fair value of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_WeightedAverageSharePriceWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_May2018PublicOfferingWarrants2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_May2018PublicOfferingWarrants2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_PublicOfferingWarrantsIn2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_PublicOfferingWarrantsIn2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsIssuedToBrokerInFebruary2017PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6750169648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Capital and Other Components of Equity - Unsecured Convertible Debentures (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Aug. 21, 2018</div></th>
<th class="th"><div>Jun. 06, 2018</div></th>
<th class="th"><div>Mar. 27, 2018</div></th>
<th class="th"><div>Dec. 27, 2017</div></th>
<th class="th"><div>Aug. 15, 2017</div></th>
<th class="th"><div>Apr. 07, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ConversionOfConvertibleInstrumentsEquitySharesIssued', window );">Number of shares (in shares)</a></td>
<td class="nump">23,723<span></span>
</td>
<td class="nump">51,807<span></span>
</td>
<td class="nump">30,348<span></span>
</td>
<td class="nump">33,605<span></span>
</td>
<td class="nump">22,783<span></span>
</td>
<td class="nump">23,885<span></span>
</td>
<td class="nump">9,496<span></span>
</td>
<td class="nump">195,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments', window );">Amount</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ConversionOfConvertibleInstrumentsEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity shares issued from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ConversionOfConvertibleInstrumentsEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the conversion of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6748893024">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Note 14 - Capital and Other Components of Equity - Warrants Outstanding (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Feb. 21, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_May2018PublicOfferingWarrants2018Member', window );">May 2018 public offering warrants 2018 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ClassOfWarrantOrRightOutstanding', window );">Warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">10,188,100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 8,246,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_SeriesDecember2017UsPublicOfferingWarrants2017Member', window );">Series December 2017 US public offering warrants 2017 [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ClassOfWarrantOrRightOutstanding', window );">Warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">9,801,861<span></span>
</td>
<td class="nump">9,802,935<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 8,017,000<span></span>
</td>
<td class="nump">$ 6,405,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember', window );">Series 8 December 2013 Public offering warrants related to liability [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ClassOfWarrantOrRightOutstanding', window );">Warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 209,000<span></span>
</td>
<td class="nump">$ 187,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsRelatingToLiabilitiesMember', window );">Warrants relating to liabilities [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ClassOfWarrantOrRightOutstanding', window );">Warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,989,961<span></span>
</td>
<td class="nump">28,202,935<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16,263,000<span></span>
</td>
<td class="nump">$ 6,426,000<span></span>
</td>
<td class="nump">$ 209,000<span></span>
</td>
<td class="nump">$ 187,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember', window );">Warrants issued to broker in May 2018 public offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ClassOfWarrantOrRightOutstanding', window );">Warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">547,975<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 283,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember', window );">Warrants issued to broker in December 2017 public offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ClassOfWarrantOrRightOutstanding', window );">Warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">495,050<span></span>
</td>
<td class="nump">495,050<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 406,000<span></span>
</td>
<td class="nump">$ 406,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_PublicOfferingWarrantsFebruary2017EquityPortionMember', window );">Public offering warrants February 2017, equity portion [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ClassOfWarrantOrRightOutstanding', window );">Warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">1,904,034<span></span>
</td>
<td class="nump">1,904,034<span></span>
</td>
<td class="nump">1,965,259<span></span>
</td>
<td class="nump">1,965,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember', window );">The 2017 Unsecured convertible debenture conversion option and contingent warrant related to equity [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ClassOfWarrantOrRightOutstanding', window );">Warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">1,052,630<span></span>
</td>
<td class="nump">1,052,630<span></span>
</td>
<td class="nump">1,052,630<span></span>
</td>
<td class="nump">1,052,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[7]</sup></td>
<td class="nump">$ 309,000<span></span>
</td>
<td class="nump">$ 309,000<span></span>
</td>
<td class="nump">$ 309,000<span></span>
</td>
<td class="nump">$ 309,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember', window );">Series 9 Private Placement warrants 2013 related to equity [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ClassOfWarrantOrRightOutstanding', window );">Warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">161,654<span></span>
</td>
<td class="nump">161,654<span></span>
</td>
<td class="nump">161,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[8]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series2017BWBrokerWarrantsRelatedToEquityMember', window );">Series 2017-BW Broker warrants related to equity [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ClassOfWarrantOrRightOutstanding', window );">Warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">234,992<span></span>
</td>
<td class="nump">234,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[9]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="nump">$ 144,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsRelatedToEquityMember', window );">Warrants related to equity [member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ClassOfWarrantOrRightOutstanding', window );">Warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,999,689<span></span>
</td>
<td class="nump">3,613,368<span></span>
</td>
<td class="nump">3,414,535<span></span>
</td>
<td class="nump">3,414,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 998,000<span></span>
</td>
<td class="nump">$ 715,000<span></span>
</td>
<td class="nump">$ 453,000<span></span>
</td>
<td class="nump">$ 453,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Warrant to acquire one Common Share of the Corporation at an exercise price of $1.31, expiring on May 9, 2023.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Warrant to acquire one Common Share of the Corporation at an exercise price of US$1.26, expiring on December 27, 2022.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">In order to obtain one Common Share of the Corporation at an exercise price of US$15.00, 10 warrants must be exercised. Warrants expired on December 3, 2018.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Warrant to acquire one Common Share of the Corporation at an exercise price of $1.05, expiring on May 9, 2023.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Warrant to acquire one Common Share of the Corporation at an exercise price of US$1.2625, expiring on December 27, 2022.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Warrant to acquire one Common Share of the Corporation at an exercise price of $2.15, expiring on February 21, 2022.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">Warrant to acquire one Common Share of the Corporation at an exercise price of $1.90 expiring on February 21, 2020, net of deferred tax expense of $129. Exercisable only for any portion of or all debentures paid by the Corporation prior to maturity.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[8]</td>
<td style="vertical-align: top;" valign="top">Warrant to acquire one Common Share of the Corporation at an exercise price of $13.30, expired on December 3, 2018.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[9]</td>
<td style="vertical-align: top;" valign="top">Warrant to acquire one Common Share of the Corporation at an exercise price of 2.15 expiring on February 21, 2018. 117,496 warrants amounted to $71 were exercised in November 2017 and 117,496 warrants expired on February 21, 2018</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_May2018PublicOfferingWarrants2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_May2018PublicOfferingWarrants2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_SeriesDecember2017UsPublicOfferingWarrants2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_SeriesDecember2017UsPublicOfferingWarrants2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series8December2013PublicOfferingWarrantsRelatedToLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsRelatingToLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsRelatingToLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsIssuedToBrokerInMay2018PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsIssuedToBrokerInDecember2017PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_PublicOfferingWarrantsFebruary2017EquityPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_PublicOfferingWarrantsFebruary2017EquityPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_The2017UnsecuredConvertibleDebentureConversionOptionAndContingentWarrantRelatedToEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series9PrivatePlacementWarrants2013RelatedToEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series2017BWBrokerWarrantsRelatedToEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_Series2017BWBrokerWarrantsRelatedToEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsRelatedToEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=acst_WarrantsRelatedToEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737336608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Personnel Expenses - Components of Personnel Expenses (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsExpense', window );">Salaries and other short-term employee benefits</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 4,144<span></span>
</td>
<td class="nump">$ 3,281<span></span>
</td>
<td class="nump">$ 2,277<span></span>
</td>
<td class="nump">$ 2,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation costs</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">929<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="nump">674<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Total personnel expenses</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 5,185<span></span>
</td>
<td class="nump">$ 4,210<span></span>
</td>
<td class="nump">$ 2,865<span></span>
</td>
<td class="nump">$ 3,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6741640304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Financial Expenses - Components of Finance Income (Expenses) (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 475<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign exchange gain (loss)</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(177)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnBorrowings', window );">Interest payable on convertible debenture</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_AccretionOfInterestOnConvertibleDebenture', window );">Accretion of interest on convertible debenture</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_WarrantTransactionCosts', window );">Transaction costs related to derivative warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(653)<span></span>
</td>
<td class="num">(1,134)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(6,287)<span></span>
</td>
<td class="num">(344)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Other charges</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">$ (51)<span></span>
</td>
<td class="num">$ (6,551)<span></span>
</td>
<td class="num">$ (1,808)<span></span>
</td>
<td class="num">$ (115)<span></span>
</td>
<td class="num">$ (166)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_AccretionOfInterestOnConvertibleDebenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion of interest on convertible debenture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_AccretionOfInterestOnConvertibleDebenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_WarrantTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_WarrantTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from foreign exchange differences. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2017-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=21&amp;date=2017-03-01&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2018-01-01<br> -Name IAS<br> -Number 18<br> -IssueDate 2017-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=18&amp;date=2017-03-02&amp;anchor=para_35_b_iii&amp;doctype=Standard&amp;book=B<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6753667776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 17 - Share-based Payments (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2">13 Months Ended</th>
<th class="th" colspan="1">37 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th">
<div>Jun. 27, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Option life, share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.94<span></span>
</td>
<td class="nump">5.89<span></span>
</td>
<td class="nump">4.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,173,523<span></span>
</td>
<td class="nump">1,121,500<span></span>
</td>
<td class="nump">1,300,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of share options exercised in share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,167<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense from share-based payment transactions with employees</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 1,041<span></span>
</td>
<td class="nump">$ 929<span></span>
</td>
<td class="nump">$ 588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=acst_CorporationStockOptionPlanMember', window );">Corporation stock option plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MaximumNumberOfSharesAuthorized', window );">Maximum number of shares authorized | shares</a></td>
<td class="nump">2,940,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,940,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,494,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MaximumNumberOfSharesAuthorizedAsPercentage', window );">Maximum number of shares authorized as percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Option life, share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of share options exercised in share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,167<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense from share-based payment transactions with employees</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 1,041<span></span>
</td>
<td class="nump">$ 929<span></span>
</td>
<td class="nump">$ 588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=acst_CorporationStockOptionPlanMember', window );">Corporation stock option plan [member] | Consultants [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_MaximumNumberOfSharesAuthorizedAsPercentage', window );">Maximum number of shares authorized as percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=acst_CorporationEquityIncentivePlanMember', window );">Corporation equity incentive plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Expense from share-based payment transactions with employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Number of other equity instruments outstanding in share-based payment arrangement at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_MaximumNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_MaximumNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_MaximumNumberOfSharesAuthorizedAsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of issued and outstanding stock stock that can issued from share-based plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_MaximumNumberOfSharesAuthorizedAsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=acst_CorporationStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=acst_CorporationStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=acst_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=acst_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=acst_CorporationEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=acst_CorporationEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737826560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 17 - Share-based Payments - Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Feb. 08, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement', window );">Weighted average exercise price, outstanding</a></td>
<td class="nump">$ 2.58<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="nump">$ 1.81<span></span>
</td>
<td class="nump">$ 2.59<span></span>
</td>
<td class="nump">$ 2.58<span></span>
</td>
<td class="nump">$ 2.59<span></span>
</td>
<td class="nump">$ 13.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at beginning of year</a></td>
<td class="nump">1,427,288<span></span>
</td>
<td class="nump">2,284,388<span></span>
</td>
<td class="nump">1,424,788<span></span>
</td>
<td class="nump">454,151<span></span>
</td>
<td class="nump">454,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Weighted average exercise price of share options granted in share-based payment arrangement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="nump">$ 1.69<span></span>
</td>
<td class="nump">$ 1.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,173,523<span></span>
</td>
<td class="nump">1,121,500<span></span>
</td>
<td class="nump">1,300,400<span></span>
</td>
<td class="nump">1,300,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Weighted average exercise price, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Options, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,167)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Weighted average exercise price, forfeited</a></td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="nump">$ 13.29<span></span>
</td>
<td class="nump">$ 13.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Options, forfeited</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="num">(407,067)<span></span>
</td>
<td class="num">(199,800)<span></span>
</td>
<td class="num">(187,638)<span></span>
</td>
<td class="num">(190,138)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Weighted average exercise price, expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18.06<span></span>
</td>
<td class="nump">$ 15.38<span></span>
</td>
<td class="nump">$ 15.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Options, expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(62,100)<span></span>
</td>
<td class="num">(139,625)<span></span>
</td>
<td class="num">(139,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding at end of year</a></td>
<td class="nump">1,424,788<span></span>
</td>
<td class="nump">4,046,677<span></span>
</td>
<td class="nump">2,284,388<span></span>
</td>
<td class="nump">1,427,288<span></span>
</td>
<td class="nump">1,424,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable at end of year</a></td>
<td class="nump">$ 6.44<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 1.92<span></span>
</td>
<td class="nump">$ 6.49<span></span>
</td>
<td class="nump">$ 6.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Exercisable at end of year</a></td>
<td class="nump">238,482<span></span>
</td>
<td class="nump">1,613,200<span></span>
</td>
<td class="nump">591,113<span></span>
</td>
<td class="nump">240,982<span></span>
</td>
<td class="nump">238,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=acst_CorporationStockOptionPlanMember', window );">Corporation stock option plan [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Options, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,167)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value of the options granted to employees and directors of the Corporation</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=acst_CorporationStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=acst_CorporationStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737323840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 17 - Share-based Payments - Weighted Average Assumptions (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted', window );">Exercise price</a></td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="nump">$ 1.69<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="nump">$ 1.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted', window );">Share price</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 1.69<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="nump">$ 1.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">0.87%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">0.87%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Estimated life (in years)</a></td>
<td class="nump">5.78<span></span>
</td>
<td class="nump">4.94<span></span>
</td>
<td class="nump">5.89<span></span>
</td>
<td class="nump">4.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">85.35%<span></span>
</td>
<td class="nump">123.50%<span></span>
</td>
<td class="nump">82.40%<span></span>
</td>
<td class="nump">123.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePriceShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted. [Refer: Option pricing model [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePriceShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6777962048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 17 - Share-based Payments - Outstanding and Exercisable Options (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th"><div>Feb. 29, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted average remaining contractual life outstanding</a></td>
<td class="nump">7.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding</a></td>
<td class="nump">4,046,677<span></span>
</td>
<td class="nump">2,284,388<span></span>
</td>
<td class="nump">1,424,788<span></span>
</td>
<td class="nump">1,427,288<span></span>
</td>
<td class="nump">454,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Weighted average exercise price exercisable</a></td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 1.92<span></span>
</td>
<td class="nump">$ 6.44<span></span>
</td>
<td class="nump">$ 6.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable</a></td>
<td class="nump">1,613,200<span></span>
</td>
<td class="nump">591,113<span></span>
</td>
<td class="nump">238,482<span></span>
</td>
<td class="nump">240,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise price</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise price</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeOneOfExercisesPricesMember', window );">Range one of exercises prices [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted average remaining contractual life outstanding</a></td>
<td class="nump">9.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding</a></td>
<td class="nump">1,898,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Weighted average exercise price exercisable</a></td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable</a></td>
<td class="nump">348,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeOneOfExercisesPricesMember', window );">Range one of exercises prices [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise price</a></td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeOneOfExercisesPricesMember', window );">Range one of exercises prices [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise price</a></td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeTwoOfExercisesPricesMember', window );">Range two of exercises prices [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted average remaining contractual life outstanding</a></td>
<td class="nump">5.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding</a></td>
<td class="nump">775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Weighted average exercise price exercisable</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable</a></td>
<td class="nump">518,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeTwoOfExercisesPricesMember', window );">Range two of exercises prices [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise price</a></td>
<td class="nump">$ 0.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeTwoOfExercisesPricesMember', window );">Range two of exercises prices [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise price</a></td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeThreeOfExercisesPricesMember', window );">Range three of exercises prices [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted average remaining contractual life outstanding</a></td>
<td class="nump">7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding</a></td>
<td class="nump">273,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Weighted average exercise price exercisable</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable</a></td>
<td class="nump">233,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeThreeOfExercisesPricesMember', window );">Range three of exercises prices [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise price</a></td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeThreeOfExercisesPricesMember', window );">Range three of exercises prices [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise price</a></td>
<td class="nump">$ 1.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeFourOfExercisesPricesMember', window );">Range four of exercises prices [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted average remaining contractual life outstanding</a></td>
<td class="nump">8.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding</a></td>
<td class="nump">790,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Weighted average exercise price exercisable</a></td>
<td class="nump">$ 1.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable</a></td>
<td class="nump">292,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeFourOfExercisesPricesMember', window );">Range four of exercises prices [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise price</a></td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeFourOfExercisesPricesMember', window );">Range four of exercises prices [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise price</a></td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeFiveOfExercisesPricesMember', window );">Range five of exercises prices [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions', window );">Weighted average remaining contractual life outstanding</a></td>
<td class="nump">3.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number of options outstanding</a></td>
<td class="nump">308,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Weighted average exercise price exercisable</a></td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number of options exercisable</a></td>
<td class="nump">220,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeFiveOfExercisesPricesMember', window );">Range five of exercises prices [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise price</a></td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeFiveOfExercisesPricesMember', window );">Range five of exercises prices [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions', window );">Exercise price</a></td>
<td class="nump">$ 6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeOneOfExercisesPricesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeOneOfExercisesPricesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeTwoOfExercisesPricesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeTwoOfExercisesPricesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeThreeOfExercisesPricesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeThreeOfExercisesPricesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeFourOfExercisesPricesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeFourOfExercisesPricesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeFiveOfExercisesPricesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=acst_RangeFiveOfExercisesPricesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737190256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 19 - Supplemental Cash Flow Disclosure - Changes in Non-cash Operating Items (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Receivables</a></td>
<td class="num">$ (40)<span></span>
</td>
<td class="num">$ (738)<span></span>
</td>
<td class="num">$ (553)<span></span>
</td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(709)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="nump">280<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Other Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="num">(659)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts', window );">Deferred financing costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(179)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="num">(255)<span></span>
</td>
<td class="nump">9,679<span></span>
</td>
<td class="nump">4,898<span></span>
</td>
<td class="nump">607<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAdjustmentsForNoncashItems', window );">Total changes in working capital items</a></td>
<td class="num">$ (328)<span></span>
</td>
<td class="nump">$ 8,090<span></span>
</td>
<td class="nump">$ 3,583<span></span>
</td>
<td class="nump">$ 1,120<span></span>
</td>
<td class="nump">$ 792<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in deferred financing costs to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_AdjustmentsForDecreaseIncreaseInDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAdjustmentsForNoncashItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAdjustmentsForNoncashItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6749779312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 19 - Supplemental Cash Flow Disclosure - Non-cash Transactions (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IssuanceOfSharesForInterestOnConvertibleDebt', window );">Issuance of shares for interest on convertible debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering', window );">Issuance of broker warrants included in net proceeds from public offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables', window );">Public offering transaction costs included in trade and other payables</a></td>
<td class="nump">381<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="nump">416<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_InterestReceivableIncludedInReceivables', window );">Interest receivable included in receivables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables', window );">Reduction in share issue costs from reduction in trade and other payables</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables', window );">Private Placement transaction costs included in trade and other payables</a></td>
<td class="nump">40<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_EquipmentIncludedInTradeAndOtherPayables', window );">Equipment included in trade and other payables</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_InterestPayableIncludedInTradeAndOtherPayables', window );">Interest payable included in trade and other payables</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_EquipmentIncludedInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash transaction related to equipment included in trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_EquipmentIncludedInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_InterestPayableIncludedInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash transaction related to interest payable included in trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_InterestPayableIncludedInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_InterestReceivableIncludedInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash transaction related to the interest receivable included in receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_InterestReceivableIncludedInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash transaction related to the issuance of broker warrants included in net proceeds from public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IssuanceOfBrokerWarrantsIncludedInNetProceedsFromPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_IssuanceOfSharesForInterestOnConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash transaction related to the issuance of shares for interest on convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_IssuanceOfSharesForInterestOnConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash transaction related to private placement transaction costs included in trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_PrivatePlacementTransactionCostsIncludedInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash transaction related to public offering transaction costs included in trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_PublicOfferingTransactionCostsIncludedInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash transaction related to reduction in share issue costs from reduction in trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ReductionInShareIssueCostsFromReductionInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6739777024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 20 - Income Taxes (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Feb. 21, 2017 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity', window );">Deferred tax relating to items credited (charged) directly to equity</a></td>
<td class="nump">$ 129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737183680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 20 - Income Taxes - Deferred Tax (Recovery) Expense (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences', window );">Origination and reversal of temporary differences</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">$ 11,599<span></span>
</td>
<td class="nump">$ 5,241<span></span>
</td>
<td class="nump">$ 2,077<span></span>
</td>
<td class="nump">$ 2,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense', window );">Change in unrecognized deductible temporary differences</a></td>
<td class="num">(163)<span></span>
</td>
<td class="num">(11,599)<span></span>
</td>
<td class="num">(5,241)<span></span>
</td>
<td class="num">(2,206)<span></span>
</td>
<td class="num">(2,369)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Total tax (recovery) expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (129)<span></span>
</td>
<td class="num">$ (129)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax expense or income relating to the creation or reversal of temporary differences. [Refer: Temporary differences [member]; Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 80<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_80_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax that relate to continuing operations. [Refer: Continuing operations [member]; Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2017-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=26&amp;date=2017-03-01&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce deferred tax expense. [Refer: Deferred tax expense (income); Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 80<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_80_f&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6751989296">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 20 - Income Taxes - Reconciliation of Effective Tax Rate (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AccountingProfit', window );">Loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (769)<span></span>
</td>
<td class="num">$ (51,566)<span></span>
</td>
<td class="num">$ (21,504)<span></span>
</td>
<td class="num">$ (10,607)<span></span>
</td>
<td class="num">$ (11,376)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Basic combined Canadian statutory income tax rate 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">26.80%<span></span>
</td>
<td class="nump">26.68%<span></span>
</td>
<td class="nump">26.78%<span></span>
</td>
<td class="nump">26.88%<span></span>
</td>
<td class="nump">26.87%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Computed income tax recovery</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (206)<span></span>
</td>
<td class="num">$ (13,758)<span></span>
</td>
<td class="num">$ (5,759)<span></span>
</td>
<td class="num">$ (2,851)<span></span>
</td>
<td class="num">$ (3,057)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences', window );">Change in unrecognized deductible temporary differences</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">162<span></span>
</td>
<td class="nump">11,599<span></span>
</td>
<td class="nump">5,241<span></span>
</td>
<td class="nump">2,207<span></span>
</td>
<td class="nump">2,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss', window );">Non-deductible stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">23<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss', window );">Non-deductible change in fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1,677<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_TaxEffectOfPermanentDifferencesAndOther', window );">Permanent differences and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxEffectFromChangeInTaxRate', window );">Change in statutory income tax rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Total tax (recovery) expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (129)<span></span>
</td>
<td class="num">$ (129)<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Canadian combined statutory income tax rate has decreased due to a reduction in the provincial statutory income tax rate.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to change in unrecognized deductible temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_TaxEffectOfChangeInUnrecognizedDeductibleTemporaryDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to not deductible change in fair value in determining taxable profit (tax loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_TaxEffectOfExpenseNotDeductibleChangeInFairValueInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible stock-based compensation in determining taxable profit (tax loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_TaxEffectOfExpenseNotDeductibleStockBasedCompensationInDeterminingTaxableProfitTaxLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_TaxEffectOfPermanentDifferencesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to permanent differences and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_TaxEffectOfPermanentDifferencesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccountingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccountingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax that relate to continuing operations. [Refer: Continuing operations [member]; Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2017-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=8&amp;date=2017-03-01&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2017-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=26&amp;date=2017-03-01&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;seq=2<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737471536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 20 - Income Taxes - Unrecognized Deferred Tax Assets (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">$ 32,053<span></span>
</td>
<td class="nump">$ 19,048<span></span>
</td>
<td class="nump">$ 13,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilityAsset', window );">Net deferred tax assets</a></td>
<td class="nump">32,040<span></span>
</td>
<td class="nump">18,981<span></span>
</td>
<td class="nump">13,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember', window );">Unused tax losses [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">23,695<span></span>
</td>
<td class="nump">12,670<span></span>
</td>
<td class="nump">8,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=acst_ResearchAndDevelopmentProjectsMember', window );">Research and development projects [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">5,362<span></span>
</td>
<td class="nump">4,927<span></span>
</td>
<td class="nump">4,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember', window );">Property, plan and equipment and intangible assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">567<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=acst_FinancingExpensesMember', window );">Financing expenses [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember', window );">Other temporary differences [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">378<span></span>
</td>
<td class="nump">768<span></span>
</td>
<td class="nump">522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember', window );">Tax basis of unsecured convertible debentures in excess of carrying value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2017-03-09<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=acst_ResearchAndDevelopmentProjectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=acst_ResearchAndDevelopmentProjectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=acst_PropertyPlanAndEquipmentAndIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=acst_FinancingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=acst_FinancingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_OtherTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=acst_TaxBasisOfUnsecuredConvertibleDebenturesInExcessOfCarryingValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6743595296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 20 - Income Taxes - Tax attributes and Temporary Differences Available to Reduce Future Years' Taxable Income (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Research and development expenses, without time limitation</a></td>
<td class="nump">$ 3,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember', window );">Country of domicile [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">89,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Research and development expenses, without time limitation</a></td>
<td class="nump">19,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Other deductible temporary differences, without time limitation</a></td>
<td class="nump">30,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=acst_ProvincialMember', window );">Provincial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">89,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Research and development expenses, without time limitation</a></td>
<td class="nump">21,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Other deductible temporary differences, without time limitation</a></td>
<td class="nump">32,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandTwentyNineMember', window );">2029 [Member] | Country of domicile [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandTwentyNineMember', window );">2029 [Member] | Provincial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyMember', window );">2030 [Member] | Country of domicile [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">1,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyMember', window );">2030 [Member] | Provincial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">1,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyOneMember', window );">2031 [Member] | Country of domicile [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">2,071<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyOneMember', window );">2031 [Member] | Provincial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">2,063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyTwoMember', window );">2032 [Member] | Country of domicile [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">2,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyTwoMember', window );">2032 [Member] | Provincial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">2,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyThreeMember', window );">2033 [Member] | Country of domicile [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">1,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyThreeMember', window );">2033 [Member] | Provincial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">1,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyFourMember', window );">2034 [Member] | Country of domicile [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">3,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyFourMember', window );">2034 [Member] | Provincial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">3,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyFiveMember', window );">2035 [Member] | Country of domicile [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">4,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyFiveMember', window );">2035 [Member] | Provincial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">4,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtySixMember', window );">2036 [Member] | Country of domicile [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">5,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtySixMember', window );">2036 [Member] | Provincial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">5,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThouandThirtySevenMember', window );">2037 [Member] | Country of domicile [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">8,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThouandThirtySevenMember', window );">2037 [Member] | Provincial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">8,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThouandThirtyEightMember', window );">2038 [member] | Country of domicile [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">17,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThouandThirtyEightMember', window );">2038 [member] | Provincial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">17,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyNineMember', window );">2039 [member] | Country of domicile [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">41,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyNineMember', window );">2039 [member] | Provincial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Tax losses carried forward</a></td>
<td class="nump">$ 41,447<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2017-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=12&amp;date=2017-03-01&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=ifrs-full_CountryOfDomicileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=acst_ProvincialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=acst_ProvincialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_TwoThousandTwentyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_TwoThousandTwentyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_TwoThousandThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_TwoThousandThirtyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_TwoThousandThirtyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_TwoThousandThirtyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_TwoThousandThirtyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_TwoThousandThirtyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_TwoThousandThirtySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_TwoThouandThirtySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_TwoThouandThirtySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_TwoThouandThirtyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_TwoThouandThirtyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=acst_TwoThousandThirtyNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=acst_TwoThousandThirtyNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6743196304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 21 - Financial Instruments - Currency Risk (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=acst_CurrencyRiskForUSDMember', window );">Currency risk for USD [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ForeignExchangeRiskCurrencyExposure', window );">Foreign exchange currency exposures</a></td>
<td class="num">$ (7,170,000)<span></span>
</td>
<td class="nump">$ 3,132,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average exchange rate</a></td>
<td class="nump">1.3122<span></span>
</td>
<td class="nump">1.2834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing exchange rate</a></td>
<td class="nump">1.3349<span></span>
</td>
<td class="nump">1.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=acst_CurrencyRiskForUSDMember', window );">Currency risk for USD [member] | Trade and other payables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ForeignExchangeRiskCurrencyExposure', window );">Foreign exchange currency exposures</a></td>
<td class="num">$ (13,251,000)<span></span>
</td>
<td class="num">$ (3,924,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=acst_CurrencyRiskForUSDMember', window );">Currency risk for USD [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ForeignExchangeRiskCurrencyExposure', window );">Foreign exchange currency exposures</a></td>
<td class="nump">3,369,000<span></span>
</td>
<td class="nump">7,024,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=acst_CurrencyRiskForUSDMember', window );">Currency risk for USD [member] | Marketable securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ForeignExchangeRiskCurrencyExposure', window );">Foreign exchange currency exposures</a></td>
<td class="nump">2,696,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=acst_CurrencyRiskForUSDMember', window );">Currency risk for USD [member] | Receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ForeignExchangeRiskCurrencyExposure', window );">Foreign exchange currency exposures</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=acst_CurrencyRiskForEuroMember', window );">Currency risk for Euro [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ForeignExchangeRiskCurrencyExposure', window );">Foreign exchange currency exposures</a></td>
<td class="num">$ (131,000)<span></span>
</td>
<td class="num">$ (627,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average exchange rate</a></td>
<td class="nump">1.5192<span></span>
</td>
<td class="nump">1.5008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Closing exchange rate</a></td>
<td class="nump">1.4975<span></span>
</td>
<td class="nump">1.5898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=acst_CurrencyRiskForEuroMember', window );">Currency risk for Euro [member] | Trade and other payables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ForeignExchangeRiskCurrencyExposure', window );">Foreign exchange currency exposures</a></td>
<td class="num">$ (131,000)<span></span>
</td>
<td class="num">$ (627,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=acst_CurrencyRiskForEuroMember', window );">Currency risk for Euro [member] | Cash and cash equivalents [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ForeignExchangeRiskCurrencyExposure', window );">Foreign exchange currency exposures</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=acst_CurrencyRiskForEuroMember', window );">Currency risk for Euro [member] | Marketable securities [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ForeignExchangeRiskCurrencyExposure', window );">Foreign exchange currency exposures</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=acst_CurrencyRiskForEuroMember', window );">Currency risk for Euro [member] | Receivables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ForeignExchangeRiskCurrencyExposure', window );">Foreign exchange currency exposures</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss', window );">Increase (decrease) in net loss</a></td>
<td class="nump">$ 364<span></span>
</td>
<td class="num">$ (88)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of change in net loss while a 5% strengthening of the US dollar and Euro.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ForeignCurrencyExposuresIncreaseDecreaseInNetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ForeignExchangeRiskCurrencyExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of currency exposure which impact profit and loss expressed as long/(short).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ForeignExchangeRiskCurrencyExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2017-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=1&amp;date=2017-03-01&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=acst_CurrencyRiskForUSDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=acst_CurrencyRiskForUSDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_TradeAndOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_TradeAndOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=acst_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=acst_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=acst_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=acst_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=acst_ReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=acst_ReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=acst_CurrencyRiskForEuroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=acst_CurrencyRiskForEuroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6749698496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 21 - Financial Instruments - Financial Liabilities (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">$ 18,572<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">18,572<span></span>
</td>
<td class="nump">6,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember', window );">Later than one year and not later than three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Gross carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">18,246<span></span>
</td>
<td class="nump">8,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_TradeAndOtherPayablesMember', window );">Trade and other payables [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">16,429<span></span>
</td>
<td class="nump">6,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_TradeAndOtherPayablesMember', window );">Trade and other payables [member] | Not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">16,429<span></span>
</td>
<td class="nump">6,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_TradeAndOtherPayablesMember', window );">Trade and other payables [member] | Later than one year and not later than three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_TradeAndOtherPayablesMember', window );">Trade and other payables [member] | Gross carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">16,429<span></span>
</td>
<td class="nump">6,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_UnsecuredConvertibleDebenturesMember', window );">Unsecured convertible debentures [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">2,143<span></span>
</td>
<td class="nump">2,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_UnsecuredConvertibleDebenturesMember', window );">Unsecured convertible debentures [member] | Not later than one year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">2,143<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_UnsecuredConvertibleDebenturesMember', window );">Unsecured convertible debentures [member] | Later than one year and not later than three years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_UnsecuredConvertibleDebenturesMember', window );">Unsecured convertible debentures [member] | Gross carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Financial liabilities</a></td>
<td class="nump">$ 1,817<span></span>
</td>
<td class="nump">$ 1,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_TradeAndOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_TradeAndOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_UnsecuredConvertibleDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=acst_UnsecuredConvertibleDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6751052080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 22 - Commitments and Contingencies (Details Textual) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis=acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember', window );">Lease for laboratory facility located in Sherbrooke, Qu&#233;bec [member] | Later than one year and not later than two years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease', window );">Minimum lease payments payable under non-cancellable operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=acst_ResearchAndDevelopmentProjectsMember', window );">Research and development projects [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities', window );">Estimated financial effect of contingent liabilities</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EstimatedFinancialEffectOfContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the estimated financial effect of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2017-01-01<br> -Paragraph 86<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=37&amp;date=2017-03-01&amp;anchor=para_86_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EstimatedFinancialEffectOfContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of future minimum lease payments payable under non-cancellable operating leases. Minimum lease payments are payments over the lease term that the lessee is or can be required to make, excluding contingent rent, costs for services and taxes to be paid by, and reimbursed to, the lessor, together with: (a) for a lessee, any amounts guaranteed by the lessee or by a party related to the lessee; or (b) for a lessor, any residual value guaranteed to the lessor by: (i) the lessee; (ii) a party related to the lessee; or (iii) a third party unrelated to the lessor that is financially capable of discharging the obligations under the guarantee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2019-01-01<br> -Name IAS<br> -Number 17<br> -IssueDate 2017-01-01<br> -Paragraph 35<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=17&amp;date=2017-03-02&amp;anchor=para_35_a&amp;doctype=Standard&amp;book=B<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis=acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ArrangementsInvolvingLegalFormOfLeaseAxis=acst_LeaseForLaboratoryFacilityLocatedInSherbrookeQuebecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfContingentLiabilitiesAxis=acst_ResearchAndDevelopmentProjectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfContingentLiabilitiesAxis=acst_ResearchAndDevelopmentProjectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6630502576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 23 - Determination of Fair Values (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss', window );">Significant unobservable inputs, increase in five percent of volatility would result in a loss</a></td>
<td class="nump">$ 569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain', window );">Significant unobservable inputs, increase in five percent of volatility would result in a gain</a></td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss', window );">Significant unobservable inputs, five percent strengthen of foreign currency would result in a loss</a></td>
<td class="nump">$ 405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of loss from the strengthening of 5% of the foreign currency used for financial instrument classified as a liability using unobservable inputs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_SignificantUnobservableInputsFivePercentStrengthenOfForeignCurrencyWouldResultInALoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of gain from the increase of 5% of the volatility used for financial instrument classified as a liability using unobservable inputs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInAGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of loss from the increase of 5% of the volatility used for financial instrument classified as a liability using unobservable inputs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_SignificantUnobservableInputsIncreaseInFivePercentOfVolatilityWouldResultInALoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6733307888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 24 - Capital Management (Details Textual)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">1.76%<span></span>
</td>
<td class="nump">1.26%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings, interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.72%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6743083616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 24 - Capital Management - Cash and Cash Equivalents (Details)<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Cash</a></td>
<td class="nump">$ 1,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,778<span></span>
</td>
<td class="nump">$ 7,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">20,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,994<span></span>
</td>
<td class="nump">$ 2,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition', window );">Total Cash and cash equivalents</a></td>
<td class="nump">22,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_TermDepositsIssuedInCadCurrencyMember', window );">Term deposits issued in CAD currency [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_TermDepositsIssuedInUsCurrencyMember', window );">Term deposits issued in US currency [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,193<span></span>
</td>
<td class="nump">$ 3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_CommercialPapersIssuedInCadCurrencyMember', window );">Commercial papers issued in CAD currency [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">5,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_CommercialPapersIssuedInUsCurrencyMember', window );">Commercial papers issued in US currency [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,418<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_PromissoryNotesIssuedInCadCurrencyMember', window );">Promissory notes issued in CAD currency [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_PromissoryNotesIssuedInUsCurrencyMember', window );">Promissory notes issued in US currency [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,029<span></span>
</td>
<td class="nump">$ 798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_BankersAcceptanceMember', window );">Bankers acceptance [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">$ 2,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents in the statement of cash flows when different from the amount of cash and cash equivalents in the statement of financial position. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_TermDepositsIssuedInCadCurrencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=acst_TermDepositsIssuedInCadCurrencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_TermDepositsIssuedInUsCurrencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=acst_TermDepositsIssuedInUsCurrencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_CommercialPapersIssuedInCadCurrencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=acst_CommercialPapersIssuedInCadCurrencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_CommercialPapersIssuedInUsCurrencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=acst_CommercialPapersIssuedInUsCurrencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_PromissoryNotesIssuedInCadCurrencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=acst_PromissoryNotesIssuedInCadCurrencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_PromissoryNotesIssuedInUsCurrencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=acst_PromissoryNotesIssuedInUsCurrencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_BankersAcceptanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=acst_BankersAcceptanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6737643584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 24 - Capital Management - Cash and Cash Equivalents (Details) (Parentheticals)<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="nump">$ 20,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,994<span></span>
</td>
<td class="nump">$ 2,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_TermDepositsIssuedInUsCurrencyMember', window );">Term deposits issued in US currency [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,193<span></span>
</td>
<td class="nump">$ 3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_CommercialPapersIssuedInUsCurrencyMember', window );">Commercial papers issued in US currency [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,418<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_PromissoryNotesIssuedInUsCurrencyMember', window );">Promissory notes issued in US currency [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,029<span></span>
</td>
<td class="nump">$ 798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&amp;num=7&amp;date=2017-03-01&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_TermDepositsIssuedInUsCurrencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=acst_TermDepositsIssuedInUsCurrencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_CommercialPapersIssuedInUsCurrencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=acst_CommercialPapersIssuedInUsCurrencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAxis=acst_PromissoryNotesIssuedInUsCurrencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAxis=acst_PromissoryNotesIssuedInUsCurrencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.2</span><table class="report" border="0" cellspacing="2" id="idp6748812064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 25 - Subsequent Events (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 10, 2019 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 15, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 23, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 21, 2017 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Weighted average exercise price of share options granted in share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="nump">$ 1.69<span></span>
</td>
<td class="nump">$ 1.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ShareIssuedPricePerShare', window );">Share issued, price per share | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="nump">$ 1.57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=acst_FormerCEOMember', window );">Former CEO [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_LegalExpense', window );">Legal expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,054,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Major ordinary share transactions [member] | Former CEO [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_NumberOfSharesIssuedForLegalSettlement', window );">Number of shares issued for legal settlement | shares</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_ShareIssuedPricePerShare', window );">Share issued, price per share | $ / shares</a></td>
<td class="nump">$ 1.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_LegalFeesReimburse', window );">Legal fees reimburse</a></td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=acst_CorporationStockOptionPlanMember', window );">Corporation stock option plan [member] | Major ordinary share transactions [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of instruments granted in share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Weighted average exercise price of share options granted in share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=acst_CorporationStockOptionPlanMember', window );">Corporation stock option plan [member] | Major ordinary share transactions [member] | Bottom of range [member] | Directors [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DescriptionOfVestingPeriodShareOptionGranted', window );">Description of vesting period, share option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=acst_CorporationStockOptionPlanMember', window );">Corporation stock option plan [member] | Major ordinary share transactions [member] | Bottom of range [member] | Employee [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_StatementLineItems', window );"><strong>Statement Line Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acst_DescriptionOfVestingPeriodShareOptionGranted', window );">Description of vesting period, share option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_DescriptionOfVestingPeriodShareOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The vesting period of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_DescriptionOfVestingPeriodShareOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_LegalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of legal expense incurred during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_LegalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_LegalFeesReimburse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of legal fees reimbursed to the counter party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_LegalFeesReimburse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_NumberOfSharesIssuedForLegalSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued for legal settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_NumberOfSharesIssuedForLegalSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_ShareIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of share issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_ShareIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acst_StatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acst_StatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acst_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of instruments granted in share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph IG23<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2017-03-09<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2017-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&amp;num=2&amp;date=2017-03-01&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2017-03-09<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=acst_FormerCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=acst_FormerCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=acst_CorporationStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=acst_CorporationStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=acst_DirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=acst_DirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=acst_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=acst_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>144
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_O"[";M@[,'^8^.K8-O K[MHOP!02P,$%     @ @4':3IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M&AE;5.E>BL*;;>39BY2]FA"%:BA1[FING?# 10I<[3\%%LWZ33"P V"4@1U
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M+A[&K8XH;X%&>!VA66M)2>%UA)WBNIVQUQBV&A2VG ):PO;ZLJ0Q;36@+:>
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M _-C50MOSZ3ZGLRM/S F05F</*D/KU2MN9L0.$@]G*DQMPW*3B1K7.]%W1]
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MVOF7C?UOM7;@4TEN_ CU_H.MAH#6A>/!G\T\9K/A]+#\(+)^X^H/4$L#!!0
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MX\O&_C?&>,!4=G<X0AU^L,60T/AP/.+93F,V&=[T\P]BRS<N_P!02P,$%
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M^E]K[0"E1#<X0BU^L,604#M_W./93&,V&4[W\P]BRS<N_@%02P,$%     @
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M?&"S(Z'VP=RC;<<U&QUONND%L?D9%W\ 4$L#!!0    ( (%!VDX_RL,AM0$
M -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;&U3VVZ<,!#]%<L?
M$"^P258K0,JFBEJIE5:IVCY[80 KOE#;+.G?=VP(H2DO]LSXG+D['XU]<1V
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M0./"\=J?S31FD^%T/_\@LGSC\@]02P,$%     @ @4':3A8V^YFX 0  T@,
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M-"X<#_YLIC&;#*?[^0>1Y1N7?P%02P,$%     @ @4':3C24Q0"V 0  T@,
M !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL;5/;;MP@$/T5Q <$&V\N
M7=F6LHFB5&JE5:HVSZP]ME&X.(#7Z=\7L->U$K\ ,YQSYL*0C]J\V0[ H0\I
ME"UPYUR_)\16'4AFKW0/RM\TVDCFO&E:8GL#K(XD*0A-DALB&5>XS*/O:,I<
M#TYP!4>#[" E,W\/(/18X!1?'"^\[5QPD#+O60N_P/WNC\9;9%&IN01EN5;(
M0%/@^W1_V 5\!/SA,-K5&85*3EJ_!>-[7> D) 0"*A<4F-_.\ !"!"&?QONL
MB9>0@;@^7]2?8NV^EA.S\*#%*Z]=5^ [C&IHV"#<BQZ?8:[G&J.Y^!]P!N'A
M(1,?H]+"QA55@W5:SBH^%<D^IIVKN(_3S?6%MDV@,X$NA+M((%.@F/DC<ZS,
MC1Z1F7K?L_#$Z9[ZWE3!&5L1[WSRUGO/)4V^Y>0<A&;,8<+0%29=$,2K+R'H
M5H@#_4+/LFU^MIEB%OG9BG]SN\W?;?)WD;];EY@FGTK<PGPNDJQZ*L&T<9HL
MJO2@XB2OO,O WM/X)O_AT[3_9*;ERJ*3=OYE8_\;K1WX5)(K/T*=_V"+(:!Q
MX7CKSV8:L\EPNI]_$%F^<?D/4$L#!!0    ( (%!VDZ=[MBUL@$  -(#   9
M    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;&U3VVZ<,!#]%<L?$"^&7+0"
MI&RB*)5::96J[;,7!K#B"[7-DOQ];<-2NN4%SPSGG+EXG(_:O-L.P*$/*90M
M<.=<OR?$5AU(9F]T#\K_:;21S'G7M,3V!E@=25(0NMO=$<FXPF4>8T=3YGIP
M@BLX&F0'*9GY/(#08X$3? F\\;9S(4#*O&<M? ?WHS\:[Y%%I>82E.5:(0--
M@1^3_2$+^ CXR6&T*QN%3DY:OP?G2UW@72@(!%0N*#!_G.$)A A"OHS?LR9>
M4@;BVKZHO\3>?2\G9N%)BU^\=EV!'S"JH6&#<&]Z?(6YGUN,YN:_PAF$AX=*
M?(Y*"QN_J!JLTW)6\:5(]C&=7,5SG/4OM&T"G0GTBD"F1+'R9^98F1L](C/-
MOF?ABI,]];.I0C".(O[SQ5L?/9<TH3DY!Z$9<Y@P=(5)%@3QZDL*NI7B0/^C
MI^DV/]TL,8W\=,6_N]_F9YO\+/*S?UI,KUK<PF172<AJIA),&[?)HDH/*F[R
M*KHL[".-=_(7/FW[-V9:KBPZ:>=O-LZ_T=J!+V5WXU>H\P]L<00T+ICWWC;3
MFDV.T_W\@LCRC,L_4$L#!!0    ( (%!VDYGPB*DM@$  -(#   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,Q+GAM;&U3VV[<(!#]%<0'A#7>2[2R+6431:W4
M2*M$;9]9>VRC<'$!KY._#V#'=5._ #.<<^;"D W:O-H6P*$W*93-<>M<=R3$
MEBU(9F]T!\K?U-I(YKQI&F([ ZR*)"D(W6SV1#*N<)%%W]D4F>Z=X K.!ME>
M2F;>3R#TD.,$?SJ>>=.ZX"!%UK$&7L#][,[&6V16J;@$9;E6R$"=X[OD>-H&
M? 3\XC#8Q1F%2BY:OP;C>Y7C34@(!)0N*#"_7>$>A A"/HT_DR:>0P;B\ORI
M_AAK][5<F(5[+7[SRK4YOL6H@IKUPCWKX1M,]>PPFHK_ 5<0'AXR\3%*+6Q<
M4=E;I^6DXE.1[&W<N8K[,-[L#A-MG4 G IT)MS$.&0/%S!^88T5F](#,V/N.
MA2=.CM3WI@S.V(IXYY.WWGLM:+++R#4(39C3B*$+3#(CB%>?0]"U$"?Z'SU-
MU_GI:HIIY*<+_OZPSM^N\K>1O_VGQ/V7$M<P7X.014\EF"9.DT6E[E6<Y(5W
M'M@[&M_D+WR<]B=F&JXLNFCG7S;VO];:@4]E<^-'J/4?;#8$U"X<#_YLQC$;
M#:>[Z0>1^1L7'U!+ P04    " "!0=I.(,2*/6,"   -"0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6QU5MN.VR 0_17+'[ 8[-Q6CJ5DJZJ56BG:
MJMMGXI#86FQ<(,GV[PO8<5T\O,1 SIPS,#,,^5W(=U4QIJ./AK=J&U=:=\\(
MJ;)B#55/HF.M^><L9$.UF<H+4IUD].2,&HY(DBQ10^LV+G*W=I!%+JZ:URT[
MR$A=FX;*/WO&Q7T;X_BQ\%I?*FT74)%W],)^,/VS.T@S0R/+J6Y8JVK11I*=
MM_$./^_QRAHXQ%O-[FHRCNQ6CD*\V\G7TS9.K$>,LU);"FH^-_;".+=,QH_?
M VD\:EK#Z?C!_MEMWFSF2!5[$?Q7?=+5-E['T8F=Z97K5W'_PH8-+>)HV/TW
M=F/<P*TG1J,47+G?J+PJ+9J!Q;C2T(_^6[?N>Q_X'V:P 1D,B&> >B'G^2>J
M:9%+<8]D?_@=M3'&S\2<36D7W5&X_XSSRJS>"H+7.;I9H@&S[S%D@L$C AGV
M48) $GLR,T]3V#X%74R=??J?BQN8( ,),D>030E(XNT1P@1VN0!%%@ !\40@
M3. HEJ#($B#(/!$(LX!%5J#("B!8>B(09@6+K$&1-4#@YQV$"01^ XILY@2I
M'W@($P@\3N 22@ */_0@*!!['"A5#%#XT0=!@?!CL%YWF  4?@* H$ &8+BN
M<0I0S.X>"!1( @R7/P9J._/3  2%\@"^ 3!0WMDL#R!0* _@2P #%9[-\@ "
MA?( O@<P4.39+ \@D)\':-*-&B8OK@^KJ!37UCT")JMCK]\1U\W^P?N'PG<J
M+W6KHJ/0IB>ZSG460C/C2_)DSK8R;Y-QPME9V^'*C&7?H/N)%MWP^$#C"ZCX
M"U!+ P04    " "!0=I.GD,.N[@!  #2 P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6QM4]MNW" 0_17$!P0O]B;;E6TIFZIJI59:I6KZS-IC&X6+
M"WB=_GT!>UTW]0LPPSEG+@SYJ,VK[0 <>I-"V0)WSO5'0FS5@63V3O>@_$VC
MC63.FZ8EMC? ZDB2@M DN2>2<87+//K.ILSUX 17<#;(#E(R\_L$0H\%WN&;
MXYFWG0L.4N8]:^$[N!_]V7B++"HUEZ LUPH9: K\N#N>LH"/@!<.HUV=4:CD
MHO5K,+[4!4Y"0B"@<D&!^>T*3R!$$/)I_)HU\1(R$-?GF_JG6+NOY<(L/&GQ
MD]>N*_ !HQH:-@CWK,?/,->SQV@N_BM<07AXR,3'J+2P<4758)V6LXI/1;*W
M:><J[N-TL[_1M@ET)M"%<(@$,@6*F7]DCI6YT2,R4^][%IYX=Z2^-U5PQE;$
M.Y^\]=YK2;-#3JY!:,:<)@Q=878+@GCU)03="G&B_]'3=)N?;J:81GZZXM\_
M;/.S37X6^=D_)7YX5^(&9I^\"T)6/95@VCA-%E5Z4'&25]YE8!]I?)._\&G:
MOS'3<F7113O_LK'_C=8.?"K)G1^ASG^PQ1#0N'!\\&<SC=ED.-W//X@LW[C\
M U!+ P04    " "!0=I.W&]!7[<!  #2 P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6QM4V%OVR 0_2N('U 2G#9=9%MJ.DV=M$I1IVV?B7VV4<'G
M H[;?S_ KNMU_@+<\=[=N^-(!S3/M@%PY%6KUF:T<:X[,&:+!K2P5]A!ZV\J
M-%HX;YJ:V<Z *"-)*\8WFQNFA6QIGD;?R>0I]D[)%DZ&V%YK8=Z.H'#(Z):^
M.YYDW;C@8'G:B1I^@OO5G8RWV!REE!I:*[$E!JJ,WFT/QUW 1\!O"8-=G$FH
MY(SX'(SO948W01 H*%R((/QV@7M0*@3R,EZFF'1.&8C+\WOT;[%V7\M96+A'
M]4>6KLGH+24E5*)7[@F'!YCJN:9D*OX'7$!Y>%#B<Q2H;%Q)T5N'>HKBI6CQ
M.NZRC?LPWNR_3+1U I\(?";<QCQL3!25?Q5.Y*G!@9BQ]YT(3[P]<-^;(CAC
M*^*=%V^]]Y+SZVW*+B'0A#F.&+[ ?""8CSZGX&LICOP_>I*L\Y-5B4GD)PO^
MS7Z=OUOE[R)_]T^)_%.):YC/(MFBIQI,':?)D@+[-D[RPCL/[!V/;_(!'Z?]
M49A:MI:<T?F7C?VO$!UX*9LK/T*-_V"SH:!RX;CW9S..V6@X[*8?Q.9OG/\%
M4$L#!!0    ( (%!VDZ&O&BKN $  -(#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;&U3VV[<(!#]%<0'A%W;NXE6MJ5LJJJ56FF5JNTS:X]M%&!<
MP.OT[PO8<=W4+\ ,YYRY,.0CFA?; 3CRJJ2V!>V<ZT^,V:H#Q>T=]J#]38-&
M<>=-TS+;&^!U)"G)DMWNR!07FI9Y]%U,F>/@I-!P,<0.2G'S^PP2QX+NZ9OC
M6;2="PY6YCUOX1NX[_W%>(LM*K50H*U 30PT!7W<G\Y9P$? #P&C79U)J.2*
M^!*,SW5!=R$AD%"YH,#]=H,GD#((^31^S9IT"1F(Z_.;^L=8NZ_ERBT\H?PI
M:M<5](&2&AH^2/>,XR>8ZSE0,A?_!6X@/3QDXF-4*&U<2358AVI6\:DH_CKM
M0L=]G&ZRXTS;)B0S(5D(#S$.FP+%S#]PQ\O<X$C,U/N>AR?>GQ+?FRHX8ROB
MG4_>>N^M3 Y9SFY!:,:<)TRRPNP7!//J2XAD*\0Y^8^>IMO\=#/%-/+3%?]X
MO\W/-OE9Y&?_E'AX5^(6YO@N"%OU5(%IXS194N&@XR2OO,O /B;Q3?["IVG_
MRDTKM"57=/YE8_\;1 <^E=V='Z'.?[#%D-"X<+SW9S.-V60X[.<?Q)9O7/X!
M4$L#!!0    ( (%!VDZ(,@6@N $  -(#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;&U3VVZ<,!#]%<L?$._")KM= 5(V4=1*K;1*U?39"P-8\87:
M9DG_OF-#*$UYL3WC<\Y</,X&8U]="^#)FY+:Y;3UOCLRYLH6%'<WI@.--[6Q
MBGLT;<-<9X%7D:0D2S:;.Z:XT+3(HN]LB\ST7@H-9TM<KQ2WOT\@S9#3+7UW
M/(NF]<'!BJSC#7P'_Z,[6[38K%()!=H)HXF%.J?WV^-I%_ 1\")@<(LS"95<
MC'D-QI<JIYN0$$@H?5#@N%WA :0,0IC&KTF3SB$#<7E^5W^*M6,M%^[@P<B?
MHO)M3@^45%#S7OIG,WR&J9Y;2J;BO\(5),)#)ABC--+%E92]\T9-*IB*XF_C
M+G3<A_$FW4^T=4(R$9*9<(AQV!@H9O[(/2\R:P9BQ]YW/#SQ]IA@;\K@C*V(
M=YB\0^^U2&[W&;L&H0ES&C') K.=$0S5YQ#)6HA3\A\]3=?YZ6J*:>2G"_[=
M?IV_6^7O(G_W3XF'#R6N83Y]",(6/55@FSA-CI2FUW&2%]YY8.^3^"9_X>.T
M?^.V$=J1B_'XLK'_M3$>,)7-#8Y0BQ]L-B34/ASW>+;CF(V&-]WT@]C\C8L_
M4$L#!!0    ( (%!VDZKO6UWQ0$  #<$   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;&U4VV[<(!#]%<0'!!OO)5K9EK*)HE9JI%6BML^L/;XH8%S
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MIG@).#36;^_=7D]O>0JLZN<Q)<M_1?D;4$L#!!0    ( (%!VDZD __<LP$
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MLJC2@XJ;O(HN"_M XYW\A4_;_HV9EBN+SMKYFXWS;[1VX$M)[OP*=?Z!+8Z
MQ@5S[VTSK=GD.-W/+X@LS[C\ U!+ P04    " "!0=I.F)C.K+<!  #2 P
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M6 (.E7';>[M7T\!,@9']_!:0Y4'*_P!02P,$%     @ @4':3D!41;C' 0
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MV.?C+[F6TH M);JQM;1VBA>'0VV<>6MM-;WER3&RG\>4+/^*XB]02P,$%
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ME=Z+\:,;"\7[Z3[!\Z56_ =02P,$%     @ @4':3G?0Y<B) @  A@H  !D
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M-5!@V='$OB-8=71B82((E#"](0AD^(F)]<ML](M 2:#E D&&7+!^&=)O:*#
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MTPU*NI'Z-57OO+WZMP/)&OM9$W3?5HO_4$L#!!0    ( (%!VD['S;(I:@,
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MVB6F6"CE" P;IB+.(S!P!"1#04L/2>DAD@XCF;=(V.N$CSA0CADI ^!HB:'
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M!D2LNCQ8G]&0 <EHR(!C-.0Q21@R9IA'#!O*&F:8ES/,8X9Y"<,\V%%<TD-
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M>JV:KV']O>BV]+J#*K_H[4KOMF>Z^A]02P,$%     @ @4':3@29Y^@C @
M@@8  !D   !X;"]W;W)K<VAE971S+W-H965T-C8N>&UL?97;CILP$(9?!?$
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MN]-$G#?]5-M?<'92$[LW_&VP^@=02P,$%     @ @4':3O7(0Y9: P  J!
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M^X )<T5T0RO<TW0'&KLI?+_#V6X*(WLI;"%"!&ID<@4 *:]JP$P,F*D!<V;
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M47I.PF6@4.BT]<A,TF/:UPJZ!%RRX)!33^ *(@PG( %$/4$AZ@E#8E$*X :
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MZ#;&5@#7.>IL=WW)];[I'E7[7 T7=<-+8\[V$M*_WH0N_@-02P,$%     @
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M!UN7YNRET'"PQ)V5XO9]#]*,%<WI9^)%G'H?$JPN!WZ"7^!_#P>+$9M56J%
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MN$O5C7<@A&.1H_\L:E*(MCQ,*GS@<C@38]HWIW["2:O[KC<T__0?4$L#!!0
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M^^S \:+:F-HF=/]^MB$,I?X2^X[GY<[Q.9N$?%,M@$8?G/4JQZW6PY$05;;
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MOY.R$THOO%')'=2A]3(HQ:[K;Q-UWXPGMW'0R:,^E0:7H_'J'U!+ P04
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M',-7"-\X%')VM5R[PN3WGS'_(7#B.#V"!.RX )W>-&;KAD-$%HETRJ>?5=Y
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MGJBPT2,GAMC1M1N$5YDIL$+E%E)ZU NC?V% V%7WR.9[SF_3!968?N(WSD:
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MNE&]>9S6YY+<_AE.]4@J%T&2TB$][ ALHC. E!]O\-$1"K>FP%X,,FL!EXP
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MM/:-QY+8-^O,UFE4SOU""=U4V ()&W?-ACFJNNAQPI7"OO>TCZO@<_Q #18
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M/F_9ACY*(]>L\4:T?YC#/!^7!_'-*-\9?N;B/>04"__!KO"1.U6T$*[72,,
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MSC]\TA9\'\_YZ_W^\(__ U!+ P04    " "!0=I.-G\!&&("  !"#0  #0
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M\.O<%&>HINK>'+$-AG"TOQCAGC_L6@P4(1SMKS@E-;,S[_C6%/T"4$L#!!0
M   ( (%!VDX'9J(QQ 8  ,D_   /    >&PO=V]R:V)O;VLN>&ULQ9M=<]HX
M%(;_BH:K[D46_&TZ36>Z2=K-;#^8DG8O=X0105,C4<F0IK^^DFF:(VJ=V1M.
MK@C&L1\D6X_>8_'B3ILO"ZV_L&^;5MGST;KKML_'8]NLQ8;;/_56*/?)2IL-
M[]Q;<SNV6R/XTJZ%Z#;M.)U,RO&&2S5Z^>+A6#,SAF]T)YI.:N4V^@V?I;BS
MCY_[MXR['?;BAB_.1Y,1X[M.OY9M)\PE[\0;HW=;J6[/1\F(K:2QW=R?N]]S
M(Y7<R.]BV;^S:WWWMS;RNU8=;^>-T6W;_Y?_H/\G=P;[:\MG83K9!#MV?/&1
M.];S43EQ!]Q+*Q>RE=W]^:C_NQ4C]RW&X&OT[?#P>FC$Y^;_-*->K60C+G6S
MVPC5'=K1B-:?7=FUW-H14WPCSD</N[!7:LFN5.=HV+4Z',KMZ[^+._7U\O"]
M.M=BC[#,/)?N W.]3#SXZ2#G_KQ^'\OTBKV6BJM&\I;-M)5N9P"9(I I)>05
M-\I=5I9QUZX7>K,%D!D"F5%"7JRYNA76=3B[^KIS70\@<P0R?T+(_U( 62"0
M!2DDMVOVNM5WECV[N1/M'D"6"&1Y6LCW;G1D"3MC'\56N_%(W?Z\QP%>A>!5
M!'BIP_N+6]FWX\R(+3?'0T^-(-8$B)E#G,M;)=T_<3]6-HW>*=^< '**0$X)
M(/.^FQLA]]R=W,*1>X(-W1,"ML*QO>/FB^@\&YN+9F?<R!U2HH(YL6%ZRM)1
M?NC6PK!7UCKO0CA,+,F)S=+#57WWND_%DLVX.6X\S"G)B:72\]6.[XW>"Z,.
MTPGK[NC.>5I 2DPJR8FMTE-.':6WR-;O#,DPDR0G5LEAE)XXM&LWM52W_O0#
MER#FD81$)-XD-X8O13^K.=PJ,W[/%Q 3\TE"(93$&^52&#<0^GD_^Y<;XT?M
MMQ)B8DY)**22>*M\4M:/A<+/$=7>1X:>Y!$3LTI"H97$>^6";Z4+/:#;W906
M3KLQPZ04ADF\8F;"6*V4:-G5-W= &PR1*>:7E,(OB1?,8WH98D3S"X5F$N^9
M^9H;<;;@MG?-?3_+A928;%(*V23>-F^UM;[+#[B0#]-,2J&9Q'MFOMMNVSXB
MN,Y^" @0$W-.2N&<]."<1F\$N^'?PDL1TTU*H9LT"6Z7:V4[L_OM6L1TDY+D
M%Z\;-QQN9'>(@X?$[^(!Q,1TDU+H)LUZ*W;";%R3^GWZ6@J7!F)BNDDI=)-"
MW;SCBM^*HZE:AKDFHW!-6O1W]\**KSL_U[W:'UV4&:::[-3%LL&@RF:ZE4T8
M&C+,-AF%;6+!.BCR9&B]C$(W1]&:/;OI7_^ D)AS,@KG1#,V@YB8<S(*YQR'
M[,'&Q-R34;AG(&W_!(68F'LR"O=$0W?0YYA[,@KW!*E[L,,Q[V0D,6<P?GM6
M6!/'U).3Q)Q(! \&S!S33TZ2="(1/,3$]).3A)U(! \Q,?WD)&DG$L%#3/2!
M#4GH&8[@[AZ"F)B <I)"VW */\+$#)23%-MB01P.[3EFH)RDV!9)NN&UB1DH
M)TD_QTEWR$(Y9J&<)/U$(F_XT!.S4$$2@(9#6G@+%9B%"@H+Q9XLLF<0$[-0
M\:0A*(.8F(4*"@M%,7.(B5FHH+#0<59ST.[0RUTP<R_0A0,4%HJEM?!.QRQ4
M4%@HBAE<FYB%"@H+_18J?[V%F)B%"@H+#:;*2]>VL%188!8J*"PTA'G&7BTW
M$+/$+%126&@8\Q]Q#V=()6:ADL)"L8P>W.DE9J&2PD)13'BGEYB%2@H+A:6$
MOO"^U>JH_EIB%BI)LM!P.<'Q0DS,0B5)%HJ5$X).1Q>PD62A6#DAP,0L5#[E
MPH-@AE1B%BI)%A[$, N(B5FH)*G(Q8HSL-,KS$(5244NA@D[O<(L5)%4Y&(U
MI* U,0M5)!6Y&&;0FIB%JB>MR,%;J,(L5)%8*(990DS,0A6)A2*%PS,XD:LP
M"U4D%HH4#D-,=#DUB84BA<-@OEEA%JI(+!3## 8DS$(5B85BF'! JC$+U206
MBF'" :G&+%236"A6+8:=7F,6JDDL%,,,.AVS4$UAH8&B=E],:&$6JC$+U106
M^AW33S]7PL"51S5FH?I)%L,="HE:-1 3LU!-LBIN /.3,@X48F(6JDE6Q0U@
MNE?&X5*N&OUA#\ESH=@#EV! PBQ4/^ES(3@@33$+34F>"T660@93CREFH2G)
M<Z'(4L@0$[/0E,)"T:=LEQ 3L]"4Q$(1S&!:/,4L-"6Q4 0S['3,0E,2"PVN
M+?5BAYB8A::]A<;]SO;EBZ582266[]TIK-O>\+:9&>9?_)&2-"_\;TQ6N[:]
M<-L^J+>:^^W],1Y^1?_R!U!+ P04    " "!0=I.4G1:<=4"   %.0  &@
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MOP%02P$"% ,4    " "!0=I.'R// \     3 @  "P              @ $
M    7W)E;',O+G)E;'-02P$"% ,4    " "!0=I.)^B'#H(   "Q    $
M            @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( (%!
MVDX[YUPX[P   "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( (%!VDZ97)PC$ 8  )PG   3              "
M ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ @4':3I$PJ6V"
M @  N D  !@              ( !^ @  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( (%!VD[&E(5YS0,   T2   8              "
M ; +  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " "!0=I.
MGX)%YV\#   E#@  &               @ &S#P  >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ @4':3C6R( JN!P  BC   !@
M     ( !6!,  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M (%!VDXB@78X& (   P&   8              "  3P;  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " "!0=I.[/OL:24&  #!(P  &
M            @ &*'0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ @4':3F1^_A&V 0  T@,  !@              ( !Y2,  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( (%!VDZKNF#"MP$  -(#
M   8              "  =$E  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " "!0=I.,%(X$;<!  #2 P  &               @ &^)P
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ @4':3L+KH+VW
M 0  T@,  !D              ( !JRD  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " "!0=I.:@JUW;<!  #2 P  &0
M@ &9*P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( (%!
MVDYX!-]GMP$  -(#   9              "  8<M  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ @4':3J1>HMZV 0  T@,  !D
M         ( !=2\  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " "!0=I.@""&];<!  #2 P  &0              @ %B,0  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( (%!VD[!)_@!N $  -(#
M   9              "  5 S  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ @4':3E>&_)NV 0  T@,  !D              ( !/S4
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "!0=I.*\SV
M2K<!  #2 P  &0              @ $L-P  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( (%!VD[0F[>'M@$  -(#   9
M  "  1HY  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
M@4':3A0E,3VW 0  T@,  !D              ( !!SL  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " "!0=I.@4(I ;<!  #2 P  &0
M            @ 'U/   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( (%!VDX[O^BQM@$  -(#   9              "  >,^  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ @4':3IXQ9!>X 0
MT@,  !D              ( !T$   'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " "!0=I.W!TK\[4!  #2 P  &0              @ &_
M0@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( (%!VDX<
MO*Z]MP$  -(#   9              "  :M$  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ @4':3CK%1RJT 0  T@,  !D
M     ( !F48  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (%!VDZ=[MBUL@$  -(#   9              "
M 3I0  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ @4':
M3F?"(J2V 0  T@,  !D              ( !(U(  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " "!0=I.(,2*/6,"   -"0  &0
M        @ $05   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( (%!VDZ>0PZ[N $  -(#   9              "  :I6  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ @4':3MQO05^W 0  T@,
M !D              ( !F5@  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " "!0=I.AKQHJ[@!  #2 P  &0              @ &'6@
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( (%!VDZ(,@6@
MN $  -(#   9              "  79<  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ @4':3JN];7?% 0  -P0  !D
M ( !95X  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "!
M0=I.&3H,N<,!   W!   &0              @ %A8   >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( (%!VDZD __<LP$  -(#   9
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M970T,RYX;6Q02P$"% ,4    " "!0=I.%ZE$;N4!   =!0  &0
M    @ $;;   >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M (%!VDXVS;]2MP$  -(#   9              "  3=N  !X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ @4':3G^_ZG.Z 0  T@,  !D
M             ( !)7   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    " "!0=I."8/8Q<X!  "<!   &0              @ $6<@  >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( (%!VDY 5$6XQP$
M #<$   9              "  1MT  !X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ @4':3K9'#W3= 0   04  !D              ( !
M&78  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " "!0=I.
M-;\9C\4!   W!   &0              @ $M>   >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;%!+ 0(4 Q0    ( (%!VDX!%L$-N $  -(#   9
M      "  2EZ  !X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%
M  @ @4':3LTS7[,R @  O@8  !D              ( !&'P  'AL+W=O<FMS
M:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " "!0=I.,\(]L]@!  #@!
M&0              @ &!?@  >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+
M 0(4 Q0    ( (%!VDYWT.7(B0(  (8*   9              "  9"   !X
M;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ @4':3C)Q"P8&
M @  \ 4  !D              ( !4(,  'AL+W=O<FMS:&5E=',O<VAE970U
M-2YX;6Q02P$"% ,4    " "!0=I.B/3MSKH"   +#   &0
M@ &-A0  >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( (%!
MVDY:,LRT6P,  -(0   9              "  7Z(  !X;"]W;W)K<VAE971S
M+W-H965T-3<N>&UL4$L! A0#%     @ @4':3DEP2,Q) @  #0<  !D
M         ( !$(P  'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4
M    " "!0=I.><O/E0H#  !G#0  &0              @ &0C@  >&PO=V]R
M:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( (%!VD['S;(I:@,  %8/
M   9              "  =&1  !X;"]W;W)K<VAE971S+W-H965T-C N>&UL
M4$L! A0#%     @ @4':3IT+6I)Q @   0@  !D              ( !<I4
M 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " "!0=I.I!@K
M96D"  #R!P  &0              @ $:F   >&PO=V]R:W-H965T<R]S:&5E
M=#8R+GAM;%!+ 0(4 Q0    ( (%!VDZ?43E%V0(  'D-   9
M  "  ;J:  !X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @
M@4':3HG4;7;F!@  32X  !D              ( !RIT  'AL+W=O<FMS:&5E
M=',O<VAE970V-"YX;6Q02P$"% ,4    " "!0=I.&LZ@DL<$   _'0  &0
M            @ 'GI   >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4
M Q0    ( (%!VDX$F>?H(P(  ((&   9              "  >6I  !X;"]W
M;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ @4':3O(,DN&F 0
MF0,  !D              ( !/ZP  'AL+W=O<FMS:&5E=',O<VAE970V-RYX
M;6Q02P$"% ,4    " "!0=I.=@MHY7@#  !"$   &0              @ $<
MK@  >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( (%!VD[U
MR$.66@,  *@0   9              "  <NQ  !X;"]W;W)K<VAE971S+W-H
M965T-CDN>&UL4$L! A0#%     @ @4':3MR"/%A( @  QP<  !D
M     ( !7+4  'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (%!VD[RC0L_!08  #@E   9              "
M 4S/  !X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ @4':
M3@NFR3EW @   @@  !D              ( !B-4  'AL+W=O<FMS:&5E=',O
M<VAE970W-BYX;6Q02P$"% ,4    " "!0=I.]-!$8Q,#  #7#   &0
M        @ $VV   >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0
M   ( (%!VDXLA@O7M@,  %,1   9              "  8#;  !X;"]W;W)K
M<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ @4':3B_]E1Q/!   %14
M !D              ( !;=\  'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q0
M2P$"% ,4    " "!0=I.EZ\)$*0"  "N"0  &0              @ 'SXP
M>&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( (%!VD[>4@-^
M+04  'D=   9              "  <[F  !X;"]W;W)K<VAE971S+W-H965T
M.#$N>&UL4$L! A0#%     @ @4':3J;Y_8W8 @  V0H  !D
M ( !,NP  'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"% ,4    " "!
M0=I.'4(F+ 4#  "X#   &0              @ %![P  >&PO=V]R:W-H965T
M<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( (%!VDXV=[+BGP$  %D#   9
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M970X."YX;6Q02P$"% ,4    " "!0=I.L"SKNJ0#  #/$0  &0
M    @ &# @$ >&PO=V]R:W-H965T<R]S:&5E=#@Y+GAM;%!+ 0(4 Q0    (
M (%!VDY"J[9E(0,  )P/   9              "  5X& 0!X;"]W;W)K<VAE
M971S+W-H965T.3 N>&UL4$L! A0#%     @ @4':3F!)]#S3 0  T@0  !D
M             ( !M@D! 'AL+W=O<FMS:&5E=',O<VAE970Y,2YX;6Q02P$"
M% ,4    " "!0=I.GQ,9+-X!  "=!   &0              @ ' "P$ >&PO
M=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    ( (%!VDY"_51ZV@$
M !L%   9              "  =4- 0!X;"]W;W)K<VAE971S+W-H965T.3,N
M>&UL4$L! A0#%     @ @4':3F0)4>!. P  )@\  !D              ( !
MY@\! 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6Q02P$"% ,4    " "!0=I.
M-!C-]'\"  !S"0  &0              @ %K$P$ >&PO=V]R:W-H965T<R]S
M:&5E=#DU+GAM;%!+ 0(4 Q0    ( (%!VDZ*#GX]% ,  (P-   9
M      "  2$6 0!X;"]W;W)K<VAE971S+W-H965T.38N>&UL4$L! A0#%
M  @ @4':3J$MQD;#A   Z#(" !0              ( !;!D! 'AL+W-H87)E
M9%-T<FEN9W,N>&UL4$L! A0#%     @ @4':3C9_ 1AB @  0@T   T
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52P4&     &D :0#1'   <:T!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>553</ContextCount>
  <ElementCount>399</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>120</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-statements-of-financial-position</Role>
      <ShortName>Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Statements of Earnings and Comprehensive Loss (Twelve Month and Month Ended 2017 Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-statements-of-earnings-and-comprehensive-loss-twelve-month-and-month-ended-2017-unaudited</Role>
      <ShortName>Statements of Earnings and Comprehensive Loss (Twelve Month and Month Ended 2017 Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Statements of Changes In Equity (Twelve Month and Month Ended 2017 Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited</Role>
      <ShortName>Statements of Changes In Equity (Twelve Month and Month Ended 2017 Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Statements of Changes In Equity (Twelve Month and Month Ended 2017 Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-statements-of-changes-in-equity-twelve-month-and-month-ended-2017-unaudited-parentheticals</Role>
      <ShortName>Statements of Changes In Equity (Twelve Month and Month Ended 2017 Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Statements of Cash Flows (Twelve Month and Month Ended 2017 Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-statements-of-cash-flows-twelve-month-and-month-ended-2017-unaudited</Role>
      <ShortName>Statements of Cash Flows (Twelve Month and Month Ended 2017 Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - Reporting Entity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-1-reporting-entity</Role>
      <ShortName>Note 1 - Reporting Entity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Basis of Preparation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-2-basis-of-preparation-</Role>
      <ShortName>Note 2 - Basis of Preparation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies</Role>
      <ShortName>Note 3 - Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-4-receivables</Role>
      <ShortName>Note 4 - Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities</Role>
      <ShortName>Note 5 - Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-6-other-assets</Role>
      <ShortName>Note 6 - Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-7-related-parties</Role>
      <ShortName>Note 7 - Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Government Assistance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance</Role>
      <ShortName>Note 8 - Government Assistance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-9-equipment-</Role>
      <ShortName>Note 9 - Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 10 - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets</Role>
      <ShortName>Note 10 - Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 11 - Trade and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables</Role>
      <ShortName>Note 11 - Trade and Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 12 - Derivative Warrant Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-</Role>
      <ShortName>Note 12 - Derivative Warrant Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 13 - Unsecured Convertible Debentures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures</Role>
      <ShortName>Note 13 - Unsecured Convertible Debentures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 14 - Capital and Other Components of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity</Role>
      <ShortName>Note 14 - Capital and Other Components of Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 15 - Personnel Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses</Role>
      <ShortName>Note 15 - Personnel Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 16 - Financial Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses</Role>
      <ShortName>Note 16 - Financial Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 17 - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments</Role>
      <ShortName>Note 17 - Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 18 - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-18-loss-per-share</Role>
      <ShortName>Note 18 - Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 19 - Supplemental Cash Flow Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure</Role>
      <ShortName>Note 19 - Supplemental Cash Flow Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 20 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes</Role>
      <ShortName>Note 20 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 21 - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments</Role>
      <ShortName>Note 21 - Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 22 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-22-commitments-and-contingencies</Role>
      <ShortName>Note 22 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 23 - Determination of Fair Values</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-23-determination-of-fair-values</Role>
      <ShortName>Note 23 - Determination of Fair Values</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 24 - Capital Management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-24-capital-management</Role>
      <ShortName>Note 24 - Capital Management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 25 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-25-subsequent-events</Role>
      <ShortName>Note 25 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 3 - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-tables</Role>
      <ShortName>Note 3 - Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 4 - Receivables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-4-receivables-tables</Role>
      <ShortName>Note 4 - Receivables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-4-receivables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 5 - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-tables</Role>
      <ShortName>Note 5 - Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 6 - Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-6-other-assets-tables</Role>
      <ShortName>Note 6 - Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-6-other-assets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 7 - Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-tables</Role>
      <ShortName>Note 7 - Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-7-related-parties</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 8 - Government Assistance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-tables</Role>
      <ShortName>Note 8 - Government Assistance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 9 - Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-9-equipment-tables</Role>
      <ShortName>Note 9 - Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-9-equipment-</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 10 - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets-tables</Role>
      <ShortName>Note 10 - Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 11 - Trade and Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables-tables</Role>
      <ShortName>Note 11 - Trade and Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 12 - Derivative Warrant Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-tables</Role>
      <ShortName>Note 12 - Derivative Warrant Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 13 - Unsecured Convertible Debentures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-tables</Role>
      <ShortName>Note 13 - Unsecured Convertible Debentures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 14 - Capital and Other Components of Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-tables</Role>
      <ShortName>Note 14 - Capital and Other Components of Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 15 - Personnel Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses-tables</Role>
      <ShortName>Note 15 - Personnel Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note 16 - Financial Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses-tables</Role>
      <ShortName>Note 16 - Financial Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Note 17 - Share-based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-tables</Role>
      <ShortName>Note 17 - Share-based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note 19 - Supplemental Cash Flow Disclosure (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-tables</Role>
      <ShortName>Note 19 - Supplemental Cash Flow Disclosure (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note 20 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-tables</Role>
      <ShortName>Note 20 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note 21 - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-tables</Role>
      <ShortName>Note 21 - Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note 24 - Capital Management (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-tables</Role>
      <ShortName>Note 24 - Capital Management (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-24-capital-management</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Note 2 - Basis of Preparation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-2-basis-of-preparation-details-textual</Role>
      <ShortName>Note 2 - Basis of Preparation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-2-basis-of-preparation-</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Note 3 - Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 3 - Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-tables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Note 3 - Significant Accounting Policies - Estimated Useful Lives and Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-3-significant-accounting-policies-estimated-useful-lives-and-rates-details</Role>
      <ShortName>Note 3 - Significant Accounting Policies - Estimated Useful Lives and Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Note 4 - Receivables - Schedule of Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-4-receivables-schedule-of-receivables-details</Role>
      <ShortName>Note 4 - Receivables - Schedule of Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Note 5 - Marketable Securities - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-marketable-securities-details</Role>
      <ShortName>Note 5 - Marketable Securities - Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Note 5 - Marketable Securities - Marketable Securities (Details) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-5-marketable-securities-marketable-securities-details-parentheticals</Role>
      <ShortName>Note 5 - Marketable Securities - Marketable Securities (Details) (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Note 6 - Other Assets - Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-6-other-assets-other-assets-details</Role>
      <ShortName>Note 6 - Other Assets - Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Note 7 - Related Parties (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-details-textual</Role>
      <ShortName>Note 7 - Related Parties (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-tables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Note 7 - Related Parties - Administrative and Research and Development Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-administrative-and-research-and-development-expenses-details</Role>
      <ShortName>Note 7 - Related Parties - Administrative and Research and Development Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Note 7 - Related Parties - Key Management Personnel Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-7-related-parties-key-management-personnel-compensation-details</Role>
      <ShortName>Note 7 - Related Parties - Key Management Personnel Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Note 8 - Government Assistance - Government Grants and Investment Tax Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-government-grants-and-investment-tax-credits-details</Role>
      <ShortName>Note 8 - Government Assistance - Government Grants and Investment Tax Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Note 8 - Government Assistance - Unrecognized Federal Tax Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-8-government-assistance-unrecognized-federal-tax-credits-details</Role>
      <ShortName>Note 8 - Government Assistance - Unrecognized Federal Tax Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Note 9 - Equipment - Components of Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-9-equipment-components-of-equipment-details</Role>
      <ShortName>Note 9 - Equipment - Components of Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Note 10 - Intangible Assets - Components of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-10-intangible-assets-components-of-intangible-assets-details</Role>
      <ShortName>Note 10 - Intangible Assets - Components of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Note 11 - Trade and Other Payables - Components of Trade and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-11-trade-and-other-payables-components-of-trade-and-other-payables-details</Role>
      <ShortName>Note 11 - Trade and Other Payables - Components of Trade and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Note 12 - Derivative Warrant Liabilities (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-details-textual</Role>
      <ShortName>Note 12 - Derivative Warrant Liabilities (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-tables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Note 12 - Derivative Warrant Liabilities - Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-reconciliation-details</Role>
      <ShortName>Note 12 - Derivative Warrant Liabilities - Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>068 - Disclosure - Note 12 - Derivative Warrant Liabilities - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-12-derivative-warrant-liabilities-assumptions-details</Role>
      <ShortName>Note 12 - Derivative Warrant Liabilities - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>069 - Disclosure - Note 13 - Unsecured Convertible Debentures (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-details-textual</Role>
      <ShortName>Note 13 - Unsecured Convertible Debentures (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-tables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>070 - Disclosure - Note 13 - Unsecured Convertible Debentures - Liability and Equity Component Portions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-13-unsecured-convertible-debentures-liability-and-equity-component-portions-details</Role>
      <ShortName>Note 13 - Unsecured Convertible Debentures - Liability and Equity Component Portions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>071 - Disclosure - Note 14 - Capital and Other Components of Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-details-textual</Role>
      <ShortName>Note 14 - Capital and Other Components of Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-tables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>072 - Disclosure - Note 14 - Capital and Other Components of Equity - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-assumptions-details</Role>
      <ShortName>Note 14 - Capital and Other Components of Equity - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>073 - Disclosure - Note 14 - Capital and Other Components of Equity - Unsecured Convertible Debentures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-unsecured-convertible-debentures-details</Role>
      <ShortName>Note 14 - Capital and Other Components of Equity - Unsecured Convertible Debentures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>074 - Disclosure - Note 14 - Capital and Other Components of Equity - Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-14-capital-and-other-components-of-equity-warrants-outstanding-details</Role>
      <ShortName>Note 14 - Capital and Other Components of Equity - Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>075 - Disclosure - Note 15 - Personnel Expenses - Components of Personnel Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-15-personnel-expenses-components-of-personnel-expenses-details</Role>
      <ShortName>Note 15 - Personnel Expenses - Components of Personnel Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>076 - Disclosure - Note 16 - Financial Expenses - Components of Finance Income (Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-16-financial-expenses-components-of-finance-income-expenses-details</Role>
      <ShortName>Note 16 - Financial Expenses - Components of Finance Income (Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>077 - Disclosure - Note 17 - Share-based Payments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-details-textual</Role>
      <ShortName>Note 17 - Share-based Payments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-tables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>078 - Disclosure - Note 17 - Share-based Payments - Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-option-activity-details</Role>
      <ShortName>Note 17 - Share-based Payments - Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>079 - Disclosure - Note 17 - Share-based Payments - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-weighted-average-assumptions-details</Role>
      <ShortName>Note 17 - Share-based Payments - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>080 - Disclosure - Note 17 - Share-based Payments - Outstanding and Exercisable Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-17-sharebased-payments-outstanding-and-exercisable-options-details</Role>
      <ShortName>Note 17 - Share-based Payments - Outstanding and Exercisable Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>081 - Disclosure - Note 19 - Supplemental Cash Flow Disclosure - Changes in Non-cash Operating Items (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-changes-in-noncash-operating-items-details</Role>
      <ShortName>Note 19 - Supplemental Cash Flow Disclosure - Changes in Non-cash Operating Items (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>082 - Disclosure - Note 19 - Supplemental Cash Flow Disclosure - Non-cash Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-19-supplemental-cash-flow-disclosure-noncash-transactions-details</Role>
      <ShortName>Note 19 - Supplemental Cash Flow Disclosure - Non-cash Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>083 - Disclosure - Note 20 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-details-textual</Role>
      <ShortName>Note 20 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-tables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>084 - Disclosure - Note 20 - Income Taxes - Deferred Tax (Recovery) Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-deferred-tax-recovery-expense-details</Role>
      <ShortName>Note 20 - Income Taxes - Deferred Tax (Recovery) Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>085 - Disclosure - Note 20 - Income Taxes - Reconciliation of Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-reconciliation-of-effective-tax-rate-details</Role>
      <ShortName>Note 20 - Income Taxes - Reconciliation of Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>086 - Disclosure - Note 20 - Income Taxes - Unrecognized Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-unrecognized-deferred-tax-assets-details</Role>
      <ShortName>Note 20 - Income Taxes - Unrecognized Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>087 - Disclosure - Note 20 - Income Taxes - Tax attributes and Temporary Differences Available to Reduce Future Years' Taxable Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-20-income-taxes-tax-attributes-and-temporary-differences-available-to-reduce-future-years-taxable-income-details</Role>
      <ShortName>Note 20 - Income Taxes - Tax attributes and Temporary Differences Available to Reduce Future Years' Taxable Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>088 - Disclosure - Note 21 - Financial Instruments - Currency Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-currency-risk-details</Role>
      <ShortName>Note 21 - Financial Instruments - Currency Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>089 - Disclosure - Note 21 - Financial Instruments - Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-21-financial-instruments-financial-liabilities-details</Role>
      <ShortName>Note 21 - Financial Instruments - Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>090 - Disclosure - Note 22 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-22-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 22 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-22-commitments-and-contingencies</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>091 - Disclosure - Note 23 - Determination of Fair Values (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-23-determination-of-fair-values-details-textual</Role>
      <ShortName>Note 23 - Determination of Fair Values (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-23-determination-of-fair-values</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>092 - Disclosure - Note 24 - Capital Management (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-details-textual</Role>
      <ShortName>Note 24 - Capital Management (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-tables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>093 - Disclosure - Note 24 - Capital Management - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-cash-and-cash-equivalents-details</Role>
      <ShortName>Note 24 - Capital Management - Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>094 - Disclosure - Note 24 - Capital Management - Cash and Cash Equivalents (Details) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-24-capital-management-cash-and-cash-equivalents-details-parentheticals</Role>
      <ShortName>Note 24 - Capital Management - Cash and Cash Equivalents (Details) (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="acst-20190331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>095 - Disclosure - Note 25 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acastipharma.com/20190331/role/statement-note-25-subsequent-events-details-textual</Role>
      <ShortName>Note 25 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acastipharma.com/20190331/role/statement-note-25-subsequent-events</ParentRole>
      <Position>96</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>acst-20190331.xml</File>
    <File>acst-20190331.xsd</File>
    <File>acst-20190331_cal.xml</File>
    <File>acst-20190331_def.xml</File>
    <File>acst-20190331_lab.xml</File>
    <File>acst-20190331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.ifrs.org/taxonomy/2017-03-09/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>150
<FILENAME>0001171843-19-004174-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-19-004174-xbrl.zip
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M<%N"@*B7NDZ8?\<+ ,>)GH:8Q!"YE'-=H\+M$*N%V*7XV T8_ZIG9#1"PEZ
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M,]SM#[\'9C,49\7/>@9A_!DV*S_PQYN_46+BQ G<=J"]Z!EG*V,4:T4>HK*
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M*4IO+54Y>?_' U[87_>5B%>>UQL#E_@ 2%(/$:[/>6\-Y$>$4$IXQX>G<^=
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M>WTX&C$K]'\NP\B=K8JB]^WI_FT(GE.4[GV:=EY1_Q-BM92 #F=T:>:W*B>
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M&L/+J-FTO+4EF6U;:L8E Z;48*I%EO2?2V\ER-H1RZB<Q5(["B!P'_VK)83
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M 4T_2EO>(*"@T90"M5:E/M2Z$Z%F6"+*M&RVDFKYYSC__X1/BJ/T'L\M\3+
MI><%4QQO/P378!)5F;!*E@]-62+>T[R+ORM10D-Y>LVS,0?$FZ9-C8*%-$G[
MK"2B.;"P:XXE<6]%;G^MMI#495BT5BNEZ2YX?GT29:6,1(6P+%%$XKEL=D%E
M!9F3\L9"*C6C"RHMG!I)XA]7>"<$P$4J^[T)X!S J\]WB=/XXUO@V\X_ER'>
M,/G\' >),_23[V 1P'@3!46 @;/.(?\9P#OH(%\%5_&34[?-']P-4$V]^FZ
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M3B[S*Z2"P]<E?/V82#T95OME+0DE=DLH>.N&SA/GL,>;-@U\C]E!@]L6^CT
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M4)="2?WC*EBB3^#"AEOU_>D[ +Y %[U]6-0J05M[8L,82TCN1AF%A4LORY!
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M7J.BV37F1>O:A=#:H)EB1BEFY3OP[ BGWYLX=U7$6-?.A=;,&C%&M#F-?*!
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MD8,GI!O/?JRV]!#3-);TLXL9(A3\[7UNG-WP5TL(\9MN.+4]?%O+9]^Y1KD
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M176(H"92Q'[UU19Y!]3!\D[[-TN(H%M"@#ZYF\V0/I9TW%>(_=<YU(>AQBL
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M QLE*MWK.M-QWAB($6#3I7D(!F>3P@+.GV^R+3K*7]\8VGTH!6@+U0$%0)I
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M1Z'A&7NV!EP)JV. H WQ&_ =X,?<#9C)!@M8,??_^^6E\MX K^.5\@DL_=<
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MS!, &EGP!\4R1)))H!L52L !T\GESIX1IA42=5F"%9!W@I[@BDJ=QT=Q9U$
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M*)%?HV(PS3!5)_8H41<#D/>?1$/H4*UHO8A1E]A\&X6HT]@H7K,KLIV"X;^
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M[3Y4&R-\M8R"6EQY1@QYH789O'^S1E^" L-/MO,-0VRBE3YUV2S.YNHMF%]
MFE;F&%?DJ8[F'%?AI9I-!CL>,9S$1^>#C*<O2A>;*2P\D_5++$LLMX+EKVO#
M\1BS+A&8I:/\Q$]:0&2M787Z\TKL=X?]WQ#/$LV=,_D3,Q_9I>#J.*<?$?5U
MNB2TIMQST%N4[=H&T[3UN@ZYIPB>Z(PUSB_H;1\?'<\8^W?'1\<SQO[M\='Q
MG+&?^.+B#TOU=0!%+W'^)57:HLI[MG1\U=DIT[LD890!4^8(-D9+O')$'NAM
M!2>!B!_D^N7ZY?I;![P#T;P75=VALO&K)6@2M'Y ZZ-[<7AD]R/]^IEIS'C$
MXR2W6)J$C>HK"\Y8:_O\<^H:SQC_6(AIL^O3[HO;&7?K]Q]WYS'(/C3L/QM]
MCCB?SV<2Y_WB?++H$N6U,/GL<']QG6U@*=F]4Y1/9\=A]\[:3^?"\<EA6]70
MPS+$ RRALL?7O;%?O3U>-*!PU9UTOOB;C)OLD&>/O^GU;=OH:^31G"H>+QH)
M:LF&=TU,BYZ56Q7O-1>DC]22)38!^'D0=R9%3"LBYF8N384&^+N47"BQ^/RP
MV*\K]Y:MF(.=Q,18 "QTL-UGI>XN)K=23I_&WI!8E%B46#PG+![#MZN4 _'5
M477&.]:2%[A5=WL.,WM)#6D0'Z^=?=<3MRU&-XT4\)$0)@E:1-#KT=VBR>&V
M).C "#J;3R4YSX><%Z H^Z;GP5GADHQ%9+P9-XG3MHRNWJ(6%<=I?K6IN<>>
M-@YUB=Y:C6G1(. 6&',(,X;O1N-%DP.B(R)-$K;4$AC-[YH<G$K"#I2PMXOV
M33Q)UJ.3]6(V;=\3VXNSVL:>)&?%;-K19#HHO5K6]JJU:1%\^NJX.HX#?&(3
MOM=Y*\AIPTY0_OOEI?+>8*;^2OFD/L#COK _?1PR]4J9S5XK_\ N^Z^4A7)Y
MV<K"*K1_2T/XS)N^+;ML^O:[;5U2.T :PJ3R-O*]=7H37,[_?S4W+-G,[3#/
M-1@;B%R3F.UL6#K-([GDW\D>0B>P?HEEB>56L!PV?1M61ZSG@7S9\^W(/=^.
MB?M.&K)44_+-4S@:5FQW[A$F&R?%'9OR]FT2,06=U21B"IJ>2<34[$=V]@A+
MM <+<9.'N 9X.DK+T):T2ULGW*?9[4>N7ZY?KO_YKK_?ID/9B'$M,?[!=7T<
MWXHS=%V<?\1'"QMB+))B6SB.*)AQJNALZ16C[?GVOVAV/"7;O33"?:.Z78G[
M)KA?7$O4GV"QBL3\"3)]CZFF!QH02\?^QASE2<61Q!ZFGVJFK_,I\1;SE*UC
M:XSI8&(X]D;9^DM /MRW G1;#P<$"@K@K\Q,Q^LBTGH3EF=9KW<]OI%X;,."
MNFXBT20>917NR7+C<>IP:^C73TDM&<_1XATK$EK6JUR]>[;L(S=A.TYUD[QX
MB<>P<.1N(O$H\3@8/%Y/>C29!^JQ!K%M)VS5G]"A3ED'_[-EC(5TI5JI)Y-8
ME#:<Q*+$XEDZHY^9[G/7$_0D'1<KANOZ3'BB%-9UXM=(?U3N0HG%P6!QTOX0
MAV>)1\F-)\>-P_1%/SG@:7I,^63"VC;PHXSORKTGL7@J6&PT:$RB4:*Q533.
MSWPV32W-^NY/W]B21I7Z,Y6J+#=;&SE<?1ZDG#,>[YHTZI)XE'AL&8\WY^F4
M[F^!=L@1JM"?!^K8 %K9'.]HUK/L8"FI*JG:G_%]A*ZDDJJ2JI*J!TC@(1&U
M2L/9^-___9.Q<MS+E6^:K]X:KF;:KN^PCZM[L/'P;$$U/U@K7"Q^N%_:OO<'
M6'F.ZX'=!D;@>SX5434_V2Y=[]Y;^J_&G[X!M^\^KMY9'OS[[CO@W%(]V]G]
M_&__2U'^._^=OZBNX7Y<O8&GX-KIE;%;L< <L?&9K8"._X/MB2['UY?C"?ZY
MN!S/+F>3%XJA_^V%.YG.9N/QW8N?*U%_I6X,$[[TJ'FGQ9X4!YMW!A0W_F+<
MS WYZ8 FL]AJ5SFC3K,]",NKBONJ:5O;SVQK ZJL!X41M];94NUV-W8X:N97
MB_R6QX=VO!T$B/>:"A^43VL5:*Q\L+0KY:(2%V6[5?-')59J.PHXD>D%5WW@
M&]L!'B"!$W_J2\6@8U7Q*[BM/@J_ZF]*;@!ZU2^^"[^[KA)[IZO<:UYB.1?_
MQR>2,E7S/?9ZR;27R@7*8>:8.^63ZGB' %!W!]XG4;QJM/ W]F:K6@:CQ2;T
M4<YB7UXI7^%=,1PA*71[8VB&R<,';T MZ"K%#PS/51SV8+@8;="Q!LK0,.-,
M,6V-R*;V@:[Y]7R40-@G4"/,PB"'[BMO0+@X]A84&VRR7]5'U1PIF76/>@#S
M?]]^30C6A.3H]M7C^UE6J ]15IV .,W9'JZ__!>#O>79BJI8_F8)H@HVK6.X
MWUQ%=5T;##7<#4^&MZ8]8UL/-NJ]K6/80#@# >81.JH@7&.^IH59FO@8O$$#
M3D"; BOT'QQU$]M]KF]Z<#O>Q%Q4DH:[IF,U;!CDH?1\,#1%-4T#NP"X="=>
MK+-'9MK;X%*TOK:D(C3F>\&[$(;P%L-!1'UCJ+(S8H(H]Q_?T2)\#?#ZCH,/
M%H] L1%_G\/ 4,561NH6KH MR3-3$:P_KKXH[VU;IY>^=?P'Y5X'N\N@I2"^
M\7N\'>[BCWKP36ZFVLX#R+F_A&2'5_+PIF;[( %0_BT92'(FEN*J:$JJ%GRK
MJ+ZW!D+\Q?0KD!>.IV*5"5%OK3XRN()9/&T6YY$+C6<"$5$E,6?#"8M?@IFN
M@>P)1'8A?D0/_SC5#<HD\L"6!5;R.?JW ,LNH.).8=\9""Q$ KUP11)Y"[\!
M'@"3(!BBM6_X2F%]/83D$Z$PV"V .]T(EDBP'A$<2H .\,29F4""C<H<VX=O
M0I<K%YE;1A[7U6 ET@D*S;5*]AU*"7 3X'(#+ <5)1&PO$H^ 3BGKA!7%GN
M[QYQN[K ]J;])%+9Q=5()3#N-#KF8%O\ N23K8 GRT;IC4CO7I'[S+@,C3W%
M6P-'//"]G&I_0I!L13K@-DP'A)T.!M8&GON%NK.-P%0EB0V/ Z&%-Z8OX2P8
M]&#!#^D.;ASH9#<6N)%1(]B'Z+[P.T_]KFB 2P-502#A05PXFH%(! B"]XUX
MB(;?;Q.N7$*6JJT-$-%<C)$^ XR[@0):!M8S1@5&BO I\(.+:L]1X3UTJ\5
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M!_F4#SIZQHAII&G/&C.2923+2)89/LL,93Y*T#^/@@ E637'[ M>,KAFJ.W
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M]XU\4*.ZKU$.DT1^W\B7@]([2<0YS4'9<OUR_7+]SW?]'4CDYF'V0U"I@=7
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ME)*&NT:FCV_'3 S-Y29E> F8?F"E@(VUB_:0R1Z921%/G:UH)RX9;*A7@\5
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M%\V@8-(9[&R>0Y$/"SG6*!1<?G&=^T)HP?-(8?_5T)G;$JR2D,>6/QOEX%@
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M]0G?&)Z8AM!_0S^PYJLCGK#&'=ALV-5P&]+/N;$B8H=; CJ=&+6]^!AJP&N
M'ETP]_W07MK93&2'#>?<-VS+F4LU^H47L6?8GV[],B7^0\O8T00QW\0B,0]J
M$H1$8.#?^V(Y!B7L/US92'M'';;T?SXS/? :CD*)CH%O1$)EQ7A&+&7+Y\<H
MA^DCXH?S.=-"3D!LZ\_0@C/LBOUY;CDZ?V7@$X_ZE,<%^(&+/E+;73*0$)V]
MQ HLQK)[ZH"*M/EG=!-VJ.4'C#8@@CXOX6WL0\E/1/=]U[!T=J1[LH('H#,
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M3KI554[U1!^Y;ELOD(N,TBQL*@M%FU&<HHES5&3J-XI3,'$.I@+ENS37DN7
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M[)5[6.C;1I-43<8:5!K'E+;[PCT#%;.TKVETD3)($_6[UV3I,COL,E^(A5K
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M!_'HCD=W/+KCT1V/[BG*4G.=&$%;(PP:FO'4D,DXZPR/WDU76CF+X.2T.2:
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M^AC_<?,G\_6K&IL#:-)4DZ6ADIZJNML<($4Y+^U+TUMW\X"72G^0+D9KOG7
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M^*@;_!UN)2UT Y?0O'A_[YFH-I5@@3;$Z@HJO, [^#<-/3JNP"R'9]"Q*"S
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M;[3S1DG&]<0X(H;6H]&QP<'>4.HSF*Z?V]C3@0QT\39A*]GHO<6/X]"XC,!
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M"G>6;5M/P'?(?]P^+LL\5MW !_6\O21X+Q*[/R=1+\$'D,[R<1Q/]8L&:4>
M2GG^B4X.<F.. \IW9J!2SR,^&RO_NS/AEP#)8'=BL)+OTJNJ-!T.QL5=ARZ;
MXL5*K/S96YBE=G2VX.+8*<G67\!Q1S+?JO O#P#8L<4:Q=)=O95F_;NZ8R3C
M1#2,>N=^-"&Z4PM=4G^"-FVKH5%SYN!SFF*26CS=D\K4.65T9-JC^$E*4FX_
M:^*[04+:!<<ZK-$X=O".EV ,JO?)1_S[<GS$C^R.N^KWWOF"@[U_UT.0(_>$
M$O_H#09C%5 Q:&1':!D3?!3-S;?<OYVVFG"3&9 S>]_;LU]^B']F8>G(LT);
M3P^'8Z*);?HE\11T\@!H,$,,<1M5S\CZV?V*/@<C[_N9C^.L6OA=,/0,&(Q5
M';!_,4,'/D#_&<1)?,X."N?8D##?._!GE@#?F^HVDHV(IW]8:@/;.UB*A$UM
MM6*@T I!'%3"-D/8Y%''#G5: 3CR^<CGF01Y%Y'.R1%$,7X"88O>A!U/<@4I
MP(R]D\ZQ8RF5!,6;< R11!)K'K@LCN]M'-N._%VB]/[ U:(>3?#1F9!$X=)#
M&LG--9D'$V0?:7LA4E(W@?24V/3;85R#'1"*J,CYZ&;0@*9NCQV+5T!;5;A#
MN8RCKT%TWP6C/1D[8LB,!G(<<+79:%)_V#92VO2Y$T5Q(J6;8M'DM(U0"TQ"
M-8!CP+T[<)EI;1L8-?X?)L?876)X.IWU[I<&9/+$4SB6TE^M.XG/2S?4)S\R
M>-P3>PJ<H",ZKJX2&'.D !T?OMMA+"W<*TP;N>GT,OH.8/ MH22E0A1Q\[^Q
MC2CH9)@TB+GZ4B1F-(8F+7S6 !5Y1('6RU-P/??!LJGY:,;^0@&A _R?Z719
M^'- 7P8(_9N.QXC=NO35&#,QHPV6IP%/1'/\%DS=SJ/EL4L%^!Y%@Z/O/0..
MBX -@%-;;V*&N!_"3._!\DRVMAF!HW&F"?UY"]_3_==JK V!QE&S^&R29;MG
MS9+S>\;CE^:(BOJHZ@;KS:'!+_?8P_ <C*[S7-U@S0N9#$=]#3CC)_Y&\&#%
M'&VN.!;6I&'O6O1U+/G\/>#I^<%!OQ?2-=CDE^2VT;P<(WA]BN 9EQ/!>Z_:
M6"GG8-$9V]TQ1O)&-Z]T86PB'^0/):$+<_0M4^NZ07<<D13#"2\I/?_CNS07
MMV_>?_YZ_*?VYA6J454(%M.\-4#W@K%!O^@(+^'7T2^_M?9[>#U=EN/$'C,3
M?J&@P./I<@'5V'I,\=!IL(^Z%A9[QN.%68G=!\O0P,!%!R<)4 R"5QEC6P)S
MD-$6#0<0A[@!X#@H/_8,G(>+=C&%+U*3RJ(\L8I6W-KCP_% ##1:?)K[2,='
MX+*OMH)UX%[GX7B";A&D8S@>T]TL  "& N4LC+D>+#2JT N-/6WB&W9AQ89?
MPH"KB! ^9G8R5K0.K+@[:^/7:(6,5DB?K)#]Y5@A7\D]#3F'SM-HA(Q&2%F"
MW)B1SE#'YR@]54*2U,?4$R7FO7K/(I-AA"Y284+#G$R+@)+LV'7>J\\=OQ)M
M-!K$,[VP-&?K'>=*I N <%I*MS!V/Y60"2>6B$ORV6M6S@DD,ZS#/LA-XPHK
M8F,20O^W&H3$#V!H[-4M\:CV"59H,K,#JZ/ 'H%?()VUP#Y!PV>KVIIN/:H.
MVJTV5H[2WF=V%'OUGWY$,<7?1RMX\\:)1JX,:QMTB;U53553J9UD=%VSV?TY
M4F)%ZR\]4W>/FUJ#-%-8_-HM>/\0)VM9[)@D+SM^W^^J#:)4%B<"\.5:F'9-
M8VDR7ZVZ?>>K">JBR*7[0,=!C4Y%*6LFKQ]OV74_WMB.UW<7R;P<%^DM:Q[&
MU/DQ*7RPX$GC*(/162KO+&DLU(4&C@F(19B*!MYPH?E(JI%W>-'^I!!"+YFF
M]EDS!C9OF*8'_LVQ#BO2GX'^!]T\[] TN+\;Q7*.5289>VO@R7KGP]^3IFJW
M;\^CH5_(' 3%5?BMQO[B6D(P-S_K6ON!#%:58)!'U0S+H:/D1@?V"6MF5!05
MV4>B.MT[2,+-P=8-X4P'@ED49VOK=W2 O&$]C0;\F!6(6Y&+U$G0<SMA60YK
MXUZG+=<H^'3:/3N.D1Q-EFJM1A^^?.U856PF'>O%XV7Y>+PL$PQ;&RK6YWZ\
MZ9H$<C]H\%KX$JE*1[OF=U8@C7^=">?@C8[)HN,2(2Q 92/W'W6TU.D$>RQ9
M#2=N8TT&KB$.<Q7).1/'@NX'ZPF'GK)J9;CL)DV?I3X?5()L'U1<>0A@PJW?
MAK/M@E6(:.1&5B[[?TT]C;%R4+*"!<CZ 6NW/8.E[L[!X2G[KVU_)+(,(;:7
MX$SX=XP^387%^11Y;'^\T'&^C1:Q']L.,,FCLXJB)W")*.W.( 6ZYITKD'2J
MX5AQ<8?1K0>BW<=B%GM+(T;8=D27S6T-R\'.$VJ?! M;<3W[E$DWEM6-3ZQ@
M3S^NJJ5M#*R"CKV!96Y9K2%=GGL<[),QQB<AX,+M#9$'7HF42]87!#&(:^#@
MJXNI^)U)#NT,0KZ'2[(];OP)(]4L_I<5#)OXG4-A?2OK]GKJO"JE\[X:W(AG
M4P>9$BU=F:-9Y KZ*@\'D-Q)*3^&YL;0W%!#<_V/S=W$$@YG4,Q2QT+F6$DG
MOV']"W$?Y/>X#T*;#Z:_4(?9WV(B1 ?(CV',,8Q9EB"W9M>&X?_Q3 )&(34,
MEY..WX[F'W@[O] YIABQ.KO(Z3J>F2%$)AC_L/U1H1B& U+X-@]S-_W4K_M\
M8*-<:6?3E$7N_.T&B:42W^+Y8SJ)5DNNO33]F::A#PTO>YWLQPHG.X(\Q+WU
MP;^WEJGI?HTS>U B8H/1ORD;8:!E0>R\.8E'4,&+DPW8D^A'=D2E<P"0-O@)
M;&,+1B,=%TW#\YE##V[V4:S[:7%T*_P)N1$\<&IK)DQTP:$_2C<[KIK8Z\'Z
M"V(DP,8S.F,L^$W:L@]\XG3V_PJ4\>@E\[SDW34<?[E8 !LU<9T!@>XM)XX3
M>)UF9.^(\8%-Q8GH<::JTN[(=9K8H\^14>VYLPR#S??'?$=82>B/C8S9'L<R
MPW"D]\$F+C.R)E>Q%. 9#-#C2/X@N\ZV>N'&+]!)72>-L8B5S]DM9X_$CKVF
M<R&*/99=.XAXR6A>^](O%<W;!]7A=*PS.:C!-!2'9)J"8P)@U&F9!/D4U6)9
MBNKBKQ/J*#^ ,%I^I6[) --D)S)B/4Q_5<]^O1%\^L1XK2/ ?V/[Z&.9HC-$
M8\3E.7)+E(N%.?VON)Y)J<[?7E[GZ_#ZS\*$7=O"_NV+C1,\S^V+3![L]MVO
MA(_=IPA5T\,9S7W($%X%GZNQ* R+;Y^QRT-<G>>BGZ5S(ZU:6\:5#C!C(XMH
MXT8D@_BDTEU$Q^F6JDD+DR/)8(.)1-K+BT.U+SSY$4P9Q]0/IL9VPIUJT 6H
MS@,!C\?P&>?FO-FR<S#1'J6%:X&<#IGACF2$*;FCPW:Z@_/*<.XL?!-L&Y,N
MLNU<W423L)M9QV]/YN!UQT_*AC7[85;VS!G9,Z@EK(]@VR>,Y^.^#<LTNIY?
MV/U,.2I8F"8.KA;CA&!N@N[$E7;0&.?SB^XDUZWL=5.'YW-#F-&?_^M'?6<[
MTYUG&*_?P34U+"RMN=U]]?;@ACS##^!RT (4T[T)$W^?_;D=[[\#.4PJ&W[^
MG_]#$/XK^V'?@F4<[\)=''_0;1[?U.^_T5T>-Z86_N8MV^@1>39M]@,'Z O9
MP1G\A244T_EB.A?QQ\UT+D]E\86@:S^]V$XEY<7/A4YMI^YU W[I4G<-*6RC
MNQ:<E/YOPORYT,UBT9M$&"459O'?>6?9&K&G6\LPU(,#CPI^>E/&500O,"NV
M<PQG<$,WS'G,C-X\Z"Z9(LB4$Y]L]9">LO5&\!$(G-!?P$3\6Q !9@?.7@O_
M3MU8_X\S)?ASEA>=&85I^2U =$#4_.F%]*(P^M0/;P+_?YP'[2!&4X0_X$WP
M\'L;KK6&O(IE>?;]W4MIOIA(\GHB*<JKG C@6OF!,Z!-FDN;DV%!\8?"?!)^
M@S<0KL0SI!_RZOA;5JVI\9P<6+.XM#H1ZO+$GPA.%B-P#E^>IU$K>DR5S_=<
M9^HC6^U,.S[((I>;=Z;B%9WI0AG.F9:^G-(U'61Z(')_3[+.[92OZ5 7 SK4
MTM=S<4TG*>?F&_MUDG6NIW)%AZJ(J<$'_3W4TM=S>44G*:VOY'JNKNA09?&2
MC=OU-9VDM!C.25:YGJ?"<,&AY\2:"CR@B4!E9=XI\^!N>:N.$F^87)U)$1[D
MC86V6WA0X\S'>W2G[#<1EZDU.[49L ;1HBQXK'R,0LA+I=7-?N5FUFQ5(_#U
M6\R9?E:?$:YJF3-'E&1Y+FUZD3UC*;([R]#:*Y"FIWFZ 'I06VM$,9WT;6=K
M#64\FHJVD/5P@@'EO=>\>W.J9#@L!,ZIP V^=(3S+"G9\GQ4,AL;.W2\!4VE
M6V,/]AFGJQQKYKOYB=<<<&)[-7),OS:PO5Q"9CA.K6%;QIZK?FOJG&;7Q]4N
MK%>!9S=,5<@EK>_XG;&VI5[QRHA_#YBTVBTK]LU*\H#=G(:DP8AA1^&XT-#]
MH8!X#]T<YAH$#L%)'T3,?GB5TK#B,):M%RNCW%KW\A:3^;).X+=UBHTG6CK:
MM9#J5)$U3+'6PJW%@;O9;FWLRHLNX4A'&SHSDVLP7:\839Q/Y%K9^=9I,YX2
MSHI=K,Y]2%W8%\7A?+\_&-8S(8*CX@1;7QC<$9/L<)BC+P]&1BLK#B9SI8XE
M,4J##@YI=?8CZH$]\!NYQ_E<Q]G,B9ZW@ZIKPJ.N8C/SWC+9=&5'>&E:+A$D
MY=7(=26Y;K.I8Y"V2)AZWG^34)SO<*9-'4TEDO3&-"@4R?.SXB@G/I&#ZYGE
MS(2.XKU-7YG:;^O4WJW!SMV2=620,S5\])Q#SFLA%:Q:^V8!\7%Y1&;E1B-,
MWTIY6Q>,7^I]G;IHR\FBA5+,]N@[<LL9N64Y66[:+9ML4EIFU81U,D%6*3U"
M-K<>K1\P?LL;P03N,BT913.83=K9LG%.AOXO3]=P$SLN+,8]PH;JN]4\38$C
M9P[@78,;S@9J?T(GNP,S,:.ZL<1(FU.ULH7K;+^0+=$?ZY;:BO)8:CO@4MM%
M5Y6V$6ZK7%Q;5BZ5F\<[UNJV7JO;Y(.K1(6V*.OML7IV+$,>RY#/5C':9O"I
MVA$GQ$(>$&@C-A-C.#LKMU(W6J]D:B1?!?)U6$*I**5*L[ZJZ&;AFEG[:/V=
MM#%3Y5^E4F7!0Q993\FZ]AT9VCG+&,8BQ$9C1[[N[44)XGB>]3W4U5A2&@7N
M5PM>9]+B$5RJC?.4MRR\A8)VR_JN(P*WE+9MKLBC4^%:\,:/-3+9U%O5R5R/
MQ7-=E!:LSWU$O:F6H5_\B,*%.&YY.==DW56O#<CQ)F4+N[$>L-2SQGK \Q:_
MQ.(*-&]7S)GN*'YW,L:>^[8A",VQ,*[]8\I?U]F#PKB10\[=/=)S!NF->5RJ
MB+)93=),=KBX+DF^;\C:9*PA;+XI4*DU]GDL.+TB9EDI_:]-+E)N&OVY4 %A
M=A%@LH;PO6KCKDOG,[&_8D=BC7I!93'6"PZX7E!<=U4PB#-E<8\MZX'MK&;P
MZNJMW^F&AP701HS>PI/JT/6<CKHG@KJG^Y3A5W>JHV\3GYT(_F?9+EU<]\H6
MOP+<7[[^X2]?5FU;-5U'>+(\N'0/ZB,1[@@QX8^N/M40"/T1'G5'MJI'-XDF
M]LR:M-Z;P8G%VZ9 U.U#L D:@-$M+5+0/1-N#$.P/)<N'*6+>ODP;2E,!\N%
MK^JJ83QC+W8 $[X*7['S7)"?W-KMJ+C-D9<IT4II=KM[_WW[H)KWY(OJDK?T
M)^?6?*LZ#R"I\?_>_\L#.6T0!FX!D:N1+:Y/=7YZ,97]K:*+U4:2-M+ZA>"9
M.ONZ[E@+25Q-MZKVXN?%>CZ?Q_ H#UPK^*V.^*U/X[?AX3>5E)XBN$2L&(*K
MDPC*<RZ"BTU/$5R50E#D(=A7].+G)TWQCO'1D[CGI[1Q _VA,[_X8V9 &!$3
M)&P=*;*8+V0>$HJX3EVS;! J0UI"'@"D"ZZ\D\1YRY"6N-@ J<*#5!:7'="T
M!*1++J3S;DF:>]< T!4/4&E=F:1PU]RXXZ-'6/&OM];^8)EX%>'>TL_>?->=
MZ4?'\0A<U@-:WK^3_1VQ^4)"D;D47LFRG!(3]#4- 4H=0_;O(,]^&EPNG>5Y
M2F@W">P-N'IHUZG&9U4'.Z\P?;E6T'*C+-N$^ MQ5?#&M,!(/ TJWZ!92?*J
M$?+FO'[!-3?6$MRP.B_?-'EC-EPY+Z))4>_*G("TRI79\*5]S2MS MBJ5V;#
M%4EK:9V2^DU"7/K*;+CB:"I*\F:1DOQ5H,U[/U>ZB/)F*=5Z^ZK!2[.<<TWM
MY5)9U9.#)P"M<&>6<Z[I7/?.G "VXIU9SOEF\G(CMPEQV3NSG'/EYU29KU?U
MKLQ)IV\YYXI#^&%>CU1+:B=NFKDR2ZX87(J;5:N YER9*( \X2=\=UZ;NO'3
M"]?VR(L?&P*JZM58YL2A:G+;"8A+7XTEWP)#<5[/M/"!S7G]BFN!22M)JJ=Y
M?1>JD:NQ6G&E72/:) _0"MIDM>)*O :T21ZP%:_,:L65D>"RK-J$N.R56:VX
M4A*TB3AOA!?R7L_W^R5Y7>;M-Z;V6V1Z>WEC<,%7&(OU8B5FPA)_:S7(3KIV
M"ZZF "IME.PK< (RQX57N43[H)NJN=55(XA@O@7P@'. LXJ0\Z^WAHIY'L[W
M?)YT"/;< T3OR",QK -V17VVK7_""T]Q*/R/>YG$].TOAU:**M^)O=4=\MG6
MM^1V=WO,2M'TT"W+3/&)\04#OA3G7VA*[W9'?\-09'_%ZQI]B_/!LCGO8<3#
M+]V:Y/@UAWTO3;>/GSY$"2>ON82;SU:K&-D*X=T>M;Y9AS.3BGOU^T:J9AGK
MVY-5@5H;KC,*U%KWB5H-,E9%4G$=87&F](I4#3/6@TVJ7$1^0 CHM>D3O9ID
MK:K$XD>O9BNQ3\1JEKD^6)Y=GEP+?HP'R"7UB5P-\E956O&#]+/U!<NM#_IC
MA9NXF',##T"N2Q5;%6DE<J,DRYDR[Q.M,E@KC@G/P#X5P&OM-./@\8S:,N!%
M(?H5J_"(5K8B):FVEGGF(]_8SH"D/N21:HH,-SP%>8XUMU*ZA3R_8B4%>8[N
M6_(%5 >0)P-$*<AS-%%=R-E.GW?ZHZX14[O!.E!L95+OJ[-]%/*H4OA^9QOZ
M].#9Y/3UJPE6%D]'P(I%J3L$*XMAHV")?0"+<6,4+*DR6*9#/MC6GD)QISI$
M^ZP^8^3K&X#BJ%L*UI^Z^Q"4,Q4J&/[KV_,!U77JJ3=8(WU/MU4Q'1VIRO[J
M6MN_&2$^&ZIY*N0F\DMSQ?DB%0BM@FI+]$H7''9"+WZE[T9*A2A[1*[TE>R&
M7/STTRI5J-0C<J5++[LA%U<#IA,D/:)66K!V0RU^[FV=2@#WB%P-B?H@M8HJ
M$/RS0B1;<.-(O:560Y*K$K6XRK&WU&I(+5:AEL(57KVE5JG^"GY]\N!,I3PL
MN3P_- ,GKP>!'Y@:F%F2AR0W^#(P8R(/1VZ8IB43@%4;D+>64[/K<S%?<V_:
M4E&2\B3ZWG(PE;K]&^[%$-?S)$&KPU3JLO)ST.(RR<BUR%0")#[;-7=PI2["
MAA_U$Y.5FZ=!TE7CQG&(RX],QT!18LV4_ H+4=RD>M$2+^3"4ZY$*>MK+(R>
MM:OK9&&2PB],6BY2:C'KY37Q4FW[63?O;VC7_\UVZ^T]NDWM'3G8 #2UV>"/
MMJL[[&=3^[@_J+I-#3U3^]6V'"?Q%"1'QN_]9%%KI.1S1S>DK(/77[^KKF<'
M%9B?+/<W. 3[VX-JWIKD_Q+5/HT^O^IA:.@G<8?O1"E"2QWP]TXZ8;52>+;T
MB6!KT\C^ 0;!UK.)]M8RZ2 80/8=N8-+ [\\S<Q+?AFXN$CV'5R)6*A+4KZV
M7XO)@NISW(\B^-67$_S\8S><U0(9ZL@+;E*S27F1=QQ\ V"MK)+=@Y=PT_.(
MP5?A:VF1;9(W28SZEXNOA#LYS>:N1:MJ=-VR5;WF1V&6F_9$_;K/VK,B)7-Z
MAKN@Y'EMZC575PX-^SJR8-VJBBR.;$W[C]_*(LFIGN,K$0IU29KC<HOM:;MF
M6:8!,9'C>G.C4KVF0FEQP:<--[?5JKMQ,B"]X@>D62CQXL1!'BWX"9UT=W3S
MM*A] ?E1\R68W=W"W]S5X4?>&[PZ-^X'X*G_5@T/6X@L[_[ALVWM=/?6ID-Y
M:_CQ[XBM/ZJ8Y/^3S5Z-?.!4A;^<$QA?I,?.E4>L#=(4%\CU2,.UQWY6<K(@
ME4GSJZJ;SF]T$N^MR>91?C3#!]SNCLC4S5NN^*,WEM(Z>8]+P-4H2J72GGQ/
M="HOD@4!Y\*H5-*4[Q%.E:10.N,1E4"(/Z)52MJP_3BA$QE;OGP 0C2($#&)
MK1J@WVZTO6[JCFO3#S8Q<U9:\&WJY3(U^?@$*+4A+S.3>L&W>!=S*27$6H:\
MS+#I!;]N1%929E0'-"\..=^8ES:I.]PIR?-GURSXEK<LI6;6M@UY1OGP6[!;
M[RU;1W/F"Z$.RF?5#@V93^3@>F;0!@I6A.9M70?>^)78C]C*23_UU3L<#/P*
MN##FUJ:%H:I!JT1.&,&RM.'RI"2FA%GG8N#L] &-RX]J=2TF,PJJST\?[@63
M4C,9NQ=I/: /OQTUF6_K7G#V@#Q\'WS5M49L33QCS6KPJYM[FU *G28-?Z)>
MRK$9JF"N2!E^3E_J6F>U)I,KDH:_3""UL&6PXK@B:?@#^KJF3&N2N")EN!Y5
M.A38<R&<AR7?TDW-,.^Y0,W!DC^Y14[ERGHN&_.PY)=-I)83]%S,Y6')M1U3
M76L]EUAY2/*C[74M0+!&K3WYIG[W_\[FBWJZ>7][(*Q=LF!(_1C]4[CAIQ/5
M&M6 R8J,18'AR;16@"D3QU;X(:.IF"J7+P)/8P3-F7"B<.-%'1 T/^RL\).P
M31.4WF;XZ#<K.L&:UD#A+VSR (^$:\>^4"]"MY+X9>-\K,I!V!JBN:)"4KA:
MJB@SU84O5WH ?#R.Z@J^,M%SA:\H^L\HN5('4..Y^J</PB:J0]X1]O\?V]ER
MRA]N(BZD3=+>*@I4<\B46FG*GSTR%954YJM[9,JM+^7O3UFEG)JS'$P)7/A[
MIM;SI+U[[G,YM9:4ZU&OE%2?17.X?/+0V/8GACB1F97%_.Q*:TOBU3.2$JM9
M9</8Z&9K!PQZ:;%9*.(F'WDN$HWBG^6!-X'_4DG/R OP%^<@?99*+_#/<NB:
MP'^5@[^\V<P5<=T_])L[_GB_69?H^Y5FK 39 ?N>[M,(RI$_FN K>_L\_;F*
M_,CWUS<Y9EC27:\,8KNXKD'11W[,PY6_;2892^LGKB)<[%7DQSQ<N>'10>!*
MA3C#U?\Q!U>)'U@;"*X@OY:1'_-PY1?Z#@37]502(S_FX9I3&C8(7,4Y:J+C
MCSFXRMRXR4!PC=I?FRF.9^7CRG5 I53=7,^1;71-,[_Z64RM,APV70IMZU2X
MM=,EXRB=H'1B<6$4K>IQNN[1XFTWC.)3L>&U57SRKEG.-O0A7+/&?-W$+M4%
MOPY''H)8+DZ78LN"%Q67>9P%I<+B9[FHN /Y+&B=%C]+[BCE<^*3=\WXD_X[
MOV;!_H[;G=]9YV3LE6W5YLF98;.2DQ7');$X(Q&*&3A5UY%WB$AQLZ;J#)P.
MD2E@S'#WF7>/1<ZMX:\][^&M:<M>R7&9E5-)F?[2H)AM(C?K0[2!2,5-[DO^
MJI)I:B38<(ZU@"'##8MT?Z9YQ\/U$N1ULI&AG>/)'1K>G>6RXO)I00&<B\>Y
M:5',@%DUR[*M85-1%BDKODN<7C4QQ&,N8!&MFG6#:Z.2=US\R5+SU/B(_AQ7
M30,I*IR;M<%;PZ.@D=.L+=X:-E4M'?[VD_2*ER%R:Y'@3;,A_MJHY)T6-\O<
MY].J61@4*87ANEN='%5Q/ K)EE7##E1KV%24+2N^%Y5>R#-$;CTM6U8-^U.U
M4<D[K1(;%/MS6EFM<A5ER[GMEH)X%)0MY[9;"F)35;;P[9;40K,A,FL!T7)V
MLZ5P'?Z*;[;T^+!JUO-&T>=)UC,H@?J2I>&4=&O85)8L_#%VJ7V00^36(J+E
MK*JP3+O2BI_)[O2TDCLC;Y],8G=9ML=E6D6A[71%")&-Q-DH4+! KUE>;1Z-
MJG%?_FA'498*LG;/3K1 I)?;X]_U<>:<#'\"I+*2YWTZFK;2W@I_>OMJ63!!
MVC,"% L'*\W6F3:/1M4X,']ANR@M"R83>W:B!4*_W)'U71]GWLEPJ]/6\]28
ML7.>3&/]GPD3CR]L%LO4%J!A$"!'V/#)D)/K+QC[[QD5JGIH?%FUDOND?!J-
M))])5)4*(?-%E;(LFOON2HDT%-M1FHVS-H] L: .=WEQ7]"H*BOX*X2+AAY[
MQI %1 5W7W#7AYEW+EQMUJMS:6RH0Q)]_AB /MLT%04-GPS<L%6?;9I6Y!2W
MSWR=&C\Z#$H4$53G49ZE LS\-@<,]C1[,JYJWF,3U8WC$#J*^5?+TIYTPTAO
M+EM28VQSUAVE.0#31WP&.,S3$_L5_AAM.2.8Q'WGQ=/S-WU+S.W)):] 4/X&
MSX6<P;271M(\TN2,[%ZF%@^U19H^;!ANZO;RIS=U=WN'0,_"MY<[NK/3V]O#
MK;= &OY"\ YO[V8 W%;X]O(7R'5V>X= S\*W5^)O]^KP]IZ/I'FDX2_VZO#V
MMFZ6E'U46U=;ZH%B'CRQB]][KM;>+#+2=%=%[CRR<37Z9I7:']T6V8[[1WI%
MMA9$0@^T_>")75@DR/P)&>)JD8[J716]\^B6L[^#;I#MBF[MFE!]$0K\R?*=
M"H5A$[NX4."7=8I@*5PWO7/HQF_X$:6LHLN!1D7Z(A06_%6QEQ/5ZXU0R!E[
MN4@OE;\R>N?1C3^Y;[&4NG(?6@^V]$4H*#F;0"\F6-@;H:#PS>"ETIEOW%-Z
MY]&-6R\L+C<9Z[A:%J85+V$4H<I#!-J$MS@?YPRPFG>MW/+@Y"N3#N'<-,@W
ME4>[M@EO<;[A;SQ;+=(U<JT>1QZ87(>N-IBTB.ZMY;C.1W/KV3;1"O7#_&+9
MMO6$-5>_/']2]\0GNWJG&[K[_!GE*DYM_L-T"#R5:)'QS>_('3 3_/+D\2RY
M*P1 S&;$:-*XM(PP*T4+B].*XAO%L'*S5Z.(U#TG?F=7J^>4T1;:#6/RVS/[
M@7!]QN3N;6Z&,8LB4O><^&O?ZIV3OZ#ZUCQ"W2.YN<K)P:1+W[D8=8)\ S*T
M<F-)"^C4E:1<P=+=R9U-JG+G+ #R&;;Q69%O@&TK5Z:W@$Y=.9L3M3G?R7$!
M7LR7%2R6]B5D'L!\#[<S@$LT-0# .1M/NB-P"7CY0Y4S,C\=T#>W$1;@Y0O+
M^N!B8Q'UMO6=3K0;YX-NJN86@VI;5W_479W4''"2MZ261^X"0#6*3YD1"ALQ
MI\VL'^B4:4G:B%SNRF@5.]OQI/")8E!3O39 X_Q6]@V_C+<-&G\A6Z(_JJ#7
M*T2@1'Z+6L;DK^0+JX"T3ATI %%Y'&7T?21&P8]@[CAN@Y)MS1\7E[4YI!1D
MC2-61L2M^:FY53X/=(]7&5FWSDF"*7U#K$P#_#IGJDW/T"HC-]?\*37B@N<C
MUT;LD9@>\2VH8FZ6Y^@F<1QP$>] 2M/&7.IJ_:);FFW=JY\\UU:WQ'/U+6#Y
MT=P&65[5)?>6K6.BXPNA2<O/JHW0^;D8NT"&4N*?/8<^402KDB&C<_O<9.#Z
M>>N,+&V#I,B8MG%N4G M[LXX@A8)GYL,7$.]?8Y(11#/2PKN6JM*'('#28KO
MDFUN88=8-?S;%L!5II2(_+AO>DI)'N"=85EX8^I*K)I*:@OT F-#N!WG;<.<
MQR/\>ME&>*3,XMF@$N/6AJ-7[6<ZX)H)'R#ZWC+9+])\__'3AZ@,RIGG1LO]
M,K'BK%$LCT438['YM1G*0DP/4>X$@X)KF>L)SM:7+G-)SA^X)JU3T;9."%YD
MXW(]*=C(/F7^1#1EL9BGPO(U2-?65&A^"^Q27'*$8,L(%)OJS&U"K7?\[4]M
MEOB!^GG*V^Z$X 6&+DM5RQ++PIA'.&X(?:FL4DG1&I1K:RCRG"LM%@K/X&@9
M@6*31N=5BYF; K/JA+YY3H].DY9$HZ;RO.JRGK(PYA&.Z]0OEDIYDR"X(N4S
M)=*"N]CF9U':R.G,3O1])8$Y*8,6_%S$2I;E4K#\/^3Y=]54[PFZ$)^)[5BF
M20QD&V*R%HI:Q@F PY])I:R32ZA/0],$_"7D/<#/'QREI))DW<!?(@T"\',5
MO22F-K]V1O\2\'-E@)1RP\Y!_EP1AK>1*S<V\Z2YT ;\J1U5->\S?Q#(9E'^
M.J2@:P7!<A>>GQ.7DI9Q7Q L)Q&X?O92+"\0.CO!$@ARDV2KI&[L"W[E9$J.
MOU]>HS:"H&6[8+?OW^\/AO5,R"_$)#L]*S1:3M;DE'-6PI0#9JL8EQ(^_*%6
MXDHIK^[.@W$I:<0/1(A*:F)/7S$N)9ZX48R,0H>^(EQ*7O%#)J*\;)&I@TZ&
M9&U*49>/GYC)B)1$7E8*C@+>7D[X8"4G;<@<.'Y77<_&$("I&L^.[GRP['?$
MUA^!JH_$KSE4#1ZT7/%-09V"7?CS_S;<-YK^*#CNLT'@&[IS,-3GUX)N&KI)
MW@@[>-QTI^YU W[IZGMX@TF>!-O:JZ;_5T?_-WDMB/.#^^)_W[MO\(DN*R4D
MAG%0-4TW[W]Z 28:_MLYJ-O@W_X[[RQ;(_9T:QF&>G#@4<%/[/GLT<(W^NY/
M\.XO^.X)^\5$^ KDV+T1]KHY9?]]TC7WX;6PFL\/W]]0B 0*DAV\C^;AMJHQ
M50W]WGPMW%FN:^TCG]2"3SX]Z"Z9(L@ E6D]V>K!Q_F)Z/</+G[7T-X(/@;L
M0:^%7PQU^[<@ M".9>C'O[O6(?SC3 G^S(BF[@]OS#OG0,GWHZME0!-[L6G9
MP'FMOQJ. M W?WJQ?%&<* %LR(<!D;<$HX1-P/NG:MLJ&&1&A.EU&B^A0-_9
MPH\4@]_59P'9GT_04[#P3WH\R2Y/\AW9TF"G(*TF>*2K\4C[>J2%U$D<E&JL
M(%-.D$^]ST=E)LMD'U-7:^F'-\+!<FAVX+5@8^D6J-0W0DH[@)M%GT7A%.DQ
MP!L#9&,_]X$E?W3M#G1>G7M1@K&EFHQMXY_H^WY7[>V#((N3.#^A4=0P\'D"
M@3$@?J C8J1?6)Y .1JT,21';AFY9>26D5L:1[(;=7C*=&K3C.R:Y0O!\X^&
M[*$F+L9(OI%\(_E&\HWD&\E7QSP Z.%]][;EF1I&JRT;T+J_>RG-%Q-)7D\D
M17F5:4*P@+2\^($/X2^JH9I;(E!(_^,[AC;@=>1>-['83[!VPH'8NJ7Q:>._
M14R^I)2WGO>0^'D:9.>6?>SZ]&./-F.A2))O"6*5G+Y-/%PW'X!D;J:=2M\P
M+1:_R>3W=@DU'N(E'F))>9[_F!8.,M^':_\HEY/%7&GA.)LBV'@KQUMY?;=2
M2J<\>GPEQ],\<9KS37^.LZ[Q_2?"F&5Q\UB"M54(FF>C47W*HF[<&:O,3;UB
M(7!V5E(-)FJ1--4SDS65RX6HWE9),AY,#P]F%&O!\2B3]4H>Q=IX>\:#&=#!
M=!&_Y=]LW=0(%BA/%[.-<H O^M7.4X3\M<!^2Q_Y_CNQM[HS&I\UN>WE2NK&
M]GPUBH"!B(#Q8,:#&0]F/)CQ8,:#Z:N96292F0;N=&-&26OT[8-JWA,@NK!3
M=5MX5 V/8(V!%K86"D_IA@P^U1LJ?BR$914^+O/@;D.IR\VR!F.W1K",&]/1
M&3<IOFJ^:RCBK3\D'6\Z[WS%R5*LX[B>B6#C@7+#Q?)XG!=TG"]KE3E4(E=.
MA&D\Q8JG**[79S_&LX6D"W!-9IDQ,;4B!<95W]FXI58[HEW[;5WR-##!HDT?
MH>6\Y>@XC([#*#W.*#V"<2F#DQXCDPRE\'Y4,:.*&57,M4J/5CWG)NC:3?*F
M7I*NY^F](AT/8TITI-E(LY%F(\U&FO6K^J+AB&IB%..'8PG%@0!T.)N?SJ[$
M&<B-6*L5QI&>>E W%FNI]W5IL\YGZ^:MUO:H6]CE;9]36G%[2[QMV(YO6V0=
MA<EYA4GSM0 ="9.15[KFE67SD=91\8R*9U0\URA,YOVW8J/.VX]T+TP(J@]V
M=!5.Z7TWJ84YNJGOO?UO1'6(OQS-@?_']_YA KJ?+'.+)3"&@;^Z!8\-'FW>
MT\]S-_W\=8/%\&R_D?/1?+2,1_J=>]4  />W._IUNJ:7_@2__$T%\JJN93]_
M4+<(Z_-OUE9UB?;1_ K'>F=;UM_D__7('=FR3;Y_A:C3Q\!'[6\/JGEKDO]+
M5/O&U#Y9;OC;;T\6_M8YL<<8_L==7+5*;D.J0[GD*7PB+M  &,=\_WU+FPU^
M5?5Z:VD7<X6[QE)*(9,-0%4P2^R#PU7L/#"GLM0JF"66N &8W)624S&U)+=Q
M<I: D[L9<II<)]TF-7/WI0&4W/V.4W&UJ@8GW#?/MN$:OB-W[D?3<6V/"2 V
MQ8B_'BVZB(QWRB=6@I=^>8&=:-R#%)=BZF+DOS\-+EOR?K.WO,2N3OUX@.)?
MOUBV;3WA^O1?GC^I>R:R_S = B\CVEO+I$%%$&_P5G@;_#)+Q"ZBJ_*6"G_;
M\7R>ND@Q0%-H>/BNVUT$WU^Q"XMIC<3.SXA.2C/O!B66J$1_!)*JVC\]!X7V
M^T=\]LT.U,D7<K!L_-UG6O])*?*[^D_+OK4UT+?V,WWQ-WB7HVX1>)\B?WU[
M/A#G=I<'ET.?]M:R#Z@+<0^@:VW_OCW@CY\-U4S3]N.G#]%[M8Y)J>]WMJ%/
M#W J+WY> FN+JQAI*Q*/=PBW+NAIMIH^\LA;SW5<U<2^NA)G$KV?E0@7P(&;
MFL 2*D0\<;'B$&^>1;>:^'9&QG779%3D/I#Q^ #Z=7:)^$LR__J"3P3Z!)-'
M/MOZEJ ]S7D2)17]$IB<QZ\Y['LGJ22OUQPJB>O-6I'D3%IE@](#&H"!78$&
MFP6'!JM5<N?G $CP8),*C+"8SSE$D%:X!WM81/A@>785&BQYC+"9KP=' Y"4
M%6@@2AP:R'.0".LST" 76I[X6LP7R^4JT])H"]P,6SJIDY8\!I.D-<KB+L'-
M\.%2X'*5PT):K+H%=TE]@4T.N!(7W(4"YH#8,7&3KF<2VA5/X )Q5U(CQ(U^
MQA<$& 2J:@%W;9ML>!22%VMQDWFW*V'<>_)5-&MXPD81UV#87!'YJII$/%4H
MR3R3Z#()6-6<XLEC:2,IV7;UA=*OHBG&\TLD:;Z0AD:_/$PEKBY<BAA]'PJJ
MITU 2>$)%64CBN)@A,IIZU&6N==?7B_6TH P/6'*R0NNHEC,-^?!M'SL.9W4
MZR16+$H*SVH7ET5MO*K!XD8(ETXS=D0XGGU75%R>E6KIK&='5"L57>\;U?(S
M[TE<N8'-X5ZM.'Z<&W J2YH)XD&WFSF/B+*7.(JA.P#S:R"2QHG$8YBE)!:Q
MP@J V"*N^8442:4M<FU.\)PEI>_(9E5C1+$[.^?E%V*D3H/'>1V?!KAS.Z)7
M2-V7DLP2US5>S%?ST[*Y()2M(EQ.LO!OVV:S/BU:^H!P*?$B<:-OXF8NRIG1
MW;XAG%_PE4*8Z^X5B/7T =UR HN;+Q77JV6GYUNQUBA]NAT9X#S"G6226G5!
M#5#L;"X+KYJJ]Q0KYZZLN24(XDKFU*+T"=M2&E%<\X)&(AQX 9%Y;FS+J4,^
MMB!)%_W'-M_<EM8<\[6"N=W(<9Q*/J^YUDE7QW&J'OJOMX;J.*%P?:L>L-N&
MR5+\RUOVE%/24UYGY-D=^M4\^<DK6&X2@U\*8Y"6__W X*8P!NG;WP\,WMV8
MVOO"6*0K2AO"(I)![.!"I&55 30B(+:/2W'&2B</^H9+\6N>ELF=X1(D+MY:
M^X-EHM5ZNV/5T!01QL,^:J<PD129?RJ2 LX1V#>='4XC"&WX-W^U%F5I)2_:
M1FC5)$++#.\U0$A<K.:2HBS;1L@OZ&L(H26?Y<3Y"IS.')>\N1-"LZL9A%8Y
M*K/6"=%&AQO:442]TP\6:Q%U'CZZ9.^4]>'BW6)K.2K#8EU5Z_DFV55U I3:
MD)?H_P3(N?U@LK).MBRV#7F)EE" ?,V#'/[</<E+ ,[M#)[*TOJL),_M&P5O
MC]LL+-*>R/J0@T7A%JLQCX$F R \T)9*LMTZ\JI24*0]8'@OCPM/N,"Y+SHE
M<&1)XG;P+J5LYN>CBX+;)@_$=/1'\M'<6GOR"]E9-OFF?J\G%Y6YPF5U1526
MRRQ(\\!I /XRTE&9<^7Z%(-5BS/ 7T9&*G/NK9B*HKPZ$_U+P,^5\=/5,O-:
M=TK]?'&IS/F"7IPOY\E&^XKPL\;S&J*$>T>7R3; ] NK@'1:F$O<:R=R[EQ1
MF+Z0+=$?L>2P"JW$%5?LBMEW*?76RL"=I)H8"W#$#:(:L 7-P2X! [M8F7-B
ME(+"G=TASS/O</R5E: Z/> A5I#<%%3?#W!Q"4YKP&D,9>NFYFO>"18Q)DZ^
MO-1<F#57*F1>P,3+JP%8:B+,FB\CLH^O"0A+S8)9<Y6OV!$)3XR!67.UJYCI
MAA2!\#@*I89&XA).43)%6?*E%2$KH)BX%%.43&5Y"K)@=!4X1S2$0:,E;RW'
MK1F1V(@Y<YT2@/)AJ -M;@TKP%=QU$\9$++D210$G@9H$(3<_"F P+,G6J,"
M$PE1$"KJG,^VM25$<S[8UOXXJ(B&_O6=3K0;QQ^ 9][?;%W]D<Z_RR00G744
M^;&-L4?\N5SB1DY&+BJAED<?/)Z@2RZ#!AM$7%P4*A>15_Q(!Q>)V/MK +H&
MOR6\T_!C/J 2UQZED?@<HG<#[U2)@YME\7@.LLAJT1VXDASY,8^\_/BGI'0%
M;XD0^89[ Y75.A6P;0/<4G'Q#=_3 ]\]J>O; +=4,'S#O6O*7.R"%TI%P#?\
ML*"<="_:)^V)H/>&ZV@H\T4CT'Y5P?F^M8.1JK>[<'1L9"975/U\!!5()^/E
M:=9<7U-:<T,9)?1^.X#G6XYK;ICC[("7NK$K[AV0I'FN2=($\&<YU1Q+.%X%
MTN-3/2$L5OSQFN<YU9WN_F8Y-97WBA]LR<SC'-];!J(R^GG%#ZYD9F:J053F
M0J_XT92I*$J+9."B,HU*0,3//Z2S)TU0*/]RK#;\F(0X7ZR2,:<B$.'-"8=[
ME]6&W-@PW_B;+L">RK#^\L%I /XREV/!MP:GXF:YX5_7]N O<Y46.?8A=@ED
MB-$NZ%\"?KZX7*5"J]U3/_^:+OA3^/&:9KEJI>&'#[G/V 7D8B'ROSS]D#V$
M)"R64VW[&1]*!U'?;+?>WC-P/\$[<K !#]I@!'^T7=UA/YO:Q_U!U6U:FV]J
MO]H 7^(I&%;*^+T_,#HL;^6"2Q_PP;.!5)Y-X"^WNYV^)>'?3ZP[D&5^CB55
MLL(%XJ*)B\EPSV6IMX(DY=Z\5-3[*BEZ7/11@J;\$D$Y0Y5<(57AKYJW#49V
MQZ@:I6/%4K%!D"J/?[AFJ+S)4(:-\T]8H-Q;_JFC1/BV4B=*I/_$+:]$^.:;
MF,S<7R=)JV@1OE6II"I6KY.J.5J$3U5^$FBQS@B"7!!9\ZC"USCS5-%K2U1A
M74N]9;8:*F?!KRWI2N7TG+BE5<Z"6P[3F<KI.4DKJ)P%M\"G.Y73<ZI64#D+
M;LW2SY(B942Y+XBL>53AAEQE,560V@95UKUGMCHJ1^*JG&47@9W^$[>\RI'X
M*J>+6]Q_DE91.1)7Y:S$+LSQ_E.UBLKA=SN"PNDBA'0^LN91A:]RE'D7]LVF
M]\Q61^7(?)73!<OUG[CE58Z<TPDVDK2BRI&Y*F<C=V$;]9^J552.S%<YFPN_
M_WE4X:N<S>8B<M9E']6A/N+7(7>A[ =.^0K*BI_V'LG=BB+C-U=>1)E!NQ0O
M5(.PX,X>&E -0C4ZYC!>WEBCBTCX]E>I+?A*[2*J%_JFU!9<I781R>+^*;5%
MSHR%C#KRD>3U7;<%-_O?B:'<4XKG$$SAZC\YJX]X> F]_NJ_)3<B=AFE%'W3
M?_PY$!WIOR&3NXK^6_+[Z+/ZD$:2U]=_2_X<N"XB%SVE>![!N"74LMR%Q=!Z
M=K&_^F]U7OTW<,J7UW\K?GW"2.XV]!]_8J@\OXC*I?[I/_X<5%F\8G&>1S'^
M".!U%P'0UG.=_56 :ZX"7%Y$243?%.":JP [J<\;.+VK:, U5P,N4@M&1I(W
MH@&Y<Z1_7DI=F-4])7D>Q;@:4!377<0I0J.A Y5SUAQ0240K2'A^QJ4+C5H2
MOTH2E9O@6'22KRZ)8A4)QA\5)<F=Q U/S@)?;+B6F[26.K6:VQ<9_.&MG99"
MMB4R<H:]=L%K)?&K(C+X$\$62J=^1HLB@S]04Y8[M'KR0.16NTAKL;HM[-G;
M!]4A+<Z-Y<Z[7/+G7<HK)852'4A;1KO4=.@E?^Q"2F#T&.?\!0GK9=5BP<9/
M)G=R+,]4Z!;*_#4+:VZBHS"4'TU7->]Q[P%;)=+NQ5[E["X3,QI+JH+9(KXG
MYDBO:_--;0A/W#]N;+ ["$_</6XT[5PT3-T[;O2I,(1</=SN!52XYLPJ7915
M&]@NT"^E816NJ;1(;5H:!OJEIL,K?+LJ8\C&(/ OM2%"R9EK-4CL2TV15[C*
M5U+26>/&\?]"'*+"0^$1[\@C,2SZ$'_[6\W1VOQ\E[R64X/D<R&I"7:IB=HY
M:2-EF9JEWB;8I09I\W,OJV7*.VN9V"6@Y@<K4NY5=Z0^,36;GT%822F)W2;4
MZ>OXUUO5)?>6K6/@Y0NA:9//JHU7GT9;/I&#ZYG$STOYL1<'7O>5V(_ZUO_4
M5^]P,/ KIO;1W-H$@5 -NG0NW6@F5;6[:E_BSI#E+HGDLV^7;)"6$V=A ]ZM
M:)P-^H!LQ1TVM<7269#E6:C-(MN:-,.M7,&O;NYM0J)!YBB>%:=V]T60Y>+)
MEV%\"S3I? Y2B%6C"C\KF2K6ZM:8.B]5^(/DSFJLG9<H_-FC77H+-<5G'*5!
MF'1Y9\)?2#L@RRP/07X=[X#D4QZ"_,G\PQ$U>?CQA^37E!JNJIM$>Z_:IF[>
MQ^-3A9+7TH(?DIR*DKQ9)*.RR7>6A^ET6(8?)IRN)'F5IMDID!Z)Z1'<8_6K
M]4AL$TGZJZV:67O52X2]9)G?8IV6/%P8:H&;FPT# "OFFDK!4")V!1!Q-6A6
M/*4UHI4 F-_JTQ6\)2)6 "]7'=*!U0T _!' LXGCUKH\BSD?T,4J+752;Z\$
M8(GH, "8$_MK";X25PG@XZM-J44"E@"0JUO2\=XVZ)=[4P \?DEQ:K9[ 0"_
M/EBV"W_:O]\?#.N9D%^(278Z^![;K>T! !5JRY1ECFFD)'-F)R%H .23%;0*
MOWALU2+$3>2Q%G/^?-"%F-H*?PJ6^K"7$E<Y4SRE5+]?^["7$F4RO\ISL>D>
M]E)2CC_!4THUGW5-]A,2D#\,$XRQI'53%O9OZG?_$S>V[H!ACL+SLTT>=<MS
MC.<_3)MLK7M3=X@&'\5-L_!_;VVBZ>ZM_8WL#Y:MVL_O]-T.Q*VYI9EPW;(_
M$_BO]@=^R_I"-&]+WA'XA$V?TH@44/BSET5120W$/2.>O29Y&>&E\ 6O(BV2
M F"D>'V1J_#5A22G2A]&BM=7% I?R8FI=3<CP>NK-R5',TOSI O2+XJ_A\=L
M703A[8-JWI./)OSRB^H65&T1(E0MV2@'1&X<"H#@"9M&@2@E__B5/?#U-&]P
MP:A-MQ(@%UZ#WA[ I2X@OR=93.V(+@LRNSH?S:VU)S?N#18Y;-4[@Y2Z)US(
M\\+B\DK) OX$0(W@4,JFR@FC*ZM4YJ$K%$I=4G[)[%2>*TD/I<-3*(["DILC
MF&8JH3,<PHE;S)]F"M]3LF1E611L5:/]R^X#L=]ZH!Q-][/ZC-^H%#3CCT,3
MEXO4J(R\M]>#]'2LC#]';+G<I-B[(4#1$(GF,O,F?322_\P),Y1 ,0EVLR@W
M7)3 WWJ1"B.>#^<"-XD_L*$W6!2X95P!UN%AT+_ZQ9AVM5Q SI3C93E$XL T
MBTB!# $_I;I(%2(VC<@7LB7Z8U7=(J[X"1DE-5+HQ/MK@WN2U.(J)QE31!'F
M0/N'Z3%?F#G!S@?+_O-!WSY\LB(>+FW__!)ZSGQ5\[OJ>K;N/ONS,%QB?P,?
MX+V!>;?_2U0;*_@^66[XEV]/Q'@D]"^GA+',-\%2@W6J('4.PD303Q+F0;==
MXA/M-&F*[VX<#&FB!$@0YX/EE2$.7^ F\^M#(4Z, $GBZ+L2M.%G2N6A7JHH
M 1*T^:I_+T$;?F5+*I<Q%-I$"9"D#<KH$M3A!MX6<E*!#H8Z,1(DZ/->OW\H
M01[^[JQ45<I0R!.C0((ZGW23E* .WY5,65]#H4Z, FDSQW2?"]*&ZW/*XE#U
M503_3,I89E$;D!M)E%.S!RZ%..Z358PX?#=?3H7+>D></+SXUJVX3(;7>H?8
M7[\2Z]Y6#_  U;BQB>KX@Q ]T[6?;W?OK+V^U8U3P:C%DK\>4-PLQ:'2X;-M
M/>ITP-=I O#GCHCS=HT.3!23+OD@+BN^/5G?'BS/44V-R014-B?I)?$'3*1*
MVBI@>@9B)9FE$2KQ)P(,E$JE60I=[>?3A,HI?$DU?0R#4L7YJ2")^&'%92HD
M.@P256.FVR(7+R>?M.(ZV+TF5DE^*D0EOM*;I^K-AD&E:BP%OSA-+/YD!&F9
MS'4-@U@E6:H(E61^.C!=I3L,*E5DJ0>;G+Z!,G^$PCK5"C,,<I5EJF)TXM=K
MK%.=;,.@4S6VPNC\:6KQLZ=*JJIN&-0JR57%R,1OAQHJF2HRE?Y8X KR@_+*
M9IA7L"Q3%2(3?W[M(I5/'P:9JC'55_W[:6+QQUXL-E>A_@I1B6NF#Y9*95CJ
M2"M,H9VF%M=.7ROK85*K$$^5)-.":ZBOL2)YB&2JQ%0T\7B:6GP[?24OAAE]
M*<=5!>G$M]-7-(XW0#I54W^%XL.+W&$"5Q'W+$8G?KG,8.E4(4G'M<#7FW1E
MZ3"H4"9%Q[6LUQMQW0(3_$EH48IV\TAL]9Z\_T[L+7SNLZUC[R:=#WE[P%UE
MCO\G+(+]:-(_W*D.5H$_T\UFMHV]:OD+TK[@1YS;7>PM"/:MYSHN7!?=O(^^
MDE*/?NG6),>O.>Q[:6)^_/0A2DV9/^AU/ENMHI1L@0P#I30(KPJ4Y@]G%&?*
M?*1T)J4Q*EB>UHLYWTZ;+961UEFTQEA9%5+S2T9& <(CM?Y8A:M%KIDHS91+
M)G4N4;@*#,3J\A*)DM'+DR"*Q)WF"4392)=(E(SVZJ0"YD<9E[/%XD*)DNS8
M3A*%']$ HFSZ3A2BE2!)@=D.">J(_,70M:WC4Z"?@3;YHUE$K@%[8C1+&<@/
MNMW,F4:$H51QM''K<.?/Z$C*='ZII;B>S2MKN@*0=TZ8_,D?21$VYUL RDQ>
M7Q)A<M>Q+F2QKYR>/T4D>:!\.[>_!PIF_X[H;LL*2<KSMM85;9B"H)^!-N4$
M9(X<F*TKFC+]I4TI&9FS&4249U)%2Z:_Q,F?NY0B#O]250_-]9<XI82QM.'?
M*N"<OEXKNIJ@/&DV*'!$)?KC)\M4M7]Z=&7N>^S==6YV+K&_D(-EX^_8V$8:
MV_E=_:=EW]J:;JKV,WWQ-WB7HVXI2'X:[-OS 8-&>7 %B2$;)T7B=[^ZUO9O
MAAGN]CT9*5KS.Z?%F511@18B:><G5LZ?6[60[>@G74JI3I&_E5F<K2K&R_M)
MEW)J,X\NRXJRKY]TR?<L*J_S[?@\3RDS_BC7WIYG))G0?*!8S%,4:[$:00I#
M?!:BG+[U8L[HB)E247OVFR@%/,^<F>0SJ:**Z#=1EE2>;/*(PN<4,(Z5BHF6
M?E.%2MEYKI3E3]" ^U-1R@Z */E!K9Q6U+,3Y8.JV_^M&AZY<7\GJN.QW=_O
M5)=D*#I^0KP+UT;FS]N>SY0\C54*R78)MNZ48/SE93,I3T3UB&"K3@F6$T=<
MY$6#^D4PNI>V$X+E3,WLCF!?R%[5<:OK6Z"%K6Y=3S5^TW<@,3GE.#VJP8R*
MM.]WMJ%/#T"+%S]O9E)>7J\TRD,@8<7B2IE#0F6VOCX25JN:E&.AWB@15[,\
M ^4B:5BU&E+AD' ]D_*,D\ND8<4R1Y%#0WFVR8O1]I>&N=CRA#]<NBXYAGZ4
M'E%F<!"LB4B0+0<C>2WR]R7E%U\?02@,ZRECJ'R.(&?J['RVD@N!7]YZ*8E1
M)%I[.LB7,RCV1'2_0XS*E?SDQ%WRX[AGP^A4>( _DK5MC#+6R)>Y,)(BI<T&
MASX8&].ES5S:G.2Q0L(I ] R62Y)B0TEB@,JKC!I*K8&:!GV!D#3&C $5)QO
M%HJ8Y[?7I6@90"4^H(O57%)R*_ ;I&C^]9+B6V,3@,Y7Z_7\M!ST 35T\^_7
M.\MR3<LEO\$_A._T5[9ED)]>/+CNX?6//SX]/<WP+3/+OO]1FL_E'_'//^('
M7_B?=\$S_^D%H$1,C< UQX<'CS>LK?\IL.0!X/\(EIQ)P;<-]8X8Q^5G4ORI
M\'W5M6P_'9<$^L;>"I:M$?NG%_/@>ZJ]/8& _XD?=V!J3(-'!5_?V=8^"QKK
MIQ>[Z5J:BG'XX%D)V+@8RQR,Y5YA+#>(\8*#\:)7&"\:Q%CA8*ST"F.E08R7
M'(R7O<)X61[CX(%Q].+?+2(IDX"Q]X$0!K=\B[_=&_!P\QXDJ#G]X^N+G[\]
M$.&M:JJ:KIJ@+/9WN@E&&?A!K@<4?!9TNF)0<-7O@HV+#A]4!]4%-J##YS0/
M_F0)JF#CXEVTH. +@@O//(2-Z?R'S?[KQQCR!7A WF >(\T#T=^7Y &I>1Z(
M04-Y8"E-Y6I<#\_*Y/KH[WN!\;)!C#,E6_3WO<!8:0YC#"%F87S\?4F,EVU@
M'($FP'A5^8PS]77T][TXXT6#9[SFG/&Z5V>\;NJ,%_-Y)E='?U\2XU7S&,>@
M"3!>5^;J3+L[^OM><+7<(%=S]/&FJCYNAZO3^K@Z5V?>X^CO>\'5Z7M<G:LS
M_>?H[WO!U5*#7,VQN395;:YVN#IM<U7GZLQ['/U]+[@Z?8^K<[7(X6JQ(L9B
M*UPMIC"6*G,UQZ[>5+6KV^'JM%U=G:NS(P:1W_>"J]/WN#I7SSE</>\55\^;
MXFJ@7G8<+/+[7IQQFJNKGS''6U2JVM7MZ..T75T](L#QG92J-E<[&*=MKHH8
M+^8BAZO%JER];H.KQ317;RICG!W!C_R^%QBG(P+5,<[.TD1^WPN,T]YB=8RS
M,W&1W_<"X[0G41WC3"LS^OM>8)RV,JMCG&F!1'_?!WTLIBV0BOH8GL6)"(A5
MM5,[9YS63M7/F.,MBE6]Q78P3GN+U3'F>!)B54^B'8S3GD1%C.7-BN,?KZI*
M+KEYC&/0!!@O*F/,\9U65257.QBG)5=UC#F>Q*JJ)[%H!>.T)Z%4QICC2:RJ
MRNIV,$[+ZNH8<R+TJZJRNAVN3LOJZES-B=ZNJLKJ=C!.R^KJ&',B>ZNJWF([
M&*>]Q>H8<_+'JZK>8CL8I[W%ZAAS<HNKJMYB.QBGO<7J&'/R3JNJWF([&*>]
MQ<H8RQQ]+%?5QRU4N,6@"3"N6-,'S^+H8[FJ/FX'X[0^KHXQ1Q_+5?5Q.QBG
M]7%UC#GZ6.Y1W68,FMH8KSF2:UU5<K5B9:[3DJNRE;GF>(OKJMYB.QBGO<7J
M&'.\Q755;[$=C/__]L[VIW4<?_O_"EKMRV$6*&> T:V1H,"HVG-H;R@[VE?(
M;4W)T-I=)X'3__YGYZ%-\] VH6EC^Y)6.YRT3>++G\OQ4[[?[&BQ<HG/"WQ\
M7M7'M:PMGF=]7'G%_+R@7WU>M5]=3XFS_>K*);XLZ(%<5NV!?*N%ZFP/Y+?*
M=5PPDCBO.I*HIXZS(XGJ=5S0Y[JLVN>JIXZS?:[J=5PP=CIOT/M0*W?S]1Y(
M02_SLFHOLYXZSO8RJ]=Q09_KO$%O^:W<S=?KN.!Y?%GU>5Q/'6>?Q]7KN*"7
M>5ZUEUE/'6=[F=7KN* '<EFU!U)/+S/; ZG>RRSH5Y]7[5?74\?9?G7U.B[H
M@5Q6[8'44\?9'DCUL5/!\_BRZO.XGA)GG\?5J2[H5Y]7[5?7T\O,]JNKCYT*
M>IGG57N9]90XV\NL7N*"/M=YU3Y7/27.]KFJ[R@O\/%551_7T@.YROJX8@_D
M_.2D8)?B2=6VNI[=QMFVNO)NXZN"?O55U7YU/76<[5=7K^."?9DG5:FNIXZS
M5%>OXX)^]575?G4]=9SM5U>OXX*=J"=5J:[A79B5N_GR&]=7!?WJJZK]ZGKJ
M.-NOKE['!7MO3ZI274\=9ZFN_KY3P=[;DZIU7$^)LW6\L<3Q"5>+MSKNVG"#
MX=VE;BR\WIH(*7\1%?/9"^*<#/_G.X(><4:/VGPZY>PH"'%UQ%^#H">)8-!'
MQ#LB[(A&03R/9D&$2/F]?Y[^VCK]17XP<X3#QO)<1S_(_.CJEZ.SD[/6VI H
M:R0XTTF"YR<IPMEOJR+<TF$0X?3H["*0XJRJ%*U:I>BPT!E*"S[PB,.^+,6W
M7T].?CDZ/3GZ#&5VCZ:^ZQT-Z.+[HU^/_HH_HV$^SA7)6DJQT\NJBIWK!(]$
MY^3;SOWS32<)(O^<?:O)0;_I),8_SWX]30EQ3P?")V)^=';Z-2$NM!+B]->K
MD[4ZR%:&44]]=T1?J5"MB K%)7]"F1N=X^SJUZ-$'GIYFLG\Z)4+><WY49"Z
M49Y8?E,=F4SDB0:4>;Z*-#DCSNAH,,_<K[Q!'C274R*_Z'CSJK5QJ5=MM'YM
MG?Q21W-]I9,.RIWKH)0R')V>7OQR?O7;\OE'IMP/@@/+F_CGQ>G1)Q6)AZ$*
M,?? /Z*V[N3T0EYYE#U)0OG,-?.43QW[+O\1'@_"GOZNHJ &D5%7HZ!&=19^
M9QHFX_@C_%?XE?_WK]7/PDLMS[GF&F$\\S574%^H=/Y$H.3C&17':\HT<CZ<
M4<SFRID>_"D5:A2Q^#!SF]%U?F]?W^;=9_"+?ZT[8^)RMY3QJ</67W"3\NDK
M9D\:?YHH=QDY"^IK@Q!;7\%W-UWA^>G+5]@+$@7WJ3D24;CE0-&B<,NK8LK'
MIWPFIDLGKR./OSJRA7.';W2ZVLZ[=/CKF'_\J]WY]S_^D*/IT_/S\].KL_BF
MEC].%6#E6M&59D$>YO3U78^((*'0'\LRQ&=9?I;Z$66C^"=169<7'B5^$!]-
M7#H^%.E74M*7&]]U&'7==A# E"SS:=S("P@^)@^^RO5 ?<\9DHG;8<,HJW1;
MWM68"T<EZGBD$_FO44^63OX[^+G\6VH6I=[8?[TMJX..%^GH$A^,Y&W\G$V<
MH1/=X]'(D=]S9?&EH1=1N8O4^<<?9.AZOV_0*+R[S*4JWLMZP?_QQ_*;2>TW
MW<,"S16=C,>^+?LZ<]FON@[Z2]?#H3_U TEOZ4S0H1-4M?Q0ZNN&?[-19RH[
MZB+(9<9&?PHNL5@]B^*^[*ET=TA=0B9YKJ8IR->!_)?VA+BN:M,ZS).C*4<.
MG:_E <]5E^)\].E,)L'YO\MQ$5NF<X)C]NZ8DN7<LF*3][U:QW"P60[NR3,S
M#P8VSL!!9WBE=F%=O:S;$UR6TINK]+OJ.G?_\YU9<,TP5>]TYGM4+(["PII9
M>&W])N^ZH*KA9Y/\?.\+YJBU)_E)]_55=KK@;$.='3R:-]8W[&V2O;^3 0]F
M_N>PM<FV+JQGV-DD.\M/HQ1QL+/)=BZL9]AYOW;..0[#;39<H6S@MR'\8KZG
MB?AC2@>NQ*R-;?[$Q(R1)L7<BS'FQ/2**:;$#(HQIL0D25E3KMVF_4!GGL^H
M_FY8OS<Z0&>EK,#ER[B\1%Y4^X&>J/B0O=?P6\&K;O&AZ[&@U(P6=]>,E;M^
M@=K1A==I#M9K9-V?24VI.MYA0Q&H3B9M[IJPS['1P&\2'M3G4Q_WMNX=1ICL
M*$Z^.V3@3)P%^-%[S(G#'=?U5<\R? O[[$*=3GNZ-^D0<59&#2!7$W(M>;86
MB,N( >#R@>/3&6>R>%)L-4STYN$VC='(42-',ND19^2P-IDY\IFA/5>YI5W9
M"K&NX&"H#$.A%:TA)Z>XX*4,+UWO+5QY]>8=>1)!7?T'PANI*2PTV"G#SB-5
M4?+HZ(X(YK"Q_@/*C>#DEQC4Y%+3G\]4;S*8^1D05XW.Y\%LN>H^CH,!L1MM
MYUE$FWKR^/"].U-_JEEVW8G:5H*H9[U)"("6!JUUW#JU)>R.*NN>)$78'83=
M:4I+LD_L&_8&AKX.T?<%"I#?!/(1=D<?QU2<9;8A[ X<C+ []AI8Z[ [L"Y>
MPS+>PA:]HP4_XP4N.-O8M[M@;[SZ!5L;\UX8[(R7QF!G8]XH,\+."+MC;=@=
ML_G%?$\3\<>4#ER)61O;_(F)&2--BKD78\R)Z1533(D9%&-,B4F2LJ9<NTW[
MWW3^@S 2OJ'0H\+EC-%)]_4NT*,KDEN)7Q[5JPS!S_I\)D^G_JF_C[;=55U&
MJMT:9*%[\G;250#^J_"/L%/ I2HN"#O5I"@\9H2=TH]UA)U"V"FMJ$=(%B-#
MLC2 (81D 2]E>$%(%DU#LC2 '81D 35KJ*D2DB4VY5"I\D'M#LM2* : VQEP
MB %D2 R@?8!VB5V?Y1^J35XD; J_EZ;SBQ ;C>*^9%&LB:(!'R)0A@$VU#<6
MQIX,>(41@^4CAJL:09.CD=/%T/3T+&CI,^D..LSUA+\DK.</I%[=UU=Y33:.
MTAZX]W0@?"+FZE3A=$!/-55<>^PV"A*W8E5D.0B$4:V7&[8&=-0%X=GQ62)&
MLH:A:Z,;+SD3D/Q)S9*^W' A^*>:"KZ9/Y!IN#/QF4F=?$%';<X^J.12/JEO
MZ4"*( ]JWZ/**W)DUFT*?BAO-ARDS0^(N.T+ESS[_$;P=RHZ+-D6KK:6NI.V
M[3.BJC) ,9HYU3S"^46S)HRSDB+"^?HG"B*<FXE]PX+=Z.L0?6/5@/PFD(_E
M%WT<8\7:#!Q<FX.Q<&.H@1NRJ@/K5K8N(EZ9;6$MPV'!SS7Y&;&RK'%V@P-I
MP=XUV1M1MNRP=;-"<,'.-=D9\;GLL'.S@G=9;&>\ZV+ NR[@%Q'.]< ?4SIP
M)69M;/,G)F:,-"GF7HPQ)Z973#$E9E",,24F2<J:$A&>&Q/AV2Q<$.&Y20%O
MFQ;AV1;6$>$9$9ZUHAX1GAL>X5E;AA#A&;R4X041G@\>X5E;=A#A&=2LH0;A
MLXP(G]5<T"XM"DE19^@[>3OG!DAZWFA)\X-!A8^9Q8.G^VIM=*A*2ARJ0=01
MM>\.&3B393 \BUFK)@5@VQXV:]$"2-5!0ABL=<PA#):9V#?LC2A]':+O"TT@
MOPGD(PR6/HXI64YMPV#!P0B#!0-K&08+UD48+%C8G'<FX6>$P8*SC7W;$O9&
M&"S8VICW-&%GA,&"G8UYP]-6.R,,EAEAL, OPF!I@#^F=.!*S-K8YD],S!AI
M4LR]&&-.3*^88DK,H!AC2DR2E#7EVFW:_Z;S'X21\*W('A4N9XQ.NJ]W@1Y=
MD=Q*_/*H7I\,?M;G,WDZ]4_]?;3MKNHR4NW6( O=D[>3K@+P7X5_A($#+E5Q
M01BX)D7%:F 8."M81Q@XA('3BOIXM''O,,+D0&G28:XG?*5!B'2?BJD<17'7
M\;H+_I=]WQON>7QJ2O=WDQH1;7F:[*&3FZ,UL*X':X.&=,UF&@.WW0/=_^13
M^ZB5I09".T<(C_KR@.%1KQ/65C_J]\DT'O6[ EI0XOIB?N-,)BY&9 '264G0
M2AL$M86-]$&(1AM=$><XGE\\7WPKK_5!/.>#_D54I%TO\07S$$Z5/D)XLP;
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MJ2V:*N9BM*+;P-F8)J.-29G=<FU*H&!$UZT-H:X8R>Z5F <1(MPXONV4L_"
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M5:26FH>J5!\J@83VB:&VE2&&9 LQ ,Q"HR>/#]_#<-QVPY(KA'F@?#L^N3I
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MKO<#)JMA)01RN1H!XIL03ZH7:0J8]P1SH?; -@=;JUX$: JZ>$%@#^2:].*
M7N!:\T*!K2EXD+=F/XA@W%0[7QA -1MZBT=2S<$;0ZHTR-GIX' A<K&(?6'F
MKM5\4LNH 60*1&JI/>(@)B,&@$EI%&UQL!V5%1E,A\2:7)1(X/A%$DS)IH@4
MA(4(V)8/$$GT=L&%R1GMD 9N9YB8F),-B<R^C(6)6<60BFL++)[>B*!M,G,\
M$G8P@T^N@\/F]#+3I8P7-C-EM;.Z;RRJ[AM4=]NBZFZCNF_5,\^B*L^4%]4>
MKKP^$C:F8:9-[GE\VGT-C@"*KR^M+J1-SE/DJ P4TRCV^0P<ULMA6F)3(>33
M&6=JGKC[&KX#&@!V/1HY:F"G\F,Z(X=%%:,];;FE35;[VH+;Q4"XI&A-S><4
MUZ[Z#G9*A__NR%_*QE;_Z:R-M5Y8:+OJ_I%ZQ&%T=$<$<]A8_S'/QHK/+[&Q
MM>XKN&>)O(IMSEQ_HBZ5>GDDZ&<-B*L2%,Z#&5^UUV1,EV$2VES,U'J U/S)
MX\/W, "6FBG6'YNT3HM\X2FU=ML#W5;ZQ=VLKP!#*?Z3\K$@LS=G*(<(*JY6
M1*.L,S'OOM[RJ2SK1/LA46XQ5Y?R<TN,6D]OE.]_\OX;]PD;]=\<X<WOG/&;
M]GV:NO H=Q>KV^+#-^Z*U0::F]!\HA]4^\>G-F@FU ::!6BZ"[7NG0\\5&M&
M,T]MH+D93>YK_^Z;1F@NU ::&]$$EOO"$DANB>2#HW]*"'VP7*H--#>B:4"R
M$GW(-#U'RB[!?')^ LQ]@;D0&V!N!#,(H (T]X5F0F[ N1G.3^TC)&J$IN'Y
MKG8$YJ<L((9 ^R(SI;95:-X_&@?7,$3J]_M'JVJR)_B'$P1B,;31B%_D7"FE
MU55L[Q:"2BSLZJ%A_;:!<AR:O%^@&1S:ND=@*PZMV!QP4 ZMWQ!0ED-S=P(T
MA4,[5_]+<@@&L=1_2/X,GN!J"(.63FJ5Y-#<!?V&8&CG(GY)"LU=O6\(A7:N
MV)>DT.2E^H9P:.OR?%D2C5V7;PJ'5J[%;T^AZ8OPA\?0CH7W_"QPP=H1I2S(
M*Y9*.*8D67RF.WTY#%05P2Y )FI5)T\9Z9O)AQFY M?"L;T 5H%Q[[P6>48.
M<:QH-TI)8!<<W!=%TB15,YJ.4AI8A<?*0S7;JLKNF/%TE)+ *CA,3TR,]+_E
MF0BV%A799:7[;A8=JVU&617L0B31XTIWQE9T,YJ0<B)8!4@PW5C4'TOVU4P&
MI*0(=@&R',]GGKV.)7B4D< V..(^>6YOG3,3>Z<9.DIH #P2GWB?W'H\5C6P
M 8^D!M&HSBP EL<+BVIH/1N:Y<CR#$-K:S7\5,7'_TG%T'%I3SA#ZMYST?4]
M=3,CAXV#B.1A>/%PI3_XD7HC9?D[-_PA6*E\U9*5$#VI-E4%H"X'M1PO NIF
M0%U<%8"Z%-2R[P*F&\%T<4T Z5)(!RM'@+H14*^K"V!=#NM/#JB; 75A31B/
MM#EY96W.Z5I<GQCSUT )!OPZXFS-:+_A.%L\U-\ASM:,\YM-L\6#_!W";-$(
MO]DX6SV\WR70MHSM&XZSE0-[C/8P]#H 0,:.KS#8V0M QHYH,+S8!SX&CR'0
MH=\30J;VVM&%WAZ?/IW.N"!B?NN\OE)!V9 ^,]^EHS[Y^9V[4H1K-EH<:0LZ
M<KPH"8S#"!M*/>]^SF1%Z,].92DB@ H$ 3@I<+K>&Q4Y/[<9H.5)-J@#FE(T
M]027U_;FO0EA\CMW__.=F2JY_+O#Y(V.G<&$7LLS>#;S%8=M*R<58$O!]DA=
M2L3P37Y^2S_HA ?Z25W_ID/PM8TZ0"J%E/SG#7$=V6=]EGV&H2\_:G/V(7VJ
MW'A+![+,\J#;87<_Y5- ?J]-A)C+;L9_R,37?A_35YG;B7R ,@5EZFL60[8\
M2:XFII(SGZE1]*/COD?):'VA9)NK(W(T?><+[>,LI\L8-2B%);6TJI^?;NVH
MZ45!S:[H8/9K0&13UB/SH/<OA)KY4G_&B:>%:BW5_)@:(GCSCFPO9:D^J!HX
M& +#1AEB2+80 \ L-'KR^/ ]G%NU&Y9<(<P#Y=OQZ<E+D(Z=BAF1G6X:30YS
M,:6B?=>-]A8]<$9&?_NNIZ9'/P+97N5/'JG42QWK!7<0_/0'^9N+KA@Y3';8
M N7[4FR7#(,)>]V)RFH5SQZO*K;;G47;RY_L\6Y3$X=!6F'W!:3C(^K_Y3__
M#U!+ P04    " "!0=I.8@R6[$ D  #HYP$ $0   &%C<W0M,C Q.3 S,S$N
M>'-D[5U9<^,XDG[?B/T/7+]LSP/+5]W1U1,J'[V.K2I[;;E[]JF#)B&)4Q2A
MX2';^^LW$[Q)@ 0EJ 26^629Q)''!R"12"1__?O3TC/6) A=ZG\Z.'YU=& 0
MWZ:.Z\\_'=S?F9.[LZNK R.,+-^Q/.J33P<^/?C[;__^;[_^AVG^3GP26!%Q
MC(=G8[J(?8<$YW1)C']\OOUBF,;1R<<W'R9?C?OIF7%R=/S!/'IKGKPUS=]^
M?0J=CZ&]($O+  K\\",\^'2PB*+5Q\/#Q\?'5X^GKV@P/SPY.CH^_,?7+W>L
M[$%:V++#J%+:LJTP<E<+*UA:KVRZ/,3>CDY/C[,:-HW]*'C.*ST]!-ZKD-BO
MYG1]F+[$2N_,HV.S5"T. I"'J%[ZEE/1(2Z_#KS XN^KQ<F3O>"7QS><"NXL
M",U9['G56OB8R2VRGJA/EQEII^;1A\.\3MZ(OR8E05;Z3=YA]=-JSY[K?Z_(
MGE5+=75ZB*\?K)!DQ7W+M4-^%^P5]G!<[<&GOA\O^7TX47 8/:_((10RH10)
M7#NOUUVI6B%T;3YE\()#5Q@4LII9X0-K&QX>)M"N%(U6@:!I>,-I.PY-I#!L
M=I"]X?2"#3LU_:6*>'.8O"P7=5O4YOHXQ.U<;4\--:<#\OC#AP^'[.V!8451
MX#[$$;FDP?*<S*S8 VIB_U^QY;DSES@PF7AD2?RH4J#T.K*".8F^64L2KBR;
M2(YIF'T,@TTA[G)%@\CP&PUTCN]D\OE";2MB4Q_6"]LJ9O^812NO@(2#P[[4
M-&'/HT5<*_EI%@U(D]&F=@$-S2KXGYG5,_&1>7S26QBR$U6;:%K;P.I_88GB
MEVG3X*^BR&;:JT\-,KK+ZN"/3?36OB!((3FOQ7Z91?T-I5"?Q:3$D%5BO[86
M!'?UE:&C4C'_;^MQS5DQ9:@I54M_FT43FPUM_B(I,\++-;\E%7&(?\ A?ORV
MGUP:*Y'D%)-5P([?;"N S9C?DG.1K2<U4K-*^&.3<5H7YX?#@'K $YFCH2XG
M"2\(*K5:)&'Y/HU84^Q9]G2U<OT931_!0S08/F:VX2V9&<R$^&@%-O;3;F@<
MK@*Z(D'D@A%4,B]9 XN S#X=X'[ S,R#OSSKX158,5F11@?5]8SQ"56(]Z4@
M+ZN+</AT$(*P/9)R_</9L2VO+SM0Q8X]IA5-F7+(K"]34,7U78UY6@6D+T]0
M)03S>"--80-3*&"XL',&<RQBEK;I4#MF/V#';L)?-WHV<2R"%8V]'!A8[_[V
M2L[63LB4;SVG,:.RT%JRLY#9.OYV='1DF,9YVE?YY\1WC O6K7%5=/OK8:VO
M!AEQ2)QK_S?VNS8ZTLIIB;:*503*UZMKF5\S?9JI54[;^:_0I#,3R .KW+4\
M<T5#5X&Z.YM7I>]C4/)=UEGY=VC0F7&9=6S<I!V/&D]40JS =_UYR,8C:!(Z
M7A _=-?$]&@8FM$C\>#WDOK1@I5)?A'?8:LZ6+RQ;\6.RTP#A5!129<JC)VT
M8NPBI=@ :HRS,L7&%Z#8^&7*2#:^(J&L4/+K DE&[^8[XSXC^6\C/!,8V O+
MGY,0E@B3_"O&Q6)?@-R.$E40/&V%X%E"(ZQLQ@6C<03=#P>=N;(":&A!(A<D
M%.J#P3IAJB#Y>I>0-'ZYJ5 ]8C2#@A4NS)E''_>W1&](@BK<O6G''1!G7")Q
MXQPHAR^?1L0\-@."?B$P9-+=V9:0$;6J"@5O<7/GAC88A7% X)]OT*&!NX';
MK,MTO_?"-7MB@LA<-G"A*U@+6$^F"O6*FE:EXW=<':,U_AG[Q>%^4_3[PO5\
M:H;NW'=GL%RBE\5FIXXX\%;4<VV7;&N12':B2O?ON;IG9G!!@3')*8 -?D+!
M"X?!:YAR;>*NK0=/C<JK#:I2[P>N>E^SZ3OO[86K\HVYM(+O)$)9F"&QX\"-
M%(UC4=.*U'M\Q%4O6FY?\WZ-N[S?%Z[HMR:%C4Y@6F%((B7ZK;6H2JW'7+6B
M*7:-W1D3UMT+U^8[F# ]*]UXJQJPS495Z?2$J]-W;"9F/1HW28\O7*WOS3E=
MD\!/#K%"L#_3 *CME2MJ6I6*3[DJ1@OK][Q?'+MIOR]<T1^8CVW%'JC0;J4]
M52I]S54I6E4766<O7(W'1Z8+S?MS%VT<=4LKMUU5:GW#]VJ@.765=SHNLTP/
MQV846 YA;L?$VEE9S\JV/6W-J]*VP(>%5M84^V8^R\2RNDG[?NE*/S$=$L#V
M,,(#X4<K"- /X;G6@^NQG822&5NB%U40X+NX$J,L)\'X,R'!^%*0\-*!<&K&
M/MNX$@P3\-<8;H43LD,>H! \5C,+2'2C"@I\CQ<SWNXS&HRS@@8 2$;#2P?#
M:].V5FYD>:79&F-'J)^'E; S2"60D.Y,%3#XOC)F IXEE)06BK.<$A:;PBAY
MZ?!X8ZY($%+?)YY)GE8$1I.:V8';L"*UG_!]:,Q$O,EZ-2[27E^ZBM^68@R5
MJIC;L"H5\_UIS"XL(A='%2>:>&>&H#2"LD,OV#,[\E>B8W[+JI3,=[ QR^\.
MNS59OVCALWY?NIK?)W&>,+$F6E&BX4:CJI3+=ZTQ6XX%?\),G6CYI:OU@QG&
MJU5RJ1>FTCR&R'1RZ2G1M$P_JI3/=\(Q>^VN1$01DU0J_<+Q<()>-- F,2/K
M2<U276]2E9;Y/KF3Q">'_1E3[.^E*_2X9"CA+>\@5K9 "]M6I6*^(XZ99X4=
M=E5T_-)U?8(;WJ4;)2&AR4T-%H5#?%611IU]J-*](,@,K;:S@H#T<D>)@)>.
M@5/3(1$)EC ^6-0?7O.RW,!<6UZL" (=7:A" -_QEIAVY?[9A3+HW_B#]?_2
M 5#XP9:6;\W9*R5JYS:L2ME\9]I)V9GV->_UI:OX#1C3#R'Y5XR/R%K9>LYK
M5Y&"3_EN,V;%W>6=&A?KE[V.=X3QJ@H:ENY&E?8;'K6.:&'CE^S72[\!TAG:
M;4;*#M>E^U(%"[X/3B*:W/AERBAYZ>BH1($K1 *W755:YSOG:D'FHX9;0\(5
MZKJC!U5:YWOEA+'GH_YY(>,*U<YO6)6V^=ZY>DCZJ&1!&+E"/0O;5J5JOI>.
M$ZD^:KLUKERASCMZ4*5YOH].&, ^ZK\9>:Y.YYQ65>F9[XFK1+6/NA6'H2M4
M<EOSJK0MB&OC!KN/:N\,2U>I_>Y>%('@M2#*K2T&?L2";)BZ0D3(]J4*%X+0
MN.[ ^!$=TJ'K*O$AWYLJA CBZF3BY4>,](QE5XF4OGVJPHL@5$\^C'Y$34O8
MNTJ$M+6O"@V"V#U^=/VH^99H>)6:;VM?E>8%=VSY0?>CYMMBY%6JOK4#5;H7
MW+@5Q>*/VI>/JE:)A1[=J4*&X"*N5"SW"!-N!+9"1 A:5J5\001@/<1[U'-[
M/+9*A7=TH4KS@G! 8>3W"(&6($V5^F]K7Y'RWPA"!?FQH*/F6Y.^.B2R7 _&
M)WF*8LO;87K9>D^JT,#W.(JRS1J_G"=T&-.$CI>.B^Z8OAU I'^GJM"R143A
M")R>.B2 B"6++(%.9[%G>NZ:)'>"\"/2N9)_#**DJ5$%-;[C4@9JIG&1$6O<
M,V*-+T@L<W3>(K$Y&E\Z"JN!J/BM0R?V"*X]Y><*@=:O0U58XKL]ZR&Q@*R4
M'ESU*L&R(UQ:8UGY3Q7"9K..5<&'[SL5Q]8*8VY'&&VN3;5?&E)'ARJ0\9VT
M6X!L_)A0:T1VY1^%4Y5,-ZHPPW??-L+ ZU'AXS0D"-W>P5ZMNQ-58."[<[F!
MXN->K$-'EK,$2L,H2"*_V"X':+ "._G@ET/6Q*-)-'!^8JMP$E%,D2J(\?W&
M/(B9QJ1"<++W2@EF_YP7!)?.G<>I2:#_[^2Y[!,N0D4PB B$5_$2[@:"_4A0
MA+FW?'<U'W/_39[+ONLBI.6L1.$(LHYK+*6G<XPS3;P\KK\F890>2#R9=D <
M5ZWEI)0>5?#C^\?%EW JSW]GY++I[BHG%T]5C;.$W!&+';J/_8#8=.Z[_P<3
MT8PX)+"\'XT_:1I488[O96_#W'V)1.,R(7'$6<?EL&;X;?)<(:3Z=*<*/7S'
M>?4ZF<D)]4TOFHU $5\%JZJP^5XA<K;J7Q64!.'"_+MJ=4QQ;K.-V.J\:%95
ML;"82J2IHT85[@3!RJW7X^KP$]^C&U$H>;EM!^ZP_IVJPI0@"%KF:MWH+NNI
M0S1&?1O^4^Z5V+AO53#:^--%R6%SB;1Q(I+6*9@W\7*%_:M=^3;J6!62!%\^
MDD+2I*!KA%&/R[B[6-$VZ%85A 2Y).0N X^K6F\]9E/#,S."TPN[N8ULKFB@
M?H[: 5F*X/=.D,5""GYF/J,],R,]O6R<V_#&34KU.+_UOD*^BUENX\Y5@4V0
M&J//1?9QQMM0I[NRO[8B0!6P!!DU>@!KM,>V@Y>L_?1C,2=-E2H@;I^JHX?9
M-Z)3%@?IOA >Q1$>N#EX+V(OB&RE1!4*!3[_7BA,-ZVA<5T0.B*O-=%+5>&<
M BH1MQT%JI F\/(+DM'4_?N\?#4CPEH2RE3UFQ0@68*!G<!, 1FJL";P_@O2
MW]2QEA0A65J$7[*"?QLAUY[(9A<[4;F>5 %'X.\7Y\X9-YDRZJ)LLV1:=N2N
M2UZ#'0)$U*,JH C<^4*@F,8UH\B8I!2-<TF[ A^).U]@/+(%^QIK3G;FE=BB
M>U5@$CCV6\#T9TJ>,4G(&UT2/2:CTG:*>="?2&"[(;L 2'\8P/I0H0AG[P4>
M_+9)J[2C8W[[@LIT0AOAUBNCF[VP_#E8O*X/E7Q6A,+FRV+I%UQH3BWV%).D
M"H@"[[Y<(CHPUQ.*#=>'BC[C"M"8DFQ<(<DC*OM (--[%%A^B#:3ZCEP:R)4
M(4_@_I=%7@ZW:8G($6N"#(:[R)?5T84JG/"]\YQLB>,&L$,_,Q+@J0K>H,%@
M/;!7GS/'C\HI9K..5<&%[T9OP@6#O1*ZV'V=7VY3POZ6>:/&N42@SUJ@)QZ3
MS&;$9K%\3,50>Y=XZM6_*ECQ?>8\6-6"3?%X)B./(0T388W8$NBV<N6O,G&H
MO^FS<=^J,,7WC?,P5;EF6)FWQAL^'9F;07M1%+@/<91FS8/B*QI8L 0Y+@S,
M@/@VOEF#^-B6/Z(PPSBQ3<Q9C$?WYC.Q M82>YTVOT,<[IQF5?CEN^AY^$6D
M%BPQ_\4T8PF:R%DR)AE+1D1A)D66C$O&DO&_R-)_8E/L?78D- *_/8.U'0<H
MVV<S<,/O2F';KT=5H!,D3Q>GT#:-LY0@XQ8(&A'3I;_B*>=ZV$Z1T]ZS*@3U
M3L)>?LZ[G_;BD72"P05+-TJTB L6F,#H 811MZ/[C+W[5(2>#X(L[B=)[$)&
M$%OBSLH$C?Z)N@9/44<D6,+8RC9R,\L-S+7EQ3L"3<\N56%&D.N=>;;*]+"0
M%Z#'^(/1,T)&ZC,-NP"*5$>JX,'WA L_##&"0D)7[/R"K0KX ^-X88R7 Y9V
M!Y/NKE4!1^ :%P#'3(Y2V,J$/RX*RD939CN-[B!'LB)*5$%-X%;?!FICGN2:
MQM^88?P0@E+Q$5GO*I!3JA]5N!'XS=^P4]Z,".-B_>)B.'\]? J=C]9JY?HS
MRIZE3WQ0DI7S^BL^(\EA. .-98?17Q/;#@B6N9Y=^6! DC"Z]DL7C_)[1P>&
M;RW)IX,^%5R/>> ^'< &&/Y'K$1N%&/MWP,:KSX=H+K=CQB0<F!$P%+V9$E]
M4&#PC'$?R.J!D3Q_L#P,X_YTX) '-\J>KDC@4F?*ZCMQ\IVC@\,VKIU_QDDJ
MQ_"2!N<$6 *47?G9W\PQGN[6_?D9#:,P%\&FM0<K#_;]*-?)@N9E!=&LIJ\$
MHNF").GX[V!Y"2?S@+ B^8=H)G-X-(=?0&@8W@34)L0I1+%Y_>')Y)*0&Q+8
M.&'-2:<$ZJ4WX=>/ET@_-E)G5AU;4]@_=W*3%MI<:1F-F_)A/6!&;CO*NL[Y
M^FSYWTD0P@1-5BRKZ%>R?"!!QI'X]48*H3[JQ*%+R]T!*U ]H'/K6XSO29R8
M=3"QU%CJ++8WU@I6:!#01U@$F.0]#&@D3K)>AE#WDEBX6'X%JV$9+Z?NDDQF
ML*I>A6&,.CJ'TCFW*EK:'VY[2B2+AD^#X5DL\TW@VAF#_:0BT=H6TQ)KKDTN
M>#1A^9&D6$K65,$(H[;)=&M9+5E*KA@C+,%"\B@-NCD35M&2P>D"C.(%]1"%
M>)4?XW4PE244.[>>PU9.N^MJ-8!Q/X8?[[N>Y<] -6#SKBQOLL0W36ZEZNS0
M1FC1JW@]"BBLG;7%I_I,OT44_243W\$_):])E8F.,OM?/M-K <6F:FH]Y6FG
M6,@2[O _>]3^GO/4J\H6+$99,^I5YUEA.&%35%UAO#<:8@_)_"QDH/Y&4P;.
MA S4WVC*P#F,[0LA$[RW&HQX).UZEB8@N0YNT7(KW5FKL-!>;O.UDMWN"[<U
M#[I(;$Y=/2KH.7'1Y1)O$UK>C87Y1Q*;[<H_LYPL=JH&Q!X5-!QD NKOPW[<
M<LKKR2SUN;,)[XV.#/AA[.&H;=#??*'!1)COYZYGI2U"*9XLV1<E<D^@5.)H
MD[J[G#![\GR+A9OL9(\WIW05M^_[-H16@#'(6"_=K/JX#X'=VXUG^76T2975
M<?SDA-]%L'HDE\5;&125TY"Y= +&R-Y+&ES$ :UQU5) >W;N[\Y;N2F_W__,
MQS] 2TC./0I=A?9QK")C%)Z354#LY$Y7\Q1%^';?IR9%0OL\A+D4P9SFD"#.
M>1R@0X>U7O"T255MC\7:V:FNPY)E=\AK\H4[9?-*P5"Z22FQ4YUAI$KJ,->$
M=N"NDHB&B<U<DPA#ZKGV,\R,N3>I_JZQ>5/2TCYW=7R9_$'"*!^7S%Y,UG/V
M9<PRTGO5T?#\]-R%F3>B01W'C<<:@#:/@T)<Y8D.KV=IFL/D2ALNB$V4;E15
M#UCFI,.F)AM,WY(,(WFJ&)8IIH7K/E7UX[JDKSQ[:A9>T\ZT;$T->6[&EG7Q
MVE%#.QZ3:$7T!,UHL&1U)P\TCHJ/Q2;?(9[X3O$5XJGUE'X;ME4:"ML>C-S8
MEP.!(9;B.OMLX$92ZFQI"#*YGE78N"4V =-L$YG(M:2=3)) +J3I#G/K,QNT
ME?6N"MIQF*YEY116K0QVE->.OWZKG;8K7(OQ65!_Y\Y]=^;:,"O7M@J PDG:
M H]MV8I;N'FC(#64E&FVG)&D=&*?I"-IU;)T3>W0?!^26>Q]@;TQ+KN8QZ>#
MT_;R>B*:VNRD 0^9 8CHYLZ7D9S']C+[PJF0IXOERJ//I!99VWBZ_PUB_C5X
MV,YYL8-K.->2R5F0+S\<7U5RNI+O?'#"2#^MP]TAU)2Z864-=)\Z5%F0)&SR
MCX^RC[GDO+65V'=,986XC*ZJ5[6]R"X9D%3 BM@1K$GNVG6([V04UCQFW<74
M#[6->?F#XG4XC* 3J:2SW+Y/,# ? DN'<),I&D/C@:*,A[8">P=5@[@PHZX^
MNJ5*[GN4Y\<A14A"=IWPMG3GH;O8WE'5I/ K7CF $7#>SDBMF';&3GZPFFVB
MJ@ND^/7^ET!8TPCLA;)#;J"0&=)A=C6QN*KXC41?:%B,G0TJ:F<0U<5P\92D
M@\>S_CIG-<8[BNZ%U4T"]H&=)0G.+JYKF&T\UB]RXS(.?!=M2K2]9[";)[EQ
M7F-&HN#^AV+A9H9]N1NRFX= <.%@+GR(&6/]JN@:YR'I7V\RW55<W_F&W6QN
MG"/F'(K>ZLM0?=J_#.@R#9PD4>01YQL0D.[^[_(/PJ3?6LGXWK:1GU0\B6FJ
M1$AY4WN/7ZVS,5U M_-%@^*RW[U=$+U:T(!_F!?GZ!I)O+"9XW)&"OY:2FAP
MN3';7J0>+TG_6>]:.@_J='^5+[(%-Z7SOCKGW<5U9KFQT!;L\5YIS$IZW?]Z
MEMQ/S;TPN5)@XY(E'\%)]B9^\%S[&A-GERY7;=_,$$24S)NP*1!E,HJ:\I"J
MHS?SP$6RM'Z+<9N0\53F55QD7TN,<+_TQ7K RP8T>!;LD]H*Z+?]^V(!K*:P
M";]@&2N(S[+5PPKRC4;YNV\NH"1[5^=VX_HZ"\/#['(\5J:/Q%N35D'TJJNQ
M$"[=F4BA=^Y3%Q[ZUM99$#0.1+R4V11)HF]UC451&<E->/O1<YLD^M;66!!W
M+/VD@)?*7"B0Q08-Z"R.TI"NC_8*HR)I]*ZOL3"F"U<\X,N3@4 8_>OK+(QB
MT:N/^#*;(E'TK*VW(+()CCOU@27>(8E^U0<LBNB1;B.*1G4-1<&<CC0H-@N7
MELWB&+Y0&U/*7?EW"Q(\!!2VP_\3DP=2RT6X30/[/Z7Y0N96%BQ;<%1YINU]
M3$;G)2'A+7&7#W%0XZ#^1F\^$F\WODB=A;5;SUV%!G-"FV?DNJ%!<K.@3W3>
MQK7W/]1X5PMJ2FXOHMF!IU##/"ZJ6FPMH:>F\-Y$M[(JI333EX@]I%O 4_I*
M7T:>,(=KYJHL9R/*(M_019U_1"NJ1\QMT\"^<XS5:$^HGL31@@9X+T+ (J>8
MYHQ,PF:RC'Y5-,LI^M5Z/CDZ?E\].,F A6_J<Z5L<?V,ZV]D%<5^[=9$_>'^
MY_MO)$H./0H2BP>Z&58%U=0_BY?L:R5KDL62EV-HVPIH-B9J3NFO,.$N:C9#
M>Q$-L4\C,J5Y^.]=]@6=] ,UT^QK/#EW<J6UBQ9&RD,>Z6&9-V&) ?%3OX$I
M57+O5RZS1?(6/_4%$TZV=$SI9Y*G8)K2ZP< FG_MDY(1E#.Z51/[MB^J5L*9
MY7G$^?Q\8=F+E(\ZFVT%]62F;M=VEM*+C33!/PUJ3@X^.RVE]QX&)Z T28*4
M#Y4.OIJEM>3KRN>'$$F6U8:G>]_-+JOQDMAU%].&DVR "X'&*Z =]=VJ:"VI
M79S2#5@%C<S#]8?[WP3=L*Q]F(K6)K4X8Y9@4S(@=OMF](VA*\<]9D.H0&,A
M@8Y2VAY$E"G'L07#*IW$:],WN]'!XU>JUO#XKX.ZDW5.A2%QS=:Z%B:S][KQ
M))Z# ^K$;!(2Q(JV%=#/MP#4+MTPI,$SVX-V?FRA1_G!,"OZU()\<2U9A3:B
M9TR9CJEQ,BBR.X'5ZS,-IGM7U,'DH*OL&/?ZT2=!N'!767A]^%_$@TWK+?$P
MB.+&"@KW[ ;U]ITMH$SR'Q1/D]@G7E)B)S[HAF+V;\+CL:O"GIAK@_':92ZQ
M!DKKSS4<@Q6;I7H+)CV+J7'5HX(&8ZY"[:9&_I:-:&?B2Z(A4^LE>0ABH )T
M^RXY*$K#4=J0(5]9]T%17 I#'F1XKI7481@$]L(*2<B@F:R,!0O<=X,Q=F\Q
MD<>EN\:[7.G^,V09LVI&@T0Y_9"8$$WC0(JYUG*:,G?M2RFNM9BFK.%7;J68
MZRBH*WN/5(JYMF(:LE9<YJXQPWFQ_YD=J*(^!F"G>:M+"7$#.G.CK[$7N2O/
MQ1.QR0I^V$CPU'KB9V-5UYP6R6AOB4/($NE@N,LRQ17<BE[O.V\<4);X9Z[\
M/$4?RR/#_%*EMZV&Z]:M#,=RO24AL<"0 2;.R9IXE#D$ +3_)';=?2!95H?!
MG1!:HO)WXI/ \H#TB;-T?1?%D9R?5BXU;%13-Y.OD -^O0V6R').1'Y^3JF2
MNCD0[J!5"]JX]\,5L=T9S*[G#$ 95VT%]%M![Z !@K&:[S[_6?4/I%ZJ*4TV
M@M51V;^:KJR_/P=3 6D$9D[Y.\2<I?R&!T\8VS6DJW@^U(^+2N&]IQ(0V:B^
MKL(H:?C=?5C%?8NO9=/*PQ"#,/K[7;<4).KN?V%GUMCG4IHS9I1-/"^Y0SFE
MY:0\LH6U,];DV64%SJR5&Q4QPGTK:<Y^8GUPMR$M[_>T#Q&/5FS4@7&W!CHG
M<["TFH?+'64T&'W%]V/N??H0 J5)0K=5##LC_$!U8NC=10'QY[ E@HUP+6/R
MGS3V'#"R83M\Y4_*J95WU;BVQGDKPUF:QRN_Q#H>\>7I\RN\_EXV>M6WJ_$4
MH9!9:31NUJYN0!3/5=D%A2^NSR;"0BJ\-]I=S<BIS+9_DR>WR4+MI1P73O31
M<:%VZ":I1'\L/U.DL,%(]E2:@\4S;LCC!Z*:@X+B>+D$O$I^6$^ZM!:NT9S:
MTK&?F"5!(2V_R'47HV.:)*G%88;#TI;'K,>:H2)1</_6"G[J+0(\/\01(W5*
MEBL:@%;.7=SD@,% PC\7KKV8!&2RMEQ&[Y0R[RZYC#$O!,M* ^TD4S^F)&]H
M>N>]: D5H!9V&&[8E5?C"K\804(H=P8;RF>86]B79ZIP4M68%I"[ *W;4?85
MZ2N_^A%"=G"  ."@I"2.K1K1S<[@22?UG7^C4<%.QFS^?:(K_YQ$)$"?NS]/
MQT=RF@;_E(VU730\5"G>13#>V>X?OTT'KY.TYXI$N7GK0Y G6/)+"[_F5QI0
MV>$>1T =Q77C6#R9 Q_G9$5#-[JN9V$0O-//'5HB=/I(A4R4WVG-1'>TOFSA
M8; IBM.7+*LADPO"'.MM)DWR##>3R65>F#T:281:#W9VW8F&8N5%7-2$TEI$
M1Y:(%<;!\V<@K<$*[Y6&+#S2Z8+&%NQ_,,WK,\N'7&.EM8C^++&TQNTL58MH
MRU*8$XSN2RY+@B)#8(G&01=+Y2(#8*F#G2&Q@@GE.]BI%!D 2TV3N:W$ !C"
MK%GM#)5+#( A%B7>P5*US!"8:FQRVDKHS1!+ MX^-32+Z,?2O>^0X#& #FLK
M$._%_IV5>#L_^VX5\]T7Y#9?Z.;,:'!1A(#@DSHKC;?[CE-',I(<$->S,\\*
MPTDELD7\>M\IN02499?A:KG2I$OOB:V6L2R?;'PPJ<7O0^)P+C(V'^L;[U%\
M#O1ZUN"B^69S1I1],#3%>&6&K3W3;7(5CHJ4[BQDVLWR9N21I.^:L:8]Z^BW
MK'<Q<(KAT_UXKE89#LO<Q :RA?<__^64S@2W8-H*Z#.5U!,IU*CGO-9M@JES
MA,=F2=Z2ZSC"Q=HI)8KL**-MXNU:%L7&;<G)#/8#GVD0T$?@)"S<]'7&-VE@
MW_9M(X5D^K'V4K)/ 9N"HGO//RE!YF2)=WY[\)57T-?@*KA884[G)G/98^T2
M:E9G\"E-KOE@K$)Q[:5ZZ86[KFU27]L5O<%,.<O,)L*0J#\<87"_H2$GA_:J
M^HJ S]T "&\]%A_>!=@*Q1A%14OV= MSPJ(:6-N$?137F8!58LU)XOA!^T5@
M>TL75[]8;JV^, O&-XM?/HV(>7QDNGEF1=-B?@G3ILL5Q<"QT*0SSGLG^9I'
M)IE=-:[=Q8U^C$:5E!T;UAV0#([-" -;3-CYF!3==>8JC6VIZ5Q83!I7*KOZ
M.20L"S:9)@8DD1-0)$L:X*Z)^9A,Q*97+#<XGN(E"ROK :\-6_V9Y!94\D4I
M%)VPX9])>K*C4;ZA 4GGU(RS R>8C?,3)V U.W+*67QF\Q!AQF\Q<YMIQN >
M(W8G??Y<,I?%9)^F!B2AUZ:=9)0H+7U56R&%Q$8KQI:M_XQRE,5;_P9_1FEU
MCCGU4.S1Y<\H\72YA4?%<<T.I-S1S8 D^\:$QD/J^\0S27+WKK[=XA20ENBV
MS0]=DK+S97OE 4GAK3G+/CDJ4GA2@)@NNW6^ :B4]#%TF<HBJ[WR@*3PSF1'
M=@]X#QC]&\M$U\SL,C'R8(TSLS2(^C8W?$F5EBJV62H.^%.V>PQ!%5T,7J*R
M0["C]N#E\)@>HIA6<HJRV6YKJ[8'),,/9HB9;-@CF)-M*UR8,X\^FHX;VAX-
MP4HW;98\(H3E"RKYK A^0XN=O)G(0P^Y*N_O)Y-UQG!41+ IEFY'#S^9/&5G
MQ5YM#4=&)T>9T1E93\SBG)$ ]^/P+_.3PSSVG%EBTCC;M-7ARJUVI(![;Y8!
M!9WJC&FHO;'X>C8^7"E*#D9AM2%S_F1:>8XT9HY&6>HJF&+RW#E@6*3YT<R(
M C P0YHY8RG2S&?,D88ML==I\YMB[@<0-%QMQ:5<8]7)K6=TRA8-#TAZQZ5-
M/09&!W%B+=MIAAHS<,/O\C+KV]Q/(*GB:?ED=FN)=37[$TA.=DGIK#\@610'
M TO+AUTH>\4L5IS&V0\\&5A;'F-1&D8;M_O3R\Y<63#U1 L2N;:U.U$VNQFZ
M9&6'9WOEX4CAU R+K.FFE7\!SUQ1S[5Q]B5 ^M)"'U+,;NO"U+Q.#3"T\^6'
MJ]*N?B8)2V*N1T/#D<YKW$QFGYHT0WL!!CNZNV>5Y[(0Z]O:4.4DB1A!I>%P
M_09FURR]O!GF^>4%3V51LFFK/[G<^MH,BCH9OE0E1V-G]>%(XFT:W9,Z 2K_
MR(Y"N38&*Q-)4(AJ#8?O=[#(L!M[.+23FP"E3ZZNDVL50?J)5O:/4WRGM7_X
MBO+NABSI[^2YO/\H@J#L4J;W+43;M_TARU)RP+94' [W[\TY'GGY[ E,/2[&
MG=BD_'2>1&CB ')]V(5%Z0[WR4R2$\B/6,6=#5_*DDCKK#Y\252.%V;$P6]V
M*\58CPZ&(\T/S!67+&C-^.KDN:S@^K4U3!E)CC=NE4%PW.47RGZTB:!'&S],
M)K\>HDC0C;.TX-__!U!+ P04    " "!0=I.]9%U.AL.  "TR   %0   &%C
M<W0M,C Q.3 S,S%?8V%L+GAM;.U=67,;N1%^3U7^ \,\P]2Q]D8N:[<HZBA5
M9%,ER=E]<T$S((EX"## C"3FUZ>!&5[2',#,D&R7\V)+%([^&HU&=Z/1_/3[
MRS3J/#&EN12GW<-W!]T.$X$,N1B?=K_>D_[]X/JZV]$Q%2&-I&"G72&[O__V
MU[]\^ALA5TPP16,6=A[GG8=)(D*FSN64=?X\N[OID,[!\<>#@_[GSM>'0>?H
MX/"$''P@1Q\(^>U3Q,7WC^:?1ZI9!X@0VOYZVIW$\>QCK_?\_/SNY5%%[Z0:
M]XX.#HY[B];=K+GY:Q@O.ZPW?M]+_[AL^F;HYV/;]O#DY*1G_[ILJGE>0QCT
ML/?GYYO[8,*FE'!A.!(86C3_J.V'-S*@L65C)81.80OS&UDT(^8C<GA$C@_?
MO>BP"USO=%+6*1FQ.S;JF/^_WEUOS$D#JF,^FU UI>\".>T9UA\<'Q_V3.L>
M4!ZS*1,Q$3)FY!>B6,#X$WV,F"8&2IA$C,C1QN<ABRF/-."UTT\4&YUV::!C
MLAC<4/CW-L:.YS.0,LVGLXAU>VN8 QH%261Y? ._9\T-IEW#3TED+S$#B<_6
M94%E)(,*)IE/OEU)V'7"T-'7FJ?2U!?A WT9*!;R6-\MIU_,&M%'%J4#UNF>
M$AT9*94J8VP1T>M[BH^4M@(:TQ<IY'1N&/HK <D\..F-DBCZ9EJL?B*!5-]6
M32QD^[EM,4B4 JK_1:.$]4/@'I"\HE6_PNK=#P?(:Q$SQ71<N(8N37% &<83
MIC+FNZQ317L<H!X4#<UV\07GV*\,Y)H2ZZN@(Q4<F:==.':?&1]/XNP,3L>A
M*GBCW3:/BZQ%3R?3J1V3<%!NB_XC):=UR)=-E0R0Y03[$!OLFOK&%>\17KQ5
M>L@5XC%>B$Z[=H7S4R_/ZMB*#?:>3*GZ#C8&T$,T"Q+%8PYF1_ZG]6RQ1G/L
MUB9K@=1&MMGGY3SWRVDRN<FSQ1R:^QQ['D1]D2+PH^MMC_9),_,XT+/>#->)
M64FM]%UY# =B(U1%<K,7=7GXGLR8TE((%A'V,F-",V/Q36=20"-MO+><!O7T
M9CN3[5:!MDFSFR;=GJU^ 2R3<\;.F& CL#DO4FH+;?2*]C@<D(RH2]B8]["F
MS$1[PELZ-TL(MHW0-# 2H?_@\60!J-@M:30:#H;<3Z2*P0*=^BZW:T=<)XR[
MN,KZ8#$<.C6!MB#1>SF9C@X(%]"*$=@5H%$5"^#@Y!%/^0-JEXU&#&A_LBV(
M"9[7/)?:F&JWIU)[%#>R[L&1O[#S#$>#"15C=BV^"D/+6/#_LO"<A0G0 -;/
M X/S4E$U/^?0'FR?(-^N;67 %LSP-3JR_?-%QJO9%[1=4JYL6.-:G#.C3+C@
M8@R=C<5WJR1L3OCE1NHJL.U.LGT&W,<R^'YF-,D +"'XLY6[;7"AX4SMLN(6
MIJ3&[%N3ND7HI *;2U<<]L.U52R&]'0Y!E+$7"3 Z.',7%&:PZ(D!N_>&0?<
MY1J9$W*QYTR$$E1F<?3:H1,>>.E2I$O3C_NS6<0#LV-<4#KVQ6H3>LFCW*%*
MPF51^K*I@8S@"O!O0SZ:'MRX[@>:<JBI'>?*C5]^"&ZXFP&NN-^CQ%WGJ$3A
M9B9K8@H>$ZR1@A^,#T6U9G'=T&?3:?;K7M:C=M_ASO.,4!"VOB6ST- I;(G#
MAELC[X;31W#S<^Z%7)NCA32WK/=!M=D#JPE:3;CT7;T:QB-!B3!OM^WZ&%C^
M9.]RH->$C"+YK$G\S*(G1J9PU$T(%6'VD]5IQ$IV(F@2 F="]].@S=EV=BBT
M3W2CL"/8S@%CH386Q<4+4P'7;#CZ@RI%Q1LM[]&CA6#1^D376AL#R4;=]:WB
M3\#$VX@&EI-55#IUQJ'+^^&_$QU;\;B4ZBX+16<>3D[8KT9/'$ '(/B71N[-
M GT%_]\X=H%BU#J_V?_+BZ5S-I.:Q\:\OQ9/+,-9G)7;XN!HV77)!84E%N.^
MN9LH-V/\NJ.%G"Y/;<@EW=%"SES"NI!+NN. O K^!-:?-:YLZMGJH3" 8%>:
M_R[^DX#>CDJW?8.Q<#!CH9Q6RLJ3 [X#8(&=)OG>4AX.(G"#^8BSL*]]-%R-
M,7"!3U-_V0;Q/OJNYC@XF&!C=IL6C$GM Z&]!F.YXEE'=3\<(+-$$4.D-46-
M6<H&4I?LY^HN2* 56=O%R*IZX -V#[I3#]5G&IOLT_EPE.D6&ET+':O$KE3=
M[;NMB9"P,5%P)!L_L56>M3$J-@:!'@>+Q=SGI &=YLRI.2(VQL . 6,VGH/G
M+F(P:8PY,S,KW9Q#38?&&B[U= AD@W@"KCOX)L"]; I7V'M;[S*IE;L[@)!%
MV1LQJAW%BBMWHPE#VH^VU<C:P"\M.]M#N\G>:,*41KYJC60._,+1C@6"_C0J
MB\;(&O=+^(^5"L3^KC[Z<\,=L5L( %<*7PM"[7$=64/E8Y7OV@%:7$K-.\)>
M92I5WM#@\JQ:Q]_:^N\LR;D!_L8W5+B48>O"X&'A[#"O]1]DO"PY9+(TLYI#
MZY^.K7%BTW;XTJNQ69U!6I.H9J[K-J;>;?[K]A"T5.CNRLZ^X8ZN2DGEI19Y
M=FTA$RIG^#S"2IKA".;>L2<F$OM^^C43"Z.T#GUPA5]KR8AT74(,UD!=A#46
M=3^%7 Y);"IY68TD33B8S.@\+;FY6:VDL%G-HBZM3[SC B];HK^1IK]A8QK=
MLSB.+*6WZ4PEA;.<.N!0J/T@4 F--N*(^<B\^N  5UA69(&@$*)S3QQ \\H&
M9E)7C-&E$WYX#_*.1:94]RW-*]#6;) ? ;[]ZWUBWODR51=^_B"XS")/R97M
MH,=@+C5![JG)<,5*_.$ZGTVXXB!M2W29.L-U"^B*W->PVH_=_X&,%I>T1?4)
MTP9L\::W:17']F;<L:7?-N&-3'RC-I@!:',R[#7#4 PDN*/*5D8X9X] 5*)R
MO[/ NW,+ 9WL-G.M9EQ>'K!+4QPV3AK$KTAFSFN$@_PKRH4V.6TV#/^ZY,AP
M=,[L+1U_*C%0:XR! _Q"Z+-J%$-Q)I62SUR,JQ\;E/3! >X+BR^E@G-0+*Y<
MS#H5XBIOC@.2/6HSQI_-O] <O>;6& ><M5#@0JI<8L&OVS9R=K9Y9YZK]:2O
MT.'R8XHPN1]8-1R5_2Y2;?6.RU.I!NJLVI'EIE0CJ]0>-3(+][7):AJMK@@_
M(!'&ZN-K/X[B"=$FWF0_ @=H6<6#A%P'D=1 )DE5N0;W!SK9]P-$+G)]+%MJ
M.XW;F7W'#N0V031S)C>>?KS-9%^4W%DF+A6Z;LU&:L'-K"+@5K$9Y6&VP6IA
M*!@"AVU917SZU*>\GEF-,7X,\&GH+@AD(ER^$;#9<!A9\C9[;2.:67D#UV@T
M' S9X[O[?=Y N9)?\B"RW@; Y<9YL*&U\PS7#57;'"@]#7%Y@BWL@5HJ#]?]
MU58T0:%)L!=GY74!VHV:LZ86+?B,\\7M3$LE>;WFV&\]WAJD(BK&NU$OWEX;
MF[+H<JCX&)2PW5(B-($/I6DT'#E\=\RVI\%A^/Q\7\R1)8[T%== J F"P6'U
MQ&6BH_FRGKQ."\]*K9<9O$.5LYKFP2J7ZI;!OZ%YNF%R%L(D8&]EICBE:?\T
M8;5/ZU>(W^:>1?;8ME$9?1R2MVM[8+/V\"J!PU9D@#G=3WW7D?945KF*H$8!
MPGPWIR2AW*E#"^&^_W]!]!XB2J$5+QJ9=\U<#.B,QS0JB1F5MD<"JB(BBC#8
MF?%Q(*=37ED<NJ@I%BA>)5]_A *OF5:ID*O<5J@ G+/'>*UZCRW1$5;A*>V$
M#-XBAV%9J\CE.U*\>J,"[($..Y3RJSS7YC@@&3T6SPLA;/X9$\F@AUU$JJPQ
M#CBO*]L!K5=2AL\\*C9M'/H@ 6<U<)6EEML*!P 7&4,K6BM+WN\T=>R' ^3Z
M<Y@*JZ>X*2(HJ<:JS,\M:8L(S$J27):FJ#4.0(5U PM!5?;  >S.7+P(%EY0
M)4J?(A0UQ 'C)WS:O<I]\$.8TP]K?#Y?74O?N!JN;)!"4#67#5>F1_F2>41H
M<65Q."Q:E8&!*R'# 5";=?)VD\KO LK!+\=5"=,!31-QVXW2J]PXY>8?+AWG
M<1X5W:?@TFYEJ^-HQ^+2;F6 G.,GN-1 27S4N>(%9@WABL\]VH]K_2J!>05>
M<*V=ZZ(U_G+PW>AW=QETOXG!)8RO0ONOGF^6.?JX!*\,1V60#)?0E4$IB9'C
M,B3*0#BE9&#<)@472*]\I?)D!XS;Q@57WAT@QGWC@L5!-^_PN<"O1*75Q\@L
M+3]&OK,YF5)!QVDKL+JU%()%MMP3N*DI+^H]'&AIMMT^(6B5Z'T_)O@GFW]>
M4GZ[('RP1G=A%->]*XYH=36]]CM9'JDVM??FI=<H#<;Z<9A14'NR$5,JQL0:
M\O>0=;D5EN ZJ;?)CM)ML]^4>9;Y'K9RN='MBDV </"T2"2U)O$SB^#GJ13Q
MQ+9)?[(*GMBMF B:@+VY\IM]<^VW0,*>DO2WAJ39%X,HF#NK3),^,3%W0:]4
MGD-+'%I^L,[6E,A"[5W2%@>8*U",BD9@4_?#*1=<Q\I&.:I>FCGVPP%R^:QI
M]61KL"RK.AREX5./56TX'@ZF%%%YQD92&7"%\)U[X@"Z^GIM\R:MY+OA\O)Z
MW'KB 'K'-.C_P%SDGK,G%DE[=U.UDYUZH2T%Z;Y$LB9H9$\T:P+VTM>X(G/N
MZN;U9:;/YL7E"WAA=K:<<*UKV0F9DVWC?-[@6DEGE*T8%4C"FW1#QUA'0V4:
MU_X2KG1NTW+_VYE\W\'/]C T<MP6Q^3:&9E_D$B1;V8T' 6'7?53^$A8C<?M
M?--B Y'<OEFU]>^9; M]+2NZ\&#*_F#^,;%*^.1_4$L#!!0    ( (%!VDY4
MR,JK8&4  -C8"  5    86-S="TR,#$Y,#,S,5]D968N>&UL[;U;D]LXTB9\
MO1NQ_Z&_WFM.M^WN=GMB9C=4)V_%V):V2F[O7$VP*$ABFR+4(*DJO;_^ TB=
MJD0"B0.II HW,VX5 .:#XX/,1.8__O?3(OEA15@6T_2?/[[YV\\__D#2B$[B
M=/;/'[_>!X/[R]O;'W_(\C"=A E-R3]_3.F/__M__8___H__+P@^DI2P,">3
M'Q[6/XSG13HA[(HNR __[^+NTP_!#S^__?NO'P:??_@ZOOSA[<]O/@0__Q:\
M_2T(_M<_DCC]_G?Q/P]A1G[@0J19^9___'&>Y\N___33X^/CWYX>6/(WRF8_
MO?WYYW<_;4O_N"DN_CK)=Q4."__Z4_7'7=&CIA_?E67??/CPX:?RK[NB65Q7
MD#?ZYJ?_]_G3?30GBS"(4]$CD9 EB_^>E3]^HE&8E]VHA/!#8PGQ7\&V6"!^
M"MZ\#=Z]^=M3-OF1]_H//U1=%[*(T83<D>D/FW]^O;L][HLXS7^:Q(N?-F5^
M"I.$BURV,&=DVBCJM@.%!+^*;__/@YKY>LFG018OE@GY\2=[H29T$<9IL""+
M!\(,Q:MMP[F@\8*D8J4$U>=,96UHQK6X<]X>BXH'$NR^:"BQI*46^YA,PR+)
M[3OY>3N- F^E?2FJ^%88A5D>+^<A6X1_B^CB)[&;_?SNW9N?2J'Y9I 3_KT\
M2&G.E^V;8!JG?'^(PZ3<*E@A_I@]AQ)&F9"W:J>46;.91B0<<9S&8B_ZQ/]S
M4UH(VB*F2ACRE!-^"&RVJJT\"8T4R,4O_[G??I%+36[Y/W>-)^$#2:IZDE*5
M"(G8ABG;=(BI"./P(2'2SS\KH?-I,039=@ED)/K;C*Y^FI!8]/_OXA]"KM^#
MG]]LMOW_R7_ZSW6:Q_GZZME^L1&KZ<^89*I?A"W*]HG,PJ228/ 4OYQ(DA*Z
MDFT%BZ<L*W>C/'RB*5VLA7CO WY^__SAIVF1)/\1)?;_"B+*_K,O4@I>_EZ6
MN(JS**%9P<AP>K-==K?[57?]M$S"5(BX?@'-J@T9^/VF,F#1#Y1QJO?/'SE=
MK#;>OXM/D<D_?^2M[U;%9D\W/UBGC"[DHT55\Y]_HD,@DH.RPB+;0RA@8@+A
MO'$^+L_7K]' U&\"M@.T^9&F.3]\KI.R7_FI2&;B']J(#VANW8 =GSD4<"YT
M/&AU5!@,QL'^L8?[CY]J^$@KE(O?+;-BN:R&GS,47GD>3!/ZR!?B%H8F_=)I
MLE,JIB^8IV6GIT 89?*TS)R6#2:3<EV+/7%*^<(M=_,'6N1?A1JLU)C%Z6RW
M<XYH5I;/!NGD4_Q7$?/JZ^&T@JK+Y]K^N">"G@AZ(NB)X(DVGI,PR-\##C(+
M^+H-,EY'FRXVU>^6&\JE\$3P]*0+HTR>".H1P>N0I7R;RT:$W8M5!N%O@#J>
M=GG:Y6F7IUUZ^\5)V-)O!^9 \K3DTY3HVC>E;73+FM22>.9T>I:"42;/G&PM
MF^0VY0M4;&]BV9E9-I5M>&;EF95G5IY9V>T?)V%:OPIE3D;3E)@S+5D;W3(M
MM2163.MP:$?;#VV&-1OSIB]X0]_KZ(]>39>,S)-"3PHQDD+/BSPO\KSH['F1
M\>EW$C;T)LA9."%!F$X"FL\)"Y;A6@R -B=2M]0M,X+*XS51IS_@,<IT'J3C
M-)JHL5AY@W0R%.MNM%EVNJHH:".><WG.Y3G7J^9<+C:0D]"OGP/>$6$ZB[EH
M09AE1/M5HZR);@F74A#/M$[/:C#*Y)F6.=.ZW2VY0;GB=$D6H+[G5YY?>7[E
M^97YWG$*:O4A('\5\;+\09-2U57ME$HU"^ IU.GI"D:9/(4RIU C1OGYG*]'
M?//*^77Q>KOV=+F43D.>5'E2Y4F5)U4.-I%3L*O? WY($):6OX19%N_B]^D0
M+44KG7(ND"R>?IV>ZF"4R=,O<_KU<;?L/K+0(!87H+XG6YYL>;+ER9;YWG$*
MCO7;QFW)R"Q87[E31B43P1.ITY,6C#)Y(F5.I$HW!S,KH+RJIT^>/GGZY.F3
MT;9Q"N;T:[ (V7>2BSX/^$E0,/X];8]V12N=<BF0+,Y>^GW>?>M^]RGP8S]0
M9?_>#POCPBC3>;! 3XT\-?+4Z.RID<T!> IR]$O 2$3BE<DCO]JZG1(AB01>
MIW3ZDQNC3.?!)A \Y+O;KSRKMWSR=CRE\I3*4ZI73:D<[2$G>=''^<F2LCQ.
M9P$IYYTFQ6INH-O7? HQ/-DZ/;'!*),G6^9DZR+,XFPXO:1I1I-X4N:"T"5:
MP#8\R?(DRY,L3[+L]H^."=:$1D7EGIU.-J0DB/=I<^!$"]A05X1+2QP8\3(Z
M2@=<B(D0Y"8)9S4':>W?6S_@+PO&Q#?Y) V3?Y.07:>3*]YU-0*JBK8NZ]5F
M)"L)1H3%='+#?ZNC)<JR'4LK^@LFZU')SB0]2)+5='6 %C^%S'5W#4C1SF2M
M9F'S I.6ZTS*,?^01+C#/W=T-;KDGV4BA]N$//V+O&3JRG)=24D7"YK>YS3Z
M7F9 R89%OLTPURPRH%)7\E?;^]U6,2'X3>UV!2F.Z=*,4:;.+_+5QZ\7A,WX
M8'UD]#&?\\FW#-/F]20MW9'$-W%"V"7?!V?'=W1%J8XDO".S.,O% X<OX:)N
MYY05ZTC&/VA2I'G(JHYJ7M0-Y3J2\AM)DG^E]#&])V%&4S*YS;)B?_<ZDE91
M_GR48]J2"66^V)/7BP>:U,A5^_=CJ?Z;\R&^G_,Q4^T[=86\2JUME1J(*GO=
M&D+=&OA21G4N1&BT;;KPU.<M$-I;I-"D]QP@MG?HL$G.)""F7]!A@JG,@/!^
M10=/2;Z!R'Y#B@QRQP5"?(\4HI3Q [']CA0;Z'X Q/@!*4; '1UZD&,]R>$Z
M,BA2? =[LW85B@G?@0Y09T/!X3O9038;*#Q\)SO0? 8%B.^ EUA;MZ#^FPP1
MUO.\67>RA=690\'N7UE IT$T#],9R0*.5H3?S==!_DB2%0GXWI[/2^-\]:_2
M_AZ4+EU%&A:3..?_N0P%$9N3/.;34>-=3?LR=.7&T!42[WIZ2H?%*K/O.'RZ
M(TDHKAQC*A8S)Z]\X#<A <0/C,R%UFNU207\ J:S]MQI7;U[64ON94Y&^!2^
M_&^#!^$-)W8S+AS?DLKC33>:O**53KWZ0;+X_?7TUG>,,GG7?FO7_M%^T0VG
M-W$:IE$<)KOIJ/VLTKQ9;ZWT#P"\D=(S-.=;RBF(VKL@BV=I/.671>%%'T6T
M2,N7BTN:Q)%^Y"]P>YV2-TVI/(TSI"5EO[+J[-_^1Z6?V-.3S<__N;E[(=CQ
M'S!1.(PR>5II3BOOB\4B9&O^C_W.,-AM#*/-OJ#+*HU;Q=%!'PF=L7 Y%ZK#
M 2-A5C/*P-)( 7U^=N"K(3TO?U:@='8/?Z^Q!@)=-U1[/O;K]J:U?W0\@,V7
M OB0T&8F@^I>ZG(^6EU:'<'U6@6O53A'K8(EI3R%4N%]P(2]JC)&&X0/;ZS?
MJ=) (865DN BIA-&9^&7(F=A1(K*6'^;1K543J>* _7!%[+,BY0TBU);P,6'
M:?Z)=S@;S\/T/G[Z+)P<ZLDMM+@/EHY%5X%1)J\_T;MX#F8SQN7C6^*8LY.+
M,)VHKI[*&F<'S'9.M0/PHLCXOI1EEW3Q$*>E;4*NVU%5P %K\S"%G\W#Z5UU
M6(^JLUH*#E8-!\1#*G@@ZUI7,ZFHBP-LM?%E8YJ'R0UE=9-0L2ZU6WAUP'%N
M4"_$?[XJ]:#+ZKX*L#A'^%]D_9EO.C.R>3:2T30ER7!: 1JR4>FWK$!OT@@.
M^,"+#;P"#EB?PUSDZ:BCL_)".,0'33J\D^I./!20=OU1"42"JU9 7:&>BH]S
M2Q[3)2>&0DP%E*:"WF38D<E0>1VC#D@P3NC RYJL ]2,$"?TVG.3&NA7<,([
M/ILH;/OOJ\%;1^^ T/*MLZJHVE2 RI[:^GZ#P43>QBA#:'*_' %TE:#X5RJ
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MW\,O/BW8PT.6,WYCK$5DVHAWPL/B\(91)N^$I^E&I-A8KD.6\O_.^ E6*H%
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MV 49V$[@*S(EC%7IQ3?!U=9EDB-YF ']ZH[9Z]>47W3I+(W_BU]6]T)4^9G
M/%:O%0<0^)6;+R3>3644D.%T$$6T2,7.,6)T&N>?^5$0+Y.83"[6 W['B2,Q
M\ERD.SX_Y+@<-^WIN^6GQ3S*<Q8_%+Q[!^ED3!9+RD*VOHJG?*:1-"+9MWD<
MS0>,#%9AG)3#0>_(I(C(32&>K?R;A"SC[8B_5"9UZ0SHYHN8;A$89?(W&W^S
M\3<;?[/IS\W&F,WU[D;3"D?JDQG$"0,& OX%#> NB=%)KK]O#MY1Q/M@"X;W
M8%AKW5Z(=63R_HVG9\$893H/9GX:#[%KOE%&^8'F\X8R$L_2ZZ>H_*4\('4=
MPTP;Q=<]=1D*='L#V(:_M?E;F[^UO>I;6QN[:9_N<@[VSY/0]'U0Z047:E;]
MR8RC YKJEJ"#!?+L_/1,&*-,GIV;T\_+,)L/THGXO^N_BG@5)N)RK$M P:UX
M"NHIJ*>@GH+:[B G(6'!0YC%90:/)2/+D)6F #[G1(Z6+!"SHPAW@PNE8UJ-
M=DO,#$3S%.WT= BC3)ZB::9"J-T.&[F8O#@22 5C7*K*/MB,I*X4*@"0#/7-
M17% V2D\%*/14,ZS>,_B/8OW+%ZU8_=3,PPY3/ODN0/<SOODFP,_:4]Q47P7
M9/$LC:=Q%/*?PIVG6+"D21QQ$2WOC,;M=WI]M)32WR0-;T9E/[.*'V[_(ZB8
MX.Z&M/GY/S=W+P0[_@.F6R1&F?S-5N_JH;AQ8+SX?21TQL+EG.]DR8"14)YA
M4EH:*2!%<D5%^;,"I;.>_5W7&@ATW5#M^=BO&[W6_M'Q $(2&ZJ&A#9S"U2Z
M"I?ST><J])HFKVER=]>7:RVZN]__&BQ"]IV4+FH!I^T%*Q4/#;]N;[G+4"@J
MYB07NX2NUY[+3W:J!7 ON)5BH":Q["U?IXQDN7!RK;NF ZLX4!G4?.ESF(N^
M65_!A:NKXD"XS[L!NQ?C56/^4A7S<2%LXT(0MK@B2YK%^3 EM=<;93FW8HP?
M*4@,7F[A7 Q6QBI=7\1)4G_74Q7#I$;"*)-7;>EI("YHGM/%)C:L0OL@*8L#
M##B%^['S SCY.WZ@BE'4J/LJP-KN&.V +M>8=,H>E4 DN&I8Z@KU5'R<TV=,
ME[ ]O:F@5R%WI$*&GSS4:A?'B?YX$Z.P?:*OFG)-HH%0:ZXS\RCX=H=*)=O%
MZCP'1;N2C""<OK5;"M6ZYB"=JQI[*8;)YVBTY 0&(23+_;-!+87&;=42J$KS
MU2U.;XGTELA^6R)A!@XTNP<4D9:!JT^.[_H6LE-8D]\'C"3\%Y%ZF>7VWN'@
M]CJU VM*967DO8CIA-%9^*7(61B1HK(BWZ91LY4(6,6!V>H+6>:%S'I76\#%
MAVG^B0\ &\_#]#Y^^LQ/A;G$;@8H[D"H$:-+RJJ0NL/'E+!L'B^WNT_V?T@R
MN5C?51-GQ.?-RV@D5FTX%O\/*EXWW(ELDIN/#M)!EE&^]]3;[K4K>P,Z%LLH
M1IF\M5;S(<)LQKA\?%<8<RI_$:83E:E"6>/L@.$TR%Q0QN@CWR\SB>\6M#@2
M2$7&M]HLNZ2+!TY8RRQ94HNEJ@(.6)>\HV>4Q4)S<7 $\_^6>Q" JB&!2,M7
MC<_?H-Y5D?'YQ><VK1FI9N 6C>'HCFJWS\8T#Y,;RNJFJ6(STF[AU0''N2N_
M$/_YNM6#+JO[*L#B'.'=\4E6)"W(]=.2I%GSN2LOC@/2O\CZ\R[H[(A?'6F:
MDF0XK<9HR$:E([IB0$T:P0$?J!" 5\ !:ZO@DY*,ND(XQ =-.KR3RKO;]41\
MG*=,J^YV'<)@X80,TLDPGQ.VB5(S"M=E6'.1(.KPT&^&:-"(]S;LR-].>06G
M#JXU.*$#+^BR#E!S?)S0:VD#-5 3XH3W^IQ(-71-"%WP=%8555L84?G0M+[?
M],9U3W.4(;>$OGK'PA3?^%<J@ !0$^<$I"NX);)DM8*1.#9"5!((Y[.:YE!=
M5Q*D<]>"\O7FA &-IJX>$(TKI(.3U%S)VZW+I'^'4H<%U<L&;(]0'(5T]@[^
M$H66=_ _]5D'!6/G3HKFR-.*K&:N9^[3>P"7?C;=;JVN<$-<X8#(?L6%#.)L
M $3V&P9D-A[BIWC%\N8M/^%8O.)+946"QY Q$?4_V:\NRU<MQNUW^LK%4DJK
M5R]?"C'1A'[TKR)F9/*M^CK?OR_X<N#,3.QL8SI\X *DPY3PK6U!TWN.K-8)
MWT%S_KV"Y:<W?7YP1MUF64$F5R0J=Y5WO,J[YB<\!M4Q/6C *)-_9&$;;^Q@
M-FI&D6NHB0-HG90*_Q5UE3.$YM,KH(F-U;2>ZE.&*29I;\W_>ML,0N4G8(2H
M+2% I7EK<4YC,-=X-:I7HYZ!&M79_?$DVHQW09&6>0G(A).C=$58'HM<!1/R
MP OQGZWU&>9?Z%:C82NG722/G;YR$$4D(4SHH2]+*<26<D.$99Y\YJ@7Q4(8
MK@?3G#!QJ/$-GC0E37#7JH,[/DR8;T0H_LADP'\.9Z1<)B,61ULIS6%"6W8*
M]7(_D?8"E5^5 U'7:TM,D0DX7U=TZ2:AE.E)*Z_>EM!C7B6;TT2,NEC#0BLI
M3#V\V%6XKE6EV;3C%,95G)4)PX;3W6^\SSAM6X;)8"'^(A<?7M])<I0GL5:V
M9][!658R;'&<W_#3<V]VVIZ&=1BL&_-Z5\M/?]V>> =KX&IWWC4K7'7JN5,/
M9QLZ)3JAW%9&A)73I3RV7B[HP_M$C;+8O#%,:EJ,,GG5L6F4EXOUEW A?U$J
M*XP3CC(_C*SX&4'"^0CU#$,,79$L8O&R\B;8LB,A9C98+I-87,8OPVS.V>GC
MB-$_252ZV3="MFL.1Y=\H4*H!CZI*H8# N_;B)!))ACAP>DL%*/QE(_"(-MH
M.]/9@ _!*I:^-[9JS9MRNGIX+#OL&OR]FD^1OEINU$<^0F.-8D"H\44"E5+?
MW53U!AEOD/$&&7=NLC(JTR?7=9>*LCZYL!OJP_ODK>Y2&]4G7W9+_76?G-N=
M7CB P-]C -Z*^1'8 ;_WK /T#)/ 3OB L!-,#6U0!M+^_>94;Y#>H&!7=E9?
M*%04M,NM^N\DGCV_!%&XC/,P"<)T$E#QX#'@M98TY66R@$X#4HZ:K7^/[7>Z
M]?)Q(ZV5K\\@'\])E5WK/DSX/)HQ4HIXS8$LQ!&QBU'QD=$LVU*'.F.F;5L.
MC+.-(MP0P6(C_B]^JFD)7UNS35%%JD0M"0\KN/ &8?0[89*L335_=_#9DGX.
MJHMD\\>;2[D2X0(D0FTI5R)<@D2H+>5*A*M!.KD&B=%8TH4H!\H%B1B-I9R(
ML&7(=^)!>OWW:XLX^/@5F1+&.(W97L<N:99GFU !=:* *C@1;/O>]OAU0_-
MP6LY$''K[ERROQO*WOPL<_]2EW8MTK;]BJ@J9:HO[D"HFS!F?X1)L=/R[-1X
MLOZ"UW(@XFT:B:RZY(I4_R_T%A7+OR=YGI#)%\Z8.&6C:U+=6!]XH<DH7"\:
MEHF3!D\-K.IVY_">-^L"I)BQPVDEP%9M+!%>7=R)[^A:.&^-BH<DCH93OFOR
MS7([=<5?FG<QS:H.A.7#=5DLBJ3<.J_B53SAA+_&-096V(5 SX;E,DSXG+I8
M7X?1?-,/M8)!*[4FH&Q#@]5P+MI&34'9L+S5[][HJ$54U6Q)U-OT^<2'"MI4
MSZ&87_D%??NVLA#?X&=33*5=J:CB4+@7MA7Y"#<6;D$@O0Y3UW(@XJ%]8ML%
M^T_7B0>KX5@TT0<<_F:6OYC?I89#)2J\A79$+Z<_4,AG95V(\PQLI538#MCF
MB&T^@[4K.Q=X^[4;\L"*D(E/OJ\XRZ@*'@457K,A!T#NR(20Q9%UMTY415$7
M#TZ("# O0%]\>SZ.FP!X8UKU1G-_&C;A3/C?MR_YQ4/^^L'=";*]\2KA.&C4
M&< /H_+>3D9)&)4:QP.V^TYSF,S;<@;GH&???\V>SQC@$K9JJ"4@C1>2]WHX
MH.VX@"$VDXN#RV>IKAHD9:-B'ER1A]J[A%;%+@0M"UQ6UAPC@>L:<"5X1=:4
MF[VJK'_A:/GI\9R42TSF9[Q7)E?WND$Z.7*E V^YG7S0R=//"6&/+,YE=J?&
M0DX$B/.MKT^Y,NL%:"CD4(#]TA._R*2H+^E(E.I&,IP>F-N:9)$4;4^84<&B
M.=]-)>HFO9KN'@8W3I^ZOW<0KO+M>SD%,*G?HMC*JY]618?OO?F^6,4!'A9Y
MEH?II$'Y!2GO_ADZF6P4_ <J-YET@&K="-D<54*[LE.!ER)\DERL9T4P/7K'
M*)-_B*_WQ'0PF<35JY%1&/.]8W,U4+SV!M7" ?""YCE=P)(.2\KB  -+E7@<
M;E<C#>;)(1Z%?;Q-LYP5XJ*D&U2XH68/@"HFJD;=5P$69YR)5Q,?>R?ND/'#
M(&0;\@2#V%P'&;A#U1D,6E,-Q,"@:[&YSEF"0[K![)SXMXY,\GDI+8X%4B$>
M#BTAK*:Q*$8HJKDG*7PF<'"NH:TK\SA\VN25NDTCNF@.!Z6J@ /6-3P5ZA%"
MC;JO BS.B2LQRL@+]51\G*-02]#SG=OZ>,YH,9N/&)W&^9!].G;6<M$4WJ[P
M67+LLN1T!_&9/WPCJMI2. #4>0,WXI 5Q@BGV1BD40,'L.?W?<4JDA4^$S@X
MMX-&]^%&;,H:.( =Y5T_ G*<F1V/X*H)5E>HI^+C7!=CNH39DIH*XH#1&'^G
M$8^RAH\0VW6R/XGFG.H=HDB!PLR6U$IW@10ZV):I2'BHL OV!7V/TUEJ@VZT
M&M4/M<H2@Q2MW!9!84HLK-@:#1.TN5Q_\!T39 KCH'V-1@XTZ"(,20[9);91
M[E0!AU!%LFYCW\00C[R=497$<$(3&-H"GB(V5+\BRBL5$0BWF=HM_T5@4(5K
M)=+=1>.LZ\WVH1XMN?*BVRW#X3&N<!A!N+"D%'&?4$3Z8@WIRK)AR59+S5&L
M_Q;H)<S;$^$T!=R\7P3_UWE7A74"N]92].8 T1ANW5B,0+2.DEFTL(95[LP(
M5Z]4/[PCVHKHI]@7J8VRO#<+$T07F@,K(T0$FYN*:,T([[@.3DSURVD@;D<9
M<AQNIAKOU1#NISHVJ)YS^'8L=%;[K:,D2"ZOG>IG%QAG<9W5Y1DPC5? 6.>O
MH17*:H(Z2E;5YOU3^G 6X5S5L7OO$PP:Q%?&.H];<Q?H#_4UF +V8>D0,DOS
MCG 6"[);15QKO6(8_;5;%49'Z(W"QW9[_^ATF]",PMDM=VVM)SH,]-<MF6IY
M[MA&HP5V1OM90%UTAF$$9<R'"M11P5Y'Y6B(?=K[%V!\VGM,M!X*!IB$!@U+
MA^*2IGI#LQ%"T8"B^Z-AS5!4;M*0HJ'(UK"/TX.B(;W6V"3)6='P5 !([<>:
M:'@G= 0U$E,"L>%)*J^?[@IZGJ-((J^1&P"*"Q%1,<BI!D6)A[;8Y)R"HL5#
M:\ 9)*'0\' ;K;QU4'AX. PDMP$4%1[V DNF!L6%@K \FXS0G(!0A'A8"S@#
M,Q0:"M(B=W;2B6P%O;^CX#&@8$E01'@8C"(K#100'K*BFUH<BA /0=')-0Q%
MAX>C-.>Y@6+!0T@,<Y! @>+A**!,3E!8>"B*21(H*$H\-$4SLSH4( JRHIE3
M":J#1\9(@$&<H.CPL)/;-&*$K[0K4OU_F:"[VD-)GO-Y^H6F9+%,Z)I4J!\.
M<F1:W-G?X>$S5EU@!AX/U;'(>PH%BX?Y&&2EA8+$0XF>W8EO*'OSLQ5Q?8>"
M ^UW8E@4>2@X/$Q(._$?%"(>&B3-S >%@X?TO%2OV5DC?D'!>([TH5M0>YAF
MZ% P'ITPUE!@*'B,=BSK/;I__/0"'/_ ]^HOY1^$='=D^H/X_Z]WMSLDCX^/
M?PNC,,OC)?_4(OP;WX1_VB;L_*G$E&UE#E*:D^#-^R#;T:=@69W 63 A>1@G
M62"\NXH]QVA* VK5: 4^BSF;(UO\-? WI9^-7-MX*]'X;R2=\+DH#6_;D!SU
MDJ99D>1A4V8X>2&=^+J- K E96%IFBU/+WXT<\SQ2OCOIC*9X/7<BGF?T^A[
M94P&BRBMXT"\S^%3O"@6SU?RH,CGE,7_59_S%EBE?>$&V;&[CX:@==4="-V\
M>1[*)MEB'8KPS'NT]O,U_J4X4@1CE,FG+?9IXGR:.,F+TU/#NB)9Q.+RM!Q.
MJU/S4SRM%&G5?V8?Q;U"DG-&OPD<T#?Z"7&-.M(;CKG 61B5PG^+\_GU1L'8
MO!RM6L/1(=MC?YC/"=LRO=W;IX/+RFUZ!'$@;I\S<JAS;4SDXZA]7)UV.-UW
MJ@;+CK)H$V_G;/8"AUVCU2*.CI%)JCI<-.J^"K X#]8QEV+[@K))?BF_TVW
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MY=2B&:Q.;1R U4FUFR/2->?A/C]HWA2"QA32M('4QR933-+SL8!(]U6$%A#
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M_EV7]]3SGGI&[D/GXJFG/H-[ZI6G9^[NIW.>I@VX3SYZIB9#($84&3<-K=Q
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M>>^/5^']X<3BHK9>;GX7_R->=_%?_G]02P,$%     @ @4':3DU(*')*B
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M?'&L?F)Z#;;-FOCSW>O#H8V>BORCIC)3 %H@?6J "K%^7CYD=@LJP#$I?.D
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M_QP4;;06.I>3"*@@4\?A]X:8_"]_^+M:][?(*&XUP,HLDRS*%@G7ZDE6E+E
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ME-#AI7*VX&IT*V+DEW .7<@74;,UR\M$OOB&P#$_@R8YJ-N1%T-FTYGTP$6
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MAN;NDKMTS^+E<R4W2B\!U+_"&+SQV9VGRC48-"FG5EX!N%B9Z;5N/+C6 ,9
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M&GH;RQ;,6=_:0Z0=*G 6TR6PH7 \TGQ]23>L2,K;C YTD1H8AQ&'KOE<RP'
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M=#,=IV)X[OM ,YI'Z2R+9_$ZR:"$LP@0C*7:*GZ'#QP-S^^:&2OPXG(S.D!
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MK-(:A&7=15(#MT$;DHW.?FBC) VO*QXY!MP_N4^*KV-W-_U#\5;[9$K7"D&
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MQA=^E]/GA&V+=-><??=1HN;0=]MU#0IU]!.6WXG]_@)?L7MQ'FZ="\=Z&TX
M)Y,7E:%P]V<5 BX2V1[^5>R*26?)?36#;3M<%0-6LGUT9PI&N!>VP27\^.7N
M-!@DO$7H?F3?JZR'A^/K8G5.ZRGJ?=%74P&G?6RM!:NNN^&'70O"?7]D4%2J
MM]Y%V/6@O?5>7CLC<_J49%#5T_148G>1VE[\P!(UCESN2L\-:S"F2\D)J'"6
M08(Q1ZW5HG9_$7.3O=]R&T>+XD)$E@X2G4^9QV R@[*(^D ]*E0$=DC)]4('
MA#+>(W;0ZWGO)H$K.J^0JR*8LG>B7J#%8<%) [9F=O?(\,T0WSGN?D(XN.E9
MUWEMJ388\[ZG=U+7,KD'W.Y%J'3EZ'89N$<D]W Z*"")(,G@KDE*3-JQR #O
M0,8YA^G1,;RA/ S3R3J@BH'^P\&68OQRTE#A?0G=1JP8NP[TJ:"G,L D@L5'
MG#(0)^XB6W@A::?<RX)-,GBA]2QDZ$,K3SVZ /A]OM&ZBIW84XQ!XO<^KQBG
MJ*'?<KW-LP22Y/B)ZG:Y3!94P7]1_@CCQXQ.[KR^78V +/8F4+#AV3A8F$T/
M)Z=/42ZN89>#! C@]:CS&\/1.KR"%WF: TE@!W_&)\^(:?SY-A(>SIO!XHKP
M7R0H2^D':+S!B<+X79$"D=WE'!TR)ANCA'%ICI(3 .[2Y.1?"LI!?4R6QS?9
MBJ-QA33Z9G6>!2\@D92#.H.2I!4:%0>0-_].HQQ3"</>>O!U&[;[M4E'[FAU
M08HNC+(/TZ2A(?NW7<,:Q+-X(@AY?,4C]WC?@\/;)0RZWV)$0Q6&WT-!PUK/
MU9M2R-+4>:OM=:5X$8H55AU C+09CQG1V%#$[G(FTC58IG 0&AV,$:+>29W7
MWVP VSCN6%R&FV/.IF.Y <1CG(>8'D7#'V:.WY_UGVMZ1^+C4<<S.K<U%4#Y
MO#"D+]Y/3*9!H0FP3[O="%NODU(\D8$[_ZYK/NU6-:@I[?2MT0+MN8G-'C>9
M*-)]NSRQL"IR,_O;VQCLD$7G_A):"J=P<=U8KMOE8Q[%(J %Y:_NZ8(FS_"*
M1]WM-YO5]$" @^Y7".(*QP.7 <I" 9JMYA_Y'E-[YPA?!+)UPD 0*_#QPU
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MBZN2':86V/''<0/)=U[9*+S>D=7_>Q7"X9_1DBJG\9>$).'ADGFPN**3>6@
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MES&]C-G@^#R3S/D[-^^E!&.D+W/6C=&US"FGI9',N?]Y1]N)-I\V';.AK]A
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MV7!'Z!=^P,1XMDF[IRI<&QC?#M!.BA&>L"VH3&D%X;)P%G&AXG.3+ZKR>)J
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M <Y$(\H)&*=W;N/4I:A[)J/&F[TW+_%K?B5-ZP9LM*[-'"I4^8#P%O0MV >
M*5XJ']-K8,TUL/.$U=ZR\S7*]JSG=X2B>(9O7Z+BE^(65XVFU1W4/GBJRE>I
MH@$<XV*T<^#!XM5TKZ9[-=VKZ6U<,?U:.@JP*=U%9]*47I-?+QA9L_)/>FH2
M8*BN=20P25Y!:D%! J /TX[ G]&K1JZJ1M=A.A_@"?^_V__D\2I,N)BJ*OV#
M1[D8^1^R=;SP[X5_+_Q[X=_(F7HF.39X"M.X*-;"YF,H%-,%DZ):81ID3+[+
MPT15HE4:M&O95H.X1E+N5S;KF.QTFMU2*BM"%DZUO0GW!3NUGCYXSLNQ;LFQ
MU2>D4&"M;AZ\M8RIG/*KI/28BWG9;V4I"WO6%QD?>TUM8V9W?$J^R%$[&!L.
MBC**EXK7<;R.XW6<L^DX&:(I^FR?HE-[?[6W)*R% R2:M!=0:"LNDDNUO<A!
M6P&1RTOGL0.\"])XAN-I'(7LIW 7/ALL21)'G,QF)@'M\3NV#C2DTQL*^F\H
M*)8$+962[7\$I?JQ4\XW/__K[N&(L-,_>,.%>X8+B2IIIU;_"9$9#9=S=K0E
M XK"M )Y8&M+&9(4NY>T]WJ^U_-[K.=#MS91WC*N(R.Q "B=B:Y;0Q16B4B4
M<1V"S@QB3CP;] 8QF&(O,W!TJ<S_'BQ"^@,5T4H!$\ES6EH:JG_=*K0E$'.4
M\1VO&L1J<LJ.57[SI#>R NPDMOO=JY-[S%8]2C,>+EZEZ *[&%"Z*V;Z$F8<
MF_4-G+BJ+@:(^[+[8(_\>U7X+67-O&6D:?XA1!<W:$G2.!MB5*F/2=N9)6/\
M3$!DL'8+XV30(NOY^BI.DFKE5-:LS3!SD^<>*!S=_$'KK68N6<VN2):1Q297
MO<164]/6#F:NDY!)?.G>8Z77^ZW>L@;NZ0"CDJ^HT-<.9HOE5OOU3EI81+CL
M<U0ULH/\,5G"S@51PYX9;[NY0[W-]V)LOO!+AS0ZP/N#V.E!3V!GJ>L0@,WA
MBH*,ZW9AS<T$U'==1P>\:@0"E.O\@P\.J6;CNO\ C$2]+-<?&!H=%P*[5'N1
MDPZ@([.7N;YT.O- 6KHX[/9 6O/L&.;-</UBA0*AY 3KUPFA!(K8^78>9_7[
M@**$_<+K=-.L>:0Y>+R.W<R*=#7R(5_%9$+)+/R:9S2,4%[:?>YQ)'9" ;L8
M<$A]1<LLKW,.5C8P,3')/K,/0,?S$#_&+U\(SN8U;CE <S-$N1+T/Z)D26B9
M8'WXC!%-Y_%R>\:F_P<EDZOU0[G&1VR)'V<>TAI#+X@:P,"?A#_K>."EO3?3
M#O @30F#LCJ. =S9*,D7$D[@7;1V^&$&LQEE]+'=-XX7Z"K$$YE/2=K##L:N
M"*7DF6W:M":82M;<MA<=5WG*]GN:7I/%$[L&BB*)M<Y+60<[V+IF4,\(C;E1
M8.\N8/]=[U<'=;.$15*\*D0'+T$?RLH;3&&XQQ5?2LRXQF"V+>7R0$S') N3
M.T*K%JKD(%(>P4K&#Q>N&LMU?>U@=G>8HA7".;I]62*<BD_AZN:V+=U_H/67
M78K($9-H"<8H&4[+KS.DHT*+EWQ*G4'L8!^H4L$[V,'6UDQ2>^54-;*#?-"B
MLW=1^3BL'L9A=<@&#2=H@"?#;([H)N7&*%P7V7MY0:[]>U+,HL(@/EO8H=W9
M1Y3U/J),JDL2 ])Y?^ ":J=UH,GE^_[ 52E9$0W#4W\@\0&)TH!$!0N0ZVYQ
MG9-%YEUSW2O>[+05:T.NKQ7P!H+9AUV'0TV&4?>.N[Z-P,M%;/[HSQ(1"2)J
M(0*N+PD5P<PP(I;&*#:[:_3-O:[CYM\)=!L=_YN=,'06XOR[D_S[)$O'8#0-
M'&OOW+ ++#/VZ_;D%5O1,A%$T=[=;"MJL#BI]BXK6W&!12ZT=XG9A4NS^-GS
M/$MX\S9@T,<K-LL*!<\AI3PA?+*7M[_9,P7M\3M^MM"0SDM)B/\UYS(Z5P#_
MD\=LEWXO@6(7[17;_8A&_!(9D^$3FQ\/,6*WR(+@1_81*B.J&PSGP\^-3;U!
M?4\@N$_3'$UN4%2H9.]8EW?B!R0:W7W,O'LQ\Z</F/>^N&(F,$%/.QBMHE(2
M)B3OXN-E?+S,1<3+P#=[=04MR0YR':@&68=J#\W^V(N5%E S <1UT'P*?V]=
M5C).&-2WSF2N>!?DN,C\B"9,BL,K1+.89X.<H"?6B/W<V&"A/T/7)HNFE#;+
MO; SB0ZB""6(<C/[=4%%RMB\0]R!CK[$.%[D"QZZ.)BR#<$/9G:H(U$6_>:C
M&K4+P,CYCKB%#TT&[.=PAHKM,J)QM*53GU'9R"TQ>_VZF%Y)*N:M9T7<KWU"
M>3W:;%U>_'<)(52-WNKN[9,]9EW2.4GXM^=[F9L?N4>+-;L)UY5F*)UQ6F+D
M)DZ+\DC#Z>XWAAL3VI9A,ECPO]0S(.]OE/ OX0O?-=M;<.]V*R1&+C_<L?OT
MU4>VO1^KN- >S"A+#MF.+]O(^FU[5>]MVIO=12VVKJKT,V<+3C?2( >A. E'
MB!9KN[AOCT^@]/39?K/!]-\^>TOQ^0VHKU_T:OTU7-0_<*UK;"<[TI(>=<UM
M8ZE':6)N4!K1>%FZWK>2!2<T'2R72<P5V^LPG3/I[GE$R;]15,3!"YG6&\XV
M4-@MS\@22&.B9K8QP?"-$)JD7)[:NRZXH3">LB\Q2#=B#)X-V&=8Q;4/GK5&
M\R^?!68U[\GI%_/ FUD0'B>^\ES'!?ZX3"K0N.YV@"\130W&=8"\7\;[9=2#
M:>MEL$L)[#=K6[N4 ']M0_REQ/*;M4==2J1_8W/]I83^&]8NP;#]X39L+?E\
MP?"]OQCX5#W)8 @_] I"?8\J&+"/;@/6VJ.X-XX+\DUC"^! .2[AFS:QGRD2
M[;<@"I=Q%B9!B"<!X:^/ ]9K23#BB@B9!JCX[DWCT9K.TW54FAEZ&\6F#;+Q
M')45PQ[#A*VF&44%B;>,D06_'W=9]3Y1DJ9;F:W*AZT[EM$H#R$1=X@K+Q'_
MC+/*> 98SVZ(Y>4>E6CD'<Q&+E'R ]&:ZE 5?S<P;2']#TK[A7AR<2M3)%R!
M2*AL98J$:Q )E:U,D7 SP)-;$!G"EB9(V;-IU9 A;&6$A*V2\, O@>KY#YH8
MW8PW&Q%FIP]?DS1+-QD\JHBI[6"8M.U3\-.W)>*/!>]E@,1MN'XA2]X1^N;7
MNF!%<6NCN!U,LYVA%'RE5!TV-TK671C3/\,DWQGZ=E;D.LSDO8P2>8\C7O 7
MW:#R_[D!J=0<'E&6)6CRE4E03(@C:U2J[T^LT604KA>"[=)H0'M8*Z$WSF Y
MK%DV^<H=3DL2MKZ+&O+%S0U'/:]YC.$H?TKB:#AE9R@[.K=+F/]%?*(I=C42
MSXRO\T6>%,?H3;R*)TP-J A.JV]\J2'6AZOH.DS8)KA:WX;1?//1*JF4=3*+
M9N5L=>=P?8\6B=M8; @=%B:*W0,Y.9&BGJT3>X\/]RJ4U.-^K1#Z#<?;Z_TF
MY[.PBS4FM7 *NK1"WI%WL/X[GS1NE20UT,2]C!*Y[^G:PO Z>16!]3U:(X[C
MP"#8K/>CE5X8;63$RD=HF_AB(P#)+-J:)>B X=)*LOUL&QE!+$0H=S9.\':V
M._1$\Y#R*=^78M>H3-4&)5YQ( .,/* )0HN32(4J4@5-S2;*0CP!-&?[ZOOA
ME]PDVAR3$@\QHII#&"/^PS8M!,\*4?UY=X1L%7@I.P8&-<;@QU%AAD"C)(P*
M<7-/8'^G^)GTQS+&SAZR[[^EARL&N(D;#=02(T*=ZKT:']!Q3+#!CY.K/1VZ
ML+\-DF)0O@YNT%.EA@'J:/:<DLU8-+@N'55:).\/8)[T4G23'OFBMCXYHK&I
MQW-4;+2Z(/97*WFI[PWPY"0T%7SP=C*AD0?-$T2?:9S5.=2$C8P0$&?;*+!B
M=U83<-3(Z-;8COZZ_?@O=70<MC1.3*FA#*=[OD01-15-NR!GE--HSL[5&H,4
MK*=18C=C"I?1_M_;F%B8N^SM^WJ10*=_BV1+E4&EC@;S&; 3LLS#/<RS- OQ
M1& <JVO?QH=_-2!M/!=[1KDZ^FJZ=4VF.-$+N'-+)"]YCK-ZPHHF/MV$R^DF
M!I-)7+Z<&H4QVZ<;H5R2I@'4RPX&KTB6D06L8'E-6SN8@941.^%+I>;IV5D\
MR6!ZC].,YEP]4<V4+>CI *.2A:K0UU9F>YK_?$?ND+)S,:2;^QK&HKB/9<SM
MVV]@K(EZ6,P8= ^*^UC"W"Y^?!LO4__):IO;PE+.7\TL(7>?L*F-K,C67$UC
M.]C9AIF.PY=-0:M[')&%.#V6J(-M:91* 3X=$[;+[P@]%*,DGTVAKR7,BLVL
M]8WL(+]25,AV(:GC.27Y;#ZB9!IG0_KY-(:AR5"V+=S.*[)TQ]I!$*B0FX-6
MMGV=JG@R(2=5C>UF2&PP!/2PC;5#\5RRA^H:V\&.,$9+R).PAVU?ZJ1L]@DK
M@LKA5A N6UI5C>P@7U2/_(2%^L+EYV9#F.]!R(^P!VQG.)C-SZ>^]*DO]YE7
M,V<1M:NR1^# 3/&DD?K8([C -GU)_3>)?;S/B/D2@O5 "4W3U4M*9N[M$4+U
MEF ",P;U"0^A*9FH66G[@\FI'D5@JHKK$-1)L_*#H\]YK4$':P&?+&.*ZZF<
MM3&I2>'27LY9RS&1Y)-Q??^ SQ.!Y<IU_L%7BC1(JS^GA@2)>B.:ZS# +UB)
MA[\_.Z-> (6\&7']]E"7NGP%>-T*\#6O"EP_6YK I9JHK+UT][9N.5D88P\W
M6[VINQ1B)=D(>[2GY->4.%=HCV!061R2]*6NW]MMW$_R5WI@U)0+:-AV]"H\
M\.C1Z0OVI1D5C97+AMBV6  !WCU:) I.#(5G;6" E*NDV+9:U%Y5]6CAJ+B>
M"SBU$G[V4-X! ]8\)4^?Y2(8>L:29[FNIS:!4C/+GNORI3G(M'+[N2YQF3[Z
M%+.JN2Z"-(&OPSQ/8)B5B[G9#[.9/(9@!)6KN[F"H&;"SAY>R3!?OPE+F*7;
M4:)XF2MO;NEFDO /2H<(QJ /51'!=1K:4[TM1$526ZD]K=I"+("YJ]O3E2W$
MQ%3EP?:N8)= JZHEV)[RZQ(RM94@VU-P[8)(XX5P>\JK7=!L0D84:N^U)^!:
MB(Q..9WV)& + 8(F*8<+?[V0B;4*1L$QZH.$W*P$#QRK/DC0"M4$X<#T08Q6
M+"4&!Z</XC(L+3T<DSX(RM"*6G!4')>-#[81O+@<')\^",@*M8SAP#@N'YO,
M00<'S7&9&9CU#6X>[(.T+"WC H>C#X*Q>FER.#Y]$(;52@;#L>F#/%Q7R@:.
M1!^$7^WR)'"8^B / XM%P4'I@SBL5Z,*CE$?1&+EPO)P>!P7C)5+3<&1Z8WT
M"\Y'"7<*]T$2OL<11>R$N4'E_Q>UU,M["V49VV%?"4:+94+6J,3L::^(:4-[
MX+L^R,Z- -2'K@]B=:.BN'"H^B!E:Y4\AD/4!_'[P&)V1^B;7QLK:.\<E[?5
M:XK H>F#U*U1_1(.4!]$;DEA2S@8?1"PCUT6S;WJ[QR7KD_\6UM(7D'2CQYT
M7+I6JU$"A\5QF5FCR,DK-G_[Y00:-LF/\F_%GSB!#VCZ$___;P_W!]R$49AF
M\9)-MPC_PBZ_7[:U?DN<TBW= 289"MZ\#]*=N!XL2ZDK#29E,O\@.\SF+ZH@
MW&C0DOTT9MH#VB)0"<"F_<GW:Y/CDCCV&\(3-/E9I[+R-<%IGF2AJ+IG?2,#
MI9VO"5T26L!8WOQ,*&(\QRO^L O7T03O9Y;,QXQ$/\J@+C")M7T,D/<E?(D7
M^>)P/P_R;$YH_%_5!;,E78S6[Y;,-4A?HY4U2-WO;I1LM6HB^Q0KUB%I3JKX
MQ-\G2_:$R0P)!\^G*J>O*+/B"[0?D65U@79?ZM36ZH,W*(UH7-PTPVEYXWR.
MIZ79L_S/]!/7"FH*^L&'L*W"VL:NPM6@$SOOF)&<AE%!_O<XF]]N#,+BE:LU
MFFV0;"_-839'="LI[5Z'[XG\]_B$R0'7'V?%B2T$R=#XML*VO^AWQH:&4&F,
MZ0(\FS/!(#B@$6V#IHY6V?6BT-<.9L>,BFW^!!'=M=*!Z@"^7J%,D :;L2S%
MQ=<K]&6=!)@H'Q:DT>'J.G#@;)IZAS \?-].>)JM*PT+G^N *>3R];5/]G/"
MU!G/X6& MF-A8A<!3?FN@]99NBU+$\SZ=%N*#GY%9TU[!ZQ[V-1YA]H[1^S"
MR81MM[TSQU:LC)FDX)$E?89.T]0)!J\W@:)&_ Y@V!P/(FW=$W&>T*>WOP9Q
M&1V<A2^H:<P3<+2.@YV4J&H4Y>0#.;1(\($<O0_DV'N44*3^9L?CF!0+ZIKM
MXAF:#.DU^W/,9)Z;F*(H2];;W. U\0/:8\*<>0Z:8;VCQSMZSF(!LM2$ZBU
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MH*UNU7T..YK26QS=LSA>LT]\^_J%A68503M;F,C0C-"8/YW9F40&:8HDQ8Z
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M/D8)_!*NN:MME#\E<32<LI,BQK/M?/PO8I>V8E<31;HJI[K'W+=34Y\+W,L
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MMK!9[M&;>!5/V,4]2$>,?"Y?S!2YUAK'#A"^;RZX07F_%?0J?W>=02[&?F5
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M[W<P#UK/E%SS  'NA"X+>KYY'Z2[N)%@N9%5 Y)GK"&>,.:*G%>HE/QY/%M
MEIRB5+/(I[D).R[\:9KP1NG!'KBP<1>O$!="2J6,*[0G=<WW,TQ!^YBH?5A,
M17*J3)Z\CRGRAE@9/'D74\2-61-E\B"=C!'X3)3)DW;QN=[:JB]I[O#:YZ.#
MZ7P"//<2X%V1+".+X;38]9+R7C5M[6!F>V 5Y]5P.GQ=PH4U;U@N6R%_L.ZV
M)0W[FO,/H<ZMI)^M;.[3>/MZ)O% BJ.0Z@$W>\^JLIL:&M4VB(I]65MI\*2%
M183+B@M6-;*)_%=YJ127[@@5;"WY)](<S$TX0-]==S@[(!F3)>R*%36T@XWO
M*)[-,S39)-X_NB_-GLPMS&7;>7W$X@/B@BM;S=<$%X:IG%>1F6H(,DT'A@'E
M5F1'9TJ0?S?=\W?3=>(4@4DL/8- 5URI0*O9/>\ZKN!":\VEQ/X$G35=@NHV
M8]>Q4UMFO5\[XC-):O'J3^BA!(EZQ:1G,!@Y3* NE!8",=W'#NP=Z\]S'7/H
M@1VS[85<.@P>U.GN^IG76?HG2\\MN],_V9LS0L]+UI[(:"]2ILUP[9TX]F*H
MZ*5L[U"R%Z(.+.7M25GVPFK4-7R>@-$/P8PP@''Q"W^-P[=0A/9_G15/PPKC
M=KS+.A!DX4L0L4\89[JAHVU,W7$0:7LL- HG_;2;_E,Q^T&^B''X<EW.?.0<
M4NFJ5^Q!0&[%!%6DU33SD89M11JVL<)!,8?M;2T??7A$EM71AP]HA7".^#.-
MX[-)' \B[W,I7NM6MI'W7_?<?^WS?MML^+$F(0Q,+.O78I"HA."KISU+C5W)
M0)MH%>=1B3\&:)O<D(DFBR7!J CTFN[]KJ?Q:HS<L4*K36$C??4NISC.<HK8
MNAA.IW&$=NDEQ8_0P)T,J$=L-Q'*NZ\!A$D;&R!H1,DDCXJT^7*"I(V]^MR6
M^JRQGT#:L?8^]<JO2\KO((KR19[P7$_[I3+V2XKPJW2Q#&,J/ -,#6<))!,F
M*7!#>Y%Z?3P/\7A.23Z;7^4I.U32])HLGF)<,),*LQ:+(3(R_''A@'.#=AU2
MNN:9+18D9Y0J+@/V'Y\H8:P?CE+W1*GM"6V$5;+YZAI;P@Y/Q\9#9(3KNOZ;
M*W6WA&5V=^89HO52%+B]'4SM[S'U$U"IMQT,5QP6DN\H[6$'8^I?3WPE_=9?
MUGYWA#7)H@3VNQ37A8Z.XST3/?=,="AB$C7IK4?(J@ERQ_G,X6>8ZY"!'TEU
MHPZY[F@YU]X&"H.NPPM?K1J*G.O@-#G]=-P1KC\-,7-;@-1IUU^1-%Y:0(=2
M?]ZY:>($]'/U:.MU>DV:\!ZXCKU_$6=S8%3G*?Z50H/ IKGV9"E["W&WX75K
M[[#IN!B"H66F6^[ B;-(@HJ&5^,\T6=O?@WB75%''K&-LO3(_'GZ=\W<_0:F
MZCIKOS&2&P6LC1A1;+J:D*NJ!C[,JK5\Z :6!2CNRMSZ\X%81V3Y0*P>!V(=
MURG>]?E$R.0Y3A(S 5G@:2R!<.][-T!(9Q0[ /!Q:3XN32$N[7AU\^^Q6=>P
MR#3@ ':PW=NHIIJO(&2MIH]MD4VFV;,LNJF&5,GR!/>T@]'/<82PJ Z6K-FE
M!&D948A\U):/VO)16Z:<IE AY[@LN\K9[#IL/G*K%_O;1VX)(K>4%!W7X6EV
M!LKL]:Z'+)BZ(>KDW!YAY$-J[#K<?$B-#ZD1>O45K$*N7W+MQ=,H^@PN,ZI&
MP4#7KP-)MM+TG4]GBJ]Y$V0TG* BWR'A%/):?OS4/;9;"9MI1ML8G[CKV)N6
M&&@4B5.(!H\HRY*"TE$YTW5.*3IY2BSOH)>WP\?J*,7J&%]&L,B=EE:OC^,Y
M(LOV.!Z:ATE:J,+Q-$:305I]6(#ZV);GYW'.;N,,T<4MNQ/(&J$KA-$T9N+*
MA@<AD]*>MK$ZYKN4O[7C>W3S.3:'N9C+NDYZ*>W/P^"8/*#":C!B>EFLR?#Q
M("Y]X3$I_OJ8+Y=)C*@N (>#P !PT-'1Y:7H?;D]]^7ZW. VV^ML?>'5Y!R^
MP/=P<)&S/7.<K> HBZKM&>3L@DC=O@%&1CEE@%W(F!&(P6@IU\*U*V6_GKYT
M)G/N;T$4+F,&WYYP>IHM+EL'SR$M"]V0USJ1NJ9<HY-V;<9M@?A&)MSBDAM.
MOY>S#>D#KU6Y5\RSRLPGZV/4D/LE7'-+V"A_2N)H.&7[FLVPF3KE?Q&_ U7L
M:J(R0.54=^B)78V4$_/^MOBZ(^ZW(;CF"6N3@4S8KMF\B&/T_NK[%24_$-W2
ML#FEQZ0D0,R"YA#&B/]P@Z)B9-;@736>.T(^Q^%3G #8,3"H,08_CFB\8E.-
MDC JCIB]I?U.\3/ICV6,G3UDWW]+A9OVO8P5O7&\RZGAU.,Y*A#'*8IR)GI=
M$[Q"['!BL]R@)S8A^['\+64'5EFOEPDWO-8V^S"O*PZ\<#N9T  PVS7'YBXN
MRE1RN]:U-WJS;B>Z3].<\U\>TO=X?P,=;A_QQV@Z5HOL5$H!ZIP AC'(!'@7
M='6G'LS#.'^]WF+!(RW5;JVZO8V*W3"7=PN2OG=W'Y%EM;M[%_%]%^,01W&8
MW.,THSE?(RGLR;2LIP.,RA[ P_M>C%_0[,GA?8(]]PGJG!O5#Y>@>]!UQ-2?
M=,$.8M>]JYHK2=_8YOKSF2: -;=6N![KWAP]8^:X]GQQ]D.IK*.UYXIS!RQM
M\P 8O#\N!SPU*Q$8P??]0]" 7P@,WX?^P=>AS1@,\\?^P6S&IP27IBU5,YI#
MJ.D]A2/70T6D%9SLA*FS:&!+U2\?#:P8GZ@:N7,IP;_*CM<SQ=O]$4RWQV"
M7I:(R3'';T7*!BB(,?L=O;;2#+8S-V/7D7:F*6\49L>CHQ%GL,C_@QC'V1!7
M29]5/D9PYP!_\/$LAJ;>G 9C]C]I6-0UNR9I5@F!H*G9KR%V%YE;Z##'MNF-
MY;W:1V19[=4NY7!4M1FJ&P68ZV<VL?")?>[T,RGT"GP]#YEF?X_OPIC^&28Y
M&DYO4*&XQJN:M[T:8]C!_/8&N2WWY!!?$4K),Y-QQ,S6]-$\Y-KC[RO*[@A%
M\0S?OD3%=_ETNOFAS>U@J7@ LL'^:OTUK) 3ZAM;]Y$>T KA'-TQ^7R[MH0,
MU;2]F(@0@U>N#P?I>3B(?R)NLU'(PBQRT@.V7RM"@@9$(&C!;OJQ! 2SG9DA
M2W,P@F7 %@)3+,6GH7VFA; 3FX&"&DI<#S!1VEC:FF0+D226+AY%[::% )%#
M8,:69@RH-[N<R6?Q/DA94_04,GQXYJI%J;$4L14!/P56/)1=TSVA-7C7GH@&
M1#9[VT_HDM""F\>,1#_*>!9>>%O\8 O:Q_L76K/G:RT7F.F^P4KT5GJ7K/1?
M<[Y9A],]%_8C__+E=A9;>B7];*OVV!:;EE5]W)*[3^/M"Z)1G/)3Z1X_[G;U
MJ-S4 RYHSXJM+P5!:U3;\I76,(,FY@&2C6F=Q;V:EV5,#:,#&-$);.X(G:(X
M,XH.<$PG\/G$%7FCZ(!&M.W8J:-5]O19H:\=S(X9%>GFHXGHKGW7KCJ '6Q_
M1SP:$$T&*T3#&=K> ",:1\CTG=S"7+9M&646M4\9XS.Y#&63J][P/.["V%0J
M,#Z3NU V$R ,S^,NC'L:;.M0@N>R',Z=<V60?4%AFM."Z)LP0Q4+!XJ;UJ 7
M$\"D9WCTL4H]CU5JH!J01JJ4Z\"!,]CHJ5RN1_PT6U<:CC#7 ?,O26T.&K3K
ML62GHF-[&\ONXMJ*CKCV]I_[:T]+ VPAA-%R0(W9Y%L(:K0<NM8-C2T$1%H?
MZF?2^]I"J&1OEJ2FI;'U($L+037IU 7CIYR&R_TEJ>5%  ,*3[CEY(+4B\&
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MY%4! Z*<'M1N0$1.5# >\-R>;N A\'2#\5#.U6DW'@+?*!@.>*9-B^&01V?
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MJ3KUX:#U05#6#@J!P^2N!&W$'PX'REU96\N/#@?&79F[G9AU.'*.2^D&'S/
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M &%C<W0M,C Q.3 S,S$N>'-D4$L! A0#%     @ @4':3O61=3H;#@  M,@
M !4              ( !-1(" &%C<W0M,C Q.3 S,S%?8V%L+GAM;%!+ 0(4
M Q0    ( (%!VDY4R,JK8&4  -C8"  5              "  8,@ @!A8W-T
M+3(P,3DP,S,Q7V1E9BYX;6Q02P$"% ,4    " "!0=I.34@H<DJ(  !'C <
M%0              @ $6A@( 86-S="TR,#$Y,#,S,5]L86(N>&UL4$L! A0#
M%     @ @4':3I\W]KDT:0  /V,) !4              ( !DPX# &%C<W0M
F,C Q.3 S,S%?<')E+GAM;%!+!08     !@ & (H!  #Z=P,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
